<SEC-DOCUMENT>0001437749-23-008834.txt : 20230331
<SEC-HEADER>0001437749-23-008834.hdr.sgml : 20230331
<ACCEPTANCE-DATETIME>20230331160141
ACCESSION NUMBER:		0001437749-23-008834
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		89
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230331
DATE AS OF CHANGE:		20230331

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PIERIS PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001583648
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				300784346
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37471
		FILM NUMBER:		23787391

	BUSINESS ADDRESS:	
		STREET 1:		225 FRANKLIN STREET
		STREET 2:		26TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02110
		BUSINESS PHONE:		857-246-8998

	MAIL ADDRESS:	
		STREET 1:		225 FRANKLIN STREET
		STREET 2:		26TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02110

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Marika Inc.
		DATE OF NAME CHANGE:	20130805
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>pirs20221231_10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<XBRL>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:srt-types="http://fasb.org/srt-types/2017-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2017-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:pirs="http://www.pieris.com/20221231" xmlns:srt="http://fasb.org/srt/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:rr="http://xbrl.sec.gov/rr/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
 <head>
  <title>pirs20221231_10k.htm</title>
  <!-- Generated by ThunderDome Portal - 3/31/2023 6:05:17 PM -->
  <meta http-equiv="Content-Type" content="text/html" /></head>
 <body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;"><div style="display: none;"><ix:header><ix:hidden>
<ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="dei:EntityCentralIndexKey" id="thunderdome-EntityCentralIndexKey">0001583648</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="dei:EntityRegistrantName" id="thunderdome-EntityRegistrantName">PIERIS PHARMACEUTICALS, INC.</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="dei:AmendmentFlag" format="ixt:booleanfalse">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="dei:DocumentFiscalYearFocus">2022</ix:nonNumeric>
<ix:nonFraction id="c96253156" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:CommitmentsAndContingencies" scale="3" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction id="c96253157" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:CommitmentsAndContingencies" scale="3" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction id="c96253161" contextRef="i_2022-12-31" unitRef="USDPerShare" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.001</ix:nonFraction>
<ix:nonFraction id="c96253162" contextRef="i_2021-12-31" unitRef="USDPerShare" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.001</ix:nonFraction>
<ix:nonFraction id="c96253163" contextRef="i_2022-12-31" unitRef="Share" name="us-gaap:PreferredStockSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">10,000,000</ix:nonFraction>
<ix:nonFraction id="c96253164" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:PreferredStockSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">10,000,000</ix:nonFraction>
<ix:nonFraction id="c96253165" contextRef="i_2022-12-31" unitRef="Share" name="us-gaap:PreferredStockSharesIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">15,617</ix:nonFraction>
<ix:nonFraction id="c96253167" contextRef="i_2022-12-31" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">15,617</ix:nonFraction>
<ix:nonFraction id="c96253166" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:PreferredStockSharesIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">15,617</ix:nonFraction>
<ix:nonFraction id="c96253168" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">15,617</ix:nonFraction>
<ix:nonFraction id="c96253171" contextRef="i_2022-12-31" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.001</ix:nonFraction>
<ix:nonFraction id="c96253172" contextRef="i_2021-12-31" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.001</ix:nonFraction>
<ix:nonFraction id="c96253173" contextRef="i_2022-12-31" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">300,000,000</ix:nonFraction>
<ix:nonFraction id="c96253174" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">300,000,000</ix:nonFraction>
<ix:nonFraction id="c96253175" contextRef="i_2022-12-31" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">74,519,103</ix:nonFraction>
<ix:nonFraction id="c96253177" contextRef="i_2022-12-31" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">74,519,103</ix:nonFraction>
<ix:nonFraction id="c96253176" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">72,222,661</ix:nonFraction>
<ix:nonFraction id="c96253178" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">72,222,661</ix:nonFraction>
<ix:nonFraction id="c96253361" contextRef="d_2021-01-01_2021-12-31_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="6" format="ixt:numdotdecimal" decimals="-5">1.5</ix:nonFraction>
<ix:nonFraction id="c96253379" contextRef="d_2021-01-01_2021-12-31_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="6" format="ixt:numdotdecimal" decimals="-5">0.1</ix:nonFraction>
<ix:nonFraction id="c96253460" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="6" format="ixt:numdotdecimal" decimals="-5">0.3</ix:nonFraction>
<ix:nonFraction id="c96253524" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember" unitRef="USD" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" format="ixt:numdotdecimal" decimals="-5">1.2</ix:nonFraction>
<ix:nonFraction id="c96253525" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember" unitRef="USD" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" format="ixt:numdotdecimal" decimals="-5">1.2</ix:nonFraction>
<ix:nonFraction id="c96253743" contextRef="i_2021-05-19_CounterpartyNameAxis-GenentechMember" unitRef="Pure" name="pirs:NumberOfInitialResearchPrograms" scale="0" format="ixt:numdotdecimal" decimals="INF">2</ix:nonFraction>
<ix:nonFraction id="c96253744" contextRef="i_2021-05-19_CounterpartyNameAxis-GenentechMember" unitRef="Pure" name="pirs:NumberOfOptionalAdditionalResearchPrograms" scale="0" format="ixt:numdotdecimal" decimals="INF">2</ix:nonFraction>
<ix:nonNumeric contextRef="d_2021-05-19_2021-05-19_CounterpartyNameAxis-GenentechMember_ProductOrServiceAxis-ResearchAndDevelopmentServicesMember" name="pirs:ResearchCollaborationAgreementPeriod" id="c96253759" format="ixt-sec:duryear">3</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2021-04-24_2021-04-24_CounterpartyNameAxis-BPAssetsXIIIncMember_ProductOrServiceAxis-LicenseMember_TypeOfArrangementAxis-ExclusiveProductLicenseAgreementMember" name="pirs:RevenueFromContractWithCustomerPeriodAfterEffectiveDateAgreementsMayBeTerminated" id="c96253792" format="ixt-sec:durmonth">9</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2017-05-02_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember" name="pirs:ResearchCollaborationAgreementPeriod" id="c96253965" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonFraction id="c96254016" contextRef="d_2022-01-01_2022-12-31_CounterpartyNameAxis-AstraZenecaABMember" unitRef="USD" name="us-gaap:CapitalizedContractCostAmortization" scale="6" format="ixt:numdotdecimal" decimals="-5">0.3</ix:nonFraction>
<ix:nonFraction id="c96254027" contextRef="d_2017-01-01_2017-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_ProductOrServiceAxis-LicenseMember_TypeOfArrangementAxis-UpFrontPaymentArrangementMember" unitRef="EUR" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" format="ixt:numdotdecimal" decimals="-7">30.0</ix:nonFraction>
<ix:nonFraction id="c96254030" contextRef="d_2022-01-01_2022-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_TypeOfArrangementAxis-CollaborativeArrangementMember" unitRef="EUR" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" format="ixt:numdotdecimal" decimals="-5">3.8</ix:nonFraction>
<ix:nonFraction id="c96254061" contextRef="d_2017-01-01_2017-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_ProductOrServiceAxis-LicenseMember_TypeOfArrangementAxis-UpFrontPaymentArrangementMember" unitRef="EUR" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" format="ixt:numdotdecimal" decimals="-7">30.0</ix:nonFraction>
<ix:nonFraction id="c96254106" contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember" unitRef="USD" name="us-gaap:CapitalizedContractCostAmortization" scale="6" format="ixt:numdotdecimal" decimals="-5">0.1</ix:nonFraction>
<ix:nonFraction id="c96254145" contextRef="i_2021-06-30" unitRef="EUR" name="us-gaap:GrantsReceivable" scale="6" format="ixt:numdotdecimal" decimals="-5">14.2</ix:nonFraction>
<ix:nonNumeric contextRef="d_2022-01-01_2022-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember_RangeAxis-MinimumMember" name="pirs:DebtSecuritiesAvailableforsaleContractualMaturityPeriod" id="c96254205" format="ixt-sec:durday">47</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2022-01-01_2022-12-31_FinancialInstrumentAxis-CorporateBondSecuritiesMember_RangeAxis-MaximumMember" name="pirs:DebtSecuritiesAvailableforsaleContractualMaturityPeriod" id="c96254241" format="ixt-sec:durday">228</ix:nonNumeric>
<ix:nonFraction id="c96254158" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" scale="6" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonNumeric contextRef="d_2022-01-01_2022-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember_IncomeTaxAuthorityNameAxis-InternalRevenueServiceIRSMember" name="us-gaap:OpenTaxYear" id="c96254311">2019 2020 2021 2022</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2022-01-01_2022-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember" name="us-gaap:OpenTaxYear" id="c96254312">2019 2020 2021 2022</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2022-01-01_2022-12-31_IncomeTaxAuthorityAxis-ForeignCountryMember" name="us-gaap:OpenTaxYear" id="c96254313">2014 2015 2016 2017</ix:nonNumeric>
<ix:nonFraction id="c96254330" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c96254518" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">300,000,000</ix:nonFraction>
<ix:nonFraction id="c96254519" contextRef="i_2022-12-31" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">74,519,103</ix:nonFraction>
<ix:nonFraction id="c96254520" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">72,222,661</ix:nonFraction>
<ix:nonFraction id="c96254521" contextRef="i_2021-12-31" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.001</ix:nonFraction>
<ix:nonFraction id="c96254522" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:PreferredStockSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">10,000,000</ix:nonFraction>
<ix:nonFraction id="c96254523" contextRef="i_2022-12-31" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">15,617</ix:nonFraction>
<ix:nonFraction id="c96254524" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">15,617</ix:nonFraction>
<ix:nonFraction id="c96254525" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:PreferredStockSharesIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">15,617</ix:nonFraction>
<ix:nonFraction id="c96254527" contextRef="i_2022-12-31_StatementClassOfStockAxis-SeriesAPreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">85</ix:nonFraction>
<ix:nonFraction id="c96254529" contextRef="i_2021-12-31_StatementClassOfStockAxis-SeriesAPreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">85</ix:nonFraction>
<ix:nonFraction id="c96254528" contextRef="i_2021-12-31_StatementClassOfStockAxis-SeriesAPreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">85</ix:nonFraction>
<ix:nonFraction id="c96254530" contextRef="i_2022-12-31_StatementClassOfStockAxis-SeriesBPreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">4,026</ix:nonFraction>
<ix:nonFraction id="c96254531" contextRef="i_2021-12-31_StatementClassOfStockAxis-SeriesBPreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">4,026</ix:nonFraction>
<ix:nonFraction id="c96254532" contextRef="i_2021-12-31_StatementClassOfStockAxis-SeriesBPreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">4,026</ix:nonFraction>
<ix:nonFraction id="c96254533" contextRef="i_2022-12-31_StatementClassOfStockAxis-SeriesCPreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">3,506</ix:nonFraction>
<ix:nonFraction id="c96254534" contextRef="i_2021-12-31_StatementClassOfStockAxis-SeriesCPreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">3,506</ix:nonFraction>
<ix:nonFraction id="c96254535" contextRef="i_2021-12-31_StatementClassOfStockAxis-SeriesCPreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">3,506</ix:nonFraction>
<ix:nonFraction id="c96254536" contextRef="i_2022-12-31_StatementClassOfStockAxis-SeriesDPreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">3,000</ix:nonFraction>
<ix:nonFraction id="c96254537" contextRef="i_2021-12-31_StatementClassOfStockAxis-SeriesDPreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">3,000</ix:nonFraction>
<ix:nonFraction id="c96254538" contextRef="i_2021-12-31_StatementClassOfStockAxis-SeriesDPreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">3,000</ix:nonFraction>
<ix:nonFraction id="c96254539" contextRef="i_2022-12-31_StatementClassOfStockAxis-SeriesEPreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">5,000</ix:nonFraction>
<ix:nonFraction id="c96254540" contextRef="i_2021-12-31_StatementClassOfStockAxis-SeriesEPreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">5,000</ix:nonFraction>
<ix:nonFraction id="c96254541" contextRef="i_2021-12-31_StatementClassOfStockAxis-SeriesEPreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">5,000</ix:nonFraction>
<ix:nonFraction id="c96254476" contextRef="d_2019-11-01_2019-11-30_StatementClassOfStockAxis-SeriesCPreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" scale="0" format="ixt:numdotdecimal" decimals="INF">1</ix:nonFraction>
<ix:nonFraction id="c96254478" contextRef="d_2019-11-01_2019-11-30_StatementClassOfStockAxis-SeriesCPreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="Share" name="pirs:SaleOfStockNumberOfWarrantsPerUnit" scale="0" format="ixt:numdotdecimal" decimals="INF">1</ix:nonFraction>
<ix:nonFraction id="c96254479" contextRef="i_2019-11-30_StatementClassOfStockAxis-SeriesCPreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" format="ixt:numdotdecimal" decimals="INF">1</ix:nonFraction>
<ix:nonFraction id="c96254489" contextRef="d_2019-11-01_2019-11-30_StatementClassOfStockAxis-SeriesCPreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="Pure" name="pirs:ConvertiblePreferredStockWeightedAverageStockPricePercent" scale="-2" format="ixt:numdotdecimal" decimals="2">3</ix:nonFraction>
<ix:nonNumeric contextRef="i_2019-11-30_RangeAxis-MaximumMember_StatementClassOfStockAxis-SeriesCPreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="c96254491" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonFraction id="c96254613" contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Pure" name="pirs:SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfPurchasePeriods" scale="0" format="ixt:numdotdecimal" decimals="INF">2</ix:nonFraction>
<ix:nonNumeric contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember" name="pirs:ShareBasedCompensationArrangementBySharebasedPaymentAwardPurchasePeriod" id="c96254614" format="ixt-sec:duryear">6</ix:nonNumeric>
<ix:footnote xml:lang="en-us" id="f603ef05d-fab0-47c7-b353-aeccab7aaca7">Variable lease costs include certain additional charges for operating costs, including insurance, maintenance, taxes, utilities,
and other costs incurred, which are billed based on both usage and as a percentage of the Company&#x2019;s share of total square
footage.</ix:footnote></ix:hidden>
<ix:references>
<link:schemaRef xlink:href="pirs-20221231.xsd" xlink:type="simple"></link:schemaRef></ix:references>
<ix:resources>
<xbrli:context id="d_2022-01-01_2022-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2022-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="Share"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2023-03-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-28</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="NonApplicable"><xbrli:measure>thunderdome:item</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2022-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="USDPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:context id="d_2021-01-01_2021-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementEquityComponentsAxis-ReceivablesFromStockholderMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-ReceivablesFromStockholderMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfPreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">pirs:ConversionOfPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfPreferredStockMember_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">pirs:ConversionOfPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfPreferredStockMember_StatementEquityComponentsAxis-ReceivablesFromStockholderMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">pirs:ConversionOfPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfPreferredStockMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">pirs:ConversionOfPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfPreferredStockMember_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">pirs:ConversionOfPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfPreferredStockMember_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">pirs:ConversionOfPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">pirs:ConversionOfPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesEPreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">pirs:ConversionOfSeriesEPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesEPreferredStockMember_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">pirs:ConversionOfSeriesEPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesEPreferredStockMember_StatementEquityComponentsAxis-ReceivablesFromStockholderMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">pirs:ConversionOfSeriesEPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesEPreferredStockMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">pirs:ConversionOfSeriesEPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesEPreferredStockMember_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">pirs:ConversionOfSeriesEPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesEPreferredStockMember_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">pirs:ConversionOfSeriesEPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesEPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">pirs:ConversionOfSeriesEPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pirs:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pirs:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pirs:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-ReceivablesFromStockholderMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pirs:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pirs:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pirs:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pirs:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-ReceivablesFromStockholderMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_StatementEquityComponentsAxis-ReceivablesFromStockholderMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-ReceivablesFromStockholderMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_StatementEquityComponentsAxis-PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_StatementEquityComponentsAxis-ReceivablesFromStockholderMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pirs:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="Pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2013-05-31_BusinessAcquisitionAxis-PierisPharmaceuticalsGmbhMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pirs:PierisPharmaceuticalsGmbhMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2013-05-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="Year"><xbrli:measure>utr:Y</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2022-01-01_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pirs:LaboratoryEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pirs:LaboratoryEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-OfficeEquipmentMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-OfficeEquipmentMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_CounterpartyNameAxis-AstraZenecaABMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:AstraZenecaABMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_CounterpartyNameAxis-AstraZenecaABMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:AstraZenecaABMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_CounterpartyNameAxis-SeattleGeneticsIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:SeattleGeneticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_CounterpartyNameAxis-SeattleGeneticsIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:SeattleGeneticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_CounterpartyNameAxis-GenentechMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:GenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_CounterpartyNameAxis-GenentechMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:GenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_CounterpartyNameAxis-BostonPharmaceuticalsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:BostonPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_CounterpartyNameAxis-BostonPharmaceuticalsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:BostonPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_CounterpartyNameAxis-AstraZenecaABMember_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-ResearchAndDevelopmentMilestonePaymentsMember_TypeOfArrangementAxis-CollaborativeArrangementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:AstraZenecaABMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pirs:ResearchAndDevelopmentMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_CounterpartyNameAxis-AstraZenecaABMember_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-SalesMilestonePaymentsMember_TypeOfArrangementAxis-CollaborativeArrangementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:AstraZenecaABMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pirs:SalesMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-ResearchAndDevelopmentMilestonePaymentsMember_TypeOfArrangementAxis-CollaborativeArrangementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pirs:ResearchAndDevelopmentMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-SalesMilestonePaymentsMember_TypeOfArrangementAxis-CollaborativeArrangementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pirs:SalesMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_CounterpartyNameAxis-SeattleGeneticsIncMember_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-ResearchAndDevelopmentMilestonePaymentsMember_TypeOfArrangementAxis-CollaborativeArrangementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:SeattleGeneticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pirs:ResearchAndDevelopmentMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_CounterpartyNameAxis-SeattleGeneticsIncMember_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-SalesMilestonePaymentsMember_TypeOfArrangementAxis-CollaborativeArrangementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:SeattleGeneticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pirs:SalesMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_CounterpartyNameAxis-BostonPharmaceuticalsMember_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-ResearchAndDevelopmentMilestonePaymentsMember_TypeOfArrangementAxis-CollaborativeArrangementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:BostonPharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pirs:ResearchAndDevelopmentMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_CounterpartyNameAxis-BostonPharmaceuticalsMember_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-SalesMilestonePaymentsMember_TypeOfArrangementAxis-CollaborativeArrangementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:BostonPharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pirs:SalesMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_CounterpartyNameAxis-GenentechMember_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-ResearchAndDevelopmentMilestonePaymentsMember_TypeOfArrangementAxis-CollaborativeArrangementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:GenentechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pirs:ResearchAndDevelopmentMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_CounterpartyNameAxis-GenentechMember_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-SalesMilestonePaymentsMember_TypeOfArrangementAxis-CollaborativeArrangementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:GenentechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pirs:SalesMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-ResearchAndDevelopmentMilestonePaymentsMember_TypeOfArrangementAxis-CollaborativeArrangementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pirs:ResearchAndDevelopmentMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-SalesMilestonePaymentsMember_TypeOfArrangementAxis-CollaborativeArrangementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pirs:SalesMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-05-19_CounterpartyNameAxis-GenentechMember_ProductOrServiceAxis-LicenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:GenentechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-19</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-05-19_CounterpartyNameAxis-GenentechMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:GenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-19</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-05-19_2021-05-19_CounterpartyNameAxis-GenentechMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:GenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-19</xbrli:startDate><xbrli:endDate>2021-05-19</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="Day"><xbrli:measure>utr:D</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2021-05-19_2021-05-19_CounterpartyNameAxis-GenentechMember_ProductOrServiceAxis-ResearchAndDevelopmentServicesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:GenentechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pirs:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-19</xbrli:startDate><xbrli:endDate>2021-05-19</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-05-19_CounterpartyNameAxis-GenentechMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:GenentechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pirs:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-19</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-05-19_CounterpartyNameAxis-GenentechMember_TypeOfArrangementAxis-PlatformTechnologyLicenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:GenentechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pirs:PlatformTechnologyLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-19</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-05-19_CounterpartyNameAxis-GenentechMember_TypeOfArrangementAxis-GovernanceCommitteeParticipationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:GenentechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pirs:GovernanceCommitteeParticipationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-19</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_CounterpartyNameAxis-GenentechMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:GenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_CounterpartyNameAxis-GenentechMember_ProductOrServiceAxis-LicenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:GenentechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-04-24_CounterpartyNameAxis-BPAssetsXIIIncMember_ProductOrServiceAxis-LicenseMember_TypeOfArrangementAxis-ExclusiveProductLicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:BPAssetsXIIIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pirs:ExclusiveProductLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-24</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-04-24_2021-04-24_CounterpartyNameAxis-BPAssetsXIIIncMember_ProductOrServiceAxis-LicenseMember_TypeOfArrangementAxis-ExclusiveProductLicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:BPAssetsXIIIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pirs:ExclusiveProductLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-24</xbrli:startDate><xbrli:endDate>2021-04-24</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="Month"><xbrli:measure>utr:M</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2021-04-24_CounterpartyNameAxis-BPAssetsXIIIncMember_ProductOrServiceAxis-LicenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:BPAssetsXIIIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-24</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_CounterpartyNameAxis-BPAssetsXIIIncMember_ProductOrServiceAxis-LicenseMember_TypeOfArrangementAxis-ExclusiveProductLicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:BPAssetsXIIIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pirs:ExclusiveProductLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2018-02-08_CounterpartyNameAxis-SeattleGeneticsIncMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:SeattleGeneticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pirs:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-02-08</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2018-02-08_CounterpartyNameAxis-SeattleGeneticsIncMember_TypeOfArrangementAxis-OtherArrangementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:SeattleGeneticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pirs:OtherArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-02-08</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2018-02-08_2018-02-08_CounterpartyNameAxis-SeattleGeneticsIncMember_ProductOrServiceAxis-LicenseMember_TypeOfArrangementAxis-UpFrontPaymentArrangementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:SeattleGeneticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:UpFrontPaymentArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-08</xbrli:startDate><xbrli:endDate>2018-02-08</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2018-02-08_2018-02-08_CounterpartyNameAxis-SeattleGeneticsIncMember_TypeOfArrangementAxis-UpFrontPaymentArrangementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:SeattleGeneticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:UpFrontPaymentArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-08</xbrli:startDate><xbrli:endDate>2018-02-08</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2018-02-08_2018-02-08_CounterpartyNameAxis-SeattleGeneticsIncMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:SeattleGeneticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pirs:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-08</xbrli:startDate><xbrli:endDate>2018-02-08</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2018-02-08_CounterpartyNameAxis-SeattleGeneticsIncMember_TypeOfArrangementAxis-PlatformTechnologyLicenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:SeattleGeneticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pirs:PlatformTechnologyLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-02-08</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2018-02-08_2018-02-08_CounterpartyNameAxis-SeattleGeneticsIncMember_TypeOfArrangementAxis-PlatformTechnologyLicenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:SeattleGeneticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pirs:PlatformTechnologyLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-08</xbrli:startDate><xbrli:endDate>2018-02-08</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2018-02-08_CounterpartyNameAxis-SeattleGeneticsIncMember_TypeOfArrangementAxis-AntibodyTargetSwapMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:SeattleGeneticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pirs:AntibodyTargetSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-02-08</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2018-02-08_CounterpartyNameAxis-SeattleGeneticsIncMember_TypeOfArrangementAxis-GovernanceCommitteeParticipationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:SeattleGeneticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pirs:GovernanceCommitteeParticipationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-02-08</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2018-02-08_CounterpartyNameAxis-SeattleGeneticsIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:SeattleGeneticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-02-08</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_CounterpartyNameAxis-SeattleGeneticsIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:SeattleGeneticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_CounterpartyNameAxis-SeattleGeneticsIncMember_TransactionTypeAxis-SalesMilestonePaymentsMember_TypeOfArrangementAxis-UpFrontPaymentArrangementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:SeattleGeneticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pirs:SalesMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:UpFrontPaymentArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-04-01_2020-06-30_CounterpartyNameAxis-SeattleGeneticsIncMember_TransactionTypeAxis-SalesMilestonePaymentsMember_TypeOfArrangementAxis-UpFrontPaymentArrangementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:SeattleGeneticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pirs:SalesMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:UpFrontPaymentArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-03-24_CounterpartyNameAxis-SeattleGeneticsIncMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:SeattleGeneticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pirs:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-24</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-03-24_2021-03-24_CounterpartyNameAxis-SeattleGeneticsIncMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:SeattleGeneticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-24</xbrli:startDate><xbrli:endDate>2021-03-24</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-03-24_CounterpartyNameAxis-SeattleGeneticsIncMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:SeattleGeneticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-24</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-03-24_2021-03-24_CounterpartyNameAxis-SeattleGeneticsIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:SeattleGeneticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-24</xbrli:startDate><xbrli:endDate>2021-03-24</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-04-01_2022-06-30_CounterpartyNameAxis-SeattleGeneticsIncMember_TransactionTypeAxis-SalesMilestonePaymentsMember_TypeOfArrangementAxis-UpFrontPaymentArrangementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:SeattleGeneticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pirs:SalesMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:UpFrontPaymentArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-01-31_CounterpartyNameAxis-SeattleGeneticsIncMember_SubsequentEventTypeAxis-SubsequentEventMember_TypeOfArrangementAxis-CollaborativeArrangementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:SeattleGeneticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_CounterpartyNameAxis-SeattleGeneticsIncMember_TypeOfArrangementAxis-CollaborativeArrangementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:SeattleGeneticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2017-05-02_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:AstraZenecaABMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pirs:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-02</xbrli:startDate><xbrli:endDate>2017-05-02</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_RangeAxis-MinimumMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:AstraZenecaABMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pirs:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-02</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:AstraZenecaABMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pirs:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-02</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2017-05-02_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:AstraZenecaABMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pirs:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-02</xbrli:startDate><xbrli:endDate>2017-05-02</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2017-05-02_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_TypeOfArrangementAxis-UpFrontPaymentArrangementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:AstraZenecaABMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:UpFrontPaymentArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-02</xbrli:startDate><xbrli:endDate>2017-05-02</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2017-05-02_2017-05-02"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-02</xbrli:startDate><xbrli:endDate>2017-05-02</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:AstraZenecaABMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pirs:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-02</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2017-05-02_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_TransactionTypeAxis-EstimatedDevelopmentAndManufacturingServicesMember_TypeOfArrangementAxis-UpFrontPaymentArrangementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:AstraZenecaABMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pirs:EstimatedDevelopmentAndManufacturingServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:UpFrontPaymentArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-02</xbrli:startDate><xbrli:endDate>2017-05-02</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2017-05-02_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_TransactionTypeAxis-SalesMilestonePaymentsMember_TypeOfArrangementAxis-UpFrontPaymentArrangementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:AstraZenecaABMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pirs:SalesMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:UpFrontPaymentArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-02</xbrli:startDate><xbrli:endDate>2017-05-02</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2017-05-02_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_TransactionTypeAxis-EstimatedPhase2aServicesMember_TypeOfArrangementAxis-UpFrontPaymentArrangementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:AstraZenecaABMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pirs:EstimatedPhase2aServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:UpFrontPaymentArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-02</xbrli:startDate><xbrli:endDate>2017-05-02</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2017-05-02_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_TypeOfArrangementAxis-AdditionalOtherResearchServicesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:AstraZenecaABMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pirs:AdditionalOtherResearchServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-02</xbrli:startDate><xbrli:endDate>2017-05-02</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2017-05-02_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:AstraZenecaABMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-02</xbrli:startDate><xbrli:endDate>2017-05-02</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_CounterpartyNameAxis-AstraZenecaABMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:AstraZenecaABMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-04-01_2021-04-01_CounterpartyNameAxis-AstraZenecaABMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:AstraZenecaABMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-01</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-04-01_CounterpartyNameAxis-AstraZenecaABMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:AstraZenecaABMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-01</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-04-01_2021-04-01_CounterpartyNameAxis-AstraZenecaABMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:AstraZenecaABMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-01</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-03-01_2021-03-31_CounterpartyNameAxis-AstraZenecaABMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:AstraZenecaABMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-01-31_CounterpartyNameAxis-AstraZenecaABMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:AstraZenecaABMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-01-31_CounterpartyNameAxis-AstraZenecaABMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:AstraZenecaABMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-08-01_2022-08-31_CounterpartyNameAxis-AstraZenecaABMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:AstraZenecaABMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:AstraZenecaABMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-02</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-01-01_CounterpartyNameAxis-AstraZenecaABMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:AstraZenecaABMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-01</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2017-01-01_2017-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pirs:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2017-01-01_2017-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="EUR"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2017-01-01_2017-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_ProductOrServiceAxis-LicenseMember_TypeOfArrangementAxis-UpFrontPaymentArrangementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:UpFrontPaymentArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_TypeOfArrangementAxis-CollaborativeArrangementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2017-01-01_2017-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_ProductOrServiceAxis-ResearchAndDevelopmentServicesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pirs:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2017-01-01_2017-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_RangeAxis-MinimumMember_TypeOfArrangementAxis-CollaborativeArrangementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2017-01-01_2017-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-CollaborativeArrangementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2017-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2017-01-04_2017-01-04_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_TypeOfArrangementAxis-CollaborativeArrangementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-04</xbrli:startDate><xbrli:endDate>2017-01-04</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2017-01-04_2017-01-04_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-04</xbrli:startDate><xbrli:endDate>2017-01-04</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2017-01-04_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pirs:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-01-04</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2017-01-04_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_TypeOfArrangementAxis-CollaborativeArrangementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-01-04</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-02-01_2020-02-29_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-29</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-02-29_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-02-29_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_TypeOfArrangementAxis-CodevelopmentCollaborationProductCollaborationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pirs:CodevelopmentCollaborationProductCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-02-29_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_TypeOfArrangementAxis-ServierDevelopedCollaborationProductsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pirs:ServierDevelopedCollaborationProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-03-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-10-01_2022-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-01-01_AdjustmentsForChangeInAccountingPrincipleAxis-AccountingStandardsUpdate201409Member_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForChangeInAccountingPrincipleAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-01</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_FinancialInstrumentAxis-MoneyMarketFundsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FinancialInstrumentAxis-MoneyMarketFundsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FinancialInstrumentAxis-MoneyMarketFundsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FinancialInstrumentAxis-MoneyMarketFundsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FinancialInstrumentAxis-USTreasurySecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FinancialInstrumentAxis-USTreasurySecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FinancialInstrumentAxis-USTreasurySecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_FinancialInstrumentAxis-ForeignGovernmentDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FinancialInstrumentAxis-ForeignGovernmentDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FinancialInstrumentAxis-ForeignGovernmentDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FinancialInstrumentAxis-ForeignGovernmentDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_FinancialInstrumentAxis-AssetBackedSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FinancialInstrumentAxis-AssetBackedSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FinancialInstrumentAxis-AssetBackedSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FinancialInstrumentAxis-AssetBackedSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_FinancialInstrumentAxis-CorporateBondSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FinancialInstrumentAxis-CorporateBondSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FinancialInstrumentAxis-CorporateBondSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FinancialInstrumentAxis-CorporateBondSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_FinancialInstrumentAxis-MoneyMarketFundsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FinancialInstrumentAxis-MoneyMarketFundsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FinancialInstrumentAxis-MoneyMarketFundsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FinancialInstrumentAxis-MoneyMarketFundsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_FinancialInstrumentAxis-ForeignGovernmentDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_FinancialInstrumentAxis-AssetBackedSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_FinancialInstrumentAxis-CorporateBondSecuritiesMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pirs:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pirs:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-OfficeEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-OfficeEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_BalanceSheetLocationAxis-AccruedLiabilitiesAndOtherCurrentLiabilitiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pirs:AccruedLiabilitiesAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_BalanceSheetLocationAxis-AccruedLiabilitiesAndOtherCurrentLiabilitiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pirs:AccruedLiabilitiesAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember_IncomeTaxAuthorityNameAxis-InternalRevenueServiceIRSMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_IncomeTaxAuthorityAxis-ForeignCountryMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_IncomeTaxAuthorityAxis-ForeignCountryMember_TaxCreditCarryforwardAxis-CorporateIncomeTaxMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">pirs:CorporateIncomeTaxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_IncomeTaxAuthorityAxis-ForeignCountryMember_TaxCreditCarryforwardAxis-TradeTaxMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">pirs:TradeTaxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_StatementClassOfStockAxis-SeriesAPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_StatementClassOfStockAxis-SeriesAPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_StatementClassOfStockAxis-SeriesBPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_StatementClassOfStockAxis-SeriesBPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_StatementClassOfStockAxis-SeriesCPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_StatementClassOfStockAxis-SeriesCPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_StatementClassOfStockAxis-SeriesDPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_StatementClassOfStockAxis-SeriesDPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_StatementClassOfStockAxis-SeriesEPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_StatementClassOfStockAxis-SeriesEPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-05-20_StatementClassOfStockAxis-SeriesAThroughEMember_StatementEquityComponentsAxis-PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pirs:SeriesAThroughEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-20</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-05-20_2021-05-20_StatementClassOfStockAxis-SeriesAThroughEMember_StatementEquityComponentsAxis-PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pirs:SeriesAThroughEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-20</xbrli:startDate><xbrli:endDate>2021-05-20</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2016-06-01_2016-06-30_SubsidiarySaleOfStockAxis-SecuritiesPurchaseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pirs:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-06-01</xbrli:startDate><xbrli:endDate>2016-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2016-06-30_SubsidiarySaleOfStockAxis-SecuritiesPurchaseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pirs:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-30_2019-01-30_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-StockExchangeSharesFromExistingShareholdersMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pirs:StockExchangeSharesFromExistingShareholdersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-30</xbrli:startDate><xbrli:endDate>2019-01-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-30_2019-01-30_StatementEquityComponentsAxis-PreferredStockMember_SubsidiarySaleOfStockAxis-PreferredShareExchangeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pirs:PreferredShareExchangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-30</xbrli:startDate><xbrli:endDate>2019-01-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-11-01_2019-11-30_StatementClassOfStockAxis-SeriesCPreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-11-30_StatementClassOfStockAxis-SeriesCPreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-11-30_RangeAxis-MaximumMember_StatementClassOfStockAxis-SeriesCPreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-11-30_StatementClassOfStockAxis-SeriesCPreferredStockMember_SubsidiarySaleOfStockAxis-PreferredShareExchangeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pirs:PreferredShareExchangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-11-01_2019-11-30_StatementClassOfStockAxis-SeriesCPreferredStockMember_SubsidiarySaleOfStockAxis-PreferredShareExchangeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pirs:PreferredShareExchangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-04-01_2020-04-01_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pirs:EmployeeDirectorAndConsultantEquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-01</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-05-20_2021-05-20_ConversionOfStockByUniqueDescriptionAxis-ConversionOfCommonStockIntoSeriesEPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">pirs:ConversionOfCommonStockIntoSeriesEPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-20</xbrli:startDate><xbrli:endDate>2021-05-20</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-08-01_2019-08-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-08-31_LegalEntityAxis-JefferiesLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">pirs:JefferiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-08-01_2021-08-31_LegalEntityAxis-JefferiesLLCMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">pirs:JefferiesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pirs:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-11-01_2022-11-30_LegalEntityAxis-JefferiesLLCMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">pirs:JefferiesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pirs:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pirs:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_LegalEntityAxis-JefferiesLLCMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">pirs:JefferiesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pirs:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_LegalEntityAxis-JefferiesLLCMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">pirs:JefferiesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pirs:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_LegalEntityAxis-JefferiesLLCMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">pirs:JefferiesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pirs:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_LegalEntityAxis-JefferiesLLCMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">pirs:JefferiesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pirs:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-06-23_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pirs:EmployeeDirectorAndConsultantEquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-23</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-06-25_2021-06-25_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pirs:EmployeeDirectorAndConsultantEquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-25</xbrli:startDate><xbrli:endDate>2021-06-25</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-06-25_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pirs:EmployeeDirectorAndConsultantEquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-25</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-06-22_2022-06-22_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pirs:EmployeeDirectorAndConsultantEquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-22</xbrli:startDate><xbrli:endDate>2022-06-22</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-06-22_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pirs:EmployeeDirectorAndConsultantEquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-22</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pirs:EmployeeDirectorAndConsultantEquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pirs:EmployeeDirectorAndConsultantEquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pirs:EmployeeDirectorAndConsultantEquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_TitleOfIndividualAxis-ExecutiveOfficersAndManagementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">pirs:ExecutiveOfficersAndManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_TitleOfIndividualAxis-ExecutiveOfficersAndManagementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">pirs:ExecutiveOfficersAndManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_TitleOfIndividualAxis-ExecutiveOfficersAndManagementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">pirs:ExecutiveOfficersAndManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="SquareFoot"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2015-08-31_LeaseContractualTermAxis-SubleaseOfficeSpaceMember_StatementGeographicalAxis-BostonMassachusettsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">pirs:SubleaseOfficeSpaceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pirs:BostonMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-08-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-02-29_LeaseContractualTermAxis-OfficeAndLaboratorySpaceMember_StatementGeographicalAxis-HallbergmoosGermanyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">pirs:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pirs:HallbergmoosGermanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-02-29_PropertyPlantAndEquipmentByTypeAxis-LeasesExpectedToBeDeliveredByOctober2024Member_StatementGeographicalAxis-HallbergmoosGermanyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pirs:LeasesExpectedToBeDeliveredByOctober2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pirs:HallbergmoosGermanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-02-29_PropertyPlantAndEquipmentByTypeAxis-LeasesWithFirstRightOfRefusalForAdditionalAreaMember_StatementGeographicalAxis-HallbergmoosGermanyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pirs:LeasesWithFirstRightOfRefusalForAdditionalAreaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pirs:HallbergmoosGermanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-02-29_StatementGeographicalAxis-HallbergmoosGermanyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pirs:HallbergmoosGermanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-02-29_2020-02-29_LeaseContractualTermAxis-OfficeAndLaboratorySpaceMember_StatementGeographicalAxis-HallbergmoosGermanyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">pirs:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pirs:HallbergmoosGermanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-29</xbrli:startDate><xbrli:endDate>2020-02-29</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-02-01_2020-02-29_LeaseContractualTermAxis-OfficeAndLaboratorySpaceMember_StatementGeographicalAxis-HallbergmoosGermanyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">pirs:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pirs:HallbergmoosGermanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-29</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-03-31_LeaseContractualTermAxis-OfficeAndLaboratorySpaceMember_StatementGeographicalAxis-HallbergmoosGermanyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001583648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">pirs:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pirs:HallbergmoosGermanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="f603ef05d-fab0-47c7-b353-aeccab7aaca7" fromRefs="c96254821 c96254822"></ix:relationship></ix:resources>
</ix:header></div>
  <div>
    &#xa0;
  </div>
  <div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xfeff;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><a href="#toc" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt">Table of Contents</a></p>
<hr style="height: 3px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0" />
<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 0 0 3pt 0" />
<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:18pt;font-variant:normal;text-align:center;margin:0pt;"><b>UNITED STATES</b></p>
<p style="font-family:Times New Roman;font-size:18pt;font-variant:normal;text-align:center;margin:0pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Washington, D.C. 20549</b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#xa0;</p>
<hr style="text-align: center; height: 3px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto" />
<p style="font-family:Times New Roman;font-size:18pt;font-variant:normal;text-align:center;margin:0pt;"><b>FORM <ix:nonNumeric name="dei:DocumentType" contextRef="d_2022-01-01_2022-12-31">10-K</ix:nonNumeric></b></p>
<hr style="text-align: center; height: 3px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto" />
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 5pt 0pt; text-indent: 0pt;"><b>(Mark One)</b></p>
<table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 12pt; width: 100%; margin-left: 0pt; margin-right: 0pt;"><tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 12pt;"><td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 12pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 12pt; font-variant: normal; margin: 0pt;"><ix:nonNumeric name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" contextRef="d_2022-01-01_2022-12-31">&#x2612;</ix:nonNumeric></p> </td><td style="vertical-align: top; width: 90%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 12pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 12pt; font-variant: normal; text-align: center; margin: 0pt;"><b>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p> </td><td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 12pt;">&#xa0;</td></tr>
</tbody></table>
<p style="font-family: Times New Roman; font-size: 9pt; font-variant: normal; text-align: center; margin: 5pt 0pt; text-indent: 0pt;"><b>For the fiscal year ended <ix:nonNumeric name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen" contextRef="d_2022-01-01_2022-12-31">December 31, 2022</ix:nonNumeric></b></p>
<p style="font-family: Times New Roman; font-size: 9pt; font-variant: normal; text-align: center; margin: 5pt 0pt; text-indent: 0pt;"><b>OR</b></p>
<table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 12pt; width: 100%; margin-left: 0pt; margin-right: 0pt;"><tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 12pt;"><td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 12pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 12pt; font-variant: normal; margin: 0pt;"><ix:nonNumeric name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" contextRef="d_2022-01-01_2022-12-31">&#x2610;</ix:nonNumeric></p> </td><td style="vertical-align: top; width: 90%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 12pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 12pt; font-variant: normal; text-align: center; margin: 0pt;"><b>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p> </td><td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 12pt;">&#xa0;</td></tr>
</tbody></table>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 5pt 0pt; text-indent: 0pt;"><b>For the transition period from </b><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><b> to </b><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">&#xa0;</span></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 5pt 0pt; text-align: center; text-indent: 0pt;"><b>Commission file number: <ix:nonNumeric name="dei:EntityFileNumber" contextRef="d_2022-01-01_2022-12-31">001-37471</ix:nonNumeric></b></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#xa0;</p>
<hr style="text-align: center; height: 3px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto" />
<p style="font-family:Times New Roman;font-size:24pt;font-variant:normal;text-align:center;margin:0pt;"><b>PIERIS PHARMACEUTICALS, INC.</b></p>
<p style="font-family: Times New Roman; font-size: 9pt; font-variant: normal; text-align: center; margin: 5pt 0pt; text-indent: 0pt;"><b>(Exact name of registrant as specified in its charter)</b></p>
<hr style="text-align: center; height: 3px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto" />
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 100%; margin-left: 0pt; margin-right: 0pt;"><tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" contextRef="d_2022-01-01_2022-12-31">Nevada</ix:nonNumeric></b></p> </td><td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>EIN <ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="d_2022-01-01_2022-12-31">30-0784346</ix:nonNumeric></b></p> </td></tr>
<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(State or other jurisdiction of</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;"><b>incorporation or organization)</b></p> </td><td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(I.R.S. Employer</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Identification No.)</b></p> </td></tr>
<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="d_2022-01-01_2022-12-31">225&#xa0;Franklin&#xa0;Street, 26th Floor</ix:nonNumeric></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="d_2022-01-01_2022-12-31">Boston</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="d_2022-01-01_2022-12-31">MA</ix:nonNumeric></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>United States</b></p> </td><td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="d_2022-01-01_2022-12-31">02110</ix:nonNumeric></b></p> </td></tr>
<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Address of principal executive offices)</b></p> </td><td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Zip Code)</b></p> </td></tr>
</tbody></table>
<p style="font-family: Times New Roman; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Registrant</b>&#x2019;<b>s telephone number, including area code</b></p>
<p style="font-family: Times New Roman; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><ix:nonNumeric name="dei:CityAreaCode" contextRef="d_2022-01-01_2022-12-31">857</ix:nonNumeric>-<ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="d_2022-01-01_2022-12-31">246-8998</ix:nonNumeric></b></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
<p style="font-family: Times New Roman; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Securities registered pursuant to Section</b>&#xa0;<b>12(b) of the Exchange Act:</b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 100%; margin-left: 0pt; margin-right: 0pt;"><tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="vertical-align: bottom; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><span style="text-decoration: underline; ">Title of each class</span></b></p> </td><td style="vertical-align: bottom; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Trading Symbol(s)</b></p> </td><td style="vertical-align: bottom; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><span style="text-decoration: underline; ">Name of each exchange on which registered</span></b></p> </td></tr>
<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><ix:nonNumeric name="dei:Security12bTitle" contextRef="d_2022-01-01_2022-12-31">Common Stock, par value $0.001 per share</ix:nonNumeric></b></p> </td><td style="vertical-align: bottom; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><ix:nonNumeric name="dei:TradingSymbol" contextRef="d_2022-01-01_2022-12-31">PIRS</ix:nonNumeric></b></p> </td><td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>The <ix:nonNumeric name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" contextRef="d_2022-01-01_2022-12-31">Nasdaq</ix:nonNumeric> Stock Market LLC</b></p> </td></tr>
</tbody></table>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#xa0;</p>
<p style="font-family: Times New Roman; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Securities registered pursuant to Section</b>&#xa0;<b>12(g) of the Act:</b></p>
<p style="font-family: Times New Roman; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>None</b></p>
<p style="font-family: Times New Roman; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Title of class)</b></p>
<hr style="text-align: center; height: 3px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto" />
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt 0pt 4pt; text-indent: 18pt; text-align: left;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#xa0;&#xa0;&#xa0;&#xa0;Yes&#xa0;&#xa0;&#x2610;&#xa0;&#xa0;&#xa0;&#xa0;<ix:nonNumeric name="dei:EntityWellKnownSeasonedIssuer" contextRef="d_2022-01-01_2022-12-31">No</ix:nonNumeric>&#xa0;&#xa0;&#x2612;</p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 4pt; text-indent: 18pt; text-align: left;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#xa0;13 or Section&#xa0;15(d) of the Act. &#xa0;&#xa0;&#xa0;&#xa0;Yes&#xa0;&#xa0;&#x2610;&#xa0;&#xa0;&#xa0;&#xa0;<ix:nonNumeric name="dei:EntityVoluntaryFilers" contextRef="d_2022-01-01_2022-12-31">No</ix:nonNumeric>&#xa0;&#xa0;&#x2612;</p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 4pt; text-indent: 18pt; text-align: left;">Indicate by check mark whether the registrant (1)&#xa0;has filed all reports required to be filed by Section&#xa0;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#xa0;has been subject to such filing requirements for the past 90 days.&#xa0;&#xa0;&#xa0;&#xa0;<ix:nonNumeric name="dei:EntityCurrentReportingStatus" contextRef="d_2022-01-01_2022-12-31">Yes</ix:nonNumeric>&#xa0;&#x2612; No&#xa0;&#xa0;&#x2610;</p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 4pt; text-indent: 18pt; text-align: left;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#xa7; 232.405) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#xa0;&#xa0;&#xa0;&#xa0;<ix:nonNumeric name="dei:EntityInteractiveDataCurrent" contextRef="d_2022-01-01_2022-12-31">Yes</ix:nonNumeric>&#xa0;&#xa0;&#xa0;&#x2612; No&#xa0;&#xa0;&#x2610;</p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 4pt; text-indent: 18pt; text-align: left;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#x201c;large accelerated filer,&#x201d; &#x201c;accelerated filer,&#x201d; &#x201c;smaller reporting company,&#x201d; and &#x201c;emerging growth company&#x201d; in Rule 12b-2 of the Exchange Act.</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-family: Times New Roman; font-size: 9pt; width: 100%; margin-left: auto; margin-right: auto;"><tbody><tr style="font-size: 9pt;"><td style="vertical-align: bottom; width: 26.6%; font-size: 9pt;"> <p style="font-family: Times New Roman; font-size: 9pt; font-variant: normal; margin: 0pt;">Large&#xa0;accelerated&#xa0;filer</p> </td><td style="vertical-align: bottom; width: 0.7%; font-size: 9pt;">&#xa0;</td><td style="vertical-align: bottom; width: 39.8%; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#x2610;</p> </td><td style="vertical-align: bottom; width: 0.7%; font-size: 9pt;">&#xa0;</td><td style="vertical-align: bottom; width: 26.6%; font-size: 9pt;"> <p style="font-family: Times New Roman; font-size: 9pt; font-variant: normal; margin: 0pt;">Accelerated filer</p> </td><td style="vertical-align: bottom; width: 0.7%; font-size: 9pt;">&#xa0;</td><td style="vertical-align: bottom; width: 5.3%; font-size: 9pt;">&#x2610;</td></tr>
<tr style="font-size: 9pt;"><td style="vertical-align: bottom; width: 26.6%; font-size: 9pt;">&#xa0;</td><td colspan="2" style="vertical-align: bottom; width: 40.6%; font-size: 9pt;">&#xa0;</td><td colspan="2" style="vertical-align: bottom; width: 27.3%; font-size: 9pt;">&#xa0;</td><td colspan="2" style="vertical-align: bottom; width: 6%; font-size: 9pt;">&#xa0;</td></tr>
<tr style="font-size: 9pt;"><td style="vertical-align: bottom; width: 26.6%; font-size: 9pt;"> <p style="font-family: Times New Roman; font-size: 9pt; font-variant: normal; margin: 0pt;"><ix:nonNumeric name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" contextRef="d_2022-01-01_2022-12-31">Non-accelerated filer</ix:nonNumeric></p> </td><td style="vertical-align: bottom; width: 0.7%; font-size: 9pt;">&#xa0;</td><td style="vertical-align: bottom; width: 39.8%; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#x2612;</p> </td><td style="vertical-align: bottom; width: 0.7%; font-size: 9pt;">&#xa0;</td><td style="vertical-align: bottom; width: 26.6%; font-size: 9pt;"> <p style="font-family: Times New Roman; font-size: 9pt; font-variant: normal; margin: 0pt;">Smaller&#xa0;reporting&#xa0;company</p> </td><td style="vertical-align: bottom; width: 0.7%; font-size: 9pt;">&#xa0;</td><td style="vertical-align: bottom; width: 5.3%; font-size: 9pt;"><ix:nonNumeric name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" contextRef="d_2022-01-01_2022-12-31">&#x2612;</ix:nonNumeric></td></tr>
<tr style="font-size: 9pt;"><td style="vertical-align: bottom; width: 26.6%; font-size: 9pt;">&#xa0;</td><td style="vertical-align: bottom; width: 0.7%; font-size: 9pt;">&#xa0;</td><td style="vertical-align: bottom; width: 39.8%; font-size: 9pt;">&#xa0;</td><td style="vertical-align: bottom; width: 0.7%; font-size: 9pt;">&#xa0;</td><td style="vertical-align: bottom; width: 26.6%; font-size: 9pt;">&#xa0;</td><td style="vertical-align: bottom; width: 0.7%; font-size: 9pt;">&#xa0;</td><td style="vertical-align: bottom; width: 5.3%; font-size: 9pt;">&#xa0;</td></tr>
<tr style="font-size: 9pt;"><td style="vertical-align: bottom; width: 26.6%; font-size: 9pt;"> <p style="font-family: Times New Roman; font-size: 9pt; font-variant: normal; margin: 0pt;">Emerging growth company</p> </td><td style="vertical-align: bottom; width: 0.7%; font-size: 9pt;">&#xa0;</td><td style="vertical-align: bottom; width: 39.8%; font-size: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" contextRef="d_2022-01-01_2022-12-31">&#x2610;</ix:nonNumeric></p> </td><td style="vertical-align: bottom; width: 0.7%; font-size: 9pt;">&#xa0;</td><td style="vertical-align: bottom; width: 26.6%; font-size: 9pt;">&#xa0;</td><td style="vertical-align: bottom; width: 0.7%; font-size: 9pt;">&#xa0;</td><td style="vertical-align: bottom; width: 5.3%; font-size: 9pt;">&#xa0;</td></tr>
</tbody></table>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
 <div class="PGFTR" style="text-align: center; width: 100%">
  <div class="hf-row">
   <div class="hf-cell PGNUM">
    &#xa0;
   </div>
  </div>
 </div>
 <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
 <div class="PGHDR" style="text-align: left; width: 100%">
  <div class="hf-row">
   <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
    <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
   </div>
  </div>
 </div>
</div>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
<p style="font-family: Times New Roman; font-size: 9pt; font-variant: normal; margin: 0pt 0pt 4pt; text-indent: 18pt; text-align: left;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#x2610;</p>
<p style="font-family: Times New Roman; font-size: 9pt; font-variant: normal; margin: 0pt 0pt 4pt; text-indent: 18pt; text-align: left;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#x2019;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. <ix:nonNumeric name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox" contextRef="d_2022-01-01_2022-12-31">&#x2610;</ix:nonNumeric></p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt 0pt 4pt; text-indent: 18pt; text-align: left;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.</p>
<div style="font-size: 10pt;">
 &#x2610;
</div>
<p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-variant: normal; margin: 0pt 0pt 4pt; text-indent: 18pt; text-align: left;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to &#xa7; 240.10D-1(b).</p>
<div style="font-size: 10pt;">
 &#x2610;
</div>
<p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#xa0;</p>
<p style="font-family: Times New Roman; font-size: 9pt; font-variant: normal; margin: 0pt 0pt 4pt; text-indent: 18pt; text-align: left;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#xa0;&#xa0;&#xa0;&#xa0;Yes&#xa0;&#xa0;<ix:nonNumeric name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" contextRef="d_2022-01-01_2022-12-31">&#x2610;</ix:nonNumeric>&#xa0;&#xa0;&#xa0;&#xa0;No&#xa0;&#xa0;&#x2612;</p>
<p style="font-family: Times New Roman; font-size: 9pt; font-variant: normal; margin: 0pt 0pt 4pt; text-indent: 18pt; text-align: left;">The aggregate market value of the registrant's common stock held by non-affiliates of the registrant on June 30, 2022, the last business day of the registrant&#x2019;s most recently completed second fiscal quarter, based on the closing price on that date of $1.87, was $<ix:nonFraction name="dei:EntityPublicFloat" scale="0" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="i_2022-06-30">114,087,344</ix:nonFraction>.</p>
<p style="font-family: Times New Roman; font-size: 9pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">&#xa0;</p>
<p style="font-family: Times New Roman; font-size: 9pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">As of March 28, 2023, the registrant had <ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="Share" decimals="INF" format="ixt:numdotdecimal" contextRef="i_2023-03-28">74,519,103</ix:nonFraction> shares of common stock outstanding.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt 0pt 5pt; text-indent: 0pt;"><b>DOCUMENTS INCORPORATED BY REFERENCE</b></p>
<p style="font-family: Times New Roman; font-size: 9pt; font-variant: normal; margin: 0pt 0pt 4pt; text-indent: 18pt; text-align: left;">Certain information required in Part III of this Annual Report on Form 10-K is incorporated from the Registrant&#x2019;s Proxy Statement for the&#xa0;2023 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission.</p>
<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0" />
<hr style="height: 3px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 0 0 3pt 0" />
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
 <div class="PGFTR" style="text-align: center; width: 100%">
  <div class="hf-row">
   <div class="hf-cell PGNUM">
    &#xa0;
   </div>
  </div>
 </div>
 <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
 <div class="PGHDR" style="text-align: left; width: 100%">
  <div class="hf-row">
   <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
    <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
   </div>
  </div>
 </div>
</div>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p></div>
  <div>
    &#xa0;
  </div>
  <div>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="toc" title="toc" href="#"></a>TABLE OF CONTENTS</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
    <tbody>
     <tr>
      <td style="vertical-align: bottom; width: 92%;">&#xa0;</td>
      <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Page</b></p> </td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 92%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#parti" style="-sec-extract:exhibit;">PART I</a></p> </td>
      <td style="vertical-align: bottom; width: 8%;">&#xa0;</td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 92%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#parti" style="-sec-extract:exhibit;">Item&#xa0;1. Business</a></p> </td>
      <td style="vertical-align: bottom; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#parti">5</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 92%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#a1a" style="-sec-extract:exhibit;">Item&#xa0;1A. Risk Factors</a></p> </td>
      <td style="vertical-align: bottom; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#a1a">46</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 92%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#a1b" style="-sec-extract:exhibit;">Item&#xa0;1B. Unresolved Staff Comments</a></p> </td>
      <td style="vertical-align: bottom; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#a1b">92</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 92%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#a2" style="-sec-extract:exhibit;">Item&#xa0;2. Properties</a></p> </td>
      <td style="vertical-align: bottom; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#a2">92</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 92%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#a3" style="-sec-extract:exhibit;">Item&#xa0;3. Legal Proceedings</a></p> </td>
      <td style="vertical-align: bottom; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#a3">92</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 92%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#a4" style="-sec-extract:exhibit;">Item&#xa0;4. Mine Safety Disclosures</a></p> </td>
      <td style="vertical-align: bottom; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#a4">92</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align: bottom; width: 92%;">&#xa0;</td>
      <td style="vertical-align: bottom; width: 8%;">&#xa0;</td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 92%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#partii" style="-sec-extract:exhibit;">PART II</a></p> </td>
      <td style="vertical-align: bottom; width: 8%;">&#xa0;</td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 92%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#a5" style="-sec-extract:exhibit;">Item 5. Market for Registrant&#x2019;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></p> </td>
      <td style="vertical-align: bottom; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#a5">93</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 92%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#a6" style="-sec-extract:exhibit;">Item&#xa0;6. [Reserved]</a></p> </td>
      <td style="vertical-align: bottom; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#a6">93</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 92%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#a7" style="-sec-extract:exhibit;">Item&#xa0;7. Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</a></p> </td>
      <td style="vertical-align: bottom; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#a7">94</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 92%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#a7a" style="-sec-extract:exhibit;">Item&#xa0;7A. Quantitative and Qualitative Disclosures About Market Risk</a></p> </td>
      <td style="vertical-align: bottom; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#a7a">104</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 92%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#a8" style="-sec-extract:exhibit;">Item&#xa0;8. Financial Statements and Supplementary Data</a></p> </td>
      <td style="vertical-align: bottom; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#a8">104</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 92%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#a9" style="-sec-extract:exhibit;">Item&#xa0;9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></p> </td>
      <td style="vertical-align: bottom; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#a9">104</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 92%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#a9a" style="-sec-extract:exhibit;">Item&#xa0;9A. Controls and Procedures</a></p> </td>
      <td style="vertical-align: bottom; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#a9a">104</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 92%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#a9b" style="-sec-extract:exhibit;">Item&#xa0;9B. Other Information</a></p> </td>
      <td style="vertical-align: bottom; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#a9b">105</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 92%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#a9c" style="-sec-extract:exhibit;">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></p> </td>
      <td style="vertical-align: bottom; width: 8%; text-align: right;"><a class="tocPGNUM" href="#a9c">105</a></td>
     </tr>

     <tr>
      <td style="vertical-align: bottom; width: 92%;">&#xa0;</td>
      <td style="vertical-align: bottom; width: 8%;">&#xa0;</td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 92%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#partiii" style="-sec-extract:exhibit;">PART III</a></p> </td>
      <td style="vertical-align: bottom; width: 8%;">&#xa0;</td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 92%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#a10" style="-sec-extract:exhibit;">Item&#xa0;10. Directors, Executive Officers and Corporate Governance</a></p> </td>
      <td style="vertical-align: bottom; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#a10">106</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 92%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#a11" style="-sec-extract:exhibit;">Item&#xa0;11. Executive Compensation</a></p> </td>
      <td style="vertical-align: bottom; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#a11">106</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 92%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#a12" style="-sec-extract:exhibit;">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></p> </td>
      <td style="vertical-align: bottom; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#a12">106</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 92%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#a13" style="-sec-extract:exhibit;">Item&#xa0;13. Certain Relationships and Related Transactions, and Director Independence</a></p> </td>
      <td style="vertical-align: bottom; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#a13">106</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 92%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#a14" style="-sec-extract:exhibit;">Item&#xa0;14. Principal Accountant Fees and Services</a></p> </td>
      <td style="vertical-align: bottom; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#a14">106</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align: bottom; width: 92%;">&#xa0;</td>
      <td style="vertical-align: bottom; width: 8%;">&#xa0;</td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 92%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#partiv" style="-sec-extract:exhibit;">PART IV</a></p> </td>
      <td style="vertical-align: bottom; width: 8%;">&#xa0;</td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 92%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#a15" style="-sec-extract:exhibit;">Item&#xa0;15. Exhibits and Financial Statement Schedules</a></p> </td>
      <td style="vertical-align: bottom; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#a15">107</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 92%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#a16summary" style="-sec-extract:exhibit;">Item&#xa0;16. Form 10-K Summary</a></p> </td>
      <td style="vertical-align: bottom; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#a16summary">111</a></p> </td>
     </tr>

    </tbody>
   </table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM">
        &#xa0;
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
      </div>
     </div>
    </div>
   </div>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  </div>
  <div>
    &#xa0;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline; ">Forward-Looking Statements</span></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>This annual report on Form 10-K for the year ended December 31, 2022, or this Annual Report on Form 10-K, contains forward-looking statements within the meaning of Section&#xa0;27A of the Securities Act of 1933, as amended, or the Securities Act, and Section&#xa0;21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, that involve risks and uncertainties, principally in the sections titled &#x201c;Business,&#x201d; &#x201c;Risk Factors&#x201d; and &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations.&#x201d; All statements other than statements of historical fact contained in this Annual Report on Form 10-K, including statements regarding future events, our future financial performance, expectations for growth and revenues, anticipated timing and amounts of milestone and other payments under collaboration agreements, business strategy and plans, objectives of management for future operations, timing and outcome of legal and other proceedings and our ability to finance our operations are forward-looking statements. We have attempted to identify forward-looking statements by terminology including &#x201c;anticipates,&#x201d; &#x201c;approach,&#x201d; &#x201c;believes,&#x201d; &#x201c;can,&#x201d; &#x201c;contemplate,&#x201d; &#x201c;continue,&#x201d; &#x201c;look forward,&#x201d; &#x201c;ongoing,&#x201d; &#x201c;could,&#x201d; &#x201c;estimates,&#x201d; &#x201c;expects,&#x201d; &#x201c;intends,&#x201d; &#x201c;may,&#x201d; &#x201c;appears,&#x201d; &#x201c;suggests,&#x201d; &#x201c;future,&#x201d; &#x201c;likely,&#x201d; &#x201c;goal,&#x201d; &#x201c;plans,&#x201d; &#x201c;potential,&#x201d; &#x201c;possibly,&#x201d; &#x201c;projects,&#x201d; &#x201c;predicts,&#x201d; &#x201c;seek,&#x201d; &#x201c;should,&#x201d; &#x201c;target,&#x201d; &#x201c;would&#x201d; or &#x201c;will&#x201d; and other similar words or expressions or the negative of these terms or other comparable terminology. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy. These statements are only predictions and involve known and unknown risks and uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements expressed or implied by these forward-looking statements, to differ materially. The description of our Business set forth in Item&#xa0;1, the Risk Factors set forth in Item&#xa0;1A and our Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations set forth in Item&#xa0;7 as well as other sections in this report, discuss some of the factors that could contribute to these differences. These forward-looking statements include, among other things, statements about:</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>the accuracy of our estimates regarding expenses, future revenues, uses of cash, capital requirements and the need for additional financing;</i></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>the initiation, cost, timing, progress and results of our development activities, preclinical studies and clinical trials;</i></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>the timing of and our ability to obtain and maintain regulatory approval of our existing product candidates, any product candidates that we may develop, and any related restrictions, and/or limitations;</i></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>our plans to research, develop and commercialize our current and future product candidates and Anticalin platform;</i></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>our collaborators</i>&#x2019;<i>&#xa0;election to pursue or continue research, development and commercialization activities;</i></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>our ability to obtain future reimbursement and/or milestone payments from our collaborators;</i></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>our ability to attract collaborators with development, regulatory and commercialization expertise;</i></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>our ability to obtain and maintain intellectual property protection for our product candidates;</i></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>our ability to successfully commercialize our product candidates;</i></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>the size and growth of the markets for our product candidates and our ability to serve those markets;</i></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>the rate and degree of market acceptance of any future products;</i></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>the success of competing drugs that are or may become available;</i></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>regulatory developments in the United States and other countries;</i></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>the performance of our third-party suppliers and manufacturers and our ability to obtain alternative sources of raw materials;</i></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>the potential impact of the coronavirus disease, or COVID-19, pandemic on our clinical trials and other business operations;</i></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>our ability to obtain additional financing;</i></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>our use of the proceeds from our securities offerings;</i></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>any restrictions on our ability to use our net operating loss carryforwards; and</i></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>our ability to attract and retain key personnel.</i></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div>
       &#xa0;
     </div>
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       3
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time and it is not possible for us to predict all risk factors, nor can we address the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause our actual results to differ materially from those contained in any forward-looking statements. Actual results could differ materially from our forward-looking statements due to a number of factors, including, without limitation, risks related to: the results of our research and development activities, including uncertainties relating to the discovery of potential drug candidates and the preclinical and ongoing or planned clinical testing of our drug candidates; the early stage of our drug candidates presently under development; our ability to obtain and, if obtained, maintain regulatory approval of our current drug candidates and any of our other future drug candidates; our need for substantial additional funds in order to continue our operations and the uncertainty of whether we will be able to obtain the funding we need; our future financial performance; our ability to retain or hire key scientific or management personnel; our ability to protect our intellectual property rights that are valuable to our business, including patent and other intellectual property rights; our dependence on third-party manufacturers, suppliers, research organizations, testing laboratories and other potential collaborators; the success of our collaborations with third parties; our ability to meet milestones; our ability to successfully market and sell our drug candidates in the future as needed; the size and growth of the potential markets for any of our approved drug candidates and the rate and degree of market acceptance of any of our approved drug candidates; competition in our industry; regulatory developments in the United States and foreign countries</i><i>; the expected impact of new accounting standards; and the length and severity of the pandemic relating to SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), or coronavirus, which causes coronavirus disease 2019, or COVID-19, which could continue to have an impact on our research, development, supply chain and clinical trials. </i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>You should not place undue reliance on any forward-looking statement, each of which applies only as of the date of this Annual Report on Form 10-K. Before you invest in our securities, you should be aware that the occurrence of the events described in the section titled </i>&#x201c;<i>Risk Factors</i>&#x201d;<i> and elsewhere in this Annual Report on Form 10-K could negatively affect our business, operating results, financial condition and stock price. All forward-looking statements included in this document are based on information available to us on the date hereof, and except as required by law, we undertake no obligation to update or revise publicly any of the forward-looking statements after the date of this Annual Report on Form 10-K to conform our statements to actual results or changed expectations.</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have registered trademarks for Pieris&#xae;, Anticalin&#xae; and Duocalin&#xae;. All other trademarks, trade names and service marks included in this Annual Report on Form 10-K are the property of their respective owners. Use or display by us of other parties&#x2019; trademarks, trade dress or products is not intended to and does not imply a relationship with, or endorsements or sponsorship of, us by the trademark, trade dress or product owner.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As used in this Annual Report on Form 10-K, unless the context indicates or otherwise requires, &#x201c;our Company&#x201d;, &#x201c;the Company&#x201d;, &#x201c;Pieris&#x201d;, &#x201c;we&#x201d;, &#x201c;us&#x201d; and &#x201c;our&#x201d; refer to Pieris Pharmaceuticals, Inc., a Nevada corporation, and its consolidated subsidiary, Pieris Pharmaceuticals GmbH (formerly known as Pieris AG), a company organized under the laws of Germany, Pieris Australia Pty Ltd., a company organized under the laws of Australia that is a consolidated subsidiary of Pieris Pharmaceuticals GmbH and Pieris Pharmaceuticals Securities Corporation, a Massachusetts securities corporation, a consolidated subsidiary of Pieris Pharmaceuticals, Inc. Effective as of August&#xa0;26, 2015 and with notification from the Amtsgericht M&#xfc;nchen as of September&#xa0;29, 2015, Pieris AG was transformed to Pieris Pharmaceuticals GmbH as a result of a change in the legal entity.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Currency Presentation and Currency Translation</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Unless otherwise indicated, all references to &#x201c;dollars,&#x201d; &#x201c;$,&#x201d; &#x201c;US $&#x201d; or &#x201c;U.S. dollars&#x201d; are to the lawful currency of the United States. All references in this Report to &#x201c;euro&#x201d; or &#x201c;&#x20ac;&#x201d; are to the currency introduced at the start of the third stage of the European Economic and Monetary Union pursuant to the Treaty establishing the European Community, as amended. We prepare our financial statements in U.S. dollars.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The functional currency for our operations is primarily the euro. With respect to our financial statements, the translation from the euro to U.S. dollars is performed for balance sheet accounts using exchange rates in effect at the balance sheet date and for revenue and expense accounts using a weighted average exchange rate during the period. The resulting translation adjustments are recorded as a component of accumulated other comprehensive loss.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Where in this Report we refer to amounts in euros, we have for your convenience also, in certain cases, provided a conversion of those amounts to U.S. dollars in parentheses. Where the numbers refer to a specific balance sheet account date or financial statement account period, we have used the exchange rate that was used to perform the conversions in connection with the applicable financial statement. In all other instances, unless otherwise indicated, the conversions have been made using the noon buying rate of &#x20ac;1.00 to U.S. $1.072041 based on Thomson Reuters as of December 31, 2022.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       4
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <div>
    &#xa0;
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="parti" title="parti" href="#"></a>PART I</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 81pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Item</b>&#xa0;<b>1.</b></p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>BUSINESS</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Corporate History</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>General</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Pieris Pharmaceuticals, Inc. was incorporated in the State of Nevada in May 2013 under the name &#x201c;Marika Inc.&#x201d; Pieris Pharmaceuticals, Inc. began operating the business of Pieris Pharmaceuticals GmbH, or Pieris GmbH, through a reverse acquisition on December&#xa0;17, 2014. Pieris GmbH (formerly Pieris AG, a German company which was founded in 2001) continues as an operating subsidiary of Pieris Pharmaceuticals, Inc.; Pieris Pharmaceuticals, Inc. is the sole stockholder of Pieris GmbH.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Pieris Pharmaceuticals, Inc.&#x2019;s corporate headquarters are located at 225 Franklin&#xa0;Street, 26th Floor, Boston, Massachusetts 02110. The research facilities of Pieris GmbH are located in Hallbergmoos, Germany. Pieris Australia Pty Ltd., a wholly-owned subsidiary of Pieris GmbH, was formed on February&#xa0;14, 2014 to conduct research and development activities in Australia. Pieris Pharmaceuticals Securities Corporation, a wholly-owned subsidiary of Pieris Pharmaceuticals, Inc., was formed on December 14, 2016 to buy, sell, deal in, or hold securities on its own behalf and not as a broker, and engages in its activities exclusively for investment purposes.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Business Overview</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We are a clinical-stage biotechnology company that discovers and develops Anticalin&#xae; protein-based drugs to target validated disease pathways in unique and transformative ways. Our clinical pipeline includes elarekibep, formerly referred to as PRS-060/AZD1402, an inhaled IL-4R&#x3b1; antagonist Anticalin protein to treat uncontrolled asthma,&#xa0;PRS-220, an inhaled CTGF antagonist to treat idiopathic pulmonary fibrosis, or IPF, and other pulmonary fibrosis indications, and an immuno-oncology, or&#xa0;IO,&#xa0;bispecific PRS-344/S095012 targeting PD-L1 and 4-1BB. Proprietary to us, Anticalin proteins are a novel class of therapeutics validated in the clinic and through partnerships with leading pharmaceutical companies.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Anticalin proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring proteins typically found in human blood plasma and other bodily fluids. Anticalin proteins function similarly to monoclonal antibodies by binding tightly and specifically to a diverse range of targets. An antibody is a large protein used by the immune system to recognize a target molecule, called an antigen. We believe Anticalin proteins possess numerous advantages over antibodies in certain applications. For example, Anticalin proteins are relatively small in size and comprised of a single polypeptide chain whereas antibodies are much bigger and comprised of four polypeptide chains. The potentially greater stability and smaller size of Anticalin proteins as compared to antibodies potentially enable unique routes of Anticalin protein drug administration such as inhaled delivery. Higher-molecular-weight entities, such as antibodies, are often too large to be delivered effectively through these methods. Our Anticalin technology is modular, which allows us to design multimeric Anticalin based bi- and multi- specific proteins to bind with specificity to two or more targets at the same time. This multispecificity offers advantages in biological settings where binding to multiple targets can enhance the ability of a drug to achieve its desired effects, such as facilitating the killing of cancer cells. Moreover, unlike antibodies, the pharmacokinetic, or PK, profile of Anticalin proteins can be adjusted to potentially enable program-specific optimal drug exposure. Such differentiating characteristics suggest that Anticalin proteins have the potential, in certain cases, to become best-in-class drugs.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have intellectual property rights directed to various aspects of our Anticalin technology platform, allowing for further development and advancement of both our platform and drug candidates. We believe that our ownership or exclusive license of intellectual property related to the Anticalin platform provides us with a strong intellectual property position, particularly in cases where we are seeking to address targets and diseases in a novel way and for which there is existing antibody intellectual property. We also believe that the drug-like properties of the Anticalin drug class have been demonstrated in various clinical trials with different Anticalin based drug candidates, including elarekibep&#xa0;and others.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our core Anticalin technology and platform were developed in Germany, and we have collaborations with multiple major pharmaceutical and biotechnology companies, as follows:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We entered into a license and collaboration agreement, or the Servier Collaboration Agreement, with Les Laboratoires Servier and Institut de Recherches Internationales Servier, or Servier, in January 2017 in IO.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In May 2017, we entered into a license and collaboration agreement with AstraZeneca AB, or AstraZeneca, to treat respiratory diseases, or the AstraZeneca License and Collaboration Agreement as well as a Non-exclusive Anticalin Platform License Agreement. On March 29, 2021, we and AstraZeneca entered into the first amendment to the Non-exclusive Anticalin Platform License Agreement dated May 2, 2017 and the second amendment to the AstraZeneca License and Collaboration Agreement dated May 2, 2017. Under the amendments, the parties agreed to restructure certain commercial economics for the elarekibep program by adjusting various milestones and royalty provisions, while fundamentally maintaining the overall value split between AstraZeneca and the Company. In connection with the amendments, we achieved a $13.0 million milestone in connection with the initiation of the phase 2a study for this program and we and AstraZeneca entered into a subscription agreement pursuant to which we issued to AstraZeneca 3,584,230 shares of our common stock for a total purchase price of $10.0 million in a private placement transaction.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       5
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In February 2018, we entered into a license and collaboration agreement, or the Seagen Collaboration Agreement, with Seagen Inc. (formerly Seattle Genetics, Inc.), or Seagen, in IO. On March 25, 2021 we announced an amendment to the Seagen Collaboration Agreement whereby our option to co-develop and co-commercialize one&#xa0;of the three programs in the collaboration was converted to a co-promotion option for one program in the United States, with Seagen solely responsible for the development and overall commercialization of that program. Under the co-promotion option, we will be entitled to increased royalties from that program in the event that we choose to exercise the option. In addition, we entered into a clinical trial and supply agreement with Seagen to evaluate the safety and efficacy of combining cinrebafusp alfa with Seagen&#x2019;s TUKYSA&#xae;&#xa0;(tucatinib), a small-molecule tyrosine kinase HER2 inhibitor, for the treatment of gastric cancer patients expressing lower HER2 levels (IHC2+/ISH- &amp; IHC1+) as part of the initiated phase 2 study, which was subsequently terminated after the discontinuation of cinrebafusp alfa. Finally, as part of this transaction, we entered into a subscription agreement pursuant to which we issued to Seagen 3,706,174 shares of our common stock for a total purchase price of $13.0&#xa0;million in a private placement transaction.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On April 24, 2021, the Company and BP Asset XII, Inc., or Boston Pharmaceuticals, a subsidiary of Boston Pharma Holdings, LLC, entered into an exclusive product license agreement, or the BP Agreement, to develop PRS-342, a 4-1BB/GPC3 preclinical immuno-oncology antibody-Anticalin fusion, or Mabcalin&#x2122;, bispecific protein.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On May 19, 2021, the Company and Genentech, Inc., or Genentech, entered into a research collaboration and license agreement, or the Genentech Agreement, to discover, develop and commercialize locally delivered respiratory and ophthalmology therapies that leverage the Company&#x2019;s proprietary Anticalin technology.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In connection with our efforts to develop multispecific Anticalin based proteins designed to engage immunomodulatory targets, we have gained non-exclusive access to antibody building blocks that can be utilized to develop multispecific Mabcalin proteins.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our current development plans continue to advance our promising clinical and preclinical programs including those in the therapeutic area of respiratory diseases. Our lead respiratory Anticalin based drug candidate, elarekibep, antagonizes IL-4R&#x3b1;, thereby inhibiting IL-4 and IL-13, two cytokines, which are small proteins mediating signaling between cells within the human body, known to be key mediators in the inflammatory cascade that drive the pathogenesis of asthma and other inflammatory diseases. We believe that the small size and biophysical stability of elarekibep facilitates direct delivery to the lungs through the use of an inhaler, which may enable relatively high pulmonary concentrations of the drug candidate to be achieved. Information regarding the clinical trials for elarekibep is provided further below. The phase 2a asthma study for elarekibep is ongoing and topline data from part 2 of this study are expected to be reported by the middle of 2024.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       6
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Upon receipt of the topline data and notice from AstraZeneca, including a product development plan and budget, the Company will have 30 days to opt into co-development of the program with AstraZeneca at one of two levels, neither of which includes an option exercise fee. If we do not choose to participate in co-development, we would still be entitled to potential sales milestones and royalties. At the first opt-in level, Pieris would be responsible for 25% of the cost-share with a predetermined cost cap for an increased amount of potential sales milestones and royalties compared to not opting-in. At the second opt-in level, we would be responsible for 50% of the cost-share without a cost cap which would result in a gross margin share. The Company also has a separate option to co-commercialize elarekibep with AstraZeneca in the United States independent of the co-development opt-in decision.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">Four discovery-stage respiratory programs were originally included in the AstraZeneca alliance beyond elarekibep, the targets and disease areas of which are undisclosed. In January 2022, Pieris and AstraZeneca jointly discontinued one of the four discovery-stage programs in the collaboration beyond elarekibep, for which an exploratory target was not able to be validated. In August 2022, we entered into an amendment of the AstraZeneca License and Collaboration Agreement and extended the research term for two of the then remaining three discovery-stage programs, and subsequently jointly discontinued the third discovery-stage program. Pieris retains co-development and U.S. co-commercialization options for the two discovery-stage programs.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company also continues to advance other proprietary discovery-stage respiratory programs. Our lead fully proprietary respiratory asset, PRS-220, an orally inhaled Anticalin protein targeting connective tissue growth factor, or CTGF, is being developed as a local treatment for IPF and other fibrotic lung diseases, entered a phase 1 healthy volunteer study in 2022. CTGF, a matricellular protein, is a driver of fibrotic tissue remodeling and the protein has been found over-expressed in lung tissue from patients suffering from IPF. Clinical data from a Phase 2 study with the monoclonal antibody pamrevlumab&#xa0;conducted by Fibrogen indicated that inhibition of CTGF reduced&#xa0;the decline in lung function in&#xa0;patients, thus demonstrating clinical proof of concept for this target. In 2021, we received a &#x20ac;14.2 million grant from the Bavarian Ministry of Economic Affairs, Regional Development and Energy supporting research and development of the program.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">PRS-220 has progressed&#xa0;in all activities required to support a regulatory submission for clinical evaluation. We presented initial preclinical data for PRS-220 at the European Respiratory Society International Congress 2021, demonstrating a more potent and durable target engagement profile compared to a clinical-stage, systemically delivered anti-CTGF antibody benchmark. Additionally, the targeting of CTGF locally in the lung showed increased attenuation of fibrotic lung remodeling<i>&#xa0;in vivo&#xa0;</i>compared to the systemically delivered antibody. This outcome correlates with superior lung tissue exposure of PRS-220 compared to that of the systemically administered antibody in head-to-head studies, where intratracheally administered PRS-220 efficiently penetrates the fibrotic, interstitial lung tissue of mice. In the fourth&#xa0;quarter of 2022, we dosed the first subject in the phase 1 study of&#xa0;PRS-220 in healthy volunteers in Australia. The study is a randomized, two-part, blinded, placebo-controlled study, designed to assess the safety, tolerability, pharmacokinetics, and immunogenicity of single and multiple ascending doses of PRS-220 when administered by oral inhalation to healthy subjects. We expect to report topline results from the study in the second half of this year.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">PRS-400 is a fully proprietary Anticalin protein targeting Jagged-1 and is being developed as a local treatment for muco-obstructive lung diseases. Jagged-1 is one of five cell surface ligands interacting with Notch receptors. It has been demonstrated that Jagged-1/Notch signaling drives secretory cell trans-differentiation in the airways and that blocking Jagged-1/Notch signaling reduces secretory cell number, mucin expression and mucus plugging <i>in vivo</i>. In September 2022, we presented preclinical data at the European Respiratory Society International Congress 2022 indicating that candidate molecules inhibit Jagged-1-induced Notch 2 signaling in a dose-dependent manner and also demonstrate that PRS-400 reduces mucin expression <i>ex vivo</i>. Additionally, PRS-400 was found <i>in vivo</i> to reduce mucin gene expression and goblet cells metaplasia in mice with IL-13-induced airway inflammation. These findings suggest that PRS-400 represents a promising opportunity to address muco-obstructive respiratory diseases locally with an attractive therapeutic index.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have also entered into a multi-program research collaboration and license agreement with Genentech, a member of the Roche Group, to discover, develop and commercialize locally delivered respiratory and ophthalmology therapies. Joint discovery activities in each of the two committed programs are ongoing.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company also has several IO assets in partnership with other major pharmaceutical and biotechnology companies.&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">Formerly the lead IO Anticalin-based drug candidate in our pipeline, cinrebafusp alfa is a bispecific Mabcalin compound comprising a HER2-targeting antibody genetically linked to 4-1BB-targeting Anticalin proteins. Cinrebafusp alfa is designed to drive tumor localized T cell activation through tumor-targeted drug clustering mediated by HER2 expressed on tumor cells. This program was the first 4-1BB bispecific T cell co-stimulatory agonist to enter clinical development. In August 2022, we announced the decision to cease further enrollment in the two-arm, multicenter, open-label phase 2 study of cinrebafusp alfa as part of a strategic pipeline prioritization to focus our resources. Cinrebafusp alfa has demonstrated clinical benefit in phase 1 studies, including single agent activity in a monotherapy setting, and in the phase 2 study in HER2-expressing gastric cancer, giving us confidence in our broader 4-1BB franchise.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In January 2017, we initiated a strategic collaboration with Servier to discover and develop multiple Anticalin-based bispecific therapeutics in IO. PRS-344/S095012, a bispecific Mabcalin compound comprising a PD-L1-targeting antibody genetically linked to 4-1BB-targeting Anticalin proteins, is a clinical stage program being developed within this alliance. Preclinical data for the PRS-344/S095012 program were presented at the SITC 2018 Annual Meeting.&#xa0;We also exercised our option to opt into co-development and U.S. commercialization of PRS-344/S095012 during the first quarter of 2019. We hold exclusive commercialization rights for PRS-344/S095012 in the United States and will receive royalties on ex-U.S. sales from Servier for this program.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We achieved two preclinical milestones under the PRS-344/S095012 program, one in December 2018 and another one in February 2019, in addition to a clinical development milestone as the first patient was dosed in a global phase 1/2 in patients with solid tumors in November 2021. Pieris and Servier presented preclinical data and the phase 1/2 study design at the American Association for Cancer Research, or AACR, medical meeting in April 2022. The study is being conducted in multiple countries, including the United States. The first-in-human phase 1/2 multicenter open-label dose escalation study is designed to determine the safety and preliminary activity of PRS-344/S095012 in patients with advanced and/or metastatic solid tumors and we plan to present the escalation data at a medical meeting in 2023.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">Formerly a program in the Servier alliance, PRS-352/S095025 is a bispecific Mabcalin compound comprising an PD-L1-targeting antibody genetically fused to Anticalin proteins specific for OX40. In December 2022, Servier decided to discontinue development of PRS-352/S095025 due to strategic portfolio reasons. The program and associated rights reverted to us and we will strategically evaluate next steps.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In February 2018, we initiated a strategic collaboration with Seagen to discover and develop up to three Anticalin-based tumor-targeted bispecific therapeutics in IO. We have already handed one of the programs in the Seagen collaboration, SGN-BB228 (also referenced as PRS-346), a CD228/4-1BB bispecific antibody-Anticalin&#xa0;compound, over to Seagen, who is responsible for further advancement and funding of the asset. In January&#xa0;2023, the first patient was dosed in a Seagen-sponsored phase 1 study of SGN-BB228, which triggered a $5.0 million payment from Seagen to us. Additionally, Seagen presented preclinical data for this program at the Society for Immunotherapy of Cancer 37th Annual Meeting in November 2022. We believe the achievement of a key clinical development milestone for this program validates our approach in IO bispecifics, complementing the encouraging clinical data seen with cinrebafusp alfa. During the third quarter of 2021, we initiated the second program, and during the fourth quarter of 2022, we initiated the third program within the collaboration with Seagen. We retain a co-promotion option for one of the programs in the United States.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">PRS-342/BOS-342 is a GPC3/4-1BB&#xa0;bispecific Mabcalin compound&#xa0;that we have exclusively licensed to Boston Pharmaceuticals. Boston Pharmaceuticals continues to advance PRS-342/BOS-342 towards the clinic, with phase 1 expected to begin in the coming months.</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       7
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Strategy</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our corporate vision is to become a fully-integrated biotechnology company by discovering and developing Anticalin-based therapeutics to target validated disease pathways in unique and transformative ways with the ultimate goal of commercializing our therapeutic products. We intend to engage with partners for many of our programs in a combination of geographic and program-based arrangements to maximize our business opportunities. We also intend to retain certain development and commercial rights on selected products as our experience in late-stage drug development grows. Key elements of our strategy include:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Collaborating with AstraZeneca on the execution of the elarekibep phase 2 studies. </i></b>We previously reported promising data from our phase 1 SAD and MAD studies of elarekibep. We achieved a $13.0 million milestone in connection with the initiation of patient enrollment in the phase 2a study of elarekibep in the first quarter of 2021. The part 2&#xa0;efficacy portion (3 mg dose) of this phase 2a study is currently ongoing following a successful sponsor evaluation of safety data from part 1a (1 and 3 mg dose compared to placebo) of the study. Successful development of elarekibep would both further validate our platform and could provide a convenient and effective option for uncontrolled asthma patients as a potential first-in-class inhaled biologic.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Advancing PRS-220 through&#xa0;phase 1 study.</i></b>&#xa0;We continue developing PRS-220 as a CTGF-targeting, inhaled treatment of IPF, an indication of high unmet medical need. In addition, we are exploring PRS-220 in other types of pulmonary fibrotic diseases. We completed the drug candidate nomination stage in 2021, followed by chemistry, manufacturing, and control, or CMC, activities such as the development of a robust process for large-scale manufacturing and the development of a nebulized formulation. In the fourth&#xa0;quarter of 2022, we dosed the first subject in the phase 1 study of PRS-220 in healthy volunteers in Australia. We expect to report the outcome of the study in 2023.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Continuing to build our platform by entering into new partnerships and license and collaborative arrangements and advancing our currently partnered programs.</i></b>&#xa0;We have entered into partnership and collaborative arrangements with pharmaceutical companies in a diverse range of therapeutic areas and geographies. We have active strategic partnerships with the global pharmaceutical companies Servier, AstraZeneca, Seagen, Boston Pharmaceuticals, and Genentech. Together with our partners, we intend to advance multiple drug candidates through preclinical studies and to select further drug candidates for clinical development in the future. We will also continue to seek to engage with new pharmaceutical partners that can contribute funding, experience and marketing ability for the successful development and commercialization of our current and future drug candidates.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Pursuing additional opportunities for our Anticalin technology.</i></b>&#xa0;The flexibility of our Anticalin&#xa0;platform presents a unique opportunity to adapt and develop Anticalin proteins with therapeutic potential across a broad range of indications. We intend to continue to identify, vet and pursue opportunities to develop novel Anticalin-based therapeutics for respiratory diseases and additional diseases.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Pursuing other platform development activities. </i></b>We continue to make investments in our Anticalin platform, including in display and other technologies used to discover and optimize Anticalin proteins against targets of interest to increase speed, throughput and caliber of the selection process. In addition, we continue to make investments in our platform for the characterization and manufacturing of Anticalin proteins to develop drug candidates with excellent drug-like properties that can be efficiently produced.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       8
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Anticalin Platform Technology</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our platform technology focuses on low molecular-weight Anticalin proteins that can bind tightly and specifically to a diverse range of targets. Anticalin proteins are derived from human proteins called lipocalins, which are naturally occurring low-molecular weight human proteins of approximately 17 to 21 kDa molecular mass typically found in blood plasma and other bodily fluids. The lipocalin class of proteins defines a group of specific extracellular binding proteins that, collectively, exhibit extremely high structural homology, yet have a low amino acid sequence identity (less than 20%), making them attractive &#x201c;templates&#x201d; for amino acid diversification. Lipocalins naturally bind to, store and transport a wide spectrum of molecules. The defining attributes of the human lipocalin class and, by extension, Anticalin proteins, engineered from the lipocalin class of proteins, are a rigidly conserved beta-barrel backbone with four flexible loops, which, together, form a cup-like binding pocket. The graphic below shows the tear lipocalin (left) and neutrophil gelatinase-associated lipocalin, or NGAL (right).</p>
  <p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="pirs20221231_10kimg001.jpg" src="pirs20221231_10kimg001.jpg" style="width:252;height:95;" /></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We currently develop our Anticalin proteins from two scaffolds, namely the tear lipocalin, found primarily in human tear fluid as well as the lung epithelium, and NGAL, a protein involved in the innate immune system, by selection from diverse libraries with mutations in the genetic code of the ligand binding regions and regions of the proteins that are amenable for amino acid exchanges. These mutations have the potential to lead to highly specific, high-affinity binding proteins for both small and large molecular targets. Mutations are introduced at pre-defined positions, creating exponentially diverse pools of Anticalin proteins, the most potent and well-behaved of which are selected and optimized in a customized manner through <i>in vitro</i> selection using techniques such as phage and yeast display, which are successful techniques in antibody-based drug discovery. The ability to generate highly-diverse and high-quality Anticalin libraries and to select for the best binders among the large pool of Anticalin proteins by display technologies gives us the opportunity to select highly specific and high affinity Anticalin proteins for a wide variety of targets. The flexibility inherent in the Anticalin proteins&#x2019; cup-like structure allows us to choose both small-molecule targets that are capable of binding inside the &#x2018;cup&#x2019; as well as larger protein targets that are predominantly bound by the flexible loop region outside of the &#x2018;cup&#x2019;. Our phase 1 studies for elarekibep, our phase 1 studies of cinrebafusp alfa, our prior phase 1 and 2 studies of PRS-080, our prior phase 1 study of PRS-050, as well as the phase 1 study of a PCSK9-specific Anticalin protein, indicate that these proteins appear to have low immunogenic potential and thereby have the potential to exhibit a favorable safety profile.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The below graphic illustrates Anticalin proteins binding to a small molecule (left), a small protein target (hepcidin, center) and a large protein target (CTLA4, right):</p>
  <p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="pirs20221231_10kimg002.jpg" src="pirs20221231_10kimg002.jpg" style="width:286;height:136;" /></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">To obtain a specific Anticalin protein, we take advantage of the breadth of our proprietary Anticalin libraries, generated through our protein engineering expertise. We created, and will continue to create, proprietary Anticalin libraries by rationally diversifying certain lipocalin regions, thereby generating Anticalin libraries suitable for identifying binders to different types of targets. By utilizing bacterial and mammalian expression platforms from the earliest stages of drug discovery through current Good Manufacturing Practice, or cGMP, manufacturing, we created seamless platforms that facilitate the selection of high-quality and cost-effective drug candidates. Anticalin-based drug candidates have been proven to be suitable for expression in standard mammalian expression systems. Thus, Anticalin protein manufacturing is not limited to bacterial systems, and the expression system can be selected on a program-by-program basis. See &#x201c;&#x2014;Manufacturing&#x201d; below.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       9
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Anticalin proteins share many of the favorable qualities of antibodies, including:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>High specificity to their targets</i>. Like antibodies, Anticalin proteins can bind their targets without binding other molecules, even molecules with very similar chemical structures or amino acid sequences, allowing for more effective treatments through, for example, minimizing off-target effects.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Tight binding and effective biological activity at their targets</i>. Like antibodies, Anticalin proteins are able to bind their targets at subnanomolar to picomolar affinities. Anticalin proteins can potentially achieve desirable biological effects by inhibiting an undesired or inducing a desired cell activity by binding to cell-surface receptors or their ligands.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Scalability for large-scale production</i>. Like antibodies, Anticalin proteins lend themselves to large-scale production, yet can also be produced in a range of expression systems ranging from prokaryotic (bacterial) to eukaryotic (for example, animal and fungal) cells. Anticalin proteins can take advantage of several well-understood and widely-practiced methods of protein production both in small amounts for preclinical testing and at larger scale for clinical trials and commercial production.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">While often compared to antibodies, we believe Anticalin proteins offer several advantages over antibodies, including:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Small size and biophysical stability</i>. Anticalin proteins are small in size and consist of one single polypeptide chain. Therefore, we believe Anticalin proteins are generally more biophysically stable than antibodies, which are composed of four polypeptide chains. This will potentially enable unique routes of administration, such as pulmonary delivery. Higher-molecular-weight entities such as antibodies are often too large to be formulated and delivered effectively through these methods. We believe Anticalin proteins may also be less expensive to manufacture than antibodies due to their lower molecular weight and less bulky structure.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Optimization of half-life</i>. Anticalin proteins can be engineered to have a half-life that is optimal for the indication area and a desired dosing schedule. Antibodies typically have half-lives of two weeks or longer, whereas Anticalin proteins can be engineered to have half-lives from hours to weeks, depending on the half-life extension technology employed, if any. This optionality allows us to exert greater control over the amount of circulating Anticalin protein in the blood and the amount of time such Anticalin proteins circulate in the blood, depending on the underlying biology we are trying to address.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Flexible formatting facilitates selection of potent T cell engagers</i>. The molecular architecture of Anticalin proteins as a single polypeptide chain that folds into a stable eight-stranded &#x3b2;-barrel with exposed N- and C-termini, both not part of the binding site, makes them ideal building blocks to generate bispecific and even multispecific fusion proteins offering novel therapeutic modalities. Multispecific Anticalin-based fusion proteins can be used to pursue innovative therapeutic strategies in IO, particularly by addressing the &#x201c;immunological synapse&#x201d;&#xa0;that forms at the interface upon contact between an immune cell and a cancer cell. This can drive an efficient activation of tumor-specific T cells in the vicinity of the tumor, thereby avoiding some of the toxicities observed with peripheral T cell activation in healthy tissues. Generally, the formatting flexibility of Anticalin-based biologics offers the ability of modulating valency and geometry of the multispecific compound according to biological needs. For example, Anticalin proteins can be genetically fused to either the N- or C- terminus of the antibody heavy or light chain, thereby resulting in different geometries of the fusion protein with the antibody as well as Anticalin binding sites covering a range of distances with regard to the T cell target on the one hand and the tumor antigen on the other.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Platform for higher-order multispecificity and avoidance of cross-linking</i>. Our Anticalin technology allows for monovalent or multivalent target engagement, including multispecificity within a single protein. We believe that a monovalent &#x201c;backbone&#x201d;&#xa0;is an advantage in situations where pure antagonism of certain cellular receptors is desired. The dual-binding nature of antibodies, which have two &#x201c;arms,&#x201d;&#xa0;can be a disadvantage when the antibodies bind to and cross-link cell-surface receptors. Such cross-linking often leads to undesirable activation of the cells bearing those receptors. Single-action, or monovalent, Anticalin proteins have only a single binding site and by that do not induce cross-linking. Further, when it is called for by the biology we are addressing, we can create multispecific Anticalin-based proteins that can simultaneously bind (i)&#xa0;two or more different targets or (ii)&#xa0;different epitopes on the same target by genetically linking Anticalin proteins with distinct specificities or by genetic fusion of an Anticalin protein with an antibody. We believe this multispecificity offers advantages in biological settings where binding to multiple targets can enhance the ability of a drug to achieve its desired effects, such as killing cancer cells. Novel Anticalin proteins genetically fused to each other or to existing antibodies for simultaneous target engagement are expressed as a fusion protein without generally compromising on manufacturability.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       10
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Implementation of the Anticalin Platform Technology: Our Drug Candidate</b> <b>Pipeline</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">All of our drug candidates are in the early stage of development, and we anticipate that it will likely be several years before any of our drug candidates could be commercialized. The following table summarizes the status of our current drug candidates and programs:</p>
  <div style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
    &#xa0;
  </div>
  <div style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center;">
   <div style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
    <div>
     <div>
      <img alt="rpv4.jpg" src="rpv4.jpg" /></div>
    </div>
   </div>
   <div style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     &#xa0;
   </div>
  </div>
  <p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div style="text-align: center;">
   <img alt="pic2.jpg" src="pic2.jpg" /></div>
  <div>
    &#xa0;
  </div>
  <div style="text-align: center;">
    &#xa0;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Elarekibep Targeting IL-4R</i></b>&#x3b1;<b><i> in Asthma</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Elarekibep is an Anticalin drug candidate targeting IL-4R&#x3b1;, a cell surface receptor expressed on immune cells in the lung. IL-4R&#x3b1; is specific for the cytokine IL-4 and the closely related cytokine IL-13, both key drivers of the immune system. Elarekibep is derived from human tear lipocalin, has a 20 pM affinity for human IL-4R&#x3b1; and has a favorable stability profile. Following the results reported in the &#x201c;Clinical data&#x201d; section below, and presented at the American Thoracic Society International Conference in May 2019 and European Respiratory Society International Congress in October 2019, AstraZeneca started a global phase 2a study of elarekibep. We believe that elarekibep represents a first-in-class inhaled biologic targeting IL-4R&#x3b1; for the treatment of asthma. Elarekibep is being developed in partnership with AstraZeneca, as further described below.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Asthma market</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Asthma is a very common chronic airway disorder affecting more than&#xa0;300&#xa0;million people worldwide according to the Global Initiative for Asthma, including approximately 25&#xa0;million Americans according to the U.S. Centers for Disease Control. Of these 25&#xa0;million, approximately 4&#xa0;million are children. Asthma is responsible for 13&#xa0;million physician visits per year including approximately 2&#xa0;million emergency visits in the United States, according to the American Lung Association. In the United States between 2008 and 2013, asthma was responsible for approximately $3 billion in losses due to missed work and school days, approximately $29 billion due to asthma-related deaths, and approximately $50 billion in medical costs. This resulted in a total cost of asthma in the United States of approximately $82 billion in 2013 according to the American Thoracic Society.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In 2021, of the approximately 22&#xa0;million asthma patients over 12 years of age in the United States, about 55%, or 12 million, had moderate-to-severe asthma; of the approximately 20&#xa0;million asthma patients over 12 years of age in&#xa0;EU5, about 54%, or 10.8&#xa0;million, had moderate-to-severe asthma. Of all GINA4 and GINA5 patients, over half&#xa0;have uncontrolled asthma, which amounts to approximately 4.6&#xa0;million patients&#xa0;in the United States and approximately 4.1&#xa0;million in EU5&#xa0;according to an analysis prepared by Artisan Healthcare Consulting. There are several biologics approved for moderate-to-severe uncontrolled asthma in the United States and Europe. Omalizumab is an anti-IgE monoclonal antibody marketed by Roche/Genentech and Novartis for moderate-to-severe persistent allergic asthma and chronic idiopathic urticaria; in 2022, Roche/Genentech and Novartis reported total global sales for omalizumab in the amount of $3,734&#xa0;million. Mepolizumab is an anti-IL5 monoclonal antibody marketed by GlaxoSmithKline, or GSK, for severe eosinophilic asthma; in 2022, GSK reported global sales for mepolizumab in the amount of $1,714&#xa0;million. Benralizumab is an anti-IL5 receptor monoclonal antibody marketed by AstraZeneca for severe eosinophilic asthma; in 2022&#xa0;AstraZeneca reported global sales for benralizumab in the amount of $1,396 million. Dupilumab is an anti-IL4R&#x3b1; monoclonal antibody marketed by Sanofi/Regeneron for atopic dermatitis and moderate-to-severe uncontrolled asthma; in 2022, Sanofi/Regeneron reported total global sales of dupilumab in the amount of $8,793 million. Tezepelumab is an anti-TSLP monoclonal antibody marketed by Amgen and AstraZeneca for severe asthma; tezepelumab was approved by the FDA in December 2021. In 2022, Amgen and AstraZeneca reporting total global sales of tezepelumab in the amount of $174 million.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       11
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Challenges in using conventional therapy</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The current standard of care for persistent, moderate-to-severe allergic asthma is high-dose inhaled corticosteroids or ICS often in combination with inhaled long-acting beta-adrenergic agonists, or LABA. In uncontrolled moderate-to-severe allergic asthma, omalizumab is sometimes given to patients in addition to ICS/LABA combinations. Omalizumab was approved for this condition in the United States in 2003. Outside of the United States, omalizumab is approved for severe asthma. Omalizumab works by binding to the immune mediator immunoglobulin E, or IgE, and inhibiting IgE-mediated activation of mast cells and basophils, types of white blood cells. It has also been shown to impact some diseases, such as asthma, which are driven by eosinophils, another important class of immune cells. However, patient response to omalizumab has been shown to be inconsistent, as reported in a publication by McNicholl and Heaney in 2008 in the journal <i>Core Evidence</i>, which explained that in only some studies did omalizumab improve lung function. Furthermore, general asthma symptoms are also typically unaffected by omalizumab. Finally, in 2007, the FDA issued a black box warning for omalizumab due to reported cases of anaphylaxis, a potentially life-threatening allergic reaction suffered by some patients who had taken the drug.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Beyond omalizumab, there are five approved biologics, or antibodies, for the treatment of asthma. Three target the IL-5 pathway, one targets IL-4R&#x3b1;, and one targets thymic stromal lymphopoietin, or TSLP. GSK's mepolizumab, which targets IL-5, was approved for severe eosinophilic asthma in adults and children older than 12 in 2015. Teva&#x2019;s reslizumab, also targeting IL-5, was approved in 2016 and AstraZeneca&#x2019;s benralizumab, which targets IL-5 receptor alpha, or IL-5R&#x3b1;, was approved in November 2017. Amgen's and AstraZeneca's tezepelumab, which targets TSLP, was approved in December 2021 as an add-on maintenance treatment for patients ages 12 years and older with severe asthma. Regeneron's and Sanofi's dupilumab is an antibody that targets IL-4R&#x3b1; that is delivered subcutaneously and was approved for the treatment of moderate-to-severe atopic dermatitis in March 2017. In October 2018, the companies announced that the FDA had approved dupilumab as &#x201c;add-on maintenance therapy in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid-dependent asthma.&#x201d; In the phase 3 Liberty Asthma Quest study, dupilumab (300 mg every 2 weeks) in the pre-specified high eosinophilic group (eosinophil blood count of &#x2265; 300 cells/microliter) demonstrated a reduction in annualized rate of severe exacerbations by 67.4% and an improvement in forced expiratory volume in one second, or FEV1, by 0.24L. The Liberty Asthma Venture trial evaluated dupilumab in oral glucocorticoid-dependent severe asthma patients. In the overall population, the percentage of patients that decreased oral corticosteroid use by 50% or more was 80% in the dupilumab group versus 50% for placebo (or a 60% relative reduction), while decreasing the rate of severe exacerbations by 59% and improving FEV1 by 0.22L versus placebo. In the high eosinophilic group, dupilumab decreased the rate of severe exacerbations by 71% and improved FEV1 by 0.32L versus placebo (Rabe et al., 2018).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Advantages to inhalation as a route of administration for elarekibep</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We believe that local delivery via inhalation may lead to a better tolerability profile than systemically administered antibodies. Since dosing by inhalation is a common route of administration in asthma patients, it could represent a more convenient dosage regimen for patients than dosing of antibodies by injection. Elarekibep was safe and well-tolerated in a SAD phase 1 study, and was evaluated in a MAD phase 1 study with interim data suggesting that elarekibep was safe and well-tolerated at all doses, led to a statistically significant reduction in FeNO and showed dose-dependent systemic target engagement in patients with mild asthma and elevated levels of FeNO.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Preclinical data</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In <i>in vitro</i> assays, elarekibep specifically bound to immobilized targets such as human IL-4R&#x3b1; in a concentration-dependent manner. We tested the binding of elarekibep to various targets in an enzyme-linked immunosorbent assay, or ELISA, a standard <i>in vitro</i> assay platform. In these tests, elarekibep bound to IL-4R&#x3b1; with subnanomolar affinity and it did not bind to three other human cell-surface interleukin receptors (IL-6R, IL-18R&#x3b1;, IL-23R&#x3b1;). Furthermore, the activity of IL-4 and IL-13 was inhibited by elarekibep in a dose-dependent manner. The charts below show the inhibition of IL-4- (left) or IL-13- (right) induced proliferation in human TF-1 cells <i>in vitro</i> by elarekibep.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="pirs20221231_10kimg004.jpg" src="pirs20221231_10kimg004.jpg" style="width:373;height:140;" /></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       12
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In <i>in vivo</i> assays in mice genetically altered to express human IL-4R&#x3b1;, human IL-4 and IL-13, low doses of lung delivered elarekibep inhibited the induction of eotaxin protein, a marker of airway inflammation, in lung tissue following pulmonary delivery. We observed this inhibition at both the RNA and protein levels compared both to buffer and to tear lipocalin (control).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The chart below shows the duration of elarekibep-mediated inhibition of eotaxin gene expression in lung tissue by a single pulmonary dose in mice:</p>
  <p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="pirs20221231_10kimg005.jpg" src="pirs20221231_10kimg005.jpg" style="width:367;height:203;" /></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">When we administered IL-13 into the lung of humanized mice (that express human IL-4, IL-13 and IL-4R&#x3b1;), inflammation was induced as determined by eotaxin expression, which was not inhibited when phosphate buffered saline, or PBS, or human wild type lipocalin was administered into the lung. In contrast to the PBS or wild-type lipocalin administration, increases in eotaxin expression were prevented when elarekibep was administered into the lung before IL-13. As demonstrated in the above chart, the model showed the inhibitory potential lasts for up to 24 hours after elarekibep administration. We have also demonstrated that elarekibep reduces the inflammation associated with antigen challenge in a mouse asthma model. The chart below shows that pre-treatment with elarekibep reduces the lung levels of the key inflammatory cells&#x2019; eosinophils and lymphocytes, a profile that supports the hypothesis that lung delivery of an IL-4R&#x3b1; antagonist to asthmatics may be viable approach to the treatment of asthma.</p>
  <p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="pirs20221231_10kimg006.jpg" src="pirs20221231_10kimg006.jpg" style="width:421;height:200;" /></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       13
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Clinical data</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Elarekibep was tested in a nebulized formulation in 54 healthy volunteers at nominal dose levels ranging from 0.25 mg to 400 mg in a phase 1 SAD study; the drug candidate was safe and well-tolerated in the volunteers in that study. Data from that study were presented at the American Thoracic Society International Conference in May 2019 showing that elarekibep was well-tolerated when given as a single inhaled or intravenous doses to healthy volunteers and there was systemic target engagement (as measured by pSTAT6 inhibition) at doses greater than 2 mg. Elarekibep was also tested in a phase 1 multiple-ascending dose, or MAD, study in 30 patients that were randomized to receive delivered doses via nebulizer ranging from 2 mg to 60 mg (5 mg to 150 mg nominal dose) twice daily for nine consecutive days and one final dose on the 10<sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup> day, and 12 patients were randomized to receive placebo at the same intervals. We presented interim data from the elarekibep phase 1 MAD study at the 2019 European Respiratory Society International Congress in October 2019 and reported that elarekibep was safe and well-tolerated at all doses, led to a statistically-significant reduction in FeNO, a validated biomarker for eosinophilic airway inflammation and showed dose-dependent systemic target engagement in patients with mild asthma and elevated levels of FeNO (&#x2265; 35ppb). Statistically significant and pronounced inhibition of FeNO relative to placebo was observed at all doses. When comparing the 20 mg elarekibep powered cohort (n=12) to placebo, the primary statistical analysis using the emax model demonstrated a 36% relative reduction in FeNO (p-value &lt;0.0001). Systemic target engagement was dose-dependent and closely aligned with systemic exposure of the drug, consistent with results of the phase 1 SAD study. Minimal systemic exposure and target engagement were observed at the 2 mg dose, suggesting that local target engagement by the drug may be sufficient to reduce airway inflammation, as evidenced by FeNO reduction at that 2 mg dose level.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">We sponsored the phase 1 SAD/MAD studies for elarekibep, after which AstraZeneca took responsibility for further clinical development of elarekibep. The phase 2a asthma study is ongoing in multiple sites globally. This phase 2a study is a two-part, multi-center, placebo-controlled clinical study of elarekibep to evaluate elarekibep at three dose levels, 1, 3 and 10 mg, using a dry powder formulation administered twice daily. In part 1a of the study, 31 asthma patients, controlled on standard of care (medium dose inhaled corticosteroids, or ICS, with long-acting beta agonists, or LABA, were randomized to receive elarekibep at 1 mg or 3 mg, or to receive a placebo twice daily over four weeks to establish the safety profile and pharmacokinetics of the dry powder formulation of elarekibep. The safety review following completion of part 1a included an evaluation, compared to placebo, of the incidence of adverse events, changes in laboratory markers (immuno-biomarkers, clinical chemistry, and hematology), and forced expiratory volume in one second, or FEV1. Following the safety review, AstraZeneca began enrollment of part 2a (1 mg and 3 mg dose efficacy) of the study to evaluate efficacy, safety, and pharmacokinetics of elarekibep administered twice daily to asthma patients, uncontrolled on medium dose ICS with LABA, that have a blood eosinophil count of &#x2265; 150 cells/&#x3bc;L and FeNO &#x2265; 25 ppb in the 1 mg and 3 mg arms and a placebo arm. Following a four-week run-in period, patients will be dosed and monitored over four weeks. FEV1 improvement at four weeks compared to placebo will be the primary endpoint in this portion of the study. Also following the safety review, AstraZeneca initiated part 1b of the study to evaluate the safety of the 10 mg dose in asthma patients controlled on standard of care who will receive elarekibep twice daily over four weeks, and has since completed enrollment in part 1b. In the second quarter of 2022, AstraZeneca conducted a reforecast of the study, which has taken into account the global challenges of recruiting for respiratory clinical trials caused by the continued impact of the COVID-19 pandemic, and broadened enrollment criteria in part 2 (previously referenced as part 2a) of the study to facilitate recruitment of the study. AstraZeneca also now plans to focus part 2 on the 3 mg cohort for the efficacy readout and plans to stop enrollment for the 1 mg cohort. AstraZeneca no longer plans to enroll the 10 mg cohort for the efficacy readout (previously referenced as part 2b). Topline results from part 2 of this study are expected to be reported by the middle of 2024.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>PRS-220 Targeting Connective Tissue Growth Factor (CTGF) in IPF</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our lead fully proprietary respiratory asset, PRS-220, an orally inhaled Anticalin protein targeting CTGF, is being developed as a local treatment for IPF and has passed the drug candidate nomination stage in 2021. The project is currently in phase 1 clinical development in Australia. The first-in-human study is a randomized, two-part, blinded, placebo-controlled study, designed to assess the safety, tolerability, pharmacokinetics, and immunogenicity of single and multiple ascending doses of PRS-220 when administered by oral inhalation to healthy subjects. We received a &#x20ac;14.2 million grant from the Bavarian Ministry of Economic Affairs, Regional Development and Energy supporting research and development of the program.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>What is IPF?</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">IPF is a devastating and fatal lung disease of unknown cause with median survival of only three to five years after diagnosis. In patients with IPF, fibrotic remodeling and excess deposition of extracellular matrix, or ECM, causes the destruction of lung architecture leading to loss of lung elasticity and lung function, impairment of gas exchange and finally organ failure. To date, there is no cure for IPF. Treatment options for IPF are very limited, with two FDA-approved drugs, Ofev (nintedanib) and Esbriet (pirfenidone), only capable of slowing down disease progression but not arresting the insidious progression of the disease. Moreover, due to gastrointestinal and other drug-related side effects, nintedanib and pirfenidone are not well-tolerated, leading many patients to discontinue treatment. Thus, a high unmet medical need exists for alternative treatment options for IPF that effectively attenuate the lung function decline or arrest the insidious decline of lung function while offering an improved safety profile with fewer side effects and greater tolerability.</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       14
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Biology of CTGF </i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">CTGF, or CCN2, is a member of the CCN family of proteins, a family of matricellular proteins associated with the ECM involved in intercellular signaling. In adulthood, CTGF is expressed at a low level but can be strongly induced by certain stimuli such as cytokines, growth factors or mechanical stress.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">CTGF contributes to the control of various biological processes, such as proliferation, differentiation, adhesion and angiogenesis. CTGF is known to interact with a variety of proteins including receptors, cytokines and ECM proteins. Among the different cytokines and growth factors that interact with CTGF, transforming growth factor &#x3b2;, or TGF-&#x3b2;, is known to play a crucial role in the development of fibrotic diseases. In order to mediate functions such as cell adhesion, motility and tissue remodeling, CTGF interacts with integrins and components of the ECM such as fibronectin, aggrecan and heparan sulfate proteoglycans. Specifically, in the context of cell adhesion, CTGF is thought to play a role as a molecular bridge between the ECM to integral cell surface proteins.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Role and validation of CTGF as a target for IPF</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The pathogenesis of fibrosis is considered to be a dysregulated wound healing process in response to repetitive microinjuries leading to excessive deposition of ECM and impairment of tissue function. CTGF has been associated with fibrotic remodeling in various organs and is highly expressed in fibrotic tissues of different origin, including renal fibrosis, scleroderma, cardiac fibrosis and IPF.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">CTGF is a key mediator of wound healing and fibrosis through its interaction with several factors regulating cell proliferation, differentiation, motility, adhesion, and ECM deposition. TGF-&#x3b2; and CTGF are widely regarded as universal mediators of fibrogenesis. TGF-&#x3b2; has been identified as a transcriptional regulator of CTGF, and as supported by preclinical studies, both cytokines are thought to promote fibrotic tissue remodeling in a collaborative manner.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In lung tissue from IPF patients, CTGF levels are found to be elevated when compared to donor tissue with epithelial cells and myofibroblasts being the main cell types expressing the protein in diseased lung tissues (Figure 1).</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="pirs20221231_10kimg007.jpg" src="pirs20221231_10kimg007.jpg" style="width:449;height:220;" /></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:11.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Figure</b>&#xa0;<b>1</b></p> </td>
     <td style="vertical-align:bottom;width:88.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Immunohistochemistry of CTGF in human (A) donor and (B) IPF lung tissues.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Inhibition of CTGF by monoclonal antibodies in preclinical models of lung fibrosis provided evidence supporting its function as a driver of fibrotic lung remodeling <i>in vivo</i>. Lung specific overexpression of CTGF in mice demonstrated that CTGF is sufficient to drive fibrotic remodeling of the lung<i> in vivo</i>. Moreover, local targeting of CTGF in the lung using an siRNA-based approach attenuated bleomycin-induced lung fibrosis in mice. Based on this evidence, we believe that local targeting of CTGF in the lung is essential to achieve anti-fibrotic activity.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       15
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Current approaches to clinical CTGF targeting </i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In a phase 2 clinical trial (PRAISE), the anti-CTGF monoclonal antibody pamrevlumab/FG-3019 attenuated disease progression in patients suffering from IPF, demonstrating proof of concept for targeting of CTGF for the treatment of IPF. In the PRAISE study, a relative reduction of the decline in percentage of predicted forced vital capacity ("FVC") by 60.3% was observed at week 48, as compared to placebo. Patients in the pamrevlumab group also experienced fewer protocol-defined progression events (defined as death or &#x2265;10 % decline in FVC %-predicted) as compared to the placebo group. In addition, pamrevlumab demonstrated good tolerability with a safety profile similar to placebo. The overall frequency of treatment-emergent adverse events was similar in the treatment and the placebo groups. The safety and efficacy of pamrevlumab will be further evaluated in phase 3 trials (ZEPHYRUS I + II; NCT03955146, NCT04419558) in patients with IPF.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Rationale for local targeting of CTGF</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Based on the high expression of CTGF in lung tissue of IPF patients and its reported pro-fibrotic role in the lung in preclinical models, local targeting of CTGF in the lung is considered essential for driving the anti-fibrotic effect. PRS-220 is being developed as a first-in-class inhaled antagonist of the pro-fibrotic mediator CTGF. The inhaled route of administration of PRS-220 offers several advantages over pamrevlumab, the parenterally administered CTGF-targeted monoclonal antibody that is currently in clinical development for IPF.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In comparison to parenteral administration of a monoclonal antibody, inhaled administration of PRS-220 is expected to result in greater exposure of the drug at the site of the disease. Meanwhile, it is known that parenterally administered monoclonal antibodies have a low lung bioavailability with approximately 15% penetrating the lung tissue. Moreover, inhaled administration of PRS-220 is also expected to result in greater lung exposure by avoidance of the CTGF drug &#x201c;sink&#x201d; in the peripheral circulation. CTGF is present in the circulation and levels were found to be increased in IPF patients. Another advantage of an inhaled therapy is the convenience of home-based dosing with a portable, handheld nebulizer, as opposed to the office-based injections or intravenous route of delivery of parenteral monoclonal antibodies such as pamrevlumab.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Preclinical data</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">PRS-220 is a NGAL-based mutant selected from Pieris&#x2019; proprietary Anticalin libraries using phage display technology and high-throughput screening. PRS-220 binds to CTGF with high affinity in the picomolar range as measured by surface plasmon resonance, or SPR, and does not show binding to other members of the CCN2 protein family. Compared to the anti-CTGF antibody pamrevlumab, PRS-220 binds with higher affinity and retains a more stable target engagement over a longer period of time (Figure 2).</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="pirs20221231_10kimg008.jpg" src="pirs20221231_10kimg008.jpg" style="width:499;height:218;" /></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:11.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Figure</b>&#xa0;<b>2</b></p> </td>
     <td style="vertical-align:bottom;width:88.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">SPR binding experiment showing the binding of PRS-220 (left) and pamrevlumab (right) to CTGF. The 1:1 binding model was used to fit the data of PRS-220. The bivalent analyte model was used to fit the data of the antibody pamrevlumab. CTGF-Fc was immobilized on a CM5 chip, and PRS-220 and pamrevlumab were used as analytes. Pamrevlumab was generated in-house.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">PRS-220 targets the functionally active epitope of CTGF as shown by competition ELISA where PRS-220 effectively displaces the clinically active pamrevlumab from CTGF (Figure 3).</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       16
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="pirs20221231_10kimg009.jpg" src="pirs20221231_10kimg009.jpg" style="width:449;height:222;" /></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:11.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Figure</b>&#xa0;<b>3</b></p> </td>
     <td style="vertical-align:bottom;width:88.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Competition of PRS-220 with pamrevlumab for binding to CTGF and competition of pamrevlumab with itself for binding to CTGF. Competition was assessed in an ELISA-based format using coated pamrevlumab and biotinylated CTGF as tracer.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">To assess the lung biodistribution of PRS-220 upon local lung delivery, we challenged mice with bleomycin to induce lung fibrosis. Once fibrosis was established in the animals, fluorescently-labeled PRS-220 was given intratracheally and the distribution of the drug was analyzed using Light Sheet imaging, revealing a favorable lung tissue distribution profile of PRS-220 in the fibrotic lungs. PRS-220 was not only detected in the airways but also penetrated the fibrotic, interstitial lung tissue (Figure 4A). Compared to intravenously administered pamrevlumab, which was analyzed in parallel, PRS-220 showed a higher coverage of the fibrotic tissue (Figure 4B).</p>
  <div style="text-align: center;">
   <img alt="figure4a.jpg" src="figure4a.jpg" /></div>
  <p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:11.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Figure</b>&#xa0;<b>4</b></p> </td>
     <td style="vertical-align:bottom;width:88.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Lung biodistribution of PRS-220 upon intratracheal delivery to fibrotic lungs of mice. (A) Alexa-647 labeled PRS-220 (100 &#xb5;g/mouse) was administered to the lungs of mice via the intratracheal route at day 21 after bleomycin challenge. The lung tissue distribution was analyzed 2, 8, and 24 hours after PRS-220 administration by Light Sheet imaging of the left lung lobes (630 nm excitation channel). The figure shows representative 3D overview images (scale bars 500 &#xb5;m) and magnified 2D sections from 3D scanned lungs (scale bars 150 &#xb5;m). Lungs of saline treated mice imaged at the PRS-220 specific wavelength served as negative controls. (B) Compound accumulation in fibrotic tissue determined by Light Sheet imaging and quantitative analysis (n = 2-5 per group). 100 &#xb5;g Alexa-647 labeled pamrevlumab was administered intravenously at day 21 after bleomycin challenge.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Developability assessments of PRS-220 showed favorable biophysical properties ensuring robustness and stability for large-scale manufacturing and nebulized inhaled administration. Aerosols generated using vibrating mesh technology show aerodynamic properties suitable for effective lung deposition.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><i><b>PRS-400 Targeting Jagged-1</b></i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div style="font-size: 10pt;">
    PRS-400 is a fully proprietary Anticalin protein targeting Jagged-1 and is being developed as an inhaled treatment for muco-obstructive lung diseases. Jagged-1 is one of five cell surface ligands interacting with Notch receptors. As the Notch pathway is active in multiple other organs, an inhaled intervention is especially suited to circumvent side effects previously described in clinical trials with systemically delivered molecules. It has been demonstrated that Jagged-1/Notch signaling drives secretory cell trans-differentiation in the airways and that blocking Jagged-1/Notch interaction reverses mucus-producing cells in favor of ciliated cells, thereby limiting mucus hypersecretion and airway obstruction, major pathogenic features in chronic airway diseases such as chronic obstructive pulmonary disease, or&#xa0;COPD, cystic fibrosis, non-cystic fibrosis bronchiectasis and asthma. Mucus hypersecretion and mucus plugging are thought to correlate with impaired lung function and exacerbation rate. We envision that PRS-400 has the potential to improve quality of life in patients with muco-obstructive lung diseases by exiting the vicious cycle of bacterial infection, inflammation and mucus hypersecretion.&#xa0;
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div style="font-size: 10pt;">
    Preclinical data demonstrated that PRS-400 Anticalin proteins potently inhibit Jagged-1-induced Notch 2 signaling in a dose-dependent manner in a cell reporter assay, locally and efficiently reduce expression of major airway mucins (MUC5AC and MUC5B) and reduce the number of goblet cells in ex vivo and in vivo models thereby addressing key pathogenic features of muco-obstructive lung diseases. These preclinical findings corroborate our vision that PRS-400 represents a promising opportunity to improve quality of live by reducing the mucus burden in patients with muco-obstructive lung diseases.
  </div>
  <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Proprietary Respiratory Platform </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We continue to evaluate opportunities for new proprietary discovery-stage respiratory programs.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       17
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>AstraZeneca Respiratory Collaboration beyond Elarekibep</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As further described below, our license and collaboration agreement with AstraZeneca, or the AstraZeneca Collaboration Agreement, includes two&#xa0;programs beyond elarekibep. We retain co-development and co-commercialization rights to both of those&#xa0;programs. Discovery work is ongoing for on all of the additional development candidates under the collaboration. The targets and disease areas of those two&#xa0;programs are undisclosed.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Genentech Collaboration</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In May 2021, we and Genentech, a member of the Roche Group, entered into a multi-program Research Collaboration and License Agreement to discover, develop and commercialize locally delivered respiratory and ophthalmology therapies that leverage the Company&#x2019;s proprietary Anticalin-based technology. These two focus areas of the collaboration are uniquely suited to the advantages offered by the small size of Anticalin proteins when delivered locally. The first two programs have been initiated and Pieris is responsible for discovery research and early preclinical development of these programs, and Genentech will be responsible for IND-enabling activities, clinical development, and commercialization of the programs. Genentech will also have the option to select additional targets in return for an option exercise fee.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       18
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>PRS-344/S095012</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">PRS-344/S095012 consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins genetically fused to each arm of the C-terminal heavy chain of the antibody.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">4-1BB is a co-stimulatory receptor belonging to the TNFR super-family. Clustering of 4-1BB on the surface of T cells leads to T cell activation, proliferation and cytokine secretion. The mode of action of PRS-344/S095012 is to promote 4-1BB clustering by bridging 4-1BB-positive T cells with PD-L1-positive tumor cells, and to thereby provide a potent co-stimulatory signal to tumor antigen-specific T cells. PRS-344/S095012 is intended to localize 4-1BB activation in the tumor in a PD-L1 dependent manner. PD-L1 is a transmembrane protein belonging to the B7 family and is expressed on a variety of cells including T cells, B cells, epithelial cells and vascular endothelial cells. Most importantly, PD-L1 is found at high levels on tumor cells of several cancer types including but not limited to melanoma, lung, bladder, colon and breast cancer. Binding of PD-L1 to its receptor PD-1 leads to exhaustion of tumor-infiltrating T cells. PRS-344/S095012 blocks the PD-1/PD-L1 interaction and thus is capable of reversing T cell exhaustion in the tumor microenvironment. Preclinical data shows that the synergistic effect observed by targeting PD-L1 and 4-1BB simultaneously is stronger with PRS-344/S095012 than with the combination of anti-PD-L1 and anti-4-1BB antibodies.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><img alt="p01.jpg" src="p01.jpg" /></p>
  <p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: Times New Roman; font-size: 10pt; width: 100%;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Figure 5</b></p> </td>
     <td style="vertical-align: top; width: 88%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The combination of anti-PD-L1 benchmark and anti-4-1BB benchmark demonstrates the strong synergistic effect of T cell co-stimulation and checkpoint blockade in T cell activation. With PRS-344/S095012, this synergistic effect is massively increased.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Regulatory clearance for the phase 1/2 study of PRS-344/S095012, a 4-1BB/PD-L1 bispecific, has been granted in multiple countries and the first patient was dosed in November 2021. The first-in-human study consists of evaluating the safety and tolerability profile of PRS-344/S095012 and determining its maximum tolerated dose, or MTD, and/or the recommended phase 2 dose, or RP2D, in patients with solid tumors. In addition, the PK profile as well as pharmacodynamic effects of PRS-344/S095012 will be characterized in the study. Any initial signs of anti-tumoral activity will be correlated to safety and PK and further explored in expansion cohorts.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       19
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>IO Market with respect to PRS-344/S095012</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In 2022, there were approximately 1.918 million estimated new cancer cases in the United States (NCI Surveillance, Epidemiology, and End Results Program) and approximately 19.3 million cancer cases worldwide in 2020 (IARC GLOBOCAN 2020). The direct medical cost for cancer in the United States in 2015 was estimated to be approximately $80.2 billion by the Agency for Healthcare research and Quality, or the AHRQ.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Checkpoint inhibitors such as PD-1 and CTLA4-targeting antibodies have revolutionized the way certain cancers are treated and in 2018 the Noble Prize in Medicine was awarded to Dr. James Allison and Dr. Tasuku Honjo for their discovery of CTLA-4 and PD-1-targeting antibodies, respectively. By the end of 2022, a total of seven anti-PD-1 or PD-L1 monoclonal antibodies and two CTLA4 targeting antibodies have been approved in the United States. In addition, other than the seven anti-PD-1 or PD-L1 monoclonal antibodies approved in the United States, nine other anti-PD-1 antibodies had been approved in China by the end of 2022. The majority of the global sales of checkpoint inhibitors comes from two anti-PD-1 monoclonal antibodies: pembrolizumab marketed by Merck &amp; Co and nivolumab marketed by Bristol-Myers Squibb. In 2022, Merck &amp; Co reported sales of $20.937 billion for pembrolizumab and Bristol-Myers Squibb reported sales of $8.249 billion for nivolumab.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Servier Collaboration beyond PRS-344/S095012</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In&#xa0;February&#xa0;2020,&#xa0;we and Servier agreed to extend the research term of the&#xa0;three programs in development beyond PRS-344/S095012 for one year. This research extension included reimbursement for Pieris&#x2019;&#xa0;internal&#xa0;efforts and an extension of the&#xa0;research license. As part of the expiration of the initial research term, the option to expand the collaboration beyond the initial five committed programs also expired. In March 2020, Servier notified us of its decision to discontinue co-development of two earlier preclinical stage programs for strategic reasons based upon an extensive portfolio review.&#xa0;In December 2022, Servier discontinued the development of PRS-352/S095025, a bispecific&#xa0;Mabcalin compound comprising an PD-L1-targeting antibody genetically fused to Anticalin proteins specific for OX40, for strategic reasons.&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Seagen Collaboration </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition, our collaboration with Seagen to discover and develop Anticalin-based tumor-targeted bispecific antibody-Anticalin therapeutics in IO includes three programs.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We achieved a key development milestone for one of the programs, a CD228 x 4-1BB, or SGN-BB228,&#xa0;bispecific tumor-targeted costimulatory agonist,&#xa0;in the Seagen collaboration in 2020,&#xa0;triggering a $5 million milestone payment. We handed the program over to Seagen, which is responsible for further advancement and funding of the asset. Seagen presented preclinical data for this program at the Society for Immunotherapy of Cancer 37th Annual Meeting. In January 2023, we announced that the first patient was dosed in a Seagen-sponsored phase 1 study of SGN-BB228, which triggered a $5 million milestone payment from Seagen to us. The program is one of&#xa0;three current programs in the Seagen alliance, and we believe the achieved milestone further validates our approach for developing immuno-oncology bispecifics, complementing the previously reported phase 1 clinical data seen with cinrebafusp alfa.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In March 2021, Seagen made a $13.0 million equity investment in Pieris as part of an ongoing collaboration between the companies. The companies also&#xa0;entered into a clinical trial and supply agreement, or CTSA, to evaluate the safety and efficacy of combining Pieris' cinrebafusp alfa with Seagen's tucatinib, a small-molecule tyrosine kinase HER2 inhibitor, for the treatment of gastric cancer patients expressing lower HER2 levels (IHC2+/ISH- &amp; IHC1+) as part of the phase 2 study&#xa0;conducted by Pieris. The CTSA&#xa0;was later terminated in the third quarter of 2022 after we ceased enrollment in cinrebafusp alfa. The companies also amended their existing immuno-oncology collaboration whereby Pieris' option to co-develop and co-commercialize the second of three programs in the collaboration was converted to a co-promotion option for one of the three programs in the United States. During the third quarter of 2021, we initiated the second program, and during the fourth quarter of 2022, we initiated the third program within the collaboration with Seagen.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       20
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Boston Pharmaceuticals Collaboration </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In April 2021, we and Boston Pharmaceuticals, a subsidiary of Boston Pharma Holdings, LLC, entered into an exclusive product license agreement to develop PRS-342/BOS-342, a GPC3/4-1BB preclinical immuno-oncology bispecific Mabcalin protein. We completed the material and know-how transfer to BP and are currently supporting BP in manufacturing and IND-readiness activities for PRS-342/BOS-342 to initiate phase 1 in 2023.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Competition</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. While we believe that our technology, development experience, scientific knowledge and strategies provide us with competitive advantages, we face and will continue to face intense competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions and governmental agencies, and public and private research institutions, both in the United States and worldwide.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We compete, or will compete, with existing and new therapies that may become available in the future. Some of these competitors are pursuing the development of pharmaceuticals that target the same diseases and conditions that our drug candidates target. Any drug candidates that we are able to develop and commercialize will compete with existing and new drugs being developed by our competitors. Our competitors may develop or market products or other novel technologies that are more effective, safer, more convenient or less costly than any that may be commercialized by us or may obtain regulatory approval for their products more rapidly than we may obtain approval for ours.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The acquisition or licensing of pharmaceutical products is also very competitive, and a number of more established companies, some of which have acknowledged strategies to license or acquire products and many of which are bigger, have more institutional experience and have greater cash flows than us, may have competitive advantages over us, as may other emerging companies taking similar or different approaches to product licenses and/or acquisitions. In addition, a number of established research-based pharmaceutical and biotechnology companies may acquire products in late stages of development to augment their internal product lines, which may provide those companies with an even greater competitive advantage.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">There are a number of other companies presently working to develop therapies for respiratory diseases and cancer, including divisions of large pharmaceutical companies and biotechnology companies of various sizes. There are also a variety of available drug therapies marketed for these diseases. Our drug candidates, if any are approved, may compete with these existing drug and other therapies, and to the extent they are ultimately used in combination with or as an adjunct to these therapies, our drug candidates may not be competitive with them. Some of the currently approved drug therapies are branded and subject to patent protection, and others are available on a generic basis. Many of these approved drugs are well-established therapies and are widely accepted by physicians, patients and third-party payors. As a result, market acceptance of, and a significant share of the market for, any of our drug candidates that we successfully introduce to the market will pose challenges.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition to currently marketed therapies, there are also a number of drugs in clinical development to treat respiratory diseases and cancer. These medicines in development may provide efficacy, safety, convenience and other benefits that are not provided by currently marketed therapies and may not be provided by any of our current or future product candidates. As a result, they may provide significant competition for any of our product candidates.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Many of our competitors will have substantially greater financial, technical and human resources than we have. Additional mergers and acquisitions in the pharmaceutical industry may result in even more resources being concentrated in some of our competitors. Competition may increase further as a result of advances made in the commercial applicability of technologies and greater availability of capital for investment in these fields. Our success will be based in part on our ability to build, obtain regulatory approval for and market acceptance of, and actively manage a portfolio of drugs that addresses unmet medical needs and creates value in patient therapy.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       21
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition, our competitors may have a variety of drugs in development or awaiting market approval that could reach the market and become established before we have a product to sell. Our competitors may also develop alternative therapies that could further limit the market for any drugs that we may develop. Many of our competitors are using technologies or methods different or similar to ours to identify and validate drug targets and to discover novel small molecule or biologic drugs. Many of our competitors and their collaborators have significantly greater experience than we do in the following:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">identifying and validating targets;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">screening compounds against targets;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">performing preclinical and clinical trials of potential pharmaceutical products; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">obtaining regulatory approval.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition, many of our competitors and their collaborators have substantially greater advantages in the following areas:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">capital resources;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">research and development resources;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">manufacturing expertise and capabilities; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">sales and marketing capabilities.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Smaller companies also may prove to be significant competitors, particularly through proprietary research discoveries and collaborative arrangements with large pharmaceutical and established biotechnology companies. Many of our competitors have products that have been approved by the FDA, or its foreign counterparts, or are in advanced development. We face competition from other companies, academic institutions, governmental agencies and other public and private research organizations for collaborative arrangements with pharmaceutical and biotechnology companies, in recruiting and retaining highly-qualified scientific and management personnel and for licenses to additional technologies. Developments by others may render our product candidates or our technologies obsolete. Our failure to compete effectively could have a material adverse effect on our business.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Elarekibep</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Like elarekibep, new developments for the treatment of uncontrolled moderate to severe asthma patients mainly include drug candidates targeting the Th2 pathway by interfering with IL-4/IL-13, IL-5, TSLP or CRTH2. Such agents include mepolizumab (GSK, IL-5), reslizumab (Teva, IL-5), benralizumab (AstraZeneca, IL-5R&#x3b1;), tezepelumab (Amgen/AstraZeneca, TSLP) and CBP201 (Connect Biopharma, IL-4R&#x3b1;). These drugs are in later clinical development than elarekibep or have been approved for severe eosinophilic asthma. Dupilumab (Sanofi/Regeneron, IL-4R&#x3b1;) has been approved for moderate to severe asthma; the antibody omalizumab, directed against IgE, is also approved and marketed for the treatment of uncontrolled, moderate to severe asthma patients. However, in contrast to elarekibep, these antibodies are given to patients through injection and distribute systemically through the blood stream. AZD8360 (AstraZeneca/Amgen), an inhaled antibody fragment that targets TSLP is currently in&#xa0;phase 1 clinical development. There are a number of other companies presently marketing or developing other therapies for asthmatic patients.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>PRS-220</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition to the currently approved drugs, Ofev (nintedanib) and Esbriet (pirfenidone), there are multiple other programs in development for the treatment of IPF. The majority of these programs are at an early stage and include a variety of targets. There is one competing program targeting CTGF in phase 3 clinical development, pamrevlumab (Fibrogen), an antibody administered by intravenous infusion. Besides pamrevlumab, there are further programs targeting CTGF at an early stage of development. Other late-stage competitors include, tyvaso (United Therapeutics, inhaled formulation of treprostinil sodium) and BI-1015550 (Boehringer Ingelheim, PDE4B), which are currently being tested in phase 3 clinical trials. Furthermore, a number of competing programs are in phase 2 clinical development, such as GB-0139 (Galecto, galectin-3), BMS-986278 (Bristol-Myers Squibb, LPA1), CC-539 (Bristol-Myers Squibb, JNK1), PLN-74809 (Pliant Therapeutics, avbeta1/avbeta 6) and setanaxib (GenKyoTex, NOX1/4),&#xa0;whereby the first listed program is administered by inhalation and the subsequent programs are administered orally. Additionally, to the previously stated competitors, there are several other programs that are being developed for the treatment of IPF.</p>
  <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>IO programs</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The rationale behind the multispecific tumor-targeted co-stimulatory molecules is to activate the immune system in the tumor microenvironment. Other companies that also develop multispecific drug candidates designed to activate the immune system in a tumor dependent manner by targeting a co-stimulatory receptor, such as 4-1BB, include Roche, Merus, Inhibrx and Genmab, among others. Additionally, there are multiple drug candidates in preclinical or clinical trials targeting other co-stimulatory receptors, either in a tumor dependent or monospecific manner, including OX40, CD40, GITR, CD27 and ICOS.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The first checkpoint inhibitor targeting CTLA-4, ipilimumab, was approved for the treatment of melanoma patients in 2011 and is being marketed by Bristol-Myers Squibb. Nivolumab from Bristol-Myers Squibb was approved for the treatment of melanoma in 2014 as the first PD-1 inhibitor. Pembrolizumab from Merck &amp; Co was the second PD-1 inhibitor to be approved and the first one in the United States. In addition to nivolumab and pembrolizumab, there are multiple approved checkpoint inhibitors targeting the PD-1/PD-L1 pathway, for example, those from Roche, AstraZeneca, Regeneron, Pfizer and Merck KGaA.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Additionally, a number of other companies, such as Amgen, Affimed, Macrogenics, F-star, Xencor, Immunocore and Zymeworks, also pursue other multispecific approaches in oncology, in which such therapies are in clinical or preclinical development.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       22
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>PRS-344/S095012</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">PRS-344/S095012 is bispecific Mabcalin&#xa0;protein targeting 4-1BB and PD-L1.&#xa0;PRS-344/S095012 is designed to promote 4-1BB clustering by bridging 4-1BB-positive T cells with&#xa0;PD-L1-positive tumor cells, and to thereby provide a co-stimulatory signal to tumor antigen-specific T cells. Furthermore, the direct PD-L1- targeting activity of PRS-344/S095012 may provide an additional therapeutic benefit by checkpoint blockade. Multiple companies have publicly disclosed competing 4-1BB and PD-L1 bispecific programs, including, for example, Genmab in collaboration with BioNTech (GEN1046), Merus (MCLA-145), Inhibrx in collaboration with Elpiscience (INBRX-105), F-star (FS-222), Numab in collaboration with CStone (NM21-1480), ABL Bio in collaboration with I-MAB (ABL503), Antengene (ATG-101), among others.</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       23
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Manufacturing</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We do not own or operate, and currently have no plans to establish, any manufacturing facilities. We currently rely and expect to continue to rely on third-party contract manufacturer organizations, or CMOs, for the manufacture of our drug candidates for larger scale preclinical and clinical testing, as well as for commercial quantities of any drug candidates that may be approved for marketing.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We currently rely on multiple CMOs for all of our clinical supplies, including drug substances and finished drug products, and label&#xa0;and packaging for our preclinical research and clinical trials, including the phase 1/2 study for PRS-344/S095012, and the&#xa0;phase 1 study for PRS-220.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We believe that we will be able to contract with other CMOs to obtain drug substances if our existing sources of drug substances were no longer available or sufficient, but there is no assurance that the drug substances would be available from other CMOs on acceptable terms, on the timeframe that our business would require or at all. We do not have supply commitments or other arrangements in place with our existing CMOs. We also do not currently have arrangements in place for redundant supply of bulk drug substance. We have also experienced reduced capacity offered by CMOs due to the COVID-19 pandemic.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We do not have any current contractual relationships for the manufacture of commercial supplies of any of our drug product candidates if they are approved. We intend to enter into agreements with a CMO and, as needed, one or more back-up manufacturers for the commercial production of our product candidates as they near potential approval.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Any drug products to be used in clinical trials and any approved product that we may commercialize will need to be manufactured in facilities, and by processes, that comply with the FDA&#x2019;s cGMP requirements and comparable requirements of the regulatory agencies of other jurisdictions in which we are seeking approval. We currently employ internal resources to manage our CMOs.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We believe that elarekibep, PRS-344/S095012, PRS-220 and our other Anticalin branded drug candidates can be manufactured in reliable and reproducible biologic processes from readily available starting materials. Elarekibep is produced using a bacterial expression system similar to those that have been used in the past for the production of other proteins and which systems are widely used in the industry. PRS-344/S095012 and PRS-220 are produced using mammalian expression systems similar to those systems that are widely used in the industry for the production of antibodies. We believe that the manufacturing process is amenable to scale-up and will not require unusual or expensive equipment. We expect to continue to develop, on our own or with our collaborators, drug candidates that can be produced cost-effectively at contract manufacturing facilities.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Intellectual Property and Exclusivity</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our commercial success depends in part on our ability to obtain and maintain exclusivity of our proprietary Anticalin-based technologies through intellectual property protection for our drug candidates, libraries of different protein scaffolds and consensus sequences, the fundamental Anticalin platform technology, including novel therapeutic and diagnostic discoveries, as well as other proprietary know-how and trade secrets, and to operate without infringing on the intellectual property rights of others.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We seek to protect our exclusive position of Anticalin technologies by, among other means, prosecuting our own international, U.S. and foreign patent applications related to our proprietary technology, inventions and improvements that are important to the development and implementation of our business. We have established intellectual property protection in relation to our Anticalin technologies in key global markets, including in North America, Europe and Asia. We also rely on trade secrets for confidential know-how, which we generally seek to protect through contractual (for example, confidentiality) agreements with employees and third parties.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have protected the goodwill of our Company and our drug candidates, created through innovation and development, by putting in place trademark registrations of the Pieris and Anticalin marks as well as several defensive registrations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We currently, and expect that we will continue to, file patent applications and maintain granted patents directed to our key drug candidates in an effort to establish intellectual property positions relating to new compositions of matter for these drug candidates, as well as novel medical applications of these compounds in the treatment, prevention or diagnosis of various indications. We also intend to seek patent protection, if available, with respect to biomarkers that may contribute to selecting the right patient population for the use of any of our drug candidates, or with respect to pharmaceutical formulations that may be useful to produce final medicinal products.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We own, or are the exclusive licensee of, a patent portfolio consisting of several issued U.S. patents, and their respective counterparts in a number of foreign jurisdictions, including pending patent applications under the Patent Cooperation Treaty, pending U.S. patent applications and corresponding pending patent applications in a number of foreign jurisdictions as well as pending provisional patent applications, as described in further detail below.</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       24
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In applicable jurisdictions, such as the United States, we will seek patent term extensions for certain issued patents of ours. If we obtain marketing approval for our drug candidates in the United States or certain jurisdictions outside of the United States, we may be eligible for regulatory protection, such as 4 years of data exclusivity and 12 years of market exclusivity for new biological entities in the United States and as mentioned below, up to five years of patent term extension potentially available in the United States, eight to 11 years of data and marketing exclusivity potentially available for new drugs in the European Union, up to five and a half years of patent extension in Europe (supplemental protection certificate) and eight years of exclusivity, similar to data exclusivity in the United States, potentially available in Japan under its re-examination system. There can be no assurance that we will qualify for any such regulatory exclusivity or that any such exclusivity will prevent competitors from seeking approval solely on the basis of their own studies. See &#x201c;Government Regulation.&#x201d;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We hold issued patents and pending patent applications in the United States and other foreign jurisdictions, which patents or patent applications are related to libraries of different scaffolds and consensus sequences such as&#xa0;human NGAL and human tear lipocalin, and are expiring or expected to expire between 2023&#xa0;and 2043, subject to any patent term adjustments and terminal disclaimers in the United States. We also own a number of patents and patent applications at various stages of prosecution directed towards compositions of matter and in some cases, formulations or methods of use, of our preclinical and clinical drug candidates. Where possible, we will pursue patent term adjustments in the United States and any applicable foreign jurisdictions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As a result of our research and licensing agreement, or the TUM License, with Technische Universit&#xe4;t M&#xfc;nchen, or TUM, we hold a worldwide exclusive license to multiple issued patents and pending patent applications. These patents and patent applications relate to Anticalin proteins derived from hNGAL lipocalin muteins and/or a library of an hNGAL scaffold of a certain consensus sequence, which patent is expected to expire in 2029, subject to any patent term adjustments or terminal disclaimers in the United States. We also hold an exclusive license to issued patents or pending patent applications related to bacterial lipocalin muteins and a1m lipocalin muteins.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We hold a number of issued patents and pending patent applications in the United States and foreign jurisdictions directed to newly-discovered or improved scaffold libraries of lipocalin muteins, compounds derived therefrom (i.e., specific drug candidates) or the uses of such compounds to treat, prevent and mitigate certain diseases and conditions whose pathological development involve the targets of interest as well as to diagnose, prognose and select treatments for the diseases and conditions. We would expect that these patents and any patents that may issue from pending applications would likely expire between 2029 and 2043&#xa0;without taking into account possible patent term adjustments or other extensions. However, any and all of these pending patent applications may not result in issued patents, and not all issued patents may be maintained in force for their entire term. We are actively pursuing intellectual property protection for our IO drug candidates in key global markets that, if granted, could expire as late as 2042 or later depending on the date of the filing of such patent applications.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition to issued patents, we hold trademarks in the United States for the Pieris and Anticalin marks. Similarly, we hold their respective counterparts, as registered trademarks, in a number of foreign jurisdictions. We&#xa0;will continue to look for trademark protection for the goodwill associated with our Company and our drug candidates in the countries or regions where we will have investment, research and development, sales or other activities.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We also rely upon unpatented trade secrets and know-how and continuing technological innovation to develop and maintain our competitive advantage. We strive to protect our proprietary information, in part, by using confidentiality agreements and/or invention assignment agreements with our collaborators, scientific advisors, employees and consultants. The confidentiality agreements are designed to protect our proprietary information and, in the case of agreements requiring invention assignment, to grant us ownership of technologies that are developed through a relationship with a third party. We also actively manage our publication and patent applications in that we only disclose information necessary to stir scientific interest or demonstrate patentability without materially compromising the secrecy of our valuable trade secrets and know-how. While we consider trade secrets and know-how to be a critical component of our intellectual property, trade secrets and know-how can be difficult to protect. In particular, with respect to our technology platform, we anticipate that these trade secrets and know-how will, over the course of time, be disseminated within the industry through independent development, the publication of journal articles describing the methodology and the movement of personnel skilled in the technology from academic to industry positions and vice versa. As a result, those proprietary trade secrets and know-how may lose their value to us over a period of time, and we may lose any competitive advantage afforded by them, as they become public knowledge.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Strategic Partnerships</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Since inception, we have entered into several strategic partnerships and other license or option agreements to complement our drug discovery and development. Specifically, we have entered into strategic partnerships with Servier, AstraZeneca, Seagen and Genentech, or collectively, the Strategic Partnerships. Under the Strategic Partnerships, we have developed and conducted or will develop and conduct selection and screening of drug candidates, as well as <i>in vitro</i> potency and efficacy testing, using our Anticalin-brand drug discovery platform, our Anticalin libraries and other proprietary methods to generate, identify and characterize drug candidates against certain biological targets associated with several diseases. The current Strategic Partnerships have provided us with approximately $172.2 million in cash from upfront and milestone payments through December 31, 2022. With respect to discontinued agreements, we have no ongoing performance obligations and do not expect to receive any significant additional consideration pursuant to those agreements.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       25
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Under our ongoing Strategic Partnerships, our partners are obligated to use commercially reasonable efforts to develop and commercialize drug candidates identified in the course of the collaboration. We are entitled to receive from our partners&#x2019; research, development and regulatory milestone payments and, in some cases, including in the Servier, AstraZeneca, Seagen&#xa0;and Genentech collaborations, royalties on net sales for products developed and commercialized under these collaborations. With respect to most of our Strategic Partnerships, we have commercial rights, including the option to co-develop, co-commercialize or co-promote one or more therapeutic programs with the applicable partners. We plan to continue to actively seek out additional collaboration partners that fit within our corporate development strategy.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Strategic Partnerships represent our collaborations in our therapeutic areas of respiratory diseases, as well as IO, and include co-development and co-commercialization options. Certain terms and conditions of these Strategic Partnerships are summarized below.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Our collaboration with AstraZeneca</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On May&#xa0;2, 2017, we entered into the AstraZeneca Collaboration Agreement and a Non-exclusive Anticalin Platform Technology License Agreement with AstraZeneca, or the AstraZeneca Platform License, collectively referred to as the AstraZeneca Agreements, which became effective on June&#xa0;10, 2017, following expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Under the AstraZeneca Agreements the parties will advance several novel inhaled Anticalin proteins. On March 29, 2021, we entered into the first amendment to the Non-exclusive Anticalin Platform License Agreement dated May 2, 2017 and the second amendment to the License and Collaboration Agreement dated May 2, 2017. Under the amendments, the parties agreed to restructure certain commercial economics for the elarekibep program by adjusting various milestones and royalty provisions, while fundamentally maintaining the overall value split between AstraZeneca and the Company. In connection with the amendments, we entered into a Subscription Agreement pursuant to which we have agreed to issue to AstraZeneca 3,584,230 shares of our common stock for a total purchase price of $10.0 million in a private placement transaction. In August 2022, we entered into an amendment to the License and Collaboration Agreement and extended the research term for two of the then remaining discovery-stage programs.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Under the AstraZeneca Agreements, we received an upfront, non-refundable payment of $45.0&#xa0;million. In addition, we initiated a phase 1 study for elarekibep, or the AstraZeneca Lead Product, in December 2017 for which we received a $12.5 million milestone payment. In March 2021, we achieved a $13.0 million milestone in connection with the initiation of the phase 2a study for this program. We are also eligible to receive research, development, commercial and sales milestone payments and royalty payments. The total potential milestones, as of December 31, 2022, were categorized as follows: research, development and commercial milestones up to $0.7&#xa0;million and sales milestones up to $3.9 billion. We may receive tiered royalties on sales of potential products commercialized by AstraZeneca and for co-developed products and gross margin share of worldwide sales, depending on our level of committed investment.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The term of each of the AstraZeneca Agreements ends upon the expiration of all of AstraZeneca&#x2019;s payment obligations under such AstraZeneca Agreement. The AstraZeneca Collaboration Agreement may be terminated by AstraZeneca in its entirety for convenience beginning 12 months after its effective date upon 90 days&#x2019; notice or, if we have obtained marketing approval for the marketing and sale of a product, upon 180 days&#x2019; notice. Each program may be terminated at AstraZeneca&#x2019;s option; if any program is terminated by AstraZeneca, we will have full rights to such program. The AstraZeneca Collaboration Agreement may also be terminated by AstraZeneca or us for material breach upon 180 days&#x2019; notice of a material breach (or 30 days with respect to payment breach), provided that the applicable party has not cured such breach by the permitted cure period (including an additional 180 days if the breach is not susceptible to cure during the initial 180-day period) and dispute resolution procedures specified in the AstraZeneca Collaboration Agreement have been followed. Each party may also terminate an AstraZeneca Agreement if the other party challenges the validity of patents related to certain intellectual property licensed under such AstraZeneca Agreement, subject to certain exceptions for infringement suits, acquisitions and newly-acquired licenses. The AstraZeneca Collaboration Agreement may also be terminated due to the other party&#x2019;s insolvency and may in certain instances be terminated on a product-by-product and/or country-by-country basis. The AstraZeneca Platform License will terminate upon termination of the AstraZeneca Collaboration Agreement, on a product-by-product and/or country-by-country basis.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Our collaboration with Servier</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On January&#xa0;4, 2017, we entered into the Servier Collaboration Agreement and a non-exclusive Anticalin platform license agreement with Servier, or the Servier Platform License, collectively referred to as the Servier Agreements. Pursuant to the terms of the Servier Agreements, we, along with Servier, initially pursued five bispecific therapeutic programs. In September 2019, Servier notified the Company of its decision to discontinue co-development of PRS-332, a PD-1-LAG-3 bispecific that served as the initial development program under the Pieris-Servier alliance, for strategic reasons. After having conducted an extensive portfolio review, Servier decided in March 2020 to discontinue development of two earlier-stage programs in the collaboration. In December 2022, Servier decided to focus on continued and accelerated development of the most advanced program, PRS-344/S095012, and discontinue PRS-352/S095025 for strategic reasons. &#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       26
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Under the Servier Agreements, we received an upfront payment of &#x20ac;30.0 million (approximately $32.0 million) and have achieved two preclinical milestones related to PRS-344/S095012 as well as one clinical milestone related to PRS-344/S095012 and one preclinical milestone related to PRS-352/S095012. We may also receive additional development-dependent and commercial milestone payments for PRS-344/S095012. The total development, regulatory and sales-based milestone payments to us, as of December 31, 2022, could be up to &#x20ac;19.0 million during the life of the collaboration and are dependent on the final number of projects pursued and the number of co-development options exercised by us. We will share preclinical and clinical development costs for each co-developed program with Servier. In addition, we will be entitled to receive tiered royalties up to low double digits on the sales of commercialized products in the Servier territories.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The term of each of the Servier Agreements ends upon the expiration of all of Servier&#x2019;s payment obligations under such Servier Agreement.&#xa0;The Servier Agreements may be terminated by either of us for material breach upon 90 days&#x2019; or 120 days&#x2019; notice of a material breach, with respect to the Servier Collaboration Agreement and the Servier Platform License, respectively, provided that the applicable party has not cured such breach by the applicable 90-day or 120-day permitted cure period, and dispute resolution procedures specified in the applicable Servier Agreement have been followed. The Servier Agreements may also be terminated due to the other party&#x2019;s insolvency or for a safety issue, and may in certain instances be terminated on a product-by-product and/or country-by-country basis. The Servier Platform License will terminate upon termination of the Servier Collaboration Agreement, on a product-by-product and/or country-by-country basis.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Our collaboration with Seagen </i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On February 8, 2018, we entered into the Seagen Collaboration Agreement and a non-exclusive Anticalin platform technology license agreement with Seagen, or the Seagen Platform License, collectively referred to as the Seagen Agreements, pursuant to which the parties will develop multiple targeted bispecific IO treatments for solid tumors and blood cancers.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Under the terms of the Seagen Agreements, Seagen paid us a $30 million upfront fee and will pay tiered royalties on net sales up to the low double-digits. Additionally, Seagen will pay us up to $1.2 billion in total success-based payments, as of December 31, 2022, across three product candidates. The companies will pursue multiple antibody-Anticalin&#xa0;proteins during a research phase, and Seagen has the option to select up to three therapeutic programs for further development. On March 25, 2021 we announced an amendment to the Seagen Collaboration Agreement whereby our option to co-develop and co-commercialize the second of three programs in the collaboration was converted to a co-promotion option for one of the three programs in the United States, with Seagen solely responsible for the development and overall commercialization of that program. We will be entitled to increased royalties in the event that we choose to exercise the co-promotion option for that program. As a result of this amendment, Seagen will solely develop, fund and commercialize all three programs. Seagen may also decide to select additional candidates from the initial research phase for further development in return for the payment to us of additional fees, milestone payments and royalties.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The term of each of the Seagen Agreements ends upon the expiration of all of Seagen&#x2019;s payment obligations under such Seagen Agreement.&#xa0;The Seagen Collaboration Agreement may be terminated by Seagen on a product-by-product basis for convenience beginning 12 months after its effective date upon 90 days&#x2019; notice or, for any program where a pivotal study has been initiated, upon 180 days&#x2019; notice. Any program may be terminated at Seagen&#x2019;s option. If any program is terminated by Seagen after a pre-defined pre-clinical stage, we will have full rights to continue such program. If any program is terminated by Seagen prior to such pre-defined pre-clinical stage, we will have the right to continue to develop such program but will be obligated to offer a co-development option to Seagen for such program. The Seagen Collaboration Agreement may also be terminated by Seagen or us for an uncured material breach by the other party upon 90 days&#x2019; notice, subject to extension for an additional 90 days if the material breach relates to diligence obligations and subject, in all cases, to dispute resolution procedures. The Seagen Collaboration Agreement may also be terminated due to the other party&#x2019;s insolvency and may in certain instances, including for reasons of safety, be terminated on a product-by-product basis. Each party may also terminate the Seagen Agreements if the other party challenges the validity of any patents licensed under the Seagen Agreements, subject to certain exceptions. The Seagen Platform License will terminate upon termination of the Seagen Collaboration Agreement, whether in its entirety or on a product-by-product basis.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In June 2020, we and Seagen entered into amendments to the Seagen Agreements, or together, the Amendment. The Amendment extended the deadline for Seagen to nominate a second and third antibody target, both of which have since been nominated,&#xa0;and triggered a $5.0&#xa0;million milestone payment due from Seagen as Seagen made a go decision on SGN-BB228. In January 2023, we announced that the first patient was dosed in SGN-BB228 and Seagen paid us a $5.0 million milestone fee in connection with this achievement.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Finally, as part of this transaction, we entered into a subscription agreement pursuant to which we agreed to issue to Seagen 3,706,174 shares of our common stock for a total purchase price of $13.0&#xa0;million, or $3.51 per share, in a private placement transaction.</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       27
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Our collaboration with Boston Pharmaceuticals</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On April 24, 2021, we and BP Asset XII, Inc., or Boston Pharmaceuticals, a subsidiary of Boston Pharma Holdings, LLC, entered into an exclusive product license agreement, or the BP Agreement, to develop PRS-342/BOS-342, a 4-1BB/GPC3 preclinical immuno-oncology Mabcalin bispecific protein.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Under the terms of the BP Agreement, Boston Pharmaceuticals exclusively licensed worldwide rights to PRS-342/BOS-342. We received an upfront payment of $10.0 million and are further entitled to receive up to $352.5 million in development, regulatory and sales-based milestone payments, tiered royalties up to low double-digits on sales of PRS-342 and a percentage of consideration received by Boston Pharmaceuticals in the event of a sublicense of a program licensed under the BP Agreement or a change of control of Boston Pharmaceuticals. We will also contribute up to $4.0&#xa0;million toward manufacturing activities.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The term of the BP Agreement ends upon the expiration of all of Boston Pharmaceuticals&#x2019; payment obligations thereunder. The BP Agreement may be terminated by Boston Pharmaceuticals in its entirety for convenience beginning nine months after its effective date upon 60 days&#x2019; notice or, for any program under the BP Agreement which has received marketing approval, upon 120 days&#x2019; notice. If any program is terminated by Boston Pharmaceuticals, we will have full rights to continue such program. The BP Agreement may also be terminated by Boston Pharmaceuticals or us for an uncured material breach by the other party upon 180 days&#x2019; notice (60 days in the case of non-payment of undisputed amounts due and payable), subject to extension for an additional 180 days in certain cases and subject, in all cases, to dispute resolution procedures. The Agreement may also be terminated due to the other party&#x2019;s insolvency. We may also terminate the BP Agreement if Boston Pharmaceuticals challenges the validity of any patents licensed under the BP Agreement, subject to certain exceptions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We do not have any obligations to assist in the research and development efforts of Boston Pharmaceuticals under the BP Agreement. However, we have an obligation to fund up to $4.0&#xa0;million in costs, including out-of-pocket costs incurred by Boston Pharmaceuticals, in connection with the manufacture of products under the BP Agreement. The arrangement with Boston Pharmaceuticals provides for the transfer of the following: (i)&#xa0;exclusive license of PRS-342/BOS-342, (ii)&#xa0;non-exclusive Pieris platform license, (iii)&#xa0;initial know-how, (iv)&#xa0;product cell line license, and (v) materials (as each such term is defined under the BP Agreement).</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       28
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Our collaboration with Genentech</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On May 19, 2021, we and Genentech, Inc., or Genentech, entered into a Research Collaboration and License Agreement, or the Genentech Agreement, to discover, develop and commercialize locally delivered respiratory and ophthalmology therapies that leverage the Company&#x2019;s proprietary Anticalin technology. Upon signing the Genentech Agreement, Genentech paid the Company a $20&#xa0;million upfront fee. In addition, we may be eligible to receive up to approximately $1.4&#xa0;billion in additional milestone payments across multiple programs, as well as tiered royalty payments on net sales at percentages ranging from the mid-single to low double-digits, subject to certain standard reductions and offsets.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Under the terms of the Genentech Agreement, we will be responsible for discovery and preclinical development of two initial programs. We will be responsible for research activities following target nomination through the late-stage research go decision. We and Genentech will then collaborate on drug candidate characterization until the development go decision. After the development go decision, Genentech will be responsible for pursuing the preclinical and clinical development of each program, and thereafter, the commercialization efforts. Each party will be responsible for the costs incurred to perform their respective responsibilities. Genentech has an option to expand the collaboration to encompass two additional programs with the payment of a $10&#xa0;million fee per additional program. If Genentech exercises its option to start additional programs, payment to us of additional fees, milestone payments and royalties would result.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Unless earlier terminated, the term of the Genentech Agreement continues until no royalty or other payment obligations are or will become due under the Genentech Agreement. The Genentech Agreement may be terminated (i) by either party based on insolvency or breach by the other party and such insolvency proceeding is not dismissed or such breach is not cured within 90 days; or (ii) after nine months from the effective date of the Genentech Agreement, by Genentech as a whole or on a product-by-product and/or country-by-country basis upon 90 days&#x2019; prior written notice before the first commercial sale of a product or upon 180 days&#x2019; prior written notice after the first commercial sale of a product.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">While the Genentech Agreement allows for up to four research programs, only two research programs are initially identified and committed in the Genentech Agreement. To reach a total of up to four research programs, we have granted Genentech options to nominate an additional two collaboration targets of their choosing, subject to the legal availability of the target to be researched. Genentech will have three years after the effective date to nominate the subsequent targets. We have also granted Genentech options to replace any of the collaboration targets identified with another target. However, at no point will there be more than four identified collaboration targets for which there are ongoing research programs.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The arrangement with Genentech provides for the transfer of the following goods or services: (i) exclusive research and commercial license for the collaboration programs, (ii) a non-exclusive platform improvement license, (iii) research and development services, (iv)&#xa0;participation in a governance committee, and (v)&#xa0;replacement target options on the first two programs upon a screening failure, which were assessed as material rights.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>In-License Agreements</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition to the Strategic Licenses and Other License Agreements, we have in-licensed a number of technologies and therapeutics, hereinafter referred to as the In-License Agreements, to advance our pipeline and programs, some of which are described below.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>TUM License</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On July&#xa0;4, 2003, we entered into our TUM License which was subsequently renewed and amended on July&#xa0;26, 2007. The TUM License established a joint research effort led by Professor Arne Skerra, Chair of Biological Chemistry of TUM, to optimize Anticalin technologies for use in therapeutic, prophylactic and diagnostic applications and as research reagents, and to gain fundamental insights in lipocalin scaffolds. We provided certain funding for TUM research efforts performed under the agreement. The research phase of this collaboration ended on February&#xa0;28, 2013.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Under the terms of the TUM License, TUM assigned to us certain materials and records resulting from the research. We retained rights to inventions made by our employees, and TUM assigned to us all inventions made under the agreement jointly by our employees and TUM personnel, provided that our employees made certain inventive contributions. With respect to all other inventions made in the course of the research, TUM granted to us worldwide exclusive license rights under patents and patent applications claiming such inventions. TUM retained rights to practice these inventions for research and teaching purposes.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As a result of research efforts to date under the TUM License, we hold a worldwide exclusive license under our agreement with TUM to multiple patents and patent applications related to certain Anticalin proteins and libraries. We bear the costs of filing, prosecution and maintenance of patents assigned or licensed to us under the agreement.</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       29
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As consideration for the assignments and licenses, we are obliged to pay to TUM license payments on development of our proprietary products claimed by patents assigned or licensed to us by TUM. For each of such proprietary products developed by us, we could be required to pay up to an aggregate of approximately &#x20ac;0.2&#xa0;million ($0.2 million) in license payments to TUM under the agreement.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We also are obliged to pay low single-digit royalties, including annual minimum royalties, on sales of such products. Should we grant licenses or sublicenses to those patents to third parties, we are obliged to share a percentage of resulting revenue with TUM, which percentage of resulting revenue is creditable against our annual license payments to TUM. Our payment obligations are reduced by our proportionate contribution to a joint invention. Payment obligations terminate on expiration or annulment of the last patent covered by the agreement.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We can terminate the licenses to any or all licensed patents upon specified advance notice to TUM. TUM may terminate the license provisions of the agreement only for cause. Termination of the agreement does not terminate our rights in patents assigned to us.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Pieris and TUM initiated discussions in the second quarter of 2018 to clarify, expand and restructure the TUM License, including the parties&#x2019; obligations under such license agreement. The parties&#x2019; discussions relate to revised commercial terms and to re-initiating additional collaborations between faculty at TUM and Pieris.&#xa0;While an amended and restated license agreement has not yet been completed, we intend to enter into such an&#xa0;amendment. These discussions may also lead to an increase in our collaborative research activities with TUM.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Kelun License Agreement</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In connection with our efforts to develop multispecific Anticalin-based proteins designed to engage immunomodulatory targets, during the second quarter of 2017, we entered into a license and transfer agreement, or the Kelun Agreement, with Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd., or Kelun. Under the Kelun Agreement, Kelun has granted to us a non-exclusive worldwide license (with the right to sublicense) under certain intellectual property owned or controlled by Kelun to research, develop, manufacture and commercialize bi- and multi- specific fusion proteins that include an antibody developed by Kelun specific for an undisclosed target and one or more Anticalin proteins.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Government Regulation</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, marketing, sales, among other things, of drug products are extensively regulated by governmental authorities in the United States and other countries. The processes for obtaining regulatory approvals in the United States and in foreign countries and jurisdictions, along with subsequent compliance with applicable statutes and regulations and other regulatory requirements, require the expenditure of substantial time and financial resources</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       30
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>U.S. Government regulation of drug and biological products </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In the United States, the FDA regulates human drugs under the Federal Food, Drug, and Cosmetic Act, or the FDCA, and in the case of biologics, also under the Public Health Service Act, or the PHSA, and their implementing regulations. Failure to comply with the applicable U.S. requirements may subject an applicant to administrative or judicial sanctions, such as FDA refusal to approve pending new drug applications, or NDAs, or biologics license applications, or BLAs, or the agency&#x2019;s issuance of warning letters, or the imposition of fines, civil penalties, product recalls, product seizures, total or partial suspension of production or distribution, injunctions and/or criminal prosecution brought by the FDA and the U.S. Department of Justice or other governmental entities.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The process required by the FDA before a drug or biologic may be marketed in the United States generally involves the following:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">completion of preclinical laboratory tests, potentially including animal studies and formulation studies according to Good Laboratory Practices regulations or other applicable regulations;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">submission to the FDA of an IND, which must become effective before human clinical trials may begin;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">approval by an independent institutional review board, or IRB, or ethics committee at each clinical trial site before each clinical trial may be initiated;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">performance of adequate and well-controlled human clinical trials in accordance with applicable IND regulations, current good clinical practices, or cGCPs, and other clinical-trial related regulations to evaluate the safety and efficacy of the investigational product for each proposed indication;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">submission to the FDA of an NDA or BLA for marketing approval, including payment of application user fees;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the drug or biologic is produced to assess compliance with cGMP to assure that the facilities, methods and controls are adequate to preserve the product's identity, strength, quality and purity;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">potential FDA audit of the clinical trial sites to assure compliance with cGCPs and the integrity of the clinical data submitted in support of the NDA or BLA; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">FDA review and approval of the NDA or BLA, including satisfactory completion of an FDA advisory committee review of the product candidate, where appropriate or if applicable, prior to any commercial marketing or sale of the product in the United States.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><span style="text-decoration: underline; ">Preclinical studies</span></i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Before testing any drug or biological product candidate in humans, the product candidate must undergo rigorous preclinical testing. The preclinical developmental stage generally involves laboratory evaluations of drug chemistry, formulation and stability, as well as studies to evaluate toxicity in animals and potential for other adverse events, which support subsequent clinical testing and rationale for subsequent therapeutic use.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div style="font-size: 10pt;">
    The Consolidated Appropriations Act for 2023, signed into law on December 29, 2022, (P.L. 117-328) amended both the FDCA and PHSA to specify that nonclinical testing for drugs and biologics, respectively, may, but is not required to, include
   <i>in vivo</i> animal testing. According to the amended language, a sponsor may fulfill nonclinical testing requirements by completing various
   <i>in vitro</i> assays (e.g., cell-based assays, organ chips, or microphysiological systems),
   <i>in silico</i> studies (i.e., computer modeling), other human or non-human biology-based tests (e.g., bioprinting), or
   <i>in vivo</i> animal tests. The sponsor must submit the results of the preclinical studies, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. An IND is a request for authorization from the FDA to administer an investigational product to humans and must become effective before human clinical trials may begin.
  </div>
  <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The conduct of preclinical studies is subject to federal regulations and requirements, including good laboratory practices, or GLP, regulations for safety and toxicology studies. Some long-term nonclinical testing, such as animal tests of reproductive adverse events and carcinogenicity, may continue after an IND for an investigational drug candidate is submitted to the FDA and human clinical trials have been initiated.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Human clinical trials in support of an NDA or BLA </i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">All clinical trials must be conducted under the supervision of qualified investigators. Clinical trials are conducted under protocols detailing the objectives of the study, the parameters to be used in monitoring the safety and effectiveness criteria to be evaluated. Each protocol must be submitted to the FDA as part of the IND. Study subjects must sign an informed consent form before participating in a clinical trial. There are also requirements governing the reporting of on-going clinical trials and clinical trial results to public registries. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence. Clinical holds may also be imposed by the FDA at any time before or during studies due to safety concerns or non-compliance.</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       31
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition, an IRB representing each institution that is participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and the IRB must thereafter conduct a continuing review and re-approve the trial at least annually. The IRB must review and approve, among other things, the trial protocol and informed consent information to be provided to clinical trial subjects. An IRB must operate in compliance with FDA regulations.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Information about certain clinical trials, including details of the protocol and eventually study results, also must be submitted within specific time frames to the National Institutes of Health, or NIH, for public dissemination on the ClinicalTrials.gov data registry. Information related to the product, patient population, phase of investigation, study sites and investigators and other aspects of the clinical trial is made public as part of the registration of the clinical trial. Sponsors are also obligated to disclose the results of their clinical trials after completion. Disclosure of the results of these trials can be delayed in some cases for up to two years after the date of completion of the trial. Failure to timely register a covered clinical study or to submit study results as provided for in the law can give rise to civil monetary penalties and also prevent the non-compliant party from receiving future grant funds from the federal government. The U.S. Department of Health and Human Services' Final Rule and NIH's complementary policy&#xa0;on ClinicalTrials.gov registration and reporting requirements became effective in 2017, and the government has begun enforcing those requirements against non-compliant clinical trial sponsors.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Phase 1:</i></b>&#xa0;The product candidate is initially introduced into healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion. In the case of some products for severe or life-threatening diseases, such as cancer, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Phase 2:</i></b>&#xa0;This phase involves studies in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Phase 3:</i></b>&#xa0;Clinical trials are undertaken with an expanded patient population to further evaluate dosage, clinical efficacy and safety in an expanded patient population, often at geographically dispersed clinical study sites. These studies are intended to establish the overall risk-benefit ratio of the product candidate and provide, if appropriate, an adequate basis for product labeling. These trials may include comparisons with placebo and/or other comparator treatments. The duration of treatment is often extended to mimic the actual use of a product during marketing.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Post-approval trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of an NDA or BLA.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Congress also recently amended the FDCA, as part of the Consolidated Appropriations Act for 2023, in order to require sponsors of a Phase 3 clinical trial, or other &#x201c;pivotal study&#x201d; of a new drug to support marketing authorization, to design and submit a diversity action plan for such clinical trial. The action plan must include the sponsor&#x2019;s diversity goals for enrollment, as well as a rationale for the goals and a description of how the sponsor will meet them. Sponsors must submit a diversity action plan to the FDA by the time the sponsor submits the relevant clinical trial protocol to the agency for review. The FDA may grant a waiver for some or all of the requirements for a diversity action plan. It is unknown at this time how the diversity action plan may affect Phase 3 trial planning and timing or what specific information FDA will expect in such plans, but if the FDA objects to a sponsor&#x2019;s diversity action plan, it may delay trial initiation.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="background-color:#ffffff;">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse events, or SAEs, occur. The FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the clinical protocol, cGCP, or other IRB requirements or if the drug has been associated with unexpected serious harm to patien</span>ts.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">During the development of a new drug or biological product, sponsors have the opportunity to meet with the FDA at certain points, including prior to submission of an IND, at the end of phase 2, and before submission of an NDA or BLA. These meetings can provide an opportunity for the sponsor to share information about the data gathered to date, for the FDA to provide advice, and for the sponsor and the FDA to reach agreement on the next phase of development. Sponsors typically use the end of phase 2 meeting to discuss their phase 2 clinical results with the agency and to present their plans for the pivotal phase 3 studies that they believe will support approval of the new drug or biological product.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Concurrent with clinical trials, companies usually complete additional nonclinical studies and must also develop additional information about the physical characteristics of the drug or biological product and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality, potency and purity of the final drug or biological product. For biological products in particular, the PHSA emphasizes the importance of manufacturing control for products whose attributes cannot be precisely defined in order to help reduce the risk of the introduction of adventitious agents. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       32
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Marketing application submission and FDA review</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Assuming successful completion of the required clinical testing, the results of the preclinical studies and clinical trials, along with information relating to the product&#x2019;s chemistry, manufacturing, and controls and proposed labeling, are submitted to the FDA as part of an NDA or BLA requesting approval to market the product for one or more indications. Our Anticalin-based product candidates are proteins that will be regulated as biological products subject to the BLA marketing pathway. BLAs must contain proof of the biological product candidate&#x2019;s safety, purity, potency and efficacy for its proposed indication or indications. Data may come from company-sponsored clinical trials intended to test the safety and efficacy of a product&#x2019;s use or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of the investigational product to the satisfaction of the FDA. Under federal law, each NDA or BLA must be accompanied by a significant user fee, and the sponsor of an approved NDA or BLA is also subject to an annual program fee. These fees are typically adjusted annually, but exemptions and waivers may be available under certain circumstances.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The FDA conducts a preliminary review of all NDAs and BLAs within 60 days of receipt and informs the sponsor by the 74<sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup> day after the FDA&#x2019;s receipt of the submission whether an application is sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA or BLA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">After the submission is accepted for filing, the FDA begins an in-depth substantive review. As noted above, the FDA has agreed to specified performance goals in the review process of NDAs and BLAs. Applications are meant to be reviewed within ten&#xa0;months from the date it is accepted for submission or filing, and the applications for &#x201c;priority review&#x201d; products are meant to be reviewed within six&#xa0;months from the date the application is accepted for submission or filing, as discussed in more detail below. The review process may be extended by the FDA for three additional&#xa0;months to consider new information or in the case of a clarification provided by the applicant to address an outstanding deficiency identified by the FDA following the original submission.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Under the goals and policies agreed to by the FDA under the Prescription Drug User Fee Act, or PDUFA, for original BLAs, the FDA has ten months from the filing date in which to complete its initial review of a standard application and respond to the applicant, and six months from the filing date for an application with "priority review." &#xa0;For all BLAs and new molecular entity, or NME, NDAs, the ten and six-month time periods run from the filing date; for all other original applications, the ten and six-month time periods run from the submission date. Despite these review goals, it is not uncommon for FDA review of an NDA or BLA to extend beyond the goal date.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Before approving an NDA or BLA, the FDA will typically conduct a pre-approval inspection of the manufacturing facilities for the new product to determine whether the manufacturing processes and facilities comply with cGMPs. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. The FDA also may inspect the sponsor and one or more clinical trial sites to assure compliance with cGCP requirements and the integrity of the clinical data submitted to the FDA.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Additionally, the FDA may refer any NDA or BLA, including applications for novel biologic candidates which present difficult questions of safety or efficacy, to an advisory committee. Typically, an advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendation of an advisory committee, but it considers such recommendations when making final decisions on approval. The FDA likely will re-analyze the clinical trial data, which could result in extensive discussions between the FDA and the applicant during the review process. The FDA also may require the development of a risk evaluation and mitigation strategy, or REMS, if it determines that a REMS is necessary to ensure that the benefits of the drug outweigh its risks and to assure the safe use of the drug or biological product. The REMS could include medication guides, physician communication plans, assessment plans and/or elements to assure safe use, such as restricted distribution methods, patient registries or other risk minimization tools. The FDA determines the requirement for a REMS, as well as the specific REMS provisions, on a case-by-case basis. If the FDA concludes a REMS is needed, the sponsor of the NDA or BLA must submit a proposed REMS. The FDA will not approve a BLA without a REMS, if required.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Under the Pediatric Research Equity Act, or PREA, as amended, a BLA or supplement to a BLA must contain data that are adequate to assess the safety and efficacy of the product candidate for the claimed indications in all relevant pediatric populations and to support dosing and administration for each pediatric population for which the product is safe and effective. The FDA may grant deferrals for submission of pediatric data or full or partial waivers. The Food and Drug Administration Safety and Innovation Act, or the FDASIA, enacted in 2012, made permanent the PREA to require a sponsor who is planning to submit a marketing application for a product that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration to submit an initial Pediatric Study Plan, or PSP, within sixty days of an end-of-phase 2 meeting or, if there is no such meeting, as early as practicable before the initiation of the phase 3 or phase 2/3 clinical trial. The initial PSP must include an outline of the pediatric study or studies that the sponsor plans to conduct, including trial objectives and design, age groups, relevant endpoints and statistical approach, or a justification for not including such detailed information, and any request for a deferral of pediatric assessments or a full or partial waiver of the requirement to provide data from pediatric studies along with supporting information. The FDA and the sponsor must reach an agreement on the PSP. A sponsor can submit amendments to an agreed upon initial PSP at any time if changes to the pediatric plan need to be considered based on data collected from pre-clinical studies, early phase clinical trials or other clinical development programs.</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       33
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The FDA reviews an NDA to determine, among other things, whether a product is safe and effective for its intended use and whether its manufacturing is cGMP-compliant to assure and preserve the product&#x2019;s identity, strength, quality and purity. The FDA reviews a BLA to determine, among other things whether the product is safe, pure and potent and that the facility (or facilities) in which it is manufactured, processed, packed or held meets standards designed to assure the product&#x2019;s continued safety, purity and potency. The approval process is lengthy and often difficult, and the FDA may refuse to approve an NDA or BLA if the applicable regulatory criteria are not satisfied or may require additional clinical or other data and information. On the basis of the FDA&#x2019;s evaluation of the NDA or BLA and accompanying information, including the results of the inspection of the manufacturing facilities, the FDA may issue either an approval letter or a Complete Response Letter, or CRL. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A CRL indicates that the review cycle of the application is complete and the application will not be approved in its present form. A CRL generally outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. The CRL may require additional clinical or other data, additional pivotal phase 3 clinical trial(s) and/or other significant and time-consuming requirements related to clinical trials, preclinical studies or manufacturing. If a CRL is issued, the applicant may choose to either resubmit the NDA or BLA addressing all of the deficiencies identified in the letter or withdraw the application. If and when those deficiencies have been addressed to the FDA&#x2019;s satisfaction in a resubmission of the NDA or BLA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in response to an issued CRL in either two or six&#xa0;months depending on the type of information included. Even with the submission of this additional information, however, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If a product receives regulatory approval from the FDA, the approval is limited to the conditions of use (e.g., patient population, indication) described in the application. Further, depending on the specific risk(s) to be addressed, the FDA may require that contraindications, warnings or precautions be included in the product labeling, require that post-approval trials, including Phase 4 clinical trials, be conducted to further assess a product&#x2019;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a REMS, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing trials or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Fast Track, Breakthrough Therapy and Priority Review Designations </i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The FDA is authorized to designate certain products for expedited development or review if they are intended to address an unmet medical need in the treatment of a serious or life-threatening disease or condition. These programs include fast track designation, breakthrough therapy designation and priority review designation.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">To be eligible for a fast track designation, the FDA must determine, based on the request of a sponsor, that a product is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address an unmet medical need by providing a therapy where none exists or a therapy that may be potentially superior to existing therapy based on efficacy or safety factors. Fast track designation provides opportunities for more frequent interactions with the FDA review team to expedite development and review of the product. The FDA may also review sections of the NDA or BLA for a fast track product on a rolling basis before the complete application is submitted, if the sponsor and the FDA agree on a schedule for the submission of the application sections and the sponsor pays any required user fees upon submission of the first section of the NDA or BLA. In addition, fast track designation may be withdrawn by the sponsor or rescinded by the FDA if the designation is no longer supported by data emerging from the clinical trial process.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition, with the enactment of FDASIA in 2012, Congress created a new regulatory program for product candidates designated by FDA as &#x201c;breakthrough therapies&#x201d; upon a request made by the IND sponsors. A breakthrough therapy is defined as a drug or biologic that is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug or biologic may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Drugs or biologics designated as breakthrough therapies may also be eligible for accelerated approval of their respective marketing applications. The FDA must take certain actions with respect to breakthrough therapies, such as holding timely meetings with and providing advice to the product sponsor, which are intended to expedite the development and review of an application for approval of a breakthrough therapy.</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       34
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Finally, the FDA may designate a product for priority review if it is a drug or biologic that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness. The FDA determines at the time that the marketing application is submitted, on a case-by-case basis, whether the proposed drug represents a significant improvement in treatment, prevention or diagnosis of disease when compared with other available therapies. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting drug reaction, documented enhancement of patient compliance that may lead to improvement in serious outcomes, or evidence of safety and effectiveness in a new subpopulation. A priority review designation is intended to direct overall attention and resources to the evaluation of such applications, and to shorten the FDA&#x2019;s goal for taking action on a marketing application from ten&#xa0;months to six&#xa0;months for an original BLA or for an NME NDA from the date of filing.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. Furthermore, fast track designation, breakthrough therapy designation and priority review do not change the standards for approval and may not ultimately expedite the development or approval process.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Accelerated approval pathway </i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition, products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may receive accelerated approval from the FDA and may be approved on the basis of adequate and well-controlled clinical trials establishing that the drug product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. The FDA may also grant accelerated approval for such a drug or biologic when the product has an effect on an intermediate clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality, or IMM, and that is reasonably likely to predict an effect on IMM or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a drug receiving accelerated approval perform post-marketing clinical trials to verify and describe the predicted effect on IMM or other clinical endpoint, and the product may be subject to expedited withdrawal procedures. Drugs and biologics granted accelerated approval must meet the same statutory standards for safety and effectiveness as those granted traditional approval.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. An intermediate clinical endpoint is a measurement of a therapeutic effect that is considered reasonably likely to predict the clinical benefit of a drug, such as an effect on IMM. The FDA has limited experience with accelerated approvals based on intermediate clinical endpoints, but has indicated that such endpoints generally may support accelerated approval when the therapeutic effect measured by the endpoint is not itself a clinical benefit and basis for traditional approval, if there is a basis for concluding that the therapeutic effect is reasonably likely to predict the ultimate long-term clinical benefit of a drug.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The accelerated approval pathway is most often used in settings in which the course of a disease is long and an extended period of time is required to measure the intended clinical benefit of a drug, even if the effect on the surrogate or intermediate clinical endpoint occurs rapidly. For example, accelerated approval has been used extensively in the development and approval of drugs for treatment of a variety of cancers in which the goal of therapy is generally to improve survival or decrease morbidity and the duration of the typical disease course requires lengthy and sometimes large clinical trials to demonstrate a clinical or survival benefit.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The accelerated approval pathway is usually contingent on a sponsor&#x2019;s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the drug&#x2019;s clinical benefit. As a result, a product candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of Phase 4 or post-approval clinical trials to confirm the effect on the clinical endpoint.</p>
  <div style="font-size: 10pt;">
    In addition, as part of the Consolidated Appropriations Act for 2023, Congress provided FDA additional statutory authority to mitigate potential risks to patients from continued marketing of ineffective drugs previously granted accelerated approval. Under these recent amendments to the FDCA, the agency may require a sponsor of a product granted accelerated approval to have a confirmatory trial underway prior to approval. The sponsor must also submit progress reports on a confirmatory trial every six months until the trial is complete, and such reports will be published on FDA&#x2019;s website.
  </div>
  <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">Failure to conduct required post-approval studies, or to confirm the predicted clinical benefit of the product during post-marketing studies, allows the FDA to withdraw approval of the drug.</p>
  <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#xa0;</p>
  <div style="font-size: 10pt;">
    Congress also recently amended the law to give FDA the option of using expedited procedures to withdraw product approval if the sponsor&#x2019;s confirmatory trial fails to verify the claimed clinical benefits of the product.
  </div>
  <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">All&#xa0;promotional materials for product candidates being considered and approved under the accelerated approval program are subject to prior review by the FDA.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Patent term restoration</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Depending upon the timing, duration and specifics of FDA approval of our drugs, some of our U.S. patents may be eligible for limited patent term extension. These patent term extensions permit a patent restoration term of up to five years as compensation for any patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product&#x2019;s approval date. The patent term restoration period is generally one-half the time between the effective date of an IND, and the submission date of an NDA or BLA, plus the time between the submission date of an NDA or BLA and the approval of that application. Only one patent applicable to an approved drug is eligible for the extension, and the extension must be applied for prior to expiration of the patent. The United States Patent and Trademark Office, or the USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration.</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       35
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Pediatric exclusivity </i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Pediatric exclusivity is a type of non-patent marketing exclusivity available in the United States and, if granted, it provides for the attachment of an additional six months of marketing protection to the term of any existing regulatory exclusivity or listed patents. This six-month exclusivity may be granted if an NDA sponsor submits pediatric data that fairly respond to a Written Request from the FDA for such data. The data do not need to show the product to be effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA&#x2019;s request, the additional protection is granted. If reports of requested pediatric studies are submitted to and accepted by the FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity or patent protection cover the product are extended by six&#xa0;months. This is not a patent term extension, but it effectively extends the regulatory period during which the FDA cannot approve another application. The issuance of a Written Request by the FDA does not require the sponsor to undertake the described studies.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Reference product exclusivity for biological products</i></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In March 2010, the Patient Protection and Affordable Care Act was enacted in the United States and included the Biologics Price Competition and Innovation Act of 2009, or the BPCIA. The BPCIA amended the PHSA to create an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. Since that time, the FDA has approved approximately 40 biosimilars, including the first interchangeable monoclonal antibody biosimilar in 2021. The FDA has also issued several guidance documents outlining its approach to reviewing and approving biosimilars and interchangeable biosimilar, and has created a public database that contains information on all FDA-licensed biological products, including biosimilars, called the Purple Book.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A biosimilar product is defined as one that is highly similar to a reference product notwithstanding minor differences in clinically inactive components and for which there are no clinically meaningful differences between the biological product and the reference product in terms of the safety, purity and potency of the product. An interchangeable product is a biosimilar product that can be expected to produce the same clinical results as the reference product in any given patient and, for products administered multiple times to an individual, that the product and the reference product may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biological product without such alternation or switch. Upon licensure by the FDA, an interchangeable biosimilar may be substituted for the reference product without the intervention of the health care provider who prescribed the reference product.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The biosimilar applicant must demonstrate that the product is biosimilar based on data from (1)&#xa0;analytical studies showing that the biosimilar product is highly similar to the reference product; (2)&#xa0;animal studies (including toxicity); and (3)&#xa0;one or more clinical studies to demonstrate safety, purity and potency in one or more appropriate conditions of use for which the reference product is approved. In addition, the applicant must show that the biosimilar and reference products have the same mechanism of action for the conditions of use on the label, route of administration, dosage and strength, and the production facility must meet standards designed to assure product safety, purity and potency.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A reference biological product is granted 12 years of market exclusivity from the time of first licensure of the product, and the first approved interchangeable biologic product will be granted an exclusivity period of up to one year after it is first commercially marketed.</p>
  <div style="font-size: 10pt;">
    As part of the Consolidated Appropriations Act for 2023, Congress amended the PHSA in order to permit multiple interchangeable products approved on the same day to receive and benefit from this one-year exclusivity period.
  </div>
  <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;"><br /> If pediatric studies are performed and accepted by the FDA as responsive to a Written Request, the 12-year exclusivity period will be extended for an additional six months. In addition, the FDA will not accept an application for a biosimilar or interchangeable product based on the reference biological product until four years after the date of first licensure of the reference product. &#x201c;First licensure&#x201d; typically means the initial date the particular product at issue was licensed in the United States. Date of first licensure does not include the date of licensure of (and a new period of exclusivity is not available for) a supplement for the reference product for a subsequent application filed by the same sponsor or manufacturer of the reference product (or licensor, predecessor in interest or other related entity) for a change that results in a new indication, route of administration, dosing schedule, dosage form, delivery system, delivery device or strength or for a modification to the structure of the biological product that does not result in a change in safety, purity or potency. Therefore, one must determine whether a new product includes a modification to the structure of a previously licensed product that results in a change in safety, purity or potency to assess whether the licensure of the new product is a first licensure that triggers its own period of exclusivity. Whether a subsequent application, if approved, warrants exclusivity as the &#x201c;first licensure&#x201d; of a biological product is determined on a case-by-case basis with data submitted by the sponsor.</p>
  <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The BPCIA is complex and is still being interpreted and implemented by the FDA and by federal judges. In addition, recent government proposals have sought to reduce the 12-year reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate impact, implementation and meaning of the BPCIA continues to be subject to uncertainty.</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       36
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Orphan drug designation and exclusivity</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Under the Orphan Drug Act, the FDA may grant orphan drug designation to a drug intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making available in the United States a drug for this type of disease or condition will be recovered from sales in the United States for that drug. Orphan drug designation must be requested before submitting an NDA or BLA. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. If a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same indication, except in very limited circumstances, for seven years. Orphan drug exclusivity, however, also could block the approval of one of our products for seven years if a competitor obtains approval of the same drug as defined by the FDA for treatment of the same indication. Recent court cases have challenged FDA&#x2019;s approach to determining the scope of orphan drug exclusivity; however, at this time the agency continues to apply its long-standing interpretation of the governing regulations and has stated that it does not plan to change any orphan drug implementing regulations.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Post-approval requirements</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Following approval of a new product, the manufacturer and the approved product are subject to pervasive and continuing regulation by the FDA, including, among other things, monitoring and recordkeeping activities, reporting of adverse experiences with the product, product sampling and distribution restrictions, complying with promotion and advertising requirements, which include restrictions on promoting drugs for unapproved uses or patient populations (i.e., &#x201c;off-label use&#x201d;) and limitations on industry-sponsored scientific and educational activities. Although physicians may prescribe legally available products for off-label uses, manufacturers may not market or promote such uses. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability. If there are any modifications to the product, including changes in indications, labeling or manufacturing processes or facilities, the applicant may be required to submit and obtain FDA approval of a new NDA/BLA or an NDA/BLA supplement, which may require the applicant to develop additional data or conduct additional nonclinical studies and clinical trials. The FDA may also place other conditions on approvals including the requirement for a REMS to assure the safe use of the product. A REMS could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products. Product approvals may be withdrawn for non-compliance with regulatory standards or if problems occur following initial marketing.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">FDA regulations require that products be manufactured in specific approved facilities and in accordance with cGMPs. The cGMP regulations include requirements relating to organization of personnel, buildings and facilities, equipment, control of components and drug product containers and closures, production and process controls, packaging and labeling controls, holding and distribution, laboratory controls, records and reports and returned or salvaged products. The manufacturing facilities for our product candidates must meet cGMP requirements and satisfy the FDA or comparable foreign regulatory authorities&#x2019; satisfaction before any product is approved and our commercial products can be manufactured. We rely, and expect to continue to rely, on third parties for the production of clinical and commercial quantities of our products in accordance with cGMP regulations. These manufacturers must comply with cGMP regulations that require, among other things, quality control and quality assurance, the maintenance of records and documentation and the obligation to investigate and correct any deviations from cGMP. Manufacturers and other entities involved in the manufacture and distribution of approved drugs or biologics are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain cGMP compliance. Future inspections by the FDA and other regulatory agencies may identify compliance issues at the facilities of our CMOs that may disrupt production or distribution or require substantial resources to correct. In addition, the discovery of conditions that violate these rules, including failure to conform to cGMPs, could result in enforcement actions, and the discovery of problems with a product after approval may result in restrictions on a product, manufacturer or holder of an approved NDA or BLA, including voluntary recall and regulatory sanctions as described below.</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       37
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Once an approval of a drug is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information, imposition of post-market surveillance studies or clinical trials to assess new safety risks, or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">fines, warning letters or other enforcement-related letters or clinical holds on post-approval clinical trials;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">refusal of the FDA to approve pending NDAs/BLAs or supplements to approved NDAs/BLAs, or suspension or revocation of product approvals;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">product seizure or detention, or refusal to permit the import or export of products;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">injunctions or the imposition of civil or criminal penalties;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">consent decrees, corporate integrity agreements, debarment or exclusion from federal health care programs; and/or</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">mandated modification of promotional materials and labeling and the issuance of corrective information.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act, or PDMA, which regulates the distribution of drugs and drug samples at the federal level, and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution. More recently, the Drug Supply Chain Security Act, or DSCSA, was enacted with the aim of building an electronic system to identify and trace certain prescription drugs distributed in the United States, including most biological products. The DSCSA mandates phased-in and resource-intensive obligations for pharmaceutical manufacturers, wholesale distributors and dispensers over a 10&#x2011;year period that is expected to culminate in November&#xa0;2023. From time to time, new legislation and regulations may be implemented that could significantly change the statutory provisions governing the approval, manufacturing and marketing of products regulated by the FDA.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div style="font-size: 10pt;">
    For example, FDA released proposed regulations in February 2022 to amend the national standards for licensing of wholesale drug distributors by the states; establish new minimum standards for state licensing third-party logistics providers; and create a federal system for licensure for use in the absence of a state program, each of which is mandated by the DSCSA.
  </div>
  <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;"><br /> It is impossible to predict whether further legislative or regulatory changes will be enacted, or FDA regulations, guidance or interpretations changed or what the impact of such changes, if any, may be.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Regulation outside of the United States</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition to regulations in the United States, we will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of our products outside of the United States. Whether or not we obtain FDA approval for a product candidate, we must obtain approval from the comparable regulatory authorities of foreign countries or economic areas, such as the 27-member European Union, before we may commence clinical trials or market products in those countries or areas. With the United Kingdom withdrawal from the European Union on January 31, 2020, UK licensing decisions were transferred from EMA to The Medicines and Healthcare Products Regulatory Agency, or MHRA, the UK Regulatory Body. For a period of two years following January 1, 2021, the UK continued to adopt decisions taken by the European Commission on the approval of new marketing authorizations. However, companies will be required to submit an identical application to the MHRA upon the Medicinal Products for Human Use, or CHMP, positive opinion of the application. The MHRA will then wait for the European Commission decision on approval. The approval process and requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly between countries and jurisdictions and can involve additional testing and additional administrative review periods. The time required to obtain approval in other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><span style="text-decoration: underline; ">European Union drug development, review and approval</span></i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In the European Union, our product candidates also may be subject to extensive regulatory requirements. As in the United States, medicinal products can be marketed only if marketing authorization from the competent regulatory agencies has been obtained. Similar to the United States, the various phases of pre-clinical and clinical research in the European Union are subject to significant regulatory controls.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Clinical Trials Directive 2001/20/EC, the Directive 2005/28/EC on GCP, and the related national implementing provisions of the individual EU Member States previously governed the system for the approval of clinical trials in the European Union. Under this system, an applicant had to obtain prior approval from the competent national authority of the EU Member States in which the clinical trial is to be conducted. Furthermore, the applicant could only start a clinical trial at a specific study site after the competent ethics committee has issued a favorable opinion.</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       38
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In 2014, the new Clinical Trials Regulation, (EU) No 536/2014, Clinical Trials Regulation, was adopted and it became effective on January 31, 2022. The Clinical Trials Regulation is directly applicable in all of the EU Member States, as it repealed the Clinical Trials Directive 2001/20/EC. The extent to which ongoing clinical trials will be governed by the Clinical Trials Regulation depends on when the Clinical Trials Regulation became applicable and on the duration of the individual clinical trial. If a clinical trial continues for more than three years from the day on which the Clinical Trials Regulation became applicable, the Clinical Trials Regulation will at that time begin to apply to the clinical trial.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Clinical Trials Regulation aims to simplify and streamline the approval of clinical trials in the European Union. The main characteristics of the regulation include: a streamlined application procedure via a single entry point, the &#x201c;EU portal&#x201d; or Clinical Trial Information System, or CTIS; a single set of documents to be prepared and submitted for the application as well as simplified reporting procedures for clinical trial sponsors; and a harmonized procedure for the assessment of applications for clinical trials, which is divided in two parts. Part I is assessed by the competent authorities of all EU Member States in which an application for authorization of a clinical trial has been submitted (Member States concerned). Part II is assessed separately by each Member State concerned. Strict deadlines have been established for the assessment of clinical trial applications. The role of the relevant ethics committees in the assessment procedure will continue to be governed by the national law of the concerned EU Member State. However, overall related timelines will be defined by the Clinical Trials Regulation. Use of the CTIS became mandatory for new clinical trial application submissions as of February 1, 2023.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">To obtain a marketing authorization of a drug in the European Union, we may submit marketing authorization applications, or MAA, either under the so-called centralized or national authorization procedures.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><span style="text-decoration: underline; ">Centralized procedure</span></i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The centralized procedure provides for the grant of a single marketing authorization following a favorable opinion by the European Medicines Agency, or EMA, that is valid in all EU member states, as well as Iceland, Liechtenstein and Norway. The centralized procedure is compulsory for medicines produced by specified biotechnological processes, products designated as orphan medicinal products, advanced-therapy medicines (such as gene-therapy, somatic cell-therapy or tissue-engineered medicines) and products with a new active substance indicated for the treatment of specified diseases, such as HIV/AIDS, cancer, diabetes, neurodegenerative disorders or autoimmune diseases and other immune dysfunctions and viral diseases. The centralized procedure is optional for products that represent a significant therapeutic, scientific or technical innovation, or whose authorization would be in the interest of public health. Under the centralized procedure the maximum timeframe for the evaluation of an MAA by the EMA is 210 days, excluding clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the Committee for Medicinal Products for Human Use, or the CHMP. Accelerated assessment might be granted by the CHMP in exceptional cases, when a medicinal product is expected to be of a major public health interest, particularly from the point of view of therapeutic innovation. The timeframe for the evaluation of an MAA under the accelerated assessment procedure is of 150 days, excluding stop-clocks.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><span style="text-decoration: underline; ">National authorization procedures</span></i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">There are also two other possible routes to authorize medicinal products in several EU countries, which are available for investigational medicinal products that fall outside the scope of the centralized procedure:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Decentralized procedure. Using the decentralized procedure, an applicant may apply for simultaneous authorization in more than one EU country of medicinal products that have not yet been authorized in any EU country and that do not fall within the mandatory scope of the centralized procedure.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Mutual recognition procedure. In the mutual recognition procedure, a medicine is first authorized in one EU Member State, in accordance with the national procedures of that country. Following this, further marketing authorizations can be sought from other EU countries in a procedure whereby the countries concerned agree to recognize the validity of the original, national marketing authorization.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Under the above-described procedures, before granting the marketing authorization, the EMA or the competent authorities of the Member States of the EEA make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy.</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       39
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><span style="text-decoration: underline; ">Conditional approval</span></i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In specific circumstances, E.U. legislation (Article&#xa0;14(7)&#xa0;Regulation (EC) No 726/2004 and Regulation (EC) No 507/2006 on Conditional Marketing Authorizations for Medicinal Products for Human Use) enables applicants to obtain a conditional marketing authorization prior to obtaining the comprehensive clinical data required for an application for a full marketing authorization. Such conditional approvals may be granted for product candidates (including medicines designated as orphan medicinal products) if (1)&#xa0;the risk-benefit balance of the product candidate is positive, (2)&#xa0;it is likely that the applicant will be in a position to provide the required comprehensive clinical trial data, (3)&#xa0;the product fulfills unmet medical needs and (4)&#xa0;the benefit to public health of the immediate availability on the market of the medicinal product concerned outweighs the risk inherent in the fact that additional data are still required. A conditional marketing authorization may contain specific obligations to be fulfilled by the marketing authorization holder, including obligations with respect to the completion of ongoing or new studies, and with respect to the collection of pharmacovigilance data. Conditional marketing authorizations are valid for one&#xa0;year, and may be renewed annually, if the risk-benefit balance remains positive, and after an assessment of the need for additional or modified conditions or specific obligations. The timelines for the centralized procedure described above also apply with respect to the review by the CHMP of applications for a conditional marketing authorization.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><span style="text-decoration: underline; ">Pediatric studies</span></i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Prior to obtaining a marketing authorization in the European Union, applicants have to demonstrate compliance with all measures included in an EMA-approved Pediatric Investigation Plan, or PIP, covering all subsets of the pediatric population, unless the EMA has granted a product-specific waiver, a class waiver, or a deferral for one or more of the measures included in the PIP. The respective requirements for all marketing authorization procedures are set forth in Regulation (EC) No 1901/2006, which is referred to as the Pediatric Regulation. This requirement also applies when a company wants to add a new indication, pharmaceutical form or route of administration for a medicine that is already authorized. The Pediatric Committee of the EMA, or PDCO, may grant deferrals for some medicines, allowing a company to delay development of the medicine in children until there is enough information to demonstrate its effectiveness and safety in adults. The PDCO may also grant waivers when development of a medicine in children is not needed or is not appropriate, such as for diseases that only affect the elderly population.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Before a marketing authorization application can be filed, or an existing marketing authorization can be amended, the EMA determines that companies actually comply with the agreed studies and measures listed in each relevant PIP.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><span style="text-decoration: underline; ">European Union regulatory exclusivity</span></i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In the European Union, new products authorized for marketing (i.e., reference products) qualify for eight years of data exclusivity and an additional two years of market exclusivity upon marketing authorization. The data exclusivity period prevents generic or biosimilar applicants from relying on the pre-clinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar marketing authorization in the European Union during a period of eight years from the date on which the reference product was first authorized in the European Union. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the EU until ten years have elapsed from the initial authorization of the reference product in the EU. The ten-year market exclusivity period can be extended to a maximum of eleven years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><span style="text-decoration: underline; ">European Union orphan designation and exclusivity</span></i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The criteria for designating an orphan medicinal product in the European Union, are similar in principle to those in the United States. Under Article 3 of Regulation (EC) 141/2000, a medicinal product may be designated as orphan if (1) it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition; (2) either (a) such condition affects no more than five in 10,000 persons in the European Union when the application is made, or (b) the product, without the benefits derived from orphan status, would not generate sufficient return in the European Union to justify investment; and (3) there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized for marketing in the European Union, or if such a method exists, the product will be of significant benefit to those affected by the condition, as defined in Regulation (EC) 847/2000. Orphan medicinal products are eligible for financial incentives such as reduction of fees or fee waivers and are, upon grant of a marketing authorization, entitled to ten years of market exclusivity for the approved therapeutic indication. The application for orphan designation must be submitted before the application for marketing authorization. The applicant will receive a fee reduction for the marketing authorization application if the orphan designation has been granted, but not if the designation is still pending at the time the marketing authorization is submitted. Orphan designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       40
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The ten-year market exclusivity in the European Union may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation, for example, if the product is sufficiently profitable not to justify maintenance of market exclusivity. Additionally, marketing authorization may be granted to a similar product for the same indication at any time if:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the second applicant can establish that its product, although similar, is safer, more effective or otherwise clinically superior;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the applicant consents to a second orphan medicinal product application; or</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the applicant cannot supply enough orphan medicinal product.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><span style="text-decoration: underline; ">PRIME designation</span></i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The EMA grants access to the Priority Medicines, or PRIME, program to investigational medicines for which it determines there to be preliminary data available showing the potential to address an unmet medical need and bring a major therapeutic advantage to patients. As part of the program, the EMA provides early and enhanced dialogue and support to optimize the development of eligible medicines and speed up their evaluation, aiming to bring promising treatments to patients sooner.&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><span style="text-decoration: underline; ">Periods of authorization and renewals</span></i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A marketing authorization is valid for five&#xa0;years in principle and the marketing authorization may be renewed after five&#xa0;years on the basis of a re-evaluation of the risk-benefit balance by the EMA or by the competent authority of the authorizing member state. To this end, the marketing authorization holder must provide the EMA or the competent authority with a consolidated version of the file in respect of quality, safety and efficacy, including all variations introduced since the marketing authorization was granted, at least six&#xa0;months before the marketing authorization ceases to be valid. Once renewed, the marketing authorization is valid for an unlimited period, unless the European Commission or the competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with one additional five-year renewal. Any authorization which is not followed by the actual placing of the drug on the E.U. market (in case of centralized procedure) or on the market of the authorizing member state within three&#xa0;years after authorization ceases to be valid (the so-called sunset clause).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><span style="text-decoration: underline; ">Rest of the world regulation</span></i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">For other countries outside of the European Union and the United States, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from jurisdiction to jurisdiction. Additionally, the clinical trials must be conducted in accordance with cGCP requirements and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><span style="text-decoration: underline; ">Coverage, pricing and reimbursement</span></i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Sales of pharmaceutical products approved by the FDA will depend in significant part on the availability of third-party coverage and reimbursement for the products. Third-party payors include government healthcare programs in the United States such as Medicare and Medicaid, managed care providers, private health insurers and other organizations. These third-party payors are increasingly challenging the price and examining the cost-effectiveness of medical products and services. In addition, significant uncertainty exists as to the reimbursement status of newly approved healthcare products. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors may limit coverage to specific products on an approved list, or formulary, which might not include all of the approved products for a particular indication. We may need to conduct expensive pharmacoeconomic studies to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain FDA or other comparable regulatory approvals. Moreover, a payor&#x2019;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Third-party reimbursement may not be sufficient to maintain price levels high enough to realize an appropriate return on investment in product development. Our product candidates may not be considered cost-effective. It is time consuming and expensive to seek reimbursement from third-party payors. Reimbursement may not be available or sufficient to allow us to sell our products on a competitive and profitable basis.</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       41
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. Some countries provide that drug products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of our product candidate to currently available therapies (so-called health technology assessment, or HTA) in order to obtain reimbursement or pricing approval. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. Other member states allow companies to fix their own prices for drug products but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched in the European Union do not follow price structures of the United States and generally tend to by significantly lower.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The downward pressure on health care costs in general, particularly prescription drugs, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU member states and parallel distribution (arbitrage between low-priced and high-priced member states) can further reduce prices. Any country that has price controls or reimbursement limitations for drug products may not allow favorable reimbursement and pricing arrangements.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div style="font-size: 10pt;">
    In the United States, President Biden signed into the law the Inflation Reduction Act (IRA) in August 2022. Among other things, the IRA has multiple provisions that may impact the prices of drug products that are both sold into the Medicare program and throughout the U.S. Starting in 2023, a manufacturer of drugs or biological products covered by Medicare Parts B or D must pay a rebate to the federal government if their drug product&#x2019;s price increases faster than the rate of inflation. This calculation is made on a drug product by drug product basis and the amount of the rebate owed to the federal government is directly dependent on the volume of a drug product that is paid for by Medicare Parts B or D. Additionally, starting for payment year 2026, the Centers for Medicare &amp; Medicaid Services (CMS) will negotiate drug prices annually for a select number of single source Part D drugs without generic or biosimilar competition. CMS will also negotiate drug prices for a select number of Part B drugs starting for payment year 2028. If a drug product is selected by CMS for negotiation, it is expected that the revenue generated from such drug will decrease. CMS has begun to implement these new authorities but their impact on the biopharmaceutical industry in the United States remains uncertain.
  </div>
  <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Other U.S. health care laws and regulations</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If our product candidates are approved in the United States, we will have to comply with various U.S. federal and state laws, rules and regulations pertaining to health care fraud and abuse, including anti-kickback laws and physician self-referral laws, rules and regulations. Violations of the fraud and abuse laws are punishable by criminal and civil sanctions, including, in some instances, exclusion from participation in federal and state health care programs, including Medicare and Medicaid. These laws include:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the federal anti-kickback statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or paying remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made, in whole or in part, under a federal health care program such as Medicare and Medicaid;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the federal False Claims Act imposes civil penalties, and provides for civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for executing a scheme to defraud any health care benefit program or making false statements relating to health care matters;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH Act, and its implementing regulations, also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the federal transparency requirements under the Physician Payments Sunshine Act require manufacturers of FDA-approved drugs, devices, biologics and medical supplies covered by Medicare, Medicaid or the Children's Health Insurance Program to report, on an annual basis, to CMS, information related to payments and other transfers of value to physicians, teaching hospitals, and certain advanced non-physician health care practitioners and physician ownership and investment interests; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving health care items or services reimbursed by nongovernmental third-party payors, including private insurers.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#x2019;s voluntary compliance guidelines, or the relevant compliance guidance promulgated by the federal government, in addition to requiring drug manufacturers to report information related to payments to physicians and other health care providers or marketing expenditures to the extent that those laws impose requirements that are more stringent than the Physician Payments Sunshine Act. State and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       42
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Health care reform in the United States and potential changes to health care laws</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The FDA&#x2019;s and other regulatory authorities&#x2019; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we are not able to maintain regulatory compliance, we may lose any marketing approval that we otherwise may have obtained and we may not achieve or sustain profitability, which would adversely affect our business, prospects, financial condition and results of operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As previously mentioned, a primary trend in the U.S. health care industry and elsewhere is cost containment. Government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medical products and services, implementing reductions in Medicare and other health care funding and applying new payment methodologies. For example, in March 2010, the Affordable Care Act was enacted, which, among other things, increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program; introduced a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; extended the Medicaid Drug Rebate Program to utilization of prescriptions of individuals enrolled in Medicaid managed care plans; imposed mandatory discounts for certain Medicare Part D beneficiaries as a condition for manufacturers&#x2019; outpatient drugs coverage under Medicare Part D; and established a Center for Medicare Innovation at the CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending.</p>
  <div style="font-size: 10pt;">
    In addition to the IRA&#x2019;s drug price negotiation provisions summarized above, President Biden&#x2019;s Executive Order 14087, issued in October 2022, called for the CMS innovation center to prepare and submit a report to the White House on potential payment and delivery modes that would complement to IRA, lower drug costs, and promote access to innovative drugs. As of mid-January 2023 the report had not been released but it is expected to further inform the current Administration&#x2019;s priorities and activities in this area.
  </div>
  <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We expect that future changes or additions to the Affordable Care Act, the Medicare and Medicaid programs, and changes stemming from other health care reform measures, especially with regard to health care access, financing or other legislation in individual states, could have a material adverse effect on the health care industry in the United States.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">There also has been heightened governmental scrutiny in recent years over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for pharmaceutical and biologic products. For example, the 2021 Consolidated Appropriations Act signed into law on December 27, 2020 incorporated extensive health care provisions and amendments to existing laws, including a requirement that all manufacturers of drug products covered under Medicare Part B report the product&#x2019;s average sales price to CMS beginning on January 1, 2022, subject to enforcement via civil money penalties.</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       43
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In December 2020, the U.S. Supreme Court held unanimously that federal law does not preempt the states&#x2019; ability to regulate pharmacy benefit managers, or PBMs, and other members of the health care and pharmaceutical supply chain, an important decision that appears to be leading to further and more aggressive efforts by states in this area.</p>
  <div style="font-size: 10pt;">
    In mid-2022, the Federal Trade Commission also launched sweeping investigations into the practices of the PBM industry that could lead to additional federal and state legislative or regulatory proposals targeting such entities&#x2019; operations, pharmacy networks, or financial arrangements. Significant efforts to change the PBM industry as it currently exists in the U.S. may affect the entire pharmaceutical supply chain and the business of other stakeholders, including biopharmaceutical developers like us.
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. We expect that additional state and federal health care reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for health care products and services.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Corporate Information</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On December&#xa0;17, 2014, Pieris, Pieris GmbH and the former stockholders of Pieris GmbH entered into an acquisition agreement, or the Acquisition Agreement. Pursuant to the Acquisition Agreement, the stockholders of Pieris GmbH contributed all of their equity interests in Pieris GmbH to Pieris in exchange for shares of Pieris common stock, which resulted in Pieris GmbH becoming a wholly-owned subsidiary of Pieris, which we refer to as the Acquisition.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Upon the closing of the Acquisition on December 17, 2014, Pieris ceased to be a &#x201c;shell company&#x201d; under applicable rules of the Securities and Exchange Commission, or the SEC. As of December 31, 2019, we no longer qualify as an &#x201c;emerging growth company&#x201d; as defined in the Jumpstart Our Business Startups Act of 2012, as amended, or the JOBS Act. As such, we are no longer eligible to take advantage of certain reduced disclosure and other requirements that are otherwise applicable to public companies, including without limitation, (i)&#xa0;providing an auditor&#x2019;s attestation report on our system of internal controls over financial reporting pursuant to Section&#xa0;404(b) of the Sarbanes-Oxley Act of 2002, as amended, or the Sarbanes-Oxley Act, and (ii)&#xa0;complying with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#x2019;s report providing additional information about the audit and the financial statements, known as the auditor discussion and analysis.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Rule&#xa0;12b-2 of the Exchange Act establishes a class of company called a &#x201c;smaller reporting company,&#x201d; which effective September 10, 2018, was amended to include companies with a public float of less than $250 million as of the last business day of their most recently completed second fiscal quarter or, if such public float is less than $700 million, had annual revenues of less than $100 million during the most recently completed fiscal year for which audited financial statements are available. For the year ended December 31, 2022, we qualify as a smaller reporting company.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As a smaller reporting company, we are eligible to and have taken advantage of certain extended accounting standards and exemptions from various reporting requirements that are not available to public reporting companies that do not qualify for those classifications. These exemptions include, but are not limited to, reduced disclosure obligations regarding executive compensation in our periodic and annual reports, exemption from the requirement to provide a compensation discussion and analysis describing compensation practices and procedures, and reduced financial statement disclosure in our registration statements, which must include two years of audited financial statements rather than the three years of audited financial statements that are required for other public reporting companies. Smaller reporting companies are also eligible to provide such reduced financial statement disclosure in annual reports on Form 10-K.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">For as long as we continue to be a smaller reporting company, we expect that we will take advantage of the reduced disclosure obligations available to us as a result of this classification. We will remain a smaller reporting company until we have a public float of $250 million or more as of the last business day of our most recently completed second fiscal quarter, and we could retain our smaller reporting company status indefinitely depending on the size of our public float.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Employees</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We consider our relationship with our employees to be good. In order to successfully develop our drug candidates, we must be able to attract and retain highly skilled personnel. We anticipate hiring additional employees for research and development, clinical and regulatory affairs, and general and administrative activities over the next few years.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Headcount Data</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of December 31, 2022, we had 127&#xa0;full-time employees and 17 permanent part-time employees. None of our employees are represented by a labor union or covered by a collective bargaining agreement. Our corporate headquarters is located in Boston, MA and our R&amp;D facility is located in Hallbergmoos, Germany. As such, 20, or 13.9%, of our employees were located in the United States and 124, or 86.1%, of our employees were located in Germany. We also utilize the services of consultants, clinical research organizations and other third parties on a regular basis from locations across the world.</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       44
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Corporate Values and Ethics</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We strongly believe that our success depends on all of our employees identifying with our company&#x2019;s purpose and understanding how their work contributes to the Company&#x2019;s overall strategy. To this end, we engaged in an inclusive all-company process to develop our company purpose, vision, mission and values.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><span style="text-decoration: underline; ">&#x201c;Improving Lives</span></i><span style="text-decoration: underline; ">&#x201d;</span><i><span style="text-decoration: underline; "> has been defined as the purpose of Pieris</span></i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our corporate culture and values, along with our employees are the most valuable assets of the Company. These values, which are the foundation of our Company culture, are:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Passion,</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Integrity,</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Excellence,</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Responsibility,</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Innovation, and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Spirit of Collaboration.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">These values form part of our goal setting and review process to ensure accountability to these values at all levels. Annual anonymous engagement surveys ensure that we can assess our company culture against expectations and intentions. In order to further ensure we live our values and our culture stays unique and strong, our Board of Directors and executive management team put significant focus on our human capital resources.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We utilize a variety of channels to facilitate open and direct communication, including: (i) monthly all-hands staff meetings, (ii) regular open learning forums to promote peer learning or town hall meetings with executives; (iii) regular ongoing update communications; and (iv) employee surveys beyond the annual engagement survey referenced above on an as-needed basis.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Employee Compensation and Benefits</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our compensation programs are designed to align the compensation of our employees with the Company&#x2019;s performance and to provide the proper incentives to attract, retain and motivate employees to achieve superior results. The structure of our compensation programs balances incentive earnings for both short-term and long-term performance. Specifically:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We provide employee base salaries that are competitive and consistent with employee positions, skill levels, experience, knowledge and geographic location.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">To foster a stronger sense of ownership and align the interests of employees with those of our shareholders, we offer both a stock option program and employee stock purchase program to eligible employees under our broad-based equity incentive plans.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We engage nationally and internationally recognized outside compensation and benefits consulting firms to independently evaluate the effectiveness of our executive compensation and benefit programs and to provide benchmarking against our peers within the industry.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Annual increases and incentive compensation are based on merit, which is communicated to employees at the time of hiring and documented through our talent management process as part of our annual review procedures and upon internal transfer and/or promotion.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">All employees are eligible for health insurance, paid and unpaid leaves, retirement benefits and life and disability/accident coverage. We also offer a variety of voluntary benefits that allow employees to select the options that meet their needs, including flexible time-off, flexible working arrangements, paid parental leave, health programs and onsite food and drink. We aim to provide location-specific attractive benefits packages in all of our locations. We pursue a shared compensation and benefits philosophy and have implemented size and phase-appropriate solutions for each country.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Diversity and Inclusion</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Ingrained in our culture is the philosophy that each individual offers diverse perspectives, backgrounds and experiences that create great outcomes when we are united as a team. We respect our people and embrace our differences. We welcome everyone and value the ideas generated by our collective uniqueness. We aspire that all of our teammates reach their full potential and we encourage them to be confident in their differences. As of December 31, 2022, approximately 60% of our global workforce was female and 40% of our employees in managerial or supervisory roles were female.</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       45
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Employee Development and Training</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We invest significant resources in developing and retaining the talent needed to achieve our business goals. To support our employees in reaching their full potential, we offer internal and promote external learning and development opportunities. Education assistance is offered to financially support employees who seek to expand their knowledge and skill base.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Response to COVID-19 </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Beginning in March 2020 and continuing through all of 2021 and 2022, we have supported our employees and government efforts to curb the COVID-19 pandemic through a multifaceted communication, infrastructure and behavior modification and enforcement effort, with the main objective to keep our laboratories in operation while protecting our employees&#x2019; health and safety:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Establishing clear and regular COVID-19 policies, safety protocols and weekly updates to all employees;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Increasing physical distancing in workspaces for employees working onsite by scheduling adjustments and adding work from home flexibility;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Adjusting attendance policies to encourage those who are sick or are able to perform their work from home to stay home;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Increasing cleaning protocols across all locations;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Providing additional personal protective equipment and cleaning supplies&#x37e;&#xa0;&#xa0;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Implementing site-specific protocols to address actual and suspected COVID-19 cases and potential exposure&#x37e;&#xa0;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Prohibiting all domestic and international non-essential travel for all employees&#x37e;&#xa0;and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Requiring masks to be worn in all locations.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Additionally, we have provided our employees with a stipend to ensure a safe and efficient workspace at home.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Available Information</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our Internet address is www.pieris.com. Copies of our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and all amendments to those reports, are available to you free of charge through the Investors section of our website as soon as reasonably practicable after such materials have been electronically filed with, or furnished to, the SEC. The information contained on, or that can be accessed through, our website is not part of this Annual Report on Form 10-K. We have included our website address in this Annual Report on Form 10-K solely as an inactive textual reference.</p>
  <div>
    &#xa0;
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 81pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b><a id="a1a" title="1a" href="#"></a>Item</b>&#xa0;<b>1A.</b></p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>RISK FACTORS</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, together with the other information contained in this Annual Report on Form 10-K, including our consolidated financial statements and the related notes, before making any decision to invest in shares of our common stock. This Annual Report on Form 10-K contains forward-looking statements. If any of the events discussed in the risk factors below occurs, our business, prospects, results of operations, financial condition and cash flows could be materially harmed. If that were to happen, the trading price of our common stock could decline, and you could lose all or part of your investment. The risks and uncertainties described below are not the only ones we face. Additional risks not currently known to us or other factors not perceived by us to present significant risks to our business at this time also may impair our business operations.</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Following is a summary of our Risk Factors:</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have incurred significant losses since our inception and anticipate that we will continue to incur losses for the foreseeable future. We currently have no product revenues and no approved products and will need to raise additional capital to operate our business.</p> </td>
    </tr>

    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;">&#x2022;</td>
     <td style="vertical-align:top;">The failure of a financial institution counterparty could adversely affect our current and projected business operations and our financial condition and results of operations.</td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We are highly dependent on the success of elarekibep, our lead candidate in our respiratory pipeline. We are executing a broad development program for&#xa0;elarekibep&#xa0;and clinical and regulatory outcomes for elarekibep, which , if not successful, will significantly harm our business.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our limited operating history as a clinical-stage company may hinder our ability to successfully meet our objectives.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our global operations subject us to various risks, and our failure to manage these risks could adversely affect our results of operations.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       46
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If we fail to comply with environmental, health and safety laws and regulations that apply to us, we could become subject to fines or penalties or incur costs that could harm our business.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our current operations are largely concentrated in two locations and any adverse events affecting these locations may have material adverse consequences on our business.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our failure to comply with data protection laws and regulations could lead to government enforcement actions, private litigation and/or adverse publicity and could negatively affect our operating results and business.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Significant disruptions of information technology systems or security breaches could adversely affect our business.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We could be subject to product liability lawsuits based on the use of our drug candidates in clinical testing or, if obtained, following our products' marketing approval and commercialization. If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to cease clinical testing or limit commercialization of our drug candidates.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our business has been and may continue to be adversely affected by the ongoing COVID-19 pandemic.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We are heavily dependent on the successful development of our drug candidates and programs and we cannot be certain that we will receive regulatory approvals or be able to successfully commercialize our products even if we receive regulatory approvals.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Preclinical and clinical testing of our drug candidates that has been conducted to date or will be conducted in the future may not have been or may not be performed in compliance with applicable regulatory requirements, which could lead to increased costs or material delays for their further development.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our research and development efforts are focused on a rapidly evolving area of science, and our approach to drug discovery and development is novel and may never lead to marketable products.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Clinical drug development involves a lengthy and expensive process with uncertain outcomes, clinical trials are difficult to design and implement, and any of our clinical trials could produce unsuccessful results or fail at any stage in the process.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If we experience delays or difficulties in the enrollment of research subjects in clinical trials, those clinical trials could take longer than expected to complete and our receipt of necessary regulatory approvals could be delayed or prevented.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and the results of our clinical trials may not satisfy the requirements of the FDA or comparable foreign regulatory authorities.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The review processes of regulatory authorities are lengthy, time consuming, expensive and inherently unpredictable. If we are unable to obtain approval for our drug candidates from applicable regulatory authorities, we will not be able to market and sell those drug candidates in those countries or regions and our business could be substantially harmed.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our failure to obtain marketing approval in jurisdictions other than the United States and Europe would prevent our product candidates from being marketed in these other jurisdictions. Any approval that we are granted for our product candidates in the United States or Europe would not assure approval of product candidates in the other or in any other jurisdiction.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our product candidates may cause undesirable side effects that could delay or prevent their marketing approval, limit their commercial potential, or result in significant negative consequences following marketing approval, if marketing approval is obtained.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We may expend our limited resources to pursue a particular drug candidate or indication that does not produce any commercially viable products and may fail to capitalize on drug candidates or indications that may be more profitable or for which there is a greater likelihood of success.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We rely on third parties to conduct our clinical trials and preclinical studies. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or otherwise conduct the trials as required or comply with regulatory requirements, we may not be able to obtain regulatory approval for our drug candidates, commercialize our product candidates when expected or at all, and our business could be substantially harmed.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       47
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We rely and expect to continue to rely completely on third parties to formulate, manufacture, and transport our preclinical, clinical trial and commercial drug supplies. The development and commercialization of any of our drug candidates could be stopped, delayed or made less profitable if those third parties fail to provide us with sufficient quantities of such drug supplies or fail to do so at acceptable quality levels, including in accordance with applicable regulatory requirements or contractual obligations, and our operations could be harmed as a result.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Disagreements with respect to the commercial terms of our sales, licensing, purchase or manufacturing agreements may limit our commercial success.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We depend on third parties and intend to continue to license or collaborate with third parties, and events involving these strategic partners or any future collaboration could delay or prevent us from developing or commercializing products.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our success depends in part on the efforts of our current and possible future collaborators, who will likely have substantial control and discretion over the continued development and commercialization of drug candidates that are the subject of our collaborations.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We may not receive any further milestone, royalty or license payments under our current collaborations.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our commercial success depends upon attaining significant market acceptance of our drug candidates, if approved, among physicians, patients, third-party payors and other members of the medical community.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Biologics carry unique risks and uncertainties, which could have a negative impact on future results of operations.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If we breach any of the agreements under which we license from third parties the intellectual property rights or commercialization rights to our drug candidates, particularly our license agreements with TUM and Kelun, we could lose license rights that are important to our business and our operations could be materially harmed.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If our efforts to protect the proprietary nature of the intellectual property related to our technologies are not adequate, we may not be able to compete effectively and our business could be harmed.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Claims that we infringe the intellectual property rights of others may prevent or delay our drug discovery and development efforts.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We may desire to, or be forced to, seek additional licenses to use intellectual property owned by third parties, and such licenses may not be available on commercially reasonable terms, or at all.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Certain technologies and patents have been developed with partners and we may face restrictions on this jointly developed intellectual property.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If we are not able to attract and retain highly qualified personnel, we may not be able to successfully implement our business strategy.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have broad discretion in how we use our cash, cash equivalents and investments, including the net proceeds from our collaborations, public and private securities offerings, and may not use these financial resources effectively, which could affect our results of operations and cause our stock price to decline.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have had and have previously reported material weaknesses in our internal controls over financial reporting. If we fail to maintain proper and effective internal controls, our ability to produce accurate and timely financial statements could be impaired, which could harm our operating results, our ability to operate our business and investors&#x2019;&#xa0;views of us.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans or otherwise, could result in dilution of the percentage ownership of our stockholders and could cause our stock price to fall.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A detailed discussion of the above Risk Factors follows below.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risks Related to Our Business, Financial Position, Capital Requirements, Managing our Growth and Other Legal Compliance Matters</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We have incurred significant losses since our inception and anticipate that we will continue to incur losses for the foreseeable future. We currently have no product revenues and no approved products and will need to raise additional capital to operate our business.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We are a clinical-stage biopharmaceutical company. To date, we have not generated any commercial sales revenue, are not profitable, and have incurred losses since our inception in 2001. For the years ended December 31, 2022 and 2021, we reported net losses of $33.3&#xa0;million and $45.7&#xa0;million, respectively. As of December 31, 2022, we had an accumulated deficit of&#xa0;$290.4 million. We expect to continue to incur losses for the foreseeable future, and we expect these losses to increase as we continue our development of, and seek regulatory approvals for, our drug candidates and the commercialization of approved products, if any.</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       48
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We are currently developing products in our therapeutic areas of respiratory diseases and IO. We have collaborations with major multi-national pharmaceutical companies. In particular, we have alliances with AstraZeneca and Genentech to treat respiratory diseases, with Genentech also in ophthalmology.&#xa0;Our partner AstraZeneca is currently in phase 2a studies of elarekibep, our lead respiratory drug candidate, in multiple countries. We also have alliances with Servier, Seagen, and Boston Pharmaceuticals in IO. Our IO program&#xa0;includes PRS-344/S095012 in partnership with Servier, which is currently in phase 1 studies. Together these programs will result in our continued incurrence of significant research, development and other expenses and resources. If our research and development efforts, including preclinical studies or clinical trials for any of our drug candidates fail or produce unsuccessful results and those drug candidates do not gain regulatory approval, or if any of our drug candidates, if approved, fail to achieve market acceptance, we may never become profitable. In addition, the failure of one drug candidate or program may have an adverse impact on other drug candidates and programs within our class of Anticalin-based therapies. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders&#x2019; equity and working capital.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><br /> <i><b><i>The failure of a financial institution counterparty could adversely affect our current and projected business operations and our financial condition and results of operations.</i></b></i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">On March 10, 2023,&#xa0;Silicon Valley Bank, or SVB, was closed by the California Department of Financial Protection and Innovation, which appointed the FDIC as receiver. Similarly, on March 12, 2023, Signature Bank and Silvergate Capital Corp. were each placed into receivership. A statement by the Department of the Treasury, the Federal Reserve and the FDIC stated that all depositors of SVB would have access to all of their money after only one business day of closure, including funds held in uninsured deposit accounts. A failure of a depository institution to return deposits could impact access to our invested cash or cash equivalents and could adversely impact our operating liquidity and financial performance.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&#xa0;</p>
  <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;"><b><i>We are highly dependent on the success of elarekibep, our lead candidate in our respiratory pipeline.</i></b>&#xa0;<b><i>We are executing a broad development program for elarekibep and clinical and regulatory outcomes for elarekibep, which, if not successful, will significantly harm our business.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our future success is highly dependent on our ability to successfully develop, obtain regulatory approval for and commercialize elarekibep. In general, most early-stage investigatory drugs, including inhaled drug candidates such as elarekibep, do not become approved drugs.&#xa0;Accordingly, there is a very meaningful risk that elarekibep will not succeed in one or more clinical trials sufficient to support one or more regulatory approvals. To date, clinical and preclinical outcomes from elarekibep have had a significant impact on our market valuation, financial position and business prospects, and we expect this to continue in future periods. If one or more clinical trials of elarekibep is not successful, it would materially harm our market valuation, prospects, financial condition and results of operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We will need substantial additional funding to continue our operations, which could result in significant dilution or restrictions on our business activities. We may not be able to raise capital when needed, if at all, or on terms acceptable to us, which would force us to delay, reduce or eliminate some or all of our product development programs or commercialization efforts and could cause our business to fail.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our operations have consumed substantial amounts of cash since our inception. We expect to need substantial additional funding to continue the preclinical and clinical development of our drug candidates, as well as to launch and commercialize any drug candidates for which we receive regulatory approval.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We will require additional capital for the further development and commercialization of our drug candidates and programs, and may need to raise additional funds sooner than we currently anticipate if we choose to and are able to expand more rapidly than we currently anticipate. Further, we expect our expenses to increase in connection with our ongoing activities, particularly as we continue to advance, expand and monitor the performance of our preclinical and clinical programs, such as elarekibep, PRS-220, PRS-400 and PRS-344/S095012, as well as additional programs that we advance through preclinical development and into the clinic and whose performance we monitor. In addition, if we obtain regulatory approval for any of our drug candidates, we expect to incur significant commercialization expenses related to regulatory requirements, product manufacturing, marketing, sales and distribution.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Furthermore, we expect to continue to incur additional costs associated with operating as a public company. We may also encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may increase our capital needs and/or cause us to spend our cash resources faster than we expect.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">To date, we have financed our operations through a mix of equity investments from private and public investors, the incurrence of debt, grant funding and the receipt of up-front and milestone payments due under our various collaboration agreements, and we expect to continue to finance our operations in part through equity investments from public investors for the foreseeable future. Additional funding from those or other sources may not be available when or in the amounts needed, on acceptable terms, or at all. Our ability to secure additional funding from those or other sources could be significantly impacted by a multitude of events that are beyond our control, including, but not limited to, changes in the macroeconomic environment and other events affecting the stock market, including the availability of research and other information, favorable or unfavorable, published by securities or industry analysts and news agencies.</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       49
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Raising capital through the sale of equity or securities convertible into equity would result in dilution to our then-existing stockholders, which could be significant depending on the price at which we may be able to sell our securities. If we raise additional capital through the incurrence of indebtedness, we would likely become subject to covenants restricting our business activities, and holders of debt instruments may have rights and privileges senior to those of our equity investors. In addition, servicing the interest and principal repayment obligations under debt facilities could divert funds that would otherwise be available to support research and development, clinical or commercialization activities.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If we obtain capital through collaborative or licensing arrangements, these arrangements could require us to relinquish rights to our Anticalin-based technology or drug candidates and could result in receipt of only a portion of the revenues associated with the potential commercialization of our partnered drug candidates.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If we are&#xa0;unable to obtain additional funding on acceptable terms when needed, we&#xa0;will defer or limit a substantial portion of our&#xa0;research, development and clinical projects, reduce discretionary expenditures and other fixed or variable personnel costs. For example, our budget and operating plan for 2023, approved by the Board, does not include such discretionary costs, and management is prepared to gate future investments on PRS-220 and PRS-400.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Any of these events could significantly harm our business, financial condition, and prospects.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our limited operating history as a clinical-stage company may hinder our ability to successfully meet our objectives.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We were formed in 2001, and since that time our focus has been on discovery of Anticalin-brand drug candidates. AstraZeneca is currently conducting clinical development of elarekibep, Seagen is conducting clinical development of SGN-BB228, &#xfeff;and we are conducting clinical development in PRS-220 and PRS-344/S095012, in partnership with Servier. We are also advancing other drug candidates, including PRS-400, through preclinical development with the intention of initiating additional clinical-stage programs. In addition to our development plans for&#xa0;respiratory diseases, we&#xa0;are also exploring additional indications that may be suitable for Anticalin-based therapies. Our drug candidates are in the early stages of development, have not obtained marketing approval, have never generated any revenue from sales and will require extensive testing before commercialization. We have limited experience with clinical-stage operations, including manufacturing required to support clinical activities and have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the biopharmaceutical area. In addition, the early-stage nature of our drug discovery and development operations can only provide limited operating results upon which investors can evaluate our business and prospects.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our limited operating history may adversely affect our ability to implement our business strategy and achieve our business goals, which include, among others, the following activities:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">developing our drug candidates using unproven technologies;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">undertaking preclinical development and clinical trials as well as formulating and manufacturing products;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">obtaining the human, financial and other resources necessary to develop, test, manufacture, commercialize and market our drug candidates;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">engaging corporate partners to assist in developing, testing, manufacturing and marketing our drug candidates;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">continuing to build and maintain an intellectual property portfolio covering our technology and drug candidates;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">satisfying the requirements of clinical trial protocols, including patient enrollment, establishing and demonstrating the clinical safety and efficacy of our drug candidates and obtaining necessary regulatory approvals;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">achieving acceptance and use by the medical community of our Anticalin platform and drug candidates after they receive regulatory approvals;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">maintaining, growing and managing our internal teams as and to the extent we increase our operations and develop new segments of our business;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">developing and maintaining successful collaboration, strategic and other relationships for the development and commercialization of our drug candidates that receive regulatory approvals with existing and new partners; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">managing our cash flows and any growth we may experience in an environment where costs and expenses relating to clinical trials, regulatory approvals and commercialization continue to increase.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If we are unsuccessful in accomplishing any or all of these objectives, we may not be able to raise capital, expand our business, develop our drug candidates or continue our operations.</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       50
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our global operations subject us to various risks, and our failure to manage these risks could adversely affect our results of operations.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our business is subject to certain risks associated with doing business globally. One of our growth strategies is to pursue opportunities for our business in several areas of the world, including the United States, Europe (including Germany), Asia and Australia, any or all of which could be adversely affected by the risks set forth below. Accordingly, we face significant operational risks as a result of doing business internationally, such as:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">fluctuations in foreign currency exchange rates;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">potentially adverse tax consequences and changes in tax laws;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">challenges in providing solutions across a significant distance, in different languages, different time zones and among different cultures (particularly, for as long as travel is limited due to the COVID-19 pandemic);</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">different, complex and changing laws governing intellectual property rights, sometimes affording reduced protection of intellectual property rights in certain countries, and data privacy and security laws;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">difficulties in staffing and managing foreign operations, particularly in new geographic locations, and related compliance with employment, immigration and labor laws for employees or other staff living abroad;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">restrictions imposed by local labor practices and laws on our business and operations;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">economic weakness, including inflation, or rapid changes in government, economic and political policies and conditions, political or civil unrest or instability, economic or trade sanctions, closure of markets to imports, terrorism or epidemics and other similar outbreaks or events;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">compliance with a wide variety of complex foreign laws, treaties and regulations;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">compliance with the U.S. Foreign Corrupt Practices Act, or the FCPA, and other anti-corruption and anti-bribery laws;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">unexpected changes in tariffs, trade barriers and other regulatory or contractual limitations on our ability to develop or sell our products in certain foreign markets; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">becoming subject to the laws, regulations and court systems of multiple jurisdictions.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our failure to manage the market and operational risks associated with our international operations could limit the future growth of our business and adversely affect our results of operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our international operations pose currency risks, which may adversely affect our operating results and net income.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Due to our operations outside of the United States, we are exposed to market risk related to changes in foreign currency exchange rates. Changes in the relative values of currencies occur regularly and, in some instances, could materially adversely affect our business, our financial condition, the results of our operations or our cash flows. Our operating results may be affected by volatility in currency exchange rates and our ability to effectively manage our currency transaction risks. Our reporting currency is the U.S. dollar, however, 75%&#xa0;of our operating expenses and all of our revenues are recorded in non-U.S. entities. As such, our financial statements are translated for reporting purposes as follows: (1)&#xa0;asset and liability accounts at year-end rates, (2)&#xa0;income statement accounts at weighted average exchange rates for the year and (3)&#xa0;stockholders&#x2019; equity accounts at historical rates. Corresponding translation gains or losses are recorded in stockholders&#x2019; equity.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We incur currency transaction risks whenever we enter into either a purchase or a sale transaction using a currency other than the euro, our functional currency, particularly in our arrangements for the purchase of supplies or licensing and collaboration agreements with partners outside of the United States. In such cases, we may suffer an exchange loss because we do not currently engage in currency swaps or other currency hedging strategies to address this risk.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As we continue to operate and enter into agreements and arrangements in the United States, Germany, Australia and elsewhere internationally, our exposure to currency risks will increase. We do not manage our foreign currency exposure in a manner that would eliminate the effects of changes in foreign exchange rates. Therefore, changes in exchange rates between these foreign currencies and the U.S. dollar will affect our revenues and expenses and could result in exchange losses in any given reporting period.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Given the volatility of exchange rates, especially as a result of ongoing developments of the COVID-19 pandemic, we can give no assurance that we will be able to effectively manage our currency transaction risks or that any volatility in currency exchange rates will not have an adverse effect on our results of operations.</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       51
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We are subject to anti-corruption laws, as well as export control laws, customs laws, sanctions laws and other laws governing our operations. If we fail to comply with these laws, we could be subject to civil or criminal penalties, other remedial measures and legal expenses, which could adversely affect our business, results of operations and financial condition.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Our operations are subject to anti-corruption laws, including the FCPA, and other anti-corruption laws that apply in countries where we do business and may do business in the future. The FCPA and these other laws generally prohibit us, our officers, and our employees and intermediaries from bribing, being bribed or making other prohibited payments to government officials or other persons to obtain or retain business or gain some other business advantage. We may in the future operate in jurisdictions that pose a high risk of potential FCPA violations and we may participate in collaborations and relationships with third parties whose actions could potentially subject us to liability under the FCPA or local anti-corruption laws. In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which our international operations might be subject or the manner in which existing laws might be administered or interpreted.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We are also subject to other laws and regulations governing our international operations, including regulations administered by the government of the United States, the United Kingdom and authorities in the European Union, such as applicable export control regulations, economic sanctions on countries and persons, customs requirements and currency exchange regulations, collectively referred to as the Trade Control laws.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">There is no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws, including the FCPA, or other legal requirements, including Trade Control laws. If we are not in compliance with the FCPA and other anti-corruption laws or Trade Control laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses, which could have an adverse impact on our business, financial condition, results of operations and liquidity. Likewise, any investigation of any potential violations of the FCPA, other anti-corruption laws or Trade Control laws by U.S. or other authorities could also have an adverse impact on our reputation, our business, results of operations and financial condition.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>If we fail to comply with environmental, health and safety laws and regulations that apply to us, we could become subject to fines or penalties or incur costs that could harm our business.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of any hazardous materials and wastes. The use of these materials in our business could result in contamination or injury, which could cause damage for which we may be responsible but may not have sufficient resources to pay. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with these laws and regulations, which we may not be able to afford.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Although we maintain workers&#x2019; compensation insurance for our operations in Germany to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations applicable to us. These current or future laws and regulations may impair our research, development or production efforts or impact the research activities we pursue, particularly with respect to research involving human subjects or animal testing. Our failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions, which could cause our financial condition to suffer.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Health and safety regulations in the United States, Germany, and Australia and in the countries where our technology and potential products are or may be developed, licensed or sold may prevent the sale or use of our technology or products in the future.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We are subject to a variety of regulations regarding worker health and safety in the United States, the European Union (Germany), Australia and in the countries where our technology and potential products are licensed or may be sold. These regulations may continue to change due to the ongoing developments of the COVID-19 pandemic. Because our technology and potential products may frequently involve the manufacture or use of certain chemical or biological compounds, we are required to certify their safety for industrial use and development in a variety of countries and contexts. As there has not been sufficient testing to determine the long-term health and environmental risks of our Anticalin-based drug candidates and the materials used in the production of such drug candidates and any future products, future regulations may ban the use of our products due to the potential risk they pose to workers or may limit the use of our drug candidates in research and commercial settings. Any such regulations may have a substantial negative impact on our business and revenues and may cause our business to fail. Because we cannot guarantee the long-term safety of use or exposure to materials used during development or manufacture of our products, we may face liability for health risks or harms caused as a result of developing, manufacturing or other processes that use such materials. Any such claims may have a negative impact on our revenues and may prove substantially disruptive to our business in the future.</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       52
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We may be limited in our use of our net operating loss carryforwards</i></b><b>.</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of December 31, 2022, we had net operating loss carryforwards for United States federal income tax purposes of $38.6&#xa0;million and net operating loss carryforwards for state income tax purposes of $42.4 million. Tax loss carryforwards that were generated prior to December 31, 2017 expire through 2037; U.S. federal tax loss carryforwards generated after that date do not expire. State loss carryforwards expire starting in 2035. In the United States, utilization of the net operating loss carryforwards may be subject to a substantial annual limitation under Section&#xa0;382 of the Internal Revenue Code of 1986, as amended, or the Code, and similar state provisions due to ownership change limitations that have occurred previously or that could occur in the future. These ownership changes may limit the amount of net operating loss carryforwards that can be utilized annually to offset future taxable income and tax, respectively. If we were to lose the benefits of these loss carryforwards, our future earnings and cash resources would be materially and adversely affected. We completed a Section 382 study through December 31, 2020. Based on the study, we underwent an ownership change for Section 382 purposes which occurred in February 2018. As a result of the ownership change, our net operating loss and tax credit carryforwards as of the ownership change dates are subject to limitation under Section 382; however, these limitations are not expected to result in any of the impacted net operating loss and tax credit carryforwards to expire unutilized. Any net operating losses or tax credits generated after the February 2018 change are not subject to this annual limitation. However, subsequent ownership changes, as defined by Section 382, may potentially further limit the amount of net operating loss and tax credit carryforwards that could be utilized to offset future taxable income and tax.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of December 31, 2022, we had German corporate income tax and trade tax net operating loss carryforwards of approximately $163.3&#xa0;million and $160.4million, respectively, which may be used to reduce our future taxable income in Germany. Under current German laws, tax loss carryforwards may only be used to offset any relevant later assessment period (calendar year) by $1.2&#xa0;million plus 60%&#xa0;of the exceeding taxable income and trade profit of such period and do not expire. In addition, certain transactions, including transfers of shares or interest in the loss holding entity, may result in the partial or total forfeiture of tax losses existing at that date. Partial or total forfeiture of tax losses may further occur in corporate reorganizations of the loss holding entity.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our business and operations would suffer in the event of system failures, and our operations are vulnerable to interruption by natural disasters, terrorist activity, power loss, adverse public health events and other events beyond our control, the occurrence of which could materially harm our business and drug development efforts.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Despite the implementation of security measures, our internal computer systems and those of our contractors and consultants are vulnerable to damage from computer viruses, hacking, ransomware, cyber-attacks, unauthorized access as well as telecommunication and electrical failures. Our information technology and other internal infrastructure systems, including corporate firewalls, servers, leased lines and connection to the Internet, face the risk of systemic failure that could materially disrupt our operations. Although we have invested significant resources to enhance the security of our computer systems, there can be no assurances we will not experience unauthorized intrusions into our computer systems, or those of our CROs, vendors, contractors and consultants, that we will successfully detect future unauthorized intrusions in a timely manner or that future unauthorized intrusions will not result in material adverse effects on our financial condition, reputation or business prospects.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">While we have not experienced any such material system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our drug development programs and operations. For example, the loss of clinical trial data from completed, ongoing, or planned clinical trials could result in delays in our regulatory approval efforts and we may incur substantial costs to attempt to recover or reproduce such data. Likewise, we currently rely, and expect to continue to rely, on third parties for the manufacture of our product candidates and any future product candidates and to conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on our business. Certain data security breaches must be reported to affected individuals and the government, and in some cases to the media, under provisions of HIPAA, other U.S. federal and state law and requirements of non-U.S. jurisdictions, and financial penalties may also apply. If any disruption or security breach resulted in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and/or the further development of our drug candidates could be delayed.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We are also vulnerable to accidents, electrical blackouts, labor strikes, terrorist activities, war, natural disasters, adverse public health events and other events beyond our control, and we have not undertaken a systematic analysis of the potential consequences to our business as a result of all of such events and do not have an applicable recovery plan in place. Any disruption to our operations or the operations of our collaborators or suppliers from these kinds of events would likely impact our drug development efforts, operating results and our financial condition. With respect to potential impacts of the ongoing COVID-19 pandemic, see &#x201c;<i>The COVID-19 pandemic and its emerging variants, or any future pandemic, could adversely affect our business, including research, clinical trials, supply chain interruptions and financial condition.</i>&#x201d;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       53
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition, certain of our development efforts, particularly those related to the phase 2 study of elarekibep and phase 1 study of PRS-220, which are being conducted in Australia, in addition to multiple other countries, are located in geographical areas that are known to be prone to certain natural disasters and weather events, including wildfires. In 2019 and 2020, dozens of wildfires erupted in New South Wales, Australia, prompting the government of Australia to declare a state of emergency. Should such a natural disaster that causes disruption to our development efforts occur again in Australia or elsewhere, thereby impeding our ability or the ability of our collaborators to timely conduct our clinical trials, our ability to conduct our business could be severely restricted and our business, clinical development efforts, prospects, and results of operations could be adversely affected as a result. The extent to which any natural disaster may impact our results will depend on future developments, which are highly uncertain and cannot be predicted.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Although we carry insurance to protect us against some losses or damages resulting from certain types of disasters, the extent of that insurance is limited in scope and amount, and we cannot assure you that our insurance coverage will be sufficient to satisfy any damages and losses. If our facilities are unable to operate because of an accident or incident or for any other reason, even for a short period of time, any or all of our research and development programs may be harmed. Any business interruption may have a material adverse effect on our business, financial position, results of operations, and prospects.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our current operations are largely concentrated in two locations, and any adverse events affecting these locations may have material adverse consequences on our business.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our current operations are carried out primarily in our facilities located in Hallbergmoos, Germany and Boston, Massachusetts. Any unplanned event, such as a flood, fire, explosion, earthquake, extreme weather condition, medical epidemic or pandemic, power shortage, telecommunication failure, or other natural or man-made accident, or an incident that prevents us from fully utilizing our facilities in these two locations, may have a material adverse effect on our ability to operate our business, particularly on a daily basis, and have significant negative consequences on our financial and operating conditions. Loss of access to these facilities may result in increased costs, delays in the development of our product candidates, or interruption of our business operations. In the event of an accident or incident at these facilities, we cannot assure you that our insurance coverage will be sufficient to satisfy any damages and losses. If our facilities are unable to operate because of an accident or incident or for any other reason, even for a short period of time, any or all of our research and development programs may be harmed. Any business interruption may have a material adverse effect on our business, financial position, results of operations and prospects.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our failure to comply with data protection laws and regulations could lead to government enforcement actions, private litigation and/or adverse publicity and could negatively affect our operating results and business.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We are subject to data protection laws and regulations that address privacy and data security. The legislative and regulatory landscape for data protection continues to evolve, and there has been an increasing focus on privacy and data security issues with the potential to affect our business. In the United States, numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy laws and federal and state consumer protection laws govern the collection, use, disclosure and protection of health-related and other personal information. Failure to comply with data protection laws and regulations could result in government enforcement actions, which could include civil or criminal penalties, private litigation and/or adverse publicity and could negatively affect our operating results and business. For example, California has enacted the California Consumer Privacy Act, or CCPA, which went into effect in January 2020. The CCPA establishes a new privacy framework for covered businesses by creating an expanded definition of personal information, establishing new data privacy rights for California residents, and creating a new and potentially severe statutory damages framework for violations of the CCPA and for businesses that fail to implement reasonable security procedures and practices to prevent data breaches. Additionally, in 2020, California voters passed the California Privacy Rights Act, or CPRA, effective January 1, 2023. The CPRA significantly amends the CCPA, potentially resulting in further uncertainty, additional costs and expenses in an effort to comply and additional potential for harm and liability for failure to comply. Among other things, the CPRA established a new regulatory authority, the California Privacy Protection Agency, which is tasked with enacting new regulations under the CPRA and will have expanded enforcement authority. Effective in 2023, Virginia,&#xa0;Colorado, Connecticut and Utah enacted similar data protection laws, and other U.S. states have proposals under consideration, increasing the regulatory compliance risk.</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       54
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Numerous other countries have, or are developing, laws governing the collection, use and transmission of personal information as well. For example, the European Union&#x2019;s General Data Protection Regulation, or GDPR, went into effect in 2018 and imposed</p>
  <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">a broad data protection framework that expanded the scope of EU data protection law, including to non-EU entities that process, or control the processing of, personal data relating to individuals located in the EU, including clinical trial data. The GDPR sets out a number of requirements that must be complied with when handling the personal data of EU based data subjects, including: providing expanded disclosures about how their personal data will be used; higher standards for organizations to demonstrate that they have obtained valid consent or have another legal basis in place to justify their data processing activities; the obligation to appoint data protection officers in certain circumstances; new rights for individuals to be &#x201c;forgotten&#x201d; and rights to data portability, as well as enhanced current rights (e.g., access requests); the principal of accountability and demonstrating compliance through policies, procedures, training and audit; and a new mandatory data breach regime. In particular, medical or health data, genetic data and biometric data are all classified as &#x201c;special category&#x201d; data under the GDPR and afford greater protection and require additional compliance obligations. Further, EU member states have a broad right to impose additional conditions&#x2014;including restrictions&#x2014;on these data categories. This is because the GDPR allows EU member states to derogate from the requirements of the GDPR mainly in regard to specific processing situations (including special category data and processing for scientific or statistical purposes). We are subject to the GDPR and the German federal data privacy law, the Bundesdatenschutzgesetz, and we are subject to the regulatory authority of the Bavarian data protection authority, the BayLDA. As the EU states continue to reframe their national legislation to harmonize with the GDPR, we will need to monitor compliance with all relevant EU member states&#x2019; laws and regulations, including where permitted derogation from the GDPR are introduced.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We are also subject to evolving EU laws on data export, because we transfer data to countries outside of the EU, including the United States and United Kingdom,&#xa0;to ourselves or third parties. The GDPR only permits exports of data outside of the EU where there is a suitable data transfer solution in place to safeguard personal data (e.g., the EU Commission approved Standard Contractual Clauses). On July 16, 2020, the Court of Justice of the EU, or the CJEU, issued a landmark opinion in the case Maximilian Schrems vs. Facebook (Case C-311/18) (Schrems II). This decision calls into question certain data transfer mechanisms as between the EU member states and the US. The CJEU is the highest court in Europe and the Schrems II decision heightens the burden on data importers to assess U.S. national security laws on their business future actions of EU data protection authorities are difficult to predict at the early date. Consequently, there is some risk of any data transfers from the EU being halted. If we have to rely on third parties to carry out services for us, including processing personal data on our behalf, we are required under GDPR to enter into contractual arrangements to help ensure that these third parties only process such data according to our instructions and have sufficient security measures in place. Any security breach or non-compliance with our contractual terms or breach of applicable law by such third parties could result in enforcement actions, litigation, fines and penalties or adverse publicity and could cause customers to lose trust in us, which would have an adverse impact on our reputation and business. Any contractual arrangements requiring the processing of personal data from the EU to us in the United States will require greater scrutiny and assessments as required under Schrems II and may have an adverse impact on cross-border transfers of personal data, or increase costs of compliance. The GDPR provides an enforcement authority to impose large penalties for noncompliance, including the potential for fines of up to &#x20ac;20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Applicable data privacy and data protection laws may conflict with each other, and by complying with the laws or regulations of one jurisdiction, we may find that we are violating the laws or regulations of another jurisdiction. Despite our efforts, we may not have fully complied in the past and may not in the future. That could require us to incur significant expenses, which could significantly affect our business. Failure to comply with data protection laws may expose us to risk of enforcement actions taken by data protection authorities or other regulatory agencies, private rights of action in some jurisdictions, and potential significant penalties if we are found to be non-compliant.</p>
  <div style="font-size: 10pt;">
    Furthermore, the number of government investigations related to data security incidents and privacy violations continue to increase and government investigations typically require significant resources and generate negative publicity, which could harm our business and reputation.
  </div>
  <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#xa0;</p>
  <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;"><b><i>Significant disruptions of information technology systems or security breaches could adversely affect our business.</i></b></p>
  <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We are increasingly dependent upon information technology systems, infrastructure and data to operate our business. In the ordinary course of business, we collect, store and transmit large amounts of confidential information (including, among other things, trade secrets or other intellectual property, proprietary business information and personal information). It is critical that we do so in a secure manner to maintain the confidentiality and integrity of such confidential information. We also have outsourced elements of our operations to third parties, and as a result we manage a number of third-party vendors who may or could have access to our confidential information. The size and complexity of our information technology systems, and those of third-party vendors with whom we contract, and the large amounts of confidential information stored on those systems, make such systems vulnerable to service interruptions or to security breaches from inadvertent or intentional actions by our employees, third-party vendors and/or business partners, or to cyber-attacks by malicious third parties. Cyber-attacks are increasing in their frequency, sophistication and intensity, and have become increasingly difficult to detect. Cyber-attacks could include the deployment of harmful malware, ransomware, denial-of-service attacks, malicious websites, social engineering and other means to affect service reliability and threaten the confidentiality, integrity and availability of information.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div style="font-size: 10pt;">
    Cyber-attacks also include manufacturing, hardware or software supply chain attacks, which could cause a delay in the manufacturing of products or lead to a data privacy or security breach.
  </div>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       55
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Significant disruptions of our information technology systems, or those of our third-party vendors or business partners, or security breaches could adversely affect our business operations and/or result in the loss, misappropriation and/or unauthorized access, use or disclosure of, or the prevention of access to, confidential information, including, among other things, trade secrets or other intellectual property, proprietary business information and personal information, and could result in financial, legal, business and reputational harm to us. For example, any such event that leads to unauthorized access, use or disclosure of personal information, including personal information regarding our patients or employees, could harm our reputation, require us to comply with federal and/or state breach notification laws and foreign law equivalents, and otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information, including the imposition of significant fines, penalties, or other liability for any noncompliance with certain privacy and data security laws. Security breaches and other inappropriate access can be difficult to detect, and any delay in identifying them may lead to increased harm of the type described above. While we have implemented security measures to protect our information technology systems and infrastructure and have adopted a business continuity plan to deal with a disruption to our information technology systems, there can be no assurance that such measures will prevent service interruptions or security breaches that could adversely affect our business. In addition, our liability insurance may not be sufficient in type or amount to cover us against costs of or claims related to security breaches, cyber-attacks or other related liabilities. A cybersecurity breach could adversely affect our reputation and could result in other negative consequences, including disruption of our internal operations, increased cybersecurity protection costs, lost revenue, penalties and fines, or litigation.</p>
  <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>U.S. tax legislation and future changes to applicable U.S. or foreign tax laws and regulations may have a material adverse effect on our business, financial condition and results of operations. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We are subject to income and other taxes in the United States and foreign jurisdictions. Changes in laws and policy relating to taxes or trade may have an adverse effect on our business, financial condition and results of operations. This Annual Report on Form 10-K does not discuss any such tax legislation or changes to tax laws and regulations, or the manner in which it might affect us or purchasers of our securities. We urge our investors to consult with their legal and tax advisors with respect to such legislation and the potential tax consequences of investing in our securities.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We are also subject to different tax regulations in each of the jurisdictions where we conduct our business or where our management is located. We expect the scope and extent of regulation in the jurisdictions in which we conduct our business, or where our management is located, as well as regulatory oversight and supervision, to generally continue to increase. Generally, future changes in applicable U.S. or foreign tax laws and regulations, or their interpretation and application could have an adverse effect on our business, financial conditions and results of operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Inadequate funding for or other adverse actions taken by the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent our product candidates from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business rely, which could negatively impact our business. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">During the global response to the COVID-19 pandemic, moreover, there have been strategic redeployments of government resources to priority projects, including FDA and EMA resources and staff, which have affected routine and for-cause manufacturing inspections and could have an impact on the timeline for review and approval of new marketing applications.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. If a prolonged government shutdown or slowdown occurs, it could significantly affect the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, in our operations as a public company, future government shutdowns or slowdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       56
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological advances. In addition, the competition in the asthma and cancer markets is intense. We have competitors in the United States and internationally, including major multinational pharmaceutical companies, fully integrated pharmaceutical and biotechnology companies, smaller companies that are collaborating with larger pharmaceutical companies, academic institutions, and other public and private research organizations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">There are several third-party drug candidates that could compete with drug candidates in our pipeline.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Drug candidates interfering with the function of type 2 helper T cells, or Th2, the biological pathway for elarekibep, and thus anticipated to compete with elarekibep, include those that are being developed or commercialized by Sanofi/Regeneron (dupilumab), GSK (mepolizumab), Teva (reslizumab), AstraZeneca (benralizumab, IL-5R&#x3b1;), Connect Biopharma (CBP-201) and Amgen/AstraZeneca (tezepelumab). Drug candidates interfering with CTGF, the biological pathway for PRS-220 and thus anticipated to compete with PRS-220 include those that are being developed by Fibrogen (pamrevlumab). Drugs targeting immunomodulatory targets and thus anticipated to compete with our partnered IO programs include those that are currently marketed by Bristol-Myers Squibb (ipilimumab and nivolumab), Merck &amp; Co (pembrolizumab), Roche (atezolizumab), Merck Serono/Pfizer (avelumab) and AstraZeneca (durvalumab), among others and drug candidates being developed by Bristol-Myers Squibb (for example, urelumab), Pfizer (for example, utomilumab) and other clinical stage drug candidates. Additionally, a number of other companies, such as Amgen, Affimed, Macrogenics, Daiichi Sankyo, F-star, Inhibrx, Xencor, Immunocore and Zymeworks, also are pursuing multispecific or targeted approaches in oncology, and have therapies in development or already commercialized. For additional information about third-party drug candidates that could compete with the drug candidates in our pipeline, see &#x201c;Business--Competition.&#x201d;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">These existing or future competing products may provide therapeutic convenience or clinical or other benefits for a specific indication greater than our products or may offer comparable performance at a lower cost. If any of our products for which we receive regulatory approval fail to capture and maintain market share, we may not achieve sufficient product revenue and our business will suffer.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Many of our competitors have substantially greater financial, technical and other resources than we do, such as larger research and development staff and experienced marketing and manufacturing organizations, as well as significantly greater experience in:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">developing drugs;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">undertaking preclinical testing and clinical trials;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">obtaining FDA and other regulatory approvals of drugs;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">prosecuting and enforcing intellectual property rights;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">formulating and manufacturing drugs; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">launching, marketing and selling drugs.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Established pharmaceutical companies may invest heavily to accelerate discovery and development of or in-license novel compounds that could make our drug candidates less competitive. In addition, any new product that competes with an approved product must demonstrate compelling advantages in efficacy, convenience, tolerability and safety in order to overcome price competition and to be commercially successful. Accordingly, our competitors may succeed in obtaining patent protection, receiving FDA, EMA, MHRA or other regulatory approval, or discovering, developing and commercializing medicines before we do, which would have an&#xa0;adverse effect on our business and ability to achieve profitability from future sales of our approved drug candidates, if any. For additional information about our competitors, please see "Business--Competition."</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       57
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We could be subject to product liability lawsuits based on the use of our drug candidates in clinical testing or, if obtained, following our products</i></b>&#x2019;<b><i> marketing approval and commercialization. If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to cease clinical testing or limit commercialization of our drug candidates.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We could be subject to product liability lawsuits if any drug candidate we develop allegedly causes injury or is found to be otherwise unsuitable for human use during product testing, manufacturing, marketing or sale. Any such product liability claim may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability and a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against these claims, we will incur substantial liabilities or be required to limit commercialization of our product candidates. Even successful defense would require significant financial and management resources.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Regardless of merit or eventual outcome, liability claims may result in:</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">reduced resources of our management to pursue our business strategy;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">decreased demand for any products that we may develop;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">injury to our reputation and significant negative media attention;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">withdrawal of clinical trial participants or sites;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">significant costs to defend the related litigation;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">substantial monetary awards to clinical trial participants or patients;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">loss of revenue;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">increased insurance costs; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the inability to commercialize any products that we may develop.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our inability to obtain and retain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the clinical testing and commercialization of products we develop on our own or with collaborators. While we currently carry insurance in an amount and on terms and conditions that are customary for similarly situated companies and that are satisfactory to our board of directors, our insurance coverage may not reimburse us or may not be sufficient to reimburse us for any expenses or losses we may suffer.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In the future, we will continue seek to obtain appropriate insurance coverage with respect to any future clinical trials of our other drug candidates, but we may not be able to obtain the levels of coverage desired on acceptable terms, or at all. If we do secure product liability insurance, we may subsequently determine that additional amounts of coverage would be desirable at later stages of clinical development of our drug candidates or upon commencing commercialization of any drug candidate that obtains required approvals, but we may not be able to obtain such additional coverage amounts when needed on acceptable terms, or at all. Unless and until we obtain such insurance, we would be solely responsible for any product liability claims relating to our preclinical and clinical development activities. Further, even after any such insurance coverage is obtained, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by any insurance policies we may then have or that is in excess of the limits of our insurance coverage. We would be required to pay any amounts awarded by a court or negotiated in a settlement that exceed the coverage limitations or that are not covered by any product liability insurance we may obtain, and we may not have, or be able to obtain, sufficient capital to pay such amounts. A successful product liability claim or series of claims brought against us could cause our stock price to fall and, if judgments exceed our insurance coverage, could decrease our cash and adversely affect our business, operations, and prospects.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We will need to grow the size of our organization, and we may not successfully manage any growth we may achieve.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our success will depend upon the expansion of our operations and our ability to successfully manage our growth. Our future growth, if any, may place a significant strain on our management and on our administrative, operational, and financial resources, requiring us to implement and improve our operational, financial, and management systems.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition, our ability to manage our growth effectively will hinge upon our ability to expand, train, manage, and motivate our employees. As of December 31, 2022, we had 127&#xa0;full-time employees and 17&#xa0;permanent part-time employees. As our development and commercialization plans and strategies develop, these demands may also require the hiring of additional research, development, managerial, operational, sales, marketing, financial, accounting, legal, and other personnel.</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       58
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Moreover, future growth could require the development of additional expertise by management and impose significant added responsibilities on members of management, including:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">effectively managing our clinical trials and submissions to regulatory authorities for marketing approvals;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">effectively managing our internal research and development efforts such as discovery research and preclinical development;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">identifying, recruiting, maintaining, motivating and integrating additional employees;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">effectively managing our internal and external business development efforts with current or future partners, such as entering into additional collaboration arrangements and increasing out-licensing revenues;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">establishing relationships with third parties essential to our business and ensuring compliance with our contractual obligations to such third parties;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">developing and managing new divisions of our internal business, including any sales and marketing segment we elect to establish;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">maintaining our compliance with public company reporting and other obligations, including establishing and maintaining effective internal control over financial reporting and disclosure controls and procedures; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">improving our managerial, development, operational and finance systems.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We may not be able to accomplish any of those tasks, and our failure to do so could prevent us from effectively managing future growth, if any, and successfully growing our company.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Any increase in resources devoted to research and product development without a corresponding increase in our operational, financial, and management systems could have a material adverse effect on our business, financial condition and results of operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We may make future acquisitions that could disrupt our business, cause dilution to our stockholders and harm our financial condition and operating results.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We may, in the future, make acquisitions of, or investments in, companies that we believe have products or capabilities that are a strategic or commercial fit with our current business or otherwise offer opportunities for our company. In connection with these acquisitions or investments, we may:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">issue common stock or other forms of equity that would dilute our existing stockholders&#x2019;&#xa0;percentage of ownership;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">incur debt and assume liabilities; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">incur amortization expenses related to intangible assets or incur large and immediate write-offs.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We may not be able to complete acquisitions on favorable terms, if at all. If we do complete an acquisition, we cannot assure you that it will ultimately strengthen our competitive position or that it will be viewed positively by financial markets or investors. Furthermore, future acquisitions could pose numerous additional risks to our operations, including:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">problems integrating the purchased business, products or technologies;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">challenges in achieving strategic objectives, cost savings and other anticipated benefits;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">increases to our expenses;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the assumption of significant liabilities that exceed the limitations of any applicable indemnification provisions or the financial resources of any indemnifying party;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">inability to maintain relationships with key business partners of the acquired businesses;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">diversion of management&#x2019;s attention from their day-to-day responsibilities;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">difficulty in maintaining controls, procedures and policies during the transition and integration;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">entrance into marketplaces where we have no or limited prior experience and where competitors have stronger marketplace positions;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">potential loss of key employees, particularly those of the acquired entity; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">that historical financial information may not be representative or indicative of our results as a combined company.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       59
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>The United Kingdom</i></b>&#x2019;<b><i>s withdrawal from the European Union may have a negative effect on global economic conditions, financial markets and our business, including our ability to obtain regulatory approvals in the United Kingdom or the European Union.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The United Kingdom officially withdrew from the European Union on January 31, 2020 in a decision commonly referred to as &#x201c;Brexit,&#x201d; and the consequent transitionary period came to an end on December 31, 2020. A substantial amount of uncertainty remains regarding the implementation of Brexit and changes to the relationship between the United Kingdom and the European Union. Depending on the ongoing implementation of Brexit, the full extent to which Brexit may impact the business and regulatory environment in the United Kingdom, the European Union or other countries, remains unknown. In addition, Brexit could also result in similar referendums or votes in other European countries in which we do business.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In connection with Brexit, the United Kingdom and the European Union entered into a trade agreement known as the Trade and Cooperation Agreement, which was provisionally applicable as of January 1, 2021 and was ratified by the European Parliament on May 1, 2021. This agreement is intended to govern the legal relationship between the European Union and the United Kingdom post-Brexit. Any disputes or breakdowns in implementation of the Trade and Cooperation Agreement or other Brexit-related arrangements negotiated by the United Kingdom and the European Union could, among other outcomes, disrupt the free movement of goods, services and people between the United Kingdom and the European Union, and result in increased legal and regulatory complexities as well as potential higher costs of conducting business in Europe. Given the lack of comparable precedent, it remains unclear what financial, trade and legal implications Brexit will have and how it will affect us.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In line with the Trade and Cooperation Agreement, the United Kingdom has established its own regulatory framework for product candidates, which is not identical to the European Union regulatory framework. Industry experience with navigating the two regulatory frameworks is limited at this point in time. Further regulatory divergences could arise. Any failure of the European Union and the United Kingdom to implement and maintain the Trade and Cooperation Agreement could result in the United Kingdom or the European Union significantly altering regulations affecting the clearance or approval of our product candidates that are developed in the United Kingdom or the European Union. Any delay in obtaining, or inability to obtain, any marketing approvals in the United Kingdom as a result of Brexit or failures in the implementation of the Trade and Cooperation Agreement or otherwise, would prevent us from commercializing our product candidates in the United Kingdom and reduce our ability to generate revenue and achieve and sustain profitability. If any of these outcomes occur, we may be forced to restrict or delay efforts to seek regulatory approval in the United Kingdom for our product candidates, which could significantly and materially harm our business.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>The COVID-19 pandemic and its emerging variants, or any future pandemic, could adversely affect our business, including research, clinical trials, supply chain interruptions and financial condition.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our business has been and could continue to be adversely affected by health epidemics in regions where we have our research and development operations, ongoing preclinical or clinical studies, contract research or manufacturing activities, collaboration partner activities or other business activities and could cause significant disruption in the operations of third-party manufacturers and contract research organizations upon which we rely. For example, the outbreak in late 2019 of the strain of virus named SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), or coronavirus, which causes coronavirus disease 2019, or COVID-19, evolved into a global pandemic that spread to most regions of the world and is still ongoing.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The COVID-19 pandemic, and its emerging variants have spread to most countries, including the United States and European and Asia-Pacific countries, and this includes countries in which we have planned or currently have active clinical trial sites. As a result we have and may continue to experience disruptions that could severely impact our business, clinical trials and pre-clinical studies, including:</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">An impact on various aspects of our planned or ongoing clinical trials. Actual and potentially continuing impacts of the COVID-19 pandemic on our various clinical trials include patient dosing and study monitoring, which have been and may continue to be paused or delayed due to changes in policies at various clinical sites, federal, state, local or foreign laws, rules and regulations, including quarantines or other travel restrictions, prioritization of healthcare resources toward pandemic efforts, including diminished attention of physicians serving as our clinical trial investigators and reduced availability of site staff supporting the conduct of our clinical trials, interruption or delays in the operations of the FDA, or other reasons related to the COVID-19 pandemic. As the pandemic continues, other aspects of our clinical trials have and may continue to be adversely affected, delayed or interrupted, including, site initiation, patient recruitment and enrollment, availability of clinical trial materials and data analysis. It is unknown how long these pauses or disruptions could continue.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       60
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our reliance on third parties to, among other things, manufacture and transport drug substance and drug product for our clinical trials, ship investigational drugs and clinical trial samples, perform quality testing and supply other goods and services to run our business. Third parties in our international supply chain for materials have and may continue to be adversely impacted by restrictions resulting from the COVID-19 pandemic, or other infectious diseases, including staffing shortages, production slowdowns or halts, and disruptions in delivery systems, which has and may continue to disrupt our supply chain, limiting our ability to manufacture our product candidates for our clinical trials and conduct our research and development operations. For example, we or our partners currently rely on multiple CMOs to produce, package, and label some or all of the clinical supplies, including APIs, drug substances and finished drug products for the preclinical research and clinical trials, including the phase 2a study of elarekibep, phase 1/2 study for PRS-344/S095012 and the phase 1 study for PRS-220, and any tariffs, differing regulatory requirements and other restrictions on the free movement of goods between the United Kingdom and the European Union, or between other countries,&#xa0;as a result of the pandemic may have an adverse impact on this part of our&#xa0;supply chain. This could therefore negatively impact our clinical operations and, in particular, the advancement of our lead respiratory program, elarekibep which would adversely affect our business, our results of operations and financial condition.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our request that most of our personnel in the United States, and some in Germany, work remotely, may negatively impact productivity, affect our ability to retain employees or disrupt, delay or otherwise adversely impact our business. In addition, this could increase our cybersecurity risk, create data accessibility concerns and make us more susceptible to communication disruptions, any of which could adversely impact our business operations or delay necessary interactions with local and federal regulators, ethics committees, manufacturing sites, research or clinical trial sites and other important agencies and contractors.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our employees and contractors conducting research and development activities who may not be able to access our laboratory for an extended period of time if they get sick and need to quarantine, or if we or governmental authorities potentially modify current restrictions. For example, during the first years of the pandemic, our lab operations experienced some impact due to our employees and contractors becoming sick and needing to quarantine at home. Although this only minimally affected our productivity, further restrictions limiting access to our laboratory for an extended period could delay timely completion of preclinical activities and initiation of additional clinical trials for our programs.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Health regulatory agencies globally may continue to experience disruptions in their operations as a result of the COVID-19 pandemic. The FDA and comparable foreign regulatory agencies may continue to have slower response times or be under-resourced to continue to monitor our clinical trials and, as a result, review, inspection and other timelines may be materially delayed. It is unknown how long these disruptions could continue. Any elongation or de-prioritization of our clinical trials or delay in regulatory review resulting from such disruptions could materially affect the development and study of our product candidates. For example, regulatory authorities may require that we not distribute a product candidate lot until the relevant agency authorizes its release. Such release authorization may be delayed as a result of the COVID-19 pandemic and could result in delays to our clinical trials.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The trading prices for our common stock and other biopharmaceutical companies have been highly volatile due to the COVID-19 pandemic. As a result, we may face difficulties raising capital through sales of our common stock or such sales may be on unfavorable terms. In addition, a recession, depression or other sustained adverse market event resulting from the spread of the coronavirus could materially and adversely affect our business and the value of our common stock.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The COVID-19 pandemic continues to evolve. The ultimate impact of the COVID-19 pandemic and its emerging variants on our business operations is highly uncertain and subject to change and will depend on future developments, which cannot be accurately predicted, including the duration of the pandemic, the geographic spread of the disease, additional or modified government actions, new information that will emerge concerning the severity and impact of COVID-19 and its emerging variants and the actions taken to contain coronavirus or address its impact in the short and long term, among others. We do not know the full extent of potential delays or impacts on our business, our clinical trials, our research programs, healthcare systems or the global economy. We will continue to monitor the situation closely.</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       61
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risks Related to the Discovery and Development of Our Drug Candidates</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We are heavily dependent on the successful development of our drug candidates and programs and we cannot be certain that we will receive regulatory approvals or be able to successfully commercialize our products even if we receive regulatory approvals.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We currently have no products that are approved for commercial sale. We expect that a substantial portion of our efforts and expenditures over the next few years will be devoted to our respiratory programs, including elarekibep, our other partnered programs with AstraZeneca, our proprietary respiratory programs, including PRS-220 and PRS-400, as well as our other programs. In partnership with AstraZeneca, the phase 2a study for elarekibep is ongoing in multiple sites globally. In our proprietary PRS-220 program, we dosed the first patient in October 2022 for the phase 1 study. We are engaged in research and development activities with respect to a number of additional drug candidates and programs. All of our other drug candidates are in the discovery or early preclinical to IND-enabling stage. Accordingly, our business is currently substantially dependent on the successful development, clinical testing, regulatory approval and commercialization of elarekibep, PRS-220, and our other respiratory and IO&#xa0;programs, which may never occur.</p>
  <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Before we can generate any revenues from sales of our lead drug candidates, we must complete the following activities for each of them, any one of which we may not be able to successfully complete:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">conduct additional preclinical and clinical development with successful outcomes;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">manage preclinical, manufacturing and clinical activities;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">obtain regulatory approval from the FDA and other comparable foreign regulatory authorities;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">establish manufacturing relationships for the clinical and post-approval supply of the applicable drug candidate in compliance with all regulatory requirements;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">build a commercial sales and marketing team, either internally or by contract with third parties;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">establish and maintain patent and trade secret protection or regulatory exclusivity for our product candidates;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">develop and implement marketing strategies for successful commercial launch of our product candidates, if and when approved;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">secure acceptance of our products, if and when approved, by patients, from the relevant medical communities and from third-party payors;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">compete effectively with other therapies;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">establish and maintain adequate health care coverage and reimbursement;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">ensure continued compliance with any post-marketing requirements imposed by regulatory authorities, including any required post-marketing clinical trials or the elements of any post-marketing REMS that may be required by the FDA or comparable requirements in other jurisdictions to ensure the benefits of the product outweigh its risks;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">maintain continued acceptable safety profile of the product candidates following approval; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">invest significant additional cash in each of the above activities.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If we are unable to address one or more of these factors in a timely manner or at all, we could experience significant delays in the successful commercialization of, or an inability to successfully commercialize, our product candidates, which would materially harm our business. If we do not receive regulatory approvals for one or more of our product candidates, we may not be able to continue our operations. Even if we successfully obtain regulatory approvals to manufacture and market our product candidates, our revenues will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval and have commercial rights, competitors products in the same markets, market acceptance, and other factors. If the markets for patient subsets that we are targeting are not as significant as we estimate, we may not generate significant revenues from sales of such products, if approved.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Clinical testing of elarekibep and PRS-220, and certain other IO programs&#xa0;is ongoing, while clinical testing for other programs, including our other respiratory programs, has not yet commenced, and the results of any future clinical trials or preclinical studies of these programs, if unsuccessful, could lead to our abandonment of the development of those drug candidates. If studies of these drug candidates produce unsuccessful results and we are forced or elect to cease their development, our business&#xa0;and prospects could be substantially harmed.</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       62
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Preclinical and clinical testing of our drug candidates that has been conducted to date or will be conducted in the future may not have been or may not be performed in compliance with applicable regulatory requirements, which could lead to increased costs or material delays for their further development.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Given the complexity as well as the uncertainty inherent in preclinical and other nonclinical studies and clinical trials, and because of our limited operating experience, we may discover that our own development activities are not in compliance with applicable regulatory requirements or are otherwise deficient, and therefore, determine that the development of our drug candidates on the basis of those trials and studies is not warranted or will be delayed.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have also entered into license, partnership and option arrangements, such as with Servier, AstraZeneca, Seagen, Boston Pharmaceuticals and Genentech, relating to certain drug candidates and we may continue to do so in the future. Under some of these arrangements, the development of some of those drug candidates has been, or in the future may be, conducted wholly by such partners or third parties with which the partners contract. As a result, we have not been or may not be closely involved with or have any control over those development activities. Although some of our partners have provided information regarding those drug candidates and the related studies conducted to date, including data that is included in this Annual Report on Form 10-K, we have not received and may not receive in the future, comprehensive information regarding all of those development activities, including the raw data from certain studies that have been conducted, information regarding the design, procedural implementation and structure and information regarding the manufacture of the drug candidates used in the studies. Because we may have limited or no input on the development of these drug candidates, we may discover that all or certain elements of the trials and studies our partners have performed have not been, or may not in the future be, in compliance with applicable regulatory standards or have otherwise been or may be deficient, and that advancement of the development of these drug candidates on the basis of those trials and studies is not warranted.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Further, the majority of our development activities for each of our drug candidates, including our ongoing phase 1 study with&#xa0;PRS-220 in Australia, phase 2a study with elarekibep at multiple sites globally, and our anticipated future clinical trials, have been, are being or may in the future be conducted in whole or in part outside of the United States, including in Europe, Australia or Asia. We may also conduct some of our future development activities in other countries or regions. As a result, although those studies may meet the standards of applicable foreign regulatory bodies, the structure and design of those clinical trials and preclinical studies may not meet applicable FDA requirements and also may not meet the requirements of the applicable regulatory authorities in other foreign countries in which we desire to pursue marketing approval.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If the studies conducted by us or our partners or collaborators do not comply with applicable regulatory requirements or are otherwise not eligible for continued development in the United States or abroad, then we or our partners may be forced to conduct new studies in order to progress the development of our drug candidates. We, or our partners, may not have the funding or other resources to conduct or complete these additional studies, which would severely delay or prevent the development plans for these drug candidates and their commercialization. Any such deficiency and delay in the development of these drug candidates could significantly harm our business plans, product revenues and prospects.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our research and development efforts are focused on a rapidly evolving area of science, and our approach to drug discovery and development is novel and may never lead to marketable products.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Biopharmaceutical product development is generally a highly speculative undertaking and by its nature involves a substantial degree of risk. Our specific line of business, the discovery of Anticalin-brand drug therapeutics for patients with a variety of diseases and conditions, such as asthma and cancer, is an emerging field, and the scientific discoveries that form the basis for our efforts to develop drug candidates are relatively new. Further, the scientific evidence to support the feasibility of developing drug candidates based on those discoveries is both preliminary and limited. In contrast to companies that focus on more traditional drug classes, such as antibodies and small molecules, we believe that we are the first, if not the only, company to work with Anticalin-brand drug therapeutics and work to advance these to a clinical stage of development. We are not aware of any company that has successfully developed and obtained approval for a drug based on Anticalin proteins. As a result, identifying drug targets based in part on their suitability with Anticalin-brand drug therapeutics, which is a fundamental aspect of our business approach, may not lead to the discovery or development of any drugs that successfully treat patients with the diseases and conditions we intend to target. Moreover, the lack of successful precedents in the development of Anticalin proteins could result in added complexities or delays in our development efforts. The failure of the scientific underpinnings of our business model to produce viable drug candidates would substantially harm our operations and prospects.</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       63
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We may not be successful in our efforts to build a pipeline of drug candidates.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A key element of our strategy is to use and expand our Anticalin-based drug platform to build a pipeline of drug candidates to address different targets and advance those drug candidates through clinical development for the treatment of a variety of different types of diseases. Although our research efforts to date have resulted in identification of a series of targets, we may not be able to develop drug candidates that have good drug-like properties (including characteristics such as target affinity, stability and half-life) and are safe and effective inhibitors or promoters of all or any of these targets. Even if we are successful in building a product pipeline, the potential drug candidates that we identify may not be suitable for clinical development for a number of reasons, including that they may cause harmful side effects or demonstrate other characteristics that indicate a low likelihood of receiving marketing approval or achieving market acceptance. If our methods of identifying potential drug candidates fail to produce a pipeline of potentially viable drug candidates, then our success as a business will be dependent on the success of fewer potential drug candidates, which introduces risks to our business model and potential limitations to any success we may achieve.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Clinical drug development involves a lengthy and expensive process with uncertain outcomes, clinical trials are difficult to design and implement, and any of our clinical trials could produce unsuccessful results or fail at any stage in the process.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Clinical trials conducted on humans are expensive and can take many years to complete, and outcomes are inherently uncertain. Failure can occur at any time during the process. Additionally, any positive results of preclinical studies and early clinical trials of a drug candidate may not be predictive of the results of later-stage clinical trials, such that drug candidates may reach later stages of clinical trials and fail to show the desired safety and efficacy traits despite having shown indications of those traits in preclinical studies and early-stage clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier phases of the trials. Therefore, the results of any ongoing or future clinical trials we conduct may not be successful.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A phase 2a study for elarekibep was initiated in 2021, a phase 1 study for PRS-220 was initiated in October 2022, a phase 1/2 study for PRS-344/S095012&#xa0;was initiated in November 2021, and a phase 1 study for SGN-BB228&#xa0;was initiated in January 2023. We or our partners may, however, experience delays in pursuing those or any other clinical trials, and any planned clinical trials may not begin on time, may require redesign, may not enroll sufficient healthy volunteers or patients in a timely manner and may not be completed on schedule, if at all.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Additional clinical trials may be delayed, suspended or prematurely terminated because costs are greater than we anticipate or for a variety of other reasons (which may be heightened as a result of the ongoing COVID-19 pandemic), such as:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">delay or failure in reaching agreement with the FDA or a comparable foreign regulatory authority on a trial design that we are able to execute;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">delay or failure in obtaining authorization to commence a trial, including approval from the appropriate IRB to conduct testing of a candidate on human subjects, or inability to comply with conditions imposed by a regulatory authority regarding the scope or design of a clinical trial;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">delay in reaching, or failure to reach, agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">inability, delay or failure in identifying and maintaining a sufficient number of trial sites, many of which may already be engaged in other clinical programs;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">delay or failure in recruiting and enrolling suitable volunteers or patients to participate in a trial;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">delay or failure in developing and validating companion diagnostics, if they are deemed necessary, on a timely basis;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">failure of trial participants to complete a trial or return for post-treatment follow-up;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">inability to monitor trial participants adequately during or after treatment;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">clinical sites and investigators deviating from trial protocols, failing to conduct the trial in accordance with regulatory requirements or dropping out of a trial;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">failure to initiate or delay of or inability to complete a clinical trial as a result of a clinical hold imposed by the FDA or comparable foreign regulatory authority due to observed safety findings or other reasons;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">negative or inconclusive results in our clinical trials, and our decision to or regulators&#x2019;&#xa0;requirement that we conduct additional non-clinical studies, clinical trials or that we abandon one or more of our product development programs; or</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">inability to manufacture sufficient quantities of a drug candidate of acceptable quality for use in clinical trials.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       64
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We rely and plan to continue to rely on CROs, CMOs and clinical trial sites to ensure the proper and timely conduct of our clinical trials. Although we have and expect that we will continue to have agreements in place with CROs and CMOs governing their contracted activities and conduct, we have limited influence over their actual performance. As a result, we ultimately do not and will not have control over a CRO&#x2019;s or CMO&#x2019;s compliance with the terms of any agreement it may have with us, its compliance with applicable regulatory requirements or its adherence to agreed-upon time schedules and deadlines, and a future CRO&#x2019;s or CMO&#x2019;s failure to perform those obligations could subject any of our clinical trials to delays or failure.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Further, we may also encounter delays if a clinical trial is suspended or terminated by us, by any IRB or ethics committee, by a Data Safety Monitoring Board, or DSMB, or by the FDA, EMA, MHRA, or other regulatory authority. A suspension or termination may occur due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements, inspection of the clinical trial operations or trial site by the FDA, EMA, MHRA or other regulatory authorities, exposing participants to health risks caused by unforeseen safety issues or adverse side effects, development of previously unseen safety issues, failure to demonstrate a benefit from using a drug candidate or changes in governmental regulations or administrative actions. We cannot predict with any certainty the schedule for commencement or completion of any currently ongoing, planned or future clinical trials.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of marketing approval for our product candidates.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If we experience delays in the commencement or completion of, or suspension or termination of, any clinical trial for our drug candidates, the commercial prospects of the drug candidate could be harmed, and our ability to generate product revenues from the drug candidate may be delayed or eliminated. In addition, any delays in completing our clinical trials will increase our costs, slow down our drug candidate development and approval process and jeopardize regulatory approval of our drug candidates and our ability to commence sales and generate revenues. The occurrence of any of these events could harm our business, financial condition, results of operations and prospects significantly.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>If we experience delays or difficulties in the enrollment of research subjects in clinical trials, those clinical trials could take longer than expected to complete and our receipt of necessary regulatory approvals could be delayed or prevented.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We may not be able to initiate or continue clinical trials for our drug candidates if we are unable to locate and enroll a sufficient number of research subjects to participate in these trials, including as a result of challenges posed by the ongoing COVID-19 pandemic. In particular, for some diseases and conditions we are or will be focusing on, our pool of suitable patients may be smaller and more selective and our ability to enroll a sufficient number of suitable patients may be limited or take longer than anticipated. In addition, some of our competitors have ongoing clinical trials for drug candidates that treat the same indications as our drug candidates, and volunteers or patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors&#x2019; drug candidates.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Patient enrollment for any of our clinical trials may also be affected by other factors, including without limitation:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the size and nature of the target patient population;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the severity of the disease under investigation;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the frequency of the molecular alteration we are seeking to target in the applicable trial;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the patient eligibility criteria for the clinical trial in question;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our ability to recruit clinical trial investigators with the appropriate competencies and experience;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the perceived risks and benefits of the drug candidate under study in the clinical trial;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the approval and availability of other therapies to treat the disease or disorder that is being investigated in the clinical trial;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the extent of the efforts to facilitate timely enrollment in clinical trials;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the patient referral practices of physicians;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the ability to monitor volunteers or patients adequately during and after treatment;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the presence of other drug candidates in clinical development for the same indication or against the same target; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the proximity and availability of clinical trial sites for prospective participants.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our inability to enroll a sufficient number of participants for our clinical trials would result in significant delays and could require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our drug candidates, and we may not have or be able to obtain sufficient cash to fund such increased costs when needed, which could result in the further delay or termination of clinical trials.</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       65
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and the results of our clinical trials may not satisfy the requirements of the FDA or comparable foreign regulatory authorities.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We currently have no products approved for sale and we cannot guarantee that we will ever have marketable products. Clinical failure can occur at any stage of clinical development. Clinical trials may produce negative or inconclusive results, and we or any future collaborators may decide, or regulators may require us, to conduct additional clinical trials or nonclinical studies. We will be required to demonstrate with substantial evidence through well-controlled clinical trials that our product candidates are safe and effective for use in a diverse population before we can seek marketing approvals for their commercial sale. Success in preclinical studies and early-stage clinical trials does not mean that future larger registration clinical trials will be successful. This is because product candidates in later-stage clinical trials may fail to demonstrate sufficient safety and efficacy to the satisfaction of the FDA and comparable foreign regulatory authorities despite having progressed through preclinical studies<b><i> </i></b>and early-stage clinical trials. In particular, no Anticalin-based drug products have been approved or commercialized in any jurisdiction, and the outcome of our preclinical studies and early-stage clinical trials may not be predictive of the success of later-stage clinical trials.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">From time to time, we may publish or report interim or preliminary data from our clinical trials. Interim or preliminary data from clinical trials that we may conduct may not be indicative of the final results of the trial and are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Interim or preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the interim or preliminary data. As a result, interim or preliminary data should be viewed with caution until the final data are available.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>The review processes of regulatory authorities are lengthy, time consuming, expensive and inherently unpredictable. If we are unable to obtain approval for our drug candidates from applicable regulatory authorities, we will not be able to market and sell those drug candidates in those countries or regions and our business could be substantially harmed.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The research, testing, manufacturing, labeling, approval, sale, marketing and distribution of drug products are, and will remain, subject to extensive regulation by the FDA in the United States and by the respective regulatory authorities in other countries where regulations differ. We are not permitted to market our biological product candidates in the United States until we receive the respective approval of a BLA from the FDA, or in any foreign countries until we receive the requisite approval from the respective regulatory authorities in such countries. The time required to obtain approval, if any, by the FDA, EMA, MHRA and comparable foreign authorities is unpredictable, but typically takes many years following the commencement of clinical trials, if approval is obtained at all, and depends upon numerous factors, including the substantial discretion of the regulatory authorities and the type, complexity and novelty of the product candidates involved. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional nonclinical studies or clinical trials. We have not submitted a marketing application such as a BLA to the FDA, an MAA to the EMA or any similar application to any other jurisdiction. We have limited experience in planning and conducting the clinical trials required for marketing approvals, and we have and expect to continue to rely on third-party CROs to assist us in this process. Obtaining marketing approval requires the submission of extensive nonclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the product candidate&#x2019;s safety and efficacy. Securing marketing approval also requires the submission of information about the product manufacturing process, and in many cases the inspection of manufacturing, processing and packaging facilities by the regulatory authorities. Our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use, or there may be deficiencies in cGMP compliance by us or by our CMOs that could result in the candidate not being approved. Moreover, we have not obtained regulatory approval for any drug candidate in any jurisdiction and it is possible that none of our existing drug candidates or any drug candidates we may seek to develop in the future will ever obtain regulatory approval.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our drug candidates could fail to receive, or could be delayed in receiving, regulatory approval for many reasons, including any one or more of the following:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the FDA, EMA, MHRA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">we may be unable to demonstrate to the satisfaction of the FDA, EMA, MHRA or comparable foreign regulatory authorities that a drug candidate is safe and effective for its proposed indication;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the results of clinical trials may not meet the level of statistical significance required by the FDA, EMA, MHRA or comparable foreign regulatory authorities for approval;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">we may be unable to demonstrate that a drug candidate&#x2019;s clinical and other benefits outweigh its safety risks;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       66
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the FDA, EMA, MHRA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the data collected from clinical trials of our drug candidates may not be sufficient to support the submission of a BLA, MAA or other submission or to obtain regulatory approval in the United States or elsewhere;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">upon review of our clinical trial sites and data, the FDA or comparable foreign regulatory authorities may find our record keeping or the record keeping of our clinical trial sites to be inadequate;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies may fail to meet the requirements of the FDA, EMA, MHRA or comparable foreign regulatory authorities;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the FDA, EMA, MHRA or comparable foreign regulatory authorities may fail to approve the companion diagnostics we contemplate developing internally or with partners; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the change of the medical standard of care or the approval policies or regulations of the FDA, EMA, MHRA or comparable foreign regulatory authorities may significantly change in a manner that renders our clinical data insufficient for approval.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The time and expense of the approval process, as well as the unpredictability of future clinical trial results and other contributing factors, may result in our failure to obtain regulatory approval to market, in one or more jurisdictions, elarekibep, PRS-220, our other respiratory programs, our discovery stage programs or any other drug candidates we are developing or may seek to develop in the future, which would significantly harm our business, results of operations and prospects. In such case, we may also not have the resources to conduct new clinical trials and/or we may determine that further clinical development of any such drug candidate is not justified and may discontinue any such programs.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition, even if we were to obtain regulatory approval in one or more jurisdictions, regulatory authorities may approve any of our drug candidates for fewer or more limited indications than we request, may not approve prices we may propose to charge for our products, may grant approval contingent on the performance of costly post-marketing clinical trials (referred to as &#x201c;conditional&#x201d; or &#x201c;accelerated&#x201d; approval depending on the jurisdiction), or may approve a drug candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that drug candidate or that includes significant warnings or contraindications. Any of the foregoing circumstances could materially harm the commercial prospects for our drug candidates.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our failure to obtain marketing approval in jurisdictions other than the United States, the U.K.&#xa0;and Europe would prevent our product candidates from being marketed in these other jurisdictions. Any approval that we are granted for our product candidates in the United States, U.K. or Europe would not assure approval of product candidates in the other or in any other jurisdiction.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In order to market and sell our future products in jurisdictions other than the United States, United Kingdom&#xa0;or Europe, we or our third-party collaborators must obtain separate marketing approvals in that jurisdiction and comply with numerous and varying regulatory requirements. The review and approval procedures can vary drastically among jurisdictions, and each jurisdiction may impose different testing and other requirements to obtain and maintain marketing approval. Further, the time required to obtain those approvals, if any, may differ substantially among jurisdictions. In addition, some countries or regions outside the United States, the U.K. and Europe require approval of the sales price of a drug before it can be marketed in that country or region. In many countries, separate procedures must be followed to obtain reimbursement. Moreover, approval by the FDA, EMA, MHRA or an equivalent foreign authority does not ensure approval by regulatory authorities in any other countries or regions. As a result, the ability to market and sell a drug candidate in more than one jurisdiction can involve significant additional time, expense and effort, and would subject us and our collaborators to the numerous and varying post-approval requirements of each jurisdiction governing commercial sales, manufacturing, pricing and distribution of our drug candidates. We or any third parties with whom we may collaborate may not have the resources to pursue those approvals, and we or they may not be able to obtain any approvals that are pursued. The failure to obtain marketing approval for our drug candidates in foreign jurisdictions could severely limit their potential market and ability to generate revenue.</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       67
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our product candidates may cause undesirable side effects that could delay or prevent their marketing approval, limit their commercial potential, or result in significant negative consequences following marketing approval, if marketing approval is obtained.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Undesirable side effects caused by our product candidates could cause us or the FDA, EMA, MHRA or other regulatory authorities to interrupt, delay or halt our clinical trials and could result in a more restrictive label or the delay or denial of marketing approval by the FDA or other regulatory authorities of our product candidates. In the event that our clinical trials produce undesirable side effects, our trials could be suspended or terminated and the FDA, EMA or MHRA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of our product candidates for any or all targeted indications. In addition to this, the product-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Clinical trials by their nature utilize a sample of the potential patient population. With a limited number of patients, rare and severe side effects of our product candidates may only be uncovered with a significantly larger number of patients exposed to the product candidate. If our product candidates receive marketing approval and we or others identify undesirable side effects caused by such product candidates (or any other similar products) after such approval, a number of potentially significant negative consequences could result, including:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">regulatory authorities may withdraw or limit their approval of such product candidates;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">regulatory authorities may require the addition of labeling statements, specific warnings or a contraindication;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">we may be required to create a medication guide outlining the risks of such side effects for distribution to patients, or we may be required to implement a REMS in the U.S. or a comparable risk mitigation plan in other jurisdictions&#xa0;to ensure that the benefits of the product outweigh the risks;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">we may be required to change the way such product candidates are distributed or administered, or change the labeling of the product candidates;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">we may be subject to regulatory investigations and government enforcement actions;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the FDA or a comparable foreign regulatory authority may require us to conduct additional clinical trials or costly post-marketing testing and surveillance to monitor the safety and efficacy of the product;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">we may decide to recall or withdraw such product candidates from the marketplace after they are approved;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">we could be sued and held liable for injury caused to individuals exposed to or taking our product candidates; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our reputation may suffer.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We believe that any of these events could prevent us from achieving or maintaining market acceptance of the affected product candidates and could substantially increase the costs of commercializing our product candidates, if approved, and significantly impact our ability to successfully commercialize our product candidates and generate revenues.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We may expend our limited resources to pursue a particular drug candidate or indication that does not produce any commercially viable products and may fail to capitalize on drug candidates or indications that may be more profitable or for which there is a greater likelihood of success.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Because we have limited financial and managerial resources, we must focus our efforts on particular research programs and drug candidates for specific indications. As a result, we may forgo or delay pursuit of opportunities with other drug candidates or for other indications that later prove to have greater commercial potential. Further, our resource allocation decisions may result in our use of funds for research and development programs and drug candidates for specific indications that may not yield any commercially viable products.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If we do not accurately evaluate the commercial potential or target market for a particular drug candidate, or if market conditions change, we may relinquish valuable rights to that drug candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such drug candidate. Any such failure to properly assess potential drug candidates could result in missed opportunities and/or our focus on drug candidates with low market potential, which would harm our business and financial condition.</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       68
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risks Related to Our Dependence on Third Parties</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We rely on third parties to conduct our clinical trials and preclinical studies. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or otherwise conduct the trials as required or comply with regulatory requirements, we may not be able to obtain regulatory approval for our drug candidates, commercialize our product candidates when expected or at all, and our business could be substantially harmed.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We depend upon independent investigators and contractors, such as CROs, universities and medical institutions, to conduct our clinical trials and preclinical studies. We rely upon, and plan to continue to rely upon, such third-party entities to execute our clinical trials and preclinical studies and to monitor and manage data produced by and relating to those studies and trials. However, in the future, we may not be able to establish arrangements with CROs when needed or on terms that are acceptable to us, or at all, which could negatively affect our development efforts with respect to our drug candidates and materially harm our business, operations and prospects. As a result of the use of third-party contractors, we will have only limited control over certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies, including each of our clinical trials, is conducted in accordance with the applicable protocol, legal and regulatory requirements as well as scientific standards, and our reliance on any third-party entity will not relieve us of our regulatory responsibilities.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition, we and our third-party contractors will be required to comply with cGCP for all of our drug candidates in clinical development. Regulatory authorities enforce cGCP through periodic inspections of trial sponsors, clinical investigators and trial sites. If we or any of our contractors fail to comply with applicable cGCP, the clinical data generated in the applicable trial may be deemed unreliable and the FDA, EMA, MHRA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving a drug candidate for marketing, which we may not have sufficient cash or other resources to support and which would delay our ability to generate revenue from future sales of such drug candidate. Any agreements governing our relationships with CROs or other contractors with whom we currently engage or may engage in the future may provide those outside contractors with certain rights to terminate a clinical trial under specified circumstances. .</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If our contractors do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the data they obtain is compromised due to a failure to adhere to our clinical protocols, legal and regulatory requirements or for other reasons, such as the COVID-19 pandemic, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for, or successfully commercialize, the affected drug candidates. In addition, we will be unable to control whether or not they devote sufficient time and resources to our preclinical and clinical programs. These outside contractors may not assign as great a priority to our programs or pursue them as diligently as we would if we were undertaking such programs ourselves. As a result, our operations and the commercial prospects for the affected drug candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed. These contractors may also have relationships with other commercial entities, some of whom may compete with us. If our contractors assist our competitors to our detriment, our competitive position would be harmed.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If our relationships with any third parties conducting our studies are terminated, we may be forced to seek an engagement with a substitute third party and&#xa0;may be unable to enter into arrangements with such third parties on commercially reasonable terms,&#xa0;or at all.&#xa0;Switching or adding third parties to conduct our studies involves substantial cost and requires extensive management time and focus. In addition, there is a natural transition period when a new third party commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines, or may result in the clinical trial not being completed. These difficulties may be exacerbated as a result of the COVID-19 pandemic. Although we carefully manage our relationships with third parties conducting our studies, we cannot assure you that we will not encounter similar&#xa0;challenges or delays in the future or that these delays or challenges will not have a material&#xa0;and&#xa0;adverse&#xa0;effect&#xa0;on our business, financial condition and&#xa0;results of operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We rely and expect to continue to rely completely on third parties to formulate and manufacture&#xa0;our preclinical, clinical trial and commercial drug supplies. The development and commercialization of any of our drug candidates could be stopped, delayed or made less profitable if those third parties fail to provide us with sufficient quantities of such drug supplies or fail to do so at acceptable quality levels, including in accordance with applicable regulatory requirements or contractual obligations, and our operations could be harmed as a result.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have no experience in drug formulation or manufacturing. We do not currently have, nor do we plan to acquire, the infrastructure or capability internally, such as our own manufacturing facilities, to manufacture our preclinical and clinical drug supplies for our clinical trials and preclinical studies or commercial quantities of any drug candidates that may obtain regulatory approval. Therefore, we lack the resources and expertise to formulate or manufacture our own drug candidates. We have entered into agreements with CMOs for the clinical-stage manufacturing of certain drug candidates, including elarekibep, PRS-220, and PRS-344/S095012 as well as other drugs involved in our clinical trials and preclinical studies. We plan to enter into agreements with one or more manufacturers to manufacture, supply, store and distribute drug supplies for our current and future clinical trials and/or commercial sales, if any. We intend to establish or continue those relationships for the supply of our drug candidates; however, there can be no assurance that we will be able to retain those relationships on commercially reasonable terms, if at all. If we are unable to maintain those relationships, we could experience delays in our development efforts as we locate and qualify new CMOs. If any of our current drug candidates or any drug candidates we may develop or acquire in the future receives regulatory approval, we will rely on one or more CMOs to manufacture the commercial supply of such drugs.</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       69
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our reliance on a limited number of CMOs exposes us to the following risks:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We may be unable to identify manufacturers on acceptable terms, or at all, because the number of qualified potential manufacturers is limited. Following BLA approval, or its foreign equivalent, if successful, a change in the manufacturing site could require additional approval from the FDA, or the respective comparable foreign regulatory authorities. This approval would require new testing and compliance inspections.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our third-party manufacturers might be unable to formulate and manufacture our drugs in the volume and of the quality and cost required to meet our clinical and commercial needs, if any.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our future CMOs may not perform as contractually agreed or may not remain in the contract manufacturing business for the time required to supply our clinical trials or to successfully produce, store and distribute our products.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Drug manufacturers are subject to ongoing periodic unannounced inspection by the FDA and some state agencies to ensure strict compliance with cGMP regulations and other U.S. and corresponding foreign requirements. We do not have control over third-party manufacturers&#x2019;&#xa0;compliance with these regulations and standards.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If any third-party manufacturer makes improvements in the manufacturing process for our products, we may not own, or may have to share, the intellectual property rights to the innovation.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Each of these risks could delay our clinical trials, the marketing approval, if any, of our drug candidates or the commercialization of our drug candidates, which could result in higher costs or could deprive us of potential product revenues.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Although our agreements with our CMOs require them to perform according to certain cGMP requirements such as those relating to quality control, quality assurance and qualified personnel, we cannot control the conduct of our CMOs to implement and maintain these standards. If any of our CMOs cannot successfully manufacture material that conforms to our specifications and the regulatory requirements of the FDA, EMA, MHRA or other comparable foreign authorities, we would be prevented from obtaining regulatory approval for our drug candidates unless and until we engage a substitute CMO that can comply with such requirements, which we may not be able to do. Any such failure by any of our CMOs would significantly impact our ability to develop, obtain regulatory approval for or market our drug candidates, if approved.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Further, we plan to rely on our manufacturers to purchase from third-party suppliers the materials necessary to produce our drug candidates for our clinical trials. We do not have, nor do we expect to enter into, any agreements for the commercial production of these raw materials, and we do not expect to have any control over the process or timing of our CMOs&#x2019; acquisition of raw materials needed to produce our drug candidates. Any significant delay in the supply of a drug candidate or the raw material components of an ongoing clinical trial due to a manufacturer&#x2019;s need to replace a third-party supplier of raw materials could considerably delay completion of our clinical trials, product testing and potential regulatory approval of our drug candidates. Additionally, if our future manufacturers or we are unable to purchase these raw materials to commercially produce any of our drug candidates that gains regulatory approvals, the commercial launch of our drug candidates would be delayed or there would be a shortage in supply, which would impair our ability to generate revenues from the sale of our drug candidates.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Disagreements with respect to the commercial terms of our sales, licensing, purchase or manufacturing agreements may limit our commercial success.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The rights and obligations of the partners to which we may license our Anticalin-based technology are governed by the licensing and collaboration agreements we enter into with those partners. In addition, our relationships with CMOs are governed by the service agreements between us and each of the manufacturers. Although we attempt to address the full range of possible events that may occur during the development or the manufacturing of Anticalin-based drug candidates and products, unanticipated or extraordinary events may occur beyond those contemplated by such agreements. Furthermore, our business relationships with our product manufacturers and our collaborators may include assumptions, understandings or agreements that are not included in our agreements with them, or that are inaccurately or incompletely represented by their terms. In addition, key terms in such agreements may be misunderstood or contested, even when we and the other party previously believed that we both had a mutual understanding of such terms.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Any differences in interpretation or misunderstandings between us and other parties may result in substantial costs and delays with respect to the development, manufacturing or sale of Anticalin-based drugs, and may negatively impact our revenues and operating results. Product manufacturers may fail to produce the products at the quality or standard required or on the agreed timeline,&#xa0;and partners may fail to develop the drug candidates with the diligence or under the timeline or in the manner we anticipated, and results may differ from the terms upon which we had agreed. As a result, we may be unable to supply drugs of the quality or in the quantity demanded or required. We may suffer harm to our reputation in the market from missed development goals or deadlines and may be unable to capitalize upon market opportunities as a result. Resolution of these problems may entail costly and lengthy litigation or dispute resolution procedures. In addition, there is no guarantee that we will prevail in any such dispute or, if we do prevail, that any remedy we receive, whether legal or otherwise, will adequately redress the harm we have suffered. The delays and costs associated with such disputes may themselves harm our business and reputation and limit our ability to successfully compete in the market.</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       70
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We depend on third parties and intend to continue to license or collaborate with third parties,</i></b>&#xa0;<b><i>and events involving these strategic partners or any future collaboration could</i></b>&#xa0;<b><i>delay or prevent us from developing or commercializing products.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our business strategy, along with our short- and long-term operating results, depend in part on our ability to execute on existing strategic collaborations and to license or partner with new strategic partners. We have entered into and expect in the future to enter into collaborative arrangements with both U.S.-based and foreign pharmaceutical and drug development companies, which will lead, finance or otherwise collaborate with us or assist us in the development, manufacturing and marketing of our drug products. We believe collaborations allow us to leverage our resources and technologies and we anticipate deriving some revenues from research and development fees, license fees, milestone payments, and royalties from our collaborative partners.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our prospects, therefore, may depend to some extent upon our ability to attract and retain collaborative partners and to develop technologies and products that meet the requirements of current or prospective collaborative partners. We have limited control over the amount and timing of resources that our current collaborators or any future collaborators devote to our collaborations or potential products, in particular with respect to our collaborations with AstraZeneca for the development of elarekibep, with Servier for the development of PRS-344/S095012, with Boston Pharmaceuticals for the development of PRS-342/BOS-342, with Seagen for the development of SGN-BB228 and other programs, and our other collaborations with Genentech. These collaborators may breach or terminate their agreements with us or otherwise fail to conduct their collaborative activities successfully and in a timely and reasonable manner. Termination of these agreements or reduction or elimination of our rights under these agreements may result in our having to negotiate new, amended or reinstated agreements with less favorable terms, or cause us to lose our rights under these agreements, including our rights to important intellectual property or technology. Further, our collaborators may not develop or commercialize products that arise out of our collaborative arrangements or devote sufficient resources to the development, manufacturing, marketing or sale of these products. In addition, our collaborative partners may have the right to guide strategy regarding prosecution of relevant patent applications, abandon research projects and/or terminate applicable agreements, including funding obligations, prior to or upon the expiration of the agreed-upon research terms. By entering into such collaborations, we may forego opportunities to collaborate with other third parties who do not wish to be associated with our existing third-party strategic partners. In the event of termination of a collaboration agreement, termination negotiations may result in less than favorable terms.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">There can be no assurance that we will be successful in establishing collaborative arrangements on acceptable terms or at all, that collaborative partners will not terminate funding before the completion of projects, that our collaborative arrangements will result in successful product commercialization, or that we will derive any revenues from such arrangements. Potential collaborators may reject collaborations based upon their assessment of our financial, regulatory or intellectual property position and our internal capabilities. Additionally, the negotiation, documentation and implementation of collaborative arrangements are complex and time-consuming. Our discussions with potential collaborators may not lead to new collaborations on favorable terms and may have the potential to provide collaborators with access to our key intellectual property rights.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our success depends in part on the efforts of our current and possible future collaborators, who will likely have substantial control and discretion over the continued development and commercialization of drug candidates that are the subject of our collaborations.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our current collaborators and future collaborators will have significant discretion in determining the effort and amount of resources that they dedicate to our collaborations. Our collaborators may determine not to proceed with clinical development or commercialization of a particular drug candidate for a number of reasons that are beyond our control, even under circumstances where we might have continued such a program, currently including elarekibep, PRS-342/BOS-342, SGN-BB228&#xfeff; and PRS-344/S095012. In addition, our rights to receive milestone payments and royalties from our collaborators will depend in part on our collaborators&#x2019; abilities to establish the safety and efficacy of our drug candidates,&#xa0;obtain regulatory approvals and achieve market acceptance of products developed from our drug candidates. We may also depend on our collaborators to manufacture clinical scale quantities of some of our drug candidates and, possibly, for commercial scale manufacture, distribution, marketing and sales. Our collaborators may not be successful in manufacturing our drug candidates or successfully commercializing them.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We face additional risks in connection with our existing and future collaborations, including the following:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our collaborators may develop and commercialize, either alone or with others, products that are similar to or competitive with the products that are the subject of the collaboration with us;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our collaborators may underfund, not commit sufficient resources to, or conduct in an unsatisfactory manner the development, testing, marketing, distribution or sale of our drug candidates;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our collaborators may not properly maintain or defend our intellectual property rights or utilize our proprietary information in such a way as to invite litigation that could jeopardize or potentially invalidate our intellectual property or proprietary information or expose us to potential liability;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our collaborators may encounter conflicts of interest, changes in business strategy or other business issues that could adversely affect their willingness or ability to fulfill their obligations to us (for example, pharmaceutical and biotechnology companies historically have re-evaluated their priorities following mergers and consolidations, which have been common in recent years in these industries);</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       71
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">we do not control the conduct and communications of our collaborators, and, thus, we are subject to the risk that their actions may negatively impact our reputation and potentially harm our business;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">disputes may arise between us and our collaborators delaying or terminating the research, development, manufacture or commercialization of our drug candidates, resulting in significant litigation or arbitration that could be time-consuming and expensive, or causing collaborators to act in their own self-interest and not in the interest of our stockholders;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">we might not have the financial or human resources to meet our obligations or take advantage of our rights under the terms of our existing and future collaborations; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our existing collaborators may exercise their respective rights to terminate their collaborations with us without cause, in which event, we might not be able to complete development and commercialization of our drug candidates on our own.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Certain of our research and development and manufacturing activities take place in China through third-party manufacturers. A significant disruption in the operation of those manufacturers could materially</i></b><b> </b><b><i>adversely affect our business and results of operations.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have relied on certain third parties located in China to manufacture and supply certain drug substance for our drug product candidates, and we expect to continue to use such third-party manufacturers for such purposes. A natural disaster, epidemic or pandemic, including the ongoing COVID-19 pandemic, trade war, trade sanctions, political unrest, economic conditions, changes in legislation, including the passage of the People&#x2019;s Republic of China Biosecurity law, which became effective on April 15, 2021, or other events in China could disrupt the business or operations of manufacturers or other third parties with whom we conduct business now or in the future. Any disruption in China that significantly impacts such third parties, including our manufacturers&#x2019; ability to produce drug substance or drug product in adequate quantities to meet our needs could impede, delay, limit or prevent the research, development or commercialization of our current and future products or product candidates. In addition, for any activities conducted in China, we are exposed to the possibility of product supply disruption and increased costs in the event of changes in the policies of the U.S. or Chinese governments, political unrest or unstable economic conditions including sanctions on China or any of our China-based vendors. Separately, we may also be exposed to fluctuations in the value of the local currency in China for goods and services. Our costs for any of these services or activities could also increase as a result of future appreciation of the local currency in China or increased labor costs if the demand for skilled laborers increases and/or the availability of skilled labor declines in China.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our collaborative relationships may not produce the financial benefits that we are anticipating, which could cause our business to suffer.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Part of our strategy is to partner with, or out-license selective products to, other pharmaceutical companies in order to mitigate the cost of developing a drug through clinical trials to commercialization. Our exclusive option agreement with ASKA Pharmaceuticals Co., Ltd., or ASKA, entered into on February 27, 2017, is an example of this strategy. In January 2020, following the phase 2a study we conducted, ASKA had an option to obtain an exclusive license to develop and commercialize PRS-080, our anemia drug, in Japan, South Korea and certain other Asian markets under the option agreement, which they did not exercise for strategic reasons. Exercising this option could have made us eligible to receive more than $80 million in combined option exercise fee and milestones associated with development and commercialization of PRS-080 in the first indication in Japan with further development milestones in additional indications from Japan and other countries within the ASKA territory. If our collaboration with other similar partners is not successful, our future revenues and business will be harmed.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We may not receive any further milestone, royalty or license payments under our current collaborations.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Although we have received upfront, milestone and other payments to date under our current drug development collaborations, we may not receive any royalty payments or additional license and milestone fees under such agreements. In general, our receipt of milestone, royalty or license payments depends on many factors, including whether our collaborators want and are able to continue to pursue potential drug candidates, intellectual property issues, the approval of biosimilars, unforeseen complications in the development or commercialization process, and the ultimate commercial success of the drugs.</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       72
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risks Related to the Commercialization of Our Drug Candidates</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Any product candidate for which we obtain marketing approval will be subject to extensive post-marketing regulatory requirements and could be subject to post-marketing restrictions or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products, when and if any of them are approved.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If the FDA, EMA, MHRA&#xa0;or a comparable foreign regulatory authority approves any of our drug candidates, activities such as the manufacturing processes, labeling, packaging, distribution, adverse event, or AE,&#xa0;reporting, storage, advertising, promotion and record keeping for the products will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMP. The FDA or a comparable foreign regulatory authority may also impose requirements for costly post-marketing nonclinical studies or clinical trials (often called &#x201c;Phase 4 trials&#x201d;) and post-marketing surveillance to monitor the safety or efficacy of the product. If we or a regulatory authority discover previously unknown problems with a product, such as AEs of unanticipated severity or frequency, production issues with the facility where the product is manufactured or processed, such as product contamination or significant non-compliance with applicable cGMPs, a regulator may impose restrictions on that product, the manufacturing facility or us. If we or our third-party providers, including our CMOs, fail to comply fully with applicable regulations, then we may be required to initiate a recall or withdrawal of our products.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition, later discovery of previously unknown problems with a product, including AEs of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in the following, among other things:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">restrictions on the manufacturing of the product, the approved manufacturers or the manufacturing process;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">restrictions on the labeling or marketing of a product;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">restrictions on product distribution or use;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">requirements to conduct post-marketing studies or clinical trials;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">withdrawal of the product from the market;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">product recalls;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">warning or untitled letters from the FDA or comparable notice of violations from foreign regulatory authorities;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">refusal of the FDA or other applicable regulatory authority to approve pending applications or supplements to approved applications;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">fines, restitution or disgorgement of profits or revenues;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">suspension or withdrawal of marketing approvals;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">suspension of any of our ongoing clinical trials;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">product seizure or detention or refusal to permit the import or export of products; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">consent decrees, injunctions or the imposition of civil or criminal penalties.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition, regulatory authorities&#x2019; policies (such as those of the FDA, MHRA, or EMA) may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our drug candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are otherwise not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, which would adversely affect our business, prospects and ability to achieve or sustain profitability.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Non-compliance with European Union requirements regarding safety monitoring or pharmacovigilance can also result in significant financial penalties. Similarly, failure to comply with the European Union requirements regarding the protection of personal information can also lead to significant penalties and sanctions.</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       73
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our commercial success depends upon attaining and maintaining significant market acceptance of our drug candidates, if approved, among physicians, patients, third-party payors and other members of the medical community.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Even if we obtain regulatory approval for our drug candidates, the approved products may nonetheless fail to gain or maintain&#xa0;sufficient market acceptance among physicians, third-party payors, patients and other members of the medical community, which is critical to commercial success. If an approved product does not achieve an adequate level of acceptance, we may not generate significant product revenues or any profits from operations. The degree of market acceptance of any drug candidate for which we receive approval depends on a number of factors, including:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the efficacy and potential advantages compared to alternative treatments or competitive products;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">perceptions by the medical community, physicians and patients regarding the safety and effectiveness of our products and the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the size of the market for such drug candidate, based on the size of the patient subsets that we are targeting, in the territories for which we gain regulatory approval and have commercial rights;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the safety of the drug candidate as demonstrated through broad commercial distribution;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the ability to offer our product candidates for sale at competitive prices;</p> </td>
    </tr>

    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;">&#x2022;</td>
     <td style="vertical-align:top;">the availability of competing drug products;</td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the availability of adequate reimbursement and pricing for our products from governmental health programs and other third-party payors;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">relative convenience and ease of administration compared to alternative treatments;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the prevalence and severity of any side effects;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the adequacy of supply of our product candidates;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the timing of any such marketing approval in relation to other product approvals;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">any restrictions on concomitant use of other medications;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">support from patient advocacy groups; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the effectiveness of sales, marketing and distribution efforts by us and our licensees, partners, and distributors, if any.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If our drug candidates are approved but fail to achieve an adequate level of acceptance by key market participants, we will not be able to generate significant revenues, and we may not become or remain profitable, which may require us to seek additional financing.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our ability to negotiate, secure and maintain third-party coverage and reimbursement for our product candidates may be affected by political, economic, legal and regulatory developments in the United States, the U.K., the European Union and other jurisdictions. Governments continue to impose cost containment measures, and third-party payors are increasingly challenging prices charged for medicines and examining their cost effectiveness, in addition to their safety and efficacy. These and other similar developments could significantly limit the degree of market acceptance of any product candidate of ours that receives marketing approval in the future.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our product candidates have never been manufactured on a commercial scale, and there are risks associated with scaling up manufacturing to commercial scale.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our product candidates have never been manufactured on a commercial scale, and there are risks associated with scaling up manufacturing to commercial scale including, among others, cost overruns, potential problems with process scale-up, process reproducibility, stability issues, lot consistency and timely availability of raw materials. There is no assurance that our manufacturers will be successful in establishing a larger-scale commercial manufacturing process for elarekibep, PRS-220, PRS-344/S095012 or other product candidates that achieves our objectives for manufacturing capacity and cost of goods. Even if we could otherwise obtain regulatory approval for any product candidate, there is no assurance that our manufacturers will be able to manufacture the approved product to specifications acceptable to the FDA, EMA, MHRA or other regulatory authorities, to produce it in sufficient quantities &#xa0;to meet the requirements for the potential launch of the product or to meet potential future demand. If our manufacturers are unable to produce timely or sufficient quantities of the approved product for commercialization, our commercialization efforts would be impaired, which would have an adverse effect on our business, financial condition, results of operations and growth prospects.</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       74
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Biologics carry unique risks and uncertainties, which could have a negative impact on future results of operations.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The successful discovery, development, manufacturing and sale of biologics is a long, expensive and uncertain process. There are unique risks and uncertainties with biologics. For example, access to and supply of necessary biological materials, such as cell lines, may be limited and governmental regulations restrict access to and regulate the transport and use of such materials. In addition, the development, manufacturing and sale of biologics is subject to regulations that are often more complex and extensive than the regulations applicable to other pharmaceutical products. Manufacturing biologics, especially in large quantities, is often complex and may require the use of innovative technologies. Such manufacturing also requires facilities specifically designed and validated for this purpose and sophisticated quality assurance and quality control procedures. Biologics are also frequently costly to manufacture because production inputs are derived from living animal or plant material, and some biologics cannot be made synthetically. Failure to successfully discover, develop, manufacture and sell our biological product candidates would adversely impact our business and future results of operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our product candidates for which we intend to seek approval may face follow-on or biosimilar competition sooner than anticipated. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Even if we are successful in achieving regulatory approval to commercialize a product candidate ahead of our competitors, our product candidates may face competition from biosimilar products. In the United States, our Anticalin-based product candidates are expected to be regulated by the FDA as biological products and we intend to seek approval for these product candidates pursuant to the BLA pathway. The BPCIA created an abbreviated pathway for FDA approval of biosimilar and interchangeable biological products based on a previously licensed reference product. Under the BPCIA, an application for a biosimilar biological product cannot be approved by the FDA until 12 years after the original reference biological product was approved under a BLA. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We believe that any of our product candidates approved as a biological product under a BLA should qualify for the 12-year period of exclusivity available to reference biological products. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our product candidates to be reference biological products pursuant to its interpretation of the exclusivity provisions of the BPCIA for competing products, potentially creating the opportunity for generic follow-on biosimilar competition sooner than anticipated. Moreover, the extent to which a biosimilar product, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing including whether a future competitor seeks an interchangeability designation for a biosimilar of one of our products. Under the BPCIA as well as state pharmacy laws, only interchangeable biosimilar products are considered substitutable for the reference biological product without the intervention of the health care provider who prescribed the original biological product. However, as with all prescribing decisions made in the context of a patient-provider relationship and a patient&#x2019;s specific medical needs, health care providers are not restricted from prescribing biosimilar products in an off-label manner. In addition, a competitor could decide to forego the abbreviated approval pathway available for biosimilar products and to submit a full BLA for product licensure after completing its own preclinical studies and clinical trials. In such a situation, any exclusivity to which we may be eligible under the BPCIA would not prevent the competitor from marketing its biological product as soon as it is approved.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In Europe, the European Commission has granted marketing authorizations for several biosimilar products pursuant to a set of general and product class-specific guidelines for biosimilar approvals issued over the past few years. In addition, companies may be developing biosimilar products in other countries that could compete with our products, if approved.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If competitors are able to obtain marketing approval for biosimilars referencing our product candidates, if approved, our future products may become subject to competition from such biosimilars, whether or not they are designated as interchangeable, with the attendant competitive pressure and potential adverse consequences. Such competitive products may be able to immediately compete with us in each indication for which our product candidates may have received approval.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Even if we are able to commercialize any of our drug candidates, such products may become subject to unfavorable pricing regulations, third-party reimbursement practices or health care reform initiatives, which would harm our business.</i></b><b> </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The regulations that govern marketing approvals, pricing, coverage and reimbursement for new drug and biological products vary widely from country to country. Current and future legislation may change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing approval is granted and, in some markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we may obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenues we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates obtain marketing approval.</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       75
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our ability to commercialize any product candidates successfully also will depend in part on the extent to which coverage and reimbursement for these product candidates and related treatments will be available from government authorities, private health insurers and other organizations. In the United States, reimbursement varies from payor to payor. Reimbursement agencies in Europe may be more conservative than federal health care programs or private health plans in the United States. For example, a number of cancer drugs are generally covered and paid for in the United States, but have not been approved for reimbursement in certain European countries. A primary trend in the U.S. health care industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of payments for particular products. For example, payors may limit coverage to specific drug products on an approved list, also known as a formulary, which might not include all of the FDA-approved drugs for a particular indication. Payors may require use of alternative therapies or a demonstration that a product is medically necessary for a particular patient before use of a product will be covered. Additionally, payors may seek to control utilization by imposing prior authorization requirements.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for products. We cannot be sure that coverage will be available for any product candidate that we commercialize and, if coverage is available, what the level of reimbursement will be. Reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. Patients are unlikely to use our products, if they are approved for marketing, unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of such products.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">There may be significant delays in obtaining coverage and reimbursement for newly approved drugs and biologics, and coverage may be more limited than the purposes for which the drug is approved by the FDA, EMA, MHRA or comparable foreign regulatory authorities. Moreover, eligibility for reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by federal health care programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. In the United States, third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. In the European Union, reference pricing systems and other measures may lead to cost containment and reduced prices. Our inability to promptly obtain coverage and profitable payment rates from both government-funded and private payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Further, there have been, and may continue to be, legislative and regulatory proposals at the U.S. federal and state levels and in foreign jurisdictions directed at broadening the availability and containing or lowering the cost of healthcare. The continuing efforts of the government, insurance companies, managed care organizations and other third-party payors to contain or reduce costs of healthcare may adversely affect our ability to set prices for our products that would allow us to achieve or sustain profitability. In addition, governments may impose price controls on any of our products that obtain marketing approval, which may adversely affect our future profitability.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Most recently, in August 2022, President Biden signed into the law the Inflation Reduction Act of 2022, or the IRA. Among other things, the IRA has multiple provisions that may impact the prices of drug products that are both sold into the Medicare program and throughout the United States. Starting in 2023, a manufacturer of drugs or biological products covered by Medicare Parts B or D must pay a rebate to the federal government if their drug product&#x2019;s price increases faster than the rate of inflation. This calculation is made on a drug product-by-drug product basis and the amount of the rebate owed to the federal government is directly dependent on the volume of a drug product that is paid for by Medicare Parts B or D. Additionally, starting for payment year 2026 Centers for Medicare &amp; Medicaid Services, or CMS, will negotiate drug prices annually for a select number of single source Part D drugs without generic or biosimilar competition. CMS will also negotiate drug prices for a select number of Part B drugs starting for payment year 2028. If a drug product is selected by CMS for negotiation, it is expected that the revenue generated from such drug will decrease. Additional state and federal healthcare reform measures are expected to be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for certain biopharmaceutical products or additional pricing pressures</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In some foreign countries, particularly the member states of the European Union, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can be a long and expensive process after the receipt of marketing approval for a drug candidate. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various European Union member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. In some countries, we may be required to conduct additional clinical trials that compare the cost-effectiveness of our drug candidates to other available therapies in order to obtain reimbursement or pricing approval. Publication of discounts by third-party payors or authorities may lead to further pressure on prices or reimbursement levels within the country of publication and other countries. If reimbursement of our products is unavailable or limited in scope or amount in a particular country, or if pricing is set at unsatisfactory levels, we may be unable to successfully commercialize and achieve or sustain profitability for sales of any of our drug candidates that are approved for marketing in that country and our business could be adversely affected.</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       76
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We have no experience selling, marketing or distributing products and currently have no internal marketing and sales force. If we are unable to establish effective marketing and sales capabilities or enter into agreements with third parties to market and sell our drug candidates, we may not be able to effectively market and sell our drug candidates, if approved, or generate product revenues.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We currently have no sales, marketing or distribution capabilities and have no experience as a company in the sale or marketing of pharmaceutical products. There can be no assurance that we will be able to market and sell our products in the United States or overseas. In order to commercialize any drug candidates, we must build on a territory-by-territory basis marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services, and we may not be successful in doing so. Therefore, with respect to the commercialization of all or certain of our drug candidates, we may choose to collaborate, either globally or on a territory-by-territory basis, with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. If so, our success will depend, in part, on our ability to enter into and maintain collaborative relationships for such capabilities, such collaborators&#x2019; strategic interest in the products under development and such collaborators&#x2019; ability to successfully market and sell any such products.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If we are unable to enter into such arrangements when needed on acceptable terms or at all, we may not be able to successfully commercialize any of our drug candidates that receive regulatory approval, or any such commercialization may experience delays or limitations. Further, to the extent that we depend on third parties for marketing and distribution, any revenues we receive will depend upon the efforts of such third parties, and there can be no assurance that such efforts will be successful.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">To the extent that we decide not to, or are unable to, enter into collaborative arrangements with respect to the sales and marketing of our products, we may in the future need to establish an internal sales and marketing team with technical expertise and supporting distribution capabilities to commercialize our drug candidates, which could be expensive, time-consuming and requiring significant attention of our executive officers to manage. Further, we may not have sufficient resources to allocate to the sales and marketing of our products.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Any failure or delay in the development of sales, marketing and distribution capabilities, through collaboration with one or more third parties or through internal efforts, would adversely impact the commercialization of any of our products that we obtain approval to market. As a result, our future product revenue will suffer and we may incur significant additional losses.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition, certain of our collaboration agreements that provide us with co-commercialization rights with respect to certain partnered programs contain specific commercialization obligations. If we fail to meet those obligations, our commercialization rights could be impaired.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our relationships with prescribers, purchasers, third-party payors and patients will be subject to applicable anti-kickback, fraud and abuse and other health care laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Although we do not currently have any products on the market, upon commercialization of our drug candidates, if approved, we will be subject to additional health care statutory and regulatory requirements and oversight by federal and state governments in the United States as well as foreign governments in the jurisdictions in which we conduct our business. Physicians, other health care providers and third-party payors will play a primary role in the recommendation, prescription and use of any product candidates for which we obtain marketing approval. Our future arrangements with such third parties may expose us to broadly applicable fraud and abuse and other health care laws and regulations that may constrain our business or financial arrangements and relationships through which we market, sell and distribute any products for which we may obtain marketing approval. Restrictions under applicable domestic and foreign health care laws and regulations include, but are not limited to, the following:</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the U.S. federal Anti-Kickback Statute, or AKS, which prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, to induce either the referral of an individual, or the furnishing, recommending, or arranging of a good or service, for which payment may be made under a federal health care program such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the AKS or specific intent to violate it to have committed a violation. Certain arrangements are protected from enforcement through AKS safe harbors and exceptions, but an arrangement must meet every element of the applicable safe harbor or exception in order to obtain this protection. The fact that an arrangement does not meet the requirements of a safe harbor or exception does not mean that it violates the AKS; such arrangements would be subject to a facts and circumstances analysis to determine compliance with the AKS or lack thereof. The definition of &#x201c;remuneration&#x201d;&#xa0;has been broadly interpreted to include anything of value, including such items as gifts, discounts, the furnishing of supplies or equipment, credit arrangements, waiver of payments, and providing anything at less than its fair market value. The AKS is broadly interpreted and aggressively enforced with the result that beneficial commercial arrangements can be criminalized in the healthcare industry because of the AKS. The penalties for violating the federal AKS include imprisonment for up to ten years, fines of up to $100,000 per violation and possible exclusion from federal health care programs such as Medicare and Medicaid. Additionally, a claim including items or services resulting from a violation of the AKS constitutes a false or fraudulent claim for purposes of the False Claims Act;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       77
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the U.S. False Claims Act, or FCA, prohibits knowingly presenting, or causing to be presented a false claim or the knowing use of false statements or records to obtain payment from the federal government. The FCA also prohibits the knowing retention of overpayments (sometimes referred to as &#x201c;reverse false claims&#x201d;). When an entity is determined to have violated the FCA, it must pay three times the actual damages sustained by the government, plus mandatory and substantial civil penalties for each separate false claim. The entity also faces the possibility of exclusion from federal healthcare programs. Suits filed under the False Claims Act, known as &#x201c;qui tam&#x201d;&#xa0;actions, can be brought by any individual on behalf of the government and such individuals (known as &#x201c;relators&#x201d;&#xa0;or, more commonly, as &#x201c;whistleblowers&#x201d;) may share in any amounts paid by the entity to the government in fines or settlement. Claims for payment by federal health care programs for items and services which results from a violation of the federal AKS may also constitute a false or fraudulent claims for purposes of the False Claims Act;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the U.S. Civil Monetary Penalties Law, or CMPL, authorizes the imposition of substantial civil money penalties and the possibility of exclusion against an individual or entity that engages in certain prohibited activities including but not limited to violations of the AKS, knowing submission of a false or fraudulent claim, employment of an excluded individual, and the provision or offer of anything of value to a Medicare or Medicaid beneficiary that the transferring party knows or should know is likely to influence beneficiary selection of a particular provider for which payment may be made in whole or part by a federal health care program, commonly known as the Beneficiary Inducement CMP;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">HIPAA, which created two new federal crimes: health care fraud and false statements relating to health care matters. The health care fraud statute prohibits knowingly and willfully executing a scheme to defraud any health care benefit program, including private payors. A violation of this statute is a felony and may result in fines, imprisonment or exclusion from government sponsored programs. The false statements statute prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services; similar to the AKS, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">analogous state and foreign laws and regulations relating to health care fraud and abuse, such as state anti-kickback and false claims laws, that may apply to sales or marketing arrangements and claims involving health care items or services reimbursed by non-governmental third-party payors, including private insurers. Penalties for violating these laws can range from fines to criminal sanctions;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the FCPA and other anti-corruption laws and regulations pertaining to our financial relationships and interactions with foreign government officials;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the U.S. federal physician payment transparency requirements, sometimes referred to as the Sunshine Act, which requires, among other things, manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid or the Children&#x2019;s Health Insurance Program to track and annually report to the Centers for Medicare &amp; Medicaid Services, or CMS, information related to certain payments and other transfers of value made to U.S.-licensed physicians (defined broadly to include doctors, dentists, optometrists, podiatrists, and chiropractors), certain advanced non-physician health care practitioners (such as physician assistants)&#xa0;and teaching hospitals. Manufacturers are also required to report certain ownership and investment interests held by physicians and their immediate family members. The law carries penalties of up to $1.15 million per year for violations, depending on the circumstances, and payments reported also have the potential to draw scrutiny on payments to and relationships with physicians, which may have implications under the AKS and other healthcare laws;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">analogous state and foreign laws that require pharmaceutical companies to track, report and disclose to the government and/or the public information related to payments, gifts, and other transfers of value or remuneration to physicians and other health care providers, marketing activities or expenditures, or product pricing or transparency information, or that require pharmaceutical companies to implement compliance programs that meet certain standards or to restrict or limit interactions between pharmaceutical manufacturers and members of the health care industry;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the U.S. federal laws that require pharmaceutical manufacturers to report certain calculated product prices to the government or provide certain discounts or rebates to government authorities or private entities, often as a condition of reimbursement under federal health care programs;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">HIPAA, which imposes obligations on certain covered entity health care providers, health plans, and health care clearinghouses as well as their business associates that perform certain services involving the use or disclosure of individually identifiable health information, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">state and foreign laws that govern the privacy and security of health information in certain circumstances, including state security breach notification laws, state health information privacy laws and federal and state consumer protection laws, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       78
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Efforts to ensure that our business arrangements with third parties will comply with applicable health care and information laws and regulations will involve substantial costs. If the FDA&#xa0;or a comparable foreign regulatory authority approves any of our product candidates, we will be subject to an expanded number of these laws and regulations and will need to expend resources to develop and implement policies and processes to promote ongoing compliance. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other health care laws and regulations, resulting in government enforcement actions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion of products from federal health care programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any of the physicians or other health care providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from federal health care programs.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risks Related to Our Intellectual Property</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>If we breach any of the agreements under which we license from third parties the intellectual property rights or commercialization rights to our drug candidates, particularly our license agreements with TUM and Kelun, we could lose license rights that are important to our business and our operations could be materially harmed.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We in-license significant intellectual property related to our Anticalin platforms from TUM. Under the terms of the TUM License, TUM assigns to us certain materials and records resulting from the research. We retain rights to inventions made by our employees, and TUM assigns to us all inventions made under the agreement jointly by our employees and TUM personnel, provided that our employees have made a certain inventive contribution. With respect to all other inventions made in the course of the research, TUM grants to us worldwide exclusive license rights under patents and patent applications claiming such inventions. TUM retains rights to practice these inventions for research and teaching purposes. We bear the costs of filing, prosecuting and maintaining the patents assigned or licensed to us under the TUM License.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As consideration for the assignments and licenses, we are obliged to pay milestone payments to TUM on development of our proprietary products claimed by patents assigned or licensed to us by TUM. We are also obliged to pay low single-digit royalties, including annual minimum royalties, on the sales of such products. Should we grant licenses or sublicenses to those patents to third parties, we are obliged to pay to TUM certain undisclosed fees as a function of out-licensing revenues in connection with those patents, or Out-License Fees, where such Out-License Fees are creditable against annual license payments to TUM. Our payment obligations are reduced by our proportionate contribution to a joint invention. Payment obligations terminate on expiration or annulment of the last patent covered by the TUM License that covers a proprietary product or is sublicensed, as applicable.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We and TUM initiated discussions in the second quarter of 2018, and are in the process of negotiating an amendment to our license agreement, to clarify, expand and restructure the TUM License, including the parties&#x2019; obligations under such license agreement. The contemplated amendment relates to revised commercial terms. We recorded the probable expected impact of the amendment in research and development expense in 2019, although the final expense could be different than what we currently have recorded. These discussions may also lead to an increase in our collaborative research activities with TUM.</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       79
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In connection with our efforts to develop multispecific Anticalin-based proteins designed to engage immunomodulatory targets, during the second quarter of 2017, we entered into the Kelun Agreement. Under the Kelun Agreement, Kelun has granted to us a non-exclusive worldwide license (with the right to sublicense) under certain intellectual property owned or controlled by Kelun to research, develop, manufacture and commercialize bi- and multi- specific fusion proteins that include an antibody developed by Kelun specific for an undisclosed target and one or more Anticalin proteins.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition to the TUM License and the Kelun Agreement, we have other in-license agreements and may seek to enter into additional agreements with other third parties in the future granting similar license rights with respect to other potential drug candidates. If we fail to comply with any of the conditions or obligations or otherwise breach the terms of the TUM License, the Kelun Agreement or any future license agreement we may enter on which our business or drug candidates are dependent, TUM, Kelun or other licensors may have the right to terminate the applicable agreement in whole or in part and thereby extinguish our rights to the licensed technology and intellectual property and/or any rights we have acquired to develop and commercialize certain drug candidates, including, with respect to the TUM License and Kelun Agreement, our Anticalin-based&#xa0;drug therapies. Under the TUM License, we can terminate the licenses to any or all licensed patents upon specified advance notice to TUM. TUM may terminate the license provisions of the agreement only for cause. Termination of the TUM License does not terminate our rights in patents assigned to us but would terminate our rights to patents licensed to us under the agreement. The loss of the rights licensed to us under our license agreement with TUM or Kelun Agreement, or any future license agreement that we may enter granting us rights on which our business or drug candidates are dependent, would eliminate our ability to further develop the applicable drug candidates and may materially harm our business, prospects, financial condition and results of operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>If our efforts to protect the proprietary nature of the intellectual property related to our technologies are not adequate, we may not be able to compete effectively and our business could be harmed.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We rely upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related to our technologies. Any disclosure to, or misappropriation by, third parties of our proprietary information could enable competitors to quickly duplicate or surpass our technological achievements, thus eroding any competitive advantage we may derive from the proprietary information.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The strength of patents in the biotechnology and pharmaceutical fields can be uncertain and involve complex legal and scientific questions. No consistent policy regarding the breadth of claims allowed in patents has emerged to date in the United States. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced, or that the scope of any patent rights could provide a sufficient degree of protection that could permit us to gain or keep our competitive advantage with respect to these products and technologies. For example, we cannot predict:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the degree and range of protection any patents will afford us against competitors, including whether third parties will find ways to make, use, sell, offer to sell or import competitive products without infringing our patents;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">if and when patents will be issued;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">how laws in the various jurisdictions, such as the USPTO or the European Patent Office, or the EPO, will change thus affecting our ability to obtain patents or maintain and enforce existing patents;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">whether or not others will obtain patents claiming inventions similar to those covered by our patents and patent applications; or</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">whether we will need to initiate litigation or administrative proceedings (for example, at the USPTO or the EPO) in connection with patent rights, which may be costly whether we win or lose.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As a result, the patent applications we own or license may fail to result in issued patents in the United States or in foreign countries. Third parties may challenge the validity, enforceability or scope of any issued patents we own or license or any applications that may issue as patents in the future, which may result in those patents being narrowed, invalidated or held unenforceable. Even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property or prevent others from developing similar products that do not fall within the scope of our patents. If the breadth or strength of protection provided by the patents we hold or pursue is threatened, our ability to commercialize any drug candidates with technology protected by those patents could be threatened. Further, if we encounter delays in our clinical trials, the period of time during which we would have patent protection for any covered drug candidates that obtain regulatory approval would be reduced. Since patent applications in the United States and most other countries are confidential for a period of time after filing, we cannot be certain at the time of filing that we are the first to file any patent application related to our drug candidates.</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       80
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">While patent term extensions under the Hatch-Waxman Act in the United States and under supplementary protection certificates in Europe may be available to extend our patent exclusivity for our drug candidates, the applicable patents may not meet the specified conditions for eligibility for any such term extension and, even if eligible, we may not be able to obtain any such term extension. Further, because filing, prosecuting, defending and enforcing patents in multiple jurisdictions can be expensive, we may elect to pursue patent protection relating to our drug candidates in only certain jurisdictions. As a result, competitors would be permitted to use our technologies in jurisdictions where we have not obtained patent protection to develop their own products, any of which could compete with our drug candidates.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition to the protection afforded by patents, we seek to rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable, processes for which patents are difficult to enforce and any other elements of our discovery platform and drug development processes that involve proprietary know-how, information or technology that is not covered by patents or not amenable to patent protection. Although we require all of our employees and certain consultants, third parties and advisors to assign inventions to us,&#xa0;they may refuse to assign the inventions which could create delay or risk assignment of inventions. We also&#xa0;require all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information or technology to enter into confidentiality agreements, our trade secrets and other proprietary information may be disclosed or competitors may otherwise gain access to such information or independently develop or reverse engineer substantially equivalent information. Further, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant difficulty in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent material disclosure of the trade secrets and other intellectual property related to our technologies to third parties, we may not be able to establish or maintain the competitive advantage that we believe is provided by such intellectual property, adversely affecting our market position and business and operational results.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Claims that we infringe the intellectual property rights of others may prevent or delay our drug discovery and development efforts.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our research, development and commercialization activities, as well as any drug candidates or products resulting from those activities, may infringe or be accused of infringing a patent or other form of intellectual property under which we do not hold a license or other rights. Third parties may assert that we are employing their proprietary technology without authorization.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">There may be third-party patents of which we are currently unaware with claims that cover the use or manufacture of our drug candidates or the practice of our related methods. Because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our drug candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our drug candidates infringes upon one or more claims of these patents. If our activities or drug candidates infringe the patents or other intellectual property rights of third parties, the holders of such intellectual property rights may be able to block our ability to commercialize such drug candidates or practice our methods unless we obtain a license under the intellectual property rights or until any applicable patents expire or are determined to be invalid or unenforceable.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Defense of any intellectual property infringement claims against us, regardless of their merit, would involve substantial litigation expense and would be a significant diversion of resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, obtain one or more licenses from third parties, limit our business to avoid the infringing activities, pay royalties and/or redesign our infringing drug candidates or alter related formulations, processes, methods or other technologies, any or all of which may be impossible or require substantial time and monetary expenditure. Further, if we were to seek a license from the third-party holder of any applicable intellectual property rights, we may not be able to obtain the applicable license rights when needed or on reasonable terms, or at all. Some of our competitors may be able to sustain the costs of complex patent litigation or proceeding more effectively than us due to their substantially greater resources. The occurrence of any of the above events could prevent us from continuing to develop and commercialize one or more of our drug candidates and our business could materially suffer.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We may desire to, or be forced to, seek additional licenses to use intellectual property owned by third parties, and such licenses may not be available on commercially reasonable terms, or at all.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Third parties may also hold intellectual property, including patent rights that are important or necessary to the development of our drug candidates, in which case we would need to obtain a license from that third party or develop a different formulation of the product that does not infringe upon the applicable intellectual property, which may not be possible. Additionally, we may identify drug candidates that we believe are promising and whose development and other intellectual property rights are held by third parties. In such a case, we may desire to seek a license to pursue the development of those drug candidates. Any license that we may desire to obtain or that we may be forced to pursue may not be available when needed on commercially reasonable terms, or at all. Inability to secure any license that we need or desire could have a material adverse effect on our business, financial condition and prospects.</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       81
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>The patent protection covering some of our drug candidates may be dependent on third parties, who may not effectively maintain that protection.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">While we expect the right to fully prosecute any patents covering drug candidates we may in-license from third-party owners, there may be instances when the prosecution and maintenance of issued patents and pending patent applications that cover our drug candidates remain controlled by our licensors. Similarly, some of our future licensing partners may retain the right, or may seek the rights, to prosecute patents covering the drug candidates we license to them and we may grant such rights to those partners for business reasons. If such third parties fail to appropriately maintain that patent protection, we may not be able to prevent competitors from developing and selling competing products or practicing competing methods and our ability to generate revenue from any commercialization of the affected drug candidates may suffer.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Certain technologies and patents have been developed with partners and we may face restrictions on this jointly developed intellectual property.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have entered into agreements with a number of commercial partners, including university partners, which cover intellectual property. We have, in some cases individually and in other cases along with our partners, filed for patent protection for a number of technologies developed under these agreements and may in the future file for further intellectual property protection and/or seek to commercialize such technologies. Under some of these agreements, certain intellectual property developed by us and the relevant partner may be subject to joint ownership and our commercial use of such intellectual property may be restricted, or may require written consent from, or a separate agreement with, the partner. In other cases, we may not have any rights to use intellectual property solely developed and owned by the partner. If we cannot obtain commercial use rights for such jointly owned intellectual property or partner-owned intellectual property, our future product development and commercialization plans may be adversely affected.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Competitors may infringe our patents or the patents of our current or potential licensors. To attempt to stop infringement or unauthorized use, we may need to enforce one or more of our patents, which can distract our management and divert our limited time and resources. Our standing to enforce such patents may sometimes be dependent on the licensor joining such suit, and a licensor's failure to join such suit may prevent us from enforcing the patent. If we pursue any litigation, a court may decide that a patent of ours or any of our licensors&#x2019; is not valid or is unenforceable or may refuse to stop the other party from using the relevant technology on the grounds that our patents do not cover the technology in question. Further, the legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, which could reduce the likelihood of success of, or the amount of damages that could be awarded resulting from, any infringement proceeding we pursue in any such jurisdiction. An adverse result in any infringement litigation or defense proceedings could put one or more of our patents at risk of being invalidated, held unenforceable, or interpreted narrowly and could put our patent applications at risk of not issuing, which could limit our ability to exclude competitors from directly competing with us in those jurisdictions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Interference proceedings may also be provoked or suggested by third parties, or brought by the USPTO or at its foreign counterparts (such as the EPO), to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to use it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms, or at all.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Litigation or interference proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees.</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       82
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>If we are unsuccessful in obtaining or maintaining patent protection for intellectual property in development, our business and competitive position would be harmed.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We are seeking patent protection of our technology and for our drug candidates. Patent prosecution is a challenging process and is not assured of success. If we are unable to secure patent protection for our technology and drug candidates, our business may be adversely impacted.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Furthermore, issued patents and pending applications require regular maintenance. Failure to maintain our portfolio may result in loss of rights that may adversely impact our intellectual property rights, such as rendering issued patents unenforceable or terminating pending applications prematurely.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition, under the European Union regulation on classification, labeling and packaging of substances and mixtures, and under other regulations in the United States or other countries related to the clinical development of our drug candidates (including, for example, submissions to regulatory authorities such as the FDA and EMA as well as submissions related to obtaining a non-proprietary, or INN and USAN, name for our clinical drug candidates to the World Health Organization, and United States Adopted Name Council, or the USAN Council), we may be required to publicly disclose the composition of our proprietary products or substances, which may facilitate infringement or avoidance of our intellectual property by third parties and may potentially reduce the margin we are able to charge for our products by allowing competitors to more accurately determine our production costs. Future development of these regulations may have a further negative impact on our revenues and a substantial negative impact on our business.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition to seeking patents for our Anticalin-brand technology and some of our drug candidates, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. We currently, and expect in the future to continue to, seek to protect these trade secrets, in part by entering into confidentiality agreements with parties who have access to them, such as our employees, collaborators, CMOs, consultants, advisors, investigators and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for any such disclosure. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they disclose the trade secrets, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>If we fail to protect our trademark rights, competitors may be able to take advantage of our goodwill, which would weaken our competitive position, reduce our revenues and increase our costs.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We believe that the protection of our trademark rights is an important factor in product recognition, maintaining goodwill, and maintaining or increasing market share. We may expend substantial cost and effort in an attempt to register, maintain and enforce our trademark rights. If we do not adequately protect our rights in our trademarks from infringement, any goodwill that we have developed in those trademarks could be lost or impaired.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Third parties may claim that the sale or promotion of our products, when and if we have any, may infringe on the trademark rights of others. Trademark infringement problems occur frequently in connection with the sale and marketing of pharmaceutical products. If we become involved in any dispute regarding our trademark rights, regardless of whether we prevail, we could be required to engage in costly, distracting and time-consuming litigation that could harm our business. If the trademarks we use are found to infringe upon the trademark of another company, we could be liable for damages and be forced to stop using those trademarks, and as result, we could lose all of the goodwill that has been developed in those trademarks.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>The future growth of our business may expose our intellectual property to a high risk of counterfeiting or unauthorized use.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As part of our business strategy, we intend to license our Anticalin-based technology and sell our potential products, if any, in many different countries. As a result, we may do business with third parties in countries where intellectual property rights have been or are routinely disregarded, and the future growth of our business may expose our intellectual property to a high risk of counterfeiting or unauthorized use. Although we attempt to obtain broad international intellectual property rights for our Anticalin technology and proteins, we cannot guarantee that such rights, to the extent we can obtain them, will be enforceable in a timely fashion or at all in any particular country or jurisdiction, or that if enforced, will offer us adequate commercial protection or adequate redress for any harm suffered. Counterfeiting or unauthorized use of our technologies or products may also expose our business to harm for which no adequate monetary redress exists, and to the extent we are unable to stop such use, may cause us to lose rights with respect to intellectual property that is crucial to our business. Any such misuse of our intellectual property may have a substantial negative impact on our business and revenues and may cause our business to fail.</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       83
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risks Related to Our Employees</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>If we are not able to attract and retain highly qualified personnel, we may not be able to successfully implement our business strategy.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract and retain highly qualified personnel. We are highly dependent on our management, scientific and medical personnel, especially Stephen S. Yoder, our Chief Executive Officer and President, whose services are critical to the successful implementation of our drug candidate development, our business development and partnerships, and our regulatory and commercialization strategies. Further, as our approach is built upon the drug discovery and development experience of our drug development team, which we believe is a significant contributor to our competitive advantage, we are dependent on the maintenance and growth of that team with qualified members containing high levels of expertise in specific scientific fields. We may in the future hire additional employees for research and development or general and administrative activities.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We are not aware of any present intention of any of our executive officers or other members of our senior management team to leave our company. However, our industry tends to experience a high rate of turnover of management personnel and our employees are generally able to terminate their relationships with us on short notice. Pursuant to German employment law, our employment arrangements with employees of Pieris GmbH are governed by employment contracts, which provide certain defined terms for either party to terminate the employment relationship.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The loss of the services of any of our executive officers, in particular Mr.&#xa0;Yoder, or other key employees, and our inability to find suitable replacements, could potentially harm our business, financial condition and prospects. Our success also depends on our ability to continue to attract, retain and motivate highly skilled junior and mid-level managers as well as junior and mid-level scientific and medical personnel.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Moreover, there is intense competition for a limited number of qualified personnel among biopharmaceutical, biotechnology, pharmaceutical and other related businesses. Many of the other companies against which we compete for qualified personnel have greater financial and other resources, different risk profiles, longer histories in the industry and greater ability to provide valuable cash or stock incentives to potential recruits than we do. They also may provide more diverse opportunities and better chances for career advancement. Some of these characteristics may be more appealing to high quality candidates than what we are able to offer as an early stage company. If we are unable to continue to attract and retain high quality personnel, the rate and success at which we can develop and commercialize our drug candidates will be limited.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We may be subject to labor claims brought by our employees against us.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In the United States, an employment relationship with no specified duration is presumed to be employment &#x201c;at-will&#x201d; and the employer or employee may terminate the employment relationship at any time, with or without cause, except for public policy reasons including discrimination, participating in union activity, or refusing to carry out an activity that violates the law.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In contrast, in Germany, there is no analogous doctrine of &#x201c;employment at will.&#x201d; By law, German employees must have written employment contracts that reflect the key aspects of the employment relationship. Our relations between German employers and employees are extensively regulated under German labor and employment laws and regulations. Employment relationships may be terminated for cause without observing the ordinary notice period. If terminated without cause, the applicable ordinary notice period must be observed. German employees have special protection against dismissals provided the employee has been employed by a company for more than six months and such company employs more than 10 full-time employees.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">German employment termination law is regulated by various codes, in particular the <i>K</i>&#xfc;<i>ndigungsschutzgesetz,</i> or the German Termination Protection Act, and is intended to give the employee maximum protection against unfair dismissal, including among other things:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the employer must observe the applicable notice period, which is ordinarily determined by law (between four weeks and seven months, depending upon the length of employment, though it is possible for the notice period to be two weeks, if a probationary period, lasting up to the first six months of employment, is agreed upon), if a longer period is not otherwise agreed by the parties, and has to deliver a written notice of termination to the employee;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">for companies with more than 10 full-time employees, the German Termination Protection Act generally restricts termination of employment if the employee has been employed for more than six months, wherein the employee may be terminated only for a particular reason, including certain behavioral or personal reasons relating to the employee or certain developments relating to the business of the employer, such as a business restructuring which reduces the number of employee positions;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       84
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">special termination protection against unlawful dismissal applies to several other groups of employees, such as an employee that is an officially acknowledged handicapped person, an employee who was appointed as a company&#x2019;s data protection officer or as a member of the works council of a company, if any, an employee on maternity leave or a pregnant employee (in these cases, approval of various German authorities is required prior to termination but usually very difficult to obtain); and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">if a company engages in a mass layoff, which is deemed to occur when the employer intends to dismiss a large percentage of its employees during a 30 calendar day period, prior written notification to the German employment office is required.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In this regard, if we downsize for any reason and fail to adhere to the complex requirements articulated by the employee protection law, we could face legal actions brought by affected employees or former employees, and, as a result, we may incur operational or financial losses and divert the attention of our executive officers from managing our business.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We may be subject to claims by third parties asserting that our employees or we have misappropriated their intellectual property or claiming ownership of what we regard as our own intellectual property.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Many of our employees were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. We may be subject to claims that these employees or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such employee&#x2019;s former employers. Litigation may be necessary to defend against any such claims.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition, while it is our policy to require our employees and contractors, who may be involved in the development of intellectual property, to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who contributes to the development of intellectual property that we regard as our own. Further, the terms of such assignment agreements may be breached and we may not be able to successfully enforce their terms, which may force us to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of intellectual property rights we may regard and treat as our own.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our employees, independent contractors, principal investigators, CROs, consultants, or vendors&#xa0;may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could cause our business to suffer.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We are exposed to the risk that our employees, independent contractors, principal investigators, contract research organizations, or CROs, consultants, or vendors may engage in fraudulent or other illegal activity. Misconduct by any of these parties could include intentional, reckless, and/or negligent conduct that may include failures to comply with FDA, MHRA, EMA or other foreign jurisdiction&#xa0;regulations, provide accurate information to the FDA, MHRA, EMA or their comparable foreign equivalents, comply with manufacturing standards we have established, comply with federal, state and international healthcare fraud and abuse laws and regulations as they may become applicable to our operations, report financial information or data accurately or disclose unauthorized activities to us. Employee and other third-party misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct by our employees and other third parties, and the precautions and procedures we currently take or may establish in the future as our operations and employee and third-party base expand to detect and prevent this type of activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid, and other federal healthcare programs, contractual damages, reputational harm, diminished potential profits and future earnings, and curtailment of our operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Certain of our employees and their inventions are subject to German law. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Many of our employees work in Germany and are subject to German employment law. Ideas, developments, discoveries and inventions made by such employees and consultants are subject to the provisions of the Gesetz &#xfc;ber Arbeitnehmererfindungen,<i> </i>or the German Act on Employees&#x2019; Inventions, which regulates the ownership of, and compensation for, inventions made by employees. We face the risk that disputes can occur between us and such employees or ex-employees pertaining to alleged non-adherence to the provisions of this act. Such disputes may be costly to defend and take up our management&#x2019;s time and efforts whether we prevail or not. In addition, under the German Act on Employees&#x2019; Inventions, certain employees retained rights to patents they invented or co-invented prior to 2009. Although most of these employees have subsequently assigned their interest in these patents to us, there is a risk that the compensation we provide to them may be deemed insufficient and we may be required under German law to increase the compensation due to such employees for the use of the patents. In those cases where employees have not assigned their interests to us, we may need to pay compensation for the use of those patents. If we are required to pay additional compensation or face other disputes under the German Act on Employees&#x2019; Inventions, our results of operations could be adversely affected.</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       85
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risks Related to the Ownership of Our Common Stock</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our share price is volatile and may be influenced by numerous factors, some of which are beyond our control.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Market prices for shares of biotechnology companies such as ours are often volatile. Thus, the quoted price of our common stock has been, and is likely to continue to be, highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control. In addition to the factors discussed in this &#x201c;Risk Factors&#x201d; section and elsewhere in this Annual Report on Form 10-K, these factors include:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the drug candidates we seek to pursue, and our ability to obtain rights to develop, commercialize and market those drug candidates;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical trial;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">actual or anticipated adverse results or delays in our clinical trials;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our failure to commercialize our drug candidates, if approved;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">unanticipated serious safety concerns related to the use of any of our drug candidates;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">adverse regulatory decisions;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">additions or departures of key scientific or management personnel;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">changes in laws or regulations applicable to our drug candidates, including without limitation clinical trial requirements for approvals;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the perception of the pharmaceutical and biotechnology industry by the public, legislatures, regulators and the investment community;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">disputes or other developments relating to patents and other proprietary rights and our ability to obtain patent protection for our drug candidates;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">significant lawsuits, including patent and stockholder class action litigation;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our dependence on third parties, including CROs and CMOs as well as our current and potential partners that produce companion diagnostic products;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">failure to meet or exceed any financial guidance or expectations regarding development milestones that we may provide to the public;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">actual or anticipated variations in quarterly operating results;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">failure to meet or exceed the estimates and projections of the investment community;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">overall performance of the equity markets and other factors that may be unrelated to our operating performance or the operating performance of our competitors, including changes in market valuations of similar companies;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">conditions or trends in the biotechnology and biopharmaceutical industries;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">introduction of new products by us or our competitors;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our ability to maintain an adequate rate of growth and manage such growth;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">issuances of debt or equity securities;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">sales of our common stock by us or our stockholders in the future, or the perception that such sales could occur;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">trading volume of our common stock;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">ineffectiveness of our internal control over financial reporting or disclosure controls and procedures;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">general political and economic conditions;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">effects of natural or man-made catastrophic events; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">other events or factors, many of which are beyond our control.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition, the stock market in general, and the stocks of biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. Furthermore, other biotechnology companies or our competitors&#x2019; programs could have positive or negative results that impact their stock prices and their results or stock fluctuations could have a positive or negative impact on our stock price regardless of whether such impact is direct or not. The realization of any of the above risks or any of a broad range of other risks, including those described in these &#x201c;Risk Factors,&#x201d; could have a dramatic and material adverse impact on the market price of our common stock.</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       86
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We have broad discretion in how we use our cash, cash equivalents and investments, including the net proceeds from our collaborations, public and private securities offerings, and may not use these financial resources effectively, which could affect our results of operations and cause our stock price to decline.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our management has considerable discretion in the application of our cash, cash equivalents and investments, including the fees and milestone payments from our collaborations and the net proceeds of our securities offerings. We intend to use the cash, cash equivalents and investments to advance our product candidates and for working capital and other general corporate purposes, which will include the hiring of additional personnel and capital expenditures. As a result, investors will be relying upon management&#x2019;s judgment with only limited information about our specific intentions for the use of the cash, cash equivalents and investments. We may use the cash, cash equivalents and investments for purposes that do not yield a significant return or any return at all for our stockholders. In addition, pending their use, we may invest the financial resources from our collaborations and securities offerings in a manner that does not produce income or that loses value.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>If securities or industry analysts do not publish, or cease publishing, research or publish inaccurate or unfavorable research about our business or our market, or if they change their recommendations regarding our stock adversely, our stock price and any trading volume could decline.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. We do not have any control over these analysts. If only a few securities or industry analysts commence coverage of our company, the trading price for our stock would likely be negatively affected and there can be no assurance that analysts will provide favorable coverage. If securities or industry analysts who initiate coverage downgrade our stock or publish inaccurate or unfavorable research about our business or our market, our stock price would likely decline. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and any trading volume to decline.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We have had, and have previously reported material weaknesses in our internal controls over financial reporting. If we fail to maintain proper and effective internal controls, our ability to produce accurate and timely financial statements could be impaired, which could harm our operating results, our ability to operate our business and investors</i></b>&#x2019;<b><i> views of us.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Pursuant to Section 404 of the Sarbanes-Oxley Act of 2002, or Section 404, we are required to furnish a report by our management on our internal control over financial reporting. However, while we remain a smaller reporting company with less than $100 million in revenue, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If we cannot favorably assess the effectiveness of our internal controls over financial reporting, investor confidence and, in turn, our stock price could be materially adversely affected.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As previously reported in our Annual Report on Form 10-K for the year ended December 31, 2019, we concluded that we had a material weakness in 2019 in our internal controls. No material financial statement misstatement was identified in relation to the previously reported material weaknesses in our internal control over financial reporting. While we took steps to address these material weaknesses and concluded in 2020 that the material weaknesses had been remediated, there is a reasonable possibility that material weaknesses may be identified in the future and that a material misstatement of our annual or interim consolidated financial statements may not be prevented or detected on a timely basis.&#xa0;Management, including our principal executive officer and principal financial officer, believes the consolidated financial statements included in this Annual Report on Form 10-K fairly represent in all material respects our financial condition, results of operations and cash flows in accordance with U.S. GAAP. However, we cannot assure you that additional material weaknesses or significant deficiencies in our internal control over financial reporting will not be identified in the future.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Ensuring that we have adequate internal financial and accounting controls and procedures in place so that we can produce accurate financial statements on a timely basis is a costly and time-consuming effort that will need to be evaluated frequently. Our failure to maintain the effectiveness of our internal controls in accordance with the requirements of the Sarbanes-Oxley Act could have a material adverse effect on the tradability of our common stock, which in turn would negatively impact our business. We could lose investor confidence in the accuracy and completeness of our financial reports, which could have an adverse effect on the price of our common stock. In addition, if our efforts to comply with new or changed laws, regulations and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to practice, regulatory authorities may initiate legal proceedings against us and our business may be harmed.</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       87
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Shares of our common stock that have not been registered under federal securities laws are subject to resale restrictions imposed by Rule 144 of the Securities Act, including those set forth in Rule 144(i) which apply to a former </i></b>&#x201c;<b><i>shell company.</i></b>&#x201d;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We were previously deemed a &#x201c;shell company&#x201d; under applicable SEC rules and regulations, prior to the reverse merger transaction in which we became a public company, because we had no or nominal operations and either no or nominal assets, assets consisting solely of cash and cash equivalents, or assets consisting of any amount of cash and cash equivalents and nominal other assets. Pursuant to Rule 144 of the Securities Act, sales of the securities of a former shell company, such as us, are not permitted unless at the time of a proposed sale, (i) we are subject to the reporting requirements of Section&#xa0;13 or 15(d) of the Exchange Act; and (ii) we have filed all reports and other materials required to be filed by Section&#xa0;13 or 15(d) of the Exchange Act, as applicable, during the preceding 12 months, other than current reports on Form 8-K. Additionally, our previous status as a shell company could also limit our use of our securities to pay for any acquisitions we may seek to pursue in the future. The lack of liquidity of our securities as a result of the inability to sell under Rule 144 for a longer period of time than a non-former shell company could cause the market price of our securities to decline.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>If we issue additional shares of our capital stock in the future, our existing stockholders will be diluted.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our Amended and Restated Articles of Incorporation authorize the issuance of up to 300,000,000 shares of our common stock and up to 10,000,000 shares of preferred stock with the terms, limitations, voting rights, relative rights and preferences and variations of each series that our Board of Directors may determine from time to time. Possible business and financial uses for our authorized capital stock include, without limitation, equity financing, future stock splits, acquiring other companies, businesses or products in exchange for shares of our capital stock, issuing shares of our capital stock to partners or other collaborators in connection with strategic alliances, attracting and retaining employees by the issuance of additional securities under our equity compensation plan, or other transactions and corporate purposes that our Board of Directors deems are in the interests of our company. Furthermore, issuances of shares of our capital stock could have the effect of delaying or preventing changes in control or our management. Any future issuances of shares of our capital stock may not be made on favorable terms or at all, they may have rights, preferences and privileges that are superior to those of our common stock and may have an adverse effect on our business or the trading price of our common stock. The issuance of any additional shares of our common stock will reduce the book value per share and may contribute to a reduction in the market price of the outstanding shares of our common stock. Additionally, any such issuance will reduce the proportionate ownership and voting power of all of our current stockholders.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Sales of a substantial number of shares of our common stock in the public market, or the perception that such sales could occur, could cause our stock price to fall.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If our existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market, the trading price of our common stock could decline. As of December 31, 2022, a total of 74,519,103&#xa0;shares of our common stock were outstanding. Any sales of those shares or any perception in the market that such sales may occur could cause the trading price of our common stock to decline.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition, shares of our common stock that are either subject to outstanding options or reserved for future issuance under our equity incentive plan, or issuable upon the conversion of our outstanding preferred stock or upon the exercise of our outstanding warrants, will be eligible for sale in the public market to the extent permitted by the provisions of applicable vesting schedules and/or terms of such securities. If these additional shares of common stock are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>The resale of shares covered by our effective resale registration statements could adversely affect the market price of our common stock in the public market, which result would in turn negatively affect our ability to raise additional equity capital.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The sale, or availability for sale, of our common stock in the public market may adversely affect the prevailing market price of our common stock and may impair our ability to raise additional equity capital. Pursuant to registration statements filed with the SEC, we previously registered for resale shares of our common stock, which included all of the shares of our common stock issued in our private placements and in connection with the closing of the reverse merger transaction in which we became a public company. For example, in March 2021, we registered for resale 3,706,174 shares of common stock in connection with a private placement transaction with Seagen, and 3,584,320 shares of common stock in connection with a private placement transaction with AstraZeneca. The resale registration statements permit the resale of these shares at any time without restriction.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The resale of a substantial number of shares of our common stock in the public market could adversely affect the market price for our common stock and make it more difficult for investors to sell shares of our common stock at times and prices that investors feel are appropriate. Furthermore, because there are a large number of shares registered pursuant to the resale registration statements, we may continue to offer shares covered by the resale registration statements for a significant period of time, the precise duration of which cannot be predicted. Accordingly, the adverse market and price pressures resulting from an offering pursuant to the resale registration statement may continue for an extended period of time and continued negative pressure on the market price of our common stock could have a material adverse effect on our ability to raise additional equity capital.</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       88
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans or otherwise, could result in dilution of the percentage ownership of our stockholders and could cause our stock price to fall.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Even after giving effect to the funds raised in the past, we expect that significant additional capital will be needed in the future to continue our planned operations. To raise capital, we may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner, in which we may determine from time to time. If we sell common stock, convertible securities or other equity securities in more than one transaction, investors in a prior transaction may be materially diluted. Additionally, new investors could gain rights, preferences and privileges senior to those of existing holders of our common stock. Further, any future sales of our common stock by us or resales of our common stock by our existing stockholders could cause the market price of our common stock to decline.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of December 31, 2022, there were 4,314,513 shares reserved for future issuance under our equity compensation plans, and 13,773,366 shares reserved for issuance upon the exercise of outstanding equity awards. Pursuant to our 2018 Employee Stock Purchase Plan, we are authorized to sell 500,000 shares to our employees. Any future grants of options, warrants or other securities exercisable or convertible into our common stock, or the exercise or conversion of such shares, and any sales of such shares in the market, could have an adverse effect on the market price of our common stock.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Anti-takeover provisions in our organizational documents could delay or prevent a change of control.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Certain provisions of our Amended and Restated Articles of Incorporation and Amended and Restated Bylaws may have an anti-takeover effect and may delay, defer or prevent a merger, acquisition, tender offer, takeover attempt or other change of control transaction that a stockholder might consider to be in its interests, including attempts that might result in a premium over the market price for the shares held by our stockholders.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">These provisions provide, among other things:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:14pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">a classified Board of Directors with staggered three-year terms;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:14pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the ability of our Board of Directors to issue one or more series of preferred stock with voting or other rights or preferences that could have the effect of impeding the success of an attempt to acquire us or otherwise effect a change of control;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:14pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">advance notice for nominations of directors by stockholders and for stockholders to include matters to be considered at stockholder meetings;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:14pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">certain limitations on convening special stockholder meetings and the prohibition of stockholder action by written consent; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:14pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">directors may only be removed for cause and only by the affirmative vote of the holders of at least 80%&#xa0;of the voting power of all of the then-outstanding shares of our capital stock entitled to vote at an election of directors, voting together as a single class.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">These anti-takeover provisions, including those noted above, could make it more difficult for a third party to acquire us, even if the third party&#x2019;s offer may be considered beneficial by many of our stockholders. As a result, our stockholders may be limited in their ability to obtain a premium for their shares.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We may incur significant costs from class action litigation due to our expected stock volatility.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our stock price may fluctuate for many reasons, including as a result of public announcements regarding the progress of our development efforts or the development efforts of current or future collaborators or competitors, the addition or departure of our key personnel, variations in our quarterly operating results and changes in market valuations of biopharmaceutical and biotechnology companies.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">This risk is especially relevant to us because biopharmaceutical and biotechnology companies have experienced significant stock price volatility in recent years. When the market price of a stock has been volatile, as our stock price may be, holders of that stock have occasionally brought securities class action litigation against the company that issued the stock. If any of our stockholders were to bring a lawsuit of this type against us, even if the lawsuit were without merit, it could result in substantial costs incurred defending the lawsuit and diversion of the time, attention and resources of our Board of Directors and management, which could significantly harm our profitability and reputation.</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       89
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our Amended and Restated Articles of Incorporation designates the Eighth Judicial District Court of Clark County, Nevada, as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, and therefore limit our stockholders</i></b>&#x2019;<b><i> ability to choose a forum for disputes with us or our directors, officers, employees or agents.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our Amended and Restated Articles of Incorporation provide that, to the fullest extent permitted by law, and unless we consent to the selection of an alternative forum, the Eighth Judicial District Court of Clark County, Nevada shall be the sole and exclusive forum for any (i)&#xa0;derivative action or proceeding brought in the name or right of the corporation or on its behalf, (ii)&#xa0;action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, employees or agents to the corporation or any of our stockholders, (iii)&#xa0;any action arising or asserting a claim arising pursuant to any provision of Chapters 78 or 92A of the Nevada Revised Statutes or any provision of our articles of incorporation or bylaws, (iv)&#xa0;any action to interpret, apply, enforce or determine the validity of our articles of incorporation or bylaws or (v)&#xa0;any action asserting a claim governed by the internal affairs doctrine. Our Amended and Restated Articles of Incorporation further provide that any person purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed, to the fullest extent permitted by law, to have notice of and consented to the foregoing provision.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We believe the choice-of-forum provision in our Amended and Restated Articles of Incorporation will help provide for the orderly, efficient and cost-effective resolution of Nevada-law issues affecting us by designating courts located in the State of Nevada (our state of incorporation) as the exclusive forum for cases involving such issues. However, this provision may limit a stockholder&#x2019;s ability to bring a claim in a judicial forum that it believes to be favorable for disputes with us or our directors, officers, employees or agents, which may discourage such actions against us and our directors, officers, employees and agents. While we are not aware of any Nevada case law addressing the enforceability of this type of provision, Nevada courts have on prior occasion found persuasive authority in Delaware case law in the absence of Nevada statutory or case law specifically addressing an issue of corporate law. The Court of Chancery of the State of Delaware ruled in June 2013 that choice-of-forum provisions of a type similar to those included in our Amended and Restated Articles of Incorporation are not facially invalid under corporate law and constitute valid and enforceable contractual forum selection clauses. However, if a court were to find the choice-of-forum provision in our Amended and Restated Articles of Incorporation inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could adversely affect our business, financial condition or results of operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>The elimination of personal liability of our directors and officers under Nevada law and the existence of indemnification rights held by our directors, officers and employees may result in substantial expenses.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our Amended and Restated Articles of Incorporation eliminate, to the furthest extent permitted under Nevada law, the personal liability of our directors and officers to us, our stockholders and creditors for damages as a result of any act or failure to act in his or her capacity as a director or officer. Further, our Amended and Restated Articles of Incorporation, our Amended and Restated Bylaws and individual indemnification agreements that we have entered with each of our directors and officers provide that we are obligated to indemnify, subject to certain exceptions, each of our directors or officers to the fullest extent authorized by Nevada law and, subject to certain conditions, to advance the expenses incurred by any director or officer in defending any action, suit or proceeding prior to its final disposition. Those indemnification obligations could expose us to substantial expenditures to cover the cost of settlement or damage awards against our directors or officers, which we may be unable to afford. Further, those provisions and resulting costs may discourage us or our stockholders from bringing a lawsuit against any of our current or former directors or officers for such damages, even if such actions might otherwise benefit our stockholders.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We do not intend to pay cash dividends on our capital stock in the foreseeable future.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have never declared or paid any cash dividends on our common stock and do not anticipate paying any dividends in the foreseeable future. We currently intend to retain all future earnings to fund the development and growth of our business. Any future payment of cash dividends in the future will be at the discretion of our Board of Directors and will depend on, among other things, our earnings, financial condition, capital requirements, level of indebtedness, statutory and contractual restrictions applying to the payment of dividends and other considerations that the Board of Directors deems relevant. Our stockholders should not expect that we will ever pay cash or other dividends on our outstanding capital stock. Any return to our stockholders will therefore be limited to the appreciation of their stock.</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       90
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We can issue and have issued shares of preferred stock, which may adversely affect the rights of holders of our common stock.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our amended and restated Certificate of Incorporation authorizes us to issue up to 10,000,000 shares of preferred stock with designations, rights, and preferences determined from time-to-time by our Board of Directors. Accordingly, our Board of Directors is empowered, without stockholder approval, to issue preferred stock with dividend, liquidation, conversion, voting or other rights superior to those of holders of our common stock. For example, an issuance of shares of preferred stock could:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:27pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">adversely affect the voting power of the holders of our common stock;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:27pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">make it more difficult for a third party to gain control of us;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:27pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">discourage bids for our common stock at a premium;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:27pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">limit or eliminate any payments that the holders of our common stock could expect to receive upon our liquidation; or</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:27pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">otherwise adversely affect the market price or our common stock.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have in the past issued, and we may at any time in the future issue, shares of preferred stock. In connection with our June 2016 private placement, we issued 4,963 shares of our Series A convertible preferred stock to certain affiliates of Biotechnology Value Fund, L.P., or BVF, each share of which is convertible into 1,000 shares of our common stock, subject to certain ownership restrictions. In January 2019, we entered into an exchange agreement with BVF to exchange 5,000,000 shares of our common stock previously held by BVF for 5,000 shares of our Series B convertible preferred stock, each share of which is convertible into 1,000 shares of our common stock, subject to certain ownership restrictions. In connection with our November 2019 private placement, we issued 3,522 shares of our Series C convertible preferred stock to certain affiliates of BVF each share of which is convertible into 1,000 shares of our common stock, subject to certain ownership restrictions. In March 2020, we entered into another exchange agreement with BVF to exchange 3,000,000 shares of our common stock previously held by BVF for 3,000 shares of our Series D convertible preferred stock, each share of which is convertible into 1,000 shares of our common stock, subject to certain ownership restrictions. In May 2021, we entered into another exchange agreement with BVF to exchange 5,000,000 shares of our common stock previously held by BVF for 5,000 shares of our Series E convertible preferred stock, each share of which is convertible into 1,000 shares of our common stock, subject to certain ownership restrictions. If the holders of our shares of preferred stock convert their shares into common stock, existing holders of our common stock will experience dilution.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Requirements associated with being a public company have increased our costs significantly and have diverted significant company resources and management attention.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Since we are no longer an &#x201c;emerging growth company&#x201d; as defined in the JOBS Act, we are no longer able to take advantage of certain exemptions from various reporting requirements that were previously available to us, but which were not available to other public companies that are not emerging growth companies. Accordingly, we are now required to comply with increased disclosure obligations regarding executive compensation in our periodic reports and proxy statements and the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. As a result, we will incur greater expenses associated with such reporting requirements. These expenses would further increase if we ceased to be a &#x201c;smaller reporting company.&#x201d;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our management and other personnel need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations have increased and will continue to increase our legal and financial compliance costs and will make some activities more time-consuming and costly.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Having availed ourselves of scaled disclosure available to smaller reporting companies, we cannot be certain if such reduced disclosure will make our common stock less attractive to investors. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Under Rule 12b-2 of the Exchange Act, a &#x201c;smaller reporting company&#x201d; is a company that is not an investment company, an asset-backed issuer or a majority-owned subsidiary of a parent company that is not a smaller reporting company, and had a public float of less than $250 million as of the last business day of its most recently completed second fiscal quarter or, if such public float is less than $700 million, had annual revenues of less than $100 million during the most recently completed fiscal year. Smaller reporting companies are permitted to provide simplified executive compensation disclosure in their filings; and they have certain other decreased disclosure obligations in their SEC filings, including, among other things, only being required to provide two years of audited financial statements in annual reports. We qualify as a smaller reporting company. For as long as we continue to be a smaller reporting company, we expect that we will take advantage of the reduced disclosure obligations available to us as a result of those respective classifications. Decreased disclosure in our SEC filings as a result of our having availed ourselves of scaled disclosure may make it harder for investors to analyze our results of operations and financial prospects.</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       91
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <div>
    &#xa0;
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 81pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b><a id="a1b" title="1b" href="#"></a>Item</b>&#xa0;<b>1B.</b></p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>UNRESOLVED STAFF COMMENTS</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Not applicable.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 81pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b><a id="a2" title="2" href="#"></a>Item</b>&#xa0;<b>2.</b></p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>PROPERTIES</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In October 2018, Pieris GmbH entered into a lease initially comprising of approximately 96,400 square feet of mixed laboratory and office space in Hallbergmoos, Germany, which became our location for all German operations in February 2020. This agreement, or the Lease Agreement, provides for an initial term of 150 months, commencing on the date the lessor first delivers the leased property to Pieris GmbH as agreed under the Lease Agreement, which occurred in February 2020. Pieris GmbH and the lessor are each entitled to terminate the Lease Agreement for due cause.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We previously leased 3,950 square feet of office space in Boston, Massachusetts under a sublease, or the Sublease, that housed our executive offices, clinical operations and other operational functions. The Sublease expired on December 31, 2022. Our corporate headquarters continue to be located in Boston, Massachusetts, but we now generally conduct our operational functions remotely.&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We believe that our facilities are sufficient to meet our needs and will look for suitable additional space as and when needed.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 81pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b><a id="a3" title="3" href="#"></a>Item</b>&#xa0;<b>3.</b></p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>LEGAL PROCEEDINGS</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of the date of this Annual Report on Form 10-K, we are not currently involved in any material legal proceedings. However, from time to time, we could be subject to various legal proceedings and claims that arise in the ordinary course of our business activities. Regardless of the outcome, legal proceedings can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 81pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b><a id="a4" title="4" href="#"></a>Item</b>&#xa0;<b>4.</b></p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>MINE SAFETY DISCLOSURES</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Not applicable.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       92
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <div>
    &#xa0;
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="partii" title="partii" href="#"></a>PART II</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 81pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b><a id="a5" title="5" href="#"></a>Item</b>&#xa0;<b>5.</b></p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>MARKET FOR REGISTRANT</b>&#x2019;<b>S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Market Information</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our common stock is listed on The Nasdaq Stock Market LLC under the symbol &#x201c;PIRS&#x201d; and on June&#xa0;30, 2015 our common stock began trading on The Nasdaq Capital Market.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Stockholders</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of March 23, 2023, there were 36 and 4 stockholders of record of our common stock and preferred stock, respectively. Because many of our shares are held by brokers and other institutions on behalf of stockholders, we are unable to estimate the total number of beneficial holders represented by these record holders.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Unregistered Sales of Securities</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">None.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Issuer Purchases of Equity Securities</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">None.</p>
  <div>
    &#xa0;
  </div>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 81pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b><a id="a6" title="6" href="#"></a>Item</b>&#xa0;<b>6.</b></p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>[RESERVED]</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       93
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <div>
    &#xa0;
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 81pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b><a id="a7" title="7" href="#"></a>Item</b>&#xa0;<b>7.</b></p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>MANAGEMENT</b>&#x2019;<b>S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and the related notes and other financial information included in this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form 10-K, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties as described under the heading </i>&#x201c;<i>Forward-Looking Statements</i>&#x201d;<i> elsewhere in this Annual Report on Form 10-K. You should review the disclosure under the heading </i>&#x201c;<i>Risk Factors</i>&#x201d;<i> in this Annual Report on Form 10-K for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Overview</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We are a clinical-stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways in unique and transformative ways. Our clinical pipeline includes elarekibep, formerly referred to as PRS-060/AZD1402, an inhaled IL-4R&#x3b1; antagonist Anticalin protein to treat uncontrolled asthma, PRS-220, an inhaled CTGF antagonist to treat IPF and other forms for fibrotic lung disease, an immuno-oncology, or IO, bispecific PRS-344/S095012 targeting PD-L1 and 4-1BB. Proprietary to us, Anticalin proteins are a novel class of therapeutics validated in the clinic and through partnerships with leading pharmaceutical companies. In particular, we have alliances with AstraZeneca and Genentech to treat respiratory diseases, with Genentech also in ophthalmology and with Servier, Seagen, and Boston Pharmaceuticals in IO. Our discovery and development programs are in varying stages and include:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:5pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"><i>Elarekibep</i>, our lead respiratory program partnered with AstraZeneca for the treatment of asthma, is a drug candidate that antagonizes IL-4R&#x3b1;, thereby inhibiting the downstream action of IL-4 and IL-13, two cytokines known to be key mediators in the inflammatory cascade that drive the pathogenesis of asthma and other inflammatory diseases.</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:27pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25e6;</p> </td>
     <td style="vertical-align:top;">Elarekibep was tested in a nebulized formulation and an IV arm for pharmacokinetic, or PK, assessment in 54 healthy volunteers at nominal dose levels ranging from 0.25 mg to 400 mg in a phase 1 single-ascending dose, or SAD, study. Data from that study were presented at the American Thoracic Society International Conference in May 2019 showing that elarekibep was well-tolerated when given as single inhaled or intravenous doses to healthy volunteers and there was systemic target engagement (as measured by pSTAT6 inhibition). Elarekibep was also tested in a phase 1 multiple-ascending dose, or MAD, study in 30 patients that were randomized to receive delivered doses via nebulizer ranging from 2 mg to 60 mg (5 mg to 150 mg nominal dose) twice daily for nine consecutive days and one final dose on the 10th day, and 12 patients were randomized to receive placebo at the same intervals. We presented interim data from the elarekibep phase 1 MAD study at the European Respiratory Society International Congress in October 2019 and reported that elarekibep was well-tolerated at all doses, led to a statistically significant reduction in FeNO, a validated biomarker for eosinophilic airway inflammation, and showed dose-dependent systemic target engagement in patients with mild asthma and elevated levels of FeNO (&#x2265; 35ppb).</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:27pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25e6;</p> </td>
     <td style="vertical-align:top;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The phase 2a asthma study is ongoing at multiple sites globally. This phase 2a study is a two-part, multi-center, placebo-controlled clinical study of elarekibep that will evaluate elarekibep at up to three dose levels using a dry powder formulation administered twice daily. In part 1a (1 mg and 3 mg dose safety) of the study, 31 asthma patients, controlled on standard of care (medium dose inhaled corticosteroids, or ICS, with long-acting beta agonists, or LABA), received elarekibep twice daily over four weeks to establish the safety profile and pharmacokinetics of the dry powder formulation of elarekibep. A safety review following completion of part 1a included an evaluation, compared to placebo, of the incidence of adverse events, changes in laboratory markers (immuno-biomarkers, clinical chemistry, and hematology), and forced expiratory volume in one second, or FEV1. Following the safety review, AstraZeneca began enrollment of part 2a (1 mg and 3 mg dose efficacy) of the study to evaluate efficacy, safety, and pharmacokinetics of elarekibep administered twice daily to asthma patients, uncontrolled on medium dose ICS with LABA, that have a blood eosinophil count of &#x2265;&#xa0;150 cells/&#x3bc;L and FeNO &#x2265;&#xa0;25 ppb in the 1 mg and 3 mg arms and a placebo arm. Following a four-week run-in period, patients will be dosed and monitored over four weeks. FEV1 improvement at four weeks compared to placebo will be the primary endpoint in this portion of the study. Also following the safety review, AstraZeneca initiated part 1b of the study to evaluate the safety of the 10 mg dose in asthma patients controlled on standard of care who will receive elarekibep twice daily over four weeks, and part 1b has now completed enrollment. In the second quarter of 2022, AstraZeneca conducted a reforecast of the study, which has taken into account the global challenges of recruiting for respiratory clinical trials caused by the continued impact of the COVID-19 pandemic, and has&#xa0;broadened&#xa0;enrollment criteria in part 2 (previously referenced as part 2a)&#xa0;of the study to facilitate recruitment of the study. AstraZeneca also now plans to focus part 2 on the 3 mg cohort for the efficacy readout and plans to stop enrollment for the 1 mg cohort. AstraZeneca no longer plans to enroll the 10 mg cohort for the efficacy readout&#xa0;(previously referenced as part 2b).</p> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</p> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Topline data from part 2 of this study are expected to be reported by the middle of 2024.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:27pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25e6;</p> </td>
     <td style="vertical-align:top;">Upon receipt of the topline data and notice from AstraZeneca, including a product development plan and budget, we will have 30 days to opt into co-development of the program with AstraZeneca at one of two levels, neither of which includes an option exercise fee. If we do not choose to participate in co-development, we would still be entitled to sales royalties from single-digit up to the mid-teens, plus the potential for more than $1 billion in sales milestones. At the first opt-in level, we would be responsible for 25% of the cost-share through regulatory approval with a predetermined cost cap. At this level, for the lifetime of this product, we would receive sales royalties from single-digit up to the high teens, plus the potential for multi-billion dollar sales milestones. The second opt-in level would be at a 50% cost share without a cost cap which, instead of sales royalties and milestones, would result in a gross margin share in the mid-twenty percent range for the lifetime of the product. We also have a separate option to co-commercialize elarekibep with AstraZeneca in the United States independent of the co-development opt-in decision.</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:5pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;">There are currently two discovery-stage programs included in the AstraZeneca alliance beyond elarekibep, the targets and disease areas of which are undisclosed. Pieris retains co-development and U.S. co-commercialization options for the two discovery-stage programs.</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:5pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;">Our lead fully proprietary respiratory asset,&#xa0;<i>PRS-220</i>, an oral inhaled Anticalin protein targeting connective tissue growth factor, or CTGF, is being developed as a local treatment for idiopathic pulmonary fibrosis, or IPF, and other forms of fibrotic lung disease. CTGF, a matricellular protein, is a driver of fibrotic tissue remodeling and the protein has been found over-expressed in lung tissue from patients suffering from IPF. Clinical data from a phase 2 study with pamrevlumab&#xa0;conducted by Fibrogen indicated that inhibition of CTGF reduced&#xa0;the decline in lung function in&#xa0;patients, thus demonstrating clinical proof of concept for this target.</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:27pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25e6;</p> </td>
     <td style="vertical-align:top;">In 2021, we received a &#x20ac;14.2 million grant from the Bavarian Ministry of Economic Affairs, Regional Development and Energy supporting research and development of the PRS-220 program.</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       94
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:27pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25e6;</p> </td>
     <td style="vertical-align:top;">We presented initial preclinical data for PRS-220 at the European Respiratory Society International Congress 2021 demonstrating a more potent and durable target engagement profile compared to a clinical-stage, systemically delivered anti-CTGF antibody benchmark. Additionally, the targeting of CTGF locally in the lung showed increased attenuation of fibrotic lung remodeling&#xa0;<i>in vivo</i>&#xa0;compared to the systemically delivered antibody. This outcome correlates with superior lung tissue exposure of PRS-220 compared to that of the systemically administered antibody in head-to-head studies, where intratracheally administered PRS-220 efficiently penetrates the fibrotic, interstitial lung tissue of mice.</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:27pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25e6;</p> </td>
     <td style="vertical-align:top;">We are conducting a phase 1 study of&#xa0;PRS-220 in healthy volunteers in Australia. The study is a randomized, two-part, blinded, placebo-controlled study, designed to assess the safety, tolerability, pharmacokinetics, and immunogenicity of single and multiple ascending doses of PRS-220 when administered by oral inhalation to healthy subjects. We expect to report the outcome of the study later this year.</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:5pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;">In May 2021, we also entered into a multi-program research collaboration and license agreement with Genentech, a member of the Roche Group, to discover, develop and commercialize locally delivered respiratory and ophthalmology therapies. We are currently conducting joint discovery activities in each of the two committed programs.</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:5pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"><i>PRS-400</i>&#xa0;is a fully proprietary Anticalin protein targeting Jagged-1 and is being developed as a local treatment for muco-obstructive lung diseases. Jagged-1 is one of five cell surface ligands interacting with Notch receptors. It has been demonstrated that Jagged-1/Notch signaling drives secretory cell trans-differentiation in the airways and that blocking Jagged-1/Notch signaling reduces secretory cell number, mucin expression and mucus plugging&#xa0;<i>in vivo</i>. In August 2022, we presented preclinical data at the European Respiratory Society International Congress 2022 indicating that candidate molecules inhibit Jagged-1-induced Notch 2 signaling in a dose-dependent manner and also demonstrate that PRS-400 reduces mucin expression <i>ex vivo</i>. Additionally, PRS-400 was found <i>in vivo</i> to reduce mucin gene expression and goblet cells in mice with IL-13-induced airway inflammation. These findings suggest that PRS-400 represents a promising opportunity to address muco-obstructive respiratory diseases locally with an attractive therapeutic index.</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:5pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"><i>Cinrebafusp alfa</i>&#xa0;is a bispecific Mabcalin compound comprising a HER2-targeting antibody genetically linked to 4-1BB-targeting Anticalin proteins. Cinrebafusp alfa is designed to drive tumor localized T cell activation through tumor-targeted drug clustering mediated by HER2 expressed on tumor cells. This program was the first 4-1BB bispecific T cell co-stimulatory agonist to enter clinical development.</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:27pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25e6;</p> </td>
     <td style="vertical-align:top;">In July 2022,&#xa0;we received fast track designation from FDA for cinrebafusp alfa. In August 2022, we announced the decision to cease further enrollment in the two-arm, multicenter, open-label phase 2 study of cinrebafusp alfa as part of a strategic pipeline prioritization to focus our resources. Cinrebafusp alfa has demonstrated clinical benefit in phase 1 studies, including single agent activity in a monotherapy setting, and in the phase 2 study in HER2-expressing gastric cancer, giving the Company confidence in its broader 4-1BB franchise.</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:5pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"><i>PRS-344/S095012</i>&#xa0;is a bispecific Mabcalin protein compound comprising a PD-L1-targeting antibody genetically linked to 4-1BB-targeting Anticalin proteins. PRS-344/S095012 is being developed as part of our IO collaboration with Servier.</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:27pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25e6;</p> </td>
     <td style="vertical-align:top;">The first patient in phase 1/2 study of PRS-344/S095012&#xa0;was dosed in November 2021 and the study is being conducted in multiple countries, including the United States.</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:27pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25e6;</p> </td>
     <td style="vertical-align:top;">The first-in-human phase 1/2 multicenter open-label dose escalation study is designed to determine the safety and preliminary activity of PRS-344/S095012 in patients with advanced and/or metastatic solid tumors. We plan to present the escalation data at a medical meeting in 2023.</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:27pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25e6;</p> </td>
     <td style="vertical-align:top;">Pieris and Servier presented preclinical data and the phase 1/2 study design at the American Association for Cancer Research, or AACR, medical meeting in April 2022.</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:27pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25e6;</p> </td>
     <td style="vertical-align:top;">We expect to initiate the expansion cohorts in a select number of jointly vetted indications later this year.</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:5pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;">Our IO portfolio also includes additional drug candidates beyond PRS-344/S095012 that are multi-specific Anticalin-based fusion proteins designed to engage immunomodulatory targets, comprising a variety of multifunctional biotherapeutics. Other IO drug candidates are being developed as part of our collaborations with Servier, Seagen, and Boston Pharmaceuticals.</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:27pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25e6;</p> </td>
     <td style="vertical-align:top;">We have already handed one of the programs in the Seagen collaboration, &#xfeff;SGN-BB228 (also referenced as PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound, over to Seagen, who is responsible for further advancement and funding of the asset. In January 2023, the first patient was dosed in a Seagen-sponsored phase 1 study of &#xfeff;SGN-BB228, upon which we achieved a $5.0 million milestone. Seagen presented preclinical data for this program at the Society for Immunotherapy of Cancer 37th Annual Meeting in November 2022.&#xa0;The program is one of three programs in the Seagen alliance, and we believe the previous achievement of a key development milestone for this program validates our approach and leadership in IO bispecifics, complementing the encouraging clinical data seen with cinrebafusp alfa. During the third quarter of 2021, we initiated the second program, and during the fourth quarter of 2022, we initiated the third program within the collaboration with Seagen.&#xa0;We retain a co-promotion option for one program in the Seagen collaboration in the United States.</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:27pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25e6;</p> </td>
     <td style="vertical-align:top;">PRS-342/BOS-342 is a 4-1BB/GPC3 bispecific Mabcalin compound&#xa0;that we have exclusively licensed to Boston Pharmaceuticals. Boston Pharmaceuticals continues to advance PRS-342/BOS-342 towards the clinic, with phase 1 expected in the coming months.</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Since inception, we have devoted nearly all of our efforts and resources to our research and development activities and have incurred significant net losses. For the years ended December 31, 2022 and 2021, we reported net losses of $33.3&#xa0;million and $45.7 million, respectively. As of December 31, 2022, we had an accumulated deficit of $290.4&#xa0;million. We expect to continue incurring substantial losses for the next several years as we continue to develop our clinical and preclinical drug candidates and programs. Our operating expenses are comprised of research and development expenses and general and administrative expenses.</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       95
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have not generated any revenues from product sales to date, and we do not expect to generate revenues from product sales for the foreseeable future. Our revenues for the fiscal years ended December 31, 2022 and 2021 were from license and collaboration agreements with our partners.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A significant portion of our operations are conducted in countries other than the United States. Since we conduct our business in U.S. dollars, our main exposure, if any, results from changes in the exchange rates between the euro and the U.S. dollar. At each period end, we remeasure assets and liabilities to the functional currency of that entity (for example, U.S. dollar payables recorded by Pieris Pharmaceuticals GmbH). Remeasurement gains and losses are recorded in the statement of operations line item &#x2018;Other income (expense), net&#x2019;. All assets and liabilities denominated in euros are translated into U.S. dollars at the exchange rate on the balance sheet date. Revenues and expenses are translated at the weighted average rate during the period. Equity transactions are translated using historical exchange rates. All adjustments resulting from translating foreign currency financial statements into U.S. dollars are included in accumulated other comprehensive income (loss).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Key Financial Terms and Metrics</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following discussion summarizes the key factors our management believes are necessary for an understanding of our consolidated financial statements.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Revenues</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have not generated any revenues from product sales to date and we do not expect to generate revenues from product sales for the foreseeable future. Our revenues for the last two years have been from the license and collaboration agreements with AstraZeneca, Servier, Seagen, Genentech and Boston Pharmaceuticals.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The revenues from AstraZeneca, Servier, Seagen, Genentech and Boston Pharmaceuticals have been comprised primarily of upfront payments, research and development services and milestone payments. For additional information about our revenue recognition policy, see &#x201c;Note 2-Summary of Significant Accounting Policies&#x201d;.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Research and Development Expenses</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The process of researching and developing drugs for human use is lengthy, unpredictable, and subject to many risks. We expect to continue incurring substantial expenses for the next several years as we continue to develop our clinical and preclinical drug candidates and programs. We are unable, with any certainty, to estimate either the costs or the timelines in which those expenses will be incurred. Our current development plans focus on the following programs: our lead respiratory program, elarekibep, our proprietary respiratory programs, PRS-220 and PRS-400, and our partnered IO programs, including PRS-344/S095012. These programs consume a large proportion of our current, as well as projected, resources.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our research and development costs include costs that are directly attributable to the creation of certain of our Anticalin drug candidates and are comprised of:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">internal recurring costs, such as personnel-related costs (salaries, employee benefits, equity compensation and other costs), materials and supplies, facilities and maintenance costs attributable to research and development functions; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">fees paid to external parties who provide us with contract services, such as preclinical testing, manufacturing and related testing and clinical trial activities.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>General and Administrative Expenses</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">General and administrative expenses consist primarily of salaries, employee benefits, equity compensation, and other personnel-related costs associated with executive, administrative and other support staff. Other significant general and administrative expenses include the costs associated with professional fees for accounting, auditing, insurance costs, consulting and legal services, along with facility and maintenance costs attributable to general and administrative functions.</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       96
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Results of Operations</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Comparison of Years Ended December 31, 2022</b><b> and December 31, 2021</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following table sets forth our revenues and operating expenses for the fiscal years ended December 31, 2022 and 2021 (in thousands):</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
   <tbody>
    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Years ended December 31,</b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>2022</b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>2021</b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Revenues</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">25,902</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">31,418</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development expenses</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">52,982</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">66,656</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">General and administrative expenses</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">16,394</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">16,593</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total operating expenses</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">69,376</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">83,249</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Interest income</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">721</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Grant income</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8,173</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">3,685</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Other (expense) income , net</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,303</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,404</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Loss before income taxes</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(33,277</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(45,738</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Benefit for income tax</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#x2014;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#x2014;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(33,277</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(45,738</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Revenues</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following table provides a comparison of revenues for the years ended December 31, 2022 and 2021 (in thousands):</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
   <tbody>
    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Year Ended December 31,</b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>2022</b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>2021</b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Increase/(Decrease)</b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Customer revenue</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">25,469</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">27,940</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(2,471</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Collaboration revenue</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">433</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,478</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(3,045</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total Revenue</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,902</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">31,418</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(5,516</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The $2.5 million decrease in customer revenue for the year ended December 31, 2022 compared to the year ended&#xa0;December 31, 2021 is driven by the following:</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:54pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25e6;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Current year revenue recorded due to the discontinuation of two&#xa0;early-stage programs under the AstraZeneca collaboration (approximately $9.2 million), completion of the performance obligation related to the material right for PRS-352 (approximately $4.9 million), milestone revenue recorded under the Seagen collaboration ($5.0 million) and completion of the performance obligation related to the expiration of the target swap for the second program under the Seagen collaboration (approximately $1.5 million) as well as program progress on the Seagen and Genentech collaborations.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:54pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25e6;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Prior year revenue was slightly higher and primarily consisted of a phase 2a milestone ($13.0 million) recognized for elarekibep under the AstraZeneca collaboration along with higher reimbursable costs incurred on this program, revenue recognized under the Boston Pharmaceuticals collaboration ($5.7 million) and higher reimbursable costs for phase 1 preparation activities&#xa0;due from &#xfeff;Servier. .</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Collaboration revenue decreased by $3.0 million in the year ended December 31, 2022 compared to the year ended December 31, 2021. The decrease relates to an updated estimate of project completion for PRS-344/S095012 under the Servier collaboration, leading to lower revenue recognized in the current period along with increased activities managed by Servier for the phase 1 study which offset our revenue generating activities.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       97
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Research and Development Expenses</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following table provides a comparison of the research and development expenses for the years ended December 31, 2022 and 2021 (in thousands):</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
   <tbody>
    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Year Ended December 31,</b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>2022</b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>2021</b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Increase/(Decrease)</b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Respiratory</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,845</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">17,158</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(4,313</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Immuno-oncology</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">13,743</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">23,210</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(9,467</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Other R&amp;D activities</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">26,394</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">26,288</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">106</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">52,982</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">66,656</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(13,674</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The $9.5&#xa0;million decrease in our immuno-oncology program spending period-over-period is due primarily to a decrease in overall costs for cinrebafusp alfa as the program was stopped during 2022, decreased manufacturing costs for PRS-344/S095012, and lower license fees given transactions that occurred in 2021, partially offset by higher clinical costs for&#xa0;PRS-344/S095012 and slightly higher pre-clinical costs for discovery stage programs.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The $4.3 million decrease for our respiratory program spending period-over-period is due to lower program costs for elarekibep as there was limited phase 1 clinical activities to complete in 2022 along with some phase 2 manufacturing costs both of which were fully reimbursed by AstraZeneca, lower manufacturing costs for PRS-220, and lower license fees given amendments to the AstraZeneca collaboration that occurred in 2021, all partially offset by higher clinical costs for PRS-220 and higher pre-clinical and consumable costs for PRS-400.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The $0.1 million increase in other research and development activities expenses is due primarily to higher personnel costs due to higher average headcount along with an increase in travel expenses, both&#xa0;partially offset by lower overall license fees, lower external consulting expenses, and lower general lab supply costs.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>General and Administrative Expenses</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">General and administrative expenses were $16.4 million for the year ended December 31, 2022 as compared to $16.6 million for the year ended December 31, 2021. The slight period-over-period decrease was driven primarily by lower personnel costs,&#xa0;facilities and IT costs, and audit and tax costs,&#xa0;partially offset by higher&#xa0;amortization of deferred costs related to costs to obtain a contract&#xfeff;, business development and travel costs.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Other income (expense), net</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our other income was $10.2 million for the year ended December 31, 2022 as compared to a other expense of $6.1 million for the year ended December 31, 2021. This period over period increase was primarily due to a full year of grant income recorded for PRS-220 in the current period as compared to a partial year in the same period in the prior year, interest income on investments in the current year as well as a strengthening US dollar for the majority of the current year, partially offset by higher foreign exchange realized losses in the current year as compared to the same period in the prior year.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Liquidity and Capital Resources</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We are subject to risks common to companies in the biotechnology industry, including but not limited to, the need for additional capital, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval and reimbursement for any drug product candidate that we may identify and develop, the need to successfully commercialize and gain market acceptance of our product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development of technological innovations by competitors, reliance on third-party manufacturers and the ability to transition from pilot-scale production to large-scale manufacturing of products.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Through December 31, 2022, we have funded our operations with $521.5 million of cash that has been obtained from the following main sources: $283.2&#xa0;million from sales of equity; $217.7&#xa0;million in total upfront and milestone payments received under license and collaboration agreements and&#xa0;$20.6&#xa0;million&#xa0;from government grants.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of December 31, 2022, we had a total of $59.2 million in cash,&#xa0;cash equivalents and investments. We have incurred losses in every period since inception including the years ended December 31, 2022 and 2021, respectively, and have a total accumulated deficit of $290.4 million as of December 31, 2022. Net losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholders&#x2019; equity and working capital. We expect to continue to incur operating losses for at least the next several years.</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       98
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following table provides a summary of operating, investing, and financing cash flows for the years ended December 31, 2022 and 2021 respectively (in thousands):</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
   <tbody>
    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Year Ended December 31,</b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>2022</b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>2021</b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Net cash used in operating activities</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(59,932</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(7,660</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Net cash used in investing activities</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(21,236</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(949</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Net cash provided by financing activities</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,214</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">59,127</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Net cash used in operating activities for the year ended December 31, 2022 and 2021 was $59.9 million and $7.7 million, respectively. Cash used in the current period is impacted by lower deferred revenue, primarily driven by higher revenue recognized for AstraZeneca, Servier and Seagen out of the deferred balance, lower accounts payable and accrued expenses and higher accounts receivable and prepaid expenses. This compares to the impact of higher deferred revenue, primarily driven by the new collaboration agreements with Boston Pharmaceuticals and Genentech and higher accounts payable and accrued expenses, offset partially by higher accounts receivables and prepaid expenses in the prior period.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The change in net cash used in investing activities for the year ended December 31, 2022 compared to net cash used in&#xa0;investing activities in&#xa0;2021 is solely attributable to the impact of net investments changes (purchase of investments as a result of rising interest rates in 2022) for which there is no activity in the comparable prior year period.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Financing activities for the year ended December 31, 2022 and 2021 provided cash of $7.2 million and $59.1 million, respectively. The decrease in 2022 compared to&#xa0;2021 is driven by equity investments from both Seagen and AstraZeneca, higher sales activity under our ATM programs and higher proceeds received from warrant and option exercises in the prior period compared to more limited ATM sales activity and warrant and option exercises in 2022 given the overall lower stock price.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In August 2019, we entered into a sales agreement pursuant to which we may offer and sell shares of our common stock, from time to time, up to an aggregate gross sales proceeds of $50.0 million through an &#x201c;at the market offering&#x201d; program, or the 2019 ATM Program, under a shelf registration statement on Form S-3 (File No. 333-226725). In August 2021, the 2019 ATM Program expired. In August 2021, we established a second ATM offering program, or the 2021 ATM Program, under the existing sales agreement with Jefferies LLC, pursuant to which the Company may offer and sell shares of its common stock, from time to time, up to an aggregate amount of gross sales proceeds of $50.0&#xa0;million. In November 2022, the sales agreement was amended to provide for an increase in the aggregate offering amount, such that under the 2021 ATM Program, as amended, the Company may offer and sell shares of its common stock, from time to time, up to an aggregate amount of gross sales proceeds of $75.0 million. The 2021 ATM Program, as amended,&#xa0;is offered under a shelf registration statement on Form S-3 (File No. 333-258497) that was filed with and declared effective by the SEC in August 2021. For the year ended December 31, 2022, we sold 2.1 million shares for gross proceeds of $7.2&#xa0;million under the ATM program at an average stock price of $3.46. For the year ended December 31, 2021, we sold 8.2 million shares for gross proceeds of $39.7 million under both ATM programs at an average stock price of $4.85.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our future success is dependent on our ability to identify and develop our product candidates, expand our corporate infrastructure and ultimately upon our ability to attain profitable operations. We have devoted substantially all of our financial resources and efforts to research and development and general and administrative expenses to support such research and development. We have several research and development programs underway in varying stages of development and we expect that these programs will continue to require increasing amounts of cash for development, conducting clinical trials, and testing and manufacturing of product material. Cash necessary to fund operations will increase significantly over the next several years as we continue to conduct these activities necessary to pursue governmental regulatory approval of clinical-stage programs and other product candidates.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Any requirements for additional capital will depend on many factors, including the following:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the scope, rate of progress, results and cost of our clinical studies, preclinical testing and other related activities;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the cost of manufacturing clinical supplies, and establishing commercial supplies, of our drug candidates and any products that we may develop;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the number and characteristics of drug candidates that we pursue;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the cost, timing and outcomes of regulatory approvals;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       99
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the cost and timing of establishing sales, marketing and distribution capabilities;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the terms and timing of any collaborative, licensing and other arrangements that we may establish;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the timing, receipt and amount of sales, profit sharing or royalties, if any, from our potential products;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the cost of preparing, filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the extent to which we acquire or invest in businesses, products or technologies, although we currently have no commitments or agreements relating to any of these types of transactions; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the effects of the COVID-19 pandemic and the cost and timing of actions taken to contain it.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition, any unfavorable development or delay in the progress of our core clinical-stage programs, including elarekibep, could have a material adverse impact on our ability to raise additional capital.&#xa0;We would need to raise additional capital over the next year to continue our&#xa0;current level of research and development activities across all of our&#xa0;active programs, as well as to maintain the general and administrative functions to support such activities. Without access to additional capital or management making decisions to reduce spending, these conditions&#xa0;raise&#xa0;substantial doubt about our&#xa0;ability&#xa0;to continue as a going concern.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">We plan&#xa0;to raise additional capital to fulfill our&#xa0;operating and capital requirements through public or private equity financings, utilization of our&#xa0;current &#x201c;at the market offering&#x201d; program, or ATM Program, strategic collaborations, licensing arrangements, government grants and/or the achievement of milestones under our&#xa0;collaborative agreements. The funding requirements of our&#xa0;operating plans, however, are based on estimates that are subject to risks and uncertainties and may&#xa0;change as a result of many factors currently unknown. Although management continues to pursue these funding plans, there is&#xa0;<i>no</i>&#xa0;assurance that we&#xa0;will be successful in obtaining sufficient funding on terms acceptable to us&#xa0;to fund continuing operations, if at all. Until such time that we&#xa0;can generate substantial product revenues, if ever, we&#xa0;expect&#xa0;to finance our&#xa0;cash needs through a combination of equity offerings, debt financings, strategic partnerships, licensing arrangements and government grants. The terms of any future financing may&#xa0;adversely affect the holdings or the rights of our existing stockholders.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">If we are&#xa0;unable to obtain additional funding on acceptable terms when needed, we&#xa0;will defer or limit a substantial portion of our&#xa0;research, development and clinical projects, reduce discretionary expenditures and other fixed or variable personnel costs&#xa0;to alleviate the substantial doubt as to our ability to continue as a going concern. Our budget and operating plan for 2023, approved by the Board, does not include such discretionary costs, and management is prepared to gate future investments on PRS-220 and PRS-400, including certain Phase 2-readiness activities for PRS-220 and IND-enabling activities for PRS-400, in the interest of achieving our&#xa0;top priority, namely, obtaining data from the elarekibep Phase 2a study in asthma.&#xa0;On the basis of our approved budget and actions within management&#x2019;s control, we believe&#xa0;that our&#xa0;currently available funds will be sufficient to fund&#xa0;our remaining limited operations through at least the next 12 months from the issuance of this Annual Report on Form 10-K. Our belief with respect to our&#xa0;ability to fund operations is based on estimates that are subject to risks and uncertainties.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Off-Balance Sheet Arrangements</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We do not have any off-balance sheet arrangements, as defined under applicable SEC rules.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Critical Accounting Policies and Estimates</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP. The preparation of these financial statements requires management to make estimates and judgments that affect reported amounts of assets and liabilities as of the date of the balance sheet and reported amounts of revenues and expenses for the periods presented. Management makes estimates and exercises judgment in revenue recognition, accrued and prepaid clinical trial expenses, share-based payments and income taxes. Judgments must also be made about the disclosure of contingent liabilities, and these estimates and assumptions form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ from those estimates and under different assumptions or conditions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">While our significant accounting policies are more fully described in the notes to our consolidated financial statements, we have identified the following accounting policies that we believe require application of management&#x2019;s most subjective judgments, often requiring the need to make estimates about the effect of matters that are inherently uncertain and may change in subsequent periods. Our actual results could differ from these estimates and such differences could be material.</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       100
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Revenue Recognition</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Pieris has entered into several licensing agreements with collaboration partners for the development of Anticalin therapeutics against a variety of targets. The terms of these agreements provide for the transfer of multiple goods or services which may include: (i)&#xa0;licenses, or options to obtain licenses, to Pieris&#x2019; Anticalin technology and/or specific programs and (ii)&#xa0;research and development activities to be performed on behalf of or with a collaborative partner. Payments to Pieris under these agreements may include upfront fees (which include license and option fees), payments for research and development activities, payments based upon the achievement of certain milestones, and royalties on product sales. There are no performance, cancellation, termination or refund provisions in any of the arrangements that could result in material financial consequences to Pieris.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company accounts for revenue recognition pursuant to FASB ASC Topic 606, Revenue Recognition, or ASC 606. The standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Collaborative Arrangements</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We consider the nature and contractual terms of an arrangement and assess whether the arrangement involves a joint operating activity pursuant to which we are an active participant and are exposed to significant risks and rewards with respect to the arrangement. If we are an active participant and are exposed to the significant risks and rewards with respect to the arrangement, we account for these arrangements pursuant to ASC 808, <i>Collaborative Arrangements</i>, or ASC 808, and apply a systematic and rational approach to recognize revenue. We classify payments received as revenue and payments made as a reduction of revenue in the period in which they are earned.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Revenue from Contracts with Customers</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In accordance with ASC 606, revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which we expect to be entitled in exchange for these goods and services. To achieve this core principle, we apply the following five steps: 1) identify the customer contract; 2) identify the contract&#x2019;s performance obligations; 3) determine the transaction price; 4) allocate the transaction price to the performance obligations; and 5) recognize revenue when or as a performance obligation is satisfied.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We evaluate all promised goods and services within a customer contract and determines which of such goods and services are separate performance obligations. This evaluation includes an assessment of whether the good or service is capable of being distinct and whether the good or service is separable from other promises in the contract. &#xa0;In assessing whether promised goods or services are distinct, we consider factors such as the stage of development of the underlying intellectual property and the capabilities of the customer to develop the intellectual property on their own or whether the required expertise is readily available.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Licensing arrangements are analyzed to determine whether the promised goods or services, which often include licenses, research and development services and governance committee services, are distinct or whether they must be accounted for as part of a combined performance obligation. If the license is considered not to be distinct, the license would then be combined with other promised goods or services as a combined performance obligation. If we are involved in a governance committee, we assess whether our involvement constitutes a separate performance obligation. When governance committee services are determined to be separate performance obligations, we determine the fair value to be allocated to this promised service.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Certain contracts contain optional and additional items, which are considered marketing offers and are accounted for as separate contracts with the customer if such option is elected by the customer, unless the option provides a material right which would not be provided without entering into the contract.&#xa0;&#xa0;An option that is considered a material right is accounted for as a separate performance obligation.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The transaction price is determined based on the consideration to which we will be entitled in exchange for transferring goods and services to the customer. A contract may contain variable consideration, including potential payments for both milestone and research and development services. For certain potential milestone payments, we estimate the amount of variable consideration by using the most likely amount method. In making this assessment, we evaluate factors such as the clinical, regulatory, commercial and other risks that must be overcome to achieve the milestone. Each reporting period we re-evaluate the probability of achievement of such variable consideration and any related constraints. We will include variable consideration, without constraint, in the transaction price to the extent it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. For potential research and development service payments, we estimate the amount of variable consideration by using the expected value method, including any approved budget updates arising from additional research or development services.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price among the performance obligations on a relative standalone selling price basis unless a portion of the transaction price is variable and meets the criteria to be allocated entirely to a performance obligation or to a distinct good or service that forms part of a single performance obligation.</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       101
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We allocate the transaction price based on the estimated standalone selling price of the underlying performance obligations or in the case of certain variable consideration to one or more performance obligations. We must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. We utilize key assumptions to determine the stand-alone selling price, which may include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs to complete the respective performance obligation. Certain variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated to each performance obligation are consistent with the amount we would expect to receive for each performance obligation.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">When a performance obligation is satisfied, revenue is recognized for the amount of the transaction price, excluding estimates of variable consideration that are constrained, that is allocated to that performance obligation on a relative standalone selling price basis. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which we are expected to complete its performance obligations under an arrangement.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">For performance obligations consisting of licenses and other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non- refundable, up-front fees. We evaluate the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we will recognize revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Milestones and Royalties</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We aggregate milestones into four categories: (i) research milestones, (ii) development milestones, (iii) commercial milestones, and (iv) sales milestones. Research milestones are typically achieved upon reaching certain success criteria as defined in each agreement related to developing an Anticalin protein against the specified target. Development milestones are typically reached when a compound reaches a defined phase of clinical research or passes such phase or upon gaining regulatory approvals. Commercial milestones are typically achieved when an approved pharmaceutical product reaches the status for commercial sale, including regulatory approval. Sales milestones are certain defined levels of net sales by the licensee, such as when a product first achieves global sales or annual sales of a specified amount.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">There is uncertainty that the events to obtain the research and development milestones will be achieved given the nature of clinical development and the stage of our technology. We have thus determined that all research and development milestones will be constrained until it is deemed probable that a significant revenue reversal will not occur. For revenues from research and development milestones, payments will be recognized consistent with the recognition pattern of the performance obligation to which they relate.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&#xa0;Commercial milestones and sales royalties are determined by sales or usage-based thresholds and will be accounted for under the royalty recognition constraint as constrained variable consideration.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Contract Balances</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We recognize a contract asset when we transfer goods or services to a customer before the customer pays consideration or before payment is due, excluding any amounts presented as a receivable (i.e., accounts receivable). A contract asset is an entity&#x2019;s right to consideration in exchange for goods or services that the entity has transferred to a customer. The contract liabilities (i.e., deferred revenue) primarily relate to contracts where we have received payment but has not yet satisfied the related performance obligations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Contingencies</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Accruals are recorded for loss contingencies when it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously. Considering facts known at the time of the assessment, we determine whether potential losses are considered reasonably possible or probable and whether they are estimable. Based upon this assessment, we carry out an evaluation of disclosure requirements and consider possible accruals in the financial statements.</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       102
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Research and Development Expense</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Research and development costs are charged to expense as incurred in performing research and development activities. Research and development expenses are comprised of costs incurred in performing research and development activities, including salaries and benefits, facilities costs, pre-clinical and clinical costs, contract services, consulting, depreciation and amortization expense, and other related costs. Costs associated with acquired technology, in the form of upfront fees or milestone payments, are charged to research and development expense as incurred.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Income Taxes</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and operating losses and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted statutory tax rates expected to apply to taxable income in the jurisdictions and years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We evaluate the realizability of our net deferred tax assets, including considering the level of historical operating results and projections of taxable income for the future. We record a full valuation allowance to reduce our net deferred tax assets when it is determined that it is more likely than not that our net deferred tax assets will not be realized.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We recognize, measure, present and disclose in our financial statements any uncertain tax positions that we have taken or expect to take on a tax return. We operate in multiple jurisdictions, both within and outside the United States, and may be subject to audits from various tax authorities. Management&#x2019;s judgment is required in determining our provision for income taxes, our deferred tax assets and liabilities, liabilities for uncertain tax positions, and any valuation allowance recorded against our net deferred tax assets. We will monitor the extent to which our deferred tax assets may be realized and adjust the valuation allowance accordingly.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our policy is to classify interest and penalties related to unrecognized tax benefits as income tax expense</p>
  <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#xa0;</p>
  <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;"><b>Recently Issued Accounting Pronouncements</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We review new accounting standards to determine the expected financial impact, if any, that the adoption of each standard will have. For the recently issued accounting standards that we believe may have an impact on our consolidated financial statements, see &#x201c;Note 2&#x2014;Summary of Significant Accounting Policies&#x201d; in our consolidated financial statements.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Smaller Reporting Company Status</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Currently, we qualify as a smaller reporting company.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As a smaller reporting company, we are eligible and have taken advantage of certain exemptions from various reporting requirements that are not available to public reporting companies that do not qualify for this classification, including, but not limited to:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">An opportunity for reduced disclosure obligations regarding executive compensation in our periodic and annual reports, including without limitation exemption from the requirement to provide a compensation discussion and analysis describing compensation practices and procedures,</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">An opportunity for reduced financial statement disclosure in registration statements and in annual reports on Form 10-K, which only requires two years of audited financial statements rather than the three years of audited financial statements that are required for other public companies,</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">An opportunity for reduced audit and other compliance expenses as we are not subject to the requirement to obtain an auditor&#x2019;s report on internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act of 2002, and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">An opportunity to utilize the non-accelerated filer time-line requirements beginning with our annual report for the year ending December 31, 2020 and quarterly filings thereafter.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">For as long as we continue to be a smaller reporting company, we expect that we will take advantage of both the reduced internal control audit requirements and the disclosure obligations available to us as a result of this classification.</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       103
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <div>
    &#xa0;
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 81pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b><a id="a7a" title="7a" href="#"></a>Item</b>&#xa0;<b>7A.</b></p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 81pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b><a id="a8" title="8" href="#"></a>Item</b>&#xa0;<b>8.</b></p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our Consolidated Financial Statements required by this Item are as set forth in Item&#xa0;15 beginning on page F-3 of this Annual Report on Form 10-K.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 81pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b><a id="a9" title="9" href="#"></a>Item</b>&#xa0;<b>9.</b></p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Not applicable.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 81pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b><a id="a9a" title="9a" href="#"></a>Item</b>&#xa0;<b>9A.</b></p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>CONTROLS AND PROCEDURES</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Evaluation of Disclosure Controls and Procedures</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our management is responsible for establishing and maintaining &#x201c;disclosure controls and procedures&#x201d; as such term is defined in Rule 13a-15(e) of the Exchange Act, as well as for establishing and maintaining &#x201c;adequate internal control over financial reporting&#x201d; as such term is defined in Rule&#xa0;13a-15(f) under the Exchange Act. Our system of internal controls over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the consolidated financial statements in accordance with generally accepted accounting principles.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Because of the inherent limitations surrounding internal controls over financial reporting, our disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A material weakness is a deficiency, or a combination of deficiencies, in internal controls over financial reporting, such that there is a reasonable possibility that a material misstatement of a company&#x2019;s annual or interim consolidated financial statements would not be prevented or detected on a timely basis.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our management, under the supervision of and with the participation of our principal executive officer and principal financial officer, assessed the effectiveness of our internal control over financial reporting and disclosure controls and procedures as of December 31, 2022. In making this assessment, management used the updated criteria set forth in 2013 by the Committee of Sponsoring Organizations of the Treadway Commission, or COSO, in Internal Control-Integrated Framework.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Based on our assessment under the COSO Internal Control-Integrated Framework, management believes that, as of December 31, 2022, our disclosure controls and procedures and internal control over financial reporting were effective.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Management, including our principal executive officer and principal financial officer, has concluded that the financial statements and other financial information included in this Annual Report on Form 10-K fairly present in all material respects our financial condition, results of operations and cash flows as of, and for, the periods presented.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Changes in Internal Control over Financial Reporting</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">There have been no changes in internal control over financial reporting identified in connection with the evaluation of such internal control required by Rules 13a-15(d) and 15d-15(d) under the Exchange Act that occurred during the fourth quarter of 2022 have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       104
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 81pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b><a id="a9b" title="9b" href="#"></a>Item</b>&#xa0;<b>9B.</b></p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>OTHER INFORMATION</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Not applicable.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 81pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b><a id="a9c" title="9c" href="#"></a>Item</b>&#xa0;<b>9C.</b></p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Not applicable.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       105
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <div>
    &#xa0;
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="partiii" title="partiii" href="#"></a>PART III</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 81pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b><a id="a10" title="10" href="#"></a>Item</b>&#xa0;<b>10.</b></p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;">The information required by this Item 10 is incorporated herein by reference to our definitive proxy statement pursuant to Regulation 14A, which proxy statement will be filed with the Securities and Exchange Commission not later than 120 days after the close of our fiscal year ended December 31, 2022.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 81pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b><a id="a11" title="11" href="#"></a>Item</b>&#xa0;<b>11.</b></p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>EXECUTIVE COMPENSATION</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;">The information required by this Item 11 is incorporated herein by reference to our definitive proxy statement pursuant to Regulation 14A, which proxy statement will be filed with the Securities and Exchange Commission not later than 120 days after the close of our fiscal year ended December 31, 2022.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 81pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b><a id="a12" title="12" href="#"></a>Item</b>&#xa0;<b>12.</b></p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;">The information required by this Item 12 is incorporated herein by reference to our definitive proxy statement pursuant to Regulation 14A, which proxy statement will be filed with the Securities and Exchange Commission not later than 120 days after the close of our fiscal year ended December 31, 2022.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 81pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b><a id="a13" title="13" href="#"></a>Item</b>&#xa0;<b>13.</b></p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;">The information required by this Item 13 is incorporated herein by reference to our definitive proxy statement pursuant to Regulation 14A, which proxy statement will be filed with the Securities and Exchange Commission not later than 120 days after the close of our fiscal year ended December 31, 2022.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 81pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b><a id="a14" title="14" href="#"></a>Item</b>&#xa0;<b>14.</b></p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>PRINCIPAL ACCOUNTING FEES AND SERVICES</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;">The information required by this Item 14 is incorporated herein by reference to our definitive proxy statement pursuant to Regulation 14A, which proxy statement will be filed with the Securities and Exchange Commission not later than 120 days after the close of our fiscal year ended December 31, 2022.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       106
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <div>
    &#xa0;
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="partiv" title="partiv" href="#"></a>PART IV</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><a id="a15" title="15" href="#"></a>Item</b>&#xa0;<b>15.</b></p> </td>
     <td style="vertical-align: top; width: 80%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>EXHIBITS, FINANCIAL STATEMENT SCHEDULES</b></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 20%;">&#xa0;</td>
     <td colspan="1" style="vertical-align: bottom; width: 80%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item</b>&#xa0;<b>15(a).</b></p> </td>
     <td style="vertical-align: top; width: 80%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following documents are filed as part of this Annual Report on Form 10-K:</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 20%;">&#xa0;</td>
     <td colspan="1" style="vertical-align: bottom; width: 80%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item</b>&#xa0;<b>15(a)(1)</b>&#xa0;<b>and</b>&#xa0;<b>(2)</b></p> </td>
     <td style="vertical-align: top; width: 80%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">See &#x201c;Index to Consolidated Financial Statements&#x201d;&#xa0;on page F-1 to this Annual Report on Form 10-K. Other financial statement schedules have not been included because they are not applicable or the information is included in the financial statements or notes thereto.</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 20%;">&#xa0;</td>
     <td colspan="1" style="vertical-align: bottom; width: 80%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item</b>&#xa0;<b>15(a)(3)</b></p> </td>
     <td style="vertical-align: top; width: 80%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Exhibits</span></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 20%;">&#xa0;</td>
     <td colspan="1" style="vertical-align: bottom; width: 80%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 20%;">&#xa0;</td>
     <td style="vertical-align: top; width: 80%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following is a list of exhibits filed as part of this Annual Report on Form 10-K.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:bottom;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Exhibit</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Number</span></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 19.8%; text-align: center;">Exhibit Description</td>
     <td style="vertical-align:bottom;width:2.7%;">&#xa0;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Incorporated&#xa0;by</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Reference&#xa0;herein</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">from Form or</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Schedule</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Filing Date</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">SEC File /</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Registration</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Number</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000119312514445590/d837896dex21.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">2.1</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Acquisition Agreement, dated as of December 17, 2014, by and among the Registrant, Pieris AG and the former stockholders of Pieris AG named therein</p> </td>
     <td style="vertical-align:bottom;width:2.7%;">&#xa0;</td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 8-K (Exhibit 2.1)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">December 18, 2014</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">333-190728</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000119312514445590/d837896dex31.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">3.1</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Amended and Restated Articles of Incorporation of the Registrant</p> </td>
     <td style="vertical-align:bottom;width:2.7%;">&#xa0;</td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 8-K (Exhibit 3.1)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">December 18, 2014</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">333-190728</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000119312516679305/d229960dex31.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">3.2</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Certificate of Designation of Series A Convertible Preferred Stock</p> </td>
     <td style="vertical-align:bottom;width:2.7%;">&#xa0;</td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 10-Q (Exhibit 3.1)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">August 11, 2016</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">001-37471</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000158364819000004/finalpirs-certificateofdes.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">3.3</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Certificate of Designation of Series B Convertible Preferred Stock</p> </td>
     <td style="vertical-align:bottom;width:2.7%;">&#xa0;</td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 8-K (Exhibit 3.1)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">February 4, 2019</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">001-37471</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000158364819000068/pieriscertificateofdesig.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">3.4</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Certificate of Designation of Series C Convertible Preferred Stock</p> </td>
     <td style="vertical-align:bottom;width:2.7%;">&#xa0;</td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 8-K (Exhibit 3.1)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">November 4, 2019</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">001-37471</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000119312520099499/d909334dex31.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">3.5</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Certificate of Designation of Series D Convertible Preferred Stock</p> </td>
     <td style="vertical-align:bottom;width:2.7%;">&#xa0;</td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 8-K (Exhibit 3.1)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">April 6, 2020</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">001-37471</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000119312521169379/d180418dex31.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">3.6</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Certificate of Designation of Series E Convertible Preferred Stock</p> </td>
     <td style="vertical-align:bottom;width:2.7%;">&#xa0;</td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 8-K (Exhibit 3.1)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">May 21, 2021</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">001-37471</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000119312514445590/d837896dex32.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">3.7</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Amended and Restated Bylaws of the Registrant</p> </td>
     <td style="vertical-align:bottom;width:2.7%;">&#xa0;</td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 8-K (Exhibit 3.2)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">December 18, 2014</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">333-190728</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000158364819000056/a190903pirsexhibit31byla.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">3.8</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Amendment to the Amended and Restated Bylaws of the Registrant</p> </td>
     <td style="vertical-align:bottom;width:2.7%;">&#xa0;</td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 8-K (Exhibit 3.1)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">September 3, 2019</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">001-37471</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000119312514445590/d837896dex41.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">4.1</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form of Common Stock certificate</p> </td>
     <td style="vertical-align:bottom;width:2.7%;">&#xa0;</td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 8-K (Exhibit 4.1)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">December 18, 2014</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">333-190728</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000119312516514870/d111873dex42.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">4.2</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form of Common Stock certificate</p> </td>
     <td style="vertical-align:bottom;width:2.7%;">&#xa0;</td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 10-K (Exhibit 4.2)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">March 23, 2016</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">001-37471</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000158364820000015/pirs12312019ex-43.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">4.3</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Description of Registered Securities</p> </td>
     <td style="vertical-align:bottom;width:2.7%;">&#xa0;</td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 10-K (Exhibit 4.3)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">March 13, 2020</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">001-37471</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000119312514445590/d837896dex101.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.1</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2014 Employee, Director and Consultant Equity Incentive Plan</p> </td>
     <td style="vertical-align:middle;width:2.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">#</p> </td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 8-K (Exhibit 10.1)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">December 18, 2014</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">333-190728</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000119312514445590/d837896dex102.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.2</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form of Stock Option Award Agreement under the Registrant&#x2019;s 2014 Employee, Director and Consultant Equity Incentive Plan</p> </td>
     <td style="vertical-align:middle;width:2.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">#</p> </td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 8-K (Exhibit 10.2)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">December 18, 2014</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">333-190728</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000119312516639240/d210965dex101.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.3</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2016 Employee, Director and Consultant Equity Incentive Plan</p> </td>
     <td style="vertical-align:middle;width:2.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">#</p> </td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 8-K (Exhibit 10.1)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">July 1, 2016</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">001-37471</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000119312517102052/d325265dex104.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.4</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form of Stock Option Award Agreement under the Registrant&#x2019;s 2016 Employee, Director and Consultant Equity Incentive Plan</p> </td>
     <td style="vertical-align:middle;width:2.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">#</p> </td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 10-K (Exhibit 10.4)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">March 30, 2017</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">001-37471</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000158364818000041/pieris2018eip.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.5</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2018 Employee, Director and Consultant Equity Incentive Plan</p> </td>
     <td style="vertical-align:middle;width:2.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">#</p> </td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 8-K (Exhibit 10.1)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">July 26, 2018</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">001-37471</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
     107
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
     &#xa0;
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000158364818000053/ex102formofstockoptionaward.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.6</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form of Stock Option Award Agreement under the Registrant&#x2019;s 2018 Employee, Director and Consultant Equity Incentive Plan</p> </td>
     <td style="vertical-align:middle;width:2.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">#</p> </td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form S-8 (Exhibit 10.2)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">August 9, 2018</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">333-226733</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000119312521237847/d210015dex102.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.7</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form of Stock Option Award Agreement under the Registrant&#x2019;s 2020 Employee, Director and Consultant Equity Incentive Plan</p> </td>
     <td style="vertical-align:middle;width:2.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">#</p> </td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form S-8 (Exhibit 10.2)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">August 5, 2021</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">333-258502</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000158364818000041/pieris2018espp.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.8</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2018 Employee Stock Purchase Plan</p> </td>
     <td style="vertical-align:middle;width:2.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">#</p> </td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 8-K (Exhibit 10.2)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">July 26, 2018</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">001-37471</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000158364819000041/pirs2019eip.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.9</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2019 Employee, Director and Consultant Equity Incentive Plan</p> </td>
     <td style="vertical-align:middle;width:2.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">#</p> </td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 8-K (Exhibit 10.1)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">July 31, 2019</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">001-37471</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000158364820000037/a2020plan202006258kfilin.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.10</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2020 Employee, Director and Consultant Equity Incentive Plan</p> </td>
     <td style="vertical-align:middle;width:2.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">#</p> </td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 8-K (Exhibit 10.1)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">June 29, 2020</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">001-37471</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000119312521203278/d169101dex101.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.11</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2020 Employee, Director and Consultant Equity Incentive Plan, as amended</p> </td>
     <td style="vertical-align:middle;width:2.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">#</p> </td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 8-K (Exhibit 10.1)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">June 29, 2021</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">001-37471</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000158364822000055/a2020employeedirectorandco.htm" style="-sec-extract:exhibit;">10.12</a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2020 Employee, Director and Consultant Equity Incentive Plan, as amended</p> </td>
     <td style="vertical-align:middle;width:2.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">#</p> </td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 8-K (Exhibit 10.1)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">June 27, 2022</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">001-37471</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000119312515109883/d889766dex1010.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.13</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Research and Licensing Agreement by and between Pieris AG and Technische Universit&#xe4;t M&#xfc;nchen, dated as of July 26, 2007</p> </td>
     <td style="vertical-align:middle;width:2.7%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">+</p> </td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 10-K (Exhibit 10.10)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">March 30, 2015</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">333-190728</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000158364818000022/pirs-serviercollaborationa.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.14</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Collaboration Agreement by and among the Registrant, Pieris Pharmaceuticals GmbH, Les Laboratoires Servier and Institut de Recherches Internationales Servier, dated as of January 4, 2017</p> </td>
     <td style="vertical-align:middle;width:2.7%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">+</p> </td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 10-K/A (Exhibit 10.15)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">April 26, 2018</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">001-37471</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000158364818000022/pirs-servierplatformagreem.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.15</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Non-Exclusive Anticalin Platform Technology License Agreement by and among the Registrant, Pieris Pharmaceuticals GmbH, Les Laboratoires Servier and Institut de Recherches Internationales Servier, dated as of January 4, 2017</p> </td>
     <td style="vertical-align:middle;width:2.7%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">+</p> </td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 10-K/A (Exhibit 10.16)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">April 26, 2018</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">001-37471</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000158364818000026/ex104.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.16</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">First Amendment to the License and Collaboration Agreement by and between Les Laboratoires Servier, Institut de Recherches Internationales Servier, Pieris Pharmaceuticals, Inc. and Pieris Pharmaceuticals GmbH, effective as of June 16, 2017</p> </td>
     <td style="vertical-align:middle;width:2.7%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">+</p> </td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 10-Q/A (Exhibit 10.4)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">April 26, 2018</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">001-37471</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000158364820000015/pirs12312019ex1016.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.17</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Letter Amendment to the License and Collaboration Agreement by and between Les Laboratoires Servier, Institut de Recherches Internationales Servier, Pieris Pharmaceuticals, Inc. and Pieris Pharmaceuticals GmbH, effective as of January 3, 2020</p> </td>
     <td style="vertical-align:middle;width:2.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">+</p> </td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 10-K (Exhibit 10.16)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">March 13, 2020</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">001-37471</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
     108
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
     &#xa0;
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000158364818000026/ex101.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.18</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">License &amp; Collaboration Agreement by and between Pieris Pharmaceuticals Inc., Pieris Pharmaceuticals GmbH &amp; Pieris Australia Pty. Limited and AstraZeneca AB, dated as of May 2, 2017</p> </td>
     <td style="vertical-align:middle;width:2.7%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">+</p> </td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 10-Q/A (Exhibit 10.1)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">April 26, 2018</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">001-37471</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000158364821000023/pirs3-31x21ex104.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.19</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Amendment No. 2, dated March 29, 2021, to the License &amp; Collaboration Agreement by and between the Registrant and AstraZeneca AB</p> </td>
     <td style="vertical-align:middle;width:2.7%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">+</p> </td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 10-Q (Exhibit 10.4)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">May 17, 2021</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">001-37471</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000158364822000065/pirs063022_exx102.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.20</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Amendment No. 3, dated June 9, 2022, to the License &amp; Collaboration Agreement by and between the Registrant and AstraZeneca AB</p> </td>
     <td style="vertical-align:middle;width:2.7%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">+</p> </td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 10-Q (Exhibit 10.2)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">August 4, 2022</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">001-37471</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000158364822000065/pirs063022_exx103.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.21</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Amendment No. 4, dated June 30, 2022, to the License &amp; Collaboration Agreement by and between the Registrant and AstraZeneca AB</p> </td>
     <td style="vertical-align:middle;width:2.7%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">+</p> </td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 10-Q (Exhibit 10.3)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">August 4, 2022</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">001-37471</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000143774922026023/ex_440606.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.22</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Amendment No. 5, dated August 1, 2022, to the License &amp; Collaboration Agreement by and between the Registrant and AstraZeneca AB</p> </td>
     <td style="vertical-align:middle;width:2.7%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">+</p> </td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 10-Q (Exhibit 10.2)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">November &#xfeff;4, 2022</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">001-37471</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000158364818000026/ex102.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.23</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Non-Exclusive Anticalin&#xae;&#xa0;Platform Technology License Agreement, by and between Pieris Pharmaceuticals Inc., Pieris Pharmaceuticals GmbH and Pieris Australia Pty. Limited and AstraZeneca AB, dated as of May 2, 2017</p> </td>
     <td style="vertical-align:middle;width:2.7%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">+</p> </td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 10-Q/A (Exhibit 10.2)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">April 26, 2018</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">001-37471</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000158364821000023/pirs3-31x21ex105.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.24</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Amendment No. 1, dated March 29, 2021, to the Non-Exclusive Anticalin&#xae;&#xa0;Platform Technology License Agreement, dated May 2, 2017, by and between the Registrant and AstraZeneca AB</p> </td>
     <td style="vertical-align:middle;width:2.7%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">+</p> </td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 10-Q (Exhibit 10.5)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">May 17, 2021</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">001-37471</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000158364821000023/pirs3-31x21ex106.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.25</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Subscription Agreement, dated March 29, 2021, by and between the Registrant and AstraZeneca AB</p> </td>
     <td style="vertical-align: middle; width: 2.7%; text-align: center;">+</td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 10-Q (Exhibit 10.6)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">May 17, 2021</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">001-37471</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000158364818000032/a18050320181q10qexhibit101.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.26</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">License and Collaboration Agreement by and among the Registrant, Pieris GmbH and Seagen, Inc., dated February 8, 2018</p> </td>
     <td style="vertical-align:middle;width:2.7%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">+</p> </td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 10-Q (Exhibit 10.1)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">May 10, 2018</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">001-37471</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000158364820000046/a200602_pirs-sgen1stamen.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.27</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Amendment No. 1 to License and Collaboration Agreement by and among the Registrant, Pieris GmbH and Seagen, Inc., dated June 2, 2020</p> </td>
     <td style="vertical-align:bottom;width:2.7%;">&#xa0;</td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 10-Q (Exhibit 10.2)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">August 10, 2020</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">001-37471</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000158364821000023/pirs3-31x21ex101.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.28</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Amended and Restated License and Collaboration Agreement, dated March 24, 2021, by and between the Registrant and Seagen Inc.</p> </td>
     <td style="vertical-align:bottom;width:2.7%;">&#xa0;</td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 10-Q (Exhibit 10.1)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">May 17, 2021</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">001-37471</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000158364821000023/pirs3-31x21ex103.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.29</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Subscription Agreement, dated March 24, 2021, by and between the Registrant and Seagen Inc.</p> </td>
     <td style="vertical-align:bottom;width:2.7%;">&#xa0;</td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 10-Q (Exhibit 10.3)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">May 17, 2021</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">001-37471</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000158364818000032/a18050320181q10qexhibit102.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.30</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Non-Exclusive Anticalin Platform Technology License Agreement by and among the Registrant, Pieris Pharmaceuticals GmbH and Seagen, Inc., dated February 8, 2018</p> </td>
     <td style="vertical-align:middle;width:2.7%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">+</p> </td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 10-Q (Exhibit 10.2)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">May 10, 2018</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">001-37471</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000158364820000046/a200602pirssgenamendment.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.31</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Amendment No. 1 to Non-Exclusive Anticalin Platform Technology License Agreement by and among the Registrant, Pieris Pharmaceuticals GmbH and Seagen, Inc., dated June 2, 2020</p> </td>
     <td style="vertical-align:bottom;width:2.7%;">&#xa0;</td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 10-Q (Exhibit 10.3)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">August 10, 2020</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">001-37471</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000158364821000034/pieris-bpexclusiveproduc.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.32</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Exclusive Product License Agreement, dated April 24, 2021, by and among the Registrant, Pieris Pharmaceuticals GmbH and BP Asset XII, Inc.</p> </td>
     <td style="vertical-align:bottom;width:2.7%;">&#xa0;</td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 10-Q (Exhibit 10.1)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">August 5, 2021</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">001-37471</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
     109
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
     &#xa0;
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000158364821000034/pieris-genentechcollabor.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.33</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Research Collaboration and License Agreement, dated May 19, 2021, by and among the Registrant, Pieris Pharmaceuticals GmbH and Genentech, Inc.</p> </td>
     <td style="vertical-align:bottom;width:2.7%;">&#xa0;</td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 10-Q (Exhibit 10.3)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">August 5, 2021</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">001-37471</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000119312514445590/d837896dex1010.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.34</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form of Indemnification Agreement by and between the Registrant and each of its current directors and executive officers</p> </td>
     <td style="vertical-align:middle;width:2.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">#</p> </td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 8-K (Exhibit 10.10)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">December 18, 2014</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">333-190728</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000119312514445590/d837896dex1015.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.35</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Employment Agreement by and between the Registrant and Stephen S. Yoder, dated as of December&#xa0;17, 2014</p> </td>
     <td style="vertical-align:middle;width:2.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">#</p> </td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 8-K (Exhibit 10.15)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">December 18, 2014</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">333-190728</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000158364821000047/pirs_9-30x21ex101.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.36</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Employment Agreement by and between the Registrant and Ahmed Mousa, dated as of October 7, 2021</p> </td>
     <td style="vertical-align:middle;width:2.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">#</p> </td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 10-Q (Exhibit 10.1)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">November 2, 2021</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">001-37471</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000158364821000047/pirs_9-30x21ex102.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.37</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Employment Agreement by and between the Registrant and Tom Bures, dated as of October 7, 2021</p> </td>
     <td style="vertical-align:middle;width:2.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">#</p> </td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 10-Q (Exhibit 10.2)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">November 2, 2021</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">001-37471</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_494066.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.38</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Non-Employee Director Compensation Policy, as amended</p> </td>
     <td style="vertical-align:middle;width:2.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">*#</p> </td>
     <td style="vertical-align:middle;width:10.7%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000158364819000011/pirs12-31x2018ex1030.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.39</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Lease Agreement by and between Pieris GmbH and Hallbergmoos Grundverm&#xf6;gen GmbH, dated October 24, 2018</p> </td>
     <td style="vertical-align:bottom;width:2.7%;">&#xa0;</td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 10-K (Exhibit 10.30)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">March 18, 2019</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">001-37471</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000158364820000015/pirs12312019exh1031.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.40</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Amendment No. 1 to Lease Agreement by and between Pieris GmbH and Hallbergmoos Grundverm&#xf6;gen GmbH, dated May 21, 2019 (English translation)</p> </td>
     <td style="vertical-align:bottom;width:2.7%;">&#xa0;</td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 10-K (Exhibit 10.31)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">March 13, 2020</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">001-37471</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000158364820000015/pirs12312019exh1032.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.41</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Amendment No. 2 to Lease Agreement by and between Pieris GmbH and Hallbergmoos Grundverm&#xf6;gen GmbH, dated February 13, 2020 (English translation)</p> </td>
     <td style="vertical-align:bottom;width:2.7%;">&#xa0;</td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 10-K (Exhibit 10.32)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">March 13, 2020</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">001-37471</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000119312514452896/d839802dex101.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.42</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form of Securities Purchase Agreement, dated December&#xa0;17, 2014, by and among the Registrant and the Purchasers</p> </td>
     <td style="vertical-align:bottom;width:2.7%;">&#xa0;</td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 8-K (Exhibit 10.1)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">December 23, 2014</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">333-190728</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000119312514452896/d839802dex102.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.43</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form of Registration Rights Agreement, dated December 17, 2014, by and among the Registrant and the investors party thereto</p> </td>
     <td style="vertical-align:bottom;width:2.7%;">&#xa0;</td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 8-K (Exhibit 10.2)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">December 23, 2014</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">333-190728</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000119312514452896/d839802dex103.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.44</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form of Warrant to Purchase Common Stock, dated December 17, 2014, issued by the Registrant</p> </td>
     <td style="vertical-align:bottom;width:2.7%;">&#xa0;</td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 8-K (Exhibit 10.3)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">December 23, 2014</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">333-190728</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000119312516612912/d202704dex101.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.45</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Securities Purchase Agreement, dated June 2, 2016, by and among the Registrant and the Investors named therein</p> </td>
     <td style="vertical-align:bottom;width:2.7%;">&#xa0;</td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 8-K (Exhibit 10.1)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">June 6, 2016</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">001-37471</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000119312516612912/d202704dex103.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.46</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Registration Rights Agreement, dated June 2, 2016, by and among the Registrant and the Investors named therein</p> </td>
     <td style="vertical-align:bottom;width:2.7%;">&#xa0;</td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 8-K (Exhibit 10.3)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">June 6, 2016</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">001-37471</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000119312516612912/d202704dex102.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.47</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form of Warrant to purchase Common Stock, dated June 2, 2016, issued by the Registrant</p> </td>
     <td style="vertical-align:bottom;width:2.7%;">&#xa0;</td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 8-K (Exhibit 10.2)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">June 6, 2016</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">001-37471</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
     110
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
     &#xa0;
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000158364819000068/pierisspapipenovembere5d.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.48</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Securities Purchase Agreement, dated November 2, 2019, by and among the Company and the Investors named therein</p> </td>
     <td style="vertical-align:bottom;width:2.7%;">&#xa0;</td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 8-K (Exhibit 10.1)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">November 4, 2019</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">001-37471</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000158364819000068/pierisregistrationrights.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.49</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Registration Rights Agreement, dated November 2, 2019, by and among the Company and the Investors named therein</p> </td>
     <td style="vertical-align:bottom;width:2.7%;">&#xa0;</td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 8-K (Exhibit 10.3)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">November 4, 2019</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">001-37471</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000158364819000068/pierisformofwarrantpipen.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.50</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form of Warrant to purchase Common Stock, dated November 2, 2019, issued by the Registrant</p> </td>
     <td style="vertical-align:bottom;width:2.7%;">&#xa0;</td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 8-K (Exhibit 10.2)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">November 4, 2019</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">001-37471</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000158364819000004/bvf-pirs3a9exchangeagreeme.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.51</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Exchange Agreement, dated January 30, 2019, by and among the Registrant and Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., and Biotechnology Value Trading Fund OS, L.P.</p> </td>
     <td style="vertical-align:bottom;width:2.7%;">&#xa0;</td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 8-K (Exhibit 10.1)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">February 4, 2019</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">001-37471</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000119312520099499/d909334dex101.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.52</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Exchange Agreement, dated March 31, 2020, by and among the Registrant and Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., and Biotechnology Value Trading Fund OS, L.P.</p> </td>
     <td style="vertical-align:bottom;width:2.7%;">&#xa0;</td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 8-K (Exhibit 10.1)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">April 6, 2020</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">001-37471</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000119312521169379/d180418dex101.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.53</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Exchange Agreement by and among the Registrant and Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., Biotechnology Value Trading Fund OS, L.P., and MSI BVF SPV, L.L.C., dated as of May 20, 2021</p> </td>
     <td style="vertical-align:bottom;width:2.7%;">&#xa0;</td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 8-K (Exhibit 10.1)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">May 21, 2021</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">001-37471</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000158364819000051/pirs_exhibit-101.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.54</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Open Market Sale Agreement, dated as of August 9, 2019, by and between Pieris Pharmaceuticals, Inc. and Jefferies LLC</p> </td>
     <td style="vertical-align:bottom;width:2.7%;">&#xa0;</td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 10-Q (Exhibit 10.1)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">August 9, 2019</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">001-37471</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000143774922026051/ex_442809.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.55</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Amendment No. 1 to Sales Agreement, dated November 4, 2022, by and between Pieris Pharmaceuticals, Inc. and Jefferies LLC</p> </td>
     <td style="vertical-align:middle;width:2.7%;">&#xa0;</td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 8-K (Exhibit 1.1)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">November &#xfeff;4, 2022</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">001-37471</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000158364819000075/pirs_exhibit-102v3.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.56</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Managing Director Services Agreement by and between Pieris Pharmaceuticals GmbH and Hitto Kaufmann, Ph.D., dated as of August 30, 2019</p> </td>
     <td style="vertical-align:middle;width:2.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">#</p> </td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 10-Q (Exhibit 10.2)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">November 12, 2019</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">001-37471</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000158364819000075/pirs_exhibit-103v1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.57</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Non-Qualified Stock Option Agreement by and between the Registrant and Hitto Kaufmann, Ph.D., dated as of August 30, 2019</p> </td>
     <td style="vertical-align:middle;width:2.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">#</p> </td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 10-Q (Exhibit 10.3)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">November 12, 2019</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">001-37471</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1583648/000143774922026023/ex_440605.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.58</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Separation Agreement by and between the Registrant and Tim Demuth, M.D., Ph.D., dated as of August 4, 2022</p> </td>
     <td style="vertical-align:middle;width:2.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">#</p> </td>
     <td style="vertical-align:middle;width:10.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 10-Q (Exhibit 10.1)</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">November 4, 2022</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">001-37471</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> </td>
     <td style="vertical-align:middle;width:2.7%;">&#xa0;</td>
     <td style="vertical-align:middle;width:10.7%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:9.1%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:5.9%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_451890.htm" style="-sec-extract:exhibit;">21.1</a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">List of Subsidiaries</p> </td>
     <td style="vertical-align:middle;width:2.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">*</p> </td>
     <td style="vertical-align:bottom;width:10.7%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:9.1%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:5.9%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_451891.htm" style="-sec-extract:exhibit;">23.1</a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Consent of Ernst &amp; Young LLP</p> </td>
     <td style="vertical-align:middle;width:2.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">*</p> </td>
     <td style="vertical-align:bottom;width:10.7%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:9.1%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:5.9%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_451892.htm" style="-sec-extract:exhibit;">31.1</a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Certification of Stephen S. Yoder, Chief Executive Officer and President, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</p> </td>
     <td style="vertical-align:middle;width:2.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">*</p> </td>
     <td style="vertical-align:bottom;width:10.7%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:9.1%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:5.9%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_451893.htm" style="-sec-extract:exhibit;">31.2</a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Certification of Thomas Bures, Chief Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</p> </td>
     <td style="vertical-align:middle;width:2.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">*</p> </td>
     <td style="vertical-align:bottom;width:10.7%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:9.1%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:5.9%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_451894.htm" style="-sec-extract:exhibit;">32.1</a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Certification of Stephen S. Yoder, Chief Executive Officer and President, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350</p> </td>
     <td style="vertical-align:middle;width:2.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">**</p> </td>
     <td style="vertical-align:bottom;width:10.7%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:9.1%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:5.9%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_451895.htm" style="-sec-extract:exhibit;">32.2</a></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Certification of Thomas Bures, Chief Financial Officer, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350</p> </td>
     <td style="vertical-align:middle;width:2.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">**</p> </td>
     <td style="vertical-align:bottom;width:10.7%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:9.1%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:5.9%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:middle;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">101.INS</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Inline XBRL Instance Document</p> </td>
     <td style="vertical-align:middle;width:2.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">*</p> </td>
     <td style="vertical-align:bottom;width:10.7%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:9.1%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:5.9%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:middle;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">101.SCH</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Inline XBRL Taxonomy Extension Schema Document</p> </td>
     <td style="vertical-align:middle;width:2.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">*</p> </td>
     <td style="vertical-align:bottom;width:10.7%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:9.1%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:5.9%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:middle;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">101.CAL</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</p> </td>
     <td style="vertical-align:middle;width:2.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">*</p> </td>
     <td style="vertical-align:bottom;width:10.7%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:9.1%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:5.9%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:middle;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">101.DEF</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Inline XBRL Taxonomy Extension Definition Linkbase Document</p> </td>
     <td style="vertical-align:middle;width:2.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">*</p> </td>
     <td style="vertical-align:bottom;width:10.7%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:9.1%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:5.9%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:middle;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">101.LAB</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Inline XBRL Taxonomy Extension Label Linkbase Document</p> </td>
     <td style="vertical-align:middle;width:2.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">*</p> </td>
     <td style="vertical-align:bottom;width:10.7%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:9.1%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:5.9%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:middle;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">101.PRE</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</p> </td>
     <td style="vertical-align:middle;width:2.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">*</p> </td>
     <td style="vertical-align:bottom;width:10.7%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:9.1%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:5.9%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:middle;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">104</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document and contained in Exhibit 101)</p> </td>
     <td style="vertical-align:middle;width:2.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">*</p> </td>
     <td style="vertical-align:bottom;width:10.7%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:9.1%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:5.9%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:middle;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">*</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Filed herewith</p> </td>
     <td style="vertical-align:bottom;width:2.7%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:10.7%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:9.1%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:5.9%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:middle;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">**</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:middle;width:19.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Furnished herewith</p> </td>
     <td style="vertical-align:bottom;width:2.7%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:10.7%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:9.1%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:5.9%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:middle;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">+</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td colspan="7" style="vertical-align:bottom;width:43.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Portions of the exhibit are omitted pursuant to Regulation S-K Item 601(b)(10)(iv). Copies of the unredacted exhibit will be furnished to the SEC upon request.</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:middle;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">#</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td colspan="7" style="vertical-align:bottom;width:43.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Indicates a management contract or compensatory plan</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 81pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b><a id="a16summary" title="16summary" href="#"></a>Item</b>&#xa0;<b>16.</b></p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>FORM 10-K SUMMARY</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We may voluntarily include a summary of information required by Form 10-K under this Item 16. We have elected not to include such summary information.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       111
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <div>
    &#xa0;
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SIGNATURES</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Pursuant to the requirements of Section&#xa0;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized<b>.</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: bottom; width: 64%;">&#xa0;</td>
     <td colspan="2" style="vertical-align: bottom; width: 4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PIERIS PHARMACEUTICALS, INC.</b></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 64%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 4%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 32%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 64%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">March 31, 2023</p> </td>
     <td style="vertical-align: bottom; width: 4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By:</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 32%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Stephen S. Yoder</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 64%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 4%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 32%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Stephen S. Yoder</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 64%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 4%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 32%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chief Executive Officer and President</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities indicated below and on the dates indicated.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: bottom; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><span style="text-decoration: underline; ">Signature</span></b></p> </td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 38%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><span style="text-decoration: underline; ">Title</span></b></p> </td>
     <td style="vertical-align: bottom; width: 19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><span style="text-decoration: underline; ">Date</span></b></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 40%;">&#xa0;</td>
     <td colspan="2" style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td colspan="1" style="vertical-align: bottom; width: 19%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Stephen S. Yoder</p> </td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 38%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">President, Chief Executive Officer and</p> </td>
     <td style="vertical-align: top; width: 19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 31, 2023</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Stephen S. Yoder</p> </td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align: top; width: 38%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director <i>(Principal Executive Officer</i>)</p> </td>
     <td style="vertical-align: bottom; width: 19%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 40%;">&#xa0;</td>
     <td colspan="2" style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td colspan="1" style="vertical-align: bottom; width: 19%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Thomas Bures</p> </td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 38%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chief Financial Officer</p> </td>
     <td style="vertical-align: top; width: 19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 31, 2023</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Thomas Bures</p> </td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align: top; width: 38%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>(Principal Financial and Accounting Officer</i>)</p> </td>
     <td style="vertical-align: bottom; width: 19%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 40%;">&#xa0;</td>
     <td colspan="2" style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td colspan="1" style="vertical-align: bottom; width: 19%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ James Geraghty</p> </td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 38%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chairman of the Board of Directors</p> </td>
     <td style="vertical-align: top; width: 19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 31, 2023</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">James Geraghty</p> </td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 38%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 19%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 40%;">&#xa0;</td>
     <td colspan="2" style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td colspan="1" style="vertical-align: bottom; width: 19%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Michael Richman</p> </td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 38%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</p> </td>
     <td style="vertical-align: top; width: 19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 31, 2023</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Michael Richman</p> </td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 38%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 19%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 40%;">&#xa0;</td>
     <td colspan="2" style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td colspan="1" style="vertical-align: bottom; width: 19%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Maya R. Said, Sc.D.</p> </td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 38%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</p> </td>
     <td style="vertical-align: top; width: 19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 31, 2023</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Maya R. Said, Sc.D.</p> </td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 38%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 19%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 40%;">&#xa0;</td>
     <td colspan="2" style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td colspan="1" style="vertical-align: bottom; width: 19%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Peter Kiener, D.Phil.</p> </td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 38%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</p> </td>
     <td style="vertical-align: top; width: 19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 31, 2023</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Peter Kiener, D.Phil.</p> </td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 38%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 19%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 40%;">&#xa0;</td>
     <td colspan="2" style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td colspan="1" style="vertical-align: bottom; width: 19%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Christopher Kiritsy</p> </td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 38%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</p> </td>
     <td style="vertical-align: top; width: 19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 31, 2023</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Christopher Kiritsy</p> </td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 38%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 19%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 40%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 38%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 19%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Ann Barbier, M.D., Ph.D.</p> </td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 38%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</p> </td>
     <td style="vertical-align: top; width: 19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 31, 2023</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Ann Barbier, M.D., Ph.D.</p> </td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 38%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 19%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 40%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 38%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 19%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Matthew L. Sherman, M.D.</p> </td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 38%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</p> </td>
     <td style="vertical-align: top; width: 19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 31, 2023</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Matthew L. Sherman, M.D.</p> </td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 38%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 19%;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       112
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <div>
    &#xa0;
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <div>
    &#xa0;
  </div>
  <div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PIERIS PHARMACEUTICALS, INC.</b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Table of Contents</b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align: top; width: 94%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; "><a style="-sec-extract:exhibit;" href="#report">Report of Independent Registered Public Accounting Firm</a></span> (PCAOB ID: 000<ix:nonNumeric name="dei:AuditorFirmId" contextRef="d_2022-01-01_2022-12-31">42</ix:nonNumeric>)</p> </td><td style="vertical-align:bottom;width:6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#report">F-2</a></p> </td></tr>
<tr><td style="vertical-align: top; width: 94%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a style="-sec-extract:exhibit;" href="#bs">Consolidated Balance Sheets as of December&#xa0;31, 2022 and 2021</a></p> </td><td style="vertical-align:bottom;width:6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#bs">F-3</a></p> </td></tr>
<tr><td style="vertical-align: top; width: 94%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a style="-sec-extract:exhibit;" href="#is">Consolidated Statements of Operations and Comprehensive Loss for the years ended December&#xa0;31, 2022 and 2021</a></p> </td><td style="vertical-align:bottom;width:6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#is">F-4</a></p> </td></tr>
<tr><td style="vertical-align: top; width: 94%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a style="-sec-extract:exhibit;" href="#equity">Consolidated Statements of Changes in Stockholders&#x2019;&#xa0;Equity for the years ended December&#xa0;31, 2022 and 2021</a></p> </td><td style="vertical-align:bottom;width:6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#equity">F-5</a></p> </td></tr>
<tr><td style="vertical-align: top; width: 94%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a style="-sec-extract:exhibit;" href="#cf">Consolidated Statements of Cash Flows for the years ended December&#xa0;31, 2022 and 2021</a></p> </td><td style="vertical-align:bottom;width:6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#cf">F-6</a></p> </td></tr>
<tr><td style="vertical-align: top; width: 94%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a style="-sec-extract:exhibit;" href="#notes">Notes to Consolidated Financial Statements</a></p> </td><td style="vertical-align:bottom;width:6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#notes">F-7</a></p> </td></tr>
</tbody></table>
<div>
 &#xa0;
</div>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
 <div class="PGFTR" style="text-align: center; width: 100%">
  <div class="hf-row">
   <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
    F-1
   </div>
  </div>
 </div>
 <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
 <div class="PGHDR" style="text-align: left; width: 100%">
  <div class="hf-row">
   <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
    <a style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;" href="#toc">Table of Contents</a>
   </div>
  </div>
 </div>
</div>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="report" title="report" href="#"></a>Report of Independent Registered Public Accounting Firm</b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">To the Stockholders and the Board of Directors of Pieris Pharmaceuticals, Inc.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Opinion on the Financial Statements</b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We have audited the accompanying consolidated balance sheets of Pieris Pharmaceuticals, Inc. (the Company) as of December 31, 2022 and 2021, the related consolidated statements of operations and comprehensive loss, changes in stockholders&#x2019; equity, and cash flows for each of the two years in the period ended December 31, 2022, and the related notes (collectively referred to as the &#x201c;consolidated financial statements&#x201d;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2022, in conformity with U.S. generally accepted accounting principles.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Basis for Opinion</b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#x2019;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#x2019;s internal control over financial reporting. Accordingly, we express no such opinion.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion</p>
<div style="font-size: 10pt; text-align: center; background-color: rgb(117, 206, 206);">
 F-2
</div>
<p>&#xa0;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
 <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
 <div class="PGHDR" style="text-align: left; width: 100%">
  <div class="hf-row">
   <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
    <a style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;" href="#toc">Table of Contents</a>
   </div>
  </div>
 </div>
</div>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Critical Audit Matter</b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;">&#xa0;</p>
<table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;"><tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="vertical-align: bottom; width: 14%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 3px; padding-bottom: 3px;">&#xa0;</td><td style="vertical-align: bottom; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 3px; padding-bottom: 3px;">&#xa0;</td><td style="vertical-align: top; width: 84%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 3px; padding-bottom: 3px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><i><b>Accrued and Prepaid Clinical Trial Expenses</b></i></p> </td></tr>
<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="vertical-align: top; width: 14%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 3px; padding-bottom: 3px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Description of the Matter</i></p> </td><td style="vertical-align: bottom; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 3px; padding-bottom: 3px;">&#xa0;</td><td style="vertical-align: top; width: 84%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 3px; padding-bottom: 3px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">As discussed in Note 2 to the consolidated financial statements, the Company records research and development expenses, which include expenses related to clinical trials, as incurred. The Company&#x2019;s determination of clinical trial costs incurred, as well as the related accrued and prepaid expenses at each reporting period incorporates judgment and utilizes various assumptions. Such judgments and assumptions include an evaluation of the information provided to the Company by third parties on actual costs incurred but not yet billed, estimated project timelines and patient enrollment. Payments for these activities are based on the terms of the individual arrangements, which differ from the pattern of costs incurred.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Auditing the Company&#x2019;s accrued and prepaid clinical trial expenses was especially challenging due to the large volume of information received from multiple sources that perform service on the Company&#x2019;s behalf.&#xa0; While the Company&#x2019;s estimates of accrued and prepaid clinical trial expenses are primarily based on information received related to each study from its vendors, the Company may need to make an estimate for additional costs incurred based on management judgment. Additionally, due to the duration of the work performed under clinical trials and the timing of invoices received from vendors, the actual amounts incurred are not typically known at the time the financial statements are issued.&#xa0;</p> </td></tr>
<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="vertical-align: top; width: 14%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 3px; padding-bottom: 3px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>How We Addressed the Matter in Our Audit</i></p> </td><td style="vertical-align: bottom; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 3px; padding-bottom: 3px;">&#xa0;</td><td style="vertical-align: top; width: 84%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 3px; padding-bottom: 3px;">To evaluate the accrued and prepaid clinical trial expenses, our audit procedures included, among others, testing the accuracy and completeness of the underlying data used in the estimates and evaluating the significant assumptions that are used by management to estimate the recorded accruals and prepayments. We corroborated the progress of research and development activities associated with clinical trials through discussion with the Company&#x2019;s research and development personnel that oversee the research and development activities. We inspected the Company&#x2019;s third-party contracts, amendments, and any pending change orders to assess the impact on amounts recorded. We also reviewed information received by the Company directly from certain third parties, which indicated the third parties&#x2019; estimate of costs incurred to date. In addition, we performed analytics over fluctuations in accruals and prepaids by vendor throughout the period subject to audit and compared subsequent invoices received from third parties to amounts accrued.</td></tr>
</tbody></table>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:bottom;width:43.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ <ix:nonNumeric name="dei:AuditorName" contextRef="d_2022-01-01_2022-12-31">Ernst &amp; Young LLP</ix:nonNumeric></p> </td></tr>
<tr><td style="vertical-align:middle;width:43.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have served as the Company's auditor since 2016.</p> </td></tr>
<tr><td style="vertical-align:middle;width:43.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric name="dei:AuditorLocation" contextRef="d_2022-01-01_2022-12-31">Boston, Massachusetts</ix:nonNumeric></p> </td></tr>
<tr><td style="vertical-align:middle;width:43.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">March 31, 2023</p> </td></tr>
</tbody></table></div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       F-2
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <div>
    &#xa0;
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="bs" title="bs" href="#"></a>PIERIS PHARMACEUTICALS, INC.</b></p>
  <p style="font-family: Times New Roman; font-size: 6pt; font-variant: normal; text-align: center; margin: 0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CONSOLIDATED BALANCE SHEETS</b></p>
  <p style="font-family: Times New Roman; font-size: 6pt; font-variant: normal; text-align: center; margin: 0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(In thousands, except share and per share data)</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#xa0;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31,</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31,</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Assets</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Current assets:</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Cash and cash equivalents</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96253121" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" format="ixt:numdotdecimal" decimals="-3">38,635</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96253122" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" format="ixt:numdotdecimal" decimals="-3">117,764</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Short term investments</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96253123" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:ShortTermInvestments" scale="3" format="ixt:numdotdecimal" decimals="-3">20,534</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c96253124" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:ShortTermInvestments" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Accounts receivable</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96253125" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:AccountsReceivableNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-4">5,810</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96253126" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:AccountsReceivableNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">3,313</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Prepaid expenses and other current assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96253127" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">8,445</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96253128" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">6,548</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Total current assets</b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96253129" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:AssetsCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">73,424</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96253130" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:AssetsCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">127,625</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96253131" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" format="ixt:numdotdecimal" decimals="-3">16,992</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96253132" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" format="ixt:numdotdecimal" decimals="-3">19,122</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Operating lease right-of-use assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96253133" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" format="ixt:numdotdecimal" decimals="-3">3,705</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96253134" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" format="ixt:numdotdecimal" decimals="-3">3,909</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Other non-current assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96253135" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:OtherAssetsNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">1,369</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96253136" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:OtherAssetsNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">2,904</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Total assets</b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96253137" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:Assets" scale="3" format="ixt:numdotdecimal" decimals="-4">95,490</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96253138" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:Assets" scale="3" format="ixt:numdotdecimal" decimals="-4">153,560</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Liabilities and stockholders&#x2019; equity</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Current liabilities:</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Accounts payable</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96253141" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:AccountsPayableCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">4,154</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96253142" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:AccountsPayableCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">8,609</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Accrued expenses and other current liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96253143" contextRef="i_2022-12-31" unitRef="USD" name="pirs:AccruedLiabilitiesAndOtherLiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">11,605</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96253144" contextRef="i_2021-12-31" unitRef="USD" name="pirs:AccruedLiabilitiesAndOtherLiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">16,836</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Deferred revenues, current portion</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96253145" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">20,824</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96253146" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">25,116</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Total current liabilities</b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96253147" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:LiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">36,583</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96253148" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:LiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">50,561</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Deferred revenue, net of current portion</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96253149" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">18,734</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96253150" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">38,403</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Operating lease liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96253151" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">12,244</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96253152" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">13,841</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Total liabilities</b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96253153" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:Liabilities" scale="3" format="ixt:numdotdecimal" decimals="-3">67,561</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96253154" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:Liabilities" scale="3" format="ixt:numdotdecimal" decimals="-3">102,805</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin-top: 0pt; margin-bottom: 0pt">Commitments and Contingencies</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;<span style="-sec-ix-hidden:c96253156">&#xa0;</span></td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;<span style="-sec-ix-hidden:c96253157">&#xa0;</span></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Stockholders&#x2019; equity:</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Convertible preferred stock, $<span style="-sec-ix-hidden:c96253161"><span style="-sec-ix-hidden:c96253162">0.001</span></span> par value per share, <span style="-sec-ix-hidden:c96253163"><span style="-sec-ix-hidden:c96253164">10,000,000</span></span> shares authorized and <span style="-sec-ix-hidden:c96253165"><span style="-sec-ix-hidden:c96253167"><span style="-sec-ix-hidden:c96253166"><span style="-sec-ix-hidden:c96253168">15,617</span></span></span></span> shares issued and outstanding at December 21, 2022 and 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c96253159" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:PreferredStockValue" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c96253160" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:PreferredStockValue" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Common stock, $<span style="-sec-ix-hidden:c96253171"><span style="-sec-ix-hidden:c96253172">0.001</span></span> par value per share, <span style="-sec-ix-hidden:c96253173"><span style="-sec-ix-hidden:c96253174">300,000,000</span></span> shares authorized and <span style="-sec-ix-hidden:c96253175"><span style="-sec-ix-hidden:c96253177">74,519,103</span></span> and <span style="-sec-ix-hidden:c96253176"><span style="-sec-ix-hidden:c96253178">72,222,661</span></span> shares issued and outstanding at December 21, 2022 and 2021, respectively</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96253169" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:CommonStockValue" scale="3" format="ixt:numdotdecimal" decimals="-3">74</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96253170" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:CommonStockValue" scale="3" format="ixt:numdotdecimal" decimals="-3">72</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Additional paid-in capital</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96253179" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:AdditionalPaidInCapital" scale="3" format="ixt:numdotdecimal" decimals="-4">318,530</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96253180" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:AdditionalPaidInCapital" scale="3" format="ixt:numdotdecimal" decimals="-3">306,998</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Accumulated other comprehensive income</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c96253181" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">254</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96253182" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3">829</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Accumulated deficit</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96253183" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">290,421</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96253184" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">257,144</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Total stockholders&#x2019; equity</b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96253185" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">27,929</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96253186" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">50,755</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Total liabilities and stockholders&#x2019; equity</b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96253187" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-4">95,490</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96253188" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-4">153,560</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       F-3
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <div>
    &#xa0;
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="is" title="is" href="#"></a>PIERIS PHARMACEUTICALS, INC.</b></p>
  <p style="font-family: Times New Roman; font-size: 6pt; font-variant: normal; text-align: center; margin: 0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</b></p>
  <p style="font-family: Times New Roman; font-size: 6pt; font-variant: normal; text-align: center; margin: 0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(In thousands, except per share data)</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#xa0;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
    <tbody>
     <tr style="vertical-align: bottom;">
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year Ended December 31,</b></b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom;">
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Revenue</p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Customer revenue</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96253190" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">25,469</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96253191" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-4">27,940</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Collaboration revenue</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96253192" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="3" format="ixt:numdotdecimal" decimals="-3">433</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96253193" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="3" format="ixt:numdotdecimal" decimals="-3">3,478</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total revenue</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96253194" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:Revenues" scale="3" format="ixt:numdotdecimal" decimals="-3">25,902</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96253195" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:Revenues" scale="3" format="ixt:numdotdecimal" decimals="-3">31,418</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating expenses</p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Research and development</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96253197" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">52,982</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96253198" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">66,656</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">General and administrative</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96253199" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">16,394</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96253200" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">16,593</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total operating expenses</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96253201" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:OperatingExpenses" scale="3" format="ixt:numdotdecimal" decimals="-3">69,376</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96253202" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:OperatingExpenses" scale="3" format="ixt:numdotdecimal" decimals="-3">83,249</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Loss from operations</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c96253203" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">43,474</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c96253204" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">51,831</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Other income (expense)</p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Interest income</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96253206" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" format="ixt:numdotdecimal" decimals="-3">721</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96253207" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" format="ixt:numdotdecimal" decimals="-3">4</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Grant income</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96253208" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:GovernmentAssistanceAmount" scale="3" format="ixt:numdotdecimal" decimals="-3">8,173</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96253209" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:GovernmentAssistanceAmount" scale="3" format="ixt:numdotdecimal" decimals="-3">3,685</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Other income</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96253210" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">1,303</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96253211" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">2,404</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c96253212" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">33,277</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c96253213" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">45,738</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Other comprehensive (loss) income:</p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Foreign currency translation</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c96253215" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-4" sign="-">1,010</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96253216" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3">1,124</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Unrealized (loss) gain on available-for-sale securities</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96253217" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">73</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c96253218" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Comprehensive loss</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c96253219" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-4" sign="-">34,360</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c96253220" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">44,614</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss per share</p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Basic and diluted</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c96253222" contextRef="d_2022-01-01_2022-12-31" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">0.45</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c96253223" contextRef="d_2021-01-01_2021-12-31" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">0.71</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted average number of common shares outstanding</p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Basic and diluted</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96253225" contextRef="d_2022-01-01_2022-12-31" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" format="ixt:numdotdecimal" decimals="-3">74,172</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96253226" contextRef="d_2021-01-01_2021-12-31" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" format="ixt:numdotdecimal" decimals="-3">64,547</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
     </tr>

    </tbody>
   </table>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       F-4
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <div>
    &#xa0;
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="equity" title="equity" href="#"></a>PIERIS PHARMACEUTICALS, INC.</b></p>
  <p style="font-family: Times New Roman; font-size: 6pt; font-variant: normal; text-align: center; margin: 0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS</b>&#x2019;<b> EQUITY</b></p>
  <p style="font-family: Times New Roman; font-size: 6pt; font-variant: normal; text-align: center; margin: 0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(In thousands)</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#xa0;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 28%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 5%;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 5%;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 5%;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 5%;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 5%;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 5%;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Accumulated</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 5%;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 5%;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 28%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 9%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;"><em style="font: inherit;">Preferred shares</em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 9%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;"><em style="font: inherit;">Common shares</em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 5%;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Additional</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">other</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 5%;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Total</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 28%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">No. of</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Share</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">No. of</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Share</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%; padding: 0px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">ATM proceeds</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">paid-in</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">comprehensive</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Accumulated</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Stockholders&#x2019;</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 28%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">shares</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">capital</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">shares</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">capital</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">receivable</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">capital</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%; padding: 0px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">income (loss)</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">deficit</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">equity</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 28%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">Balance as of January 1, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253263" contextRef="i_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="3" format="ixt:numdotdecimal" decimals="-3">14</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253264" contextRef="i_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253265" contextRef="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="3" format="ixt:numdotdecimal" decimals="-3">56,003</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253266" contextRef="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">56</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253267" contextRef="i_2020-12-31_StatementEquityComponentsAxis-ReceivablesFromStockholderMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253268" contextRef="i_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">242,672</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c96253269" contextRef="i_2020-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">295</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c96253270" contextRef="i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">211,406</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253271" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">31,027</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 28%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253273" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253275" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253276" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-ReceivablesFromStockholderMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253277" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253278" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c96253279" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">45,738</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c96253280" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">45,738</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 28%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Foreign currency translation adjustment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253282" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253284" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253285" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-ReceivablesFromStockholderMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253286" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253287" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3">1,124</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253288" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253289" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3">1,124</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 28%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Stock based compensation expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253291" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253293" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253294" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-ReceivablesFromStockholderMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253295" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:numdotdecimal" decimals="-3">5,215</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253296" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253297" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253298" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:numdotdecimal" decimals="-3">5,215</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 28%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Issuance of common stock resulting from exercise of stock options</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253299" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253300" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253301" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-3">482</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253302" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253303" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-ReceivablesFromStockholderMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253304" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-3">1,024</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253305" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253306" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253307" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-3">1,024</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 28%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Issuance of common stock resulting from purchase of employee stock purchase plan shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253308" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253309" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253310" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" format="ixt:numdotdecimal" decimals="-3">64</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253311" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253312" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-ReceivablesFromStockholderMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253313" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" format="ixt:numdotdecimal" decimals="-3">165</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253314" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253315" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253316" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" format="ixt:numdotdecimal" decimals="-3">165</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 28%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Issuance of common stock resulting from exercise of warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253317" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="pirs:StockIssuedDuringPeriodSharesExerciseOfWarrants" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253318" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="pirs:StockIssuedDuringPeriodValueExerciseOfWarrants" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253319" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="pirs:StockIssuedDuringPeriodSharesExerciseOfWarrants" scale="3" format="ixt:numdotdecimal" decimals="-3">1,391</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253320" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="pirs:StockIssuedDuringPeriodValueExerciseOfWarrants" scale="3" format="ixt:numdotdecimal" decimals="-3">1</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253321" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-ReceivablesFromStockholderMember" unitRef="USD" name="pirs:StockIssuedDuringPeriodValueExerciseOfWarrants" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253322" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="pirs:StockIssuedDuringPeriodValueExerciseOfWarrants" scale="3" format="ixt:numdotdecimal" decimals="-3">836</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253323" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="pirs:StockIssuedDuringPeriodValueExerciseOfWarrants" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253324" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="pirs:StockIssuedDuringPeriodValueExerciseOfWarrants" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253325" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="pirs:StockIssuedDuringPeriodValueExerciseOfWarrants" scale="3" format="ixt:numdotdecimal" decimals="-3">837</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 28%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Issuance of common stock resulting from conversion of preferred stock</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c96253326" contextRef="d_2021-01-01_2021-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfPreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:ConversionOfStockSharesConverted1" scale="3" format="ixt:numdotdecimal" decimals="-3">4</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253327" contextRef="d_2021-01-01_2021-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfPreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253328" contextRef="d_2021-01-01_2021-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfPreferredStockMember_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">3,812</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253329" contextRef="d_2021-01-01_2021-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfPreferredStockMember_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:ConversionOfStockSharesIssued1" scale="3" format="ixt:numdotdecimal" decimals="-3">4</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253330" contextRef="d_2021-01-01_2021-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfPreferredStockMember_StatementEquityComponentsAxis-ReceivablesFromStockholderMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c96253331" contextRef="d_2021-01-01_2021-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfPreferredStockMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">4</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253332" contextRef="d_2021-01-01_2021-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfPreferredStockMember_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253333" contextRef="d_2021-01-01_2021-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfPreferredStockMember_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253334" contextRef="d_2021-01-01_2021-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfPreferredStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 28%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Preferred stock conversion (Series E)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253335" contextRef="d_2021-01-01_2021-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesEPreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">5</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253336" contextRef="d_2021-01-01_2021-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesEPreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c96253337" contextRef="d_2021-01-01_2021-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesEPreferredStockMember_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:ConversionOfStockSharesConverted1" scale="3" format="ixt:numdotdecimal" decimals="-6">5,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c96253338" contextRef="d_2021-01-01_2021-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesEPreferredStockMember_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">5</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253339" contextRef="d_2021-01-01_2021-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesEPreferredStockMember_StatementEquityComponentsAxis-ReceivablesFromStockholderMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253340" contextRef="d_2021-01-01_2021-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesEPreferredStockMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">5</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253341" contextRef="d_2021-01-01_2021-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesEPreferredStockMember_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253342" contextRef="d_2021-01-01_2021-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesEPreferredStockMember_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253343" contextRef="d_2021-01-01_2021-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesEPreferredStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 28%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Issuance of common stock pursuant to ATM offering program, net of $<span style="-sec-ix-hidden:c96253361">1.5</span> million in offering costs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253344" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253345" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253346" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" format="ixt:numdotdecimal" decimals="-4">8,180</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253347" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:numdotdecimal" decimals="-3">8</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253348" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-ReceivablesFromStockholderMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253349" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:numdotdecimal" decimals="-4">38,180</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253350" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253351" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253352" contextRef="d_2021-01-01_2021-12-31_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:numdotdecimal" decimals="-3">38,188</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 28%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Issuance of common stock pursuant to private placement offering, net of $<span style="-sec-ix-hidden:c96253379">0.1</span> million in offering costs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96253362" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96253363" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96253364" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" format="ixt:numdotdecimal" decimals="-4">7,290</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96253365" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:numdotdecimal" decimals="-3">8</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96253366" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-ReceivablesFromStockholderMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96253367" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:numdotdecimal" decimals="-3">18,905</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96253368" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96253369" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96253370" contextRef="d_2021-01-01_2021-12-31_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:numdotdecimal" decimals="-3">18,913</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 28%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt;">Balance at December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96253380" contextRef="i_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="3" format="ixt:numdotdecimal" decimals="-3">16</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96253381" contextRef="i_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96253382" contextRef="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="3" format="ixt:numdotdecimal" decimals="-3">72,222</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96253383" contextRef="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">72</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96253384" contextRef="i_2021-12-31_StatementEquityComponentsAxis-ReceivablesFromStockholderMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96253385" contextRef="i_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">306,998</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96253386" contextRef="i_2021-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">829</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c96253387" contextRef="i_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">257,144</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96253388" contextRef="i_2021-12-31_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">50,755</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 28%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253390" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253392" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253393" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-ReceivablesFromStockholderMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253394" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253395" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c96253396" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">33,277</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c96253397" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">33,277</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 28%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Foreign currency translation adjustment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253399" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253401" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253402" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-ReceivablesFromStockholderMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253403" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c96253404" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-4" sign="-">1,010</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253405" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c96253406" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-4" sign="-">1,010</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 28%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Unrealized loss on investments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253408" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253410" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253411" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-ReceivablesFromStockholderMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253412" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c96253413" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">73</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253414" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">(<ix:nonFraction id="c96253415" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">73</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 28%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Stock based compensation expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253417" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253419" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253420" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-ReceivablesFromStockholderMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253421" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:numdotdecimal" decimals="-3">4,402</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253422" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253423" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253424" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:numdotdecimal" decimals="-3">4,402</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 28%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Issuance of common stock resulting from exercise of stock options</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253425" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="pirs:StockIssuedDuringPeriodSharesExerciseOfWarrants" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253426" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253427" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="pirs:StockIssuedDuringPeriodSharesExerciseOfWarrants" scale="3" format="ixt:numdotdecimal" decimals="-3">46</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253428" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253429" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-ReceivablesFromStockholderMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253430" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-3">95</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253431" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253432" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253433" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-3">95</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 28%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Issuance of common stock resulting from purchase of employee stock purchase plan shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253434" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253435" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253436" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" format="ixt:numdotdecimal" decimals="-3">182</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253437" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253438" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-ReceivablesFromStockholderMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253439" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" format="ixt:numdotdecimal" decimals="-3">197</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253440" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253441" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c96253442" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" format="ixt:numdotdecimal" decimals="-3">197</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 28%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Issuance of common stock pursuant to ATM offering program, net of $<span style="-sec-ix-hidden:c96253460">0.3</span> million in offering costs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96253443" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96253444" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96253445" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" format="ixt:numdotdecimal" decimals="-3">2,069</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96253446" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:numdotdecimal" decimals="-3">2</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96253447" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-ReceivablesFromStockholderMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96253448" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:numdotdecimal" decimals="-3">6,838</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96253449" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96253450" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96253451" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:numdotdecimal" decimals="-4">6,840</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 28%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Balance at December 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96253461" contextRef="i_2022-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="3" format="ixt:numdotdecimal" decimals="-3">16</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96253462" contextRef="i_2022-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96253463" contextRef="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="3" format="ixt:numdotdecimal" decimals="-3">74,519</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96253464" contextRef="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">74</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96253465" contextRef="i_2022-12-31_StatementEquityComponentsAxis-ReceivablesFromStockholderMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96253466" contextRef="i_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-4">318,530</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c96253467" contextRef="i_2022-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">254</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c96253468" contextRef="i_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">290,421</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96253469" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">27,929</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       F-5
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <div>
    &#xa0;
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="cf" title="cf" href="#"></a>PIERIS PHARMACEUTICALS, INC.</b></p>
  <p style="font-family: Times New Roman; font-size: 6pt; font-variant: normal; text-align: center; margin: 0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p>
  <p style="font-family: Times New Roman; font-size: 6pt; font-variant: normal; text-align: center; margin: 0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(In thousands)</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#xa0;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Year Ended December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Operating activities:</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Net loss</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c96253476" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">33,277</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c96253477" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">45,738</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Depreciation and amortization</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96253479" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" format="ixt:numdotdecimal" decimals="-4">2,770</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96253480" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" format="ixt:numdotdecimal" decimals="-3">2,459</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Right-of-use asset (accretion) amortization</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c96253481" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="pirs:OperatingLeaseRightOfUseAssetAccretion" scale="3" format="ixt:numdotdecimal" decimals="-4" sign="-">10</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c96253482" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="pirs:OperatingLeaseRightOfUseAssetAccretion" scale="3" format="ixt:numdotdecimal" decimals="-3">91</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Stock-based compensation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96253483" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="3" format="ixt:numdotdecimal" decimals="-3">4,402</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96253484" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="3" format="ixt:numdotdecimal" decimals="-3">5,215</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Realized investment gains</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c96253485" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:RealizedInvestmentGainsLosses" scale="3" format="ixt:numdotdecimal" decimals="-3">376</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c96253486" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:RealizedInvestmentGainsLosses" scale="3" format="ixt:zerodash" decimals="-3" sign="-">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Other non-cash transactions</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c96253487" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:OtherNoncashIncomeExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">91</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c96253488" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:OtherNoncashIncomeExpense" scale="3" format="ixt:numdotdecimal" decimals="-4">30</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Changes in operating assets and liabilities:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 54pt;">Accounts receivable</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c96253490" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" format="ixt:numdotdecimal" decimals="-3">2,624</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c96253491" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" format="ixt:numdotdecimal" decimals="-3">1,813</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 54pt;">Prepaid expenses and other assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c96253492" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" format="ixt:numdotdecimal" decimals="-3">1,358</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c96253493" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" format="ixt:numdotdecimal" decimals="-3">3,154</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 54pt;">Deferred revenue</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c96253494" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">20,185</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96253495" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="3" format="ixt:numdotdecimal" decimals="-3">19,555</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 54pt;">Accounts payable</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c96253496" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">4,208</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96253497" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" format="ixt:numdotdecimal" decimals="-3">7,049</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 54pt;">Accrued expenses and other current liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c96253498" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">4,005</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96253499" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" format="ixt:numdotdecimal" decimals="-3">9,876</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 54pt;">Lease liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96253500" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="pirs:IncreaseDecreaseInOperatingLeaseLiabilities" scale="3" format="ixt:numdotdecimal" decimals="-4">990</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96253501" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="pirs:IncreaseDecreaseInOperatingLeaseLiabilities" scale="3" format="ixt:numdotdecimal" decimals="-3">988</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Net cash used in operating activities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c96253502" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">59,932</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c96253503" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" format="ixt:numdotdecimal" decimals="-4" sign="-">7,660</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Investing activities:</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Purchases of property and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c96253505" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" format="ixt:numdotdecimal" decimals="-3">1,041</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c96253506" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" format="ixt:numdotdecimal" decimals="-3">949</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Proceeds from maturity of investments</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96253507" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="3" format="ixt:numdotdecimal" decimals="-5">28,200</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c96253508" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Purchases of investments</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96253509" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:PaymentsToAcquireInvestments" scale="3" format="ixt:numdotdecimal" decimals="-3">48,395</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c96253510" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:PaymentsToAcquireInvestments" scale="3" format="ixt:zerodash" decimals="-3" sign="-">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Net cash used in investing activities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c96253511" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">21,236</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c96253512" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">949</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Financing activities:</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Proceeds from exercise of stock options</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96253514" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-3">95</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96253515" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-3">1,024</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Proceeds from exercise of warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c96253516" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:ProceedsFromWarrantExercises" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96253517" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:ProceedsFromWarrantExercises" scale="3" format="ixt:numdotdecimal" decimals="-3">837</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Proceeds from employee stock purchase plan</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96253518" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:ProceedsFromStockPlans" scale="3" format="ixt:numdotdecimal" decimals="-3">197</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96253519" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:ProceedsFromStockPlans" scale="3" format="ixt:numdotdecimal" decimals="-3">165</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Proceeds from issuance of common stock from private placement, net of issuance costs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c96253520" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96253521" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="3" format="ixt:numdotdecimal" decimals="-3">18,913</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Proceeds from issuance of common stock resulting from ATM sales, net of $<span style="-sec-ix-hidden:c96253524"><span style="-sec-ix-hidden:c96253525">1.2</span></span> million in transaction costs</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96253522" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" format="ixt:numdotdecimal" decimals="-3">6,922</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96253523" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" format="ixt:numdotdecimal" decimals="-3">38,188</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Net cash provided by financing activities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96253526" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" format="ixt:numdotdecimal" decimals="-3">7,214</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96253527" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" format="ixt:numdotdecimal" decimals="-3">59,127</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Effect of exchange rate change on cash and cash equivalents</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96253528" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">5,175</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96253529" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:numdotdecimal" decimals="-4" sign="-">3,190</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net increase (decrease) in cash and cash equivalents</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c96253530" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">79,129</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96253531" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" format="ixt:numdotdecimal" decimals="-3">47,328</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash and cash equivalents at beginning of period</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96253532" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:numdotdecimal" decimals="-3">117,764</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96253533" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:numdotdecimal" decimals="-3">70,436</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash and cash equivalents at end of period</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96253534" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:numdotdecimal" decimals="-3">38,635</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96253535" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:numdotdecimal" decimals="-3">117,764</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Supplemental cash flow disclosures:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Net unrealized loss on investments</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c96253537" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">73</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96253538" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Property and equipment included in accounts payable</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96253539" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" format="ixt:numdotdecimal" decimals="-3">193</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96253540" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" format="ixt:numdotdecimal" decimals="-3">237</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       F-6
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="notes" title="notes" href="#"></a>PIERIS PHARMACEUTICALS, INC.</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="c2344183" escape="true">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><em style="font: inherit;">1.</em> </b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Corporate Information</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Pieris Pharmaceuticals, Inc., was founded in <em style="font: inherit;"> May 2013, </em>and acquired <ix:nonFraction id="c96253542" contextRef="i_2013-05-31_BusinessAcquisitionAxis-PierisPharmaceuticalsGmbhMember" unitRef="Pure" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" format="ixt:numdotdecimal" decimals="0">100</ix:nonFraction>% interest in Pieris Pharmaceuticals GmbH (formerly Pieris AG, a German company which was founded in <em style="font: inherit;">2001</em>) in <em style="font: inherit;"> December&#xa0;</em><em style="font: inherit;">2014.</em> Pieris Pharmaceuticals, Inc. and its wholly-owned subsidiaries, hereinafter collectively Pieris, or the Company, is a clinical-stage biopharmaceutical company that discovers and develops Anticalin-based drugs to target validated disease pathways in unique and transformative ways. Pieris' corporate headquarters is located in Boston, Massachusetts and its research facility, as of <em style="font: inherit;"> December 31, 2022</em>, is located in Hallbergmoos, Germany.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Pieris&#x2019; clinical pipeline includes elarekibep, formerly referred to as PRS-<em style="font: inherit;">060/AZD1402,</em> an inhaled IL-<em style="font: inherit;">4R&#x3b1;</em> antagonist Anticalin protein to treat uncontrolled asthma,&#xa0;PRS-<em style="font: inherit;">220,</em> an inhaled CTGF antagonist to treat idiopathic pulmonary fibrosis, or IPF, and other pulmonary fibrosis indications, and an immuno-oncology, or&#xa0;IO,&#xa0;bispecific PRS-<em style="font: inherit;">344/S095012</em> targeting PD-<em style="font: inherit;">L1</em> and <em style="font: inherit;">4</em>-<em style="font: inherit;">1BB.</em> Proprietary to us, Anticalin proteins are a novel class of therapeutics validated in the clinic and through partnerships with leading pharmaceutical companies.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">The Company&#x2019;s core Anticalin technology and platform was developed in Germany, and the Company has partnership arrangements with several major multi-national pharmaceutical companies.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">The Company is subject to risks common to companies in the biotechnology industry, including but&#xa0;<i><em style="font: inherit;">not</em></i>&#xa0;limited to, the need for additional capital, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval and reimbursement for any drug product candidate that it&#xa0;<i><em style="font: inherit;"> may</em></i>&#xa0;identify and develop, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development of technological innovations by competitors, reliance on&#xa0;<i><em style="font: inherit;">third</em></i>-party manufacturers and the ability to transition from pilot-scale production to large-scale manufacturing of products.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">The future success of the Company is dependent on its ability to identify and develop its product candidates, expand its corporate infrastructure and ultimately upon its ability to attain profitable operations. The Company has devoted substantially all of its financial resources and efforts to research and development and general and administrative expenses to support such research and development. The Company has several research and development programs underway in varying stages of development, and it expects that these programs will continue to require increasing amounts of cash for development, conducting clinical trials, and testing and manufacturing of product material. Cash necessary to fund operations will increase significantly over the next several years as the Company continues to conduct these activities necessary to pursue governmental regulatory approval of clinical-stage programs and other product candidates.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Going Concern Uncertainties</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of <em style="font: inherit;"> December 31, 2022</em>, cash, cash equivalents, and investments were $<ix:nonFraction id="c96253554" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" format="ixt:numdotdecimal" decimals="-5">59.2</ix:nonFraction>&#xa0;million. The Company&#x2019;s net loss was $<ix:nonFraction id="c96253555" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="6" format="ixt:numdotdecimal" decimals="-5" sign="-">33.3</ix:nonFraction>&#xa0;million and $<ix:nonFraction id="c96253556" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="6" format="ixt:numdotdecimal" decimals="-5" sign="-">45.7</ix:nonFraction>&#xa0;million for the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em>, respectively. The Company has incurred net losses since inception and had an accumulated deficit of $<ix:nonFraction id="c96253558" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" format="ixt:numdotdecimal" decimals="-5" sign="-">290.4</ix:nonFraction>&#xa0;million as of <em style="font: inherit;"> December 31, 2022</em>. Net losses and negative cash flows have had, and will continue to have, an adverse effect on the Company&#x2019;s stockholders&#x2019; equity and working capital. The Company expects to continue to incur operating losses for at least the next several years.&#xa0;The Company would need to raise additional capital over the next year to continue its current level of research and development activities across all of its active programs, as well as to maintain the general and administrative functions to support such activities. Without access to additional capital or management making decisions to reduce spending, these conditions&#xa0;raise&#xa0;substantial doubt about the ability of the Company to continue as a going concern.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">The Company plans to raise additional capital to fulfill its operating and capital requirements through public or private equity financings, utilization of its current &#x201c;at the market offering&#x201d; program, or ATM Program, strategic collaborations, licensing arrangements, government grants and/or the achievement of milestones under its collaborative agreements. The funding requirements of the Company&#x2019;s operating plans, however, are based on estimates that are subject to risks and uncertainties and <em style="font: inherit;"> may&#xa0;</em>change as a result of many factors currently unknown. Although management continues to pursue these funding plans, there is&#xa0;<i><em style="font: inherit;">no</em></i>&#xa0;assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all. Until such time that the Company can generate substantial product revenues, if ever, the Company expects to finance its cash needs through a combination of equity offerings, debt financings, strategic partnerships, licensing arrangements and government grants. The terms of any future financing <em style="font: inherit;"> may&#xa0;</em>adversely affect the holdings or the rights of the Company&#x2019;s existing stockholders.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">If the Company is unable to obtain additional funding on acceptable terms when needed, the Company will defer or limit a substantial portion of its research, development and clinical projects, reduce discretionary expenditures and other fixed or variable personnel costs&#xa0;to alleviate the substantial doubt as to the Company&#x2019;s ability to continue as a going concern. The Company&#x2019;s budget and operating plan for <em style="font: inherit;">2023,</em> approved by the Board, does <em style="font: inherit;">not</em> include such discretionary costs, and management is prepared to gate future investments on PRS-<em style="font: inherit;">220</em> and PRS-<em style="font: inherit;">400,</em> including certain Phase <em style="font: inherit;">2</em>-readiness activities for PRS-<em style="font: inherit;">220</em> and IND-enabling activities for PRS-<em style="font: inherit;">400,</em> in the interest of achieving its top priority, namely, obtaining data from the elarekibep Phase <em style="font: inherit;">2a</em> study in asthma.&#xa0;On the basis of the Company&#x2019;s approved budget and actions within management&#x2019;s control, the Company believes that its currently available funds will be sufficient to fund the Company&#x2019;s remaining limited operations through at least the next <em style="font: inherit;">12</em> months from the issuance of this Annual Report on Form <em style="font: inherit;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted">10</em>-K. The Company&#x2019;s belief with respect to its ability to fund operations is based on estimates that are subject to risks and uncertainties.</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted">7</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  </ix:nonNumeric>
  <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="c2344184" escape="true">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><em style="font: inherit;">2.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Summary of Significant Accounting Policies </b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b></b></p><ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="c96258219" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Basis of Presentation and Use of Estimates</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The accompanying consolidated financial statements of Pieris Pharmaceuticals, Inc. and its wholly-owned subsidiaries were prepared in accordance with U.S. GAAP. The consolidated financial statements include the accounts of all subsidiaries. All intercompany balances and transactions have been eliminated.</p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:UseOfEstimates" id="c96258221" escape="true">The preparation of the financial statements in accordance with U.S. GAAP requires management to make estimates, judgments, and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and the related disclosures at the date of the financial statements and during the reporting period. Significant estimates are used for, but are <em style="font: inherit;">not</em> limited to, revenue recognition; deferred tax assets, deferred tax liabilities and valuation allowances; determination of the incremental borrowing rate to calculate right-of-use assets and lease liabilities; beneficial conversion features; fair value of stock options, preferred stock, and warrants; and prepaid and accrued clinical trial expenses. Management evaluates its estimates on an ongoing basis. Actual results and outcomes could differ materially from management&#x2019;s estimates, judgments, and assumptions.</ix:nonNumeric></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b></b></p><ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="c96258222" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Foreign Currency Translation</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The financial statements of the Company&#x2019;s foreign subsidiaries are translated from local currency into reporting currency, which is U.S. dollars, using the current exchange rate at the balance sheet date for assets and liabilities, and the weighted average exchange rate prevailing during the period for revenues and expenses. The functional currency for Pieris&#x2019; foreign subsidiaries is considered to be the local currency for each entity and, accordingly, translation adjustments for these subsidiaries are included in accumulated other comprehensive loss within stockholders&#x2019; equity.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Realized and unrealized gains and losses resulting from foreign currency transactions denominated in currencies other than the functional currency are reflected as other (expense) income, net in the consolidated statements of operations. Foreign currency gains and losses on available-for-sale investment transactions are recorded to other comprehensive income (loss) on the Company's balance sheet per Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic <em style="font: inherit;">830,</em> <i>Foreign Currency Matters.</i></p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i></i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b></b></p><ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="c96258223" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Cash, Cash Equivalents and Investments</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company determines the appropriate classification of its investments at the time of purchase. All liquid investments with original maturities of <em style="font: inherit;">90</em> days or less from the purchase date and for which there is an active market are considered to be cash equivalents. The Company&#x2019;s investments are comprised of money market, asset backed securities, government treasuries, and corporate bonds that are classified as available-for-sale in accordance with FASB ASC <em style="font: inherit;">320,</em> <i>Investments</i>&#x2014;<i>Debt and Equity Securities</i>. The Company classifies investments available to fund current operations as current assets on its balance sheets.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Available-for-sale investments are recorded at fair value, with unrealized gains or losses included in accumulated other comprehensive income (loss) on the Company&#x2019;s balance sheets. Realized gains and losses are determined using the specific identification method and are included as a component of other income (expense).</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company reviews investments for other-than-temporary impairment whenever the fair value of an investment is less than the amortized cost and evidence indicates that an investment&#x2019;s carrying amount is <em style="font: inherit;">not</em> recoverable within a reasonable period of time. To determine whether an impairment is other-than temporary, the Company considers its intent to sell, or whether it is more likely than <em style="font: inherit;">not</em> that the Company will be required to sell the investment before recovery of the investment&#x2019;s amortized cost basis. Evidence considered in this assessment includes reasons for the impairment, the severity and the duration of the impairment, and changes in value subsequent to period end.</p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b></b></p><ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:ConcentrationRiskCreditRisk" id="c96258225" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Concentration of Credit Risk and Off-Balance Sheet Risk</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company has <em style="font: inherit;">no</em> financial instruments with off&#x2011;balance sheet risk such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Financial instruments that subject Pieris to concentrations of credit risk include cash and cash equivalents, investments, and accounts receivable. The Company&#x2019;s cash, cash equivalents, and investments are held in accounts with financial institutions that management believes are creditworthy. The Company&#x2019;s investment policy includes guidelines on the quality of the institutions and financial instruments and defines allowable investments that the Company believes minimizes the exposure to concentration of credit risk. The Company has <em style="font: inherit;">not</em> experienced any credit losses in such accounts and does <em style="font: inherit;">not</em> believe it is exposed to any significant credit risk on these funds. Accounts receivable primarily consist of amounts due under strategic partnership and other license agreements with major multi-national pharmaceutical companies for which the Company does <em style="font: inherit;">not</em> obtain collateral.</p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">8</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b></b></p><ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="c96259154" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Fair Value Measurement</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. FASB ASC Topic <em style="font: inherit;">820,</em> <i>Fair Value Measurement and Disclosures</i>, or ASC <em style="font: inherit;">820,</em> established a hierarchy of inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the financial instrument based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the inputs that market participants would use in pricing the financial instrument and are developed based on the best information available in the circumstances. The fair value hierarchy applies only to the valuation inputs used in determining the reported or disclosed fair value of the financial instruments and is <em style="font: inherit;">not</em> a measure of the investment credit quality. Fair value measurements are classified and disclosed in <em style="font: inherit;">one</em> of the following <em style="font: inherit;">three</em> categories:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"><tbody><tr><td style="width:18pt;">&#xa0;</td><td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td><td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Level <em style="font: inherit;">1</em> inputs are quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"><tbody><tr><td style="width:18pt;">&#xa0;</td><td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td><td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Level <em style="font: inherit;">2</em> utilizes quoted market prices in markets that are <em style="font: inherit;">not</em> active, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency.</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"><tbody><tr><td style="width:18pt;">&#xa0;</td><td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td><td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Level <em style="font: inherit;">3</em> inputs are unobservable inputs for the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level <em style="font: inherit;">3.</em> A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Financial instruments measured at fair value on a recurring basis include cash equivalents and investments, if any (<i>Note <em style="font: inherit;">6</em></i>).</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">An entity <em style="font: inherit;"> may </em>elect to measure many financial instruments and certain other items at fair value at specified election dates. Subsequent unrealized gains and losses on items for which the fair value option has been elected will be reported in net loss. The Company did <em style="font: inherit;">not</em> elect to measure any additional financial instruments or other items at fair value.</p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b></b></p><ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="c96259277" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Fair Values of Financial Instruments</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The fair value of cash, accounts receivable, and accounts payable approximates the carrying value of these financial instruments because of the short-term nature of any maturities. The Company determines the estimated fair values of other financial instruments, using available market information and valuation methodologies, primarily input from independent <em style="font: inherit;">third</em> party pricing sources.</p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b></b></p><ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="c96259576" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Accounts Receivable</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Accounts receivable are recorded net of allowances for doubtful accounts and represent amounts due from strategic partners. The Company monitors and evaluates collectability of receivables on an ongoing basis and considers whether an allowance for doubtful accounts is necessary. The Company determined that <em style="font: inherit;">no</em> such reserve is needed as of <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em>. Historically, Pieris has <em style="font: inherit;">not</em> had collectability issues.</p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">9</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b></b></p><ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="c96259857" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Property and Equipment</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Property and equipment are recorded at acquisition cost, less accumulated depreciation and impairment. Depreciation on property and equipment is calculated using the straight-line method over the remaining estimated useful lives of the assets. Maintenance and repairs to these assets are charged to expenses as occurred. Substantially all of the Company's fixed assets are located in Germany. The estimated useful life of the different groups of property and equipment is as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="pirs:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" id="c2344185" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>Asset Classification</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 43%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Estimated useful life (in years)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Leasehold improvements</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 43%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">shorter of useful life or remaining life of the lease</em></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Laboratory furniture and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 43%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><ix:nonNumeric contextRef="d_2022-01-01_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember_RangeAxis-MinimumMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="c96253730" format="ixt-sec:duryear">8</ix:nonNumeric>-<ix:nonNumeric contextRef="d_2022-01-01_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember_RangeAxis-MaximumMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="c96253732" format="ixt-sec:duryear">14</ix:nonNumeric></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Office furniture and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 43%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><ix:nonNumeric contextRef="d_2022-01-01_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-OfficeEquipmentMember_RangeAxis-MinimumMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="c96253733" format="ixt-sec:duryear">5</ix:nonNumeric>-<ix:nonNumeric contextRef="d_2022-01-01_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-OfficeEquipmentMember_RangeAxis-MaximumMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="c96253735" format="ixt-sec:duryear">13</ix:nonNumeric></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Computer and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 43%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><ix:nonNumeric contextRef="d_2022-01-01_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember_RangeAxis-MinimumMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="c96253736" format="ixt-sec:duryear">3</ix:nonNumeric> - <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember_RangeAxis-MaximumMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="c96253738" format="ixt-sec:duryear">7</ix:nonNumeric></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table></ix:nonNumeric></ix:nonNumeric><div>
   </div>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b></b></p><ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="c96259863" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Impairment of Long-lived Assets</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company reviews its long-lived assets to be held and used for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be fully recoverable. The Company evaluates the realizability of its long-lived assets based on profitability and cash flow expectations for the related asset. Any write-downs are treated as permanent reductions in the carrying amount of the assets. The Company believes that, as of each of the balance sheets presented, <em style="font: inherit;">none</em> of the Company&#x2019;s long-lived assets were impaired.</p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b></b></p><ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="c96259865" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Revenue Recognition</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">Pieris has entered into several licensing agreements with collaboration partners for the development of Anticalin therapeutics against a variety of targets. The terms of these agreements provide for the transfer of multiple goods or services which&#xa0;<i><em style="font: inherit;"> may</em></i>&#xa0;include: (i)&#xa0;licenses, or options to obtain licenses, to Pieris&#x2019; Anticalin technology and/or specific programs and (ii)&#xa0;research and development activities to be performed on behalf of or with a collaborative partner. Payments to Pieris under these agreements&#xa0;<i><em style="font: inherit;"> may</em></i>&#xa0;include upfront fees (which include license and option fees), payments for research and development activities, payments based upon the achievement of certain milestones, and royalties on product sales. There are&#xa0;<i><em style="font: inherit;">no</em></i>&#xa0;performance, cancellation, termination or refund provisions in any of the arrangements that could result in material financial consequences to Pieris. As the Company's intellectual property assets are considered to be located in Germany, the Company records all consolidated revenue in its subsidiary, Pieris Pharmaceuticals, GmbH.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Collaborative Arrangements</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company considers the nature and contractual terms of an arrangement and assess whether the arrangement involves a joint operating activity pursuant to which it is an active participant and exposed to significant risks and rewards with respect to the arrangement. If the Company is an active participant and exposed to the significant risks and rewards with respect to the arrangement, it accounts for these arrangements pursuant to ASC <em style="font: inherit;">808,</em> <i>Collaborative Arrangements</i>, or ASC <em style="font: inherit;">808,</em> and applies a systematic and rational approach to recognize revenue. The Company classifies payments received as revenue and payments made as a reduction of revenue in the period in which they are earned. Revenue recognized under a collaborative arrangement involving a participant that is <em style="font: inherit;">not</em> a customer is presented as Collaboration Revenue in the Statement of Operations.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Revenue from Contracts with Customers</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In accordance with ASC <em style="font: inherit;">606,</em> revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled in exchange for these goods and services. To achieve this core principle, the Company applies the following <em style="font: inherit;">five</em> steps: <em style="font: inherit;">1</em>) identify the customer contract; <em style="font: inherit;">2</em>) identify the contract&#x2019;s performance obligations; <em style="font: inherit;">3</em>) determine the transaction price; <em style="font: inherit;">4</em>) allocate the transaction price to the performance obligations; and <em style="font: inherit;">5</em>) recognize revenue when or as a performance obligation is satisfied.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company evaluates all promised goods and services within a customer contract and determines which of such goods and services are separate performance obligations. This evaluation includes an assessment of whether the good or service is capable of being distinct and whether the good or service is separable from other promises in the contract. &#xa0;In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property and the capabilities of the customer to develop the intellectual property on their own or whether the required expertise is readily available.</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">10</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Licensing arrangements are analyzed to determine whether the promised goods or services, which often include licenses, research and development services and governance committee services, are distinct or whether they must be accounted for as part of a combined performance obligation. If the license is considered <em style="font: inherit;">not</em> to be distinct, the license would then be combined with other promised goods or services as a combined performance obligation. If the Company is involved in a governance committee, it assesses whether its involvement constitutes a separate performance obligation. When governance committee services are determined to be separate performance obligations, the Company determines the fair value to be allocated to this promised service.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Certain contracts contain optional and additional items, which are considered marketing offers and are accounted for as separate contracts with the customer if such option is elected by the customer, unless the option provides a material right which would <em style="font: inherit;">not</em> be provided without entering into the contract.&#xa0;&#xa0;An option that is considered a material right is accounted for as a separate performance obligation.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The transaction price is determined based on the consideration to which the Company will be entitled in exchange for transferring goods and services to the customer. A contract <em style="font: inherit;"> may </em>contain variable consideration, including potential payments for both milestone and research and development services. For certain potential milestone payments, the Company estimates the amount of variable consideration by using the most likely amount method. In making this assessment, the Company evaluates factors such as the clinical, regulatory, commercial and other risks that must be overcome to achieve the milestone. Each reporting period the Company re-evaluates the probability of achievement of such variable consideration and any related constraints. Pieris will include variable consideration, without constraint, in the transaction price to the extent it is probable that a significant reversal in the amount of cumulative revenue recognized will <em style="font: inherit;">not</em> occur when the uncertainty associated with the variable consideration is subsequently resolved. For potential research and development service payments, the Company estimates the amount of variable consideration by using the expected value method, including any approved budget updates arising from additional research or development services.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price among the performance obligations on a relative standalone selling price basis unless a portion of the transaction price is variable and meets the criteria to be allocated entirely to a performance obligation or to a distinct good or service that forms part of a single performance obligation.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company allocates the transaction price based on the estimated standalone selling price of the underlying performance obligations or in the case of certain variable consideration to <em style="font: inherit;">one</em> or more performance obligations. The Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company utilizes key assumptions to determine the stand-alone selling price, which <em style="font: inherit;"> may </em>include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs to complete the respective performance obligation. Certain variable consideration is allocated specifically to <em style="font: inherit;">one</em> or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated to each performance obligation are consistent with the amount the Company would expect to receive for each performance obligation.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">When a performance obligation is satisfied, revenue is recognized for the amount of the transaction price, excluding estimates of variable consideration that are constrained, that is allocated to that performance obligation on a relative standalone selling price basis. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations under an arrangement.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">For performance obligations consisting of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non- refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Revenue recognized under an arrangement involving a participant that is a customer is presented as Customer Revenue.</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">11</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Milestones and Royalties</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company aggregates milestones into <em style="font: inherit;">four</em> categories (i) research milestones, (ii) development milestones, (iii) commercial milestones and (iv) sales milestones. Research milestones are typically achieved upon reaching certain success criteria as defined in each agreement related to developing an Anticalin protein against the specified target. Development milestones are typically reached when a compound reaches a defined phase of clinical research or passes such phase, or upon gaining regulatory approvals. Commercial milestones are typically achieved when an approved pharmaceutical product reaches the status for commercial sale, including regulatory approval. Sales milestones are certain defined levels of net sales by the licensee, such as when a product <em style="font: inherit;">first</em> achieves global sales or annual sales of a specified amount.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">There is uncertainty that the events to obtain the research and development milestones will be achieved given the nature of clinical development and the stage of the Company&#x2019;s technology. The Company has thus determined that all research and development milestones will be constrained until it is deemed probable that a significant revenue reversal will <em style="font: inherit;">not</em> occur. For revenues from research and development milestones, payments will be recognized consistent with the recognition pattern of the performance obligation to which they relate.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&#xa0;Commercial milestones and sales royalties are determined by sales or usage-based thresholds and will be accounted for under the royalty recognition constraint as constrained variable consideration.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company calculates the maximum amount of potential milestones achievable under each collaboration agreement and discloses such potential future milestones for all current collaborations using such a maximum calculation.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Contract Balances</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company recognizes a contract asset when the Company transfers goods or services to a customer before the customer pays consideration or before payment is due, excluding any amounts presented as a receivable (i.e., accounts receivable). A contract asset is an entity&#x2019;s right to consideration in exchange for goods or services that the entity has transferred to a customer. The contract liabilities (i.e., deferred revenue) primarily relate to contracts where the Company has received payment but has <em style="font: inherit;">not</em> yet satisfied the related performance obligations.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In the event of an early termination of a collaboration agreement, any contract liabilities would be recognized in the period in which all Company obligations under the agreement have been fulfilled.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Costs to Obtain and Fulfill a Contract with a Customer</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Certain costs to obtain customer contracts, including success-based fees paid to <em style="font: inherit;">third</em>-party service providers, and costs to fulfill customer contracts are capitalized in accordance with FASB ASC <em style="font: inherit;">340,</em> <i>Other Assets and Deferred Costs</i>, or ASC <em style="font: inherit;">340.</em> These costs are amortized to expense on a systemic basis that is consistent with the transfer to the customer of the goods or services to which the asset relates. The Company will expense the amortization of costs to obtain customer contracts to general and administrative expense and costs to fulfill customer contracts to research and development expense.</p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p><ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="c96259866" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Research and Development</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Research and development expenses are charged to the statement of operations as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including salaries and benefits, facilities costs, pre-clinical and clinical costs, contract services, consulting, depreciation and amortization expense, and other related costs. Costs associated with acquired technology, in the form of upfront fees or milestone payments, are charged to research and development expense as incurred.</p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">12</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b></b></p><ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:IncomeTaxPolicyTextBlock" id="c96259868" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Income Taxes</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company applies ASC Topic <em style="font: inherit;">740</em> <i>Income Taxes</i>, which established financial accounting and reporting requirements for the effects of income taxes that result from the Company&#x2019;s activities during the current and preceding years. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and operating losses and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted statutory tax rates expected to apply to taxable income in the jurisdictions and years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Where the Company determines that it is more likely than <em style="font: inherit;">not</em> that some portion or all of the deferred tax assets will <em style="font: inherit;">not</em> be realized in the future, the deferred tax assets are reduced by a valuation allowance. The Company records interest and penalties related to uncertain tax positions as part of income tax expense.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Tax Cuts and Jobs Act&#xa0;(TCJA) subjects a U.S. shareholder to tax on global-intangible low tax income (GILTI) earned by certain foreign subsidiaries. The Company has made an accounting policy election to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only.</p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b></b></p><ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="c96259869" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Stock-based Compensation</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company measures share-based payments in accordance with ASC Topic <em style="font: inherit;">718,</em> <i>Stock Compensation</i>. Pieris records its stock-based compensation expense over the requisite service period and records forfeitures as they occur. Determining the appropriate fair value model and related assumptions requires judgment, including estimating share price volatility and expected terms of the awards. For employee options, the fair value measurement date is generally on the date of grant and the related compensation expense is recognized on a straight-line basis over the requisite service period of the awards, less expense for actual forfeitures.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company uses the Black-Scholes option pricing model to determine the estimated fair value for stock-based awards. Option-pricing models require the input of various subjective assumptions, including the option&#x2019;s expected life, expected dividend yield, price volatility, risk free interest rate and forfeitures of the underlying stock. Due to the limited operating history of the Company as a public entity and a lack of company specific historical and implied volatility data, the Company has based its estimate of expected volatility on the historical volatility of a group of similar companies that are publicly traded. When selecting these public companies on which it has based its expected stock price volatility, the Company selected companies with comparable characteristics to it, including enterprise value, risk profiles, position within the industry, and with historical share price information sufficient to meet the expected term of the stock-based awards. The Company computes historical volatility data using the daily closing prices for the selected companies&#x2019; shares during the equivalent period of the calculated expected term of the stock-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Due to the lack of Company specific historical option activity, the Company has estimated the expected term of its employee stock options using the &#x201c;simplified&#x201d; method, whereby, the expected term equals the arithmetic average of the vesting term and the original contractual term of the option. The expected term for non-employee awards is the remaining contractual term of the option. The risk-free interest rates are based on the U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The Company has never paid, and does <em style="font: inherit;">not</em> expect to pay dividends in the foreseeable future.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">All excess tax benefits and tax deficiencies are recorded as income tax expense or benefit in the Company's statement of operations and comprehensive loss. For the years ended&#xa0;<em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em>, the Company did <em style="font: inherit;">not</em> record an income statement benefit for excess tax benefits as a valuation allowance is also required on these amounts.</p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b></b></p><ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:GovernmentAssistancePolicyTextBlock" id="c96259870" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Government Grants</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company recognizes grants from governmental agencies when there is reasonable assurance that the Company will comply with the conditions attached to the grant arrangement and the grant will be received. The Company evaluates the conditions of each grant as of each reporting period to evaluate whether the Company has reached reasonable assurance of meeting the conditions of each grant arrangement and that it is expected that the grant will be received as a result of meeting the necessary conditions. Grants are recognized in the consolidated statements of operations on a systematic basis over the periods in which the Company recognizes the related costs for which the government grant is intended to compensate. Specifically, grant income related to research and development costs is recognized as such expenses are incurred. Grant income is included as a separate caption within Other income (expense), net in the consolidated statements of operations.</p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">13</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b></b></p><ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:LesseeLeasesPolicyTextBlock" id="c96259871" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Leases</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company accounts for leases pursuant to ASC <em style="font: inherit;">842</em> <i>Leases (Topic <em style="font: inherit;">842</em>)</i>, or ASC <em style="font: inherit;">842.</em> As a lessee, the Company is required to recognize (i) a lease liability, which is a lessees obligation to make lease payments arising from a lease, measured on a discounted basis; and (ii) a right-of-use asset, which is an asset that represents the lessee&#x2019;s right to use, or control the use of, a specified asset for the lease term for all leases (with the exception of short-term leases) at the commencement date.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company determines if an arrangement is a lease at inception. The Company&#x2019;s contracts are determined to contain a lease within the scope of ASC <em style="font: inherit;">842</em> when all of the following criteria based on the specific circumstances of the arrangement are met: (<em style="font: inherit;">1</em>) there is an identified asset for which there are <em style="font: inherit;">no</em> substantive substitution rights; (<em style="font: inherit;">2</em>) the Company has the right to obtain substantially all of the economic benefits from the identified asset; and (<em style="font: inherit;">3</em>) the Company has the right to direct the use of the identified asset. In addition, the Company does <em style="font: inherit;">not</em> apply the recognition requirements in the lease standard to short-term leases (a lease that at commencement date has a lease term of <em style="font: inherit;">12</em> months or less and does <em style="font: inherit;">not</em> contain a purchase option that it is reasonably certain to exercise) and does <em style="font: inherit;">not</em> separate lease and non-lease components for all asset classes. Any variable components of lease costs are excluded from lease payments and are recognized in the period incurred, including increases to rent based on German Consumer Price Index , or CPI.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">At the commencement date, operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of future lease payments over the expected lease term. The Company&#x2019;s lease agreements do <em style="font: inherit;">not</em> provide an implicit rate. As a result, the Company utilizes an estimated incremental borrowing rate to discount lease payments, which is based on the rate of interest the Company would have to pay to borrow a similar amount on a collateralized basis over a similar term and based on observable market data points. Certain adjustments to the right-of-use asset <em style="font: inherit;"> may </em>be required for items such as initial direct costs paid or lease incentives received. Operating lease cost is recognized over the expected term on a straight-line basis.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company typically only includes an initial lease term in its assessment of a lease agreement. Options to renew a lease are <em style="font: inherit;">not</em> included in the Company&#x2019;s assessment unless there is reasonable certainty that the Company will renew. The expected lease term includes noncancelable lease periods and, when applicable, periods covered by an option to extend the lease if the Company is reasonably certain to exercise that option, as well as periods covered by an option to terminate the lease if the Company is reasonably certain <em style="font: inherit;">not</em> to exercise that option.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Assumptions made by the Company at the commencement date are re-evaluated upon occurrence of certain events, including a lease modification. A lease modification results in a separate contract when the modification grants the lessee an additional right of use <em style="font: inherit;">not</em> included in the original lease and when lease payments increase commensurate with the standalone price for the additional right of use. When a lease modification results in a separate contract, it is accounted for in the same manner as a new lease.</p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b></b></p><ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="c96259873" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Contingencies</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Accruals are recorded for loss contingencies when it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. The Company evaluates, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously. Considering facts known at the time of the assessment, the Company determines whether potential losses are considered reasonably possible or probable and whether they are estimable. Based upon this assessment, the Company carries out an evaluation of disclosure requirements and considers possible accruals in the financial statements.</p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b></b></p><ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="c96260122" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Segment Reporting</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Operating segments are identified as components of an enterprise where separate discrete financial information is evaluated by the chief operating decision maker in making decisions on how to allocate resources and assess performance. The Company operates as a single segment dedicated to the discovery and development of biotechnological applications and the Company&#x2019;s chief operating decision maker, or CODM, makes decisions based on the Company as a whole. The Company has determined that its CODM is its Chief Executive Officer.</p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b></b></p><ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:EarningsPerSharePolicyTextBlock" id="c96260123" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Earnings per Share</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Basic earnings per share attributable to common stockholders is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period, without consideration for common stock equivalents.</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">14</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Diluted earnings per share attributable to common stockholders is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share attributable to common stockholders' calculation, preferred stock, stock options, unvested restricted stock, and warrants are considered to be common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to common stockholders, as their effect would be anti-dilutive for all periods presented. Therefore, basic and diluted net loss per share were the same for all periods presented.</p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b></b></p><ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="c96260124" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Recent Accounting Pronouncements <em style="font: inherit;">Not</em> Yet Adopted</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In <em style="font: inherit;"> June 2016, </em>the FASB issued ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2016</em>-<em style="font: inherit;">13,</em> <i>Financial Instruments - Credit Losses</i> <i>(Topic <em style="font: inherit;">326</em>): Measurement of Credit Losses on Financial Statements, </i>or ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13.</em> ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> significantly changes the impairment model for most financial assets and certain other instruments. The new standard requires that expected credit losses relating to financial assets measured on an amortized cost basis and available-for-sale debt securities be recorded through an allowance for credit losses. It also limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value, and requires the reversal of previously recognized credit losses if fair value increases. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Subsequently, in <em style="font: inherit;"> November 2018, </em>the FASB issued ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2018</em>-<em style="font: inherit;">19,</em> <i>Codification Improvements to Topic <em style="font: inherit;">326,</em> Financial Instruments-Credit Losses</i>, which clarifies codification and corrects unintended application of the guidance. In <em style="font: inherit;"> November 2019, </em>the FASB issued ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2019</em>-<em style="font: inherit;">11,</em> <i>Codification Improvements to Topic <em style="font: inherit;">326,</em> Financial Instruments-Credit Losses</i>, which clarifies or addresses specific issues about certain aspects of ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13.</em> In <em style="font: inherit;"> November 2019 </em>the FASB also issued ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2019</em>-<em style="font: inherit;">10,</em> <i>Financial Instruments-Credit Losses (Topic <em style="font: inherit;">326</em>), Derivatives and Hedging (Topic <em style="font: inherit;">815</em>), and Leases (Topic <em style="font: inherit;">842</em>): Effective Dates</i>, which delays the effective date of ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> by <em style="font: inherit;">three</em> years for certain smaller reporting companies such as the Company. The guidance in ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> is effective for the Company for financial statements issued for fiscal years beginning after <em style="font: inherit;"> December 15, 2022 </em>and interim periods within those fiscal years, with early adoption permitted. The Company expects that adoption of this standard will <em style="font: inherit;">not</em> have a material impact on its financial statements.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company has considered other recent accounting pronouncements and concluded that they are either <em style="font: inherit;">not</em> applicable to the business, or that the effect is <em style="font: inherit;">not</em> expected to be material to the unaudited consolidated financial statements as a result of future adoption.</p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">15</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="c2344186" escape="true">
    &#xfeff;
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><em style="font: inherit;">3.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Revenue</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>General</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company has <em style="font: inherit;">not</em> generated revenue from product sales. The Company has generated revenue from contracts with customers (option,&#xa0;license and collaboration agreements), which include upfront payments for licenses or options to obtain licenses, payments for research and development services and milestone payments.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">During the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em>, respectively, the Company recognized revenue from the following strategic partnerships and other license agreements (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="c2344187" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Year Ended December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">AstraZeneca</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254117" contextRef="d_2022-01-01_2022-12-31_CounterpartyNameAxis-AstraZenecaABMember" unitRef="USD" name="us-gaap:Revenues" scale="3" format="ixt:numdotdecimal" decimals="-3">9,117</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254118" contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-AstraZenecaABMember" unitRef="USD" name="us-gaap:Revenues" scale="3" format="ixt:numdotdecimal" decimals="-3">18,919</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Seagen</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254119" contextRef="d_2022-01-01_2022-12-31_CounterpartyNameAxis-SeattleGeneticsIncMember" unitRef="USD" name="us-gaap:Revenues" scale="3" format="ixt:numdotdecimal" decimals="-3">8,287</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254120" contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-SeattleGeneticsIncMember" unitRef="USD" name="us-gaap:Revenues" scale="3" format="ixt:numdotdecimal" decimals="-3">768</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Servier</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254121" contextRef="d_2022-01-01_2022-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember" unitRef="USD" name="us-gaap:Revenues" scale="3" format="ixt:numdotdecimal" decimals="-3">5,359</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254122" contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember" unitRef="USD" name="us-gaap:Revenues" scale="3" format="ixt:numdotdecimal" decimals="-4">4,070</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Genentech</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254123" contextRef="d_2022-01-01_2022-12-31_CounterpartyNameAxis-GenentechMember" unitRef="USD" name="us-gaap:Revenues" scale="3" format="ixt:numdotdecimal" decimals="-3">3,139</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c96254124" contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-GenentechMember" unitRef="USD" name="us-gaap:Revenues" scale="3" format="ixt:numdotdecimal" decimals="-4">1,950</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Boston Pharmaceuticals</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96254125" contextRef="d_2022-01-01_2022-12-31_CounterpartyNameAxis-BostonPharmaceuticalsMember" unitRef="USD" name="us-gaap:Revenues" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96254126" contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-BostonPharmaceuticalsMember" unitRef="USD" name="us-gaap:Revenues" scale="3" format="ixt:numdotdecimal" decimals="-3">5,711</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"><b>Total Revenue</b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96254127" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:Revenues" scale="3" format="ixt:numdotdecimal" decimals="-3">25,902</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96254128" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:Revenues" scale="3" format="ixt:numdotdecimal" decimals="-3">31,418</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Under the Company&#xb4;s existing strategic partnerships and other license agreements, the Company could receive the following potential milestone payments (in millions) as of <em style="font: inherit;"> December 31, 2022</em>:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="pirs:RevenueFromContractWithCustomerMilestonePaymentsTableTextBlock" id="c2344188" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Research, Development, Regulatory &amp; Commercial Milestones</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Sales Milestones</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">AstraZeneca</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254131" contextRef="i_2022-12-31_CounterpartyNameAxis-AstraZenecaABMember_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-ResearchAndDevelopmentMilestonePaymentsMember_TypeOfArrangementAxis-CollaborativeArrangementMember" unitRef="USD" name="us-gaap:ContractsReceivableClaimsAndUncertainAmounts" scale="6" format="ixt:numdotdecimal" decimals="-6">702</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254132" contextRef="i_2022-12-31_CounterpartyNameAxis-AstraZenecaABMember_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-SalesMilestonePaymentsMember_TypeOfArrangementAxis-CollaborativeArrangementMember" unitRef="USD" name="us-gaap:ContractsReceivableClaimsAndUncertainAmounts" scale="6" format="ixt:numdotdecimal" decimals="-6">3,925</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Servier</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254133" contextRef="i_2022-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-ResearchAndDevelopmentMilestonePaymentsMember_TypeOfArrangementAxis-CollaborativeArrangementMember" unitRef="USD" name="us-gaap:ContractsReceivableClaimsAndUncertainAmounts" scale="6" format="ixt:numdotdecimal" decimals="-7">20</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254134" contextRef="i_2022-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-SalesMilestonePaymentsMember_TypeOfArrangementAxis-CollaborativeArrangementMember" unitRef="USD" name="us-gaap:ContractsReceivableClaimsAndUncertainAmounts" scale="6" format="ixt:zerodash" decimals="-6">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Seagen</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254135" contextRef="i_2022-12-31_CounterpartyNameAxis-SeattleGeneticsIncMember_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-ResearchAndDevelopmentMilestonePaymentsMember_TypeOfArrangementAxis-CollaborativeArrangementMember" unitRef="USD" name="us-gaap:ContractsReceivableClaimsAndUncertainAmounts" scale="6" format="ixt:numdotdecimal" decimals="-6">759</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254136" contextRef="i_2022-12-31_CounterpartyNameAxis-SeattleGeneticsIncMember_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-SalesMilestonePaymentsMember_TypeOfArrangementAxis-CollaborativeArrangementMember" unitRef="USD" name="us-gaap:ContractsReceivableClaimsAndUncertainAmounts" scale="6" format="ixt:numdotdecimal" decimals="-7">450</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Boston Pharmaceuticals</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254137" contextRef="i_2022-12-31_CounterpartyNameAxis-BostonPharmaceuticalsMember_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-ResearchAndDevelopmentMilestonePaymentsMember_TypeOfArrangementAxis-CollaborativeArrangementMember" unitRef="USD" name="us-gaap:ContractsReceivableClaimsAndUncertainAmounts" scale="6" format="ixt:numdotdecimal" decimals="-6">88</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254138" contextRef="i_2022-12-31_CounterpartyNameAxis-BostonPharmaceuticalsMember_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-SalesMilestonePaymentsMember_TypeOfArrangementAxis-CollaborativeArrangementMember" unitRef="USD" name="us-gaap:ContractsReceivableClaimsAndUncertainAmounts" scale="6" format="ixt:numdotdecimal" decimals="-6">265</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Genentech</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96254139" contextRef="i_2022-12-31_CounterpartyNameAxis-GenentechMember_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-ResearchAndDevelopmentMilestonePaymentsMember_TypeOfArrangementAxis-CollaborativeArrangementMember" unitRef="USD" name="us-gaap:ContractsReceivableClaimsAndUncertainAmounts" scale="6" format="ixt:numdotdecimal" decimals="-6">834</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96254140" contextRef="i_2022-12-31_CounterpartyNameAxis-GenentechMember_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-SalesMilestonePaymentsMember_TypeOfArrangementAxis-CollaborativeArrangementMember" unitRef="USD" name="us-gaap:ContractsReceivableClaimsAndUncertainAmounts" scale="6" format="ixt:numdotdecimal" decimals="-8">600</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"><b>Total potential milestone payments</b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96254141" contextRef="i_2022-12-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-ResearchAndDevelopmentMilestonePaymentsMember_TypeOfArrangementAxis-CollaborativeArrangementMember" unitRef="USD" name="us-gaap:ContractsReceivableClaimsAndUncertainAmounts" scale="6" format="ixt:numdotdecimal" decimals="-6">2,403</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96254142" contextRef="i_2022-12-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-SalesMilestonePaymentsMember_TypeOfArrangementAxis-CollaborativeArrangementMember" unitRef="USD" name="us-gaap:ContractsReceivableClaimsAndUncertainAmounts" scale="6" format="ixt:numdotdecimal" decimals="-7">5,240</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Strategic Partnerships </b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i><span style="text-decoration: underline; ">Genentech</span></i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> May 19, 2021, </em>the Company and Genentech, Inc., or Genentech, entered into a Research Collaboration and License Agreement, or the Genentech Agreement, to discover, develop and commercialize locally delivered respiratory and ophthalmology therapies that leverage the Company&#x2019;s proprietary Anticalin technology. Upon signing the Genentech Agreement, Genentech paid the Company a $<ix:nonFraction id="c96253742" contextRef="i_2021-05-19_CounterpartyNameAxis-GenentechMember_ProductOrServiceAxis-LicenseMember" unitRef="USD" name="us-gaap:ContractWithCustomerLiability" scale="6" format="ixt:numdotdecimal" decimals="-7">20</ix:nonFraction>&#xa0;million upfront fee. In addition, the Company <em style="font: inherit;"> may </em>be eligible to receive additional milestone payments across multiple programs, as well as tiered royalty payments on net sales at percentages ranging from the mid-single to low double-digits, subject to certain standard reductions and offsets.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Under the terms of the Genentech Agreement, the Company will be responsible for discovery and preclinical development of <span style="-sec-ix-hidden:c96253743">two</span> initial programs. The Company will be responsible for research activities following target nomination through the late-stage research go decision. The parties will then collaborate on drug candidate characterization until the development go decision. After the development go decision, Genentech will be responsible for pursuing the preclinical and clinical development of each program, and thereafter, the commercialization efforts. Each party will be responsible for the costs incurred to perform their respective responsibilities. Genentech has an option to expand the collaboration to encompass <span style="-sec-ix-hidden:c96253744">two</span> additional programs with the payment of a $<ix:nonFraction id="c96253745" contextRef="d_2021-05-19_2021-05-19_CounterpartyNameAxis-GenentechMember" unitRef="USD" name="pirs:RevenueFromContractWithCustomerCollaborationFeeOnAdditionalProgram" scale="6" format="ixt:numdotdecimal" decimals="-7">10</ix:nonFraction>&#xa0;million fee per additional program. If Genentech exercises its option to start additional programs, payment to the Company of additional fees, milestone payments and royalties would result.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Unless earlier terminated, the term of the Genentech Agreement continues until <em style="font: inherit;">no</em> royalty or other payment obligations are or will become due under the Genentech Agreement. The Genentech Agreement <em style="font: inherit;"> may </em>be terminated (i) by either party based on insolvency or breach by the other party and such insolvency proceeding is <em style="font: inherit;">not</em> dismissed or such breach is <em style="font: inherit;">not</em> cured within <ix:nonNumeric contextRef="d_2021-05-19_2021-05-19_CounterpartyNameAxis-GenentechMember" name="pirs:RevenueFromContractWithCustomerAgreementTerminationNoticePeriodWithinMaterialBreach" id="c96253749" format="ixt-sec:durday">90</ix:nonNumeric> days; or (ii) after <em style="font: inherit;">9</em> months from the effective date of the Genentech Agreement, by Genentech as a whole or on a product-by-product and/or country-by-country basis upon <ix:nonNumeric contextRef="d_2021-05-19_2021-05-19_CounterpartyNameAxis-GenentechMember" name="pirs:RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodBeforeFirstCommercialSale" id="c96253751" format="ixt-sec:durday">90</ix:nonNumeric> days prior written notice before the <em style="font: inherit;">first</em> commercial sale of a product or upon <ix:nonNumeric contextRef="d_2021-05-19_2021-05-19_CounterpartyNameAxis-GenentechMember" name="pirs:RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodAfterFirstCommercialSale" id="c96253753" format="ixt-sec:durday">180</ix:nonNumeric> days prior written notice after the <em style="font: inherit;">first</em> commercial sale of a product.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">While the Genentech Agreement allows for up to <ix:nonFraction id="c96253755" contextRef="i_2021-05-19_CounterpartyNameAxis-GenentechMember" unitRef="Pure" name="pirs:NumberOfResearchPrograms" scale="0" format="ixt-sec:numwordsen" decimals="INF">four</ix:nonFraction> research programs, only <ix:nonFraction id="c96253756" contextRef="i_2021-05-19_CounterpartyNameAxis-GenentechMember" unitRef="Pure" name="pirs:NumberOfInitialResearchPrograms" scale="0" format="ixt-sec:numwordsen" decimals="INF">two</ix:nonFraction> research programs are initially identified and committed in the Genentech Agreement. To reach a total of up to <ix:nonFraction id="c96253757" contextRef="i_2021-05-19_CounterpartyNameAxis-GenentechMember" unitRef="Pure" name="pirs:NumberOfResearchPrograms" scale="0" format="ixt-sec:numwordsen" decimals="INF">four</ix:nonFraction> research programs, the Company has granted Genentech options to nominate an additional <ix:nonFraction id="c96253758" contextRef="i_2021-05-19_CounterpartyNameAxis-GenentechMember" unitRef="Pure" name="pirs:NumberOfOptionalAdditionalResearchPrograms" scale="0" format="ixt-sec:numwordsen" decimals="INF">two</ix:nonFraction> collaboration targets of their choosing, subject to the legal availability of the target to be researched. Genentech will have <span style="-sec-ix-hidden:c96253759">three</span> years after the effective date to nominate the subsequent targets. The Company has also granted Genentech options to replace any of the collaboration targets identified with another target. However, at <em style="font: inherit;">no</em> point will there be more than <ix:nonFraction id="c96253761" contextRef="i_2021-05-19_CounterpartyNameAxis-GenentechMember" unitRef="Pure" name="pirs:NumberOfResearchPrograms" scale="0" format="ixt-sec:numwordsen" decimals="INF">four</ix:nonFraction> identified collaboration targets for which there are ongoing research programs.</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">16</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The arrangement with Genentech provides for the transfer of the following goods or services: (i) exclusive research and commercial license for the collaboration programs, (ii) a non-exclusive platform improvement license, (iii) research and development services, (iv)&#xa0;participation in a governance committee, and (v)&#xa0;replacement target options on the <em style="font: inherit;">first</em> <ix:nonFraction id="c96253764" contextRef="i_2021-05-19_CounterpartyNameAxis-GenentechMember" unitRef="Pure" name="pirs:NumberOfInitialResearchPrograms" scale="0" format="ixt-sec:numwordsen" decimals="INF">two</ix:nonFraction> programs upon a screening failure which were assessed as material rights.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Management evaluated all of the promised goods or services within the contract and determined which such goods and services were separate performance obligations. The Company determined that the licenses granted, at arrangement inception, should be combined with the research and development services to be provided for the related target programs as they are <em style="font: inherit;">not</em> capable of being distinct. A <em style="font: inherit;">third</em> party would <em style="font: inherit;">not</em> be able to provide the research and development services due to the specific nature of the intellectual property and knowledge required to perform the services, and Genentech could <em style="font: inherit;">not</em> benefit from the licenses without the corresponding services. The Company determined that the participation in the governance committees was distinct as the services could be performed by an outside party.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As a result, management concluded there were <ix:nonFraction id="c96253769" contextRef="i_2021-05-19_CounterpartyNameAxis-GenentechMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember" unitRef="Pure" name="pirs:NumberOfPerformanceObligations" scale="0" format="ixt-sec:numwordsen" decimals="INF">five</ix:nonFraction> separate performance obligations at the inception of the Genentech Agreement: (i)&#xa0;<ix:nonFraction id="c96253770" contextRef="i_2021-05-19_CounterpartyNameAxis-GenentechMember_TypeOfArrangementAxis-PlatformTechnologyLicenseMember" unitRef="Pure" name="pirs:NumberOfPerformanceObligations" scale="0" format="ixt-sec:numwordsen" decimals="INF">two</ix:nonFraction> combined performance obligations, each comprised of an exclusive research and commercial license, a non-exclusive platform improvement license, and research and development services for the <em style="font: inherit;">first</em> <ix:nonFraction id="c96253772" contextRef="i_2021-05-19_CounterpartyNameAxis-GenentechMember" unitRef="Pure" name="pirs:NumberOfInitialResearchPrograms" scale="0" format="ixt-sec:numwordsen" decimals="INF">two</ix:nonFraction> Genentech programs, (ii) <ix:nonFraction id="c96253773" contextRef="i_2021-05-19_CounterpartyNameAxis-GenentechMember" unitRef="Pure" name="pirs:NumberOfPerformanceObligations" scale="0" format="ixt-sec:numwordsen" decimals="INF">two</ix:nonFraction> performance obligations each comprised of a material right for a target swap option for the <em style="font: inherit;">first</em> <ix:nonFraction id="c96253775" contextRef="i_2021-05-19_CounterpartyNameAxis-GenentechMember" unitRef="Pure" name="pirs:NumberOfInitialResearchPrograms" scale="0" format="ixt-sec:numwordsen" decimals="INF">two</ix:nonFraction> Genentech programs, and (iii) <ix:nonFraction id="c96253776" contextRef="i_2021-05-19_CounterpartyNameAxis-GenentechMember_TypeOfArrangementAxis-GovernanceCommitteeParticipationMember" unitRef="Pure" name="pirs:NumberOfPerformanceObligations" scale="0" format="ixt-sec:numwordsen" decimals="INF">one</ix:nonFraction> performance obligation comprised of the participation on the governance committee.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company allocated consideration to the performance obligations based on the relative proportion of their standalone selling prices. The Company developed standalone selling prices for licenses by applying a risk adjusted, net present value, estimate of future potential cash flows approach, which included the cost of obtaining research and development services at arm&#x2019;s length from a <em style="font: inherit;">third</em>-party provider, as well as internal full-time equivalent costs to support these services. The Company developed the standalone selling price for committee participation by using management&#x2019;s estimate of the anticipated participation hours multiplied by a market rate for comparable participants.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The transaction price at inception is comprised of fixed consideration of $<ix:nonFraction id="c96253778" contextRef="i_2021-05-19_CounterpartyNameAxis-GenentechMember_ProductOrServiceAxis-LicenseMember" unitRef="USD" name="us-gaap:ContractWithCustomerLiability" scale="6" format="ixt:numdotdecimal" decimals="-7">20.0</ix:nonFraction>&#xa0;million in upfront fees and was allocated to each of the performance obligations based on the relative proportion of their standalone selling prices. The amounts allocated to the performance obligations for the <ix:nonFraction id="c96253779" contextRef="i_2021-05-19_CounterpartyNameAxis-GenentechMember" unitRef="Pure" name="pirs:NumberOfInitialResearchPrograms" scale="0" format="ixt-sec:numwordsen" decimals="INF">two</ix:nonFraction> research programs will be recognized on a proportional performance basis through the completion of each respective estimated research term of the individual research programs. The amounts allocated to the material right for the target options will be recognized either at the time the material right expires or, if exercised, on a proportional performance basis over the estimated research term for that program along with any remaining deferred revenue associated with the replacement target. The amounts allocated to the participation on the committee will be recognized on a straight-line basis over the anticipated research term for all research programs. As of <em style="font: inherit;"> December 31, 2022</em>, there was $<ix:nonFraction id="c96253780" contextRef="i_2022-12-31_CounterpartyNameAxis-GenentechMember" unitRef="USD" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" format="ixt:numdotdecimal" decimals="-5">12.6</ix:nonFraction>&#xa0;million of aggregate transaction price allocated to remaining performance obligations.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Under the Genentech Agreement, the Company is eligible to receive various research, development, commercial and sales milestones. There is uncertainty that the events to obtain the research and development milestones will be achieved given the nature of clinical development and the stage of the Company&#x2019;s technology. The Company has determined that all other research and development milestones will be constrained until it is deemed probable that a significant revenue reversal will <em style="font: inherit;">not</em> occur.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of <em style="font: inherit;"> December 31, 2022</em>, there were $<ix:nonFraction id="c96253782" contextRef="i_2022-12-31_CounterpartyNameAxis-GenentechMember_ProductOrServiceAxis-LicenseMember" unitRef="USD" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" format="ixt:numdotdecimal" decimals="-5">7.8</ix:nonFraction>&#xa0;million and $<ix:nonFraction id="c96253783" contextRef="i_2022-12-31_CounterpartyNameAxis-GenentechMember_ProductOrServiceAxis-LicenseMember" unitRef="USD" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" format="ixt:numdotdecimal" decimals="-5">4.8</ix:nonFraction>&#xa0;million of current and non-current deferred revenue, respectively, related to the Genentech Agreement.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i><span style="text-decoration: underline; ">Boston Pharmaceuticals</span></i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> April 24, 2021, </em>the Company and BP Asset XII, Inc., or Boston Pharmaceuticals, a subsidiary of Boston Pharma Holdings, LLC, entered into an Exclusive Product License Agreement, or the BP Agreement, to develop PRS-<em style="font: inherit;">342,</em> a <em style="font: inherit;">4</em>-<em style="font: inherit;">1BB/GPC3</em> preclinical immuno-oncology Anticalin-antibody bispecific fusion protein.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Under the terms of the BP Agreement, Boston Pharmaceuticals exclusively licensed worldwide rights to PRS-<em style="font: inherit;">342.</em> The Company received an upfront payment of $<ix:nonFraction id="c96253788" contextRef="i_2021-04-24_CounterpartyNameAxis-BPAssetsXIIIncMember_ProductOrServiceAxis-LicenseMember_TypeOfArrangementAxis-ExclusiveProductLicenseAgreementMember" unitRef="USD" name="us-gaap:ContractWithCustomerLiability" scale="6" format="ixt:numdotdecimal" decimals="-7">10.0</ix:nonFraction>&#xa0;million and is further entitled to receive development, regulatory and sales-based milestone payments, tiered royalties up to low double-digits on sales of PRS-<em style="font: inherit;">342</em> and a percentage of consideration received by Boston Pharmaceuticals in the event of a sublicense of a program licensed under the BP Agreement or a change of control of Boston Pharmaceuticals. The Company will also contribute up to $<ix:nonFraction id="c96253790" contextRef="d_2021-04-24_2021-04-24_CounterpartyNameAxis-BPAssetsXIIIncMember_ProductOrServiceAxis-LicenseMember_TypeOfArrangementAxis-ExclusiveProductLicenseAgreementMember" unitRef="USD" name="pirs:RevenueFromContractWithCustomerContributionTowardsManufacturingActivities" scale="6" format="ixt:numdotdecimal" decimals="-6">4.0</ix:nonFraction>&#xa0;million toward manufacturing activities.</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">17</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The term of the BP Agreement ends upon the expiration of all of Boston Pharmaceuticals&#x2019; payment obligations thereunder. The BP Agreement <em style="font: inherit;"> may </em>be terminated by Boston Pharmaceuticals in its entirety for convenience beginning <span style="-sec-ix-hidden:c96253792">nine</span> months after its effective date upon <ix:nonNumeric contextRef="d_2021-04-24_2021-04-24_CounterpartyNameAxis-BPAssetsXIIIncMember_ProductOrServiceAxis-LicenseMember_TypeOfArrangementAxis-ExclusiveProductLicenseAgreementMember" name="pirs:RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriod" id="c96253793" format="ixt-sec:durday">60</ix:nonNumeric> days&#x2019; notice or, for any program under the BP Agreement which has received marketing approval, upon <ix:nonNumeric contextRef="d_2021-04-24_2021-04-24_CounterpartyNameAxis-BPAssetsXIIIncMember_ProductOrServiceAxis-LicenseMember_TypeOfArrangementAxis-ExclusiveProductLicenseAgreementMember" name="pirs:RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodIfMarketingApprovalObtained" id="c96253794" format="ixt-sec:durday">120</ix:nonNumeric> days&#x2019; notice. If any program is terminated by Boston Pharmaceuticals, the Company will have full rights to continue such program. The BP Agreement <em style="font: inherit;"> may </em>also be terminated by Boston Pharmaceuticals or the Company for an uncured material breach by the other party upon <ix:nonNumeric contextRef="d_2021-04-24_2021-04-24_CounterpartyNameAxis-BPAssetsXIIIncMember_ProductOrServiceAxis-LicenseMember_TypeOfArrangementAxis-ExclusiveProductLicenseAgreementMember" name="pirs:RevenueFromContractWithCustomerAgreementTerminationNoticePeriodUponMaterialBreach" id="c96253795" format="ixt-sec:durday">180</ix:nonNumeric> days&#x2019; notice (<ix:nonNumeric contextRef="d_2021-04-24_2021-04-24_CounterpartyNameAxis-BPAssetsXIIIncMember_ProductOrServiceAxis-LicenseMember_TypeOfArrangementAxis-ExclusiveProductLicenseAgreementMember" name="pirs:RevenueFromContractWithCustomerAgreementTerminationNoticePeriodNonpaymentOfUndisputedAmounts" id="c96253796" format="ixt-sec:durday">60</ix:nonNumeric> days in the case of non-payment of undisputed amounts due and payable), subject to extension for an additional <ix:nonNumeric contextRef="d_2021-04-24_2021-04-24_CounterpartyNameAxis-BPAssetsXIIIncMember_ProductOrServiceAxis-LicenseMember_TypeOfArrangementAxis-ExclusiveProductLicenseAgreementMember" name="pirs:RevenueFromContractWithCustomerAgreementTerminationAdditionalNoticePeriodUponMaterialBreach" id="c96253797" format="ixt-sec:durday">180</ix:nonNumeric> days in certain cases and subject, in all cases, to dispute resolution procedures. The Agreement <em style="font: inherit;"> may </em>also be terminated due to the other party&#x2019;s insolvency. The Company <em style="font: inherit;"> may </em>also terminate the BP Agreement if Boston Pharmaceuticals challenges the validity of any patents licensed under the BP Agreement, subject to certain exceptions.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company does <em style="font: inherit;">not</em> have any obligations to assist in the research and development efforts of Boston Pharmaceuticals under the BP Agreement. However, the Company has an obligation to fund up to $<ix:nonFraction id="c96253799" contextRef="d_2021-04-24_2021-04-24_CounterpartyNameAxis-BPAssetsXIIIncMember_ProductOrServiceAxis-LicenseMember_TypeOfArrangementAxis-ExclusiveProductLicenseAgreementMember" unitRef="USD" name="pirs:RevenueFromContractWithCustomerAgreementObligationCost" scale="6" format="ixt:numdotdecimal" decimals="-6">4.0</ix:nonFraction>&#xa0;million in costs, including out-of-pocket costs incurred by Boston Pharmaceuticals, in connection with the manufacture of products under the BP Agreement.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The arrangement with Boston Pharmaceuticals provides for the transfer of the following: (i)&#xa0;exclusive license of PRS-<em style="font: inherit;">342,</em> (ii)&#xa0;non-exclusive Pieris platform license, (iii)&#xa0;initial know-how, (iv)&#xa0;product cell line license, and (v) materials (as each such term is defined under the BP Agreement).</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Management evaluated all of the promised goods or services within the BP Agreement and determined which such goods and services were separate performance obligations. The Company determined that the licenses granted, at arrangement inception, should be combined with the transfer of know-how, materials and the product cell line license. Boston Pharmaceuticals could <em style="font: inherit;">not</em> benefit from the exclusive and non-exclusive licenses without the corresponding transfer of know-how and materials.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As a result, management concluded there was only <em style="font: inherit;">one</em> combined performance obligation. The transaction price at inception is comprised of fixed consideration of $<ix:nonFraction id="c96253803" contextRef="i_2021-04-24_CounterpartyNameAxis-BPAssetsXIIIncMember_ProductOrServiceAxis-LicenseMember_TypeOfArrangementAxis-ExclusiveProductLicenseAgreementMember" unitRef="USD" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" format="ixt:numdotdecimal" decimals="-7">10.0</ix:nonFraction>&#xa0;million in upfront fees, offset by $<ix:nonFraction id="c96253804" contextRef="i_2021-04-24_CounterpartyNameAxis-BPAssetsXIIIncMember_ProductOrServiceAxis-LicenseMember" unitRef="USD" name="us-gaap:ContractWithCustomerAssetNet" scale="6" format="ixt:numdotdecimal" decimals="-6">4.0</ix:nonFraction>&#xa0;million in consideration payable to Boston Pharmaceuticals to reimburse them for expected out-of-pocket manufacturing costs, for a total transaction price of $<ix:nonFraction id="c96253805" contextRef="i_2021-04-24_CounterpartyNameAxis-BPAssetsXIIIncMember_ProductOrServiceAxis-LicenseMember" unitRef="USD" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" format="ixt:numdotdecimal" decimals="-6">6.0</ix:nonFraction>&#xa0;million. Management has assessed the forms of variable consideration within the BP Agreement and concluded that the payments are either constrained by the royalty recognition constraint or because management has assessed the most likely amount associated with the payments as zero.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The amounts allocated to the performance obligations did <em style="font: inherit;">not</em> meet the criteria to be recognized over time on a proportional performance basis and thus will be recognized at a point in time. The Company determined that the performance obligation will be fully satisfied when all of the deliverables in the combined performance obligation are transferred to Boston Pharmaceuticals as that is the point at which Boston Pharmaceuticals can fully use and benefit from the license to PRS-<em style="font: inherit;">342.</em> The Company transferred all such deliverables to Boston Pharmaceuticals in the <em style="font: inherit;">fourth</em> quarter of <em style="font: inherit;">2021.</em> As of <em style="font: inherit;"> December 31, 2021, </em>the Company had recognized the full transaction price, or $<ix:nonFraction id="c96253810" contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-BPAssetsXIIIncMember_ProductOrServiceAxis-LicenseMember_TypeOfArrangementAxis-ExclusiveProductLicenseAgreementMember" unitRef="USD" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" format="ixt:numdotdecimal" decimals="-5">5.7</ix:nonFraction>&#xa0;million, as revenue and there is <em style="font: inherit;">no</em> remaining deferred revenue.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><span style="text-decoration: underline; ">Seagen</span></i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xfeff;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> February 8, 2018, </em>the Company entered into a license and collaboration agreement, or the Seagen Collaboration Agreement, and a non-exclusive Anticalin platform technology license agreement, or the Seagen Platform License, and together with the Seagen Collaboration Agreement, the Seagen Agreements, with Seagen, Inc., or Seagen, pursuant to which the parties will develop multiple targeted bispecific IO treatments for solid tumors and blood cancers.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Under the terms of the Seagen Agreements, the companies will pursue multiple Anticalin-antibody fusion proteins during the research phase. The Seagen Agreements provide Seagen a base option to select up to <ix:nonFraction id="c96253812" contextRef="i_2018-02-08_CounterpartyNameAxis-SeattleGeneticsIncMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember" unitRef="Pure" name="pirs:NumberOfResearchPrograms" scale="0" format="ixt-sec:numwordsen" decimals="INF">three</ix:nonFraction> programs for further development. Prior to the initiation of a pivotal trial, the Company <em style="font: inherit;"> may </em>opt into global co-development and U.S. commercialization of the <em style="font: inherit;">second</em> program and share in global costs and profits on an equal basis. Seagen will solely develop, fund and commercialize the other <ix:nonFraction id="c96253814" contextRef="i_2018-02-08_CounterpartyNameAxis-SeattleGeneticsIncMember_TypeOfArrangementAxis-OtherArrangementMember" unitRef="Pure" name="pirs:NumberOfResearchPrograms" scale="0" format="ixt-sec:numwordsen" decimals="INF">two</ix:nonFraction> programs. Seagen <em style="font: inherit;"> may </em>also decide to select additional candidates from the initial research phase for further development in return for the payment to us of additional fees, milestone payments, and royalties</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Seagen Platform License grants Seagen a non-exclusive license to certain intellectual property related to the Anticalin platform technology.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Upon signing the Seagen Agreements, Seagen paid the Company a $<ix:nonFraction id="c96253815" contextRef="d_2018-02-08_2018-02-08_CounterpartyNameAxis-SeattleGeneticsIncMember_ProductOrServiceAxis-LicenseMember_TypeOfArrangementAxis-UpFrontPaymentArrangementMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" format="ixt:numdotdecimal" decimals="-7">30.0</ix:nonFraction> million upfront fee and an additional $<ix:nonFraction id="c96253816" contextRef="d_2018-02-08_2018-02-08_CounterpartyNameAxis-SeattleGeneticsIncMember_TypeOfArrangementAxis-UpFrontPaymentArrangementMember" unitRef="USD" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" scale="6" format="ixt:numdotdecimal" decimals="-5">4.9</ix:nonFraction> million was estimated to be paid for research and development services as reimbursement to the Company through the end of the research term. In addition, the Company <em style="font: inherit;"> may </em>receive tiered royalties on net sales up to the low double-digits and success-based research, development, commercial, and sales milestones payments across the product candidates, depending on the successful development and commercialization of those candidates. If Seagen exercises its option to select additional candidates from the initial research phase for further development, payment to Pieris of additional fees, milestone payments, and royalties would result.</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">18</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The term of each of the Seagen Agreements ends upon the expiration of all of Seagen's payment obligations under each agreement. The Seagen Collaboration Agreement <em style="font: inherit;"> may </em>be terminated by Seagen on a product-by-product basis for convenience beginning <ix:nonNumeric contextRef="d_2018-02-08_2018-02-08_CounterpartyNameAxis-SeattleGeneticsIncMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember" name="pirs:RevenueFromContractWithCustomerPeriodAfterEffectiveDateAgreementsMayBeTerminated" id="c96253818" format="ixt-sec:durmonth">12</ix:nonNumeric> months after its effective date upon <ix:nonNumeric contextRef="d_2018-02-08_2018-02-08_CounterpartyNameAxis-SeattleGeneticsIncMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember" name="pirs:RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriod" id="c96253819" format="ixt-sec:durday">90</ix:nonNumeric> days' notice or, for any program where a pivotal study has been initiated, upon <ix:nonNumeric contextRef="d_2018-02-08_2018-02-08_CounterpartyNameAxis-SeattleGeneticsIncMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember" name="pirs:RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodIfMarketingApprovalObtained" id="c96253820" format="ixt-sec:durday">180</ix:nonNumeric> days' notice. Any program <em style="font: inherit;"> may </em>be terminated at Seagen's option. If any program is terminated by Seagen after a pre-defined pre-clinical stage, the Company will have full rights to continue such program. If any program is terminated by Seagen prior to such pre-defined pre-clinical stage, the Company will have the right to continue to develop such program, but will be obligated to offer a co-development option to Seagen for such program. The Seagen Collaboration Agreement <em style="font: inherit;"> may </em>also be terminated by Seagen or the Company for an uncured material breach by the other party upon <ix:nonNumeric contextRef="d_2018-02-08_2018-02-08_CounterpartyNameAxis-SeattleGeneticsIncMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember" name="pirs:RevenueFromContractWithCustomerAgreementTerminationNoticePeriodUponMaterialBreach" id="c96253821" format="ixt-sec:durday">90</ix:nonNumeric> days' notice, subject to extension for an additional <ix:nonNumeric contextRef="d_2018-02-08_2018-02-08_CounterpartyNameAxis-SeattleGeneticsIncMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember" name="pirs:RevenueFromContractWithCustomerAgreementTerminationAdditionalNoticePeriodUponMaterialBreach" id="c96253822" format="ixt-sec:durday">90</ix:nonNumeric> days if the material breach relates to diligence obligations and subject, in all cases, to dispute resolution procedures. The Seagen Collaboration Agreement <em style="font: inherit;"> may </em>also be terminated due to the other party&#x2019;s insolvency and <em style="font: inherit;"> may </em>in certain instances, including for reasons of safety, be terminated on a product-by-product basis. Each party <em style="font: inherit;"> may </em>also terminate the Seagen Agreements if the other party challenges the validity of any patents licensed under the Seagen Agreements, subject to certain exceptions. The Seagen Platform License will terminate upon termination of the Seagen Collaboration Agreement, whether in its entirety or on a product-by-product basis.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company determined that the Seagen Agreements should be combined and evaluated as a single arrangement under ASC <em style="font: inherit;">606</em> as they were executed on the same date. The arrangement with Seagen provides for the transfer of the following goods or services: (i)&#xa0;<ix:nonFraction id="c96253824" contextRef="d_2018-02-08_2018-02-08_CounterpartyNameAxis-SeattleGeneticsIncMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember" unitRef="Pure" name="pirs:NumberOfLicenses" scale="0" format="ixt-sec:numwordsen" decimals="INF">three</ix:nonFraction> candidate research licenses that each consist of a non-exclusive platform technology license, a co-exclusive candidate research license, and research and development services, (ii)&#xa0;research, development and manufacturing services associated with each candidate research license, (iii)&#xa0;participation on various governance committees, and (iv)&#xa0;<ix:nonFraction id="c96253825" contextRef="d_2018-02-08_2018-02-08_CounterpartyNameAxis-SeattleGeneticsIncMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember" unitRef="Pure" name="pirs:NumberOfSwapOptions" scale="0" format="ixt-sec:numwordsen" decimals="INF">two</ix:nonFraction> antibody target swap options which were assessed as material rights.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Management evaluated all of the promised goods or services within the contract and determined which such goods and services were separate performance obligations. The Company determined that the licenses granted, at arrangement inception, should be combined with the research and development services to be provided for the related antibody target programs as they are <em style="font: inherit;">not</em> capable of being distinct. A <em style="font: inherit;">third</em> party would <em style="font: inherit;">not</em> be able to provide the research and development services due to the specific nature of the intellectual property and knowledge required to perform the services, and Seagen could <em style="font: inherit;">not</em> benefit from the licenses without the corresponding services. The Company determined that the participation on the various governance committees was distinct as the services could be performed by an outside party.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As a result, management concluded there are <ix:nonFraction id="c96253830" contextRef="i_2018-02-08_CounterpartyNameAxis-SeattleGeneticsIncMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember" unitRef="Pure" name="pirs:NumberOfPerformanceObligations" scale="0" format="ixt-sec:numwordsen" decimals="INF">six</ix:nonFraction> separate performance obligations at the inception of the Seagen Agreements: (i)&#xa0;<ix:nonFraction id="c96253831" contextRef="i_2018-02-08_CounterpartyNameAxis-SeattleGeneticsIncMember_TypeOfArrangementAxis-PlatformTechnologyLicenseMember" unitRef="Pure" name="pirs:NumberOfPerformanceObligations" scale="0" format="ixt-sec:numwordsen" decimals="INF">three</ix:nonFraction> combined performance obligations, each comprised of a non-exclusive platform technology license, a co-exclusive candidate research license, and research and development services for the <em style="font: inherit;">first</em> <ix:nonFraction id="c96253833" contextRef="d_2018-02-08_2018-02-08_CounterpartyNameAxis-SeattleGeneticsIncMember_TypeOfArrangementAxis-PlatformTechnologyLicenseMember" unitRef="Pure" name="pirs:NumberOfTargetPrograms" scale="0" format="ixt-sec:numwordsen" decimals="INF">three</ix:nonFraction> approved Seagen antibody target programs, (ii) <ix:nonFraction id="c96253834" contextRef="i_2018-02-08_CounterpartyNameAxis-SeattleGeneticsIncMember_TypeOfArrangementAxis-AntibodyTargetSwapMember" unitRef="Pure" name="pirs:NumberOfPerformanceObligations" scale="0" format="ixt-sec:numwordsen" decimals="INF">two</ix:nonFraction> performance obligations each comprised of a material right for an antibody target swap option for the <em style="font: inherit;">first</em> and the <em style="font: inherit;">second</em> approved Seagen antibody target for <em style="font: inherit;">no</em> additional consideration, and (iii)&#xa0;<ix:nonFraction id="c96253838" contextRef="i_2018-02-08_CounterpartyNameAxis-SeattleGeneticsIncMember_TypeOfArrangementAxis-GovernanceCommitteeParticipationMember" unitRef="Pure" name="pirs:NumberOfPerformanceObligations" scale="0" format="ixt-sec:numwordsen" decimals="INF">one</ix:nonFraction> performance obligation comprised of the participation on the various governance committees.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company allocated consideration to the performance obligations based on the relative proportion of their standalone selling prices. The Company developed standalone selling prices for licenses by applying a risk adjusted, net present value, estimate of future potential cash flows approach, which included the cost of obtaining research and development services at arm&#x2019;s length from a <em style="font: inherit;">third</em>-party provider, as well as internal full-time equivalent costs to support these services. The Company developed the standalone selling price for committee participation by using management&#x2019;s estimate of the anticipated participation hours multiplied by a market rate for comparable participants.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The transaction price at inception is comprised of fixed consideration of $<ix:nonFraction id="c96253840" contextRef="d_2018-02-08_2018-02-08_CounterpartyNameAxis-SeattleGeneticsIncMember_ProductOrServiceAxis-LicenseMember_TypeOfArrangementAxis-UpFrontPaymentArrangementMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" format="ixt:numdotdecimal" decimals="-7">30.0</ix:nonFraction> million in upfront fees and variable consideration of $<ix:nonFraction id="c96253841" contextRef="d_2018-02-08_2018-02-08_CounterpartyNameAxis-SeattleGeneticsIncMember_TypeOfArrangementAxis-UpFrontPaymentArrangementMember" unitRef="USD" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" scale="6" format="ixt:numdotdecimal" decimals="-5">4.9</ix:nonFraction> million of estimated research and development services to be reimbursed as research and development occurs through the research term. The $<ix:nonFraction id="c96253842" contextRef="d_2018-02-08_2018-02-08_CounterpartyNameAxis-SeattleGeneticsIncMember_ProductOrServiceAxis-LicenseMember_TypeOfArrangementAxis-UpFrontPaymentArrangementMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" format="ixt:numdotdecimal" decimals="-7">30.0</ix:nonFraction> million upfront fee, which represents the fixed consideration in the transaction price, was allocated to each of the performance obligations based on the relative proportion of their standalone selling prices. The $<ix:nonFraction id="c96253843" contextRef="d_2018-02-08_2018-02-08_CounterpartyNameAxis-SeattleGeneticsIncMember_TypeOfArrangementAxis-UpFrontPaymentArrangementMember" unitRef="USD" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" scale="6" format="ixt:numdotdecimal" decimals="-5">4.9</ix:nonFraction> million in variable consideration related to the research and development services is allocated specifically to the <ix:nonFraction id="c96253844" contextRef="i_2018-02-08_CounterpartyNameAxis-SeattleGeneticsIncMember" unitRef="Pure" name="pirs:NumberOfPerformanceObligations" scale="0" format="ixt-sec:numwordsen" decimals="INF">three</ix:nonFraction> target program performance obligations based upon the budgeted services for each program</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The amounts allocated to the performance obligations for the <ix:nonFraction id="c96253845" contextRef="i_2018-02-08_CounterpartyNameAxis-SeattleGeneticsIncMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember" unitRef="Pure" name="pirs:NumberOfResearchPrograms" scale="0" format="ixt-sec:numwordsen" decimals="INF">three</ix:nonFraction> research programs will be recognized on a proportional performance basis through the completion of each respective estimated research term of the individual research programs. The amounts allocated to the material right for the antibody target swap option will be recognized either at the time the material right expires, or if exercised, on a proportional performance basis over the estimated research term for that program. The amounts allocated to the participation on each of the committees will be recognized straight-line over the anticipated research term for all research programs. As of <em style="font: inherit;"> December 31, 2022</em>, there was $<ix:nonFraction id="c96253846" contextRef="i_2022-12-31_CounterpartyNameAxis-SeattleGeneticsIncMember" unitRef="USD" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" format="ixt:numdotdecimal" decimals="-5">17.1</ix:nonFraction>&#xa0;million of aggregate transaction price allocated to remaining performance obligations.</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">19</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In <em style="font: inherit;"> June 2020, </em>Seagen and the Company entered into amendments to the Seagen Agreements, or together, the First Seagen Amendment. The Seagen Amendment extended the deadline for Seagen to nominate a <em style="font: inherit;">second</em> and <em style="font: inherit;">third</em> antibody target. As a result of the Seagen Amendment, which completed the remaining performance obligations under the research term for the <em style="font: inherit;">first</em> antibody target, the Company recorded $<ix:nonFraction id="c96253851" contextRef="d_2020-01-01_2020-12-31_CounterpartyNameAxis-SeattleGeneticsIncMember_TransactionTypeAxis-SalesMilestonePaymentsMember_TypeOfArrangementAxis-UpFrontPaymentArrangementMember" unitRef="USD" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" format="ixt:numdotdecimal" decimals="-5">4.2</ix:nonFraction>&#xa0;million of previously deferred revenue for the year ended <em style="font: inherit;"> December&#xa0;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2020.</em> The Company also recorded $<ix:nonFraction id="c96253854" contextRef="d_2020-04-01_2020-06-30_CounterpartyNameAxis-SeattleGeneticsIncMember_TransactionTypeAxis-SalesMilestonePaymentsMember_TypeOfArrangementAxis-UpFrontPaymentArrangementMember" unitRef="USD" name="pirs:CollaborativeArrangementAllocableArrangementConsiderationAllocation" scale="6" format="ixt:numdotdecimal" decimals="-6">5.0</ix:nonFraction> million of milestone revenue in <em style="font: inherit;"> June 2020.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On <em style="font: inherit;"> March 24, 2021, </em>the Company announced that Seagen made a strategic equity investment in Pieris, and that the companies had entered into a combination study agreement, or the Combination Study Agreement, to evaluate the safety and efficacy of combining Pieris&#x2019; cinrebafusp alfa with Seagen&#x2019;s tucatinib, a small-molecule tyrosine kinase <em style="font: inherit;">HER2</em> inhibitor, for the treatment of gastric cancer patients expressing lower <em style="font: inherit;">HER2</em> levels (<em style="font: inherit;">IHC2</em>+/ISH- &amp; <em style="font: inherit;">IHC1</em>+) as part of the upcoming phase <em style="font: inherit;">2</em> study to be conducted by Pieris. The companies have also entered into an Amended and Restated License and Collaboration Agreement, or the Second Seagen Amendment, in which their existing immuno-oncology collaboration agreement has been amended relating to joint development and commercial rights for the <em style="font: inherit;">second</em> program in the alliance.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Specifically, under the Second Seagen Amendment, Pieris&#x2019; option to co-develop and co-commercialize the <em style="font: inherit;">second</em> of <ix:nonFraction id="c96253862" contextRef="i_2021-03-24_CounterpartyNameAxis-SeattleGeneticsIncMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember" unitRef="Pure" name="pirs:NumberOfResearchPrograms" scale="0" format="ixt-sec:numwordsen" decimals="INF">three</ix:nonFraction> programs in the collaboration has been converted to a co-promotion option in the United States, with Seagen solely responsible for the development and overall commercialization of that program. Pieris will also be entitled to increased royalties from that program in the event that it chooses to exercise the co-promotion option. In connection with the agreements described above, the Company and Seagen entered into a subscription agreement, or the Seagen Subscription Agreement, pursuant to which the Company agreed to issue to Seagen, and Seagen agreed to acquire from the Company, <ix:nonFraction id="c96253863" contextRef="d_2021-03-24_2021-03-24_CounterpartyNameAxis-SeattleGeneticsIncMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="Share" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" format="ixt:numdotdecimal" decimals="INF">3,706,174</ix:nonFraction> shares of the Company&#x2019;s common stock for a total purchase price of $<ix:nonFraction id="c96253864" contextRef="d_2021-03-24_2021-03-24_CounterpartyNameAxis-SeattleGeneticsIncMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USD" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" format="ixt:numdotdecimal" decimals="-6">13.0</ix:nonFraction>&#xa0;million, or $<ix:nonFraction id="c96253865" contextRef="i_2021-03-24_CounterpartyNameAxis-SeattleGeneticsIncMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USDPerShare" name="us-gaap:SaleOfStockPricePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">3.51</ix:nonFraction> per share, in a private placement transaction pursuant to Section <em style="font: inherit;">4</em>(a)(<em style="font: inherit;">2</em>) of the Securities Act of <em style="font: inherit;">1933,</em> as amended. The Seagen Subscription Agreement includes a provision to the effect that Seagen <em style="font: inherit;"> may </em>ask the Company to file a registration statement to register the resale of the shares issued to Seagen, at any time beginning on the date that is <ix:nonNumeric contextRef="d_2021-03-24_2021-03-24_CounterpartyNameAxis-SeattleGeneticsIncMember" name="pirs:AmendedCollaborationAgreementResaleOfStockPeriod" id="c96253869" format="ixt-sec:durday">60</ix:nonNumeric> calendar days from the date of issuance of the shares. The Company assessed the ASC <em style="font: inherit;">606</em> implications of the Seagen Subscription Agreement and concluded that the fair value of the shares on a per share basis was $<ix:nonFraction id="c96253871" contextRef="i_2021-03-24_CounterpartyNameAxis-SeattleGeneticsIncMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USDPerShare" name="pirs:SaleOfStockFairValuePricePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">2.61</ix:nonFraction> per share as of the transaction date. This resulted in a premium paid for the shares of $<ix:nonFraction id="c96253872" contextRef="i_2021-03-24_CounterpartyNameAxis-SeattleGeneticsIncMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USD" name="us-gaap:ContractWithCustomerLiability" scale="6" format="ixt:numdotdecimal" decimals="-5">3.3</ix:nonFraction>&#xa0;million, all of which was recorded in deferred revenue upon contract execution and allocated to the remaining performance obligations.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company has concluded that the Combination Study Agreement is within the scope of ASC <em style="font: inherit;">808,</em> which defines collaborative arrangements and addresses the presentation of the transactions between the <em style="font: inherit;">two</em> parties in the income statement and related disclosures. However, ASC <em style="font: inherit;">808</em> does <em style="font: inherit;">not</em> provide guidance on the recognition of consideration exchanged or accounting for the obligations that <em style="font: inherit;"> may </em>arise between the parties. The Company has concluded that ASC <em style="font: inherit;">730,</em> <i>Research and Development</i>, should be applied by analogy. There is <em style="font: inherit;">no</em> financial statement impact for the Combination Study Agreement as the value of the drug supply received from Seagen is offset against the drug supply cost.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In the <em style="font: inherit;">second</em> quarter of <em style="font: inherit;">2022,</em> the Company recorded approximately $<ix:nonFraction id="c96253881" contextRef="d_2022-04-01_2022-06-30_CounterpartyNameAxis-SeattleGeneticsIncMember_TransactionTypeAxis-SalesMilestonePaymentsMember_TypeOfArrangementAxis-UpFrontPaymentArrangementMember" unitRef="USD" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" format="ixt:numdotdecimal" decimals="-5">1.5</ix:nonFraction> million in revenue related to completion of the performance obligation for the expiration of the target swap under the <em style="font: inherit;">second</em> program in the collaboration.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Under the Seagen Agreements, the Company is eligible to receive various research, development, commercial and sales milestones. There is uncertainty that the events to obtain the research and development milestones will be achieved given the nature of clinical development and the stage of the Company&#x2019;s technology. The Company has thus determined that all research and development milestones will be constrained until it is deemed probable that a significant revenue reversal will <em style="font: inherit;">not</em> occur, with the exception of the $<ix:nonFraction id="c96253884" contextRef="d_2023-01-01_2023-01-31_CounterpartyNameAxis-SeattleGeneticsIncMember_SubsequentEventTypeAxis-SubsequentEventMember_TypeOfArrangementAxis-CollaborativeArrangementMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" format="ixt:numdotdecimal" decimals="-6">5.0</ix:nonFraction> million milestone as described in the following paragraph.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In <em style="font: inherit;"> January 2023, </em>the Company achieved a milestone for the <em style="font: inherit;">first</em> program in the collaboration for $<ix:nonFraction id="c96253886" contextRef="d_2023-01-01_2023-01-31_CounterpartyNameAxis-SeattleGeneticsIncMember_SubsequentEventTypeAxis-SubsequentEventMember_TypeOfArrangementAxis-CollaborativeArrangementMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" format="ixt:numdotdecimal" decimals="-6">5.0</ix:nonFraction> million. The Company evaluated the recognition of the milestone under ASC <em style="font: inherit;">606</em> and concluded that the constraints on the milestone <em style="font: inherit;">no</em> longer existed as of <em style="font: inherit;"> December 31, 2022</em> and therefore recorded the full $<ix:nonFraction id="c96253889" contextRef="d_2022-01-01_2022-12-31_CounterpartyNameAxis-SeattleGeneticsIncMember_TypeOfArrangementAxis-CollaborativeArrangementMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" format="ixt:numdotdecimal" decimals="-6">5.0</ix:nonFraction> million as revenue for the year ended <em style="font: inherit;"> December 31, 2022</em>.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">As of <em style="font: inherit;"> December 31, 2022</em>, there is $<ix:nonFraction id="c96253890" contextRef="i_2022-12-31_CounterpartyNameAxis-SeattleGeneticsIncMember" unitRef="USD" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" format="ixt:numdotdecimal" decimals="-5">11.6</ix:nonFraction>&#xa0;million and $<ix:nonFraction id="c96253891" contextRef="i_2022-12-31_CounterpartyNameAxis-SeattleGeneticsIncMember" unitRef="USD" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" format="ixt:numdotdecimal" decimals="-5">2.9</ix:nonFraction>&#xa0;million of current and non-current deferred revenue, respectively, related to the Seagen Agreements.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><span style="text-decoration: underline; ">AstraZeneca</span></i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> May&#xa0;</em><em style="font: inherit;">2,</em> <em style="font: inherit;">2017,</em> the Company entered into a license and collaboration agreement, or the AstraZeneca Collaboration Agreement, and a non-exclusive Anticalin platform technology license agreement, or AstraZeneca Platform License, and together with the AstraZeneca Collaboration Agreement, the AstraZeneca Agreements with AstraZeneca AB, or AstraZeneca, which became effective on <em style="font: inherit;"> June&#xa0;</em><em style="font: inherit;">10,</em> <em style="font: inherit;">2017,</em> following expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of <em style="font: inherit;">1976.</em> Under the AstraZeneca Agreements the parties will advance several novel inhaled Anticalin proteins.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition to the Company&#x2019;s lead inhaled drug candidate, PRS-<em style="font: inherit;">060/AZD1402,</em> or the AstraZeneca Lead Product, the Company and AstraZeneca, under the original terms of the AstraZeneca Collaboration Agreement, would also collaborate to progress <ix:nonFraction id="c96253898" contextRef="d_2017-05-02_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember" unitRef="Pure" name="pirs:NumberOfNovelProteins" scale="0" format="ixt-sec:numwordsen" decimals="INF">four</ix:nonFraction> additional novel Anticalin proteins against undisclosed targets for respiratory diseases, or the AstraZeneca Collaboration Products, and together with the AstraZeneca Lead Product, the AstraZeneca Products. The Company is responsible for advancing the AstraZeneca Lead Product&#xa0;through its phase <em style="font: inherit;">1</em> study, with the associated costs funded by AstraZeneca. The parties will collaborate thereafter to conduct a phase <em style="font: inherit;">2a</em> study in asthma patients, with AstraZeneca continuing to fund development costs. After completion of a phase <em style="font: inherit;">2a</em> study, Pieris has the option to co-develop the AstraZeneca Lead Product and also has a separate option to co-commercialize the AstraZeneca Lead Product in the United States. For the AstraZeneca Collaboration Products, the Company will be responsible for the initial discovery of the novel Anticalin proteins, after which AstraZeneca will take the lead on continued development of the AstraZeneca Collaboration Products. The Company has the option to co-develop <ix:nonFraction id="c96253902" contextRef="i_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_RangeAxis-MinimumMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember" unitRef="Pure" name="pirs:NumberOfCollaborationProducts" scale="0" format="ixt-sec:numwordsen" decimals="INF">two</ix:nonFraction> of the <ix:nonFraction id="c96253903" contextRef="i_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember" unitRef="Pure" name="pirs:NumberOfCollaborationProducts" scale="0" format="ixt-sec:numwordsen" decimals="INF">four</ix:nonFraction> AstraZeneca Collaboration Products beginning at a pre-defined preclinical stage and would also have the option to co-commercialize these <ix:nonFraction id="c96253904" contextRef="d_2017-05-02_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember" unitRef="Pure" name="pirs:NumberOfPrograms" scale="0" format="ixt-sec:numwordsen" decimals="INF">two</ix:nonFraction> programs in the United States, while AstraZeneca will be responsible for development and commercialization of the other programs worldwide.</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">20</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The term of each of the AstraZeneca Agreements ends upon the expiration of all of AstraZeneca&#x2019;s payment obligations under such agreement. The AstraZeneca Collaboration Agreement <em style="font: inherit;"> may </em>be terminated by AstraZeneca in its entirety for convenience beginning <ix:nonNumeric contextRef="d_2017-05-02_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember" name="pirs:RevenueFromContractWithCustomerPeriodAfterEffectiveDateAgreementsMayBeTerminated" id="c96253906" format="ixt-sec:durmonth">12</ix:nonNumeric> months after its effective date upon <ix:nonNumeric contextRef="d_2017-05-02_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember" name="pirs:RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriod" id="c96253907" format="ixt-sec:durday">90</ix:nonNumeric> days&#x2019; notice or, if the Company has obtained marketing approval for the marketing and sale of a product, upon <ix:nonNumeric contextRef="d_2017-05-02_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember" name="pirs:RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodIfMarketingApprovalObtained" id="c96253908" format="ixt-sec:durday">180</ix:nonNumeric> days&#x2019; notice. Each program <em style="font: inherit;"> may </em>be terminated at AstraZeneca&#x2019;s option; if any program is terminated by AstraZeneca, the Company will have full rights to such program. The AstraZeneca Collaboration Agreement <em style="font: inherit;"> may </em>also be terminated by AstraZeneca or the Company for material breach upon <ix:nonNumeric contextRef="d_2017-05-02_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember" name="pirs:RevenueFromContractWithCustomerAgreementTerminationNoticePeriodUponMaterialBreach" id="c96253909" format="ixt-sec:durday">180</ix:nonNumeric> days&#x2019; notice of a material breach (or <ix:nonNumeric contextRef="d_2017-05-02_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember" name="pirs:AgreementTerminationNoticePeriodUponOfBreachOfPaymentObligations" id="c96253910" format="ixt-sec:durday">30</ix:nonNumeric> days with respect to payment breach), provided that the applicable party has <em style="font: inherit;">not</em> cured such breach by the permitted cure period (including an additional <ix:nonNumeric contextRef="d_2017-05-02_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember" name="pirs:RevenueFromContractWithCustomerAgreementTerminationAdditionalNoticePeriodUponMaterialBreach" id="c96253912" format="ixt-sec:durday">180</ix:nonNumeric> days if the breach is <em style="font: inherit;">not</em> susceptible to cure during the initial <ix:nonNumeric contextRef="d_2017-05-02_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember" name="pirs:RevenueFromContractWithCustomerAgreementTerminationNoticePeriodUponMaterialBreach" id="c96253914" format="ixt-sec:durday">180</ix:nonNumeric>-day period) and dispute resolution procedures specified in the agreement have been followed. The AstraZeneca Collaboration Agreement <em style="font: inherit;"> may </em>also be terminated due to the other party&#x2019;s insolvency and <em style="font: inherit;"> may </em>in certain instances be terminated on a product-by-product and/or country-by-country basis. Each party <em style="font: inherit;"> may </em>also terminate an AstraZeneca Agreement if the other party challenges the validity of patents related to certain intellectual property licensed under such AstraZeneca Agreement, subject to certain exceptions for infringement suits, acquisitions and newly-acquired licenses. The AstraZeneca Platform License will terminate upon termination of the AstraZeneca Collaboration Agreement, on a product-by-product and/or country-by-country basis.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">At inception, AstraZeneca is granted the following licenses: (i)&#xa0;research and development license for the AstraZeneca Lead Product, (ii)&#xa0;commercial license for the AstraZeneca Lead Product, (iii)&#xa0;individual research licenses for each of the <ix:nonFraction id="c96253915" contextRef="i_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember" unitRef="Pure" name="pirs:NumberOfCollaborationProducts" scale="0" format="ixt-sec:numwordsen" decimals="INF">four</ix:nonFraction> AstraZeneca Collaboration Products, (iv)&#xa0;individual commercial licenses for each of the <ix:nonFraction id="c96253916" contextRef="i_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember" unitRef="Pure" name="pirs:NumberOfCollaborationProducts" scale="0" format="ixt-sec:numwordsen" decimals="INF">four</ix:nonFraction> AstraZeneca Collaboration Products, and (v)&#xa0;individual non-exclusive platform technology licenses for the AstraZeneca Lead Product and the <ix:nonFraction id="c96253917" contextRef="i_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember" unitRef="Pure" name="pirs:NumberOfCollaborationProducts" scale="0" format="ixt-sec:numwordsen" decimals="INF">four</ix:nonFraction> AstraZeneca Collaboration Products. AstraZeneca will be granted individual development licenses for each of the <ix:nonFraction id="c96253918" contextRef="i_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember" unitRef="Pure" name="pirs:NumberOfCollaborationProducts" scale="0" format="ixt-sec:numwordsen" decimals="INF">four</ix:nonFraction> AstraZeneca Collaboration Products upon completion of the initial discovery of Anticalin proteins.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The collaboration will be managed on an overall basis by a Joint Steering Committee, or JSC, formed by an equal number of representatives from the Company and AstraZeneca. In addition to the JSC, the AstraZeneca Collaboration Agreement also requires each party to designate an alliance manager to facilitate communication and coordination of the parties' activities under the agreement, and further requires participation of both parties on a joint development committee, or JDC, and a commercialization committee. The responsibilities of these committees vary, depending on the stage of development and commercialization of each product.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Under the AstraZeneca Agreements, the Company received an upfront, non-refundable payment of $<ix:nonFraction id="c96253919" contextRef="d_2017-05-02_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_TypeOfArrangementAxis-UpFrontPaymentArrangementMember" unitRef="USD" name="pirs:RevenueFromContractWithCustomerAllocableArrangementConsiderationAllocation" scale="6" format="ixt:numdotdecimal" decimals="-6">45.0</ix:nonFraction> million. In addition, the Company will receive payments to conduct a phase <em style="font: inherit;">1</em> clinical study for the AstraZeneca Lead Product. The Company is also eligible to receive research, development, commercial, sales milestone payments, and royalty payments. The Company <em style="font: inherit;"> may </em>receive tiered royalties on sales of potential products commercialized by AstraZeneca and for co-developed products, gross margin share on worldwide sales equal dependent on the Company&#x2019;s level of committed investment.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company determined that the AstraZeneca Agreements should be combined and evaluated as a single arrangement under ASC <em style="font: inherit;">606</em> as they were executed on the same date. The arrangement with AstraZeneca, including the impact of any modifications, provides for the transfer of the following goods and services: (i)&#xa0;<ix:nonFraction id="c96253922" contextRef="d_2017-05-02_2017-05-02" unitRef="Pure" name="pirs:NumberOfTechnologyLicenses" scale="0" format="ixt-sec:numwordsen" decimals="INF">five</ix:nonFraction> non-exclusive platform technology licenses, (ii)&#xa0;research and development license for the AstraZeneca Lead Product, (iii)&#xa0;commercial license for the AstraZeneca Lead Product, (iv)&#xa0;development and manufacturing services for the AstraZeneca Lead Product (or the phase <em style="font: inherit;">1</em> services), (v) technology transfer services for the AstraZeneca Lead Product, (vi)&#xa0;research services related to the AstraZeneca Lead Product, (vii)&#xa0;participation on each of the committees, (viii)&#xa0;<ix:nonFraction id="c96253924" contextRef="d_2017-05-02_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember" unitRef="Pure" name="pirs:NumberOfResearchLicenses" scale="0" format="ixt-sec:numwordsen" decimals="INF">four</ix:nonFraction> research licenses for the AstraZeneca Collaboration Products, (ix)&#xa0;<ix:nonFraction id="c96253925" contextRef="d_2017-05-02_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember" unitRef="Pure" name="pirs:NumberOfResearchLicenses" scale="0" format="ixt-sec:numwordsen" decimals="INF">four</ix:nonFraction> commercial licenses for the AstraZeneca Collaboration Products, (<em style="font: inherit;">x</em>)&#xa0;research services for the AstraZeneca Collaboration Products and (xi) certain phase <em style="font: inherit;">2a</em> services for the AstraZeneca Lead Product. Additionally, as the development licenses on the <ix:nonFraction id="c96253928" contextRef="i_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember" unitRef="Pure" name="pirs:NumberOfCollaborationProducts" scale="0" format="ixt-sec:numwordsen" decimals="INF">four</ix:nonFraction> AstraZeneca Collaboration Products <em style="font: inherit;"> may </em>be granted at a discount in the future, the Company determined such discounts should be assessed as material rights at inception.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Management evaluated all of the promised goods or services within the contract and determined which such goods and services were separate performance obligations. The Company determined that the licenses granted for the AstraZeneca Lead Product at the inception of the arrangement should be combined with the research services related to the AstraZeneca Lead Product and the licenses granted for the AstraZeneca Collaboration Products should be combined with the research services for the AstraZeneca Collaboration Products, as the licenses are <em style="font: inherit;">not</em> capable of being distinct. A <em style="font: inherit;">third</em> party would <em style="font: inherit;">not</em> be able to provide the research and development services, due to the specific nature of the intellectual property and knowledge required to perform the services and AstraZeneca could <em style="font: inherit;">not</em> benefit from the licenses without the corresponding services. The Company also determined that each of the phase <em style="font: inherit;">1</em> services and the phase <em style="font: inherit;">2a</em> services for the AstraZeneca Lead Product were distinct and that the participation on the various committees was also distinct as all of the phase <em style="font: inherit;">1</em> services, phase <em style="font: inherit;">2a</em> services and the committee services could be performed by an outside party. The Company determined that the commercial licenses for the AstraZeneca Collaboration Products granted at the inception of the arrangement should be combined with the development licenses for the AstraZeneca Collaboration Products as the company would <em style="font: inherit;">not</em> benefit from the commercial license without the ability to develop each product.</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">21</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As a result, management concluded that there were <ix:nonFraction id="c96253939" contextRef="i_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember" unitRef="Pure" name="pirs:NumberOfPerformanceObligations" scale="0" format="ixt:numdotdecimal" decimals="INF">16</ix:nonFraction> performance obligations: (i)&#xa0;combined performance obligation comprised of a non-exclusive platform technology license, research and development license, and commercial licenses for the AstraZeneca Lead Product and research services for the AstraZeneca Lead Product, (ii) combined performance obligation comprised of&#xa0;development and manufacturing services, and technology transfer services for the AstraZeneca Lead Product, (iii)&#xa0;committee participation, (iv-vii) <ix:nonFraction id="c96253940" contextRef="i_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember" unitRef="Pure" name="pirs:NumberOfCollaborationProducts" scale="0" format="ixt-sec:numwordsen" decimals="INF">four</ix:nonFraction> combined performance obligations each comprised of a non-exclusive platform technology license, research licenses, and research services for each AstraZeneca Collaboration Product (viii-xi) <ix:nonFraction id="c96253941" contextRef="i_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember" unitRef="Pure" name="pirs:NumberOfCollaborationProducts" scale="0" format="ixt-sec:numwordsen" decimals="INF">four</ix:nonFraction> performance obligations comprised of a material right to acquire the development licenses granted for the AstraZeneca Collaboration Products, (xii-xv) <ix:nonFraction id="c96253942" contextRef="i_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember" unitRef="Pure" name="pirs:NumberOfCollaborationProducts" scale="0" format="ixt-sec:numwordsen" decimals="INF">four</ix:nonFraction> performance obligations comprised of the commercial licenses granted for the AstraZeneca Collaboration Products and (xvi) phase <em style="font: inherit;">2a</em> services.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company allocated consideration to the performance obligations based on the relative proportion of their standalone selling prices. The Company developed standalone selling prices for licenses and corresponding research services by applying a risk adjusted, net present value, estimate of future potential cash flow approach, which included the cost of obtaining research services at arm&#x2019;s length from a <em style="font: inherit;">third</em>-party provider, as well as internal full-time equivalent costs to support these services. The Company developed its standalone selling price for development and manufacturing services, and technology transfer services for the AstraZeneca Lead Product using estimated internal and external costs to be incurred.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company developed its standalone selling price for committee participation by using management&#x2019;s estimate of the anticipated participation hours multiplied by a market rate for comparable participants.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company developed its standalone selling price for the commercial licenses and material rights granted on the development licenses by probability weighting multiple cash flow scenarios using the income approach.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The transaction price was comprised of fixed consideration of $<ix:nonFraction id="c96253945" contextRef="d_2017-05-02_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_TypeOfArrangementAxis-UpFrontPaymentArrangementMember" unitRef="USD" name="pirs:RevenueFromContractWithCustomerAllocableArrangementConsiderationAllocation" scale="6" format="ixt:numdotdecimal" decimals="-6">45.0</ix:nonFraction> million in upfront fees and variable consideration of (i) $<ix:nonFraction id="c96253946" contextRef="d_2017-05-02_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_TransactionTypeAxis-EstimatedDevelopmentAndManufacturingServicesMember_TypeOfArrangementAxis-UpFrontPaymentArrangementMember" unitRef="USD" name="pirs:RevenueFromContractWithCustomerAllocableArrangementConsiderationAllocation" scale="6" format="ixt:numdotdecimal" decimals="-5">14.2</ix:nonFraction> million in estimated phase <em style="font: inherit;">1</em> services, (ii) $<ix:nonFraction id="c96253948" contextRef="d_2017-05-02_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_TransactionTypeAxis-SalesMilestonePaymentsMember_TypeOfArrangementAxis-UpFrontPaymentArrangementMember" unitRef="USD" name="pirs:RevenueFromContractWithCustomerAllocableArrangementConsiderationAllocation" scale="6" format="ixt:numdotdecimal" decimals="-5">12.5</ix:nonFraction> million in milestone payments achieved upon the initiation of a phase <em style="font: inherit;">1</em> study in <em style="font: inherit;"> December 2017, </em>and (iii) $<ix:nonFraction id="c96253950" contextRef="d_2017-05-02_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_TransactionTypeAxis-EstimatedPhase2aServicesMember_TypeOfArrangementAxis-UpFrontPaymentArrangementMember" unitRef="USD" name="pirs:RevenueFromContractWithCustomerAllocableArrangementConsiderationAllocation" scale="6" format="ixt:numdotdecimal" decimals="-5">4.7</ix:nonFraction> million in estimated phase <em style="font: inherit;">2a</em> services. The $<ix:nonFraction id="c96253952" contextRef="d_2017-05-02_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_TypeOfArrangementAxis-UpFrontPaymentArrangementMember" unitRef="USD" name="pirs:RevenueFromContractWithCustomerAllocableArrangementConsiderationAllocation" scale="6" format="ixt:numdotdecimal" decimals="-6">45.0</ix:nonFraction> million upfront fee, which represents the fixed consideration in the transaction price, was allocated to each of the performance obligations based on the relative proportion of their standalone selling prices. Variable consideration of $<ix:nonFraction id="c96253953" contextRef="d_2017-05-02_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_TransactionTypeAxis-EstimatedDevelopmentAndManufacturingServicesMember_TypeOfArrangementAxis-UpFrontPaymentArrangementMember" unitRef="USD" name="pirs:RevenueFromContractWithCustomerAllocableArrangementConsiderationAllocation" scale="6" format="ixt:numdotdecimal" decimals="-5">14.2</ix:nonFraction> million is related to the phase <em style="font: inherit;">1</em> services and will be allocated entirely to the performance obligation to which they relate. Variable consideration of $<ix:nonFraction id="c96253955" contextRef="d_2017-05-02_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_TransactionTypeAxis-SalesMilestonePaymentsMember_TypeOfArrangementAxis-UpFrontPaymentArrangementMember" unitRef="USD" name="pirs:RevenueFromContractWithCustomerAllocableArrangementConsiderationAllocation" scale="6" format="ixt:numdotdecimal" decimals="-5">12.5</ix:nonFraction> million related to the phase <em style="font: inherit;">1</em> trial milestone was allocated by relative selling price to the combined performance obligation comprised of a non-exclusive platform technology license, research and development license and commercial licenses for the AstraZeneca Lead Product and research services for the AstraZeneca Lead Product, and the combined performance obligation comprised of&#xa0;development and manufacturing services and technology transfer services for the AstraZeneca Lead Product performance obligations. Variable consideration of $<ix:nonFraction id="c96253957" contextRef="d_2017-05-02_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_TypeOfArrangementAxis-AdditionalOtherResearchServicesMember" unitRef="USD" name="pirs:RevenueFromContractWithCustomerAllocableArrangementConsiderationAllocation" scale="6" format="ixt:numdotdecimal" decimals="-5">4.7</ix:nonFraction> million for phase <em style="font: inherit;">2a</em> services was allocated specifically to the related performance obligation.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The amounts allocated to the license performance obligation for the AstraZeneca Lead Product and the <ix:nonFraction id="c96253959" contextRef="i_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember" unitRef="Pure" name="pirs:NumberOfCollaborationProducts" scale="0" format="ixt-sec:numwordsen" decimals="INF">four</ix:nonFraction> performance obligations for the <ix:nonFraction id="c96253960" contextRef="d_2017-05-02_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember" unitRef="Pure" name="pirs:NumberOfResearchLicenses" scale="0" format="ixt-sec:numwordsen" decimals="INF">four</ix:nonFraction> research licenses for AstraZeneca Collaboration Products will be recognized on a proportional performance basis as the activities are conducted over the life of the arrangement. The amounts allocated to the performance obligation for phase <em style="font: inherit;">1</em> services, technology transfer services for the AstraZeneca Lead Product will be recognized on a proportional performance basis over the estimated term of development through phase <em style="font: inherit;">2a</em> study. The amounts allocated to the performance obligation for phase <em style="font: inherit;">2a</em> services for the AstraZeneca Lead Product will be recognized on a proportionate performance basis over an estimated term of <ix:nonNumeric contextRef="d_2017-05-02_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember" name="pirs:RemainingPerformanceObligationEstimatedTerm" id="c96253964" format="ixt-sec:durmonth">12</ix:nonNumeric> months.&#xa0;The amounts allocated to the performance obligation for participation on each of the committees will be recognized on a straight-line basis over the expected term of development of the AstraZeneca Lead Product and the AstraZeneca Collaboration Products. The term of performance is approximately <span style="-sec-ix-hidden:c96253965">five</span> years. The amounts allocated to the <ix:nonFraction id="c96253966" contextRef="i_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember" unitRef="Pure" name="pirs:NumberOfCollaborationProducts" scale="0" format="ixt-sec:numwordsen" decimals="INF">four</ix:nonFraction> performance obligations for the material rights to acquire a development license and the <ix:nonFraction id="c96253967" contextRef="i_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember" unitRef="Pure" name="pirs:NumberOfCollaborationProducts" scale="0" format="ixt-sec:numwordsen" decimals="INF">four</ix:nonFraction> performance obligations for commercial licenses for the AstraZeneca Collaboration Products will be recognized upon exercise of the specific material right and delivery of each of the development licenses. As of <em style="font: inherit;"> December 31, 2022</em>, there was $<ix:nonFraction id="c96253968" contextRef="i_2022-12-31_CounterpartyNameAxis-AstraZenecaABMember" unitRef="USD" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" format="ixt:numdotdecimal" decimals="-5">7.5</ix:nonFraction>&#xa0;million of aggregate transaction price allocated to remaining performance obligations.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Additionally, the Company evaluated payments required to be made between both parties as a result of the shared development costs of the AstraZeneca Lead Product and the <ix:nonFraction id="c96253969" contextRef="i_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_RangeAxis-MinimumMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember" unitRef="Pure" name="pirs:NumberOfCollaborationProducts" scale="0" format="ixt-sec:numwordsen" decimals="INF">two</ix:nonFraction> AstraZeneca Collaboration Products for which the Company has a co-development option. The Company will classify payments made as a reduction of revenue and will classify payments received as revenue, in the period they are earned.</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">22</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Under the AstraZeneca Agreements, the Company is eligible to receive various research, development, commercial and sales milestones. There is uncertainty that the events to obtain the research and development milestones will be achieved given the nature of clinical development and the stage of the Company&#x2019;s technology. The Company has thus determined that all research and development milestones, other than the phase <em style="font: inherit;">1</em> initiation milestone achieved in <em style="font: inherit;"> December 2017 </em>and included in the impact of adoption of ASC <em style="font: inherit;">606,</em> will be constrained until it is deemed probable that a significant revenue reversal will <em style="font: inherit;">not</em> occur.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> March 29, 2021, </em>the Company and AstraZeneca entered into (<em style="font: inherit;">1</em>) Amendment <em style="font: inherit;">No.</em> <em style="font: inherit;">1</em> to the Non-exclusive Anticalin&#xae;<b><sup style="vertical-align:top;line-height:120%;font-size:pt"> </sup></b>Platform License Agreement dated <em style="font: inherit;"> May 2, 2017 </em>and (<em style="font: inherit;">2</em>) Amendment <em style="font: inherit;">No.</em> <em style="font: inherit;">2</em> to the License and Collaboration Agreement dated <em style="font: inherit;"> May 2, 2017, </em>as previously amended by Amendment <em style="font: inherit;">No.</em> <em style="font: inherit;">1</em> dated <em style="font: inherit;"> September 14, 2020, </em>collectively, the Amended Collaboration Agreement. Under the Amended Collaboration Agreement, the parties agreed to restructure certain commercial economics for the PRS-<em style="font: inherit;">060/AZD1402</em> program by increasing potential sales milestones and reducing potential sales royalties, while fundamentally maintaining the overall value split between AstraZeneca and the Company.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In connection with the Amended Collaboration Agreement, the Company and AstraZeneca entered into a Subscription Agreement pursuant to which the Company agreed to issue to AstraZeneca, and AstraZeneca agreed to acquire from the Company, <ix:nonFraction id="c96253983" contextRef="d_2021-04-01_2021-04-01_CounterpartyNameAxis-AstraZenecaABMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="Share" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" format="ixt:numdotdecimal" decimals="INF">3,584,230</ix:nonFraction> shares of the Company&#x2019;s common stock for a total purchase price of $<ix:nonFraction id="c96253984" contextRef="d_2021-04-01_2021-04-01_CounterpartyNameAxis-AstraZenecaABMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USD" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" format="ixt:numdotdecimal" decimals="-7">10.0</ix:nonFraction>&#xa0;million, or $<ix:nonFraction id="c96253985" contextRef="i_2021-04-01_CounterpartyNameAxis-AstraZenecaABMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USDPerShare" name="us-gaap:SaleOfStockPricePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">2.79</ix:nonFraction> per share, in a private placement transaction pursuant to Section <em style="font: inherit;">4</em>(a)(<em style="font: inherit;">2</em>) of the Securities Act of <em style="font: inherit;">1933,</em> as amended. The Subscription Agreement closed on <em style="font: inherit;"> April 1, 2021 </em>and includes a requirement that the Company file a registration statement to register the resale of the shares issued to AstraZeneca within <ix:nonNumeric contextRef="d_2021-04-01_2021-04-01_CounterpartyNameAxis-AstraZenecaABMember" name="pirs:AmendedCollaborationAgreementResaleOfStockPeriod" id="c96253989" format="ixt-sec:durday">60</ix:nonNumeric> calendar days of the issuance of the shares. The Company assessed the payment under ASC <em style="font: inherit;">606</em> and concluded that the fair value of the shares on a per share basis was $<ix:nonFraction id="c96253991" contextRef="i_2021-04-01_CounterpartyNameAxis-AstraZenecaABMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USDPerShare" name="pirs:SaleOfStockFairValuePricePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">2.60</ix:nonFraction> per share as of the transaction date. This resulted in a premium paid for the shares of $<ix:nonFraction id="c96253992" contextRef="i_2022-12-31_CounterpartyNameAxis-AstraZenecaABMember" unitRef="USD" name="us-gaap:ContractWithCustomerLiability" scale="6" format="ixt:numdotdecimal" decimals="-5">0.7</ix:nonFraction>&#xa0;million, which was added to the deferred revenue balance and will be recognized over time in line with our revenue recognition pattern for all remaining performance obligations.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Also in <em style="font: inherit;"> March 2021, </em>the Company earned a $<ix:nonFraction id="c96253993" contextRef="d_2021-03-01_2021-03-31_CounterpartyNameAxis-AstraZenecaABMember" unitRef="USD" name="us-gaap:Revenues" scale="6" format="ixt:numdotdecimal" decimals="-6">13.0</ix:nonFraction>&#xa0;million milestone from AstraZeneca related to the initiation of the phase <em style="font: inherit;">2a</em> study for PRS-<em style="font: inherit;">060/AZD1402.</em> The Company assessed the milestone payment under ASC <em style="font: inherit;">606</em> and determined that there <em style="font: inherit;">no</em> longer existed a constraint on the milestone as the performance obligation related to the phase <em style="font: inherit;">2a</em> study was fully satisfied. Therefore, the Company realized the full $<ix:nonFraction id="c96253999" contextRef="d_2021-03-01_2021-03-31_CounterpartyNameAxis-AstraZenecaABMember" unitRef="USD" name="us-gaap:Revenues" scale="6" format="ixt:numdotdecimal" decimals="-6">13.0</ix:nonFraction>&#xa0;million as milestone revenue for the year ended <em style="font: inherit;"> December 31, 2021.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In <em style="font: inherit;"> January 2022, </em>the Company and AstraZeneca jointly discontinued <ix:nonFraction id="c96254000" contextRef="i_2022-01-31_CounterpartyNameAxis-AstraZenecaABMember" unitRef="Pure" name="pirs:NumberOfDiscoveryProgramsDiscontinued" scale="0" format="ixt-sec:numwordsen" decimals="INF">one</ix:nonFraction> discovery-stage programs as they were <em style="font: inherit;">not</em> able to validate an exploratory target. Approximately $<ix:nonFraction id="c96254002" contextRef="d_2022-01-01_2022-01-31_CounterpartyNameAxis-AstraZenecaABMember" unitRef="USD" name="pirs:RevenueFromContractWithCustomerAllocableArrangementConsiderationAllocation" scale="6" format="ixt:numdotdecimal" decimals="-5">4.7</ix:nonFraction>&#xa0;million of revenue was recorded related to remaining performance obligations related to the program.</p>
   <div style="font-size: 10pt; white-space: pre-wrap;">
     &#xa0;
   </div>
   <div style="font-size: 10pt;">
     In
    <em style="font: inherit;"> August 2022, </em>the Company and AstraZeneca entered into another amendment of the License and Collaboration Agreement dated
    <em style="font: inherit;"> May 2, 2017, </em>and extended the research term for
    <em style="font: inherit;">two</em> discovery-stage programs through
    <em style="font: inherit;"> December 2023 </em>and subsequently jointly discontinued the
    <em style="font: inherit;">third</em> discovery-stage program. Approximately
    $<ix:nonFraction id="c96254005" contextRef="d_2022-08-01_2022-08-31_CounterpartyNameAxis-AstraZenecaABMember" unitRef="USD" name="pirs:RevenueFromContractWithCustomerAllocableArrangementConsiderationAllocation" scale="6" format="ixt:numdotdecimal" decimals="-6">5.0</ix:nonFraction> million of revenue was recorded pursuant to a performance obligation related to transfer of a license that ceased with the discontinuation of this program.
   </div>
   <div style="font-size: 10pt;">
     &#xa0;
   </div>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of <em style="font: inherit;"> December 31, 2022</em>, there is $<ix:nonFraction id="c96254006" contextRef="i_2022-12-31_CounterpartyNameAxis-AstraZenecaABMember" unitRef="USD" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" format="ixt:numdotdecimal" decimals="-5">0.5</ix:nonFraction>&#xa0;million and $<ix:nonFraction id="c96254007" contextRef="i_2022-12-31_CounterpartyNameAxis-AstraZenecaABMember" unitRef="USD" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" format="ixt:numdotdecimal" decimals="-5">6.9</ix:nonFraction>&#xa0;million of current and non-current deferred revenue, respectively, related to the AstraZeneca Agreements.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company incurred $<ix:nonFraction id="c96254008" contextRef="i_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember" unitRef="USD" name="us-gaap:CapitalizedContractCostNet" scale="6" format="ixt:numdotdecimal" decimals="-5">1.6</ix:nonFraction> million of <em style="font: inherit;">third</em>-party success fees to obtain the contract with AstraZeneca. Upon adoption of ASC <em style="font: inherit;">606,</em> the Company capitalized $<ix:nonFraction id="c96254011" contextRef="i_2019-01-01_CounterpartyNameAxis-AstraZenecaABMember" unitRef="USD" name="us-gaap:CapitalizedContractCostGross" scale="6" format="ixt:numdotdecimal" decimals="-5">1.1</ix:nonFraction> million in accordance with ASC <em style="font: inherit;">340.</em> As of <em style="font: inherit;"> December 31, 2022</em>, the remaining balance of the asset recognized from transaction costs to obtain the AstraZeneca contract is $<ix:nonFraction id="c96254013" contextRef="i_2022-12-31_CounterpartyNameAxis-AstraZenecaABMember" unitRef="USD" name="us-gaap:CapitalizedContractCostNet" scale="6" format="ixt:numdotdecimal" decimals="-5">0.2</ix:nonFraction>&#xa0;million. Amortization during the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em> was $<ix:nonFraction id="c96254015" contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-AstraZenecaABMember" unitRef="USD" name="us-gaap:CapitalizedContractCostAmortization" scale="6" format="ixt:numdotdecimal" decimals="-5">0.3</ix:nonFraction> million and de minimis, respectively.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><span style="text-decoration: underline; ">Servier</span></i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> January&#xa0;</em><em style="font: inherit;">4,</em> <em style="font: inherit;">2017,</em> the Company entered into a license and collaboration agreement, or Servier Collaboration Agreement, and a non-exclusive Anticalin platform license agreement, or Servier Platform License, and together with the Servier Collaboration Agreement, the Servier Agreements with Les Laboratoires Servier and Institut de Recherches Internationales Servier, or Servier, pursuant to which the Company and Servier agreed to initially pursue <ix:nonFraction id="c96254019" contextRef="d_2017-01-01_2017-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember" unitRef="Pure" name="pirs:NumberOfPrograms" scale="0" format="ixt-sec:numwordsen" decimals="INF">five</ix:nonFraction> bispecific therapeutic programs.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Five committed programs were initially defined, which <em style="font: inherit;"> may </em>combine antibodies from the Servier portfolio with <ix:nonFraction id="c96254020" contextRef="d_2017-01-01_2017-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember" unitRef="Pure" name="pirs:NumberOfNovelProteins" scale="0" format="ixt-sec:numwordsen" decimals="INF">one</ix:nonFraction> or more Anticalin proteins based on the Company&#x2019;s proprietary platform to generate innovative IO bispecific drug candidates, or the Collaboration Products. The collaboration <em style="font: inherit;"> may </em>be expanded by up to <ix:nonFraction id="c96254021" contextRef="d_2017-01-01_2017-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember" unitRef="Pure" name="pirs:NumberOfPrograms" scale="0" format="ixt-sec:numwordsen" decimals="INF">three</ix:nonFraction> additional therapeutic programs. The Company had the option to co-develop and retain commercial rights in the United States for PRS-<em style="font: inherit;">332,</em> the initial lead program under the collaboration, or the Initial Lead, and has a similar option on up to <em style="font: inherit;">three</em> additional programs, or the Co-Development Collaboration Products, while Servier will be responsible for development and commercialization of the other programs worldwide, or the Servier Worldwide Collaboration Products. Each party is responsible for an agreed upon percentage of shared costs, as set forth in the budget for the collaboration plan, and as further discussed below.</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">23</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Co-Development Collaboration Products <em style="font: inherit;"> may </em>be jointly developed, according to a collaboration plan, through marketing approval from the U.S. Food and Drug Administration or the European Medicines Agency. Servier Worldwide Collaboration Products <em style="font: inherit;"> may </em>be jointly developed, according to a collaboration plan, through specified preclinical activities, at which point Servier becomes responsible for further development of the Collaboration Product.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">At inception, Servier was granted the following licenses: (i)&#xa0;development license for the Initial Lead, (ii)&#xa0;commercial license for the Initial Lead, (iii)&#xa0;individual research licenses for each of the <em style="font: inherit;">four</em> Collaboration Products, and (iv)&#xa0;individual non-exclusive platform technology licenses for the Initial Lead and for each of the <em style="font: inherit;">four</em> Collaboration Products. Upon achievement of certain development activities, specified by the collaboration for each Servier Agreement, Servier will be granted a development license and a commercial license. For the Initial Lead and the Co-Development Collaboration Products, the licenses granted are with respect to the entire world except for the United States. For Servier Worldwide Collaboration Products, the licenses granted are with respect to the entire world.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Servier Agreements are managed on an overall basis by a joint executive committee, or JEC, formed by an equal number of members from the Company and Servier. Decisions by the JEC will be made by consensus; however, in the event of a disagreement, each party will have final-decision making authority as it relates to the applicable territory in which such party has commercialization rights for the applicable product. In addition to the JEC, the Servier Collaboration Agreement requires the participation of both parties on: (i)&#xa0;a JSC, (ii) a JDC, (iii) a joint intellectual property committee, or JIPC, and (iv)&#xa0;a joint research committee, or JRC. The responsibilities of these committees vary, depending on the stage of development and commercialization of the Collaboration Products.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">For the Initial Lead and Co-Development Collaboration Products, the Company and Servier are responsible for an agreed upon percent of the shared costs required to develop the products through commercialization. In the event that the Company fails to exercise its option to co-develop the Co-Development Collaboration Products, Servier has the right to continue with the development and will be responsible for all costs required to develop the products through commercialization.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Under the Servier Agreements, the Company received an upfront, non-refundable payment of <span style="-sec-ix-hidden:c96254027">&#x20ac;30.0</span> million (approximately $<ix:nonFraction id="c96254028" contextRef="d_2017-01-01_2017-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_ProductOrServiceAxis-LicenseMember_TypeOfArrangementAxis-UpFrontPaymentArrangementMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" format="ixt:numdotdecimal" decimals="-6">32.0</ix:nonFraction> million). In addition, the Company is eligible to receive research, development, commercial, and sales milestone payments as well as tiered royalties up to low double digits on the sales of commercialized products in the Servier territories. Since inception of the Servier Collaboration Agreement, the Company has achieved <em style="font: inherit;">four</em> development milestones under Servier Agreements totaling <span style="-sec-ix-hidden:c96254030">&#x20ac;3.8</span> million (approximately $<ix:nonFraction id="c96254031" contextRef="d_2022-01-01_2022-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_TypeOfArrangementAxis-CollaborativeArrangementMember" unitRef="USD" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" format="ixt:numdotdecimal" decimals="-5">4.3</ix:nonFraction> million), all of which became billable on their respective achievement dates.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The initial research collaboration term, as it relates to the Initial Lead and Collaboration Products, shall continue for <ix:nonFraction id="c96254032" contextRef="d_2017-01-01_2017-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_ProductOrServiceAxis-ResearchAndDevelopmentServicesMember" unitRef="Pure" name="pirs:NumberOfDevelopmentMilestones" scale="0" format="ixt-sec:numwordsen" decimals="INF">three</ix:nonFraction> years from the effective date of the Servier agreements, and <em style="font: inherit;"> may </em>be mutually extended for <em style="font: inherit;">two one</em>-year terms consecutively applied.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The term of each Servier Agreement ends upon the expiration of all of Servier&#x2019;s payment obligations under such Servier Agreement.&#xa0;The Servier Agreements <em style="font: inherit;"> may </em>be terminated by Servier for convenience beginning <em style="font: inherit;">12</em> months after their effective date upon <em style="font: inherit;">180</em> days&#x2019; notice. The Servier Agreements <em style="font: inherit;"> may </em>also be terminated by Servier or the Company for material breach upon <ix:nonNumeric contextRef="d_2017-01-01_2017-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_RangeAxis-MinimumMember_TypeOfArrangementAxis-CollaborativeArrangementMember" name="pirs:RevenueFromContractWithCustomerAgreementTerminationNoticePeriodUponMaterialBreach" id="c96254036" format="ixt-sec:durday">90</ix:nonNumeric> days&#x2019; or <ix:nonNumeric contextRef="d_2017-01-01_2017-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-CollaborativeArrangementMember" name="pirs:RevenueFromContractWithCustomerAgreementTerminationNoticePeriodUponMaterialBreach" id="c96254037" format="ixt-sec:durday">120</ix:nonNumeric> days&#x2019; notice under the Servier Collaboration Agreement and the Servier Platform License, respectively, provided that the applicable party has <em style="font: inherit;">not</em> cured such breach by the applicable <ix:nonNumeric contextRef="d_2017-01-01_2017-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_RangeAxis-MinimumMember_TypeOfArrangementAxis-CollaborativeArrangementMember" name="pirs:RevenueFromContractWithCustomerAgreementTerminationNoticePeriodUponMaterialBreach" id="c96254039" format="ixt-sec:durday">90</ix:nonNumeric>-day or <ix:nonNumeric contextRef="d_2017-01-01_2017-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-CollaborativeArrangementMember" name="pirs:RevenueFromContractWithCustomerAgreementTerminationNoticePeriodUponMaterialBreach" id="c96254040" format="ixt-sec:durday">120</ix:nonNumeric>-day permitted cure period, and dispute resolution procedures specified in the applicable Servier Agreement have been followed. The Servier Agreements <em style="font: inherit;"> may </em>also be terminated due to the other party&#x2019;s insolvency or for a safety issue and <em style="font: inherit;"> may </em>in certain instances be terminated on a product-by-product and/or country-by-country basis. The Servier Platform License will terminate upon termination of the Servier Collaboration Agreement, on a product-by-product and/or country-by-country basis. In <em style="font: inherit;"> February 2020, </em>the research term was extended for <em style="font: inherit;">12</em> months. The research term was then extended for another <em style="font: inherit;">12</em> months in <em style="font: inherit;"> February 2021.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As the Company and Servier are considered to be active participants in the Servier Agreements and are exposed to significant risks and rewards, certain units of account within the Servier Agreements are within the scope of ASC <em style="font: inherit;">808.</em> The arrangement with Servier provides for the transfer of the following goods and services: (i)&#xa0;<em style="font: inherit;">five</em> non-exclusive platform technology licenses, a&#xa0;development license, a&#xa0;commercial license and research and development services for the Initial Lead, (ii)&#xa0;participation on each of the committees, (iii)&#xa0;<em style="font: inherit;">four</em> research licenses for Collaboration Products, and (iv)&#xa0;research and development services for the Collaboration Products. Additionally, as the development and commercial licenses on the <em style="font: inherit;">four</em> Collaboration Products <em style="font: inherit;"> may </em>be granted at a discount in the future, the Company determined such discounts should be assessed as material rights at inception.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Management evaluated all of the promised goods or services within the contract and determined which goods and services were separate performance obligations. The Company determined that the licenses granted at the inception of the Servier collaboration, should be combined with the research and development services to be provided for the Initial Lead and Collaboration Products, over the term of the Servier Agreements, as such licenses are <em style="font: inherit;">not</em> capable of being distinct. A <em style="font: inherit;">third</em> party would <em style="font: inherit;">not</em> be able to provide the research and development services, due to the specific nature of the intellectual property and knowledge required to perform the services, and Servier could <em style="font: inherit;">not</em> benefit from the licenses without the corresponding services. The Company determined that the participation on the various committees was distinct as the services could be performed by an outside party.</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">24</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As a result, management concluded that there are <ix:nonFraction id="c96254052" contextRef="i_2017-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember" unitRef="Pure" name="pirs:NumberOfPerformanceObligations" scale="0" format="ixt:numdotdecimal" decimals="INF">10</ix:nonFraction> performance obligations at the inception of the Servier Agreements. The following performance obligations are within the scope of ASC <em style="font: inherit;">808:</em> (i)&#xa0;combined performance obligation comprised of a non-exclusive platform technology license, commercial license, development license and research and development services for the Initial Lead, (ii)&#xa0;<ix:nonFraction id="c96254054" contextRef="d_2017-01-04_2017-01-04_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_TypeOfArrangementAxis-CollaborativeArrangementMember" unitRef="Pure" name="pirs:NumberOfSeparatePerformanceObligations" scale="0" format="ixt-sec:numwordsen" decimals="INF">two</ix:nonFraction> separate performance obligations each comprised of a combined non-exclusive platform technology license, research license, and research and development services for each Co-Development Collaboration Product (iii)&#xa0;<em style="font: inherit;">one</em> performance obligation comprised of participation in the various governance committees, and (iv)&#xa0;<ix:nonFraction id="c96254056" contextRef="d_2017-01-04_2017-01-04_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_TypeOfArrangementAxis-CollaborativeArrangementMember" unitRef="Pure" name="pirs:NumberOfCombinedPerformanceObligations" scale="0" format="ixt-sec:numwordsen" decimals="INF">two</ix:nonFraction> combined performance obligations comprised of the development and commercial licenses granted for the Co-Development Collaboration Products (and corresponding discounts) upon the achievement of specified preclinical activities, resulting in material rights. Revenue recognized associated with these performance obligations are presented as Collaboration Revenue within the Statement of Operations. The following performance obligations are within the scope of ASC <em style="font: inherit;">606:</em> (i) <ix:nonFraction id="c96254058" contextRef="d_2017-01-04_2017-01-04_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember" unitRef="Pure" name="pirs:NumberOfSeparatePerformanceObligations" scale="0" format="ixt-sec:numwordsen" decimals="INF">two</ix:nonFraction> separate performance obligations each comprised of a combined non-exclusive platform technology license, research license and research and development services for each Servier Worldwide Collaboration Product, and (ii) <ix:nonFraction id="c96254059" contextRef="d_2017-01-04_2017-01-04_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember" unitRef="Pure" name="pirs:NumberOfCombinedPerformanceObligations" scale="0" format="ixt-sec:numwordsen" decimals="INF">two</ix:nonFraction> combined performance obligations comprised of the development and commercial licenses granted for the Servier Worldwide Collaboration Products (and corresponding discounts) upon the achievement of specified preclinical activities, resulting in material rights. Revenue recognized associated with these performance obligations are presented as Customer Revenue within the Statement of Operations.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company allocated consideration to the performance obligations based on the relative proportion of their standalone selling prices. The Company developed its standalone selling prices for licenses by applying a risk adjusted, net present value, estimate of future potential cash flows approach, which included the cost of obtaining research and development services at arm&#x2019;s length from a <em style="font: inherit;">third</em>-party provider, as well as internal full-time equivalent costs to support these services.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company developed its estimate of standalone selling price for committee participation by using management&#x2019;s estimate of the anticipated participation hours multiplied by a market rate for comparable participants.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company developed its estimate of standalone selling price for the material rights granted on the development and commercial licenses granted for the Collaboration Products by probability weighting multiple cash flow scenarios using the income approach.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The transaction price at inception is comprised of the fixed upfront fee of <span style="-sec-ix-hidden:c96254061">&#x20ac;30.0</span> million (approximately $<ix:nonFraction id="c96254062" contextRef="d_2017-01-01_2017-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_ProductOrServiceAxis-LicenseMember_TypeOfArrangementAxis-UpFrontPaymentArrangementMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" format="ixt:numdotdecimal" decimals="-6">32.0</ix:nonFraction> million) and was allocated to the performance obligations based on the relative proportion of their standalone selling prices. &#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The amounts allocated to the performance obligation for the Initial Lead and the <ix:nonFraction id="c96254063" contextRef="i_2017-01-04_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember" unitRef="Pure" name="pirs:NumberOfPerformanceObligations" scale="0" format="ixt-sec:numwordsen" decimals="INF">four</ix:nonFraction> performance obligations for the <ix:nonFraction id="c96254064" contextRef="i_2017-01-04_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_TypeOfArrangementAxis-CollaborativeArrangementMember" unitRef="Pure" name="pirs:NumberOfCollaborationProducts" scale="0" format="ixt-sec:numwordsen" decimals="INF">four</ix:nonFraction> research and development licenses for Collaboration Products will be recognized on a proportional performance basis as the activities are conducted over the life of the arrangement. The term of the performance at inception of the Servier Agreements for the Initial Lead and each of the Co-Development Collaboration Products <em style="font: inherit;"> may </em>be through approval of certain regulatory bodies; a period which could be many years. The term of the performance for each of the other <ix:nonFraction id="c96254065" contextRef="i_2017-01-04_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember" unitRef="Pure" name="pirs:NumberOfCollaborationProducts" scale="0" format="ixt-sec:numwordsen" decimals="INF">two</ix:nonFraction> Servier Worldwide Collaboration Products is through the initial research and collaboration term, plus potential extensions. The amounts allocated to the performance obligation for participation on each of the committees will be recognized on a straight-line basis over the anticipated performance period over the entirety of the arrangement with Servier. The amounts allocated to the <ix:nonFraction id="c96254066" contextRef="i_2017-01-04_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember" unitRef="Pure" name="pirs:NumberOfPerformanceObligations" scale="0" format="ixt-sec:numwordsen" decimals="INF">four</ix:nonFraction> performance obligations for the material rights to acquire development and commercial licenses for the Co-Development Collaboration Products are granted in the future will be recognized over time upon delivery of each of the licenses through marketing approval. The amounts allocated to the <ix:nonFraction id="c96254067" contextRef="i_2017-01-04_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember" unitRef="Pure" name="pirs:NumberOfPerformanceObligations" scale="0" format="ixt-sec:numwordsen" decimals="INF">four</ix:nonFraction> performance obligations for the material rights to acquire development and commercial licenses for the Servier Developed Collaboration Products are granted in the future will be recognized upon delivery of each of the licenses. As of <em style="font: inherit;"> December 31, 2022</em>, there was $<ix:nonFraction id="c96254068" contextRef="i_2022-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember" unitRef="USD" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" format="ixt:numdotdecimal" decimals="-6">5.0</ix:nonFraction>&#xa0;million of aggregate transaction price allocated to remaining performance obligations.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Additionally, the Company evaluated payments required to be made between both parties as a result of the shared development costs of the Initial Lead and Collaboration Products. The Company will classify payments made as a reduction of revenue and will classify payments received as revenue, in the period they are earned.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Under the Servier Agreements the Company is eligible to receive various research, development, commercial, and sales milestones. There is uncertainty that the events to obtain the research and development milestones will be achieved given the nature of clinical development and the stage of the Company&#x2019;s technology. The Company has thus determined that all research and development milestones will be constrained until it is deemed probable that a significant revenue reversal will <em style="font: inherit;">not</em> occur.</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">25</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In <em style="font: inherit;"> September 2019, </em>Servier notified the Company of its decision to discontinue co-development of PRS-<em style="font: inherit;">332,</em> a PD-<em style="font: inherit;">1</em>-LAG-<em style="font: inherit;">3</em> bispecific that served as the initial development program under the Pieris-Servier alliance, for strategic reasons. The Company does <em style="font: inherit;">not</em> presently intend to continue development of PRS-<em style="font: inherit;">332</em> but retains full rights to advance the development and commercialization of the product on a world-wide basis in the future.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In <em style="font: inherit;"> February 2020, </em>the research term was extended for <ix:nonNumeric contextRef="d_2020-02-01_2020-02-29_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember" name="pirs:ResearchTermExtensionPeriod" id="c96254076" format="ixt-sec:duryear">12</ix:nonNumeric> months. The Company updated the transaction price for the extension for revenue recognition purposes and allocated it ratably over all unsatisfied performance obligations. As part of the expiration of the initial research term, the option to expand the collaboration beyond the initial <ix:nonFraction id="c96254077" contextRef="d_2020-02-01_2020-02-29_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember" unitRef="Pure" name="pirs:NumberOfPrograms" scale="0" format="ixt-sec:numwordsen" decimals="INF">five</ix:nonFraction> committed programs also expired. In <em style="font: inherit;"> March 2020, </em>Servier notified the Company of its decision to discontinue co-development of <ix:nonFraction id="c96254078" contextRef="i_2020-02-29_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember" unitRef="Pure" name="pirs:NumberOfPreclinicalStagePrograms" scale="0" format="ixt-sec:numwordsen" decimals="INF">two</ix:nonFraction> earlier preclinical stage programs for strategic reasons based upon an extensive portfolio review. The notification required a <em style="font: inherit;">60</em>-day period to complete remaining obligations on the programs; however, the Company determined that the material rights to acquire development and commercial licenses for <ix:nonFraction id="c96254080" contextRef="i_2020-02-29_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_TypeOfArrangementAxis-CodevelopmentCollaborationProductCollaborationMember" unitRef="Pure" name="pirs:NumberOfCollaborationProducts" scale="0" format="ixt-sec:numwordsen" decimals="INF">one</ix:nonFraction> Co-Development Collaboration Product and for <ix:nonFraction id="c96254081" contextRef="i_2020-02-29_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_TypeOfArrangementAxis-ServierDevelopedCollaborationProductsMember" unitRef="Pure" name="pirs:NumberOfCollaborationProducts" scale="0" format="ixt-sec:numwordsen" decimals="INF">one</ix:nonFraction> Servier Developed Collaboration Products lapsed in <em style="font: inherit;"> March 2020 </em>and recognized $<ix:nonFraction id="c96254082" contextRef="d_2020-01-01_2020-03-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember" unitRef="USD" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" format="ixt:numdotdecimal" decimals="-5">7.1</ix:nonFraction>&#xa0;million of previously deferred revenue associated with these material rights during <em style="font: inherit;">2020.</em> The discontinuation of the <ix:nonFraction id="c96254084" contextRef="i_2020-02-29_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember" unitRef="Pure" name="pirs:NumberOfPreclinicalStagePrograms" scale="0" format="ixt-sec:numwordsen" decimals="INF">two</ix:nonFraction> earlier preclinical stage programs decreased the future potential milestone payments the Company could achieve. The parties continue to advance the development of <ix:nonFraction id="c96254085" contextRef="i_2020-02-29_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember" unitRef="Pure" name="pirs:NumberOfPreclinicalStagePrograms" scale="0" format="ixt-sec:numwordsen" decimals="INF">two</ix:nonFraction> preclinical programs: PRS-<em style="font: inherit;">344/S095012,</em> a <em style="font: inherit;">4</em>-<em style="font: inherit;">1BB/PD</em>-<em style="font: inherit;">L1</em> bispecific designed as a co-development program, and PRS-<em style="font: inherit;">352,</em> which addresses undisclosed targets and for which Servier has worldwide rights.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In the <em style="font: inherit;">first</em> quarter of <em style="font: inherit;">2022,</em> the Company satisfied the performance obligation related to the material right for PRS-<em style="font: inherit;">352/S095025</em><i>,</i>&#xa0;which led to point-in-time recognition of revenue for $<ix:nonFraction id="c96254094" contextRef="d_2022-10-01_2022-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember" unitRef="USD" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" format="ixt:numdotdecimal" decimals="-5">4.9</ix:nonFraction>&#xa0;million of revenue previously deferred. In the <em style="font: inherit;">fourth</em> quarter of <em style="font: inherit;">2022,</em> Servier discontinued development of PRS-<em style="font: inherit;">352/S095025</em> based upon a strategic portfolio review.</p>
   <div style="font-size: 10pt;">
     &#xa0;
   </div>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of <em style="font: inherit;"> December 31, 2022</em>, there is $<ix:nonFraction id="c96254098" contextRef="i_2022-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember" unitRef="USD" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" format="ixt:numdotdecimal" decimals="-5">0.9</ix:nonFraction>&#xa0;million and $<ix:nonFraction id="c96254099" contextRef="i_2022-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember" unitRef="USD" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" format="ixt:numdotdecimal" decimals="-5">4.1</ix:nonFraction>&#xa0;million of current and non-current deferred revenue, respectively, related to the Servier Agreements.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company incurred costs to obtain the contract with Servier. Upon adoption of ASC <em style="font: inherit;">606,</em> the Company capitalized $<ix:nonFraction id="c96254101" contextRef="i_2019-01-01_AdjustmentsForChangeInAccountingPrincipleAxis-AccountingStandardsUpdate201409Member_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember" unitRef="USD" name="us-gaap:CapitalizedContractCostNet" scale="6" format="ixt:numdotdecimal" decimals="-5">0.5</ix:nonFraction> million of <em style="font: inherit;">third</em>-party service fees in accordance with ASC <em style="font: inherit;">340.</em> As of <em style="font: inherit;"> December 31, 2022</em>, there was <ix:nonFraction id="c96254104" contextRef="i_2022-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember" unitRef="USD" name="us-gaap:CapitalizedContractCostNet" scale="6" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction>&#xa0;remaining balance of the asset recognized from costs to obtain the Servier contract. Amortization expense for the years&#xa0;ended <em style="font: inherit;"> December 31, 2022</em> and <em style="font: inherit;"> December 31, 2021</em> was $<ix:nonFraction id="c96254105" contextRef="d_2022-01-01_2022-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember" unitRef="USD" name="us-gaap:CapitalizedContractCostAmortization" scale="6" format="ixt:numdotdecimal" decimals="-5">0.1</ix:nonFraction> million and de minimis, respectively</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Contract Balances</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company receives payments from its collaboration partners based on payments established in each contract. Upfront payments and fees are recorded as deferred revenue upon receipt or when due until such time as the Company satisfies its performance obligations under each arrangement. A contract asset is a conditional right to consideration in exchange for goods or services that the Company has transferred to a customer. Amounts are recorded as accounts receivable when the Company&#x2019;s right is unconditional.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">There were <ix:nonFraction id="c96254107" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> additions to deferred revenue during the year&#xa0;ended <em style="font: inherit;"> December 31, 2022</em> and reductions to deferred revenue were $<ix:nonFraction id="c96254108" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" format="ixt:numdotdecimal" decimals="-5">20.4</ix:nonFraction>&#xa0;million for the year&#xa0;ended <em style="font: inherit;"> December 31, 2022</em>.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">26</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;&#xa0;</ix:exclude>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:GovernmentAssistanceTextBlock" id="c2344189" escape="true">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><em style="font: inherit;">4.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Grant Income</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">One of the Company's proprietary respiratory assets is PRS-<em style="font: inherit;">220,</em> an oral inhaled Anticalin protein targeting connective tissue growth factor, or CTGF, and it is being developed as a local treatment for idiopathic pulmonary fibrosis. In <em style="font: inherit;"> June 2021, </em>the Company received a <span style="-sec-ix-hidden:c96254145">&#x20ac;14.2</span> million (approximately $<ix:nonFraction id="c96254146" contextRef="i_2021-06-30" unitRef="USD" name="us-gaap:GrantsReceivable" scale="6" format="ixt:numdotdecimal" decimals="-6">17.0</ix:nonFraction> million) grant from the Bavarian Ministry of Economic Affairs, Regional Development and Energy (the Bavarian Grant) supporting research and development for post-acute sequelae of SARS-CoV-<em style="font: inherit;">2</em> infection (PASC) pulmonary fibrosis, or PASC-PF, also known as post-COVID-<em style="font: inherit;">19</em> syndrome pulmonary fibrosis, or &#x201c;long COVID&#x201d;.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Bavarian Grant provides partial reimbursement for qualifying research and development activities on PRS-<em style="font: inherit;">220,</em> including drug manufacturing costs, activities and costs to support an IND filing, and phase <em style="font: inherit;">1</em> clinical trials costs. The Bavarian Grant provides reimbursement of qualifying costs incurred through <em style="font: inherit;"> August 2023, </em>which follows the expected development timeline of this program. Qualifying costs incurred <em style="font: inherit;"> may </em>exceed the annual grant funding thresholds. If the Company receives any proceeds from the sale of or licensing income from PRS-<em style="font: inherit;">220,</em> the funds available for reimbursement will be reduced proportionally if they are obtained prior to <em style="font: inherit;"> August 2023. </em>The Company is required to communicate such proceeds in each case with the request to draw-down the funds.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;&#xa0;</p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" id="c2344190" escape="true">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><em style="font: inherit;">5.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Cash, Cash Equivalents and Investments</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">As of&#xa0;<em style="font: inherit;"> December 31, 2022</em>, cash, cash equivalents and investments comprised funds in depository, money market accounts, U.S. and foreign treasury securities, asset-backed securities and corporate bonds. As of&#xa0;<em style="font: inherit;"> December 31, 2021</em>, cash equivalents were comprised of only money market accounts. The following table presents the cash equivalents and investments carried at fair value in accordance with the hierarchy defined in Note&#xa0;<em style="font: inherit;">2</em>&#xa0;at <em style="font: inherit;"> December 31, 2022</em>.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="c947F62FA-00EE-4B56-8B71-707F0C74A1FC" escape="true" continuedAt="c5F7F737D-0F4D-4F87-A1F5-D90C4B3B2751">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Total</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Quoted prices in active markets (Level 1)</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Significant other observable inputs (Level 2)</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Significant unobservable inputs (Level 3)</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>December 31, 2022</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Money market funds, included in cash equivalents</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254164" contextRef="i_2022-12-31_FinancialInstrumentAxis-MoneyMarketFundsMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" format="ixt:numdotdecimal" decimals="-3">17,618</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254165" contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FinancialInstrumentAxis-MoneyMarketFundsMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" format="ixt:numdotdecimal" decimals="-3">17,618</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254166" contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FinancialInstrumentAxis-MoneyMarketFundsMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254167" contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FinancialInstrumentAxis-MoneyMarketFundsMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Investments - US treasuries</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254168" contextRef="i_2022-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">3,573</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254169" contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FinancialInstrumentAxis-USTreasurySecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">3,573</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254170" contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FinancialInstrumentAxis-USTreasurySecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254171" contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FinancialInstrumentAxis-USTreasurySecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Investments - Foreign treasuries</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254172" contextRef="i_2022-12-31_FinancialInstrumentAxis-ForeignGovernmentDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">896</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254173" contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FinancialInstrumentAxis-ForeignGovernmentDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">896</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254174" contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FinancialInstrumentAxis-ForeignGovernmentDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254175" contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FinancialInstrumentAxis-ForeignGovernmentDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Investments - Asset-backed securities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254176" contextRef="i_2022-12-31_FinancialInstrumentAxis-AssetBackedSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">499</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254177" contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FinancialInstrumentAxis-AssetBackedSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254178" contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FinancialInstrumentAxis-AssetBackedSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">499</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254179" contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FinancialInstrumentAxis-AssetBackedSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Investments - Corporate bonds</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96254180" contextRef="i_2022-12-31_FinancialInstrumentAxis-CorporateBondSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">15,566</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96254181" contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FinancialInstrumentAxis-CorporateBondSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96254182" contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FinancialInstrumentAxis-CorporateBondSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">15,566</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96254183" contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FinancialInstrumentAxis-CorporateBondSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96254184" contextRef="i_2022-12-31" unitRef="USD" name="pirs:CashEquivalentsAndInvestments" scale="3" format="ixt:numdotdecimal" decimals="-3">38,152</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96254185" contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member" unitRef="USD" name="pirs:CashEquivalentsAndInvestments" scale="3" format="ixt:numdotdecimal" decimals="-3">22,087</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96254186" contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member" unitRef="USD" name="pirs:CashEquivalentsAndInvestments" scale="3" format="ixt:numdotdecimal" decimals="-3">16,065</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96254187" contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member" unitRef="USD" name="pirs:CashEquivalentsAndInvestments" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:continuation id="c5F7F737D-0F4D-4F87-A1F5-D90C4B3B2751">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Total</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Quoted prices in active markets (Level 1)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Significant other observable inputs (Level 2)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Significant unobservable inputs (Level 3)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>December 31, 2021</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Money market funds, included in cash equivalents</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96254189" contextRef="i_2021-12-31_FinancialInstrumentAxis-MoneyMarketFundsMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" format="ixt:numdotdecimal" decimals="-3">56,885</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96254190" contextRef="i_2021-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FinancialInstrumentAxis-MoneyMarketFundsMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" format="ixt:numdotdecimal" decimals="-3">56,885</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96254191" contextRef="i_2021-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FinancialInstrumentAxis-MoneyMarketFundsMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96254192" contextRef="i_2021-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FinancialInstrumentAxis-MoneyMarketFundsMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96254193" contextRef="i_2021-12-31" unitRef="USD" name="pirs:CashEquivalentsAndInvestments" scale="3" format="ixt:numdotdecimal" decimals="-3">56,885</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96254194" contextRef="i_2021-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member" unitRef="USD" name="pirs:CashEquivalentsAndInvestments" scale="3" format="ixt:numdotdecimal" decimals="-3">56,885</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96254195" contextRef="i_2021-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member" unitRef="USD" name="pirs:CashEquivalentsAndInvestments" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96254196" contextRef="i_2021-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member" unitRef="USD" name="pirs:CashEquivalentsAndInvestments" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:continuation>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">Cash equivalents and marketable securities have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing&#xa0;<em style="font: inherit;">third</em>&#xa0;party pricing services or other market observable data. The pricing services utilize industry standard valuation models, including both income and market-based approaches and observable market inputs to determine value. The Company validates the prices provided by its&#xa0;<em style="font: inherit;">third</em>-party pricing services by reviewing their pricing methods and obtaining market values from other pricing sources, as needed. After completing its validation procedures, the Company did&#xa0;<em style="font: inherit;">not</em>&#xa0;adjust any fair value measurements provided by the pricing services as of&#xa0;<em style="font: inherit;"> December 31, 2022</em>.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">Investments at&#xa0;<em style="font: inherit;"> December 31, 2022</em>&#xa0;consist of the following (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="c2344193" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 37%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Contractual maturity</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 11%;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 11%;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 37%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><span style="-sec-ix-hidden:c96254205">(in days)</span></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Amortized Cost</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Unrealized gains</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Unrealized losses</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Fair Value</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 37%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Investments</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 11%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 11%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 37%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">US treasuries</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><em style="font: inherit;">47</em>-<em style="font: inherit;">110</em></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254215" contextRef="i_2022-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" format="ixt:numdotdecimal" decimals="-3">3,575</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254216" contextRef="i_2022-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c96254217" contextRef="i_2022-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" format="ixt:numdotdecimal" decimals="-3">2</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254218" contextRef="i_2022-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">3,573</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 37%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Foreign treasuries</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><ix:nonNumeric contextRef="d_2022-01-01_2022-12-31_FinancialInstrumentAxis-ForeignGovernmentDebtSecuritiesMember" name="pirs:DebtSecuritiesAvailableforsaleContractualMaturityPeriod" id="c96254220" format="ixt-sec:durday">74</ix:nonNumeric></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254222" contextRef="i_2022-12-31_FinancialInstrumentAxis-ForeignGovernmentDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" format="ixt:numdotdecimal" decimals="-3">899</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 11%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c96254223" contextRef="i_2022-12-31_FinancialInstrumentAxis-ForeignGovernmentDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c96254224" contextRef="i_2022-12-31_FinancialInstrumentAxis-ForeignGovernmentDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" format="ixt:numdotdecimal" decimals="-3">3</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254225" contextRef="i_2022-12-31_FinancialInstrumentAxis-ForeignGovernmentDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">896</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 37%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Asset-backed securities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><ix:nonNumeric contextRef="d_2022-01-01_2022-12-31_FinancialInstrumentAxis-AssetBackedSecuritiesMember" name="pirs:DebtSecuritiesAvailableforsaleContractualMaturityPeriod" id="c96254227" format="ixt-sec:durday">15</ix:nonNumeric></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254229" contextRef="i_2022-12-31_FinancialInstrumentAxis-AssetBackedSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" format="ixt:numdotdecimal" decimals="-5">500</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 11%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c96254230" contextRef="i_2022-12-31_FinancialInstrumentAxis-AssetBackedSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c96254231" contextRef="i_2022-12-31_FinancialInstrumentAxis-AssetBackedSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" format="ixt:numdotdecimal" decimals="-3">1</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254232" contextRef="i_2022-12-31_FinancialInstrumentAxis-AssetBackedSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">499</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 37%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Corporate bonds</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><em style="font: inherit;">5</em>-<em style="font: inherit;">228</em></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96254236" contextRef="i_2022-12-31_FinancialInstrumentAxis-CorporateBondSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" format="ixt:numdotdecimal" decimals="-3">15,633</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 11%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c96254237" contextRef="i_2022-12-31_FinancialInstrumentAxis-CorporateBondSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96254238" contextRef="i_2022-12-31_FinancialInstrumentAxis-CorporateBondSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" format="ixt:numdotdecimal" decimals="-3">67</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96254239" contextRef="i_2022-12-31_FinancialInstrumentAxis-CorporateBondSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">15,566</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 37%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 9%;"><span style="-sec-ix-hidden:c96254241">&#xa0;</span></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96254243" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" format="ixt:numdotdecimal" decimals="-3">20,607</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96254244" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c96254245" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" format="ixt:numdotdecimal" decimals="-3">73</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96254246" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">20,534</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">The Company recorded&#xa0;realized gains from the maturity of available-for-sale securities of&#xa0;$<ix:nonFraction id="c96254157" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" scale="6" format="ixt:numdotdecimal" decimals="-5">0.4</ix:nonFraction> million for the year ended&#xa0;<em style="font: inherit;"> December 31, 2022</em> and recorded&#xa0;<span style="-sec-ix-hidden:c96254158">no</span>&#xa0;realized gains or losses from the maturity of available-for-sale securities for the year ended&#xa0;<em style="font: inherit;"> December 31, 2021</em>.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">As of&#xa0;<em style="font: inherit;"> December 31, 2022</em>, there were&#xa0;<em style="font: inherit;">no</em>&#xa0;investments with a fair value that was significantly lower than the amortized cost basis or any investments that had been in an unrealized loss position for a significant period.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="c2344194" escape="true">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><em style="font: inherit;">6.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Property and Equipment, Net</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Property and equipment are summarized as follows (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="c2344195" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Years Ended December 31,</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2022</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2021</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Laboratory furniture and equipment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254253" contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:numdotdecimal" decimals="-4">11,970</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254254" contextRef="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:numdotdecimal" decimals="-3">11,354</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Office furniture and equipment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254255" contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-OfficeEquipmentMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:numdotdecimal" decimals="-3">1,861</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254256" contextRef="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-OfficeEquipmentMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:numdotdecimal" decimals="-3">1,959</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Computer equipment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254257" contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:numdotdecimal" decimals="-3">364</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254258" contextRef="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:numdotdecimal" decimals="-3">396</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Leasehold improvements</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96254259" contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:numdotdecimal" decimals="-3">12,444</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96254260" contextRef="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:numdotdecimal" decimals="-4">13,130</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Property and equipment, cost</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254261" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:numdotdecimal" decimals="-3">26,639</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254262" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:numdotdecimal" decimals="-3">26,839</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Accumulated depreciation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96254263" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" format="ixt:numdotdecimal" decimals="-3">9,647</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96254264" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" format="ixt:numdotdecimal" decimals="-3">7,717</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"><b>Property and equipment, net</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96254265" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" format="ixt:numdotdecimal" decimals="-3">16,992</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96254266" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" format="ixt:numdotdecimal" decimals="-3">19,122</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Depreciation expense was $<ix:nonFraction id="c96254248" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:Depreciation" scale="6" format="ixt:numdotdecimal" decimals="-5">2.3</ix:nonFraction>&#xa0;million and $<ix:nonFraction id="c96254249" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:Depreciation" scale="6" format="ixt:numdotdecimal" decimals="-5">2.4</ix:nonFraction> million for the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em>, respectively. There were <em style="font: inherit;">no</em> other changes in accumulated depreciation other than the foreign currency impact.</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">27</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="c2344196" escape="true">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><em style="font: inherit;">7.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Accrued Expenses</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Accrued expenses and other current liabilities consisted of the following (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="c2344197" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Years Ended December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development fees</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254272" contextRef="i_2022-12-31" unitRef="USD" name="pirs:AccruedResearchAndDevelopmentCosts" scale="3" format="ixt:numdotdecimal" decimals="-3">5,758</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254273" contextRef="i_2021-12-31" unitRef="USD" name="pirs:AccruedResearchAndDevelopmentCosts" scale="3" format="ixt:numdotdecimal" decimals="-3">5,682</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Compensation expense</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254274" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">3,015</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254275" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">3,581</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued license obligations</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254276" contextRef="i_2022-12-31" unitRef="USD" name="pirs:AccruedLicenseObligationsCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">245</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254277" contextRef="i_2021-12-31" unitRef="USD" name="pirs:AccruedLicenseObligationsCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">1,541</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued accounts payable</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254278" contextRef="i_2022-12-31" unitRef="USD" name="pirs:AccruedAccountsPayableCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">1,245</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254279" contextRef="i_2021-12-31" unitRef="USD" name="pirs:AccruedAccountsPayableCurrent" scale="3" format="ixt:numdotdecimal" decimals="-4">2,980</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Lease liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254280" contextRef="i_2022-12-31_BalanceSheetLocationAxis-AccruedLiabilitiesAndOtherCurrentLiabilitiesMember" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">859</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254281" contextRef="i_2021-12-31_BalanceSheetLocationAxis-AccruedLiabilitiesAndOtherCurrentLiabilitiesMember" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">1,049</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Other current liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254282" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">483</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254283" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">393</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Collaboration cost-sharing obligation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96254284" contextRef="i_2022-12-31" unitRef="USD" name="pirs:AccruedCollaborationCostsCurrent" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96254285" contextRef="i_2021-12-31" unitRef="USD" name="pirs:AccruedCollaborationCostsCurrent" scale="3" format="ixt:numdotdecimal" decimals="-4">1,610</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96254286" contextRef="i_2022-12-31" unitRef="USD" name="pirs:AccruedLiabilitiesAndOtherLiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">11,605</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96254287" contextRef="i_2021-12-31" unitRef="USD" name="pirs:AccruedLiabilitiesAndOtherLiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">16,836</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:IncomeTaxDisclosureTextBlock" id="c2344198" escape="true">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><em style="font: inherit;">8.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Income Taxes</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company reported a loss before income taxes consisting of the following (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="c2344199" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Years Ended December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Domestic</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c96254336" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">11,765</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c96254337" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">11,312</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Foreign</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96254338" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">21,512</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96254339" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">34,426</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Loss before income taxes</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c96254340" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">33,277</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c96254341" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">45,738</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The components of the provision for income taxes are as follows (in thousands):</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="c2344200" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Years Ended December 31,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Current:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Federal</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254347" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254348" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">State</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254349" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254350" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Foreign</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96254351" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96254352" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total current</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254353" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254354" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Deferred:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Federal</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254356" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254357" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">State</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254358" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254359" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Foreign</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96254360" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96254361" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total deferred</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96254362" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96254363" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Provision for income taxes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96254364" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96254365" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The reconciliation of the federal statutory rate to the Company&#x2019;s effective tax rate is as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="c2344201" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Federal income tax rate</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254368" contextRef="d_2022-01-01_2022-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" format="ixt:numdotdecimal" decimals="2">21.0</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254369" contextRef="d_2021-01-01_2021-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" format="ixt:numdotdecimal" decimals="2">21.0</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Foreign rate differential</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254370" contextRef="d_2022-01-01_2022-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" format="ixt:numdotdecimal" decimals="2">5.0</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254371" contextRef="d_2021-01-01_2021-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" format="ixt:numdotdecimal" decimals="3">5.6</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">State tax, net of federal benefit</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254372" contextRef="d_2022-01-01_2022-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" format="ixt:numdotdecimal" decimals="2">2.0</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254373" contextRef="d_2021-01-01_2021-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" format="ixt:numdotdecimal" decimals="3">1.2</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Share-based awards compensation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c96254374" contextRef="d_2022-01-01_2022-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" format="ixt:numdotdecimal" decimals="3" sign="-">2.2</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c96254375" contextRef="d_2021-01-01_2021-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" format="ixt:numdotdecimal" decimals="3" sign="-">3.5</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)%</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Permanent items</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254376" contextRef="d_2022-01-01_2022-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" format="ixt:numdotdecimal" decimals="3">0.3</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c96254377" contextRef="d_2021-01-01_2021-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" format="ixt:numdotdecimal" decimals="3" sign="-">0.2</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)%</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Provision to return</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254378" contextRef="d_2022-01-01_2022-12-31" unitRef="Pure" name="pirs:EffectiveIncomeTaxRateReconciliationProvisionToReturnPercent" scale="-2" format="ixt:zerodash" decimals="0">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c96254379" contextRef="d_2021-01-01_2021-12-31" unitRef="Pure" name="pirs:EffectiveIncomeTaxRateReconciliationProvisionToReturnPercent" scale="-2" format="ixt:numdotdecimal" decimals="3">3.3</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c96254380" contextRef="d_2022-01-01_2022-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" format="ixt:numdotdecimal" decimals="2">1.0</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254381" contextRef="d_2021-01-01_2021-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" format="ixt:zerodash" decimals="0">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Credits</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c96254382" contextRef="d_2022-01-01_2022-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" format="ixt:numdotdecimal" decimals="3">1.2</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c96254383" contextRef="d_2021-01-01_2021-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" format="ixt:zerodash" decimals="0">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Change in valuation allowance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96254384" contextRef="d_2022-01-01_2022-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" format="ixt:numdotdecimal" decimals="3" sign="-">28.3</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96254385" contextRef="d_2021-01-01_2021-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" format="ixt:numdotdecimal" decimals="3" sign="-">27.4</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)%</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Effective income tax rate</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96254386" contextRef="d_2022-01-01_2022-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" format="ixt:zerodash" decimals="0">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96254387" contextRef="d_2021-01-01_2021-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" format="ixt:zerodash" decimals="0">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">%</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">28</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The components of deferred tax assets and liabilities related to net tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income taxes purposes were as follows (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="c2344202" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Years Ended December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Deferred tax assets:</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Net operating loss carryforwards</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254393" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" format="ixt:numdotdecimal" decimals="-3">54,845</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254394" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" format="ixt:numdotdecimal" decimals="-4">49,280</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Share-based awards compensation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254395" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="3" format="ixt:numdotdecimal" decimals="-3">3,112</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254396" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="3" format="ixt:numdotdecimal" decimals="-3">2,739</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Accrued expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254397" contextRef="i_2022-12-31" unitRef="USD" name="pirs:DeferredTaxAssetsAccruedCompensationAndOther" scale="3" format="ixt:numdotdecimal" decimals="-3">216</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254398" contextRef="i_2021-12-31" unitRef="USD" name="pirs:DeferredTaxAssetsAccruedCompensationAndOther" scale="3" format="ixt:numdotdecimal" decimals="-3">323</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 18pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">R&amp;D Credits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c96254399" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" format="ixt:numdotdecimal" decimals="-3">413</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c96254400" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Depreciation and other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254401" contextRef="i_2022-12-31" unitRef="USD" name="pirs:DeferredTaxAssetsDepreciationAndOther" scale="3" format="ixt:numdotdecimal" decimals="-3">384</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254402" contextRef="i_2021-12-31" unitRef="USD" name="pirs:DeferredTaxAssetsDepreciationAndOther" scale="3" format="ixt:numdotdecimal" decimals="-3">384</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Unrealized foreign currency</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254403" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses" scale="3" format="ixt:numdotdecimal" decimals="-3">359</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254404" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses" scale="3" format="ixt:numdotdecimal" decimals="-3">256</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 18pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Capitalized R&amp;D</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c96254405" contextRef="i_2022-12-31" unitRef="USD" name="pirs:DeferredTaxAssetsCapitalizedResearchAndDevelopment" scale="3" format="ixt:numdotdecimal" decimals="-3">952</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c96254406" contextRef="i_2021-12-31" unitRef="USD" name="pirs:DeferredTaxAssetsCapitalizedResearchAndDevelopment" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 18pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Accrued Expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Lease liability</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96254409" contextRef="i_2022-12-31" unitRef="USD" name="pirs:DeferredTaxAssetLeaseLiability" scale="3" format="ixt:numdotdecimal" decimals="-3">3,541</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96254410" contextRef="i_2021-12-31" unitRef="USD" name="pirs:DeferredTaxAssetLeaseLiability" scale="3" format="ixt:numdotdecimal" decimals="-3">4,022</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Total deferred tax assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96254411" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsGross" scale="3" format="ixt:numdotdecimal" decimals="-3">63,822</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96254412" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsGross" scale="3" format="ixt:numdotdecimal" decimals="-3">57,004</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Deferred tax liabilities:</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Right-of-use asset</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c96254414" contextRef="i_2022-12-31" unitRef="USD" name="pirs:DeferredTaxLiabilitiesLeaseRightofuseAsset" scale="3" format="ixt:numdotdecimal" decimals="-4">3,270</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c96254415" contextRef="i_2021-12-31" unitRef="USD" name="pirs:DeferredTaxLiabilitiesLeaseRightofuseAsset" scale="3" format="ixt:numdotdecimal" decimals="-3">3,729</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Accrued expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96254416" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:DeferredTaxLiabilitiesDeferredExpense" scale="3" format="ixt:zerodash" decimals="-3" sign="-">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c96254417" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:DeferredTaxLiabilitiesDeferredExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">68</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Total deferred tax liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96254418" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" format="ixt:numdotdecimal" decimals="-4">3,270</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96254419" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" format="ixt:numdotdecimal" decimals="-3">3,797</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Less: valuation allowance:</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96254420" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" format="ixt:numdotdecimal" decimals="-3">60,552</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96254421" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" format="ixt:numdotdecimal" decimals="-3">53,207</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Net deferred tax asset</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96254422" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsNet" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96254423" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsNet" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company operates in multiple jurisdictions. Accordingly, the Company files U.S. federal and state income tax returns as well as returns in multiple foreign jurisdictions. In assessing the realizability of deferred tax assets, management considers whether it is more likely than <em style="font: inherit;">not</em> that some portion or all deferred tax assets will <em style="font: inherit;">not</em> be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax-planning strategies in making this assessment. Management believes it is more likely than <em style="font: inherit;">not</em> that the results of future operations will <em style="font: inherit;">not</em> generate sufficient taxable income in the United States or in its foreign jurisdictions to realize the full benefits of its deferred tax assets. As of <em style="font: inherit;"> December 31, 2022</em>, the Company continues to maintain a full valuation allowance against all net deferred tax assets.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The cumulative amount of earnings of our foreign subsidiaries are expected to be permanently invested in the foreign subsidiaries. Deferred taxes have <em style="font: inherit;">not</em> been provided on the excess of book basis over tax basis, or the excess tax basis over book basis in the shares of our foreign subsidiaries because these basis differences are <em style="font: inherit;">not</em> expected to reverse in the foreseeable future and are essentially permanent in duration. Our intention is to reinvest the earnings of the foreign subsidiaries indefinitely.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The increase in the valuation allowance of deferred tax assets of $<ix:nonFraction id="c96254296" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" format="ixt:numdotdecimal" decimals="-5">7.3</ix:nonFraction> million for the year ended <em style="font: inherit;"> December 31, 2022</em> was primarily a result of the operating losses generated in current tax year.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of <em style="font: inherit;"> December 31, 2022</em>, the Company had net operating loss carryforwards for U.S. federal income tax purposes of $<ix:nonFraction id="c96254297" contextRef="i_2022-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember" unitRef="USD" name="us-gaap:OperatingLossCarryforwards" scale="6" format="ixt:numdotdecimal" decimals="-5">38.6</ix:nonFraction>&#xa0;million and net operating loss carryforwards for state income tax purposes of $<ix:nonFraction id="c96254298" contextRef="i_2022-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember" unitRef="USD" name="us-gaap:OperatingLossCarryforwards" scale="6" format="ixt:numdotdecimal" decimals="-5">42.4</ix:nonFraction> million. Federal tax loss carryforwards that were created prior to <em style="font: inherit;"> December 31, 2017 </em>expire through <em style="font: inherit;">2037</em> and federal losses created after that date do <em style="font: inherit;">not</em> expire. State loss carryforwards expire starting in <em style="font: inherit;">2035.</em> Pursuant to Section <em style="font: inherit;">382</em> of the Internal Revenue Code, and similar state tax law, certain substantial changes in the Company&#x2019;s ownership <em style="font: inherit;"> may </em>result in a limitation on the amount of net operating loss and tax credit carryforwards that <em style="font: inherit;"> may </em>be used in future years. Utilization of the net operating loss and tax credit carryforwards <em style="font: inherit;"> may </em>be subject to an annual limitation under Section <em style="font: inherit;">382</em> of the Internal Revenue Code of <em style="font: inherit;">1986</em> due to ownership change limitations that have occurred previously or that could occur in the future. These ownership changes <em style="font: inherit;"> may </em>limit the amount of net operating loss and tax credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. The Company completed a Section <em style="font: inherit;">382</em> study through <em style="font: inherit;"> December 31, 2020. </em>Based on the study, the Company underwent an ownership change for Section <em style="font: inherit;">382</em> purposes which occurred in <em style="font: inherit;"> February 2018. </em>As a result of the ownership change, the Company&#x2019;s net operating loss and tax credit carryforwards as of the ownership change dates are subject to limitation under Section <em style="font: inherit;">382;</em> however, these limitations are <em style="font: inherit;">not</em> expected to result in any of the impacted net operating loss and tax credit carryforwards to expire unutilized. Any net operating losses or tax credits generated after the <em style="font: inherit;"> February 2018 </em>change are <em style="font: inherit;">not</em> subject to this annual limitation. However, subsequent ownership changes, as defined by Section <em style="font: inherit;">382,</em> <em style="font: inherit;"> may </em>potentially further limit the amount of net operating loss and tax credit carryforwards that could be utilized to offset future taxable income and tax. The Company is currently open to examination under the statute of limitations by the Internal Revenue Service and state jurisdictions for the tax years ended <span style="-sec-ix-hidden:c96254311">2019</span> through the current year. Carryforward tax attributes generated in years past <em style="font: inherit;"> may </em>still be adjusted upon future examination if they have or will be used in a future period. The Company is currently under examination in Germany for <span style="-sec-ix-hidden:c96254312">2014</span> through <span style="-sec-ix-hidden:c96254313">2017;</span> however, the Company is <em style="font: inherit;">not</em> under examination by the Internal Revenue Service or any other jurisdictions for any tax years.</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">29</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of <em style="font: inherit;"> December 31, 2022</em>, the Company had German corporate income tax and trade tax net operating loss carryforwards of approximately $<ix:nonFraction id="c96254316" contextRef="i_2022-12-31_IncomeTaxAuthorityAxis-ForeignCountryMember_TaxCreditCarryforwardAxis-CorporateIncomeTaxMember" unitRef="USD" name="us-gaap:OperatingLossCarryforwards" scale="6" format="ixt:numdotdecimal" decimals="-5">163.3</ix:nonFraction> million and $<ix:nonFraction id="c96254317" contextRef="i_2022-12-31_IncomeTaxAuthorityAxis-ForeignCountryMember_TaxCreditCarryforwardAxis-TradeTaxMember" unitRef="USD" name="us-gaap:OperatingLossCarryforwards" scale="6" format="ixt:numdotdecimal" decimals="-5">160.4</ix:nonFraction> million respectively. Under current German laws, tax loss carryforwards <em style="font: inherit;"> may </em>only be used to offset any relevant later assessment period (calendar year) of <em style="font: inherit;">$1.2</em> million plus <em style="font: inherit;">60%</em> of the exceeding taxable income and trade profit of such period and do <em style="font: inherit;">not</em> expire. In addition, certain transactions, including transfers of shares or interest in the loss holding entity, <em style="font: inherit;"> may </em>result in the partial or total forfeiture of tax losses existing at that date. Partial or total forfeiture of tax losses <em style="font: inherit;"> may </em>further occur in corporate reorganizations of the loss holding entity.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company accounts for uncertain tax positions pursuant to ASC <em style="font: inherit;">740,</em> <i>Income Taxes</i>, which prescribes a recognition threshold and measurement process for financial statement recognition of uncertain tax positions taken or expected to be taken in a tax return. If the tax position meets this threshold, the benefit to be recognized is measured at the largest amount of benefit that is more likely than <em style="font: inherit;">not</em> (determined by cumulative probability) of being realized upon ultimate settlement with the taxing authority. The Company recorded an uncertain tax position related to a prior year position, that if successfully challenged by tax authorities could result in the loss of certain tax attributes. The balance of uncertain tax positions will remain until such time that settlement is reached with the relevant tax authorities or should the statute of limitations expire. The Company recognizes interest and penalties, if any, related to uncertain tax positions in income tax expense. <ix:nonFraction id="c96254323" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="0" format="ixt-sec:numwordsen" decimals="-3">No</ix:nonFraction> interest and penalties related to uncertain tax positions were accrued at <em style="font: inherit;"> December 31, 2022</em> and <em style="font: inherit;"> December 31, 2021</em>.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> December 22, 2017, </em>the Tax Cuts and Jobs Act, or the TCJA, was signed into law. Under the TCJA provisions, effective with tax years beginning on or after <em style="font: inherit;"> January 1, 2022, </em>taxpayers can <em style="font: inherit;">no</em> longer immediately expense qualified research and development expenditures. Taxpayers are now required to capitalize and amortize these costs over <em style="font: inherit;">five</em> years for research conducted within the United States or <em style="font: inherit;">15</em> years for research conducted abroad. As a result, the Company capitalized $<ix:nonFraction id="c96254327" contextRef="i_2022-12-31" unitRef="USD" name="pirs:DeferredTaxAssetsCapitalizedResearchAndDevelopment" scale="6" format="ixt:numdotdecimal" decimals="-6">1.0</ix:nonFraction> million of research and development expenses for the year ended <em style="font: inherit;"> December 31, 2022</em>.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following table sets forth a reconciliation of the beginning and ending amounts of unrecognized tax benefits, excluding the impact of interest and penalties, for the years ended <em style="font: inherit;"> December 31, 2022</em> (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:SummaryOfIncomeTaxContingenciesTextBlock" id="c2344203" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Unrecognized tax benefits at December 31, 2021</b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254424" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefits" scale="3" format="ixt:numdotdecimal" decimals="-3">5,665</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Currency translation adjustment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96254425" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation" scale="3" format="ixt:numdotdecimal" decimals="-3">302</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Unrecognized tax benefits at December 31, 2022</b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96254426" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefits" scale="3" format="ixt:numdotdecimal" decimals="-3">5,363</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company does <em style="font: inherit;">not</em> expect unrecognized tax benefits to change significantly over the next <em style="font: inherit;">12</em> months. The full amount of unrecognized tax benefits would impact the effective rate, subject to valuation allowance considerations, if recognized.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="c2344204" escape="true">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><em style="font: inherit;">9.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Stockholders</b>&#x2019;<b> equity</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company had <ix:nonFraction id="c96254428" contextRef="i_2022-12-31" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">300,000,000</ix:nonFraction> shares authorized and <ix:nonFraction id="c96254429" contextRef="i_2022-12-31" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">74,519,103</ix:nonFraction> and <ix:nonFraction id="c96254430" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">72,222,661</ix:nonFraction>shares of common stock issued and outstanding as of <em style="font: inherit;"> December 31, 2022</em> and <em style="font: inherit;"> December 31, 2021</em>, respectively, with a par value of $<ix:nonFraction id="c96254431" contextRef="i_2022-12-31" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.001</ix:nonFraction> per share.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company had <ix:nonFraction id="c96254432" contextRef="i_2022-12-31" unitRef="Share" name="us-gaap:PreferredStockSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">10,000,000</ix:nonFraction> shares authorized and <ix:nonFraction id="c96254433" contextRef="i_2022-12-31" unitRef="Share" name="us-gaap:PreferredStockSharesIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">15,617</ix:nonFraction> shares of preferred stock issued and outstanding as of <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em>. Preferred stock has a par value of $<ix:nonFraction id="c96254435" contextRef="i_2022-12-31" unitRef="USDPerShare" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.001</ix:nonFraction> per share, and consists of the following tranches:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"><tbody><tr><td style="width:18pt;">&#xa0;</td><td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td><td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Series A Convertible, <ix:nonFraction id="c96254436" contextRef="i_2022-12-31_StatementClassOfStockAxis-SeriesAPreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">85</ix:nonFraction> shares issued and outstanding at&#xa0;<em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em></p> </td></tr>
</tbody></table>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"><tbody><tr><td style="width:18pt;">&#xa0;</td><td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td><td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Series B Convertible, <ix:nonFraction id="c96254438" contextRef="i_2022-12-31_StatementClassOfStockAxis-SeriesBPreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">4,026</ix:nonFraction> shares issued and outstanding at <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em></p> </td></tr>
</tbody></table>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"><tbody><tr><td style="width:18pt;">&#xa0;</td><td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td><td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Series C Convertible, <ix:nonFraction id="c96254440" contextRef="i_2022-12-31_StatementClassOfStockAxis-SeriesCPreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">3,506</ix:nonFraction> shares issued and outstanding at <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em></p> </td></tr>
</tbody></table>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"><tbody><tr><td style="width:18pt;">&#xa0;</td><td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td><td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Series D Convertible, <ix:nonFraction id="c96254442" contextRef="i_2022-12-31_StatementClassOfStockAxis-SeriesDPreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">3,000</ix:nonFraction> shares issued and outstanding at both <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em></p> </td></tr>
</tbody></table>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"><tbody><tr><td style="width:18pt;">&#xa0;</td><td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td><td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Series E Convertible, <ix:nonFraction id="c96254444" contextRef="i_2022-12-31_StatementClassOfStockAxis-SeriesEPreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">5,000</ix:nonFraction> shares issued and outstanding at <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Common Stock</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Each share of the Company&#x2019;s common stock is entitled to <ix:nonFraction id="c96254446" contextRef="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Pure" name="pirs:NumberOfVotesPerShare" scale="0" format="ixt-sec:numwordsen" decimals="INF">one</ix:nonFraction> vote and all shares rank equally as to voting and other matters. Dividends <em style="font: inherit;"> may </em>be declared and paid on the common stock from funds legally available therefor, if, as and when determined by the Board of Directors.</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">30</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Preferred Stock</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company has issued multiple series (Series A through E) of preferred stock to certain entities affiliated with Biotechnology Value Fund, L.P., or BVF. In each case, each share Preferred Stock is convertible into <ix:nonFraction id="c96254448" contextRef="i_2021-05-20_StatementClassOfStockAxis-SeriesAThroughEMember_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" format="ixt:numdotdecimal" decimals="INF">1,000</ix:nonFraction> shares of the Company's common stock (subject to adjustment as provided in the Certificate of Designation for each series) at any time at the option of the holder, provided that the holder is prohibited from converting the Preferred Stock into shares of the Company's common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than <ix:nonFraction id="c96254449" contextRef="i_2021-05-20_StatementClassOfStockAxis-SeriesAThroughEMember_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Pure" name="pirs:ConvertiblePreferredStockCommonStockOwnershipLimitPercent" scale="-2" format="ixt:numdotdecimal" decimals="4">9.99</ix:nonFraction>% of the total number of shares of Common Stock then issued and outstanding, or the Beneficial Ownership Limitation. The holder <em style="font: inherit;"> may </em>reset the Beneficial Ownership Limitation to a higher or lower number, <em style="font: inherit;">not</em> to exceed <ix:nonFraction id="c96254451" contextRef="i_2021-05-20_StatementClassOfStockAxis-SeriesAThroughEMember_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Pure" name="pirs:ConvertiblePreferredStockBeneficialOwnershipLimitationPercent" scale="-2" format="ixt:numdotdecimal" decimals="4">19.99</ix:nonFraction>% of the total number of common shares issued and outstanding immediately after giving effect to a conversion, upon providing written notice to the Company. Any such notice providing for an increase to the Beneficial Ownership Limitation will be effective <ix:nonNumeric contextRef="d_2021-05-20_2021-05-20_StatementClassOfStockAxis-SeriesAThroughEMember_StatementEquityComponentsAxis-PreferredStockMember" name="pirs:ConvertiblePreferredStockBeneficialOwnershipLimitationNoticePeriodBeforeIncrease" id="c96254452" format="ixt-sec:duryear">61</ix:nonNumeric> days after delivery to the Company.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Series A, Series B, Series C, Series D and Series E Preferred Stock rank senior to the Company&#x2019;s common stock; senior to any class or series of capital stock of the Company created after the designation of and specifically ranking by its terms as junior to the <em style="font: inherit;">five</em> series of Preferred Stock; in parity with each other and with any class or series of capital stock of the Company created after the designation of and specifically ranking by its terms as in parity with the existing <em style="font: inherit;">five</em> series of Preferred Stock; and junior to any class or series of capital stock of the Company created after the designation of and specifically ranking by its terms as senior to the existing <em style="font: inherit;">five</em> series of Preferred Stock. In the event of the Company&#x2019;s liquidation, dissolution or winding up, subject to the rights of holders of, holders are entitled to receive a payment equal to $<ix:nonFraction id="c96254456" contextRef="i_2021-05-20_StatementClassOfStockAxis-SeriesAThroughEMember_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USDPerShare" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.001</ix:nonFraction> per share of Preferred Stock pursuant to the rights and preferences discussed above, plus an additional amount equal to any dividends declared but unpaid on such shares. However, if the assets of the Company are insufficient to comply with the preceding sentence, then all remaining assets of the Company shall be distributed ratably to holders of the shares of the existing <em style="font: inherit;">five</em> series of Preferred Stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">For each series of Preferred Stock, the Company designated the requisite number of shares of its authorized and unissued preferred stock as a specific series of Preferred Stock and filed a Certificate of Designation with the Nevada Secretary of State.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Shares of Preferred Stock generally have <em style="font: inherit;">no</em> voting rights, except as required by law and except that the consent of holders of a majority of the then outstanding Preferred Stock is required to amend the terms of the Certificate of Designation for each respective series of Preferred Stock. Holders of Preferred Stock are entitled to receive any dividends payable to holders of the Company's common stock subject to the rights and preferences discussed above, in each case, as to distributions of assets upon the Company&#x2019;s liquidation, dissolution or winding up whether voluntarily or involuntarily and/or the right to receive dividends.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Series A Preferred Stock</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In <em style="font: inherit;"> June 2016, </em>the Company entered into a securities purchase agreement for a private placement of the Company&#x2019;s securities with a select group of institutional investors, or the <em style="font: inherit;">2016</em> PIPE. The <em style="font: inherit;">2016</em> PIPE sale transaction, by the Company, consisted of <ix:nonFraction id="c96254461" contextRef="d_2016-06-01_2016-06-30_SubsidiarySaleOfStockAxis-SecuritiesPurchaseAgreementMember" unitRef="Share" name="us-gaap:PartnersCapitalAccountUnitsSoldInPrivatePlacement" scale="0" format="ixt:numdotdecimal" decimals="INF">8,188,804</ix:nonFraction> units at a price of $<ix:nonFraction id="c96254462" contextRef="i_2016-06-30_SubsidiarySaleOfStockAxis-SecuritiesPurchaseAgreementMember" unitRef="USDPerShare" name="us-gaap:SharesIssuedPricePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">2.015</ix:nonFraction> per unit for gross proceeds, to the Company, of approximately $<ix:nonFraction id="c96254463" contextRef="d_2016-06-01_2016-06-30_SubsidiarySaleOfStockAxis-SecuritiesPurchaseAgreementMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="6" format="ixt:numdotdecimal" decimals="-5">16.5</ix:nonFraction> million. After deducting for placement agent fees and offering expenses, the aggregate net proceeds from the private placement was approximately $<ix:nonFraction id="c96254464" contextRef="d_2016-06-01_2016-06-30_SubsidiarySaleOfStockAxis-SecuritiesPurchaseAgreementMember" unitRef="USD" name="pirs:ProceedsFromIssuanceOfPrivatePlacementNet" scale="6" format="ixt:numdotdecimal" decimals="-5">15.3</ix:nonFraction> million. In connection with the <em style="font: inherit;">2016</em> PIPE, the Company issued <ix:nonFraction id="c96254466" contextRef="d_2016-06-01_2016-06-30_SubsidiarySaleOfStockAxis-SecuritiesPurchaseAgreementMember" unitRef="Share" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" format="ixt:numdotdecimal" decimals="INF">3,225,804</ix:nonFraction> shares of common stock and <ix:nonFraction id="c96254467" contextRef="i_2016-06-30_SubsidiarySaleOfStockAxis-SecuritiesPurchaseAgreementMember" unitRef="Share" name="us-gaap:PreferredStockSharesIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">4,963</ix:nonFraction> shares of Series A Preferred Stock to the <em style="font: inherit;">2016</em> PIPE investors.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Series B Preferred Stock</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> January 30, 2019, </em>the Company and certain entities affiliated with Biotechnology Value Fund, L.P., or BVF entered into an exchange agreement pursuant to which BVF agreed to exchange an aggregate of <ix:nonFraction id="c96254469" contextRef="d_2019-01-30_2019-01-30_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-StockExchangeSharesFromExistingShareholdersMember" unitRef="Share" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" format="ixt:numdotdecimal" decimals="INF">5,000,000</ix:nonFraction> shares of the Company&#x2019;s common stock owned by BVF for an aggregate of <ix:nonFraction id="c96254470" contextRef="d_2019-01-30_2019-01-30_StatementEquityComponentsAxis-PreferredStockMember_SubsidiarySaleOfStockAxis-PreferredShareExchangeMember" unitRef="Share" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" format="ixt:numdotdecimal" decimals="INF">5,000</ix:nonFraction> shares of Series B Preferred Stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Series C and <em style="font: inherit;">2019</em> Private Placement</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In <em style="font: inherit;"> November 2019, </em>the Company entered into a securities purchase agreement for a private placement, or the Purchase Agreement with a select group of institutional investors, including lead investor BVF as well as existing and new investors, or Investors. The private placement consisted of <ix:nonFraction id="c96254472" contextRef="d_2019-11-01_2019-11-30_StatementClassOfStockAxis-SeriesCPreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="Share" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" format="ixt:numdotdecimal" decimals="INF">9,014,960</ix:nonFraction> units, at a price of $<ix:nonFraction id="c96254473" contextRef="i_2019-11-30_StatementClassOfStockAxis-SeriesCPreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USDPerShare" name="us-gaap:SaleOfStockPricePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">3.55</ix:nonFraction> per unit, or the Financing, for gross proceeds of approximately $<ix:nonFraction id="c96254474" contextRef="d_2019-11-01_2019-11-30_StatementClassOfStockAxis-SeriesCPreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USD" name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" scale="6" format="ixt:numdotdecimal" decimals="-6">32.0</ix:nonFraction> million, and net proceeds to the Company of approximately $<ix:nonFraction id="c96254475" contextRef="d_2019-11-01_2019-11-30_StatementClassOfStockAxis-SeriesCPreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USD" name="pirs:ProceedsFromIssuanceOfPrivatePlacementNet" scale="6" format="ixt:numdotdecimal" decimals="-6">31.0</ix:nonFraction> million. Each unit consists of (i)&#xa0;<span style="-sec-ix-hidden:c96254476">one</span> share of the Company&#x2019;s common stock, or Common Shares, or <ix:nonFraction id="c96254477" contextRef="i_2019-11-30_StatementClassOfStockAxis-SeriesCPreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="Share" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" format="ixt:numdotdecimal" decimals="INF">0.001</ix:nonFraction> shares of non-voting Series C convertible preferred stock, or Series C Preferred Shares, and together with the Common Shares, or Shares, and (ii)&#xa0;<span style="-sec-ix-hidden:c96254478">one</span> immediately-exercisable warrant to purchase <span style="-sec-ix-hidden:c96254479">one</span> share of the Company&#x2019;s common stock with an exercise price of $<ix:nonFraction id="c96254480" contextRef="i_2019-11-30_StatementClassOfStockAxis-SeriesCPreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">7.10</ix:nonFraction>, or Exercise Price.</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">31</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If (i) the initial public disclosure of the phase <em style="font: inherit;">2a</em> Study of PRS-<em style="font: inherit;">060/AZD1402</em> that includes the &#x201c;p&#x201d; value achieved for the primary endpoint of such study reveals top-line data on the primary efficacy endpoint in the phase <em style="font: inherit;">2a</em> Study with a &#x201c;p&#x201d; value below <em style="font: inherit;">0.05</em> (i.e., p &lt; <em style="font: inherit;">0.05</em>) in at least <em style="font: inherit;">one</em> dose level; and (ii) the <em style="font: inherit;">10</em>-day volume weighted average stock price commencing on the trading day immediately after the initial public disclosure is at least <span style="-sec-ix-hidden:c96254489">three</span> percent more than the Exercise Price, ((i) and (ii), collectively, the &#x201c;Performance Condition&#x201d;), then the warrants will be exercisable for a period of <em style="font: inherit;">60</em> days from the date of the initial data disclosure and <em style="font: inherit;"> may </em>only be exercised for cash. Otherwise, the warrants will be exercisable for a period of <span style="-sec-ix-hidden:c96254491">five</span> years from the date of issuance, or Exercise Date. If the Performance Condition has <em style="font: inherit;">not</em> been met and the last reported sale price of the Company&#x2019;s common stock immediately prior to the Expiration Date was greater than the Exercise Price, then the warrants shall be automatically deemed exercised on a cashless basis on the Expiration Date.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Upon issuance, each Series C Preferred Share included an embedded beneficial conversion feature as the market price of the Company&#x2019;s Common Stock on the date of issuance of the Series C convertible preferred stock was $<ix:nonFraction id="c96254493" contextRef="i_2019-11-30_StatementClassOfStockAxis-SeriesCPreferredStockMember_SubsidiarySaleOfStockAxis-PreferredShareExchangeMember" unitRef="USDPerShare" name="us-gaap:SaleOfStockPricePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">3.43</ix:nonFraction> per share. As a result, the Company recorded the intrinsic value of the beneficial conversion feature of $<ix:nonFraction id="c96254494" contextRef="d_2019-11-01_2019-11-30_StatementClassOfStockAxis-SeriesCPreferredStockMember_SubsidiarySaleOfStockAxis-PreferredShareExchangeMember" unitRef="USD" name="us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature" scale="6" format="ixt:numdotdecimal" decimals="-5">2.8</ix:nonFraction> million as a discount on the Series C convertible preferred stock at issuance. As the Series C Preferred Shares are immediately convertible upon issuance and do <em style="font: inherit;">not</em> include a stated redemption date, the discount was immediately accreted as a deemed dividend.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Series D Preferred Stock Conversion</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> March 31, 2020, </em>the Company and certain entities affiliated with BVF entered into an exchange agreement pursuant to which, on <em style="font: inherit;"> April 1, 2020, </em>BVF exchanged an aggregate of <ix:nonFraction id="c96254496" contextRef="d_2020-04-01_2020-04-01_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">3,000,000</ix:nonFraction> shares of the Company&#x2019;s common stock owned by BVF for an aggregate of <ix:nonFraction id="c96254497" contextRef="d_2020-04-01_2020-04-01_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" unitRef="Share" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" format="ixt:numdotdecimal" decimals="INF">3,000</ix:nonFraction> shares of Series D Preferred Stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Series E Preferred Stock Conversion</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> May 20, 2021, </em>the Company and certain entities affiliated with BVF entered into an exchange agreement pursuant to which, BVF exchanged an aggregate of <ix:nonFraction id="c96254498" contextRef="d_2021-05-20_2021-05-20_ConversionOfStockByUniqueDescriptionAxis-ConversionOfCommonStockIntoSeriesEPreferredStockMember" unitRef="Share" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" format="ixt:numdotdecimal" decimals="INF">5,000,000</ix:nonFraction> shares of the Company&#x2019;s common stock owned by BVF for an aggregate of <ix:nonFraction id="c96254499" contextRef="d_2021-05-20_2021-05-20_ConversionOfStockByUniqueDescriptionAxis-ConversionOfCommonStockIntoSeriesEPreferredStockMember" unitRef="Share" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" format="ixt:numdotdecimal" decimals="INF">5,000</ix:nonFraction> shares of Series E Preferred Stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Open Market Sales Agreement</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In <em style="font: inherit;"> August 2019, </em>the Company entered into a sales agreement with Jefferies LLC pursuant to which the Company <em style="font: inherit;"> may </em>offer and sell shares of its common stock, from time to time, up to an aggregate gross sales proceeds of $<ix:nonFraction id="c96254500" contextRef="d_2019-08-01_2019-08-31" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" format="ixt:numdotdecimal" decimals="-7">50.0</ix:nonFraction> million (the <em style="font: inherit;">2019</em> ATM Program). In <em style="font: inherit;"> August 2021, </em>the <em style="font: inherit;">2019</em> ATM Program expired, and the Company established a <em style="font: inherit;">second</em> ATM offering program, or the <em style="font: inherit;">2021</em> ATM Program, under the existing sales agreement with Jefferies LLC, pursuant to which the Company <em style="font: inherit;"> may </em>offer and sell shares of its common stock, par value $<ix:nonFraction id="c96254505" contextRef="i_2021-08-31_LegalEntityAxis-JefferiesLLCMember" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.001</ix:nonFraction> per share, from time to time, up to an aggregate amount of gross sales proceeds of $<ix:nonFraction id="c96254506" contextRef="d_2021-08-01_2021-08-31_LegalEntityAxis-JefferiesLLCMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember" unitRef="USD" name="pirs:SaleOfStockAuthorizedAmount" scale="6" format="ixt:numdotdecimal" decimals="-7">50.0</ix:nonFraction>&#xa0;million. In <em style="font: inherit;"> November 2022, </em>the sales agreement was amended to provide for an increase in the aggregate offering amount, such that under the <em style="font: inherit;">2021</em> ATM Program, as amended, the Company <em style="font: inherit;"> may </em>offer and sell shares of its common stock, from time to time, up to an aggregate amount of gross sales proceeds of $<ix:nonFraction id="c96254508" contextRef="d_2022-11-01_2022-11-30_LegalEntityAxis-JefferiesLLCMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember" unitRef="USD" name="pirs:SaleOfStockAuthorizedAmount" scale="6" format="ixt:numdotdecimal" decimals="-6">75.0</ix:nonFraction> million. The <em style="font: inherit;">2021</em> ATM Program, as amended, is offered under a shelf registration statement on Form S-<em style="font: inherit;">3</em> that was filed with and declared effective by the SEC in <em style="font: inherit;"> August 2021. </em>For the year ended <em style="font: inherit;"> December 31, 2022</em>, the Company sold <ix:nonFraction id="c96254511" contextRef="d_2022-01-01_2022-12-31_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember" unitRef="Share" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="6" format="ixt:numdotdecimal" decimals="-5">2.1</ix:nonFraction> million shares for gross proceeds of $<ix:nonFraction id="c96254512" contextRef="d_2022-01-01_2022-12-31_LegalEntityAxis-JefferiesLLCMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember" unitRef="USD" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" format="ixt:numdotdecimal" decimals="-5">7.2</ix:nonFraction>&#xa0;million under the <em style="font: inherit;">2021ATM</em> program at an average stock price of $<ix:nonFraction id="c96254514" contextRef="i_2022-12-31_LegalEntityAxis-JefferiesLLCMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember" unitRef="USDPerShare" name="us-gaap:SaleOfStockPricePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">3.46</ix:nonFraction>. For the year ended <em style="font: inherit;"> December 31, 2021</em>, the Company sold <ix:nonFraction id="c96254515" contextRef="d_2021-01-01_2021-12-31_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember" unitRef="Share" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="6" format="ixt:numdotdecimal" decimals="-5">8.2</ix:nonFraction> million shares for gross proceeds of $<ix:nonFraction id="c96254516" contextRef="d_2021-01-01_2021-12-31_LegalEntityAxis-JefferiesLLCMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember" unitRef="USD" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" format="ixt:numdotdecimal" decimals="-5">39.7</ix:nonFraction>&#xa0;million under both ATM programs at an average stock price of $<ix:nonFraction id="c96254517" contextRef="i_2021-12-31_LegalEntityAxis-JefferiesLLCMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember" unitRef="USDPerShare" name="us-gaap:SaleOfStockPricePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">4.85</ix:nonFraction>.</p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:EarningsPerShareTextBlock" id="c2344205" escape="true">
   <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><em style="font: inherit;">10.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Net Loss per Share</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Basic net loss per share is calculated by dividing net income (loss) by the weighted average shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share calculation, preferred stock, stock options, and warrants are considered to be common stock equivalents but have been excluded from the calculation of diluted net loss per share, as their effect would be anti-dilutive for all periods presented. Therefore, basic and diluted net loss per share were the same for all periods presented.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">For the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em>, and as calculated using the treasury stock method, approximately <ix:nonFraction id="c96254553" contextRef="d_2022-01-01_2022-12-31" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" format="ixt:numdotdecimal" decimals="-5">38.4</ix:nonFraction> million and <ix:nonFraction id="c96254554" contextRef="d_2021-01-01_2021-12-31" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" format="ixt:numdotdecimal" decimals="-5">36.8</ix:nonFraction> million of weighted average shares, respectively, were excluded from the calculation of diluted weighted average shares outstanding as their effect was antidilutive.</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">32</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="c2344206" escape="true">
    &#xa0;
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><em style="font: inherit;">11.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Stock and Employee Benefit Plans</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Employee, Director and Consultant Equity Incentive Plans</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">At the Annual Shareholder Meeting, held on <em style="font: inherit;"> June 23, 2020, </em>the shareholders approved the <em style="font: inherit;">2020</em> Employee, Director and Consultant Equity Incentive Plan, or the <em style="font: inherit;">2020</em> Plan. The <em style="font: inherit;">2020</em> Plan originally permitted the Company to issue up to&#xa0;<ix:nonFraction id="c96254560" contextRef="i_2020-06-23_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" unitRef="Share" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" format="ixt:numdotdecimal" decimals="INF">3,500,000</ix:nonFraction>&#xa0;shares of common stock pursuant to awards granted under the <em style="font: inherit;">2020</em> Plan. Upon approval of the <em style="font: inherit;">2020</em> Plan, the <em style="font: inherit;">2019</em> Employee, Director and Consultant Equity Incentive Plan, or the <em style="font: inherit;">2019</em> Plan, was terminated; all unissued options were canceled and <em style="font: inherit;">no</em> additional awards will be made thereunder. All outstanding awards under the <em style="font: inherit;">2019</em> Plan will remain in effect and any awards forfeited from the outstanding awards will be allocated back into the <em style="font: inherit;">2020</em> Plan. The <em style="font: inherit;">2020</em> Plan, similar to the <em style="font: inherit;">2019</em> Plan, provided for the grant of stock options, restricted and unrestricted stock awards, and other stock-based awards to employees of the Company, non-employee directors of the Company, and certain other consultants performing services for the Company as designated by either the Board of Directors or the compensation committee of the Board of Directors. At the <em style="font: inherit;">2021</em> Annual Meeting of Stockholders, held on <em style="font: inherit;"> June 25, 2021, </em>the Company&#x2019;s stockholders approved the <em style="font: inherit;">first</em> amendment to the <em style="font: inherit;">2020</em> Plan to add <ix:nonFraction id="c96254573" contextRef="d_2021-06-25_2021-06-25_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">2,250,000</ix:nonFraction> shares for issuance under the <em style="font: inherit;">2020</em> Plan, which increased the total permitted for issuance under the <em style="font: inherit;">2020</em> Plan to <ix:nonFraction id="c96254576" contextRef="i_2021-06-25_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" unitRef="Share" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" format="ixt:numdotdecimal" decimals="INF">5,750,000</ix:nonFraction>. At the <em style="font: inherit;">2022</em> Annual Meeting of Stockholders, held on <em style="font: inherit;"> June 22, 2022, </em>the Company&#x2019;s stockholders approved the <em style="font: inherit;">second</em> amendment to the <em style="font: inherit;">2020</em> Plan to add an additional <ix:nonFraction id="c96254580" contextRef="d_2022-06-22_2022-06-22_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">3,000,000</ix:nonFraction> shares for issuance under the <em style="font: inherit;">2020</em> Plan, which increased the total permitted for issuance under the <em style="font: inherit;">2020</em> Plan to <ix:nonFraction id="c96254583" contextRef="i_2022-06-22_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" unitRef="Share" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" format="ixt:numdotdecimal" decimals="INF">8,750,000</ix:nonFraction>.</p>
   <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">The <em style="font: inherit;">2020</em> Plan permits the Company to issue up to <ix:nonFraction id="c96254585" contextRef="i_2022-06-22_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" unitRef="Share" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" format="ixt:numdotdecimal" decimals="INF">8,750,000</ix:nonFraction> shares reserved for issuance pursuant to the <em style="font: inherit;">2020</em> Plan and any additional shares which <em style="font: inherit;"> may </em>be issued if awards outstanding under the Registrant&#x2019;s <em style="font: inherit;">2014,</em> <em style="font: inherit;">2016,</em> <em style="font: inherit;">2018</em> and <em style="font: inherit;">2019</em> Plans are canceled or expire.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company&#x2019;s stock options have a maximum term of <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="c96254591" format="ixt-sec:duryear">10</ix:nonNumeric> years from the date of grant. Stock options granted <em style="font: inherit;"> may </em>be either incentive stock options or nonqualified stock options and the exercise price of stock options must be at least equal to the fair market value of the common stock on the date of grant. The Company&#x2019;s general policy is to issue common shares upon the exercise of stock options.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company estimates the fair value of each stock award on the grant date using the Black-Scholes option-pricing model based on the following assumptions:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="c579E1972-BF43-4B33-8F56-5F0D68443003" escape="true" continuedAt="F2328708-3D02-4961-8135-092158CF05F3">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Years Ended December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Risk free interest rate</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254627" contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" format="ixt:numdotdecimal" decimals="4">1.43</ix:nonFraction>% - <ix:nonFraction id="c96254629" contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" format="ixt:numdotdecimal" decimals="4">3.39</ix:nonFraction>%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254630" contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" format="ixt:numdotdecimal" decimals="4">0.46</ix:nonFraction>% - <ix:nonFraction id="c96254632" contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" format="ixt:numdotdecimal" decimals="3">1.20</ix:nonFraction>%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected term (in years)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="c96254633" format="ixt-sec:duryear">5.5</ix:nonNumeric> - <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="c96254635" format="ixt-sec:duryear">5.73</ix:nonNumeric></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="c96254636" format="ixt-sec:duryear">5.31</ix:nonNumeric> - <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="c96254638" format="ixt-sec:duryear">5.73</ix:nonNumeric></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Dividend yield</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c96254640" contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" format="ixt:zerodash" decimals="0">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c96254643" contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" format="ixt:zerodash" decimals="0">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected volatility</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254645" contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" format="ixt:numdotdecimal" decimals="3">79.9</ix:nonFraction>% - <ix:nonFraction id="c96254647" contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" format="ixt:numdotdecimal" decimals="3">81.1</ix:nonFraction>%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254648" contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" format="ixt:numdotdecimal" decimals="2">75.0</ix:nonFraction>% - <ix:nonFraction id="c96254650" contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" format="ixt:numdotdecimal" decimals="3">81.7</ix:nonFraction>%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The weighted-average fair value of the <ix:nonFraction id="c96254592" contextRef="d_2022-01-01_2022-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:numdotdecimal" decimals="INF">3,075,282</ix:nonFraction> and <ix:nonFraction id="c96254593" contextRef="d_2021-01-01_2021-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:numdotdecimal" decimals="INF">3,182,696</ix:nonFraction> options granted during the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em> was $<ix:nonFraction id="c96254595" contextRef="d_2022-01-01_2022-12-31" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" format="ixt:numdotdecimal" decimals="INF">1.96</ix:nonFraction> and $<ix:nonFraction id="c96254596" contextRef="d_2021-01-01_2021-12-31" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" format="ixt:numdotdecimal" decimals="INF">2.04</ix:nonFraction>, respectively. As of <em style="font: inherit;"> December 31, 2022</em>, there were <ix:nonFraction id="c96254597" contextRef="i_2022-12-31_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" format="ixt:numdotdecimal" decimals="INF">4,314,513</ix:nonFraction> shares available for future grant under the <em style="font: inherit;">2020</em> Plan.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following table summarizes stock option activity for employees and non-employees:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="c8C585FE4-9F5E-478C-BF95-2582B3E44E41" escape="true" continuedAt="c594FAC31-E16F-4207-8C66-17BFF06B2C00">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted-</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted-</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Average</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Aggregate</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Average</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Remaining</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Intrinsic</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Number of</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Exercise</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Contractual</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Value</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Options</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Price</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Life (in years)</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">(in thousands)</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, December 31, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254671" contextRef="i_2021-12-31_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">11,475,713</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254672" contextRef="i_2021-12-31_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">3.35</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254674" contextRef="i_2021-12-31_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" format="ixt:numdotdecimal" decimals="-4">11,310</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254675" contextRef="d_2022-01-01_2022-12-31_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:numdotdecimal" decimals="INF">3,075,282</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254676" contextRef="d_2022-01-01_2022-12-31_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">2.88</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c96254678" contextRef="d_2022-01-01_2022-12-31_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" unitRef="USD" name="pirs:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodAggregateIntrinsicValue" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Exercised</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254679" contextRef="d_2022-01-01_2022-12-31_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:numdotdecimal" decimals="INF">46,233</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254680" contextRef="d_2022-01-01_2022-12-31_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">2.07</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254682" contextRef="d_2022-01-01_2022-12-31_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" format="ixt:numdotdecimal" decimals="-3">66</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Canceled</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96254683" contextRef="d_2022-01-01_2022-12-31_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" format="ixt:numdotdecimal" decimals="INF">1,031,396</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254684" contextRef="d_2022-01-01_2022-12-31_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">3.80</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254686" contextRef="d_2022-01-01_2022-12-31_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" unitRef="USD" name="pirs:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAggregateIntrinsicValue" scale="3" format="ixt:numdotdecimal" decimals="-3">17</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, December 31, 2022</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96254687" contextRef="i_2022-12-31_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">13,473,366</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96254688" contextRef="i_2022-12-31_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">3.21</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2022-01-01_2022-12-31_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="c96254689" format="ixt-sec:duryear">6.31</ix:nonNumeric></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96254690" contextRef="i_2022-12-31_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Vested or expected to vest, December 31, 2022</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96254691" contextRef="i_2022-12-31_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">13,473,366</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96254692" contextRef="i_2022-12-31_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">3.21</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2022-01-01_2022-12-31_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="c96254693" format="ixt-sec:duryear">6.31</ix:nonNumeric></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96254694" contextRef="i_2022-12-31_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercisable, December 31, 2022</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96254695" contextRef="i_2022-12-31_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">9,096,001</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96254696" contextRef="i_2022-12-31_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">3.38</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2022-01-01_2022-12-31_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" name="pirs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm2Exercised" id="c96254697" format="ixt-sec:duryear">5.16</ix:nonNumeric></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96254698" contextRef="i_2022-12-31_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">33</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Periodically, the Company grants inducement options, which are awards outside of approved stock option plans, and which are material awards to the executive officers or other personnel entering senior leadership roles with the Company. The terms of inducement option awards were substantially the same as those issued under our <em style="font: inherit;">2020</em> Plan. These awards are excluded from the table above. The following table summarizes stock option activity for these inducement options (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:continuation id="c594FAC31-E16F-4207-8C66-17BFF06B2C00">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted-</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted-</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Average</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Aggregate</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Average</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Remaining</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Intrinsic</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Number of</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Exercise</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Contractual</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Value</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Options</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Price</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Life (in years)</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">(in thousands)</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254719" contextRef="i_2021-12-31_TitleOfIndividualAxis-ExecutiveOfficersAndManagementMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">660,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254720" contextRef="i_2021-12-31_TitleOfIndividualAxis-ExecutiveOfficersAndManagementMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">4.01</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254722" contextRef="i_2021-12-31_TitleOfIndividualAxis-ExecutiveOfficersAndManagementMember" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" format="ixt:numdotdecimal" decimals="-3">108</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c96254723" contextRef="d_2022-01-01_2022-12-31_TitleOfIndividualAxis-ExecutiveOfficersAndManagementMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254724" contextRef="d_2022-01-01_2022-12-31_TitleOfIndividualAxis-ExecutiveOfficersAndManagementMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254726" contextRef="d_2022-01-01_2022-12-31_TitleOfIndividualAxis-ExecutiveOfficersAndManagementMember" unitRef="USD" name="pirs:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodAggregateIntrinsicValue" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Canceled or Expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c96254727" contextRef="d_2022-01-01_2022-12-31_TitleOfIndividualAxis-ExecutiveOfficersAndManagementMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" format="ixt:numdotdecimal" decimals="INF">360,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254728" contextRef="d_2022-01-01_2022-12-31_TitleOfIndividualAxis-ExecutiveOfficersAndManagementMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">3.48</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254730" contextRef="d_2022-01-01_2022-12-31_TitleOfIndividualAxis-ExecutiveOfficersAndManagementMember" unitRef="USD" name="pirs:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAggregateIntrinsicValue" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, December 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96254731" contextRef="i_2022-12-31_TitleOfIndividualAxis-ExecutiveOfficersAndManagementMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">300,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96254732" contextRef="i_2022-12-31_TitleOfIndividualAxis-ExecutiveOfficersAndManagementMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">4.65</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonNumeric contextRef="d_2022-01-01_2022-12-31_TitleOfIndividualAxis-ExecutiveOfficersAndManagementMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="c96254733" format="ixt-sec:duryear">6.66</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96254734" contextRef="i_2022-12-31_TitleOfIndividualAxis-ExecutiveOfficersAndManagementMember" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Vested or expected to vest, December 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c96254735" contextRef="i_2022-12-31_TitleOfIndividualAxis-ExecutiveOfficersAndManagementMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">300,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96254736" contextRef="i_2022-12-31_TitleOfIndividualAxis-ExecutiveOfficersAndManagementMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">4.65</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonNumeric contextRef="d_2022-01-01_2022-12-31_TitleOfIndividualAxis-ExecutiveOfficersAndManagementMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="c96254737" format="ixt-sec:duryear">6.66</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96254738" contextRef="i_2022-12-31_TitleOfIndividualAxis-ExecutiveOfficersAndManagementMember" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercisable, December 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c96254739" contextRef="i_2022-12-31_TitleOfIndividualAxis-ExecutiveOfficersAndManagementMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">243,750</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96254740" contextRef="i_2022-12-31_TitleOfIndividualAxis-ExecutiveOfficersAndManagementMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">4.65</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonNumeric contextRef="d_2022-01-01_2022-12-31_TitleOfIndividualAxis-ExecutiveOfficersAndManagementMember" name="pirs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm2Exercised" id="c96254741" format="ixt-sec:duryear">6.66</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96254742" contextRef="i_2022-12-31_TitleOfIndividualAxis-ExecutiveOfficersAndManagementMember" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:continuation>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Employee Stock Purchase Plans</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The <em style="font: inherit;">2018</em> ESPP provides eligible employees with the opportunity, through regular payroll deductions, to purchase shares of the Company&#x2019;s common stock at&#xa0;<ix:nonFraction id="c96254602" contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Pure" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" format="ixt:numdotdecimal" decimals="2">85</ix:nonFraction>%&#xa0;of the lower closing market price of the common stock at the beginning date or ending date of each purchase period. The plan includes <em style="font: inherit;"><span style="-sec-ix-hidden:c96254613">two</span> <span style="-sec-ix-hidden:c96254614">six</span></em>-month purchase periods per year beginning in both <em style="font: inherit;"> June </em>and <em style="font: inherit;"> December. </em>The Company has reserved <ix:nonFraction id="c96254604" contextRef="i_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Share" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" format="ixt:numdotdecimal" decimals="INF">500,000</ix:nonFraction> shares of common stock for the administration of the <em style="font: inherit;">2018</em> ESPP. Total shares purchased under the plan were <ix:nonFraction id="c96254606" contextRef="d_2022-01-01_2022-12-31" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" format="ixt:numdotdecimal" decimals="INF">181,466</ix:nonFraction> and <ix:nonFraction id="c96254607" contextRef="d_2021-01-01_2021-12-31" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" format="ixt:numdotdecimal" decimals="INF">64,257</ix:nonFraction> for the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em>, respectively. The fair value of shares expected to be purchased under the <em style="font: inherit;">2018</em> ESPP was determined using the Black-Scholes model with the following assumptions:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:continuation id="F2328708-3D02-4961-8135-092158CF05F3">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Years Ended December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Risk free interest rate</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254755" contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" format="ixt:numdotdecimal" decimals="4">1.62</ix:nonFraction>% - <ix:nonFraction id="c96254757" contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" format="ixt:numdotdecimal" decimals="3">4.60</ix:nonFraction>%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254758" contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" format="ixt:numdotdecimal" decimals="4">0.04</ix:nonFraction>% - <ix:nonFraction id="c96254760" contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" format="ixt:numdotdecimal" decimals="3">0.10</ix:nonFraction>%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected term (in years)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="c96254762" format="ixt-sec:duryear">0.5</ix:nonNumeric></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="c96254765" format="ixt-sec:duryear">0.5</ix:nonNumeric></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Dividend yield</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c96254768" contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" format="ixt:zerodash" decimals="0">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c96254771" contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" format="ixt:zerodash" decimals="0">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected volatility</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254773" contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" format="ixt:numdotdecimal" decimals="4">53.46</ix:nonFraction>% - <ix:nonFraction id="c96254775" contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" format="ixt:numdotdecimal" decimals="4">70.17</ix:nonFraction>%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254776" contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" format="ixt:numdotdecimal" decimals="4">60.46</ix:nonFraction>% - <ix:nonFraction id="c96254778" contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" format="ixt:numdotdecimal" decimals="4">131.21</ix:nonFraction>%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:continuation>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Total Stock-based Compensation Expense</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total stock-based compensation expense is recorded in operating expenses based upon the functional responsibilities of the individuals holding the respective options as follows (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="c2344211" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Years Ended December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254783" contextRef="d_2022-01-01_2022-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">1,905</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254784" contextRef="d_2021-01-01_2021-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">2,274</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">General and administrative</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96254785" contextRef="d_2022-01-01_2022-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">2,497</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96254786" contextRef="d_2021-01-01_2021-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">2,941</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total stock-based compensation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96254787" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">4,402</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96254788" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">5,215</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of <em style="font: inherit;"> December 31, 2022</em>, the total unrecognized compensation cost related to all non-vested awards was $<ix:nonFraction id="c96254610" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" format="ixt:numdotdecimal" decimals="-6">7.0</ix:nonFraction> million of which $<ix:nonFraction id="c96254611" contextRef="i_2022-12-31_TitleOfIndividualAxis-ExecutiveOfficersAndManagementMember" unitRef="USD" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" format="ixt:numdotdecimal" decimals="-5">0.2</ix:nonFraction> million are for inducement options. The Company expects to recognize the compensation cost over a remaining weighted-average period of <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="c96254612" format="ixt-sec:duryear">2.49</ix:nonNumeric> years.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="pirs:LicenseAndTransferAgreementTextBlock" id="c2344212" escape="true">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><em style="font: inherit;">12.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>License Agreement</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>TUM License</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company and the Technical University of Munich, or TUM, initiated discussions in the <em style="font: inherit;">second</em> quarter of <em style="font: inherit;">2018</em> to clarify, expand and restructure the research and licensing agreement with TUM, the TUM License, including the parties&#x2019; obligations under the TUM License. The TUM License assigns or exclusively licenses to the Company certain intellectual property related to the Company's Anticalin platform technology. The parties' discussions relate to revised commercial terms and to re-initiating additional collaborations between faculty at TUM and Pieris.&#xa0; While an amended and restated license agreement has <em style="font: inherit;">not</em> yet been completed, the Company intends to enter into such an&#xa0;amendment. These discussions <em style="font: inherit;"> may </em>also lead to an increase in the Company's collaborative research activities with TUM.</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">34</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:LesseeOperatingLeasesTextBlock" id="c2344213" escape="true">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><em style="font: inherit;">13.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Leases</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company entered into a sublease to lease approximately <ix:nonFraction id="c96254795" contextRef="i_2015-08-31_LeaseContractualTermAxis-SubleaseOfficeSpaceMember_StatementGeographicalAxis-BostonMassachusettsMember" unitRef="SquareFoot" name="us-gaap:AreaOfRealEstateProperty" scale="0" format="ixt:numdotdecimal" decimals="INF">3,950</ix:nonFraction> square feet in Boston, Massachusetts which expired on <em style="font: inherit;"> December 31, 2022. </em>The Company generally conducts its operational functions in the United States remotely.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In <em style="font: inherit;"> October 2018, </em>Pieris GmbH entered into a lease for office and laboratory space located in Hallbergmoos, Germany, or the Hallbergmoos Lease. Pieris GmbH moved its operations to the Hallbergmoos facility in <em style="font: inherit;"> February 2020.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Under the Hallbergmoos Lease, Pieris GmbH rents approximately <ix:nonFraction id="c96254796" contextRef="i_2020-02-29_LeaseContractualTermAxis-OfficeAndLaboratorySpaceMember_StatementGeographicalAxis-HallbergmoosGermanyMember" unitRef="SquareFoot" name="us-gaap:AreaOfRealEstateProperty" scale="0" format="ixt:numdotdecimal" decimals="INF">105,000</ix:nonFraction> square feet. An additional approximately <ix:nonFraction id="c96254797" contextRef="i_2020-02-29_PropertyPlantAndEquipmentByTypeAxis-LeasesExpectedToBeDeliveredByOctober2024Member_StatementGeographicalAxis-HallbergmoosGermanyMember" unitRef="SquareFoot" name="us-gaap:AreaOfRealEstateProperty" scale="0" format="ixt:numdotdecimal" decimals="INF">22,300</ix:nonFraction> square feet is expected to be delivered by the lessor by <em style="font: inherit;"> October 2024. </em>Pieris GmbH has a <em style="font: inherit;">first</em> right of refusal to lease an additional approximate <ix:nonFraction id="c96254799" contextRef="i_2020-02-29_PropertyPlantAndEquipmentByTypeAxis-LeasesWithFirstRightOfRefusalForAdditionalAreaMember_StatementGeographicalAxis-HallbergmoosGermanyMember" unitRef="SquareFoot" name="us-gaap:AreaOfRealEstateProperty" scale="0" format="ixt:numdotdecimal" decimals="INF">13,400</ix:nonFraction> square feet.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Hallbergmoos Lease provides for an initial rental term of&#xa0;<ix:nonNumeric contextRef="i_2020-02-29_StatementGeographicalAxis-HallbergmoosGermanyMember" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="c96254800" format="ixt-sec:duryear">12.5</ix:nonNumeric> years which commenced in <em style="font: inherit;"> February 2020 </em>when the leased property was delivered to Pieris GmbH. Pieris GmbH also has an option to extend the Hallbergmoos Lease for <ix:nonFraction id="c96254801" contextRef="d_2020-02-29_2020-02-29_LeaseContractualTermAxis-OfficeAndLaboratorySpaceMember_StatementGeographicalAxis-HallbergmoosGermanyMember" unitRef="Pure" name="pirs:NumberOfAgreementExtensionOptions" scale="0" format="ixt-sec:numwordsen" decimals="INF">two</ix:nonFraction> additional <ix:nonNumeric contextRef="i_2020-02-29_LeaseContractualTermAxis-OfficeAndLaboratorySpaceMember_StatementGeographicalAxis-HallbergmoosGermanyMember" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="c96254802" format="ixt-sec:durmonth">60</ix:nonNumeric>-month periods. The Company is <em style="font: inherit;">not</em> reasonably certain to exercise the option to extend the lease expiration beyond its current expiration date. Pieris GmbH <em style="font: inherit;"> may </em>sublease space within the leased property with lessor&#x2019;s consent, which <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be unreasonably withheld.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Monthly base rent for the <ix:nonFraction id="c96254805" contextRef="i_2020-02-29_LeaseContractualTermAxis-OfficeAndLaboratorySpaceMember_StatementGeographicalAxis-HallbergmoosGermanyMember" unitRef="SquareFoot" name="us-gaap:AreaOfRealEstateProperty" scale="0" format="ixt:numdotdecimal" decimals="INF">105,000</ix:nonFraction> square feet of the leased property, including parking spaces, totals approximately $<ix:nonFraction id="c96254806" contextRef="d_2020-02-01_2020-02-29_LeaseContractualTermAxis-OfficeAndLaboratorySpaceMember_StatementGeographicalAxis-HallbergmoosGermanyMember" unitRef="USD" name="pirs:LesseeOperatingLeaseMonthlyRentExpense" scale="6" format="ixt:numdotdecimal" decimals="-5">0.2</ix:nonFraction> million per month, which amount shall be adjusted starting on the <em style="font: inherit;">second</em> anniversary of the commencement date by an amount equal to the German consumer price index. In addition to the base rent, Pieris GmbH is also responsible for certain administrative and operational costs in accordance with the Hallbergmoos Lease. Pieris GmbH provided a security deposit of $<ix:nonFraction id="c96254808" contextRef="i_2020-02-29_LeaseContractualTermAxis-OfficeAndLaboratorySpaceMember_StatementGeographicalAxis-HallbergmoosGermanyMember" unitRef="USD" name="us-gaap:SecurityDeposit" scale="6" format="ixt:numdotdecimal" decimals="-5">0.8</ix:nonFraction> million at upon signing the lease agreement. The Company will serve as a guarantor for the Hallbergmoos Lease.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Hallbergmoos Lease included $<ix:nonFraction id="c96254809" contextRef="i_2019-03-31_LeaseContractualTermAxis-OfficeAndLaboratorySpaceMember_StatementGeographicalAxis-HallbergmoosGermanyMember" unitRef="USD" name="us-gaap:TenantImprovements" scale="6" format="ixt:numdotdecimal" decimals="-5">11.5</ix:nonFraction> million of tenant improvements allowance for normal tenant improvements which was incurred prior to commencing the lease. The Company capitalized the leasehold incentives which are included in Property and equipment, net on the Consolidated Balance Sheet and are amortized on a straight-line basis over the shorter of the useful life or the remaining lease term.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following table summarizes operating lease costs included in operating expenses (in thousands):</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:LeaseCostTableTextBlock" id="c56919BDE-C600-4831-8383-5A7DCF685D6C" escape="true" continuedAt="c91853370-4F33-4ECD-BB00-B09A7C950A5E">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Year Ended December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating lease costs</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254819" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:OperatingLeaseCost" scale="3" format="ixt:numdotdecimal" decimals="-3">1,356</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254820" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:OperatingLeaseCost" scale="3" format="ixt:numdotdecimal" decimals="-3">1,483</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Variable lease costs (1)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96254821" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:VariableLeaseCost" scale="3" format="ixt:numdotdecimal" decimals="-3">737</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96254822" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:VariableLeaseCost" scale="3" format="ixt:numdotdecimal" decimals="-3">739</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total lease cost</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96254823" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:LeaseCost" scale="3" format="ixt:numdotdecimal" decimals="-3">2,093</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96254824" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:LeaseCost" scale="3" format="ixt:numdotdecimal" decimals="-3">2,222</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td colspan="4" style="vertical-align:top;width:100%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(<em style="font: inherit;">1</em>) Variable lease costs include certain additional charges for operating costs, including insurance, maintenance, taxes, utilities and other costs incurred, which are billed based on both usage and as a percentage of the Company&#x2019;s share of total square footage. These costs also included costs associated with increases rent expense based on CPI.</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following table summarizes the weighted-average remaining lease term and discount rate:</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:continuation id="c91853370-4F33-4ECD-BB00-B09A7C950A5E">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 771px; text-align: center;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 187px; text-align: center;"><b><em style="font: inherit;">As of December 31, 2022</em></b></td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 771px;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted-average remaining lease term (years)</p> </td><td style="width: 187px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: right;"><ix:nonNumeric contextRef="i_2022-12-31" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="c96254826" format="ixt-sec:duryear">9.6</ix:nonNumeric></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 771px;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted-average discount rate</p> </td><td style="width: 187px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: right;"><ix:nonFraction id="c96254827" contextRef="i_2022-12-31" unitRef="Pure" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" format="ixt:numdotdecimal" decimals="3">10.5</ix:nonFraction>%</td></tr>
</tbody></table>
   </ix:continuation>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cash paid for amounts included in the measurement of the lease liabilities were $<ix:nonFraction id="c96254811" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:OperatingLeasePayments" scale="6" format="ixt:numdotdecimal" decimals="-5">2.4</ix:nonFraction> million and $<ix:nonFraction id="c96254812" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:OperatingLeasePayments" scale="6" format="ixt:numdotdecimal" decimals="-5">2.6</ix:nonFraction> million for the year&#xa0;ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em>, respectively.</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">35</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of <em style="font: inherit;"> December 31, 2022</em>, the maturities of the Company&#x2019;s operating lease liabilities and future minimum lease payments were as follows (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-12-31" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="c2344216" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Total</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254829" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" format="ixt:numdotdecimal" decimals="-3">2,116</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">2024</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254830" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" format="ixt:numdotdecimal" decimals="-3">2,116</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">2025</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254831" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" format="ixt:numdotdecimal" decimals="-3">2,116</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">2026</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254832" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" format="ixt:numdotdecimal" decimals="-3">2,116</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">2027</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254833" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" format="ixt:numdotdecimal" decimals="-3">2,116</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Thereafter</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96254834" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="3" format="ixt:numdotdecimal" decimals="-3">9,699</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total undiscounted lease payments</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c96254835" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" format="ixt:numdotdecimal" decimals="-3">20,279</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; vertical-align: top;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Less: present value adjustment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c96254836" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" format="ixt:numdotdecimal" decimals="-3">7,176</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; vertical-align: top;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Present value of lease liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c96254837" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:OperatingLeaseLiability" scale="3" format="ixt:numdotdecimal" decimals="-3">13,103</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  </ix:nonNumeric>
  <div class="LAST-PAGE-BREAK">
   <div class="PGFTR">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       F-36
     </div>
    </div>
   </div>
  </div>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.38
<SEQUENCE>2
<FILENAME>ex_494066.htm
<DESCRIPTION>EXHIBIT 10.38
<TEXT>
<html>
	<head>

		<title>
			ex_494066.htm
		</title><!-- Generated by ThunderDome Portal 3/28/2023 1:43:59 PM -->
		<meta charset="utf-8" />
		<meta name="format-detection" content="telephone=no" />

	</head>
	<body style="font-size:10pt;font-family:&#39;Times New Roman&#39;;padding:0in .1in;">
		<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt 0pt 0pt 108pt;text-indent:-108pt;"><b>EXHIBIT 10.38</b></p>
		<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 108pt;text-indent:-108pt;"><b>PIERIS PHARMACEUTICALS, INC.</b></p>
		<p style="font-family:&#39;Times New Roman&#39;;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
		<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 108pt;text-indent:-108pt;"><b>AMENDED AND RESTATED</b></p>
		<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 108pt;text-indent:-108pt;"><b>NON-EMPLOYEE DIRECTOR COMPENSATION POLICY</b></p>
		<p style="font-family:&#39;Times New Roman&#39;;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
		<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;">The Board of Directors of Pieris Pharmaceuticals, Inc. (the &#8220;<u>Company</u>&#8221;) has approved the following Amended and Restated Non-Employee Director Compensation Policy (this &#8220;<u>Policy</u>&#8221;) which establishes compensation to be paid to non-employee directors of the Company, effective as of March 22, 2023 (&#8220;<u>Effective Time</u>&#8221;), to provide an inducement to obtain and retain the services of qualified persons to serve as members of the Company&#8217;s Board of Directors.</p>
		<p style="font-family:&#39;Times New Roman&#39;;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
		<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Applicable Persons</b></p>
		<p style="font-family:&#39;Times New Roman&#39;;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
		<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;">This Policy shall apply to each director of the Company who is not an employee of the Company or any Affiliate (each, a &#8220;<u>Non-Employee Director</u>&#8221;).  &#8220;<u>Affiliate</u>&#8221; shall mean an entity which is a direct or indirect parent or subsidiary of the Company, as determined pursuant to Section 424 of the Internal Revenue Code of 1986, as amended. &#8220;<u>Stock Plan</u>&#8221; shall mean the Company&#8217;s then-current Employee, Director, and Consultant Equity Incentive Plan, and as of the Effective Time the 2020 Employee, Director, and Consultant Equity Incentive Plan, as amended.</p>
		<p style="font-family:&#39;Times New Roman&#39;;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
		<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Stock Option Grants </b></p>
		<p style="font-family:&#39;Times New Roman&#39;;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
		<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;">All stock option amounts set forth herein shall be subject to automatic adjustment in the event of any stock split or other recapitalization affecting the Company&#8217;s common stock, par value $0.001 per share (the&nbsp;&#8220;<u>Common Stock</u>&#8221;).</p>
		<p style="font-family:&#39;Times New Roman&#39;;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
		<p style="font-family:&#39;Times New Roman&#39;;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
		<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;"><u>Annual Stock Option Grants</u></p>
		<p style="font-family:&#39;Times New Roman&#39;;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
		<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;">  Each calendar year, (i) each Non-Employee Director shall be automatically granted a non-qualified stock option to purchase 40,000 shares of Common Stock under the Stock Plan on the date of the annual meeting of the Board of Directors coincident with or immediately following the Company&#8217;s annual meeting of stockholders (the &#8220;<u>Annual Stockholders Meeting</u>&#8221;), and (ii) the Chairperson shall be automatically granted an additional non-qualified stock option to purchase 5,000 shares of Common Stock under the Stock Plan (together, the &#8220;<u>Annual Director Awards</u>&#8221;). To the extent that the Non-Employee Director or Chairperson, as applicable, has served in that position for less than one year, then the Annual Director Award shall be pro-rated with respect to such Non-Employee Director or Chairperson.</p>
		<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p>
		<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;"><u>Initial Stock Option Grant for Newly Appointed or Elected Directors and Chairperson</u></p>
		<p style="font-family:&#39;Times New Roman&#39;;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
		<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;">Each new Non-Employee Director shall be automatically granted a non-qualified stock option to purchase 80,000 shares of Common Stock under the Stock Plan at the first regularly scheduled meeting of the Board of Directors on or after his or her initial appointment or election to the Board of Directors (the &#8220;<u>Initial Director Award</u>&#8221;).   </p>
		<p style="font-family:&#39;Times New Roman&#39;;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
		<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;"><u>Terms for All Option Grants</u></p>
		<p style="font-family:&#39;Times New Roman&#39;;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
		<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;">Unless otherwise specified in this Policy or by the Board of Directors or the Compensation Committee at the time of grant, all options granted under this Policy shall: (i) vest, in the case of (A) the Annual Director Awards, at the end of the &#8220;<u>Directors</u><u>&#8217;</u><u> Compensation Year</u>&#8221;, which shall be defined as the approximately one-year period beginning on the date of each regular Annual Stockholders Meeting and ending on the date of the next regular Annual Stockholders Meeting, subject to the Non-Employee Director&#8217;s continued service on the Board of Directors through the applicable Directors&#8217; Compensation Year and (B) the Initial Director Award, as to thirty-three percent (33%) of the shares underlying the Initial Director Award on the first anniversary of the date of the Non-Employee Director&#8217;s initial appointment or election as Director on the Board of Directors (the&nbsp;&#8220;<u>Initial Vesting Date</u>&#8221;), with the remaining sixty-seven percent (67%) of the shares underlying the Initial Director Award vesting in eight (8) equal quarterly installments at the end of each full calendar quarter following the Initial Vesting Date, subject to the Non-Employee Director&#8217;s continued service on the Board of Directors on the vesting date; (ii) have an exercise price equal to the fair market value of the Common Stock on the grant date, as determined in the Stock Plan; (iii) terminate ten years after the grant date; and (iv) contain such other terms and conditions as set forth in the form of option agreement approved by the Board of Directors or the Compensation Committee prior to the grant date.</p>
		<p style="font-family:&#39;Times New Roman&#39;;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
		<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Annual Fees</b></p>
		<p style="font-family:&#39;Times New Roman&#39;;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
		<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Each Non-Employee serving on the Board of Directors and the Audit Committee, Compensation Committee, Nominating and Corporate Governance Committee, and/or Science and Technology Committee, as applicable, shall be entitled to the following annual amounts (the &#8220;<u>Annual Fees</u>&#8221;):   </p>
		<p style="font-family:&#39;Times New Roman&#39;;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
		<table border="0" cellspacing="0" cellpadding="0" style="font-family:Times New Roman;font-size:10pt;width:75.5065359477124%;margin-left:0pt;margin-right:auto;">
			<tr>
				<td style="border-bottom:solid 1px #000000;vertical-align:top;width:34%;"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Board of Directors or Committee of Board of Directors</b></p>
				</td>
				<td style="border-bottom:solid 1px #000000;vertical-align:top;width:33.6%;"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Annual Retainer Amount for Member</b></p>
				</td>
				<td style="border-bottom:solid 1px #000000;vertical-align:top;width:33.6%;"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Annual Retainer Amount for Chair</b></p>
				</td>

			</tr>
			<tr>
				<td style="border-bottom:solid 1px #000000;vertical-align:top;width:34%;"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Board of Directors</p>
				</td>
				<td style="border-bottom:solid 1px #000000;vertical-align:top;width:33.6%;"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">$35,000</p>
				</td>
				<td style="border-bottom:solid 1px #000000;vertical-align:top;width:33.6%;"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">$30,000* </p>
				</td>

			</tr>
			<tr>
				<td style="border-bottom:solid 1px #000000;vertical-align:top;width:34%;"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Audit Committee</p>
				</td>
				<td style="border-bottom:solid 1px #000000;vertical-align:top;width:33.6%;"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">$7,500</p>
				</td>
				<td style="border-bottom:solid 1px #000000;vertical-align:top;width:33.6%;"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">$15,000**</p>
				</td>

			</tr>
			<tr>
				<td style="border-bottom:solid 1px #000000;vertical-align:top;width:34%;"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Science and Technology Committee</p>
				</td>
				<td style="border-bottom:solid 1px #000000;vertical-align:top;width:33.6%;"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">$5,000</p>
				</td>
				<td style="border-bottom:solid 1px #000000;vertical-align:top;width:33.6%;"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">$10,000**</p>
				</td>

			</tr>
			<tr>
				<td style="border-bottom:solid 1px #000000;vertical-align:top;width:34%;"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Compensation Committee</p>
				</td>
				<td style="border-bottom:solid 1px #000000;vertical-align:top;width:33.6%;"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">$5,000</p>
				</td>
				<td style="border-bottom:solid 1px #000000;vertical-align:top;width:33.6%;"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">$10,000**</p>
				</td>

			</tr>
			<tr>
				<td style="border-bottom:solid 1px #000000;vertical-align:top;width:34%;"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Nominating and Corporate Governance Committee</p>
				</td>
				<td style="border-bottom:solid 1px #000000;vertical-align:top;width:33.6%;"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">$4,000</p>
				</td>
				<td style="border-bottom:solid 1px #000000;vertical-align:top;width:33.6%;"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">$8,000**</p>
				</td>

			</tr>

		</table>
		<p style="font-family:&#39;Times New Roman&#39;;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
		<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">* The annual retainer amount for the Chair of the Board of Directors is in addition to the annual retainer amount for a Member of the Board of Directors.</p>
		<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">** Annual retainer amounts for the Chair of Committees of the Board of Directors are in lieu of the annual retainer amount for a Member of the applicable Committee of the Board of Directors.</p>
		<p style="font-family:&#39;Times New Roman&#39;;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
		<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;">Except as otherwise set forth in this Policy, all Annual Fees shall be paid for the period from January 1 through December 31 of each year. Such Annual Fees shall be paid in cash or a grant of an option to purchase Common Stock under the Stock Plan, at the election of each Non-Employee Director, as follows:</p>
		<p style="font-family:&#39;Times New Roman&#39;;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
		<table border="0" cellspacing="0" cellpadding="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
			<tr>
				<td style="width:54pt;">&nbsp;</td>
				<td style="vertical-align:top;width:18pt;"><p style="font-family:&#39;Times New Roman&#39;;font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
				</td>
				<td style="vertical-align:top;"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">cash in the amount of each Non-Employee Director&#8217;s Annual Fees; </p>
				</td>

			</tr>

		</table>
		<p style="font-family:&#39;Times New Roman&#39;;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
		<table border="0" cellspacing="0" cellpadding="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
			<tr>
				<td style="width:54pt;">&nbsp;</td>
				<td style="vertical-align:top;width:18pt;"><p style="font-family:&#39;Times New Roman&#39;;font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
				</td>
				<td style="vertical-align:top;"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">an option to purchase such number of shares of Common Stock as is equal to the full dollar amount of each Non-Employee Director&#8217;s Annual Fees (as calculated below under &#8220;Calculation of Shares and Grant Terms&#8221;); or</p>
				</td>

			</tr>

		</table>
		<p style="font-family:&#39;Times New Roman&#39;;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
		<table border="0" cellspacing="0" cellpadding="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
			<tr>
				<td style="width:54pt;">&nbsp;</td>
				<td style="vertical-align:top;width:18pt;"><p style="font-family:&#39;Times New Roman&#39;;font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
				</td>
				<td style="vertical-align:top;"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">or a combination of cash and options to purchase shares of Common Stock in a percentage to be specified by the Non-Employee Director.</p>
				</td>

			</tr>

		</table>
		<p style="font-family:&#39;Times New Roman&#39;;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;">&nbsp;</p>
		<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;"><u>Election</u></p>
		<p style="font-family:&#39;Times New Roman&#39;;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
		<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;">Each Non-Employee Director shall make an annual election on the form provided by the Company, indicating the combination of cash and/or Common Stock elected in the year prior to the payment, indicating his or her election for the following calendar year.  If no election has been made prior to the first date of the calendar year, then the Non-Employee Director shall receive all Annual Fees in cash. Each newly elected or appointed Non-Employee Director shall make an election prior to the beginning of the next calendar quarter after his or her initial appointment or election.  </p>
		<p style="font-family:&#39;Times New Roman&#39;;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
		<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;"><u>Payments</u></p>
		<p style="font-family:&#39;Times New Roman&#39;;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
		<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;">Payments payable to Non-Employee Directors shall be paid quarterly in arrears promptly following the end of each calendar quarter, provided that (i) the amount of such payment shall be prorated for any portion of such quarter that such director was not serving on the Board or a committee or, in the case of the Annual Fees paid for service as a chairperson, as a chairperson, and (ii) no fee shall be payable in respect of any period prior to the date such director was elected to the Board or a committee or, in the case of the Annual Fees paid for service as a chairperson, as a chairperson.</p>
		<p style="font-family:&#39;Times New Roman&#39;;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
		<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;"><u>Calculation of Shares and Grant Terms</u></p>
		<p style="font-family:&#39;Times New Roman&#39;;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
		<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;">If an option to purchase Common Stock is to be received as payment, the number of shares underlying such option shall equal the Black Scholes value of the options computed in accordance with FASB Topic 718 on the 25th day of the month following the end of each calendar quarter (the &#8220;<u>Calculation Date</u>&#8221;) (rounded down to the nearest whole number so that no fractional shares shall be issued).  The option shall be automatically and without any further action required by the Board of Directors issued as of the Calculation Date and shall be fully vested as of the date of grant.</p>
		<p style="font-family:&#39;Times New Roman&#39;;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
		<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Expenses</b></p>
		<p style="font-family:&#39;Times New Roman&#39;;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
		<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;">Upon presentation of documentation of such expenses reasonably satisfactory to the Company, each Non-Employee Director shall be reimbursed for his or her reasonable out-of-pocket business expenses incurred in connection with attending meetings of the Board of Directors and committees thereof or in connection with other business related to the Board of Directors. </p>
		<p style="font-family:&#39;Times New Roman&#39;;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
		<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 108pt;text-indent:-108pt;"><b>Amendments</b></p>
		<p style="font-family:&#39;Times New Roman&#39;;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
		<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;">The Compensation Committee shall periodically review this Policy to assess whether any amendments in the type and amount of compensation provided herein should be made and shall make recommendations to the Board of Directors for its approval of any amendments to this Policy.</p>

	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>ex_451890.htm
<DESCRIPTION>EXHIBIT 21.1
<TEXT>
<html><head>
	<title>HTML Editor</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><b>Exhibit 21.1</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Subsidiaries</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: Times New Roman; font-size: 10pt; width: 100%;">

		<tr>
			<td style="vertical-align: middle; width: 47%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 6%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 47%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="1" style="vertical-align: bottom; width: 47%; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Entity</b></p>
			</td>
			<td style="vertical-align: bottom; width: 6%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: bottom; width: 47%; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Jurisdiction of Organization</b></p>
			</td>
		</tr>
		<tr>
			<td colspan="1" style="vertical-align: top; width: 47%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Pieris Pharmaceuticals GmbH</p>
			</td>
			<td style="vertical-align: top; width: 6%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: top; width: 47%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Germany</p>
			</td>
		</tr>
		<tr>
			<td colspan="1" style="vertical-align: top; width: 47%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Pieris Australia Pty Limited</p>
			</td>
			<td style="vertical-align: top; width: 6%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: top; width: 47%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Australia</p>
			</td>
		</tr>
		<tr>
			<td colspan="1" style="vertical-align: top; width: 47%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Pieris Pharmaceuticals Securities Corporation</p>
			</td>
			<td style="vertical-align: top; width: 6%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: top; width: 47%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Massachusetts</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>ex_451891.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<html><head>
	<title>HTML Editor</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><b>Exhibit 23.1</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Consent of Independent Registered Public Accounting Firm</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">We consent to the incorporation by reference in the following Registration Statements:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(1)</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Registration Statement (Form S-3 Nos. 333-212439 and 333-235350),</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(2)</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Registration Statement (Form S-8 No. 333-204487) pertaining to the Pieris Pharmaceuticals, Inc. 2014 Employee, Director and Consultant Equity Incentive Plan,</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(3)</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Registration Statement (Form S-8 No. 333-209308) pertaining to the Pieris Pharmaceuticals, Inc. 2014 Employee, Director and Consultant Equity Incentive Plan and Inducement Stock Option Award for Louis Matis, M.D.,</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(4)</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Registration Statement (Form S-8 No. 333-213771) pertaining to the Pieris Pharmaceuticals, Inc. 2016 Employee, Director and Consultant Equity Incentive Plan,</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(5)</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Registration Statement (Post-Effective Amendment to Form S-1 on Form S-3 No. 333-202123),</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(6)</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Registration Statement (Form S-8 No. 333-226733) pertaining to the Pieris Pharmaceuticals, Inc. 2018 Employee, Director and Consultant Equity Incentive Plan,</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(7)</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Registration Statement (Form S-8 No. 333-226735) pertaining to the Pieris Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan,</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(8)</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Registration Statement (Form S-8 No. 333-233194) pertaining to the Pieris Pharmaceuticals, Inc. 2019 Employee, Director and Consultant Equity Incentive Plan,</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(9)</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Registration Statement (Form S-8 No. 333-234625) pertaining to the Non-Qualified Stock Option Agreement, dated August 30, 2019,</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(10)</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Registration Statements (Form S-8 No. 333-243735) pertaining to the Pieris Pharmaceuticals, Inc. 2020 Employee, Director and Consultant Equity Incentive Plan,</p>
			</td>
		</tr>
		<tr>
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">(11)</td>
			<td style="width: auto;">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Registration Statement (Form S-3 No. 333-256218 and 333-258497),&nbsp;&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt; vertical-align: top;">(12)</td>
			<td style="width: auto;">Registration Statement&nbsp;(Form S-8 No. 333-258502) pertaining to the Pieris Pharmaceuticals, Inc. 2020 Employee, Director and Consultant Equity Incentive Plan, as amended and the Inducement Stock Option Award for Tim Demuth, M.D., Ph.D, and</td>
		</tr>
		<tr>
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt; vertical-align: top;">(13)</td>
			<td style="width: auto;">Registration Statement&nbsp;(Form S-8 No. 333-266539) pertaining to the Pieris Pharmaceuticals, Inc. 2020 Employee, Director and Consultant Equity Incentive Plan, as amended;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">of our report dated March 31, 2023, with respect to the consolidated financial statements of Pieris Pharmaceuticals, Inc. included in this Annual Report (Form 10-K) of Pieris Pharmaceuticals, Inc. for the year ended <a data-tblloc="5x1" data-tblname="316342" data-tblv="40" id="led316342F202210301669846971014">December 31, 2022</a>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">/s/ Ernst&nbsp;&amp; Young LLP</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Boston, Massachusetts</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">March 31, 2023</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>ex_451892.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html><head>
	<title>HTML Editor</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; padding:0in .1in;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Exhibit 31.1</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">CERTIFICATIONS UNDER SECTION 302</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">I, Stephen S. Yoder, certify that:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">1. I have reviewed this annual report on Form 10-K of Pieris Pharmaceuticals, Inc.;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">c) evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">d) disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Dated: <a data-tblloc="21x1" data-tblname="316342" data-tblv="40" id="led316342F202210301669847481834">March 31, 2023</a></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Stephen S. Yoder</p>

<hr class="hr-custom" style="text-align: left;height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 0pt auto 0pt 0pt;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Stephen S. Yoder</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Title:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chief&nbsp;Executive&nbsp;Officer&nbsp;and&nbsp;President&nbsp;(principal executive officer)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>ex_451893.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<html><head>
	<title>HTML Editor</title>

	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; padding:0in .1in;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Exhibit 31.2</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">CERTIFICATIONS UNDER SECTION 302</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">I, Thomas Bures, certify that:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">1. I have reviewed this annual report on Form 10-K of Pieris Pharmaceuticals, Inc.;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">c) evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">d) disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Dated: <a data-tblloc="21x1" data-tblname="316342" data-tblv="40" id="led316342F202210301669847449869">March 31, 2023</a></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Thomas Bures</p>

<hr class="hr-custom" style="text-align: left;height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 0pt auto 0pt 0pt;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Thomas Bures</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Title:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Senior VP, Chief Financial Officer and Treasurer&nbsp;(principal financial officer)</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>ex_451894.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html><head>
	<title>HTML Editor</title>

	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="margin: 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b>Exhibit 32.1</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">CERTIFICATIONS UNDER SECTION 906</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a)&nbsp;and (b) of section 1350, chapter 63 of title 18, United States Code), the undersigned officer of Pieris Pharmaceuticals, Inc., a Nevada corporation (the &#8220;Company&#8221;), does hereby certify, to such officer&#8217;s knowledge, that:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">The Annual Report for the year ended <a data-tblloc="5x1" data-tblname="316342" data-tblv="40" id="led316342F202210301669847910384">December 31, 2022</a> (the &#8220;Form 10-K&#8221;) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="text-indent: 0; width: 100%;font-family: 'Times New Roman', Times, serif; font-size: 10pt">

		<tr>
			<td align="left" style="text-align: left; width: 52%;" valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0;">Dated: <a data-tblloc="21x1" data-tblname="316342" data-tblv="40" id="led316342F202210301669847586035">March 31, 2023</a></p>
			</td>
			<td align="left" nowrap="nowrap" style="border-bottom: 1px solid rgb(0, 0, 0); width: 36%;" valign="top" width="35%">/s/ Stephen&nbsp;S.&nbsp;Yoder</td>
			<td style="width: 12%;" valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 52%;" valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 36%;" valign="top" width="35%">
			<p style="margin-top: 0; margin-bottom: 0;">Stephen S. Yoder<font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 12%;" valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 52%;" valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 36%;" valign="top" width="35%">
			<p style="margin-top: 0; margin-bottom: 0;">Title:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chief&nbsp;Executive&nbsp;Officer&nbsp;and&nbsp;President<font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>(principal executive officer)</p>
			</td>
			<td style="width: 12%;" valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>ex_451895.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<html><head>
	<title>HTML Editor</title>

	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><b>Exhibit 32.2</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">CERTIFICATIONS UNDER SECTION 906</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a)&nbsp;and (b) of section 1350, chapter 63 of title 18, United States Code), the undersigned officer of Pieris Pharmaceuticals, Inc., a Nevada corporation (the &#8220;Company&#8221;), does hereby certify, to such officer&#8217;s knowledge, that:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">The Annual Report for the year ended <a data-tblloc="5x1" data-tblname="316342" data-tblv="40" id="led316342F202210301669848018501">December 31, 2022</a> (the &#8220;Form 10-K&#8221;) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="text-indent: 0; width: 100%;font-family: 'Times New Roman', Times, serif; font-size: 10pt">

		<tr>
			<td align="left" style="text-align: left; width: 52%;" valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0;">Dated: <a data-tblloc="21x1" data-tblname="316342" data-tblv="40" id="led316342F202210301669848082068">March 31, 2023</a></p>
			</td>
			<td align="left" nowrap="nowrap" style="border-bottom: 1px solid rgb(0, 0, 0); width: 36%;" valign="top" width="35%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">/s/&nbsp;</font>Thomas Bures</p>
			</td>
			<td style="width: 12%;" valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 52%;" valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 36%;" valign="top" width="35%">
			<p style="margin-top: 0; margin-bottom: 0;">Thomas Bures<font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 12%;" valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 52%;" valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 36%;" valign="top" width="35%">
			<p style="margin-top: 0; margin-bottom: 0;">Title:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Senior VP, Chief Financial Officer and Treasurer</p>

			<p style="margin-top: 0; margin-bottom: 0;">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;(principal financial officer)</p>
			</td>
			<td style="width: 12%;" valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>pirs-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 06:44PM UTC 2023-03-31--><xsd:schema xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:pirs="http://www.pieris.com/20221231" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.pieris.com/20221231">
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/naics/2022" schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xsd:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd"/>
  <xsd:import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd"/>
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/exch/2022" schemaLocation="https://xbrl.sec.gov/exch/2022/exch-2022.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/currency/2022" schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xsd:import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd"/>
  <xsd:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pirs-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pirs-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pirs-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pirs-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="statement-document-and-entity-information" roleURI="http://www.pieris.com/20221231/role/statement-document-and-entity-information">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-balance-sheets" roleURI="http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">001 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-balance-sheets-parentheticals" roleURI="http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">002 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-operations-and-comprehensive-loss" roleURI="http://www.pieris.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">003 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-changes-in-stockholders-equity" roleURI="http://www.pieris.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">004 - Statement - Consolidated Statements of Changes in Stockholders' Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-changes-in-stockholders-equity-parentheticals" roleURI="http://www.pieris.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">005 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-cash-flows" roleURI="http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">006 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-cash-flows-parentheticals" roleURI="http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">007 - Statement - Consolidated Statements of Cash Flows (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-corporate-information-" roleURI="http://www.pieris.com/20221231/role/statement-note-1-corporate-information-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">008 - Disclosure - Note 1 - Corporate Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-summary-of-significant-accounting-policies" roleURI="http://www.pieris.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">009 - Disclosure - Note 2 - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-revenue-" roleURI="http://www.pieris.com/20221231/role/statement-note-3-revenue-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">010 - Disclosure - Note 3 - Revenue</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-grant-income" roleURI="http://www.pieris.com/20221231/role/statement-note-4-grant-income">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">011 - Disclosure - Note 4 - Grant Income</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-cash-cash-equivalents-and-investments" roleURI="http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">012 - Disclosure - Note 5 - Cash, Cash Equivalents and Investments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-property-and-equipment-net" roleURI="http://www.pieris.com/20221231/role/statement-note-6-property-and-equipment-net">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">013 - Disclosure - Note 6 - Property and Equipment, Net</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-accrued-expenses" roleURI="http://www.pieris.com/20221231/role/statement-note-7-accrued-expenses">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">014 - Disclosure - Note 7 - Accrued Expenses</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-income-taxes" roleURI="http://www.pieris.com/20221231/role/statement-note-8-income-taxes">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">015 - Disclosure - Note 8 - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-stockholders-equity" roleURI="http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">016 - Disclosure - Note 9 - Stockholders' Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-net-loss-per-share" roleURI="http://www.pieris.com/20221231/role/statement-note-10-net-loss-per-share">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">017 - Disclosure - Note 10 - Net Loss Per Share</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-stock-and-employee-benefit-plans" roleURI="http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">018 - Disclosure - Note 11 - Stock and Employee Benefit Plans</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-license-agreement" roleURI="http://www.pieris.com/20221231/role/statement-note-12-license-agreement">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">019 - Disclosure - Note 12 - License Agreement</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-leases" roleURI="http://www.pieris.com/20221231/role/statement-note-13-leases">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">020 - Disclosure - Note 13 - Leases</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-significant-accounting-policies-policies" roleURI="http://www.pieris.com/20221231/role/statement-significant-accounting-policies-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">021 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-summary-of-significant-accounting-policies-tables" roleURI="http://www.pieris.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">022 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-revenue-tables" roleURI="http://www.pieris.com/20221231/role/statement-note-3-revenue-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">023 - Disclosure - Note 3 - Revenue (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-cash-cash-equivalents-and-investments-tables" roleURI="http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">024 - Disclosure - Note 5 - Cash, Cash Equivalents and Investments (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-property-and-equipment-net-tables" roleURI="http://www.pieris.com/20221231/role/statement-note-6-property-and-equipment-net-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">025 - Disclosure - Note 6 - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-accrued-expenses-tables" roleURI="http://www.pieris.com/20221231/role/statement-note-7-accrued-expenses-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">026 - Disclosure - Note 7 - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-income-taxes-tables" roleURI="http://www.pieris.com/20221231/role/statement-note-8-income-taxes-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">027 - Disclosure - Note 8 - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-stock-and-employee-benefit-plans-tables" roleURI="http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">028 - Disclosure - Note 11 - Stock and Employee Benefit Plans (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-leases-tables" roleURI="http://www.pieris.com/20221231/role/statement-note-13-leases-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">029 - Disclosure - Note 13 - Leases (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-corporate-information-details-textual" roleURI="http://www.pieris.com/20221231/role/statement-note-1-corporate-information-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">030 - Disclosure - Note 1 - Corporate Information (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-summary-of-significant-accounting-policies-schedule-of-property-plant-and-equipment-useful-lives-details" roleURI="http://www.pieris.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-property-plant-and-equipment-useful-lives-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">031 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment, Useful Lives (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-revenue-details-textual" roleURI="http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">032 - Disclosure - Note 3 - Revenue (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-revenue-disaggregation-of-revenue-details" roleURI="http://www.pieris.com/20221231/role/statement-note-3-revenue-disaggregation-of-revenue-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">033 - Disclosure - Note 3 - Revenue - Disaggregation of Revenue (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-revenue-potential-milestone-payments-received-details" roleURI="http://www.pieris.com/20221231/role/statement-note-3-revenue-potential-milestone-payments-received-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">034 - Disclosure - Note 3 - Revenue - Potential Milestone Payments Received (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-grant-income-details-textual" roleURI="http://www.pieris.com/20221231/role/statement-note-4-grant-income-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">035 - Disclosure - Note 4 - Grant Income (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-cash-cash-equivalents-and-investments-details-textual" roleURI="http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">036 - Disclosure - Note 5 - Cash, Cash Equivalents and Investments (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-cash-cash-equivalents-and-investments-cash-equivalents-and-investments-carried-at-fair-value-details" roleURI="http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-cash-equivalents-and-investments-carried-at-fair-value-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">037 - Disclosure - Note 5 - Cash, Cash Equivalents and Investments - Cash Equivalents and Investments Carried at Fair Value (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-cash-cash-equivalents-and-investments-investments-details" roleURI="http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-investments-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">038 - Disclosure - Note 5 - Cash, Cash Equivalents and Investments - Investments (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-property-and-equipment-net-details-textual" roleURI="http://www.pieris.com/20221231/role/statement-note-6-property-and-equipment-net-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">039 - Disclosure - Note 6 - Property and Equipment, Net (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-property-and-equipment-net-property-and-equipment-details" roleURI="http://www.pieris.com/20221231/role/statement-note-6-property-and-equipment-net-property-and-equipment-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">040 - Disclosure - Note 6 - Property and Equipment, Net - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-accrued-expenses-accrued-expenses-and-other-current-liabilities-details" roleURI="http://www.pieris.com/20221231/role/statement-note-7-accrued-expenses-accrued-expenses-and-other-current-liabilities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">041 - Disclosure - Note 7 - Accrued Expenses - Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-income-taxes-details-textual" roleURI="http://www.pieris.com/20221231/role/statement-note-8-income-taxes-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">042 - Disclosure - Note 8 - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details" roleURI="http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">043 - Disclosure - Note 8 - Income Taxes - Schedule of Income Before Income Tax Domestic and Foreign (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details" roleURI="http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">044 - Disclosure - Note 8 - Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" roleURI="http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">045 - Disclosure - Note 8 - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details" roleURI="http://www.pieris.com/20221231/role/statement-note-8-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">046 - Disclosure - Note 8 - Income Tax - Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-income-taxes-summary-of-income-tax-contingencies-details" roleURI="http://www.pieris.com/20221231/role/statement-note-8-income-taxes-summary-of-income-tax-contingencies-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">047 - Disclosure - Note 8 - Income Taxes - Summary of Income Tax Contingencies (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-stockholders-equity-details-textual" roleURI="http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">048 - Disclosure - Note 9 - Stockholders' Equity (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-net-loss-per-share-details-textual" roleURI="http://www.pieris.com/20221231/role/statement-note-10-net-loss-per-share-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">049 - Disclosure - Note 10 - Net Loss Per Share (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-stock-and-employee-benefit-plans-details-textual" roleURI="http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">050 - Disclosure - Note 11 - Stock and Employee Benefit Plans (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-stock-and-employee-benefit-plans-schedule-of-sharebased-payment-award-stock-options-details" roleURI="http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-schedule-of-sharebased-payment-award-stock-options-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">051 - Disclosure - Note 11 - Stock and Employee Benefit Plans - Schedule of Share-based Payment Award, Stock Options (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-stock-and-employee-benefit-plans-stock-options-activity-details" roleURI="http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-stock-options-activity-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">052 - Disclosure - Note 11 - Stock and Employee Benefit Plans - Stock Options Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-stock-and-employee-benefit-plans-schedule-of-employee-service-sharebased-compensation-costs-details" roleURI="http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-schedule-of-employee-service-sharebased-compensation-costs-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">053 - Disclosure - Note 11 - Stock and Employee Benefit Plans - Schedule of Employee Service Share-based Compensation Costs (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-leases-details-textual" roleURI="http://www.pieris.com/20221231/role/statement-note-13-leases-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">054 - Disclosure - Note 13 - Leases (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-leases-operating-lease-costs-details" roleURI="http://www.pieris.com/20221231/role/statement-note-13-leases-operating-lease-costs-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">055 - Disclosure - Note 13 - Leases - Operating Lease Costs (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-leases-maturities-of-operating-lease-liabilities-details" roleURI="http://www.pieris.com/20221231/role/statement-note-13-leases-maturities-of-operating-lease-liabilities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">056 - Disclosure - Note 13 - Leases - Maturities of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="pirs_AccruedAccountsPayableCurrent" name="AccruedAccountsPayableCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="pirs_AccruedCollaborationCostsCurrent" name="AccruedCollaborationCostsCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="pirs_AccruedLiabilitiesAndOtherCurrentLiabilitiesMember" name="AccruedLiabilitiesAndOtherCurrentLiabilitiesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="pirs_AccruedLiabilitiesAndOtherLiabilitiesCurrent" name="AccruedLiabilitiesAndOtherLiabilitiesCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="pirs_AccruedLicenseObligationsCurrent" name="AccruedLicenseObligationsCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="pirs_AccruedResearchAndDevelopmentCosts" name="AccruedResearchAndDevelopmentCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="pirs_AdditionalOtherResearchServicesMember" name="AdditionalOtherResearchServicesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="pirs_AgreementTerminationNoticePeriodUponOfBreachOfPaymentObligations" name="AgreementTerminationNoticePeriodUponOfBreachOfPaymentObligations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="pirs_AmendedCollaborationAgreementResaleOfStockPeriod" name="AmendedCollaborationAgreementResaleOfStockPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_AntibodyTargetSwapMember" name="AntibodyTargetSwapMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_AstraZenecaABMember" name="AstraZenecaABMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_AtTheMarketOfferingMember" name="AtTheMarketOfferingMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_BPAssetsXIIIncMember" name="BPAssetsXIIIncMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_BostonMassachusettsMember" name="BostonMassachusettsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_BostonPharmaceuticalsMember" name="BostonPharmaceuticalsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="pirs_CashEquivalentsAndInvestments" name="CashEquivalentsAndInvestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="pirs_CodevelopmentCollaborationProductCollaborationMember" name="CodevelopmentCollaborationProductCollaborationMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="pirs_CollaborativeArrangementAllocableArrangementConsiderationAllocation" name="CollaborativeArrangementAllocableArrangementConsiderationAllocation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_ConversionOfCommonStockIntoSeriesEPreferredStockMember" name="ConversionOfCommonStockIntoSeriesEPreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_ConversionOfPreferredStockMember" name="ConversionOfPreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_ConversionOfSeriesEPreferredStockMember" name="ConversionOfSeriesEPreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="pirs_ConvertiblePreferredStockBeneficialOwnershipLimitationNoticePeriodBeforeIncrease" name="ConvertiblePreferredStockBeneficialOwnershipLimitationNoticePeriodBeforeIncrease" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="pirs_ConvertiblePreferredStockBeneficialOwnershipLimitationPercent" name="ConvertiblePreferredStockBeneficialOwnershipLimitationPercent" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="pirs_ConvertiblePreferredStockCommonStockOwnershipLimitPercent" name="ConvertiblePreferredStockCommonStockOwnershipLimitPercent" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="pirs_ConvertiblePreferredStockWeightedAverageStockPricePercent" name="ConvertiblePreferredStockWeightedAverageStockPricePercent" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_CorporateIncomeTaxMember" name="CorporateIncomeTaxMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="pirs_DebtSecuritiesAvailableforsaleContractualMaturityPeriod" name="DebtSecuritiesAvailableforsaleContractualMaturityPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="pirs_DeferredTaxAssetLeaseLiability" name="DeferredTaxAssetLeaseLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="pirs_DeferredTaxAssetsAccruedCompensationAndOther" name="DeferredTaxAssetsAccruedCompensationAndOther" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="pirs_DeferredTaxAssetsCapitalizedResearchAndDevelopment" name="DeferredTaxAssetsCapitalizedResearchAndDevelopment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="pirs_DeferredTaxAssetsDepreciationAndOther" name="DeferredTaxAssetsDepreciationAndOther" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="pirs_DeferredTaxLiabilitiesLeaseRightofuseAsset" name="DeferredTaxLiabilitiesLeaseRightofuseAsset" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="pirs_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="pirs_EffectiveIncomeTaxRateReconciliationProvisionToReturnPercent" name="EffectiveIncomeTaxRateReconciliationProvisionToReturnPercent" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" name="EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_EstimatedDevelopmentAndManufacturingServicesMember" name="EstimatedDevelopmentAndManufacturingServicesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_EstimatedPhase2aServicesMember" name="EstimatedPhase2aServicesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_ExclusiveProductLicenseAgreementMember" name="ExclusiveProductLicenseAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_ExecutiveOfficersAndManagementMember" name="ExecutiveOfficersAndManagementMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_GenentechMember" name="GenentechMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_GovernanceCommitteeParticipationMember" name="GovernanceCommitteeParticipationMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_HallbergmoosGermanyMember" name="HallbergmoosGermanyMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="pirs_IncreaseDecreaseInOperatingLeaseLiabilities" name="IncreaseDecreaseInOperatingLeaseLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_JefferiesLLCMember" name="JefferiesLLCMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_LeasesExpectedToBeDeliveredByOctober2024Member" name="LeasesExpectedToBeDeliveredByOctober2024Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_LeasesWithFirstRightOfRefusalForAdditionalAreaMember" name="LeasesWithFirstRightOfRefusalForAdditionalAreaMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember" name="LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="pirs_LesseeOperatingLeaseMonthlyRentExpense" name="LesseeOperatingLeaseMonthlyRentExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_LicenseAndCollaborationAgreementMember" name="LicenseAndCollaborationAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="pirs_LicenseAndTransferAgreementTextBlock" name="LicenseAndTransferAgreementTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_NoteToFinancialStatementDetailsTextual" name="NoteToFinancialStatementDetailsTextual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_NotesToFinancialStatements" name="NotesToFinancialStatements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_NotesToFinancialStatementsAbstract" name="NotesToFinancialStatementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="pirs_NumberOfAgreementExtensionOptions" name="NumberOfAgreementExtensionOptions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
  <xsd:element id="pirs_NumberOfCollaborationProducts" name="NumberOfCollaborationProducts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant"/>
  <xsd:element id="pirs_NumberOfCombinedPerformanceObligations" name="NumberOfCombinedPerformanceObligations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
  <xsd:element id="pirs_NumberOfDevelopmentMilestones" name="NumberOfDevelopmentMilestones" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
  <xsd:element id="pirs_NumberOfDiscoveryProgramsDiscontinued" name="NumberOfDiscoveryProgramsDiscontinued" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant"/>
  <xsd:element id="pirs_NumberOfInitialResearchPrograms" name="NumberOfInitialResearchPrograms" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant"/>
  <xsd:element id="pirs_NumberOfLicenses" name="NumberOfLicenses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
  <xsd:element id="pirs_NumberOfNovelProteins" name="NumberOfNovelProteins" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
  <xsd:element id="pirs_NumberOfOptionalAdditionalResearchPrograms" name="NumberOfOptionalAdditionalResearchPrograms" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant"/>
  <xsd:element id="pirs_NumberOfPerformanceObligations" name="NumberOfPerformanceObligations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant"/>
  <xsd:element id="pirs_NumberOfPreclinicalStagePrograms" name="NumberOfPreclinicalStagePrograms" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant"/>
  <xsd:element id="pirs_NumberOfPrograms" name="NumberOfPrograms" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
  <xsd:element id="pirs_NumberOfResearchLicenses" name="NumberOfResearchLicenses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
  <xsd:element id="pirs_NumberOfResearchPrograms" name="NumberOfResearchPrograms" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant"/>
  <xsd:element id="pirs_NumberOfSeparatePerformanceObligations" name="NumberOfSeparatePerformanceObligations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
  <xsd:element id="pirs_NumberOfSwapOptions" name="NumberOfSwapOptions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
  <xsd:element id="pirs_NumberOfTargetPrograms" name="NumberOfTargetPrograms" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
  <xsd:element id="pirs_NumberOfTechnologyLicenses" name="NumberOfTechnologyLicenses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
  <xsd:element id="pirs_NumberOfVotesPerShare" name="NumberOfVotesPerShare" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="pirs_OfficeAndLaboratorySpaceMember" name="OfficeAndLaboratorySpaceMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="pirs_OperatingLeaseRightOfUseAssetAccretion" name="OperatingLeaseRightOfUseAssetAccretion" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_OtherArrangementMember" name="OtherArrangementMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_PierisPharmaceuticalsGmbhMember" name="PierisPharmaceuticalsGmbhMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_PlatformTechnologyLicenseMember" name="PlatformTechnologyLicenseMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_PreferredShareExchangeMember" name="PreferredShareExchangeMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="pirs_ProceedsFromIssuanceOfPrivatePlacementNet" name="ProceedsFromIssuanceOfPrivatePlacementNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="pirs_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" name="PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="pirs_RemainingPerformanceObligationEstimatedTerm" name="RemainingPerformanceObligationEstimatedTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_ResearchAndDevelopmentMilestonePaymentsMember" name="ResearchAndDevelopmentMilestonePaymentsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_ResearchAndDevelopmentServicesMember" name="ResearchAndDevelopmentServicesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="pirs_ResearchCollaborationAgreementPeriod" name="ResearchCollaborationAgreementPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="pirs_ResearchTermExtensionPeriod" name="ResearchTermExtensionPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="pirs_RevenueFromContractWithCustomerAgreementObligationCost" name="RevenueFromContractWithCustomerAgreementObligationCost" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="pirs_RevenueFromContractWithCustomerAgreementTerminationAdditionalNoticePeriodUponMaterialBreach" name="RevenueFromContractWithCustomerAgreementTerminationAdditionalNoticePeriodUponMaterialBreach" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriod" name="RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodAfterFirstCommercialSale" name="RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodAfterFirstCommercialSale" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodBeforeFirstCommercialSale" name="RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodBeforeFirstCommercialSale" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodIfMarketingApprovalObtained" name="RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodIfMarketingApprovalObtained" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="pirs_RevenueFromContractWithCustomerAgreementTerminationNoticePeriodNonpaymentOfUndisputedAmounts" name="RevenueFromContractWithCustomerAgreementTerminationNoticePeriodNonpaymentOfUndisputedAmounts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="pirs_RevenueFromContractWithCustomerAgreementTerminationNoticePeriodUponMaterialBreach" name="RevenueFromContractWithCustomerAgreementTerminationNoticePeriodUponMaterialBreach" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="pirs_RevenueFromContractWithCustomerAgreementTerminationNoticePeriodWithinMaterialBreach" name="RevenueFromContractWithCustomerAgreementTerminationNoticePeriodWithinMaterialBreach" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="pirs_RevenueFromContractWithCustomerAllocableArrangementConsiderationAllocation" name="RevenueFromContractWithCustomerAllocableArrangementConsiderationAllocation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="pirs_RevenueFromContractWithCustomerCollaborationFeeOnAdditionalProgram" name="RevenueFromContractWithCustomerCollaborationFeeOnAdditionalProgram" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="pirs_RevenueFromContractWithCustomerContributionTowardsManufacturingActivities" name="RevenueFromContractWithCustomerContributionTowardsManufacturingActivities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="pirs_RevenueFromContractWithCustomerMilestonePaymentsTableTextBlock" name="RevenueFromContractWithCustomerMilestonePaymentsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="pirs_RevenueFromContractWithCustomerPeriodAfterEffectiveDateAgreementsMayBeTerminated" name="RevenueFromContractWithCustomerPeriodAfterEffectiveDateAgreementsMayBeTerminated" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="pirs_SaleOfStockAuthorizedAmount" name="SaleOfStockAuthorizedAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="pirs_SaleOfStockFairValuePricePerShare" name="SaleOfStockFairValuePricePerShare" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="instant"/>
  <xsd:element id="pirs_SaleOfStockNumberOfWarrantsPerUnit" name="SaleOfStockNumberOfWarrantsPerUnit" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_SalesMilestonePaymentsMember" name="SalesMilestonePaymentsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_SeattleGeneticsIncMember" name="SeattleGeneticsIncMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_SecuritiesPurchaseAgreementMember" name="SecuritiesPurchaseAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_SeriesAThroughEMember" name="SeriesAThroughEMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_ServierDevelopedCollaborationProductsMember" name="ServierDevelopedCollaborationProductsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm2Exercised" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm2Exercised" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="pirs_ShareBasedCompensationArrangementBySharebasedPaymentAwardPurchasePeriod" name="ShareBasedCompensationArrangementBySharebasedPaymentAwardPurchasePeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfPurchasePeriods" name="SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfPurchasePeriods" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
  <xsd:element id="pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAggregateIntrinsicValue" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAggregateIntrinsicValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodAggregateIntrinsicValue" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodAggregateIntrinsicValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_StockExchangeSharesFromExistingShareholdersMember" name="StockExchangeSharesFromExistingShareholdersMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="pirs_StockIssuedDuringPeriodSharesExerciseOfWarrants" name="StockIssuedDuringPeriodSharesExerciseOfWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="pirs_StockIssuedDuringPeriodValueExerciseOfWarrants" name="StockIssuedDuringPeriodValueExerciseOfWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_SubleaseOfficeSpaceMember" name="SubleaseOfficeSpaceMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_TradeTaxMember" name="TradeTaxMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_statement-statement-note-11-stock-and-employee-benefit-plans-schedule-of-employee-service-sharebased-compensation-costs-details" name="statement-statement-note-11-stock-and-employee-benefit-plans-schedule-of-employee-service-sharebased-compensation-costs-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_statement-statement-note-11-stock-and-employee-benefit-plans-schedule-of-sharebased-payment-award-stock-options-details" name="statement-statement-note-11-stock-and-employee-benefit-plans-schedule-of-sharebased-payment-award-stock-options-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_statement-statement-note-11-stock-and-employee-benefit-plans-stock-options-activity-details" name="statement-statement-note-11-stock-and-employee-benefit-plans-stock-options-activity-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_statement-statement-note-11-stock-and-employee-benefit-plans-tables" name="statement-statement-note-11-stock-and-employee-benefit-plans-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_statement-statement-note-13-leases-maturities-of-operating-lease-liabilities-details" name="statement-statement-note-13-leases-maturities-of-operating-lease-liabilities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_statement-statement-note-13-leases-operating-lease-costs-details" name="statement-statement-note-13-leases-operating-lease-costs-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_statement-statement-note-13-leases-tables" name="statement-statement-note-13-leases-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_statement-statement-note-2-summary-of-significant-accounting-policies-schedule-of-property-plant-and-equipment-useful-lives-details" name="statement-statement-note-2-summary-of-significant-accounting-policies-schedule-of-property-plant-and-equipment-useful-lives-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_statement-statement-note-2-summary-of-significant-accounting-policies-tables" name="statement-statement-note-2-summary-of-significant-accounting-policies-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_statement-statement-note-3-revenue-disaggregation-of-revenue-details" name="statement-statement-note-3-revenue-disaggregation-of-revenue-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_statement-statement-note-3-revenue-potential-milestone-payments-received-details" name="statement-statement-note-3-revenue-potential-milestone-payments-received-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_statement-statement-note-3-revenue-tables" name="statement-statement-note-3-revenue-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_statement-statement-note-5-cash-cash-equivalents-and-investments-cash-equivalents-and-investments-carried-at-fair-value-details" name="statement-statement-note-5-cash-cash-equivalents-and-investments-cash-equivalents-and-investments-carried-at-fair-value-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_statement-statement-note-5-cash-cash-equivalents-and-investments-investments-details" name="statement-statement-note-5-cash-cash-equivalents-and-investments-investments-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_statement-statement-note-5-cash-cash-equivalents-and-investments-tables" name="statement-statement-note-5-cash-cash-equivalents-and-investments-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_statement-statement-note-6-property-and-equipment-net-property-and-equipment-details" name="statement-statement-note-6-property-and-equipment-net-property-and-equipment-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_statement-statement-note-6-property-and-equipment-net-tables" name="statement-statement-note-6-property-and-equipment-net-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_statement-statement-note-7-accrued-expenses-accrued-expenses-and-other-current-liabilities-details" name="statement-statement-note-7-accrued-expenses-accrued-expenses-and-other-current-liabilities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_statement-statement-note-7-accrued-expenses-tables" name="statement-statement-note-7-accrued-expenses-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_statement-statement-note-8-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details" name="statement-statement-note-8-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_statement-statement-note-8-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details" name="statement-statement-note-8-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_statement-statement-note-8-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" name="statement-statement-note-8-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_statement-statement-note-8-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details" name="statement-statement-note-8-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_statement-statement-note-8-income-taxes-summary-of-income-tax-contingencies-details" name="statement-statement-note-8-income-taxes-summary-of-income-tax-contingencies-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_statement-statement-note-8-income-taxes-tables" name="statement-statement-note-8-income-taxes-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pirs_statement-statement-significant-accounting-policies-policies" name="statement-statement-significant-accounting-policies-policies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>pirs-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 06:44PM UTC 2023-03-31--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" xlink:href="pirs-20221231.xsd#statement-note-8-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" xlink:type="extended">
    <link:loc xlink:href="pirs-20221231.xsd#pirs_EffectiveIncomeTaxRateReconciliationProvisionToReturnPercent" xlink:label="pirs_EffectiveIncomeTaxRateReconciliationProvisionToReturnPercent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="pirs_EffectiveIncomeTaxRateReconciliationProvisionToReturnPercent" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-13-leases-maturities-of-operating-lease-liabilities-details" xlink:href="pirs-20221231.xsd#statement-note-13-leases-maturities-of-operating-lease-liabilities-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.pieris.com/20221231/role/statement-note-13-leases-maturities-of-operating-lease-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" xlink:href="pirs-20221231.xsd#statement-consolidated-statements-of-operations-and-comprehensive-loss" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.pieris.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentAssistanceAmount" xlink:label="us-gaap_GovernmentAssistanceAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:label="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_GovernmentAssistanceAmount" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows" xlink:href="pirs-20221231.xsd#statement-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="pirs-20221231.xsd#pirs_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="pirs_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_OperatingLeaseRightOfUseAssetAccretion" xlink:label="pirs_OperatingLeaseRightOfUseAssetAccretion" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:label="us-gaap_RealizedInvestmentGainsLosses" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="pirs_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_RealizedInvestmentGainsLosses" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherNoncashIncomeExpense" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:type="arc"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="pirs_OperatingLeaseRightOfUseAssetAccretion" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="arc"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireInvestments" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockPlans" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-6-property-and-equipment-net-property-and-equipment-details" xlink:href="pirs-20221231.xsd#statement-note-6-property-and-equipment-net-property-and-equipment-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.pieris.com/20221231/role/statement-note-6-property-and-equipment-net-property-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-7-accrued-expenses-accrued-expenses-and-other-current-liabilities-details" xlink:href="pirs-20221231.xsd#statement-note-7-accrued-expenses-accrued-expenses-and-other-current-liabilities-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.pieris.com/20221231/role/statement-note-7-accrued-expenses-accrued-expenses-and-other-current-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="pirs-20221231.xsd#pirs_AccruedAccountsPayableCurrent" xlink:label="pirs_AccruedAccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_AccruedCollaborationCostsCurrent" xlink:label="pirs_AccruedCollaborationCostsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:label="pirs_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_AccruedLicenseObligationsCurrent" xlink:label="pirs_AccruedLicenseObligationsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_AccruedResearchAndDevelopmentCosts" xlink:label="pirs_AccruedResearchAndDevelopmentCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pirs_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="pirs_AccruedCollaborationCostsCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pirs_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pirs_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pirs_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="pirs_AccruedLicenseObligationsCurrent" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pirs_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="pirs_AccruedAccountsPayableCurrent" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pirs_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="pirs_AccruedResearchAndDevelopmentCosts" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pirs_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details" xlink:href="pirs-20221231.xsd#statement-note-8-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-13-leases-operating-lease-costs-details" xlink:href="pirs-20221231.xsd#statement-note-13-leases-operating-lease-costs-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.pieris.com/20221231/role/statement-note-13-leases-operating-lease-costs-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets" xlink:href="pirs-20221231.xsd#statement-consolidated-balance-sheets" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="pirs-20221231.xsd#pirs_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:label="pirs_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ShortTermInvestments" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="pirs_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details" xlink:href="pirs-20221231.xsd#statement-note-8-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-8-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:href="pirs-20221231.xsd#statement-note-8-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.pieris.com/20221231/role/statement-note-8-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="pirs-20221231.xsd#pirs_DeferredTaxAssetLeaseLiability" xlink:label="pirs_DeferredTaxAssetLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_DeferredTaxAssetsAccruedCompensationAndOther" xlink:label="pirs_DeferredTaxAssetsAccruedCompensationAndOther" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:label="pirs_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_DeferredTaxAssetsDepreciationAndOther" xlink:label="pirs_DeferredTaxAssetsDepreciationAndOther" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_DeferredTaxLiabilitiesLeaseRightofuseAsset" xlink:label="pirs_DeferredTaxLiabilitiesLeaseRightofuseAsset" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xlink:label="us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpense" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpense" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="pirs_DeferredTaxAssetsAccruedCompensationAndOther" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="pirs_DeferredTaxAssetLeaseLiability" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="pirs_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="pirs_DeferredTaxAssetsDepreciationAndOther" xlink:type="arc"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="pirs_DeferredTaxLiabilitiesLeaseRightofuseAsset" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>pirs-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 06:44PM UTC 2023-03-31--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-12-license-agreement" xlink:href="pirs-20221231.xsd#statement-note-12-license-agreement" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.pieris.com/20221231/role/statement-note-12-license-agreement" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_LicenseAndTransferAgreementTextBlock" xlink:label="pirs_LicenseAndTransferAgreementTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="pirs_LicenseAndTransferAgreementTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-7-accrued-expenses" xlink:href="pirs-20221231.xsd#statement-note-7-accrued-expenses" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.pieris.com/20221231/role/statement-note-7-accrued-expenses" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-document-and-entity-information" xlink:href="pirs-20221231.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.pieris.com/20221231/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
    <link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" xlink:type="arc"/>
    <link:definitionArc order="25" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:definitionArc order="26" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" xlink:type="arc"/>
    <link:definitionArc order="27" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:definitionArc order="28" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
    <link:definitionArc order="29" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <link:definitionArc order="30" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" xlink:type="arc"/>
    <link:definitionArc order="31" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" xlink:type="arc"/>
    <link:definitionArc order="32" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" xlink:type="arc"/>
    <link:definitionArc order="33" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="34" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" xlink:type="arc"/>
    <link:definitionArc order="35" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" xlink:type="arc"/>
    <link:definitionArc order="36" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-parentheticals" xlink:href="pirs-20221231.xsd#statement-consolidated-statements-of-changes-in-stockholders-equity-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.pieris.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-parentheticals" xlink:type="extended">
    <link:loc xlink:href="pirs-20221231.xsd#pirs_AtTheMarketOfferingMember" xlink:label="pirs_AtTheMarketOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pirs_AtTheMarketOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows-parentheticals" xlink:href="pirs-20221231.xsd#statement-consolidated-statements-of-cash-flows-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_AtTheMarketOfferingMember" xlink:label="pirs_AtTheMarketOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pirs_AtTheMarketOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-1-corporate-information-" xlink:href="pirs-20221231.xsd#statement-note-1-corporate-information-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.pieris.com/20221231/role/statement-note-1-corporate-information-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_PierisPharmaceuticalsGmbhMember" xlink:label="pirs_PierisPharmaceuticalsGmbhMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="pirs_PierisPharmaceuticalsGmbhMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies" xlink:href="pirs-20221231.xsd#statement-note-2-summary-of-significant-accounting-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.pieris.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-3-revenue-" xlink:href="pirs-20221231.xsd#statement-note-3-revenue-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.pieris.com/20221231/role/statement-note-3-revenue-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_AdditionalOtherResearchServicesMember" xlink:label="pirs_AdditionalOtherResearchServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_AntibodyTargetSwapMember" xlink:label="pirs_AntibodyTargetSwapMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_AstraZenecaABMember" xlink:label="pirs_AstraZenecaABMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_BPAssetsXIIIncMember" xlink:label="pirs_BPAssetsXIIIncMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_CodevelopmentCollaborationProductCollaborationMember" xlink:label="pirs_CodevelopmentCollaborationProductCollaborationMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_EstimatedDevelopmentAndManufacturingServicesMember" xlink:label="pirs_EstimatedDevelopmentAndManufacturingServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_EstimatedPhase2aServicesMember" xlink:label="pirs_EstimatedPhase2aServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_ExclusiveProductLicenseAgreementMember" xlink:label="pirs_ExclusiveProductLicenseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_GenentechMember" xlink:label="pirs_GenentechMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_GovernanceCommitteeParticipationMember" xlink:label="pirs_GovernanceCommitteeParticipationMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember" xlink:label="pirs_LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_LicenseAndCollaborationAgreementMember" xlink:label="pirs_LicenseAndCollaborationAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_OtherArrangementMember" xlink:label="pirs_OtherArrangementMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_PlatformTechnologyLicenseMember" xlink:label="pirs_PlatformTechnologyLicenseMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_ResearchAndDevelopmentServicesMember" xlink:label="pirs_ResearchAndDevelopmentServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_SalesMilestonePaymentsMember" xlink:label="pirs_SalesMilestonePaymentsMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_SeattleGeneticsIncMember" xlink:label="pirs_SeattleGeneticsIncMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_ServierDevelopedCollaborationProductsMember" xlink:label="pirs_ServierDevelopedCollaborationProductsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="us-gaap_AccountingStandardsUpdate201409Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis" xlink:label="us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleMember" xlink:label="us-gaap_ChangeInAccountingPrincipleMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleMember" xlink:label="us-gaap_ChangeInAccountingPrincipleMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UpFrontPaymentArrangementMember" xlink:label="us-gaap_UpFrontPaymentArrangementMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis" xlink:to="us-gaap_ChangeInAccountingPrincipleMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="pirs_GenentechMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="pirs_ResearchAndDevelopmentServicesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pirs_LicenseAndCollaborationAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pirs_PlatformTechnologyLicenseMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pirs_GovernanceCommitteeParticipationMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="pirs_BPAssetsXIIIncMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pirs_ExclusiveProductLicenseAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="pirs_SeattleGeneticsIncMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pirs_OtherArrangementMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_UpFrontPaymentArrangementMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pirs_AntibodyTargetSwapMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TransactionTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransactionDomain" xlink:to="pirs_SalesMilestonePaymentsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="pirs_AstraZenecaABMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransactionDomain" xlink:to="pirs_EstimatedDevelopmentAndManufacturingServicesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransactionDomain" xlink:to="pirs_EstimatedPhase2aServicesMember" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pirs_AdditionalOtherResearchServicesMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="pirs_LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pirs_CodevelopmentCollaborationProductCollaborationMember" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pirs_ServierDevelopedCollaborationProductsMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingPrincipleMember" xlink:to="us-gaap_AccountingStandardsUpdate201409Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis" xlink:to="us-gaap_ChangeInAccountingPrincipleMember-default" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-4-grant-income" xlink:href="pirs-20221231.xsd#statement-note-4-grant-income" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.pieris.com/20221231/role/statement-note-4-grant-income" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentAssistanceTextBlock" xlink:label="us-gaap_GovernmentAssistanceTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_GovernmentAssistanceTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments" xlink:href="pirs-20221231.xsd#statement-note-5-cash-cash-equivalents-and-investments" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-6-property-and-equipment-net" xlink:href="pirs-20221231.xsd#statement-note-6-property-and-equipment-net" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.pieris.com/20221231/role/statement-note-6-property-and-equipment-net" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-8-income-taxes" xlink:href="pirs-20221231.xsd#statement-note-8-income-taxes" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.pieris.com/20221231/role/statement-note-8-income-taxes" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_CorporateIncomeTaxMember" xlink:label="pirs_CorporateIncomeTaxMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_TradeTaxMember" xlink:label="pirs_TradeTaxMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="pirs_CorporateIncomeTaxMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="pirs_TradeTaxMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity" xlink:href="pirs-20221231.xsd#statement-note-9-stockholders-equity" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_AtTheMarketOfferingMember" xlink:label="pirs_AtTheMarketOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_ConversionOfCommonStockIntoSeriesEPreferredStockMember" xlink:label="pirs_ConversionOfCommonStockIntoSeriesEPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" xlink:label="pirs_EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_JefferiesLLCMember" xlink:label="pirs_JefferiesLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_PreferredShareExchangeMember" xlink:label="pirs_PreferredShareExchangeMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_SecuritiesPurchaseAgreementMember" xlink:label="pirs_SecuritiesPurchaseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_SeriesAThroughEMember" xlink:label="pirs_SeriesAThroughEMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_StockExchangeSharesFromExistingShareholdersMember" xlink:label="pirs_StockExchangeSharesFromExistingShareholdersMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="us-gaap_SeriesEPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesEPreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pirs_SeriesAThroughEMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pirs_SecuritiesPurchaseAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pirs_StockExchangeSharesFromExistingShareholdersMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pirs_PreferredShareExchangeMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pirs_EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="pirs_ConversionOfCommonStockIntoSeriesEPreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="pirs_JefferiesLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pirs_AtTheMarketOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-10-net-loss-per-share" xlink:href="pirs-20221231.xsd#statement-note-10-net-loss-per-share" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.pieris.com/20221231/role/statement-note-10-net-loss-per-share" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans" xlink:href="pirs-20221231.xsd#statement-note-11-stock-and-employee-benefit-plans" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" xlink:label="pirs_EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_ExecutiveOfficersAndManagementMember" xlink:label="pirs_ExecutiveOfficersAndManagementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pirs_EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="pirs_ExecutiveOfficersAndManagementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-13-leases" xlink:href="pirs-20221231.xsd#statement-note-13-leases" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.pieris.com/20221231/role/statement-note-13-leases" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_BostonMassachusettsMember" xlink:label="pirs_BostonMassachusettsMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_HallbergmoosGermanyMember" xlink:label="pirs_HallbergmoosGermanyMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_LeasesExpectedToBeDeliveredByOctober2024Member" xlink:label="pirs_LeasesExpectedToBeDeliveredByOctober2024Member" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_LeasesWithFirstRightOfRefusalForAdditionalAreaMember" xlink:label="pirs_LeasesWithFirstRightOfRefusalForAdditionalAreaMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_OfficeAndLaboratorySpaceMember" xlink:label="pirs_OfficeAndLaboratorySpaceMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_SubleaseOfficeSpaceMember" xlink:label="pirs_SubleaseOfficeSpaceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseContractualTermAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="pirs_SubleaseOfficeSpaceMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="pirs_BostonMassachusettsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="pirs_OfficeAndLaboratorySpaceMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="pirs_HallbergmoosGermanyMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pirs_LeasesExpectedToBeDeliveredByOctober2024Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pirs_LeasesWithFirstRightOfRefusalForAdditionalAreaMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-significant-accounting-policies-policies" xlink:href="pirs-20221231.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.pieris.com/20221231/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentAssistancePolicyTextBlock" xlink:label="us-gaap_GovernmentAssistancePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GovernmentAssistancePolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables" xlink:href="pirs-20221231.xsd#statement-note-2-summary-of-significant-accounting-policies-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.pieris.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:label="pirs_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="pirs_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-3-revenue-tables" xlink:href="pirs-20221231.xsd#statement-note-3-revenue-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.pieris.com/20221231/role/statement-note-3-revenue-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_RevenueFromContractWithCustomerMilestonePaymentsTableTextBlock" xlink:label="pirs_RevenueFromContractWithCustomerMilestonePaymentsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="pirs_RevenueFromContractWithCustomerMilestonePaymentsTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-tables" xlink:href="pirs-20221231.xsd#statement-note-5-cash-cash-equivalents-and-investments-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-6-property-and-equipment-net-tables" xlink:href="pirs-20221231.xsd#statement-note-6-property-and-equipment-net-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.pieris.com/20221231/role/statement-note-6-property-and-equipment-net-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-7-accrued-expenses-tables" xlink:href="pirs-20221231.xsd#statement-note-7-accrued-expenses-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.pieris.com/20221231/role/statement-note-7-accrued-expenses-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-8-income-taxes-tables" xlink:href="pirs-20221231.xsd#statement-note-8-income-taxes-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.pieris.com/20221231/role/statement-note-8-income-taxes-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-tables" xlink:href="pirs-20221231.xsd#statement-note-11-stock-and-employee-benefit-plans-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-13-leases-tables" xlink:href="pirs-20221231.xsd#statement-note-13-leases-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.pieris.com/20221231/role/statement-note-13-leases-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-1-corporate-information-details-textual" xlink:href="pirs-20221231.xsd#statement-note-1-corporate-information-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.pieris.com/20221231/role/statement-note-1-corporate-information-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_PierisPharmaceuticalsGmbhMember" xlink:label="pirs_PierisPharmaceuticalsGmbhMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="pirs_PierisPharmaceuticalsGmbhMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-property-plant-and-equipment-useful-lives-details" xlink:href="pirs-20221231.xsd#statement-note-2-summary-of-significant-accounting-policies-schedule-of-property-plant-and-equipment-useful-lives-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.pieris.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-property-plant-and-equipment-useful-lives-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_LaboratoryEquipmentMember" xlink:label="pirs_LaboratoryEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pirs_LaboratoryEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual" xlink:href="pirs-20221231.xsd#statement-note-3-revenue-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_AdditionalOtherResearchServicesMember" xlink:label="pirs_AdditionalOtherResearchServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_AgreementTerminationNoticePeriodUponOfBreachOfPaymentObligations" xlink:label="pirs_AgreementTerminationNoticePeriodUponOfBreachOfPaymentObligations" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_AmendedCollaborationAgreementResaleOfStockPeriod" xlink:label="pirs_AmendedCollaborationAgreementResaleOfStockPeriod" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_AntibodyTargetSwapMember" xlink:label="pirs_AntibodyTargetSwapMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_AstraZenecaABMember" xlink:label="pirs_AstraZenecaABMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_BPAssetsXIIIncMember" xlink:label="pirs_BPAssetsXIIIncMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_CodevelopmentCollaborationProductCollaborationMember" xlink:label="pirs_CodevelopmentCollaborationProductCollaborationMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_CollaborativeArrangementAllocableArrangementConsiderationAllocation" xlink:label="pirs_CollaborativeArrangementAllocableArrangementConsiderationAllocation" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_EstimatedDevelopmentAndManufacturingServicesMember" xlink:label="pirs_EstimatedDevelopmentAndManufacturingServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_EstimatedPhase2aServicesMember" xlink:label="pirs_EstimatedPhase2aServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_ExclusiveProductLicenseAgreementMember" xlink:label="pirs_ExclusiveProductLicenseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_GenentechMember" xlink:label="pirs_GenentechMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_GovernanceCommitteeParticipationMember" xlink:label="pirs_GovernanceCommitteeParticipationMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember" xlink:label="pirs_LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_LicenseAndCollaborationAgreementMember" xlink:label="pirs_LicenseAndCollaborationAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NumberOfCollaborationProducts" xlink:label="pirs_NumberOfCollaborationProducts" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NumberOfCombinedPerformanceObligations" xlink:label="pirs_NumberOfCombinedPerformanceObligations" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NumberOfDevelopmentMilestones" xlink:label="pirs_NumberOfDevelopmentMilestones" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NumberOfDiscoveryProgramsDiscontinued" xlink:label="pirs_NumberOfDiscoveryProgramsDiscontinued" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NumberOfInitialResearchPrograms" xlink:label="pirs_NumberOfInitialResearchPrograms" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NumberOfLicenses" xlink:label="pirs_NumberOfLicenses" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NumberOfNovelProteins" xlink:label="pirs_NumberOfNovelProteins" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NumberOfOptionalAdditionalResearchPrograms" xlink:label="pirs_NumberOfOptionalAdditionalResearchPrograms" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NumberOfPerformanceObligations" xlink:label="pirs_NumberOfPerformanceObligations" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NumberOfPreclinicalStagePrograms" xlink:label="pirs_NumberOfPreclinicalStagePrograms" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NumberOfPrograms" xlink:label="pirs_NumberOfPrograms" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NumberOfResearchLicenses" xlink:label="pirs_NumberOfResearchLicenses" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NumberOfResearchPrograms" xlink:label="pirs_NumberOfResearchPrograms" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NumberOfSeparatePerformanceObligations" xlink:label="pirs_NumberOfSeparatePerformanceObligations" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NumberOfSwapOptions" xlink:label="pirs_NumberOfSwapOptions" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NumberOfTargetPrograms" xlink:label="pirs_NumberOfTargetPrograms" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NumberOfTechnologyLicenses" xlink:label="pirs_NumberOfTechnologyLicenses" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_OtherArrangementMember" xlink:label="pirs_OtherArrangementMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_PlatformTechnologyLicenseMember" xlink:label="pirs_PlatformTechnologyLicenseMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_RemainingPerformanceObligationEstimatedTerm" xlink:label="pirs_RemainingPerformanceObligationEstimatedTerm" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_ResearchAndDevelopmentServicesMember" xlink:label="pirs_ResearchAndDevelopmentServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_ResearchCollaborationAgreementPeriod" xlink:label="pirs_ResearchCollaborationAgreementPeriod" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_ResearchTermExtensionPeriod" xlink:label="pirs_ResearchTermExtensionPeriod" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_RevenueFromContractWithCustomerAgreementObligationCost" xlink:label="pirs_RevenueFromContractWithCustomerAgreementObligationCost" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_RevenueFromContractWithCustomerAgreementTerminationAdditionalNoticePeriodUponMaterialBreach" xlink:label="pirs_RevenueFromContractWithCustomerAgreementTerminationAdditionalNoticePeriodUponMaterialBreach" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriod" xlink:label="pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriod" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodAfterFirstCommercialSale" xlink:label="pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodAfterFirstCommercialSale" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodBeforeFirstCommercialSale" xlink:label="pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodBeforeFirstCommercialSale" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodIfMarketingApprovalObtained" xlink:label="pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodIfMarketingApprovalObtained" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_RevenueFromContractWithCustomerAgreementTerminationNoticePeriodNonpaymentOfUndisputedAmounts" xlink:label="pirs_RevenueFromContractWithCustomerAgreementTerminationNoticePeriodNonpaymentOfUndisputedAmounts" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_RevenueFromContractWithCustomerAgreementTerminationNoticePeriodUponMaterialBreach" xlink:label="pirs_RevenueFromContractWithCustomerAgreementTerminationNoticePeriodUponMaterialBreach" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_RevenueFromContractWithCustomerAgreementTerminationNoticePeriodWithinMaterialBreach" xlink:label="pirs_RevenueFromContractWithCustomerAgreementTerminationNoticePeriodWithinMaterialBreach" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_RevenueFromContractWithCustomerAllocableArrangementConsiderationAllocation" xlink:label="pirs_RevenueFromContractWithCustomerAllocableArrangementConsiderationAllocation" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_RevenueFromContractWithCustomerCollaborationFeeOnAdditionalProgram" xlink:label="pirs_RevenueFromContractWithCustomerCollaborationFeeOnAdditionalProgram" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_RevenueFromContractWithCustomerContributionTowardsManufacturingActivities" xlink:label="pirs_RevenueFromContractWithCustomerContributionTowardsManufacturingActivities" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_RevenueFromContractWithCustomerPeriodAfterEffectiveDateAgreementsMayBeTerminated" xlink:label="pirs_RevenueFromContractWithCustomerPeriodAfterEffectiveDateAgreementsMayBeTerminated" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_SaleOfStockFairValuePricePerShare" xlink:label="pirs_SaleOfStockFairValuePricePerShare" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_SalesMilestonePaymentsMember" xlink:label="pirs_SalesMilestonePaymentsMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_SeattleGeneticsIncMember" xlink:label="pirs_SeattleGeneticsIncMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_ServierDevelopedCollaborationProductsMember" xlink:label="pirs_ServierDevelopedCollaborationProductsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="us-gaap_AccountingStandardsUpdate201409Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis" xlink:label="us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortization" xlink:label="us-gaap_CapitalizedContractCostAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostGross" xlink:label="us-gaap_CapitalizedContractCostGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleMember" xlink:label="us-gaap_ChangeInAccountingPrincipleMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleMember" xlink:label="us-gaap_ChangeInAccountingPrincipleMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UpFrontPaymentArrangementMember" xlink:label="us-gaap_UpFrontPaymentArrangementMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis" xlink:to="us-gaap_ChangeInAccountingPrincipleMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="pirs_GenentechMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="pirs_ResearchAndDevelopmentServicesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pirs_LicenseAndCollaborationAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pirs_PlatformTechnologyLicenseMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pirs_GovernanceCommitteeParticipationMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="pirs_BPAssetsXIIIncMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pirs_ExclusiveProductLicenseAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="pirs_SeattleGeneticsIncMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pirs_OtherArrangementMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_UpFrontPaymentArrangementMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pirs_AntibodyTargetSwapMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TransactionTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransactionDomain" xlink:to="pirs_SalesMilestonePaymentsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="pirs_AstraZenecaABMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransactionDomain" xlink:to="pirs_EstimatedDevelopmentAndManufacturingServicesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransactionDomain" xlink:to="pirs_EstimatedPhase2aServicesMember" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pirs_AdditionalOtherResearchServicesMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="pirs_LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pirs_CodevelopmentCollaborationProductCollaborationMember" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pirs_ServierDevelopedCollaborationProductsMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingPrincipleMember" xlink:to="us-gaap_AccountingStandardsUpdate201409Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis" xlink:to="us-gaap_ChangeInAccountingPrincipleMember-default" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_NumberOfInitialResearchPrograms" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_NumberOfOptionalAdditionalResearchPrograms" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_RevenueFromContractWithCustomerCollaborationFeeOnAdditionalProgram" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_RevenueFromContractWithCustomerAgreementTerminationNoticePeriodWithinMaterialBreach" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodBeforeFirstCommercialSale" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodAfterFirstCommercialSale" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_NumberOfResearchPrograms" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_ResearchCollaborationAgreementPeriod" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_NumberOfPerformanceObligations" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_RevenueFromContractWithCustomerContributionTowardsManufacturingActivities" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_RevenueFromContractWithCustomerPeriodAfterEffectiveDateAgreementsMayBeTerminated" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriod" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodIfMarketingApprovalObtained" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_RevenueFromContractWithCustomerAgreementTerminationNoticePeriodUponMaterialBreach" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_RevenueFromContractWithCustomerAgreementTerminationNoticePeriodNonpaymentOfUndisputedAmounts" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_RevenueFromContractWithCustomerAgreementTerminationAdditionalNoticePeriodUponMaterialBreach" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_RevenueFromContractWithCustomerAgreementObligationCost" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNet" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc"/>
    <link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc"/>
    <link:definitionArc order="25" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:type="arc"/>
    <link:definitionArc order="26" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_NumberOfLicenses" xlink:type="arc"/>
    <link:definitionArc order="27" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_NumberOfSwapOptions" xlink:type="arc"/>
    <link:definitionArc order="28" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_NumberOfTargetPrograms" xlink:type="arc"/>
    <link:definitionArc order="29" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_CollaborativeArrangementAllocableArrangementConsiderationAllocation" xlink:type="arc"/>
    <link:definitionArc order="30" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc"/>
    <link:definitionArc order="31" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc"/>
    <link:definitionArc order="32" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" xlink:type="arc"/>
    <link:definitionArc order="33" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_AmendedCollaborationAgreementResaleOfStockPeriod" xlink:type="arc"/>
    <link:definitionArc order="34" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_SaleOfStockFairValuePricePerShare" xlink:type="arc"/>
    <link:definitionArc order="35" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_NumberOfNovelProteins" xlink:type="arc"/>
    <link:definitionArc order="36" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_NumberOfCollaborationProducts" xlink:type="arc"/>
    <link:definitionArc order="37" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_NumberOfPrograms" xlink:type="arc"/>
    <link:definitionArc order="38" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_AgreementTerminationNoticePeriodUponOfBreachOfPaymentObligations" xlink:type="arc"/>
    <link:definitionArc order="39" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_RevenueFromContractWithCustomerAllocableArrangementConsiderationAllocation" xlink:type="arc"/>
    <link:definitionArc order="40" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_NumberOfTechnologyLicenses" xlink:type="arc"/>
    <link:definitionArc order="41" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_NumberOfResearchLicenses" xlink:type="arc"/>
    <link:definitionArc order="42" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_RemainingPerformanceObligationEstimatedTerm" xlink:type="arc"/>
    <link:definitionArc order="43" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" xlink:type="arc"/>
    <link:definitionArc order="44" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_NumberOfDiscoveryProgramsDiscontinued" xlink:type="arc"/>
    <link:definitionArc order="45" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CapitalizedContractCostNet" xlink:type="arc"/>
    <link:definitionArc order="46" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CapitalizedContractCostGross" xlink:type="arc"/>
    <link:definitionArc order="47" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CapitalizedContractCostAmortization" xlink:type="arc"/>
    <link:definitionArc order="48" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_NumberOfDevelopmentMilestones" xlink:type="arc"/>
    <link:definitionArc order="49" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_NumberOfSeparatePerformanceObligations" xlink:type="arc"/>
    <link:definitionArc order="50" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_NumberOfCombinedPerformanceObligations" xlink:type="arc"/>
    <link:definitionArc order="51" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_ResearchTermExtensionPeriod" xlink:type="arc"/>
    <link:definitionArc order="52" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_NumberOfPreclinicalStagePrograms" xlink:type="arc"/>
    <link:definitionArc order="53" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-4-grant-income-details-textual" xlink:href="pirs-20221231.xsd#statement-note-4-grant-income-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.pieris.com/20221231/role/statement-note-4-grant-income-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantsReceivable" xlink:label="us-gaap_GrantsReceivable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GrantsReceivable" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-details-textual" xlink:href="pirs-20221231.xsd#statement-note-5-cash-cash-equivalents-and-investments-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-6-property-and-equipment-net-details-textual" xlink:href="pirs-20221231.xsd#statement-note-6-property-and-equipment-net-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.pieris.com/20221231/role/statement-note-6-property-and-equipment-net-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-8-income-taxes-details-textual" xlink:href="pirs-20221231.xsd#statement-note-8-income-taxes-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.pieris.com/20221231/role/statement-note-8-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_CorporateIncomeTaxMember" xlink:label="pirs_CorporateIncomeTaxMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:label="pirs_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_TradeTaxMember" xlink:label="pirs_TradeTaxMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="pirs_CorporateIncomeTaxMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="pirs_TradeTaxMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OpenTaxYear" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual" xlink:href="pirs-20221231.xsd#statement-note-9-stockholders-equity-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_AtTheMarketOfferingMember" xlink:label="pirs_AtTheMarketOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_ConversionOfCommonStockIntoSeriesEPreferredStockMember" xlink:label="pirs_ConversionOfCommonStockIntoSeriesEPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_ConvertiblePreferredStockBeneficialOwnershipLimitationNoticePeriodBeforeIncrease" xlink:label="pirs_ConvertiblePreferredStockBeneficialOwnershipLimitationNoticePeriodBeforeIncrease" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_ConvertiblePreferredStockBeneficialOwnershipLimitationPercent" xlink:label="pirs_ConvertiblePreferredStockBeneficialOwnershipLimitationPercent" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_ConvertiblePreferredStockCommonStockOwnershipLimitPercent" xlink:label="pirs_ConvertiblePreferredStockCommonStockOwnershipLimitPercent" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_ConvertiblePreferredStockWeightedAverageStockPricePercent" xlink:label="pirs_ConvertiblePreferredStockWeightedAverageStockPricePercent" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" xlink:label="pirs_EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_JefferiesLLCMember" xlink:label="pirs_JefferiesLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NumberOfVotesPerShare" xlink:label="pirs_NumberOfVotesPerShare" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_PreferredShareExchangeMember" xlink:label="pirs_PreferredShareExchangeMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_ProceedsFromIssuanceOfPrivatePlacementNet" xlink:label="pirs_ProceedsFromIssuanceOfPrivatePlacementNet" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_SaleOfStockAuthorizedAmount" xlink:label="pirs_SaleOfStockAuthorizedAmount" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_SaleOfStockNumberOfWarrantsPerUnit" xlink:label="pirs_SaleOfStockNumberOfWarrantsPerUnit" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_SecuritiesPurchaseAgreementMember" xlink:label="pirs_SecuritiesPurchaseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_SeriesAThroughEMember" xlink:label="pirs_SeriesAThroughEMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_StockExchangeSharesFromExistingShareholdersMember" xlink:label="pirs_StockExchangeSharesFromExistingShareholdersMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PartnersCapitalAccountUnitsSoldInPrivatePlacement" xlink:label="us-gaap_PartnersCapitalAccountUnitsSoldInPrivatePlacement" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="us-gaap_SeriesEPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesEPreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pirs_SeriesAThroughEMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pirs_SecuritiesPurchaseAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pirs_StockExchangeSharesFromExistingShareholdersMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pirs_PreferredShareExchangeMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pirs_EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="pirs_ConversionOfCommonStockIntoSeriesEPreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="pirs_JefferiesLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pirs_AtTheMarketOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_NumberOfVotesPerShare" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_ConvertiblePreferredStockCommonStockOwnershipLimitPercent" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_ConvertiblePreferredStockBeneficialOwnershipLimitationPercent" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_ConvertiblePreferredStockBeneficialOwnershipLimitationNoticePeriodBeforeIncrease" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PartnersCapitalAccountUnitsSoldInPrivatePlacement" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_ProceedsFromIssuanceOfPrivatePlacementNet" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_SaleOfStockNumberOfWarrantsPerUnit" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_ConvertiblePreferredStockWeightedAverageStockPricePercent" xlink:type="arc"/>
    <link:definitionArc order="25" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc"/>
    <link:definitionArc order="26" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:type="arc"/>
    <link:definitionArc order="27" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="28" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" xlink:type="arc"/>
    <link:definitionArc order="29" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" xlink:type="arc"/>
    <link:definitionArc order="30" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="31" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_SaleOfStockAuthorizedAmount" xlink:type="arc"/>
    <link:definitionArc order="32" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc"/>
    <link:definitionArc order="33" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-10-net-loss-per-share-details-textual" xlink:href="pirs-20221231.xsd#statement-note-10-net-loss-per-share-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.pieris.com/20221231/role/statement-note-10-net-loss-per-share-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-details-textual" xlink:href="pirs-20221231.xsd#statement-note-11-stock-and-employee-benefit-plans-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" xlink:label="pirs_EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_ExecutiveOfficersAndManagementMember" xlink:label="pirs_ExecutiveOfficersAndManagementMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_ShareBasedCompensationArrangementBySharebasedPaymentAwardPurchasePeriod" xlink:label="pirs_ShareBasedCompensationArrangementBySharebasedPaymentAwardPurchasePeriod" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfPurchasePeriods" xlink:label="pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfPurchasePeriods" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pirs_EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="pirs_ExecutiveOfficersAndManagementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfPurchasePeriods" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_ShareBasedCompensationArrangementBySharebasedPaymentAwardPurchasePeriod" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-schedule-of-sharebased-payment-award-stock-options-details" xlink:href="pirs-20221231.xsd#statement-note-11-stock-and-employee-benefit-plans-schedule-of-sharebased-payment-award-stock-options-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-schedule-of-sharebased-payment-award-stock-options-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-13-leases-details-textual" xlink:href="pirs-20221231.xsd#statement-note-13-leases-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.pieris.com/20221231/role/statement-note-13-leases-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_BostonMassachusettsMember" xlink:label="pirs_BostonMassachusettsMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_HallbergmoosGermanyMember" xlink:label="pirs_HallbergmoosGermanyMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_LeasesExpectedToBeDeliveredByOctober2024Member" xlink:label="pirs_LeasesExpectedToBeDeliveredByOctober2024Member" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_LeasesWithFirstRightOfRefusalForAdditionalAreaMember" xlink:label="pirs_LeasesWithFirstRightOfRefusalForAdditionalAreaMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_LesseeOperatingLeaseMonthlyRentExpense" xlink:label="pirs_LesseeOperatingLeaseMonthlyRentExpense" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NumberOfAgreementExtensionOptions" xlink:label="pirs_NumberOfAgreementExtensionOptions" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_OfficeAndLaboratorySpaceMember" xlink:label="pirs_OfficeAndLaboratorySpaceMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_SubleaseOfficeSpaceMember" xlink:label="pirs_SubleaseOfficeSpaceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseContractualTermAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="pirs_SubleaseOfficeSpaceMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="pirs_BostonMassachusettsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="pirs_OfficeAndLaboratorySpaceMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="pirs_HallbergmoosGermanyMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pirs_LeasesExpectedToBeDeliveredByOctober2024Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pirs_LeasesWithFirstRightOfRefusalForAdditionalAreaMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_NumberOfAgreementExtensionOptions" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_LesseeOperatingLeaseMonthlyRentExpense" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SecurityDeposit" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TenantImprovements" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasePayments" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets-parentheticals" xlink:href="pirs-20221231.xsd#statement-consolidated-balance-sheets-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-8-income-taxes-summary-of-income-tax-contingencies-details" xlink:href="pirs-20221231.xsd#statement-note-8-income-taxes-summary-of-income-tax-contingencies-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.pieris.com/20221231/role/statement-note-8-income-taxes-summary-of-income-tax-contingencies-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-investments-details" xlink:href="pirs-20221231.xsd#statement-note-5-cash-cash-equivalents-and-investments-investments-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-investments-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_DebtSecuritiesAvailableforsaleContractualMaturityPeriod" xlink:label="pirs_DebtSecuritiesAvailableforsaleContractualMaturityPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:label="us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_AssetBackedSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateBondSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_DebtSecuritiesAvailableforsaleContractualMaturityPeriod" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-3-revenue-potential-milestone-payments-received-details" xlink:href="pirs-20221231.xsd#statement-note-3-revenue-potential-milestone-payments-received-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.pieris.com/20221231/role/statement-note-3-revenue-potential-milestone-payments-received-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_AstraZenecaABMember" xlink:label="pirs_AstraZenecaABMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_BostonPharmaceuticalsMember" xlink:label="pirs_BostonPharmaceuticalsMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_GenentechMember" xlink:label="pirs_GenentechMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember" xlink:label="pirs_LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_ResearchAndDevelopmentMilestonePaymentsMember" xlink:label="pirs_ResearchAndDevelopmentMilestonePaymentsMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_SalesMilestonePaymentsMember" xlink:label="pirs_SalesMilestonePaymentsMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_SeattleGeneticsIncMember" xlink:label="pirs_SeattleGeneticsIncMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractsReceivableClaimsAndUncertainAmounts" xlink:label="us-gaap_ContractsReceivableClaimsAndUncertainAmounts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="pirs_ResearchAndDevelopmentMilestonePaymentsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="pirs_AstraZenecaABMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="pirs_SalesMilestonePaymentsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="pirs_LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="pirs_SeattleGeneticsIncMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="pirs_BostonPharmaceuticalsMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="pirs_GenentechMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractsReceivableClaimsAndUncertainAmounts" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" xlink:href="pirs-20221231.xsd#statement-note-8-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_EffectiveIncomeTaxRateReconciliationProvisionToReturnPercent" xlink:label="pirs_EffectiveIncomeTaxRateReconciliationProvisionToReturnPercent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_EffectiveIncomeTaxRateReconciliationProvisionToReturnPercent" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-13-leases-maturities-of-operating-lease-liabilities-details" xlink:href="pirs-20221231.xsd#statement-note-13-leases-maturities-of-operating-lease-liabilities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.pieris.com/20221231/role/statement-note-13-leases-maturities-of-operating-lease-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiability" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" xlink:href="pirs-20221231.xsd#statement-consolidated-statements-of-operations-and-comprehensive-loss" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.pieris.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentAssistanceAmount" xlink:label="us-gaap_GovernmentAssistanceAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:label="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_Revenues" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_GovernmentAssistanceAmount" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows" xlink:href="pirs-20221231.xsd#statement-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="pirs_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_OperatingLeaseRightOfUseAssetAccretion" xlink:label="pirs_OperatingLeaseRightOfUseAssetAccretion" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:label="us-gaap_RealizedInvestmentGainsLosses" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="pirs_OperatingLeaseRightOfUseAssetAccretion" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_RealizedInvestmentGainsLosses" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="pirs_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireInvestments" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-3-revenue-disaggregation-of-revenue-details" xlink:href="pirs-20221231.xsd#statement-note-3-revenue-disaggregation-of-revenue-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.pieris.com/20221231/role/statement-note-3-revenue-disaggregation-of-revenue-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_AstraZenecaABMember" xlink:label="pirs_AstraZenecaABMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_BostonPharmaceuticalsMember" xlink:label="pirs_BostonPharmaceuticalsMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_GenentechMember" xlink:label="pirs_GenentechMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember" xlink:label="pirs_LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_SeattleGeneticsIncMember" xlink:label="pirs_SeattleGeneticsIncMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="pirs_AstraZenecaABMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="pirs_SeattleGeneticsIncMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="pirs_LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="pirs_GenentechMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="pirs_BostonPharmaceuticalsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-cash-equivalents-and-investments-carried-at-fair-value-details" xlink:href="pirs-20221231.xsd#statement-note-5-cash-cash-equivalents-and-investments-cash-equivalents-and-investments-carried-at-fair-value-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-cash-equivalents-and-investments-carried-at-fair-value-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_CashEquivalentsAndInvestments" xlink:label="pirs_CashEquivalentsAndInvestments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:label="us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_AssetBackedSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateBondSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_CashEquivalentsAndInvestments" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-6-property-and-equipment-net-property-and-equipment-details" xlink:href="pirs-20221231.xsd#statement-note-6-property-and-equipment-net-property-and-equipment-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.pieris.com/20221231/role/statement-note-6-property-and-equipment-net-property-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_LaboratoryEquipmentMember" xlink:label="pirs_LaboratoryEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pirs_LaboratoryEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-7-accrued-expenses-accrued-expenses-and-other-current-liabilities-details" xlink:href="pirs-20221231.xsd#statement-note-7-accrued-expenses-accrued-expenses-and-other-current-liabilities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.pieris.com/20221231/role/statement-note-7-accrued-expenses-accrued-expenses-and-other-current-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_AccruedAccountsPayableCurrent" xlink:label="pirs_AccruedAccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_AccruedCollaborationCostsCurrent" xlink:label="pirs_AccruedCollaborationCostsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_AccruedLiabilitiesAndOtherCurrentLiabilitiesMember" xlink:label="pirs_AccruedLiabilitiesAndOtherCurrentLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:label="pirs_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_AccruedLicenseObligationsCurrent" xlink:label="pirs_AccruedLicenseObligationsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_AccruedResearchAndDevelopmentCosts" xlink:label="pirs_AccruedResearchAndDevelopmentCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="pirs_AccruedLiabilitiesAndOtherCurrentLiabilitiesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_AccruedResearchAndDevelopmentCosts" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_AccruedLicenseObligationsCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_AccruedAccountsPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_AccruedCollaborationCostsCurrent" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details" xlink:href="pirs-20221231.xsd#statement-note-8-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-schedule-of-employee-service-sharebased-compensation-costs-details" xlink:href="pirs-20221231.xsd#statement-note-11-stock-and-employee-benefit-plans-schedule-of-employee-service-sharebased-compensation-costs-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-schedule-of-employee-service-sharebased-compensation-costs-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-13-leases-operating-lease-costs-details" xlink:href="pirs-20221231.xsd#statement-note-13-leases-operating-lease-costs-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.pieris.com/20221231/role/statement-note-13-leases-operating-lease-costs-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseCost" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_VariableLeaseCost" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LeaseCost" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets" xlink:href="pirs-20221231.xsd#statement-consolidated-balance-sheets" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:label="pirs_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="pirs_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_Liabilities" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details" xlink:href="pirs-20221231.xsd#statement-note-8-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-8-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:href="pirs-20221231.xsd#statement-note-8-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.pieris.com/20221231/role/statement-note-8-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_DeferredTaxAssetLeaseLiability" xlink:label="pirs_DeferredTaxAssetLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_DeferredTaxAssetsAccruedCompensationAndOther" xlink:label="pirs_DeferredTaxAssetsAccruedCompensationAndOther" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:label="pirs_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_DeferredTaxAssetsDepreciationAndOther" xlink:label="pirs_DeferredTaxAssetsDepreciationAndOther" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_DeferredTaxLiabilitiesLeaseRightofuseAsset" xlink:label="pirs_DeferredTaxLiabilitiesLeaseRightofuseAsset" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xlink:label="us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpense" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_DeferredTaxAssetsAccruedCompensationAndOther" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_DeferredTaxAssetsDepreciationAndOther" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_DeferredTaxAssetLeaseLiability" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsGross" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_DeferredTaxLiabilitiesLeaseRightofuseAsset" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpense" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity" xlink:href="pirs-20221231.xsd#statement-consolidated-statements-of-changes-in-stockholders-equity" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.pieris.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="pirs-20221231.xsd#pirs_AtTheMarketOfferingMember" xlink:label="pirs_AtTheMarketOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_ConversionOfPreferredStockMember" xlink:label="pirs_ConversionOfPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_ConversionOfSeriesEPreferredStockMember" xlink:label="pirs_ConversionOfSeriesEPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="pirs_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:label="pirs_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesFromStockholderMember" xlink:label="us-gaap_ReceivablesFromStockholderMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="pirs_ConversionOfPreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="pirs_ConversionOfSeriesEPreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pirs_AtTheMarketOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_ReceivablesFromStockholderMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-stock-options-activity-details" xlink:href="pirs-20221231.xsd#statement-note-11-stock-and-employee-benefit-plans-stock-options-activity-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-stock-options-activity-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" xlink:label="pirs_EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_ExecutiveOfficersAndManagementMember" xlink:label="pirs_ExecutiveOfficersAndManagementMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm2Exercised" xlink:label="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm2Exercised" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAggregateIntrinsicValue" xlink:label="pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAggregateIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodAggregateIntrinsicValue" xlink:label="pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodAggregateIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pirs_EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="pirs_ExecutiveOfficersAndManagementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodAggregateIntrinsicValue" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAggregateIntrinsicValue" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm2Exercised" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>pirs-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 06:44PM UTC 2023-03-31--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="pirs-20221231.xsd#pirs_DocumentAndEntityInformation" xlink:label="pirs_DocumentAndEntityInformation" xlink:type="locator"/>
    <link:label xlink:label="pirs_DocumentAndEntityInformation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_DocumentAndEntityInformation" xlink:to="pirs_DocumentAndEntityInformation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividend yield</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NoteToFinancialStatementDetailsTextual" xlink:label="pirs_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:label xlink:label="pirs_NoteToFinancialStatementDetailsTextual-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note To Financial Statement Details Textual</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_NoteToFinancialStatementDetailsTextual" xlink:to="pirs_NoteToFinancialStatementDetailsTextual-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_statement-statement-significant-accounting-policies-policies" xlink:label="pirs_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:label xlink:label="pirs_statement-statement-significant-accounting-policies-policies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_statement-statement-significant-accounting-policies-policies" xlink:to="pirs_statement-statement-significant-accounting-policies-policies-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_statement-statement-note-2-summary-of-significant-accounting-policies-tables" xlink:label="pirs_statement-statement-note-2-summary-of-significant-accounting-policies-tables" xlink:type="locator"/>
    <link:label xlink:label="pirs_statement-statement-note-2-summary-of-significant-accounting-policies-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 2 - Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_statement-statement-note-2-summary-of-significant-accounting-policies-tables" xlink:to="pirs_statement-statement-note-2-summary-of-significant-accounting-policies-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_statement-statement-note-3-revenue-tables" xlink:label="pirs_statement-statement-note-3-revenue-tables" xlink:type="locator"/>
    <link:label xlink:label="pirs_statement-statement-note-3-revenue-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 3 - Revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_statement-statement-note-3-revenue-tables" xlink:to="pirs_statement-statement-note-3-revenue-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantsReceivable" xlink:label="us-gaap_GrantsReceivable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GrantsReceivable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_GrantsReceivable</link:label>
    <link:label xlink:label="us-gaap_GrantsReceivable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grants Receivable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantsReceivable" xlink:to="us-gaap_GrantsReceivable-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_statement-statement-note-5-cash-cash-equivalents-and-investments-tables" xlink:label="pirs_statement-statement-note-5-cash-cash-equivalents-and-investments-tables" xlink:type="locator"/>
    <link:label xlink:label="pirs_statement-statement-note-5-cash-cash-equivalents-and-investments-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 5 - Cash, Cash Equivalents and Investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_statement-statement-note-5-cash-cash-equivalents-and-investments-tables" xlink:to="pirs_statement-statement-note-5-cash-cash-equivalents-and-investments-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risk free interest rate, maximum</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_statement-statement-note-6-property-and-equipment-net-tables" xlink:label="pirs_statement-statement-note-6-property-and-equipment-net-tables" xlink:type="locator"/>
    <link:label xlink:label="pirs_statement-statement-note-6-property-and-equipment-net-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 6 - Property and Equipment, Net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_statement-statement-note-6-property-and-equipment-net-tables" xlink:to="pirs_statement-statement-note-6-property-and-equipment-net-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_statement-statement-note-7-accrued-expenses-tables" xlink:label="pirs_statement-statement-note-7-accrued-expenses-tables" xlink:type="locator"/>
    <link:label xlink:label="pirs_statement-statement-note-7-accrued-expenses-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Accrued Expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_statement-statement-note-7-accrued-expenses-tables" xlink:to="pirs_statement-statement-note-7-accrued-expenses-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_statement-statement-note-8-income-taxes-tables" xlink:label="pirs_statement-statement-note-8-income-taxes-tables" xlink:type="locator"/>
    <link:label xlink:label="pirs_statement-statement-note-8-income-taxes-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Income Taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_statement-statement-note-8-income-taxes-tables" xlink:to="pirs_statement-statement-note-8-income-taxes-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:label="pirs_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:type="locator"/>
    <link:label xlink:label="pirs_DeferredTaxAssetsCapitalizedResearchAndDevelopment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capitalized R&amp;D</link:label>
    <link:label xlink:label="pirs_DeferredTaxAssetsCapitalizedResearchAndDevelopment-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Capitalized Research and Development</link:label>
    <link:label xlink:label="pirs_DeferredTaxAssetsCapitalizedResearchAndDevelopment-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to capitalized research and development.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:to="pirs_DeferredTaxAssetsCapitalizedResearchAndDevelopment-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_statement-statement-note-11-stock-and-employee-benefit-plans-tables" xlink:label="pirs_statement-statement-note-11-stock-and-employee-benefit-plans-tables" xlink:type="locator"/>
    <link:label xlink:label="pirs_statement-statement-note-11-stock-and-employee-benefit-plans-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 11 - Stock and Employee Benefit Plans</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_statement-statement-note-11-stock-and-employee-benefit-plans-tables" xlink:to="pirs_statement-statement-note-11-stock-and-employee-benefit-plans-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_statement-statement-note-13-leases-tables" xlink:label="pirs_statement-statement-note-13-leases-tables" xlink:type="locator"/>
    <link:label xlink:label="pirs_statement-statement-note-13-leases-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 13 - Leases</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_statement-statement-note-13-leases-tables" xlink:to="pirs_statement-statement-note-13-leases-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized (loss) gain on available-for-sale securities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="pirs_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="locator"/>
    <link:label xlink:label="pirs_IncreaseDecreaseInOperatingLeaseLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">pirs_IncreaseDecreaseInOperatingLeaseLiabilities</link:label>
    <link:label xlink:label="pirs_IncreaseDecreaseInOperatingLeaseLiabilities-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:label xlink:label="pirs_IncreaseDecreaseInOperatingLeaseLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of increase (decrease) in operating lease liabilities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="pirs_IncreaseDecreaseInOperatingLeaseLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_statement-statement-note-2-summary-of-significant-accounting-policies-schedule-of-property-plant-and-equipment-useful-lives-details" xlink:label="pirs_statement-statement-note-2-summary-of-significant-accounting-policies-schedule-of-property-plant-and-equipment-useful-lives-details" xlink:type="locator"/>
    <link:label xlink:label="pirs_statement-statement-note-2-summary-of-significant-accounting-policies-schedule-of-property-plant-and-equipment-useful-lives-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 2 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment, Useful Lives (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_statement-statement-note-2-summary-of-significant-accounting-policies-schedule-of-property-plant-and-equipment-useful-lives-details" xlink:to="pirs_statement-statement-note-2-summary-of-significant-accounting-policies-schedule-of-property-plant-and-equipment-useful-lives-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risk free interest rate, minimum</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_statement-statement-note-3-revenue-disaggregation-of-revenue-details" xlink:label="pirs_statement-statement-note-3-revenue-disaggregation-of-revenue-details" xlink:type="locator"/>
    <link:label xlink:label="pirs_statement-statement-note-3-revenue-disaggregation-of-revenue-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 3 - Revenue - Disaggregation of Revenue (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_statement-statement-note-3-revenue-disaggregation-of-revenue-details" xlink:to="pirs_statement-statement-note-3-revenue-disaggregation-of-revenue-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized loss on investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected volatility, minimum</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_statement-statement-note-3-revenue-potential-milestone-payments-received-details" xlink:label="pirs_statement-statement-note-3-revenue-potential-milestone-payments-received-details" xlink:type="locator"/>
    <link:label xlink:label="pirs_statement-statement-note-3-revenue-potential-milestone-payments-received-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 3 - Revenue - Potential Milestone Payments Received (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_statement-statement-note-3-revenue-potential-milestone-payments-received-details" xlink:to="pirs_statement-statement-note-3-revenue-potential-milestone-payments-received-details-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_statement-statement-note-5-cash-cash-equivalents-and-investments-cash-equivalents-and-investments-carried-at-fair-value-details" xlink:label="pirs_statement-statement-note-5-cash-cash-equivalents-and-investments-cash-equivalents-and-investments-carried-at-fair-value-details" xlink:type="locator"/>
    <link:label xlink:label="pirs_statement-statement-note-5-cash-cash-equivalents-and-investments-cash-equivalents-and-investments-carried-at-fair-value-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 5 - Cash, Cash Equivalents and Investments - Cash Equivalents and Investments Carried at Fair Value (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_statement-statement-note-5-cash-cash-equivalents-and-investments-cash-equivalents-and-investments-carried-at-fair-value-details" xlink:to="pirs_statement-statement-note-5-cash-cash-equivalents-and-investments-cash-equivalents-and-investments-carried-at-fair-value-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected volatility, maximum</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_statement-statement-note-5-cash-cash-equivalents-and-investments-investments-details" xlink:label="pirs_statement-statement-note-5-cash-cash-equivalents-and-investments-investments-details" xlink:type="locator"/>
    <link:label xlink:label="pirs_statement-statement-note-5-cash-cash-equivalents-and-investments-investments-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 5 - Cash, Cash Equivalents and Investments - Investments (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_statement-statement-note-5-cash-cash-equivalents-and-investments-investments-details" xlink:to="pirs_statement-statement-note-5-cash-cash-equivalents-and-investments-investments-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesCurrent</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_ResearchTermExtensionPeriod" xlink:label="pirs_ResearchTermExtensionPeriod" xlink:type="locator"/>
    <link:label xlink:label="pirs_ResearchTermExtensionPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">pirs_ResearchTermExtensionPeriod</link:label>
    <link:label xlink:label="pirs_ResearchTermExtensionPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research Term ,Extension Period (Year)</link:label>
    <link:label xlink:label="pirs_ResearchTermExtensionPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period in which research term is extended.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_ResearchTermExtensionPeriod" xlink:to="pirs_ResearchTermExtensionPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_statement-statement-note-6-property-and-equipment-net-property-and-equipment-details" xlink:label="pirs_statement-statement-note-6-property-and-equipment-net-property-and-equipment-details" xlink:type="locator"/>
    <link:label xlink:label="pirs_statement-statement-note-6-property-and-equipment-net-property-and-equipment-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 6 - Property and Equipment, Net - Property and Equipment (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_statement-statement-note-6-property-and-equipment-net-property-and-equipment-details" xlink:to="pirs_statement-statement-note-6-property-and-equipment-net-property-and-equipment-details-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NumberOfPreclinicalStagePrograms" xlink:label="pirs_NumberOfPreclinicalStagePrograms" xlink:type="locator"/>
    <link:label xlink:label="pirs_NumberOfPreclinicalStagePrograms-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">pirs_NumberOfPreclinicalStagePrograms</link:label>
    <link:label xlink:label="pirs_NumberOfPreclinicalStagePrograms-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number Of Preclinical Stage Programs</link:label>
    <link:label xlink:label="pirs_NumberOfPreclinicalStagePrograms-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the number of preclinical stage programs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_NumberOfPreclinicalStagePrograms" xlink:to="pirs_NumberOfPreclinicalStagePrograms-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_statement-statement-note-7-accrued-expenses-accrued-expenses-and-other-current-liabilities-details" xlink:label="pirs_statement-statement-note-7-accrued-expenses-accrued-expenses-and-other-current-liabilities-details" xlink:type="locator"/>
    <link:label xlink:label="pirs_statement-statement-note-7-accrued-expenses-accrued-expenses-and-other-current-liabilities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Accrued Expenses - Accrued Expenses and Other Current Liabilities (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_statement-statement-note-7-accrued-expenses-accrued-expenses-and-other-current-liabilities-details" xlink:to="pirs_statement-statement-note-7-accrued-expenses-accrued-expenses-and-other-current-liabilities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_CodevelopmentCollaborationProductCollaborationMember" xlink:label="pirs_CodevelopmentCollaborationProductCollaborationMember" xlink:type="locator"/>
    <link:label xlink:label="pirs_CodevelopmentCollaborationProductCollaborationMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Co-Development Collaboration Product Collaboration [Member]</link:label>
    <link:label xlink:label="pirs_CodevelopmentCollaborationProductCollaborationMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to collaboration in the Co-Development Collaboration Product</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_CodevelopmentCollaborationProductCollaborationMember" xlink:to="pirs_CodevelopmentCollaborationProductCollaborationMember-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_statement-statement-note-8-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details" xlink:label="pirs_statement-statement-note-8-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details" xlink:type="locator"/>
    <link:label xlink:label="pirs_statement-statement-note-8-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Income Taxes - Schedule of Income Before Income Tax Domestic and Foreign (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_statement-statement-note-8-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details" xlink:to="pirs_statement-statement-note-8-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_ServierDevelopedCollaborationProductsMember" xlink:label="pirs_ServierDevelopedCollaborationProductsMember" xlink:type="locator"/>
    <link:label xlink:label="pirs_ServierDevelopedCollaborationProductsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Servier Developed Collaboration Products [Member]</link:label>
    <link:label xlink:label="pirs_ServierDevelopedCollaborationProductsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to the Servier Developed Collaboration Products</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_ServierDevelopedCollaborationProductsMember" xlink:to="pirs_ServierDevelopedCollaborationProductsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected term (in years) (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetBackedSecuritiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset-Backed Securities [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetBackedSecuritiesMember" xlink:to="us-gaap_AssetBackedSecuritiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_statement-statement-note-8-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details" xlink:label="pirs_statement-statement-note-8-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details" xlink:type="locator"/>
    <link:label xlink:label="pirs_statement-statement-note-8-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_statement-statement-note-8-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details" xlink:to="pirs_statement-statement-note-8-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_statement-statement-note-8-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" xlink:label="pirs_statement-statement-note-8-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" xlink:type="locator"/>
    <link:label xlink:label="pirs_statement-statement-note-8-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_statement-statement-note-8-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" xlink:to="pirs_statement-statement-note-8-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_CollaborativeArrangementAllocableArrangementConsiderationAllocation" xlink:label="pirs_CollaborativeArrangementAllocableArrangementConsiderationAllocation" xlink:type="locator"/>
    <link:label xlink:label="pirs_CollaborativeArrangementAllocableArrangementConsiderationAllocation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">pirs_CollaborativeArrangementAllocableArrangementConsiderationAllocation</link:label>
    <link:label xlink:label="pirs_CollaborativeArrangementAllocableArrangementConsiderationAllocation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Allocable Arrangement Consideration Allocation</link:label>
    <link:label xlink:label="pirs_CollaborativeArrangementAllocableArrangementConsiderationAllocation-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of allocated to collaborative arrangement allocable arrangement consideration.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_CollaborativeArrangementAllocableArrangementConsiderationAllocation" xlink:to="pirs_CollaborativeArrangementAllocableArrangementConsiderationAllocation-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_statement-statement-note-8-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:label="pirs_statement-statement-note-8-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:type="locator"/>
    <link:label xlink:label="pirs_statement-statement-note-8-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Income Tax - Schedule of Deferred Tax Assets and Liabilities (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_statement-statement-note-8-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:to="pirs_statement-statement-note-8-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NumberOfSeparatePerformanceObligations" xlink:label="pirs_NumberOfSeparatePerformanceObligations" xlink:type="locator"/>
    <link:label xlink:label="pirs_NumberOfSeparatePerformanceObligations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">pirs_NumberOfSeparatePerformanceObligations</link:label>
    <link:label xlink:label="pirs_NumberOfSeparatePerformanceObligations-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number Of Separate Performance Obligations</link:label>
    <link:label xlink:label="pirs_NumberOfSeparatePerformanceObligations-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents number of separate performance obligations</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_NumberOfSeparatePerformanceObligations" xlink:to="pirs_NumberOfSeparatePerformanceObligations-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_statement-statement-note-8-income-taxes-summary-of-income-tax-contingencies-details" xlink:label="pirs_statement-statement-note-8-income-taxes-summary-of-income-tax-contingencies-details" xlink:type="locator"/>
    <link:label xlink:label="pirs_statement-statement-note-8-income-taxes-summary-of-income-tax-contingencies-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Income Taxes - Summary of Income Tax Contingencies (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_statement-statement-note-8-income-taxes-summary-of-income-tax-contingencies-details" xlink:to="pirs_statement-statement-note-8-income-taxes-summary-of-income-tax-contingencies-details-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NumberOfCombinedPerformanceObligations" xlink:label="pirs_NumberOfCombinedPerformanceObligations" xlink:type="locator"/>
    <link:label xlink:label="pirs_NumberOfCombinedPerformanceObligations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">pirs_NumberOfCombinedPerformanceObligations</link:label>
    <link:label xlink:label="pirs_NumberOfCombinedPerformanceObligations-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Combined Performance Obligations</link:label>
    <link:label xlink:label="pirs_NumberOfCombinedPerformanceObligations-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the number of combined performance obligations</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_NumberOfCombinedPerformanceObligations" xlink:to="pirs_NumberOfCombinedPerformanceObligations-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_statement-statement-note-11-stock-and-employee-benefit-plans-schedule-of-sharebased-payment-award-stock-options-details" xlink:label="pirs_statement-statement-note-11-stock-and-employee-benefit-plans-schedule-of-sharebased-payment-award-stock-options-details" xlink:type="locator"/>
    <link:label xlink:label="pirs_statement-statement-note-11-stock-and-employee-benefit-plans-schedule-of-sharebased-payment-award-stock-options-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 11 - Stock and Employee Benefit Plans - Schedule of Share-based Payment Award, Stock Options (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_statement-statement-note-11-stock-and-employee-benefit-plans-schedule-of-sharebased-payment-award-stock-options-details" xlink:to="pirs_statement-statement-note-11-stock-and-employee-benefit-plans-schedule-of-sharebased-payment-award-stock-options-details-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_TradeTaxMember" xlink:label="pirs_TradeTaxMember" xlink:type="locator"/>
    <link:label xlink:label="pirs_TradeTaxMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade Tax [Member]</link:label>
    <link:label xlink:label="pirs_TradeTaxMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to trade tax</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_TradeTaxMember" xlink:to="pirs_TradeTaxMember-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_statement-statement-note-11-stock-and-employee-benefit-plans-stock-options-activity-details" xlink:label="pirs_statement-statement-note-11-stock-and-employee-benefit-plans-stock-options-activity-details" xlink:type="locator"/>
    <link:label xlink:label="pirs_statement-statement-note-11-stock-and-employee-benefit-plans-stock-options-activity-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 11 - Stock and Employee Benefit Plans - Stock Options Activity (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_statement-statement-note-11-stock-and-employee-benefit-plans-stock-options-activity-details" xlink:to="pirs_statement-statement-note-11-stock-and-employee-benefit-plans-stock-options-activity-details-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_LicenseAndTransferAgreementTextBlock" xlink:label="pirs_LicenseAndTransferAgreementTextBlock" xlink:type="locator"/>
    <link:label xlink:label="pirs_LicenseAndTransferAgreementTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License and Transfer Agreement [Text Block]</link:label>
    <link:label xlink:label="pirs_LicenseAndTransferAgreementTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of the entity's license and transfer agreements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_LicenseAndTransferAgreementTextBlock" xlink:to="pirs_LicenseAndTransferAgreementTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_statement-statement-note-11-stock-and-employee-benefit-plans-schedule-of-employee-service-sharebased-compensation-costs-details" xlink:label="pirs_statement-statement-note-11-stock-and-employee-benefit-plans-schedule-of-employee-service-sharebased-compensation-costs-details" xlink:type="locator"/>
    <link:label xlink:label="pirs_statement-statement-note-11-stock-and-employee-benefit-plans-schedule-of-employee-service-sharebased-compensation-costs-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 11 - Stock and Employee Benefit Plans - Schedule of Employee Service Share-based Compensation Costs (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_statement-statement-note-11-stock-and-employee-benefit-plans-schedule-of-employee-service-sharebased-compensation-costs-details" xlink:to="pirs_statement-statement-note-11-stock-and-employee-benefit-plans-schedule-of-employee-service-sharebased-compensation-costs-details-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_statement-statement-note-13-leases-operating-lease-costs-details" xlink:label="pirs_statement-statement-note-13-leases-operating-lease-costs-details" xlink:type="locator"/>
    <link:label xlink:label="pirs_statement-statement-note-13-leases-operating-lease-costs-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 13 - Leases - Operating Lease Costs (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_statement-statement-note-13-leases-operating-lease-costs-details" xlink:to="pirs_statement-statement-note-13-leases-operating-lease-costs-details-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_statement-statement-note-13-leases-maturities-of-operating-lease-liabilities-details" xlink:label="pirs_statement-statement-note-13-leases-maturities-of-operating-lease-liabilities-details" xlink:type="locator"/>
    <link:label xlink:label="pirs_statement-statement-note-13-leases-maturities-of-operating-lease-liabilities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 13 - Leases - Maturities of Operating Lease Liabilities (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_statement-statement-note-13-leases-maturities-of-operating-lease-liabilities-details" xlink:to="pirs_statement-statement-note-13-leases-maturities-of-operating-lease-liabilities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:label="us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ForeignGovernmentDebtSecuritiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Security, Government, Non-US [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:to="us-gaap_ForeignGovernmentDebtSecuritiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NotesToFinancialStatements" xlink:label="pirs_NotesToFinancialStatements" xlink:type="locator"/>
    <link:label xlink:label="pirs_NotesToFinancialStatements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_NotesToFinancialStatements" xlink:to="pirs_NotesToFinancialStatements-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NotesToFinancialStatementsAbstract" xlink:label="pirs_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:label xlink:label="pirs_NotesToFinancialStatementsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_NotesToFinancialStatementsAbstract" xlink:to="pirs_NotesToFinancialStatementsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_CorporateIncomeTaxMember" xlink:label="pirs_CorporateIncomeTaxMember" xlink:type="locator"/>
    <link:label xlink:label="pirs_CorporateIncomeTaxMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Income Tax [Member]</link:label>
    <link:label xlink:label="pirs_CorporateIncomeTaxMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to corporate income tax</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_CorporateIncomeTaxMember" xlink:to="pirs_CorporateIncomeTaxMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</link:label>
    <link:label xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_USTreasurySecuritiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign currency translation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_EffectiveIncomeTaxRateReconciliationProvisionToReturnPercent" xlink:label="pirs_EffectiveIncomeTaxRateReconciliationProvisionToReturnPercent" xlink:type="locator"/>
    <link:label xlink:label="pirs_EffectiveIncomeTaxRateReconciliationProvisionToReturnPercent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provision to return</link:label>
    <link:label xlink:label="pirs_EffectiveIncomeTaxRateReconciliationProvisionToReturnPercent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) from provision to return.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_EffectiveIncomeTaxRateReconciliationProvisionToReturnPercent" xlink:to="pirs_EffectiveIncomeTaxRateReconciliationProvisionToReturnPercent-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_DeferredTaxAssetsAccruedCompensationAndOther" xlink:label="pirs_DeferredTaxAssetsAccruedCompensationAndOther" xlink:type="locator"/>
    <link:label xlink:label="pirs_DeferredTaxAssetsAccruedCompensationAndOther-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued expenses, tax assets</link:label>
    <link:label xlink:label="pirs_DeferredTaxAssetsAccruedCompensationAndOther-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued compensation and other costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_DeferredTaxAssetsAccruedCompensationAndOther" xlink:to="pirs_DeferredTaxAssetsAccruedCompensationAndOther-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from maturity of investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_DeferredTaxAssetsDepreciationAndOther" xlink:label="pirs_DeferredTaxAssetsDepreciationAndOther" xlink:type="locator"/>
    <link:label xlink:label="pirs_DeferredTaxAssetsDepreciationAndOther-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation and other</link:label>
    <link:label xlink:label="pirs_DeferredTaxAssetsDepreciationAndOther-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from depreciation and other expenses.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_DeferredTaxAssetsDepreciationAndOther" xlink:to="pirs_DeferredTaxAssetsDepreciationAndOther-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_DeferredTaxAssetLeaseLiability" xlink:label="pirs_DeferredTaxAssetLeaseLiability" xlink:type="locator"/>
    <link:label xlink:label="pirs_DeferredTaxAssetLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease liability</link:label>
    <link:label xlink:label="pirs_DeferredTaxAssetLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liability</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_DeferredTaxAssetLeaseLiability" xlink:to="pirs_DeferredTaxAssetLeaseLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vested or expected to vest, contractual life (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercisable, intrinsic value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vested or expected to vest, balance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vested or expected to vest, exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_SeriesAThroughEMember" xlink:label="pirs_SeriesAThroughEMember" xlink:type="locator"/>
    <link:label xlink:label="pirs_SeriesAThroughEMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A Through E [Member]</link:label>
    <link:label xlink:label="pirs_SeriesAThroughEMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to Series A through E Preferred stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_SeriesAThroughEMember" xlink:to="pirs_SeriesAThroughEMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vested or expected to vest, intrinsic value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_DeferredTaxLiabilitiesLeaseRightofuseAsset" xlink:label="pirs_DeferredTaxLiabilitiesLeaseRightofuseAsset" xlink:type="locator"/>
    <link:label xlink:label="pirs_DeferredTaxLiabilitiesLeaseRightofuseAsset-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">pirs_DeferredTaxLiabilitiesLeaseRightofuseAsset</link:label>
    <link:label xlink:label="pirs_DeferredTaxLiabilitiesLeaseRightofuseAsset-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Right-of-use asset</link:label>
    <link:label xlink:label="pirs_DeferredTaxLiabilitiesLeaseRightofuseAsset-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of deferred tax liability attributable to taxable temporary differences from lease right-of-use assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_DeferredTaxLiabilitiesLeaseRightofuseAsset" xlink:to="pirs_DeferredTaxLiabilitiesLeaseRightofuseAsset-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercisable, exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsToAcquireInvestments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsToAcquireInvestments</link:label>
    <link:label xlink:label="us-gaap_PaymentsToAcquireInvestments-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInvestments" xlink:to="us-gaap_PaymentsToAcquireInvestments-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NumberOfVotesPerShare" xlink:label="pirs_NumberOfVotesPerShare" xlink:type="locator"/>
    <link:label xlink:label="pirs_NumberOfVotesPerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">pirs_NumberOfVotesPerShare</link:label>
    <link:label xlink:label="pirs_NumberOfVotesPerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number Of Votes Per Share</link:label>
    <link:label xlink:label="pirs_NumberOfVotesPerShare-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the number of votes per share</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_NumberOfVotesPerShare" xlink:to="pirs_NumberOfVotesPerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_ProceedsFromIssuanceOfPrivatePlacementNet" xlink:label="pirs_ProceedsFromIssuanceOfPrivatePlacementNet" xlink:type="locator"/>
    <link:label xlink:label="pirs_ProceedsFromIssuanceOfPrivatePlacementNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">pirs_ProceedsFromIssuanceOfPrivatePlacementNet</link:label>
    <link:label xlink:label="pirs_ProceedsFromIssuanceOfPrivatePlacementNet-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds From Issuance Of Private Placement Net</link:label>
    <link:label xlink:label="pirs_ProceedsFromIssuanceOfPrivatePlacementNet-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of net proceeds from issuance of private placement</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_ProceedsFromIssuanceOfPrivatePlacementNet" xlink:to="pirs_ProceedsFromIssuanceOfPrivatePlacementNet-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_StockExchangeSharesFromExistingShareholdersMember" xlink:label="pirs_StockExchangeSharesFromExistingShareholdersMember" xlink:type="locator"/>
    <link:label xlink:label="pirs_StockExchangeSharesFromExistingShareholdersMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Exchange Shares from Existing Shareholders [Member]</link:label>
    <link:label xlink:label="pirs_StockExchangeSharesFromExistingShareholdersMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to stock exchange shares from existing shareholders</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_StockExchangeSharesFromExistingShareholdersMember" xlink:to="pirs_StockExchangeSharesFromExistingShareholdersMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercised, intrinsic value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_PreferredShareExchangeMember" xlink:label="pirs_PreferredShareExchangeMember" xlink:type="locator"/>
    <link:label xlink:label="pirs_PreferredShareExchangeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Share Exchange [Member]</link:label>
    <link:label xlink:label="pirs_PreferredShareExchangeMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to preferred share exchange</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_PreferredShareExchangeMember" xlink:to="pirs_PreferredShareExchangeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_SaleOfStockNumberOfWarrantsPerUnit" xlink:label="pirs_SaleOfStockNumberOfWarrantsPerUnit" xlink:type="locator"/>
    <link:label xlink:label="pirs_SaleOfStockNumberOfWarrantsPerUnit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">pirs_SaleOfStockNumberOfWarrantsPerUnit</link:label>
    <link:label xlink:label="pirs_SaleOfStockNumberOfWarrantsPerUnit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Warrants, Per Unit (in shares)</link:label>
    <link:label xlink:label="pirs_SaleOfStockNumberOfWarrantsPerUnit-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the number of warrants issued per unit in a sale of stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_SaleOfStockNumberOfWarrantsPerUnit" xlink:to="pirs_SaleOfStockNumberOfWarrantsPerUnit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercisable, balance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_ConvertiblePreferredStockCommonStockOwnershipLimitPercent" xlink:label="pirs_ConvertiblePreferredStockCommonStockOwnershipLimitPercent" xlink:type="locator"/>
    <link:label xlink:label="pirs_ConvertiblePreferredStockCommonStockOwnershipLimitPercent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">pirs_ConvertiblePreferredStockCommonStockOwnershipLimitPercent</link:label>
    <link:label xlink:label="pirs_ConvertiblePreferredStockCommonStockOwnershipLimitPercent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Common Stock Ownership Limit, Percent</link:label>
    <link:label xlink:label="pirs_ConvertiblePreferredStockCommonStockOwnershipLimitPercent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of common stock ownership limit of convertible preferred stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_ConvertiblePreferredStockCommonStockOwnershipLimitPercent" xlink:to="pirs_ConvertiblePreferredStockCommonStockOwnershipLimitPercent-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_ConvertiblePreferredStockBeneficialOwnershipLimitationPercent" xlink:label="pirs_ConvertiblePreferredStockBeneficialOwnershipLimitationPercent" xlink:type="locator"/>
    <link:label xlink:label="pirs_ConvertiblePreferredStockBeneficialOwnershipLimitationPercent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">pirs_ConvertiblePreferredStockBeneficialOwnershipLimitationPercent</link:label>
    <link:label xlink:label="pirs_ConvertiblePreferredStockBeneficialOwnershipLimitationPercent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Beneficial Ownership Limitation, Percent</link:label>
    <link:label xlink:label="pirs_ConvertiblePreferredStockBeneficialOwnershipLimitationPercent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of beneficial ownership limitation for convertible preferred stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_ConvertiblePreferredStockBeneficialOwnershipLimitationPercent" xlink:to="pirs_ConvertiblePreferredStockBeneficialOwnershipLimitationPercent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding, contractual life (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_ConvertiblePreferredStockBeneficialOwnershipLimitationNoticePeriodBeforeIncrease" xlink:label="pirs_ConvertiblePreferredStockBeneficialOwnershipLimitationNoticePeriodBeforeIncrease" xlink:type="locator"/>
    <link:label xlink:label="pirs_ConvertiblePreferredStockBeneficialOwnershipLimitationNoticePeriodBeforeIncrease-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">pirs_ConvertiblePreferredStockBeneficialOwnershipLimitationNoticePeriodBeforeIncrease</link:label>
    <link:label xlink:label="pirs_ConvertiblePreferredStockBeneficialOwnershipLimitationNoticePeriodBeforeIncrease-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Beneficial Ownership Limitation, Notice Period Before Increase (Year)</link:label>
    <link:label xlink:label="pirs_ConvertiblePreferredStockBeneficialOwnershipLimitationNoticePeriodBeforeIncrease-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period in which the entity must notify an increase in beneficial ownership limitation.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_ConvertiblePreferredStockBeneficialOwnershipLimitationNoticePeriodBeforeIncrease" xlink:to="pirs_ConvertiblePreferredStockBeneficialOwnershipLimitationNoticePeriodBeforeIncrease-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, intrinsic value</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, intrinsic value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_SecuritiesPurchaseAgreementMember" xlink:label="pirs_SecuritiesPurchaseAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="pirs_SecuritiesPurchaseAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
    <link:label xlink:label="pirs_SecuritiesPurchaseAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to securities purchase agreement</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_SecuritiesPurchaseAgreementMember" xlink:to="pirs_SecuritiesPurchaseAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_ExecutiveOfficersAndManagementMember" xlink:label="pirs_ExecutiveOfficersAndManagementMember" xlink:type="locator"/>
    <link:label xlink:label="pirs_ExecutiveOfficersAndManagementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Officers and Management [Member]</link:label>
    <link:label xlink:label="pirs_ExecutiveOfficersAndManagementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to executive officers and management</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_ExecutiveOfficersAndManagementMember" xlink:to="pirs_ExecutiveOfficersAndManagementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodAggregateIntrinsicValue" xlink:label="pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodAggregateIntrinsicValue" xlink:type="locator"/>
    <link:label xlink:label="pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodAggregateIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted, intrinsic value</link:label>
    <link:label xlink:label="pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodAggregateIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount by which the current fair value of the underlying stock exceeds the exercise price of options granted</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodAggregateIntrinsicValue" xlink:to="pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodAggregateIntrinsicValue-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAggregateIntrinsicValue" xlink:label="pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAggregateIntrinsicValue" xlink:type="locator"/>
    <link:label xlink:label="pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAggregateIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Canceled, intrinsic value</link:label>
    <link:label xlink:label="pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAggregateIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount by which the current fair value of the underlying stock exceeds the exercise price of options canceled</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAggregateIntrinsicValue" xlink:to="pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAggregateIntrinsicValue-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm2Exercised" xlink:label="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm2Exercised" xlink:type="locator"/>
    <link:label xlink:label="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm2Exercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercisable, contractual life (Year)</link:label>
    <link:label xlink:label="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm2Exercised-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period in which stock options are exercisable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm2Exercised" xlink:to="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm2Exercised-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_ConvertiblePreferredStockWeightedAverageStockPricePercent" xlink:label="pirs_ConvertiblePreferredStockWeightedAverageStockPricePercent" xlink:type="locator"/>
    <link:label xlink:label="pirs_ConvertiblePreferredStockWeightedAverageStockPricePercent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">pirs_ConvertiblePreferredStockWeightedAverageStockPricePercent</link:label>
    <link:label xlink:label="pirs_ConvertiblePreferredStockWeightedAverageStockPricePercent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Weighted Average Stock Price, Percent</link:label>
    <link:label xlink:label="pirs_ConvertiblePreferredStockWeightedAverageStockPricePercent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of weighted average convertible preferred stock price</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_ConvertiblePreferredStockWeightedAverageStockPricePercent" xlink:to="pirs_ConvertiblePreferredStockWeightedAverageStockPricePercent-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfPurchasePeriods" xlink:label="pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfPurchasePeriods" xlink:type="locator"/>
    <link:label xlink:label="pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfPurchasePeriods-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfPurchasePeriods</link:label>
    <link:label xlink:label="pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfPurchasePeriods-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-based Payment Award, Number of Purchase Periods</link:label>
    <link:label xlink:label="pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfPurchasePeriods-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the number of purchase periods for share based payment award</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfPurchasePeriods" xlink:to="pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfPurchasePeriods-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_ShareBasedCompensationArrangementBySharebasedPaymentAwardPurchasePeriod" xlink:label="pirs_ShareBasedCompensationArrangementBySharebasedPaymentAwardPurchasePeriod" xlink:type="locator"/>
    <link:label xlink:label="pirs_ShareBasedCompensationArrangementBySharebasedPaymentAwardPurchasePeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">pirs_ShareBasedCompensationArrangementBySharebasedPaymentAwardPurchasePeriod</link:label>
    <link:label xlink:label="pirs_ShareBasedCompensationArrangementBySharebasedPaymentAwardPurchasePeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement by Sharebased Payment Award, Purchase Period (Year)</link:label>
    <link:label xlink:label="pirs_ShareBasedCompensationArrangementBySharebasedPaymentAwardPurchasePeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period in which share based compensation awards that can be purchased</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_ShareBasedCompensationArrangementBySharebasedPaymentAwardPurchasePeriod" xlink:to="pirs_ShareBasedCompensationArrangementBySharebasedPaymentAwardPurchasePeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, exercise price (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred revenues, current portion</link:label>
    <link:label xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FinancialInstrumentAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Canceled, exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted, exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercised, exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeasesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, balance (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, balance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property and equipment included in accounts payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Canceled, balance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PolicyTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_PolicyTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</link:label>
    <link:label xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_AccruedLiabilitiesAndOtherCurrentLiabilitiesMember" xlink:label="pirs_AccruedLiabilitiesAndOtherCurrentLiabilitiesMember" xlink:type="locator"/>
    <link:label xlink:label="pirs_AccruedLiabilitiesAndOtherCurrentLiabilitiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities and Other Current Liabilities [Member]</link:label>
    <link:label xlink:label="pirs_AccruedLiabilitiesAndOtherCurrentLiabilitiesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to accrued liabilities and other current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_AccruedLiabilitiesAndOtherCurrentLiabilitiesMember" xlink:to="pirs_AccruedLiabilitiesAndOtherCurrentLiabilitiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SupplementalCashFlowInformationAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental cash flow disclosures:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Assets</link:label>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CapitalizedContractCostNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CapitalizedContractCostNet</link:label>
    <link:label xlink:label="us-gaap_CapitalizedContractCostNet-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized Contract Cost, Net, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedContractCostNet" xlink:to="us-gaap_CapitalizedContractCostNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ContractWithCustomerAssetNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ContractWithCustomerAssetNet</link:label>
    <link:label xlink:label="us-gaap_ContractWithCustomerAssetNet-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetNet" xlink:to="us-gaap_ContractWithCustomerAssetNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent, Total</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AwardTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeStockOptionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</link:label>
    <link:label xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property and equipment, cost</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss per share</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeTaxExpenseBenefit</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Provision for income taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TenantImprovements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TenantImprovements</link:label>
    <link:label xlink:label="us-gaap_TenantImprovements-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tenant Improvements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TenantImprovements" xlink:to="us-gaap_TenantImprovements-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingExpenses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingExpenses</link:label>
    <link:label xlink:label="us-gaap_OperatingExpenses-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccountsPayableTrade</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GeneralAndAdministrativeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based payment arrangement expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Beneficial Conversion Feature</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:to="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ComprehensiveIncomeNetOfTax</link:label>
    <link:label xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UseOfEstimates-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesOutstanding</link:label>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding (in shares)</link:label>
    <link:label xlink:label="us-gaap_CommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding, Ending Balance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding (in shares)</link:label>
    <link:label xlink:label="us-gaap_PreferredStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding, Ending Balance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_CurrentFiscalYearEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VariableLeaseCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable lease costs (1)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LeaseCost</link:label>
    <link:label xlink:label="us-gaap_LeaseCost-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease cost</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss</link:label>
    <link:label xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Realized Gain (Loss), Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalPeriodFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating lease costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalYearFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseCostTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted-average remaining lease term (years) (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:label xlink:label="dei_EntitySmallBusiness-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityShellCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AreaOfRealEstateProperty-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AreaOfRealEstateProperty</link:label>
    <link:label xlink:label="us-gaap_AreaOfRealEstateProperty-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Area of Real Estate Property (Square Foot)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityPublicFloat-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFilerCategory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCurrentReportingStatus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityVoluntaryFilers-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityWellKnownSeasonedIssuer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostGross" xlink:label="us-gaap_CapitalizedContractCostGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CapitalizedContractCostGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CapitalizedContractCostGross</link:label>
    <link:label xlink:label="us-gaap_CapitalizedContractCostGross-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized Contract Cost, Gross</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedContractCostGross" xlink:to="us-gaap_CapitalizedContractCostGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortization" xlink:label="us-gaap_CapitalizedContractCostAmortization" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CapitalizedContractCostAmortization-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CapitalizedContractCostAmortization</link:label>
    <link:label xlink:label="us-gaap_CapitalizedContractCostAmortization-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized Contract Cost, Amortization</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedContractCostAmortization" xlink:to="us-gaap_CapitalizedContractCostAmortization-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccountsReceivable</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock based compensation expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityTaxIdentificationNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock issuance costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:label="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:to="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Units (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock resulting from conversion of preferred stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock resulting from conversion of stock (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock resulting from purchase of employee stock purchase plan shares (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock resulting from exercise of stock options (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TableTextBlock</link:label>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Tables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_TableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock resulting from purchase of employee stock purchase plan shares</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock resulting from exercise of stock options</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted, balance (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_WarrantsAndRightsOutstandingTerm</link:label>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Term (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CollaborativeArrangementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="us-gaap_CollaborativeArrangementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesAndStockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit), Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MoneyMarketFundsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DisclosureTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes to Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherNoncashIncomeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OtherNoncashIncomeExpense</link:label>
    <link:label xlink:label="us-gaap_OtherNoncashIncomeExpense-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other non-cash transactions</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseLiabilityCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseRightOfUseAsset-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total undiscounted lease payments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: present value adjustment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredIncomeTaxExpenseBenefit</link:label>
    <link:label xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnrealizedGainLossOnInvestments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net unrealized loss on investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnInvestments" xlink:to="us-gaap_UnrealizedGainLossOnInvestments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2023</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensation</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherAssetsNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other non-current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeLeasesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Revenues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total revenue</link:label>
    <link:label xlink:label="us-gaap_Revenues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues, Total</link:label>
    <link:label xlink:label="us-gaap_Revenues-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingExpensesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseTermOfContract</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseRenewalTerm</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term (Month)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Depreciation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Depreciation</link:label>
    <link:label xlink:label="us-gaap_Depreciation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConversionOfStockSharesIssued1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock resulting from conversion of preferred stock (in shares)</link:label>
    <link:label xlink:label="us-gaap_ConversionOfStockSharesIssued1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Shares Issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DepreciationDepletionAndAmortization-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConversionOfStockSharesConverted1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ConversionOfStockSharesConverted1</link:label>
    <link:label xlink:label="us-gaap_ConversionOfStockSharesConverted1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Shares Converted (in shares)</link:label>
    <link:label xlink:label="us-gaap_ConversionOfStockSharesConverted1-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock resulting from conversion of preferred stock (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesIssuedPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesIssuedPricePerShare</link:label>
    <link:label xlink:label="us-gaap_SharesIssuedPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares Issued, Price Per Share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Conversion Description [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConversionOfStockNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="us-gaap_ConversionOfStockNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AssetsCurrent</link:label>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money market funds, included in cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:label="us-gaap_RealizedInvestmentGainsLosses" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RealizedInvestmentGainsLosses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_RealizedInvestmentGainsLosses</link:label>
    <link:label xlink:label="us-gaap_RealizedInvestmentGainsLosses-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Realized investment gains</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RealizedInvestmentGainsLosses" xlink:to="us-gaap_RealizedInvestmentGainsLosses-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_AtTheMarketOfferingMember" xlink:label="pirs_AtTheMarketOfferingMember" xlink:type="locator"/>
    <link:label xlink:label="pirs_AtTheMarketOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At the Market Offering [Member]</link:label>
    <link:label xlink:label="pirs_AtTheMarketOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents at the market offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_AtTheMarketOfferingMember" xlink:to="pirs_AtTheMarketOfferingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:label="pirs_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:type="locator"/>
    <link:label xlink:label="pirs_StockIssuedDuringPeriodValueExerciseOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock resulting from exercise of warrants</link:label>
    <link:label xlink:label="pirs_StockIssuedDuringPeriodValueExerciseOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Value of stock issued during the period for exercising of warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:to="pirs_StockIssuedDuringPeriodValueExerciseOfWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="pirs_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:type="locator"/>
    <link:label xlink:label="pirs_StockIssuedDuringPeriodSharesExerciseOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock resulting from exercise of warrants (in shares)</link:label>
    <link:label xlink:label="pirs_StockIssuedDuringPeriodSharesExerciseOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares issued during the period as a result of exercising of warrants .</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:to="pirs_StockIssuedDuringPeriodSharesExerciseOfWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, $0.001 par value per share, 300,000,000 shares authorized and 74,519,103 and 72,222,661 shares issued and outstanding at December 21, 2022 and 2021, respectively</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_ConversionOfSeriesEPreferredStockMember" xlink:label="pirs_ConversionOfSeriesEPreferredStockMember" xlink:type="locator"/>
    <link:label xlink:label="pirs_ConversionOfSeriesEPreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Series E Preferred Stock [Member]</link:label>
    <link:label xlink:label="pirs_ConversionOfSeriesEPreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents conversion of series E preferred stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_ConversionOfSeriesEPreferredStockMember" xlink:to="pirs_ConversionOfSeriesEPreferredStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized (in shares)</link:label>
    <link:label xlink:label="us-gaap_CommonStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued (in shares)</link:label>
    <link:label xlink:label="us-gaap_CommonStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par Value (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</link:label>
    <link:label xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_ConversionOfPreferredStockMember" xlink:label="pirs_ConversionOfPreferredStockMember" xlink:type="locator"/>
    <link:label xlink:label="pirs_ConversionOfPreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Preferred Stock [Member]</link:label>
    <link:label xlink:label="pirs_ConversionOfPreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents conversion of preferred stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_ConversionOfPreferredStockMember" xlink:to="pirs_ConversionOfPreferredStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</link:label>
    <link:label xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsValuationAllowance</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: valuation allowance:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeasePayments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeasePayments</link:label>
    <link:label xlink:label="us-gaap_OperatingLeasePayments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_OperatingLeaseRightOfUseAssetAccretion" xlink:label="pirs_OperatingLeaseRightOfUseAssetAccretion" xlink:type="locator"/>
    <link:label xlink:label="pirs_OperatingLeaseRightOfUseAssetAccretion-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">pirs_OperatingLeaseRightOfUseAssetAccretion</link:label>
    <link:label xlink:label="pirs_OperatingLeaseRightOfUseAssetAccretion-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Right-of-use asset (accretion) amortization</link:label>
    <link:label xlink:label="pirs_OperatingLeaseRightOfUseAssetAccretion-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents right of use asset accretion for operating lease.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_OperatingLeaseRightOfUseAssetAccretion" xlink:to="pirs_OperatingLeaseRightOfUseAssetAccretion-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_PierisPharmaceuticalsGmbhMember" xlink:label="pirs_PierisPharmaceuticalsGmbhMember" xlink:type="locator"/>
    <link:label xlink:label="pirs_PierisPharmaceuticalsGmbhMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pieris Pharmaceuticals GmbH [Member]</link:label>
    <link:label xlink:label="pirs_PierisPharmaceuticalsGmbhMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Pieris Pharmaceuticals GmbH.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_PierisPharmaceuticalsGmbhMember" xlink:to="pirs_PierisPharmaceuticalsGmbhMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:label xlink:label="srt_MaximumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:label xlink:label="srt_MinimumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_ProductOrServiceAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_ProductsAndServicesDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsNet</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax asset</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, $0.001 par value per share, 10,000,000 shares authorized and 15,617 shares issued and outstanding at December 21, 2022 and 2021</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued (in shares)</link:label>
    <link:label xlink:label="us-gaap_PreferredStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_StatementGeographicalAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_SegmentGeographicalDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsGross</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsGross-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized (in shares)</link:label>
    <link:label xlink:label="us-gaap_PreferredStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredIncomeTaxLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredIncomeTaxLiabilities</link:label>
    <link:label xlink:label="us-gaap_DeferredIncomeTaxLiabilities-label" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par Value (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</link:label>
    <link:label xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueInputsLevel3Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xlink:label="us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized foreign currency</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xlink:to="us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueInputsLevel1Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueInputsLevel2Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_GenentechMember" xlink:label="pirs_GenentechMember" xlink:type="locator"/>
    <link:label xlink:label="pirs_GenentechMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Genentech [Member]</link:label>
    <link:label xlink:label="pirs_GenentechMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Genentech.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_GenentechMember" xlink:to="pirs_GenentechMember-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_LaboratoryEquipmentMember" xlink:label="pirs_LaboratoryEquipmentMember" xlink:type="locator"/>
    <link:label xlink:label="pirs_LaboratoryEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label xlink:label="pirs_LaboratoryEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents laboratory equipment.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_LaboratoryEquipmentMember" xlink:to="pirs_LaboratoryEquipmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NumberOfOptionalAdditionalResearchPrograms" xlink:label="pirs_NumberOfOptionalAdditionalResearchPrograms" xlink:type="locator"/>
    <link:label xlink:label="pirs_NumberOfOptionalAdditionalResearchPrograms-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">pirs_NumberOfOptionalAdditionalResearchPrograms</link:label>
    <link:label xlink:label="pirs_NumberOfOptionalAdditionalResearchPrograms-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number Of Optional Additional Research Programs</link:label>
    <link:label xlink:label="pirs_NumberOfOptionalAdditionalResearchPrograms-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents number of optional additional research program.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_NumberOfOptionalAdditionalResearchPrograms" xlink:to="pirs_NumberOfOptionalAdditionalResearchPrograms-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property and equipment, useful life (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NumberOfInitialResearchPrograms" xlink:label="pirs_NumberOfInitialResearchPrograms" xlink:type="locator"/>
    <link:label xlink:label="pirs_NumberOfInitialResearchPrograms-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">pirs_NumberOfInitialResearchPrograms</link:label>
    <link:label xlink:label="pirs_NumberOfInitialResearchPrograms-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number Of Initial Research Programs</link:label>
    <link:label xlink:label="pirs_NumberOfInitialResearchPrograms-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents number of initial research programs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_NumberOfInitialResearchPrograms" xlink:to="pirs_NumberOfInitialResearchPrograms-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsReceivableNetCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based awards compensation, tax assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsAndShortTermInvestments</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapital-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_RevenueFromContractWithCustomerCollaborationFeeOnAdditionalProgram" xlink:label="pirs_RevenueFromContractWithCustomerCollaborationFeeOnAdditionalProgram" xlink:type="locator"/>
    <link:label xlink:label="pirs_RevenueFromContractWithCustomerCollaborationFeeOnAdditionalProgram-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">pirs_RevenueFromContractWithCustomerCollaborationFeeOnAdditionalProgram</link:label>
    <link:label xlink:label="pirs_RevenueFromContractWithCustomerCollaborationFeeOnAdditionalProgram-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Collaboration Fee On Additional Program</link:label>
    <link:label xlink:label="pirs_RevenueFromContractWithCustomerCollaborationFeeOnAdditionalProgram-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents revenue from contract with customer related to collaboration fee on additional program.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_RevenueFromContractWithCustomerCollaborationFeeOnAdditionalProgram" xlink:to="pirs_RevenueFromContractWithCustomerCollaborationFeeOnAdditionalProgram-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenuesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShortTermInvestments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short term investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseholdImprovementsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_RevenueFromContractWithCustomerAgreementTerminationNoticePeriodWithinMaterialBreach" xlink:label="pirs_RevenueFromContractWithCustomerAgreementTerminationNoticePeriodWithinMaterialBreach" xlink:type="locator"/>
    <link:label xlink:label="pirs_RevenueFromContractWithCustomerAgreementTerminationNoticePeriodWithinMaterialBreach-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">pirs_RevenueFromContractWithCustomerAgreementTerminationNoticePeriodWithinMaterialBreach</link:label>
    <link:label xlink:label="pirs_RevenueFromContractWithCustomerAgreementTerminationNoticePeriodWithinMaterialBreach-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Agreement Termination Notice Period Within Material Breach (Day)</link:label>
    <link:label xlink:label="pirs_RevenueFromContractWithCustomerAgreementTerminationNoticePeriodWithinMaterialBreach-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents revenue from contract with customer for termination notice period within material breach.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_RevenueFromContractWithCustomerAgreementTerminationNoticePeriodWithinMaterialBreach" xlink:to="pirs_RevenueFromContractWithCustomerAgreementTerminationNoticePeriodWithinMaterialBreach-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis" xlink:label="us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Accounting Principle, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis" xlink:to="us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherNonoperatingIncomeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other income</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodBeforeFirstCommercialSale" xlink:label="pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodBeforeFirstCommercialSale" xlink:type="locator"/>
    <link:label xlink:label="pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodBeforeFirstCommercialSale-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodBeforeFirstCommercialSale</link:label>
    <link:label xlink:label="pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodBeforeFirstCommercialSale-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Agreement Termination Advance Notice Period Before First Commercial Sale (Day)</link:label>
    <link:label xlink:label="pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodBeforeFirstCommercialSale-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents termination advance notice period before first commercial sale for revenue from contract with customer agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodBeforeFirstCommercialSale" xlink:to="pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodBeforeFirstCommercialSale-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleMember" xlink:label="us-gaap_ChangeInAccountingPrincipleMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ChangeInAccountingPrincipleMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Accounting Principle, Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleMember" xlink:to="us-gaap_ChangeInAccountingPrincipleMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodAfterFirstCommercialSale" xlink:label="pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodAfterFirstCommercialSale" xlink:type="locator"/>
    <link:label xlink:label="pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodAfterFirstCommercialSale-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodAfterFirstCommercialSale</link:label>
    <link:label xlink:label="pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodAfterFirstCommercialSale-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Agreement Termination Advance Notice Period After First Commercial Sale (Day)</link:label>
    <link:label xlink:label="pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodAfterFirstCommercialSale-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents agreement termination advance notice period after first commercial sale for revenue from contract with customer.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodAfterFirstCommercialSale" xlink:to="pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodAfterFirstCommercialSale-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</link:label>
    <link:label xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">R&amp;D Credits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SaleOfStockPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SaleOfStockPricePerShare</link:label>
    <link:label xlink:label="us-gaap_SaleOfStockPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SaleOfStockConsiderationReceivedPerTransaction</link:label>
    <link:label xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received Per Transaction</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NumberOfResearchPrograms" xlink:label="pirs_NumberOfResearchPrograms" xlink:type="locator"/>
    <link:label xlink:label="pirs_NumberOfResearchPrograms-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">pirs_NumberOfResearchPrograms</link:label>
    <link:label xlink:label="pirs_NumberOfResearchPrograms-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Research Programs</link:label>
    <link:label xlink:label="pirs_NumberOfResearchPrograms-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents number of research programs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_NumberOfResearchPrograms" xlink:to="pirs_NumberOfResearchPrograms-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_ResearchCollaborationAgreementPeriod" xlink:label="pirs_ResearchCollaborationAgreementPeriod" xlink:type="locator"/>
    <link:label xlink:label="pirs_ResearchCollaborationAgreementPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">pirs_ResearchCollaborationAgreementPeriod</link:label>
    <link:label xlink:label="pirs_ResearchCollaborationAgreementPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research Collaboration Agreement Period (Year)</link:label>
    <link:label xlink:label="pirs_ResearchCollaborationAgreementPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents research collaboration agreement period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_ResearchCollaborationAgreementPeriod" xlink:to="pirs_ResearchCollaborationAgreementPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_ResearchAndDevelopmentServicesMember" xlink:label="pirs_ResearchAndDevelopmentServicesMember" xlink:type="locator"/>
    <link:label xlink:label="pirs_ResearchAndDevelopmentServicesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Services [Member]</link:label>
    <link:label xlink:label="pirs_ResearchAndDevelopmentServicesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents research and development services.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_ResearchAndDevelopmentServicesMember" xlink:to="pirs_ResearchAndDevelopmentServicesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NumberOfPerformanceObligations" xlink:label="pirs_NumberOfPerformanceObligations" xlink:type="locator"/>
    <link:label xlink:label="pirs_NumberOfPerformanceObligations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">pirs_NumberOfPerformanceObligations</link:label>
    <link:label xlink:label="pirs_NumberOfPerformanceObligations-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Performance Obligations</link:label>
    <link:label xlink:label="pirs_NumberOfPerformanceObligations-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents number of performance obligations.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_NumberOfPerformanceObligations" xlink:to="pirs_NumberOfPerformanceObligations-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</link:label>
    <link:label xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrivatePlacementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LicenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseMember" xlink:to="us-gaap_LicenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SecurityDeposit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SecurityDeposit</link:label>
    <link:label xlink:label="us-gaap_SecurityDeposit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Deposit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of exchange rate change on cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInFinancingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Liabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Liabilities</link:label>
    <link:label xlink:label="us-gaap_Liabilities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommitmentsAndContingencies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsidiarySaleOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_LicenseAndCollaborationAgreementMember" xlink:label="pirs_LicenseAndCollaborationAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="pirs_LicenseAndCollaborationAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License and Collaboration Agreement [Member]</link:label>
    <link:label xlink:label="pirs_LicenseAndCollaborationAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents license and collaboration agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_LicenseAndCollaborationAgreementMember" xlink:to="pirs_LicenseAndCollaborationAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_PlatformTechnologyLicenseMember" xlink:label="pirs_PlatformTechnologyLicenseMember" xlink:type="locator"/>
    <link:label xlink:label="pirs_PlatformTechnologyLicenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Platform Technology License [Member]</link:label>
    <link:label xlink:label="pirs_PlatformTechnologyLicenseMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents platform technology license.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_PlatformTechnologyLicenseMember" xlink:to="pirs_PlatformTechnologyLicenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingIncomeLoss</link:label>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_GovernanceCommitteeParticipationMember" xlink:label="pirs_GovernanceCommitteeParticipationMember" xlink:type="locator"/>
    <link:label xlink:label="pirs_GovernanceCommitteeParticipationMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Governance Committee Participation [Member]</link:label>
    <link:label xlink:label="pirs_GovernanceCommitteeParticipationMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents governance committee participation.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_GovernanceCommitteeParticipationMember" xlink:to="pirs_GovernanceCommitteeParticipationMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</link:label>
    <link:label xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other income (expense)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInOperatingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInInvestingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_CounterpartyNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="us-gaap_AccountingStandardsUpdate201409Member" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountingStandardsUpdate201409Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2014-09 [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201409Member" xlink:to="us-gaap_AccountingStandardsUpdate201409Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpense" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxLiabilitiesDeferredExpense</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpense-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesDeferredExpense" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ContractWithCustomerLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ContractWithCustomerLiability</link:label>
    <link:label xlink:label="us-gaap_ContractWithCustomerLiability-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</link:label>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsOfStockIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsOfStockIssuanceCosts</link:label>
    <link:label xlink:label="us-gaap_PaymentsOfStockIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issuance costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskCreditRisk-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromStockPlans-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from employee stock purchase plan</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromWarrantExercises-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesFromStockholderMember" xlink:label="us-gaap_ReceivablesFromStockholderMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ReceivablesFromStockholderMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables from Stockholder [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesFromStockholderMember" xlink:to="us-gaap_ReceivablesFromStockholderMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Private Placement</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</link:label>
    <link:label xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock resulting from ATM sales, net of $1.2 million in transaction costs</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_TitleOfIndividualAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State, deferred</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign, tax expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign, deferred</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapitalMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Federal, deferred</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_RevenueFromContractWithCustomerPeriodAfterEffectiveDateAgreementsMayBeTerminated" xlink:label="pirs_RevenueFromContractWithCustomerPeriodAfterEffectiveDateAgreementsMayBeTerminated" xlink:type="locator"/>
    <link:label xlink:label="pirs_RevenueFromContractWithCustomerPeriodAfterEffectiveDateAgreementsMayBeTerminated-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">pirs_RevenueFromContractWithCustomerPeriodAfterEffectiveDateAgreementsMayBeTerminated</link:label>
    <link:label xlink:label="pirs_RevenueFromContractWithCustomerPeriodAfterEffectiveDateAgreementsMayBeTerminated-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Period After Effective Date Agreements May Be Terminated (Month)</link:label>
    <link:label xlink:label="pirs_RevenueFromContractWithCustomerPeriodAfterEffectiveDateAgreementsMayBeTerminated-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period after effective date agreements may be terminated.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_RevenueFromContractWithCustomerPeriodAfterEffectiveDateAgreementsMayBeTerminated" xlink:to="pirs_RevenueFromContractWithCustomerPeriodAfterEffectiveDateAgreementsMayBeTerminated-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriod" xlink:label="pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriod" xlink:type="locator"/>
    <link:label xlink:label="pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriod</link:label>
    <link:label xlink:label="pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Agreement Termination Advance Notice Period (Day)</link:label>
    <link:label xlink:label="pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract termination advance notice period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriod" xlink:to="pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementEquityComponentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodIfMarketingApprovalObtained" xlink:label="pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodIfMarketingApprovalObtained" xlink:type="locator"/>
    <link:label xlink:label="pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodIfMarketingApprovalObtained-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodIfMarketingApprovalObtained</link:label>
    <link:label xlink:label="pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodIfMarketingApprovalObtained-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Agreement Termination Advance Notice Period If Marketing Approval Obtained (Day)</link:label>
    <link:label xlink:label="pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodIfMarketingApprovalObtained-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Agreement termination advance notice period if marketing approval obtained.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodIfMarketingApprovalObtained" xlink:to="pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodIfMarketingApprovalObtained-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityComponentDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_RevenueFromContractWithCustomerAgreementTerminationNoticePeriodUponMaterialBreach" xlink:label="pirs_RevenueFromContractWithCustomerAgreementTerminationNoticePeriodUponMaterialBreach" xlink:type="locator"/>
    <link:label xlink:label="pirs_RevenueFromContractWithCustomerAgreementTerminationNoticePeriodUponMaterialBreach-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">pirs_RevenueFromContractWithCustomerAgreementTerminationNoticePeriodUponMaterialBreach</link:label>
    <link:label xlink:label="pirs_RevenueFromContractWithCustomerAgreementTerminationNoticePeriodUponMaterialBreach-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Agreement Termination Notice Period Upon Material Breach (Day)</link:label>
    <link:label xlink:label="pirs_RevenueFromContractWithCustomerAgreementTerminationNoticePeriodUponMaterialBreach-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Agreement termination notice period upon material breach by the Company.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_RevenueFromContractWithCustomerAgreementTerminationNoticePeriodUponMaterialBreach" xlink:to="pirs_RevenueFromContractWithCustomerAgreementTerminationNoticePeriodUponMaterialBreach-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_ExclusiveProductLicenseAgreementMember" xlink:label="pirs_ExclusiveProductLicenseAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="pirs_ExclusiveProductLicenseAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exclusive Product License Agreement [Member]</link:label>
    <link:label xlink:label="pirs_ExclusiveProductLicenseAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Exclusive Product License Agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_ExclusiveProductLicenseAgreementMember" xlink:to="pirs_ExclusiveProductLicenseAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_BPAssetsXIIIncMember" xlink:label="pirs_BPAssetsXIIIncMember" xlink:type="locator"/>
    <link:label xlink:label="pirs_BPAssetsXIIIncMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">B P Assets X I I Inc [Member]</link:label>
    <link:label xlink:label="pirs_BPAssetsXIIIncMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents BP Assets XII Inc.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_BPAssetsXIIIncMember" xlink:to="pirs_BPAssetsXIIIncMember-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_RevenueFromContractWithCustomerContributionTowardsManufacturingActivities" xlink:label="pirs_RevenueFromContractWithCustomerContributionTowardsManufacturingActivities" xlink:type="locator"/>
    <link:label xlink:label="pirs_RevenueFromContractWithCustomerContributionTowardsManufacturingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">pirs_RevenueFromContractWithCustomerContributionTowardsManufacturingActivities</link:label>
    <link:label xlink:label="pirs_RevenueFromContractWithCustomerContributionTowardsManufacturingActivities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Contribution Towards Manufacturing Activities</link:label>
    <link:label xlink:label="pirs_RevenueFromContractWithCustomerContributionTowardsManufacturingActivities-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of revenue from contract with customers contribution towards manufacturing activities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_RevenueFromContractWithCustomerContributionTowardsManufacturingActivities" xlink:to="pirs_RevenueFromContractWithCustomerContributionTowardsManufacturingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CurrentIncomeTaxExpenseBenefit</link:label>
    <link:label xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_OtherArrangementMember" xlink:label="pirs_OtherArrangementMember" xlink:type="locator"/>
    <link:label xlink:label="pirs_OtherArrangementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Arrangement [Member]</link:label>
    <link:label xlink:label="pirs_OtherArrangementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Arrangement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_OtherArrangementMember" xlink:to="pirs_OtherArrangementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UpFrontPaymentArrangementMember" xlink:label="us-gaap_UpFrontPaymentArrangementMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UpFrontPaymentArrangementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Up-front Payment Arrangement [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UpFrontPaymentArrangementMember" xlink:to="us-gaap_UpFrontPaymentArrangementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NumberOfLicenses" xlink:label="pirs_NumberOfLicenses" xlink:type="locator"/>
    <link:label xlink:label="pirs_NumberOfLicenses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">pirs_NumberOfLicenses</link:label>
    <link:label xlink:label="pirs_NumberOfLicenses-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number Of Licenses</link:label>
    <link:label xlink:label="pirs_NumberOfLicenses-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of licenses.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_NumberOfLicenses" xlink:to="pirs_NumberOfLicenses-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenueRemainingPerformanceObligation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_RevenueRemainingPerformanceObligation</link:label>
    <link:label xlink:label="us-gaap_RevenueRemainingPerformanceObligation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligation" xlink:to="us-gaap_RevenueRemainingPerformanceObligation-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NumberOfSwapOptions" xlink:label="pirs_NumberOfSwapOptions" xlink:type="locator"/>
    <link:label xlink:label="pirs_NumberOfSwapOptions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">pirs_NumberOfSwapOptions</link:label>
    <link:label xlink:label="pirs_NumberOfSwapOptions-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number Of Swap Options</link:label>
    <link:label xlink:label="pirs_NumberOfSwapOptions-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of swap options.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_NumberOfSwapOptions" xlink:to="pirs_NumberOfSwapOptions-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NumberOfTargetPrograms" xlink:label="pirs_NumberOfTargetPrograms" xlink:type="locator"/>
    <link:label xlink:label="pirs_NumberOfTargetPrograms-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">pirs_NumberOfTargetPrograms</link:label>
    <link:label xlink:label="pirs_NumberOfTargetPrograms-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Target Programs</link:label>
    <link:label xlink:label="pirs_NumberOfTargetPrograms-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of target programs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_NumberOfTargetPrograms" xlink:to="pirs_NumberOfTargetPrograms-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_RevenueFromContractWithCustomerAgreementTerminationNoticePeriodNonpaymentOfUndisputedAmounts" xlink:label="pirs_RevenueFromContractWithCustomerAgreementTerminationNoticePeriodNonpaymentOfUndisputedAmounts" xlink:type="locator"/>
    <link:label xlink:label="pirs_RevenueFromContractWithCustomerAgreementTerminationNoticePeriodNonpaymentOfUndisputedAmounts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">pirs_RevenueFromContractWithCustomerAgreementTerminationNoticePeriodNonpaymentOfUndisputedAmounts</link:label>
    <link:label xlink:label="pirs_RevenueFromContractWithCustomerAgreementTerminationNoticePeriodNonpaymentOfUndisputedAmounts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Agreement Termination Notice Period, Non-Payment Of Undisputed Amounts (Day)</link:label>
    <link:label xlink:label="pirs_RevenueFromContractWithCustomerAgreementTerminationNoticePeriodNonpaymentOfUndisputedAmounts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Agreement termination notice period due to non-payment of undisputed amounts.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_RevenueFromContractWithCustomerAgreementTerminationNoticePeriodNonpaymentOfUndisputedAmounts" xlink:to="pirs_RevenueFromContractWithCustomerAgreementTerminationNoticePeriodNonpaymentOfUndisputedAmounts-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_RevenueFromContractWithCustomerAgreementTerminationAdditionalNoticePeriodUponMaterialBreach" xlink:label="pirs_RevenueFromContractWithCustomerAgreementTerminationAdditionalNoticePeriodUponMaterialBreach" xlink:type="locator"/>
    <link:label xlink:label="pirs_RevenueFromContractWithCustomerAgreementTerminationAdditionalNoticePeriodUponMaterialBreach-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">pirs_RevenueFromContractWithCustomerAgreementTerminationAdditionalNoticePeriodUponMaterialBreach</link:label>
    <link:label xlink:label="pirs_RevenueFromContractWithCustomerAgreementTerminationAdditionalNoticePeriodUponMaterialBreach-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Agreement Termination, Additional Notice Period Upon Material Breach (Day)</link:label>
    <link:label xlink:label="pirs_RevenueFromContractWithCustomerAgreementTerminationAdditionalNoticePeriodUponMaterialBreach-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract termination due to material breach, additional notice period if the breach is not susceptible.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_RevenueFromContractWithCustomerAgreementTerminationAdditionalNoticePeriodUponMaterialBreach" xlink:to="pirs_RevenueFromContractWithCustomerAgreementTerminationAdditionalNoticePeriodUponMaterialBreach-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_RevenueFromContractWithCustomerAgreementObligationCost" xlink:label="pirs_RevenueFromContractWithCustomerAgreementObligationCost" xlink:type="locator"/>
    <link:label xlink:label="pirs_RevenueFromContractWithCustomerAgreementObligationCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">pirs_RevenueFromContractWithCustomerAgreementObligationCost</link:label>
    <link:label xlink:label="pirs_RevenueFromContractWithCustomerAgreementObligationCost-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Agreement Obligation Cost</link:label>
    <link:label xlink:label="pirs_RevenueFromContractWithCustomerAgreementObligationCost-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of agreement obligation cost of of revenue from contract with customers.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_RevenueFromContractWithCustomerAgreementObligationCost" xlink:to="pirs_RevenueFromContractWithCustomerAgreementObligationCost-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_SeattleGeneticsIncMember" xlink:label="pirs_SeattleGeneticsIncMember" xlink:type="locator"/>
    <link:label xlink:label="pirs_SeattleGeneticsIncMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Seattle Genetics Inc. [Member]</link:label>
    <link:label xlink:label="pirs_SeattleGeneticsIncMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Seattle Genetics Inc..</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_SeattleGeneticsIncMember" xlink:to="pirs_SeattleGeneticsIncMember-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_RevenueFromContractWithCustomerAllocableArrangementConsiderationAllocation" xlink:label="pirs_RevenueFromContractWithCustomerAllocableArrangementConsiderationAllocation" xlink:type="locator"/>
    <link:label xlink:label="pirs_RevenueFromContractWithCustomerAllocableArrangementConsiderationAllocation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">pirs_RevenueFromContractWithCustomerAllocableArrangementConsiderationAllocation</link:label>
    <link:label xlink:label="pirs_RevenueFromContractWithCustomerAllocableArrangementConsiderationAllocation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Allocable Arrangement Consideration Allocation</link:label>
    <link:label xlink:label="pirs_RevenueFromContractWithCustomerAllocableArrangementConsiderationAllocation-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of revenue from contract with customers allocable arrangement consideration allocation.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_RevenueFromContractWithCustomerAllocableArrangementConsiderationAllocation" xlink:to="pirs_RevenueFromContractWithCustomerAllocableArrangementConsiderationAllocation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</link:label>
    <link:label xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before income taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_AmendedCollaborationAgreementResaleOfStockPeriod" xlink:label="pirs_AmendedCollaborationAgreementResaleOfStockPeriod" xlink:type="locator"/>
    <link:label xlink:label="pirs_AmendedCollaborationAgreementResaleOfStockPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">pirs_AmendedCollaborationAgreementResaleOfStockPeriod</link:label>
    <link:label xlink:label="pirs_AmendedCollaborationAgreementResaleOfStockPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amended Collaboration Agreement, Resale of Stock, Period (Day)</link:label>
    <link:label xlink:label="pirs_AmendedCollaborationAgreementResaleOfStockPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Resale of stock period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_AmendedCollaborationAgreementResaleOfStockPeriod" xlink:to="pirs_AmendedCollaborationAgreementResaleOfStockPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_AntibodyTargetSwapMember" xlink:label="pirs_AntibodyTargetSwapMember" xlink:type="locator"/>
    <link:label xlink:label="pirs_AntibodyTargetSwapMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antibody Target Swap [Member]</link:label>
    <link:label xlink:label="pirs_AntibodyTargetSwapMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Antibody Target Swap.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_AntibodyTargetSwapMember" xlink:to="pirs_AntibodyTargetSwapMember-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_SalesMilestonePaymentsMember" xlink:label="pirs_SalesMilestonePaymentsMember" xlink:type="locator"/>
    <link:label xlink:label="pirs_SalesMilestonePaymentsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Milestone Payments [Member]</link:label>
    <link:label xlink:label="pirs_SalesMilestonePaymentsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales Milestone Payments.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_SalesMilestonePaymentsMember" xlink:to="pirs_SalesMilestonePaymentsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_ResearchAndDevelopmentMilestonePaymentsMember" xlink:label="pirs_ResearchAndDevelopmentMilestonePaymentsMember" xlink:type="locator"/>
    <link:label xlink:label="pirs_ResearchAndDevelopmentMilestonePaymentsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Milestone Payments [Member]</link:label>
    <link:label xlink:label="pirs_ResearchAndDevelopmentMilestonePaymentsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Milestone Payments.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_ResearchAndDevelopmentMilestonePaymentsMember" xlink:to="pirs_ResearchAndDevelopmentMilestonePaymentsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_BostonPharmaceuticalsMember" xlink:label="pirs_BostonPharmaceuticalsMember" xlink:type="locator"/>
    <link:label xlink:label="pirs_BostonPharmaceuticalsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Boston Pharmaceuticals [Member]</link:label>
    <link:label xlink:label="pirs_BostonPharmaceuticalsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Boston Pharmaceuticals.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_BostonPharmaceuticalsMember" xlink:to="pirs_BostonPharmaceuticalsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_IcfrAuditorAttestationFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_SaleOfStockFairValuePricePerShare" xlink:label="pirs_SaleOfStockFairValuePricePerShare" xlink:type="locator"/>
    <link:label xlink:label="pirs_SaleOfStockFairValuePricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">pirs_SaleOfStockFairValuePricePerShare</link:label>
    <link:label xlink:label="pirs_SaleOfStockFairValuePricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock, Fair Value, Price Per Share (in dollars per share)</link:label>
    <link:label xlink:label="pirs_SaleOfStockFairValuePricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Price per share of sale of stock, fair value.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_SaleOfStockFairValuePricePerShare" xlink:to="pirs_SaleOfStockFairValuePricePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive (loss) income:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_AstraZenecaABMember" xlink:label="pirs_AstraZenecaABMember" xlink:type="locator"/>
    <link:label xlink:label="pirs_AstraZenecaABMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Astra Zeneca A B [Member]</link:label>
    <link:label xlink:label="pirs_AstraZenecaABMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Astra Zeneca A B.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_AstraZenecaABMember" xlink:to="pirs_AstraZenecaABMember-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember" xlink:label="pirs_LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember" xlink:type="locator"/>
    <link:label xlink:label="pirs_LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Les Laboratoires Servier And Institut De Recherches Internationales Servier [Member]</link:label>
    <link:label xlink:label="pirs_LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Les Laboratoires Servier And Institut De Recherches Internationales Servier.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember" xlink:to="pirs_LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_RevenueFromContractWithCustomerMilestonePaymentsTableTextBlock" xlink:label="pirs_RevenueFromContractWithCustomerMilestonePaymentsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="pirs_RevenueFromContractWithCustomerMilestonePaymentsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue From Contract With Customer, Milestone Payments [Table Text Block]</link:label>
    <link:label xlink:label="pirs_RevenueFromContractWithCustomerMilestonePaymentsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of the milestone payments for revenue from contract with customer.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_RevenueFromContractWithCustomerMilestonePaymentsTableTextBlock" xlink:to="pirs_RevenueFromContractWithCustomerMilestonePaymentsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StateAndLocalJurisdictionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxAuthorityNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxAuthorityNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InternalRevenueServiceIRSMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InternalRevenueServiceIRSMember" xlink:to="us-gaap_InternalRevenueServiceIRSMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxAuthorityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxAuthorityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DomesticCountryMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ForeignCountryMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OfficeEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentAnnualReport-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PartnersCapitalAccountUnitsSoldInPrivatePlacement" xlink:label="us-gaap_PartnersCapitalAccountUnitsSoldInPrivatePlacement" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PartnersCapitalAccountUnitsSoldInPrivatePlacement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PartnersCapitalAccountUnitsSoldInPrivatePlacement</link:label>
    <link:label xlink:label="us-gaap_PartnersCapitalAccountUnitsSoldInPrivatePlacement-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Partners' Capital Account, Units, Sold in Private Placement (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PartnersCapitalAccountUnitsSoldInPrivatePlacement" xlink:to="us-gaap_PartnersCapitalAccountUnitsSoldInPrivatePlacement-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ComputerEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BalanceSheetLocationAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BalanceSheetLocationDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefits-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_UnrecognizedTaxBenefits</link:label>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefits-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits at December 31, 2021</link:label>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefits-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits at December 31, 2022</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountingPoliciesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OpenTaxYear-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OpenTaxYear</link:label>
    <link:label xlink:label="us-gaap_OpenTaxYear-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Open Tax Year</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OpenTaxYear" xlink:to="us-gaap_OpenTaxYear-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentTransitionReport-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation</link:label>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Currency translation adjustment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityInteractiveDataCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_DebtSecuritiesAvailableforsaleContractualMaturityPeriod" xlink:label="pirs_DebtSecuritiesAvailableforsaleContractualMaturityPeriod" xlink:type="locator"/>
    <link:label xlink:label="pirs_DebtSecuritiesAvailableforsaleContractualMaturityPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Maturity Period (Day)</link:label>
    <link:label xlink:label="pirs_DebtSecuritiesAvailableforsaleContractualMaturityPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contractual maturity period for debt securities, available-for-sale securities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_DebtSecuritiesAvailableforsaleContractualMaturityPeriod" xlink:to="pirs_DebtSecuritiesAvailableforsaleContractualMaturityPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_AccruedResearchAndDevelopmentCosts" xlink:label="pirs_AccruedResearchAndDevelopmentCosts" xlink:type="locator"/>
    <link:label xlink:label="pirs_AccruedResearchAndDevelopmentCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development fees</link:label>
    <link:label xlink:label="pirs_AccruedResearchAndDevelopmentCosts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of accrued research and development costs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_AccruedResearchAndDevelopmentCosts" xlink:to="pirs_AccruedResearchAndDevelopmentCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentAssistanceAmount" xlink:label="us-gaap_GovernmentAssistanceAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GovernmentAssistanceAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grant income</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentAssistanceAmount" xlink:to="us-gaap_GovernmentAssistanceAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_AccruedLicenseObligationsCurrent" xlink:label="pirs_AccruedLicenseObligationsCurrent" xlink:type="locator"/>
    <link:label xlink:label="pirs_AccruedLicenseObligationsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued license obligations</link:label>
    <link:label xlink:label="pirs_AccruedLicenseObligationsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of current portion of accrued license obligation.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_AccruedLicenseObligationsCurrent" xlink:to="pirs_AccruedLicenseObligationsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:label xlink:label="dei_SecurityExchangeName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:label xlink:label="dei_Security12bTitle-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_CashEquivalentsAndInvestments" xlink:label="pirs_CashEquivalentsAndInvestments" xlink:type="locator"/>
    <link:label xlink:label="pirs_CashEquivalentsAndInvestments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label xlink:label="pirs_CashEquivalentsAndInvestments-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair value portion of cash, cash equivalents and investments.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_CashEquivalentsAndInvestments" xlink:to="pirs_CashEquivalentsAndInvestments-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_ConversionOfCommonStockIntoSeriesEPreferredStockMember" xlink:label="pirs_ConversionOfCommonStockIntoSeriesEPreferredStockMember" xlink:type="locator"/>
    <link:label xlink:label="pirs_ConversionOfCommonStockIntoSeriesEPreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Common Stock into Series E Preferred Stock [Member]</link:label>
    <link:label xlink:label="pirs_ConversionOfCommonStockIntoSeriesEPreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Conversion of Common Stock into Series E Preferred Stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_ConversionOfCommonStockIntoSeriesEPreferredStockMember" xlink:to="pirs_ConversionOfCommonStockIntoSeriesEPreferredStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_SaleOfStockAuthorizedAmount" xlink:label="pirs_SaleOfStockAuthorizedAmount" xlink:type="locator"/>
    <link:label xlink:label="pirs_SaleOfStockAuthorizedAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">pirs_SaleOfStockAuthorizedAmount</link:label>
    <link:label xlink:label="pirs_SaleOfStockAuthorizedAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock, Authorized Amount</link:label>
    <link:label xlink:label="pirs_SaleOfStockAuthorizedAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Authorized amount of sale of stock during a period of time.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_SaleOfStockAuthorizedAmount" xlink:to="pirs_SaleOfStockAuthorizedAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_JefferiesLLCMember" xlink:label="pirs_JefferiesLLCMember" xlink:type="locator"/>
    <link:label xlink:label="pirs_JefferiesLLCMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Jefferies L L C [Member]</link:label>
    <link:label xlink:label="pirs_JefferiesLLCMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Jefferies LLC.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_JefferiesLLCMember" xlink:to="pirs_JefferiesLLCMember-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_AccruedCollaborationCostsCurrent" xlink:label="pirs_AccruedCollaborationCostsCurrent" xlink:type="locator"/>
    <link:label xlink:label="pirs_AccruedCollaborationCostsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration cost-sharing obligation</link:label>
    <link:label xlink:label="pirs_AccruedCollaborationCostsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of current portion of accrued collaboration costs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_AccruedCollaborationCostsCurrent" xlink:to="pirs_AccruedCollaborationCostsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" xlink:label="pirs_EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" xlink:type="locator"/>
    <link:label xlink:label="pirs_EmployeeDirectorAndConsultantEquityIncentivePlan2020Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Director And Consultant Equity Incentive Plan2020 [Member]</link:label>
    <link:label xlink:label="pirs_EmployeeDirectorAndConsultantEquityIncentivePlan2020Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Director And Consultant Equity Incentive Plan2020.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" xlink:to="pirs_EmployeeDirectorAndConsultantEquityIncentivePlan2020Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentAssistanceTextBlock" xlink:label="us-gaap_GovernmentAssistanceTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GovernmentAssistanceTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Assistance [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentAssistanceTextBlock" xlink:to="us-gaap_GovernmentAssistanceTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_LeasesExpectedToBeDeliveredByOctober2024Member" xlink:label="pirs_LeasesExpectedToBeDeliveredByOctober2024Member" xlink:type="locator"/>
    <link:label xlink:label="pirs_LeasesExpectedToBeDeliveredByOctober2024Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases Expected to be Delivered by October 2024 [Member]</link:label>
    <link:label xlink:label="pirs_LeasesExpectedToBeDeliveredByOctober2024Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Leases Expected to be Delivered by October 2024.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_LeasesExpectedToBeDeliveredByOctober2024Member" xlink:to="pirs_LeasesExpectedToBeDeliveredByOctober2024Member-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_LeasesWithFirstRightOfRefusalForAdditionalAreaMember" xlink:label="pirs_LeasesWithFirstRightOfRefusalForAdditionalAreaMember" xlink:type="locator"/>
    <link:label xlink:label="pirs_LeasesWithFirstRightOfRefusalForAdditionalAreaMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases with First Right of Refusal for Additional Area [Member]</link:label>
    <link:label xlink:label="pirs_LeasesWithFirstRightOfRefusalForAdditionalAreaMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Leases with First Right of Refusal for Additional Area.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_LeasesWithFirstRightOfRefusalForAdditionalAreaMember" xlink:to="pirs_LeasesWithFirstRightOfRefusalForAdditionalAreaMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentAssistancePolicyTextBlock" xlink:label="us-gaap_GovernmentAssistancePolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GovernmentAssistancePolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Assistance [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentAssistancePolicyTextBlock" xlink:to="us-gaap_GovernmentAssistancePolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_SubleaseOfficeSpaceMember" xlink:label="pirs_SubleaseOfficeSpaceMember" xlink:type="locator"/>
    <link:label xlink:label="pirs_SubleaseOfficeSpaceMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sublease Office Space [Member]</link:label>
    <link:label xlink:label="pirs_SubleaseOfficeSpaceMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sublease Office Space.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_SubleaseOfficeSpaceMember" xlink:to="pirs_SubleaseOfficeSpaceMember-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_BostonMassachusettsMember" xlink:label="pirs_BostonMassachusettsMember" xlink:type="locator"/>
    <link:label xlink:label="pirs_BostonMassachusettsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Boston Massachusetts [Member]</link:label>
    <link:label xlink:label="pirs_BostonMassachusettsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Boston Massachusetts</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_BostonMassachusettsMember" xlink:to="pirs_BostonMassachusettsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_OfficeAndLaboratorySpaceMember" xlink:label="pirs_OfficeAndLaboratorySpaceMember" xlink:type="locator"/>
    <link:label xlink:label="pirs_OfficeAndLaboratorySpaceMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office and Laboratory Space [Member]</link:label>
    <link:label xlink:label="pirs_OfficeAndLaboratorySpaceMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Office and Laboratory Space.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_OfficeAndLaboratorySpaceMember" xlink:to="pirs_OfficeAndLaboratorySpaceMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_HallbergmoosGermanyMember" xlink:label="pirs_HallbergmoosGermanyMember" xlink:type="locator"/>
    <link:label xlink:label="pirs_HallbergmoosGermanyMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hallbergmoos Germany [Member]</link:label>
    <link:label xlink:label="pirs_HallbergmoosGermanyMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Hallbergmoos Germany.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_HallbergmoosGermanyMember" xlink:to="pirs_HallbergmoosGermanyMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NumberOfCollaborationProducts" xlink:label="pirs_NumberOfCollaborationProducts" xlink:type="locator"/>
    <link:label xlink:label="pirs_NumberOfCollaborationProducts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">pirs_NumberOfCollaborationProducts</link:label>
    <link:label xlink:label="pirs_NumberOfCollaborationProducts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Collaboration Products</link:label>
    <link:label xlink:label="pirs_NumberOfCollaborationProducts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of collaboration products.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_NumberOfCollaborationProducts" xlink:to="pirs_NumberOfCollaborationProducts-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TypeOfArrangementAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NumberOfPrograms" xlink:label="pirs_NumberOfPrograms" xlink:type="locator"/>
    <link:label xlink:label="pirs_NumberOfPrograms-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">pirs_NumberOfPrograms</link:label>
    <link:label xlink:label="pirs_NumberOfPrograms-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Programs</link:label>
    <link:label xlink:label="pirs_NumberOfPrograms-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of programs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_NumberOfPrograms" xlink:to="pirs_NumberOfPrograms-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_AgreementTerminationNoticePeriodUponOfBreachOfPaymentObligations" xlink:label="pirs_AgreementTerminationNoticePeriodUponOfBreachOfPaymentObligations" xlink:type="locator"/>
    <link:label xlink:label="pirs_AgreementTerminationNoticePeriodUponOfBreachOfPaymentObligations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">pirs_AgreementTerminationNoticePeriodUponOfBreachOfPaymentObligations</link:label>
    <link:label xlink:label="pirs_AgreementTerminationNoticePeriodUponOfBreachOfPaymentObligations-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreement Termination Notice Period Upon Of Breach Of Payment Obligations (Day)</link:label>
    <link:label xlink:label="pirs_AgreementTerminationNoticePeriodUponOfBreachOfPaymentObligations-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Agreement termination notice period upon breach of payment obligations by the Company.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_AgreementTerminationNoticePeriodUponOfBreachOfPaymentObligations" xlink:to="pirs_AgreementTerminationNoticePeriodUponOfBreachOfPaymentObligations-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NumberOfAgreementExtensionOptions" xlink:label="pirs_NumberOfAgreementExtensionOptions" xlink:type="locator"/>
    <link:label xlink:label="pirs_NumberOfAgreementExtensionOptions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">pirs_NumberOfAgreementExtensionOptions</link:label>
    <link:label xlink:label="pirs_NumberOfAgreementExtensionOptions-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Agreement Extension Options</link:label>
    <link:label xlink:label="pirs_NumberOfAgreementExtensionOptions-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of agreement extension options.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_NumberOfAgreementExtensionOptions" xlink:to="pirs_NumberOfAgreementExtensionOptions-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_LesseeOperatingLeaseMonthlyRentExpense" xlink:label="pirs_LesseeOperatingLeaseMonthlyRentExpense" xlink:type="locator"/>
    <link:label xlink:label="pirs_LesseeOperatingLeaseMonthlyRentExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">pirs_LesseeOperatingLeaseMonthlyRentExpense</link:label>
    <link:label xlink:label="pirs_LesseeOperatingLeaseMonthlyRentExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Monthly Rent Expense</link:label>
    <link:label xlink:label="pirs_LesseeOperatingLeaseMonthlyRentExpense-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Monthly rent expense under operating lease for lessee.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_LesseeOperatingLeaseMonthlyRentExpense" xlink:to="pirs_LesseeOperatingLeaseMonthlyRentExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NumberOfNovelProteins" xlink:label="pirs_NumberOfNovelProteins" xlink:type="locator"/>
    <link:label xlink:label="pirs_NumberOfNovelProteins-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">pirs_NumberOfNovelProteins</link:label>
    <link:label xlink:label="pirs_NumberOfNovelProteins-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Novel Proteins</link:label>
    <link:label xlink:label="pirs_NumberOfNovelProteins-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of novel proteins.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_NumberOfNovelProteins" xlink:to="pirs_NumberOfNovelProteins-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xlink:type="locator"/>
    <link:label xlink:label="dei_AuditorName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_AdditionalOtherResearchServicesMember" xlink:label="pirs_AdditionalOtherResearchServicesMember" xlink:type="locator"/>
    <link:label xlink:label="pirs_AdditionalOtherResearchServicesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Other Research Services [Member]</link:label>
    <link:label xlink:label="pirs_AdditionalOtherResearchServicesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional Other Research Services.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_AdditionalOtherResearchServicesMember" xlink:to="pirs_AdditionalOtherResearchServicesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_RemainingPerformanceObligationEstimatedTerm" xlink:label="pirs_RemainingPerformanceObligationEstimatedTerm" xlink:type="locator"/>
    <link:label xlink:label="pirs_RemainingPerformanceObligationEstimatedTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">pirs_RemainingPerformanceObligationEstimatedTerm</link:label>
    <link:label xlink:label="pirs_RemainingPerformanceObligationEstimatedTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining Performance Obligation, Estimated Term (Month)</link:label>
    <link:label xlink:label="pirs_RemainingPerformanceObligationEstimatedTerm-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period of license performance obligation.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_RemainingPerformanceObligationEstimatedTerm" xlink:to="pirs_RemainingPerformanceObligationEstimatedTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Income Tax Contingencies [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:to="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NumberOfDiscoveryProgramsDiscontinued" xlink:label="pirs_NumberOfDiscoveryProgramsDiscontinued" xlink:type="locator"/>
    <link:label xlink:label="pirs_NumberOfDiscoveryProgramsDiscontinued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">pirs_NumberOfDiscoveryProgramsDiscontinued</link:label>
    <link:label xlink:label="pirs_NumberOfDiscoveryProgramsDiscontinued-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Discovery Programs Discontinued</link:label>
    <link:label xlink:label="pirs_NumberOfDiscoveryProgramsDiscontinued-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of discovery programs discontinued.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_NumberOfDiscoveryProgramsDiscontinued" xlink:to="pirs_NumberOfDiscoveryProgramsDiscontinued-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NumberOfTechnologyLicenses" xlink:label="pirs_NumberOfTechnologyLicenses" xlink:type="locator"/>
    <link:label xlink:label="pirs_NumberOfTechnologyLicenses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">pirs_NumberOfTechnologyLicenses</link:label>
    <link:label xlink:label="pirs_NumberOfTechnologyLicenses-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Technology Licenses</link:label>
    <link:label xlink:label="pirs_NumberOfTechnologyLicenses-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of technology licenses.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_NumberOfTechnologyLicenses" xlink:to="pirs_NumberOfTechnologyLicenses-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xlink:type="locator"/>
    <link:label xlink:label="dei_AuditorFirmId-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NumberOfResearchLicenses" xlink:label="pirs_NumberOfResearchLicenses" xlink:type="locator"/>
    <link:label xlink:label="pirs_NumberOfResearchLicenses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">pirs_NumberOfResearchLicenses</link:label>
    <link:label xlink:label="pirs_NumberOfResearchLicenses-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Research Licenses</link:label>
    <link:label xlink:label="pirs_NumberOfResearchLicenses-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of research licenses.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_NumberOfResearchLicenses" xlink:to="pirs_NumberOfResearchLicenses-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_EstimatedDevelopmentAndManufacturingServicesMember" xlink:label="pirs_EstimatedDevelopmentAndManufacturingServicesMember" xlink:type="locator"/>
    <link:label xlink:label="pirs_EstimatedDevelopmentAndManufacturingServicesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Development And Manufacturing Services [Member]</link:label>
    <link:label xlink:label="pirs_EstimatedDevelopmentAndManufacturingServicesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Estimated Development And Manufacturing Services.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_EstimatedDevelopmentAndManufacturingServicesMember" xlink:to="pirs_EstimatedDevelopmentAndManufacturingServicesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xlink:type="locator"/>
    <link:label xlink:label="dei_AuditorLocation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_EstimatedPhase2aServicesMember" xlink:label="pirs_EstimatedPhase2aServicesMember" xlink:type="locator"/>
    <link:label xlink:label="pirs_EstimatedPhase2aServicesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Phase 2a Services [Member]</link:label>
    <link:label xlink:label="pirs_EstimatedPhase2aServicesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Estimated Phase2a Services</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_EstimatedPhase2aServicesMember" xlink:to="pirs_EstimatedPhase2aServicesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:label="pirs_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="pirs_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Estimated Useful Life [Table Text Block]</link:label>
    <link:label xlink:label="pirs_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of estimated useful life of physical assets.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:to="pirs_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_AccruedAccountsPayableCurrent" xlink:label="pirs_AccruedAccountsPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="pirs_AccruedAccountsPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued accounts payable</link:label>
    <link:label xlink:label="pirs_AccruedAccountsPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of current portion of accrued accounts payable.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_AccruedAccountsPayableCurrent" xlink:to="pirs_AccruedAccountsPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NumberOfDevelopmentMilestones" xlink:label="pirs_NumberOfDevelopmentMilestones" xlink:type="locator"/>
    <link:label xlink:label="pirs_NumberOfDevelopmentMilestones-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">pirs_NumberOfDevelopmentMilestones</link:label>
    <link:label xlink:label="pirs_NumberOfDevelopmentMilestones-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Development Milestones</link:label>
    <link:label xlink:label="pirs_NumberOfDevelopmentMilestones-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of development milestones.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_NumberOfDevelopmentMilestones" xlink:to="pirs_NumberOfDevelopmentMilestones-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</link:label>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxCreditCarryforwardAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxCreditCarryforwardNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLossCarryforwards</link:label>
    <link:label xlink:label="us-gaap_OperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable-label" xlink:type="arc"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:label="pirs_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="pirs_AccruedLiabilitiesAndOtherLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label xlink:label="pirs_AccruedLiabilitiesAndOtherLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label xlink:label="pirs_AccruedLiabilitiesAndOtherLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of current portion of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pirs_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="pirs_AccruedLiabilitiesAndOtherLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic and diluted (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateContinuingOperations</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Effective income tax rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessAcquisitionAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareBasic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic and diluted (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average number of common shares outstanding</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:to="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfCashFlowsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseContractualTermDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseContractualTermAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractsReceivableClaimsAndUncertainAmounts" xlink:label="us-gaap_ContractsReceivableClaimsAndUncertainAmounts" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ContractsReceivableClaimsAndUncertainAmounts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">milestone</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractsReceivableClaimsAndUncertainAmounts" xlink:to="us-gaap_ContractsReceivableClaimsAndUncertainAmounts-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Permanent items</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TransactionDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transaction [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransactionDomain" xlink:to="us-gaap_TransactionDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based awards compensation, tax rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TransactionTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transaction Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State tax, net of federal benefit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign rate differential</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Federal income tax rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</link:label>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Compensation Earned</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CorporateBondSecuritiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateBondSecuritiesMember" xlink:to="us-gaap_CorporateBondSecuritiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SeriesCPreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series C Preferred Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SeriesDPreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series D Preferred Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesDPreferredStockMember" xlink:to="us-gaap_SeriesDPreferredStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="us-gaap_SeriesEPreferredStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SeriesEPreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series E Preferred Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesEPreferredStockMember" xlink:to="us-gaap_SeriesEPreferredStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SeriesAPreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SeriesBPreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series B Preferred Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred revenue, net of current portion</link:label>
    <link:label xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementClassOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfStockDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</link:label>
    <link:label xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Unrealized losses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized gains</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortized cost</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis-label" xlink:type="arc"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>pirs-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 06:44PM UTC 2023-03-31--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-12-license-agreement" xlink:href="pirs-20221231.xsd#statement-note-12-license-agreement" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.pieris.com/20221231/role/statement-note-12-license-agreement" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_LicenseAndTransferAgreementTextBlock" xlink:label="pirs_LicenseAndTransferAgreementTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NotesToFinancialStatementsAbstract" xlink:label="pirs_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="pirs_LicenseAndTransferAgreementTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-7-accrued-expenses" xlink:href="pirs-20221231.xsd#statement-note-7-accrued-expenses" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.pieris.com/20221231/role/statement-note-7-accrued-expenses" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NotesToFinancialStatementsAbstract" xlink:label="pirs_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-document-and-entity-information" xlink:href="pirs-20221231.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.pieris.com/20221231/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" xlink:type="arc"/>
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" xlink:type="arc"/>
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" xlink:type="arc"/>
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" xlink:type="arc"/>
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" xlink:type="arc"/>
    <link:presentationArc order="32" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="33" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" xlink:type="arc"/>
    <link:presentationArc order="34" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" xlink:type="arc"/>
    <link:presentationArc order="35" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-parentheticals" xlink:href="pirs-20221231.xsd#statement-consolidated-statements-of-changes-in-stockholders-equity-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.pieris.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-parentheticals" xlink:type="extended">
    <link:loc xlink:href="pirs-20221231.xsd#pirs_AtTheMarketOfferingMember" xlink:label="pirs_AtTheMarketOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="pirs_AtTheMarketOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows-parentheticals" xlink:href="pirs-20221231.xsd#statement-consolidated-statements-of-cash-flows-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_AtTheMarketOfferingMember" xlink:label="pirs_AtTheMarketOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="pirs_AtTheMarketOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-1-corporate-information-" xlink:href="pirs-20221231.xsd#statement-note-1-corporate-information-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.pieris.com/20221231/role/statement-note-1-corporate-information-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NotesToFinancialStatementsAbstract" xlink:label="pirs_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_PierisPharmaceuticalsGmbhMember" xlink:label="pirs_PierisPharmaceuticalsGmbhMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="pirs_PierisPharmaceuticalsGmbhMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies" xlink:href="pirs-20221231.xsd#statement-note-2-summary-of-significant-accounting-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.pieris.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NotesToFinancialStatementsAbstract" xlink:label="pirs_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-3-revenue-" xlink:href="pirs-20221231.xsd#statement-note-3-revenue-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.pieris.com/20221231/role/statement-note-3-revenue-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_AdditionalOtherResearchServicesMember" xlink:label="pirs_AdditionalOtherResearchServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_AntibodyTargetSwapMember" xlink:label="pirs_AntibodyTargetSwapMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_AstraZenecaABMember" xlink:label="pirs_AstraZenecaABMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_BPAssetsXIIIncMember" xlink:label="pirs_BPAssetsXIIIncMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_CodevelopmentCollaborationProductCollaborationMember" xlink:label="pirs_CodevelopmentCollaborationProductCollaborationMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_EstimatedDevelopmentAndManufacturingServicesMember" xlink:label="pirs_EstimatedDevelopmentAndManufacturingServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_EstimatedPhase2aServicesMember" xlink:label="pirs_EstimatedPhase2aServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_ExclusiveProductLicenseAgreementMember" xlink:label="pirs_ExclusiveProductLicenseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_GenentechMember" xlink:label="pirs_GenentechMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_GovernanceCommitteeParticipationMember" xlink:label="pirs_GovernanceCommitteeParticipationMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember" xlink:label="pirs_LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_LicenseAndCollaborationAgreementMember" xlink:label="pirs_LicenseAndCollaborationAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NotesToFinancialStatementsAbstract" xlink:label="pirs_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_OtherArrangementMember" xlink:label="pirs_OtherArrangementMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_PlatformTechnologyLicenseMember" xlink:label="pirs_PlatformTechnologyLicenseMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_ResearchAndDevelopmentServicesMember" xlink:label="pirs_ResearchAndDevelopmentServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_SalesMilestonePaymentsMember" xlink:label="pirs_SalesMilestonePaymentsMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_SeattleGeneticsIncMember" xlink:label="pirs_SeattleGeneticsIncMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_ServierDevelopedCollaborationProductsMember" xlink:label="pirs_ServierDevelopedCollaborationProductsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="us-gaap_AccountingStandardsUpdate201409Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis" xlink:label="us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleMember" xlink:label="us-gaap_ChangeInAccountingPrincipleMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UpFrontPaymentArrangementMember" xlink:label="us-gaap_UpFrontPaymentArrangementMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis" xlink:to="us-gaap_ChangeInAccountingPrincipleMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="us-gaap_LicenseMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="pirs_GenentechMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="pirs_ResearchAndDevelopmentServicesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="pirs_LicenseAndCollaborationAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="pirs_PlatformTechnologyLicenseMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="pirs_GovernanceCommitteeParticipationMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="pirs_BPAssetsXIIIncMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="pirs_ExclusiveProductLicenseAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="pirs_SeattleGeneticsIncMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="pirs_OtherArrangementMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_UpFrontPaymentArrangementMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="pirs_AntibodyTargetSwapMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TransactionTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="pirs_SalesMilestonePaymentsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_CollaborativeArrangementMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="pirs_AstraZenecaABMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="pirs_EstimatedDevelopmentAndManufacturingServicesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="pirs_EstimatedPhase2aServicesMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="pirs_AdditionalOtherResearchServicesMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="pirs_LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="pirs_CodevelopmentCollaborationProductCollaborationMember" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="pirs_ServierDevelopedCollaborationProductsMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis" xlink:to="us-gaap_AccountingStandardsUpdate201409Member" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-4-grant-income" xlink:href="pirs-20221231.xsd#statement-note-4-grant-income" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.pieris.com/20221231/role/statement-note-4-grant-income" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NotesToFinancialStatementsAbstract" xlink:label="pirs_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentAssistanceTextBlock" xlink:label="us-gaap_GovernmentAssistanceTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_GovernmentAssistanceTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments" xlink:href="pirs-20221231.xsd#statement-note-5-cash-cash-equivalents-and-investments" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NotesToFinancialStatementsAbstract" xlink:label="pirs_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-6-property-and-equipment-net" xlink:href="pirs-20221231.xsd#statement-note-6-property-and-equipment-net" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.pieris.com/20221231/role/statement-note-6-property-and-equipment-net" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NotesToFinancialStatementsAbstract" xlink:label="pirs_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-8-income-taxes" xlink:href="pirs-20221231.xsd#statement-note-8-income-taxes" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.pieris.com/20221231/role/statement-note-8-income-taxes" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_CorporateIncomeTaxMember" xlink:label="pirs_CorporateIncomeTaxMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NotesToFinancialStatementsAbstract" xlink:label="pirs_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_TradeTaxMember" xlink:label="pirs_TradeTaxMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_ForeignCountryMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="pirs_CorporateIncomeTaxMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="pirs_TradeTaxMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity" xlink:href="pirs-20221231.xsd#statement-note-9-stockholders-equity" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_AtTheMarketOfferingMember" xlink:label="pirs_AtTheMarketOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_ConversionOfCommonStockIntoSeriesEPreferredStockMember" xlink:label="pirs_ConversionOfCommonStockIntoSeriesEPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" xlink:label="pirs_EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_JefferiesLLCMember" xlink:label="pirs_JefferiesLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NotesToFinancialStatementsAbstract" xlink:label="pirs_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_PreferredShareExchangeMember" xlink:label="pirs_PreferredShareExchangeMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_SecuritiesPurchaseAgreementMember" xlink:label="pirs_SecuritiesPurchaseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_SeriesAThroughEMember" xlink:label="pirs_SeriesAThroughEMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_StockExchangeSharesFromExistingShareholdersMember" xlink:label="pirs_StockExchangeSharesFromExistingShareholdersMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="us-gaap_SeriesEPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesBPreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesCPreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesDPreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesEPreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_PreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="pirs_SeriesAThroughEMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="pirs_SecuritiesPurchaseAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="pirs_StockExchangeSharesFromExistingShareholdersMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="pirs_PreferredShareExchangeMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="pirs_EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="pirs_ConversionOfCommonStockIntoSeriesEPreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="pirs_JefferiesLLCMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="pirs_AtTheMarketOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-10-net-loss-per-share" xlink:href="pirs-20221231.xsd#statement-note-10-net-loss-per-share" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.pieris.com/20221231/role/statement-note-10-net-loss-per-share" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NotesToFinancialStatementsAbstract" xlink:label="pirs_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans" xlink:href="pirs-20221231.xsd#statement-note-11-stock-and-employee-benefit-plans" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" xlink:label="pirs_EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_ExecutiveOfficersAndManagementMember" xlink:label="pirs_ExecutiveOfficersAndManagementMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NotesToFinancialStatementsAbstract" xlink:label="pirs_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="pirs_EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="pirs_ExecutiveOfficersAndManagementMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-13-leases" xlink:href="pirs-20221231.xsd#statement-note-13-leases" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.pieris.com/20221231/role/statement-note-13-leases" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_BostonMassachusettsMember" xlink:label="pirs_BostonMassachusettsMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_HallbergmoosGermanyMember" xlink:label="pirs_HallbergmoosGermanyMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_LeasesExpectedToBeDeliveredByOctober2024Member" xlink:label="pirs_LeasesExpectedToBeDeliveredByOctober2024Member" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_LeasesWithFirstRightOfRefusalForAdditionalAreaMember" xlink:label="pirs_LeasesWithFirstRightOfRefusalForAdditionalAreaMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NotesToFinancialStatementsAbstract" xlink:label="pirs_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_OfficeAndLaboratorySpaceMember" xlink:label="pirs_OfficeAndLaboratorySpaceMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_SubleaseOfficeSpaceMember" xlink:label="pirs_SubleaseOfficeSpaceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseContractualTermAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="pirs_SubleaseOfficeSpaceMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="pirs_BostonMassachusettsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="pirs_OfficeAndLaboratorySpaceMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="pirs_HallbergmoosGermanyMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="pirs_LeasesExpectedToBeDeliveredByOctober2024Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="pirs_LeasesWithFirstRightOfRefusalForAdditionalAreaMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-significant-accounting-policies-policies" xlink:href="pirs-20221231.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.pieris.com/20221231/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_statement-statement-significant-accounting-policies-policies" xlink:label="pirs_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentAssistancePolicyTextBlock" xlink:label="us-gaap_GovernmentAssistancePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_statement-statement-significant-accounting-policies-policies" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GovernmentAssistancePolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables" xlink:href="pirs-20221231.xsd#statement-note-2-summary-of-significant-accounting-policies-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.pieris.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:label="pirs_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_statement-statement-note-2-summary-of-significant-accounting-policies-tables" xlink:label="pirs_statement-statement-note-2-summary-of-significant-accounting-policies-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_statement-statement-note-2-summary-of-significant-accounting-policies-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="pirs_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-3-revenue-tables" xlink:href="pirs-20221231.xsd#statement-note-3-revenue-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.pieris.com/20221231/role/statement-note-3-revenue-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_RevenueFromContractWithCustomerMilestonePaymentsTableTextBlock" xlink:label="pirs_RevenueFromContractWithCustomerMilestonePaymentsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_statement-statement-note-3-revenue-tables" xlink:label="pirs_statement-statement-note-3-revenue-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_statement-statement-note-3-revenue-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="pirs_RevenueFromContractWithCustomerMilestonePaymentsTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-tables" xlink:href="pirs-20221231.xsd#statement-note-5-cash-cash-equivalents-and-investments-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_statement-statement-note-5-cash-cash-equivalents-and-investments-tables" xlink:label="pirs_statement-statement-note-5-cash-cash-equivalents-and-investments-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_statement-statement-note-5-cash-cash-equivalents-and-investments-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-6-property-and-equipment-net-tables" xlink:href="pirs-20221231.xsd#statement-note-6-property-and-equipment-net-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.pieris.com/20221231/role/statement-note-6-property-and-equipment-net-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_statement-statement-note-6-property-and-equipment-net-tables" xlink:label="pirs_statement-statement-note-6-property-and-equipment-net-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_statement-statement-note-6-property-and-equipment-net-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-7-accrued-expenses-tables" xlink:href="pirs-20221231.xsd#statement-note-7-accrued-expenses-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.pieris.com/20221231/role/statement-note-7-accrued-expenses-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_statement-statement-note-7-accrued-expenses-tables" xlink:label="pirs_statement-statement-note-7-accrued-expenses-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_statement-statement-note-7-accrued-expenses-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-8-income-taxes-tables" xlink:href="pirs-20221231.xsd#statement-note-8-income-taxes-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.pieris.com/20221231/role/statement-note-8-income-taxes-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_statement-statement-note-8-income-taxes-tables" xlink:label="pirs_statement-statement-note-8-income-taxes-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_statement-statement-note-8-income-taxes-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-tables" xlink:href="pirs-20221231.xsd#statement-note-11-stock-and-employee-benefit-plans-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_statement-statement-note-11-stock-and-employee-benefit-plans-tables" xlink:label="pirs_statement-statement-note-11-stock-and-employee-benefit-plans-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_statement-statement-note-11-stock-and-employee-benefit-plans-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-13-leases-tables" xlink:href="pirs-20221231.xsd#statement-note-13-leases-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.pieris.com/20221231/role/statement-note-13-leases-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_statement-statement-note-13-leases-tables" xlink:label="pirs_statement-statement-note-13-leases-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_statement-statement-note-13-leases-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-1-corporate-information-details-textual" xlink:href="pirs-20221231.xsd#statement-note-1-corporate-information-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.pieris.com/20221231/role/statement-note-1-corporate-information-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NoteToFinancialStatementDetailsTextual" xlink:label="pirs_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_PierisPharmaceuticalsGmbhMember" xlink:label="pirs_PierisPharmaceuticalsGmbhMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-n2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-n2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="pirs_PierisPharmaceuticalsGmbhMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss-n2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-n2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-property-plant-and-equipment-useful-lives-details" xlink:href="pirs-20221231.xsd#statement-note-2-summary-of-significant-accounting-policies-schedule-of-property-plant-and-equipment-useful-lives-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.pieris.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-property-plant-and-equipment-useful-lives-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_LaboratoryEquipmentMember" xlink:label="pirs_LaboratoryEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_statement-statement-note-2-summary-of-significant-accounting-policies-schedule-of-property-plant-and-equipment-useful-lives-details" xlink:label="pirs_statement-statement-note-2-summary-of-significant-accounting-policies-schedule-of-property-plant-and-equipment-useful-lives-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_statement-statement-note-2-summary-of-significant-accounting-policies-schedule-of-property-plant-and-equipment-useful-lives-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="pirs_LaboratoryEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_OfficeEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual" xlink:href="pirs-20221231.xsd#statement-note-3-revenue-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_AdditionalOtherResearchServicesMember" xlink:label="pirs_AdditionalOtherResearchServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_AgreementTerminationNoticePeriodUponOfBreachOfPaymentObligations" xlink:label="pirs_AgreementTerminationNoticePeriodUponOfBreachOfPaymentObligations-2" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_AmendedCollaborationAgreementResaleOfStockPeriod" xlink:label="pirs_AmendedCollaborationAgreementResaleOfStockPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_AntibodyTargetSwapMember" xlink:label="pirs_AntibodyTargetSwapMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_AstraZenecaABMember" xlink:label="pirs_AstraZenecaABMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_BPAssetsXIIIncMember" xlink:label="pirs_BPAssetsXIIIncMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_CodevelopmentCollaborationProductCollaborationMember" xlink:label="pirs_CodevelopmentCollaborationProductCollaborationMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_CollaborativeArrangementAllocableArrangementConsiderationAllocation" xlink:label="pirs_CollaborativeArrangementAllocableArrangementConsiderationAllocation-2" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_EstimatedDevelopmentAndManufacturingServicesMember" xlink:label="pirs_EstimatedDevelopmentAndManufacturingServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_EstimatedPhase2aServicesMember" xlink:label="pirs_EstimatedPhase2aServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_ExclusiveProductLicenseAgreementMember" xlink:label="pirs_ExclusiveProductLicenseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_GenentechMember" xlink:label="pirs_GenentechMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_GovernanceCommitteeParticipationMember" xlink:label="pirs_GovernanceCommitteeParticipationMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember" xlink:label="pirs_LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_LicenseAndCollaborationAgreementMember" xlink:label="pirs_LicenseAndCollaborationAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NoteToFinancialStatementDetailsTextual" xlink:label="pirs_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NumberOfCollaborationProducts" xlink:label="pirs_NumberOfCollaborationProducts-2" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NumberOfCombinedPerformanceObligations" xlink:label="pirs_NumberOfCombinedPerformanceObligations-2" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NumberOfDevelopmentMilestones" xlink:label="pirs_NumberOfDevelopmentMilestones-2" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NumberOfDiscoveryProgramsDiscontinued" xlink:label="pirs_NumberOfDiscoveryProgramsDiscontinued-2" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NumberOfInitialResearchPrograms" xlink:label="pirs_NumberOfInitialResearchPrograms-2" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NumberOfLicenses" xlink:label="pirs_NumberOfLicenses-2" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NumberOfNovelProteins" xlink:label="pirs_NumberOfNovelProteins-2" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NumberOfOptionalAdditionalResearchPrograms" xlink:label="pirs_NumberOfOptionalAdditionalResearchPrograms-2" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NumberOfPerformanceObligations" xlink:label="pirs_NumberOfPerformanceObligations-2" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NumberOfPreclinicalStagePrograms" xlink:label="pirs_NumberOfPreclinicalStagePrograms-2" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NumberOfPrograms" xlink:label="pirs_NumberOfPrograms-2" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NumberOfResearchLicenses" xlink:label="pirs_NumberOfResearchLicenses-2" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NumberOfResearchPrograms" xlink:label="pirs_NumberOfResearchPrograms-2" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NumberOfSeparatePerformanceObligations" xlink:label="pirs_NumberOfSeparatePerformanceObligations-2" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NumberOfSwapOptions" xlink:label="pirs_NumberOfSwapOptions-2" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NumberOfTargetPrograms" xlink:label="pirs_NumberOfTargetPrograms-2" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NumberOfTechnologyLicenses" xlink:label="pirs_NumberOfTechnologyLicenses-2" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_OtherArrangementMember" xlink:label="pirs_OtherArrangementMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_PlatformTechnologyLicenseMember" xlink:label="pirs_PlatformTechnologyLicenseMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_RemainingPerformanceObligationEstimatedTerm" xlink:label="pirs_RemainingPerformanceObligationEstimatedTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_ResearchAndDevelopmentServicesMember" xlink:label="pirs_ResearchAndDevelopmentServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_ResearchCollaborationAgreementPeriod" xlink:label="pirs_ResearchCollaborationAgreementPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_ResearchTermExtensionPeriod" xlink:label="pirs_ResearchTermExtensionPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_RevenueFromContractWithCustomerAgreementObligationCost" xlink:label="pirs_RevenueFromContractWithCustomerAgreementObligationCost-2" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_RevenueFromContractWithCustomerAgreementTerminationAdditionalNoticePeriodUponMaterialBreach" xlink:label="pirs_RevenueFromContractWithCustomerAgreementTerminationAdditionalNoticePeriodUponMaterialBreach-2" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriod" xlink:label="pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodAfterFirstCommercialSale" xlink:label="pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodAfterFirstCommercialSale-2" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodBeforeFirstCommercialSale" xlink:label="pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodBeforeFirstCommercialSale-2" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodIfMarketingApprovalObtained" xlink:label="pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodIfMarketingApprovalObtained-2" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_RevenueFromContractWithCustomerAgreementTerminationNoticePeriodNonpaymentOfUndisputedAmounts" xlink:label="pirs_RevenueFromContractWithCustomerAgreementTerminationNoticePeriodNonpaymentOfUndisputedAmounts-2" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_RevenueFromContractWithCustomerAgreementTerminationNoticePeriodUponMaterialBreach" xlink:label="pirs_RevenueFromContractWithCustomerAgreementTerminationNoticePeriodUponMaterialBreach-2" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_RevenueFromContractWithCustomerAgreementTerminationNoticePeriodWithinMaterialBreach" xlink:label="pirs_RevenueFromContractWithCustomerAgreementTerminationNoticePeriodWithinMaterialBreach-2" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_RevenueFromContractWithCustomerAllocableArrangementConsiderationAllocation" xlink:label="pirs_RevenueFromContractWithCustomerAllocableArrangementConsiderationAllocation-2" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_RevenueFromContractWithCustomerCollaborationFeeOnAdditionalProgram" xlink:label="pirs_RevenueFromContractWithCustomerCollaborationFeeOnAdditionalProgram-2" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_RevenueFromContractWithCustomerContributionTowardsManufacturingActivities" xlink:label="pirs_RevenueFromContractWithCustomerContributionTowardsManufacturingActivities-2" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_RevenueFromContractWithCustomerPeriodAfterEffectiveDateAgreementsMayBeTerminated" xlink:label="pirs_RevenueFromContractWithCustomerPeriodAfterEffectiveDateAgreementsMayBeTerminated-2" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_SaleOfStockFairValuePricePerShare" xlink:label="pirs_SaleOfStockFairValuePricePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_SalesMilestonePaymentsMember" xlink:label="pirs_SalesMilestonePaymentsMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_SeattleGeneticsIncMember" xlink:label="pirs_SeattleGeneticsIncMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_ServierDevelopedCollaborationProductsMember" xlink:label="pirs_ServierDevelopedCollaborationProductsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="us-gaap_AccountingStandardsUpdate201409Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis" xlink:label="us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortization" xlink:label="us-gaap_CapitalizedContractCostAmortization-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostGross" xlink:label="us-gaap_CapitalizedContractCostGross-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleMember" xlink:label="us-gaap_ChangeInAccountingPrincipleMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UpFrontPaymentArrangementMember" xlink:label="us-gaap_UpFrontPaymentArrangementMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis" xlink:to="us-gaap_ChangeInAccountingPrincipleMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="us-gaap_LicenseMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="pirs_GenentechMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="pirs_ResearchAndDevelopmentServicesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="pirs_LicenseAndCollaborationAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="pirs_PlatformTechnologyLicenseMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="pirs_GovernanceCommitteeParticipationMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="pirs_BPAssetsXIIIncMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="pirs_ExclusiveProductLicenseAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="pirs_SeattleGeneticsIncMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="pirs_OtherArrangementMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_UpFrontPaymentArrangementMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="pirs_AntibodyTargetSwapMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TransactionTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="pirs_SalesMilestonePaymentsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_CollaborativeArrangementMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="pirs_AstraZenecaABMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="pirs_EstimatedDevelopmentAndManufacturingServicesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="pirs_EstimatedPhase2aServicesMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="pirs_AdditionalOtherResearchServicesMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="pirs_LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="pirs_CodevelopmentCollaborationProductCollaborationMember" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="pirs_ServierDevelopedCollaborationProductsMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis" xlink:to="us-gaap_AccountingStandardsUpdate201409Member" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractWithCustomerLiability-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_NumberOfInitialResearchPrograms-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_NumberOfOptionalAdditionalResearchPrograms-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_RevenueFromContractWithCustomerCollaborationFeeOnAdditionalProgram-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_RevenueFromContractWithCustomerAgreementTerminationNoticePeriodWithinMaterialBreach-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodBeforeFirstCommercialSale-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodAfterFirstCommercialSale-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_NumberOfResearchPrograms-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_ResearchCollaborationAgreementPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_NumberOfPerformanceObligations-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_RevenueFromContractWithCustomerContributionTowardsManufacturingActivities-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_RevenueFromContractWithCustomerPeriodAfterEffectiveDateAgreementsMayBeTerminated-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriod-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodIfMarketingApprovalObtained-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_RevenueFromContractWithCustomerAgreementTerminationNoticePeriodUponMaterialBreach-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_RevenueFromContractWithCustomerAgreementTerminationNoticePeriodNonpaymentOfUndisputedAmounts-2" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_RevenueFromContractWithCustomerAgreementTerminationAdditionalNoticePeriodUponMaterialBreach-2" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_RevenueFromContractWithCustomerAgreementObligationCost-2" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNet-2" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized-2" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax-2" xlink:type="arc"/>
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned-2" xlink:type="arc"/>
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_NumberOfLicenses-2" xlink:type="arc"/>
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_NumberOfSwapOptions-2" xlink:type="arc"/>
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_NumberOfTargetPrograms-2" xlink:type="arc"/>
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_CollaborativeArrangementAllocableArrangementConsiderationAllocation-2" xlink:type="arc"/>
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction-2" xlink:type="arc"/>
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction-2" xlink:type="arc"/>
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_AmendedCollaborationAgreementResaleOfStockPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_SaleOfStockFairValuePricePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_NumberOfNovelProteins-2" xlink:type="arc"/>
    <link:presentationArc order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_NumberOfCollaborationProducts-2" xlink:type="arc"/>
    <link:presentationArc order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_NumberOfPrograms-2" xlink:type="arc"/>
    <link:presentationArc order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_AgreementTerminationNoticePeriodUponOfBreachOfPaymentObligations-2" xlink:type="arc"/>
    <link:presentationArc order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_RevenueFromContractWithCustomerAllocableArrangementConsiderationAllocation-2" xlink:type="arc"/>
    <link:presentationArc order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_NumberOfTechnologyLicenses-2" xlink:type="arc"/>
    <link:presentationArc order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_NumberOfResearchLicenses-2" xlink:type="arc"/>
    <link:presentationArc order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_RemainingPerformanceObligationEstimatedTerm-2" xlink:type="arc"/>
    <link:presentationArc order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues-2" xlink:type="arc"/>
    <link:presentationArc order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_NumberOfDiscoveryProgramsDiscontinued-2" xlink:type="arc"/>
    <link:presentationArc order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CapitalizedContractCostNet-2" xlink:type="arc"/>
    <link:presentationArc order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CapitalizedContractCostGross-2" xlink:type="arc"/>
    <link:presentationArc order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CapitalizedContractCostAmortization-2" xlink:type="arc"/>
    <link:presentationArc order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_NumberOfDevelopmentMilestones-2" xlink:type="arc"/>
    <link:presentationArc order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_NumberOfSeparatePerformanceObligations-2" xlink:type="arc"/>
    <link:presentationArc order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_NumberOfCombinedPerformanceObligations-2" xlink:type="arc"/>
    <link:presentationArc order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_ResearchTermExtensionPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="51" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_NumberOfPreclinicalStagePrograms-2" xlink:type="arc"/>
    <link:presentationArc order="52" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-4-grant-income-details-textual" xlink:href="pirs-20221231.xsd#statement-note-4-grant-income-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.pieris.com/20221231/role/statement-note-4-grant-income-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NoteToFinancialStatementDetailsTextual" xlink:label="pirs_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantsReceivable" xlink:label="us-gaap_GrantsReceivable-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GrantsReceivable-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-details-textual" xlink:href="pirs-20221231.xsd#statement-note-5-cash-cash-equivalents-and-investments-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NoteToFinancialStatementDetailsTextual" xlink:label="pirs_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-6-property-and-equipment-net-details-textual" xlink:href="pirs-20221231.xsd#statement-note-6-property-and-equipment-net-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.pieris.com/20221231/role/statement-note-6-property-and-equipment-net-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NoteToFinancialStatementDetailsTextual" xlink:label="pirs_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Depreciation-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-8-income-taxes-details-textual" xlink:href="pirs-20221231.xsd#statement-note-8-income-taxes-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.pieris.com/20221231/role/statement-note-8-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_CorporateIncomeTaxMember" xlink:label="pirs_CorporateIncomeTaxMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:label="pirs_DeferredTaxAssetsCapitalizedResearchAndDevelopment-2" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NoteToFinancialStatementDetailsTextual" xlink:label="pirs_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_TradeTaxMember" xlink:label="pirs_TradeTaxMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_ForeignCountryMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="pirs_CorporateIncomeTaxMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="pirs_TradeTaxMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwards-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OpenTaxYear-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_DeferredTaxAssetsCapitalizedResearchAndDevelopment-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual" xlink:href="pirs-20221231.xsd#statement-note-9-stockholders-equity-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_AtTheMarketOfferingMember" xlink:label="pirs_AtTheMarketOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_ConversionOfCommonStockIntoSeriesEPreferredStockMember" xlink:label="pirs_ConversionOfCommonStockIntoSeriesEPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_ConvertiblePreferredStockBeneficialOwnershipLimitationNoticePeriodBeforeIncrease" xlink:label="pirs_ConvertiblePreferredStockBeneficialOwnershipLimitationNoticePeriodBeforeIncrease-2" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_ConvertiblePreferredStockBeneficialOwnershipLimitationPercent" xlink:label="pirs_ConvertiblePreferredStockBeneficialOwnershipLimitationPercent-2" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_ConvertiblePreferredStockCommonStockOwnershipLimitPercent" xlink:label="pirs_ConvertiblePreferredStockCommonStockOwnershipLimitPercent-2" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_ConvertiblePreferredStockWeightedAverageStockPricePercent" xlink:label="pirs_ConvertiblePreferredStockWeightedAverageStockPricePercent-2" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" xlink:label="pirs_EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_JefferiesLLCMember" xlink:label="pirs_JefferiesLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NoteToFinancialStatementDetailsTextual" xlink:label="pirs_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NumberOfVotesPerShare" xlink:label="pirs_NumberOfVotesPerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_PreferredShareExchangeMember" xlink:label="pirs_PreferredShareExchangeMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_ProceedsFromIssuanceOfPrivatePlacementNet" xlink:label="pirs_ProceedsFromIssuanceOfPrivatePlacementNet-2" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_SaleOfStockAuthorizedAmount" xlink:label="pirs_SaleOfStockAuthorizedAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_SaleOfStockNumberOfWarrantsPerUnit" xlink:label="pirs_SaleOfStockNumberOfWarrantsPerUnit-2" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_SecuritiesPurchaseAgreementMember" xlink:label="pirs_SecuritiesPurchaseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_SeriesAThroughEMember" xlink:label="pirs_SeriesAThroughEMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_StockExchangeSharesFromExistingShareholdersMember" xlink:label="pirs_StockExchangeSharesFromExistingShareholdersMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PartnersCapitalAccountUnitsSoldInPrivatePlacement" xlink:label="us-gaap_PartnersCapitalAccountUnitsSoldInPrivatePlacement-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="us-gaap_SeriesEPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesBPreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesCPreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesDPreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesEPreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_PreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="pirs_SeriesAThroughEMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="pirs_SecuritiesPurchaseAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="pirs_StockExchangeSharesFromExistingShareholdersMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="pirs_PreferredShareExchangeMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="pirs_EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="pirs_ConversionOfCommonStockIntoSeriesEPreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="pirs_JefferiesLLCMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="pirs_AtTheMarketOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_NumberOfVotesPerShare-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_ConvertiblePreferredStockCommonStockOwnershipLimitPercent-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_ConvertiblePreferredStockBeneficialOwnershipLimitationPercent-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_ConvertiblePreferredStockBeneficialOwnershipLimitationNoticePeriodBeforeIncrease-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PartnersCapitalAccountUnitsSoldInPrivatePlacement-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_ProceedsFromIssuanceOfPrivatePlacementNet-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction-2" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits-2" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_SaleOfStockNumberOfWarrantsPerUnit-2" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-2" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_ConvertiblePreferredStockWeightedAverageStockPricePercent-2" xlink:type="arc"/>
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="arc"/>
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature-2" xlink:type="arc"/>
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1-2" xlink:type="arc"/>
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1-2" xlink:type="arc"/>
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="arc"/>
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_SaleOfStockAuthorizedAmount-2" xlink:type="arc"/>
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction-2" xlink:type="arc"/>
    <link:presentationArc order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-10-net-loss-per-share-details-textual" xlink:href="pirs-20221231.xsd#statement-note-10-net-loss-per-share-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.pieris.com/20221231/role/statement-note-10-net-loss-per-share-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NoteToFinancialStatementDetailsTextual" xlink:label="pirs_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-details-textual" xlink:href="pirs-20221231.xsd#statement-note-11-stock-and-employee-benefit-plans-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" xlink:label="pirs_EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_ExecutiveOfficersAndManagementMember" xlink:label="pirs_ExecutiveOfficersAndManagementMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NoteToFinancialStatementDetailsTextual" xlink:label="pirs_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_ShareBasedCompensationArrangementBySharebasedPaymentAwardPurchasePeriod" xlink:label="pirs_ShareBasedCompensationArrangementBySharebasedPaymentAwardPurchasePeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfPurchasePeriods" xlink:label="pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfPurchasePeriods-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="pirs_EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="pirs_ExecutiveOfficersAndManagementMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfPurchasePeriods-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_ShareBasedCompensationArrangementBySharebasedPaymentAwardPurchasePeriod-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-schedule-of-sharebased-payment-award-stock-options-details" xlink:href="pirs-20221231.xsd#statement-note-11-stock-and-employee-benefit-plans-schedule-of-sharebased-payment-award-stock-options-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-schedule-of-sharebased-payment-award-stock-options-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_statement-statement-note-11-stock-and-employee-benefit-plans-schedule-of-sharebased-payment-award-stock-options-details" xlink:label="pirs_statement-statement-note-11-stock-and-employee-benefit-plans-schedule-of-sharebased-payment-award-stock-options-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_statement-statement-note-11-stock-and-employee-benefit-plans-schedule-of-sharebased-payment-award-stock-options-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-13-leases-details-textual" xlink:href="pirs-20221231.xsd#statement-note-13-leases-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.pieris.com/20221231/role/statement-note-13-leases-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_BostonMassachusettsMember" xlink:label="pirs_BostonMassachusettsMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_HallbergmoosGermanyMember" xlink:label="pirs_HallbergmoosGermanyMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_LeasesExpectedToBeDeliveredByOctober2024Member" xlink:label="pirs_LeasesExpectedToBeDeliveredByOctober2024Member" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_LeasesWithFirstRightOfRefusalForAdditionalAreaMember" xlink:label="pirs_LeasesWithFirstRightOfRefusalForAdditionalAreaMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_LesseeOperatingLeaseMonthlyRentExpense" xlink:label="pirs_LesseeOperatingLeaseMonthlyRentExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NoteToFinancialStatementDetailsTextual" xlink:label="pirs_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_NumberOfAgreementExtensionOptions" xlink:label="pirs_NumberOfAgreementExtensionOptions-2" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_OfficeAndLaboratorySpaceMember" xlink:label="pirs_OfficeAndLaboratorySpaceMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_SubleaseOfficeSpaceMember" xlink:label="pirs_SubleaseOfficeSpaceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseContractualTermAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="pirs_SubleaseOfficeSpaceMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="pirs_BostonMassachusettsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="pirs_OfficeAndLaboratorySpaceMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="pirs_HallbergmoosGermanyMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="pirs_LeasesExpectedToBeDeliveredByOctober2024Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="pirs_LeasesWithFirstRightOfRefusalForAdditionalAreaMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_NumberOfAgreementExtensionOptions-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_LesseeOperatingLeaseMonthlyRentExpense-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SecurityDeposit-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TenantImprovements-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasePayments-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets-parentheticals" xlink:href="pirs-20221231.xsd#statement-consolidated-balance-sheets-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-8-income-taxes-summary-of-income-tax-contingencies-details" xlink:href="pirs-20221231.xsd#statement-note-8-income-taxes-summary-of-income-tax-contingencies-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.pieris.com/20221231/role/statement-note-8-income-taxes-summary-of-income-tax-contingencies-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_statement-statement-note-8-income-taxes-summary-of-income-tax-contingencies-details" xlink:label="pirs_statement-statement-note-8-income-taxes-summary-of-income-tax-contingencies-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation-n8" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_statement-statement-note-8-income-taxes-summary-of-income-tax-contingencies-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-investments-details" xlink:href="pirs-20221231.xsd#statement-note-5-cash-cash-equivalents-and-investments-investments-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-investments-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_DebtSecuritiesAvailableforsaleContractualMaturityPeriod" xlink:label="pirs_DebtSecuritiesAvailableforsaleContractualMaturityPeriod" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_statement-statement-note-5-cash-cash-equivalents-and-investments-investments-details" xlink:label="pirs_statement-statement-note-5-cash-cash-equivalents-and-investments-investments-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:label="us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_statement-statement-note-5-cash-cash-equivalents-and-investments-investments-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_USTreasurySecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_AssetBackedSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_CorporateBondSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_DebtSecuritiesAvailableforsaleContractualMaturityPeriod" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-n8" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-3-revenue-potential-milestone-payments-received-details" xlink:href="pirs-20221231.xsd#statement-note-3-revenue-potential-milestone-payments-received-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.pieris.com/20221231/role/statement-note-3-revenue-potential-milestone-payments-received-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_AstraZenecaABMember" xlink:label="pirs_AstraZenecaABMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_BostonPharmaceuticalsMember" xlink:label="pirs_BostonPharmaceuticalsMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_GenentechMember" xlink:label="pirs_GenentechMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember" xlink:label="pirs_LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_ResearchAndDevelopmentMilestonePaymentsMember" xlink:label="pirs_ResearchAndDevelopmentMilestonePaymentsMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_SalesMilestonePaymentsMember" xlink:label="pirs_SalesMilestonePaymentsMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_SeattleGeneticsIncMember" xlink:label="pirs_SeattleGeneticsIncMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_statement-statement-note-3-revenue-potential-milestone-payments-received-details" xlink:label="pirs_statement-statement-note-3-revenue-potential-milestone-payments-received-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractsReceivableClaimsAndUncertainAmounts" xlink:label="us-gaap_ContractsReceivableClaimsAndUncertainAmounts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_statement-statement-note-3-revenue-potential-milestone-payments-received-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="pirs_ResearchAndDevelopmentMilestonePaymentsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_CollaborativeArrangementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="pirs_AstraZenecaABMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="pirs_SalesMilestonePaymentsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="pirs_LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="pirs_SeattleGeneticsIncMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="pirs_BostonPharmaceuticalsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="pirs_GenentechMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractsReceivableClaimsAndUncertainAmounts" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" xlink:href="pirs-20221231.xsd#statement-note-8-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_EffectiveIncomeTaxRateReconciliationProvisionToReturnPercent" xlink:label="pirs_EffectiveIncomeTaxRateReconciliationProvisionToReturnPercent" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_statement-statement-note-8-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" xlink:label="pirs_statement-statement-note-8-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_statement-statement-note-8-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_EffectiveIncomeTaxRateReconciliationProvisionToReturnPercent" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-13-leases-maturities-of-operating-lease-liabilities-details" xlink:href="pirs-20221231.xsd#statement-note-13-leases-maturities-of-operating-lease-liabilities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.pieris.com/20221231/role/statement-note-13-leases-maturities-of-operating-lease-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_statement-statement-note-13-leases-maturities-of-operating-lease-liabilities-details" xlink:label="pirs_statement-statement-note-13-leases-maturities-of-operating-lease-liabilities-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_statement-statement-note-13-leases-maturities-of-operating-lease-liabilities-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-3" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-n8" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiability" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" xlink:href="pirs-20221231.xsd#statement-consolidated-statements-of-operations-and-comprehensive-loss" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.pieris.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentAssistanceAmount" xlink:label="us-gaap_GovernmentAssistanceAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:label="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_Revenues-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_GovernmentAssistanceAmount" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NetIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows" xlink:href="pirs-20221231.xsd#statement-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="pirs_IncreaseDecreaseInOperatingLeaseLiabilities-n8" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_OperatingLeaseRightOfUseAssetAccretion" xlink:label="pirs_OperatingLeaseRightOfUseAssetAccretion-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n9" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:label="us-gaap_RealizedInvestmentGainsLosses-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="pirs_OperatingLeaseRightOfUseAssetAccretion-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_RealizedInvestmentGainsLosses-n8" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n9" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade-1" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities-1" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="pirs_IncreaseDecreaseInOperatingLeaseLiabilities-n8" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireInvestments-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-3" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-4" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-5" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-3-revenue-disaggregation-of-revenue-details" xlink:href="pirs-20221231.xsd#statement-note-3-revenue-disaggregation-of-revenue-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.pieris.com/20221231/role/statement-note-3-revenue-disaggregation-of-revenue-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_AstraZenecaABMember" xlink:label="pirs_AstraZenecaABMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_BostonPharmaceuticalsMember" xlink:label="pirs_BostonPharmaceuticalsMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_GenentechMember" xlink:label="pirs_GenentechMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember" xlink:label="pirs_LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_SeattleGeneticsIncMember" xlink:label="pirs_SeattleGeneticsIncMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_statement-statement-note-3-revenue-disaggregation-of-revenue-details" xlink:label="pirs_statement-statement-note-3-revenue-disaggregation-of-revenue-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_statement-statement-note-3-revenue-disaggregation-of-revenue-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="pirs_AstraZenecaABMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="pirs_SeattleGeneticsIncMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="pirs_LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="pirs_GenentechMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="pirs_BostonPharmaceuticalsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-cash-equivalents-and-investments-carried-at-fair-value-details" xlink:href="pirs-20221231.xsd#statement-note-5-cash-cash-equivalents-and-investments-cash-equivalents-and-investments-carried-at-fair-value-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-cash-equivalents-and-investments-carried-at-fair-value-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_CashEquivalentsAndInvestments" xlink:label="pirs_CashEquivalentsAndInvestments" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_statement-statement-note-5-cash-cash-equivalents-and-investments-cash-equivalents-and-investments-carried-at-fair-value-details" xlink:label="pirs_statement-statement-note-5-cash-cash-equivalents-and-investments-cash-equivalents-and-investments-carried-at-fair-value-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:label="us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_statement-statement-note-5-cash-cash-equivalents-and-investments-cash-equivalents-and-investments-carried-at-fair-value-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_MoneyMarketFundsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel1Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel3Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_USTreasurySecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_AssetBackedSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_CorporateBondSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_CashEquivalentsAndInvestments" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-6-property-and-equipment-net-property-and-equipment-details" xlink:href="pirs-20221231.xsd#statement-note-6-property-and-equipment-net-property-and-equipment-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.pieris.com/20221231/role/statement-note-6-property-and-equipment-net-property-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_LaboratoryEquipmentMember" xlink:label="pirs_LaboratoryEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_statement-statement-note-6-property-and-equipment-net-property-and-equipment-details" xlink:label="pirs_statement-statement-note-6-property-and-equipment-net-property-and-equipment-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_statement-statement-note-6-property-and-equipment-net-property-and-equipment-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="pirs_LaboratoryEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_OfficeEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-7-accrued-expenses-accrued-expenses-and-other-current-liabilities-details" xlink:href="pirs-20221231.xsd#statement-note-7-accrued-expenses-accrued-expenses-and-other-current-liabilities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.pieris.com/20221231/role/statement-note-7-accrued-expenses-accrued-expenses-and-other-current-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_AccruedAccountsPayableCurrent" xlink:label="pirs_AccruedAccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_AccruedCollaborationCostsCurrent" xlink:label="pirs_AccruedCollaborationCostsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_AccruedLiabilitiesAndOtherCurrentLiabilitiesMember" xlink:label="pirs_AccruedLiabilitiesAndOtherCurrentLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:label="pirs_AccruedLiabilitiesAndOtherLiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_AccruedLicenseObligationsCurrent" xlink:label="pirs_AccruedLicenseObligationsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_AccruedResearchAndDevelopmentCosts" xlink:label="pirs_AccruedResearchAndDevelopmentCosts" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_statement-statement-note-7-accrued-expenses-accrued-expenses-and-other-current-liabilities-details" xlink:label="pirs_statement-statement-note-7-accrued-expenses-accrued-expenses-and-other-current-liabilities-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_statement-statement-note-7-accrued-expenses-accrued-expenses-and-other-current-liabilities-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="pirs_AccruedLiabilitiesAndOtherCurrentLiabilitiesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_AccruedResearchAndDevelopmentCosts" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_AccruedLicenseObligationsCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_AccruedAccountsPayableCurrent" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_AccruedCollaborationCostsCurrent" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_AccruedLiabilitiesAndOtherLiabilitiesCurrent-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details" xlink:href="pirs-20221231.xsd#statement-note-8-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_statement-statement-note-8-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details" xlink:label="pirs_statement-statement-note-8-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_statement-statement-note-8-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-schedule-of-employee-service-sharebased-compensation-costs-details" xlink:href="pirs-20221231.xsd#statement-note-11-stock-and-employee-benefit-plans-schedule-of-employee-service-sharebased-compensation-costs-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-schedule-of-employee-service-sharebased-compensation-costs-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_statement-statement-note-11-stock-and-employee-benefit-plans-schedule-of-employee-service-sharebased-compensation-costs-details" xlink:label="pirs_statement-statement-note-11-stock-and-employee-benefit-plans-schedule-of-employee-service-sharebased-compensation-costs-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_statement-statement-note-11-stock-and-employee-benefit-plans-schedule-of-employee-service-sharebased-compensation-costs-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-13-leases-operating-lease-costs-details" xlink:href="pirs-20221231.xsd#statement-note-13-leases-operating-lease-costs-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.pieris.com/20221231/role/statement-note-13-leases-operating-lease-costs-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_statement-statement-note-13-leases-operating-lease-costs-details" xlink:label="pirs_statement-statement-note-13-leases-operating-lease-costs-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_statement-statement-note-13-leases-operating-lease-costs-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseCost" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_VariableLeaseCost" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LeaseCost-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets" xlink:href="pirs-20221231.xsd#statement-consolidated-balance-sheets" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:label="pirs_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="pirs_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_Liabilities-3" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details" xlink:href="pirs-20221231.xsd#statement-note-8-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_statement-statement-note-8-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details" xlink:label="pirs_statement-statement-note-8-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_statement-statement-note-8-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit-3" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-8-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:href="pirs-20221231.xsd#statement-note-8-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.pieris.com/20221231/role/statement-note-8-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_DeferredTaxAssetLeaseLiability" xlink:label="pirs_DeferredTaxAssetLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_DeferredTaxAssetsAccruedCompensationAndOther" xlink:label="pirs_DeferredTaxAssetsAccruedCompensationAndOther" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:label="pirs_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_DeferredTaxAssetsDepreciationAndOther" xlink:label="pirs_DeferredTaxAssetsDepreciationAndOther" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_DeferredTaxLiabilitiesLeaseRightofuseAsset" xlink:label="pirs_DeferredTaxLiabilitiesLeaseRightofuseAsset-n8" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_statement-statement-note-8-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:label="pirs_statement-statement-note-8-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities-n10" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xlink:label="us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpense" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpense-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_statement-statement-note-8-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_DeferredTaxAssetsAccruedCompensationAndOther" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_DeferredTaxAssetsDepreciationAndOther" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_DeferredTaxAssetLeaseLiability" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsGross-3" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_DeferredTaxLiabilitiesLeaseRightofuseAsset-n8" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpense-n8" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredIncomeTaxLiabilities-n10" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance-n8" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsNet-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity" xlink:href="pirs-20221231.xsd#statement-consolidated-statements-of-changes-in-stockholders-equity" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.pieris.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="pirs-20221231.xsd#pirs_AtTheMarketOfferingMember" xlink:label="pirs_AtTheMarketOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_ConversionOfPreferredStockMember" xlink:label="pirs_ConversionOfPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_ConversionOfSeriesEPreferredStockMember" xlink:label="pirs_ConversionOfSeriesEPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="pirs_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:label="pirs_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesFromStockholderMember" xlink:label="us-gaap_ReceivablesFromStockholderMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="pirs_ConversionOfPreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="pirs_ConversionOfSeriesEPreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="pirs_AtTheMarketOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_PreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_ReceivablesFromStockholderMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1-n8" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-5" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-stock-options-activity-details" xlink:href="pirs-20221231.xsd#statement-note-11-stock-and-employee-benefit-plans-stock-options-activity-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-stock-options-activity-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" xlink:label="pirs_EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_ExecutiveOfficersAndManagementMember" xlink:label="pirs_ExecutiveOfficersAndManagementMember" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm2Exercised" xlink:label="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm2Exercised" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAggregateIntrinsicValue" xlink:label="pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAggregateIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodAggregateIntrinsicValue" xlink:label="pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodAggregateIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="pirs-20221231.xsd#pirs_statement-statement-note-11-stock-and-employee-benefit-plans-stock-options-activity-details" xlink:label="pirs_statement-statement-note-11-stock-and-employee-benefit-plans-stock-options-activity-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pirs_statement-statement-note-11-stock-and-employee-benefit-plans-stock-options-activity-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="pirs_EmployeeDirectorAndConsultantEquityIncentivePlan2020Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="pirs_ExecutiveOfficersAndManagementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-4" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodAggregateIntrinsicValue" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAggregateIntrinsicValue" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-5" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm2Exercised" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>figure4a.jpg
<TEXT>
begin 644 figure4a.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 B17AI9@  34T *@    @  0$2  ,
M   !  $       #_VP!#  (! 0(! 0(" @(" @(" P4# P,# P8$! ,%!P8'
M!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_VP!# 0(" @,#
M P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# S_P  1" '# O\# 2(  A$! Q$!_\0 'P   04! 0$!
M 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%! 0   %] 0(#
M  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*%A<8&1HE)B<H
M*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^+/^"]OP
ME^-G[1'_  35\7_#GX$>%9/%7B_Q]=6VCWR1ZM::<UEI9<S74OF74T4;+(L*
MVY4,6VW1P,*67YX_8;_X-7?V8_#_ .R/\/+;XT?">37OBL^BPW'BJZD\5ZI
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M/_Z-(^/'_@]\$_\ R_H ^AZ*^>/^&S/B?_T:1\>/_![X)_\ E_1_PV9\3_\
MHTCX\?\ @]\$_P#R_H ^AZ*^>/\ ALSXG_\ 1I'QX_\ ![X)_P#E_1_PV9\3
M_P#HTCX\?^#WP3_\OZ /H>BOGC_ALSXG_P#1I'QX_P#![X)_^7]'_#9GQ/\
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M_@]\$_\ R_H ^AZ*^>/^&S/B?_T:1\>/_![X)_\ E_1_PV9\3_\ HTCX\?\
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MZ /H>BOGC_ALSXG_ /1I'QX_\'O@G_Y?T?\ #9OQ._Z-)^/'_@]\$_\ R_H
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M -&D?'C_ ,'O@G_Y?T?\-F?$_P#Z-(^/'_@]\$__ "_H ^AZ*^>/^&S/B?\
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ML$F$:7NKV\^T$C!:)<]JT/\ ALSXG_\ 1I'QX_\ ![X)_P#E_0!]#T5\\?\
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MRR?:+A2, NL3CE%(X7_@LSI'[3%Q^Q[^U.?%%Y\&[SX$S^"[P>'[31[74O\
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MQ'K&CWGAM=:O-9U[3M(N;46TFGZ?>ZK=7-HNP<*KPRQRJ/[LJCI0!]P4444
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M  S'B?\ ^0J/^'G?@_\ Z)W^T?\ ^&8\3_\ R%7TA10!\W_\/._!_P#T3O\
M:/\ _#,>)_\ Y"H_X>=^#_\ HG?[1_\ X9CQ/_\ (5?2%% 'S?\ \/._!_\
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M1_P\[\'_ /1._P!H_P#\,QXG_P#D*OI"B@#YO_X>=^#_ /HG?[1__AF/$_\
M\A4?\/._!_\ T3O]H_\ \,QXG_\ D*OI"B@#YO\ ^'G?@_\ Z)W^T?\ ^&8\
M3_\ R%1_P\[\'_\ 1._VC_\ PS'B?_Y"KZ0W49H ^;_^'G?@_P#Z)W^T?_X9
MCQ/_ /(5'_#SOP?_ -$[_:/_ /#,>)__ )"KZ0S1F@#YO_X>=^#_ /HG?[1_
M_AF/$_\ \A4?\/._!_\ T3O]H_\ \,QXG_\ D*OI"B@#YO\ ^'G?@_\ Z)W^
MT?\ ^&8\3_\ R%1_P\[\'_\ 1._VC_\ PS'B?_Y"KZ0HH ^;_P#AYWX/_P"B
M=_M'_P#AF/$__P A4?\ #SOP?_T3O]H__P ,QXG_ /D*OI"B@#YO_P"'G?@_
M_HG?[1__ (9CQ/\ _(5*O_!3GP>[*/\ A7G[1PR1R?@QXGX_\DJ^CZ* /GG_
M ()8^&=6\'?L&_#O3]<T?5M U1;>[GFT_5+.2SO+42WMQ*BRPR /&VQU.U@"
M,\XKZ$E&8S_A3J* /B']G;]IRW_93\5_&'P_XL^'OQQDO+_XF:YK-I/HOPRU
MS6+&\M+F5'AFBN;6U>*167/W6)!!!Q7IW_#SOP?_ -$[_:/_ /#,>)__ )"K
MZ0HH ^;_ /AYWX/_ .B=_M'_ /AF/$__ ,A4?\/._!__ $3O]H__ ,,QXG_^
M0J^D** /F_\ X>=^#_\ HG?[1_\ X9CQ/_\ (5'_  \[\'_]$[_:/_\ #,>)
M_P#Y"KZ0HH ^;_\ AYWX/_Z)W^T?_P"&8\3_ /R%1_P\[\'_ /1._P!H_P#\
M,QXG_P#D*OI"B@#YO_X>=^#_ /HG?[1__AF/$_\ \A4?\/._!_\ T3O]H_\
M\,QXG_\ D*OI"B@#YO\ ^'G?@_\ Z)W^T?\ ^&8\3_\ R%1_P\[\'_\ 1._V
MC_\ PS'B?_Y"KZ0HH ^;_P#AYWX/_P"B=_M'_P#AF/$__P A4?\ #SOP?_T3
MO]H__P ,QXG_ /D*OI"B@#YO_P"'G?@__HG?[1__ (9CQ/\ _(5'_#SOP?\
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MK[Q)\;+5]8;QGXI\.V?A:\62Y#62VEK(TD>R/:"'+,<L6(/& * /6J*-U&:
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MJGARUL8M?NKH[GN;B]BD-T\@?#9,F> ,@#%=Y^R#_P $'O@A^Q!^W#K7QF\
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M-<#/_D"NL_X,9?O?M0?]RG_+6J_ (]* /W1_XCA/'/\ T;_X3_\ "FN/_C%
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MZ-_\)_\ A37'_P 8K\+:* /W2_XCA/'/_1O_ (3_ /"FN/\ XQ1_Q'">.?\
MHW_PG_X4UQ_\8K\+:* /W2_XCA/'/_1O_A/_ ,*:X_\ C%'_ !'">.?^C?\
MPG_X4UQ_\8K\+:* /W2_XCA/'/\ T;_X3_\ "FN/_C%'_$<)XY_Z-_\ "?\
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M!KKZ'SLC^+[_ (+S_P#*8G]H;_L<+G_T%*^1Z^N/^"\__*8G]H;_ +'"Y_\
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M<QK['[]?\&,OWOVH/^Y3_EK5?@$>E?O[_P &,OWOVH/^Y3_EK5?@$>E6<HE
MZT4#K0 O\?XU/8_ZTU!_'^-6+(_O3]/Z5,OA-J'\1%L#YJFB&$J*W#!]P#';
MR<59QG^9KCD?18?<%Z?6I(>9*:J@5)'\K?C4G="(V6/:V<4TGBKKPX/S?E2R
MVJ3SXA1ECP,@^N.3^=9QEW-YX:3?NE6"W\X^U$\) VU:D*VXP/RJJ]PV^A2N
M]!U*<(1Y9;D+0!0/7O[4QTVU/)N3Y3UJ%LD5H<,H);$=%.*G'W:&3:N:9D0T
M4459@%,N/]0_T-/IL_\ J'_W33CN34^%G]U7[*/_ ":_\-_^Q5TO_P!)(J[T
M_<_ UP7[*/\ R:_\-_\ L5=+_P#22*N]/W/P-=?0^=D?Q??\%Y_^4Q/[0W_8
MX7/_ *"E?(]?7'_!>?\ Y3$_M#?]CA<_^@I7R/0 4444 %%%% !1110 4444
M %%%% !1110 4448XH **** "BBB@ K^OW_@UQ_Y04? S_N/_P#J0:G7\@5?
MU^_\&N/_ "@H^!G_ ''_ /U(-3H ^_Z*** "BBB@ KP?_@H#%XJTC]GG7O$G
MA?Q?XJ\*-X7TG4KNZ/AO1$UC4[L&RECB-O;L1YDD,S),J C>80N<$U[Q7AW_
M  4@^,FO?L]_L"_&+QUX7U :3XC\'^$M1U;3+TVT5PMM<0P.R/Y4I$;X8?=?
M@^AZ4 ?"7_!-;5W^-/QVT+5O#/[=5GXRFT^_BEUKP7>>#M/\/ZUJ*??DM9X6
MCCN<G'.T'!&<GBOM3_@KU_RBF_:3_P"R8^(O_3;<5\4_\$^_@K^R;\;/C'\+
M_C9XN_:*@^.'QZU2*UU'0!X@\3VEO<Z1=31JPM8-,MS&J.CDKL9"P8'O7VM_
MP5Z_Y13?M)_]DQ\1?^FVXH _B6MON?A4_>J]I]PU8[UC+<]*A_#$/1J?'3#T
M:GQUG(ZZ>XZG[<K3*EB'45)TQ.]T.VA_X1.Q#12"XD(VMGY-@)S^)XKZ>^$G
M[.?B&;P#;:YI]K=W7ANX'GWWV'"W,87 .=W]W[PQQWKYYT'19O\ A$M.N!S&
MI\H J>O4_P Z_3#]GKX8MX"_9_\  ]QK%^9-2UB[B:30V_>+%;['9)GQ@A6X
M!4<].:_*>-LZE@Z494];R:L_T/Z8X+P4:-*,IQU<8V^XY3]D;X0> ;+4]-TF
MYAFOO$&K2[Q=7-PR?V9LE[H!ARR9&,X'7/:M3]JWX=Z;I&J:QH]KH<,UIJ^F
MF&S>9/->VG7(#!R,KD+D <XXKVRX^#'AV\\&7'B2QCCDU?29H[5[73K=[>0I
MO+K+D$EF8G !Y('6OH'QK_P3ZFBT[P[XJUB]M]&T/^RHKZ1[F$S7D=P0>63O
MG<%7)R.N*_%JG$%5XOZ[3<G%?%?I_DCZK$9K@L-*-+$3MS:6>KOOHO\ (_$'
M7O@?JT,4EG%)+(O!N)"I*J!U.,>O HM?AOX,\#6+7&N7=]?3<>3%!M7S&[@C
M^''N?PKZV_X*-?#OQ=X>N[Z^\,V<1\#VI,-[>6RDW,,Q8%A<>@8G@CY:^(]6
MFMXE-K<[A)&P.<[N3R>?I7[)D.9ULRP<:[E9/I%W?S[>AP8S!X2#=6,=4M+[
M?<=%??$W2ENY[:TT0R6-Y&(S;S2\87H0 /O5GVOAW3?$\!;3=+OI+JWRTT0.
MY-OL>,5R*6]U&S2Q;OW.<./EZ]*L:#K^H>&&9HY[BW2;APC8R*^A>%Y87I/7
MU9Y4<>IU+8B/N^FW],=XH\-WGA&XCCOK.>W:8;XDD'S!>QQZ&L&.Z:5OF!55
M]!75?$/Q7<>+S8W5Q=R7DEO;K 9'XQMZ+^7>N2$GE1R,?O-QCL:[L-=P]Y:G
M@9FXQK?NW[IG:W.EL)<#<NT@$UPC')/UKJM9D,5E-(>A&T9[&N36OH\%&T6?
MC7%&(YZ\5Y,6BBBNT^7/1/V)O^3S_A#_ -CMHW_I?#7ZL?\ ![?_ ,GJ_!W_
M +$F7_TOFK\I_P!B8_\ &9_PA_[';1O_ $OAK]6/^#V__D]7X._]B3+_ .E\
MU="/+J?$?BG5B+[C57'6K2GY:F1IA]QM%% ZU)T$MEQ<K_O"MC;O.*QH?]</
MK6U ?WGXUSUSULJU3BS8T*'RC^\^49P*M7&CO+>+Y*98GD8JF4:[LO,7=E#@
M@5V'@<AYV2.9;B2&W#E]I3J@#I[[2<9[XS7CXBI*FG41^E93AZ6)G#!SZ[,8
MTTF@:)MMVVS2K@Y 7<HY)YKC[^_DFE(_BD/)]:ZGX@S%M43Y6"K&FU>V HS_
M "_G7)W2);W&5^9F['UJ<'&+CS]67Q!6E&I[!/W8:?\ !(WA%I$"RC<W054G
MN2P..*??2/Y^V3*MW![>U+:6+2=NV>:]!1LKL^1E-U)<E,J_-,5]J)K=H(LM
MU:K4S+9K\OS-['I526Y:;.16D6V<56G"&C>I7H<;HC0.M*O]:V/.Y=#/88-*
MIXI;@?,U,%=!Y+T=@S4<OW/QJ2FOS$?KF@RJ;'[\?\&,OWOVH/\ N4_Y:U7X
M!'I7[^_\&,OWOVH?^Y3_ ):U7X!'I6AQB4#K10.M "_Q_C4]C_K&J#^/\:GL
M?OM4R^$WP_\ $1H6[;9,!NO%3U55MIJTFUAQGI^M<<CZ7#_RBT]!Q^M,ZU(.
ME2=<1=YSG)W#H:T].=3![]ZS8QD8K1TX@KM'UK"ML>GE^E2Y4U$_Z0V.F:J-
MRU6]1_X^'^M5"N#5T]CBQ?\ $?J-8D]3GM2$&G[#CH?RIO0_-^%:',QA.:;)
M]RGL?FIK_=H,9;$%%!ZT5H<H4V?_ %#_ .Z:=39_]0_^Z:<=R:GPL_NJ_91_
MY-?^&_\ V*NE_P#I)%7>G[GX&N"_91_Y-?\ AO\ ]BKI?_I)%7>G[GX&NOH?
M.R/XOO\ @O/_ ,IB?VAO^QPN?_04KY'KZX_X+S_\IB?VAO\ L<+G_P!!2OD>
M@ HHHH ***<$XH ;C%*IPU.7+&D9<&@KE&DY-.!^6A%XI&^]0#6@E':BG1J2
MWW=WX4$C:*D.T#Y0?KBF-UH*Y1*51EN:2B@D<[9Z#']:;3FD+"FT#D%%%% @
MK^OW_@UQ_P"4%'P,_P"X_P#^I!J=?R!5_7[_ ,&N/_*"CX&?]Q__ -2#4Z /
MO^BBB@ HHHH *\7_ ."@_P 0]+^$?[#'Q>\4:YX2L_'FC^&_"6I:E>>'KN,2
M6^L1Q6TDAMY5((\MMH#'!XR<<5[17G/[4[7G_#-?CA]/\;:'\-[Q=%N6B\4:
MU;P7.G: ?*)-U<1SL(7A0<LLA"[0<G% 'X@?\$NOVW_"7B#]LWP'H^H?"G]F
M'5O%7B#Q]H=GI?\ P@GABVM;K1+&]\/7&I2W5K(K-*QL[D6\4LLA8CRY5.UC
M\OZ]_P#!7K_E%-^TG_V3'Q%_Z;;BOSI_X)4?M<^'_#_[=]KX-\*_L]_ [XC:
MAJURUAJ7QD^"/ANYTW2]*5AF4WS7%J(MS$AF%O<LO)P"2%K]%O\ @KU_RBF_
M:3_[)CXB_P#3;<4 ?Q*VO3\ZL=ZKVO2K!.#6,MST\/\  )ZT^.F>M/2LY'53
MW'#EOQK0\.V(U+5X8F;RT9QEL9Q5!5PU;O@F-?M\DC''E(67W-8U9<L&ST\L
MP_M,3"G+JSVO]FWQ3::5\7O#MOJELU]H_P!OC66W/((8@$@>O>OU5T7P%=Q_
M$:?6O#-PTUG=016\2W=JTRQK'\H'3Y>G5>*_-?\ 8*\!Z#XR^+&G3:W#=74=
MG=(?L<)VM-D$C!]> !]17] 7P7_X)V:YI7P+CM9L1ZE?;+E+)9O/^PB0C:&;
M"] >5W9..XXK^;?$YU:N-A2P<'*2BU)=-?+N?TOEF>X?*LOA5Q\TE4=H^G7[
MCR+_ ()Z_M3Z/JGQK'A/Q;>Z7I4<,X2>WLX%47+QY$;N0I/YGO7U9\:I]7^*
MMYXVTZ^NI6TN&)I-$DA26!;9%VJ\<@(^?KD$9'->*?#'_@F)-\"?CSX@U-=$
MM?%!N+3]S+=KY,4,@(VOQ]]AV/;-:GPJ^*_C;QM\3/$GAC7X5GT'1[,[[F.=
MI)GD+@,Q Y55' 4 C"]<U^:8FM[*A+")<J>K33N[*S7HGJO,^4SJ.'Q^/>9Y
M9)24%%[JRU6J6Z;M;7IL>8_M,_#G2O!/[,?Q%TOQ%X:;3;/5EW6U]+'SJ:A%
MQ'\WS [OF! ((':OQ3U3X+QZ?=3K'<1RQI\\\[1EMI!(PHZ^W-?K=_P4P^%.
MI?$_Q[;W&M?%S5--\)Q6RRZ3I][<(J8 *L%&?ER ,9' !KXW\*?"]O!/A;Q7
MKFCWD>M:/)$EM/>S2>6(T#<O&"H)(]@V??-?:\(9E3R[#R5"HY<S6EM+^NU_
M^ ?H?#^%]MA/:XBSE/7?;2W7^DSX5O=$U$7*PL)8UN&!C&,;^<#GM1?:'_9>
MH1Q:PMPUO;OF8(>6'?:>F??I7LW[06H6.D:N88[R!KJ*)4D+6DELT88;@%4I
MVZ'/4GBO$]?\01ZA&JR223K;H559'QL'7 %?M67XFIB*:FXV/-S+#8?#73G=
MOHRCK&K0ZHDOV*W\FRM6/DAB/,VEN-Q&-Q^@KF9[HA\EMPW9(]*M>(-9>[CV
M^2MMM4$(%VY'K61;HTLR[OND_G7TE&BDC\PS+'^TJJ,'?\%]QG>+[W]RL2_=
M/SU@D_+BKOB*?S]4D^;Y5X6J5>[1CRP1^4YIB'6Q4Y?(*#THSQ03Q6IYYZ)^
MQ1_R>A\(?^QVT;_TOAK]6/\ @]O_ .3U?@[_ -B3+_Z7S5^5/[%7_)Z'P@_[
M';1O_2^&OU6_X/;_ /D]7X._]B3+_P"E\U;1V/+J_$?BL/X?J*F/W14 /W?K
M4Y^Z*)&E#9B4445)T#HSAJW+23<V36$GWJV;#G;]!7/7V/4RN5JAO6%Y-:6L
M@BE:-95"2<_>'6NJ^'FM6NF7J>;=^3]J MYG$>[RXVX8C\!7,Z?'&(6\Z-9%
M9"J_-MV''!JUHNA[I<^:IQ@\')KQ<1&,HM,_3LHJ5:5>$J:3.D^)WAZ2SN9P
MOF2-:R%?NG+(2<-[?_7%<;%X?DF3S)=RJ_0FO;[#3;Z[T>.-9)(VU:TV2R2.
M,R1I'O9<=ONYSWZ5X[XBU5IIH[>&/:A< 9; STY/:N/+L1*2]E'='T7%F6X>
ME)8RJ_B6WF4IM-AM5\QF7>X+9/KFL^XU'R@RQ\YZM3IY)M6E4+EI%4G&<< $
MD_AC\:H"38&R/R]:]JG3=O>/S3%8R-^6BN5=Q'(5L5&.K4;N:='$3)C'M70>
M1\3(=N#2@-FGW";7_G3&;8N?3FFC&2L[%"8YGJ.3^&E+9DS0_P!ZNOH>')W;
M8E(_W#]*6D;E30*6Q^^__!C*>?VH?^Y3_EK5?@$>E?O[_P &,WWOVHOKX4_]
MS=?@$>E:' )0.M% ZT +_'^-3V/^M-0?Q_C4]C]]JF7PF^'_ (B+C\M4]N<"
MH*=$^UJY3WX2L[ER)MK5,NQSSQS5=#QZU,AP*QD>I3D6%BC)ZUI:- KSJJ_-
MNXK(4$CBK^B,PO(^3]X<URU;\I[67RC[:*:W':MI/EWGS9^;L*CC:..V:'RX
MR2=Q<_>X'2K7BJ7RIE^8Y89.:S+N>%X(?+619,'SF9LACGC'IQ54;R@KBS+V
M5*O*,$,EF53\OK568;ONTZ;Y3Q3:Z(H\2M/FT&[.*AEJ8AJKRGFM(G)4T0VB
MBBJ.8*;/_J'_ -TTZFS_ .H?_=-..Y-3X6?W5?LH_P#)K_PW_P"Q5TO_ -)(
MJ[T_<_ UP7[*/_)K_P -_P#L5=+_ /22*N]/W/P-=?0^=D?Q??\ !>?_ )3$
M_M#?]CA<_P#H*5\CU]<?\%Y_^4Q/[0W_ &.%S_Z"E?(] !1110 4Y7YIM.0X
M>@<=QZ?>I).AI0?FI#TI&S$#;12?>-'>E"\4R-]! G-2%_+7TSZ5'C YH"$=
M: CH2(=ZXZ"HY/2G ;C1+^'IQ0-WL1T444&04444 %%%% !7]?O_  :X_P#*
M"CX&?]Q__P!2#4Z_D"K^OW_@UQ_Y04? S_N/_P#J0:G0!]_T444 %%%% !7B
M/_!1CQ_IOPF_8(^,GBC5O"&E^/--\.^$-3U.X\.ZE )K'6!#;/(8)T(.Z%MO
MSY!^7)[5[=7._$7Q5X?\$^!M6U3Q=J6BZ/X8LK9FU2\UBXCMK"" @AS,\A$:
MIS@ESM(.* /R;_8K_;M^-7P+^*W[*]OX@^,GP6^+_@G]IADLSX'\&^'++2;K
MP%OLVN!):FV8M-;V\G[N9IT!781@,25^_/\ @KU_RBF_:3_[)CXB_P#3;<5P
MO[ _P;_8?_X6_K?BC]G.Q^ -[XUCA=K^?P;=V-W>:? ^U'V)"S-;PN2%.Q41
MLXYS7=?\%>O^44W[2?\ V3'Q%_Z;;B@#^)2TZ?C5FJMF?FJUFLZAZ&'^ *D/
M2F+_ $J1>E8RW.^GL.P *W/!\7FK/_>P,8[<UB'[M=-\.X!/>E6^Z2JG'IGF
MN?%RY:39[N0TO:8ZG#N?J%_P17_9#7QWX#\0^)!(MQJUK);[+26U*M;Q/)C>
M&/#9 .,=,5^T'Q$_:YU']F_X$03/8W,VI:/;)!-*Z;$:%!@2'_;(&/J*^(/^
M"87B#PG\!/V:-!\/Z]-?Z;/XHLCK<M\=S7 F+>7;)M4D8\L,0,8'6OJKP-\0
M_!.N?#B#PWXU\0+K>GZJX?-N^;B1RQVDAFR@4 $J>>GK7\<<09YB*F>5:U*K
MR\VB\K?EZG[)GV!4U2I8F@YTJ+5E9W:>]N^J>GH>O?L1_'31/CWH)A;5KR]U
M%0Q^S7TW^F6;LA+Y4X;:1R, @>@KE[7X/^&_V:F\675B\/\ ;/BB5IKA&U![
MB1D!(01;R-H!))QG&*ZS]FCX)^"_!^JZIK'@S4+>\FNH&>&9MA>(NIRS<[]K
M=>>_L:W]>^&$EQ\)[J&:SM]<U3RWEM[I$0C>=W.2<*N3U!ZYS7;B:=>OE=.D
MX)SCS>_>_NZ==WY'YOB,9A:&9U(X=RC1DXWBU9][?(_)G]K'P/#\:/BYXD:3
M6[B#4;5%2V"HHFPB[?L\1&0Q+ O\P)YQ7Q3\3OB1K'PG\17VC7U]>/IE]$5O
M+4 _9^4Q\G8'(!/ ^;-?MYI7P9^'/@3X-ZOX5\67&I6.HQ2PZG*=-0R*D@!(
M=)0I;EB=Q8@?-QTS7X__ /!3OXF^%HO&%KX6T"/3[:VLV:\NIGLTFEGE8D#=
MD$D*.QQR<UT<(592Q=/!2M4A*-WWC;J^J_S/Z#X?SN.+I3ITJ;BJ=DFUI)6W
M3\SX=^)7B*\UG4VGFG:7<HX,F\+Q@<DG.*\_OV?<LC.O7&,\\=S7HFK>&0^D
MSW4DEPF0/*#1H@ED9OE&"<J@&3GD=N*X;5=!N'C\P/$R^8T042JSA@/0'.W_
M &NAK^D,OC!04(GYUQ/[6=9SLS.UN[AN57RW9FVX;=65+>_V: P8,&'Y58O4
M6S+*IW,PP21TK'UB0J@6O;HTUL?F^:8RHN:HU9HHRR>8^3USFF@4H&*3/->B
M?%.5W=B]Z:3@?A3N]-?_ %=!,MCTC]BO_D]+X0?]CKHW_I=#7ZK_ /![=_R>
MM\'?^Q)E_P#2^:ORF_8H_P"3T/A#_P!CMHW_ *70U^K/_![=_P GK?!S_L29
M?_2^:MHGFUOB/Q47AJL+]PU7'WZL*?EHD:X<;1114FP?Q5L:><2+G[N*Q\9-
M:VFG=MS^-8UOA/0RW^*:7S-,-N=OH3UK5L/W/E_,-S8.%/2GZ-HG]J0CYE53
MT=^-OM]357#6=Q(N?NG&<<UY<I*6A]_AZ<J4E4>S/:/!>O2S^%+%EMYIDLKD
MVLK^7NB*ODJN?[QW$8]!7CGBR'['J]Q#LQY<C+@GT/%>G_!#5;%-&UJ*\:^1
M6\F>$P7'EQK*K'ATVD,I&X Y!!QS7G_Q1M_(\4W&WYT<!@P[<#C^E>/E\53Q
M,Z??4^WXFG+$9/1Q+WO8Y4GRFRI96P1UYYIPL9);,S*J[-_ECYAN.02/EZ]L
M9]ZGL]/-S(%PQ9N1BKW]ALJ?-N54Z#UKW_:I'YC'+ZM57BC#@@;S!Z@YQ3KV
M;[/+M7'O[5H2W"1.PRO0C %8]X?,DSGOQ5TWS.[./%05&%H[B-)O[\U5O)\C
M;4S' JG/$R 'UKJC'4\/$U)6(Z***V//"@=:*!UH _?C_@QGX?\ :C_[E3_W
M-5^ !Z5^_P#_ ,&-?^M_:B_[E/\ EK5?@ >E:'!+<2@=:*!UH$+_ !_C4]E_
MK&_&H/XOQJ>R_P!8U3+X3?#_ ,1%P=:>,$TS-2)R5KE/>6Y:MUW-^E3^0RC^
ME,A&%JPC,77O7/)GM8>FK68FXI#TK4\+;GU"'Y&*J<]*J/9^;C9U[YKL/AIX
M5CU#4XUFD\A.I9NX],^M<.(JQC3;9]/DN7U:^,C&.R.5\:-G4E5OO(,']:R7
M&5Z' KK/$]G96^OW"LPD57(4YSFJ:"SN%9551^=:4:WN1LC#,<K=3%5'*:5W
M^1SGD%Q3""#WK6O#! YVE?IZUGS;67=GGL*ZHSN>!B,*J?N\VI7D;@U7DJPX
M^7CFJ\E;1/+K#:***HYPIL_^H?\ W33J;/\ ZA_]TTX[DU/A9_=5^RC_ ,FO
M_#?_ +%72_\ TDBKO3]S\#7!?LH_\FO_  W_ .Q5TO\ ])(J[T_<_ UU]#YV
M1_%]_P %Y_\ E,3^T-_V.%S_ .@I7R/7UQ_P7G_Y3$_M#?\ 8X7/_H*5\CT
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MHF99%VQMQN5>H. 3C!-4O&/Q"71OC[J6CZ=HEQ<Z5>6D4#_:[F*5K.9D(<D
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M*NE_^DD5=Z?N?@:X']E#_DU[X;?]BKI?_I)%7?'[GX&NOH?/RZG\7W_!>?\
MY3$_M#?]CA<_^@I7R/7UQ_P7G_Y3$_M#?]CA<_\ H*5\CT""BBB@ HHHH **
M** "BBB@ HHHH *5&V-FDHH ,T44 X- !13G.YOY#TIM !1110 5_7[_ ,&N
M/_*"CX&?]Q__ -2#4Z_D"K^OW_@UQ_Y04? S_N/_ /J0:G0!]_T444 %%%%
M!494@8QUZ^A]JDHH A*_-D+][C..>_7CMU^OUKY[_P""O7_**;]I/_LF/B+_
M --MQ7T57SK_ ,%>O^44W[2?_9,?$7_IMN* /XDX3AV^E64^[52(_O:M)P@K
M.9W878=WJ0?>J+/-21'FL9'H4R3/->J?LD*X^*5OMO(=.6174W$BLRJ"#QA>
M>>GXUY@L.(<U[)^R]HFGS^,]%6_D$-G>7D45Q*Z!EB0L,DJ.6XY[5Y.>5(K!
M5%+JC[C@/!2J9S1FOLNY];_"GX[ZM\%_%%OXAO(7DT]9(I;2<2[7.1@8.20O
M7</EP#[BOLI_C!;_  D^%\?Q$U[1?#_]H>/+T:;IEY9LD[VENX)6[C\MRVW*
MLFT$L0,-BOFJ=/!%KXLO/#0B_M_PS.A;9L6&XTN96 2YB8OCR\;3MDX8<%00
M*] ^!'_!/KQK^V'\6&C?Q%I&G>"]/M(Y1JELP^RVMI%B/<D2LH:X?##:, EB
M2V*_FK,,+@,55C5KKV?X<T>R\^Y_4&:5*=&@\16E:$=WU:Z(_1#_ ()<>._$
M5G^QWJ^N:]9[?^$RUZX&G1F$#[/91C8C;6PS!F#C)],U\+_\%5;^#XY_%'Q-
MJGA_3X-9O=!1=)O+J*5_,MK>)0"JY3!0,7R.A/>OO#3?CSX7_9K^!MYK&O:A
M=>#/A_X;,6@:/I-F<ZMJLBKL2% K+&[LRESG&W>Y+8YKY#3]MO2!K%S<3#XB
MW4-P_P!I>*XU*WT^:R65V:..!0K<]R S ].:^<IXRLJT<=@J;=-:12=DTGKY
MZ[^I\!PQA:CS/$X^4/>;[/JMETNE9.VFI^:_C?PG>:)X7OKBWT\QVKLH+RP^
M8S!/^6@<_<.3C ZXKR'4Y)T#3I\JQ-U!QU]J_3[]J']HGPKXE\)W$TT%EJ%L
MUVEHUOJ/ABVU"^A/+E79"B.0<$-GD,<A#7QK\4/''@7599([;2_"T-GN/F00
MZ7-93[O3<K$@#DXW%?K7ZYPWGU>O"]:A):^I]GCL,Z]*]^4^=Y;IM0MY/*C:
M1F/S''05S6O6L>G-\V!,Y(*YSMKTWXDZSH=M T/A&-K6WDC!NB9I')/]T;@.
M!ZUY#J>Z2=OO,WKG%?IV7R]I[UN5=NI^/\525.*C+WI=^GR,75R=U9^,_A5W
M5)=TNT=%'.*J#I7T5+2)^+XV7-6;0 4&C-(?E6M#AE(&/%1.>10S_-_GBD;E
MJN)F>G_L4G_C,WX1_P#8ZZ+_ .E\-?JI_P 'M_\ R>K\'?\ L29?_2^:ORK_
M &*?^3SOA'_V.VB_^ET-?JI_P>W_ /)ZOP=_[$F7_P!+YJN.QRXCXC\5[?[]
M29J.W^]4E$C:C\(4445)H*/N_C4]CD2)4(X'XU-IXVS+D=ZF6QI0^.)T6GVZ
MW3PCS$5F8(<DKM]R3QBI;R)H)_+RH\LXW*<@^^:J6MSY+?*%//3UK;2PDO9(
MVW(%DQD]H_3FO+J/E=V??8&G[6')#<[KX9":Q^'>L+_H8^W7D49,A8SDHKY"
M=MOSC/H=OM7,?%:)QJ\,+H\;PPH&5@0P)&3GTZUW6DZ8?#<\>GZ?>0W9M9-_
MG6[;T>11RZDCE1Z^@KEO%WB^SU3Q+=27EU<7DR_(98@IWE?E!R3R"!FO#P]1
MRQ+J15T?IV:X2%')J>$JS46[;Z^9Q]KI,$A;[1+(K,IP1'NPV/E'WN 3@$]J
MJ1Z1<2SLJ0LVWDD#( ]36_+XDL<JQ:X(W=6B5NG_  +!JIJ?C>.?=Y4;MV#2
M$?HHX%>Q&=5]#\[Q&%P$%K5^Y7*Z6$-K$7;/F+[C&:Q;U][,6/S-[T7M[)/*
M69FY.<9JK)(96Z]N]==.FT[L^>QV.A->SIQM^I7G_K4);K4DS=:A!S7;'8^9
MJ2]X****HR"@=:*!UH _?G_@QN_UW[4/_<I_^YNOY_STK^@#_@QN_P!=^U#_
M -RG_P"YNOY_STK0X9;B4#K10.M!(O\ '^-3V/\ K34'\7XU8L.934R^$WP_
M\1%W&YJN6@\OZU5@3-7(DV_E7'(^GPT=>8M+<?(HSE5Z"K&GLUQ-LXY/!)Z5
M31&V],UI>'-+?4KV..-=SR,%4>IKCJ2LFSZ+!1G4JQA'J>E>&+8:%HL2MY"2
M20^9O)Y53G(/N1VKA+ZRDUR2XO-R_-(1C'3T%>D:9X$N]8TB[6T\^:2UMMY6
M. R$ G;@XZ')XJC<_!+6-$T<-/:W$,=RQ 4E-Y/NF[=Q[BO!PV(IQE*5];GZ
MSG&55:M*EAU#W(Q?7KT/-A9XC*J&9L9XYQ4VD"2&X$D;-'(AW*V.AKOO#_PJ
M\R.[DO+J2W:! ;=&MR1<-G&"Q.U,>O.*S]=M[/PFD;+<6,TCH?DAD$K)S_$>
MBGZ5V_75)\D-SY:/#LJ</;UI**71O4XN?2+A[G#(V2<D8ZGUJGK#LLBQ_P!T
M8QZ5N7WB]959E63>W<FL"\NOM 8M]XG-=]%SDTY(^8S.&%IQ<:$[W*$YP#54
M]:L7)ZU7)YKNB?(5OB"BBBJ,0IL_^H?_ '33J;/_ *A_]TTX[DU/A9_=5^RC
M_P FO_#?_L5=+_\ 22*N]/W/P-<%^RC_ ,FO_#;_ +%72_\ TDBKO3]S\#77
MT/G6?Q??\%Y_^4Q/[0W_ &.%S_Z"E?(]?7'_  7G_P"4Q/[0W_8X7/\ Z"E?
M(] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7]?O_!KC
M_P H*/@9_P!Q_P#]2#4Z_D"K^OW_ (-<?^4%'P,_[C__ *D&IT ??]%%% !1
M110 4444 %?.O_!7K_E%-^TG_P!DQ\1?^FVXKZ*KYU_X*]?\HIOVD_\ LF/B
M+_TVW% '\2$'^LJZO*U2A'SU;C^ZM9U#LPHX#%"G#449PU9G;'<U-'MVU"=8
M5Q\W4GM7H7@W4O[*OX?+Q'Y+ #:>A'?ZUYM8:F;(%EW*Q]#6WHOBF&V96;S&
MDW< =/QKR\?AY58V/O>%<XH8.K&<GK^A]E6UUK'C+0[<GQ#:W%UJPCTV'1GA
MEDU)Y)'7:(D49DYPWW@5S@ U^T/[)OPRM_V)?V-YM!U35+.;4+6)]5\1:W<1
MN8=/4*?E6-<-\B?+@MN+DX!X6OQF_8*_:X\-_L[?%RQ\<:QX?U7Q!K&DVICL
M+BVN$5[&0C:)0K_Q*N5!##:.F:^@OVD_^"QL?Q\\!_\ "(:;HNJ:;X-O))#J
M*7LZ?:;^4XVNSKNX7D[0?O'-?S[Q9D^88O$0P-&C:BM92TU?9=?GU/WS-</6
MS10A3:]GI+=_-_+HCSS]IC]M?5OVM?VB+74M$T'5)?A[X(NBVC:6UOYBW1Y'
MVJ\1LKYLIQR<^6F%'?-7Q9\5O$^B>%K75_%%KI\D>N7+21VZHL7V?<I7!^\0
MJJHV@X4=0:\"T;XL3>"M76;3':W6W<[HFD++.-W'(].*G^,'Q,O_ (C:W]HO
M(UMC,$;]W)YKX(XRWITXQ7TG]@QE4IT:=)1I15EWTZ?/=L^@P<J&%H>SIN[)
M_%OQ+DFAN&^V&1I[EY9E$K,K9 "X^@[UY7KVNELJ9%YR5&.?Q-5_$?B".SN9
MDFO%40DX60_,:X_7_'MN(/+A7S'_ +X[5]QEF3\GPH^#XDXPP]*#CSI-=+W9
M->ZMY$['=M7H1GKFN;U?6F,C;6W%NXJC?ZS)>R,S-C-56FW<GK7U]#"<FK/P
M/-.(98B\(/0<SEF^O6FYP*:9<TT2X_\ U5V6/F95$2EN*8S<U'YH)ZB@M_M+
M^=5RF7,AV QHV8J/>/[PH\Y:=F+VD3U+]B@Y_;-^$7_8[:-_Z7PU^JW_  >V
M_P#)ZOP=_P"Q(E_]+YJ_*7]B60']L_X0X_Z'71O_ $OAK]6/^#V__D]7X._]
MB1+_ .E\U5$Y:DN9W/Q7M_O5)FH[<?-4F,42.BE\(4445)H /-7+-"L!?Y>#
MC'>J@6K<#_N2M34V-L/I-LT-/.Z1?KFN_P#ANBB>YN-NY?\ 50HXR&SUS_P$
M8_&O/-.5I9%1<MN/%>E:46TW3;6./'V6,G+$?+N/5L=R/Z5XN8RM'E74_3.#
M*:E65:?PQU?F'CC7H_#NE^5"VVXNAD@?P)['W_E7!31NL(F#QLS,4*#JH'<_
M_7KJ/%>C+K.I--#/')&/E7=\O ]C6->Z>S0P@HH6)=J[$&YADG)]^3^&*C \
MD(66[W.CB>6+Q6*<VK0C\-NQDZE"UI<R1&2.7RV*;XV#(^.,J1P<\=*J@LC!
MN_7Z5:GC8[1MVJ..E-2S;SL8ZBO1C)'Q-2C-R*LDS3MS\W/I391LCJXEO';D
M^81[#-4+M_WAYXK2.NQRUX\D;R*LYZTP4Z7YLXIH!]*ZCQI;A1110(*%ZT4J
M?>'UH"Y^_'_!C=_KOVH?^Y3_ /<W7\_YZ5_0!_P8V\R_M0_]RG_[FZ_G_)XK
M0X9;B4444$@.M6M.XN:JCK5BQ;_2:F6QM0_BHU(V J:*2JM.1\&N.Q]13J6T
M-:.:-[98]L@D.=Y)R#Z8KL? FA+'!]H?[V?E!_G7'>'K5KZ_CC49W&N^?65T
MHAH$W16RX4'OCUKQ\PD_X<>I^B\'TJ?/]<Q&T=BUX\^*]YHVB_V#I\[P6\FV
M2["8!E<# ![X /3W]JX.:]O"AD:23<XW$@FDU&26]O&N#N,C-NXZ\UIZQX2O
M/#MCI\URUJ8=4MA=P&*9)24+E/FV$E'RARC8(&#CD4Z&'I48**2NS#,LRQ6-
MQ4IRE+EZ6>R,5K^9O^6K?3-0R%F&=_X9K2OK2-#MCD\S SP.E4S K>WO73!K
MHCR*U*I>TG?YE5I/RZ5')P#4LT80U7N7VI^M=%/<\K$7CN5+A\FHEZTKMN-"
M]*Z#PY2O(**** "F7'^H?Z&GDXJ.X/[AOH:<=S.H_=9_=9^RD?\ C%WX:?\
M8JZ7_P"DD5=Z/N-]*X+]E'_DUWX:_P#8JZ7_ .DD5=]C"-]*Z^A\_P!S^+W_
M (+S_P#*8G]H;_L<+G_T%*^1Z^N/^"\__*8G]H;_ +'"Y_\ 04KY'H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_K]_X-<?^4%'P,_[
MC_\ ZD&IU_(%7]?O_!KC_P H*/@9_P!Q_P#]2#4Z /O^BBB@ HHHH **** "
MOG7_ (*\MG_@E/\ M)_]DQ\1?^FVXKZ*)KS/]KSX>^$_BO\ LH?$KPM\0-<_
MX1CP-XC\,:CIGB'5_MD-G_9=A-;21W%QY\RM%%Y<;.V^12BXR01Q0!_$F_[,
M/CV+3M-O(_#&IW4&KQ+/9&VC$[31F,2[MJDD*$(8DC R!7(ZQIEUX>U.XL;Z
MWFM;RSD,<T4@PT; X(([5_15X>_X)P?L$^$= LM)T?\ X*0?$C2-+T]/*M;2
MR^/^A006Z_W418 JCDG  'S&N%?_ ((1?\$P/%WB#/\ PV=J&IZEJ,Q9B/BU
MX7GN+N9VR3_QYEF=F/7J34SM:\CHHRG=1BKL_ 7SP/6F_:*_H(U[_@W<_P""
M9WA;4YK'4_VLO$&G7EO)Y4L%S\2_#44D;]=K*UD"#[&L^X_X($_\$N+4D3?M
MC7L1'4/\5?"RX_.SK&G4I32<))W[.YV5*.+IJ\Z<EZIK]#\!_M'O^M"WFQE;
MT]*_?>'_ ((%?\$M[A-T?[8UY(O]Y?BKX6(_/['4MM_P;^_\$O;Q]L/[8&I3
M-Z1_%'PPQ_2SJFZ:W:)IT\7)KDA)WVLF?A;I'Q9NM*AVJQ&!CIUJY%\=;N.+
M9Y:]=P/O7[E-_P &^?\ P3$%JT[?M=:L(5;:9#\4/#.T'TS]BZU)HG_!O1_P
M3(\2ZG#9:;^UMK6H7EPVR*"V^)OAF621O0*MD23]*X:F%P+O.=M.MUH?3TN)
M>)*2C2IN:MLN5_Y'X3W/QGOI5;:BH).O0UEW?Q+U2Z)_TAQP!RW8=*_H&UC_
M (-G/^"=?AZVEFO_ -ICQI8PPC=(\_Q \/1J@]238<?C7,M_P0&_X)<QG#?M
MBWJG..?BKX7'_MG1AHX":O1<9>C3_(Y,9G7$,U>O*HODU^A^!-WJLUXQ:1]Q
M[]\U7%RU?O\ ?\."/^"7&W=_PV+> >O_  M7PO\ _(=$?_! ;_@ES(=J_MB7
MS-C.!\5/"Y_]LZ]",J<596/GYT<74G>2DWZ,_  R,>XI-[?WJ_H"'_! /_@E
MT?\ F\*__P##I^%__D.G#_@W]_X)>E=W_#8&I;<XS_PM'PQ_\AT>VI]U]X1P
M.+>U.7W/_(_GZ^;WH^;WK]_Y?^"!O_!+6$GS/VQ[R/;UW?%7PL,?^2=-7_@@
MG_P2S?[O[95P?I\5_"W_ ,AU7,GJF<\J-5/E<7?T9^ -%?O\W_!!/_@ED@^;
M]LJX7Z_%?PM_\ATT_P#!!G_@E>O7]LZ1?K\6?"H_]M*?,B)4YQW3/P#HK]_D
M_P"""7_!+.1-R_ME7#+G&1\5_"Q'_I'2-_P06_X)8I][]LR9?K\6/"O_ ,AT
M<R'[*=KV?W'XI?L1?\GH?"'_ +'71O\ TNAK]:O^#U#PYJ'BK]N+X/VVFV-U
MJ%PO@::0QV\32N%%_,"<*"<#(_.O:O@K_P $.O\ @F9X&^,GA'6_#O[7EQJ?
MB#2=:LKW2K,_%#PS,+RZCG1X8O+2T#OOD"KM4ACG (.*^B/^"XW[$7P]^//[
M7_P\\>^(OVQ/AI^S3XJ\-^&9=-LM-\3:?IE[)JEN]S(YG6.]O859-Q*8,;C<
MF001@.Z>Q,H2C\2L?RQOH=YISS+<6=U ;=MDN^)E\MO1LC@^QJ(K7[C_ !?_
M ."5WP9^.WA%=!\2?\%3/V=9])6?[2;>R\+^&=-W29)R6MM3C8C))VDD9YQF
MO+3_ ,&[G[*?_233X$_^ VD__+J@VIU$E9GY$<>]!Q[U^N__ !#N?LI?])-/
M@3_X#:5_\NJ/^(=O]E(_\Y-/@3_X#:5_\NJCE+]LC\AUW9J19"M?KI_Q#M_L
MI_\ 237X$_\ @/I7_P NJ/\ B';_ &4Q_P Y-/@1_P" ^E?_ "ZI<HXUHH_)
MG2=36SN5D==RJ>F<5OCXBR6T$JVZK%)*,>8#\RCT!Z#-?J7!_P &YW[+-UGR
MO^"EWP/EQ_<L]+;^6LU))_P;A?LOQ1[G_P""E'P311U9M/TP#\_[9KGJ4*4G
M[S1[F"S3'4:3^KQER]TG^9^57_"R+Z2;=--Y^X ,74<@=O\ Z]13^-O,7Y(U
MC?DY'-?JDW_!NW^RGG_E)I\!Q_V[:5_\NJ;_ ,0[7[*O_23;X#_^ ND__+JC
MZG2[&?\ K)BTN7G;/RAF\622-N\M=V,=.M0/XBF*[<<'O7ZRG_@W:_94_P"D
MFWP)_P# ;2O_ )=4'_@W:_93/_.3;X$_^ VE?_+JM5AX=CCJ9QB);R9^2$M\
M[]:@,^X=1^=?KI_Q#J_LI$_\I-/@1_X#:5_\NJ!_P;J?LI_])-/@/_X#:5_\
MNJTY$MCAEBIRU9^17F?[0H,JX^]7Z[G_ (-U/V4_^DFOP'_\!]*_^75-_P"(
M=3]E/_I)I\!__ ;2O_EU3Y3/VTC\B/. H^T>U?KO_P 0Z?[*?_233X#_ /@-
MI7_RZH_XAU/V4_\ I)I\!_\ P&TK_P"75/E)]K(_(;SV]ORI?/9N/Z5^O'_$
M.G^RG_TDT^ __@-I7_RZH/\ P;J?LI@?\I-/@/\ ^ VE?_+NF3S,^@O^#&=L
MO^U#GO\ \(G_ "UJOP<A^&_B&X\+#6X]#U9]&8,POA:2&V(5@K'S,;>&(4\\
M$@=:_J>_X-PO^"=GPK_8(F^,Q^&'[37@7]HT>+&T,ZI_PCD5HO\ 8'V<:CY7
MFF"^N<^>9Y"N[9_Q[MC=R5^&/A%_P2M^"_P3\ )X9\/_ /!4C]G"#15N&NQ;
MW?A/PO?$R.4+$O<ZE(^,QH=I;:"H( -!)^&NH:7=:3/Y5U;7%K)M#[)8RC;2
M,@X/8CG-5Z_:CXR_\$0OV=_V@?&\GB+Q9_P5$^ 6I:Q)"EN9HM)T.S3RT&$4
M1PZNB#'LH)KD_P#B'4_93_Z2:? ?_P !M*_^75 'Y!U):_+.OUK]>/\ B'4_
M93_Z2:? ?_P&TK_Y=4J_\&ZW[*:L#_P\T^ _!_Y]M*_^75#*B[-,_)8,V:D1
MR&!QWK];/^(>/]E/_I)G\"?^_&E?_+J@?\&\O[*8/_*3+X$_]^-*_P#EU7/[
M-GKQQM,_*'3-:N-+EW1JOH<KVK>L_B9=V>GS6WV>T:.<#S"4RQ]@:_4+_B'H
M_95S_P I-/@3_P!^-*_^75'_ !#U?LJ@_P#*33X$_P#@/I7_ ,NJPG@U/5H]
M7"\25</'DI5&D?EHOC!E?*V\2@]0!Q3YO%JRV[1BUA&[^( YQP?Z?K7ZEC_@
MWM_94'_.3/X%?]^=*_\ EU0?^#>[]E0C_E)G\"O^_&E?_+JE]2B=/^M56UG/
M\/\ @'Y0F^8^V?2D74/+#9[C'TK]73_P;U_LJ_\ 23/X$?\ @/I7_P NJ8W_
M  ;S?LJO_P Y-/@/_P" VE?_ "ZK3ZN<4L\6ZN?D[-?YJK+,96YK]:6_X-W_
M -E5O^<FWP'_ / ;2?\ Y=4S_B'9_95(_P"4FWP(_P# ;2O_ )=5I&A8\^MF
MKGT/R58JM-,Z@>E?K6?^#=7]E,_\Y-?@1_X#Z5_\NJ0_\&ZO[*9_YR:_ ?\
M\!M*_P#EU5>R1RO'OHC\D_M2_P!ZFM>*%K];O^(=7]E'_I)I\"/_  &TK_Y=
M4?\ $.I^RC_TDT^ _P#X#:5_\NJKV:,_KLS\C6O:CDNRZGWXK]=O^(=3]E(?
M\Y-/@/\ ^ VE?_+J@_\ !NK^RGC_ )2:_ ?_ ,!M*_\ EU5<J,98B<C^C[]D
M\Y_9>^&O_8J:7_Z1Q5Z Y^4_2N3^"'A^S\*?!KP?I>GZG!KECI>B6=I:ZE!C
MR=0B2!$2=-K,-LB@,,,1ANI'-=40Q''\\51B?QA_\%X;>2?_ (+%?M#>7&[X
M\87.=JDX^5*^1I;>2 _/&Z?[RXK^G7]K?_@FK^POXE_;#^)GB[Q/^VEXD^%O
MC_Q9K,EWXET32_B[H6AK977 :)H)(#*FW'W9&9AFO&_''_!&?_@FE\3=0ANO
M$O[=VO>(KN%/*CFU/XT>&KN2).NU6DM20/;I0!_/717[^?\ #AK_ ()7?]'H
M-_X=KPI_\B4?\.&O^"5W_1Z#?^':\*?_ ")0!^ =%?OY_P .&O\ @E=_T>@W
M_AVO"G_R)1_PX:_X)7?]'H-_X=KPI_\ (E 'X!T5^_G_  X:_P""5W_1Z#?^
M':\*?_(E'_#AK_@E=_T>@W_AVO"G_P B4 ?@'17[^?\ #AK_ ()7?]'H-_X=
MKPI_\B4?\.&O^"5W_1Z#?^':\*?_ ")0!^ =%?OY_P .&O\ @E=_T>@W_AVO
M"G_R)1_PX:_X)7?]'H-_X=KPI_\ (E 'X!T5^_G_  X:_P""5W_1Z#?^':\*
M?_(E'_#AK_@E=_T>@W_AVO"G_P B4 ?@'17[^?\ #AK_ ()7?]'H-_X=KPI_
M\B4?\.&O^"5W_1Z#?^':\*?_ ")0!^ =%?OY_P .&O\ @E=_T>@W_AVO"G_R
M)1_PX:_X)7?]'H-_X=KPI_\ (E 'X!T5^_G_  X:_P""5W_1Z#?^':\*?_(E
M'_#AK_@E=_T>@W_AVO"G_P B4 ?@'7]?O_!KD<?\$*?@9_W'_P#U(-3K\_&_
MX(-_\$KP./VSV_\ #M>%/_D.OV _X);? ;X6?LR?L+>!? _P3\:'XA_#'1?[
M0_L;Q"=7M-6.H>;J-U//_I-JB02;+B6:/Y%&WR]IRRDD ^@J*** "BBB@ I-
MXSUI:XWXU?'CP7^SAX#E\4>/_%&A^#O#<$T5M-JFL7B6MG!)*P1%>1R%7+$
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MLM\X'G*1&%W$^BXR#UKYG\2_"_PWI=WK5K<:I-)=Z?(&MH(K;_CZ)/W23]S
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MU_D45'-(3"WT-3LN.V?2H)D(BD/^R:J)C54N5V/[J_V3^/V7OAK_ -BKI?\
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M,?:=';5^O0S?VD=:2;Q[!+)=6LUG;QQ+;V-J=D=O'C.S '!%=E^R7KFK3?M
M?#]H?,T^QTG6X;[:S-&MVWF)M^O>L[]J;Q/H.OW6EV*6MA:3Z&C23W:2H?ML
M9?:D8"G(VA?ND9 .:ZS]F/QKX9OO'FCZK;V.H74?AZ:(6L0NOW;3;@=TBGG;
MGH!7%B*TH94I.FT[-7=G;HGYMG14IPG.=)RLK;?+KY'Z2?\ !PK^T9X@^&GP
MZ\-Z;]LM+.XU"\;4($BD_>"+ "D<=.3FOAO_ ()V?&UOB;\:/LNL>*+I;Z2)
MY(;)B1'=$#IN[?2JG_!QA\>;WQW^V_9Z=*TD=EI/AW3S!&3QF6$.2!VKX[^
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MS]XD8_"N3^)^BR:9KOV@Q[4U!!<(1T(;G_$5>^'>JM<^'M6TII2%N%68(?\
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M/$2336\,DL=NH+-MX [ ^]/TG6+?1;J:>\A2?RX7$8)QM?H&'TSFOLW]E_\
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MW_!37QEIOQ3_ ."37@7Q=8V9L_#\ECI\6E,Z []L>R12.O# ]:_*&X^)&F^
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MG]H;_L<+G_T%*^1Z!!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7]?O\ P:X_\H*/@9_W'_\ U(-3K^0*OZ_?^#7'_E!1\#/^X_\ ^I!J
M= 'W_1110 4444 %?''_  7;_99\9?ME_P#!-'QM\/? FDV.L>(M4O-*N8[>
M]U%;&U\NVOX+F4RR-A=@CB;()'7/4"OL>ODK_@MU\"?B/^TK_P $S/B1X/\
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M]\?\'LO'[;/P=_[$B7_TOFK\R?V.?#=W9_M>?"-Y(77'C712<C_I_@K]-O\
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M<_\ H*5\CU]<?\%Y_P#E,3^T-_V.%S_Z"E?(] !1110 4444 %%%% !1110
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M(Y-6%UK#QB2X@B4>7!D9 W=SZUV5\51IM*>[[(^;R[)<=BHR>'?NPWN[*_\
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M444 %%%% !7]?O\ P:X_\H*/@9_W'_\ U(-3K^0*OZ_?^#7'_E!1\#/^X_\
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MD,560[<&OD886$XR=-[']%5\^Q5&K3H8J*3GH[='Y'=> =*D\0^-4@,UG")
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M^]W_ !W/U2_X-J%TO6?VH-2M+EM&5EL-X:^0;A\P&$)Z'VKY8_X*)>-&\?\
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M3K^0*OZ_?^#7'_E!1\#/^X__ .I!J= 'W_1110 4444 %?)_[>?_  3HU_\
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M;L2.@IP. .<>M>3EW"ZP\%"K4<[>21]O/Q?S'ZO&A&G%.*2O=W=NI_'MI7[
MW[0LMO(MU\!?CO'&RY '@+5>2.G6"DM_^">?Q_C+2?\ "B/C9@<_\B%JN?\
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M?VY?-Z?K1\V:<:26Q-3,*L]['\2J?\$Q/VGUQ_QCC\?,8_Z)]J_'_DO4;?\
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MO^C;?CY_X;[5O_D>O[@** /X?_\ AU3^U%_T;;\?/_#?:M_\CT?\.J?VHO\
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MCJ7A+5(]/LEL_&T5B,SBPW78D#8#%/M26ZR!24+#&8/A9_P5O^'OQZM=4O?
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M)=0"LEP@@NIK60K$2P5YU 8 .% -8^G?\%'->^#/["OB+Q!=>+->^)OQ%O\
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M5>(=2UW6=&\/>&M.T]+O2_#MC</$)W,SVD/E@)QOD::1F 4,:TO"/_!$/2/
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
D0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>p01.jpg
<TEXT>
begin 644 p01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH _,'XX_\ !UA\!_V>_'.M:#XD^&7[1%M)HNJ3:.]Z
M/"MDMG=31NRGR9)+Y=ZMM8KP"0,X%?1G_!-S_@KQX#_X*=:UXHL?!W@?XL>$
M9/",%M<7#^,="ATV.[6=G"B QSR[R-AW9Q@$=<U\E_\ !WP\D7[!_P *U$C;
M6^*NEDC/!Q;7F/RR?SK]3/ Y:X\&:.S,S,;*$DDYR=BU-&THR<NCY?P3O^(5
M=)QC'JK_ (M&L3M'L#1NW+D<CU'>FS'Y<==QK\(OV,/@)XX_X+B6_P"TU\8O
M&_[0WQ2^%/B+P?XPO-#\*6NC:Y)9Z-X-M[9!*C7%LKH)$"LJM\Z$B-V+9.1-
M[R:[*_Y+]0Z7?>W]?<?NZ9MH_P !1OQC[V/7%?,GC/XP^*/V0?\ @E'KWC2\
M\9:?\8O%WP[\!W=^/$UM:+!;>)+JWMW,=R\:22#!95,FUSDAR,9P/P<^%?Q%
M_:%^)7[+/A?XW?#NW_;X\6_M&ZAJ[:V=?@T1K[X=:M!]J>-K6-$G.Z,(N,"'
M'F!TV!<$5=<[AVM?Y[?D$;N"GWO^"U/Z,?VROVL?#G[#O[,GB[XK^+K/6K[P
MYX+LUO;ZWTF&.:]D0R)$!&LDD:%MSC[SJ,9YKRKXY?\ !7'X9_ #_@G/HO[3
MNM:3XUN?A_KUGIUY;V5G96[ZNJ7SHD0:)IUB# N-V)2 ,XW5Y?\ \%Q_%-]X
M[_X($_%C7M4TF[T#4M:\&6%_=Z7=(4GTV::>T=[>13R'C9BA!Z%37QK_ ,%,
MC_QR#_#?U_L#PC_Z.MZB3E'G7\LH+_P)M/\ +0*=I.'9J3^Y)K\S]I/AOX[L
M_B?\/-!\2Z?'<QZ?XBTVWU.V2=0LJ131+*@<*2 P5AD D9[GK6P)!OV_-N^E
M>=?L@?+^R+\+N=H_X1#2>?\ MSAKXF_X."?B?X5TOP_\)_!GB'XO?&+PA<>)
MM>+P^!_A7I9O?%'Q#56B7[-#()8OLZJ6QN9P&:3[KE0!K7M"?*N]D31]^',^
MU_P/T>9L_P!X'W% ?++U/KQTK\5_^#?_ .+?CKPA_P %=?CM\&;J7XT:+\.[
M3P='XDTKPO\ $[5AJ.N:/,+BQ2-G8.XBWI=2'8&Z%=V2,UV7[<LOBS_@HK_P
M7PTO]E[5OB-X[^'/PI\&^!3XHFM/">JOI=YXAO'13EYEY8*)E '( A? !8D'
M*U**CKS)OTLFW^14?M7Z?K9?J?KL9=G56SCIBN'T/]IKP%XF^/&L_#'3?%.D
MZEX^\.:='JVJZ+:R^=<Z9;2,$C:?;E8V8D$(Y#E6#!=I!KP?_@E7^S+XC_9"
M\#^-O FM?M!S?'K3=)UUSI":@JR:MX3A.]3974_GR/*WRJ?F6/:PDP,'"_GQ
M_P $T/V;/$UE_P '*_[3R2?%SQQ<'P;%8:IJ1<09\5PS1PE+2[^3_50B1579
MM/[I<D\Y4;.M&G?1IO[N@I75%U.J:7WL_4/PU^WMX?\ %7[>'B+]G^/PG\0(
M/$/AO1HM;FU^?2XU\.W4<B1.(HKGS2[2@2@%3& "KC)QS[HTA3\OSK\PO@S\
M</&FI?\ !TI\7/ D_BSQ%-X)T_X=V-[:Z!)?R-IMM.;>Q)E2#.Q7)=B6 R=Q
MKP[XK?MW>)?^"+O[</[9?@_QCXKU[5O#WC/P@?B+\*AJ^HRW7DW<Q:(V5OYK
M,$1+B651&#]RT4X&:RC4O3BWNU)_.+>GS2_ ?*W.45T<5\I):_)L_:XR;1EN
MG7ITH#[59L-M'/ S7R'_ ,$4_@UXM_9U_P""8'@%_B=XFU[6/&GB&P?Q;X@O
M]?U"6ZFLGNQYZPLTK$HL$'DHRY"AD<\9-?B-^V'\5?M_[/GQ+^,?PH^*O[:7
MQ8\3:'XI^UCXL_-X<\ V2&>-3;0P&<M)AG"@+$@^=/E"\':7NU'!]/\ .P0]
M^/,C^FGQ!XDL?"N@7VJ:I>6NG:;ID#W5Y=W4RPP6L**6>21V(545026)  !)
MKE_A/^T-X/\ CW\'[?QYX)UJW\4>$]0AN)K+4;$,T-\L$DD;F,L!N&^-P&^Z
MV 02""?D_P#;A_X2/]I__@W]\3:]=^*M6\.:]K7P<7Q/JE[IL<:O?M_8_P!J
MN;5U92!#<?/&X !"2'&#BO//^#;3X8:S\.?^",_A?7[SQQXB\06WBC2;J_TS
M3+[8+;PPD<MTAAM2H#;'93(=Q)W'C%1+W54CU@E\[W_R_K0(>][-K[3_  T_
MS/K_ /8+_;CT'_@H%\!(_B#X=\+^.O!^G27\^G_V=XMTV/3]2#Q;<N8HY9!L
M;=P=V3@\"O:&DRN=K-^%?C?_ ,$B_P!O;XB?#;_@VV^*'QKU?7=<\=^./!K:
M]<:;>:[=R:A*LL8C6#S&D8LT4;N'*Y^ZK 8KP'Q7^S9\3_AA_P $8=/_ &[+
M/]J#XR77QH6*S\5313Z\9/#]PEQ?QVIL?LOW>%ER!]TL"NT @C2I:+:>R2O\
M_P#AF33O+U;:7R?_  Q_0<),]/7@T[?MS][UZ5\HZY^T-K?QU_X(T:I\3YHY
M] \1>(_A;/K;?9G:%[.Z?3FD+Q,,,GS_ #*1R!CFOQ=B\ ?$[3_^#?3P]^U_
M-^T!\:IOB=X+U>U&D6K>)9O[+ALAJRV?D/#G,K,7,C22,23\A^7BHE[M2<);
M1Y;_ #;7Z#IWG&$H_:O9>BN?TH>8'QCOTXK@OVH?V@-._96^ 'BCXAZMH_B+
MQ!IOA.Q:_N-.T&T6ZU*[52 4@B9T5WYZ%ATZU+^S7\0KCXL_L_\ @?Q5>*JW
MGB+0;'49PHPHDEMT=L?\"8UX?_P6V\>ZW\,?^"4GQP\0>&]7U+0=<TKPS-/9
MZAI]P]O<VD@9<-'(A#*W/4&IQ3E2C+R?ZV'AY*KROHSW+]G7XW6/[2/P(\)^
M/]-TG7M#T_Q?I<&JV^GZU:K;ZC9QRJ&5)XU9PL@!&5#, >]=MG/9J_&W]OKX
M[^.-/_X-._ 'C:W\8>*+7QE?>'/#$UQKL&J3Q:E/))- )':X5A(6?)W$M\V3
MFO._CSX*^(G_  3G^,O[#_QCM?C=\5O&7B?XTZYINC>.;/7=;>?2M1%[%;EE
MBM1B.*-!(RJH!/RJV=V2=I17MI4MO>Y?F]OR,XR?LHS>[3?R5K_F?NLK!XU;
M^]7E?[9G[9GP_P#V"/V?=<^)GQ+U>31_"^B!$=H8&N+BZG?B*WAC7EY';@#A
M1R695#,/5 A*U\1_\%\_@I\'?VCOV#;KP+\8OBGI/PAL=<U>W;0?$%^ \46I
MQ[C$ICROF(5+AE#+@$G<,9K&I*7+I_6J_0VIV<O>/,O@G_P= _!#XC?%+PIX
M=\7> ?C9\(;'QY<1V_AWQ#XR\.QVFD:B9"%C)FCF<JK,RC>%:-=V6=5!-?>/
M[2OQ_P!%_9<_9[\:?$KQ%;ZG=Z%X#T:ZUS4(-/B22[E@MXVD=8ED=%+D*0 S
MJ"<<@<U^(O[;'Q!_:^_X)O\ P_\ "-S^V1X*^"O[5G[/NDZS:V@U)$C.H6,K
M;A')&72"07!B5\%HI(B?E+C(:OU0_P""N>KV^N_\$B/V@[ZUD\VSO?AIJ]Q"
M_0NCV+LI_$$55:RI2G#I?\KJ_F31NZL82ZV?XV=O(^5]#_X.U?@3XETB'4--
M^#O[4&H6-P,PW%MX,LYHIAG!*NM\0<$$=>H-?HI^SQ\=M-_:5^!?A?Q_I.FZ
M]H^F^+-/34K>RUFU%KJ%LC@D)-&&8(XQRH8X]:_'+_@D'\/O^"CFL_\ !-CX
M3W'P=\>?LRZ7\-9M+D.@VWB.#46U2&'[3-N$YCLG3=O#_==A@CG-?M-X&CUR
M#X?:0GB:73YO$B:="NJO8[OLKW8B F,6X*WEF3<5R =N.!TK2HE!/R)BVVC\
MWM0_X.OO@%8^+O$&DP_#/]HK4E\,ZE<:7?WUAX4L[JSBEA<HYWI>D[?EW#(!
MP0<#I7VU^P_^WO\ "_\ X*(_!:+QY\*O$#:]H?VAK*Z26VDM;K3KI I>">*0
M!D<!U/=6!!4L.:_$[_@C+X7_ &V-;\.?M&']F'Q%\$]&\,K\4-52_3QBETVH
M-?<?-!Y=O+%LV>7]]A\P/&.3]7_\&K>N:?X0\#?M ?#/7-,U73_C1X0\=RW_
M ,09)KN&ZLKZ[N3(D<MJ8E54C_T:0%/FP>=V& 54X\T?>_E3[;V_S_(*_NR=
MMN9KOU?^1^M"G<OIQ35D#].>WTH4X7\*_&'_ (*P:]X3^.W_  4D\2^#X?B#
M^UA\5?$GAWPTL<7PS^#=K_9]CX.G9(V6[O[]IXT;>6#$%'*F102  E92E:2C
MZO[C2,;IOM_G8_9PS#/\0YQR.M+G</NL..N*_-?_ (-9?VA/''[0G_!-'4I/
M'_B#7/$FI>$/'6I^';2ZUBX-U?"TB@M)4BEF))D9'GD&XD\8&<"OSU_;ANOB
M]\'_ -J/XW:Y^TEIO[5Y\.WWB&6;P;\1?A7XD>;0?"^GJ[&!/L2,ELV(]I9)
M9HI%&=RY^8U4]R?(^U_R_P _P)A[T7)=';^O2WXG]&(=<?CCZT[=\OW6]>E?
M/O[*'Q03XU_\$Y_#/B+X<_$:3XC7>J>$F&B^,=:MEM9-3O$A>)+B[B"@1NLZ
M8E7;D,C Y(-?@OX6^(?C3]EOQ!HMS^U1K'[:'P5^)EMXH>XN_BQI.L/XA\)Z
M@IN'(7[(2+8P!2HS ;@,4.(R#L5_\O72?E^=OP%%WI\Z/Z9S+@]&ZX-*2R '
M#5\X_P#!1[XU>'? /_!.KQMXKOOB]-\*M#O-$B-OXZTRR&I7%JLY01R6L*\R
MR2A@J[,$>9N!7&X?B?\ !SXJ>)/V;?V\/V.-8^&M]^U]I?A?XF>)[#0]=U?X
MMW_DZ?X^BN)K=)9[2Q\^8K&\<V]68\!X\'(W%TX\U7V?FE\]?Z[BE*U/VGE?
M[DC^CX-@YY]SZ4))N88S^5?G5_P<GZ=\1/AM^QQX;^.'PQU_Q!I.N_ KQ38^
M([ZST_4)K>WU73_/C66.XCC8":-7\EF5@1L\S/&:X#]F/]I;5/\ @J)_P7DA
M\5^#/%VO+\$_@C\/K*]:PL]1EBL=4U;5;?S(TN(D81RM''/(3NSM>W45-.\W
M;SL_)6O?Y[>HZEHQYON^^UOQN?JU1115#"BBB@ HHHH **** "BBB@ HHHH
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M9WY?ZWM^>A#DDG+I_P "_P"6I^F5%?F;^U7_ ,%J_B=\&OVF_B?_ ,(WX-\
MWWP5^!7BGPYX/\83:A=7:^(M3NM6V[KBQ*#[/'';&50R2J[2;"0R[@%^Q?VL
M/VP=4_9@TW0;K2_@]\7?BXNNEPR>!=,M;QM-VJI!G$]Q#M#[OEQNZ'..,J+Y
MH\R_K1/\F.6DN1[_ -(]MHKQW]@G]L_P_P#\%!_V5?"WQ=\*Z7KVBZ!XL-ZE
MM9:U#%#?6[6M[/92"18I)$&9+=R,.?E(S@Y ]BH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MN J#  [8'2K6* ,5,?=BH+9?Y6_)#:N^9[_TSX1_X-ICN_X(N_"/_K\\2?\
MJ2:I7W=7PC_P;2?\H6_A'_U^>)/_ %)-4K[NI@%%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!\(_\&TG_*%OX1_]?GB3_P!235*^[J^$?^#:3_E"W\(_^OSQ)_ZD
MFJ5]W4 %%%% !1110 4444 %%%% !1110 44$X%>):E_P4$^&^E?MVZ=^SE+
M>:I_PL[4_#[>)H;86#_9!9@N,F?[NX^6_P O/3M0![;1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M5.=3:]U&VA^]B3;W*T^HHH]LGWL[?6I:\T^;UZA1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !37.*=37/- 'B__!0S]JR3]B/]B?XE_%:.UL[^Z\$Z%/J%G:W3
M%8;NY VPQ.5.X*TC*IQS@\5X1_P3W_X*A:Q^T%^RA\2OBGXZ\1?!C7K#P':?
M;I;7X>76HO<:<J6SSRPWL5]'')'*=H"%5*, Q!(%?3G[4?PQ\1?&;X%>(O#?
MA'Q<? OB;4K<+IFN_P!G1:BNGSJZNK/;R_)*AV[64X)5FP0<$?/'[,/_  32
M\1>&Y?VA-?\ C-XXT;QOXT_:-L;'2=?E\/:-_9.FV-E96<]G;K#$\DCF4K<2
MLSLV"=HP .<??Y9VWMIZZ?\ !*]WW;]]3C_^"='_  5O\>?M._M!>'/ _P 3
MO /AGP>/B=\.H_BCX)N=#U.:^SIAN?):UOA)&NRZ56C?,>4P2,YKG_V:O^"V
MGC+XQ_M"_#<:U\/?#NE?!GXW>*=?\'^"-7MM4FEUQ+S2F=#)>V[((EBG:*4(
M(V++M^;J,]-_P3L_X)&^+/V4_CUX?\<?$3XD:/X^E^&_P^C^&'@>VT[0VTT6
MFE+<^>T]V7ED\VZ8!(\IM0*K<$GCG_V;?^").O\ P6_:)^']YJWQ+TW7/@_\
M&?$^O>+O _AR+1&@U2&]U9F9DO+HR%)(X&DE*;(U+&3G  %='N\Z[6_79^?+
M^)G*_+*V_P#P/RYB#]I[_@MIXQ^"O[37Q&LM%^'_ (<U;X/_  5\2^'O"/C3
M6+K5)HM:>\U?;B6R@6,Q-%;F1 XD8,Q!*Y!&/JK]L+]MF3]D72_#UW#\(_C5
M\6(_$$KQ[/AYX;769--"*K;KE6EC\M6#?*><D$5\O?M.?\$2=>^.G[3'C_6-
M*^)>E:+\)OC%XC\/^+?&WAR?0S<:C+>Z/M"+:70E5(XKCRT,F^-B"#MX.!^A
M5I&L8CC3:%C   [  8%13_AJ^_\ P%O\[V\AR_B-QV_X/^6_F?"W_!LO<-=_
M\$4/@[,T;PF6X\1N8W&&0GQ'JAP?<=*^\Z^$?^#:0?\ &ESX1_\ 7WXD_P#4
MDU2ONZF,**** "BBB@ HHHH **** "BBB@ ;I7X3Z_\ \EHU+_LY*Y_]65)7
M[L'I7X3Z_P#\EIU+_LY*Y_\ 5E25]-PQ_$Q'_7J?Z'Z5X:J]7'W_ .@:K^A^
MZPCVMNIU%%?,GYJ%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M63E]X!P ,?I/Y:YSM&:78N?NC\JT4G?FZ[?C?[[ZBM=-/K_E;\M#\V/VH_\
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MOX7H4J-#.82:?UI4^6VEE)._<A\$_P#)N?[<G_9-/"7_ *6^(:]$_P""<?\
MR>@W_9+=<_\ 1^G5YWX)_P"3<_VY/^R:>$O_ $M\0UZ)_P $X_\ D]!O^R6Z
MY_Z/TZO=QW\',/\ $OT/N,]_W?/_ /K[#]#QC_@G]_R7G]D/_L(6_P#Z9YJ3
M7_\ DM.I?]G)7/\ ZLJ2E_X)_?\ )>?V0_\ L(6__IFFI-?_ .2TZE_V<E<_
M^K*DKHQ/^_U?^P=_DCTL=_R.<3_V /\ )'[L4445^6G\QA1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)?H>AGO^[Y__ -?8?H>,?\$_O^2\_LA_]A"W_P#3--2:_P#\EIU+_LY*Y_\
M5E24O_!/[_DO/[(?_80M_P#TS34FO_\ ):=2_P"SDKG_ -65)71B?]_J_P#8
M._R1Z6._Y'.)_P"P!_DC]V****_+3^8PHHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MGS^SW_P43\':+^SO:'6?B=J'AW4[^RU;1O%MWK6F:=:QA8YXIQ)=.J2.LGR
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M:A?Z/M\K[-?^>OV>*<)'YJF&0Y5B&PP5?ORU"HB*ORJH"@#MCM6=-KV:OO\
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M#/\ E%I\6?\ LY/2?_1NA5H^.O\ E'S^Q=_V$]?_ /2*^K.\&?\ *+3XL_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*_+3^8PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2W7/_1^G5T8[^#F'^)?H>AGO^[Y__P!?8?H>,?\ !/[_ )+S^R'_ -A"W_\
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MB@ HHHH **** "BBB@ HHHH **** "BBB@!OD+G\<T;*=10 U(PG2AQS3J*
M/,OVN/A_XX^+7[._BSPO\-_&-O\ #_QKKEC]DTWQ'-8M>C2"[ 22K&'0F01[
MPAW?*Y5L$*0?G'_@GQ_P3"\4?LO_ +(?CCX,?$#Q;X)\5>%_%5@]I%<^'O#4
MNDZA+-<).M]>7\\MQ,UW<S%X3YC8*^61R" OVRT2MVZ4>0A_A%3R*TEWT97,
M]/+4^"?^"=G_  20\8?LK_'KP]XX^)'Q"T/QT_PV^'L?PP\$6VE:-)IXM]+%
MR9WN;LO*XDNF41QDKM7"MP217/\ [-G_  1)\2_!?]H7X=SZQ\1]'UGX._!7
MQ1KWB_P/H$&CO!JT=YJKLYCO+DR%'CMVDE*%$!;S.<8%?HMY*_W11Y2^E5JI
M<W];W_/7U(:337?_ "M^6A^='[3?_!$WQ+\<OVF?B!JFC_$;1]'^$?QD\2^'
MO%OC7P_<:/)/JAO=(V[4L[D2!(X[CRXS)O1B#G;P0*_1&T"QQQJF J@*![#M
M4WEKZ4")5/2IBFHJ'1?Y6_0'=RYWO_7YGPG_ ,&TW'_!%GX1_P#7WXD_]235
M*]"_X+2?\H^/$7_8?\-_^GVPKSW_ (-IO^4+7PC_ .OOQ)_ZDFJ5Z%_P6D/_
M !KX\1?]A[PW_P"GVPKJP7^\0]5^9Z>3_P#(PH_XX_FC\\/ ?_)*_P!N#_LW
M+5?_ $FU*O5/^"=W_*3WPO\ ]B/XG_\ 2C2:\K\!_P#)*_VX/^S<M5_])M2K
MU3_@G=_RD]\+_P#8C^)__2C2:_1,R^/,O^X?ZG[YQ%OQ%ZT?_;CP+_@F+_R/
MG[(/_8SQ?^F;5Z;^W=_R-G[1G_90;O\ ]*+2G?\ !,7_ )'W]D+_ +&:+_TS
M:O3?V[O^1L_:,_[*#=_^E%I78_\ D8R_Z\_H>M+_ )*"I_V!_H>G?\%./^3T
M/VC/^P;I_P#Z8XJ;^TY_R<%\"O\ LW[0?_2IJ=_P4X_Y/0_:,_[!NG_^F.*F
M_M.?\G!? K_LW[0?_2IJY\I^/+?29Y_#/\7A[_!6(_'7_*/G]B[_ +">O_\
MI%?5G>#/^46GQ9_[.3TG_P!&Z%6CXZ_Y1\_L7?\ 83U__P!(KZL[P9_RBT^+
M/_9R>D_^C="KAI_\B^'_ &$?JCQ<+_R3]#_L._5$7@G_ )-S_;D_[)IX2_\
M2WQ#7HG_  3C_P"3T&_[);KG_H_3J\[\$_\ )N?[<G_9-/"7_I;XAKT3_@G'
M_P GH-_V2W7/_1^G5T8[^#F'^)?H>AGO^[Y__P!?8?H>,?\ !/[_ )+S^R'_
M -A"W_\ 3/-2:_\ \EIU+_LY*Y_]65)2_P#!/[_DO/[(?_80M_\ TSS4FO\
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M#?Q7XPUS2_#/AK1)O$EQ?ZGJ-PMO:V<?_"2ZFNYW8@*,L!SW(KO?^"HWQ?\
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MHG_!./\ Y/0;_LENN?\ H_3J\[\$_P#)N?[<G_9-/"7_ *6^(:]$_P""<?\
MR>@W_9+=<_\ 1^G5T8[^#F'^)?H>AGO^[Y__ -?8?H>,?\$_O^2\_LA_]A"W
M_P#3/-2:_P#\EIU+_LY*Y_\ 5E24O_!/[_DO/[(?_80M_P#TSS4FO_\ ):=2
M_P"SDKG_ -65)71B?]_J_P#8._R1Z6._Y'.)_P"P!_DC]V****_+3^8PHHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MMCO7EO\ P7%_Y2U?&;_L,:7_ .D-E6/\"?\ E,]X/_[+Q;?^GX5L?\%QN?\
M@K7\9_\ L,:7_P"D%E7ZUEN P^%S2FJ$;<V%<GYMQ=V?HV!P='#YC!45;FP[
MD_5IW_(]3_X.7/\ D_CPA_V1K0/_ $XZY7[5_P#!++_E&Q\!_P#L0]'_ /2.
M*OQ4_P"#ES_D_CPA_P!D:T#_ -..N5^U?_!++_E&Q\!_^Q#T?_TCBKX_//\
MDGLO_P"XG_I;/F<V_P"1+@O^XG_I3/>J***^'/DPHHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M ,$[O^4GOA?_ +$?Q/\ ^E&DUY9X%_Y)9^W!_P!FYZK_ .DVI5ZG_P $[O\
ME)[X7_[$?Q/_ .E&DU]#F/Q9E_W#_4^^XC^+B/UH_G(\"_X)B_\ (^_L@_\
M8SQ?^F;5Z;^W=_R-G[1G_90;O_THM*=_P3%_Y'S]D'_L9XO_ $S:O3?V[O\
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MPA;_ /IFFI-?_P"2TZE_V<E<_P#JRI*7_@G]_P EY_9#_P"PA;_^F>:DU_\
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M:ZG-']H:VN-Q)\R)95CSD[O+SP3@?7%$9*2YH[#J4Y4Y.$TTUNGNO4****9
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M_I$0HHHK[H^-"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJQO@0/\ C=!X0_[+Q;?^GX5L_P#!<7_E+7\9_P#L,:7_ .D%E7T='_D:T?\
ML$?Y2/<I_P#(RI?]@S_*1ZG_ ,'+G_)_'A#_ +(UH'_IQUROVK_X)9?\HV/@
M/_V(>C_^D<5?BI_P<N?\G\>$/^R-:!_Z<=<K]J_^"67_ "C8^ __ &(>C_\
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MJKNZPWK-^Z"6[2S$,A)?> <8&.C3G7:WZ]?/E^5R7?D??_@=/+F_ ZK]I/\
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M^PGK_P#Z17U9W@S_ )1:?%G_ +.3TG_T;H5<-/\ Y%\/^PC]4>+A?^2?H?\
M8=^J(O!/_)N?[<G_ &33PE_Z6^(:]$_X)Q_\GH-_V2W7/_1^G5YWX)_Y-S_;
MD_[)IX2_]+?$->B?\$X_^3T&_P"R6ZY_Z/TZNC'?P<P_Q+]#T,]_W?/_ /K[
M#]#QC_@G]_R7G]D/_L(6_P#Z9IJ37_\ DM.I?]G)7/\ ZLJ2E_X)_?\ )>?V
M0_\ L(6__IGFI-?_ .2TZE_V<E<_^K*DKHQ/^_U?^P=_DCTL=_R.<3_V /\
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M/XJ^#?B?4O"G@Q8?#FDRVVD:7=_V6T]LZR6[&XW9 ,DK%QCY67)KV;]MA/\
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M\C- 'I#RE3TI/M!P"5P&[DU2US6(]$T:\O[A6:*Q@DN'"X)*HI8X'X5^0O\
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M_P!<M5_]1O4*^WS1?[1F[7_/N/Z'UF8+]_F7^"/Z&7\"?^4SW@__ ++Q;?\
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M%% !1110 4444 %%%% !1110 4444 %%%% !01FBB@!K1JW6D:W1^JYS3Z*
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M_M.?\G!? K_LW[0?_2IJY\I^/+?29Y_#/\7A[_!6(_'7_*/G]B[_ +">O_\
MI%?5G>#/^46GQ9_[.3TG_P!&Z%6CXZ_Y1\_L7?\ 83U__P!(KZL[P9_RBT^+
M/_9R>D_^C="KAI_\B^'_ &$?JCQ<+_R3]#_L._5$7@G_ )-S_;D_[)IX2_\
M2WQ#7HG_  3C_P"3T&_[);KG_H_3J\[\$_\ )N?[<G_9-/"7_I;XAKT3_@G'
M_P GH-_V2W7/_1^G5T8[^#F'^)?H>AGO^[Y__P!?8?H>,?\ !/[_ )+S^R'_
M -A"W_\ 3--2:_\ \EIU+_LY*Y_]65)2_P#!/[_DO/[(?_80M_\ TSS4FO\
M_):=2_[.2N?_ %94E=&)_P!_J_\ 8._R1Z6._P"1SB?^P!_DC]V****_+3^8
MPHHHH **** "N=^+_C__ (53\*?$GBC^S;[6/^$<TRYU,V-F!]HO!#$TACCS
MQN;;@9[FNA8\5\ ?\'+OQ&\3?"S_ ()3^)M5\)^*/$GA+5AKFDVIO=$U.;3[
MEH9;I8Y8C+$ROL=6(9<X8'!!%>CD^65<QQU' 4+<]62BK[7D[*Y-2:A%R?0^
MD_\ @GE^V9;_ /!0/]C_ ,'_ !>L?#&N>#]/\9)<S6NF:MM-U'%%<RP)(2H
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MH_[)G+_Z6I7@/_!O)_RE2_9S_P"N6J_^HWJ%?39I_O&<?]>X?H>[F'\?,_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 ?@?\!O\ E"[^Q-_V//C'_P!..MUZ]X9_Y1<?M%?]E?\
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MP_0]#,/X^9_X(_H9?P)_Y3/>#_\ LO%M_P"GX5L?\%QN?^"M?QG_ .PQI?\
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M,*RCBZ2I^PBYJ+E>7O6B]967;8_FVM4JQK0C%>Z[W/Z:/"W[0_P_\<_%77/
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M\7YQBH8RDZ=3+%3C+GC:53EIKD3O9RT>F^AC3PU7V%./*[J=_D=U_P ''_\
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M!BW[R"/XQS:M!XRK).Z<Y6:UW;[=/,^FP]%SCI;17U:6W:[5WY+4^Q_V_?\
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MCQ?_ &;X(TR_TO79(? ^MW#:;=26<4:Q.D=HS[BP/ !P,$X!KSW]G3_@I/\
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M2J13A5DY*ZNDWN^R\SZ.E_Y, ^+7_9?/!W_J0>'*FT+_ ))O^VC_ -D:B_\
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M!+:2^ ]:TR.'P9;:->V]G#+]DM(D>".1[93&27(4%U*@FI/ 7_!2WX(_"/\
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MQCH.NZ/X(CTWX^W&I?$C59-/2Z6XTRZ@L].MU@@+NRM$<J3O&[)//05\K_\
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MUT66RNETN15OBB171^U1$QF,2I)Y<D6XX *\U^-_[8/_  4%\-_'_P#X)?\
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MJ,S#RV*NM-KVBBNK_K_A@5W!R[+^KGVM^TM\!_!?C[]ISX*_&;Q!X\L_#3?
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MZRO-INL3H'*,EM)Y4,C,@WR&$JK;:XG]J[]F/X"Z]^VQX]\37OQ"^,%OI_\
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M=:_J&D6_@7QSHOCZTFL52;[=+IT_GQ0,3P(W.,L.1P1FL_\ X*3_ +-GAO\
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M>%%TR]N[>WM9QJ<T4B/(\C J^;4A5'W\''W:_.3]H#]F3X!ZE^VUXM\57?Q
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M)\,_"#X??LC?#MOB9I/PA\#^%O"MQ:WVB1#5X9-#TJ[C+/;/9W<PC\QBN6W
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MSMK'7-8L-!TGP]';Q6HE%O\ 9[&SMDM@X\YR[RI*90%5\HJH%):-+MI]RO\
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M9C=&DD4QQR"4%7W*<DJQ4S]FWG_3&[-W?]=CE_$W["?C2Y_9Q^%7P[\"S/\
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M;JNK>,M/^%=[\:-;LD:ST7Q%XVD\/Q>)Y8XQ%;)>PQ2XFC*HD>Z2"4E%"@,
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M8EE+%!D(%!.:DU=Z]/Q2T_K\"(IV3\_NU-GX;6_P7UOXX?"_1OA2OPA\3?\
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MJ'C)O!FFW6E>&["+P=H/AQ+*"XC6)_M,NG6D,MVPC10/,8(&R^S=@C'^%O\
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MPN-"?0;>]U'6X;1&AE:&:>T@FD,7G1I*D;*VW*\, A8Y\S\7?LV?L_\ C/\
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M\;7_ (=_M>SMWD>""Y2!PD@C::;8^!(HE8!L<#Z)HI<NE@ZW.7^#_P )=!^
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M\4^$M:\0?VGH^LPWH+7:VECR+7[(Y$9,8&PD [2=I^MO^"Y/B_QX/VJ?V/\
MP3X+^)'C3X;VOQ"\:W6DZS<Z!J36LEQ;- FY67E'(4MLWJP5B& R!523BXQZ
MN7*_)V7X:F<9)J_3EYOEK_D?I,9PIP<BL'XH_%/1?@U\-/$'B_Q%=?V?X?\
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ME P0H_.25W<G!&:Y/P+_ ,$Q_@1\+-,^&UGX?^'&CZ7;_"&^N]3\'I%/<?\
M$DN;K N)4)D)=GP,^9NZ#I7O=-?DU'+;;^OZO<J6NY\7?\%KOV)/C%_P4(_9
MOMOA7\--8^'NA^'=<NX+KQ-/XA^U?:@+6[MKJV%J8491EX6#[QT(QW-?8?A+
M37T7PMIME(RM)9VL4#E<X)5 IQGGM5QTW-^!IR<(*<?=3BNKO\[)?H#U=^RM
M^HZBBC- !1110 449HS0 4449H ***,T %%%% !1110 4444 %%%% !1110
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M&M:OIO@?Q[X3\77^@$+J5OI.J17<MGEBH+JA) )4C/3(QFOG'7?%'A?XL_\
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M,#%"MS%\BR(CL&W@HU;)>\XOIM_P2=7%/[_P/M>BBBI*"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /BS_ (+H^-=?
M\$?LF>&9O#GB+Q!X8O+SQUI5G->:->M9W1A=9RT>]>=K;1D>U?G$?B9\2!_S
M6+XP?AXKN<?SK]*O^"VGPF\7_%_]E;P[9>"_"NM>,-4T[QKI>HRZ=I2(UP8(
MQ,'D&YE7:N]<Y(K\\6_9?^.1)_XL#\5?_ :R_P#DJN>HI7T/YS\9L/Q?/,:#
MX=]KR<CYO9MI7YNNJ6QB)\3?B,6'_%XOC%]?^$KN?\:_3_\ X(M>*]:\:_\
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M[*NK?$WX8?L0Z#K?@>ZUS3_!.L:7<^(["ZLO/ATI8-#FCS=(PVA4GV*=W&[
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M8G-<PHY;@U>K5DHQ3=KMZ+4BI44(\\MD?;W_  RU\,0/^2<> OK_ ,(_:?\
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M]TRSQY;H%R>U'6WHOOV#I<[ZBHC=J)&3^)1DC-2J<B@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH Y/XM_&SP?\  ?P]'K/C7Q)H
MOA72)KJ.Q2]U2[2UMVGDSLCWN0-S;3@9[5P/_#Q3X!L,K\9OAGC_ +&*U_\
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M.A>);+Q/H5GJ>GW$5YI^H0)<VUQ$VZ.>)U#*ZGN"I!%7E.15-6T8;ZH****
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MA3L5<#)^LEC5T_'\Z=Y8SW] 2:(JT.39-6T[:=?DON%)W=WWO]__  Y\F_\
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MQ2.)_:!_9K\#_M2?#YO"OQ"\-Z7XL\/M<QWGV"_0M#YT>?+? (Y7)_.O(/\
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M>HW/G)<0K.BQK;Q_ZU<&/%;QM[1I[>[^-[_H0^;ELM]?TM^I^S@/ KQ#6O\
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M\D[_ 'Z'T)10O2BJ*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH ^7?^"HZY\/\ P5XSGXJZ1D$9!_T>
M][55P:]E_:7_ &9?"_[5?@RQT'Q8=:CL]+U2#6;2;2=5N-+N[6ZA#!)$N(&6
M1,!W!VL,@XKRX?\ !*KX<D#_ (J;XW?^'0U[_P"2J ,V,$2+UZBM3_@E O\
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M(6T>\\<'X@RM]M7SSJ3:E_:1 ;9@0^>/N8SMXW9YKWA5W-NVKTZTK?NTGO\
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M]H?Q NI]0\2ZQ<ZB)-:UJ\GF26:ZEG*;?,8HB_+&%5%"JJ@#'I%M^SUH-O\
MM&W7Q21M1'B:]\/0^&I%\X?9?LD<[W"X3;D2;Y&RV[IQCO0KWN^R^^VOWO\
M .C[W=O_  )?^VW/0(3F,4ZF0#;"H]!3Z"@HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ KQ#]L;]M/1?V-(?"C:IX5\9^+K[QIJ<NE
MZ;8>&X;22X,D=M)<R.YNKB"-4$<+?QDYP,'.:]OKXE_X*[Y?XC_L[@?,1XKU
M4<?]@*^KS,ZQT\'@*V+IJ[A%R2[M*]CTLGP<<7CJ6&F[*<DG;S-#_A\58?\
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MJN>5!#'@C.51<O/TM?\ !/\ )H+:\O6]OQM^:/O .JCJ!1YB_P!X>G6OS_\
M@Y^UY\4O'7A7]F7P!\+=+\">&YOB=\+[_P 6W.H:[]MU2/0EL9--C6*-3,LE
MQO-]L)DDW#.XD[2K=H?^"DOB35O^">/A'XD:?X;T5?B'XT\16O@BQT^>:3^R
M(M7FU)M.,SN/WGV971Y<9W%0%SDYK63MO_6O+^>@1UM;^M+_ )'V8)%/\0I=
MXQU%?+G[''[0WQ7\5_M5?&+X4?%2'P/=7/PSTSP]J.F:UX<@GMEUJ'4QJ)9Y
M8)9',+(;,($#MR&;)# #!_X*MZUXZTGQ)^SC#\.;C3HO$NH?%*VMT74KB>/3
MWC.G7V]KE(65YHT W>6"-Q51D=:<M+7ZA'=K^MD_R9]@AU;H10)%*YW#'KFO
MA+XO?M2^,?B%^P[^V)X/\7KI>E_$?X+:+J6EWFI>'&GM[/4([G0TU"RO;<.S
M20.8IPKQ[V*21,5<@C&YI_[1GQ<^('Q%\._"CX3R^!]-U+PM\,M&\7ZWJWBZ
MWNKX:C+>>;#;6D:121LJDVLK2SDN5W* I.<J^C;VT^YIO\A+5V]?P:7ZGV@9
M%'<4HD4C[P_.OC9?^"DNM?$W]AOX(^/O!OA_2['QM\>-3L/#VG66KR/+I^AW
MTWG?:I)3'AYHH?LUQL"E3+A.5#$CB_\ @HYX^^+G@+_@EM\:+CXG7WAFSUCP
MQJ6D-8>(/!DUU;'4; ZEI[M*UMN>:VF&9(S&LDF\#*_>VT]FT^CL_P +_=<7
M-=*W7^D??H=3W%&]?[PY]Z^?OV"?VK-:_;2^'6O>/;C3=.T'PY-KEYI>B:*Z
MR+KNF):2O;RIJT;D"WO3(C$VP&85959F))K/_P""F?[>>G_L&?LR>+O$JV?B
M"^\4P^&M5U+P\EKX6U/5M/:\MK9I(A>3VD+Q6L1DV9>=XUV[CN 4D34ER*[+
MIKG=EWL?2/F+G[P].M'F+G[P_.O*/V2_VI-"_:R^%5OXBT6#Q);>6D4-VFL^
M&=2T%O/:%)&\J.^@A>6/YN)$#(>@8D5Y9_P4+_:\\0?LZ>*O!.A^'_%OP_\
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MG\2+.+PAKGPN^'7Q2N;B_P!.U6:[EUJ_MA::?]J2SD$GDVJP1L&CC:-Q*[2
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MIK?=/!J2B@ 7I1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=X@M/#$-W;P>)M?OO$M^)[AI]][>/YDS+G[JEAPHX XK!_:O_8X\,?MD>%=
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@% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>pic2.jpg
<TEXT>
begin 644 pic2.jpg
M_]C_X  02D9)1@ ! 0$ \ #P  #_X1#T17AI9@  34T *@    @ !0$2  ,
M   !  $   $[  (    *   (5H=I  0    !   (8)R=  $    4   0V.H<
M  <   @,    2@     <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M     $UI:V4@4F5I9   !9 #  (    4   0KI $  (    4   0PI*1  (
M   #,C4  )*2  (    #,C4  .H<  <   @,   (H@     <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                 #(P,C,Z,#,Z,C0@,38Z,#<Z,3$
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M# P,# P,# P,# S_P  1" #7 NX# 2(  A$! Q$!_\0 'P   04! 0$! 0$
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MC92K#=817,B>7(ZKF15W9RNX<T1P^%E\*C^ W5K+=L^X/^(G[]L#_H;O!_\
MX2MM1_Q$_?M@?]#=X/\ _"5MJ_/GST\O=N7;_>SQ0TZ+'N+*%]2>*OZG0_D7
MW$_6*G\S/T&_XB?OVP/^AN\'_P#A*VU'_$3]^V!_T-W@_P#\)6VK\^@X/<4C
M3(I7+*-W R>M'U.A_(ON#ZQ4_F9^@W_$3]^V!_T-W@__ ,)6VH_XB?OVP/\
MH;O!_P#X2MM7Y\M,JGEE&>!D]:=NR:/J=#^1?<'UBI_,S]!/^(G[]L#_ *&[
MP?\ ^$K;5Z%X8_X.._VJ]4_9,\>^+IO%7A1M<T#QCX8T:SE'AJW$:6U]8^(I
MKA2G0L7TZU()^Z%8#[QK\N:]<\$?\F!?%;_LHW@C_P!-?C&HJ8.@EI%;KIYH
MJ.(J=V?5 _X.?OVP"/\ D;O!_P#X2MM1_P 1/W[8'_0W>#__  E;:OS['2O:
M/V8O^"=?QN_;.\*:AKGPO^'VH^,-(TF_72[NZ@O[*V2&Z:-9!#BXFC+,4=#\
MH(^8=Z<L+AHJ\HI?<3&M5>B;/IS_ (B?OVP/^AN\'_\ A*VU'_$3]^V!_P!#
M=X/_ /"5MJ^'?C!\(O%/[/?Q)U?P?XYT'4_"OBC091#?Z9J47DSVS,JNN1T*
MLC*ZNI*LK*RD@@GFQ,K/MW+N')&>136#P[5U%?<'MZO5L_0;_B)^_; _Z&[P
M?_X2MM1_Q$_?M@?]#=X/_P#"5MJ^"_!7A/4OB3XWT;PUH-JVI:]X@U"WTK3K
M.)U62ZNKB5888@6(4%Y'506(&3R0.:[#XJ_LJ?$3X'^&;S6O%GAFXT73-/\
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MS[K8^''P\USXO_$30_"?AG3Y-7\1>)K^'2]+L8W2-[RYF<)'&&=E12S,!EF
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M^3,BN%+*&;H,\FCS5W[=R[L9QGFG]3H?R+[@^L5/YF?H-_Q$_?M@?]#=X/\
M_"5MJ/\ B)^_; _Z&[P?_P"$K;5\C_LR?L9?%;]M#Q%J6E?"OP+KGC:\T6%)
M]0^Q+''#8K(66/S9I62)&D*N$1G#/L?:&VMCA?&W@G6OAIXRU3P[XBTK4-#U
M[1+E[/4-.OX&@N;*9#AHW1@"K _F,'H0:GZKAK\O*K]@]M5M>[/O+_B)^_;
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M[_V)FC_^A75?G#'%'%NVJJ[CN;  R?6NBAAXU:-/FV2_-&=2K*%2?+W/U+\
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MOI+8WEM;%[0R8^SE"P\S8MJS_OLL?F'X?^#H9/\ @G3X%O/A;H7[,5_\.)?
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M&KD[H)/]TU[)_P %#SC_ (*%_M ?]E.\3_\ IWNZW?\ $7H_T,_LGD->Y_\
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MSM_: \??]C-J?_I9+7);Z5/X5Z();E77QNT.\&,YA<8]?E-?KA_P58_X*"^
M?V1/^"AWQTU3P1\,;C7OBUXP\!V?A)_&DWC+SM)@MKS1[%7>+38[8"218TC0
M"2X92Z;\#[A_)DMD4V*.."/;&JHOHHP*SJ8>-22<ME?3UM_D7"K**M$_8O\
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M4KCPUIMGK&KWGA_P5J^NZ=IEE=P&XM[B:ZL[>6)(WA5W#%ONHY_A..@^-/\
MP4/^$?P"\(6.O>(/$\LFCZIX:B\86=UI>FW.I+=:7+>6-E#<(($8MYL^I6BH
MH&YPSL 1&Y5_7,5_,Q>QH]D?&/\ Q"<?LT_]#1\;?_!]IW_ROH_XA./V:?\
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MM?#_ (=_:4UGXT7/CJ;[.^@WN@W,5W)#"LOF^:]Y(]VL#P>7N7:6)V@D>9_
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M[PQIFFZ/J.G^;LFT:U\Y[*W42'=''$;FX_=L%96D<.-P('Q_\0/$GQB^ ?\
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ML56KYYUB34O%<"1ZMKFHZI$ES<7JI>W[W"K<7#*UQ, [$>9*RJ9'^\Y52Q)
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M9O+:2)9,X"%P&)^G6I/^6PC_ .6C9PG\1QUXZ\9'YT7\@,W^V[G_ * ^I_\
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M*2?M'C_FOOQF_P#"RU#_ ..UI]3GW7XD?6(=C^I[_A ?#G_1-['_ , =/_\
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M^H'_ (1C2/\ H08O_ 6P_P#CE*/#.DC_ )D*/_P%L/\ XY7\OX_X*)_M$?\
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MHKBN=1D?\)+>?] '5O\ OY:__'J/^$EO/^@#JW_?RU_^/5KT47 R/^$EO/\
MH ZM_P!_+7_X]1_PDMY_T =6_P"_EK_\>K7HHN!D?\)+>?\ 0!U;_OY:_P#Q
MZC_A);S_ * .K?\ ?RU_^/5KT47 R/\ A);S_H ZM_W\M?\ X]1_PDMY_P!
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M(WK^5>L0^ PO\'Z5=@\# 8^2JY6+G9Y'%X+9OX6JU#X&S_RS)^IKUR#P&/\
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M=7D8\LQY)KJJ^2K2C*;E!61]!3C)12EN%%%%9F@4444 %%%% !1110 4444
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M /%5I[V_O&DW-_>:C0#-_P"$ST?_ *"VE_\ @9'_ /%4?\)GH_\ T%M+_P#
MR/\ ^*K2WMG[QI=[?WC1H!F?\)GH_P#T%M+_ / R/_XJC_A,]'_Z"VE_^!D?
M_P 56GN;^\U&YO[S4: 9G_"9Z/\ ]!;2_P#P,C_^*H_X3/1_^@MI?_@9'_\
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M_P!G[?@?4J?\&ZW[.*?\U.^)7XZYH_\ \@U(O_!N_P#LYK_S4SXD?^#S2/\
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MO_!%GX$I_P U"\:_^#G3/_D2ON^BG]>K_P S^\/JM+^4^$T_X(P? I#_ ,E
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M)YH?_09TG_P+C_QK6HHT R?^$\T/_H,Z3_X%Q_XT?\)YH?\ T&=)_P# N/\
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M:9I DKKPFY=NYM$YZ?\ !_KH1[J/I[2OA+^TQ\/?A=H^J:?\8/#GBSQMX?\
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M?%&B:I$UY:/>ZSJVF0VQ>YE+ RV]NL\LL%LJ%&N&LKR3$D1A-??VF'&EVO\
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MD*U;?P )5VF/<IX(8=:]5L_ AX^7]*U+3P)S]S_.:J-,ER/NS_@CO_P5DNO
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M\#)/_BJ/^$=B_P"?C4/_  ,D_P#BJ.:ZLW^ **6J-#-&:S_^$=B_Y^-0_P#
MR3_XJC_A'8O^?C4/_ R3_P"*J;+O^!1H9HS6?_PCL7_/QJ'_ (&2?_%4?\([
M%_S\:A_X&2?_ !5%EW_ #0S1FL__ (1V+_GXU#_P,D_^*H_X1V+_ )^-0_\
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MW-&:S_\ A'8_^?C5/_ Z7_XJC_A'8O\ GXU3_P #Y?\ XJBR[_@!H9HS6?\
M\([%_P _&J?^!\O_ ,51_P (['_S\:I_X'2__%467?\  #0S1FL__A'8O^?C
M5/\ P/E_^*H_X1V+_GXU3_P/E_\ BJ++O^ &AFC-9_\ PCL7_/QJG_@?+_\
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MES2P@X9XENXXO-"G&[R]Q7()P",IXO$)7:_ 7U>B]$_Q/RZMO^#>;]H&,?\
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MC3K&Z,S:G)GB.1MHV1#&6QRV<<#)K] _^$0M_P#GZU7_ ,&$W_Q5)_PA]O\
M\_6K?^#";_XJIEFE>4>6_P"!4<#23N:&G:=!I-C#:VL,-O;6Z+%%%$@2.)%&
M%55' 4   #@ 5-63_P (?;_\_6K?^#";_P"*H_X0^W_Y^M6_\&$W_P 57FG8
M:U%9/_"'V_\ S]:M_P"#";_XJC_A#[?_ )^M6_\ !A-_\50!K45D_P#"'V__
M #]:M_X,)O\ XJC_ (0^W_Y^M6_\&$W_ ,50!K45D_\ "'V__/UJW_@PF_\
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M6VK7\]HB7(*I'>)',&C8G="MSY@ X->)^$_V-?BI;_##XR-HOP"\8^!4\9?
M&ZT-M&TOP7>:;;WWB&+5K&;[/MDO;VYO[A8WG"7MTZ2W*K*50*K4_8K:X>T?
M8_<O;_Z-\CK_ ,M.NS_>_P!GK21KYMRL"X::1=ZQ@_.RYQN ZXSWZ5^0/[6W
M_!+,PZ-^UC)X-^#OB*2\LO!G@W4OAT=.L+N1Y?$'!U.[LL$F74?W4?GS+NF^
M9]S?O)-W>?%/]F+QMH7_  5U_P"$[\._"'Q1XNOM4^)&E:M-JWB?PK%/I]CI
MPBACN+^Q\36M[%-;0Q0J^W3+B&1=P"F.3.TKV2[ASOJC[L_9L_;7^&O[6^L^
M+['P#XDM=<N/!&H#3]2$97#;D5TGCPQW0.2Z*YVDO#*-HV@GU:O&?V3OV6]?
M_9P\0_$J]UKXF>+/B%'XZ\2-KENFL0Z?&;0&VMX#(YM;2WW7#^2%;'[H1Q0[
M8U?S7D]FK.5KZ%QO;4W=-_Y!5K_N-_Z,>IW'E-&K?*TH)0-P7P,G'K@<\=J@
MTP9TJU_W6_\ 1CU^17Q'_92COO'/Q,^(L?A6YD^)5C^UEIFK>&]54M]NM_#8
MFTTW-W:_-\MFVZZ\V1!L?R1O)\E=I&*>[L7&G4E\$6_0_7P#)'*KEE7).!DD
M #/N2 /<UQ?P&_: \*_M+> Y/$W@Z^GU+1HM3OM'>::TEM6%U9W#VUPFR15;
M"RQNN[&#C()!!KX9_P""BWCC1?VH/BI\'?$&O_"OQM\0/@W\,O'/B72?&'@J
M2SMI[K7IA:BWTO6[>P^T[;W3A-YK1S,5(28N4 R#V7_!%[5]8^!G[+/@?X;Z
MS\.OB!I=]KWB3QC>O.;=+VP\+11:E)/!%J-WYQ*O<13)Y#J)!.59MV"&8]UQ
MNGJ.=&K#646EYIGW11114D!1110 4444 %/7_CV;_?'\C3*>/^/9O]\?R- #
M)#Y4#2N0D2D NQVJ">!ST[C\Z=L8R;=K;O3'-?FO_P %(_V5]'_:._;_ /B!
M-XL\*1^)O#=K^S9?V6D&Z4M9GQ*NIW4EI"@R%:^6.8R1*<NOF!U .#5?XW^+
M_%WQN_X(U6WP9L-#\;/\1-&^&'@BYUXWUU%IZ>*%'V-M7T:"[:<2M?\ D6US
M'/$RJV9E3+&0U7N:>\C14*SU4';T9]]>"_V@_"?Q"^,WC3P!I.HR77BCX?6V
MF7FN6_V:18K:+48YI+1DE*B.7>D$I/ELVW;@XR*[2OS/_P"";&LZ/^S_ /M5
M?M$>*_!?P!^*'@OX<^.F\!:;X6\,V6A0_;+=!_:5M>79M%GV6UK!-,)9U#EH
MDE60H#*%/Z8,-K$=<'&11))/0S<91TFK,****D HHHH *#THH/2@#\Q_^#M.
M+S?V/OA/[>.,_P#E-O*_"6&QX^[7[R?\'7L/G?LA?"KV\;_^XV[K\,H+&O9P
M,;TOF>=BI6F5(;'!JY!8$]JN066/X>:U-/\ #TMTZ_+\OKBN^,#EYC+M[+!'
M?ZBNK^&FL^(/ASXUTGQ)X:U2^T'7]#NEO-/U"S?RY[29>CH>G<@@@JP)4@J2
M#I:#X$SMW+DYKM-"\!]/W=:*%]#-SL?NM_P28_X*MZ;^W;X'C\.^*/L>B_%;
M1;8-?6<?[NWUJ)< WEJ">G3S(N3&3W0JU?9^<U_/=^P#^R'X]_: ^/FD0?#^
MZN=!U'09X]0N/$<>53P^@)Q,2/O.V&5(L_O3N!P@D9?Z"=(M9K'2K:&XN7O+
MB&)4EN'14:=@ "Y50%!8Y.  !GCBO QU"%*I:+^78]7"UI5(WE]Y8HHHKB.H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /B?]N?_ (*<>*OV6_C]
MXD\$_#_PGH/QA\70^&-,U:R\&VVM-IVK6LTU[<0N[_N)!(DL?E-&JG*O!Y;E
M'O+19JO['O\ P6GL_C+H?Q.TGXM?##Q9\$?BA\(="?Q/KOA+4@;J6]TI0V+R
MRD9(3,A=0ARBJK21@.X)84_C%^RWXA_9Q_X*L:Y^T5IO@#4_BAX%^)W@J#PE
MXIM-'6&;6O#-S;SPM%>16\CH;BTDCAA5XX"TR21+(%8# Z[Q+\%/''[27QY\
M3?&+2?"&F^#;_2_AO?\ @'PI8^-;))I/$S7UW;WEQ+J%O"[&*Q'V2"&*.1O.
M)N+QI(4"Q^;.J3L<=2-2E2J.#N]7'2[3MM;2ZOMZVO9(ZS]G#]N_Q5\:?%_A
M.UU[X,^*/"7A[X@6$FI>'/$%OJ$&M6$T21"8+>-;C%E(\9!59"=S'8#N! ]:
M\&_M,_#OXC7VL6OA[QYX+UZZ\.HTFK1:?K5M<OIB+G<TX1SY:C!!+8 (/I7P
M#X*_X)]_$C7O'-J/!OPPN_V:TU+P[K&G^,+RU\9I?:/K5Q<V$EO +:QAFE*J
MD[K*"1&(U7(S(BYK_#_]@;XQVO@.U_XH?5(?%/@7P!?^&]-B\2ZWX=N_#NJ2
MSQ+"UG%96MF'N;5U#3)_:$RA)1'O$F92W#&O62LXM_+T\E^*\O,^+P>>9M3B
MH5:$ZFKO+E:OI'1)0@UN[<T5=KE3=N8^]O#W[9/PD\6>&=>UO2_BC\.]0T7P
MK!]JUK4+?Q'9R6NDP\_O;B02;8H^#\SD+P>:I^#OV[_@C\0_"6JZ_H/QB^%N
MLZ'H.GC5=4U"R\56,]MIEF7>,7$\BRE8HO,CD3>Y"[HW7.5('Y8_\%&OV-OB
M+>_ [QYXV\;0R>$?"ND^!O#]D]SX[O-*?3[FXL?$5A=#2[B#1(F2WL9%39&5
MB9$VHTKH"0GFOB7X0>./^"I?[1?Q[\0?#/PMX#TV_P!*7X=^(;_P_P"!_%>G
M:O8ZW_9]S?N^G2:HT!TQ]0:+RID$D<ULH@M5E#@,!UT9RE&\E8^LR?&5\5A_
M:XB#A*[5FFKI;.SU5_GZG[,:?^W?\$-5^&UEXRMOC%\+9O".I7<MA::TOBJQ
M_L^YN8HFGE@2?S=C2I$CR,@.Y45F( !-;WPG_::^'/QYT/3=4\#^//!_C#3=
M8DFBL;O1=8M[^&[>$ S(CQ.P9HPREE!RN>0*_*_P]_P29^*?C?XL^"?'&J_#
MOQPT>K?'/P[XO\5V/CGQ7X9U&Z?3=,TV^@;4Y;32[6VLH9':XA1HH9+J6801
MNX1E.[[,_P""87['VO?LU_$#]I"]\3>$=.T&S\8?&+5_%?A%XWM9O,TVZL[*
M/SXQ$S&#S'AD#(VQSMY7!!.IZI]>4444".*\<_\ (PG_ *YK_6LC%=%XF\(:
MIK.KO/#-I\<6 JAU<MQZX-9__"N]9_Y^M+_[XD_QIV S<<T5I?\ "N]9_P"?
MK2_^^)/\:/\ A7>L_P#/UI?_ 'Q)_C3L!@^(- LO%6@7^E:E:PWNFZI;2V=Y
M;2KNCN894*21L.ZLK,I'H:K^"?!.D_#?P9I/AW0-/M=(T'0;*'3M-L+9=L-E
M;0H(XHD'95154#T%=-_PKO6?^?K2_P#OB3_&C_A7>L_\_6E_]\2?XT6 S=M>
M;_'_ /8\^%/[5C:4WQ+^'/@WQV^AL[:?)K6EQ74EGOP75&8;@K%5)7.TE02#
M@5ZU_P *[UG_ )^M+_[XD_QH_P"%=ZS_ ,_6E_\ ?$G^-'S Q-'T:S\/:/::
M?I]G:Z?I^GP1VMK:VL*PP6L,:A(XHT4!415 554      59Q6E_PKO6?^?K2
M_P#OB3_&C_A7>L_\_6E_]\2?XTK(#-Q1MK2_X5WK/_/UI?\ WQ)_C1_PKO6?
M^?K2_P#OB3_&BR S:*TO^%=ZS_S]:7_WQ)_C1_PKO6?^?K2_^^)/\:=@+>FC
M.DVO^XW_ *,>K(GD4?ZQ_P ZCMO#&LV]K%%YFEMY8(SB09RQ/]:?_P (]K/]
M_2__ ")2L OGR?\ /23_ +ZIK,SG+,S'W-+_ ,(]K/\ ?TO_ ,B4?\(]K/\
M?TO_ ,B46 2BE_X1[6?[^E_^1*/^$>UG^_I?_D2BP"44O_"/:S_?TO\ \B4?
M\(]K/]_2_P#R)18!**7_ (1[6?[^E_\ D2C_ (1[6?[^E_\ D2BP"4\<VK?[
MX_D:;_PCVL_W]+_\B4O]@ZR(BN[2^6#9_>>_^-%@$61D&%9E^AI?.?\ OO\
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M[XQG;Q"\\UEJ7V*UBM8]/>WMYX7NGE?4B\<0<_/:B14D>%4(!]845\)>)/\
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M\E^QMII[S29\LAG6-K^S+0322S32 'WI17S7^S]^U'X^^)_[0.GZ9JB>#?\
MA#_$EMXKO-)CT^TN!?Q6FDZS;6%K=RW#3-$ZW45P'$2PK]TN)"-T:^7_ !+_
M ."GGB;PF?'FI:=?_#&ZAT6#Q1:VGAIQ.=5\/3Z5-+9VM]JMP)]BV]U>I#'Y
M'D0NBWD96:78YH ^Y**^ ?BK^W;\0)=3DETWQE\.]2A\$R^*-<M9M%L+E-/\
M?PV&CV"16$,GVX@M'?ZV()&1I TUD&Q"T4D(T[K_ (*&^*_ UGKVF:#J'P[\
M0W&BV.OZ-I?AHRWMYKFD7NEW!TVQNM5NGNI'>.^OEAC\IT2=3>)B:X*224 ?
M==%?-<G[3?CKPY^SO\>]:UR/PKK'B#X;ZA>:7H+:5;7-C9ZQ-_9=G<06Y#3R
M2;Q>W36C.LB;VBW!8B=HJ_LY?M$^./$OQJT#PU<MX6D\%ZA_PE-GID"Q7LVL
M?9-!U&WTP7\][/<R+-YTTJC849V65)3.270 'T]17Q+\1/\ @IAXF\-Z_P",
MKK2)OA_JT>@R^*K"/P='',_B+23HT5TD6I7THN-BV]W>V]M#'#Y$9*ZI9LL[
M%BIP_CE_P4F^*7P)UW5/"NI1_#N?7K#6KNWEUN"TAM=+LH;;2](O9+7R=2UB
MQ6XFW:M&HF2Z1F6&5A:Y1PH!][45\\_M"?M7Z[\+?!OPYCU+4/ ?PCUKQI8S
M7VK:IXTG%YH_AIK>T2>>S^2XM1=7!9RJ@3Q QP7,WS"+8W(_LA?$;QE\=_BE
MXK^+7C#6'\.Z)H/A/1M)'A;R]1MK?0K^;2K36+Z::)[H13N/M\<>^6U29$A2
M-3&RS>< ?6E%?GC^SS^TK\8+;3?#7BZY\4:#XMBNK7P=I6LV'V2\G^WWVKW4
M^J7\-A&E\\<4UMI>HV3B9C.)%M B1PHPV^R?\$X?VW_&G[8^H>(+K7M$\.V>
MAPZ;I^IV<VE7NGW/]GR72O)]@EDM=2O?/98Q&XG>.S9@P)MDW+0!]545\+_#
M+_@I%X_^+L.@_P#",ZA\)?$UUX^33[C2[73H;IV\)K=:HB);ZDPN6\VY?2EO
M[GRT6 Q2Z7<(P=2K"4?\%*_&'AYM8N;W4/A;KS:9;ZS:WNBV4-S8WGA>73KU
M=/\ [5U6=KF=;6QEN,R/"T0DMHI"1-<B"1R ?<=%?%/A/]O[QU?>(/$$$_B/
MX5ZWX7\#_P!M:MK/B_1M"OI;*]TG2;72)[DVUM'>S,)WFU"ZM5Q+*JMI\L@$
MA'D'!^%7_!2+XG?%6>ZTBWG^&5C>V^OFSO-:GLX[JQT:RCT>]U"[9X;#5[M+
MAK=H]/&\7<)D%]M:& KO(!]Z45\):G_P40^+'AOX27>I:U_PJK2?$%YI?A>^
ML[>:)K==/NM0MKN[O].VW>H6T5]=06MM'.JFYLP4G89=H@)O2?VC?VO[[P3^
MRO\ #?QG"MEK%QX@TV7Q1=FR^W:>DUM9:%=ZN)8HO-CG6.6YM[.$P3,PVW?E
MR*^2" ?4E%?/?PY_:(\::'X(^-%Q\0K[P4MS\*4#7&H:)IMS'964G]CP:E-
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MDK26MO(T\0@E9HPQDC&2$8]U^9N#QR?6BB@!9=&LYV+26MO(S3+<$M&&S(N
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=8-V_;LWYZ[MORYZXXZ444 6!Q1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>pirs20221231_10kimg001.jpg
<TEXT>
begin 644 pirs20221231_10kimg001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !? /P# 2(  A$! Q$!_\0
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M ';*JHH50 H& !VI:S/#^J+K.BV]X#EF&'XQ\PX/%:= !1110 4444 %%%%
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MW6.48930!1T31%T1;Q([AY8[BX:=490!'N_A'M6K110 4444 %%%% !1110
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MJ7@K6?'GB#5?$=C8>3I1(%F#A3<(HVY4>^*]EUOP5INKO)*$\F27'G(O^JN
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M CM=3NK"XO\ 5I[F'5-/*_ZVS #0A<D!ESSP>M3VFKP:_>Z>T]K+:KL:1$N
M,2Y&!M/0\'-7=9\-0ZE$QM+E].N"AC,L"@AD/!#*>&X]>E7X=+M4TNWL)4$T
M4$:QJ7'/ QGV- &''ITUGKCZ;%J4D%K<@W"*B#>2, KN[ <=JUSI]Z5,?]JR
M^61@@QKNQ]:++0K*QOC=Q><TNSRU\R5G"+G)"@]*TZ (K:WCM+>."%=L<:[5
,%2T44 %)2TE '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>pirs20221231_10kimg002.jpg
<TEXT>
begin 644 pirs20221231_10kimg002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "( 1X# 2(  A$! Q$!_\0
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M&.JL?8UP>MV_]LS&[=%B>=LL4'*J.WUKJ?!VB6WD_P!H.7=UD*Q@G@8'7ZT
M=E1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MK]M2TV.X=0KDE6QTR* +]%%,,L8<(74,>BYYH ?1110 4444 %%%% !1110
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MS$QHW&5]JP_(.GVUOH<CL6N3NG<')"^E=KH&R^N(;)IVMX(4V^8$SM]!GH*
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MK0M3N--M+_1[59([5RUQ'"@$A']X>H'I0!S=YXLUF>R>6[ADETHSJ&1QEH&
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MGT_NGVKO?#7BM/%VNV-C%HT5K;V:>;O R4*] /137G$U_J=]IDD:RW,FDVS
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>A5*F>0Y=LG)R:OA5'0 ?0444 +1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>pirs20221231_10kimg004.jpg
<TEXT>
begin 644 pirs20221231_10kimg004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ", 74# 2(  A$! Q$!_\0
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M/UF_FL[/S6DA&YF*87&>H/O6PTJ*RH74,WW03RWTH YS_A%M0_Z&O6/SC_\
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M_(@:U_U['^8K9TC_ ) MC_U[Q_\ H(K&^(/_ "(&M?\ 7L?YBMG2?^0-8_\
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M$5C?$'_D0-:_Z]C_ #%;.D?\@6Q_Z]X__010!P_AG7-/T"VU^[U*?R86U>1
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MQJ/PIX@OM:FO(+ZTBMY;3".%;DMWX]* .GHHHH **** "BBB@ HHHH ****
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M>S5TM<S\0O\ D0-:_P"O9J -/P[_ ,BSI7_7G%_Z *TZS/#O_(LZ5_UYQ?\
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$0!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>pirs20221231_10kimg005.jpg
<TEXT>
begin 644 pirs20221231_10kimg005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #+ 6\# 2(  A$! Q$!_\0
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M'S^%:U9/AG_D5]+_ .O6/_T&M:@ HHHH **** "BBB@ HHHH **** "BBB@
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MAONGZ4B_<7Z4-]T_2@#ZY\,?\BOI?_7K'_Z#6M63X8_Y%?2_^O6/_P!!K6H
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M?_H-:M9/AC_D5]+_ .O6/_T&M:@ HHHH **** "BBB@ HHHH **** "BBB@
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M/TH7[BT-]TT ?7/AC_D5]+_Z]8__ $&M:LKPS_R*^E_]>L?_ *#6K0 4444
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MK?ZK;6\X )CD?! -7C<3_P#/HW_?0KR+QY\./$7B?Q5+J=E%;I"\:J!))@Y
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M "BBB@ I-HS2T4 &.:*** "BBB@!,#&*,4M% !1110 4F.<TM% "8I<8HHH
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>pirs20221231_10kimg006.jpg
<TEXT>
begin 644 pirs20221231_10kimg006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #( :4# 2(  A$! Q$!_\0
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MUO)=0+.L9D,1D&\(.K8ZX]Z +5%5;#4(-2MEN+9F:)NA9"N?P/-6J "BBB@
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MTLOW1]* (GMXI)8Y7C5I(\['(Y7(P<>G%1#3K47[7PMXA=,NTS!?F(^M6Z*
M*/\ 8^G^9!)]B@WVY)B.S[F3DX_'GZU= Q2T4 %%%% !1110!$\$<DD<DB*S
MQ,6C8CE3@C(]."1^-#P1/-',T:F6,$(Y'*@XS@^^!^52T4 4)](L+D8FLX)/
MWOG?,@Y?IN^O J\!BEHH **** "BBN?U'7=3T^[CB&BB6.:<0PR"Z4;R02,C
M''0T =!15:RFN9K97N[86TQ)S&) ^/Q%6: *[V5NZSJT$96<YF!48DX Y]>
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MMS"=NH(3B0<#:U<[\75!T33\@'_2CU_W#7D>U1T4<^U 'TRMY:NP5;F%F)P
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M 4444 %%%% !1110 =JX[QO]MENM'@M7NI8'DD-Q8V5X+:XN %&"C97(4G)
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M4?8+C@?ZIOY5@_#O_DF_AO\ [!T'_H H B^(_P#R(U]_O1_^AK7A=>Z?$?\
MY$:^_P!Z/_T-:\+H 5?OK]17TZOW1]*^8E^^OU%?3J_='TH 6BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@#SSXN?\@33_ /KZ/_H!KR.O7/BY_P @33_^
MOH_^@&O(Z -?PI_R-^C_ /7W'_.OHBOG?PI_R-^C_P#7W'_.OHB@ HHHH **
M** "BBB@ IAAC9LM&A)[E13Z* &"&('(B3(_V11)&LL;1NH9&&&5AD$=P:?1
M0!&T*. '56"D$!AG!'(IKVT4F_S(XW\Q=C[E!W+SP?4<GCWJ:B@"DND:<EFU
MFNGVBVKG<T(@4(3ZE<8["IGL[>6:&62WA:2'/E.R M'GKM/;\*GHH @2TMX[
MB2XC@B2>7 DE5 &?'3)ZFIZ** "BBB@ HHHH **** "BBB@!.@K@?B=H6J:[
M;:;'IUC'<B)Y6=F@BD9&V94#S 0 V""1W*]J[X]*\A\>V-YI_C>*]FLH-1LM
M2^6*W%Q<+,"D8R D0/&>20._.* .V^'VG7.F>$;>VNK1[602RL(W1%;:7)4L
MJ?*K$8R!QFNIKG/!./\ A&(,6#6 WO\ N&:4D?,><R@/S[CZ5FRZSKH\?IIT
M%[83VJG=-8QI\\4.SY7>0D8D9^ @'W>: .UHK@-5\?2WGAK4[[P]&4ETZ5([
MI[N,8B<MAX@ ?F<9'/W>>":CNO%6L'QG+8Q7MFEM_:']F)8^7^^R;?S1/NSG
M ;C&W&* .[O3_H-P/^F3?RK!^'?_ "3?PW_V#H/_ $ 5F76N7WA/PG"NKZ5J
MVHW4WF1G[!$;EEX^\_S':"<]S^'0:?P[_P"2;^&_^P=!_P"@"@"+XC_\B-??
M[T?_ *&M>%U[I\1_^1&OO]Z/_P!#6O"Z %7[Z_45].K]T?2OF)?OK]17TZOW
M1]* %HHHS0 4444 %%%% !1110 4444 %%%% !1110!YY\7/^0)I_P#U]'_T
M UY'7KGQ<_Y FG_]?1_] ->1T :_A3_D;]'_ .ON/^=?1%?._A3_ )&_1_\
MK[C_ )U]$4 %%%&: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZY\7/^0)I_\ U]'_ - ->1T :_A3_D;]'_Z^X_YU]#D@#)Z5\\>%/^1OT?\
MZ^X_YU]"R_ZE_P#=- $$E]$N-CQOZ_.!BFQ:A')RY1%QWD&?RKGQTI: .J5E
M=0RD%3T(I:K6'_'A#_NU9H **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BL?7?$^D^&UMVU2[$'GR+&F1U)(&?H,\^U:D,T=Q#'-$VZ.10RL.X/0T 24
M444 %%%% "=16)J/@[P[JUZ][J&D6US<N &ED7)( P/TK<HH IZ9I5CHUDME
MIMK%:VRDLL42X4$G)/XFKE%% !45S<P6<#3W,T<,*?>DE<*J_4FI:YCQOI5W
MJFG6!M=/CU(6E]'<RV,CJHN$ 8%<M\N06#8/'RT ;MS(DNFS/&P9&A8JRG((
MQU%8?P[_ .2;^&_^P=!_Z *R;70/%UCX&TG2M)NM-L;N)7%RERC3(JL2512/
M[H./3BJ&D^&_B9HVD6>F6FO>'OL]I"L,6^TD)VJ,#)]>* .@^(__ "(U]_O1
M_P#H:UX77J6K^&?B7K6F2V%WKWA_R)<;MEI(#P01S]17,_\ "GO&7_0=T;_O
MP] '*+]]?J*^G5^Z/I7AH^$'C+(/]O:-P<_ZAZWI;GXJ1>)[?1?[0T5EEM6N
M/M8L)/*7!QL)_O'K0!ULW_'Q)_OG^=,K ;P[\3&8L==\.Y)R?]#>D_X1OXF?
M]!WP[_X!O0!WFD?\>1_WS5^O/(=(^*,";$U[PYC.?^/.2I/[.^*G_0>\.?\
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M]G?%3_H/>'/_  #D_P : ._HK@/[.^*G_0>\.?\ @')_C2?V?\4_^@_X<_\
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C54D,3D\UVP&.E%% "T444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>pirs20221231_10kimg007.jpg
<TEXT>
begin 644 pirs20221231_10kimg007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #< <$# 2(  A$! Q$!_\0
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MA(SYDSG:@_,Y/L#4/@/Q+<>)O#GGZA$D&J6L\EK?0(,".9#@C!).,8/XT<S
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MV]S;,&3$;*N[D^O/;CFM<@E<;L.1U'8^M)V$95WJR?:5LX0^Y@6F;HT<8ZD
M_E0^NZ38P*3.5C   522,]./6L[3XKQKN1A#'<I Y5V5POF,.G7OWQG%:%]J
M6G[H[6>,">?/E"1!]X8SS['%597&33:Q;HT4:I*[2]MA4+_O9Z4-J>GPD/-=
MKD_*K%3CZ"JNEZLL=LL=_=Q DYBD+$;@3TY_B%:<L-O?(CD^8G8JW##TX[4G
MH!F-KEO-<VYBW-;E\;\$!L\?H:T+N_CL]CR*3 3M>52-L9[9^I-4K[13?SHY
MN# J+M00^GT/'_ZJ9J-H+>TL[*U*)&9  F/FE8?=]B.Y/M1H!9N=9BB>ZBAC
M>6:!%? ^Z=QP.:IV4+S[R!(MZ02TKC*Q9Z8[9/MT%,^RV]K+-9([2,D:S3,Q
M&YV)(4?3.:U;<Q6$=M9O)^\<';G^(CD\T;; 8D@-U%<&]F3S+8-@8PR]N3T(
MS@C/M6[9O%'8V:<1;XU"(>#G&<8K/UQ5MQ%,8BT$I,4Z)@9SR&],@CK[U=MX
M&DN([N10@2+RXH]P; )Y;/N *;V$$%TT@EGFD2.!'9!Z-@XR3VYXQ6GISJ]W
M&R,&!S@@Y[5BVEE LE]"T3@33;VW'A_I[<=/\:U]+MXK:Z1(8PBGL/I4RL!O
M&O'I;281W#BV5U8LP_>@>9SR#ST^M>PFO()8;NW$K(%F?)53(WWUYX;L>_:G
M3*145;B\ O5FD2&7Y=D?0+TQ@]\CI5\+9FSVW),<3+T4;77GC&.V?6JED5,J
M71FQ&#^^,AVEL @ #^'DCYJL2M)#&LOG+*ZGF +E6SC !]N>O>K?88B3BVMX
MC'!+:J9E2-&4MVY&#U_"KJ),\B2%P<CAP.<CM[9^E5I[B]O+42;Y(;B->!*-
MQR?3ISCBFK--;QQ'R,N,!F8E2X [>AYXQVH!DK,]Q#+$LCK/&PC#HP!P>BDX
M(SSQW[5-<,$6'RV1)I'6$-(,Y.X#)]>O2JBR+YC+%*B@8[?)ECG)]3[]:F,!
M\N) YD\N194W+@D@@\<=R!5;$E2PO'FMXP6=I!N\U-ZC:P)'XX(Z#U[U>,*I
MY1=MIE4D''#]QQ[]JH6_V6.YU&V8^3Y5V\Q9@5"AL%?F [YQCWK1FWK9QS6X
MBN&9\/OQN53V'TZ<YI 4V5Y-0,<[LKQG.X+R#C!QGMC S5W1AE;R"-B80BS.
MR$$,>0R$=B1BFF^D=(EO%C8CA< #RSW0L>V,&IGFETWP1?WWE 7)B?AOESSM
M'Z=/K1)Z#,.*]B@U@V=G;S&/RU:4O.)8T)4?(H'7GN<GTJ>6 MJ++-.JR>8%
MDBCY\L#)STP#@\]A[U%8VJ:?9^5;VTD>V$$,^T\CH,DYP3Q3+B FT6VMW5=S
M;YGC7[AS\RENW/?H:+#&1V:SD.I>(2 *HEQ(H7GE0.O!_2K[QS.;8(?+MW)5
M=JG<"!PQQZXZ'I45M;VUDY$D^Z9@LBA')4 ?[0]>N*G=X[:Z_=2!4VLSY;)'
MT/\ /K1<0Y889M1BB#S#?&A Z'@D'YL?C1&%BLY);?4(+R(2D(J L0^<XQTR
M!_\ JJJ&CE9I)%!N91\I8DX4=,'KS3[81BTEM83Y6&V,OWAD=3FDT,5"DK;$
MD9#$VW>Z#E6ZX'MS4TEJB%[1MI21LAV0;FR#\I4_EFG26]QOAEFLRD$9W!IH
MP> O'T/?)J!2&B>43>8QP5=VSN)/ [C/TH 9$\-I%'!(WG KM#*O*YS@>_&?
M6K]C'LM&NHTE2)&WHSC[_P#> []!BJ$C+)=+'MCCBC4?.R< YX ]<?KGBKSW
M:LFVXDV$' \QN"<C&!VYQS0)CKF"VN()'>&/[--@B5N7R<=C_7IBN=UC0!+;
M V\<4T2M\I8'Y?48QQSC%=#%*F#+$TDDN[]Z58?+[\GH:%O9(;Q98@9,XW?)
MP_I[9YIJ36PSE9=/NXK2.RTNW.FPA2]S-$=LDSCDC=U"^PXK8\(RW>OZ))'?
MS+<"WD#0RN,&*13T)!R?7FM/5':5I86:,$JP?&&;Z#\:I>"W2RO;RSF(69EW
M.1A0^!U ]<=30]8BN7M0@EMU>-[B999I XF1?EVYSTZ#/I^5(UHJZGE9$6/S
M4'F"/)B0Y)Y/!W$=>2,UC:'=2S_VK;1:B\L+QI=VLTA+$(QVL.>^1T]:WVEN
M(5A@"PM&&W;I<<CN"/S_ "J'V'8]-HI,#T%%9$C91F%QQRIZC(Z5Y_/8WLMW
MFZA2>*,@Q211J"H^AZD=NU>@O_JV^AKE+^Y:TM&E1/,E)VQQY^\QZ"JBP"VC
MM;6V,D*X5_G9OXG..I)ZFL^TU2%FQ<0[&25E5V()&3Q_/%5)2+?3H;:[,TMQ
MYJR9:,!0<YV#/08!Q5O3=,CNK".748EF=MS(CC(C0G(7^1YJ@(]6-]*L\<DR
MV]HCJKB)<NZ,0.2> .N<<T_1A<1WNH1;(_LPF^0*Q^08X ]<_ABDU.=;&-;"
MVLU$ET=D;'&UC_4CT]!6EI]DMA:+#NW/]Z1L8W,>N/04= +58NI7L\U]_9D,
M;(NW=-.7 54[^^16O*<0R')&%)RHYZ=JYA+J6\NKH)M_?Q@+(3CHHR/YYQ1%
M 7=-AALIQ%9:K!+ V7D1]I?IP01VJU:00R3W5Y!/,DDDFUSP1QZ9'W?QJAI&
MD!;[[4RQ^5&NU/W94N>W7^$<X/&<^U;%U.E@BR"$D22*C;!ZG&30P9F:[8:O
M?PI#;2VAB657;<"&8#MZ5)8Z-/"!-+.@N A"K&/E5B,9S[5LXYI:7,[6 YMM
M(O+I]TUY:,T2%%B@#9#9SRQ/6J<J:MY BD1VLIV*,'/F,I&>G<=.M7KW3FTZ
MWVVOS0^:TN#P4SVR/?H:S+34)("TEV'92QD#LY81.!SCW [58(N:+>PZ9+<0
M7&Q%*+(OE'*D'L!VXQ^M2W6KF9I)3,+6!5^5@ID,B]P<=/YUI:;;+/I,+S!)
M&<%T8H.%/*C\C60FEW]A9-#>2"_ASMMK2"/;SNSEVZG [TDU<#4T<P6OA^U;
M(ACD4L@(VGG)''KCM6/=PDPK/<R/++*Q56(RVTCL/X1V]ZVHX[ZZ#27=O$N_
M"I#NSL7N3[].E7T@BBCV"-!GKA1S1>S$<Y)>_:DE,"Q36T<6QANX5CP,=!G'
M:I[N]N8+>W\C=;P[ #OC!)[=,]?<>M;4T:"UD155!M)^Z,#W]*R$LH]0,MN;
MJ;RH]I55Q\A!/8@]>N?RQ1<8VQO#I]D;?+W;)S$H&UMI]<^E0*LM]<HTMXL%
MS.V4$;[_ "U!^Z!Q@D9YJQ!HEGI0N;F[N9)X20P$O\!''&.I.<4Z;5[.%OM#
M )<!2B1&/+!CT)(&1QCCTH] ( TCZP[R0/+_ *3M&W SC.TG/4#V[UJ:I:&Y
M@216<26[B5 IP&([&L;37ETV&ZU>Z::2*;:D<8&2W)^;';.?RJTFOR?:IP8$
M:%'PK;MI VY&<^XIM.^@!<O)J_AB5(MOV@MY>)#P&#?Q'L"/T-:=I-(T<Z2(
MJO"Y11TRH'!]LUCSSF"UCU"*WD6UD >>W+#:@_O CC&.O-:Q=AJ"&-$DBN4&
M2" 0 #\Q]1R!^-)H1 8&N)X+A5<VJQ<1J^,-Z'U'X]JT-/EFEU:W\F6/RE+>
M8A4YQMXY]>16==/<6BW A4F%?WN\ 8C'<!?XN_3I5_1]3AN]2BCMTED0 YEV
MX4<=*E[ =.:\;\^#4+>:)&78&:-8\-C Y(YZ>YKV0]*\:5(X+%@)84DC+(%0
M[MV3DG &%S_2G I#&G$2R(YAN'157R5;Y'W=!N/8<].F*-/)-QY,B^9*<AC(
MI4J,]3[XQVI8Y4L[B-(U1EA8$!%W$G^]M/.<D\#U%7)Y=03S'ED*%"^Q77)&
M1W/8'TK2]RBM=7!N)EV0%?G*/)%'O,H7G;_WUGD4^QD\Z]M'W1,IXG.ULAOF
MR,9PH^G6JCZ2LZK=+<C>FTKL0\\CYAVY'<]14NF7GFBX6_#F<NQ!SL(4'C!Z
M$$C^=%M!7-*!XS K"-8T(+L#P0/Z\4^&%59P)IGN [",RR97!'0<U23;/-&+
M>58I"#S(=Q(ZG"]^_-9DOFZCYEO9*%MX)E2:=U.V#.2Q(.,X Z^XH;%8W9))
M(%EE&+AFCPR <29SA?<@?K6-.MS8%$65U59@W*@^82.=QYQ@_P O>KV_R+1<
METR?W:N KOD8!(X&3@?04743B/>@D9&5!'Y8^^3WW<X Z9]Z: 2Y<VNE,PG_
M '\:9GFB/R9(PI!(YZUOQ(E\-2TJ>-;BW:&-HEDR4D5D['N-P[=*P;:U2*&6
M4Q+%$S@H#S@DG(VCC'7I6CH<;17,*1"0^7)*CKU 5\,"">B@J>/>IDM!7.<T
M423V)TF[BEAE@'ERH0<J-W3=W%:OE?8XVDG=!&O[N-%7.6.=N.Y('Y5)?ZC<
M3:A<&WBA6$3^46/RM\IP6;^]D\ 54L_LFH3RDW)BO5&8XI&V@9& V.@)Z>M/
MI=C+%M'*LD#1%FZJ6Z!1C[I!ZGCKTYJ66"WC06R(%=\; C#))^8D8_6H82TL
MGV8W*R%&+2.BY7:./O \L,5*"EZ(D4%6&"VX @KZYQGGOBEH BW,6Z4,9_,W
MKE#'ESD=@.HIUO.D\3R2?-&Q(*+'P<''(%,F,<,DD?RQR>82(U;#%3C.#U(S
M],T6JLENWE11V^WD%G^]SG:O;N:0R2*WB&I*/),K,DBSJF<-&1QN7OGWJC D
MOGI%;VJO%$A>-002PYY([,>WT-&I7-Y HEM,/,CQG;&W.<]&/K4UY#/!B^$-
MQ9M+<*/+=0=C=2ZL,X'7&1UI[!J68]'U+S1)&KI$Q+F.1ASD9Q@\]?>JJ+OO
M7BGQ'<%3YB,AWD?PACGMDX.,5;>SBN]-C=X7G>:1W-P92NT="RCOGM^-1_9V
M,-N96CDE@E*1$LPRG\(8XSVH3 :93#:8F8A@Q224Q@$G^'=CV_E5BW4Q1?;9
M%"PQN<+C/S#@&E*YW"?(C:-U96!*L,DX)Y_#O5&ZGV(D4*S+)E0D: ["!R3[
MCCDXI!T(98[=[>:>:Z!!D&]F XYR%4],DXSUKE[O4YO[4MYK:/9(@;<+?#D1
M<[B,]^O'M6_!H'B#7;A+J58H+9R=KRN<A<CY@@'MQFNEM]$\.>'9;9I$B-XY
M,<4MP=TCD]<?UXJN>P:(Q_AYI3)I-Q<W"?Z-.=L2/'MW(I.&P>>1@_A741:-
M8$P--'%+Y1#(6.0I[')Z\>M<5?>+=1U*[U&YT_\ <:=86C"$E?\ 6R.0B,?8
M'.!CM4VM7E[)X7T348;W8\CI!.<!1)DXR!T!X-0TVPLSVCBBDV^_Z45D2-G*
MBWD+_<"$M],5Y_9NTM_;W%[-$?(B9U9/NH.0,_[6TY.*] GR;>3"[CM.!Z\5
MQ=C]GO[);:2&/S+=E$B*PX8=P1VS^=5$"+5_+VK,@\\2D1LBD'(&3G\LYQ6A
M97L-[;F2$C",49?[I!Q6-JUG%#8R76GL(&D<EP=RYY.X@?WOYUF:PSSV=K<Q
M*+>-D >61?DD/'!'OZU:5T!OWFH(NM6MN57;'\\DC,/E# @<?UK7K#TZU?4X
MDO;T)\T(C78"&/())_(5N9R:E@'UK!MM$@MM3$6]WA\MF5"!P2?4=/3WK>JC
M'"#K=Q<>83M@2/9G@<DYH3 O#IC\*YV^'V/6EN;,75U'(V+VV0[XT]'P>C#C
M@5T+#<I&2,\9'6F0JD8:*.,*JGH!U]Z$[ $,\4ZEHG#8Z^H^H[5+5:8"*YCN
M0/\ IG)C^Z>A/T/\ZGW!L;6!YYP:0%#779=+,:[MTTBQ KU&35,6<6G&2VFE
ME$,P5_/#<F1>N?K5[5/.EM]EL5\R-A(Q/8 Y_.H)KFSU2V4H8I94C:4(X)P0
M/RR#BJ6P&A:W*7=NLT:,L;?=#+M.![=JFJO80K;:=;0)]U(E'Z58J1#)(UEC
M:.1=R,,$9ZBJ4&FR6RR117TXMV;*HWS-'Z@,><?6M"BBX%"=?LQA#3N;9FV2
M"0YY/3YCSC/'XU4-RND*R+;_ &ALXD%NN"&Q\JX)Y&.,YK89$E4I(JLC<,K#
M(-<U&Z7=M#"CRP323/#&V?X%.,_X&J6H$[C4+Y<.A(A42%>.9#T7'J!S^ J(
M69NM6NC?"-H;:4.\DG&Y<97MCC&3]:T+F[733;V5N@>5U9R7/W5')9O7)K'6
MXG@,5Y9H\HNU9IY&R\<A';!.4QZ4UJ,V+MI+R2$0$"U!'[T8()(XQ[#^=4$L
MX=.NT@NY$D@G1$WNN&5ESR3ZGU.*= 6A\RW@DC-O-\X.[+!R!TQZ'FFZI>V]
MU:R[(6-Q'A'\QC'CC/8C/?Z4_("+5C+^[MI0UM';D%B& CF4\!OP]/6K>D W
M\0\S<5M@8XYE."V>HS[8%4;M+K_A$;99[?S<R#*Y+[$/W3SR0./?I2:9J'E0
MW4,\FRVB)RRKG##[ZX')ST]:?019DMK-/.+ZI=2Q[@!#YP;)/X=_TQ6CX<N(
M8+RWM%CE@4LPC0H</U.<]ZQ; 6]]J#"WB2*%%RG.-O/7GO\ 6KVF6]U/XXM;
MV(O):[&4RD94@+C@CU-)K2S ] /2O''8Q>;,MS&J^8RR1O& ,XQU[@].E>QG
MI7C.HQ:%9Z>NHJ+MI+H.MO%%,P3.2.A[?I4092%9K:VNH)]I#!69!&<X*].<
M X)XQZU?A$5TLH<;[GA@'S]T_>/(Y ..>M95NK7.D*U^WE;'+*P.0O ^7..
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MF.^>]6[=1F?-+(-L4*%V#Y4*27SSZYW<FK%CJ$NFS,&C!61MTJL,'/ ZCO\
M6HK_ $Z_LD\G2K/+.2'U&X<,^".2,<(,<=JRXFM++3K:W_M1#<['<RJC20S,
MQ.-S '&#UIW3'8[%M2\^1XQ$CP%.,G#!N<]>.@JQX?BADU%9UF+@,1%N;)(
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M*K%XQA_]C'3/MCIQ4CW3./WL[>3%,3)\N 2WW2<#D C'\ZEAN9[:%_+>%6R
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M@I(><CV..?>H8%B34FLYF-I(AP\3L7B<ALX7.<$#G'>I+DQI;P/&79C\PD#
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MY;WGVD22#[-"5C 8<!PP)88Y)'3TZU,GT!*Y-X?ALX+2_P!4M'+!@4#8P@
M.%]L_P JJS"%)C& /+54)+C[G?(Q[U?GMQ8>$8+5BI$C*KO&<+\QSGCMTK.N
M_)4M)$K*I(#!FW$CZ]OK0NX+<C>YG^U?9TA0[ 9'<MR 1RQQDY.,=.@I[?9I
M94$VY&C;=M4YSQQCIZU")8);B*:&)-A#/)-O)'' 1N[=CZ]:F0HUWRH421AR
MS1[>3T%,8V\\HS0B22;J&0Q1[A'QC)Y'X58>-A+("X%OP0'Y]_R]NE.\ME?]
MTZB-P=R  Y)Z&G?NKA54M\ZD(Q(P.?:CKJ!5:\C<Q,K+@OPHRO'KZ5+,\?WG
M=) OS;E;&*A@8Q^9&CR0MG!"892>?X6&#^'-5S9_9I9+MI8I91P%5%B7GI\O
M S]:8%F*Y1VA)#GS&(7=\I'88'7!^E),MK*MO*)5\S 95 VDMGCY?49Q^521
MR8VM-&D08%@X8,0>,?[W/%-; 5LHKR L ZJ,LW4[0/N],<?G2] (5+13+"-Z
M-'C!) W<]#[GO3C;_:71(_,1P_\ JT7!5NH_+@U3F"07"3)(8S.%4M)\RJP[
M8]<Y[]JU'F;>OD2I+((R51#GD_Y_"@"C<3[]2FGF8N[C:PP2I ^[]#D]/4TM
M]+%$S12*"&<;69=W(()X_P ]*ED221?)PFV1=S*3@]@H!]:KZF^^YCMH/D0N
MQ\P DD<94'LV0?PIMC2&)!/<RB(S)#9N T<FP)R>=N#TW#O_ "J11&]FZ&.(
M)@*2\NYB,G (]NV.Q% $EZS)$(XV6)3('?!0 <@>IZ<GTI[K$/,MXH9#,\0\
MV4N/F<GGCCH/<5(,=]HA<Q(LCS*"R._;Y0<Y;KZ4DBY!>; 0'*8'/O\ 7IFE
MMBI9B JHN9&^;!//''N.?QJ:6.+:=\9V$;1(&*X)QD@^M/H(JR&X,<:HS/#&
M<EFQGGH<'MTJ6&4V]Y'(<+))\Q=1@, >F.A [U/($23$L3%B=W[XD*WX^AZF
MG6*;I29UC@$K;I%7E7'H/\CK1T!GJV:*6BL2"*Y9DM967[P1B/KBO*[*"XUF
M2UN!F6:-F=I"2N,= V>N3V%>K2H)('1ONLI!_*O-O]"74%AT^SDGV#:%CEPF
MX9[_ $SG-7 "62&T693]FE>17'GR.X&&^AZ+[KZ4V6TU^VOS_9TD:Z>_[S:6
M#-GN 3QR<<U;T^SB$HO9-JI!$ZLP)VL23D#/55!(J73M*2&VC=)YX]PW!$?"
M@'D#!]JJX&E;+*EM$MQ())@HWN!@%N]2TE+4"$HHHH *6BB@9GW,*W6L6:LH
M9;96F8'LQX7^M:%9D5R;>1Y9(I)4N9/DFC&1C^$$=14S:M8QS&&6<12A=Q20
M%2!3L!=/W3QGCIZUSUI$L-M/+#)(CO&S21^7M* $X4'H,5O^8@4,74*QP"3P
M:R[K5O+GFM[2W6X:/F3)VH/[PSW/2A7 Y*]@<Z4\=K&\TTZJB!3DL6Z9/YY-
M=))=W6EZ+;6Y@?SH85$S11DJH QP>E9E_-=JMQ<Z?/''.7_=QY7Y,8(! ['H
M:AMO%U_>W,=K9V(2]9<W7FL2D+\@*![XS[U<KL:V-/[#%!H$M_&G^DLIDA:8
M"4QD]-H8@$\GKZUCZ3 9XTV,SHY=I"XV-_M%N>I.1Z=*OW^DWFH0DZQ?&6/A
MA;C")QT.T')Y]ZMQ3:; H1PVU2"-HP"0.!^'Y4*Z"^@^R,T,-VL<(O%1]L4>
MT#Y5'.6/4YS^5:;K<3*"K1VSXRK8#L.G_P"HUEC5X(T\FPM< \GJ"??CJ:@D
M%W<RLTI5$< ,0V./I^5*Q)=EU2TL 8+.-9)223CH6[^YJJ89;YA-J,N0@/[J
M,=/KZ5-%:1VVT*-S,<&0@9__ %>U.RLA;CYEX//6CT L.QE7:PR!RH[ T]?*
M?3G%R<QIR-_'N :A2.661<!=P7^(] >N:S-6NM[>7&6,4&1U&'([X'^>*$K@
M4Y[KR(C*VQ3@9 'WCZ =>U68)4^P^=;VCWC2#>Z0C/E@\8&.K;3^%6]#CC,+
MSSVP8>:6C=T&$ [J>IZGMZUJVMM;K;K-]GAB_B'E=AVY'M5-I: 5=&M9=-A$
M+F=_..]8W8-Y(Z8S^I[9K=T]RVH[-C +T8]&R.U8K7<%]<6LD+9C20D2*^-W
M!R,>F0.O%:FAW8O95D"[=KLA'TK-]P.B->2:A=0S0;!"LR<A6<84_P"UCN/?
MK7K9Z5XZML+N66W68P6\#%7!BW.7_A*]CQZ^@%$"D01WUO!-<3Y1@MLIC0C+
M$YZD=!CD?C5I]0E6W2ZMH(K2X?:TT]Q+D%3SL![ D#.*N6VFZ4MY;B^NYGN
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M3D#O2$>E4445B217 S:RCCE#U^E<+I-AYB>>RQPQ-QY<)'S8/&XCC'M7>O\
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MH99MYN':*6)PQ1][#&<=AW''%)*UK&;B*201@@[CYF"H]<YXIQFB24PJ478
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HM2VW$B85),\C/\1)STKTG8G]Q>N>E&Q/[HX.>G>ES V.HHHJ1'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>pirs20221231_10kimg008.jpg
<TEXT>
begin 644 pirs20221231_10kimg008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #: ?,# 2(  A$! Q$!_\0
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M'Q$M]3T^0WI\3:D=>O##%HNEZ>Y15D&/,++R'4G))/0<5F^)=2UR^U#QE?\
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M>1EQ ) .1W&*T+?XH:06VRZO]G;NM[9O'C\1Q1S2OL+V>FC/2*KVEQ]IB9\
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M=]Q'XGG\^:J^(;$7NG@&146,[F+,%&",'D@@=:NZ8)%T^%7\KA<#RR",=N@
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MR*\*GLC-\$I)EY:+5+B3Z9D=?\*]FT2\%_H.GWBG(GMHY,_50:E!T-"BBBJ
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MF&#\KO<0D\?[2FG>78JT>YZI'(DT2R(<HX#*?4&GUY7:>(O%,-M$BG19%5
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MA/26,_1A5?3F#02$'@S/_P"A&L;[!J@/S:1H[?[L[K_[)5:UMM2:$DZ):O\
M.P^2_9<8)_V>E'NV%[UT=;FJC'_B;QC_ *8-_,5A?9[_ /Z $@]=FHC^M0YU
M&*\54T>_C81DY2\C8]?<]*:4>X-R['7"JNI?\>$OX?S%80U/7XUPVF71P<?<
MC/'KP_6H;W6=5^RN)M*O"@(R%@&3R/\ :I1CKN$I:;'745SG_"5R*?WGA[6E
M],6V[^1I1XPMOX]+UE,],V$G]!4\K*YD;5G(\L;ESDB1E''8&K%<=:ZQI=PC
MR3W&HQJ97VQ_9Y4"\]\+UJ?^TO#H^]J%TI'=A*,?I5-1ON3%RML=$LS&^>'
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M'+YG,GQ5;X/^F6JD=FCE'_LM=(AW1JV0<C/%.HI-W&E8****0PHHHH ****
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MY57)^7OT[]^U &A14/ES_P#/?_QP4>7/_P ]_P#QP4 3&J#J?[=B;M]G<?\
MCPJQY<__ #W_ /'!43HRW,>;F,2,"%!4;B/:DU<:+E%0^7/_ ,]__'!1Y<__
M #W_ /'!3$345#Y<_P#SW_\ '!44DHB8K)?1(P7<0P ./7KTH MT52$V.'OX
M0P(! QWZ=^]3>7/_ ,]__'!0!/14/ES_ //?_P <%'ES_P#/?_QP4 3452:<
M+S_:$( &YL[>%Z9Z^M2(7D+!+M&*'#!5!P?>@"S14/ES_P#/?_QP4>7/_P ]
M_P#QP4 3455=S$0)+Q$+ D!@!G'6HQ< !B^H0 <,"-OW3T/7O0!>HJ#RYO\
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M#,EVB#!/S*!P.M1B< '??P@@C^[T/W>_>@"[14/ES_\ /?\ \<%'ES_\]_\
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M025(/X8/YT 9\?A-85C$=V3Y1W)OB!^;W]5QV]>:T-)T9=)WA)C(I4(N5P<
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MVS;Y?^K&[9G<>?[V?XO3BM;3-._LZV:+S!(6?<2%VCH!P/H!5ZBBX$%W UQ
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MU/4[FV-N(8PLDC$>7*A.0!ZCI_,G%;%% VU;8YRQUJ^FN(TFM\KY;%ML9&[
M)W*?3( ]>:BE\0:IO(33=H*+MRK-AMV3D\<;?U%=113N2)58W4H) LIS@]<K
M_C5JC%2TWL,J?:Y2<?8I_P U_P :RK[5M2MKN6-+5)%63$8",?,&%(7/8\DY
MZ<5T%%"NMP9SNGZS?W%ZD4L"F,@G<L3+O 4G<,] #\N/QJ"7Q#JGF,(],VYC
M4KD,V&)R<G XV9_$5U-%5<04444AA1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
544 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>pirs20221231_10kimg009.jpg
<TEXT>
begin 644 pirs20221231_10kimg009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #> <$# 2(  A$! Q$!_\0
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MHH **0L%!+$ #DD]J7- !13?,3;NWKMSC.>*=0 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%97VS6/^@1%_X&#_ .)H^V:Q_P! B+_P,'_Q-'*_Z8<R-6BLK[9K'_0(B_\
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M]9H 1E5U*LH92,$$9!I-B9SM7(&.G;TIU% #/*C\L1^6FP=%VC _"N0^*_\
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M9&S16-_:6H?\\;7_ +^-_A1_:6H?\\;7_OXW^%'LY!S(V:*QO[2U#_GC:_\
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M2L]L)-S0MG@'IU'/3O53I2Y?:Q^%@GT.DHHHK 84444 %%%% !1110 4444
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M=!3I45%RA.]MDUN=W14<-Q#<IO@FCE7.-R,&&?PJ2LSG"BBB@ HHHH ****
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M+W;Z>;'0]+MQ!=I+<#R/];$ <IQZDCKZ5H_\*U\$_P#0L:9_WX%>77FI2?\
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M G(^T1RNPF<I_&2H&21QCM0!ZG_PK7P3_P!"OIG_ 'X%'_"M?!/_ $*^F?\
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MXMXI[.2V20B"2Y\^WC23)&0N)<^HR1S0!Z717-^%[G5IM0UV'6)87F@ND5!
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4B@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>rpv4.jpg
<TEXT>
begin 644 rpv4.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#T17AI9@  34T *@    @ !0$2  ,
M   !  $   $[  (    *   (5H=I  0    !   (8)R=  $    4   0V.H<
M  <   @,    2@     <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M     $UI:V4@4F5I9   !9 #  (    4   0KI $  (    4   0PI*1  (
M   #.#,  )*2  (    #.#,  .H<  <   @,   (H@     <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                 #(P,C,Z,#,Z,CD@,3$Z-#,Z,C
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M# P,# P,# P,# S_P  1" $A NX# 2(  A$! Q$!_\0 'P   04! 0$! 0$
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M2OA3\1_#/PXU#3)/$C77Q0\67G@G3-*DTMH]1LM4LS,+N*[A+?N%A\AV=F)
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M>T_Y^K;_ +_#_&C^V;4!C]JM\+C)\U<#.<9Y[X/Y'TI!<O%<TFP52.L6N?\
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M9#<?;?*GO0D,C/;Q,\D84;@,C)]8P_=?@3[.IV9\\?8%'\4W_?Y_\:7["O\
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M(!C&1D^L4=^9?@3[.IV9X%]A7^]-_P!_7_QIOV12/O3_ /?U_P#&O?\ 1?\
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MS_Q6WB#_ +"]]_Z42U1)R:(Q5E9=$*4G<A^QKC[TW_?Y_P#&E^QJ1]Z;_O\
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M1<9*ZV,Y.2=F0M:J@SNGSV_>O_C7]'7_  :/0J/^";'B+[W_ "/%^/F8L?\
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M3WWD;D<-*^1(68+\V2",?KUXY.-8C_ZY#^9KXZU__@E;:R?%WQ[XP\,_'O\
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MBO _V+/VJ/'WQ2_;GT_PEX@\13ZAX=F_9\\,>,GLVAC57U>[N62XNLA0VYU
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M$FD^,+3Q-:""60QFUN);>-%@O8FQOB4RJ,\2'%3RS*]T^HCX+T?_ * NA_\
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MQ?X;Z3=0Z]/HT&H^%?%$6J:#KB(L;I<VLCL)8R1(08)U252A)7:RD_/>E?\
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M\/K=?C9\8+/Q/X$\.W/@>;Q587%K#JOB+PU/(LATJ[+1.I5-B!)E"R+L4C)
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M&1_Q:_QMT_Z!;UI&C02:4]_0SE4JO7E/0OV?'NH?!-MX/7XFZ3>?$3P]\/\
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M^7-OHMU&8IM3E4@@RCJL [KU<X' R&BMBJ5*/->_H53P\YOE2L<I_P $?O\
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M/$*3V<=U'>V$#0M'<VFZ3R,I*9?,AG_=_(-WG/['O_!2/XC?$_P'\+],\1>
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M_?N+_P")K2!S14\PS-_L6Z_Z"EY_W[B_^)H_L6Z_Z"EY_P!^XO\ XFM*BCF
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MD*"0J@$ECP "3BML/155M,RJ5.0_J$_X? _LPC_FY3P5_P"!L7_Q%*/^"O\
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MIQPD&[)_D+ZQ+L?TSC_@KW^S&?\ FY+P7_X&Q?\ Q%*/^"O/[,A_YN1\%_\
M@;%_\17\N4EK%;?ZUHD^7(W,%('<XI\<-NI^]#TSG(QCU^@_SVS7U*/?\A?6
MI=C^HL?\%>/V9?\ HY#P9_X&Q?\ Q% _X*[_ +,I_P";D/!G_@;%_P#&Z_EV
M6.WD)^:'ID\@\>O%;GPT^&VH?%SQQIOAWP[:0ZAK&J%_LT'FH@<)$\SG<3@
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M+?B'\$_^%9_#N.&SNK_1M!NY-=\96,$7E0V\L<S>39':$+21,Y)48XR#]?7
MS=2?[Q_F:8%P??UJN:PK'@4?[+'B!?\ @I\/C8UWH[>$_P#A6#^"6L?,D^W-
M>-J,5UO*[=OD^6A&=V[<1\I%?)/QO_X(R_%/Q%\%]8^!_A^\^ _C+X+W.MZA
MKOAB]\<Z?J/]O> )KWS3((([5Q#=-$9Y6AD=D*E_F#!0*_3/8/\ (H*[O_KT
M<[%RH^$_AY_P1>\-V'[2?AO4?'^E^!/BC\-?!_PBTSX?Z=9Z[IBSW4FI6ETK
MM>?9W5HHE:'</E<L-VWIU^X= \/V/A71++3-+L[?3]-TV!+6TM;>,1PVT2*%
M2-%'"JJ@  = *ME,^OI2T2E?5E;!1114@.M_^/B/_>%?*O\ P6K\):QX_P#^
M"57QJT7P_I&K:]K=_HT,=IIVF6DEW=W1^V0$B.*,%V(4$\#.,]A7U5;_ /'S
M'_O"H825/#,OT-"MN!^7?@O]BCXR?';]OW]K"ST/XC>+/@CX1\6:+X1TV^NO
M^$*@U"/Q3"?#-I;SI;W%UM$;PD2QL8B2K$AL%<5N)_P3=U[PS_P4.\*^ _AK
MX]^+7PG\$?#_ . &FZ#9^+=#LX96U*2'6;PFSFN)X7@,N'$QC4!AN!P%K]*R
MF5Q2XRNW+%?0G_/I5^T9/*?,_A3_ ()@>#=,_:BT'XQ:YXD\:>+/'6AV5E#]
MJO\ 4'CCO;FVL(K-;V2*)EC\UPDDC*J",M/(-N#S]+ <GTZ8ST%. P:,8J>:
MY04444@"BBB@ HHHH TM"_Y!<G^\W\J_DE^"&HS>%/VE/[4M_B)?_">6PU>_
MG'BFQ@N+BYTW;-*?W<4!5Y&?[@4D*2WS'&:_K:T,XTB4_P"TU?Q_>(KJS'BO
M6MUU;Y75+P\2C@_:)/>O0R]7<CDQ5U9H^OK3]J_PS\6/VH_ =S\-[[1/A;XT
MT*SU>UD^*_BS1--M7\7W$]G+#%'>6%O&MC9B4%HQ<.9&4S;G)P<]D/$&@:E\
M*#\.O%^O?">/X]^.OAQK^AZMK6EZCIMOHD4/]IVMWHUA>WMH%L6O7CBO5,JD
M!4EB65\D8^!OM5BXP;FU*XQ_K!3XY+-DVK-:[>V&7'U^O4YZY)KN^K+34P]L
MT?9<_P <]2^"GC;X&?"OPOK?PIU35/#W@_3M%\3W^M20ZIX<T74TUN[UBWNH
M[F.:..2;3_/5MZR-&TFY,258^+__  I[]HK]F_Q?XL:;2XIO"UEK6E^%YKSQ
M+]GUK2FMKFV;38TTL,HNCJ\L^I7]Y<&-R)[B0;T6-%KXQA%N(U59H54=%60*
MH_ ''8?3%2QVL,GS&2VW#H2ZY'.>M-8:.]R?;2MJ?1_[(OB_7/"_[%_Q4L_A
MCXXT#X8_%ZX\1:9=/KVLZU;:''=:!':W/FVT=Y<8B*I<[)IK<-NFC"_)(J$5
M]8?\%'?CC=^#_B9\1O!^G_$ZS\%KXN^.UC8>*3#.DP.BR^&K"*>6YL\EY;$,
M2S1,/+DVA#G&*^!?@E^T7XP^ 5GJ5IX:UG0UTW5Y[>[O--U;1[#6["6XMV9K
M>Y%O>12QI/&6;;*BAU#'FN;\1ZEJ'Q \6:MKVN:S)K&MZ]>2W^I:A<W'F7%]
M/*Q>21V[DL3QT48    ">%YIW;T)]LE'0_532/BQX=MO'?@.3Q=\3;?6;WPW
M\;=$U;3[SQ)\3M$UUX=."W<4][:6]BD<.EV+@QC[.';:-NY4V@GPW]F#]LGQ
M!XS\"?"[7_%/Q7AA\?6'Q8\0:/:ZE?ZW!9W>EZ'=Z'*(X-V5\G33>+;;0P$"
M.D9&W:*^%8?"UL =LENN[L&4 ].W3L*MQ>%K5_O2VY[8+KR/0^OX^I]336!C
MU8/%+0^E?^"=OQ*\*_"#_@H%\']5U37O'.A_$2'Q%+;^//$VL>+-/FT#4/,M
MKC[6RSQJ&:*6<1L'DF='P#DD@CT#]FWQ@?B[?_LO_%+Q%\2O"8E\$^ =;T7Q
M7=^(O%-O;ZW'JTHU!DB>&5Q/(T_VB,B0 IRVY@>*^-;;PM:K'M$UMM]-X_S_
M /7JW#X4M&=6\RUW@8W?*&QZ9_ITXJI8.+V9,<0D?6^G_M)S:OX<\(?#?5/&
MUG-\+KK]EF?3]5\/C48!I\VM1Z+(UO'*.@U!+A(1%D^<CHBKC@5VOQ<^*<^N
M?"[XZ3R?$CP7?? ;Q!X+T6W\!^$;?7[,W5FL=_I;SVT&G BXMYDCBN_/&U3*
MQ#?.0&7XA@\*VC?\MK<\Y/SC/USGK[BKL/A.S$AD$ENKM_$) &_.CZG&ZU[!
M]:MLC]$/C5^T'X!O?B7>S>,I/!_B3X0WGQ"T/4/"7VCXB6OB"/2;."[WK/IF
MBP68DTVV2V CNH)Y$0QL5Q(^#7B_Q^^(7BK2_P!GCP[-\9/'GAGXN:MI?QE3
M7[.ST7Q?:7E['IB6IV2K);^88X/-7,,+CY -A\L, /F.#PG:A]PFM=YY+"0;
MC]3U/XU<M/"5JK;EEM0W3(9=WY]?;Z<=*J.!2W?X \4WT.>^/]_I_P 6/CGX
MO\3:'I=UH^E^(M8NM2@M;BY^T2KYTK2%F;:N"V[)49"] S  US$7@EFZA_K7
MJT7A2W./WUOQ_MBK<'A6WS_K(#_P,5U1IV21SRJ-NYY-'X$9G^Z]7;?P!N_@
M/Y5ZS!X3MR?]9#[?,*NV_A.W)_UD(_X$/\:KV9+DV>2P> !G[I_*KUOX!^[\
MC?E7JZ>%8,\20_F/\:N6_A2W/_+2WX]2*M01.IY/#X""C[@X]JN0>!!_=]ON
MUZQ%X5MQ_P M(?S%7(/"-N?^6D///WA3]F&IY/#X$_V6_*KD'@/<?NG\J]9A
M\)6^WY9H/;D"K=OX4AQ_K(O^^A3Y?(7,>3V_@#_8_'%7(? (5?N_I7K,'A*#
M _>0?]]#_&K<'A"W(YDA_!A_C2Y?(BYY/#X$4?PGCT'-?0__  30^#?Q-U[]
MK/1;[X5W3:1JVDIOU74YT9["VT]W7S(KE1PZR[1MBSN+)N7&PN-W]FG]CW7O
MVHOB%#H'AV-4A7$FH:E(N;?3(<\NY'5CT5!RQ]!EA^PW[.'[-_A?]F'X:6GA
MGPO9BWMXSYMU<L!]HU"<C#32L/O,0/H!@#I7G9ABHTX^S5FV=V#P\IOG>B.\
MM%*K\V-W\1 P"?8=A[5-35C"&G5\Z>T%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% 'G_Q&EOHO$"FWAMI4:(<
MO*4;J>V#^=8/VG5O^?2R_P# AO\ XFNJ\=<ZO'_UR'\S7S+XQ_X*G_LZ_#OX
MQ7WP_P!?^+OA/1O&6FZFNCW6FWGG1-;7;%5$+R,GE@DNHR6"_,/FQDU40/</
MM.K?\^EE_P"!#?\ Q-'VG5O^?2R_\"&_^)KPOXF_\%6_V</@S\4]6\$^+/C!
MX3T#Q1H=V+'4+"Z6Y#64Q (61Q%L7A@=Q;;@YKH/CM_P4)^!_P"S'XFTC1_'
MWQ2\(^%]2UVWCO;*"ZNF8S6\AQ'/NC5E2)B1M=RJD<YQR+5^P'JGVG5O^?2R
M_P# AO\ XFC[3JW_ #Z67_@0W_Q-6K.]CU&TAN+:6"XM[A%DAEA<21S(P!5E
M(X*D$$$<$$&O/+W]K[X7Z;H'CS5;CQQX?CTWX77RZ7XLN3(WE:)=MLVV\AV_
M-(QDC4*FXEG50"QQ2U8'<_:=6_Y]++_P(;_XFC[3JW_/I9?^!#?_ !->:WO[
M=/P?TWX)V/Q$F^(6@CP;JVH/I%G?JLSM<WJ.Z26JP!#.9T*/NC\O<@4D@8KT
M/P/XZT?XF^#M+\1>'M4L=<T+6K=+NPU"SE$MO>1.,AT8=0>?U'8T7TN!/]IU
M;_GTLO\ P(;_ .)H^TZM_P ^EE_X$-_\36BHQ2U/,!F_:=6_Y]++_P "&_\
MB:/M.K?\^EE_X$-_\36E11S 9OVG5O\ GTLO_ AO_B:/M.K?\^EE_P"!#?\
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M&A C293_ '68BOY3]>_X*H_M/Q>*M8CC^/OQ0CCBU&[C1%U4!459Y%50-O0
M ?A6E&C*HWRF=2HHJ[/Z?A\!/#0_YIS\/A_W#X/_ (S0/@+X:'_-.?A__P""
M^'_XS7\O*_\ !5/]J #G]H#XI?\ @V'_ ,34B?\ !5']IYC_ ,E^^*1_[BH_
M^)KI^IS[HR^M0[']0G_"AO#0_P":=_#_ /\ !?#_ /&:4? CPV.GP[\ ?AI\
M/_QFOY?T_P""I?[3SC_DOOQ0_P#!L/\ XFGI_P %2OVGAG_B_GQ0_P#!L/\
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M_!2;]IJ5?^2Z?$S_ ,&O_P!C3_L^J_M+\0^M4S^E4?"717Z>!_ Y'_7K%_\
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M / >/_XU2CX9V"_\R;X/_P"_$?\ \:KMZ*.9CY4<3_PK6Q_Z$WPC_P!^8_\
MXW0/AS9Y_P"1/\(_]^4_^-UVU%',PY5V.8T;0[CPXDB:?H>AZ?'(VZ1;9_*5
MSTR0L8R:OBZUH?\ +C8?^!+?_$5L44K]Q[&/]LUS_GQL/_ EO_B*/MFN?\^-
MA_X$M_\ $5L44 8_VS7/^?&P_P# EO\ XBC[9KG_ #XV'_@2W_Q%;%% &/\
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MSXP?M<>&_$/Q \3?#WX1^,OBN9-4\/+X1M6E\7V2P6,KS6VHW"^;%&QB\L/
M&4&,D')-?J)XZ&=7C_ZXC^9K'=V<+N9B%&%RQ^7Z5496%RW/R%_:1_8W^,WC
M!OVP/$G@^Z^)%OX3C\?V_P#:OPXL;5+>'XC^'AIULEY]BGDA,S7 B4HKPN0W
ME%<%R#73?MFZ'_8OCR;7/ WPL_:&\):;XM^&VD:-X3U#P?X6'B;3?%MG';,B
M:'X@TB]A;[(]ON6)O,V,R%B3E:_5*2:3<AWN?+'R?,?E^GI^% NIE+,)I5:3
M[QW'YOKZU?M97NB?9GR;!-^U]I/P.TFW\+^%/@/X<O\ _A7UM;VVF3W5U9WN
MA^(6M41E"HCV:6UO(2RKSD1A,YZ?%_PY_8]^)'PM^#?QBT&U^%WBC3]'\#_&
M'P;XUN8QJ$FNZCXC@LOLSZC+!L@0W\G+W;/$&WR!XD0R* W[ K'\O\L]J<\D
MF$_>/^[^YR?D^E+VC[!RL_,CP/X(\5> _CIX7_:"U+P3\0%^&LG[07C#QD;>
M+PO>SZYI^D:CH0TNTU)](2(WZ)-=1,=I@\Q(Y$E9 K\_5?\ P2?^$GB;X(?\
M$_\ X?>'_&&FWNC:\D=Y?S:?>*$N=/CN;R:>&&502$=8I5RF<J20<$5]%I/(
M9_,\R3S/[VXY_/K1M.[KQU.:'.ZL"BTQ5/'\Z6D7I2UF6%%%% !1110 'I2I
M_K5_WQ_.D/2E3_6K_OC^= &%^UG\0/&?PH_9^\9^)OA[X/C^(/C30K!KW2_#
M;736IUEXW#/"CJK'S#&)"B@$NX51]ZOS<^(WB3Q[^T+8?M>?&S1O@)\6)/#W
MCCPCX.\)V'AW7[&]T/5-4:UGN6U.1+>V=;Z6WMXYT+"+:TZET3=\V/UCO!NN
M'[_,?YFFM-*T@9F<LO0YZ?2JB[:DN[/PUU;X-?$:S_9P^/6EZ;X/\:6_PTU#
MXG^#?$&K^&]#\':CX-B\3>%_)<:E#I&G76)HP\R0%H@RSR)"Q=%W$'*N?A]#
MK-K^U;IWPY^&OQ2\-?#6T\5_#2XUOP'<7$FG^))_"X^VR7UA%%)/YJ"6-2ZV
MN_?L.-J@X'[7_'[X">$/VH_A??>"OB%X?LO%GA?4GBEGL+S=M,D3B2.164AT
M='56#*0W'7!.?,M)_P""7/[/^C_ OQ!\-HOA;H4W@WQ5J$>JZO9W4D]S+?WD
M8 BG>XDD,WF(  K;\J,XQFM/:+JB>0_);5O@MKWCV+]JS2?@C\._BAX1\ 6_
MBOX=W.M>"KFPG?Q"WAF.UU.2ZM4T]IQ.R&5[:;[%YJ2-"&7"Y*5Z!>?LO>)]
M,_8T\+S0^!?CMXD_9Y3XR1:_XH^'<GA270;]]#^R[&^P:2MY<7C:=]LVR&"1
ME9B&<+M;>/U<_9G_ &1OAW^QYX<U+2_AOX7M?#-OK5W]OU*1)Y;BYU"<+M$D
MTTSO)(0O W,<#/3->D;Y ^_=)OS][=\WYU/M'V&H'YB_\$S_ ()_%O0/!'[0
M,?P3TFZ^ ,.K?%>+4M'M/BKX5OKR631#I"(B)$\RR;A-Y1#>8X18VC)R,#U?
MQ]^S*OP__P""RW[/?BCPYX(CM;?4_#?B_4O&FOZ3H[1V=WJT]M OG74P!P\A
M5@BR.2%X7I7W+O:;EF9F P"23BB+<L17+*K'E<\&ASZE^0ZU.;F/_KH*^8_^
M"QOA'6/'7_!+WXU:/X=TO5M:UR_T#R[*RTRUDNKR>3[1"1Y<4:L[, ,\#-?3
MUL/](C_WA44!9&W*Q5AT(/(J$Q,_.+]G_P"#^F_\$T/VW?B5X@\+^ ?B6OPU
M7X*Z)K>JVFBV%]K$FN:X+Z1)FC1V/G7[1E&=0P;&6; )S\Y_\%7O@!K'CKXK
M_M6WGC3X)?&SXF>*?&WA:QD^#&O^'=*O;W3- L$L-MU:N('"6\BS?ZZ*1&>7
M^Z00S?M8KR1D;9&&#N')X/3-",\?W9'7G/!/)]:?M+$\IX_^R5\3UUSPC8^"
M)M!\8:3K'@'PWH$%_=:IHTMG87LD^FPR;;2=\+<-']R4*,QOE3TKU_=A:&=F
M**S,P7)&6-*?>IW+"BBB@ HHHH **** -+03_P 2F;W+5_'/XAL/^*LUK<.N
MJ7OM_P O$E?V,:$?^)5)]6K^0#Q+8Y\4ZU_V%+P_^3$E>EE^[./&-I*Q@+9+
M[_Y_&I8K'[I^M:2:?G'-31607H.GM7J<J.&[,Q++!Q@T]+%L=#6M%IDDOW5R
M/:K,/A^9Q]TU7*+F,5=/W#IC^M2+IZJ!726GA.27UW>F*TK3P-O7YE;\J?*E
ML+F./BL/ESM^[QQWJPFENP&U6/X=:[RS\ CLE:5EX" V_*V,U?*1S'G,.@32
M+_JVJ_;^$YG?[N.]>G6O@%2/]7^E:MGX" _A;V&*J,&]A.IV/*[7P/(^/E:M
M2U\ ;B/W?;GBO5;7P$IQ^[(^@K5M? :[<;6Z57LF3[1GE=CX!&U?W??TK3L_
M ''^KKU6T\ C:ORMU]*U+3P'C^#J?[M4J=]S-RU/*[/P#EN$(Y!^7A@>V".1
MC&<CI^M?L9_P1A_X*'>)OCI:M\,?'5OJ^MZYX?L//L?$:V[2K<6J841WK@82
M8<!9&QYN""=_WOA/]G+]D+Q'^TU\2K?PSX:ME:;"RWEY*A-MID!./.EQ_#P0
M%ZL00.Y'[0?LD_LE>%_V0/A;#X9\,VXD9\2ZCJ4RC[5JT^.99".@_NJ.$& .
MY/E9G4I*'*]7^1Z&!A-OFZ'JD)W1J?X3S4E-1=JTZO"/6"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MH&?_ ,)7;_\ /'4/_ &;_P")H_X2J _\LM1_\ )O_B:T/*/K1Y1]:/= S_\
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M^6]3+_P=#?M1MTT/X!GU_P"*4U;_ .6]'+BN_P")/^S>1]P1?\&_GPKA4_\
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MW_Q-'_";6G_/'4O_  !F_P#B:UO+_P!IOSH\K/=OSHYD!D_\)K:_\\-3_P#
M";_XFC_A-K7_ )XZE_X S?\ Q-:WE8[M^='DC_:_.CF0&3_PFUK_ ,\=2_\
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M\=2_\ 9O_B:/^$VM/^>.I?\ @#-_\36MY(_VOSH,>?XF_.CF0&3_ ,)K:_\
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M_P"05)_O-_(U_')X@T\GQ3K77_D*WO\ Z42U_8WH)_XE<O\ O-7\?FN63?\
M"4ZU_P!A6]_]*)*]++M7(X\9*R1B0V(W'/J:LPV62>!T[U?2R  R.:M6VEM,
M_P J-\PZUZO*</-J9\.GX;VVBK4%@JN/\*VK#PE),1\O4]JW](\";B-R8_\
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M13?P32EV4974^6(VXUIT^:YZ&7Y>\3S>\E9:7ZO^5>J3/T[DGBC7<TBJOJ2
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MHN/^0+HW_@!#_P#$T?\ "%Z*3_R!=&_\ (?_ (FBT>[ TMLG_/*3\J7;(?\
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MJ4Z=1<M35>>J!5)WNFS<6-8AA8\ #C"]*?&6]/SK&7X<>'B/^0#HO_@#%_\
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MZS;*HCUEK9+.X@MW >7]Y=0AU!!"DL"""HZC7/\ @E9\,Y+[23X:U#QQ\/\
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MH7[6GQGD_9O_ &8OBE\1H=/CU:;X>^$M7\31V$DIA2^:RLYKE8BX!*AS&%)
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M)?ZC#\NT)"Z*H_-35+_A4UO_ -!/6/\ OY%_\10BCGMX]11O'J*Z'_A4UO\
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MK[A1N%9'_"*S_P#0:U;_ +ZC_P#B*/\ A%9_^@UJW_?4?_Q% &ON%&X5D?\
M"*S_ /0:U;_OJ/\ ^(H_X16?_H-:M_WU'_\ $4 :^X4;A61_PBL__0:U;_OJ
M/_XBC_A%9_\ H-:M_P!]1_\ Q% &ON%&X5D?\(K/_P!!K5O^^H__ (BC_A%9
M_P#H-:M_WU'_ /$4 :^X4;A61_PBL_\ T&M6_P"^H_\ XBC_ (16?_H-:M_W
MU'_\10!K[A1N%9'_  BL_P#T&M6_[ZC_ /B*/^$5G_Z#6K?]]1__ !% &ON%
M&X5D?\(K/_T&M6_[ZC_^(H_X16?_ *#6K?\ ?4?_ ,10!K[A1N%9'_"*S_\
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M6_[ZC_\ B* *.H_"?P[K&OG5+O1]/N-08AS-)#N)8&,AL=-W[J/YL9(C49P
M*Q;_ /9K\&WLMC(FB6-K)I[PE'@3:TB1-O6)R<EH]V"1WVJ.@Q74?\(K/_T&
MM6_[ZC_^(H_X16?_ *#6K?\ ?4?_ ,10!HVENEG L4:I''&-J*HVJH P !V
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M_",^&=<U*XU25+F2S-[H&H:=:ZLMN^R=K.XN((X;L(>28'?Y?F^[S7B?PC^
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MC\++F'P+X=\#^&H)[*V\7Z1<O/K6I1MO:"ZALYH3#;7H9U>665IU:5)'"$2
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MQ1-MQ%>R1@Y4;) JR'C8^ 0IP6^(? '[,GQ#\0^$/#]YH/PG\07WB35[O4M
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M+PC\;/B9XWG\-V7@/PHZ'1=/LY9&N=-%IIT<FH0W4FSEA=-(@95)^0X7 7<
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M;[=/IT#R)&<^<&4<E* /6_&'_!,+P+J?BOPO:QV%Q?\ A6+4I-5\0C6]=O\
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M5-L$5O-#,CG[VP &OK7_  3$U30O@MJ&E:;IWP_\::UOT?3A_P )!/>V9O\
M2;&W"BWBU"/SKFPG%UFX60+< ^6(W5@Y9/3KC]C[5M>_9^^#W@/Q!)X7UC3_
M  ;JUKJ_B6W2U^SV.JR6L<\UO&D2H%91?&VD8LBAO)+; 3MKHOV.?CYXL^-%
MWXRTWQEI_@VUUGPCJ%M9M-X6U.74=/<36L<YA,DB(3-$6*/C*_=/'('N0A4"
M@#X)7_@EWXD\'#2=2T/2?A?JU]X>TC24&BWQEL+#Q'=_VA>WVJ1W<T=O*5B:
M0Z6T#&*7:;-P4"OQ-KO_  2JUSQ'\#_%VFW%]X/7QA?Z=9P:5<:8)M,L]/SJ
M]QJ^H6-LVR5[*TEDN&MHW5976%%+*_*'[P$2CM1Y0H ^1?"/[!WB#P/^P'XG
M^':OH.J>)/&6IOJ^I66J:Q<W>FDS7$+2V@NG@W[##"%,BVR*TC.XACW;1A^,
MO^"<7B;4QJ&J:+=^#]+\57LWBK47OHMT4CR:@\-K8VBS>4QC@BTU&B+%'"2"
M-EB;;7VLT*M_A1Y2YZ4 ?G[\.?\ @EKXPL/A?XFL]?;P7>:QJ$6O7FE07-]-
MJ]KI^HW>D6&EV;R2S6T?G&".UG+R^3'O:0E8XU(1/:/VFOV)[CXL^#O"_AW2
M3H,VC^"/!VKZ/I,.M(9U&I3V45C97$B%65DBB\]B2"VYEP.I'TUY"_W:%@5>
MU 'Y]^(/^"7OQ(G^/&J:SIFN>&X/#NFZ;>Z?X9DEU6Y,]G$V@OI-C ]I]GVJ
M;8NY><W,K3C!V1G(/L'_  P5-I?[)_Q:\#Z#?:3HNM?$C4+VX%TL;_9Y+;]U
M;VMK.\>R4QO8VT,,Q4[_ -[*RDG&?J3R5QC;TH\E<YV\^M 'R7\#/V'=7TKX
MZ:'XZ\6:#\-=!2QN+[5H_#7AF)KBPT2]:UM+.T,$TD$/FR+"ETTDHAARTL8"
M?NPQY'QS_P $Y?B%KO[7OCWXC:7XLLK*35#>:QX:U2ZUFXN'TS4)-%.G6L+Z
M9]G$)@MY&:4NUQ*DJX4VX8F2ON'[.O\ =_\ KTOD+[\G/6@#X+_9K_X)B^)_
MAT;>X\66O@[4+6UU8:]#HUYK5QX@C6XM=)DL=/CFN9;2V$RK)=74CL($QB'
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M@>+M$\!VC^'/ X\/:?:>#OM%Q=:R\=S-=75[=/)#&S3W/EVQ6-0Y1C,/,DW
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M[M]-L;C3H=1\1-8W%M<:64NVUNXAT&V9'C6![F<6T<C2H]L(O,Q.X$8[ _\
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M$\THO+='0RZE=-*B&.>X\J(FW7>L.UOWTI;(^D_(7/3OFE$8&/;I0 ZBBB@
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M8:IX T:QU,>,9M-MY?[-6>XODC@2:0>='+']CDFP0 (YX9%)64,8UUSX2_M
M?#[X1VNM?"_2=5TWXP33Z]I.EZOHMI,+%WM)+Z:]F1LA6=2-S+EBTXSUK6^#
MW['.K^'O!OQ<M_&_BVS\1^(OC#,1J.IZ'H0T./3+4:5;Z=%:VT+37!"Q>5-*
MC/(YW7!!R!5'X.?LD^/_  )XET;7/$GQ \+^(M4\': OA;PO#8^#I-+TW2[%
MY;5KJ26 WTSS7<T=G#&)%ECCC"_+%AV5@ T?]ISPSX0_:+U[P/X7^&NN70T'
M4=*\/>(M;T.SL_)TR::RMYK(2VZR"Z:UCM[J!?M"1&"/<Z[AY4@3>^+WPN^
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M=**** $/WA2T44 (_P!VEHHH **** "BBB@ HHHH **** "CO110 4444 %%
M%% !1110 4444 %%%% !1110 =Z*** "BBB@ HHHH **** "BBB@ HHHH **
=** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139857069281232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 28, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001583648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PIERIS PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">30-0784346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">225&#160;Franklin&#160;Street, 26th Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">246-8998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PIRS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 114,087,344<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,519,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Boston, Massachusetts<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139857064041664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 38,635<span></span>
</td>
<td class="nump">$ 117,764<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short term investments</a></td>
<td class="nump">20,534<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">5,810<span></span>
</td>
<td class="nump">3,313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">8,445<span></span>
</td>
<td class="nump">6,548<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">73,424<span></span>
</td>
<td class="nump">127,625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">16,992<span></span>
</td>
<td class="nump">19,122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">3,705<span></span>
</td>
<td class="nump">3,909<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">1,369<span></span>
</td>
<td class="nump">2,904<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">95,490<span></span>
</td>
<td class="nump">153,560<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">4,154<span></span>
</td>
<td class="nump">8,609<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_AccruedLiabilitiesAndOtherLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">11,605<span></span>
</td>
<td class="nump">16,836<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenues, current portion</a></td>
<td class="nump">20,824<span></span>
</td>
<td class="nump">25,116<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">36,583<span></span>
</td>
<td class="nump">50,561<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">18,734<span></span>
</td>
<td class="nump">38,403<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">12,244<span></span>
</td>
<td class="nump">13,841<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">67,561<span></span>
</td>
<td class="nump">102,805<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Convertible preferred stock, $0.001 par value per share, 10,000,000 shares authorized and 15,617 shares issued and outstanding at December 21, 2022 and 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value per share, 300,000,000 shares authorized and 74,519,103 and 72,222,661 shares issued and outstanding at December 21, 2022 and 2021, respectively</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">318,530<span></span>
</td>
<td class="nump">306,998<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="num">(254)<span></span>
</td>
<td class="nump">829<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(290,421)<span></span>
</td>
<td class="num">(257,144)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">27,929<span></span>
</td>
<td class="nump">50,755<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 95,490<span></span>
</td>
<td class="nump">$ 153,560<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_AccruedLiabilitiesAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current portion of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_AccruedLiabilitiesAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139857068491744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par Value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued (in shares)</a></td>
<td class="nump">15,617<span></span>
</td>
<td class="nump">15,617<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding (in shares)</a></td>
<td class="nump">15,617<span></span>
</td>
<td class="nump">15,617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par Value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized (in shares)</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued (in shares)</a></td>
<td class="nump">74,519,103<span></span>
</td>
<td class="nump">72,222,661<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding (in shares)</a></td>
<td class="nump">74,519,103<span></span>
</td>
<td class="nump">72,222,661<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139857063897264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Customer revenue</a></td>
<td class="nump">$ 25,469<span></span>
</td>
<td class="nump">$ 27,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenue</a></td>
<td class="nump">433<span></span>
</td>
<td class="nump">3,478<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">25,902<span></span>
</td>
<td class="nump">31,418<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">52,982<span></span>
</td>
<td class="nump">66,656<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">16,394<span></span>
</td>
<td class="nump">16,593<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">69,376<span></span>
</td>
<td class="nump">83,249<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(43,474)<span></span>
</td>
<td class="num">(51,831)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income</a></td>
<td class="nump">721<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceAmount', window );">Grant income</a></td>
<td class="nump">8,173<span></span>
</td>
<td class="nump">3,685<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="nump">1,303<span></span>
</td>
<td class="nump">2,404<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(33,277)<span></span>
</td>
<td class="num">(45,738)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive (loss) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation</a></td>
<td class="num">(1,010)<span></span>
</td>
<td class="nump">1,124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized (loss) gain on available-for-sale securities</a></td>
<td class="num">(73)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (34,360)<span></span>
</td>
<td class="num">$ (44,614)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.45)<span></span>
</td>
<td class="num">$ (0.71)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract', window );"><strong>Weighted average number of common shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic and diluted (in shares)</a></td>
<td class="nump">74,172<span></span>
</td>
<td class="nump">64,547<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of government assistance recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342832&amp;loc=SL128342943-244231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30304-110892<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28129-110885<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a-c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126928961&amp;loc=SL5834089-161433<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139857060828816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Conversion of Preferred Stock [Member] </div>
<div>Preferred Stock [Member]</div>
</th>
<th class="th">
<div>Conversion of Preferred Stock [Member] </div>
<div>Common Stock [Member]</div>
</th>
<th class="th">
<div>Conversion of Preferred Stock [Member] </div>
<div>Receivables from Stockholder [Member]</div>
</th>
<th class="th">
<div>Conversion of Preferred Stock [Member] </div>
<div>Additional Paid-in Capital [Member]</div>
</th>
<th class="th">
<div>Conversion of Preferred Stock [Member] </div>
<div>AOCI Attributable to Parent [Member]</div>
</th>
<th class="th">
<div>Conversion of Preferred Stock [Member] </div>
<div>Retained Earnings [Member]</div>
</th>
<th class="th"><div>Conversion of Preferred Stock [Member]</div></th>
<th class="th">
<div>Conversion of Series E Preferred Stock [Member] </div>
<div>Preferred Stock [Member]</div>
</th>
<th class="th">
<div>Conversion of Series E Preferred Stock [Member] </div>
<div>Common Stock [Member]</div>
</th>
<th class="th">
<div>Conversion of Series E Preferred Stock [Member] </div>
<div>Receivables from Stockholder [Member]</div>
</th>
<th class="th">
<div>Conversion of Series E Preferred Stock [Member] </div>
<div>Additional Paid-in Capital [Member]</div>
</th>
<th class="th">
<div>Conversion of Series E Preferred Stock [Member] </div>
<div>AOCI Attributable to Parent [Member]</div>
</th>
<th class="th">
<div>Conversion of Series E Preferred Stock [Member] </div>
<div>Retained Earnings [Member]</div>
</th>
<th class="th"><div>Conversion of Series E Preferred Stock [Member]</div></th>
<th class="th">
<div>At the Market Offering [Member] </div>
<div>Preferred Stock [Member]</div>
</th>
<th class="th">
<div>At the Market Offering [Member] </div>
<div>Common Stock [Member]</div>
</th>
<th class="th">
<div>At the Market Offering [Member] </div>
<div>Receivables from Stockholder [Member]</div>
</th>
<th class="th">
<div>At the Market Offering [Member] </div>
<div>Additional Paid-in Capital [Member]</div>
</th>
<th class="th">
<div>At the Market Offering [Member] </div>
<div>AOCI Attributable to Parent [Member]</div>
</th>
<th class="th">
<div>At the Market Offering [Member] </div>
<div>Retained Earnings [Member]</div>
</th>
<th class="th"><div>At the Market Offering [Member]</div></th>
<th class="th">
<div>Private Placement [Member] </div>
<div>Preferred Stock [Member]</div>
</th>
<th class="th">
<div>Private Placement [Member] </div>
<div>Common Stock [Member]</div>
</th>
<th class="th">
<div>Private Placement [Member] </div>
<div>Receivables from Stockholder [Member]</div>
</th>
<th class="th">
<div>Private Placement [Member] </div>
<div>Additional Paid-in Capital [Member]</div>
</th>
<th class="th">
<div>Private Placement [Member] </div>
<div>AOCI Attributable to Parent [Member]</div>
</th>
<th class="th">
<div>Private Placement [Member] </div>
<div>Retained Earnings [Member]</div>
</th>
<th class="th"><div>Private Placement [Member]</div></th>
<th class="th"><div>Preferred Stock [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Receivables from Stockholder [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000<span></span>
</td>
<td class="nump">56,003,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 56<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 242,672<span></span>
</td>
<td class="num">$ (295)<span></span>
</td>
<td class="num">$ (211,406)<span></span>
</td>
<td class="nump">$ 31,027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(45,738)<span></span>
</td>
<td class="num">(45,738)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,124<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,215<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,215<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock resulting from exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">482,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock resulting from exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,024<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1,024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock resulting from purchase of employee stock purchase plan shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">64,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,257<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock resulting from purchase of employee stock purchase plan shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">165<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 165<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Issuance of common stock resulting from exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,391,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_StockIssuedDuringPeriodValueExerciseOfWarrants', window );">Issuance of common stock resulting from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">836<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">837<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Issuance of common stock resulting from conversion of preferred stock (in shares)</a></td>
<td class="num">(4,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock resulting from conversion of preferred stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (4)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (5)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock resulting from conversion of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,812,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Issuance of common stock resulting from conversion of preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,290,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 38,180<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 38,188<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 18,905<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 18,913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
<td class="nump">72,222,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 72<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 306,998<span></span>
</td>
<td class="nump">$ 829<span></span>
</td>
<td class="num">$ (257,144)<span></span>
</td>
<td class="nump">$ 50,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,755<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(33,277)<span></span>
</td>
<td class="num">(33,277)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,010)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,010)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,402<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,402<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock resulting from exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock resulting from purchase of employee stock purchase plan shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">182,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">181,466<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock resulting from purchase of employee stock purchase plan shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">197<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Issuance of common stock resulting from exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">46,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,069,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,838<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,840<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(73)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(73)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
<td class="nump">74,519,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 74<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 318,530<span></span>
</td>
<td class="num">$ (254)<span></span>
</td>
<td class="num">$ (290,421)<span></span>
</td>
<td class="nump">$ 27,929<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_StockIssuedDuringPeriodSharesExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of exercising of warrants .</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_StockIssuedDuringPeriodSharesExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_StockIssuedDuringPeriodValueExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period for exercising of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_StockIssuedDuringPeriodValueExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139857067579600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Equity (Parentheticals) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pirs_AtTheMarketOfferingMember', window );">At the Market Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pirs_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pirs_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139857069313456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (33,277)<span></span>
</td>
<td class="num">$ (45,738)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2,770<span></span>
</td>
<td class="nump">2,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_OperatingLeaseRightOfUseAssetAccretion', window );">Right-of-use asset (accretion) amortization</a></td>
<td class="nump">10<span></span>
</td>
<td class="num">(91)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">4,402<span></span>
</td>
<td class="nump">5,215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RealizedInvestmentGainsLosses', window );">Realized investment gains</a></td>
<td class="num">(376)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other non-cash transactions</a></td>
<td class="num">(91)<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(2,624)<span></span>
</td>
<td class="num">(1,813)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(1,358)<span></span>
</td>
<td class="num">(3,154)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="num">(20,185)<span></span>
</td>
<td class="nump">19,555<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Accounts payable</a></td>
<td class="num">(4,208)<span></span>
</td>
<td class="nump">7,049<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(4,005)<span></span>
</td>
<td class="nump">9,876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="num">(990)<span></span>
</td>
<td class="num">(988)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(59,932)<span></span>
</td>
<td class="num">(7,660)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(1,041)<span></span>
</td>
<td class="num">(949)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Proceeds from maturity of investments</a></td>
<td class="nump">28,200<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(48,395)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(21,236)<span></span>
</td>
<td class="num">(949)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">95<span></span>
</td>
<td class="nump">1,024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">837<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from employee stock purchase plan</a></td>
<td class="nump">197<span></span>
</td>
<td class="nump">165<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from Issuance of Private Placement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">18,913<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock resulting from ATM sales, net of $1.2 million in transaction costs</a></td>
<td class="nump">6,922<span></span>
</td>
<td class="nump">38,188<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">7,214<span></span>
</td>
<td class="nump">59,127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of exchange rate change on cash and cash equivalents</a></td>
<td class="num">(5,175)<span></span>
</td>
<td class="num">(3,190)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(79,129)<span></span>
</td>
<td class="nump">47,328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">117,764<span></span>
</td>
<td class="nump">70,436<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">38,635<span></span>
</td>
<td class="nump">117,764<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow disclosures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Net unrealized loss on investments</a></td>
<td class="num">(73)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment included in accounts payable</a></td>
<td class="nump">$ 193<span></span>
</td>
<td class="nump">$ 237<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_OperatingLeaseRightOfUseAssetAccretion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents right of use asset accretion for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_OperatingLeaseRightOfUseAssetAccretion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedInvestmentGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.3(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedInvestmentGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139857069244272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Parentheticals) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pirs_AtTheMarketOfferingMember', window );">At the Market Offering [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pirs_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pirs_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139857071554640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Corporate Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</a></td>
<td class="text">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><em style="font: inherit;">1.</em> </b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Corporate Information</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Pieris Pharmaceuticals, Inc., was founded in <em style="font: inherit;"> May 2013, </em>and acquired 100% interest in Pieris Pharmaceuticals GmbH (formerly Pieris AG, a German company which was founded in <em style="font: inherit;">2001</em>) in <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">2014.</em> Pieris Pharmaceuticals, Inc. and its wholly-owned subsidiaries, hereinafter collectively Pieris, or the Company, is a clinical-stage biopharmaceutical company that discovers and develops Anticalin-based drugs to target validated disease pathways in unique and transformative ways. Pieris' corporate headquarters is located in Boston, Massachusetts and its research facility, as of <em style="font: inherit;"> December 31, 2022</em>, is located in Hallbergmoos, Germany.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Pieris&#8217; clinical pipeline includes elarekibep, formerly referred to as PRS-<em style="font: inherit;">060/AZD1402,</em> an inhaled IL-<em style="font: inherit;">4R&#945;</em> antagonist Anticalin protein to treat uncontrolled asthma,&#160;PRS-<em style="font: inherit;">220,</em> an inhaled CTGF antagonist to treat idiopathic pulmonary fibrosis, or IPF, and other pulmonary fibrosis indications, and an immuno-oncology, or&#160;IO,&#160;bispecific PRS-<em style="font: inherit;">344/S095012</em> targeting PD-<em style="font: inherit;">L1</em> and <em style="font: inherit;">4</em>-<em style="font: inherit;">1BB.</em> Proprietary to us, Anticalin proteins are a novel class of therapeutics validated in the clinic and through partnerships with leading pharmaceutical companies.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">The Company&#8217;s core Anticalin technology and platform was developed in Germany, and the Company has partnership arrangements with several major multi-national pharmaceutical companies.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">The Company is subject to risks common to companies in the biotechnology industry, including but&#160;<i><em style="font: inherit;">not</em></i>&#160;limited to, the need for additional capital, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval and reimbursement for any drug product candidate that it&#160;<i><em style="font: inherit;"> may</em></i>&#160;identify and develop, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development of technological innovations by competitors, reliance on&#160;<i><em style="font: inherit;">third</em></i>-party manufacturers and the ability to transition from pilot-scale production to large-scale manufacturing of products.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">The future success of the Company is dependent on its ability to identify and develop its product candidates, expand its corporate infrastructure and ultimately upon its ability to attain profitable operations. The Company has devoted substantially all of its financial resources and efforts to research and development and general and administrative expenses to support such research and development. The Company has several research and development programs underway in varying stages of development, and it expects that these programs will continue to require increasing amounts of cash for development, conducting clinical trials, and testing and manufacturing of product material. Cash necessary to fund operations will increase significantly over the next several years as the Company continues to conduct these activities necessary to pursue governmental regulatory approval of clinical-stage programs and other product candidates.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Going Concern Uncertainties</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of <em style="font: inherit;"> December 31, 2022</em>, cash, cash equivalents, and investments were $59.2&#160;million. The Company&#8217;s net loss was $33.3&#160;million and $45.7&#160;million for the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em>, respectively. The Company has incurred net losses since inception and had an accumulated deficit of $290.4&#160;million as of <em style="font: inherit;"> December 31, 2022</em>. Net losses and negative cash flows have had, and will continue to have, an adverse effect on the Company&#8217;s stockholders&#8217; equity and working capital. The Company expects to continue to incur operating losses for at least the next several years.&#160;The Company would need to raise additional capital over the next year to continue its current level of research and development activities across all of its active programs, as well as to maintain the general and administrative functions to support such activities. Without access to additional capital or management making decisions to reduce spending, these conditions&#160;raise&#160;substantial doubt about the ability of the Company to continue as a going concern.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">The Company plans to raise additional capital to fulfill its operating and capital requirements through public or private equity financings, utilization of its current &#8220;at the market offering&#8221; program, or ATM Program, strategic collaborations, licensing arrangements, government grants and/or the achievement of milestones under its collaborative agreements. The funding requirements of the Company&#8217;s operating plans, however, are based on estimates that are subject to risks and uncertainties and <em style="font: inherit;"> may&#160;</em>change as a result of many factors currently unknown. Although management continues to pursue these funding plans, there is&#160;<i><em style="font: inherit;">no</em></i>&#160;assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all. Until such time that the Company can generate substantial product revenues, if ever, the Company expects to finance its cash needs through a combination of equity offerings, debt financings, strategic partnerships, licensing arrangements and government grants. The terms of any future financing <em style="font: inherit;"> may&#160;</em>adversely affect the holdings or the rights of the Company&#8217;s existing stockholders.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">If the Company is unable to obtain additional funding on acceptable terms when needed, the Company will defer or limit a substantial portion of its research, development and clinical projects, reduce discretionary expenditures and other fixed or variable personnel costs&#160;to alleviate the substantial doubt as to the Company&#8217;s ability to continue as a going concern. The Company&#8217;s budget and operating plan for <em style="font: inherit;">2023,</em> approved by the Board, does <em style="font: inherit;">not</em> include such discretionary costs, and management is prepared to gate future investments on PRS-<em style="font: inherit;">220</em> and PRS-<em style="font: inherit;">400,</em> including certain Phase <em style="font: inherit;">2</em>-readiness activities for PRS-<em style="font: inherit;">220</em> and IND-enabling activities for PRS-<em style="font: inherit;">400,</em> in the interest of achieving its top priority, namely, obtaining data from the elarekibep Phase <em style="font: inherit;">2a</em> study in asthma.&#160;On the basis of the Company&#8217;s approved budget and actions within management&#8217;s control, the Company believes that its currently available funds will be sufficient to fund the Company&#8217;s remaining limited operations through at least the next <em style="font: inherit;">12</em> months from the issuance of this Annual Report on Form <em class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="font: inherit;">10</em>-K. The Company&#8217;s belief with respect to its ability to fund operations is based on estimates that are subject to risks and uncertainties.</p>

   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139857071586992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
<td class="text">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><em style="font: inherit;">2.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Summary of Significant Accounting Policies </b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b/></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Basis of Presentation and Use of Estimates</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The accompanying consolidated financial statements of Pieris Pharmaceuticals, Inc. and its wholly-owned subsidiaries were prepared in accordance with U.S. GAAP. The consolidated financial statements include the accounts of all subsidiaries. All intercompany balances and transactions have been eliminated.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The preparation of the financial statements in accordance with U.S. GAAP requires management to make estimates, judgments, and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and the related disclosures at the date of the financial statements and during the reporting period. Significant estimates are used for, but are <em style="font: inherit;">not</em> limited to, revenue recognition; deferred tax assets, deferred tax liabilities and valuation allowances; determination of the incremental borrowing rate to calculate right-of-use assets and lease liabilities; beneficial conversion features; fair value of stock options, preferred stock, and warrants; and prepaid and accrued clinical trial expenses. Management evaluates its estimates on an ongoing basis. Actual results and outcomes could differ materially from management&#8217;s estimates, judgments, and assumptions.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b/></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Foreign Currency Translation</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The financial statements of the Company&#8217;s foreign subsidiaries are translated from local currency into reporting currency, which is U.S. dollars, using the current exchange rate at the balance sheet date for assets and liabilities, and the weighted average exchange rate prevailing during the period for revenues and expenses. The functional currency for Pieris&#8217; foreign subsidiaries is considered to be the local currency for each entity and, accordingly, translation adjustments for these subsidiaries are included in accumulated other comprehensive loss within stockholders&#8217; equity.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Realized and unrealized gains and losses resulting from foreign currency transactions denominated in currencies other than the functional currency are reflected as other (expense) income, net in the consolidated statements of operations. Foreign currency gains and losses on available-for-sale investment transactions are recorded to other comprehensive income (loss) on the Company's balance sheet per Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic <em style="font: inherit;">830,</em> <i>Foreign Currency Matters.</i></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i/></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b/></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Cash, Cash Equivalents and Investments</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company determines the appropriate classification of its investments at the time of purchase. All liquid investments with original maturities of <em style="font: inherit;">90</em> days or less from the purchase date and for which there is an active market are considered to be cash equivalents. The Company&#8217;s investments are comprised of money market, asset backed securities, government treasuries, and corporate bonds that are classified as available-for-sale in accordance with FASB ASC <em style="font: inherit;">320,</em> <i>Investments</i>&#8212;<i>Debt and Equity Securities</i>. The Company classifies investments available to fund current operations as current assets on its balance sheets.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Available-for-sale investments are recorded at fair value, with unrealized gains or losses included in accumulated other comprehensive income (loss) on the Company&#8217;s balance sheets. Realized gains and losses are determined using the specific identification method and are included as a component of other income (expense).</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company reviews investments for other-than-temporary impairment whenever the fair value of an investment is less than the amortized cost and evidence indicates that an investment&#8217;s carrying amount is <em style="font: inherit;">not</em> recoverable within a reasonable period of time. To determine whether an impairment is other-than temporary, the Company considers its intent to sell, or whether it is more likely than <em style="font: inherit;">not</em> that the Company will be required to sell the investment before recovery of the investment&#8217;s amortized cost basis. Evidence considered in this assessment includes reasons for the impairment, the severity and the duration of the impairment, and changes in value subsequent to period end.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b/></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Concentration of Credit Risk and Off-Balance Sheet Risk</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company has <em style="font: inherit;">no</em> financial instruments with off&#8209;balance sheet risk such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Financial instruments that subject Pieris to concentrations of credit risk include cash and cash equivalents, investments, and accounts receivable. The Company&#8217;s cash, cash equivalents, and investments are held in accounts with financial institutions that management believes are creditworthy. The Company&#8217;s investment policy includes guidelines on the quality of the institutions and financial instruments and defines allowable investments that the Company believes minimizes the exposure to concentration of credit risk. The Company has <em style="font: inherit;">not</em> experienced any credit losses in such accounts and does <em style="font: inherit;">not</em> believe it is exposed to any significant credit risk on these funds. Accounts receivable primarily consist of amounts due under strategic partnership and other license agreements with major multi-national pharmaceutical companies for which the Company does <em style="font: inherit;">not</em> obtain collateral.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/>

   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b/></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Fair Value Measurement</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. FASB ASC Topic <em style="font: inherit;">820,</em> <i>Fair Value Measurement and Disclosures</i>, or ASC <em style="font: inherit;">820,</em> established a hierarchy of inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the financial instrument based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the financial instrument and are developed based on the best information available in the circumstances. The fair value hierarchy applies only to the valuation inputs used in determining the reported or disclosed fair value of the financial instruments and is <em style="font: inherit;">not</em> a measure of the investment credit quality. Fair value measurements are classified and disclosed in <em style="font: inherit;">one</em> of the following <em style="font: inherit;">three</em> categories:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"><tbody><tr><td style="width:18pt;">&#160;</td><td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td><td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Level <em style="font: inherit;">1</em> inputs are quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"><tbody><tr><td style="width:18pt;">&#160;</td><td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td><td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Level <em style="font: inherit;">2</em> utilizes quoted market prices in markets that are <em style="font: inherit;">not</em> active, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency.</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"><tbody><tr><td style="width:18pt;">&#160;</td><td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td><td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Level <em style="font: inherit;">3</em> inputs are unobservable inputs for the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level <em style="font: inherit;">3.</em> A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Financial instruments measured at fair value on a recurring basis include cash equivalents and investments, if any (<i>Note <em style="font: inherit;">6</em></i>).</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">An entity <em style="font: inherit;"> may </em>elect to measure many financial instruments and certain other items at fair value at specified election dates. Subsequent unrealized gains and losses on items for which the fair value option has been elected will be reported in net loss. The Company did <em style="font: inherit;">not</em> elect to measure any additional financial instruments or other items at fair value.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b/></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Fair Values of Financial Instruments</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The fair value of cash, accounts receivable, and accounts payable approximates the carrying value of these financial instruments because of the short-term nature of any maturities. The Company determines the estimated fair values of other financial instruments, using available market information and valuation methodologies, primarily input from independent <em style="font: inherit;">third</em> party pricing sources.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b/></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Accounts Receivable</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Accounts receivable are recorded net of allowances for doubtful accounts and represent amounts due from strategic partners. The Company monitors and evaluates collectability of receivables on an ongoing basis and considers whether an allowance for doubtful accounts is necessary. The Company determined that <em style="font: inherit;">no</em> such reserve is needed as of <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em>. Historically, Pieris has <em style="font: inherit;">not</em> had collectability issues.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/>

   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b/></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Property and Equipment</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Property and equipment are recorded at acquisition cost, less accumulated depreciation and impairment. Depreciation on property and equipment is calculated using the straight-line method over the remaining estimated useful lives of the assets. Maintenance and repairs to these assets are charged to expenses as occurred. Substantially all of the Company's fixed assets are located in Germany. The estimated useful life of the different groups of property and equipment is as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>Asset Classification</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 43%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Estimated useful life (in years)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Leasehold improvements</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 43%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">shorter of useful life or remaining life of the lease</em></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Laboratory furniture and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 43%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">8-14</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Office furniture and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 43%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">5-13</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Computer and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 43%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">3 - 7</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table><div>
   </div>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b/></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Impairment of Long-lived Assets</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company reviews its long-lived assets to be held and used for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be fully recoverable. The Company evaluates the realizability of its long-lived assets based on profitability and cash flow expectations for the related asset. Any write-downs are treated as permanent reductions in the carrying amount of the assets. The Company believes that, as of each of the balance sheets presented, <em style="font: inherit;">none</em> of the Company&#8217;s long-lived assets were impaired.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b/></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Revenue Recognition</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">Pieris has entered into several licensing agreements with collaboration partners for the development of Anticalin therapeutics against a variety of targets. The terms of these agreements provide for the transfer of multiple goods or services which&#160;<i><em style="font: inherit;"> may</em></i>&#160;include: (i)&#160;licenses, or options to obtain licenses, to Pieris&#8217; Anticalin technology and/or specific programs and (ii)&#160;research and development activities to be performed on behalf of or with a collaborative partner. Payments to Pieris under these agreements&#160;<i><em style="font: inherit;"> may</em></i>&#160;include upfront fees (which include license and option fees), payments for research and development activities, payments based upon the achievement of certain milestones, and royalties on product sales. There are&#160;<i><em style="font: inherit;">no</em></i>&#160;performance, cancellation, termination or refund provisions in any of the arrangements that could result in material financial consequences to Pieris. As the Company's intellectual property assets are considered to be located in Germany, the Company records all consolidated revenue in its subsidiary, Pieris Pharmaceuticals, GmbH.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Collaborative Arrangements</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company considers the nature and contractual terms of an arrangement and assess whether the arrangement involves a joint operating activity pursuant to which it is an active participant and exposed to significant risks and rewards with respect to the arrangement. If the Company is an active participant and exposed to the significant risks and rewards with respect to the arrangement, it accounts for these arrangements pursuant to ASC <em style="font: inherit;">808,</em> <i>Collaborative Arrangements</i>, or ASC <em style="font: inherit;">808,</em> and applies a systematic and rational approach to recognize revenue. The Company classifies payments received as revenue and payments made as a reduction of revenue in the period in which they are earned. Revenue recognized under a collaborative arrangement involving a participant that is <em style="font: inherit;">not</em> a customer is presented as Collaboration Revenue in the Statement of Operations.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Revenue from Contracts with Customers</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In accordance with ASC <em style="font: inherit;">606,</em> revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled in exchange for these goods and services. To achieve this core principle, the Company applies the following <em style="font: inherit;">five</em> steps: <em style="font: inherit;">1</em>) identify the customer contract; <em style="font: inherit;">2</em>) identify the contract&#8217;s performance obligations; <em style="font: inherit;">3</em>) determine the transaction price; <em style="font: inherit;">4</em>) allocate the transaction price to the performance obligations; and <em style="font: inherit;">5</em>) recognize revenue when or as a performance obligation is satisfied.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company evaluates all promised goods and services within a customer contract and determines which of such goods and services are separate performance obligations. This evaluation includes an assessment of whether the good or service is capable of being distinct and whether the good or service is separable from other promises in the contract. &#160;In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property and the capabilities of the customer to develop the intellectual property on their own or whether the required expertise is readily available.</p>

   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Licensing arrangements are analyzed to determine whether the promised goods or services, which often include licenses, research and development services and governance committee services, are distinct or whether they must be accounted for as part of a combined performance obligation. If the license is considered <em style="font: inherit;">not</em> to be distinct, the license would then be combined with other promised goods or services as a combined performance obligation. If the Company is involved in a governance committee, it assesses whether its involvement constitutes a separate performance obligation. When governance committee services are determined to be separate performance obligations, the Company determines the fair value to be allocated to this promised service.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Certain contracts contain optional and additional items, which are considered marketing offers and are accounted for as separate contracts with the customer if such option is elected by the customer, unless the option provides a material right which would <em style="font: inherit;">not</em> be provided without entering into the contract.&#160;&#160;An option that is considered a material right is accounted for as a separate performance obligation.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The transaction price is determined based on the consideration to which the Company will be entitled in exchange for transferring goods and services to the customer. A contract <em style="font: inherit;"> may </em>contain variable consideration, including potential payments for both milestone and research and development services. For certain potential milestone payments, the Company estimates the amount of variable consideration by using the most likely amount method. In making this assessment, the Company evaluates factors such as the clinical, regulatory, commercial and other risks that must be overcome to achieve the milestone. Each reporting period the Company re-evaluates the probability of achievement of such variable consideration and any related constraints. Pieris will include variable consideration, without constraint, in the transaction price to the extent it is probable that a significant reversal in the amount of cumulative revenue recognized will <em style="font: inherit;">not</em> occur when the uncertainty associated with the variable consideration is subsequently resolved. For potential research and development service payments, the Company estimates the amount of variable consideration by using the expected value method, including any approved budget updates arising from additional research or development services.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price among the performance obligations on a relative standalone selling price basis unless a portion of the transaction price is variable and meets the criteria to be allocated entirely to a performance obligation or to a distinct good or service that forms part of a single performance obligation.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company allocates the transaction price based on the estimated standalone selling price of the underlying performance obligations or in the case of certain variable consideration to <em style="font: inherit;">one</em> or more performance obligations. The Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company utilizes key assumptions to determine the stand-alone selling price, which <em style="font: inherit;"> may </em>include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs to complete the respective performance obligation. Certain variable consideration is allocated specifically to <em style="font: inherit;">one</em> or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated to each performance obligation are consistent with the amount the Company would expect to receive for each performance obligation.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">When a performance obligation is satisfied, revenue is recognized for the amount of the transaction price, excluding estimates of variable consideration that are constrained, that is allocated to that performance obligation on a relative standalone selling price basis. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations under an arrangement.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">For performance obligations consisting of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non- refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Revenue recognized under an arrangement involving a participant that is a customer is presented as Customer Revenue.</p>

   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Milestones and Royalties</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company aggregates milestones into <em style="font: inherit;">four</em> categories (i) research milestones, (ii) development milestones, (iii) commercial milestones and (iv) sales milestones. Research milestones are typically achieved upon reaching certain success criteria as defined in each agreement related to developing an Anticalin protein against the specified target. Development milestones are typically reached when a compound reaches a defined phase of clinical research or passes such phase, or upon gaining regulatory approvals. Commercial milestones are typically achieved when an approved pharmaceutical product reaches the status for commercial sale, including regulatory approval. Sales milestones are certain defined levels of net sales by the licensee, such as when a product <em style="font: inherit;">first</em> achieves global sales or annual sales of a specified amount.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">There is uncertainty that the events to obtain the research and development milestones will be achieved given the nature of clinical development and the stage of the Company&#8217;s technology. The Company has thus determined that all research and development milestones will be constrained until it is deemed probable that a significant revenue reversal will <em style="font: inherit;">not</em> occur. For revenues from research and development milestones, payments will be recognized consistent with the recognition pattern of the performance obligation to which they relate.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&#160;Commercial milestones and sales royalties are determined by sales or usage-based thresholds and will be accounted for under the royalty recognition constraint as constrained variable consideration.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company calculates the maximum amount of potential milestones achievable under each collaboration agreement and discloses such potential future milestones for all current collaborations using such a maximum calculation.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Contract Balances</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company recognizes a contract asset when the Company transfers goods or services to a customer before the customer pays consideration or before payment is due, excluding any amounts presented as a receivable (i.e., accounts receivable). A contract asset is an entity&#8217;s right to consideration in exchange for goods or services that the entity has transferred to a customer. The contract liabilities (i.e., deferred revenue) primarily relate to contracts where the Company has received payment but has <em style="font: inherit;">not</em> yet satisfied the related performance obligations.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In the event of an early termination of a collaboration agreement, any contract liabilities would be recognized in the period in which all Company obligations under the agreement have been fulfilled.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Costs to Obtain and Fulfill a Contract with a Customer</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Certain costs to obtain customer contracts, including success-based fees paid to <em style="font: inherit;">third</em>-party service providers, and costs to fulfill customer contracts are capitalized in accordance with FASB ASC <em style="font: inherit;">340,</em> <i>Other Assets and Deferred Costs</i>, or ASC <em style="font: inherit;">340.</em> These costs are amortized to expense on a systemic basis that is consistent with the transfer to the customer of the goods or services to which the asset relates. The Company will expense the amortization of costs to obtain customer contracts to general and administrative expense and costs to fulfill customer contracts to research and development expense.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Research and Development</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Research and development expenses are charged to the statement of operations as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including salaries and benefits, facilities costs, pre-clinical and clinical costs, contract services, consulting, depreciation and amortization expense, and other related costs. Costs associated with acquired technology, in the form of upfront fees or milestone payments, are charged to research and development expense as incurred.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/>

   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b/></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Income Taxes</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company applies ASC Topic <em style="font: inherit;">740</em> <i>Income Taxes</i>, which established financial accounting and reporting requirements for the effects of income taxes that result from the Company&#8217;s activities during the current and preceding years. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and operating losses and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted statutory tax rates expected to apply to taxable income in the jurisdictions and years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Where the Company determines that it is more likely than <em style="font: inherit;">not</em> that some portion or all of the deferred tax assets will <em style="font: inherit;">not</em> be realized in the future, the deferred tax assets are reduced by a valuation allowance. The Company records interest and penalties related to uncertain tax positions as part of income tax expense.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Tax Cuts and Jobs Act&#160;(TCJA) subjects a U.S. shareholder to tax on global-intangible low tax income (GILTI) earned by certain foreign subsidiaries. The Company has made an accounting policy election to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b/></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Stock-based Compensation</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company measures share-based payments in accordance with ASC Topic <em style="font: inherit;">718,</em> <i>Stock Compensation</i>. Pieris records its stock-based compensation expense over the requisite service period and records forfeitures as they occur. Determining the appropriate fair value model and related assumptions requires judgment, including estimating share price volatility and expected terms of the awards. For employee options, the fair value measurement date is generally on the date of grant and the related compensation expense is recognized on a straight-line basis over the requisite service period of the awards, less expense for actual forfeitures.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company uses the Black-Scholes option pricing model to determine the estimated fair value for stock-based awards. Option-pricing models require the input of various subjective assumptions, including the option&#8217;s expected life, expected dividend yield, price volatility, risk free interest rate and forfeitures of the underlying stock. Due to the limited operating history of the Company as a public entity and a lack of company specific historical and implied volatility data, the Company has based its estimate of expected volatility on the historical volatility of a group of similar companies that are publicly traded. When selecting these public companies on which it has based its expected stock price volatility, the Company selected companies with comparable characteristics to it, including enterprise value, risk profiles, position within the industry, and with historical share price information sufficient to meet the expected term of the stock-based awards. The Company computes historical volatility data using the daily closing prices for the selected companies&#8217; shares during the equivalent period of the calculated expected term of the stock-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Due to the lack of Company specific historical option activity, the Company has estimated the expected term of its employee stock options using the &#8220;simplified&#8221; method, whereby, the expected term equals the arithmetic average of the vesting term and the original contractual term of the option. The expected term for non-employee awards is the remaining contractual term of the option. The risk-free interest rates are based on the U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The Company has never paid, and does <em style="font: inherit;">not</em> expect to pay dividends in the foreseeable future.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">All excess tax benefits and tax deficiencies are recorded as income tax expense or benefit in the Company's statement of operations and comprehensive loss. For the years ended&#160;<em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em>, the Company did <em style="font: inherit;">not</em> record an income statement benefit for excess tax benefits as a valuation allowance is also required on these amounts.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b/></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Government Grants</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company recognizes grants from governmental agencies when there is reasonable assurance that the Company will comply with the conditions attached to the grant arrangement and the grant will be received. The Company evaluates the conditions of each grant as of each reporting period to evaluate whether the Company has reached reasonable assurance of meeting the conditions of each grant arrangement and that it is expected that the grant will be received as a result of meeting the necessary conditions. Grants are recognized in the consolidated statements of operations on a systematic basis over the periods in which the Company recognizes the related costs for which the government grant is intended to compensate. Specifically, grant income related to research and development costs is recognized as such expenses are incurred. Grant income is included as a separate caption within Other income (expense), net in the consolidated statements of operations.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/>

   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b/></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Leases</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company accounts for leases pursuant to ASC <em style="font: inherit;">842</em> <i>Leases (Topic <em style="font: inherit;">842</em>)</i>, or ASC <em style="font: inherit;">842.</em> As a lessee, the Company is required to recognize (i) a lease liability, which is a lessees obligation to make lease payments arising from a lease, measured on a discounted basis; and (ii) a right-of-use asset, which is an asset that represents the lessee&#8217;s right to use, or control the use of, a specified asset for the lease term for all leases (with the exception of short-term leases) at the commencement date.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company determines if an arrangement is a lease at inception. The Company&#8217;s contracts are determined to contain a lease within the scope of ASC <em style="font: inherit;">842</em> when all of the following criteria based on the specific circumstances of the arrangement are met: (<em style="font: inherit;">1</em>) there is an identified asset for which there are <em style="font: inherit;">no</em> substantive substitution rights; (<em style="font: inherit;">2</em>) the Company has the right to obtain substantially all of the economic benefits from the identified asset; and (<em style="font: inherit;">3</em>) the Company has the right to direct the use of the identified asset. In addition, the Company does <em style="font: inherit;">not</em> apply the recognition requirements in the lease standard to short-term leases (a lease that at commencement date has a lease term of <em style="font: inherit;">12</em> months or less and does <em style="font: inherit;">not</em> contain a purchase option that it is reasonably certain to exercise) and does <em style="font: inherit;">not</em> separate lease and non-lease components for all asset classes. Any variable components of lease costs are excluded from lease payments and are recognized in the period incurred, including increases to rent based on German Consumer Price Index , or CPI.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">At the commencement date, operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of future lease payments over the expected lease term. The Company&#8217;s lease agreements do <em style="font: inherit;">not</em> provide an implicit rate. As a result, the Company utilizes an estimated incremental borrowing rate to discount lease payments, which is based on the rate of interest the Company would have to pay to borrow a similar amount on a collateralized basis over a similar term and based on observable market data points. Certain adjustments to the right-of-use asset <em style="font: inherit;"> may </em>be required for items such as initial direct costs paid or lease incentives received. Operating lease cost is recognized over the expected term on a straight-line basis.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company typically only includes an initial lease term in its assessment of a lease agreement. Options to renew a lease are <em style="font: inherit;">not</em> included in the Company&#8217;s assessment unless there is reasonable certainty that the Company will renew. The expected lease term includes noncancelable lease periods and, when applicable, periods covered by an option to extend the lease if the Company is reasonably certain to exercise that option, as well as periods covered by an option to terminate the lease if the Company is reasonably certain <em style="font: inherit;">not</em> to exercise that option.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Assumptions made by the Company at the commencement date are re-evaluated upon occurrence of certain events, including a lease modification. A lease modification results in a separate contract when the modification grants the lessee an additional right of use <em style="font: inherit;">not</em> included in the original lease and when lease payments increase commensurate with the standalone price for the additional right of use. When a lease modification results in a separate contract, it is accounted for in the same manner as a new lease.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b/></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Contingencies</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Accruals are recorded for loss contingencies when it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. The Company evaluates, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously. Considering facts known at the time of the assessment, the Company determines whether potential losses are considered reasonably possible or probable and whether they are estimable. Based upon this assessment, the Company carries out an evaluation of disclosure requirements and considers possible accruals in the financial statements.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b/></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Segment Reporting</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Operating segments are identified as components of an enterprise where separate discrete financial information is evaluated by the chief operating decision maker in making decisions on how to allocate resources and assess performance. The Company operates as a single segment dedicated to the discovery and development of biotechnological applications and the Company&#8217;s chief operating decision maker, or CODM, makes decisions based on the Company as a whole. The Company has determined that its CODM is its Chief Executive Officer.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b/></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Earnings per Share</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Basic earnings per share attributable to common stockholders is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period, without consideration for common stock equivalents.</p>

   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Diluted earnings per share attributable to common stockholders is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share attributable to common stockholders' calculation, preferred stock, stock options, unvested restricted stock, and warrants are considered to be common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to common stockholders, as their effect would be anti-dilutive for all periods presented. Therefore, basic and diluted net loss per share were the same for all periods presented.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b/></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Recent Accounting Pronouncements <em style="font: inherit;">Not</em> Yet Adopted</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In <em style="font: inherit;"> June 2016, </em>the FASB issued ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2016</em>-<em style="font: inherit;">13,</em> <i>Financial Instruments - Credit Losses</i> <i>(Topic <em style="font: inherit;">326</em>): Measurement of Credit Losses on Financial Statements, </i>or ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13.</em> ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> significantly changes the impairment model for most financial assets and certain other instruments. The new standard requires that expected credit losses relating to financial assets measured on an amortized cost basis and available-for-sale debt securities be recorded through an allowance for credit losses. It also limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value, and requires the reversal of previously recognized credit losses if fair value increases. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Subsequently, in <em style="font: inherit;"> November 2018, </em>the FASB issued ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2018</em>-<em style="font: inherit;">19,</em> <i>Codification Improvements to Topic <em style="font: inherit;">326,</em> Financial Instruments-Credit Losses</i>, which clarifies codification and corrects unintended application of the guidance. In <em style="font: inherit;"> November 2019, </em>the FASB issued ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2019</em>-<em style="font: inherit;">11,</em> <i>Codification Improvements to Topic <em style="font: inherit;">326,</em> Financial Instruments-Credit Losses</i>, which clarifies or addresses specific issues about certain aspects of ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13.</em> In <em style="font: inherit;"> November 2019 </em>the FASB also issued ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2019</em>-<em style="font: inherit;">10,</em> <i>Financial Instruments-Credit Losses (Topic <em style="font: inherit;">326</em>), Derivatives and Hedging (Topic <em style="font: inherit;">815</em>), and Leases (Topic <em style="font: inherit;">842</em>): Effective Dates</i>, which delays the effective date of ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> by <em style="font: inherit;">three</em> years for certain smaller reporting companies such as the Company. The guidance in ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> is effective for the Company for financial statements issued for fiscal years beginning after <em style="font: inherit;"> December 15, 2022 </em>and interim periods within those fiscal years, with early adoption permitted. The Company expects that adoption of this standard will <em style="font: inherit;">not</em> have a material impact on its financial statements.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company has considered other recent accounting pronouncements and concluded that they are either <em style="font: inherit;">not</em> applicable to the business, or that the effect is <em style="font: inherit;">not</em> expected to be material to the unaudited consolidated financial statements as a result of future adoption.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/>

  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139857069246992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue from Contract with Customer [Text Block]</a></td>
<td class="text">
    &#65279;
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><em style="font: inherit;">3.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Revenue</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>General</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company has <em style="font: inherit;">not</em> generated revenue from product sales. The Company has generated revenue from contracts with customers (option,&#160;license and collaboration agreements), which include upfront payments for licenses or options to obtain licenses, payments for research and development services and milestone payments.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">During the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em>, respectively, the Company recognized revenue from the following strategic partnerships and other license agreements (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Year Ended December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">AstraZeneca</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,117</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">18,919</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Seagen</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8,287</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">768</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Servier</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,359</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,070</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Genentech</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">3,139</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">1,950</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Boston Pharmaceuticals</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">5,711</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"><b>Total Revenue</b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,902</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">31,418</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Under the Company&#180;s existing strategic partnerships and other license agreements, the Company could receive the following potential milestone payments (in millions) as of <em style="font: inherit;"> December 31, 2022</em>:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Research, Development, Regulatory &amp; Commercial Milestones</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Sales Milestones</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">AstraZeneca</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">702</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,925</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Servier</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">20</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Seagen</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">759</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">450</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Boston Pharmaceuticals</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">88</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">265</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Genentech</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">834</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">600</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"><b>Total potential milestone payments</b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,403</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,240</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Strategic Partnerships </b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i><span style="text-decoration: underline; ">Genentech</span></i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> May 19, 2021, </em>the Company and Genentech, Inc., or Genentech, entered into a Research Collaboration and License Agreement, or the Genentech Agreement, to discover, develop and commercialize locally delivered respiratory and ophthalmology therapies that leverage the Company&#8217;s proprietary Anticalin technology. Upon signing the Genentech Agreement, Genentech paid the Company a $20&#160;million upfront fee. In addition, the Company <em style="font: inherit;"> may </em>be eligible to receive additional milestone payments across multiple programs, as well as tiered royalty payments on net sales at percentages ranging from the mid-single to low double-digits, subject to certain standard reductions and offsets.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Under the terms of the Genentech Agreement, the Company will be responsible for discovery and preclinical development of <span style="-sec-ix-hidden:c96253743">two</span> initial programs. The Company will be responsible for research activities following target nomination through the late-stage research go decision. The parties will then collaborate on drug candidate characterization until the development go decision. After the development go decision, Genentech will be responsible for pursuing the preclinical and clinical development of each program, and thereafter, the commercialization efforts. Each party will be responsible for the costs incurred to perform their respective responsibilities. Genentech has an option to expand the collaboration to encompass <span style="-sec-ix-hidden:c96253744">two</span> additional programs with the payment of a $10&#160;million fee per additional program. If Genentech exercises its option to start additional programs, payment to the Company of additional fees, milestone payments and royalties would result.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Unless earlier terminated, the term of the Genentech Agreement continues until <em style="font: inherit;">no</em> royalty or other payment obligations are or will become due under the Genentech Agreement. The Genentech Agreement <em style="font: inherit;"> may </em>be terminated (i) by either party based on insolvency or breach by the other party and such insolvency proceeding is <em style="font: inherit;">not</em> dismissed or such breach is <em style="font: inherit;">not</em> cured within 90 days; or (ii) after <em style="font: inherit;">9</em> months from the effective date of the Genentech Agreement, by Genentech as a whole or on a product-by-product and/or country-by-country basis upon 90 days prior written notice before the <em style="font: inherit;">first</em> commercial sale of a product or upon 180 days prior written notice after the <em style="font: inherit;">first</em> commercial sale of a product.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">While the Genentech Agreement allows for up to four research programs, only two research programs are initially identified and committed in the Genentech Agreement. To reach a total of up to four research programs, the Company has granted Genentech options to nominate an additional two collaboration targets of their choosing, subject to the legal availability of the target to be researched. Genentech will have <span style="-sec-ix-hidden:c96253759">three</span> years after the effective date to nominate the subsequent targets. The Company has also granted Genentech options to replace any of the collaboration targets identified with another target. However, at <em style="font: inherit;">no</em> point will there be more than four identified collaboration targets for which there are ongoing research programs.</p>

   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The arrangement with Genentech provides for the transfer of the following goods or services: (i) exclusive research and commercial license for the collaboration programs, (ii) a non-exclusive platform improvement license, (iii) research and development services, (iv)&#160;participation in a governance committee, and (v)&#160;replacement target options on the <em style="font: inherit;">first</em> two programs upon a screening failure which were assessed as material rights.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Management evaluated all of the promised goods or services within the contract and determined which such goods and services were separate performance obligations. The Company determined that the licenses granted, at arrangement inception, should be combined with the research and development services to be provided for the related target programs as they are <em style="font: inherit;">not</em> capable of being distinct. A <em style="font: inherit;">third</em> party would <em style="font: inherit;">not</em> be able to provide the research and development services due to the specific nature of the intellectual property and knowledge required to perform the services, and Genentech could <em style="font: inherit;">not</em> benefit from the licenses without the corresponding services. The Company determined that the participation in the governance committees was distinct as the services could be performed by an outside party.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As a result, management concluded there were five separate performance obligations at the inception of the Genentech Agreement: (i)&#160;two combined performance obligations, each comprised of an exclusive research and commercial license, a non-exclusive platform improvement license, and research and development services for the <em style="font: inherit;">first</em> two Genentech programs, (ii) two performance obligations each comprised of a material right for a target swap option for the <em style="font: inherit;">first</em> two Genentech programs, and (iii) one performance obligation comprised of the participation on the governance committee.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company allocated consideration to the performance obligations based on the relative proportion of their standalone selling prices. The Company developed standalone selling prices for licenses by applying a risk adjusted, net present value, estimate of future potential cash flows approach, which included the cost of obtaining research and development services at arm&#8217;s length from a <em style="font: inherit;">third</em>-party provider, as well as internal full-time equivalent costs to support these services. The Company developed the standalone selling price for committee participation by using management&#8217;s estimate of the anticipated participation hours multiplied by a market rate for comparable participants.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The transaction price at inception is comprised of fixed consideration of $20.0&#160;million in upfront fees and was allocated to each of the performance obligations based on the relative proportion of their standalone selling prices. The amounts allocated to the performance obligations for the two research programs will be recognized on a proportional performance basis through the completion of each respective estimated research term of the individual research programs. The amounts allocated to the material right for the target options will be recognized either at the time the material right expires or, if exercised, on a proportional performance basis over the estimated research term for that program along with any remaining deferred revenue associated with the replacement target. The amounts allocated to the participation on the committee will be recognized on a straight-line basis over the anticipated research term for all research programs. As of <em style="font: inherit;"> December 31, 2022</em>, there was $12.6&#160;million of aggregate transaction price allocated to remaining performance obligations.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Under the Genentech Agreement, the Company is eligible to receive various research, development, commercial and sales milestones. There is uncertainty that the events to obtain the research and development milestones will be achieved given the nature of clinical development and the stage of the Company&#8217;s technology. The Company has determined that all other research and development milestones will be constrained until it is deemed probable that a significant revenue reversal will <em style="font: inherit;">not</em> occur.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of <em style="font: inherit;"> December 31, 2022</em>, there were $7.8&#160;million and $4.8&#160;million of current and non-current deferred revenue, respectively, related to the Genentech Agreement.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i><span style="text-decoration: underline; ">Boston Pharmaceuticals</span></i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> April 24, 2021, </em>the Company and BP Asset XII, Inc., or Boston Pharmaceuticals, a subsidiary of Boston Pharma Holdings, LLC, entered into an Exclusive Product License Agreement, or the BP Agreement, to develop PRS-<em style="font: inherit;">342,</em> a <em style="font: inherit;">4</em>-<em style="font: inherit;">1BB/GPC3</em> preclinical immuno-oncology Anticalin-antibody bispecific fusion protein.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Under the terms of the BP Agreement, Boston Pharmaceuticals exclusively licensed worldwide rights to PRS-<em style="font: inherit;">342.</em> The Company received an upfront payment of $10.0&#160;million and is further entitled to receive development, regulatory and sales-based milestone payments, tiered royalties up to low double-digits on sales of PRS-<em style="font: inherit;">342</em> and a percentage of consideration received by Boston Pharmaceuticals in the event of a sublicense of a program licensed under the BP Agreement or a change of control of Boston Pharmaceuticals. The Company will also contribute up to $4.0&#160;million toward manufacturing activities.</p>

   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The term of the BP Agreement ends upon the expiration of all of Boston Pharmaceuticals&#8217; payment obligations thereunder. The BP Agreement <em style="font: inherit;"> may </em>be terminated by Boston Pharmaceuticals in its entirety for convenience beginning <span style="-sec-ix-hidden:c96253792">nine</span> months after its effective date upon 60 days&#8217; notice or, for any program under the BP Agreement which has received marketing approval, upon 120 days&#8217; notice. If any program is terminated by Boston Pharmaceuticals, the Company will have full rights to continue such program. The BP Agreement <em style="font: inherit;"> may </em>also be terminated by Boston Pharmaceuticals or the Company for an uncured material breach by the other party upon 180 days&#8217; notice (60 days in the case of non-payment of undisputed amounts due and payable), subject to extension for an additional 180 days in certain cases and subject, in all cases, to dispute resolution procedures. The Agreement <em style="font: inherit;"> may </em>also be terminated due to the other party&#8217;s insolvency. The Company <em style="font: inherit;"> may </em>also terminate the BP Agreement if Boston Pharmaceuticals challenges the validity of any patents licensed under the BP Agreement, subject to certain exceptions.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company does <em style="font: inherit;">not</em> have any obligations to assist in the research and development efforts of Boston Pharmaceuticals under the BP Agreement. However, the Company has an obligation to fund up to $4.0&#160;million in costs, including out-of-pocket costs incurred by Boston Pharmaceuticals, in connection with the manufacture of products under the BP Agreement.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The arrangement with Boston Pharmaceuticals provides for the transfer of the following: (i)&#160;exclusive license of PRS-<em style="font: inherit;">342,</em> (ii)&#160;non-exclusive Pieris platform license, (iii)&#160;initial know-how, (iv)&#160;product cell line license, and (v) materials (as each such term is defined under the BP Agreement).</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Management evaluated all of the promised goods or services within the BP Agreement and determined which such goods and services were separate performance obligations. The Company determined that the licenses granted, at arrangement inception, should be combined with the transfer of know-how, materials and the product cell line license. Boston Pharmaceuticals could <em style="font: inherit;">not</em> benefit from the exclusive and non-exclusive licenses without the corresponding transfer of know-how and materials.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As a result, management concluded there was only <em style="font: inherit;">one</em> combined performance obligation. The transaction price at inception is comprised of fixed consideration of $10.0&#160;million in upfront fees, offset by $4.0&#160;million in consideration payable to Boston Pharmaceuticals to reimburse them for expected out-of-pocket manufacturing costs, for a total transaction price of $6.0&#160;million. Management has assessed the forms of variable consideration within the BP Agreement and concluded that the payments are either constrained by the royalty recognition constraint or because management has assessed the most likely amount associated with the payments as zero.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The amounts allocated to the performance obligations did <em style="font: inherit;">not</em> meet the criteria to be recognized over time on a proportional performance basis and thus will be recognized at a point in time. The Company determined that the performance obligation will be fully satisfied when all of the deliverables in the combined performance obligation are transferred to Boston Pharmaceuticals as that is the point at which Boston Pharmaceuticals can fully use and benefit from the license to PRS-<em style="font: inherit;">342.</em> The Company transferred all such deliverables to Boston Pharmaceuticals in the <em style="font: inherit;">fourth</em> quarter of <em style="font: inherit;">2021.</em> As of <em style="font: inherit;"> December 31, 2021, </em>the Company had recognized the full transaction price, or $5.7&#160;million, as revenue and there is <em style="font: inherit;">no</em> remaining deferred revenue.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><span style="text-decoration: underline; ">Seagen</span></i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#65279;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> February 8, 2018, </em>the Company entered into a license and collaboration agreement, or the Seagen Collaboration Agreement, and a non-exclusive Anticalin platform technology license agreement, or the Seagen Platform License, and together with the Seagen Collaboration Agreement, the Seagen Agreements, with Seagen, Inc., or Seagen, pursuant to which the parties will develop multiple targeted bispecific IO treatments for solid tumors and blood cancers.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Under the terms of the Seagen Agreements, the companies will pursue multiple Anticalin-antibody fusion proteins during the research phase. The Seagen Agreements provide Seagen a base option to select up to three programs for further development. Prior to the initiation of a pivotal trial, the Company <em style="font: inherit;"> may </em>opt into global co-development and U.S. commercialization of the <em style="font: inherit;">second</em> program and share in global costs and profits on an equal basis. Seagen will solely develop, fund and commercialize the other two programs. Seagen <em style="font: inherit;"> may </em>also decide to select additional candidates from the initial research phase for further development in return for the payment to us of additional fees, milestone payments, and royalties</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Seagen Platform License grants Seagen a non-exclusive license to certain intellectual property related to the Anticalin platform technology.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Upon signing the Seagen Agreements, Seagen paid the Company a $30.0 million upfront fee and an additional $4.9 million was estimated to be paid for research and development services as reimbursement to the Company through the end of the research term. In addition, the Company <em style="font: inherit;"> may </em>receive tiered royalties on net sales up to the low double-digits and success-based research, development, commercial, and sales milestones payments across the product candidates, depending on the successful development and commercialization of those candidates. If Seagen exercises its option to select additional candidates from the initial research phase for further development, payment to Pieris of additional fees, milestone payments, and royalties would result.</p>

   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The term of each of the Seagen Agreements ends upon the expiration of all of Seagen's payment obligations under each agreement. The Seagen Collaboration Agreement <em style="font: inherit;"> may </em>be terminated by Seagen on a product-by-product basis for convenience beginning 12 months after its effective date upon 90 days' notice or, for any program where a pivotal study has been initiated, upon 180 days' notice. Any program <em style="font: inherit;"> may </em>be terminated at Seagen's option. If any program is terminated by Seagen after a pre-defined pre-clinical stage, the Company will have full rights to continue such program. If any program is terminated by Seagen prior to such pre-defined pre-clinical stage, the Company will have the right to continue to develop such program, but will be obligated to offer a co-development option to Seagen for such program. The Seagen Collaboration Agreement <em style="font: inherit;"> may </em>also be terminated by Seagen or the Company for an uncured material breach by the other party upon 90 days' notice, subject to extension for an additional 90 days if the material breach relates to diligence obligations and subject, in all cases, to dispute resolution procedures. The Seagen Collaboration Agreement <em style="font: inherit;"> may </em>also be terminated due to the other party&#8217;s insolvency and <em style="font: inherit;"> may </em>in certain instances, including for reasons of safety, be terminated on a product-by-product basis. Each party <em style="font: inherit;"> may </em>also terminate the Seagen Agreements if the other party challenges the validity of any patents licensed under the Seagen Agreements, subject to certain exceptions. The Seagen Platform License will terminate upon termination of the Seagen Collaboration Agreement, whether in its entirety or on a product-by-product basis.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company determined that the Seagen Agreements should be combined and evaluated as a single arrangement under ASC <em style="font: inherit;">606</em> as they were executed on the same date. The arrangement with Seagen provides for the transfer of the following goods or services: (i)&#160;three candidate research licenses that each consist of a non-exclusive platform technology license, a co-exclusive candidate research license, and research and development services, (ii)&#160;research, development and manufacturing services associated with each candidate research license, (iii)&#160;participation on various governance committees, and (iv)&#160;two antibody target swap options which were assessed as material rights.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Management evaluated all of the promised goods or services within the contract and determined which such goods and services were separate performance obligations. The Company determined that the licenses granted, at arrangement inception, should be combined with the research and development services to be provided for the related antibody target programs as they are <em style="font: inherit;">not</em> capable of being distinct. A <em style="font: inherit;">third</em> party would <em style="font: inherit;">not</em> be able to provide the research and development services due to the specific nature of the intellectual property and knowledge required to perform the services, and Seagen could <em style="font: inherit;">not</em> benefit from the licenses without the corresponding services. The Company determined that the participation on the various governance committees was distinct as the services could be performed by an outside party.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As a result, management concluded there are six separate performance obligations at the inception of the Seagen Agreements: (i)&#160;three combined performance obligations, each comprised of a non-exclusive platform technology license, a co-exclusive candidate research license, and research and development services for the <em style="font: inherit;">first</em> three approved Seagen antibody target programs, (ii) two performance obligations each comprised of a material right for an antibody target swap option for the <em style="font: inherit;">first</em> and the <em style="font: inherit;">second</em> approved Seagen antibody target for <em style="font: inherit;">no</em> additional consideration, and (iii)&#160;one performance obligation comprised of the participation on the various governance committees.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company allocated consideration to the performance obligations based on the relative proportion of their standalone selling prices. The Company developed standalone selling prices for licenses by applying a risk adjusted, net present value, estimate of future potential cash flows approach, which included the cost of obtaining research and development services at arm&#8217;s length from a <em style="font: inherit;">third</em>-party provider, as well as internal full-time equivalent costs to support these services. The Company developed the standalone selling price for committee participation by using management&#8217;s estimate of the anticipated participation hours multiplied by a market rate for comparable participants.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The transaction price at inception is comprised of fixed consideration of $30.0 million in upfront fees and variable consideration of $4.9 million of estimated research and development services to be reimbursed as research and development occurs through the research term. The $30.0 million upfront fee, which represents the fixed consideration in the transaction price, was allocated to each of the performance obligations based on the relative proportion of their standalone selling prices. The $4.9 million in variable consideration related to the research and development services is allocated specifically to the three target program performance obligations based upon the budgeted services for each program</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The amounts allocated to the performance obligations for the three research programs will be recognized on a proportional performance basis through the completion of each respective estimated research term of the individual research programs. The amounts allocated to the material right for the antibody target swap option will be recognized either at the time the material right expires, or if exercised, on a proportional performance basis over the estimated research term for that program. The amounts allocated to the participation on each of the committees will be recognized straight-line over the anticipated research term for all research programs. As of <em style="font: inherit;"> December 31, 2022</em>, there was $17.1&#160;million of aggregate transaction price allocated to remaining performance obligations.</p>

   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In <em style="font: inherit;"> June 2020, </em>Seagen and the Company entered into amendments to the Seagen Agreements, or together, the First Seagen Amendment. The Seagen Amendment extended the deadline for Seagen to nominate a <em style="font: inherit;">second</em> and <em style="font: inherit;">third</em> antibody target. As a result of the Seagen Amendment, which completed the remaining performance obligations under the research term for the <em style="font: inherit;">first</em> antibody target, the Company recorded $4.2&#160;million of previously deferred revenue for the year ended <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2020.</em> The Company also recorded $5.0 million of milestone revenue in <em style="font: inherit;"> June 2020.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On <em style="font: inherit;"> March 24, 2021, </em>the Company announced that Seagen made a strategic equity investment in Pieris, and that the companies had entered into a combination study agreement, or the Combination Study Agreement, to evaluate the safety and efficacy of combining Pieris&#8217; cinrebafusp alfa with Seagen&#8217;s tucatinib, a small-molecule tyrosine kinase <em style="font: inherit;">HER2</em> inhibitor, for the treatment of gastric cancer patients expressing lower <em style="font: inherit;">HER2</em> levels (<em style="font: inherit;">IHC2</em>+/ISH- &amp; <em style="font: inherit;">IHC1</em>+) as part of the upcoming phase <em style="font: inherit;">2</em> study to be conducted by Pieris. The companies have also entered into an Amended and Restated License and Collaboration Agreement, or the Second Seagen Amendment, in which their existing immuno-oncology collaboration agreement has been amended relating to joint development and commercial rights for the <em style="font: inherit;">second</em> program in the alliance.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Specifically, under the Second Seagen Amendment, Pieris&#8217; option to co-develop and co-commercialize the <em style="font: inherit;">second</em> of three programs in the collaboration has been converted to a co-promotion option in the United States, with Seagen solely responsible for the development and overall commercialization of that program. Pieris will also be entitled to increased royalties from that program in the event that it chooses to exercise the co-promotion option. In connection with the agreements described above, the Company and Seagen entered into a subscription agreement, or the Seagen Subscription Agreement, pursuant to which the Company agreed to issue to Seagen, and Seagen agreed to acquire from the Company, 3,706,174 shares of the Company&#8217;s common stock for a total purchase price of $13.0&#160;million, or $3.51 per share, in a private placement transaction pursuant to Section <em style="font: inherit;">4</em>(a)(<em style="font: inherit;">2</em>) of the Securities Act of <em style="font: inherit;">1933,</em> as amended. The Seagen Subscription Agreement includes a provision to the effect that Seagen <em style="font: inherit;"> may </em>ask the Company to file a registration statement to register the resale of the shares issued to Seagen, at any time beginning on the date that is 60 calendar days from the date of issuance of the shares. The Company assessed the ASC <em style="font: inherit;">606</em> implications of the Seagen Subscription Agreement and concluded that the fair value of the shares on a per share basis was $2.61 per share as of the transaction date. This resulted in a premium paid for the shares of $3.3&#160;million, all of which was recorded in deferred revenue upon contract execution and allocated to the remaining performance obligations.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company has concluded that the Combination Study Agreement is within the scope of ASC <em style="font: inherit;">808,</em> which defines collaborative arrangements and addresses the presentation of the transactions between the <em style="font: inherit;">two</em> parties in the income statement and related disclosures. However, ASC <em style="font: inherit;">808</em> does <em style="font: inherit;">not</em> provide guidance on the recognition of consideration exchanged or accounting for the obligations that <em style="font: inherit;"> may </em>arise between the parties. The Company has concluded that ASC <em style="font: inherit;">730,</em> <i>Research and Development</i>, should be applied by analogy. There is <em style="font: inherit;">no</em> financial statement impact for the Combination Study Agreement as the value of the drug supply received from Seagen is offset against the drug supply cost.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In the <em style="font: inherit;">second</em> quarter of <em style="font: inherit;">2022,</em> the Company recorded approximately $1.5 million in revenue related to completion of the performance obligation for the expiration of the target swap under the <em style="font: inherit;">second</em> program in the collaboration.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Under the Seagen Agreements, the Company is eligible to receive various research, development, commercial and sales milestones. There is uncertainty that the events to obtain the research and development milestones will be achieved given the nature of clinical development and the stage of the Company&#8217;s technology. The Company has thus determined that all research and development milestones will be constrained until it is deemed probable that a significant revenue reversal will <em style="font: inherit;">not</em> occur, with the exception of the $5.0 million milestone as described in the following paragraph.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In <em style="font: inherit;"> January 2023, </em>the Company achieved a milestone for the <em style="font: inherit;">first</em> program in the collaboration for $5.0 million. The Company evaluated the recognition of the milestone under ASC <em style="font: inherit;">606</em> and concluded that the constraints on the milestone <em style="font: inherit;">no</em> longer existed as of <em style="font: inherit;"> December 31, 2022</em> and therefore recorded the full $5.0 million as revenue for the year ended <em style="font: inherit;"> December 31, 2022</em>.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">As of <em style="font: inherit;"> December 31, 2022</em>, there is $11.6&#160;million and $2.9&#160;million of current and non-current deferred revenue, respectively, related to the Seagen Agreements.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><span style="text-decoration: underline; ">AstraZeneca</span></i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> May&#160;</em><em style="font: inherit;">2,</em> <em style="font: inherit;">2017,</em> the Company entered into a license and collaboration agreement, or the AstraZeneca Collaboration Agreement, and a non-exclusive Anticalin platform technology license agreement, or AstraZeneca Platform License, and together with the AstraZeneca Collaboration Agreement, the AstraZeneca Agreements with AstraZeneca AB, or AstraZeneca, which became effective on <em style="font: inherit;"> June&#160;</em><em style="font: inherit;">10,</em> <em style="font: inherit;">2017,</em> following expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of <em style="font: inherit;">1976.</em> Under the AstraZeneca Agreements the parties will advance several novel inhaled Anticalin proteins.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition to the Company&#8217;s lead inhaled drug candidate, PRS-<em style="font: inherit;">060/AZD1402,</em> or the AstraZeneca Lead Product, the Company and AstraZeneca, under the original terms of the AstraZeneca Collaboration Agreement, would also collaborate to progress four additional novel Anticalin proteins against undisclosed targets for respiratory diseases, or the AstraZeneca Collaboration Products, and together with the AstraZeneca Lead Product, the AstraZeneca Products. The Company is responsible for advancing the AstraZeneca Lead Product&#160;through its phase <em style="font: inherit;">1</em> study, with the associated costs funded by AstraZeneca. The parties will collaborate thereafter to conduct a phase <em style="font: inherit;">2a</em> study in asthma patients, with AstraZeneca continuing to fund development costs. After completion of a phase <em style="font: inherit;">2a</em> study, Pieris has the option to co-develop the AstraZeneca Lead Product and also has a separate option to co-commercialize the AstraZeneca Lead Product in the United States. For the AstraZeneca Collaboration Products, the Company will be responsible for the initial discovery of the novel Anticalin proteins, after which AstraZeneca will take the lead on continued development of the AstraZeneca Collaboration Products. The Company has the option to co-develop two of the four AstraZeneca Collaboration Products beginning at a pre-defined preclinical stage and would also have the option to co-commercialize these two programs in the United States, while AstraZeneca will be responsible for development and commercialization of the other programs worldwide.</p>

   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The term of each of the AstraZeneca Agreements ends upon the expiration of all of AstraZeneca&#8217;s payment obligations under such agreement. The AstraZeneca Collaboration Agreement <em style="font: inherit;"> may </em>be terminated by AstraZeneca in its entirety for convenience beginning 12 months after its effective date upon 90 days&#8217; notice or, if the Company has obtained marketing approval for the marketing and sale of a product, upon 180 days&#8217; notice. Each program <em style="font: inherit;"> may </em>be terminated at AstraZeneca&#8217;s option; if any program is terminated by AstraZeneca, the Company will have full rights to such program. The AstraZeneca Collaboration Agreement <em style="font: inherit;"> may </em>also be terminated by AstraZeneca or the Company for material breach upon 180 days&#8217; notice of a material breach (or 30 days with respect to payment breach), provided that the applicable party has <em style="font: inherit;">not</em> cured such breach by the permitted cure period (including an additional 180 days if the breach is <em style="font: inherit;">not</em> susceptible to cure during the initial 180-day period) and dispute resolution procedures specified in the agreement have been followed. The AstraZeneca Collaboration Agreement <em style="font: inherit;"> may </em>also be terminated due to the other party&#8217;s insolvency and <em style="font: inherit;"> may </em>in certain instances be terminated on a product-by-product and/or country-by-country basis. Each party <em style="font: inherit;"> may </em>also terminate an AstraZeneca Agreement if the other party challenges the validity of patents related to certain intellectual property licensed under such AstraZeneca Agreement, subject to certain exceptions for infringement suits, acquisitions and newly-acquired licenses. The AstraZeneca Platform License will terminate upon termination of the AstraZeneca Collaboration Agreement, on a product-by-product and/or country-by-country basis.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">At inception, AstraZeneca is granted the following licenses: (i)&#160;research and development license for the AstraZeneca Lead Product, (ii)&#160;commercial license for the AstraZeneca Lead Product, (iii)&#160;individual research licenses for each of the four AstraZeneca Collaboration Products, (iv)&#160;individual commercial licenses for each of the four AstraZeneca Collaboration Products, and (v)&#160;individual non-exclusive platform technology licenses for the AstraZeneca Lead Product and the four AstraZeneca Collaboration Products. AstraZeneca will be granted individual development licenses for each of the four AstraZeneca Collaboration Products upon completion of the initial discovery of Anticalin proteins.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The collaboration will be managed on an overall basis by a Joint Steering Committee, or JSC, formed by an equal number of representatives from the Company and AstraZeneca. In addition to the JSC, the AstraZeneca Collaboration Agreement also requires each party to designate an alliance manager to facilitate communication and coordination of the parties' activities under the agreement, and further requires participation of both parties on a joint development committee, or JDC, and a commercialization committee. The responsibilities of these committees vary, depending on the stage of development and commercialization of each product.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Under the AstraZeneca Agreements, the Company received an upfront, non-refundable payment of $45.0 million. In addition, the Company will receive payments to conduct a phase <em style="font: inherit;">1</em> clinical study for the AstraZeneca Lead Product. The Company is also eligible to receive research, development, commercial, sales milestone payments, and royalty payments. The Company <em style="font: inherit;"> may </em>receive tiered royalties on sales of potential products commercialized by AstraZeneca and for co-developed products, gross margin share on worldwide sales equal dependent on the Company&#8217;s level of committed investment.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company determined that the AstraZeneca Agreements should be combined and evaluated as a single arrangement under ASC <em style="font: inherit;">606</em> as they were executed on the same date. The arrangement with AstraZeneca, including the impact of any modifications, provides for the transfer of the following goods and services: (i)&#160;five non-exclusive platform technology licenses, (ii)&#160;research and development license for the AstraZeneca Lead Product, (iii)&#160;commercial license for the AstraZeneca Lead Product, (iv)&#160;development and manufacturing services for the AstraZeneca Lead Product (or the phase <em style="font: inherit;">1</em> services), (v) technology transfer services for the AstraZeneca Lead Product, (vi)&#160;research services related to the AstraZeneca Lead Product, (vii)&#160;participation on each of the committees, (viii)&#160;four research licenses for the AstraZeneca Collaboration Products, (ix)&#160;four commercial licenses for the AstraZeneca Collaboration Products, (<em style="font: inherit;">x</em>)&#160;research services for the AstraZeneca Collaboration Products and (xi) certain phase <em style="font: inherit;">2a</em> services for the AstraZeneca Lead Product. Additionally, as the development licenses on the four AstraZeneca Collaboration Products <em style="font: inherit;"> may </em>be granted at a discount in the future, the Company determined such discounts should be assessed as material rights at inception.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Management evaluated all of the promised goods or services within the contract and determined which such goods and services were separate performance obligations. The Company determined that the licenses granted for the AstraZeneca Lead Product at the inception of the arrangement should be combined with the research services related to the AstraZeneca Lead Product and the licenses granted for the AstraZeneca Collaboration Products should be combined with the research services for the AstraZeneca Collaboration Products, as the licenses are <em style="font: inherit;">not</em> capable of being distinct. A <em style="font: inherit;">third</em> party would <em style="font: inherit;">not</em> be able to provide the research and development services, due to the specific nature of the intellectual property and knowledge required to perform the services and AstraZeneca could <em style="font: inherit;">not</em> benefit from the licenses without the corresponding services. The Company also determined that each of the phase <em style="font: inherit;">1</em> services and the phase <em style="font: inherit;">2a</em> services for the AstraZeneca Lead Product were distinct and that the participation on the various committees was also distinct as all of the phase <em style="font: inherit;">1</em> services, phase <em style="font: inherit;">2a</em> services and the committee services could be performed by an outside party. The Company determined that the commercial licenses for the AstraZeneca Collaboration Products granted at the inception of the arrangement should be combined with the development licenses for the AstraZeneca Collaboration Products as the company would <em style="font: inherit;">not</em> benefit from the commercial license without the ability to develop each product.</p>

   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As a result, management concluded that there were 16 performance obligations: (i)&#160;combined performance obligation comprised of a non-exclusive platform technology license, research and development license, and commercial licenses for the AstraZeneca Lead Product and research services for the AstraZeneca Lead Product, (ii) combined performance obligation comprised of&#160;development and manufacturing services, and technology transfer services for the AstraZeneca Lead Product, (iii)&#160;committee participation, (iv-vii) four combined performance obligations each comprised of a non-exclusive platform technology license, research licenses, and research services for each AstraZeneca Collaboration Product (viii-xi) four performance obligations comprised of a material right to acquire the development licenses granted for the AstraZeneca Collaboration Products, (xii-xv) four performance obligations comprised of the commercial licenses granted for the AstraZeneca Collaboration Products and (xvi) phase <em style="font: inherit;">2a</em> services.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company allocated consideration to the performance obligations based on the relative proportion of their standalone selling prices. The Company developed standalone selling prices for licenses and corresponding research services by applying a risk adjusted, net present value, estimate of future potential cash flow approach, which included the cost of obtaining research services at arm&#8217;s length from a <em style="font: inherit;">third</em>-party provider, as well as internal full-time equivalent costs to support these services. The Company developed its standalone selling price for development and manufacturing services, and technology transfer services for the AstraZeneca Lead Product using estimated internal and external costs to be incurred.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company developed its standalone selling price for committee participation by using management&#8217;s estimate of the anticipated participation hours multiplied by a market rate for comparable participants.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company developed its standalone selling price for the commercial licenses and material rights granted on the development licenses by probability weighting multiple cash flow scenarios using the income approach.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The transaction price was comprised of fixed consideration of $45.0 million in upfront fees and variable consideration of (i) $14.2 million in estimated phase <em style="font: inherit;">1</em> services, (ii) $12.5 million in milestone payments achieved upon the initiation of a phase <em style="font: inherit;">1</em> study in <em style="font: inherit;"> December 2017, </em>and (iii) $4.7 million in estimated phase <em style="font: inherit;">2a</em> services. The $45.0 million upfront fee, which represents the fixed consideration in the transaction price, was allocated to each of the performance obligations based on the relative proportion of their standalone selling prices. Variable consideration of $14.2 million is related to the phase <em style="font: inherit;">1</em> services and will be allocated entirely to the performance obligation to which they relate. Variable consideration of $12.5 million related to the phase <em style="font: inherit;">1</em> trial milestone was allocated by relative selling price to the combined performance obligation comprised of a non-exclusive platform technology license, research and development license and commercial licenses for the AstraZeneca Lead Product and research services for the AstraZeneca Lead Product, and the combined performance obligation comprised of&#160;development and manufacturing services and technology transfer services for the AstraZeneca Lead Product performance obligations. Variable consideration of $4.7 million for phase <em style="font: inherit;">2a</em> services was allocated specifically to the related performance obligation.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The amounts allocated to the license performance obligation for the AstraZeneca Lead Product and the four performance obligations for the four research licenses for AstraZeneca Collaboration Products will be recognized on a proportional performance basis as the activities are conducted over the life of the arrangement. The amounts allocated to the performance obligation for phase <em style="font: inherit;">1</em> services, technology transfer services for the AstraZeneca Lead Product will be recognized on a proportional performance basis over the estimated term of development through phase <em style="font: inherit;">2a</em> study. The amounts allocated to the performance obligation for phase <em style="font: inherit;">2a</em> services for the AstraZeneca Lead Product will be recognized on a proportionate performance basis over an estimated term of 12 months.&#160;The amounts allocated to the performance obligation for participation on each of the committees will be recognized on a straight-line basis over the expected term of development of the AstraZeneca Lead Product and the AstraZeneca Collaboration Products. The term of performance is approximately <span style="-sec-ix-hidden:c96253965">five</span> years. The amounts allocated to the four performance obligations for the material rights to acquire a development license and the four performance obligations for commercial licenses for the AstraZeneca Collaboration Products will be recognized upon exercise of the specific material right and delivery of each of the development licenses. As of <em style="font: inherit;"> December 31, 2022</em>, there was $7.5&#160;million of aggregate transaction price allocated to remaining performance obligations.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Additionally, the Company evaluated payments required to be made between both parties as a result of the shared development costs of the AstraZeneca Lead Product and the two AstraZeneca Collaboration Products for which the Company has a co-development option. The Company will classify payments made as a reduction of revenue and will classify payments received as revenue, in the period they are earned.</p>

   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Under the AstraZeneca Agreements, the Company is eligible to receive various research, development, commercial and sales milestones. There is uncertainty that the events to obtain the research and development milestones will be achieved given the nature of clinical development and the stage of the Company&#8217;s technology. The Company has thus determined that all research and development milestones, other than the phase <em style="font: inherit;">1</em> initiation milestone achieved in <em style="font: inherit;"> December 2017 </em>and included in the impact of adoption of ASC <em style="font: inherit;">606,</em> will be constrained until it is deemed probable that a significant revenue reversal will <em style="font: inherit;">not</em> occur.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> March 29, 2021, </em>the Company and AstraZeneca entered into (<em style="font: inherit;">1</em>) Amendment <em style="font: inherit;">No.</em> <em style="font: inherit;">1</em> to the Non-exclusive Anticalin&#174;<b><sup style="vertical-align:top;line-height:120%;font-size:pt"> </sup></b>Platform License Agreement dated <em style="font: inherit;"> May 2, 2017 </em>and (<em style="font: inherit;">2</em>) Amendment <em style="font: inherit;">No.</em> <em style="font: inherit;">2</em> to the License and Collaboration Agreement dated <em style="font: inherit;"> May 2, 2017, </em>as previously amended by Amendment <em style="font: inherit;">No.</em> <em style="font: inherit;">1</em> dated <em style="font: inherit;"> September 14, 2020, </em>collectively, the Amended Collaboration Agreement. Under the Amended Collaboration Agreement, the parties agreed to restructure certain commercial economics for the PRS-<em style="font: inherit;">060/AZD1402</em> program by increasing potential sales milestones and reducing potential sales royalties, while fundamentally maintaining the overall value split between AstraZeneca and the Company.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In connection with the Amended Collaboration Agreement, the Company and AstraZeneca entered into a Subscription Agreement pursuant to which the Company agreed to issue to AstraZeneca, and AstraZeneca agreed to acquire from the Company, 3,584,230 shares of the Company&#8217;s common stock for a total purchase price of $10.0&#160;million, or $2.79 per share, in a private placement transaction pursuant to Section <em style="font: inherit;">4</em>(a)(<em style="font: inherit;">2</em>) of the Securities Act of <em style="font: inherit;">1933,</em> as amended. The Subscription Agreement closed on <em style="font: inherit;"> April 1, 2021 </em>and includes a requirement that the Company file a registration statement to register the resale of the shares issued to AstraZeneca within 60 calendar days of the issuance of the shares. The Company assessed the payment under ASC <em style="font: inherit;">606</em> and concluded that the fair value of the shares on a per share basis was $2.60 per share as of the transaction date. This resulted in a premium paid for the shares of $0.7&#160;million, which was added to the deferred revenue balance and will be recognized over time in line with our revenue recognition pattern for all remaining performance obligations.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Also in <em style="font: inherit;"> March 2021, </em>the Company earned a $13.0&#160;million milestone from AstraZeneca related to the initiation of the phase <em style="font: inherit;">2a</em> study for PRS-<em style="font: inherit;">060/AZD1402.</em> The Company assessed the milestone payment under ASC <em style="font: inherit;">606</em> and determined that there <em style="font: inherit;">no</em> longer existed a constraint on the milestone as the performance obligation related to the phase <em style="font: inherit;">2a</em> study was fully satisfied. Therefore, the Company realized the full $13.0&#160;million as milestone revenue for the year ended <em style="font: inherit;"> December 31, 2021.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In <em style="font: inherit;"> January 2022, </em>the Company and AstraZeneca jointly discontinued one discovery-stage programs as they were <em style="font: inherit;">not</em> able to validate an exploratory target. Approximately $4.7&#160;million of revenue was recorded related to remaining performance obligations related to the program.</p>
   <div style="font-size: 10pt; white-space: pre-wrap;">
     &#160;
   </div>
   <div style="font-size: 10pt;">
     In
    <em style="font: inherit;"> August 2022, </em>the Company and AstraZeneca entered into another amendment of the License and Collaboration Agreement dated
    <em style="font: inherit;"> May 2, 2017, </em>and extended the research term for
    <em style="font: inherit;">two</em> discovery-stage programs through
    <em style="font: inherit;"> December 2023 </em>and subsequently jointly discontinued the
    <em style="font: inherit;">third</em> discovery-stage program. Approximately
    $5.0 million of revenue was recorded pursuant to a performance obligation related to transfer of a license that ceased with the discontinuation of this program.
   </div>
   <div style="font-size: 10pt;">
     &#160;
   </div>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of <em style="font: inherit;"> December 31, 2022</em>, there is $0.5&#160;million and $6.9&#160;million of current and non-current deferred revenue, respectively, related to the AstraZeneca Agreements.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company incurred $1.6 million of <em style="font: inherit;">third</em>-party success fees to obtain the contract with AstraZeneca. Upon adoption of ASC <em style="font: inherit;">606,</em> the Company capitalized $1.1 million in accordance with ASC <em style="font: inherit;">340.</em> As of <em style="font: inherit;"> December 31, 2022</em>, the remaining balance of the asset recognized from transaction costs to obtain the AstraZeneca contract is $0.2&#160;million. Amortization during the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em> was $0.3 million and de minimis, respectively.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><span style="text-decoration: underline; ">Servier</span></i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> January&#160;</em><em style="font: inherit;">4,</em> <em style="font: inherit;">2017,</em> the Company entered into a license and collaboration agreement, or Servier Collaboration Agreement, and a non-exclusive Anticalin platform license agreement, or Servier Platform License, and together with the Servier Collaboration Agreement, the Servier Agreements with Les Laboratoires Servier and Institut de Recherches Internationales Servier, or Servier, pursuant to which the Company and Servier agreed to initially pursue five bispecific therapeutic programs.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Five committed programs were initially defined, which <em style="font: inherit;"> may </em>combine antibodies from the Servier portfolio with one or more Anticalin proteins based on the Company&#8217;s proprietary platform to generate innovative IO bispecific drug candidates, or the Collaboration Products. The collaboration <em style="font: inherit;"> may </em>be expanded by up to three additional therapeutic programs. The Company had the option to co-develop and retain commercial rights in the United States for PRS-<em style="font: inherit;">332,</em> the initial lead program under the collaboration, or the Initial Lead, and has a similar option on up to <em style="font: inherit;">three</em> additional programs, or the Co-Development Collaboration Products, while Servier will be responsible for development and commercialization of the other programs worldwide, or the Servier Worldwide Collaboration Products. Each party is responsible for an agreed upon percentage of shared costs, as set forth in the budget for the collaboration plan, and as further discussed below.</p>

   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Co-Development Collaboration Products <em style="font: inherit;"> may </em>be jointly developed, according to a collaboration plan, through marketing approval from the U.S. Food and Drug Administration or the European Medicines Agency. Servier Worldwide Collaboration Products <em style="font: inherit;"> may </em>be jointly developed, according to a collaboration plan, through specified preclinical activities, at which point Servier becomes responsible for further development of the Collaboration Product.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">At inception, Servier was granted the following licenses: (i)&#160;development license for the Initial Lead, (ii)&#160;commercial license for the Initial Lead, (iii)&#160;individual research licenses for each of the <em style="font: inherit;">four</em> Collaboration Products, and (iv)&#160;individual non-exclusive platform technology licenses for the Initial Lead and for each of the <em style="font: inherit;">four</em> Collaboration Products. Upon achievement of certain development activities, specified by the collaboration for each Servier Agreement, Servier will be granted a development license and a commercial license. For the Initial Lead and the Co-Development Collaboration Products, the licenses granted are with respect to the entire world except for the United States. For Servier Worldwide Collaboration Products, the licenses granted are with respect to the entire world.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Servier Agreements are managed on an overall basis by a joint executive committee, or JEC, formed by an equal number of members from the Company and Servier. Decisions by the JEC will be made by consensus; however, in the event of a disagreement, each party will have final-decision making authority as it relates to the applicable territory in which such party has commercialization rights for the applicable product. In addition to the JEC, the Servier Collaboration Agreement requires the participation of both parties on: (i)&#160;a JSC, (ii) a JDC, (iii) a joint intellectual property committee, or JIPC, and (iv)&#160;a joint research committee, or JRC. The responsibilities of these committees vary, depending on the stage of development and commercialization of the Collaboration Products.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">For the Initial Lead and Co-Development Collaboration Products, the Company and Servier are responsible for an agreed upon percent of the shared costs required to develop the products through commercialization. In the event that the Company fails to exercise its option to co-develop the Co-Development Collaboration Products, Servier has the right to continue with the development and will be responsible for all costs required to develop the products through commercialization.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Under the Servier Agreements, the Company received an upfront, non-refundable payment of <span style="-sec-ix-hidden:c96254027">&#8364;30.0</span> million (approximately $32.0 million). In addition, the Company is eligible to receive research, development, commercial, and sales milestone payments as well as tiered royalties up to low double digits on the sales of commercialized products in the Servier territories. Since inception of the Servier Collaboration Agreement, the Company has achieved <em style="font: inherit;">four</em> development milestones under Servier Agreements totaling <span style="-sec-ix-hidden:c96254030">&#8364;3.8</span> million (approximately $4.3 million), all of which became billable on their respective achievement dates.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The initial research collaboration term, as it relates to the Initial Lead and Collaboration Products, shall continue for three years from the effective date of the Servier agreements, and <em style="font: inherit;"> may </em>be mutually extended for <em style="font: inherit;">two one</em>-year terms consecutively applied.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The term of each Servier Agreement ends upon the expiration of all of Servier&#8217;s payment obligations under such Servier Agreement.&#160;The Servier Agreements <em style="font: inherit;"> may </em>be terminated by Servier for convenience beginning <em style="font: inherit;">12</em> months after their effective date upon <em style="font: inherit;">180</em> days&#8217; notice. The Servier Agreements <em style="font: inherit;"> may </em>also be terminated by Servier or the Company for material breach upon 90 days&#8217; or 120 days&#8217; notice under the Servier Collaboration Agreement and the Servier Platform License, respectively, provided that the applicable party has <em style="font: inherit;">not</em> cured such breach by the applicable 90-day or 120-day permitted cure period, and dispute resolution procedures specified in the applicable Servier Agreement have been followed. The Servier Agreements <em style="font: inherit;"> may </em>also be terminated due to the other party&#8217;s insolvency or for a safety issue and <em style="font: inherit;"> may </em>in certain instances be terminated on a product-by-product and/or country-by-country basis. The Servier Platform License will terminate upon termination of the Servier Collaboration Agreement, on a product-by-product and/or country-by-country basis. In <em style="font: inherit;"> February 2020, </em>the research term was extended for <em style="font: inherit;">12</em> months. The research term was then extended for another <em style="font: inherit;">12</em> months in <em style="font: inherit;"> February 2021.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As the Company and Servier are considered to be active participants in the Servier Agreements and are exposed to significant risks and rewards, certain units of account within the Servier Agreements are within the scope of ASC <em style="font: inherit;">808.</em> The arrangement with Servier provides for the transfer of the following goods and services: (i)&#160;<em style="font: inherit;">five</em> non-exclusive platform technology licenses, a&#160;development license, a&#160;commercial license and research and development services for the Initial Lead, (ii)&#160;participation on each of the committees, (iii)&#160;<em style="font: inherit;">four</em> research licenses for Collaboration Products, and (iv)&#160;research and development services for the Collaboration Products. Additionally, as the development and commercial licenses on the <em style="font: inherit;">four</em> Collaboration Products <em style="font: inherit;"> may </em>be granted at a discount in the future, the Company determined such discounts should be assessed as material rights at inception.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Management evaluated all of the promised goods or services within the contract and determined which goods and services were separate performance obligations. The Company determined that the licenses granted at the inception of the Servier collaboration, should be combined with the research and development services to be provided for the Initial Lead and Collaboration Products, over the term of the Servier Agreements, as such licenses are <em style="font: inherit;">not</em> capable of being distinct. A <em style="font: inherit;">third</em> party would <em style="font: inherit;">not</em> be able to provide the research and development services, due to the specific nature of the intellectual property and knowledge required to perform the services, and Servier could <em style="font: inherit;">not</em> benefit from the licenses without the corresponding services. The Company determined that the participation on the various committees was distinct as the services could be performed by an outside party.</p>

   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As a result, management concluded that there are 10 performance obligations at the inception of the Servier Agreements. The following performance obligations are within the scope of ASC <em style="font: inherit;">808:</em> (i)&#160;combined performance obligation comprised of a non-exclusive platform technology license, commercial license, development license and research and development services for the Initial Lead, (ii)&#160;two separate performance obligations each comprised of a combined non-exclusive platform technology license, research license, and research and development services for each Co-Development Collaboration Product (iii)&#160;<em style="font: inherit;">one</em> performance obligation comprised of participation in the various governance committees, and (iv)&#160;two combined performance obligations comprised of the development and commercial licenses granted for the Co-Development Collaboration Products (and corresponding discounts) upon the achievement of specified preclinical activities, resulting in material rights. Revenue recognized associated with these performance obligations are presented as Collaboration Revenue within the Statement of Operations. The following performance obligations are within the scope of ASC <em style="font: inherit;">606:</em> (i) two separate performance obligations each comprised of a combined non-exclusive platform technology license, research license and research and development services for each Servier Worldwide Collaboration Product, and (ii) two combined performance obligations comprised of the development and commercial licenses granted for the Servier Worldwide Collaboration Products (and corresponding discounts) upon the achievement of specified preclinical activities, resulting in material rights. Revenue recognized associated with these performance obligations are presented as Customer Revenue within the Statement of Operations.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company allocated consideration to the performance obligations based on the relative proportion of their standalone selling prices. The Company developed its standalone selling prices for licenses by applying a risk adjusted, net present value, estimate of future potential cash flows approach, which included the cost of obtaining research and development services at arm&#8217;s length from a <em style="font: inherit;">third</em>-party provider, as well as internal full-time equivalent costs to support these services.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company developed its estimate of standalone selling price for committee participation by using management&#8217;s estimate of the anticipated participation hours multiplied by a market rate for comparable participants.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company developed its estimate of standalone selling price for the material rights granted on the development and commercial licenses granted for the Collaboration Products by probability weighting multiple cash flow scenarios using the income approach.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The transaction price at inception is comprised of the fixed upfront fee of <span style="-sec-ix-hidden:c96254061">&#8364;30.0</span> million (approximately $32.0 million) and was allocated to the performance obligations based on the relative proportion of their standalone selling prices. &#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The amounts allocated to the performance obligation for the Initial Lead and the four performance obligations for the four research and development licenses for Collaboration Products will be recognized on a proportional performance basis as the activities are conducted over the life of the arrangement. The term of the performance at inception of the Servier Agreements for the Initial Lead and each of the Co-Development Collaboration Products <em style="font: inherit;"> may </em>be through approval of certain regulatory bodies; a period which could be many years. The term of the performance for each of the other two Servier Worldwide Collaboration Products is through the initial research and collaboration term, plus potential extensions. The amounts allocated to the performance obligation for participation on each of the committees will be recognized on a straight-line basis over the anticipated performance period over the entirety of the arrangement with Servier. The amounts allocated to the four performance obligations for the material rights to acquire development and commercial licenses for the Co-Development Collaboration Products are granted in the future will be recognized over time upon delivery of each of the licenses through marketing approval. The amounts allocated to the four performance obligations for the material rights to acquire development and commercial licenses for the Servier Developed Collaboration Products are granted in the future will be recognized upon delivery of each of the licenses. As of <em style="font: inherit;"> December 31, 2022</em>, there was $5.0&#160;million of aggregate transaction price allocated to remaining performance obligations.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Additionally, the Company evaluated payments required to be made between both parties as a result of the shared development costs of the Initial Lead and Collaboration Products. The Company will classify payments made as a reduction of revenue and will classify payments received as revenue, in the period they are earned.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Under the Servier Agreements the Company is eligible to receive various research, development, commercial, and sales milestones. There is uncertainty that the events to obtain the research and development milestones will be achieved given the nature of clinical development and the stage of the Company&#8217;s technology. The Company has thus determined that all research and development milestones will be constrained until it is deemed probable that a significant revenue reversal will <em style="font: inherit;">not</em> occur.</p>

   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In <em style="font: inherit;"> September 2019, </em>Servier notified the Company of its decision to discontinue co-development of PRS-<em style="font: inherit;">332,</em> a PD-<em style="font: inherit;">1</em>-LAG-<em style="font: inherit;">3</em> bispecific that served as the initial development program under the Pieris-Servier alliance, for strategic reasons. The Company does <em style="font: inherit;">not</em> presently intend to continue development of PRS-<em style="font: inherit;">332</em> but retains full rights to advance the development and commercialization of the product on a world-wide basis in the future.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In <em style="font: inherit;"> February 2020, </em>the research term was extended for 12 months. The Company updated the transaction price for the extension for revenue recognition purposes and allocated it ratably over all unsatisfied performance obligations. As part of the expiration of the initial research term, the option to expand the collaboration beyond the initial five committed programs also expired. In <em style="font: inherit;"> March 2020, </em>Servier notified the Company of its decision to discontinue co-development of two earlier preclinical stage programs for strategic reasons based upon an extensive portfolio review. The notification required a <em style="font: inherit;">60</em>-day period to complete remaining obligations on the programs; however, the Company determined that the material rights to acquire development and commercial licenses for one Co-Development Collaboration Product and for one Servier Developed Collaboration Products lapsed in <em style="font: inherit;"> March 2020 </em>and recognized $7.1&#160;million of previously deferred revenue associated with these material rights during <em style="font: inherit;">2020.</em> The discontinuation of the two earlier preclinical stage programs decreased the future potential milestone payments the Company could achieve. The parties continue to advance the development of two preclinical programs: PRS-<em style="font: inherit;">344/S095012,</em> a <em style="font: inherit;">4</em>-<em style="font: inherit;">1BB/PD</em>-<em style="font: inherit;">L1</em> bispecific designed as a co-development program, and PRS-<em style="font: inherit;">352,</em> which addresses undisclosed targets and for which Servier has worldwide rights.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In the <em style="font: inherit;">first</em> quarter of <em style="font: inherit;">2022,</em> the Company satisfied the performance obligation related to the material right for PRS-<em style="font: inherit;">352/S095025</em><i>,</i>&#160;which led to point-in-time recognition of revenue for $4.9&#160;million of revenue previously deferred. In the <em style="font: inherit;">fourth</em> quarter of <em style="font: inherit;">2022,</em> Servier discontinued development of PRS-<em style="font: inherit;">352/S095025</em> based upon a strategic portfolio review.</p>
   <div style="font-size: 10pt;">
     &#160;
   </div>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of <em style="font: inherit;"> December 31, 2022</em>, there is $0.9&#160;million and $4.1&#160;million of current and non-current deferred revenue, respectively, related to the Servier Agreements.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company incurred costs to obtain the contract with Servier. Upon adoption of ASC <em style="font: inherit;">606,</em> the Company capitalized $0.5 million of <em style="font: inherit;">third</em>-party service fees in accordance with ASC <em style="font: inherit;">340.</em> As of <em style="font: inherit;"> December 31, 2022</em>, there was no&#160;remaining balance of the asset recognized from costs to obtain the Servier contract. Amortization expense for the years&#160;ended <em style="font: inherit;"> December 31, 2022</em> and <em style="font: inherit;"> December 31, 2021</em> was $0.1 million and de minimis, respectively</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Contract Balances</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company receives payments from its collaboration partners based on payments established in each contract. Upfront payments and fees are recorded as deferred revenue upon receipt or when due until such time as the Company satisfies its performance obligations under each arrangement. A contract asset is a conditional right to consideration in exchange for goods or services that the Company has transferred to a customer. Amounts are recorded as accounts receivable when the Company&#8217;s right is unconditional.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">There were no additions to deferred revenue during the year&#160;ended <em style="font: inherit;"> December 31, 2022</em> and reductions to deferred revenue were $20.4&#160;million for the year&#160;ended <em style="font: inherit;"> December 31, 2022</em>.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139857071530592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Grant Income<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceTextBlock', window );">Government Assistance [Text Block]</a></td>
<td class="text">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><em style="font: inherit;">4.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Grant Income</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">One of the Company's proprietary respiratory assets is PRS-<em style="font: inherit;">220,</em> an oral inhaled Anticalin protein targeting connective tissue growth factor, or CTGF, and it is being developed as a local treatment for idiopathic pulmonary fibrosis. In <em style="font: inherit;"> June 2021, </em>the Company received a <span style="-sec-ix-hidden:c96254145">&#8364;14.2</span> million (approximately $17.0 million) grant from the Bavarian Ministry of Economic Affairs, Regional Development and Energy (the Bavarian Grant) supporting research and development for post-acute sequelae of SARS-CoV-<em style="font: inherit;">2</em> infection (PASC) pulmonary fibrosis, or PASC-PF, also known as post-COVID-<em style="font: inherit;">19</em> syndrome pulmonary fibrosis, or &#8220;long COVID&#8221;.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Bavarian Grant provides partial reimbursement for qualifying research and development activities on PRS-<em style="font: inherit;">220,</em> including drug manufacturing costs, activities and costs to support an IND filing, and phase <em style="font: inherit;">1</em> clinical trials costs. The Bavarian Grant provides reimbursement of qualifying costs incurred through <em style="font: inherit;"> August 2023, </em>which follows the expected development timeline of this program. Qualifying costs incurred <em style="font: inherit;"> may </em>exceed the annual grant funding thresholds. If the Company receives any proceeds from the sale of or licensing income from PRS-<em style="font: inherit;">220,</em> the funds available for reimbursement will be reduced proportionally if they are obtained prior to <em style="font: inherit;"> August 2023. </em>The Company is required to communicate such proceeds in each case with the request to draw-down the funds.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for government assistance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342832&amp;loc=SL128342950-244231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128342832&amp;loc=SL128342950-244231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342832&amp;loc=SL128342943-244231<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342832&amp;loc=SL128342950-244231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342832&amp;loc=SL128342950-244231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139857158500464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Cash, Cash Equivalents and Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Cash, Cash Equivalents, and Marketable Securities [Text Block]</a></td>
<td class="text">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><em style="font: inherit;">5.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Cash, Cash Equivalents and Investments</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">As of&#160;<em style="font: inherit;"> December 31, 2022</em>, cash, cash equivalents and investments comprised funds in depository, money market accounts, U.S. and foreign treasury securities, asset-backed securities and corporate bonds. As of&#160;<em style="font: inherit;"> December 31, 2021</em>, cash equivalents were comprised of only money market accounts. The following table presents the cash equivalents and investments carried at fair value in accordance with the hierarchy defined in Note&#160;<em style="font: inherit;">2</em>&#160;at <em style="font: inherit;"> December 31, 2022</em>.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Total</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Quoted prices in active markets (Level 1)</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Significant other observable inputs (Level 2)</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Significant unobservable inputs (Level 3)</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>December 31, 2022</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Money market funds, included in cash equivalents</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">17,618</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">17,618</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Investments - US treasuries</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,573</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,573</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Investments - Foreign treasuries</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">896</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">896</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Investments - Asset-backed securities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">499</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">499</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Investments - Corporate bonds</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">15,566</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">15,566</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">38,152</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">22,087</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">16,065</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Total</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Quoted prices in active markets (Level 1)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Significant other observable inputs (Level 2)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Significant unobservable inputs (Level 3)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>December 31, 2021</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Money market funds, included in cash equivalents</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">56,885</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">56,885</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">56,885</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">56,885</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">Cash equivalents and marketable securities have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing&#160;<em style="font: inherit;">third</em>&#160;party pricing services or other market observable data. The pricing services utilize industry standard valuation models, including both income and market-based approaches and observable market inputs to determine value. The Company validates the prices provided by its&#160;<em style="font: inherit;">third</em>-party pricing services by reviewing their pricing methods and obtaining market values from other pricing sources, as needed. After completing its validation procedures, the Company did&#160;<em style="font: inherit;">not</em>&#160;adjust any fair value measurements provided by the pricing services as of&#160;<em style="font: inherit;"> December 31, 2022</em>.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">Investments at&#160;<em style="font: inherit;"> December 31, 2022</em>&#160;consist of the following (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 37%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Contractual maturity</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 11%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 11%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 37%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><span style="-sec-ix-hidden:c96254205">(in days)</span></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Amortized Cost</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Unrealized gains</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Unrealized losses</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Fair Value</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 37%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Investments</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 11%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 11%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 37%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">US treasuries</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><em style="font: inherit;">47</em>-<em style="font: inherit;">110</em></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,575</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(2</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,573</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 37%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Foreign treasuries</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">74</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">899</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 11%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(3</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">896</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 37%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Asset-backed securities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">15</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">500</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 11%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(1</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">499</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 37%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Corporate bonds</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><em style="font: inherit;">5</em>-<em style="font: inherit;">228</em></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">15,633</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 11%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(67</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">15,566</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 37%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 9%;"><span style="-sec-ix-hidden:c96254241">&#160;</span></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">20,607</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(73</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">20,534</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">The Company recorded&#160;realized gains from the maturity of available-for-sale securities of&#160;$0.4 million for the year ended&#160;<em style="font: inherit;"> December 31, 2022</em> and recorded&#160;<span style="-sec-ix-hidden:c96254158">no</span>&#160;realized gains or losses from the maturity of available-for-sale securities for the year ended&#160;<em style="font: inherit;"> December 31, 2021</em>.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">As of&#160;<em style="font: inherit;"> December 31, 2022</em>, there were&#160;<em style="font: inherit;">no</em>&#160;investments with a fair value that was significantly lower than the amortized cost basis or any investments that had been in an unrealized loss position for a significant period.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139857071670480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment Disclosure [Text Block]</a></td>
<td class="text">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><em style="font: inherit;">6.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Property and Equipment, Net</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Property and equipment are summarized as follows (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Years Ended December 31,</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2022</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2021</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Laboratory furniture and equipment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">11,970</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">11,354</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Office furniture and equipment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,861</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,959</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Computer equipment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">364</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">396</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Leasehold improvements</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,444</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">13,130</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Property and equipment, cost</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">26,639</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">26,839</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Accumulated depreciation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(9,647</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(7,717</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"><b>Property and equipment, net</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">16,992</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">19,122</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Depreciation expense was $2.3&#160;million and $2.4 million for the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em>, respectively. There were <em style="font: inherit;">no</em> other changes in accumulated depreciation other than the foreign currency impact.</p>

   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139857069246992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</a></td>
<td class="text">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><em style="font: inherit;">7.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Accrued Expenses</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Accrued expenses and other current liabilities consisted of the following (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Years Ended December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development fees</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,758</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,682</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Compensation expense</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,015</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,581</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued license obligations</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">245</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,541</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued accounts payable</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,245</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,980</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Lease liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">859</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,049</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Other current liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">483</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">393</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Collaboration cost-sharing obligation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,610</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,605</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">16,836</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139857071665760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Tax Disclosure [Text Block]</a></td>
<td class="text">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><em style="font: inherit;">8.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Income Taxes</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company reported a loss before income taxes consisting of the following (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Years Ended December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Domestic</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(11,765</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(11,312</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Foreign</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(21,512</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(34,426</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Loss before income taxes</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(33,277</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(45,738</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The components of the provision for income taxes are as follows (in thousands):</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Years Ended December 31,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Current:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Federal</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">State</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Foreign</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total current</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Deferred:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Federal</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">State</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Foreign</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total deferred</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Provision for income taxes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The reconciliation of the federal statutory rate to the Company&#8217;s effective tax rate is as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Federal income tax rate</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">21.0</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">21.0</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Foreign rate differential</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5.0</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5.6</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">State tax, net of federal benefit</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.0</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.2</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Share-based awards compensation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(2.2</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(3.5</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)%</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Permanent items</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.3</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(0.2</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)%</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Provision to return</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">3.3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">1.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Credits</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">1.2</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Change in valuation allowance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(28.3</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(27.4</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)%</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Effective income tax rate</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">%</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The components of deferred tax assets and liabilities related to net tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income taxes purposes were as follows (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Years Ended December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Deferred tax assets:</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Net operating loss carryforwards</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">54,845</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">49,280</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Share-based awards compensation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,112</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,739</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Accrued expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">216</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">323</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 18pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">R&amp;D Credits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">413</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Depreciation and other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">384</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">384</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Unrealized foreign currency</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">359</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">256</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 18pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Capitalized R&amp;D</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">952</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 18pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Accrued Expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Lease liability</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,541</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,022</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Total deferred tax assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">63,822</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">57,004</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Deferred tax liabilities:</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Right-of-use asset</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(3,270</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(3,729</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Accrued expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(68</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Total deferred tax liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,270</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,797</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Less: valuation allowance:</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(60,552</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(53,207</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Net deferred tax asset</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company operates in multiple jurisdictions. Accordingly, the Company files U.S. federal and state income tax returns as well as returns in multiple foreign jurisdictions. In assessing the realizability of deferred tax assets, management considers whether it is more likely than <em style="font: inherit;">not</em> that some portion or all deferred tax assets will <em style="font: inherit;">not</em> be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax-planning strategies in making this assessment. Management believes it is more likely than <em style="font: inherit;">not</em> that the results of future operations will <em style="font: inherit;">not</em> generate sufficient taxable income in the United States or in its foreign jurisdictions to realize the full benefits of its deferred tax assets. As of <em style="font: inherit;"> December 31, 2022</em>, the Company continues to maintain a full valuation allowance against all net deferred tax assets.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The cumulative amount of earnings of our foreign subsidiaries are expected to be permanently invested in the foreign subsidiaries. Deferred taxes have <em style="font: inherit;">not</em> been provided on the excess of book basis over tax basis, or the excess tax basis over book basis in the shares of our foreign subsidiaries because these basis differences are <em style="font: inherit;">not</em> expected to reverse in the foreseeable future and are essentially permanent in duration. Our intention is to reinvest the earnings of the foreign subsidiaries indefinitely.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The increase in the valuation allowance of deferred tax assets of $7.3 million for the year ended <em style="font: inherit;"> December 31, 2022</em> was primarily a result of the operating losses generated in current tax year.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of <em style="font: inherit;"> December 31, 2022</em>, the Company had net operating loss carryforwards for U.S. federal income tax purposes of $38.6&#160;million and net operating loss carryforwards for state income tax purposes of $42.4 million. Federal tax loss carryforwards that were created prior to <em style="font: inherit;"> December 31, 2017 </em>expire through <em style="font: inherit;">2037</em> and federal losses created after that date do <em style="font: inherit;">not</em> expire. State loss carryforwards expire starting in <em style="font: inherit;">2035.</em> Pursuant to Section <em style="font: inherit;">382</em> of the Internal Revenue Code, and similar state tax law, certain substantial changes in the Company&#8217;s ownership <em style="font: inherit;"> may </em>result in a limitation on the amount of net operating loss and tax credit carryforwards that <em style="font: inherit;"> may </em>be used in future years. Utilization of the net operating loss and tax credit carryforwards <em style="font: inherit;"> may </em>be subject to an annual limitation under Section <em style="font: inherit;">382</em> of the Internal Revenue Code of <em style="font: inherit;">1986</em> due to ownership change limitations that have occurred previously or that could occur in the future. These ownership changes <em style="font: inherit;"> may </em>limit the amount of net operating loss and tax credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. The Company completed a Section <em style="font: inherit;">382</em> study through <em style="font: inherit;"> December 31, 2020. </em>Based on the study, the Company underwent an ownership change for Section <em style="font: inherit;">382</em> purposes which occurred in <em style="font: inherit;"> February 2018. </em>As a result of the ownership change, the Company&#8217;s net operating loss and tax credit carryforwards as of the ownership change dates are subject to limitation under Section <em style="font: inherit;">382;</em> however, these limitations are <em style="font: inherit;">not</em> expected to result in any of the impacted net operating loss and tax credit carryforwards to expire unutilized. Any net operating losses or tax credits generated after the <em style="font: inherit;"> February 2018 </em>change are <em style="font: inherit;">not</em> subject to this annual limitation. However, subsequent ownership changes, as defined by Section <em style="font: inherit;">382,</em> <em style="font: inherit;"> may </em>potentially further limit the amount of net operating loss and tax credit carryforwards that could be utilized to offset future taxable income and tax. The Company is currently open to examination under the statute of limitations by the Internal Revenue Service and state jurisdictions for the tax years ended <span style="-sec-ix-hidden:c96254311">2019</span> through the current year. Carryforward tax attributes generated in years past <em style="font: inherit;"> may </em>still be adjusted upon future examination if they have or will be used in a future period. The Company is currently under examination in Germany for <span style="-sec-ix-hidden:c96254312">2014</span> through <span style="-sec-ix-hidden:c96254313">2017;</span> however, the Company is <em style="font: inherit;">not</em> under examination by the Internal Revenue Service or any other jurisdictions for any tax years.</p>

   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of <em style="font: inherit;"> December 31, 2022</em>, the Company had German corporate income tax and trade tax net operating loss carryforwards of approximately $163.3 million and $160.4 million respectively. Under current German laws, tax loss carryforwards <em style="font: inherit;"> may </em>only be used to offset any relevant later assessment period (calendar year) of <em style="font: inherit;">$1.2</em> million plus <em style="font: inherit;">60%</em> of the exceeding taxable income and trade profit of such period and do <em style="font: inherit;">not</em> expire. In addition, certain transactions, including transfers of shares or interest in the loss holding entity, <em style="font: inherit;"> may </em>result in the partial or total forfeiture of tax losses existing at that date. Partial or total forfeiture of tax losses <em style="font: inherit;"> may </em>further occur in corporate reorganizations of the loss holding entity.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company accounts for uncertain tax positions pursuant to ASC <em style="font: inherit;">740,</em> <i>Income Taxes</i>, which prescribes a recognition threshold and measurement process for financial statement recognition of uncertain tax positions taken or expected to be taken in a tax return. If the tax position meets this threshold, the benefit to be recognized is measured at the largest amount of benefit that is more likely than <em style="font: inherit;">not</em> (determined by cumulative probability) of being realized upon ultimate settlement with the taxing authority. The Company recorded an uncertain tax position related to a prior year position, that if successfully challenged by tax authorities could result in the loss of certain tax attributes. The balance of uncertain tax positions will remain until such time that settlement is reached with the relevant tax authorities or should the statute of limitations expire. The Company recognizes interest and penalties, if any, related to uncertain tax positions in income tax expense. No interest and penalties related to uncertain tax positions were accrued at <em style="font: inherit;"> December 31, 2022</em> and <em style="font: inherit;"> December 31, 2021</em>.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> December 22, 2017, </em>the Tax Cuts and Jobs Act, or the TCJA, was signed into law. Under the TCJA provisions, effective with tax years beginning on or after <em style="font: inherit;"> January 1, 2022, </em>taxpayers can <em style="font: inherit;">no</em> longer immediately expense qualified research and development expenditures. Taxpayers are now required to capitalize and amortize these costs over <em style="font: inherit;">five</em> years for research conducted within the United States or <em style="font: inherit;">15</em> years for research conducted abroad. As a result, the Company capitalized $1.0 million of research and development expenses for the year ended <em style="font: inherit;"> December 31, 2022</em>.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following table sets forth a reconciliation of the beginning and ending amounts of unrecognized tax benefits, excluding the impact of interest and penalties, for the years ended <em style="font: inherit;"> December 31, 2022</em> (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Unrecognized tax benefits at December 31, 2021</b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,665</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Currency translation adjustment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(302</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Unrecognized tax benefits at December 31, 2022</b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,363</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company does <em style="font: inherit;">not</em> expect unrecognized tax benefits to change significantly over the next <em style="font: inherit;">12</em> months. The full amount of unrecognized tax benefits would impact the effective rate, subject to valuation allowance considerations, if recognized.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139857071585760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity Note Disclosure [Text Block]</a></td>
<td class="text">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><em style="font: inherit;">9.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Stockholders</b>&#8217;<b> equity</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company had 300,000,000 shares authorized and 74,519,103 and 72,222,661shares of common stock issued and outstanding as of <em style="font: inherit;"> December 31, 2022</em> and <em style="font: inherit;"> December 31, 2021</em>, respectively, with a par value of $0.001 per share.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company had 10,000,000 shares authorized and 15,617 shares of preferred stock issued and outstanding as of <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em>. Preferred stock has a par value of $0.001 per share, and consists of the following tranches:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"><tbody><tr><td style="width:18pt;">&#160;</td><td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td><td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Series A Convertible, 85 shares issued and outstanding at&#160;<em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em></p> </td></tr>
</tbody></table>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"><tbody><tr><td style="width:18pt;">&#160;</td><td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td><td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Series B Convertible, 4,026 shares issued and outstanding at <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em></p> </td></tr>
</tbody></table>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"><tbody><tr><td style="width:18pt;">&#160;</td><td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td><td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Series C Convertible, 3,506 shares issued and outstanding at <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em></p> </td></tr>
</tbody></table>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"><tbody><tr><td style="width:18pt;">&#160;</td><td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td><td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Series D Convertible, 3,000 shares issued and outstanding at both <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em></p> </td></tr>
</tbody></table>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"><tbody><tr><td style="width:18pt;">&#160;</td><td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td><td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Series E Convertible, 5,000 shares issued and outstanding at <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Common Stock</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Each share of the Company&#8217;s common stock is entitled to one vote and all shares rank equally as to voting and other matters. Dividends <em style="font: inherit;"> may </em>be declared and paid on the common stock from funds legally available therefor, if, as and when determined by the Board of Directors.</p>

   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Preferred Stock</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company has issued multiple series (Series A through E) of preferred stock to certain entities affiliated with Biotechnology Value Fund, L.P., or BVF. In each case, each share Preferred Stock is convertible into 1,000 shares of the Company's common stock (subject to adjustment as provided in the Certificate of Designation for each series) at any time at the option of the holder, provided that the holder is prohibited from converting the Preferred Stock into shares of the Company's common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 9.99% of the total number of shares of Common Stock then issued and outstanding, or the Beneficial Ownership Limitation. The holder <em style="font: inherit;"> may </em>reset the Beneficial Ownership Limitation to a higher or lower number, <em style="font: inherit;">not</em> to exceed 19.99% of the total number of common shares issued and outstanding immediately after giving effect to a conversion, upon providing written notice to the Company. Any such notice providing for an increase to the Beneficial Ownership Limitation will be effective 61 days after delivery to the Company.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Series A, Series B, Series C, Series D and Series E Preferred Stock rank senior to the Company&#8217;s common stock; senior to any class or series of capital stock of the Company created after the designation of and specifically ranking by its terms as junior to the <em style="font: inherit;">five</em> series of Preferred Stock; in parity with each other and with any class or series of capital stock of the Company created after the designation of and specifically ranking by its terms as in parity with the existing <em style="font: inherit;">five</em> series of Preferred Stock; and junior to any class or series of capital stock of the Company created after the designation of and specifically ranking by its terms as senior to the existing <em style="font: inherit;">five</em> series of Preferred Stock. In the event of the Company&#8217;s liquidation, dissolution or winding up, subject to the rights of holders of, holders are entitled to receive a payment equal to $0.001 per share of Preferred Stock pursuant to the rights and preferences discussed above, plus an additional amount equal to any dividends declared but unpaid on such shares. However, if the assets of the Company are insufficient to comply with the preceding sentence, then all remaining assets of the Company shall be distributed ratably to holders of the shares of the existing <em style="font: inherit;">five</em> series of Preferred Stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">For each series of Preferred Stock, the Company designated the requisite number of shares of its authorized and unissued preferred stock as a specific series of Preferred Stock and filed a Certificate of Designation with the Nevada Secretary of State.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Shares of Preferred Stock generally have <em style="font: inherit;">no</em> voting rights, except as required by law and except that the consent of holders of a majority of the then outstanding Preferred Stock is required to amend the terms of the Certificate of Designation for each respective series of Preferred Stock. Holders of Preferred Stock are entitled to receive any dividends payable to holders of the Company's common stock subject to the rights and preferences discussed above, in each case, as to distributions of assets upon the Company&#8217;s liquidation, dissolution or winding up whether voluntarily or involuntarily and/or the right to receive dividends.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Series A Preferred Stock</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In <em style="font: inherit;"> June 2016, </em>the Company entered into a securities purchase agreement for a private placement of the Company&#8217;s securities with a select group of institutional investors, or the <em style="font: inherit;">2016</em> PIPE. The <em style="font: inherit;">2016</em> PIPE sale transaction, by the Company, consisted of 8,188,804 units at a price of $2.015 per unit for gross proceeds, to the Company, of approximately $16.5 million. After deducting for placement agent fees and offering expenses, the aggregate net proceeds from the private placement was approximately $15.3 million. In connection with the <em style="font: inherit;">2016</em> PIPE, the Company issued 3,225,804 shares of common stock and 4,963 shares of Series A Preferred Stock to the <em style="font: inherit;">2016</em> PIPE investors.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Series B Preferred Stock</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> January 30, 2019, </em>the Company and certain entities affiliated with Biotechnology Value Fund, L.P., or BVF entered into an exchange agreement pursuant to which BVF agreed to exchange an aggregate of 5,000,000 shares of the Company&#8217;s common stock owned by BVF for an aggregate of 5,000 shares of Series B Preferred Stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Series C and <em style="font: inherit;">2019</em> Private Placement</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In <em style="font: inherit;"> November 2019, </em>the Company entered into a securities purchase agreement for a private placement, or the Purchase Agreement with a select group of institutional investors, including lead investor BVF as well as existing and new investors, or Investors. The private placement consisted of 9,014,960 units, at a price of $3.55 per unit, or the Financing, for gross proceeds of approximately $32.0 million, and net proceeds to the Company of approximately $31.0 million. Each unit consists of (i)&#160;<span style="-sec-ix-hidden:c96254476">one</span> share of the Company&#8217;s common stock, or Common Shares, or 0.001 shares of non-voting Series C convertible preferred stock, or Series C Preferred Shares, and together with the Common Shares, or Shares, and (ii)&#160;<span style="-sec-ix-hidden:c96254478">one</span> immediately-exercisable warrant to purchase <span style="-sec-ix-hidden:c96254479">one</span> share of the Company&#8217;s common stock with an exercise price of $7.10, or Exercise Price.</p>

   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If (i) the initial public disclosure of the phase <em style="font: inherit;">2a</em> Study of PRS-<em style="font: inherit;">060/AZD1402</em> that includes the &#8220;p&#8221; value achieved for the primary endpoint of such study reveals top-line data on the primary efficacy endpoint in the phase <em style="font: inherit;">2a</em> Study with a &#8220;p&#8221; value below <em style="font: inherit;">0.05</em> (i.e., p &lt; <em style="font: inherit;">0.05</em>) in at least <em style="font: inherit;">one</em> dose level; and (ii) the <em style="font: inherit;">10</em>-day volume weighted average stock price commencing on the trading day immediately after the initial public disclosure is at least <span style="-sec-ix-hidden:c96254489">three</span> percent more than the Exercise Price, ((i) and (ii), collectively, the &#8220;Performance Condition&#8221;), then the warrants will be exercisable for a period of <em style="font: inherit;">60</em> days from the date of the initial data disclosure and <em style="font: inherit;"> may </em>only be exercised for cash. Otherwise, the warrants will be exercisable for a period of <span style="-sec-ix-hidden:c96254491">five</span> years from the date of issuance, or Exercise Date. If the Performance Condition has <em style="font: inherit;">not</em> been met and the last reported sale price of the Company&#8217;s common stock immediately prior to the Expiration Date was greater than the Exercise Price, then the warrants shall be automatically deemed exercised on a cashless basis on the Expiration Date.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Upon issuance, each Series C Preferred Share included an embedded beneficial conversion feature as the market price of the Company&#8217;s Common Stock on the date of issuance of the Series C convertible preferred stock was $3.43 per share. As a result, the Company recorded the intrinsic value of the beneficial conversion feature of $2.8 million as a discount on the Series C convertible preferred stock at issuance. As the Series C Preferred Shares are immediately convertible upon issuance and do <em style="font: inherit;">not</em> include a stated redemption date, the discount was immediately accreted as a deemed dividend.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Series D Preferred Stock Conversion</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> March 31, 2020, </em>the Company and certain entities affiliated with BVF entered into an exchange agreement pursuant to which, on <em style="font: inherit;"> April 1, 2020, </em>BVF exchanged an aggregate of 3,000,000 shares of the Company&#8217;s common stock owned by BVF for an aggregate of 3,000 shares of Series D Preferred Stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Series E Preferred Stock Conversion</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> May 20, 2021, </em>the Company and certain entities affiliated with BVF entered into an exchange agreement pursuant to which, BVF exchanged an aggregate of 5,000,000 shares of the Company&#8217;s common stock owned by BVF for an aggregate of 5,000 shares of Series E Preferred Stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Open Market Sales Agreement</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In <em style="font: inherit;"> August 2019, </em>the Company entered into a sales agreement with Jefferies LLC pursuant to which the Company <em style="font: inherit;"> may </em>offer and sell shares of its common stock, from time to time, up to an aggregate gross sales proceeds of $50.0 million (the <em style="font: inherit;">2019</em> ATM Program). In <em style="font: inherit;"> August 2021, </em>the <em style="font: inherit;">2019</em> ATM Program expired, and the Company established a <em style="font: inherit;">second</em> ATM offering program, or the <em style="font: inherit;">2021</em> ATM Program, under the existing sales agreement with Jefferies LLC, pursuant to which the Company <em style="font: inherit;"> may </em>offer and sell shares of its common stock, par value $0.001 per share, from time to time, up to an aggregate amount of gross sales proceeds of $50.0&#160;million. In <em style="font: inherit;"> November 2022, </em>the sales agreement was amended to provide for an increase in the aggregate offering amount, such that under the <em style="font: inherit;">2021</em> ATM Program, as amended, the Company <em style="font: inherit;"> may </em>offer and sell shares of its common stock, from time to time, up to an aggregate amount of gross sales proceeds of $75.0 million. The <em style="font: inherit;">2021</em> ATM Program, as amended, is offered under a shelf registration statement on Form S-<em style="font: inherit;">3</em> that was filed with and declared effective by the SEC in <em style="font: inherit;"> August 2021. </em>For the year ended <em style="font: inherit;"> December 31, 2022</em>, the Company sold 2.1 million shares for gross proceeds of $7.2&#160;million under the <em style="font: inherit;">2021ATM</em> program at an average stock price of $3.46. For the year ended <em style="font: inherit;"> December 31, 2021</em>, the Company sold 8.2 million shares for gross proceeds of $39.7&#160;million under both ATM programs at an average stock price of $4.85.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139857071618880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share [Text Block]</a></td>
<td class="text">
   <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><em style="font: inherit;">10.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Net Loss per Share</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Basic net loss per share is calculated by dividing net income (loss) by the weighted average shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share calculation, preferred stock, stock options, and warrants are considered to be common stock equivalents but have been excluded from the calculation of diluted net loss per share, as their effect would be anti-dilutive for all periods presented. Therefore, basic and diluted net loss per share were the same for all periods presented.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">For the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em>, and as calculated using the treasury stock method, approximately 38.4 million and 36.8 million of weighted average shares, respectively, were excluded from the calculation of diluted weighted average shares outstanding as their effect was antidilutive.</p>

  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139857069427424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Stock and Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Payment Arrangement [Text Block]</a></td>
<td class="text">
    &#160;
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><em style="font: inherit;">11.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Stock and Employee Benefit Plans</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Employee, Director and Consultant Equity Incentive Plans</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">At the Annual Shareholder Meeting, held on <em style="font: inherit;"> June 23, 2020, </em>the shareholders approved the <em style="font: inherit;">2020</em> Employee, Director and Consultant Equity Incentive Plan, or the <em style="font: inherit;">2020</em> Plan. The <em style="font: inherit;">2020</em> Plan originally permitted the Company to issue up to&#160;3,500,000&#160;shares of common stock pursuant to awards granted under the <em style="font: inherit;">2020</em> Plan. Upon approval of the <em style="font: inherit;">2020</em> Plan, the <em style="font: inherit;">2019</em> Employee, Director and Consultant Equity Incentive Plan, or the <em style="font: inherit;">2019</em> Plan, was terminated; all unissued options were canceled and <em style="font: inherit;">no</em> additional awards will be made thereunder. All outstanding awards under the <em style="font: inherit;">2019</em> Plan will remain in effect and any awards forfeited from the outstanding awards will be allocated back into the <em style="font: inherit;">2020</em> Plan. The <em style="font: inherit;">2020</em> Plan, similar to the <em style="font: inherit;">2019</em> Plan, provided for the grant of stock options, restricted and unrestricted stock awards, and other stock-based awards to employees of the Company, non-employee directors of the Company, and certain other consultants performing services for the Company as designated by either the Board of Directors or the compensation committee of the Board of Directors. At the <em style="font: inherit;">2021</em> Annual Meeting of Stockholders, held on <em style="font: inherit;"> June 25, 2021, </em>the Company&#8217;s stockholders approved the <em style="font: inherit;">first</em> amendment to the <em style="font: inherit;">2020</em> Plan to add 2,250,000 shares for issuance under the <em style="font: inherit;">2020</em> Plan, which increased the total permitted for issuance under the <em style="font: inherit;">2020</em> Plan to 5,750,000. At the <em style="font: inherit;">2022</em> Annual Meeting of Stockholders, held on <em style="font: inherit;"> June 22, 2022, </em>the Company&#8217;s stockholders approved the <em style="font: inherit;">second</em> amendment to the <em style="font: inherit;">2020</em> Plan to add an additional 3,000,000 shares for issuance under the <em style="font: inherit;">2020</em> Plan, which increased the total permitted for issuance under the <em style="font: inherit;">2020</em> Plan to 8,750,000.</p>
   <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">The <em style="font: inherit;">2020</em> Plan permits the Company to issue up to 8,750,000 shares reserved for issuance pursuant to the <em style="font: inherit;">2020</em> Plan and any additional shares which <em style="font: inherit;"> may </em>be issued if awards outstanding under the Registrant&#8217;s <em style="font: inherit;">2014,</em> <em style="font: inherit;">2016,</em> <em style="font: inherit;">2018</em> and <em style="font: inherit;">2019</em> Plans are canceled or expire.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company&#8217;s stock options have a maximum term of 10 years from the date of grant. Stock options granted <em style="font: inherit;"> may </em>be either incentive stock options or nonqualified stock options and the exercise price of stock options must be at least equal to the fair market value of the common stock on the date of grant. The Company&#8217;s general policy is to issue common shares upon the exercise of stock options.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company estimates the fair value of each stock award on the grant date using the Black-Scholes option-pricing model based on the following assumptions:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Years Ended December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Risk free interest rate</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.43% - 3.39%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.46% - 1.20%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected term (in years)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5.5 - 5.73</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5.31 - 5.73</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Dividend yield</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected volatility</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">79.9% - 81.1%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">75.0% - 81.7%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The weighted-average fair value of the 3,075,282 and 3,182,696 options granted during the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em> was $1.96 and $2.04, respectively. As of <em style="font: inherit;"> December 31, 2022</em>, there were 4,314,513 shares available for future grant under the <em style="font: inherit;">2020</em> Plan.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following table summarizes stock option activity for employees and non-employees:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted-</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted-</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Average</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Aggregate</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Average</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Remaining</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Intrinsic</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Number of</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Exercise</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Contractual</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Value</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Options</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Price</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Life (in years)</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">(in thousands)</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, December 31, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,475,713</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.35</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,310</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,075,282</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.88</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Exercised</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">46,233</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.07</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">66</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Canceled</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,031,396</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.80</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">17</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, December 31, 2022</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13,473,366</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3.21</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6.31</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Vested or expected to vest, December 31, 2022</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13,473,366</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3.21</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6.31</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercisable, December 31, 2022</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">9,096,001</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3.38</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5.16</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Periodically, the Company grants inducement options, which are awards outside of approved stock option plans, and which are material awards to the executive officers or other personnel entering senior leadership roles with the Company. The terms of inducement option awards were substantially the same as those issued under our <em style="font: inherit;">2020</em> Plan. These awards are excluded from the table above. The following table summarizes stock option activity for these inducement options (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted-</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted-</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Average</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Aggregate</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Average</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Remaining</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Intrinsic</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Number of</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Exercise</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Contractual</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Value</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Options</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Price</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Life (in years)</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">(in thousands)</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">660,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4.01</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">108</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Canceled or Expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">360,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">3.48</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, December 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">300,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4.65</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">6.66</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Vested or expected to vest, December 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">300,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4.65</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">6.66</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercisable, December 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">243,750</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4.65</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">6.66</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Employee Stock Purchase Plans</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The <em style="font: inherit;">2018</em> ESPP provides eligible employees with the opportunity, through regular payroll deductions, to purchase shares of the Company&#8217;s common stock at&#160;85%&#160;of the lower closing market price of the common stock at the beginning date or ending date of each purchase period. The plan includes <em style="font: inherit;"><span style="-sec-ix-hidden:c96254613">two</span> <span style="-sec-ix-hidden:c96254614">six</span></em>-month purchase periods per year beginning in both <em style="font: inherit;"> June </em>and <em style="font: inherit;"> December. </em>The Company has reserved 500,000 shares of common stock for the administration of the <em style="font: inherit;">2018</em> ESPP. Total shares purchased under the plan were 181,466 and 64,257 for the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em>, respectively. The fair value of shares expected to be purchased under the <em style="font: inherit;">2018</em> ESPP was determined using the Black-Scholes model with the following assumptions:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Years Ended December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Risk free interest rate</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.62% - 4.60%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.04% - 0.10%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected term (in years)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.5</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.5</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Dividend yield</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected volatility</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">53.46% - 70.17%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">60.46% - 131.21%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Total Stock-based Compensation Expense</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total stock-based compensation expense is recorded in operating expenses based upon the functional responsibilities of the individuals holding the respective options as follows (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Years Ended December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,905</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,274</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">General and administrative</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,497</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,941</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total stock-based compensation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,402</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,215</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of <em style="font: inherit;"> December 31, 2022</em>, the total unrecognized compensation cost related to all non-vested awards was $7.0 million of which $0.2 million are for inducement options. The Company expects to recognize the compensation cost over a remaining weighted-average period of 2.49 years.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139857069548064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - License Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_LicenseAndTransferAgreementTextBlock', window );">License and Transfer Agreement [Text Block]</a></td>
<td class="text">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><em style="font: inherit;">12.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>License Agreement</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>TUM License</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company and the Technical University of Munich, or TUM, initiated discussions in the <em style="font: inherit;">second</em> quarter of <em style="font: inherit;">2018</em> to clarify, expand and restructure the research and licensing agreement with TUM, the TUM License, including the parties&#8217; obligations under the TUM License. The TUM License assigns or exclusively licenses to the Company certain intellectual property related to the Company's Anticalin platform technology. The parties' discussions relate to revised commercial terms and to re-initiating additional collaborations between faculty at TUM and Pieris.&#160; While an amended and restated license agreement has <em style="font: inherit;">not</em> yet been completed, the Company intends to enter into such an&#160;amendment. These discussions <em style="font: inherit;"> may </em>also lead to an increase in the Company's collaborative research activities with TUM.</p>

   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_LicenseAndTransferAgreementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the entity's license and transfer agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_LicenseAndTransferAgreementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139857071670480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Lessee, Operating Leases [Text Block]</a></td>
<td class="text">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><em style="font: inherit;">13.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Leases</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company entered into a sublease to lease approximately 3,950 square feet in Boston, Massachusetts which expired on <em style="font: inherit;"> December 31, 2022. </em>The Company generally conducts its operational functions in the United States remotely.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In <em style="font: inherit;"> October 2018, </em>Pieris GmbH entered into a lease for office and laboratory space located in Hallbergmoos, Germany, or the Hallbergmoos Lease. Pieris GmbH moved its operations to the Hallbergmoos facility in <em style="font: inherit;"> February 2020.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Under the Hallbergmoos Lease, Pieris GmbH rents approximately 105,000 square feet. An additional approximately 22,300 square feet is expected to be delivered by the lessor by <em style="font: inherit;"> October 2024. </em>Pieris GmbH has a <em style="font: inherit;">first</em> right of refusal to lease an additional approximate 13,400 square feet.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Hallbergmoos Lease provides for an initial rental term of&#160;12.5 years which commenced in <em style="font: inherit;"> February 2020 </em>when the leased property was delivered to Pieris GmbH. Pieris GmbH also has an option to extend the Hallbergmoos Lease for two additional 60-month periods. The Company is <em style="font: inherit;">not</em> reasonably certain to exercise the option to extend the lease expiration beyond its current expiration date. Pieris GmbH <em style="font: inherit;"> may </em>sublease space within the leased property with lessor&#8217;s consent, which <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be unreasonably withheld.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Monthly base rent for the 105,000 square feet of the leased property, including parking spaces, totals approximately $0.2 million per month, which amount shall be adjusted starting on the <em style="font: inherit;">second</em> anniversary of the commencement date by an amount equal to the German consumer price index. In addition to the base rent, Pieris GmbH is also responsible for certain administrative and operational costs in accordance with the Hallbergmoos Lease. Pieris GmbH provided a security deposit of $0.8 million at upon signing the lease agreement. The Company will serve as a guarantor for the Hallbergmoos Lease.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Hallbergmoos Lease included $11.5 million of tenant improvements allowance for normal tenant improvements which was incurred prior to commencing the lease. The Company capitalized the leasehold incentives which are included in Property and equipment, net on the Consolidated Balance Sheet and are amortized on a straight-line basis over the shorter of the useful life or the remaining lease term.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following table summarizes operating lease costs included in operating expenses (in thousands):</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Year Ended December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating lease costs</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,356</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,483</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Variable lease costs (1)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">737</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">739</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total lease cost</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,093</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,222</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td colspan="4" style="vertical-align:top;width:100%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(<em style="font: inherit;">1</em>) Variable lease costs include certain additional charges for operating costs, including insurance, maintenance, taxes, utilities and other costs incurred, which are billed based on both usage and as a percentage of the Company&#8217;s share of total square footage. These costs also included costs associated with increases rent expense based on CPI.</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following table summarizes the weighted-average remaining lease term and discount rate:</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 771px; text-align: center;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 187px; text-align: center;"><b><em style="font: inherit;">As of December 31, 2022</em></b></td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 771px;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted-average remaining lease term (years)</p> </td><td style="width: 187px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: right;">9.6</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 771px;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted-average discount rate</p> </td><td style="width: 187px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: right;">10.5%</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cash paid for amounts included in the measurement of the lease liabilities were $2.4 million and $2.6 million for the year&#160;ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em>, respectively.</p>

   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of <em style="font: inherit;"> December 31, 2022</em>, the maturities of the Company&#8217;s operating lease liabilities and future minimum lease payments were as follows (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Total</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,116</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">2024</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,116</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">2025</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,116</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">2026</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,116</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">2027</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,116</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Thereafter</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">9,699</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total undiscounted lease payments</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">20,279</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; vertical-align: top;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Less: present value adjustment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(7,176</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; vertical-align: top;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Present value of lease liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13,103</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139857068592512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Accounting, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Basis of Presentation and Use of Estimates</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The accompanying consolidated financial statements of Pieris Pharmaceuticals, Inc. and its wholly-owned subsidiaries were prepared in accordance with U.S. GAAP. The consolidated financial statements include the accounts of all subsidiaries. All intercompany balances and transactions have been eliminated.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text Block]</a></td>
<td class="text">The preparation of the financial statements in accordance with U.S. GAAP requires management to make estimates, judgments, and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and the related disclosures at the date of the financial statements and during the reporting period. Significant estimates are used for, but are <em style="font: inherit;">not</em> limited to, revenue recognition; deferred tax assets, deferred tax liabilities and valuation allowances; determination of the incremental borrowing rate to calculate right-of-use assets and lease liabilities; beneficial conversion features; fair value of stock options, preferred stock, and warrants; and prepaid and accrued clinical trial expenses. Management evaluates its estimates on an ongoing basis. Actual results and outcomes could differ materially from management&#8217;s estimates, judgments, and assumptions.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Transactions and Translations Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Foreign Currency Translation</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The financial statements of the Company&#8217;s foreign subsidiaries are translated from local currency into reporting currency, which is U.S. dollars, using the current exchange rate at the balance sheet date for assets and liabilities, and the weighted average exchange rate prevailing during the period for revenues and expenses. The functional currency for Pieris&#8217; foreign subsidiaries is considered to be the local currency for each entity and, accordingly, translation adjustments for these subsidiaries are included in accumulated other comprehensive loss within stockholders&#8217; equity.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Realized and unrealized gains and losses resulting from foreign currency transactions denominated in currencies other than the functional currency are reflected as other (expense) income, net in the consolidated statements of operations. Foreign currency gains and losses on available-for-sale investment transactions are recorded to other comprehensive income (loss) on the Company's balance sheet per Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic <em style="font: inherit;">830,</em> <i>Foreign Currency Matters.</i></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Cash, Cash Equivalents and Investments</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company determines the appropriate classification of its investments at the time of purchase. All liquid investments with original maturities of <em style="font: inherit;">90</em> days or less from the purchase date and for which there is an active market are considered to be cash equivalents. The Company&#8217;s investments are comprised of money market, asset backed securities, government treasuries, and corporate bonds that are classified as available-for-sale in accordance with FASB ASC <em style="font: inherit;">320,</em> <i>Investments</i>&#8212;<i>Debt and Equity Securities</i>. The Company classifies investments available to fund current operations as current assets on its balance sheets.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Available-for-sale investments are recorded at fair value, with unrealized gains or losses included in accumulated other comprehensive income (loss) on the Company&#8217;s balance sheets. Realized gains and losses are determined using the specific identification method and are included as a component of other income (expense).</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company reviews investments for other-than-temporary impairment whenever the fair value of an investment is less than the amortized cost and evidence indicates that an investment&#8217;s carrying amount is <em style="font: inherit;">not</em> recoverable within a reasonable period of time. To determine whether an impairment is other-than temporary, the Company considers its intent to sell, or whether it is more likely than <em style="font: inherit;">not</em> that the Company will be required to sell the investment before recovery of the investment&#8217;s amortized cost basis. Evidence considered in this assessment includes reasons for the impairment, the severity and the duration of the impairment, and changes in value subsequent to period end.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration Risk, Credit Risk, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Concentration of Credit Risk and Off-Balance Sheet Risk</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company has <em style="font: inherit;">no</em> financial instruments with off&#8209;balance sheet risk such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Financial instruments that subject Pieris to concentrations of credit risk include cash and cash equivalents, investments, and accounts receivable. The Company&#8217;s cash, cash equivalents, and investments are held in accounts with financial institutions that management believes are creditworthy. The Company&#8217;s investment policy includes guidelines on the quality of the institutions and financial instruments and defines allowable investments that the Company believes minimizes the exposure to concentration of credit risk. The Company has <em style="font: inherit;">not</em> experienced any credit losses in such accounts and does <em style="font: inherit;">not</em> believe it is exposed to any significant credit risk on these funds. Accounts receivable primarily consist of amounts due under strategic partnership and other license agreements with major multi-national pharmaceutical companies for which the Company does <em style="font: inherit;">not</em> obtain collateral.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Fair Value Measurement</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. FASB ASC Topic <em style="font: inherit;">820,</em> <i>Fair Value Measurement and Disclosures</i>, or ASC <em style="font: inherit;">820,</em> established a hierarchy of inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the financial instrument based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the financial instrument and are developed based on the best information available in the circumstances. The fair value hierarchy applies only to the valuation inputs used in determining the reported or disclosed fair value of the financial instruments and is <em style="font: inherit;">not</em> a measure of the investment credit quality. Fair value measurements are classified and disclosed in <em style="font: inherit;">one</em> of the following <em style="font: inherit;">three</em> categories:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"><tbody><tr><td style="width:18pt;">&#160;</td><td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td><td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Level <em style="font: inherit;">1</em> inputs are quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"><tbody><tr><td style="width:18pt;">&#160;</td><td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td><td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Level <em style="font: inherit;">2</em> utilizes quoted market prices in markets that are <em style="font: inherit;">not</em> active, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency.</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"><tbody><tr><td style="width:18pt;">&#160;</td><td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td><td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Level <em style="font: inherit;">3</em> inputs are unobservable inputs for the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level <em style="font: inherit;">3.</em> A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Financial instruments measured at fair value on a recurring basis include cash equivalents and investments, if any (<i>Note <em style="font: inherit;">6</em></i>).</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">An entity <em style="font: inherit;"> may </em>elect to measure many financial instruments and certain other items at fair value at specified election dates. Subsequent unrealized gains and losses on items for which the fair value option has been elected will be reported in net loss. The Company did <em style="font: inherit;">not</em> elect to measure any additional financial instruments or other items at fair value.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Fair Values of Financial Instruments</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The fair value of cash, accounts receivable, and accounts payable approximates the carrying value of these financial instruments because of the short-term nature of any maturities. The Company determines the estimated fair values of other financial instruments, using available market information and valuation methodologies, primarily input from independent <em style="font: inherit;">third</em> party pricing sources.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Accounts Receivable</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Accounts receivable are recorded net of allowances for doubtful accounts and represent amounts due from strategic partners. The Company monitors and evaluates collectability of receivables on an ongoing basis and considers whether an allowance for doubtful accounts is necessary. The Company determined that <em style="font: inherit;">no</em> such reserve is needed as of <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em>. Historically, Pieris has <em style="font: inherit;">not</em> had collectability issues.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Property and Equipment</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Property and equipment are recorded at acquisition cost, less accumulated depreciation and impairment. Depreciation on property and equipment is calculated using the straight-line method over the remaining estimated useful lives of the assets. Maintenance and repairs to these assets are charged to expenses as occurred. Substantially all of the Company's fixed assets are located in Germany. The estimated useful life of the different groups of property and equipment is as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>Asset Classification</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 43%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Estimated useful life (in years)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Leasehold improvements</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 43%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">shorter of useful life or remaining life of the lease</em></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Laboratory furniture and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 43%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">8-14</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Office furniture and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 43%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">5-13</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Computer and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 43%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">3 - 7</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Impairment of Long-lived Assets</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company reviews its long-lived assets to be held and used for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be fully recoverable. The Company evaluates the realizability of its long-lived assets based on profitability and cash flow expectations for the related asset. Any write-downs are treated as permanent reductions in the carrying amount of the assets. The Company believes that, as of each of the balance sheets presented, <em style="font: inherit;">none</em> of the Company&#8217;s long-lived assets were impaired.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue from Contract with Customer [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Revenue Recognition</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">Pieris has entered into several licensing agreements with collaboration partners for the development of Anticalin therapeutics against a variety of targets. The terms of these agreements provide for the transfer of multiple goods or services which&#160;<i><em style="font: inherit;"> may</em></i>&#160;include: (i)&#160;licenses, or options to obtain licenses, to Pieris&#8217; Anticalin technology and/or specific programs and (ii)&#160;research and development activities to be performed on behalf of or with a collaborative partner. Payments to Pieris under these agreements&#160;<i><em style="font: inherit;"> may</em></i>&#160;include upfront fees (which include license and option fees), payments for research and development activities, payments based upon the achievement of certain milestones, and royalties on product sales. There are&#160;<i><em style="font: inherit;">no</em></i>&#160;performance, cancellation, termination or refund provisions in any of the arrangements that could result in material financial consequences to Pieris. As the Company's intellectual property assets are considered to be located in Germany, the Company records all consolidated revenue in its subsidiary, Pieris Pharmaceuticals, GmbH.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Collaborative Arrangements</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company considers the nature and contractual terms of an arrangement and assess whether the arrangement involves a joint operating activity pursuant to which it is an active participant and exposed to significant risks and rewards with respect to the arrangement. If the Company is an active participant and exposed to the significant risks and rewards with respect to the arrangement, it accounts for these arrangements pursuant to ASC <em style="font: inherit;">808,</em> <i>Collaborative Arrangements</i>, or ASC <em style="font: inherit;">808,</em> and applies a systematic and rational approach to recognize revenue. The Company classifies payments received as revenue and payments made as a reduction of revenue in the period in which they are earned. Revenue recognized under a collaborative arrangement involving a participant that is <em style="font: inherit;">not</em> a customer is presented as Collaboration Revenue in the Statement of Operations.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Revenue from Contracts with Customers</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In accordance with ASC <em style="font: inherit;">606,</em> revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled in exchange for these goods and services. To achieve this core principle, the Company applies the following <em style="font: inherit;">five</em> steps: <em style="font: inherit;">1</em>) identify the customer contract; <em style="font: inherit;">2</em>) identify the contract&#8217;s performance obligations; <em style="font: inherit;">3</em>) determine the transaction price; <em style="font: inherit;">4</em>) allocate the transaction price to the performance obligations; and <em style="font: inherit;">5</em>) recognize revenue when or as a performance obligation is satisfied.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company evaluates all promised goods and services within a customer contract and determines which of such goods and services are separate performance obligations. This evaluation includes an assessment of whether the good or service is capable of being distinct and whether the good or service is separable from other promises in the contract. &#160;In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property and the capabilities of the customer to develop the intellectual property on their own or whether the required expertise is readily available.</p>

   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Licensing arrangements are analyzed to determine whether the promised goods or services, which often include licenses, research and development services and governance committee services, are distinct or whether they must be accounted for as part of a combined performance obligation. If the license is considered <em style="font: inherit;">not</em> to be distinct, the license would then be combined with other promised goods or services as a combined performance obligation. If the Company is involved in a governance committee, it assesses whether its involvement constitutes a separate performance obligation. When governance committee services are determined to be separate performance obligations, the Company determines the fair value to be allocated to this promised service.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Certain contracts contain optional and additional items, which are considered marketing offers and are accounted for as separate contracts with the customer if such option is elected by the customer, unless the option provides a material right which would <em style="font: inherit;">not</em> be provided without entering into the contract.&#160;&#160;An option that is considered a material right is accounted for as a separate performance obligation.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The transaction price is determined based on the consideration to which the Company will be entitled in exchange for transferring goods and services to the customer. A contract <em style="font: inherit;"> may </em>contain variable consideration, including potential payments for both milestone and research and development services. For certain potential milestone payments, the Company estimates the amount of variable consideration by using the most likely amount method. In making this assessment, the Company evaluates factors such as the clinical, regulatory, commercial and other risks that must be overcome to achieve the milestone. Each reporting period the Company re-evaluates the probability of achievement of such variable consideration and any related constraints. Pieris will include variable consideration, without constraint, in the transaction price to the extent it is probable that a significant reversal in the amount of cumulative revenue recognized will <em style="font: inherit;">not</em> occur when the uncertainty associated with the variable consideration is subsequently resolved. For potential research and development service payments, the Company estimates the amount of variable consideration by using the expected value method, including any approved budget updates arising from additional research or development services.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price among the performance obligations on a relative standalone selling price basis unless a portion of the transaction price is variable and meets the criteria to be allocated entirely to a performance obligation or to a distinct good or service that forms part of a single performance obligation.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company allocates the transaction price based on the estimated standalone selling price of the underlying performance obligations or in the case of certain variable consideration to <em style="font: inherit;">one</em> or more performance obligations. The Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company utilizes key assumptions to determine the stand-alone selling price, which <em style="font: inherit;"> may </em>include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs to complete the respective performance obligation. Certain variable consideration is allocated specifically to <em style="font: inherit;">one</em> or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated to each performance obligation are consistent with the amount the Company would expect to receive for each performance obligation.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">When a performance obligation is satisfied, revenue is recognized for the amount of the transaction price, excluding estimates of variable consideration that are constrained, that is allocated to that performance obligation on a relative standalone selling price basis. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations under an arrangement.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">For performance obligations consisting of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non- refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Revenue recognized under an arrangement involving a participant that is a customer is presented as Customer Revenue.</p>

   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Milestones and Royalties</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company aggregates milestones into <em style="font: inherit;">four</em> categories (i) research milestones, (ii) development milestones, (iii) commercial milestones and (iv) sales milestones. Research milestones are typically achieved upon reaching certain success criteria as defined in each agreement related to developing an Anticalin protein against the specified target. Development milestones are typically reached when a compound reaches a defined phase of clinical research or passes such phase, or upon gaining regulatory approvals. Commercial milestones are typically achieved when an approved pharmaceutical product reaches the status for commercial sale, including regulatory approval. Sales milestones are certain defined levels of net sales by the licensee, such as when a product <em style="font: inherit;">first</em> achieves global sales or annual sales of a specified amount.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">There is uncertainty that the events to obtain the research and development milestones will be achieved given the nature of clinical development and the stage of the Company&#8217;s technology. The Company has thus determined that all research and development milestones will be constrained until it is deemed probable that a significant revenue reversal will <em style="font: inherit;">not</em> occur. For revenues from research and development milestones, payments will be recognized consistent with the recognition pattern of the performance obligation to which they relate.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&#160;Commercial milestones and sales royalties are determined by sales or usage-based thresholds and will be accounted for under the royalty recognition constraint as constrained variable consideration.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company calculates the maximum amount of potential milestones achievable under each collaboration agreement and discloses such potential future milestones for all current collaborations using such a maximum calculation.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Contract Balances</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company recognizes a contract asset when the Company transfers goods or services to a customer before the customer pays consideration or before payment is due, excluding any amounts presented as a receivable (i.e., accounts receivable). A contract asset is an entity&#8217;s right to consideration in exchange for goods or services that the entity has transferred to a customer. The contract liabilities (i.e., deferred revenue) primarily relate to contracts where the Company has received payment but has <em style="font: inherit;">not</em> yet satisfied the related performance obligations.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In the event of an early termination of a collaboration agreement, any contract liabilities would be recognized in the period in which all Company obligations under the agreement have been fulfilled.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Costs to Obtain and Fulfill a Contract with a Customer</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Certain costs to obtain customer contracts, including success-based fees paid to <em style="font: inherit;">third</em>-party service providers, and costs to fulfill customer contracts are capitalized in accordance with FASB ASC <em style="font: inherit;">340,</em> <i>Other Assets and Deferred Costs</i>, or ASC <em style="font: inherit;">340.</em> These costs are amortized to expense on a systemic basis that is consistent with the transfer to the customer of the goods or services to which the asset relates. The Company will expense the amortization of costs to obtain customer contracts to general and administrative expense and costs to fulfill customer contracts to research and development expense.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Research and Development</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Research and development expenses are charged to the statement of operations as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including salaries and benefits, facilities costs, pre-clinical and clinical costs, contract services, consulting, depreciation and amortization expense, and other related costs. Costs associated with acquired technology, in the form of upfront fees or milestone payments, are charged to research and development expense as incurred.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Tax, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Income Taxes</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company applies ASC Topic <em style="font: inherit;">740</em> <i>Income Taxes</i>, which established financial accounting and reporting requirements for the effects of income taxes that result from the Company&#8217;s activities during the current and preceding years. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and operating losses and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted statutory tax rates expected to apply to taxable income in the jurisdictions and years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Where the Company determines that it is more likely than <em style="font: inherit;">not</em> that some portion or all of the deferred tax assets will <em style="font: inherit;">not</em> be realized in the future, the deferred tax assets are reduced by a valuation allowance. The Company records interest and penalties related to uncertain tax positions as part of income tax expense.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Tax Cuts and Jobs Act&#160;(TCJA) subjects a U.S. shareholder to tax on global-intangible low tax income (GILTI) earned by certain foreign subsidiaries. The Company has made an accounting policy election to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Payment Arrangement [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Stock-based Compensation</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company measures share-based payments in accordance with ASC Topic <em style="font: inherit;">718,</em> <i>Stock Compensation</i>. Pieris records its stock-based compensation expense over the requisite service period and records forfeitures as they occur. Determining the appropriate fair value model and related assumptions requires judgment, including estimating share price volatility and expected terms of the awards. For employee options, the fair value measurement date is generally on the date of grant and the related compensation expense is recognized on a straight-line basis over the requisite service period of the awards, less expense for actual forfeitures.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company uses the Black-Scholes option pricing model to determine the estimated fair value for stock-based awards. Option-pricing models require the input of various subjective assumptions, including the option&#8217;s expected life, expected dividend yield, price volatility, risk free interest rate and forfeitures of the underlying stock. Due to the limited operating history of the Company as a public entity and a lack of company specific historical and implied volatility data, the Company has based its estimate of expected volatility on the historical volatility of a group of similar companies that are publicly traded. When selecting these public companies on which it has based its expected stock price volatility, the Company selected companies with comparable characteristics to it, including enterprise value, risk profiles, position within the industry, and with historical share price information sufficient to meet the expected term of the stock-based awards. The Company computes historical volatility data using the daily closing prices for the selected companies&#8217; shares during the equivalent period of the calculated expected term of the stock-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Due to the lack of Company specific historical option activity, the Company has estimated the expected term of its employee stock options using the &#8220;simplified&#8221; method, whereby, the expected term equals the arithmetic average of the vesting term and the original contractual term of the option. The expected term for non-employee awards is the remaining contractual term of the option. The risk-free interest rates are based on the U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The Company has never paid, and does <em style="font: inherit;">not</em> expect to pay dividends in the foreseeable future.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">All excess tax benefits and tax deficiencies are recorded as income tax expense or benefit in the Company's statement of operations and comprehensive loss. For the years ended&#160;<em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em>, the Company did <em style="font: inherit;">not</em> record an income statement benefit for excess tax benefits as a valuation allowance is also required on these amounts.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistancePolicyTextBlock', window );">Government Assistance [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Government Grants</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company recognizes grants from governmental agencies when there is reasonable assurance that the Company will comply with the conditions attached to the grant arrangement and the grant will be received. The Company evaluates the conditions of each grant as of each reporting period to evaluate whether the Company has reached reasonable assurance of meeting the conditions of each grant arrangement and that it is expected that the grant will be received as a result of meeting the necessary conditions. Grants are recognized in the consolidated statements of operations on a systematic basis over the periods in which the Company recognizes the related costs for which the government grant is intended to compensate. Specifically, grant income related to research and development costs is recognized as such expenses are incurred. Grant income is included as a separate caption within Other income (expense), net in the consolidated statements of operations.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Lessee, Leases [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Leases</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company accounts for leases pursuant to ASC <em style="font: inherit;">842</em> <i>Leases (Topic <em style="font: inherit;">842</em>)</i>, or ASC <em style="font: inherit;">842.</em> As a lessee, the Company is required to recognize (i) a lease liability, which is a lessees obligation to make lease payments arising from a lease, measured on a discounted basis; and (ii) a right-of-use asset, which is an asset that represents the lessee&#8217;s right to use, or control the use of, a specified asset for the lease term for all leases (with the exception of short-term leases) at the commencement date.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company determines if an arrangement is a lease at inception. The Company&#8217;s contracts are determined to contain a lease within the scope of ASC <em style="font: inherit;">842</em> when all of the following criteria based on the specific circumstances of the arrangement are met: (<em style="font: inherit;">1</em>) there is an identified asset for which there are <em style="font: inherit;">no</em> substantive substitution rights; (<em style="font: inherit;">2</em>) the Company has the right to obtain substantially all of the economic benefits from the identified asset; and (<em style="font: inherit;">3</em>) the Company has the right to direct the use of the identified asset. In addition, the Company does <em style="font: inherit;">not</em> apply the recognition requirements in the lease standard to short-term leases (a lease that at commencement date has a lease term of <em style="font: inherit;">12</em> months or less and does <em style="font: inherit;">not</em> contain a purchase option that it is reasonably certain to exercise) and does <em style="font: inherit;">not</em> separate lease and non-lease components for all asset classes. Any variable components of lease costs are excluded from lease payments and are recognized in the period incurred, including increases to rent based on German Consumer Price Index , or CPI.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">At the commencement date, operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of future lease payments over the expected lease term. The Company&#8217;s lease agreements do <em style="font: inherit;">not</em> provide an implicit rate. As a result, the Company utilizes an estimated incremental borrowing rate to discount lease payments, which is based on the rate of interest the Company would have to pay to borrow a similar amount on a collateralized basis over a similar term and based on observable market data points. Certain adjustments to the right-of-use asset <em style="font: inherit;"> may </em>be required for items such as initial direct costs paid or lease incentives received. Operating lease cost is recognized over the expected term on a straight-line basis.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company typically only includes an initial lease term in its assessment of a lease agreement. Options to renew a lease are <em style="font: inherit;">not</em> included in the Company&#8217;s assessment unless there is reasonable certainty that the Company will renew. The expected lease term includes noncancelable lease periods and, when applicable, periods covered by an option to extend the lease if the Company is reasonably certain to exercise that option, as well as periods covered by an option to terminate the lease if the Company is reasonably certain <em style="font: inherit;">not</em> to exercise that option.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Assumptions made by the Company at the commencement date are re-evaluated upon occurrence of certain events, including a lease modification. A lease modification results in a separate contract when the modification grants the lessee an additional right of use <em style="font: inherit;">not</em> included in the original lease and when lease payments increase commensurate with the standalone price for the additional right of use. When a lease modification results in a separate contract, it is accounted for in the same manner as a new lease.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Commitments and Contingencies, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Contingencies</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Accruals are recorded for loss contingencies when it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. The Company evaluates, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously. Considering facts known at the time of the assessment, the Company determines whether potential losses are considered reasonably possible or probable and whether they are estimable. Based upon this assessment, the Company carries out an evaluation of disclosure requirements and considers possible accruals in the financial statements.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Segment Reporting</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Operating segments are identified as components of an enterprise where separate discrete financial information is evaluated by the chief operating decision maker in making decisions on how to allocate resources and assess performance. The Company operates as a single segment dedicated to the discovery and development of biotechnological applications and the Company&#8217;s chief operating decision maker, or CODM, makes decisions based on the Company as a whole. The Company has determined that its CODM is its Chief Executive Officer.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Earnings per Share</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Basic earnings per share attributable to common stockholders is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period, without consideration for common stock equivalents.</p>

   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Diluted earnings per share attributable to common stockholders is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share attributable to common stockholders' calculation, preferred stock, stock options, unvested restricted stock, and warrants are considered to be common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to common stockholders, as their effect would be anti-dilutive for all periods presented. Therefore, basic and diluted net loss per share were the same for all periods presented.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Recent Accounting Pronouncements <em style="font: inherit;">Not</em> Yet Adopted</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In <em style="font: inherit;"> June 2016, </em>the FASB issued ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2016</em>-<em style="font: inherit;">13,</em> <i>Financial Instruments - Credit Losses</i> <i>(Topic <em style="font: inherit;">326</em>): Measurement of Credit Losses on Financial Statements, </i>or ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13.</em> ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> significantly changes the impairment model for most financial assets and certain other instruments. The new standard requires that expected credit losses relating to financial assets measured on an amortized cost basis and available-for-sale debt securities be recorded through an allowance for credit losses. It also limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value, and requires the reversal of previously recognized credit losses if fair value increases. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Subsequently, in <em style="font: inherit;"> November 2018, </em>the FASB issued ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2018</em>-<em style="font: inherit;">19,</em> <i>Codification Improvements to Topic <em style="font: inherit;">326,</em> Financial Instruments-Credit Losses</i>, which clarifies codification and corrects unintended application of the guidance. In <em style="font: inherit;"> November 2019, </em>the FASB issued ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2019</em>-<em style="font: inherit;">11,</em> <i>Codification Improvements to Topic <em style="font: inherit;">326,</em> Financial Instruments-Credit Losses</i>, which clarifies or addresses specific issues about certain aspects of ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13.</em> In <em style="font: inherit;"> November 2019 </em>the FASB also issued ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2019</em>-<em style="font: inherit;">10,</em> <i>Financial Instruments-Credit Losses (Topic <em style="font: inherit;">326</em>), Derivatives and Hedging (Topic <em style="font: inherit;">815</em>), and Leases (Topic <em style="font: inherit;">842</em>): Effective Dates</i>, which delays the effective date of ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> by <em style="font: inherit;">three</em> years for certain smaller reporting companies such as the Company. The guidance in ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> is effective for the Company for financial statements issued for fiscal years beginning after <em style="font: inherit;"> December 15, 2022 </em>and interim periods within those fiscal years, with early adoption permitted. The Company expects that adoption of this standard will <em style="font: inherit;">not</em> have a material impact on its financial statements.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company has considered other recent accounting pronouncements and concluded that they are either <em style="font: inherit;">not</em> applicable to the business, or that the effect is <em style="font: inherit;">not</em> expected to be material to the unaudited consolidated financial statements as a result of future adoption.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12565-110249<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistancePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for government assistance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342832&amp;loc=SL128342943-244231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=128342832&amp;loc=SL128342957-244231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistancePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139857071700096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock', window );">Property, Plant and Equipment, Estimated Useful Life [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>Asset Classification</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 43%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Estimated useful life (in years)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Leasehold improvements</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 43%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">shorter of useful life or remaining life of the lease</em></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Laboratory furniture and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 43%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">8-14</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Office furniture and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 43%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">5-13</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Computer and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 43%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">3 - 7</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of estimated useful life of physical assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139857068562848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Year Ended December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">AstraZeneca</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,117</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">18,919</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Seagen</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8,287</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">768</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Servier</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,359</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,070</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Genentech</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">3,139</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">1,950</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Boston Pharmaceuticals</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">5,711</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"><b>Total Revenue</b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,902</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">31,418</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_RevenueFromContractWithCustomerMilestonePaymentsTableTextBlock', window );">Revenue From Contract With Customer, Milestone Payments [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Research, Development, Regulatory &amp; Commercial Milestones</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Sales Milestones</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">AstraZeneca</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">702</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,925</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Servier</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">20</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Seagen</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">759</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">450</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Boston Pharmaceuticals</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">88</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">265</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Genentech</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">834</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">600</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"><b>Total potential milestone payments</b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,403</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,240</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_RevenueFromContractWithCustomerMilestonePaymentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the milestone payments for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_RevenueFromContractWithCustomerMilestonePaymentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139857071696816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Cash, Cash Equivalents and Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Cash, Cash Equivalents and Investments [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Total</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Quoted prices in active markets (Level 1)</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Significant other observable inputs (Level 2)</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Significant unobservable inputs (Level 3)</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>December 31, 2022</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Money market funds, included in cash equivalents</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">17,618</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">17,618</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Investments - US treasuries</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,573</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,573</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Investments - Foreign treasuries</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">896</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">896</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Investments - Asset-backed securities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">499</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">499</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Investments - Corporate bonds</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">15,566</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">15,566</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">38,152</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">22,087</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">16,065</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Total</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Quoted prices in active markets (Level 1)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Significant other observable inputs (Level 2)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Significant unobservable inputs (Level 3)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>December 31, 2021</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Money market funds, included in cash equivalents</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">56,885</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">56,885</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">56,885</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">56,885</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Debt Securities, Available-for-Sale [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 37%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Contractual maturity</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 11%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 11%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 37%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><span style="-sec-ix-hidden:c96254205">(in days)</span></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Amortized Cost</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Unrealized gains</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Unrealized losses</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Fair Value</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 37%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Investments</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 11%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 11%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 37%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">US treasuries</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><em style="font: inherit;">47</em>-<em style="font: inherit;">110</em></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,575</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(2</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,573</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 37%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Foreign treasuries</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">74</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">899</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 11%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(3</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">896</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 37%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Asset-backed securities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">15</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">500</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 11%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(1</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">499</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 37%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Corporate bonds</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><em style="font: inherit;">5</em>-<em style="font: inherit;">228</em></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">15,633</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 11%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(67</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">15,566</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 37%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 9%;"><span style="-sec-ix-hidden:c96254241">&#160;</span></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">20,607</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(73</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">20,534</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139857071707360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Years Ended December 31,</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2022</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2021</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Laboratory furniture and equipment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">11,970</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">11,354</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Office furniture and equipment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,861</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,959</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Computer equipment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">364</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">396</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Leasehold improvements</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,444</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">13,130</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Property and equipment, cost</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">26,639</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">26,839</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Accumulated depreciation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(9,647</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(7,717</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"><b>Property and equipment, net</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">16,992</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">19,122</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139857071530592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Years Ended December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development fees</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,758</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,682</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Compensation expense</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,015</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,581</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued license obligations</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">245</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,541</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued accounts payable</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,245</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,980</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Lease liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">859</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,049</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Other current liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">483</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">393</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Collaboration cost-sharing obligation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,610</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,605</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">16,836</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139857158516272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Years Ended December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Domestic</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(11,765</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(11,312</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Foreign</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(21,512</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(34,426</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Loss before income taxes</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(33,277</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(45,738</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Years Ended December 31,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Current:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Federal</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">State</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Foreign</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total current</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Deferred:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Federal</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">State</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Foreign</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total deferred</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Provision for income taxes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Federal income tax rate</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">21.0</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">21.0</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Foreign rate differential</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5.0</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5.6</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">State tax, net of federal benefit</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.0</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.2</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Share-based awards compensation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(2.2</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(3.5</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)%</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Permanent items</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.3</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(0.2</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)%</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Provision to return</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">3.3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">1.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Credits</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">1.2</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Change in valuation allowance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(28.3</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(27.4</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)%</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Effective income tax rate</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">%</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Years Ended December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Deferred tax assets:</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Net operating loss carryforwards</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">54,845</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">49,280</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Share-based awards compensation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,112</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,739</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Accrued expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">216</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">323</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 18pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">R&amp;D Credits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">413</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Depreciation and other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">384</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">384</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Unrealized foreign currency</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">359</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">256</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 18pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Capitalized R&amp;D</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">952</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 18pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Accrued Expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Lease liability</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,541</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,022</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Total deferred tax assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">63,822</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">57,004</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Deferred tax liabilities:</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Right-of-use asset</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(3,270</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(3,729</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Accrued expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(68</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Total deferred tax liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,270</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,797</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Less: valuation allowance:</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(60,552</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(53,207</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Net deferred tax asset</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock', window );">Summary of Income Tax Contingencies [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Unrecognized tax benefits at December 31, 2021</b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,665</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Currency translation adjustment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(302</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Unrecognized tax benefits at December 31, 2022</b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,363</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfIncomeTaxContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139857070154880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Stock and Employee Benefit Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Years Ended December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Risk free interest rate</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.43% - 3.39%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.46% - 1.20%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected term (in years)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5.5 - 5.73</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5.31 - 5.73</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Dividend yield</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected volatility</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">79.9% - 81.1%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">75.0% - 81.7%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Years Ended December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Risk free interest rate</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.62% - 4.60%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.04% - 0.10%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected term (in years)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.5</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.5</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Dividend yield</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected volatility</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">53.46% - 70.17%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">60.46% - 131.21%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted-</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted-</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Average</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Aggregate</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Average</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Remaining</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Intrinsic</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Number of</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Exercise</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Contractual</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Value</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Options</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Price</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Life (in years)</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">(in thousands)</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, December 31, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,475,713</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.35</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,310</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,075,282</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.88</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Exercised</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">46,233</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.07</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">66</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Canceled</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,031,396</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.80</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">17</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, December 31, 2022</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13,473,366</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3.21</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6.31</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Vested or expected to vest, December 31, 2022</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13,473,366</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3.21</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6.31</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercisable, December 31, 2022</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">9,096,001</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3.38</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5.16</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted-</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted-</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Average</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Aggregate</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Average</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Remaining</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Intrinsic</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Number of</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Exercise</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Contractual</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Value</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Options</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Price</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Life (in years)</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">(in thousands)</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">660,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4.01</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">108</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Canceled or Expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">360,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">3.48</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, December 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">300,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4.65</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">6.66</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Vested or expected to vest, December 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">300,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4.65</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">6.66</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercisable, December 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">243,750</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4.65</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">6.66</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Years Ended December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,905</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,274</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">General and administrative</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,497</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,941</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total stock-based compensation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,402</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,215</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139857071604928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Lease, Cost [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Year Ended December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating lease costs</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,356</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,483</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Variable lease costs (1)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">737</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">739</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total lease cost</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,093</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,222</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 771px; text-align: center;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 187px; text-align: center;"><b><em style="font: inherit;">As of December 31, 2022</em></b></td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 771px;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted-average remaining lease term (years)</p> </td><td style="width: 187px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: right;">9.6</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 771px;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted-average discount rate</p> </td><td style="width: 187px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: right;">10.5%</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Total</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,116</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">2024</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,116</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">2025</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,116</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">2026</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,116</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">2027</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,116</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Thereafter</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">9,699</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total undiscounted lease payments</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">20,279</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; vertical-align: top;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Less: present value adjustment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(7,176</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; vertical-align: top;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Present value of lease liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13,103</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139857063895056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Corporate Information (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>May 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, Cash Equivalents, and Short-Term Investments, Total</a></td>
<td class="nump">$ 59,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent, Total</a></td>
<td class="num">(33,277)<span></span>
</td>
<td class="num">$ (45,738)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained Earnings (Accumulated Deficit), Total</a></td>
<td class="num">$ (290,421)<span></span>
</td>
<td class="num">$ (257,144)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pirs_PierisPharmaceuticalsGmbhMember', window );">Pieris Pharmaceuticals GmbH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Business Acquisition, Percentage of Voting Interests Acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pirs_PierisPharmaceuticalsGmbhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pirs_PierisPharmaceuticalsGmbhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139857058027552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment, Useful Lives (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pirs_LaboratoryEquipmentMember', window );">Laboratory Equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life (Year)</a></td>
<td class="text">8 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pirs_LaboratoryEquipmentMember', window );">Laboratory Equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life (Year)</a></td>
<td class="text">14 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life (Year)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life (Year)</a></td>
<td class="text">13 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life (Year)</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life (Year)</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pirs_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pirs_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139857045745488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Revenue (Details Textual)<br> $ / shares in Units, $ in Thousands, &#8364; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="6">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 19, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 24, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 01, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 24, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 08, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 02, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jan. 04, 2017</div></th>
<th class="th">
<div>Jan. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Feb. 29, 2020</div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jan. 01, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract with Customer, Liability, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contract with Customer, Liability, Noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Contract with Customer, Liability, Revenue Recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_NumberOfTechnologyLicenses', window );">Number of Technology Licenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Increase (Decrease) in Contract with Customer, Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pirs_GenentechMember', window );">Genentech [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_NumberOfInitialResearchPrograms', window );">Number Of Initial Research Programs</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_NumberOfOptionalAdditionalResearchPrograms', window );">Number Of Optional Additional Research Programs</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_RevenueFromContractWithCustomerCollaborationFeeOnAdditionalProgram', window );">Revenue from Contract with Customer, Collaboration Fee On Additional Program</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_RevenueFromContractWithCustomerAgreementTerminationNoticePeriodWithinMaterialBreach', window );">Revenue from Contract with Customer, Agreement Termination Notice Period Within Material Breach (Day)</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodBeforeFirstCommercialSale', window );">Revenue from Contract with Customer, Agreement Termination Advance Notice Period Before First Commercial Sale (Day)</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodAfterFirstCommercialSale', window );">Revenue from Contract with Customer, Agreement Termination Advance Notice Period After First Commercial Sale (Day)</a></td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_NumberOfResearchPrograms', window );">Number of Research Programs</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_NumberOfPerformanceObligations', window );">Number of Performance Obligations</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, Remaining Performance Obligation, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pirs_GenentechMember', window );">Genentech [Member] | License and Collaboration Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_NumberOfPerformanceObligations', window );">Number of Performance Obligations</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pirs_GenentechMember', window );">Genentech [Member] | Platform Technology License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_NumberOfPerformanceObligations', window );">Number of Performance Obligations</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pirs_GenentechMember', window );">Genentech [Member] | Governance Committee Participation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_NumberOfPerformanceObligations', window );">Number of Performance Obligations</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pirs_SeattleGeneticsIncMember', window );">Seattle Genetics Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_NumberOfPerformanceObligations', window );">Number of Performance Obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, Remaining Performance Obligation, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract with Customer, Liability, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contract with Customer, Liability, Noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_AmendedCollaborationAgreementResaleOfStockPeriod', window );">Amended Collaboration Agreement, Resale of Stock, Period (Day)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pirs_SeattleGeneticsIncMember', window );">Seattle Genetics Inc. [Member] | Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with Customer, Liability, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of Stock, Number of Shares Issued in Transaction (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,706,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of Stock, Consideration Received on Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_SaleOfStockFairValuePricePerShare', window );">Sale of Stock, Fair Value, Price Per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pirs_SeattleGeneticsIncMember', window );">Seattle Genetics Inc. [Member] | License and Collaboration Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_NumberOfResearchPrograms', window );">Number of Research Programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_NumberOfPerformanceObligations', window );">Number of Performance Obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_RevenueFromContractWithCustomerPeriodAfterEffectiveDateAgreementsMayBeTerminated', window );">Revenue from Contract with Customer, Period After Effective Date Agreements May Be Terminated (Month)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriod', window );">Revenue from Contract with Customer, Agreement Termination Advance Notice Period (Day)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodIfMarketingApprovalObtained', window );">Revenue from Contract with Customer, Agreement Termination Advance Notice Period If Marketing Approval Obtained (Day)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_RevenueFromContractWithCustomerAgreementTerminationNoticePeriodUponMaterialBreach', window );">Revenue from Contract with Customer, Agreement Termination Notice Period Upon Material Breach (Day)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_RevenueFromContractWithCustomerAgreementTerminationAdditionalNoticePeriodUponMaterialBreach', window );">Revenue from Contract with Customer, Agreement Termination, Additional Notice Period Upon Material Breach (Day)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_NumberOfLicenses', window );">Number Of Licenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_NumberOfSwapOptions', window );">Number Of Swap Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pirs_SeattleGeneticsIncMember', window );">Seattle Genetics Inc. [Member] | Platform Technology License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_NumberOfPerformanceObligations', window );">Number of Performance Obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_NumberOfTargetPrograms', window );">Number of Target Programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pirs_SeattleGeneticsIncMember', window );">Seattle Genetics Inc. [Member] | Governance Committee Participation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_NumberOfPerformanceObligations', window );">Number of Performance Obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pirs_SeattleGeneticsIncMember', window );">Seattle Genetics Inc. [Member] | Other Arrangement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_NumberOfResearchPrograms', window );">Number of Research Programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pirs_SeattleGeneticsIncMember', window );">Seattle Genetics Inc. [Member] | Up-front Payment Arrangement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Research and Development Arrangement, Contract to Perform for Others, Compensation Earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pirs_SeattleGeneticsIncMember', window );">Seattle Genetics Inc. [Member] | Up-front Payment Arrangement [Member] | Sales Milestone Payments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Contract with Customer, Liability, Revenue Recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_CollaborativeArrangementAllocableArrangementConsiderationAllocation', window );">Collaborative Arrangement Allocable Arrangement Consideration Allocation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pirs_SeattleGeneticsIncMember', window );">Seattle Genetics Inc. [Member] | Antibody Target Swap [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_NumberOfPerformanceObligations', window );">Number of Performance Obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pirs_SeattleGeneticsIncMember', window );">Seattle Genetics Inc. [Member] | Collaborative Arrangement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from Contract with Customer, Excluding Assessed Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pirs_SeattleGeneticsIncMember', window );">Seattle Genetics Inc. [Member] | Collaborative Arrangement [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from Contract with Customer, Excluding Assessed Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pirs_AstraZenecaABMember', window );">Astra Zeneca A B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with Customer, Liability, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_ResearchCollaborationAgreementPeriod', window );">Research Collaboration Agreement Period (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, Remaining Performance Obligation, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract with Customer, Liability, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contract with Customer, Liability, Noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_AmendedCollaborationAgreementResaleOfStockPeriod', window );">Amended Collaboration Agreement, Resale of Stock, Period (Day)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_RevenueFromContractWithCustomerAllocableArrangementConsiderationAllocation', window );">Revenue from Contract with Customer, Allocable Arrangement Consideration Allocation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 4,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_NumberOfDiscoveryProgramsDiscontinued', window );">Number of Discovery Programs Discontinued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNet', window );">Capitalized Contract Cost, Net, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostGross', window );">Capitalized Contract Cost, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Capitalized Contract Cost, Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pirs_AstraZenecaABMember', window );">Astra Zeneca A B [Member] | Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of Stock, Number of Shares Issued in Transaction (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,584,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of Stock, Consideration Received on Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_SaleOfStockFairValuePricePerShare', window );">Sale of Stock, Fair Value, Price Per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pirs_AstraZenecaABMember', window );">Astra Zeneca A B [Member] | License and Collaboration Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_NumberOfPerformanceObligations', window );">Number of Performance Obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_RevenueFromContractWithCustomerPeriodAfterEffectiveDateAgreementsMayBeTerminated', window );">Revenue from Contract with Customer, Period After Effective Date Agreements May Be Terminated (Month)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriod', window );">Revenue from Contract with Customer, Agreement Termination Advance Notice Period (Day)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodIfMarketingApprovalObtained', window );">Revenue from Contract with Customer, Agreement Termination Advance Notice Period If Marketing Approval Obtained (Day)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_RevenueFromContractWithCustomerAgreementTerminationNoticePeriodUponMaterialBreach', window );">Revenue from Contract with Customer, Agreement Termination Notice Period Upon Material Breach (Day)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_RevenueFromContractWithCustomerAgreementTerminationAdditionalNoticePeriodUponMaterialBreach', window );">Revenue from Contract with Customer, Agreement Termination, Additional Notice Period Upon Material Breach (Day)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_NumberOfNovelProteins', window );">Number of Novel Proteins</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_AgreementTerminationNoticePeriodUponOfBreachOfPaymentObligations', window );">Agreement Termination Notice Period Upon Of Breach Of Payment Obligations (Day)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_RemainingPerformanceObligationEstimatedTerm', window );">Remaining Performance Obligation, Estimated Term (Month)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pirs_AstraZenecaABMember', window );">Astra Zeneca A B [Member] | License and Collaboration Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_NumberOfCollaborationProducts', window );">Number of Collaboration Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pirs_AstraZenecaABMember', window );">Astra Zeneca A B [Member] | License and Collaboration Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_NumberOfCollaborationProducts', window );">Number of Collaboration Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_NumberOfPrograms', window );">Number of Programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_NumberOfResearchLicenses', window );">Number of Research Licenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pirs_AstraZenecaABMember', window );">Astra Zeneca A B [Member] | Up-front Payment Arrangement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_RevenueFromContractWithCustomerAllocableArrangementConsiderationAllocation', window );">Revenue from Contract with Customer, Allocable Arrangement Consideration Allocation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pirs_AstraZenecaABMember', window );">Astra Zeneca A B [Member] | Up-front Payment Arrangement [Member] | Sales Milestone Payments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_RevenueFromContractWithCustomerAllocableArrangementConsiderationAllocation', window );">Revenue from Contract with Customer, Allocable Arrangement Consideration Allocation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pirs_AstraZenecaABMember', window );">Astra Zeneca A B [Member] | Up-front Payment Arrangement [Member] | Estimated Development And Manufacturing Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_RevenueFromContractWithCustomerAllocableArrangementConsiderationAllocation', window );">Revenue from Contract with Customer, Allocable Arrangement Consideration Allocation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pirs_AstraZenecaABMember', window );">Astra Zeneca A B [Member] | Up-front Payment Arrangement [Member] | Estimated Phase 2a Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_RevenueFromContractWithCustomerAllocableArrangementConsiderationAllocation', window );">Revenue from Contract with Customer, Allocable Arrangement Consideration Allocation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pirs_AstraZenecaABMember', window );">Astra Zeneca A B [Member] | Additional Other Research Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_RevenueFromContractWithCustomerAllocableArrangementConsiderationAllocation', window );">Revenue from Contract with Customer, Allocable Arrangement Consideration Allocation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pirs_LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember', window );">Les Laboratoires Servier And Institut De Recherches Internationales Servier [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_NumberOfPerformanceObligations', window );">Number of Performance Obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, Remaining Performance Obligation, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract with Customer, Liability, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contract with Customer, Liability, Noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Contract with Customer, Liability, Revenue Recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_NumberOfNovelProteins', window );">Number of Novel Proteins</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_NumberOfPrograms', window );">Number of Programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNet', window );">Capitalized Contract Cost, Net, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Capitalized Contract Cost, Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_NumberOfSeparatePerformanceObligations', window );">Number Of Separate Performance Obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_NumberOfCombinedPerformanceObligations', window );">Number of Combined Performance Obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_ResearchTermExtensionPeriod', window );">Research Term ,Extension Period (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_NumberOfPreclinicalStagePrograms', window );">Number Of Preclinical Stage Programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pirs_LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember', window );">Les Laboratoires Servier And Institut De Recherches Internationales Servier [Member] | Accounting Standards Update 2014-09 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNet', window );">Capitalized Contract Cost, Net, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pirs_LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember', window );">Les Laboratoires Servier And Institut De Recherches Internationales Servier [Member] | License and Collaboration Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_NumberOfPerformanceObligations', window );">Number of Performance Obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_NumberOfCollaborationProducts', window );">Number of Collaboration Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_NumberOfPrograms', window );">Number of Programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pirs_LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember', window );">Les Laboratoires Servier And Institut De Recherches Internationales Servier [Member] | Collaborative Arrangement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Contract with Customer, Liability, Revenue Recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,300<span></span>
</td>
<td class="nump">&#8364; 3.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_NumberOfCollaborationProducts', window );">Number of Collaboration Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_NumberOfSeparatePerformanceObligations', window );">Number Of Separate Performance Obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_NumberOfCombinedPerformanceObligations', window );">Number of Combined Performance Obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pirs_LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember', window );">Les Laboratoires Servier And Institut De Recherches Internationales Servier [Member] | Collaborative Arrangement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_RevenueFromContractWithCustomerAgreementTerminationNoticePeriodUponMaterialBreach', window );">Revenue from Contract with Customer, Agreement Termination Notice Period Upon Material Breach (Day)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pirs_LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember', window );">Les Laboratoires Servier And Institut De Recherches Internationales Servier [Member] | Collaborative Arrangement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_RevenueFromContractWithCustomerAgreementTerminationNoticePeriodUponMaterialBreach', window );">Revenue from Contract with Customer, Agreement Termination Notice Period Upon Material Breach (Day)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">120 days<span></span>
</td>
<td class="text">120 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pirs_LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember', window );">Les Laboratoires Servier And Institut De Recherches Internationales Servier [Member] | Co-Development Collaboration Product Collaboration [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_NumberOfCollaborationProducts', window );">Number of Collaboration Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pirs_LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember', window );">Les Laboratoires Servier And Institut De Recherches Internationales Servier [Member] | Servier Developed Collaboration Products [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_NumberOfCollaborationProducts', window );">Number of Collaboration Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License [Member] | Genentech [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with Customer, Liability, Total</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract with Customer, Liability, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contract with Customer, Liability, Noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License [Member] | B P Assets X I I Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, Remaining Performance Obligation, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract with Customer, Asset, after Allowance for Credit Loss, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License [Member] | B P Assets X I I Inc [Member] | Exclusive Product License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with Customer, Liability, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, Remaining Performance Obligation, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_RevenueFromContractWithCustomerContributionTowardsManufacturingActivities', window );">Revenue from Contract with Customer, Contribution Towards Manufacturing Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_RevenueFromContractWithCustomerPeriodAfterEffectiveDateAgreementsMayBeTerminated', window );">Revenue from Contract with Customer, Period After Effective Date Agreements May Be Terminated (Month)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriod', window );">Revenue from Contract with Customer, Agreement Termination Advance Notice Period (Day)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodIfMarketingApprovalObtained', window );">Revenue from Contract with Customer, Agreement Termination Advance Notice Period If Marketing Approval Obtained (Day)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">120 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_RevenueFromContractWithCustomerAgreementTerminationNoticePeriodUponMaterialBreach', window );">Revenue from Contract with Customer, Agreement Termination Notice Period Upon Material Breach (Day)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_RevenueFromContractWithCustomerAgreementTerminationNoticePeriodNonpaymentOfUndisputedAmounts', window );">Revenue from Contract with Customer, Agreement Termination Notice Period, Non-Payment Of Undisputed Amounts (Day)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_RevenueFromContractWithCustomerAgreementTerminationAdditionalNoticePeriodUponMaterialBreach', window );">Revenue from Contract with Customer, Agreement Termination, Additional Notice Period Upon Material Breach (Day)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_RevenueFromContractWithCustomerAgreementObligationCost', window );">Revenue from Contract with Customer, Agreement Obligation Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Contract with Customer, Liability, Revenue Recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License [Member] | Seattle Genetics Inc. [Member] | Up-front Payment Arrangement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from Contract with Customer, Excluding Assessed Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License [Member] | Les Laboratoires Servier And Institut De Recherches Internationales Servier [Member] | Up-front Payment Arrangement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from Contract with Customer, Excluding Assessed Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,000<span></span>
</td>
<td class="nump">&#8364; 30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pirs_ResearchAndDevelopmentServicesMember', window );">Research And Development Services [Member] | Genentech [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_ResearchCollaborationAgreementPeriod', window );">Research Collaboration Agreement Period (Year)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pirs_ResearchAndDevelopmentServicesMember', window );">Research And Development Services [Member] | Les Laboratoires Servier And Institut De Recherches Internationales Servier [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_NumberOfDevelopmentMilestones', window );">Number of Development Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_AgreementTerminationNoticePeriodUponOfBreachOfPaymentObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement termination notice period upon breach of payment obligations by the Company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_AgreementTerminationNoticePeriodUponOfBreachOfPaymentObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_AmendedCollaborationAgreementResaleOfStockPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Resale of stock period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_AmendedCollaborationAgreementResaleOfStockPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_CollaborativeArrangementAllocableArrangementConsiderationAllocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allocated to collaborative arrangement allocable arrangement consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_CollaborativeArrangementAllocableArrangementConsiderationAllocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_NumberOfCollaborationProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of collaboration products.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_NumberOfCollaborationProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_NumberOfCombinedPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of combined performance obligations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_NumberOfCombinedPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_NumberOfDevelopmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of development milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_NumberOfDevelopmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_NumberOfDiscoveryProgramsDiscontinued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of discovery programs discontinued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_NumberOfDiscoveryProgramsDiscontinued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_NumberOfInitialResearchPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents number of initial research programs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_NumberOfInitialResearchPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_NumberOfLicenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of licenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_NumberOfLicenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_NumberOfNovelProteins">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of novel proteins.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_NumberOfNovelProteins</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_NumberOfOptionalAdditionalResearchPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents number of optional additional research program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_NumberOfOptionalAdditionalResearchPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_NumberOfPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents number of performance obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_NumberOfPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_NumberOfPreclinicalStagePrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of preclinical stage programs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_NumberOfPreclinicalStagePrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_NumberOfPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of programs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_NumberOfPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_NumberOfResearchLicenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of research licenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_NumberOfResearchLicenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_NumberOfResearchPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents number of research programs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_NumberOfResearchPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_NumberOfSeparatePerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents number of separate performance obligations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_NumberOfSeparatePerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_NumberOfSwapOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of swap options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_NumberOfSwapOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_NumberOfTargetPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of target programs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_NumberOfTargetPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_NumberOfTechnologyLicenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of technology licenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_NumberOfTechnologyLicenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_RemainingPerformanceObligationEstimatedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of license performance obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_RemainingPerformanceObligationEstimatedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_ResearchCollaborationAgreementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents research collaboration agreement period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_ResearchCollaborationAgreementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_ResearchTermExtensionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period in which research term is extended.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_ResearchTermExtensionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_RevenueFromContractWithCustomerAgreementObligationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of agreement obligation cost of of revenue from contract with customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_RevenueFromContractWithCustomerAgreementObligationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_RevenueFromContractWithCustomerAgreementTerminationAdditionalNoticePeriodUponMaterialBreach">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract termination due to material breach, additional notice period if the breach is not susceptible.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_RevenueFromContractWithCustomerAgreementTerminationAdditionalNoticePeriodUponMaterialBreach</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract termination advance notice period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodAfterFirstCommercialSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents agreement termination advance notice period after first commercial sale for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodAfterFirstCommercialSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodBeforeFirstCommercialSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents termination advance notice period before first commercial sale for revenue from contract with customer agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodBeforeFirstCommercialSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodIfMarketingApprovalObtained">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement termination advance notice period if marketing approval obtained.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodIfMarketingApprovalObtained</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_RevenueFromContractWithCustomerAgreementTerminationNoticePeriodNonpaymentOfUndisputedAmounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement termination notice period due to non-payment of undisputed amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_RevenueFromContractWithCustomerAgreementTerminationNoticePeriodNonpaymentOfUndisputedAmounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_RevenueFromContractWithCustomerAgreementTerminationNoticePeriodUponMaterialBreach">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement termination notice period upon material breach by the Company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_RevenueFromContractWithCustomerAgreementTerminationNoticePeriodUponMaterialBreach</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_RevenueFromContractWithCustomerAgreementTerminationNoticePeriodWithinMaterialBreach">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents revenue from contract with customer for termination notice period within material breach.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_RevenueFromContractWithCustomerAgreementTerminationNoticePeriodWithinMaterialBreach</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_RevenueFromContractWithCustomerAllocableArrangementConsiderationAllocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from contract with customers allocable arrangement consideration allocation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_RevenueFromContractWithCustomerAllocableArrangementConsiderationAllocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_RevenueFromContractWithCustomerCollaborationFeeOnAdditionalProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents revenue from contract with customer related to collaboration fee on additional program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_RevenueFromContractWithCustomerCollaborationFeeOnAdditionalProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_RevenueFromContractWithCustomerContributionTowardsManufacturingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from contract with customers contribution towards manufacturing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_RevenueFromContractWithCustomerContributionTowardsManufacturingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_RevenueFromContractWithCustomerPeriodAfterEffectiveDateAgreementsMayBeTerminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period after effective date agreements may be terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_RevenueFromContractWithCustomerPeriodAfterEffectiveDateAgreementsMayBeTerminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_SaleOfStockFairValuePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price per share of sale of stock, fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_SaleOfStockFairValuePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905575&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905575&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905575&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pirs_GenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pirs_GenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=pirs_LicenseAndCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=pirs_LicenseAndCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=pirs_PlatformTechnologyLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=pirs_PlatformTechnologyLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=pirs_GovernanceCommitteeParticipationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=pirs_GovernanceCommitteeParticipationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pirs_SeattleGeneticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pirs_SeattleGeneticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=pirs_OtherArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=pirs_OtherArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_UpFrontPaymentArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_UpFrontPaymentArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=pirs_SalesMilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=pirs_SalesMilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=pirs_AntibodyTargetSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=pirs_AntibodyTargetSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pirs_AstraZenecaABMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pirs_AstraZenecaABMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=pirs_EstimatedDevelopmentAndManufacturingServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=pirs_EstimatedDevelopmentAndManufacturingServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=pirs_EstimatedPhase2aServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=pirs_EstimatedPhase2aServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=pirs_AdditionalOtherResearchServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=pirs_AdditionalOtherResearchServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pirs_LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pirs_LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis=us-gaap_AccountingStandardsUpdate201409Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis=us-gaap_AccountingStandardsUpdate201409Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=pirs_CodevelopmentCollaborationProductCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=pirs_CodevelopmentCollaborationProductCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=pirs_ServierDevelopedCollaborationProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=pirs_ServierDevelopedCollaborationProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pirs_BPAssetsXIIIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pirs_BPAssetsXIIIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=pirs_ExclusiveProductLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=pirs_ExclusiveProductLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pirs_ResearchAndDevelopmentServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pirs_ResearchAndDevelopmentServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139857063992736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Revenue - Disaggregation of Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,902<span></span>
</td>
<td class="nump">$ 31,418<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pirs_AstraZenecaABMember', window );">Astra Zeneca A B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 13,000<span></span>
</td>
<td class="nump">9,117<span></span>
</td>
<td class="nump">18,919<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pirs_SeattleGeneticsIncMember', window );">Seattle Genetics Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,287<span></span>
</td>
<td class="nump">768<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pirs_LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember', window );">Les Laboratoires Servier And Institut De Recherches Internationales Servier [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,359<span></span>
</td>
<td class="nump">4,070<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pirs_GenentechMember', window );">Genentech [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,139<span></span>
</td>
<td class="nump">1,950<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pirs_BostonPharmaceuticalsMember', window );">Boston Pharmaceuticals [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,711<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pirs_AstraZenecaABMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pirs_AstraZenecaABMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pirs_SeattleGeneticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pirs_SeattleGeneticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pirs_LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pirs_LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pirs_GenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pirs_GenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pirs_BostonPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pirs_BostonPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139857069319856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 3 - Revenue - Potential Milestone Payments Received (Details) - Collaborative Arrangement [Member]<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pirs_ResearchAndDevelopmentMilestonePaymentsMember', window );">Research And Development Milestone Payments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractsReceivableClaimsAndUncertainAmounts', window );">milestone</a></td>
<td class="nump">$ 2,403<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pirs_ResearchAndDevelopmentMilestonePaymentsMember', window );">Research And Development Milestone Payments [Member] | Astra Zeneca A B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractsReceivableClaimsAndUncertainAmounts', window );">milestone</a></td>
<td class="nump">702<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pirs_ResearchAndDevelopmentMilestonePaymentsMember', window );">Research And Development Milestone Payments [Member] | Les Laboratoires Servier And Institut De Recherches Internationales Servier [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractsReceivableClaimsAndUncertainAmounts', window );">milestone</a></td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pirs_ResearchAndDevelopmentMilestonePaymentsMember', window );">Research And Development Milestone Payments [Member] | Seattle Genetics Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractsReceivableClaimsAndUncertainAmounts', window );">milestone</a></td>
<td class="nump">759<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pirs_ResearchAndDevelopmentMilestonePaymentsMember', window );">Research And Development Milestone Payments [Member] | Boston Pharmaceuticals [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractsReceivableClaimsAndUncertainAmounts', window );">milestone</a></td>
<td class="nump">88<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pirs_ResearchAndDevelopmentMilestonePaymentsMember', window );">Research And Development Milestone Payments [Member] | Genentech [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractsReceivableClaimsAndUncertainAmounts', window );">milestone</a></td>
<td class="nump">834<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pirs_SalesMilestonePaymentsMember', window );">Sales Milestone Payments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractsReceivableClaimsAndUncertainAmounts', window );">milestone</a></td>
<td class="nump">5,240<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pirs_SalesMilestonePaymentsMember', window );">Sales Milestone Payments [Member] | Astra Zeneca A B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractsReceivableClaimsAndUncertainAmounts', window );">milestone</a></td>
<td class="nump">3,925<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pirs_SalesMilestonePaymentsMember', window );">Sales Milestone Payments [Member] | Les Laboratoires Servier And Institut De Recherches Internationales Servier [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractsReceivableClaimsAndUncertainAmounts', window );">milestone</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pirs_SalesMilestonePaymentsMember', window );">Sales Milestone Payments [Member] | Seattle Genetics Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractsReceivableClaimsAndUncertainAmounts', window );">milestone</a></td>
<td class="nump">450<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pirs_SalesMilestonePaymentsMember', window );">Sales Milestone Payments [Member] | Boston Pharmaceuticals [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractsReceivableClaimsAndUncertainAmounts', window );">milestone</a></td>
<td class="nump">265<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pirs_SalesMilestonePaymentsMember', window );">Sales Milestone Payments [Member] | Genentech [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractsReceivableClaimsAndUncertainAmounts', window );">milestone</a></td>
<td class="nump">$ 600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractsReceivableClaimsAndUncertainAmounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of billed or unbilled claims or other similar items subject to uncertainty concerning their determination or ultimate realization under long-term contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 910<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126937589&amp;loc=SL119991585-234733<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(c)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractsReceivableClaimsAndUncertainAmounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pirs_ResearchAndDevelopmentMilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pirs_ResearchAndDevelopmentMilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pirs_AstraZenecaABMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pirs_AstraZenecaABMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pirs_LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pirs_LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pirs_SeattleGeneticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pirs_SeattleGeneticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pirs_BostonPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pirs_BostonPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pirs_GenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pirs_GenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pirs_SalesMilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pirs_SalesMilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139857069517984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 4 - Grant Income (Details Textual) - Jun. 30, 2021<br> &#8364; in Millions, $ in Millions</strong></div></th>
<th class="th"><div>USD ($)</div></th>
<th class="th"><div>EUR (&#8364;)</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Grants Receivable</a></td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">&#8364; 14.2<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139857071585760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Cash, Cash Equivalents and Investments (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss', window );">Debt Securities, Available-for-Sale, Realized Gain (Loss), Total</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139857058506240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 5 - Cash, Cash Equivalents and Investments - Cash Equivalents and Investments Carried at Fair Value (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">$ 20,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_CashEquivalentsAndInvestments', window );">Total</a></td>
<td class="nump">38,152<span></span>
</td>
<td class="nump">$ 56,885<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_CashEquivalentsAndInvestments', window );">Total</a></td>
<td class="nump">22,087<span></span>
</td>
<td class="nump">56,885<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_CashEquivalentsAndInvestments', window );">Total</a></td>
<td class="nump">16,065<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_CashEquivalentsAndInvestments', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds, included in cash equivalents</a></td>
<td class="nump">17,618<span></span>
</td>
<td class="nump">56,885<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds, included in cash equivalents</a></td>
<td class="nump">17,618<span></span>
</td>
<td class="nump">56,885<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds, included in cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds, included in cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">3,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury Securities [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">3,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury Securities [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury Securities [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Debt Security, Government, Non-US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Debt Security, Government, Non-US [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Debt Security, Government, Non-US [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Debt Security, Government, Non-US [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-Backed Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-Backed Securities [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-Backed Securities [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-Backed Securities [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate Bond Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">15,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate Bond Securities [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate Bond Securities [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">15,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate Bond Securities [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_CashEquivalentsAndInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of cash, cash equivalents and investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_CashEquivalentsAndInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139857045574336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Cash, Cash Equivalents and Investments - Investments (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">$ 20,607<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized losses</a></td>
<td class="num">(73)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">20,534<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">3,575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized losses</a></td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">$ 3,573<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury Securities [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_DebtSecuritiesAvailableforsaleContractualMaturityPeriod', window );">Contractual Maturity Period (Day)</a></td>
<td class="text">47 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Debt Security, Government, Non-US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_DebtSecuritiesAvailableforsaleContractualMaturityPeriod', window );">Contractual Maturity Period (Day)</a></td>
<td class="text">74 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">$ 899<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized losses</a></td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">$ 896<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-Backed Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_DebtSecuritiesAvailableforsaleContractualMaturityPeriod', window );">Contractual Maturity Period (Day)</a></td>
<td class="text">15 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">$ 500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized losses</a></td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">499<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate Bond Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">15,633<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized losses</a></td>
<td class="num">(67)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">$ 15,566<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate Bond Securities [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_DebtSecuritiesAvailableforsaleContractualMaturityPeriod', window );">Contractual Maturity Period (Day)</a></td>
<td class="text">228 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_DebtSecuritiesAvailableforsaleContractualMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual maturity period for debt securities, available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_DebtSecuritiesAvailableforsaleContractualMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139857071645152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Property and Equipment, Net (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation, Total</a></td>
<td class="nump">$ 2.3<span></span>
</td>
<td class="nump">$ 2.4<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139857158495520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 6 - Property and Equipment, Net - Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, cost</a></td>
<td class="nump">$ 26,639<span></span>
</td>
<td class="nump">$ 26,839<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(9,647)<span></span>
</td>
<td class="num">(7,717)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">16,992<span></span>
</td>
<td class="nump">19,122<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pirs_LaboratoryEquipmentMember', window );">Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, cost</a></td>
<td class="nump">11,970<span></span>
</td>
<td class="nump">11,354<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, cost</a></td>
<td class="nump">1,861<span></span>
</td>
<td class="nump">1,959<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, cost</a></td>
<td class="nump">364<span></span>
</td>
<td class="nump">396<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, cost</a></td>
<td class="nump">$ 12,444<span></span>
</td>
<td class="nump">$ 13,130<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pirs_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pirs_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139857072595280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 7 - Accrued Expenses - Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_AccruedResearchAndDevelopmentCosts', window );">Research and development fees</a></td>
<td class="nump">$ 5,758<span></span>
</td>
<td class="nump">$ 5,682<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation expense</a></td>
<td class="nump">3,015<span></span>
</td>
<td class="nump">3,581<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_AccruedLicenseObligationsCurrent', window );">Accrued license obligations</a></td>
<td class="nump">245<span></span>
</td>
<td class="nump">1,541<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_AccruedAccountsPayableCurrent', window );">Accrued accounts payable</a></td>
<td class="nump">1,245<span></span>
</td>
<td class="nump">2,980<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">483<span></span>
</td>
<td class="nump">393<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_AccruedCollaborationCostsCurrent', window );">Collaboration cost-sharing obligation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,610<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_AccruedLiabilitiesAndOtherLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">11,605<span></span>
</td>
<td class="nump">16,836<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=pirs_AccruedLiabilitiesAndOtherCurrentLiabilitiesMember', window );">Accrued Liabilities and Other Current Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities</a></td>
<td class="nump">$ 859<span></span>
</td>
<td class="nump">$ 1,049<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_AccruedAccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current portion of accrued accounts payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_AccruedAccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_AccruedCollaborationCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current portion of accrued collaboration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_AccruedCollaborationCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_AccruedLiabilitiesAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current portion of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_AccruedLiabilitiesAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_AccruedLicenseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current portion of accrued license obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_AccruedLicenseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_AccruedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_AccruedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=pirs_AccruedLiabilitiesAndOtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=pirs_AccruedLiabilitiesAndOtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139857045717360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Income Taxes (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</a></td>
<td class="nump">$ 7,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_DeferredTaxAssetsCapitalizedResearchAndDevelopment', window );">Deferred Tax Assets, Capitalized Research and Development</a></td>
<td class="nump">952<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">$ 38,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Tax Year</a></td>
<td class="text">2019 2020 2021 2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">$ 42,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Tax Year</a></td>
<td class="text">2019 2020 2021 2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Tax Year</a></td>
<td class="text">2014 2015 2016 2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Authority [Member] | Corporate Income Tax [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">$ 163,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Authority [Member] | Trade Tax [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">$ 160,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_DeferredTaxAssetsCapitalizedResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to capitalized research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_DeferredTaxAssetsCapitalizedResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in YYYY format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=pirs_CorporateIncomeTaxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=pirs_CorporateIncomeTaxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=pirs_TradeTaxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=pirs_TradeTaxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139857069270976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Income Taxes - Schedule of Income Before Income Tax Domestic and Foreign (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="num">$ (11,765)<span></span>
</td>
<td class="num">$ (11,312)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(21,512)<span></span>
</td>
<td class="num">(34,426)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">$ (33,277)<span></span>
</td>
<td class="num">$ (45,738)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139857068459680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign, tax expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal, deferred</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State, deferred</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign, deferred</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139857072401312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign rate differential</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax, net of federal benefit</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Share-based awards compensation, tax rate</a></td>
<td class="num">(2.20%)<span></span>
</td>
<td class="num">(3.50%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Permanent items</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_EffectiveIncomeTaxRateReconciliationProvisionToReturnPercent', window );">Provision to return</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">3.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Credits</a></td>
<td class="nump">1.20%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(28.30%)<span></span>
</td>
<td class="num">(27.40%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_EffectiveIncomeTaxRateReconciliationProvisionToReturnPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) from provision to return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_EffectiveIncomeTaxRateReconciliationProvisionToReturnPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139857064026240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 8 - Income Tax - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 54,845<span></span>
</td>
<td class="nump">$ 49,280<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Share-based awards compensation, tax assets</a></td>
<td class="nump">3,112<span></span>
</td>
<td class="nump">2,739<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_DeferredTaxAssetsAccruedCompensationAndOther', window );">Accrued expenses, tax assets</a></td>
<td class="nump">216<span></span>
</td>
<td class="nump">323<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">R&amp;D Credits</a></td>
<td class="nump">413<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_DeferredTaxAssetsDepreciationAndOther', window );">Depreciation and other</a></td>
<td class="nump">384<span></span>
</td>
<td class="nump">384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses', window );">Unrealized foreign currency</a></td>
<td class="nump">359<span></span>
</td>
<td class="nump">256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_DeferredTaxAssetsCapitalizedResearchAndDevelopment', window );">Capitalized R&amp;D</a></td>
<td class="nump">952<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_DeferredTaxAssetLeaseLiability', window );">Lease liability</a></td>
<td class="nump">3,541<span></span>
</td>
<td class="nump">4,022<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">63,822<span></span>
</td>
<td class="nump">57,004<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_DeferredTaxLiabilitiesLeaseRightofuseAsset', window );">Right-of-use asset</a></td>
<td class="num">(3,270)<span></span>
</td>
<td class="num">(3,729)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDeferredExpense', window );">Accrued expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(68)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(3,270)<span></span>
</td>
<td class="num">(3,797)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance:</a></td>
<td class="num">(60,552)<span></span>
</td>
<td class="num">(53,207)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax asset</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_DeferredTaxAssetLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_DeferredTaxAssetLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_DeferredTaxAssetsAccruedCompensationAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued compensation and other costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_DeferredTaxAssetsAccruedCompensationAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_DeferredTaxAssetsCapitalizedResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to capitalized research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_DeferredTaxAssetsCapitalizedResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_DeferredTaxAssetsDepreciationAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from depreciation and other expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_DeferredTaxAssetsDepreciationAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_DeferredTaxLiabilitiesLeaseRightofuseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from lease right-of-use assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_DeferredTaxLiabilitiesLeaseRightofuseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from unrealized losses on foreign currency transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDeferredExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from capitalized costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDeferredExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139857068499840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Income Taxes - Summary of Income Tax Contingencies (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits at December 31, 2021</a></td>
<td class="nump">$ 5,665<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation', window );">Currency translation adjustment</a></td>
<td class="num">(302)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits at December 31, 2022</a></td>
<td class="nump">$ 5,363<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139857062880960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Stockholders' Equity (Details Textual)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 22, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 25, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 20, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 01, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 30, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 30, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,519,103<span></span>
</td>
<td class="nump">72,222,661<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,617<span></span>
</td>
<td class="nump">15,617<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding, Ending Balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,617<span></span>
</td>
<td class="nump">15,617<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from Issuance of Private Placement | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 18,913<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,922<span></span>
</td>
<td class="nump">$ 38,188<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding, Ending Balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,519,103<span></span>
</td>
<td class="nump">72,222,661<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=pirs_JefferiesLLCMember', window );">Jefferies L L C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=pirs_ConversionOfCommonStockIntoSeriesEPreferredStockMember', window );">Conversion of Common Stock into Series E Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of Stock, Shares Converted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of Stock, Shares Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pirs_EmployeeDirectorAndConsultantEquityIncentivePlan2020Member', window );">Employee Director And Consultant Equity Incentive Plan2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of Stock, Number of Shares Issued in Transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">2,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pirs_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PartnersCapitalAccountUnitsSoldInPrivatePlacement', window );">Partners' Capital Account, Units, Sold in Private Placement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,188,804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from Issuance of Private Placement | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_ProceedsFromIssuanceOfPrivatePlacementNet', window );">Proceeds From Issuance Of Private Placement Net | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of Stock, Number of Shares Issued in Transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,225,804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pirs_AtTheMarketOfferingMember', window );">At the Market Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of Stock, Number of Shares Issued in Transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="nump">8,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pirs_AtTheMarketOfferingMember', window );">At the Market Offering [Member] | Jefferies L L C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.46<span></span>
</td>
<td class="nump">$ 4.85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_SaleOfStockAuthorizedAmount', window );">Sale of Stock, Authorized Amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of Stock, Consideration Received on Transaction | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,200<span></span>
</td>
<td class="nump">$ 39,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_NumberOfVotesPerShare', window );">Number Of Votes Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Stock Exchange Shares from Existing Shareholders [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of Stock, Number of Shares Issued in Transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock [Member] | Preferred Share Exchange [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of Stock, Number of Shares Issued in Transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding, Ending Balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,026<span></span>
</td>
<td class="nump">4,026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding, Ending Balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,026<span></span>
</td>
<td class="nump">4,026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,506<span></span>
</td>
<td class="nump">3,506<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding, Ending Balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,506<span></span>
</td>
<td class="nump">3,506<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member] | Preferred Share Exchange [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Debt Instrument, Convertible, Beneficial Conversion Feature | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member] | Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible Preferred Stock, Shares Issued upon Conversion (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_ProceedsFromIssuanceOfPrivatePlacementNet', window );">Proceeds From Issuance Of Private Placement Net | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of Stock, Number of Shares Issued in Transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,014,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Sale of Stock, Consideration Received Per Transaction | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Stock Issued During Period, Shares, Conversion of Units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_SaleOfStockNumberOfWarrantsPerUnit', window );">Sale of Stock, Number of Warrants, Per Unit (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_ConvertiblePreferredStockWeightedAverageStockPricePercent', window );">Convertible Preferred Stock, Weighted Average Stock Price, Percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member] | Private Placement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding, Ending Balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesEPreferredStockMember', window );">Series E Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding, Ending Balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pirs_SeriesAThroughEMember', window );">Series A Through E [Member] | Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible Preferred Stock, Shares Issued upon Conversion (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_ConvertiblePreferredStockCommonStockOwnershipLimitPercent', window );">Convertible Preferred Stock, Common Stock Ownership Limit, Percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_ConvertiblePreferredStockBeneficialOwnershipLimitationPercent', window );">Convertible Preferred Stock, Beneficial Ownership Limitation, Percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_ConvertiblePreferredStockBeneficialOwnershipLimitationNoticePeriodBeforeIncrease', window );">Convertible Preferred Stock, Beneficial Ownership Limitation, Notice Period Before Increase (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">61 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_ConvertiblePreferredStockBeneficialOwnershipLimitationNoticePeriodBeforeIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period in which the entity must notify an increase in beneficial ownership limitation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_ConvertiblePreferredStockBeneficialOwnershipLimitationNoticePeriodBeforeIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_ConvertiblePreferredStockBeneficialOwnershipLimitationPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of beneficial ownership limitation for convertible preferred stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_ConvertiblePreferredStockBeneficialOwnershipLimitationPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_ConvertiblePreferredStockCommonStockOwnershipLimitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of common stock ownership limit of convertible preferred stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_ConvertiblePreferredStockCommonStockOwnershipLimitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_ConvertiblePreferredStockWeightedAverageStockPricePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of weighted average convertible preferred stock price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_ConvertiblePreferredStockWeightedAverageStockPricePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_NumberOfVotesPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of votes per share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_NumberOfVotesPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_ProceedsFromIssuanceOfPrivatePlacementNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net proceeds from issuance of private placement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_ProceedsFromIssuanceOfPrivatePlacementNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_SaleOfStockAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Authorized amount of sale of stock during a period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_SaleOfStockAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_SaleOfStockNumberOfWarrantsPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of warrants issued per unit in a sale of stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_SaleOfStockNumberOfWarrantsPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PartnersCapitalAccountUnitsSoldInPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of units sold in a private placement of each class of partners' capital account. Units represent shares of ownership of the general, limited, and preferred partners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 4.F)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187171-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PartnersCapitalAccountUnitsSoldInPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=pirs_JefferiesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=pirs_JefferiesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=pirs_ConversionOfCommonStockIntoSeriesEPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=pirs_ConversionOfCommonStockIntoSeriesEPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pirs_EmployeeDirectorAndConsultantEquityIncentivePlan2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pirs_EmployeeDirectorAndConsultantEquityIncentivePlan2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pirs_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pirs_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pirs_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pirs_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pirs_StockExchangeSharesFromExistingShareholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pirs_StockExchangeSharesFromExistingShareholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pirs_PreferredShareExchangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pirs_PreferredShareExchangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesEPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesEPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pirs_SeriesAThroughEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pirs_SeriesAThroughEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139857069606080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Net Loss Per Share (Details Textual) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)</a></td>
<td class="nump">38.4<span></span>
</td>
<td class="nump">36.8<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139857063432016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Stock and Employee Benefit Plans (Details Textual)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 22, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 25, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 01, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 23, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,075,282<span></span>
</td>
<td class="nump">3,182,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.96<span></span>
</td>
<td class="nump">$ 2.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Stock Issued During Period, Shares, Employee Stock Purchase Plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">181,466<span></span>
</td>
<td class="nump">64,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 5 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=pirs_ExecutiveOfficersAndManagementMember', window );">Executive Officers and Management [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfPurchasePeriods', window );">Share-Based Compensation Arrangement by Share-based Payment Award, Number of Purchase Periods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_ShareBasedCompensationArrangementBySharebasedPaymentAwardPurchasePeriod', window );">Share Based Compensation Arrangement by Sharebased Payment Award, Purchase Period (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pirs_EmployeeDirectorAndConsultantEquityIncentivePlan2020Member', window );">Employee Director And Consultant Equity Incentive Plan2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance (in shares)</a></td>
<td class="nump">8,750,000<span></span>
</td>
<td class="nump">5,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">2,250,000<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,075,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,314,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_ShareBasedCompensationArrangementBySharebasedPaymentAwardPurchasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period in which share based compensation awards that can be purchased</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_ShareBasedCompensationArrangementBySharebasedPaymentAwardPurchasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfPurchasePeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of purchase periods for share based payment award</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfPurchasePeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=pirs_ExecutiveOfficersAndManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=pirs_ExecutiveOfficersAndManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pirs_EmployeeDirectorAndConsultantEquityIncentivePlan2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pirs_EmployeeDirectorAndConsultantEquityIncentivePlan2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139857063887584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Stock and Employee Benefit Plans - Schedule of Share-based Payment Award, Stock Options (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk free interest rate, minimum</a></td>
<td class="nump">1.43%<span></span>
</td>
<td class="nump">0.46%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk free interest rate, maximum</a></td>
<td class="nump">3.39%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">79.90%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">81.10%<span></span>
</td>
<td class="nump">81.70%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years) (Year)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 3 months 21 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years) (Year)</a></td>
<td class="text">5 years 8 months 23 days<span></span>
</td>
<td class="text">5 years 8 months 23 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk free interest rate, minimum</a></td>
<td class="nump">1.62%<span></span>
</td>
<td class="nump">0.04%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk free interest rate, maximum</a></td>
<td class="nump">4.60%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years) (Year)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">53.46%<span></span>
</td>
<td class="nump">60.46%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">70.17%<span></span>
</td>
<td class="nump">131.21%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139857062750368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Stock and Employee Benefit Plans - Stock Options Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted, balance (in shares)</a></td>
<td class="nump">3,075,282<span></span>
</td>
<td class="nump">3,182,696<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=pirs_ExecutiveOfficersAndManagementMember', window );">Executive Officers and Management [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, balance (in shares)</a></td>
<td class="nump">660,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, exercise price (in dollars per share)</a></td>
<td class="nump">$ 4.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, intrinsic value</a></td>
<td class="nump">$ 108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted, balance (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted, exercise price (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodAggregateIntrinsicValue', window );">Granted, intrinsic value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Canceled, balance (in shares)</a></td>
<td class="nump">360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Canceled, exercise price (in dollars per share)</a></td>
<td class="nump">$ 3.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAggregateIntrinsicValue', window );">Canceled, intrinsic value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, balance (in shares)</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">660,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, exercise price (in dollars per share)</a></td>
<td class="nump">$ 4.65<span></span>
</td>
<td class="nump">$ 4.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, contractual life (Year)</a></td>
<td class="text">6 years 7 months 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, intrinsic value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 108<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested or expected to vest, balance (in shares)</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested or expected to vest, exercise price (in dollars per share)</a></td>
<td class="nump">$ 4.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested or expected to vest, contractual life (Year)</a></td>
<td class="text">6 years 7 months 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested or expected to vest, intrinsic value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable, balance (in shares)</a></td>
<td class="nump">243,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, exercise price (in dollars per share)</a></td>
<td class="nump">$ 4.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm2Exercised', window );">Exercisable, contractual life (Year)</a></td>
<td class="text">6 years 7 months 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Exercisable, intrinsic value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pirs_EmployeeDirectorAndConsultantEquityIncentivePlan2020Member', window );">Employee Director And Consultant Equity Incentive Plan2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, balance (in shares)</a></td>
<td class="nump">11,475,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, exercise price (in dollars per share)</a></td>
<td class="nump">$ 3.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, intrinsic value</a></td>
<td class="nump">$ 11,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted, balance (in shares)</a></td>
<td class="nump">3,075,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted, exercise price (in dollars per share)</a></td>
<td class="nump">$ 2.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodAggregateIntrinsicValue', window );">Granted, intrinsic value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock resulting from exercise of stock options (in shares)</a></td>
<td class="nump">46,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised, exercise price (in dollars per share)</a></td>
<td class="nump">$ 2.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Exercised, intrinsic value</a></td>
<td class="nump">$ 66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Canceled, balance (in shares)</a></td>
<td class="nump">1,031,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Canceled, exercise price (in dollars per share)</a></td>
<td class="nump">$ 3.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAggregateIntrinsicValue', window );">Canceled, intrinsic value</a></td>
<td class="nump">$ 17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, balance (in shares)</a></td>
<td class="nump">13,473,366<span></span>
</td>
<td class="nump">11,475,713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, exercise price (in dollars per share)</a></td>
<td class="nump">$ 3.21<span></span>
</td>
<td class="nump">$ 3.35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, contractual life (Year)</a></td>
<td class="text">6 years 3 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, intrinsic value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 11,310<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested or expected to vest, balance (in shares)</a></td>
<td class="nump">13,473,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested or expected to vest, exercise price (in dollars per share)</a></td>
<td class="nump">$ 3.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested or expected to vest, contractual life (Year)</a></td>
<td class="text">6 years 3 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested or expected to vest, intrinsic value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable, balance (in shares)</a></td>
<td class="nump">9,096,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, exercise price (in dollars per share)</a></td>
<td class="nump">$ 3.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm2Exercised', window );">Exercisable, contractual life (Year)</a></td>
<td class="text">5 years 1 month 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Exercisable, intrinsic value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm2Exercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period in which stock options are exercisable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm2Exercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options canceled</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=pirs_ExecutiveOfficersAndManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=pirs_ExecutiveOfficersAndManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pirs_EmployeeDirectorAndConsultantEquityIncentivePlan2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pirs_EmployeeDirectorAndConsultantEquityIncentivePlan2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139857063561808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Stock and Employee Benefit Plans - Schedule of Employee Service Share-based Compensation Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment arrangement expense</a></td>
<td class="nump">$ 4,402<span></span>
</td>
<td class="nump">$ 5,215<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment arrangement expense</a></td>
<td class="nump">1,905<span></span>
</td>
<td class="nump">2,274<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment arrangement expense</a></td>
<td class="nump">$ 2,497<span></span>
</td>
<td class="nump">$ 2,941<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139857063432640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - Leases (Details Textual)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 29, 2020 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Feb. 29, 2020 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2015 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating Lease, Payments | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.4<span></span>
</td>
<td class="nump">$ 2.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=pirs_HallbergmoosGermanyMember', window );">Hallbergmoos Germany [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, Operating Lease, Term of Contract (Year)</a></td>
<td class="text">12 years 6 months<span></span>
</td>
<td class="text">12 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=pirs_HallbergmoosGermanyMember', window );">Hallbergmoos Germany [Member] | Leases Expected to be Delivered by October 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of Real Estate Property (Square Foot) | ft&#178;</a></td>
<td class="nump">22,300<span></span>
</td>
<td class="nump">22,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=pirs_HallbergmoosGermanyMember', window );">Hallbergmoos Germany [Member] | Leases with First Right of Refusal for Additional Area [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of Real Estate Property (Square Foot) | ft&#178;</a></td>
<td class="nump">13,400<span></span>
</td>
<td class="nump">13,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=pirs_SubleaseOfficeSpaceMember', window );">Sublease Office Space [Member] | Boston Massachusetts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of Real Estate Property (Square Foot) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,950<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=pirs_OfficeAndLaboratorySpaceMember', window );">Office and Laboratory Space [Member] | Hallbergmoos Germany [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of Real Estate Property (Square Foot) | ft&#178;</a></td>
<td class="nump">105,000<span></span>
</td>
<td class="nump">105,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_NumberOfAgreementExtensionOptions', window );">Number of Agreement Extension Options</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, Operating Lease, Renewal Term (Month)</a></td>
<td class="text">60 months<span></span>
</td>
<td class="text">60 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pirs_LesseeOperatingLeaseMonthlyRentExpense', window );">Lessee, Operating Lease, Monthly Rent Expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security Deposit | $</a></td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TenantImprovements', window );">Tenant Improvements | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_LesseeOperatingLeaseMonthlyRentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Monthly rent expense under operating lease for lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_LesseeOperatingLeaseMonthlyRentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pirs_NumberOfAgreementExtensionOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of agreement extension options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pirs_NumberOfAgreementExtensionOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pirs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=pirs_HallbergmoosGermanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=pirs_HallbergmoosGermanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pirs_LeasesExpectedToBeDeliveredByOctober2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pirs_LeasesExpectedToBeDeliveredByOctober2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pirs_LeasesWithFirstRightOfRefusalForAdditionalAreaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pirs_LeasesWithFirstRightOfRefusalForAdditionalAreaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=pirs_SubleaseOfficeSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=pirs_SubleaseOfficeSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=pirs_BostonMassachusettsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=pirs_BostonMassachusettsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=pirs_OfficeAndLaboratorySpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=pirs_OfficeAndLaboratorySpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139857068497200">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Note 13 - Leases - Operating Lease Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,356<span></span>
</td>
<td class="nump">$ 1,483<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease costs (1)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">737<span></span>
</td>
<td class="nump">739<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,093<span></span>
</td>
<td class="nump">$ 2,222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (years) (Year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">9 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Variable lease costs include certain additional charges for operating costs, including insurance, maintenance, taxes, utilities,
and other costs incurred, which are billed based on both usage and as a percentage of the Company&#8217;s share of total square
footage.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139857070231824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 13 - Leases - Maturities of Operating Lease Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 2,116<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">2,116<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">2,116<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">2,116<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">2,116<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">9,699<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">20,279<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: present value adjustment</a></td>
<td class="num">(7,176)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 13,103<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>pirs20221231_10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:pirs="http://www.pieris.com/20221231"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:thunderdome="http://www.RDGFilings.com"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="pirs-20221231.xsd" xlink:type="simple"/>
    <context id="d_2022-01-01_2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i_2022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i_2023-03-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
        </entity>
        <period>
            <instant>2023-03-28</instant>
        </period>
    </context>
    <context id="i_2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_StatementEquityComponentsAxis-ReceivablesFromStockholderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-ReceivablesFromStockholderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfPreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">pirs:ConversionOfPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfPreferredStockMember_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">pirs:ConversionOfPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfPreferredStockMember_StatementEquityComponentsAxis-ReceivablesFromStockholderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">pirs:ConversionOfPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfPreferredStockMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">pirs:ConversionOfPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfPreferredStockMember_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">pirs:ConversionOfPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfPreferredStockMember_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">pirs:ConversionOfPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">pirs:ConversionOfPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesEPreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">pirs:ConversionOfSeriesEPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesEPreferredStockMember_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">pirs:ConversionOfSeriesEPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesEPreferredStockMember_StatementEquityComponentsAxis-ReceivablesFromStockholderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">pirs:ConversionOfSeriesEPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesEPreferredStockMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">pirs:ConversionOfSeriesEPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesEPreferredStockMember_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">pirs:ConversionOfSeriesEPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesEPreferredStockMember_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">pirs:ConversionOfSeriesEPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesEPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">pirs:ConversionOfSeriesEPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pirs:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pirs:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pirs:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-ReceivablesFromStockholderMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pirs:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pirs:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pirs:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pirs:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-ReceivablesFromStockholderMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_StatementEquityComponentsAxis-ReceivablesFromStockholderMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-ReceivablesFromStockholderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i_2022-12-31_StatementEquityComponentsAxis-PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_StatementEquityComponentsAxis-ReceivablesFromStockholderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pirs:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i_2013-05-31_BusinessAcquisitionAxis-PierisPharmaceuticalsGmbhMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pirs:PierisPharmaceuticalsGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-05-31</instant>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pirs:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pirs:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-OfficeEquipmentMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-OfficeEquipmentMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_CounterpartyNameAxis-AstraZenecaABMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:AstraZenecaABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_CounterpartyNameAxis-AstraZenecaABMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:AstraZenecaABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_CounterpartyNameAxis-SeattleGeneticsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:SeattleGeneticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_CounterpartyNameAxis-SeattleGeneticsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:SeattleGeneticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_CounterpartyNameAxis-GenentechMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:GenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_CounterpartyNameAxis-GenentechMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:GenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_CounterpartyNameAxis-BostonPharmaceuticalsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:BostonPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_CounterpartyNameAxis-BostonPharmaceuticalsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:BostonPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i_2022-12-31_CounterpartyNameAxis-AstraZenecaABMember_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-ResearchAndDevelopmentMilestonePaymentsMember_TypeOfArrangementAxis-CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:AstraZenecaABMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pirs:ResearchAndDevelopmentMilestonePaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_CounterpartyNameAxis-AstraZenecaABMember_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-SalesMilestonePaymentsMember_TypeOfArrangementAxis-CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:AstraZenecaABMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pirs:SalesMilestonePaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-ResearchAndDevelopmentMilestonePaymentsMember_TypeOfArrangementAxis-CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pirs:ResearchAndDevelopmentMilestonePaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-SalesMilestonePaymentsMember_TypeOfArrangementAxis-CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pirs:SalesMilestonePaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_CounterpartyNameAxis-SeattleGeneticsIncMember_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-ResearchAndDevelopmentMilestonePaymentsMember_TypeOfArrangementAxis-CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:SeattleGeneticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pirs:ResearchAndDevelopmentMilestonePaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_CounterpartyNameAxis-SeattleGeneticsIncMember_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-SalesMilestonePaymentsMember_TypeOfArrangementAxis-CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:SeattleGeneticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pirs:SalesMilestonePaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_CounterpartyNameAxis-BostonPharmaceuticalsMember_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-ResearchAndDevelopmentMilestonePaymentsMember_TypeOfArrangementAxis-CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:BostonPharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pirs:ResearchAndDevelopmentMilestonePaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_CounterpartyNameAxis-BostonPharmaceuticalsMember_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-SalesMilestonePaymentsMember_TypeOfArrangementAxis-CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:BostonPharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pirs:SalesMilestonePaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_CounterpartyNameAxis-GenentechMember_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-ResearchAndDevelopmentMilestonePaymentsMember_TypeOfArrangementAxis-CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:GenentechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pirs:ResearchAndDevelopmentMilestonePaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_CounterpartyNameAxis-GenentechMember_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-SalesMilestonePaymentsMember_TypeOfArrangementAxis-CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:GenentechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pirs:SalesMilestonePaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-ResearchAndDevelopmentMilestonePaymentsMember_TypeOfArrangementAxis-CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pirs:ResearchAndDevelopmentMilestonePaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-SalesMilestonePaymentsMember_TypeOfArrangementAxis-CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pirs:SalesMilestonePaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2021-05-19_CounterpartyNameAxis-GenentechMember_ProductOrServiceAxis-LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:GenentechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-19</instant>
        </period>
    </context>
    <context id="i_2021-05-19_CounterpartyNameAxis-GenentechMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:GenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-19</instant>
        </period>
    </context>
    <context id="d_2021-05-19_2021-05-19_CounterpartyNameAxis-GenentechMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:GenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-19</startDate>
            <endDate>2021-05-19</endDate>
        </period>
    </context>
    <context id="d_2021-05-19_2021-05-19_CounterpartyNameAxis-GenentechMember_ProductOrServiceAxis-ResearchAndDevelopmentServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:GenentechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pirs:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-19</startDate>
            <endDate>2021-05-19</endDate>
        </period>
    </context>
    <context id="i_2021-05-19_CounterpartyNameAxis-GenentechMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:GenentechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pirs:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-19</instant>
        </period>
    </context>
    <context id="i_2021-05-19_CounterpartyNameAxis-GenentechMember_TypeOfArrangementAxis-PlatformTechnologyLicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:GenentechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pirs:PlatformTechnologyLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-19</instant>
        </period>
    </context>
    <context id="i_2021-05-19_CounterpartyNameAxis-GenentechMember_TypeOfArrangementAxis-GovernanceCommitteeParticipationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:GenentechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pirs:GovernanceCommitteeParticipationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-19</instant>
        </period>
    </context>
    <context id="i_2022-12-31_CounterpartyNameAxis-GenentechMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:GenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_CounterpartyNameAxis-GenentechMember_ProductOrServiceAxis-LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:GenentechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2021-04-24_CounterpartyNameAxis-BPAssetsXIIIncMember_ProductOrServiceAxis-LicenseMember_TypeOfArrangementAxis-ExclusiveProductLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:BPAssetsXIIIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pirs:ExclusiveProductLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-24</instant>
        </period>
    </context>
    <context id="d_2021-04-24_2021-04-24_CounterpartyNameAxis-BPAssetsXIIIncMember_ProductOrServiceAxis-LicenseMember_TypeOfArrangementAxis-ExclusiveProductLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:BPAssetsXIIIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pirs:ExclusiveProductLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-24</startDate>
            <endDate>2021-04-24</endDate>
        </period>
    </context>
    <context id="i_2021-04-24_CounterpartyNameAxis-BPAssetsXIIIncMember_ProductOrServiceAxis-LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:BPAssetsXIIIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-24</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_CounterpartyNameAxis-BPAssetsXIIIncMember_ProductOrServiceAxis-LicenseMember_TypeOfArrangementAxis-ExclusiveProductLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:BPAssetsXIIIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pirs:ExclusiveProductLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i_2018-02-08_CounterpartyNameAxis-SeattleGeneticsIncMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:SeattleGeneticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pirs:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-02-08</instant>
        </period>
    </context>
    <context id="i_2018-02-08_CounterpartyNameAxis-SeattleGeneticsIncMember_TypeOfArrangementAxis-OtherArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:SeattleGeneticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pirs:OtherArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-02-08</instant>
        </period>
    </context>
    <context id="d_2018-02-08_2018-02-08_CounterpartyNameAxis-SeattleGeneticsIncMember_ProductOrServiceAxis-LicenseMember_TypeOfArrangementAxis-UpFrontPaymentArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:SeattleGeneticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:UpFrontPaymentArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-08</startDate>
            <endDate>2018-02-08</endDate>
        </period>
    </context>
    <context id="d_2018-02-08_2018-02-08_CounterpartyNameAxis-SeattleGeneticsIncMember_TypeOfArrangementAxis-UpFrontPaymentArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:SeattleGeneticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:UpFrontPaymentArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-08</startDate>
            <endDate>2018-02-08</endDate>
        </period>
    </context>
    <context id="d_2018-02-08_2018-02-08_CounterpartyNameAxis-SeattleGeneticsIncMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:SeattleGeneticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pirs:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-08</startDate>
            <endDate>2018-02-08</endDate>
        </period>
    </context>
    <context id="i_2018-02-08_CounterpartyNameAxis-SeattleGeneticsIncMember_TypeOfArrangementAxis-PlatformTechnologyLicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:SeattleGeneticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pirs:PlatformTechnologyLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-02-08</instant>
        </period>
    </context>
    <context id="d_2018-02-08_2018-02-08_CounterpartyNameAxis-SeattleGeneticsIncMember_TypeOfArrangementAxis-PlatformTechnologyLicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:SeattleGeneticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pirs:PlatformTechnologyLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-08</startDate>
            <endDate>2018-02-08</endDate>
        </period>
    </context>
    <context id="i_2018-02-08_CounterpartyNameAxis-SeattleGeneticsIncMember_TypeOfArrangementAxis-AntibodyTargetSwapMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:SeattleGeneticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pirs:AntibodyTargetSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-02-08</instant>
        </period>
    </context>
    <context id="i_2018-02-08_CounterpartyNameAxis-SeattleGeneticsIncMember_TypeOfArrangementAxis-GovernanceCommitteeParticipationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:SeattleGeneticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pirs:GovernanceCommitteeParticipationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-02-08</instant>
        </period>
    </context>
    <context id="i_2018-02-08_CounterpartyNameAxis-SeattleGeneticsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:SeattleGeneticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-02-08</instant>
        </period>
    </context>
    <context id="i_2022-12-31_CounterpartyNameAxis-SeattleGeneticsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:SeattleGeneticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_CounterpartyNameAxis-SeattleGeneticsIncMember_TransactionTypeAxis-SalesMilestonePaymentsMember_TypeOfArrangementAxis-UpFrontPaymentArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:SeattleGeneticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pirs:SalesMilestonePaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:UpFrontPaymentArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-04-01_2020-06-30_CounterpartyNameAxis-SeattleGeneticsIncMember_TransactionTypeAxis-SalesMilestonePaymentsMember_TypeOfArrangementAxis-UpFrontPaymentArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:SeattleGeneticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pirs:SalesMilestonePaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:UpFrontPaymentArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i_2021-03-24_CounterpartyNameAxis-SeattleGeneticsIncMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:SeattleGeneticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pirs:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-24</instant>
        </period>
    </context>
    <context id="d_2021-03-24_2021-03-24_CounterpartyNameAxis-SeattleGeneticsIncMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:SeattleGeneticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-24</startDate>
            <endDate>2021-03-24</endDate>
        </period>
    </context>
    <context id="i_2021-03-24_CounterpartyNameAxis-SeattleGeneticsIncMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:SeattleGeneticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-24</instant>
        </period>
    </context>
    <context id="d_2021-03-24_2021-03-24_CounterpartyNameAxis-SeattleGeneticsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:SeattleGeneticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-24</startDate>
            <endDate>2021-03-24</endDate>
        </period>
    </context>
    <context id="d_2022-04-01_2022-06-30_CounterpartyNameAxis-SeattleGeneticsIncMember_TransactionTypeAxis-SalesMilestonePaymentsMember_TypeOfArrangementAxis-UpFrontPaymentArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:SeattleGeneticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pirs:SalesMilestonePaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:UpFrontPaymentArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-01-31_CounterpartyNameAxis-SeattleGeneticsIncMember_SubsequentEventTypeAxis-SubsequentEventMember_TypeOfArrangementAxis-CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:SeattleGeneticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_CounterpartyNameAxis-SeattleGeneticsIncMember_TypeOfArrangementAxis-CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:SeattleGeneticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2017-05-02_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:AstraZenecaABMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pirs:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-02</startDate>
            <endDate>2017-05-02</endDate>
        </period>
    </context>
    <context id="i_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_RangeAxis-MinimumMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:AstraZenecaABMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pirs:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-02</instant>
        </period>
    </context>
    <context id="i_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:AstraZenecaABMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pirs:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-02</instant>
        </period>
    </context>
    <context id="d_2017-05-02_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:AstraZenecaABMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pirs:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-02</startDate>
            <endDate>2017-05-02</endDate>
        </period>
    </context>
    <context id="d_2017-05-02_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_TypeOfArrangementAxis-UpFrontPaymentArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:AstraZenecaABMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:UpFrontPaymentArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-02</startDate>
            <endDate>2017-05-02</endDate>
        </period>
    </context>
    <context id="d_2017-05-02_2017-05-02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
        </entity>
        <period>
            <startDate>2017-05-02</startDate>
            <endDate>2017-05-02</endDate>
        </period>
    </context>
    <context id="i_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:AstraZenecaABMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pirs:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-02</instant>
        </period>
    </context>
    <context id="d_2017-05-02_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_TransactionTypeAxis-EstimatedDevelopmentAndManufacturingServicesMember_TypeOfArrangementAxis-UpFrontPaymentArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:AstraZenecaABMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pirs:EstimatedDevelopmentAndManufacturingServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:UpFrontPaymentArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-02</startDate>
            <endDate>2017-05-02</endDate>
        </period>
    </context>
    <context id="d_2017-05-02_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_TransactionTypeAxis-SalesMilestonePaymentsMember_TypeOfArrangementAxis-UpFrontPaymentArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:AstraZenecaABMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pirs:SalesMilestonePaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:UpFrontPaymentArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-02</startDate>
            <endDate>2017-05-02</endDate>
        </period>
    </context>
    <context id="d_2017-05-02_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_TransactionTypeAxis-EstimatedPhase2aServicesMember_TypeOfArrangementAxis-UpFrontPaymentArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:AstraZenecaABMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pirs:EstimatedPhase2aServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:UpFrontPaymentArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-02</startDate>
            <endDate>2017-05-02</endDate>
        </period>
    </context>
    <context id="d_2017-05-02_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_TypeOfArrangementAxis-AdditionalOtherResearchServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:AstraZenecaABMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pirs:AdditionalOtherResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-02</startDate>
            <endDate>2017-05-02</endDate>
        </period>
    </context>
    <context id="d_2017-05-02_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:AstraZenecaABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-02</startDate>
            <endDate>2017-05-02</endDate>
        </period>
    </context>
    <context id="i_2022-12-31_CounterpartyNameAxis-AstraZenecaABMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:AstraZenecaABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="d_2021-04-01_2021-04-01_CounterpartyNameAxis-AstraZenecaABMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:AstraZenecaABMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-01</endDate>
        </period>
    </context>
    <context id="i_2021-04-01_CounterpartyNameAxis-AstraZenecaABMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:AstraZenecaABMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-01</instant>
        </period>
    </context>
    <context id="d_2021-04-01_2021-04-01_CounterpartyNameAxis-AstraZenecaABMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:AstraZenecaABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-01</endDate>
        </period>
    </context>
    <context id="d_2021-03-01_2021-03-31_CounterpartyNameAxis-AstraZenecaABMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:AstraZenecaABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i_2022-01-31_CounterpartyNameAxis-AstraZenecaABMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:AstraZenecaABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="d_2022-01-01_2022-01-31_CounterpartyNameAxis-AstraZenecaABMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:AstraZenecaABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="d_2022-08-01_2022-08-31_CounterpartyNameAxis-AstraZenecaABMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:AstraZenecaABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="i_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:AstraZenecaABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-02</instant>
        </period>
    </context>
    <context id="i_2019-01-01_CounterpartyNameAxis-AstraZenecaABMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:AstraZenecaABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="d_2017-01-01_2017-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pirs:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="d_2017-01-01_2017-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="d_2017-01-01_2017-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_ProductOrServiceAxis-LicenseMember_TypeOfArrangementAxis-UpFrontPaymentArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:UpFrontPaymentArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_TypeOfArrangementAxis-CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2017-01-01_2017-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_ProductOrServiceAxis-ResearchAndDevelopmentServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pirs:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="d_2017-01-01_2017-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_RangeAxis-MinimumMember_TypeOfArrangementAxis-CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="d_2017-01-01_2017-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i_2017-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="d_2017-01-04_2017-01-04_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_TypeOfArrangementAxis-CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-04</startDate>
            <endDate>2017-01-04</endDate>
        </period>
    </context>
    <context id="d_2017-01-04_2017-01-04_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-04</startDate>
            <endDate>2017-01-04</endDate>
        </period>
    </context>
    <context id="i_2017-01-04_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pirs:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-01-04</instant>
        </period>
    </context>
    <context id="i_2017-01-04_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_TypeOfArrangementAxis-CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-01-04</instant>
        </period>
    </context>
    <context id="i_2022-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="d_2020-02-01_2020-02-29_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="i_2020-02-29_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="i_2020-02-29_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_TypeOfArrangementAxis-CodevelopmentCollaborationProductCollaborationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pirs:CodevelopmentCollaborationProductCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="i_2020-02-29_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_TypeOfArrangementAxis-ServierDevelopedCollaborationProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pirs:ServierDevelopedCollaborationProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="d_2020-01-01_2020-03-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="d_2022-10-01_2022-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i_2019-01-01_AdjustmentsForChangeInAccountingPrincipleAxis-AccountingStandardsUpdate201409Member_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pirs:LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForChangeInAccountingPrincipleAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="i_2021-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i_2022-12-31_FinancialInstrumentAxis-MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FinancialInstrumentAxis-MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FinancialInstrumentAxis-MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FinancialInstrumentAxis-MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FinancialInstrumentAxis-USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FinancialInstrumentAxis-USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FinancialInstrumentAxis-USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_FinancialInstrumentAxis-ForeignGovernmentDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FinancialInstrumentAxis-ForeignGovernmentDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FinancialInstrumentAxis-ForeignGovernmentDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FinancialInstrumentAxis-ForeignGovernmentDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_FinancialInstrumentAxis-AssetBackedSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FinancialInstrumentAxis-AssetBackedSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FinancialInstrumentAxis-AssetBackedSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FinancialInstrumentAxis-AssetBackedSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_FinancialInstrumentAxis-CorporateBondSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FinancialInstrumentAxis-CorporateBondSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FinancialInstrumentAxis-CorporateBondSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FinancialInstrumentAxis-CorporateBondSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_FinancialInstrumentAxis-MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FinancialInstrumentAxis-MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FinancialInstrumentAxis-MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FinancialInstrumentAxis-MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_FinancialInstrumentAxis-ForeignGovernmentDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_FinancialInstrumentAxis-AssetBackedSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_FinancialInstrumentAxis-CorporateBondSecuritiesMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pirs:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pirs:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_BalanceSheetLocationAxis-AccruedLiabilitiesAndOtherCurrentLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pirs:AccruedLiabilitiesAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_BalanceSheetLocationAxis-AccruedLiabilitiesAndOtherCurrentLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pirs:AccruedLiabilitiesAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember_IncomeTaxAuthorityNameAxis-InternalRevenueServiceIRSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_IncomeTaxAuthorityAxis-ForeignCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i_2022-12-31_IncomeTaxAuthorityAxis-ForeignCountryMember_TaxCreditCarryforwardAxis-CorporateIncomeTaxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">pirs:CorporateIncomeTaxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_IncomeTaxAuthorityAxis-ForeignCountryMember_TaxCreditCarryforwardAxis-TradeTaxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">pirs:TradeTaxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_StatementClassOfStockAxis-SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_StatementClassOfStockAxis-SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_StatementClassOfStockAxis-SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_StatementClassOfStockAxis-SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_StatementClassOfStockAxis-SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_StatementClassOfStockAxis-SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_StatementClassOfStockAxis-SeriesDPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_StatementClassOfStockAxis-SeriesDPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_StatementClassOfStockAxis-SeriesEPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_StatementClassOfStockAxis-SeriesEPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-05-20_StatementClassOfStockAxis-SeriesAThroughEMember_StatementEquityComponentsAxis-PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pirs:SeriesAThroughEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-20</instant>
        </period>
    </context>
    <context id="d_2021-05-20_2021-05-20_StatementClassOfStockAxis-SeriesAThroughEMember_StatementEquityComponentsAxis-PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pirs:SeriesAThroughEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-20</startDate>
            <endDate>2021-05-20</endDate>
        </period>
    </context>
    <context id="d_2016-06-01_2016-06-30_SubsidiarySaleOfStockAxis-SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pirs:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-06-01</startDate>
            <endDate>2016-06-30</endDate>
        </period>
    </context>
    <context id="i_2016-06-30_SubsidiarySaleOfStockAxis-SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pirs:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-06-30</instant>
        </period>
    </context>
    <context id="d_2019-01-30_2019-01-30_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-StockExchangeSharesFromExistingShareholdersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pirs:StockExchangeSharesFromExistingShareholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-30</startDate>
            <endDate>2019-01-30</endDate>
        </period>
    </context>
    <context id="d_2019-01-30_2019-01-30_StatementEquityComponentsAxis-PreferredStockMember_SubsidiarySaleOfStockAxis-PreferredShareExchangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pirs:PreferredShareExchangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-30</startDate>
            <endDate>2019-01-30</endDate>
        </period>
    </context>
    <context id="d_2019-11-01_2019-11-30_StatementClassOfStockAxis-SeriesCPreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="i_2019-11-30_StatementClassOfStockAxis-SeriesCPreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="i_2019-11-30_RangeAxis-MaximumMember_StatementClassOfStockAxis-SeriesCPreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="i_2019-11-30_StatementClassOfStockAxis-SeriesCPreferredStockMember_SubsidiarySaleOfStockAxis-PreferredShareExchangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pirs:PreferredShareExchangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="d_2019-11-01_2019-11-30_StatementClassOfStockAxis-SeriesCPreferredStockMember_SubsidiarySaleOfStockAxis-PreferredShareExchangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pirs:PreferredShareExchangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="d_2020-04-01_2020-04-01_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pirs:EmployeeDirectorAndConsultantEquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-01</endDate>
        </period>
    </context>
    <context id="d_2021-05-20_2021-05-20_ConversionOfStockByUniqueDescriptionAxis-ConversionOfCommonStockIntoSeriesEPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">pirs:ConversionOfCommonStockIntoSeriesEPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-20</startDate>
            <endDate>2021-05-20</endDate>
        </period>
    </context>
    <context id="d_2019-08-01_2019-08-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="i_2021-08-31_LegalEntityAxis-JefferiesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pirs:JefferiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="d_2021-08-01_2021-08-31_LegalEntityAxis-JefferiesLLCMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pirs:AtTheMarketOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pirs:JefferiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="d_2022-11-01_2022-11-30_LegalEntityAxis-JefferiesLLCMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pirs:AtTheMarketOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pirs:JefferiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pirs:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_LegalEntityAxis-JefferiesLLCMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pirs:AtTheMarketOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pirs:JefferiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i_2022-12-31_LegalEntityAxis-JefferiesLLCMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pirs:AtTheMarketOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pirs:JefferiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_LegalEntityAxis-JefferiesLLCMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pirs:AtTheMarketOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pirs:JefferiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i_2021-12-31_LegalEntityAxis-JefferiesLLCMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pirs:AtTheMarketOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pirs:JefferiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2020-06-23_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pirs:EmployeeDirectorAndConsultantEquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-23</instant>
        </period>
    </context>
    <context id="d_2021-06-25_2021-06-25_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pirs:EmployeeDirectorAndConsultantEquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-25</startDate>
            <endDate>2021-06-25</endDate>
        </period>
    </context>
    <context id="i_2021-06-25_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pirs:EmployeeDirectorAndConsultantEquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-25</instant>
        </period>
    </context>
    <context id="d_2022-06-22_2022-06-22_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pirs:EmployeeDirectorAndConsultantEquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-22</startDate>
            <endDate>2022-06-22</endDate>
        </period>
    </context>
    <context id="i_2022-06-22_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pirs:EmployeeDirectorAndConsultantEquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-22</instant>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pirs:EmployeeDirectorAndConsultantEquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i_2022-12-31_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pirs:EmployeeDirectorAndConsultantEquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pirs:EmployeeDirectorAndConsultantEquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_TitleOfIndividualAxis-ExecutiveOfficersAndManagementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">pirs:ExecutiveOfficersAndManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_TitleOfIndividualAxis-ExecutiveOfficersAndManagementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">pirs:ExecutiveOfficersAndManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i_2022-12-31_TitleOfIndividualAxis-ExecutiveOfficersAndManagementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">pirs:ExecutiveOfficersAndManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i_2015-08-31_LeaseContractualTermAxis-SubleaseOfficeSpaceMember_StatementGeographicalAxis-BostonMassachusettsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pirs:BostonMassachusettsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">pirs:SubleaseOfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-08-31</instant>
        </period>
    </context>
    <context id="i_2020-02-29_LeaseContractualTermAxis-OfficeAndLaboratorySpaceMember_StatementGeographicalAxis-HallbergmoosGermanyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pirs:HallbergmoosGermanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">pirs:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="i_2020-02-29_PropertyPlantAndEquipmentByTypeAxis-LeasesExpectedToBeDeliveredByOctober2024Member_StatementGeographicalAxis-HallbergmoosGermanyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pirs:HallbergmoosGermanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pirs:LeasesExpectedToBeDeliveredByOctober2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="i_2020-02-29_PropertyPlantAndEquipmentByTypeAxis-LeasesWithFirstRightOfRefusalForAdditionalAreaMember_StatementGeographicalAxis-HallbergmoosGermanyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pirs:HallbergmoosGermanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pirs:LeasesWithFirstRightOfRefusalForAdditionalAreaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="i_2020-02-29_StatementGeographicalAxis-HallbergmoosGermanyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pirs:HallbergmoosGermanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="d_2020-02-29_2020-02-29_LeaseContractualTermAxis-OfficeAndLaboratorySpaceMember_StatementGeographicalAxis-HallbergmoosGermanyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pirs:HallbergmoosGermanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">pirs:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-29</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="d_2020-02-01_2020-02-29_LeaseContractualTermAxis-OfficeAndLaboratorySpaceMember_StatementGeographicalAxis-HallbergmoosGermanyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pirs:HallbergmoosGermanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">pirs:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="i_2019-03-31_LeaseContractualTermAxis-OfficeAndLaboratorySpaceMember_StatementGeographicalAxis-HallbergmoosGermanyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001583648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pirs:HallbergmoosGermanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">pirs:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Share">
        <measure>shares</measure>
    </unit>
    <unit id="NonApplicable">
        <measure>thunderdome:item</measure>
    </unit>
    <unit id="USDPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Year">
        <measure>utr:Y</measure>
    </unit>
    <unit id="Day">
        <measure>utr:D</measure>
    </unit>
    <unit id="Month">
        <measure>utr:M</measure>
    </unit>
    <unit id="EUR">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="SquareFoot">
        <measure>utr:sqft</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="d_2022-01-01_2022-12-31"
      id="thunderdome-EntityCentralIndexKey">0001583648</dei:EntityCentralIndexKey>
    <dei:EntityRegistrantName
      contextRef="d_2022-01-01_2022-12-31"
      id="thunderdome-EntityRegistrantName">PIERIS PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:AmendmentFlag contextRef="d_2022-01-01_2022-12-31">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="d_2022-01-01_2022-12-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="d_2022-01-01_2022-12-31">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="d_2022-01-01_2022-12-31">2022</dei:DocumentFiscalYearFocus>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i_2022-12-31"
      id="c96253156"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i_2021-12-31"
      id="c96253157"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96253161"
      unitRef="USDPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96253162"
      unitRef="USDPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96253163"
      unitRef="Share">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96253164"
      unitRef="Share">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96253165"
      unitRef="Share">15617</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96253167"
      unitRef="Share">15617</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96253166"
      unitRef="Share">15617</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96253168"
      unitRef="Share">15617</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96253171"
      unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96253172"
      unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96253173"
      unitRef="Share">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96253174"
      unitRef="Share">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96253175"
      unitRef="Share">74519103</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96253177"
      unitRef="Share">74519103</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96253176"
      unitRef="Share">72222661</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96253178"
      unitRef="Share">72222661</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="d_2021-01-01_2021-12-31_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember"
      decimals="-5"
      id="c96253361"
      unitRef="USD">1500000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="d_2021-01-01_2021-12-31_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="-5"
      id="c96253379"
      unitRef="USD">100000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-5"
      id="c96253460"
      unitRef="USD">300000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember"
      decimals="-5"
      id="c96253524"
      unitRef="USD">1200000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember"
      decimals="-5"
      id="c96253525"
      unitRef="USD">1200000</us-gaap:PaymentsOfStockIssuanceCosts>
    <pirs:NumberOfInitialResearchPrograms
      contextRef="i_2021-05-19_CounterpartyNameAxis-GenentechMember"
      decimals="INF"
      id="c96253743"
      unitRef="Pure">2</pirs:NumberOfInitialResearchPrograms>
    <pirs:NumberOfOptionalAdditionalResearchPrograms
      contextRef="i_2021-05-19_CounterpartyNameAxis-GenentechMember"
      decimals="INF"
      id="c96253744"
      unitRef="Pure">2</pirs:NumberOfOptionalAdditionalResearchPrograms>
    <pirs:ResearchCollaborationAgreementPeriod
      contextRef="d_2021-05-19_2021-05-19_CounterpartyNameAxis-GenentechMember_ProductOrServiceAxis-ResearchAndDevelopmentServicesMember"
      id="c96253759">P3Y</pirs:ResearchCollaborationAgreementPeriod>
    <pirs:RevenueFromContractWithCustomerPeriodAfterEffectiveDateAgreementsMayBeTerminated
      contextRef="d_2021-04-24_2021-04-24_CounterpartyNameAxis-BPAssetsXIIIncMember_ProductOrServiceAxis-LicenseMember_TypeOfArrangementAxis-ExclusiveProductLicenseAgreementMember"
      id="c96253792">P9M</pirs:RevenueFromContractWithCustomerPeriodAfterEffectiveDateAgreementsMayBeTerminated>
    <pirs:ResearchCollaborationAgreementPeriod
      contextRef="d_2017-05-02_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember"
      id="c96253965">P5Y</pirs:ResearchCollaborationAgreementPeriod>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="d_2022-01-01_2022-12-31_CounterpartyNameAxis-AstraZenecaABMember"
      decimals="-5"
      id="c96254016"
      unitRef="USD">300000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2017-01-01_2017-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_ProductOrServiceAxis-LicenseMember_TypeOfArrangementAxis-UpFrontPaymentArrangementMember"
      decimals="-7"
      id="c96254027"
      unitRef="EUR">30000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="d_2022-01-01_2022-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_TypeOfArrangementAxis-CollaborativeArrangementMember"
      decimals="-5"
      id="c96254030"
      unitRef="EUR">3800000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2017-01-01_2017-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_ProductOrServiceAxis-LicenseMember_TypeOfArrangementAxis-UpFrontPaymentArrangementMember"
      decimals="-7"
      id="c96254061"
      unitRef="EUR">30000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember"
      decimals="-5"
      id="c96254106"
      unitRef="USD">100000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:GrantsReceivable
      contextRef="i_2021-06-30"
      decimals="-5"
      id="c96254145"
      unitRef="EUR">14200000</us-gaap:GrantsReceivable>
    <pirs:DebtSecuritiesAvailableforsaleContractualMaturityPeriod
      contextRef="d_2022-01-01_2022-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember_RangeAxis-MinimumMember"
      id="c96254205">P47D</pirs:DebtSecuritiesAvailableforsaleContractualMaturityPeriod>
    <pirs:DebtSecuritiesAvailableforsaleContractualMaturityPeriod
      contextRef="d_2022-01-01_2022-12-31_FinancialInstrumentAxis-CorporateBondSecuritiesMember_RangeAxis-MaximumMember"
      id="c96254241">P228D</pirs:DebtSecuritiesAvailableforsaleContractualMaturityPeriod>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96254158"
      unitRef="USD">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:OpenTaxYear
      contextRef="d_2022-01-01_2022-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember_IncomeTaxAuthorityNameAxis-InternalRevenueServiceIRSMember"
      id="c96254311">2019 2020 2021 2022</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="d_2022-01-01_2022-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember"
      id="c96254312">2019 2020 2021 2022</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="d_2022-01-01_2022-12-31_IncomeTaxAuthorityAxis-ForeignCountryMember"
      id="c96254313">2014 2015 2016 2017</us-gaap:OpenTaxYear>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c96254330"
      unitRef="USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96254518"
      unitRef="Share">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96254519"
      unitRef="Share">74519103</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96254520"
      unitRef="Share">72222661</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96254521"
      unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96254522"
      unitRef="Share">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96254523"
      unitRef="Share">15617</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96254524"
      unitRef="Share">15617</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96254525"
      unitRef="Share">15617</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i_2022-12-31_StatementClassOfStockAxis-SeriesAPreferredStockMember"
      decimals="INF"
      id="c96254527"
      unitRef="Share">85</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i_2021-12-31_StatementClassOfStockAxis-SeriesAPreferredStockMember"
      decimals="INF"
      id="c96254529"
      unitRef="Share">85</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2021-12-31_StatementClassOfStockAxis-SeriesAPreferredStockMember"
      decimals="INF"
      id="c96254528"
      unitRef="Share">85</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i_2022-12-31_StatementClassOfStockAxis-SeriesBPreferredStockMember"
      decimals="INF"
      id="c96254530"
      unitRef="Share">4026</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2021-12-31_StatementClassOfStockAxis-SeriesBPreferredStockMember"
      decimals="INF"
      id="c96254531"
      unitRef="Share">4026</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i_2021-12-31_StatementClassOfStockAxis-SeriesBPreferredStockMember"
      decimals="INF"
      id="c96254532"
      unitRef="Share">4026</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i_2022-12-31_StatementClassOfStockAxis-SeriesCPreferredStockMember"
      decimals="INF"
      id="c96254533"
      unitRef="Share">3506</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i_2021-12-31_StatementClassOfStockAxis-SeriesCPreferredStockMember"
      decimals="INF"
      id="c96254534"
      unitRef="Share">3506</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2021-12-31_StatementClassOfStockAxis-SeriesCPreferredStockMember"
      decimals="INF"
      id="c96254535"
      unitRef="Share">3506</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i_2022-12-31_StatementClassOfStockAxis-SeriesDPreferredStockMember"
      decimals="INF"
      id="c96254536"
      unitRef="Share">3000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i_2021-12-31_StatementClassOfStockAxis-SeriesDPreferredStockMember"
      decimals="INF"
      id="c96254537"
      unitRef="Share">3000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2021-12-31_StatementClassOfStockAxis-SeriesDPreferredStockMember"
      decimals="INF"
      id="c96254538"
      unitRef="Share">3000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i_2022-12-31_StatementClassOfStockAxis-SeriesEPreferredStockMember"
      decimals="INF"
      id="c96254539"
      unitRef="Share">5000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i_2021-12-31_StatementClassOfStockAxis-SeriesEPreferredStockMember"
      decimals="INF"
      id="c96254540"
      unitRef="Share">5000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2021-12-31_StatementClassOfStockAxis-SeriesEPreferredStockMember"
      decimals="INF"
      id="c96254541"
      unitRef="Share">5000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="d_2019-11-01_2019-11-30_StatementClassOfStockAxis-SeriesCPreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="INF"
      id="c96254476"
      unitRef="Share">1</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <pirs:SaleOfStockNumberOfWarrantsPerUnit
      contextRef="d_2019-11-01_2019-11-30_StatementClassOfStockAxis-SeriesCPreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="INF"
      id="c96254478"
      unitRef="Share">1</pirs:SaleOfStockNumberOfWarrantsPerUnit>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="i_2019-11-30_StatementClassOfStockAxis-SeriesCPreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="INF"
      id="c96254479"
      unitRef="Share">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <pirs:ConvertiblePreferredStockWeightedAverageStockPricePercent
      contextRef="d_2019-11-01_2019-11-30_StatementClassOfStockAxis-SeriesCPreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="2"
      id="c96254489"
      unitRef="Pure">0.03</pirs:ConvertiblePreferredStockWeightedAverageStockPricePercent>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i_2019-11-30_RangeAxis-MaximumMember_StatementClassOfStockAxis-SeriesCPreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      id="c96254491">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <pirs:SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfPurchasePeriods
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c96254613"
      unitRef="Pure">2</pirs:SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfPurchasePeriods>
    <pirs:ShareBasedCompensationArrangementBySharebasedPaymentAwardPurchasePeriod
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      id="c96254614">P6Y</pirs:ShareBasedCompensationArrangementBySharebasedPaymentAwardPurchasePeriod>
    <dei:DocumentType contextRef="d_2022-01-01_2022-12-31">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="d_2022-01-01_2022-12-31">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="d_2022-01-01_2022-12-31">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="d_2022-01-01_2022-12-31">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="d_2022-01-01_2022-12-31">001-37471</dei:EntityFileNumber>
    <dei:EntityIncorporationStateCountryCode contextRef="d_2022-01-01_2022-12-31">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="d_2022-01-01_2022-12-31">30-0784346</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="d_2022-01-01_2022-12-31">225&#160;Franklin&#160;Street, 26th Floor</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="d_2022-01-01_2022-12-31">Boston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d_2022-01-01_2022-12-31">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="d_2022-01-01_2022-12-31">02110</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="d_2022-01-01_2022-12-31">857</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="d_2022-01-01_2022-12-31">246-8998</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="d_2022-01-01_2022-12-31">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="d_2022-01-01_2022-12-31">PIRS</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="d_2022-01-01_2022-12-31">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="d_2022-01-01_2022-12-31">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="d_2022-01-01_2022-12-31">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="d_2022-01-01_2022-12-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="d_2022-01-01_2022-12-31">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="d_2022-01-01_2022-12-31">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="d_2022-01-01_2022-12-31">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="d_2022-01-01_2022-12-31">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="d_2022-01-01_2022-12-31">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="d_2022-01-01_2022-12-31">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="i_2022-06-30" decimals="INF" unitRef="USD">114087344</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="i_2023-03-28" decimals="INF" unitRef="Share">74519103</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorFirmId contextRef="d_2022-01-01_2022-12-31">42</dei:AuditorFirmId>
    <dei:AuditorName contextRef="d_2022-01-01_2022-12-31">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="d_2022-01-01_2022-12-31">Boston, Massachusetts</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c96253121"
      unitRef="USD">38635000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c96253122"
      unitRef="USD">117764000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c96253123"
      unitRef="USD">20534000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c96253124"
      unitRef="USD">0</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i_2022-12-31"
      decimals="-4"
      id="c96253125"
      unitRef="USD">5810000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c96253126"
      unitRef="USD">3313000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c96253127"
      unitRef="USD">8445000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c96253128"
      unitRef="USD">6548000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c96253129"
      unitRef="USD">73424000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c96253130"
      unitRef="USD">127625000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c96253131"
      unitRef="USD">16992000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c96253132"
      unitRef="USD">19122000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c96253133"
      unitRef="USD">3705000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c96253134"
      unitRef="USD">3909000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c96253135"
      unitRef="USD">1369000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c96253136"
      unitRef="USD">2904000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i_2022-12-31"
      decimals="-4"
      id="c96253137"
      unitRef="USD">95490000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i_2021-12-31"
      decimals="-4"
      id="c96253138"
      unitRef="USD">153560000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c96253141"
      unitRef="USD">4154000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c96253142"
      unitRef="USD">8609000</us-gaap:AccountsPayableCurrent>
    <pirs:AccruedLiabilitiesAndOtherLiabilitiesCurrent
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c96253143"
      unitRef="USD">11605000</pirs:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <pirs:AccruedLiabilitiesAndOtherLiabilitiesCurrent
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c96253144"
      unitRef="USD">16836000</pirs:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c96253145"
      unitRef="USD">20824000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c96253146"
      unitRef="USD">25116000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c96253147"
      unitRef="USD">36583000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c96253148"
      unitRef="USD">50561000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c96253149"
      unitRef="USD">18734000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c96253150"
      unitRef="USD">38403000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c96253151"
      unitRef="USD">12244000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c96253152"
      unitRef="USD">13841000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c96253153"
      unitRef="USD">67561000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c96253154"
      unitRef="USD">102805000</us-gaap:Liabilities>
    <us-gaap:PreferredStockValue
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c96253159"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c96253160"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c96253169"
      unitRef="USD">74000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c96253170"
      unitRef="USD">72000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i_2022-12-31"
      decimals="-4"
      id="c96253179"
      unitRef="USD">318530000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c96253180"
      unitRef="USD">306998000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c96253181"
      unitRef="USD">-254000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c96253182"
      unitRef="USD">829000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c96253183"
      unitRef="USD">-290421000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c96253184"
      unitRef="USD">-257144000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c96253185"
      unitRef="USD">27929000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c96253186"
      unitRef="USD">50755000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2022-12-31"
      decimals="-4"
      id="c96253187"
      unitRef="USD">95490000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2021-12-31"
      decimals="-4"
      id="c96253188"
      unitRef="USD">153560000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96253190"
      unitRef="USD">25469000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-4"
      id="c96253191"
      unitRef="USD">27940000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96253192"
      unitRef="USD">433000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96253193"
      unitRef="USD">3478000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:Revenues
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96253194"
      unitRef="USD">25902000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96253195"
      unitRef="USD">31418000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96253197"
      unitRef="USD">52982000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96253198"
      unitRef="USD">66656000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96253199"
      unitRef="USD">16394000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96253200"
      unitRef="USD">16593000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96253201"
      unitRef="USD">69376000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96253202"
      unitRef="USD">83249000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96253203"
      unitRef="USD">-43474000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96253204"
      unitRef="USD">-51831000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96253206"
      unitRef="USD">721000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96253207"
      unitRef="USD">4000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:GovernmentAssistanceAmount
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96253208"
      unitRef="USD">8173000</us-gaap:GovernmentAssistanceAmount>
    <us-gaap:GovernmentAssistanceAmount
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96253209"
      unitRef="USD">3685000</us-gaap:GovernmentAssistanceAmount>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96253210"
      unitRef="USD">1303000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96253211"
      unitRef="USD">2404000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96253212"
      unitRef="USD">-33277000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96253213"
      unitRef="USD">-45738000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-4"
      id="c96253215"
      unitRef="USD">-1010000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96253216"
      unitRef="USD">1124000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96253217"
      unitRef="USD">-73000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96253218"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-4"
      id="c96253219"
      unitRef="USD">-34360000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96253220"
      unitRef="USD">-44614000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96253222"
      unitRef="USDPerShare">-0.45</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96253223"
      unitRef="USDPerShare">-0.71</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96253225"
      unitRef="Share">74172000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96253226"
      unitRef="Share">64547000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="-3"
      id="c96253263"
      unitRef="Share">14000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="-3"
      id="c96253264"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c96253265"
      unitRef="Share">56003000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c96253266"
      unitRef="USD">56000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-ReceivablesFromStockholderMember"
      decimals="-3"
      id="c96253267"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c96253268"
      unitRef="USD">242672000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c96253269"
      unitRef="USD">-295000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c96253270"
      unitRef="USD">-211406000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c96253271"
      unitRef="USD">31027000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="-3"
      id="c96253273"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c96253275"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-ReceivablesFromStockholderMember"
      decimals="-3"
      id="c96253276"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c96253277"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c96253278"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c96253279"
      unitRef="USD">-45738000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96253280"
      unitRef="USD">-45738000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="-3"
      id="c96253282"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c96253284"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-ReceivablesFromStockholderMember"
      decimals="-3"
      id="c96253285"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c96253286"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c96253287"
      unitRef="USD">1124000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c96253288"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96253289"
      unitRef="USD">1124000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="-3"
      id="c96253291"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c96253293"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-ReceivablesFromStockholderMember"
      decimals="-3"
      id="c96253294"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c96253295"
      unitRef="USD">5215000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c96253296"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c96253297"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96253298"
      unitRef="USD">5215000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="-3"
      id="c96253299"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="-3"
      id="c96253300"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c96253301"
      unitRef="Share">482000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c96253302"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-ReceivablesFromStockholderMember"
      decimals="-3"
      id="c96253303"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c96253304"
      unitRef="USD">1024000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c96253305"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c96253306"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96253307"
      unitRef="USD">1024000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="-3"
      id="c96253308"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="-3"
      id="c96253309"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c96253310"
      unitRef="Share">64000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c96253311"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-ReceivablesFromStockholderMember"
      decimals="-3"
      id="c96253312"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c96253313"
      unitRef="USD">165000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c96253314"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c96253315"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96253316"
      unitRef="USD">165000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <pirs:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="-3"
      id="c96253317"
      unitRef="Share">0</pirs:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <pirs:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="-3"
      id="c96253318"
      unitRef="USD">0</pirs:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <pirs:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c96253319"
      unitRef="Share">1391000</pirs:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <pirs:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c96253320"
      unitRef="USD">1000</pirs:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <pirs:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-ReceivablesFromStockholderMember"
      decimals="-3"
      id="c96253321"
      unitRef="USD">0</pirs:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <pirs:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c96253322"
      unitRef="USD">836000</pirs:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <pirs:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c96253323"
      unitRef="USD">0</pirs:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <pirs:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c96253324"
      unitRef="USD">0</pirs:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <pirs:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96253325"
      unitRef="USD">837000</pirs:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="d_2021-01-01_2021-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfPreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="-3"
      id="c96253326"
      unitRef="Share">4000</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2021-01-01_2021-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfPreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="-3"
      id="c96253327"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="d_2021-01-01_2021-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfPreferredStockMember_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c96253328"
      unitRef="Share">3812000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="d_2021-01-01_2021-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfPreferredStockMember_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c96253329"
      unitRef="Share">4000</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2021-01-01_2021-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfPreferredStockMember_StatementEquityComponentsAxis-ReceivablesFromStockholderMember"
      decimals="-3"
      id="c96253330"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2021-01-01_2021-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfPreferredStockMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c96253331"
      unitRef="USD">-4000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2021-01-01_2021-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfPreferredStockMember_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c96253332"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2021-01-01_2021-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfPreferredStockMember_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c96253333"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2021-01-01_2021-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfPreferredStockMember"
      decimals="-3"
      id="c96253334"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="d_2021-01-01_2021-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesEPreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="-3"
      id="c96253335"
      unitRef="Share">5000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2021-01-01_2021-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesEPreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="-3"
      id="c96253336"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="d_2021-01-01_2021-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesEPreferredStockMember_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-6"
      id="c96253337"
      unitRef="Share">5000000</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2021-01-01_2021-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesEPreferredStockMember_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c96253338"
      unitRef="USD">-5000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2021-01-01_2021-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesEPreferredStockMember_StatementEquityComponentsAxis-ReceivablesFromStockholderMember"
      decimals="-3"
      id="c96253339"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2021-01-01_2021-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesEPreferredStockMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c96253340"
      unitRef="USD">5000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2021-01-01_2021-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesEPreferredStockMember_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c96253341"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2021-01-01_2021-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesEPreferredStockMember_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c96253342"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2021-01-01_2021-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesEPreferredStockMember"
      decimals="-3"
      id="c96253343"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember"
      decimals="-3"
      id="c96253344"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember"
      decimals="-3"
      id="c96253345"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember"
      decimals="-4"
      id="c96253346"
      unitRef="Share">8180000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember"
      decimals="-3"
      id="c96253347"
      unitRef="USD">8000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-ReceivablesFromStockholderMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember"
      decimals="-3"
      id="c96253348"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember"
      decimals="-4"
      id="c96253349"
      unitRef="USD">38180000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember"
      decimals="-3"
      id="c96253350"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember"
      decimals="-3"
      id="c96253351"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2021-01-01_2021-12-31_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember"
      decimals="-3"
      id="c96253352"
      unitRef="USD">38188000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="-3"
      id="c96253362"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="-3"
      id="c96253363"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="-4"
      id="c96253364"
      unitRef="Share">7290000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="-3"
      id="c96253365"
      unitRef="USD">8000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-ReceivablesFromStockholderMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="-3"
      id="c96253366"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="-3"
      id="c96253367"
      unitRef="USD">18905000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="-3"
      id="c96253368"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="-3"
      id="c96253369"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2021-01-01_2021-12-31_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="-3"
      id="c96253370"
      unitRef="USD">18913000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharesOutstanding
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="-3"
      id="c96253380"
      unitRef="Share">16000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="-3"
      id="c96253381"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="-3"
      id="c96253382"
      unitRef="Share">72222000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="-3"
      id="c96253383"
      unitRef="USD">72000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-ReceivablesFromStockholderMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="-3"
      id="c96253384"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="-3"
      id="c96253385"
      unitRef="USD">306998000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="-3"
      id="c96253386"
      unitRef="USD">829000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="-3"
      id="c96253387"
      unitRef="USD">-257144000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-12-31_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="-3"
      id="c96253388"
      unitRef="USD">50755000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="-3"
      id="c96253390"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c96253392"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-ReceivablesFromStockholderMember"
      decimals="-3"
      id="c96253393"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c96253394"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c96253395"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c96253396"
      unitRef="USD">-33277000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96253397"
      unitRef="USD">-33277000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="-3"
      id="c96253399"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c96253401"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-ReceivablesFromStockholderMember"
      decimals="-3"
      id="c96253402"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c96253403"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-4"
      id="c96253404"
      unitRef="USD">-1010000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c96253405"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-4"
      id="c96253406"
      unitRef="USD">-1010000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="-3"
      id="c96253408"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c96253410"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-ReceivablesFromStockholderMember"
      decimals="-3"
      id="c96253411"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c96253412"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c96253413"
      unitRef="USD">-73000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c96253414"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96253415"
      unitRef="USD">-73000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="-3"
      id="c96253417"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c96253419"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-ReceivablesFromStockholderMember"
      decimals="-3"
      id="c96253420"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c96253421"
      unitRef="USD">4402000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c96253422"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c96253423"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96253424"
      unitRef="USD">4402000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <pirs:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="-3"
      id="c96253425"
      unitRef="Share">0</pirs:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="-3"
      id="c96253426"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <pirs:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c96253427"
      unitRef="Share">46000</pirs:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c96253428"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-ReceivablesFromStockholderMember"
      decimals="-3"
      id="c96253429"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c96253430"
      unitRef="USD">95000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c96253431"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c96253432"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96253433"
      unitRef="USD">95000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="-3"
      id="c96253434"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="-3"
      id="c96253435"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c96253436"
      unitRef="Share">182000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c96253437"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-ReceivablesFromStockholderMember"
      decimals="-3"
      id="c96253438"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c96253439"
      unitRef="USD">197000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c96253440"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c96253441"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96253442"
      unitRef="USD">197000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="-3"
      id="c96253443"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="-3"
      id="c96253444"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c96253445"
      unitRef="Share">2069000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c96253446"
      unitRef="USD">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-ReceivablesFromStockholderMember"
      decimals="-3"
      id="c96253447"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c96253448"
      unitRef="USD">6838000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c96253449"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c96253450"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-4"
      id="c96253451"
      unitRef="USD">6840000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharesOutstanding
      contextRef="i_2022-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="-3"
      id="c96253461"
      unitRef="Share">16000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="-3"
      id="c96253462"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c96253463"
      unitRef="Share">74519000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c96253464"
      unitRef="USD">74000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-12-31_StatementEquityComponentsAxis-ReceivablesFromStockholderMember"
      decimals="-3"
      id="c96253465"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-4"
      id="c96253466"
      unitRef="USD">318530000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c96253467"
      unitRef="USD">-254000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c96253468"
      unitRef="USD">-290421000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c96253469"
      unitRef="USD">27929000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96253476"
      unitRef="USD">-33277000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96253477"
      unitRef="USD">-45738000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-4"
      id="c96253479"
      unitRef="USD">2770000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96253480"
      unitRef="USD">2459000</us-gaap:DepreciationDepletionAndAmortization>
    <pirs:OperatingLeaseRightOfUseAssetAccretion
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-4"
      id="c96253481"
      unitRef="USD">-10000</pirs:OperatingLeaseRightOfUseAssetAccretion>
    <pirs:OperatingLeaseRightOfUseAssetAccretion
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96253482"
      unitRef="USD">91000</pirs:OperatingLeaseRightOfUseAssetAccretion>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96253483"
      unitRef="USD">4402000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96253484"
      unitRef="USD">5215000</us-gaap:ShareBasedCompensation>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96253485"
      unitRef="USD">376000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96253486"
      unitRef="USD">-0</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96253487"
      unitRef="USD">91000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-4"
      id="c96253488"
      unitRef="USD">30000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96253490"
      unitRef="USD">2624000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96253491"
      unitRef="USD">1813000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96253492"
      unitRef="USD">1358000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96253493"
      unitRef="USD">3154000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96253494"
      unitRef="USD">-20185000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96253495"
      unitRef="USD">19555000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96253496"
      unitRef="USD">-4208000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96253497"
      unitRef="USD">7049000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96253498"
      unitRef="USD">-4005000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96253499"
      unitRef="USD">9876000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <pirs:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-4"
      id="c96253500"
      unitRef="USD">990000</pirs:IncreaseDecreaseInOperatingLeaseLiabilities>
    <pirs:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96253501"
      unitRef="USD">988000</pirs:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96253502"
      unitRef="USD">-59932000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-4"
      id="c96253503"
      unitRef="USD">-7660000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96253505"
      unitRef="USD">1041000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96253506"
      unitRef="USD">949000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-5"
      id="c96253507"
      unitRef="USD">28200000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96253508"
      unitRef="USD">0</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96253509"
      unitRef="USD">48395000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96253510"
      unitRef="USD">-0</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96253511"
      unitRef="USD">-21236000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96253512"
      unitRef="USD">-949000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96253514"
      unitRef="USD">95000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96253515"
      unitRef="USD">1024000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96253516"
      unitRef="USD">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96253517"
      unitRef="USD">837000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromStockPlans
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96253518"
      unitRef="USD">197000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96253519"
      unitRef="USD">165000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96253520"
      unitRef="USD">0</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96253521"
      unitRef="USD">18913000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96253522"
      unitRef="USD">6922000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96253523"
      unitRef="USD">38188000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96253526"
      unitRef="USD">7214000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96253527"
      unitRef="USD">59127000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96253528"
      unitRef="USD">-5175000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-4"
      id="c96253529"
      unitRef="USD">-3190000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96253530"
      unitRef="USD">-79129000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96253531"
      unitRef="USD">47328000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c96253532"
      unitRef="USD">117764000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c96253533"
      unitRef="USD">70436000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c96253534"
      unitRef="USD">38635000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c96253535"
      unitRef="USD">117764000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96253537"
      unitRef="USD">-73000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96253538"
      unitRef="USD">0</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96253539"
      unitRef="USD">193000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96253540"
      unitRef="USD">237000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2344183">
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 27pt;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;1.&lt;/em&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;Corporate Information&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Pieris Pharmaceuticals, Inc., was founded in &lt;em style="font: inherit;"&gt; May 2013, &lt;/em&gt;and acquired 100% interest in Pieris Pharmaceuticals GmbH (formerly Pieris AG, a German company which was founded in &lt;em style="font: inherit;"&gt;2001&lt;/em&gt;) in &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;2014.&lt;/em&gt; Pieris Pharmaceuticals, Inc. and its wholly-owned subsidiaries, hereinafter collectively Pieris, or the Company, is a clinical-stage biopharmaceutical company that discovers and develops Anticalin-based drugs to target validated disease pathways in unique and transformative ways. Pieris' corporate headquarters is located in Boston, Massachusetts and its research facility, as of &lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt;, is located in Hallbergmoos, Germany.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Pieris&#x2019; clinical pipeline includes elarekibep, formerly referred to as PRS-&lt;em style="font: inherit;"&gt;060/AZD1402,&lt;/em&gt; an inhaled IL-&lt;em style="font: inherit;"&gt;4R&#x3b1;&lt;/em&gt; antagonist Anticalin protein to treat uncontrolled asthma,&#160;PRS-&lt;em style="font: inherit;"&gt;220,&lt;/em&gt; an inhaled CTGF antagonist to treat idiopathic pulmonary fibrosis, or IPF, and other pulmonary fibrosis indications, and an immuno-oncology, or&#160;IO,&#160;bispecific PRS-&lt;em style="font: inherit;"&gt;344/S095012&lt;/em&gt; targeting PD-&lt;em style="font: inherit;"&gt;L1&lt;/em&gt; and &lt;em style="font: inherit;"&gt;4&lt;/em&gt;-&lt;em style="font: inherit;"&gt;1BB.&lt;/em&gt; Proprietary to us, Anticalin proteins are a novel class of therapeutics validated in the clinic and through partnerships with leading pharmaceutical companies.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company&#x2019;s core Anticalin technology and platform was developed in Germany, and the Company has partnership arrangements with several major multi-national pharmaceutical companies.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company is subject to risks common to companies in the biotechnology industry, including but&#160;&lt;i&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt;&lt;/i&gt;&#160;limited to, the need for additional capital, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval and reimbursement for any drug product candidate that it&#160;&lt;i&gt;&lt;em style="font: inherit;"&gt; may&lt;/em&gt;&lt;/i&gt;&#160;identify and develop, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development of technological innovations by competitors, reliance on&#160;&lt;i&gt;&lt;em style="font: inherit;"&gt;third&lt;/em&gt;&lt;/i&gt;-party manufacturers and the ability to transition from pilot-scale production to large-scale manufacturing of products.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;The future success of the Company is dependent on its ability to identify and develop its product candidates, expand its corporate infrastructure and ultimately upon its ability to attain profitable operations. The Company has devoted substantially all of its financial resources and efforts to research and development and general and administrative expenses to support such research and development. The Company has several research and development programs underway in varying stages of development, and it expects that these programs will continue to require increasing amounts of cash for development, conducting clinical trials, and testing and manufacturing of product material. Cash necessary to fund operations will increase significantly over the next several years as the Company continues to conduct these activities necessary to pursue governmental regulatory approval of clinical-stage programs and other product candidates.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Going Concern Uncertainties&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;As of &lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt;, cash, cash equivalents, and investments were $59.2&#160;million. The Company&#x2019;s net loss was $33.3&#160;million and $45.7&#160;million for the years ended &lt;em style="font: inherit;"&gt; December 31, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021&lt;/em&gt;, respectively. The Company has incurred net losses since inception and had an accumulated deficit of $290.4&#160;million as of &lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt;. Net losses and negative cash flows have had, and will continue to have, an adverse effect on the Company&#x2019;s stockholders&#x2019; equity and working capital. The Company expects to continue to incur operating losses for at least the next several years.&#160;The Company would need to raise additional capital over the next year to continue its current level of research and development activities across all of its active programs, as well as to maintain the general and administrative functions to support such activities. Without access to additional capital or management making decisions to reduce spending, these conditions&#160;raise&#160;substantial doubt about the ability of the Company to continue as a going concern.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company plans to raise additional capital to fulfill its operating and capital requirements through public or private equity financings, utilization of its current &#x201c;at the market offering&#x201d; program, or ATM Program, strategic collaborations, licensing arrangements, government grants and/or the achievement of milestones under its collaborative agreements. The funding requirements of the Company&#x2019;s operating plans, however, are based on estimates that are subject to risks and uncertainties and &lt;em style="font: inherit;"&gt; may&#160;&lt;/em&gt;change as a result of many factors currently unknown. Although management continues to pursue these funding plans, there is&#160;&lt;i&gt;&lt;em style="font: inherit;"&gt;no&lt;/em&gt;&lt;/i&gt;&#160;assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all. Until such time that the Company can generate substantial product revenues, if ever, the Company expects to finance its cash needs through a combination of equity offerings, debt financings, strategic partnerships, licensing arrangements and government grants. The terms of any future financing &lt;em style="font: inherit;"&gt; may&#160;&lt;/em&gt;adversely affect the holdings or the rights of the Company&#x2019;s existing stockholders.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;If the Company is unable to obtain additional funding on acceptable terms when needed, the Company will defer or limit a substantial portion of its research, development and clinical projects, reduce discretionary expenditures and other fixed or variable personnel costs&#160;to alleviate the substantial doubt as to the Company&#x2019;s ability to continue as a going concern. The Company&#x2019;s budget and operating plan for &lt;em style="font: inherit;"&gt;2023,&lt;/em&gt; approved by the Board, does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; include such discretionary costs, and management is prepared to gate future investments on PRS-&lt;em style="font: inherit;"&gt;220&lt;/em&gt; and PRS-&lt;em style="font: inherit;"&gt;400,&lt;/em&gt; including certain Phase &lt;em style="font: inherit;"&gt;2&lt;/em&gt;-readiness activities for PRS-&lt;em style="font: inherit;"&gt;220&lt;/em&gt; and IND-enabling activities for PRS-&lt;em style="font: inherit;"&gt;400,&lt;/em&gt; in the interest of achieving its top priority, namely, obtaining data from the elarekibep Phase &lt;em style="font: inherit;"&gt;2a&lt;/em&gt; study in asthma.&#160;On the basis of the Company&#x2019;s approved budget and actions within management&#x2019;s control, the Company believes that its currently available funds will be sufficient to fund the Company&#x2019;s remaining limited operations through at least the next &lt;em style="font: inherit;"&gt;12&lt;/em&gt; months from the issuance of this Annual Report on Form &lt;em class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="font: inherit;"&gt;10&lt;/em&gt;-K. The Company&#x2019;s belief with respect to its ability to fund operations is based on estimates that are subject to risks and uncertainties.&lt;/p&gt;

   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
  </us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i_2013-05-31_BusinessAcquisitionAxis-PierisPharmaceuticalsGmbhMember"
      decimals="0"
      id="c96253542"
      unitRef="Pure">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i_2022-12-31"
      decimals="-5"
      id="c96253554"
      unitRef="USD">59200000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-5"
      id="c96253555"
      unitRef="USD">-33300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-5"
      id="c96253556"
      unitRef="USD">-45700000</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2022-12-31"
      decimals="-5"
      id="c96253558"
      unitRef="USD">-290400000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2344184">
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 27pt;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2.&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;Summary of Significant Accounting Policies &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b/&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Basis of Presentation and Use of Estimates&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The accompanying consolidated financial statements of Pieris Pharmaceuticals, Inc. and its wholly-owned subsidiaries were prepared in accordance with U.S. GAAP. The consolidated financial statements include the accounts of all subsidiaries. All intercompany balances and transactions have been eliminated.&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The preparation of the financial statements in accordance with U.S. GAAP requires management to make estimates, judgments, and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and the related disclosures at the date of the financial statements and during the reporting period. Significant estimates are used for, but are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; limited to, revenue recognition; deferred tax assets, deferred tax liabilities and valuation allowances; determination of the incremental borrowing rate to calculate right-of-use assets and lease liabilities; beneficial conversion features; fair value of stock options, preferred stock, and warrants; and prepaid and accrued clinical trial expenses. Management evaluates its estimates on an ongoing basis. Actual results and outcomes could differ materially from management&#x2019;s estimates, judgments, and assumptions.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b/&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Foreign Currency Translation&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The financial statements of the Company&#x2019;s foreign subsidiaries are translated from local currency into reporting currency, which is U.S. dollars, using the current exchange rate at the balance sheet date for assets and liabilities, and the weighted average exchange rate prevailing during the period for revenues and expenses. The functional currency for Pieris&#x2019; foreign subsidiaries is considered to be the local currency for each entity and, accordingly, translation adjustments for these subsidiaries are included in accumulated other comprehensive loss within stockholders&#x2019; equity.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Realized and unrealized gains and losses resulting from foreign currency transactions denominated in currencies other than the functional currency are reflected as other (expense) income, net in the consolidated statements of operations. Foreign currency gains and losses on available-for-sale investment transactions are recorded to other comprehensive income (loss) on the Company's balance sheet per Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic &lt;em style="font: inherit;"&gt;830,&lt;/em&gt; &lt;i&gt;Foreign Currency Matters.&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i/&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b/&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Cash, Cash Equivalents and Investments&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company determines the appropriate classification of its investments at the time of purchase. All liquid investments with original maturities of &lt;em style="font: inherit;"&gt;90&lt;/em&gt; days or less from the purchase date and for which there is an active market are considered to be cash equivalents. The Company&#x2019;s investments are comprised of money market, asset backed securities, government treasuries, and corporate bonds that are classified as available-for-sale in accordance with FASB ASC &lt;em style="font: inherit;"&gt;320,&lt;/em&gt; &lt;i&gt;Investments&lt;/i&gt;&#x2014;&lt;i&gt;Debt and Equity Securities&lt;/i&gt;. The Company classifies investments available to fund current operations as current assets on its balance sheets.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Available-for-sale investments are recorded at fair value, with unrealized gains or losses included in accumulated other comprehensive income (loss) on the Company&#x2019;s balance sheets. Realized gains and losses are determined using the specific identification method and are included as a component of other income (expense).&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company reviews investments for other-than-temporary impairment whenever the fair value of an investment is less than the amortized cost and evidence indicates that an investment&#x2019;s carrying amount is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; recoverable within a reasonable period of time. To determine whether an impairment is other-than temporary, the Company considers its intent to sell, or whether it is more likely than &lt;em style="font: inherit;"&gt;not&lt;/em&gt; that the Company will be required to sell the investment before recovery of the investment&#x2019;s amortized cost basis. Evidence considered in this assessment includes reasons for the impairment, the severity and the duration of the impairment, and changes in value subsequent to period end.&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b/&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Concentration of Credit Risk and Off-Balance Sheet Risk&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company has &lt;em style="font: inherit;"&gt;no&lt;/em&gt; financial instruments with off&#x2011;balance sheet risk such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Financial instruments that subject Pieris to concentrations of credit risk include cash and cash equivalents, investments, and accounts receivable. The Company&#x2019;s cash, cash equivalents, and investments are held in accounts with financial institutions that management believes are creditworthy. The Company&#x2019;s investment policy includes guidelines on the quality of the institutions and financial instruments and defines allowable investments that the Company believes minimizes the exposure to concentration of credit risk. The Company has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; experienced any credit losses in such accounts and does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; believe it is exposed to any significant credit risk on these funds. Accounts receivable primarily consist of amounts due under strategic partnership and other license agreements with major multi-national pharmaceutical companies for which the Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; obtain collateral.&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/&gt;

   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b/&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Fair Value Measurement&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. FASB ASC Topic &lt;em style="font: inherit;"&gt;820,&lt;/em&gt; &lt;i&gt;Fair Value Measurement and Disclosures&lt;/i&gt;, or ASC &lt;em style="font: inherit;"&gt;820,&lt;/em&gt; established a hierarchy of inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the financial instrument based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the inputs that market participants would use in pricing the financial instrument and are developed based on the best information available in the circumstances. The fair value hierarchy applies only to the valuation inputs used in determining the reported or disclosed fair value of the financial instruments and is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; a measure of the investment credit quality. Fair value measurements are classified and disclosed in &lt;em style="font: inherit;"&gt;one&lt;/em&gt; of the following &lt;em style="font: inherit;"&gt;three&lt;/em&gt; categories:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:top;width:18pt;"&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#x2022;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:top;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Level &lt;em style="font: inherit;"&gt;1&lt;/em&gt; inputs are quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:top;width:18pt;"&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#x2022;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:top;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Level &lt;em style="font: inherit;"&gt;2&lt;/em&gt; utilizes quoted market prices in markets that are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; active, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:top;width:18pt;"&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#x2022;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:top;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Level &lt;em style="font: inherit;"&gt;3&lt;/em&gt; inputs are unobservable inputs for the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level &lt;em style="font: inherit;"&gt;3.&lt;/em&gt; A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Financial instruments measured at fair value on a recurring basis include cash equivalents and investments, if any (&lt;i&gt;Note &lt;em style="font: inherit;"&gt;6&lt;/em&gt;&lt;/i&gt;).&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;An entity &lt;em style="font: inherit;"&gt; may &lt;/em&gt;elect to measure many financial instruments and certain other items at fair value at specified election dates. Subsequent unrealized gains and losses on items for which the fair value option has been elected will be reported in net loss. The Company did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; elect to measure any additional financial instruments or other items at fair value.&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b/&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Fair Values of Financial Instruments&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The fair value of cash, accounts receivable, and accounts payable approximates the carrying value of these financial instruments because of the short-term nature of any maturities. The Company determines the estimated fair values of other financial instruments, using available market information and valuation methodologies, primarily input from independent &lt;em style="font: inherit;"&gt;third&lt;/em&gt; party pricing sources.&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b/&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Accounts Receivable&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Accounts receivable are recorded net of allowances for doubtful accounts and represent amounts due from strategic partners. The Company monitors and evaluates collectability of receivables on an ongoing basis and considers whether an allowance for doubtful accounts is necessary. The Company determined that &lt;em style="font: inherit;"&gt;no&lt;/em&gt; such reserve is needed as of &lt;em style="font: inherit;"&gt; December 31, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021&lt;/em&gt;. Historically, Pieris has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; had collectability issues.&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/&gt;

   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b/&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Property and Equipment&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Property and equipment are recorded at acquisition cost, less accumulated depreciation and impairment. Depreciation on property and equipment is calculated using the straight-line method over the remaining estimated useful lives of the assets. Maintenance and repairs to these assets are charged to expenses as occurred. Substantially all of the Company's fixed assets are located in Germany. The estimated useful life of the different groups of property and equipment is as follows:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;Asset Classification&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 43%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Estimated useful life (in years)&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Leasehold improvements&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 43%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;shorter of useful life or remaining life of the lease&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Laboratory furniture and equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 43%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;8-14&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Office furniture and equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 43%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;5-13&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Computer and equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 43%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;3 - 7&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;&lt;div&gt;
   &lt;/div&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b/&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Impairment of Long-lived Assets&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company reviews its long-lived assets to be held and used for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; be fully recoverable. The Company evaluates the realizability of its long-lived assets based on profitability and cash flow expectations for the related asset. Any write-downs are treated as permanent reductions in the carrying amount of the assets. The Company believes that, as of each of the balance sheets presented, &lt;em style="font: inherit;"&gt;none&lt;/em&gt; of the Company&#x2019;s long-lived assets were impaired.&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b/&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Revenue Recognition&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;Pieris has entered into several licensing agreements with collaboration partners for the development of Anticalin therapeutics against a variety of targets. The terms of these agreements provide for the transfer of multiple goods or services which&#160;&lt;i&gt;&lt;em style="font: inherit;"&gt; may&lt;/em&gt;&lt;/i&gt;&#160;include: (i)&#160;licenses, or options to obtain licenses, to Pieris&#x2019; Anticalin technology and/or specific programs and (ii)&#160;research and development activities to be performed on behalf of or with a collaborative partner. Payments to Pieris under these agreements&#160;&lt;i&gt;&lt;em style="font: inherit;"&gt; may&lt;/em&gt;&lt;/i&gt;&#160;include upfront fees (which include license and option fees), payments for research and development activities, payments based upon the achievement of certain milestones, and royalties on product sales. There are&#160;&lt;i&gt;&lt;em style="font: inherit;"&gt;no&lt;/em&gt;&lt;/i&gt;&#160;performance, cancellation, termination or refund provisions in any of the arrangements that could result in material financial consequences to Pieris. As the Company's intellectual property assets are considered to be located in Germany, the Company records all consolidated revenue in its subsidiary, Pieris Pharmaceuticals, GmbH.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Collaborative Arrangements&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company considers the nature and contractual terms of an arrangement and assess whether the arrangement involves a joint operating activity pursuant to which it is an active participant and exposed to significant risks and rewards with respect to the arrangement. If the Company is an active participant and exposed to the significant risks and rewards with respect to the arrangement, it accounts for these arrangements pursuant to ASC &lt;em style="font: inherit;"&gt;808,&lt;/em&gt; &lt;i&gt;Collaborative Arrangements&lt;/i&gt;, or ASC &lt;em style="font: inherit;"&gt;808,&lt;/em&gt; and applies a systematic and rational approach to recognize revenue. The Company classifies payments received as revenue and payments made as a reduction of revenue in the period in which they are earned. Revenue recognized under a collaborative arrangement involving a participant that is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; a customer is presented as Collaboration Revenue in the Statement of Operations.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;In accordance with ASC &lt;em style="font: inherit;"&gt;606,&lt;/em&gt; revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled in exchange for these goods and services. To achieve this core principle, the Company applies the following &lt;em style="font: inherit;"&gt;five&lt;/em&gt; steps: &lt;em style="font: inherit;"&gt;1&lt;/em&gt;) identify the customer contract; &lt;em style="font: inherit;"&gt;2&lt;/em&gt;) identify the contract&#x2019;s performance obligations; &lt;em style="font: inherit;"&gt;3&lt;/em&gt;) determine the transaction price; &lt;em style="font: inherit;"&gt;4&lt;/em&gt;) allocate the transaction price to the performance obligations; and &lt;em style="font: inherit;"&gt;5&lt;/em&gt;) recognize revenue when or as a performance obligation is satisfied.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company evaluates all promised goods and services within a customer contract and determines which of such goods and services are separate performance obligations. This evaluation includes an assessment of whether the good or service is capable of being distinct and whether the good or service is separable from other promises in the contract. &#160;In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property and the capabilities of the customer to develop the intellectual property on their own or whether the required expertise is readily available.&lt;/p&gt;

   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Licensing arrangements are analyzed to determine whether the promised goods or services, which often include licenses, research and development services and governance committee services, are distinct or whether they must be accounted for as part of a combined performance obligation. If the license is considered &lt;em style="font: inherit;"&gt;not&lt;/em&gt; to be distinct, the license would then be combined with other promised goods or services as a combined performance obligation. If the Company is involved in a governance committee, it assesses whether its involvement constitutes a separate performance obligation. When governance committee services are determined to be separate performance obligations, the Company determines the fair value to be allocated to this promised service.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Certain contracts contain optional and additional items, which are considered marketing offers and are accounted for as separate contracts with the customer if such option is elected by the customer, unless the option provides a material right which would &lt;em style="font: inherit;"&gt;not&lt;/em&gt; be provided without entering into the contract.&#160;&#160;An option that is considered a material right is accounted for as a separate performance obligation.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The transaction price is determined based on the consideration to which the Company will be entitled in exchange for transferring goods and services to the customer. A contract &lt;em style="font: inherit;"&gt; may &lt;/em&gt;contain variable consideration, including potential payments for both milestone and research and development services. For certain potential milestone payments, the Company estimates the amount of variable consideration by using the most likely amount method. In making this assessment, the Company evaluates factors such as the clinical, regulatory, commercial and other risks that must be overcome to achieve the milestone. Each reporting period the Company re-evaluates the probability of achievement of such variable consideration and any related constraints. Pieris will include variable consideration, without constraint, in the transaction price to the extent it is probable that a significant reversal in the amount of cumulative revenue recognized will &lt;em style="font: inherit;"&gt;not&lt;/em&gt; occur when the uncertainty associated with the variable consideration is subsequently resolved. For potential research and development service payments, the Company estimates the amount of variable consideration by using the expected value method, including any approved budget updates arising from additional research or development services.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price among the performance obligations on a relative standalone selling price basis unless a portion of the transaction price is variable and meets the criteria to be allocated entirely to a performance obligation or to a distinct good or service that forms part of a single performance obligation.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company allocates the transaction price based on the estimated standalone selling price of the underlying performance obligations or in the case of certain variable consideration to &lt;em style="font: inherit;"&gt;one&lt;/em&gt; or more performance obligations. The Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company utilizes key assumptions to determine the stand-alone selling price, which &lt;em style="font: inherit;"&gt; may &lt;/em&gt;include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs to complete the respective performance obligation. Certain variable consideration is allocated specifically to &lt;em style="font: inherit;"&gt;one&lt;/em&gt; or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated to each performance obligation are consistent with the amount the Company would expect to receive for each performance obligation.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;When a performance obligation is satisfied, revenue is recognized for the amount of the transaction price, excluding estimates of variable consideration that are constrained, that is allocated to that performance obligation on a relative standalone selling price basis. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations under an arrangement.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;For performance obligations consisting of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non- refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Revenue recognized under an arrangement involving a participant that is a customer is presented as Customer Revenue.&lt;/p&gt;

   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Milestones and Royalties&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company aggregates milestones into &lt;em style="font: inherit;"&gt;four&lt;/em&gt; categories (i) research milestones, (ii) development milestones, (iii) commercial milestones and (iv) sales milestones. Research milestones are typically achieved upon reaching certain success criteria as defined in each agreement related to developing an Anticalin protein against the specified target. Development milestones are typically reached when a compound reaches a defined phase of clinical research or passes such phase, or upon gaining regulatory approvals. Commercial milestones are typically achieved when an approved pharmaceutical product reaches the status for commercial sale, including regulatory approval. Sales milestones are certain defined levels of net sales by the licensee, such as when a product &lt;em style="font: inherit;"&gt;first&lt;/em&gt; achieves global sales or annual sales of a specified amount.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;There is uncertainty that the events to obtain the research and development milestones will be achieved given the nature of clinical development and the stage of the Company&#x2019;s technology. The Company has thus determined that all research and development milestones will be constrained until it is deemed probable that a significant revenue reversal will &lt;em style="font: inherit;"&gt;not&lt;/em&gt; occur. For revenues from research and development milestones, payments will be recognized consistent with the recognition pattern of the performance obligation to which they relate.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&#160;Commercial milestones and sales royalties are determined by sales or usage-based thresholds and will be accounted for under the royalty recognition constraint as constrained variable consideration.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company calculates the maximum amount of potential milestones achievable under each collaboration agreement and discloses such potential future milestones for all current collaborations using such a maximum calculation.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Contract Balances&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company recognizes a contract asset when the Company transfers goods or services to a customer before the customer pays consideration or before payment is due, excluding any amounts presented as a receivable (i.e., accounts receivable). A contract asset is an entity&#x2019;s right to consideration in exchange for goods or services that the entity has transferred to a customer. The contract liabilities (i.e., deferred revenue) primarily relate to contracts where the Company has received payment but has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; yet satisfied the related performance obligations.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;In the event of an early termination of a collaboration agreement, any contract liabilities would be recognized in the period in which all Company obligations under the agreement have been fulfilled.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Costs to Obtain and Fulfill a Contract with a Customer&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Certain costs to obtain customer contracts, including success-based fees paid to &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party service providers, and costs to fulfill customer contracts are capitalized in accordance with FASB ASC &lt;em style="font: inherit;"&gt;340,&lt;/em&gt; &lt;i&gt;Other Assets and Deferred Costs&lt;/i&gt;, or ASC &lt;em style="font: inherit;"&gt;340.&lt;/em&gt; These costs are amortized to expense on a systemic basis that is consistent with the transfer to the customer of the goods or services to which the asset relates. The Company will expense the amortization of costs to obtain customer contracts to general and administrative expense and costs to fulfill customer contracts to research and development expense.&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Research and Development&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Research and development expenses are charged to the statement of operations as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including salaries and benefits, facilities costs, pre-clinical and clinical costs, contract services, consulting, depreciation and amortization expense, and other related costs. Costs associated with acquired technology, in the form of upfront fees or milestone payments, are charged to research and development expense as incurred.&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/&gt;

   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b/&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Income Taxes&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company applies ASC Topic &lt;em style="font: inherit;"&gt;740&lt;/em&gt; &lt;i&gt;Income Taxes&lt;/i&gt;, which established financial accounting and reporting requirements for the effects of income taxes that result from the Company&#x2019;s activities during the current and preceding years. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and operating losses and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted statutory tax rates expected to apply to taxable income in the jurisdictions and years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Where the Company determines that it is more likely than &lt;em style="font: inherit;"&gt;not&lt;/em&gt; that some portion or all of the deferred tax assets will &lt;em style="font: inherit;"&gt;not&lt;/em&gt; be realized in the future, the deferred tax assets are reduced by a valuation allowance. The Company records interest and penalties related to uncertain tax positions as part of income tax expense.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Tax Cuts and Jobs Act&#160;(TCJA) subjects a U.S. shareholder to tax on global-intangible low tax income (GILTI) earned by certain foreign subsidiaries. The Company has made an accounting policy election to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only.&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b/&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Stock-based Compensation&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company measures share-based payments in accordance with ASC Topic &lt;em style="font: inherit;"&gt;718,&lt;/em&gt; &lt;i&gt;Stock Compensation&lt;/i&gt;. Pieris records its stock-based compensation expense over the requisite service period and records forfeitures as they occur. Determining the appropriate fair value model and related assumptions requires judgment, including estimating share price volatility and expected terms of the awards. For employee options, the fair value measurement date is generally on the date of grant and the related compensation expense is recognized on a straight-line basis over the requisite service period of the awards, less expense for actual forfeitures.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company uses the Black-Scholes option pricing model to determine the estimated fair value for stock-based awards. Option-pricing models require the input of various subjective assumptions, including the option&#x2019;s expected life, expected dividend yield, price volatility, risk free interest rate and forfeitures of the underlying stock. Due to the limited operating history of the Company as a public entity and a lack of company specific historical and implied volatility data, the Company has based its estimate of expected volatility on the historical volatility of a group of similar companies that are publicly traded. When selecting these public companies on which it has based its expected stock price volatility, the Company selected companies with comparable characteristics to it, including enterprise value, risk profiles, position within the industry, and with historical share price information sufficient to meet the expected term of the stock-based awards. The Company computes historical volatility data using the daily closing prices for the selected companies&#x2019; shares during the equivalent period of the calculated expected term of the stock-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Due to the lack of Company specific historical option activity, the Company has estimated the expected term of its employee stock options using the &#x201c;simplified&#x201d; method, whereby, the expected term equals the arithmetic average of the vesting term and the original contractual term of the option. The expected term for non-employee awards is the remaining contractual term of the option. The risk-free interest rates are based on the U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The Company has never paid, and does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; expect to pay dividends in the foreseeable future.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;All excess tax benefits and tax deficiencies are recorded as income tax expense or benefit in the Company's statement of operations and comprehensive loss. For the years ended&#160;&lt;em style="font: inherit;"&gt; December 31, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021&lt;/em&gt;, the Company did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; record an income statement benefit for excess tax benefits as a valuation allowance is also required on these amounts.&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b/&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Government Grants&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company recognizes grants from governmental agencies when there is reasonable assurance that the Company will comply with the conditions attached to the grant arrangement and the grant will be received. The Company evaluates the conditions of each grant as of each reporting period to evaluate whether the Company has reached reasonable assurance of meeting the conditions of each grant arrangement and that it is expected that the grant will be received as a result of meeting the necessary conditions. Grants are recognized in the consolidated statements of operations on a systematic basis over the periods in which the Company recognizes the related costs for which the government grant is intended to compensate. Specifically, grant income related to research and development costs is recognized as such expenses are incurred. Grant income is included as a separate caption within Other income (expense), net in the consolidated statements of operations.&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/&gt;

   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b/&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Leases&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company accounts for leases pursuant to ASC &lt;em style="font: inherit;"&gt;842&lt;/em&gt; &lt;i&gt;Leases (Topic &lt;em style="font: inherit;"&gt;842&lt;/em&gt;)&lt;/i&gt;, or ASC &lt;em style="font: inherit;"&gt;842.&lt;/em&gt; As a lessee, the Company is required to recognize (i) a lease liability, which is a lessees obligation to make lease payments arising from a lease, measured on a discounted basis; and (ii) a right-of-use asset, which is an asset that represents the lessee&#x2019;s right to use, or control the use of, a specified asset for the lease term for all leases (with the exception of short-term leases) at the commencement date.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company determines if an arrangement is a lease at inception. The Company&#x2019;s contracts are determined to contain a lease within the scope of ASC &lt;em style="font: inherit;"&gt;842&lt;/em&gt; when all of the following criteria based on the specific circumstances of the arrangement are met: (&lt;em style="font: inherit;"&gt;1&lt;/em&gt;) there is an identified asset for which there are &lt;em style="font: inherit;"&gt;no&lt;/em&gt; substantive substitution rights; (&lt;em style="font: inherit;"&gt;2&lt;/em&gt;) the Company has the right to obtain substantially all of the economic benefits from the identified asset; and (&lt;em style="font: inherit;"&gt;3&lt;/em&gt;) the Company has the right to direct the use of the identified asset. In addition, the Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; apply the recognition requirements in the lease standard to short-term leases (a lease that at commencement date has a lease term of &lt;em style="font: inherit;"&gt;12&lt;/em&gt; months or less and does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; contain a purchase option that it is reasonably certain to exercise) and does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; separate lease and non-lease components for all asset classes. Any variable components of lease costs are excluded from lease payments and are recognized in the period incurred, including increases to rent based on German Consumer Price Index , or CPI.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;At the commencement date, operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of future lease payments over the expected lease term. The Company&#x2019;s lease agreements do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; provide an implicit rate. As a result, the Company utilizes an estimated incremental borrowing rate to discount lease payments, which is based on the rate of interest the Company would have to pay to borrow a similar amount on a collateralized basis over a similar term and based on observable market data points. Certain adjustments to the right-of-use asset &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be required for items such as initial direct costs paid or lease incentives received. Operating lease cost is recognized over the expected term on a straight-line basis.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company typically only includes an initial lease term in its assessment of a lease agreement. Options to renew a lease are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; included in the Company&#x2019;s assessment unless there is reasonable certainty that the Company will renew. The expected lease term includes noncancelable lease periods and, when applicable, periods covered by an option to extend the lease if the Company is reasonably certain to exercise that option, as well as periods covered by an option to terminate the lease if the Company is reasonably certain &lt;em style="font: inherit;"&gt;not&lt;/em&gt; to exercise that option.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Assumptions made by the Company at the commencement date are re-evaluated upon occurrence of certain events, including a lease modification. A lease modification results in a separate contract when the modification grants the lessee an additional right of use &lt;em style="font: inherit;"&gt;not&lt;/em&gt; included in the original lease and when lease payments increase commensurate with the standalone price for the additional right of use. When a lease modification results in a separate contract, it is accounted for in the same manner as a new lease.&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b/&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Contingencies&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Accruals are recorded for loss contingencies when it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. The Company evaluates, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously. Considering facts known at the time of the assessment, the Company determines whether potential losses are considered reasonably possible or probable and whether they are estimable. Based upon this assessment, the Company carries out an evaluation of disclosure requirements and considers possible accruals in the financial statements.&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b/&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Segment Reporting&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Operating segments are identified as components of an enterprise where separate discrete financial information is evaluated by the chief operating decision maker in making decisions on how to allocate resources and assess performance. The Company operates as a single segment dedicated to the discovery and development of biotechnological applications and the Company&#x2019;s chief operating decision maker, or CODM, makes decisions based on the Company as a whole. The Company has determined that its CODM is its Chief Executive Officer.&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b/&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Earnings per Share&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Basic earnings per share attributable to common stockholders is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period, without consideration for common stock equivalents.&lt;/p&gt;

   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Diluted earnings per share attributable to common stockholders is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share attributable to common stockholders' calculation, preferred stock, stock options, unvested restricted stock, and warrants are considered to be common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to common stockholders, as their effect would be anti-dilutive for all periods presented. Therefore, basic and diluted net loss per share were the same for all periods presented.&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b/&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Recent Accounting Pronouncements &lt;em style="font: inherit;"&gt;Not&lt;/em&gt; Yet Adopted&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;In &lt;em style="font: inherit;"&gt; June 2016, &lt;/em&gt;the FASB issued ASU &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13,&lt;/em&gt; &lt;i&gt;Financial Instruments - Credit Losses&lt;/i&gt; &lt;i&gt;(Topic &lt;em style="font: inherit;"&gt;326&lt;/em&gt;): Measurement of Credit Losses on Financial Statements, &lt;/i&gt;or ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13.&lt;/em&gt; ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13&lt;/em&gt; significantly changes the impairment model for most financial assets and certain other instruments. The new standard requires that expected credit losses relating to financial assets measured on an amortized cost basis and available-for-sale debt securities be recorded through an allowance for credit losses. It also limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value, and requires the reversal of previously recognized credit losses if fair value increases. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Subsequently, in &lt;em style="font: inherit;"&gt; November 2018, &lt;/em&gt;the FASB issued ASU &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;2018&lt;/em&gt;-&lt;em style="font: inherit;"&gt;19,&lt;/em&gt; &lt;i&gt;Codification Improvements to Topic &lt;em style="font: inherit;"&gt;326,&lt;/em&gt; Financial Instruments-Credit Losses&lt;/i&gt;, which clarifies codification and corrects unintended application of the guidance. In &lt;em style="font: inherit;"&gt; November 2019, &lt;/em&gt;the FASB issued ASU &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;2019&lt;/em&gt;-&lt;em style="font: inherit;"&gt;11,&lt;/em&gt; &lt;i&gt;Codification Improvements to Topic &lt;em style="font: inherit;"&gt;326,&lt;/em&gt; Financial Instruments-Credit Losses&lt;/i&gt;, which clarifies or addresses specific issues about certain aspects of ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13.&lt;/em&gt; In &lt;em style="font: inherit;"&gt; November 2019 &lt;/em&gt;the FASB also issued ASU &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;2019&lt;/em&gt;-&lt;em style="font: inherit;"&gt;10,&lt;/em&gt; &lt;i&gt;Financial Instruments-Credit Losses (Topic &lt;em style="font: inherit;"&gt;326&lt;/em&gt;), Derivatives and Hedging (Topic &lt;em style="font: inherit;"&gt;815&lt;/em&gt;), and Leases (Topic &lt;em style="font: inherit;"&gt;842&lt;/em&gt;): Effective Dates&lt;/i&gt;, which delays the effective date of ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13&lt;/em&gt; by &lt;em style="font: inherit;"&gt;three&lt;/em&gt; years for certain smaller reporting companies such as the Company. The guidance in ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13&lt;/em&gt; is effective for the Company for financial statements issued for fiscal years beginning after &lt;em style="font: inherit;"&gt; December 15, 2022 &lt;/em&gt;and interim periods within those fiscal years, with early adoption permitted. The Company expects that adoption of this standard will &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have a material impact on its financial statements.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company has considered other recent accounting pronouncements and concluded that they are either &lt;em style="font: inherit;"&gt;not&lt;/em&gt; applicable to the business, or that the effect is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; expected to be material to the unaudited consolidated financial statements as a result of future adoption.&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/&gt;

  </us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="d_2022-01-01_2022-12-31" id="c96258219">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Basis of Presentation and Use of Estimates&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The accompanying consolidated financial statements of Pieris Pharmaceuticals, Inc. and its wholly-owned subsidiaries were prepared in accordance with U.S. GAAP. The consolidated financial statements include the accounts of all subsidiaries. All intercompany balances and transactions have been eliminated.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="d_2022-01-01_2022-12-31" id="c96258221">The preparation of the financial statements in accordance with U.S. GAAP requires management to make estimates, judgments, and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and the related disclosures at the date of the financial statements and during the reporting period. Significant estimates are used for, but are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; limited to, revenue recognition; deferred tax assets, deferred tax liabilities and valuation allowances; determination of the incremental borrowing rate to calculate right-of-use assets and lease liabilities; beneficial conversion features; fair value of stock options, preferred stock, and warrants; and prepaid and accrued clinical trial expenses. Management evaluates its estimates on an ongoing basis. Actual results and outcomes could differ materially from management&#x2019;s estimates, judgments, and assumptions.</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="d_2022-01-01_2022-12-31" id="c96258222">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Foreign Currency Translation&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The financial statements of the Company&#x2019;s foreign subsidiaries are translated from local currency into reporting currency, which is U.S. dollars, using the current exchange rate at the balance sheet date for assets and liabilities, and the weighted average exchange rate prevailing during the period for revenues and expenses. The functional currency for Pieris&#x2019; foreign subsidiaries is considered to be the local currency for each entity and, accordingly, translation adjustments for these subsidiaries are included in accumulated other comprehensive loss within stockholders&#x2019; equity.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Realized and unrealized gains and losses resulting from foreign currency transactions denominated in currencies other than the functional currency are reflected as other (expense) income, net in the consolidated statements of operations. Foreign currency gains and losses on available-for-sale investment transactions are recorded to other comprehensive income (loss) on the Company's balance sheet per Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic &lt;em style="font: inherit;"&gt;830,&lt;/em&gt; &lt;i&gt;Foreign Currency Matters.&lt;/i&gt;&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="d_2022-01-01_2022-12-31" id="c96258223">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Cash, Cash Equivalents and Investments&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company determines the appropriate classification of its investments at the time of purchase. All liquid investments with original maturities of &lt;em style="font: inherit;"&gt;90&lt;/em&gt; days or less from the purchase date and for which there is an active market are considered to be cash equivalents. The Company&#x2019;s investments are comprised of money market, asset backed securities, government treasuries, and corporate bonds that are classified as available-for-sale in accordance with FASB ASC &lt;em style="font: inherit;"&gt;320,&lt;/em&gt; &lt;i&gt;Investments&lt;/i&gt;&#x2014;&lt;i&gt;Debt and Equity Securities&lt;/i&gt;. The Company classifies investments available to fund current operations as current assets on its balance sheets.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Available-for-sale investments are recorded at fair value, with unrealized gains or losses included in accumulated other comprehensive income (loss) on the Company&#x2019;s balance sheets. Realized gains and losses are determined using the specific identification method and are included as a component of other income (expense).&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company reviews investments for other-than-temporary impairment whenever the fair value of an investment is less than the amortized cost and evidence indicates that an investment&#x2019;s carrying amount is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; recoverable within a reasonable period of time. To determine whether an impairment is other-than temporary, the Company considers its intent to sell, or whether it is more likely than &lt;em style="font: inherit;"&gt;not&lt;/em&gt; that the Company will be required to sell the investment before recovery of the investment&#x2019;s amortized cost basis. Evidence considered in this assessment includes reasons for the impairment, the severity and the duration of the impairment, and changes in value subsequent to period end.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="d_2022-01-01_2022-12-31" id="c96258225">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Concentration of Credit Risk and Off-Balance Sheet Risk&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company has &lt;em style="font: inherit;"&gt;no&lt;/em&gt; financial instruments with off&#x2011;balance sheet risk such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Financial instruments that subject Pieris to concentrations of credit risk include cash and cash equivalents, investments, and accounts receivable. The Company&#x2019;s cash, cash equivalents, and investments are held in accounts with financial institutions that management believes are creditworthy. The Company&#x2019;s investment policy includes guidelines on the quality of the institutions and financial instruments and defines allowable investments that the Company believes minimizes the exposure to concentration of credit risk. The Company has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; experienced any credit losses in such accounts and does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; believe it is exposed to any significant credit risk on these funds. Accounts receivable primarily consist of amounts due under strategic partnership and other license agreements with major multi-national pharmaceutical companies for which the Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; obtain collateral.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="d_2022-01-01_2022-12-31" id="c96259154">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Fair Value Measurement&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. FASB ASC Topic &lt;em style="font: inherit;"&gt;820,&lt;/em&gt; &lt;i&gt;Fair Value Measurement and Disclosures&lt;/i&gt;, or ASC &lt;em style="font: inherit;"&gt;820,&lt;/em&gt; established a hierarchy of inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the financial instrument based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the inputs that market participants would use in pricing the financial instrument and are developed based on the best information available in the circumstances. The fair value hierarchy applies only to the valuation inputs used in determining the reported or disclosed fair value of the financial instruments and is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; a measure of the investment credit quality. Fair value measurements are classified and disclosed in &lt;em style="font: inherit;"&gt;one&lt;/em&gt; of the following &lt;em style="font: inherit;"&gt;three&lt;/em&gt; categories:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:top;width:18pt;"&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#x2022;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:top;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Level &lt;em style="font: inherit;"&gt;1&lt;/em&gt; inputs are quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:top;width:18pt;"&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#x2022;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:top;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Level &lt;em style="font: inherit;"&gt;2&lt;/em&gt; utilizes quoted market prices in markets that are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; active, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:top;width:18pt;"&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#x2022;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:top;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Level &lt;em style="font: inherit;"&gt;3&lt;/em&gt; inputs are unobservable inputs for the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level &lt;em style="font: inherit;"&gt;3.&lt;/em&gt; A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Financial instruments measured at fair value on a recurring basis include cash equivalents and investments, if any (&lt;i&gt;Note &lt;em style="font: inherit;"&gt;6&lt;/em&gt;&lt;/i&gt;).&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;An entity &lt;em style="font: inherit;"&gt; may &lt;/em&gt;elect to measure many financial instruments and certain other items at fair value at specified election dates. Subsequent unrealized gains and losses on items for which the fair value option has been elected will be reported in net loss. The Company did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; elect to measure any additional financial instruments or other items at fair value.&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="d_2022-01-01_2022-12-31" id="c96259277">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Fair Values of Financial Instruments&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The fair value of cash, accounts receivable, and accounts payable approximates the carrying value of these financial instruments because of the short-term nature of any maturities. The Company determines the estimated fair values of other financial instruments, using available market information and valuation methodologies, primarily input from independent &lt;em style="font: inherit;"&gt;third&lt;/em&gt; party pricing sources.&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="d_2022-01-01_2022-12-31" id="c96259576">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Accounts Receivable&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Accounts receivable are recorded net of allowances for doubtful accounts and represent amounts due from strategic partners. The Company monitors and evaluates collectability of receivables on an ongoing basis and considers whether an allowance for doubtful accounts is necessary. The Company determined that &lt;em style="font: inherit;"&gt;no&lt;/em&gt; such reserve is needed as of &lt;em style="font: inherit;"&gt; December 31, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021&lt;/em&gt;. Historically, Pieris has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; had collectability issues.&lt;/p&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="d_2022-01-01_2022-12-31" id="c96259857">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Property and Equipment&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Property and equipment are recorded at acquisition cost, less accumulated depreciation and impairment. Depreciation on property and equipment is calculated using the straight-line method over the remaining estimated useful lives of the assets. Maintenance and repairs to these assets are charged to expenses as occurred. Substantially all of the Company's fixed assets are located in Germany. The estimated useful life of the different groups of property and equipment is as follows:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;Asset Classification&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 43%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Estimated useful life (in years)&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Leasehold improvements&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 43%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;shorter of useful life or remaining life of the lease&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Laboratory furniture and equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 43%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;8-14&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Office furniture and equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 43%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;5-13&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Computer and equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 43%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;3 - 7&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <pirs:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2344185">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;Asset Classification&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 43%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Estimated useful life (in years)&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Leasehold improvements&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 43%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;shorter of useful life or remaining life of the lease&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Laboratory furniture and equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 43%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;8-14&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Office furniture and equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 43%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;5-13&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Computer and equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 43%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;3 - 7&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;</pirs:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="d_2022-01-01_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember_RangeAxis-MinimumMember"
      id="c96253730">P8Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="d_2022-01-01_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember_RangeAxis-MaximumMember"
      id="c96253732">P14Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="d_2022-01-01_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-OfficeEquipmentMember_RangeAxis-MinimumMember"
      id="c96253733">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="d_2022-01-01_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-OfficeEquipmentMember_RangeAxis-MaximumMember"
      id="c96253735">P13Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="d_2022-01-01_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember_RangeAxis-MinimumMember"
      id="c96253736">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="d_2022-01-01_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember_RangeAxis-MaximumMember"
      id="c96253738">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="d_2022-01-01_2022-12-31" id="c96259863">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Impairment of Long-lived Assets&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company reviews its long-lived assets to be held and used for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; be fully recoverable. The Company evaluates the realizability of its long-lived assets based on profitability and cash flow expectations for the related asset. Any write-downs are treated as permanent reductions in the carrying amount of the assets. The Company believes that, as of each of the balance sheets presented, &lt;em style="font: inherit;"&gt;none&lt;/em&gt; of the Company&#x2019;s long-lived assets were impaired.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="d_2022-01-01_2022-12-31" id="c96259865">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Revenue Recognition&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;Pieris has entered into several licensing agreements with collaboration partners for the development of Anticalin therapeutics against a variety of targets. The terms of these agreements provide for the transfer of multiple goods or services which&#160;&lt;i&gt;&lt;em style="font: inherit;"&gt; may&lt;/em&gt;&lt;/i&gt;&#160;include: (i)&#160;licenses, or options to obtain licenses, to Pieris&#x2019; Anticalin technology and/or specific programs and (ii)&#160;research and development activities to be performed on behalf of or with a collaborative partner. Payments to Pieris under these agreements&#160;&lt;i&gt;&lt;em style="font: inherit;"&gt; may&lt;/em&gt;&lt;/i&gt;&#160;include upfront fees (which include license and option fees), payments for research and development activities, payments based upon the achievement of certain milestones, and royalties on product sales. There are&#160;&lt;i&gt;&lt;em style="font: inherit;"&gt;no&lt;/em&gt;&lt;/i&gt;&#160;performance, cancellation, termination or refund provisions in any of the arrangements that could result in material financial consequences to Pieris. As the Company's intellectual property assets are considered to be located in Germany, the Company records all consolidated revenue in its subsidiary, Pieris Pharmaceuticals, GmbH.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Collaborative Arrangements&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company considers the nature and contractual terms of an arrangement and assess whether the arrangement involves a joint operating activity pursuant to which it is an active participant and exposed to significant risks and rewards with respect to the arrangement. If the Company is an active participant and exposed to the significant risks and rewards with respect to the arrangement, it accounts for these arrangements pursuant to ASC &lt;em style="font: inherit;"&gt;808,&lt;/em&gt; &lt;i&gt;Collaborative Arrangements&lt;/i&gt;, or ASC &lt;em style="font: inherit;"&gt;808,&lt;/em&gt; and applies a systematic and rational approach to recognize revenue. The Company classifies payments received as revenue and payments made as a reduction of revenue in the period in which they are earned. Revenue recognized under a collaborative arrangement involving a participant that is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; a customer is presented as Collaboration Revenue in the Statement of Operations.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;In accordance with ASC &lt;em style="font: inherit;"&gt;606,&lt;/em&gt; revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled in exchange for these goods and services. To achieve this core principle, the Company applies the following &lt;em style="font: inherit;"&gt;five&lt;/em&gt; steps: &lt;em style="font: inherit;"&gt;1&lt;/em&gt;) identify the customer contract; &lt;em style="font: inherit;"&gt;2&lt;/em&gt;) identify the contract&#x2019;s performance obligations; &lt;em style="font: inherit;"&gt;3&lt;/em&gt;) determine the transaction price; &lt;em style="font: inherit;"&gt;4&lt;/em&gt;) allocate the transaction price to the performance obligations; and &lt;em style="font: inherit;"&gt;5&lt;/em&gt;) recognize revenue when or as a performance obligation is satisfied.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company evaluates all promised goods and services within a customer contract and determines which of such goods and services are separate performance obligations. This evaluation includes an assessment of whether the good or service is capable of being distinct and whether the good or service is separable from other promises in the contract. &#160;In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property and the capabilities of the customer to develop the intellectual property on their own or whether the required expertise is readily available.&lt;/p&gt;

   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Licensing arrangements are analyzed to determine whether the promised goods or services, which often include licenses, research and development services and governance committee services, are distinct or whether they must be accounted for as part of a combined performance obligation. If the license is considered &lt;em style="font: inherit;"&gt;not&lt;/em&gt; to be distinct, the license would then be combined with other promised goods or services as a combined performance obligation. If the Company is involved in a governance committee, it assesses whether its involvement constitutes a separate performance obligation. When governance committee services are determined to be separate performance obligations, the Company determines the fair value to be allocated to this promised service.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Certain contracts contain optional and additional items, which are considered marketing offers and are accounted for as separate contracts with the customer if such option is elected by the customer, unless the option provides a material right which would &lt;em style="font: inherit;"&gt;not&lt;/em&gt; be provided without entering into the contract.&#160;&#160;An option that is considered a material right is accounted for as a separate performance obligation.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The transaction price is determined based on the consideration to which the Company will be entitled in exchange for transferring goods and services to the customer. A contract &lt;em style="font: inherit;"&gt; may &lt;/em&gt;contain variable consideration, including potential payments for both milestone and research and development services. For certain potential milestone payments, the Company estimates the amount of variable consideration by using the most likely amount method. In making this assessment, the Company evaluates factors such as the clinical, regulatory, commercial and other risks that must be overcome to achieve the milestone. Each reporting period the Company re-evaluates the probability of achievement of such variable consideration and any related constraints. Pieris will include variable consideration, without constraint, in the transaction price to the extent it is probable that a significant reversal in the amount of cumulative revenue recognized will &lt;em style="font: inherit;"&gt;not&lt;/em&gt; occur when the uncertainty associated with the variable consideration is subsequently resolved. For potential research and development service payments, the Company estimates the amount of variable consideration by using the expected value method, including any approved budget updates arising from additional research or development services.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price among the performance obligations on a relative standalone selling price basis unless a portion of the transaction price is variable and meets the criteria to be allocated entirely to a performance obligation or to a distinct good or service that forms part of a single performance obligation.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company allocates the transaction price based on the estimated standalone selling price of the underlying performance obligations or in the case of certain variable consideration to &lt;em style="font: inherit;"&gt;one&lt;/em&gt; or more performance obligations. The Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company utilizes key assumptions to determine the stand-alone selling price, which &lt;em style="font: inherit;"&gt; may &lt;/em&gt;include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs to complete the respective performance obligation. Certain variable consideration is allocated specifically to &lt;em style="font: inherit;"&gt;one&lt;/em&gt; or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated to each performance obligation are consistent with the amount the Company would expect to receive for each performance obligation.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;When a performance obligation is satisfied, revenue is recognized for the amount of the transaction price, excluding estimates of variable consideration that are constrained, that is allocated to that performance obligation on a relative standalone selling price basis. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations under an arrangement.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;For performance obligations consisting of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non- refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Revenue recognized under an arrangement involving a participant that is a customer is presented as Customer Revenue.&lt;/p&gt;

   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Milestones and Royalties&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company aggregates milestones into &lt;em style="font: inherit;"&gt;four&lt;/em&gt; categories (i) research milestones, (ii) development milestones, (iii) commercial milestones and (iv) sales milestones. Research milestones are typically achieved upon reaching certain success criteria as defined in each agreement related to developing an Anticalin protein against the specified target. Development milestones are typically reached when a compound reaches a defined phase of clinical research or passes such phase, or upon gaining regulatory approvals. Commercial milestones are typically achieved when an approved pharmaceutical product reaches the status for commercial sale, including regulatory approval. Sales milestones are certain defined levels of net sales by the licensee, such as when a product &lt;em style="font: inherit;"&gt;first&lt;/em&gt; achieves global sales or annual sales of a specified amount.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;There is uncertainty that the events to obtain the research and development milestones will be achieved given the nature of clinical development and the stage of the Company&#x2019;s technology. The Company has thus determined that all research and development milestones will be constrained until it is deemed probable that a significant revenue reversal will &lt;em style="font: inherit;"&gt;not&lt;/em&gt; occur. For revenues from research and development milestones, payments will be recognized consistent with the recognition pattern of the performance obligation to which they relate.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&#160;Commercial milestones and sales royalties are determined by sales or usage-based thresholds and will be accounted for under the royalty recognition constraint as constrained variable consideration.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company calculates the maximum amount of potential milestones achievable under each collaboration agreement and discloses such potential future milestones for all current collaborations using such a maximum calculation.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Contract Balances&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company recognizes a contract asset when the Company transfers goods or services to a customer before the customer pays consideration or before payment is due, excluding any amounts presented as a receivable (i.e., accounts receivable). A contract asset is an entity&#x2019;s right to consideration in exchange for goods or services that the entity has transferred to a customer. The contract liabilities (i.e., deferred revenue) primarily relate to contracts where the Company has received payment but has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; yet satisfied the related performance obligations.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;In the event of an early termination of a collaboration agreement, any contract liabilities would be recognized in the period in which all Company obligations under the agreement have been fulfilled.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Costs to Obtain and Fulfill a Contract with a Customer&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Certain costs to obtain customer contracts, including success-based fees paid to &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party service providers, and costs to fulfill customer contracts are capitalized in accordance with FASB ASC &lt;em style="font: inherit;"&gt;340,&lt;/em&gt; &lt;i&gt;Other Assets and Deferred Costs&lt;/i&gt;, or ASC &lt;em style="font: inherit;"&gt;340.&lt;/em&gt; These costs are amortized to expense on a systemic basis that is consistent with the transfer to the customer of the goods or services to which the asset relates. The Company will expense the amortization of costs to obtain customer contracts to general and administrative expense and costs to fulfill customer contracts to research and development expense.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="d_2022-01-01_2022-12-31" id="c96259866">&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Research and Development&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Research and development expenses are charged to the statement of operations as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including salaries and benefits, facilities costs, pre-clinical and clinical costs, contract services, consulting, depreciation and amortization expense, and other related costs. Costs associated with acquired technology, in the form of upfront fees or milestone payments, are charged to research and development expense as incurred.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="d_2022-01-01_2022-12-31" id="c96259868">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Income Taxes&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company applies ASC Topic &lt;em style="font: inherit;"&gt;740&lt;/em&gt; &lt;i&gt;Income Taxes&lt;/i&gt;, which established financial accounting and reporting requirements for the effects of income taxes that result from the Company&#x2019;s activities during the current and preceding years. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and operating losses and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted statutory tax rates expected to apply to taxable income in the jurisdictions and years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Where the Company determines that it is more likely than &lt;em style="font: inherit;"&gt;not&lt;/em&gt; that some portion or all of the deferred tax assets will &lt;em style="font: inherit;"&gt;not&lt;/em&gt; be realized in the future, the deferred tax assets are reduced by a valuation allowance. The Company records interest and penalties related to uncertain tax positions as part of income tax expense.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Tax Cuts and Jobs Act&#160;(TCJA) subjects a U.S. shareholder to tax on global-intangible low tax income (GILTI) earned by certain foreign subsidiaries. The Company has made an accounting policy election to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="d_2022-01-01_2022-12-31" id="c96259869">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Stock-based Compensation&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company measures share-based payments in accordance with ASC Topic &lt;em style="font: inherit;"&gt;718,&lt;/em&gt; &lt;i&gt;Stock Compensation&lt;/i&gt;. Pieris records its stock-based compensation expense over the requisite service period and records forfeitures as they occur. Determining the appropriate fair value model and related assumptions requires judgment, including estimating share price volatility and expected terms of the awards. For employee options, the fair value measurement date is generally on the date of grant and the related compensation expense is recognized on a straight-line basis over the requisite service period of the awards, less expense for actual forfeitures.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company uses the Black-Scholes option pricing model to determine the estimated fair value for stock-based awards. Option-pricing models require the input of various subjective assumptions, including the option&#x2019;s expected life, expected dividend yield, price volatility, risk free interest rate and forfeitures of the underlying stock. Due to the limited operating history of the Company as a public entity and a lack of company specific historical and implied volatility data, the Company has based its estimate of expected volatility on the historical volatility of a group of similar companies that are publicly traded. When selecting these public companies on which it has based its expected stock price volatility, the Company selected companies with comparable characteristics to it, including enterprise value, risk profiles, position within the industry, and with historical share price information sufficient to meet the expected term of the stock-based awards. The Company computes historical volatility data using the daily closing prices for the selected companies&#x2019; shares during the equivalent period of the calculated expected term of the stock-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Due to the lack of Company specific historical option activity, the Company has estimated the expected term of its employee stock options using the &#x201c;simplified&#x201d; method, whereby, the expected term equals the arithmetic average of the vesting term and the original contractual term of the option. The expected term for non-employee awards is the remaining contractual term of the option. The risk-free interest rates are based on the U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The Company has never paid, and does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; expect to pay dividends in the foreseeable future.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;All excess tax benefits and tax deficiencies are recorded as income tax expense or benefit in the Company's statement of operations and comprehensive loss. For the years ended&#160;&lt;em style="font: inherit;"&gt; December 31, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021&lt;/em&gt;, the Company did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; record an income statement benefit for excess tax benefits as a valuation allowance is also required on these amounts.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:GovernmentAssistancePolicyTextBlock contextRef="d_2022-01-01_2022-12-31" id="c96259870">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Government Grants&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company recognizes grants from governmental agencies when there is reasonable assurance that the Company will comply with the conditions attached to the grant arrangement and the grant will be received. The Company evaluates the conditions of each grant as of each reporting period to evaluate whether the Company has reached reasonable assurance of meeting the conditions of each grant arrangement and that it is expected that the grant will be received as a result of meeting the necessary conditions. Grants are recognized in the consolidated statements of operations on a systematic basis over the periods in which the Company recognizes the related costs for which the government grant is intended to compensate. Specifically, grant income related to research and development costs is recognized as such expenses are incurred. Grant income is included as a separate caption within Other income (expense), net in the consolidated statements of operations.&lt;/p&gt;</us-gaap:GovernmentAssistancePolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="d_2022-01-01_2022-12-31" id="c96259871">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Leases&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company accounts for leases pursuant to ASC &lt;em style="font: inherit;"&gt;842&lt;/em&gt; &lt;i&gt;Leases (Topic &lt;em style="font: inherit;"&gt;842&lt;/em&gt;)&lt;/i&gt;, or ASC &lt;em style="font: inherit;"&gt;842.&lt;/em&gt; As a lessee, the Company is required to recognize (i) a lease liability, which is a lessees obligation to make lease payments arising from a lease, measured on a discounted basis; and (ii) a right-of-use asset, which is an asset that represents the lessee&#x2019;s right to use, or control the use of, a specified asset for the lease term for all leases (with the exception of short-term leases) at the commencement date.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company determines if an arrangement is a lease at inception. The Company&#x2019;s contracts are determined to contain a lease within the scope of ASC &lt;em style="font: inherit;"&gt;842&lt;/em&gt; when all of the following criteria based on the specific circumstances of the arrangement are met: (&lt;em style="font: inherit;"&gt;1&lt;/em&gt;) there is an identified asset for which there are &lt;em style="font: inherit;"&gt;no&lt;/em&gt; substantive substitution rights; (&lt;em style="font: inherit;"&gt;2&lt;/em&gt;) the Company has the right to obtain substantially all of the economic benefits from the identified asset; and (&lt;em style="font: inherit;"&gt;3&lt;/em&gt;) the Company has the right to direct the use of the identified asset. In addition, the Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; apply the recognition requirements in the lease standard to short-term leases (a lease that at commencement date has a lease term of &lt;em style="font: inherit;"&gt;12&lt;/em&gt; months or less and does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; contain a purchase option that it is reasonably certain to exercise) and does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; separate lease and non-lease components for all asset classes. Any variable components of lease costs are excluded from lease payments and are recognized in the period incurred, including increases to rent based on German Consumer Price Index , or CPI.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;At the commencement date, operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of future lease payments over the expected lease term. The Company&#x2019;s lease agreements do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; provide an implicit rate. As a result, the Company utilizes an estimated incremental borrowing rate to discount lease payments, which is based on the rate of interest the Company would have to pay to borrow a similar amount on a collateralized basis over a similar term and based on observable market data points. Certain adjustments to the right-of-use asset &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be required for items such as initial direct costs paid or lease incentives received. Operating lease cost is recognized over the expected term on a straight-line basis.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company typically only includes an initial lease term in its assessment of a lease agreement. Options to renew a lease are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; included in the Company&#x2019;s assessment unless there is reasonable certainty that the Company will renew. The expected lease term includes noncancelable lease periods and, when applicable, periods covered by an option to extend the lease if the Company is reasonably certain to exercise that option, as well as periods covered by an option to terminate the lease if the Company is reasonably certain &lt;em style="font: inherit;"&gt;not&lt;/em&gt; to exercise that option.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Assumptions made by the Company at the commencement date are re-evaluated upon occurrence of certain events, including a lease modification. A lease modification results in a separate contract when the modification grants the lessee an additional right of use &lt;em style="font: inherit;"&gt;not&lt;/em&gt; included in the original lease and when lease payments increase commensurate with the standalone price for the additional right of use. When a lease modification results in a separate contract, it is accounted for in the same manner as a new lease.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="d_2022-01-01_2022-12-31" id="c96259873">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Contingencies&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Accruals are recorded for loss contingencies when it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. The Company evaluates, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously. Considering facts known at the time of the assessment, the Company determines whether potential losses are considered reasonably possible or probable and whether they are estimable. Based upon this assessment, the Company carries out an evaluation of disclosure requirements and considers possible accruals in the financial statements.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="d_2022-01-01_2022-12-31" id="c96260122">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Segment Reporting&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Operating segments are identified as components of an enterprise where separate discrete financial information is evaluated by the chief operating decision maker in making decisions on how to allocate resources and assess performance. The Company operates as a single segment dedicated to the discovery and development of biotechnological applications and the Company&#x2019;s chief operating decision maker, or CODM, makes decisions based on the Company as a whole. The Company has determined that its CODM is its Chief Executive Officer.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="d_2022-01-01_2022-12-31" id="c96260123">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Earnings per Share&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Basic earnings per share attributable to common stockholders is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period, without consideration for common stock equivalents.&lt;/p&gt;

   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Diluted earnings per share attributable to common stockholders is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share attributable to common stockholders' calculation, preferred stock, stock options, unvested restricted stock, and warrants are considered to be common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to common stockholders, as their effect would be anti-dilutive for all periods presented. Therefore, basic and diluted net loss per share were the same for all periods presented.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="d_2022-01-01_2022-12-31" id="c96260124">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Recent Accounting Pronouncements &lt;em style="font: inherit;"&gt;Not&lt;/em&gt; Yet Adopted&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;In &lt;em style="font: inherit;"&gt; June 2016, &lt;/em&gt;the FASB issued ASU &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13,&lt;/em&gt; &lt;i&gt;Financial Instruments - Credit Losses&lt;/i&gt; &lt;i&gt;(Topic &lt;em style="font: inherit;"&gt;326&lt;/em&gt;): Measurement of Credit Losses on Financial Statements, &lt;/i&gt;or ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13.&lt;/em&gt; ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13&lt;/em&gt; significantly changes the impairment model for most financial assets and certain other instruments. The new standard requires that expected credit losses relating to financial assets measured on an amortized cost basis and available-for-sale debt securities be recorded through an allowance for credit losses. It also limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value, and requires the reversal of previously recognized credit losses if fair value increases. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Subsequently, in &lt;em style="font: inherit;"&gt; November 2018, &lt;/em&gt;the FASB issued ASU &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;2018&lt;/em&gt;-&lt;em style="font: inherit;"&gt;19,&lt;/em&gt; &lt;i&gt;Codification Improvements to Topic &lt;em style="font: inherit;"&gt;326,&lt;/em&gt; Financial Instruments-Credit Losses&lt;/i&gt;, which clarifies codification and corrects unintended application of the guidance. In &lt;em style="font: inherit;"&gt; November 2019, &lt;/em&gt;the FASB issued ASU &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;2019&lt;/em&gt;-&lt;em style="font: inherit;"&gt;11,&lt;/em&gt; &lt;i&gt;Codification Improvements to Topic &lt;em style="font: inherit;"&gt;326,&lt;/em&gt; Financial Instruments-Credit Losses&lt;/i&gt;, which clarifies or addresses specific issues about certain aspects of ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13.&lt;/em&gt; In &lt;em style="font: inherit;"&gt; November 2019 &lt;/em&gt;the FASB also issued ASU &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;2019&lt;/em&gt;-&lt;em style="font: inherit;"&gt;10,&lt;/em&gt; &lt;i&gt;Financial Instruments-Credit Losses (Topic &lt;em style="font: inherit;"&gt;326&lt;/em&gt;), Derivatives and Hedging (Topic &lt;em style="font: inherit;"&gt;815&lt;/em&gt;), and Leases (Topic &lt;em style="font: inherit;"&gt;842&lt;/em&gt;): Effective Dates&lt;/i&gt;, which delays the effective date of ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13&lt;/em&gt; by &lt;em style="font: inherit;"&gt;three&lt;/em&gt; years for certain smaller reporting companies such as the Company. The guidance in ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13&lt;/em&gt; is effective for the Company for financial statements issued for fiscal years beginning after &lt;em style="font: inherit;"&gt; December 15, 2022 &lt;/em&gt;and interim periods within those fiscal years, with early adoption permitted. The Company expects that adoption of this standard will &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have a material impact on its financial statements.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company has considered other recent accounting pronouncements and concluded that they are either &lt;em style="font: inherit;"&gt;not&lt;/em&gt; applicable to the business, or that the effect is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; expected to be material to the unaudited consolidated financial statements as a result of future adoption.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2344186">
    &#xfeff;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 27pt;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;3.&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;Revenue&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;General&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; generated revenue from product sales. The Company has generated revenue from contracts with customers (option,&#160;license and collaboration agreements), which include upfront payments for licenses or options to obtain licenses, payments for research and development services and milestone payments.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;During the years ended &lt;em style="font: inherit;"&gt; December 31, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021&lt;/em&gt;, respectively, the Company recognized revenue from the following strategic partnerships and other license agreements (in thousands):&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Year Ended December 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;AstraZeneca&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;9,117&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;18,919&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Seagen&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;8,287&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;768&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Servier&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;5,359&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;4,070&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Genentech&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;3,139&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1,950&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Boston Pharmaceuticals&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;5,711&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;&lt;b&gt;Total Revenue&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;25,902&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;31,418&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Under the Company&#xb4;s existing strategic partnerships and other license agreements, the Company could receive the following potential milestone payments (in millions) as of &lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt;:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Research, Development, Regulatory &amp;amp; Commercial Milestones&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Sales Milestones&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;AstraZeneca&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;702&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,925&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Servier&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;20&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Seagen&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;759&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;450&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Boston Pharmaceuticals&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;88&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;265&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Genentech&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;834&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;600&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;&lt;b&gt;Total potential milestone payments&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,403&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;5,240&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Strategic Partnerships &lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;&lt;span style="text-decoration: underline; "&gt;Genentech&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;On &lt;em style="font: inherit;"&gt; May 19, 2021, &lt;/em&gt;the Company and Genentech, Inc., or Genentech, entered into a Research Collaboration and License Agreement, or the Genentech Agreement, to discover, develop and commercialize locally delivered respiratory and ophthalmology therapies that leverage the Company&#x2019;s proprietary Anticalin technology. Upon signing the Genentech Agreement, Genentech paid the Company a $20&#160;million upfront fee. In addition, the Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be eligible to receive additional milestone payments across multiple programs, as well as tiered royalty payments on net sales at percentages ranging from the mid-single to low double-digits, subject to certain standard reductions and offsets.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Under the terms of the Genentech Agreement, the Company will be responsible for discovery and preclinical development of &lt;span style="-sec-ix-hidden:c96253743"&gt;two&lt;/span&gt; initial programs. The Company will be responsible for research activities following target nomination through the late-stage research go decision. The parties will then collaborate on drug candidate characterization until the development go decision. After the development go decision, Genentech will be responsible for pursuing the preclinical and clinical development of each program, and thereafter, the commercialization efforts. Each party will be responsible for the costs incurred to perform their respective responsibilities. Genentech has an option to expand the collaboration to encompass &lt;span style="-sec-ix-hidden:c96253744"&gt;two&lt;/span&gt; additional programs with the payment of a $10&#160;million fee per additional program. If Genentech exercises its option to start additional programs, payment to the Company of additional fees, milestone payments and royalties would result.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Unless earlier terminated, the term of the Genentech Agreement continues until &lt;em style="font: inherit;"&gt;no&lt;/em&gt; royalty or other payment obligations are or will become due under the Genentech Agreement. The Genentech Agreement &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be terminated (i) by either party based on insolvency or breach by the other party and such insolvency proceeding is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; dismissed or such breach is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; cured within 90 days; or (ii) after &lt;em style="font: inherit;"&gt;9&lt;/em&gt; months from the effective date of the Genentech Agreement, by Genentech as a whole or on a product-by-product and/or country-by-country basis upon 90 days prior written notice before the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; commercial sale of a product or upon 180 days prior written notice after the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; commercial sale of a product.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;While the Genentech Agreement allows for up to four research programs, only two research programs are initially identified and committed in the Genentech Agreement. To reach a total of up to four research programs, the Company has granted Genentech options to nominate an additional two collaboration targets of their choosing, subject to the legal availability of the target to be researched. Genentech will have &lt;span style="-sec-ix-hidden:c96253759"&gt;three&lt;/span&gt; years after the effective date to nominate the subsequent targets. The Company has also granted Genentech options to replace any of the collaboration targets identified with another target. However, at &lt;em style="font: inherit;"&gt;no&lt;/em&gt; point will there be more than four identified collaboration targets for which there are ongoing research programs.&lt;/p&gt;

   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The arrangement with Genentech provides for the transfer of the following goods or services: (i) exclusive research and commercial license for the collaboration programs, (ii) a non-exclusive platform improvement license, (iii) research and development services, (iv)&#160;participation in a governance committee, and (v)&#160;replacement target options on the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; two programs upon a screening failure which were assessed as material rights.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Management evaluated all of the promised goods or services within the contract and determined which such goods and services were separate performance obligations. The Company determined that the licenses granted, at arrangement inception, should be combined with the research and development services to be provided for the related target programs as they are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; capable of being distinct. A &lt;em style="font: inherit;"&gt;third&lt;/em&gt; party would &lt;em style="font: inherit;"&gt;not&lt;/em&gt; be able to provide the research and development services due to the specific nature of the intellectual property and knowledge required to perform the services, and Genentech could &lt;em style="font: inherit;"&gt;not&lt;/em&gt; benefit from the licenses without the corresponding services. The Company determined that the participation in the governance committees was distinct as the services could be performed by an outside party.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;As a result, management concluded there were five separate performance obligations at the inception of the Genentech Agreement: (i)&#160;two combined performance obligations, each comprised of an exclusive research and commercial license, a non-exclusive platform improvement license, and research and development services for the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; two Genentech programs, (ii) two performance obligations each comprised of a material right for a target swap option for the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; two Genentech programs, and (iii) one performance obligation comprised of the participation on the governance committee.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company allocated consideration to the performance obligations based on the relative proportion of their standalone selling prices. The Company developed standalone selling prices for licenses by applying a risk adjusted, net present value, estimate of future potential cash flows approach, which included the cost of obtaining research and development services at arm&#x2019;s length from a &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party provider, as well as internal full-time equivalent costs to support these services. The Company developed the standalone selling price for committee participation by using management&#x2019;s estimate of the anticipated participation hours multiplied by a market rate for comparable participants.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The transaction price at inception is comprised of fixed consideration of $20.0&#160;million in upfront fees and was allocated to each of the performance obligations based on the relative proportion of their standalone selling prices. The amounts allocated to the performance obligations for the two research programs will be recognized on a proportional performance basis through the completion of each respective estimated research term of the individual research programs. The amounts allocated to the material right for the target options will be recognized either at the time the material right expires or, if exercised, on a proportional performance basis over the estimated research term for that program along with any remaining deferred revenue associated with the replacement target. The amounts allocated to the participation on the committee will be recognized on a straight-line basis over the anticipated research term for all research programs. As of &lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt;, there was $12.6&#160;million of aggregate transaction price allocated to remaining performance obligations.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Under the Genentech Agreement, the Company is eligible to receive various research, development, commercial and sales milestones. There is uncertainty that the events to obtain the research and development milestones will be achieved given the nature of clinical development and the stage of the Company&#x2019;s technology. The Company has determined that all other research and development milestones will be constrained until it is deemed probable that a significant revenue reversal will &lt;em style="font: inherit;"&gt;not&lt;/em&gt; occur.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;As of &lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt;, there were $7.8&#160;million and $4.8&#160;million of current and non-current deferred revenue, respectively, related to the Genentech Agreement.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;&lt;span style="text-decoration: underline; "&gt;Boston Pharmaceuticals&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;On &lt;em style="font: inherit;"&gt; April 24, 2021, &lt;/em&gt;the Company and BP Asset XII, Inc., or Boston Pharmaceuticals, a subsidiary of Boston Pharma Holdings, LLC, entered into an Exclusive Product License Agreement, or the BP Agreement, to develop PRS-&lt;em style="font: inherit;"&gt;342,&lt;/em&gt; a &lt;em style="font: inherit;"&gt;4&lt;/em&gt;-&lt;em style="font: inherit;"&gt;1BB/GPC3&lt;/em&gt; preclinical immuno-oncology Anticalin-antibody bispecific fusion protein.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Under the terms of the BP Agreement, Boston Pharmaceuticals exclusively licensed worldwide rights to PRS-&lt;em style="font: inherit;"&gt;342.&lt;/em&gt; The Company received an upfront payment of $10.0&#160;million and is further entitled to receive development, regulatory and sales-based milestone payments, tiered royalties up to low double-digits on sales of PRS-&lt;em style="font: inherit;"&gt;342&lt;/em&gt; and a percentage of consideration received by Boston Pharmaceuticals in the event of a sublicense of a program licensed under the BP Agreement or a change of control of Boston Pharmaceuticals. The Company will also contribute up to $4.0&#160;million toward manufacturing activities.&lt;/p&gt;

   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The term of the BP Agreement ends upon the expiration of all of Boston Pharmaceuticals&#x2019; payment obligations thereunder. The BP Agreement &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be terminated by Boston Pharmaceuticals in its entirety for convenience beginning &lt;span style="-sec-ix-hidden:c96253792"&gt;nine&lt;/span&gt; months after its effective date upon 60 days&#x2019; notice or, for any program under the BP Agreement which has received marketing approval, upon 120 days&#x2019; notice. If any program is terminated by Boston Pharmaceuticals, the Company will have full rights to continue such program. The BP Agreement &lt;em style="font: inherit;"&gt; may &lt;/em&gt;also be terminated by Boston Pharmaceuticals or the Company for an uncured material breach by the other party upon 180 days&#x2019; notice (60 days in the case of non-payment of undisputed amounts due and payable), subject to extension for an additional 180 days in certain cases and subject, in all cases, to dispute resolution procedures. The Agreement &lt;em style="font: inherit;"&gt; may &lt;/em&gt;also be terminated due to the other party&#x2019;s insolvency. The Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;also terminate the BP Agreement if Boston Pharmaceuticals challenges the validity of any patents licensed under the BP Agreement, subject to certain exceptions.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have any obligations to assist in the research and development efforts of Boston Pharmaceuticals under the BP Agreement. However, the Company has an obligation to fund up to $4.0&#160;million in costs, including out-of-pocket costs incurred by Boston Pharmaceuticals, in connection with the manufacture of products under the BP Agreement.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The arrangement with Boston Pharmaceuticals provides for the transfer of the following: (i)&#160;exclusive license of PRS-&lt;em style="font: inherit;"&gt;342,&lt;/em&gt; (ii)&#160;non-exclusive Pieris platform license, (iii)&#160;initial know-how, (iv)&#160;product cell line license, and (v) materials (as each such term is defined under the BP Agreement).&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;Management evaluated all of the promised goods or services within the BP Agreement and determined which such goods and services were separate performance obligations. The Company determined that the licenses granted, at arrangement inception, should be combined with the transfer of know-how, materials and the product cell line license. Boston Pharmaceuticals could &lt;em style="font: inherit;"&gt;not&lt;/em&gt; benefit from the exclusive and non-exclusive licenses without the corresponding transfer of know-how and materials.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;As a result, management concluded there was only &lt;em style="font: inherit;"&gt;one&lt;/em&gt; combined performance obligation. The transaction price at inception is comprised of fixed consideration of $10.0&#160;million in upfront fees, offset by $4.0&#160;million in consideration payable to Boston Pharmaceuticals to reimburse them for expected out-of-pocket manufacturing costs, for a total transaction price of $6.0&#160;million. Management has assessed the forms of variable consideration within the BP Agreement and concluded that the payments are either constrained by the royalty recognition constraint or because management has assessed the most likely amount associated with the payments as zero.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The amounts allocated to the performance obligations did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; meet the criteria to be recognized over time on a proportional performance basis and thus will be recognized at a point in time. The Company determined that the performance obligation will be fully satisfied when all of the deliverables in the combined performance obligation are transferred to Boston Pharmaceuticals as that is the point at which Boston Pharmaceuticals can fully use and benefit from the license to PRS-&lt;em style="font: inherit;"&gt;342.&lt;/em&gt; The Company transferred all such deliverables to Boston Pharmaceuticals in the &lt;em style="font: inherit;"&gt;fourth&lt;/em&gt; quarter of &lt;em style="font: inherit;"&gt;2021.&lt;/em&gt; As of &lt;em style="font: inherit;"&gt; December 31, 2021, &lt;/em&gt;the Company had recognized the full transaction price, or $5.7&#160;million, as revenue and there is &lt;em style="font: inherit;"&gt;no&lt;/em&gt; remaining deferred revenue.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;&lt;span style="text-decoration: underline; "&gt;Seagen&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#xfeff;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;On &lt;em style="font: inherit;"&gt; February 8, 2018, &lt;/em&gt;the Company entered into a license and collaboration agreement, or the Seagen Collaboration Agreement, and a non-exclusive Anticalin platform technology license agreement, or the Seagen Platform License, and together with the Seagen Collaboration Agreement, the Seagen Agreements, with Seagen, Inc., or Seagen, pursuant to which the parties will develop multiple targeted bispecific IO treatments for solid tumors and blood cancers.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Under the terms of the Seagen Agreements, the companies will pursue multiple Anticalin-antibody fusion proteins during the research phase. The Seagen Agreements provide Seagen a base option to select up to three programs for further development. Prior to the initiation of a pivotal trial, the Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;opt into global co-development and U.S. commercialization of the &lt;em style="font: inherit;"&gt;second&lt;/em&gt; program and share in global costs and profits on an equal basis. Seagen will solely develop, fund and commercialize the other two programs. Seagen &lt;em style="font: inherit;"&gt; may &lt;/em&gt;also decide to select additional candidates from the initial research phase for further development in return for the payment to us of additional fees, milestone payments, and royalties&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Seagen Platform License grants Seagen a non-exclusive license to certain intellectual property related to the Anticalin platform technology.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Upon signing the Seagen Agreements, Seagen paid the Company a $30.0 million upfront fee and an additional $4.9 million was estimated to be paid for research and development services as reimbursement to the Company through the end of the research term. In addition, the Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;receive tiered royalties on net sales up to the low double-digits and success-based research, development, commercial, and sales milestones payments across the product candidates, depending on the successful development and commercialization of those candidates. If Seagen exercises its option to select additional candidates from the initial research phase for further development, payment to Pieris of additional fees, milestone payments, and royalties would result.&lt;/p&gt;

   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The term of each of the Seagen Agreements ends upon the expiration of all of Seagen's payment obligations under each agreement. The Seagen Collaboration Agreement &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be terminated by Seagen on a product-by-product basis for convenience beginning 12 months after its effective date upon 90 days' notice or, for any program where a pivotal study has been initiated, upon 180 days' notice. Any program &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be terminated at Seagen's option. If any program is terminated by Seagen after a pre-defined pre-clinical stage, the Company will have full rights to continue such program. If any program is terminated by Seagen prior to such pre-defined pre-clinical stage, the Company will have the right to continue to develop such program, but will be obligated to offer a co-development option to Seagen for such program. The Seagen Collaboration Agreement &lt;em style="font: inherit;"&gt; may &lt;/em&gt;also be terminated by Seagen or the Company for an uncured material breach by the other party upon 90 days' notice, subject to extension for an additional 90 days if the material breach relates to diligence obligations and subject, in all cases, to dispute resolution procedures. The Seagen Collaboration Agreement &lt;em style="font: inherit;"&gt; may &lt;/em&gt;also be terminated due to the other party&#x2019;s insolvency and &lt;em style="font: inherit;"&gt; may &lt;/em&gt;in certain instances, including for reasons of safety, be terminated on a product-by-product basis. Each party &lt;em style="font: inherit;"&gt; may &lt;/em&gt;also terminate the Seagen Agreements if the other party challenges the validity of any patents licensed under the Seagen Agreements, subject to certain exceptions. The Seagen Platform License will terminate upon termination of the Seagen Collaboration Agreement, whether in its entirety or on a product-by-product basis.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company determined that the Seagen Agreements should be combined and evaluated as a single arrangement under ASC &lt;em style="font: inherit;"&gt;606&lt;/em&gt; as they were executed on the same date. The arrangement with Seagen provides for the transfer of the following goods or services: (i)&#160;three candidate research licenses that each consist of a non-exclusive platform technology license, a co-exclusive candidate research license, and research and development services, (ii)&#160;research, development and manufacturing services associated with each candidate research license, (iii)&#160;participation on various governance committees, and (iv)&#160;two antibody target swap options which were assessed as material rights.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Management evaluated all of the promised goods or services within the contract and determined which such goods and services were separate performance obligations. The Company determined that the licenses granted, at arrangement inception, should be combined with the research and development services to be provided for the related antibody target programs as they are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; capable of being distinct. A &lt;em style="font: inherit;"&gt;third&lt;/em&gt; party would &lt;em style="font: inherit;"&gt;not&lt;/em&gt; be able to provide the research and development services due to the specific nature of the intellectual property and knowledge required to perform the services, and Seagen could &lt;em style="font: inherit;"&gt;not&lt;/em&gt; benefit from the licenses without the corresponding services. The Company determined that the participation on the various governance committees was distinct as the services could be performed by an outside party.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;As a result, management concluded there are six separate performance obligations at the inception of the Seagen Agreements: (i)&#160;three combined performance obligations, each comprised of a non-exclusive platform technology license, a co-exclusive candidate research license, and research and development services for the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; three approved Seagen antibody target programs, (ii) two performance obligations each comprised of a material right for an antibody target swap option for the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; and the &lt;em style="font: inherit;"&gt;second&lt;/em&gt; approved Seagen antibody target for &lt;em style="font: inherit;"&gt;no&lt;/em&gt; additional consideration, and (iii)&#160;one performance obligation comprised of the participation on the various governance committees.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company allocated consideration to the performance obligations based on the relative proportion of their standalone selling prices. The Company developed standalone selling prices for licenses by applying a risk adjusted, net present value, estimate of future potential cash flows approach, which included the cost of obtaining research and development services at arm&#x2019;s length from a &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party provider, as well as internal full-time equivalent costs to support these services. The Company developed the standalone selling price for committee participation by using management&#x2019;s estimate of the anticipated participation hours multiplied by a market rate for comparable participants.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The transaction price at inception is comprised of fixed consideration of $30.0 million in upfront fees and variable consideration of $4.9 million of estimated research and development services to be reimbursed as research and development occurs through the research term. The $30.0 million upfront fee, which represents the fixed consideration in the transaction price, was allocated to each of the performance obligations based on the relative proportion of their standalone selling prices. The $4.9 million in variable consideration related to the research and development services is allocated specifically to the three target program performance obligations based upon the budgeted services for each program&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The amounts allocated to the performance obligations for the three research programs will be recognized on a proportional performance basis through the completion of each respective estimated research term of the individual research programs. The amounts allocated to the material right for the antibody target swap option will be recognized either at the time the material right expires, or if exercised, on a proportional performance basis over the estimated research term for that program. The amounts allocated to the participation on each of the committees will be recognized straight-line over the anticipated research term for all research programs. As of &lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt;, there was $17.1&#160;million of aggregate transaction price allocated to remaining performance obligations.&lt;/p&gt;

   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;In &lt;em style="font: inherit;"&gt; June 2020, &lt;/em&gt;Seagen and the Company entered into amendments to the Seagen Agreements, or together, the First Seagen Amendment. The Seagen Amendment extended the deadline for Seagen to nominate a &lt;em style="font: inherit;"&gt;second&lt;/em&gt; and &lt;em style="font: inherit;"&gt;third&lt;/em&gt; antibody target. As a result of the Seagen Amendment, which completed the remaining performance obligations under the research term for the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; antibody target, the Company recorded $4.2&#160;million of previously deferred revenue for the year ended &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2020.&lt;/em&gt; The Company also recorded $5.0 million of milestone revenue in &lt;em style="font: inherit;"&gt; June 2020.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;On &lt;em style="font: inherit;"&gt; March 24, 2021, &lt;/em&gt;the Company announced that Seagen made a strategic equity investment in Pieris, and that the companies had entered into a combination study agreement, or the Combination Study Agreement, to evaluate the safety and efficacy of combining Pieris&#x2019; cinrebafusp alfa with Seagen&#x2019;s tucatinib, a small-molecule tyrosine kinase &lt;em style="font: inherit;"&gt;HER2&lt;/em&gt; inhibitor, for the treatment of gastric cancer patients expressing lower &lt;em style="font: inherit;"&gt;HER2&lt;/em&gt; levels (&lt;em style="font: inherit;"&gt;IHC2&lt;/em&gt;+/ISH- &amp;amp; &lt;em style="font: inherit;"&gt;IHC1&lt;/em&gt;+) as part of the upcoming phase &lt;em style="font: inherit;"&gt;2&lt;/em&gt; study to be conducted by Pieris. The companies have also entered into an Amended and Restated License and Collaboration Agreement, or the Second Seagen Amendment, in which their existing immuno-oncology collaboration agreement has been amended relating to joint development and commercial rights for the &lt;em style="font: inherit;"&gt;second&lt;/em&gt; program in the alliance.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Specifically, under the Second Seagen Amendment, Pieris&#x2019; option to co-develop and co-commercialize the &lt;em style="font: inherit;"&gt;second&lt;/em&gt; of three programs in the collaboration has been converted to a co-promotion option in the United States, with Seagen solely responsible for the development and overall commercialization of that program. Pieris will also be entitled to increased royalties from that program in the event that it chooses to exercise the co-promotion option. In connection with the agreements described above, the Company and Seagen entered into a subscription agreement, or the Seagen Subscription Agreement, pursuant to which the Company agreed to issue to Seagen, and Seagen agreed to acquire from the Company, 3,706,174 shares of the Company&#x2019;s common stock for a total purchase price of $13.0&#160;million, or $3.51 per share, in a private placement transaction pursuant to Section &lt;em style="font: inherit;"&gt;4&lt;/em&gt;(a)(&lt;em style="font: inherit;"&gt;2&lt;/em&gt;) of the Securities Act of &lt;em style="font: inherit;"&gt;1933,&lt;/em&gt; as amended. The Seagen Subscription Agreement includes a provision to the effect that Seagen &lt;em style="font: inherit;"&gt; may &lt;/em&gt;ask the Company to file a registration statement to register the resale of the shares issued to Seagen, at any time beginning on the date that is 60 calendar days from the date of issuance of the shares. The Company assessed the ASC &lt;em style="font: inherit;"&gt;606&lt;/em&gt; implications of the Seagen Subscription Agreement and concluded that the fair value of the shares on a per share basis was $2.61 per share as of the transaction date. This resulted in a premium paid for the shares of $3.3&#160;million, all of which was recorded in deferred revenue upon contract execution and allocated to the remaining performance obligations.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company has concluded that the Combination Study Agreement is within the scope of ASC &lt;em style="font: inherit;"&gt;808,&lt;/em&gt; which defines collaborative arrangements and addresses the presentation of the transactions between the &lt;em style="font: inherit;"&gt;two&lt;/em&gt; parties in the income statement and related disclosures. However, ASC &lt;em style="font: inherit;"&gt;808&lt;/em&gt; does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; provide guidance on the recognition of consideration exchanged or accounting for the obligations that &lt;em style="font: inherit;"&gt; may &lt;/em&gt;arise between the parties. The Company has concluded that ASC &lt;em style="font: inherit;"&gt;730,&lt;/em&gt; &lt;i&gt;Research and Development&lt;/i&gt;, should be applied by analogy. There is &lt;em style="font: inherit;"&gt;no&lt;/em&gt; financial statement impact for the Combination Study Agreement as the value of the drug supply received from Seagen is offset against the drug supply cost.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;In the &lt;em style="font: inherit;"&gt;second&lt;/em&gt; quarter of &lt;em style="font: inherit;"&gt;2022,&lt;/em&gt; the Company recorded approximately $1.5 million in revenue related to completion of the performance obligation for the expiration of the target swap under the &lt;em style="font: inherit;"&gt;second&lt;/em&gt; program in the collaboration.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Under the Seagen Agreements, the Company is eligible to receive various research, development, commercial and sales milestones. There is uncertainty that the events to obtain the research and development milestones will be achieved given the nature of clinical development and the stage of the Company&#x2019;s technology. The Company has thus determined that all research and development milestones will be constrained until it is deemed probable that a significant revenue reversal will &lt;em style="font: inherit;"&gt;not&lt;/em&gt; occur, with the exception of the $5.0 million milestone as described in the following paragraph.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;In &lt;em style="font: inherit;"&gt; January 2023, &lt;/em&gt;the Company achieved a milestone for the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; program in the collaboration for $5.0 million. The Company evaluated the recognition of the milestone under ASC &lt;em style="font: inherit;"&gt;606&lt;/em&gt; and concluded that the constraints on the milestone &lt;em style="font: inherit;"&gt;no&lt;/em&gt; longer existed as of &lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt; and therefore recorded the full $5.0 million as revenue for the year ended &lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt;.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;As of &lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt;, there is $11.6&#160;million and $2.9&#160;million of current and non-current deferred revenue, respectively, related to the Seagen Agreements.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;&lt;span style="text-decoration: underline; "&gt;AstraZeneca&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;On &lt;em style="font: inherit;"&gt; May&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;2,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2017,&lt;/em&gt; the Company entered into a license and collaboration agreement, or the AstraZeneca Collaboration Agreement, and a non-exclusive Anticalin platform technology license agreement, or AstraZeneca Platform License, and together with the AstraZeneca Collaboration Agreement, the AstraZeneca Agreements with AstraZeneca AB, or AstraZeneca, which became effective on &lt;em style="font: inherit;"&gt; June&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;10,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2017,&lt;/em&gt; following expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of &lt;em style="font: inherit;"&gt;1976.&lt;/em&gt; Under the AstraZeneca Agreements the parties will advance several novel inhaled Anticalin proteins.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;In addition to the Company&#x2019;s lead inhaled drug candidate, PRS-&lt;em style="font: inherit;"&gt;060/AZD1402,&lt;/em&gt; or the AstraZeneca Lead Product, the Company and AstraZeneca, under the original terms of the AstraZeneca Collaboration Agreement, would also collaborate to progress four additional novel Anticalin proteins against undisclosed targets for respiratory diseases, or the AstraZeneca Collaboration Products, and together with the AstraZeneca Lead Product, the AstraZeneca Products. The Company is responsible for advancing the AstraZeneca Lead Product&#160;through its phase &lt;em style="font: inherit;"&gt;1&lt;/em&gt; study, with the associated costs funded by AstraZeneca. The parties will collaborate thereafter to conduct a phase &lt;em style="font: inherit;"&gt;2a&lt;/em&gt; study in asthma patients, with AstraZeneca continuing to fund development costs. After completion of a phase &lt;em style="font: inherit;"&gt;2a&lt;/em&gt; study, Pieris has the option to co-develop the AstraZeneca Lead Product and also has a separate option to co-commercialize the AstraZeneca Lead Product in the United States. For the AstraZeneca Collaboration Products, the Company will be responsible for the initial discovery of the novel Anticalin proteins, after which AstraZeneca will take the lead on continued development of the AstraZeneca Collaboration Products. The Company has the option to co-develop two of the four AstraZeneca Collaboration Products beginning at a pre-defined preclinical stage and would also have the option to co-commercialize these two programs in the United States, while AstraZeneca will be responsible for development and commercialization of the other programs worldwide.&lt;/p&gt;

   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The term of each of the AstraZeneca Agreements ends upon the expiration of all of AstraZeneca&#x2019;s payment obligations under such agreement. The AstraZeneca Collaboration Agreement &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be terminated by AstraZeneca in its entirety for convenience beginning 12 months after its effective date upon 90 days&#x2019; notice or, if the Company has obtained marketing approval for the marketing and sale of a product, upon 180 days&#x2019; notice. Each program &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be terminated at AstraZeneca&#x2019;s option; if any program is terminated by AstraZeneca, the Company will have full rights to such program. The AstraZeneca Collaboration Agreement &lt;em style="font: inherit;"&gt; may &lt;/em&gt;also be terminated by AstraZeneca or the Company for material breach upon 180 days&#x2019; notice of a material breach (or 30 days with respect to payment breach), provided that the applicable party has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; cured such breach by the permitted cure period (including an additional 180 days if the breach is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; susceptible to cure during the initial 180-day period) and dispute resolution procedures specified in the agreement have been followed. The AstraZeneca Collaboration Agreement &lt;em style="font: inherit;"&gt; may &lt;/em&gt;also be terminated due to the other party&#x2019;s insolvency and &lt;em style="font: inherit;"&gt; may &lt;/em&gt;in certain instances be terminated on a product-by-product and/or country-by-country basis. Each party &lt;em style="font: inherit;"&gt; may &lt;/em&gt;also terminate an AstraZeneca Agreement if the other party challenges the validity of patents related to certain intellectual property licensed under such AstraZeneca Agreement, subject to certain exceptions for infringement suits, acquisitions and newly-acquired licenses. The AstraZeneca Platform License will terminate upon termination of the AstraZeneca Collaboration Agreement, on a product-by-product and/or country-by-country basis.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;At inception, AstraZeneca is granted the following licenses: (i)&#160;research and development license for the AstraZeneca Lead Product, (ii)&#160;commercial license for the AstraZeneca Lead Product, (iii)&#160;individual research licenses for each of the four AstraZeneca Collaboration Products, (iv)&#160;individual commercial licenses for each of the four AstraZeneca Collaboration Products, and (v)&#160;individual non-exclusive platform technology licenses for the AstraZeneca Lead Product and the four AstraZeneca Collaboration Products. AstraZeneca will be granted individual development licenses for each of the four AstraZeneca Collaboration Products upon completion of the initial discovery of Anticalin proteins.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The collaboration will be managed on an overall basis by a Joint Steering Committee, or JSC, formed by an equal number of representatives from the Company and AstraZeneca. In addition to the JSC, the AstraZeneca Collaboration Agreement also requires each party to designate an alliance manager to facilitate communication and coordination of the parties' activities under the agreement, and further requires participation of both parties on a joint development committee, or JDC, and a commercialization committee. The responsibilities of these committees vary, depending on the stage of development and commercialization of each product.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Under the AstraZeneca Agreements, the Company received an upfront, non-refundable payment of $45.0 million. In addition, the Company will receive payments to conduct a phase &lt;em style="font: inherit;"&gt;1&lt;/em&gt; clinical study for the AstraZeneca Lead Product. The Company is also eligible to receive research, development, commercial, sales milestone payments, and royalty payments. The Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;receive tiered royalties on sales of potential products commercialized by AstraZeneca and for co-developed products, gross margin share on worldwide sales equal dependent on the Company&#x2019;s level of committed investment.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company determined that the AstraZeneca Agreements should be combined and evaluated as a single arrangement under ASC &lt;em style="font: inherit;"&gt;606&lt;/em&gt; as they were executed on the same date. The arrangement with AstraZeneca, including the impact of any modifications, provides for the transfer of the following goods and services: (i)&#160;five non-exclusive platform technology licenses, (ii)&#160;research and development license for the AstraZeneca Lead Product, (iii)&#160;commercial license for the AstraZeneca Lead Product, (iv)&#160;development and manufacturing services for the AstraZeneca Lead Product (or the phase &lt;em style="font: inherit;"&gt;1&lt;/em&gt; services), (v) technology transfer services for the AstraZeneca Lead Product, (vi)&#160;research services related to the AstraZeneca Lead Product, (vii)&#160;participation on each of the committees, (viii)&#160;four research licenses for the AstraZeneca Collaboration Products, (ix)&#160;four commercial licenses for the AstraZeneca Collaboration Products, (&lt;em style="font: inherit;"&gt;x&lt;/em&gt;)&#160;research services for the AstraZeneca Collaboration Products and (xi) certain phase &lt;em style="font: inherit;"&gt;2a&lt;/em&gt; services for the AstraZeneca Lead Product. Additionally, as the development licenses on the four AstraZeneca Collaboration Products &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be granted at a discount in the future, the Company determined such discounts should be assessed as material rights at inception.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Management evaluated all of the promised goods or services within the contract and determined which such goods and services were separate performance obligations. The Company determined that the licenses granted for the AstraZeneca Lead Product at the inception of the arrangement should be combined with the research services related to the AstraZeneca Lead Product and the licenses granted for the AstraZeneca Collaboration Products should be combined with the research services for the AstraZeneca Collaboration Products, as the licenses are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; capable of being distinct. A &lt;em style="font: inherit;"&gt;third&lt;/em&gt; party would &lt;em style="font: inherit;"&gt;not&lt;/em&gt; be able to provide the research and development services, due to the specific nature of the intellectual property and knowledge required to perform the services and AstraZeneca could &lt;em style="font: inherit;"&gt;not&lt;/em&gt; benefit from the licenses without the corresponding services. The Company also determined that each of the phase &lt;em style="font: inherit;"&gt;1&lt;/em&gt; services and the phase &lt;em style="font: inherit;"&gt;2a&lt;/em&gt; services for the AstraZeneca Lead Product were distinct and that the participation on the various committees was also distinct as all of the phase &lt;em style="font: inherit;"&gt;1&lt;/em&gt; services, phase &lt;em style="font: inherit;"&gt;2a&lt;/em&gt; services and the committee services could be performed by an outside party. The Company determined that the commercial licenses for the AstraZeneca Collaboration Products granted at the inception of the arrangement should be combined with the development licenses for the AstraZeneca Collaboration Products as the company would &lt;em style="font: inherit;"&gt;not&lt;/em&gt; benefit from the commercial license without the ability to develop each product.&lt;/p&gt;

   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;As a result, management concluded that there were 16 performance obligations: (i)&#160;combined performance obligation comprised of a non-exclusive platform technology license, research and development license, and commercial licenses for the AstraZeneca Lead Product and research services for the AstraZeneca Lead Product, (ii) combined performance obligation comprised of&#160;development and manufacturing services, and technology transfer services for the AstraZeneca Lead Product, (iii)&#160;committee participation, (iv-vii) four combined performance obligations each comprised of a non-exclusive platform technology license, research licenses, and research services for each AstraZeneca Collaboration Product (viii-xi) four performance obligations comprised of a material right to acquire the development licenses granted for the AstraZeneca Collaboration Products, (xii-xv) four performance obligations comprised of the commercial licenses granted for the AstraZeneca Collaboration Products and (xvi) phase &lt;em style="font: inherit;"&gt;2a&lt;/em&gt; services.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company allocated consideration to the performance obligations based on the relative proportion of their standalone selling prices. The Company developed standalone selling prices for licenses and corresponding research services by applying a risk adjusted, net present value, estimate of future potential cash flow approach, which included the cost of obtaining research services at arm&#x2019;s length from a &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party provider, as well as internal full-time equivalent costs to support these services. The Company developed its standalone selling price for development and manufacturing services, and technology transfer services for the AstraZeneca Lead Product using estimated internal and external costs to be incurred.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company developed its standalone selling price for committee participation by using management&#x2019;s estimate of the anticipated participation hours multiplied by a market rate for comparable participants.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company developed its standalone selling price for the commercial licenses and material rights granted on the development licenses by probability weighting multiple cash flow scenarios using the income approach.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The transaction price was comprised of fixed consideration of $45.0 million in upfront fees and variable consideration of (i) $14.2 million in estimated phase &lt;em style="font: inherit;"&gt;1&lt;/em&gt; services, (ii) $12.5 million in milestone payments achieved upon the initiation of a phase &lt;em style="font: inherit;"&gt;1&lt;/em&gt; study in &lt;em style="font: inherit;"&gt; December 2017, &lt;/em&gt;and (iii) $4.7 million in estimated phase &lt;em style="font: inherit;"&gt;2a&lt;/em&gt; services. The $45.0 million upfront fee, which represents the fixed consideration in the transaction price, was allocated to each of the performance obligations based on the relative proportion of their standalone selling prices. Variable consideration of $14.2 million is related to the phase &lt;em style="font: inherit;"&gt;1&lt;/em&gt; services and will be allocated entirely to the performance obligation to which they relate. Variable consideration of $12.5 million related to the phase &lt;em style="font: inherit;"&gt;1&lt;/em&gt; trial milestone was allocated by relative selling price to the combined performance obligation comprised of a non-exclusive platform technology license, research and development license and commercial licenses for the AstraZeneca Lead Product and research services for the AstraZeneca Lead Product, and the combined performance obligation comprised of&#160;development and manufacturing services and technology transfer services for the AstraZeneca Lead Product performance obligations. Variable consideration of $4.7 million for phase &lt;em style="font: inherit;"&gt;2a&lt;/em&gt; services was allocated specifically to the related performance obligation.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The amounts allocated to the license performance obligation for the AstraZeneca Lead Product and the four performance obligations for the four research licenses for AstraZeneca Collaboration Products will be recognized on a proportional performance basis as the activities are conducted over the life of the arrangement. The amounts allocated to the performance obligation for phase &lt;em style="font: inherit;"&gt;1&lt;/em&gt; services, technology transfer services for the AstraZeneca Lead Product will be recognized on a proportional performance basis over the estimated term of development through phase &lt;em style="font: inherit;"&gt;2a&lt;/em&gt; study. The amounts allocated to the performance obligation for phase &lt;em style="font: inherit;"&gt;2a&lt;/em&gt; services for the AstraZeneca Lead Product will be recognized on a proportionate performance basis over an estimated term of 12 months.&#160;The amounts allocated to the performance obligation for participation on each of the committees will be recognized on a straight-line basis over the expected term of development of the AstraZeneca Lead Product and the AstraZeneca Collaboration Products. The term of performance is approximately &lt;span style="-sec-ix-hidden:c96253965"&gt;five&lt;/span&gt; years. The amounts allocated to the four performance obligations for the material rights to acquire a development license and the four performance obligations for commercial licenses for the AstraZeneca Collaboration Products will be recognized upon exercise of the specific material right and delivery of each of the development licenses. As of &lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt;, there was $7.5&#160;million of aggregate transaction price allocated to remaining performance obligations.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Additionally, the Company evaluated payments required to be made between both parties as a result of the shared development costs of the AstraZeneca Lead Product and the two AstraZeneca Collaboration Products for which the Company has a co-development option. The Company will classify payments made as a reduction of revenue and will classify payments received as revenue, in the period they are earned.&lt;/p&gt;

   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Under the AstraZeneca Agreements, the Company is eligible to receive various research, development, commercial and sales milestones. There is uncertainty that the events to obtain the research and development milestones will be achieved given the nature of clinical development and the stage of the Company&#x2019;s technology. The Company has thus determined that all research and development milestones, other than the phase &lt;em style="font: inherit;"&gt;1&lt;/em&gt; initiation milestone achieved in &lt;em style="font: inherit;"&gt; December 2017 &lt;/em&gt;and included in the impact of adoption of ASC &lt;em style="font: inherit;"&gt;606,&lt;/em&gt; will be constrained until it is deemed probable that a significant revenue reversal will &lt;em style="font: inherit;"&gt;not&lt;/em&gt; occur.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;On &lt;em style="font: inherit;"&gt; March 29, 2021, &lt;/em&gt;the Company and AstraZeneca entered into (&lt;em style="font: inherit;"&gt;1&lt;/em&gt;) Amendment &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;1&lt;/em&gt; to the Non-exclusive Anticalin&#xae;&lt;b&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt; &lt;/sup&gt;&lt;/b&gt;Platform License Agreement dated &lt;em style="font: inherit;"&gt; May 2, 2017 &lt;/em&gt;and (&lt;em style="font: inherit;"&gt;2&lt;/em&gt;) Amendment &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;2&lt;/em&gt; to the License and Collaboration Agreement dated &lt;em style="font: inherit;"&gt; May 2, 2017, &lt;/em&gt;as previously amended by Amendment &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;1&lt;/em&gt; dated &lt;em style="font: inherit;"&gt; September 14, 2020, &lt;/em&gt;collectively, the Amended Collaboration Agreement. Under the Amended Collaboration Agreement, the parties agreed to restructure certain commercial economics for the PRS-&lt;em style="font: inherit;"&gt;060/AZD1402&lt;/em&gt; program by increasing potential sales milestones and reducing potential sales royalties, while fundamentally maintaining the overall value split between AstraZeneca and the Company.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;In connection with the Amended Collaboration Agreement, the Company and AstraZeneca entered into a Subscription Agreement pursuant to which the Company agreed to issue to AstraZeneca, and AstraZeneca agreed to acquire from the Company, 3,584,230 shares of the Company&#x2019;s common stock for a total purchase price of $10.0&#160;million, or $2.79 per share, in a private placement transaction pursuant to Section &lt;em style="font: inherit;"&gt;4&lt;/em&gt;(a)(&lt;em style="font: inherit;"&gt;2&lt;/em&gt;) of the Securities Act of &lt;em style="font: inherit;"&gt;1933,&lt;/em&gt; as amended. The Subscription Agreement closed on &lt;em style="font: inherit;"&gt; April 1, 2021 &lt;/em&gt;and includes a requirement that the Company file a registration statement to register the resale of the shares issued to AstraZeneca within 60 calendar days of the issuance of the shares. The Company assessed the payment under ASC &lt;em style="font: inherit;"&gt;606&lt;/em&gt; and concluded that the fair value of the shares on a per share basis was $2.60 per share as of the transaction date. This resulted in a premium paid for the shares of $0.7&#160;million, which was added to the deferred revenue balance and will be recognized over time in line with our revenue recognition pattern for all remaining performance obligations.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Also in &lt;em style="font: inherit;"&gt; March 2021, &lt;/em&gt;the Company earned a $13.0&#160;million milestone from AstraZeneca related to the initiation of the phase &lt;em style="font: inherit;"&gt;2a&lt;/em&gt; study for PRS-&lt;em style="font: inherit;"&gt;060/AZD1402.&lt;/em&gt; The Company assessed the milestone payment under ASC &lt;em style="font: inherit;"&gt;606&lt;/em&gt; and determined that there &lt;em style="font: inherit;"&gt;no&lt;/em&gt; longer existed a constraint on the milestone as the performance obligation related to the phase &lt;em style="font: inherit;"&gt;2a&lt;/em&gt; study was fully satisfied. Therefore, the Company realized the full $13.0&#160;million as milestone revenue for the year ended &lt;em style="font: inherit;"&gt; December 31, 2021.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;In &lt;em style="font: inherit;"&gt; January 2022, &lt;/em&gt;the Company and AstraZeneca jointly discontinued one discovery-stage programs as they were &lt;em style="font: inherit;"&gt;not&lt;/em&gt; able to validate an exploratory target. Approximately $4.7&#160;million of revenue was recorded related to remaining performance obligations related to the program.&lt;/p&gt;
   &lt;div style="font-size: 10pt; white-space: pre-wrap;"&gt;
     &#160;
   &lt;/div&gt;
   &lt;div style="font-size: 10pt;"&gt;
     In
    &lt;em style="font: inherit;"&gt; August 2022, &lt;/em&gt;the Company and AstraZeneca entered into another amendment of the License and Collaboration Agreement dated
    &lt;em style="font: inherit;"&gt; May 2, 2017, &lt;/em&gt;and extended the research term for
    &lt;em style="font: inherit;"&gt;two&lt;/em&gt; discovery-stage programs through
    &lt;em style="font: inherit;"&gt; December 2023 &lt;/em&gt;and subsequently jointly discontinued the
    &lt;em style="font: inherit;"&gt;third&lt;/em&gt; discovery-stage program. Approximately
    $5.0 million of revenue was recorded pursuant to a performance obligation related to transfer of a license that ceased with the discontinuation of this program.
   &lt;/div&gt;
   &lt;div style="font-size: 10pt;"&gt;
     &#160;
   &lt;/div&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;As of &lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt;, there is $0.5&#160;million and $6.9&#160;million of current and non-current deferred revenue, respectively, related to the AstraZeneca Agreements.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company incurred $1.6 million of &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party success fees to obtain the contract with AstraZeneca. Upon adoption of ASC &lt;em style="font: inherit;"&gt;606,&lt;/em&gt; the Company capitalized $1.1 million in accordance with ASC &lt;em style="font: inherit;"&gt;340.&lt;/em&gt; As of &lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt;, the remaining balance of the asset recognized from transaction costs to obtain the AstraZeneca contract is $0.2&#160;million. Amortization during the years ended &lt;em style="font: inherit;"&gt; December 31, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; was $0.3 million and de minimis, respectively.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;&lt;span style="text-decoration: underline; "&gt;Servier&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;On &lt;em style="font: inherit;"&gt; January&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;4,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2017,&lt;/em&gt; the Company entered into a license and collaboration agreement, or Servier Collaboration Agreement, and a non-exclusive Anticalin platform license agreement, or Servier Platform License, and together with the Servier Collaboration Agreement, the Servier Agreements with Les Laboratoires Servier and Institut de Recherches Internationales Servier, or Servier, pursuant to which the Company and Servier agreed to initially pursue five bispecific therapeutic programs.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Five committed programs were initially defined, which &lt;em style="font: inherit;"&gt; may &lt;/em&gt;combine antibodies from the Servier portfolio with one or more Anticalin proteins based on the Company&#x2019;s proprietary platform to generate innovative IO bispecific drug candidates, or the Collaboration Products. The collaboration &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be expanded by up to three additional therapeutic programs. The Company had the option to co-develop and retain commercial rights in the United States for PRS-&lt;em style="font: inherit;"&gt;332,&lt;/em&gt; the initial lead program under the collaboration, or the Initial Lead, and has a similar option on up to &lt;em style="font: inherit;"&gt;three&lt;/em&gt; additional programs, or the Co-Development Collaboration Products, while Servier will be responsible for development and commercialization of the other programs worldwide, or the Servier Worldwide Collaboration Products. Each party is responsible for an agreed upon percentage of shared costs, as set forth in the budget for the collaboration plan, and as further discussed below.&lt;/p&gt;

   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Co-Development Collaboration Products &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be jointly developed, according to a collaboration plan, through marketing approval from the U.S. Food and Drug Administration or the European Medicines Agency. Servier Worldwide Collaboration Products &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be jointly developed, according to a collaboration plan, through specified preclinical activities, at which point Servier becomes responsible for further development of the Collaboration Product.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;At inception, Servier was granted the following licenses: (i)&#160;development license for the Initial Lead, (ii)&#160;commercial license for the Initial Lead, (iii)&#160;individual research licenses for each of the &lt;em style="font: inherit;"&gt;four&lt;/em&gt; Collaboration Products, and (iv)&#160;individual non-exclusive platform technology licenses for the Initial Lead and for each of the &lt;em style="font: inherit;"&gt;four&lt;/em&gt; Collaboration Products. Upon achievement of certain development activities, specified by the collaboration for each Servier Agreement, Servier will be granted a development license and a commercial license. For the Initial Lead and the Co-Development Collaboration Products, the licenses granted are with respect to the entire world except for the United States. For Servier Worldwide Collaboration Products, the licenses granted are with respect to the entire world.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Servier Agreements are managed on an overall basis by a joint executive committee, or JEC, formed by an equal number of members from the Company and Servier. Decisions by the JEC will be made by consensus; however, in the event of a disagreement, each party will have final-decision making authority as it relates to the applicable territory in which such party has commercialization rights for the applicable product. In addition to the JEC, the Servier Collaboration Agreement requires the participation of both parties on: (i)&#160;a JSC, (ii) a JDC, (iii) a joint intellectual property committee, or JIPC, and (iv)&#160;a joint research committee, or JRC. The responsibilities of these committees vary, depending on the stage of development and commercialization of the Collaboration Products.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;For the Initial Lead and Co-Development Collaboration Products, the Company and Servier are responsible for an agreed upon percent of the shared costs required to develop the products through commercialization. In the event that the Company fails to exercise its option to co-develop the Co-Development Collaboration Products, Servier has the right to continue with the development and will be responsible for all costs required to develop the products through commercialization.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Under the Servier Agreements, the Company received an upfront, non-refundable payment of &lt;span style="-sec-ix-hidden:c96254027"&gt;&#x20ac;30.0&lt;/span&gt; million (approximately $32.0 million). In addition, the Company is eligible to receive research, development, commercial, and sales milestone payments as well as tiered royalties up to low double digits on the sales of commercialized products in the Servier territories. Since inception of the Servier Collaboration Agreement, the Company has achieved &lt;em style="font: inherit;"&gt;four&lt;/em&gt; development milestones under Servier Agreements totaling &lt;span style="-sec-ix-hidden:c96254030"&gt;&#x20ac;3.8&lt;/span&gt; million (approximately $4.3 million), all of which became billable on their respective achievement dates.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The initial research collaboration term, as it relates to the Initial Lead and Collaboration Products, shall continue for three years from the effective date of the Servier agreements, and &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be mutually extended for &lt;em style="font: inherit;"&gt;two one&lt;/em&gt;-year terms consecutively applied.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The term of each Servier Agreement ends upon the expiration of all of Servier&#x2019;s payment obligations under such Servier Agreement.&#160;The Servier Agreements &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be terminated by Servier for convenience beginning &lt;em style="font: inherit;"&gt;12&lt;/em&gt; months after their effective date upon &lt;em style="font: inherit;"&gt;180&lt;/em&gt; days&#x2019; notice. The Servier Agreements &lt;em style="font: inherit;"&gt; may &lt;/em&gt;also be terminated by Servier or the Company for material breach upon 90 days&#x2019; or 120 days&#x2019; notice under the Servier Collaboration Agreement and the Servier Platform License, respectively, provided that the applicable party has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; cured such breach by the applicable 90-day or 120-day permitted cure period, and dispute resolution procedures specified in the applicable Servier Agreement have been followed. The Servier Agreements &lt;em style="font: inherit;"&gt; may &lt;/em&gt;also be terminated due to the other party&#x2019;s insolvency or for a safety issue and &lt;em style="font: inherit;"&gt; may &lt;/em&gt;in certain instances be terminated on a product-by-product and/or country-by-country basis. The Servier Platform License will terminate upon termination of the Servier Collaboration Agreement, on a product-by-product and/or country-by-country basis. In &lt;em style="font: inherit;"&gt; February 2020, &lt;/em&gt;the research term was extended for &lt;em style="font: inherit;"&gt;12&lt;/em&gt; months. The research term was then extended for another &lt;em style="font: inherit;"&gt;12&lt;/em&gt; months in &lt;em style="font: inherit;"&gt; February 2021.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;As the Company and Servier are considered to be active participants in the Servier Agreements and are exposed to significant risks and rewards, certain units of account within the Servier Agreements are within the scope of ASC &lt;em style="font: inherit;"&gt;808.&lt;/em&gt; The arrangement with Servier provides for the transfer of the following goods and services: (i)&#160;&lt;em style="font: inherit;"&gt;five&lt;/em&gt; non-exclusive platform technology licenses, a&#160;development license, a&#160;commercial license and research and development services for the Initial Lead, (ii)&#160;participation on each of the committees, (iii)&#160;&lt;em style="font: inherit;"&gt;four&lt;/em&gt; research licenses for Collaboration Products, and (iv)&#160;research and development services for the Collaboration Products. Additionally, as the development and commercial licenses on the &lt;em style="font: inherit;"&gt;four&lt;/em&gt; Collaboration Products &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be granted at a discount in the future, the Company determined such discounts should be assessed as material rights at inception.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Management evaluated all of the promised goods or services within the contract and determined which goods and services were separate performance obligations. The Company determined that the licenses granted at the inception of the Servier collaboration, should be combined with the research and development services to be provided for the Initial Lead and Collaboration Products, over the term of the Servier Agreements, as such licenses are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; capable of being distinct. A &lt;em style="font: inherit;"&gt;third&lt;/em&gt; party would &lt;em style="font: inherit;"&gt;not&lt;/em&gt; be able to provide the research and development services, due to the specific nature of the intellectual property and knowledge required to perform the services, and Servier could &lt;em style="font: inherit;"&gt;not&lt;/em&gt; benefit from the licenses without the corresponding services. The Company determined that the participation on the various committees was distinct as the services could be performed by an outside party.&lt;/p&gt;

   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;As a result, management concluded that there are 10 performance obligations at the inception of the Servier Agreements. The following performance obligations are within the scope of ASC &lt;em style="font: inherit;"&gt;808:&lt;/em&gt; (i)&#160;combined performance obligation comprised of a non-exclusive platform technology license, commercial license, development license and research and development services for the Initial Lead, (ii)&#160;two separate performance obligations each comprised of a combined non-exclusive platform technology license, research license, and research and development services for each Co-Development Collaboration Product (iii)&#160;&lt;em style="font: inherit;"&gt;one&lt;/em&gt; performance obligation comprised of participation in the various governance committees, and (iv)&#160;two combined performance obligations comprised of the development and commercial licenses granted for the Co-Development Collaboration Products (and corresponding discounts) upon the achievement of specified preclinical activities, resulting in material rights. Revenue recognized associated with these performance obligations are presented as Collaboration Revenue within the Statement of Operations. The following performance obligations are within the scope of ASC &lt;em style="font: inherit;"&gt;606:&lt;/em&gt; (i) two separate performance obligations each comprised of a combined non-exclusive platform technology license, research license and research and development services for each Servier Worldwide Collaboration Product, and (ii) two combined performance obligations comprised of the development and commercial licenses granted for the Servier Worldwide Collaboration Products (and corresponding discounts) upon the achievement of specified preclinical activities, resulting in material rights. Revenue recognized associated with these performance obligations are presented as Customer Revenue within the Statement of Operations.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company allocated consideration to the performance obligations based on the relative proportion of their standalone selling prices. The Company developed its standalone selling prices for licenses by applying a risk adjusted, net present value, estimate of future potential cash flows approach, which included the cost of obtaining research and development services at arm&#x2019;s length from a &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party provider, as well as internal full-time equivalent costs to support these services.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company developed its estimate of standalone selling price for committee participation by using management&#x2019;s estimate of the anticipated participation hours multiplied by a market rate for comparable participants.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company developed its estimate of standalone selling price for the material rights granted on the development and commercial licenses granted for the Collaboration Products by probability weighting multiple cash flow scenarios using the income approach.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The transaction price at inception is comprised of the fixed upfront fee of &lt;span style="-sec-ix-hidden:c96254061"&gt;&#x20ac;30.0&lt;/span&gt; million (approximately $32.0 million) and was allocated to the performance obligations based on the relative proportion of their standalone selling prices. &#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The amounts allocated to the performance obligation for the Initial Lead and the four performance obligations for the four research and development licenses for Collaboration Products will be recognized on a proportional performance basis as the activities are conducted over the life of the arrangement. The term of the performance at inception of the Servier Agreements for the Initial Lead and each of the Co-Development Collaboration Products &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be through approval of certain regulatory bodies; a period which could be many years. The term of the performance for each of the other two Servier Worldwide Collaboration Products is through the initial research and collaboration term, plus potential extensions. The amounts allocated to the performance obligation for participation on each of the committees will be recognized on a straight-line basis over the anticipated performance period over the entirety of the arrangement with Servier. The amounts allocated to the four performance obligations for the material rights to acquire development and commercial licenses for the Co-Development Collaboration Products are granted in the future will be recognized over time upon delivery of each of the licenses through marketing approval. The amounts allocated to the four performance obligations for the material rights to acquire development and commercial licenses for the Servier Developed Collaboration Products are granted in the future will be recognized upon delivery of each of the licenses. As of &lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt;, there was $5.0&#160;million of aggregate transaction price allocated to remaining performance obligations.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Additionally, the Company evaluated payments required to be made between both parties as a result of the shared development costs of the Initial Lead and Collaboration Products. The Company will classify payments made as a reduction of revenue and will classify payments received as revenue, in the period they are earned.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Under the Servier Agreements the Company is eligible to receive various research, development, commercial, and sales milestones. There is uncertainty that the events to obtain the research and development milestones will be achieved given the nature of clinical development and the stage of the Company&#x2019;s technology. The Company has thus determined that all research and development milestones will be constrained until it is deemed probable that a significant revenue reversal will &lt;em style="font: inherit;"&gt;not&lt;/em&gt; occur.&lt;/p&gt;

   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;In &lt;em style="font: inherit;"&gt; September 2019, &lt;/em&gt;Servier notified the Company of its decision to discontinue co-development of PRS-&lt;em style="font: inherit;"&gt;332,&lt;/em&gt; a PD-&lt;em style="font: inherit;"&gt;1&lt;/em&gt;-LAG-&lt;em style="font: inherit;"&gt;3&lt;/em&gt; bispecific that served as the initial development program under the Pieris-Servier alliance, for strategic reasons. The Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; presently intend to continue development of PRS-&lt;em style="font: inherit;"&gt;332&lt;/em&gt; but retains full rights to advance the development and commercialization of the product on a world-wide basis in the future.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;In &lt;em style="font: inherit;"&gt; February 2020, &lt;/em&gt;the research term was extended for 12 months. The Company updated the transaction price for the extension for revenue recognition purposes and allocated it ratably over all unsatisfied performance obligations. As part of the expiration of the initial research term, the option to expand the collaboration beyond the initial five committed programs also expired. In &lt;em style="font: inherit;"&gt; March 2020, &lt;/em&gt;Servier notified the Company of its decision to discontinue co-development of two earlier preclinical stage programs for strategic reasons based upon an extensive portfolio review. The notification required a &lt;em style="font: inherit;"&gt;60&lt;/em&gt;-day period to complete remaining obligations on the programs; however, the Company determined that the material rights to acquire development and commercial licenses for one Co-Development Collaboration Product and for one Servier Developed Collaboration Products lapsed in &lt;em style="font: inherit;"&gt; March 2020 &lt;/em&gt;and recognized $7.1&#160;million of previously deferred revenue associated with these material rights during &lt;em style="font: inherit;"&gt;2020.&lt;/em&gt; The discontinuation of the two earlier preclinical stage programs decreased the future potential milestone payments the Company could achieve. The parties continue to advance the development of two preclinical programs: PRS-&lt;em style="font: inherit;"&gt;344/S095012,&lt;/em&gt; a &lt;em style="font: inherit;"&gt;4&lt;/em&gt;-&lt;em style="font: inherit;"&gt;1BB/PD&lt;/em&gt;-&lt;em style="font: inherit;"&gt;L1&lt;/em&gt; bispecific designed as a co-development program, and PRS-&lt;em style="font: inherit;"&gt;352,&lt;/em&gt; which addresses undisclosed targets and for which Servier has worldwide rights.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;In the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; quarter of &lt;em style="font: inherit;"&gt;2022,&lt;/em&gt; the Company satisfied the performance obligation related to the material right for PRS-&lt;em style="font: inherit;"&gt;352/S095025&lt;/em&gt;&lt;i&gt;,&lt;/i&gt;&#160;which led to point-in-time recognition of revenue for $4.9&#160;million of revenue previously deferred. In the &lt;em style="font: inherit;"&gt;fourth&lt;/em&gt; quarter of &lt;em style="font: inherit;"&gt;2022,&lt;/em&gt; Servier discontinued development of PRS-&lt;em style="font: inherit;"&gt;352/S095025&lt;/em&gt; based upon a strategic portfolio review.&lt;/p&gt;
   &lt;div style="font-size: 10pt;"&gt;
     &#160;
   &lt;/div&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;As of &lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt;, there is $0.9&#160;million and $4.1&#160;million of current and non-current deferred revenue, respectively, related to the Servier Agreements.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company incurred costs to obtain the contract with Servier. Upon adoption of ASC &lt;em style="font: inherit;"&gt;606,&lt;/em&gt; the Company capitalized $0.5 million of &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party service fees in accordance with ASC &lt;em style="font: inherit;"&gt;340.&lt;/em&gt; As of &lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt;, there was no&#160;remaining balance of the asset recognized from costs to obtain the Servier contract. Amortization expense for the years&#160;ended &lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt; and &lt;em style="font: inherit;"&gt; December 31, 2021&lt;/em&gt; was $0.1 million and de minimis, respectively&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Contract Balances&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company receives payments from its collaboration partners based on payments established in each contract. Upfront payments and fees are recorded as deferred revenue upon receipt or when due until such time as the Company satisfies its performance obligations under each arrangement. A contract asset is a conditional right to consideration in exchange for goods or services that the Company has transferred to a customer. Amounts are recorded as accounts receivable when the Company&#x2019;s right is unconditional.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;There were no additions to deferred revenue during the year&#160;ended &lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt; and reductions to deferred revenue were $20.4&#160;million for the year&#160;ended &lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt;.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


  </us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2344187">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Year Ended December 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;AstraZeneca&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;9,117&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;18,919&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Seagen&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;8,287&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;768&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Servier&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;5,359&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;4,070&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Genentech&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;3,139&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1,950&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Boston Pharmaceuticals&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;5,711&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;&lt;b&gt;Total Revenue&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;25,902&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;31,418&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="d_2022-01-01_2022-12-31_CounterpartyNameAxis-AstraZenecaABMember"
      decimals="-3"
      id="c96254117"
      unitRef="USD">9117000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-AstraZenecaABMember"
      decimals="-3"
      id="c96254118"
      unitRef="USD">18919000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="d_2022-01-01_2022-12-31_CounterpartyNameAxis-SeattleGeneticsIncMember"
      decimals="-3"
      id="c96254119"
      unitRef="USD">8287000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-SeattleGeneticsIncMember"
      decimals="-3"
      id="c96254120"
      unitRef="USD">768000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="d_2022-01-01_2022-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember"
      decimals="-3"
      id="c96254121"
      unitRef="USD">5359000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember"
      decimals="-4"
      id="c96254122"
      unitRef="USD">4070000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="d_2022-01-01_2022-12-31_CounterpartyNameAxis-GenentechMember"
      decimals="-3"
      id="c96254123"
      unitRef="USD">3139000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-GenentechMember"
      decimals="-4"
      id="c96254124"
      unitRef="USD">1950000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="d_2022-01-01_2022-12-31_CounterpartyNameAxis-BostonPharmaceuticalsMember"
      decimals="-3"
      id="c96254125"
      unitRef="USD">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-BostonPharmaceuticalsMember"
      decimals="-3"
      id="c96254126"
      unitRef="USD">5711000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96254127"
      unitRef="USD">25902000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96254128"
      unitRef="USD">31418000</us-gaap:Revenues>
    <pirs:RevenueFromContractWithCustomerMilestonePaymentsTableTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2344188">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Research, Development, Regulatory &amp;amp; Commercial Milestones&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Sales Milestones&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;AstraZeneca&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;702&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,925&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Servier&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;20&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Seagen&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;759&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;450&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Boston Pharmaceuticals&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;88&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;265&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Genentech&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;834&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;600&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;&lt;b&gt;Total potential milestone payments&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,403&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;5,240&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </pirs:RevenueFromContractWithCustomerMilestonePaymentsTableTextBlock>
    <us-gaap:ContractsReceivableClaimsAndUncertainAmounts
      contextRef="i_2022-12-31_CounterpartyNameAxis-AstraZenecaABMember_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-ResearchAndDevelopmentMilestonePaymentsMember_TypeOfArrangementAxis-CollaborativeArrangementMember"
      decimals="-6"
      id="c96254131"
      unitRef="USD">702000000</us-gaap:ContractsReceivableClaimsAndUncertainAmounts>
    <us-gaap:ContractsReceivableClaimsAndUncertainAmounts
      contextRef="i_2022-12-31_CounterpartyNameAxis-AstraZenecaABMember_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-SalesMilestonePaymentsMember_TypeOfArrangementAxis-CollaborativeArrangementMember"
      decimals="-6"
      id="c96254132"
      unitRef="USD">3925000000</us-gaap:ContractsReceivableClaimsAndUncertainAmounts>
    <us-gaap:ContractsReceivableClaimsAndUncertainAmounts
      contextRef="i_2022-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-ResearchAndDevelopmentMilestonePaymentsMember_TypeOfArrangementAxis-CollaborativeArrangementMember"
      decimals="-7"
      id="c96254133"
      unitRef="USD">20000000</us-gaap:ContractsReceivableClaimsAndUncertainAmounts>
    <us-gaap:ContractsReceivableClaimsAndUncertainAmounts
      contextRef="i_2022-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-SalesMilestonePaymentsMember_TypeOfArrangementAxis-CollaborativeArrangementMember"
      decimals="-6"
      id="c96254134"
      unitRef="USD">0</us-gaap:ContractsReceivableClaimsAndUncertainAmounts>
    <us-gaap:ContractsReceivableClaimsAndUncertainAmounts
      contextRef="i_2022-12-31_CounterpartyNameAxis-SeattleGeneticsIncMember_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-ResearchAndDevelopmentMilestonePaymentsMember_TypeOfArrangementAxis-CollaborativeArrangementMember"
      decimals="-6"
      id="c96254135"
      unitRef="USD">759000000</us-gaap:ContractsReceivableClaimsAndUncertainAmounts>
    <us-gaap:ContractsReceivableClaimsAndUncertainAmounts
      contextRef="i_2022-12-31_CounterpartyNameAxis-SeattleGeneticsIncMember_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-SalesMilestonePaymentsMember_TypeOfArrangementAxis-CollaborativeArrangementMember"
      decimals="-7"
      id="c96254136"
      unitRef="USD">450000000</us-gaap:ContractsReceivableClaimsAndUncertainAmounts>
    <us-gaap:ContractsReceivableClaimsAndUncertainAmounts
      contextRef="i_2022-12-31_CounterpartyNameAxis-BostonPharmaceuticalsMember_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-ResearchAndDevelopmentMilestonePaymentsMember_TypeOfArrangementAxis-CollaborativeArrangementMember"
      decimals="-6"
      id="c96254137"
      unitRef="USD">88000000</us-gaap:ContractsReceivableClaimsAndUncertainAmounts>
    <us-gaap:ContractsReceivableClaimsAndUncertainAmounts
      contextRef="i_2022-12-31_CounterpartyNameAxis-BostonPharmaceuticalsMember_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-SalesMilestonePaymentsMember_TypeOfArrangementAxis-CollaborativeArrangementMember"
      decimals="-6"
      id="c96254138"
      unitRef="USD">265000000</us-gaap:ContractsReceivableClaimsAndUncertainAmounts>
    <us-gaap:ContractsReceivableClaimsAndUncertainAmounts
      contextRef="i_2022-12-31_CounterpartyNameAxis-GenentechMember_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-ResearchAndDevelopmentMilestonePaymentsMember_TypeOfArrangementAxis-CollaborativeArrangementMember"
      decimals="-6"
      id="c96254139"
      unitRef="USD">834000000</us-gaap:ContractsReceivableClaimsAndUncertainAmounts>
    <us-gaap:ContractsReceivableClaimsAndUncertainAmounts
      contextRef="i_2022-12-31_CounterpartyNameAxis-GenentechMember_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-SalesMilestonePaymentsMember_TypeOfArrangementAxis-CollaborativeArrangementMember"
      decimals="-8"
      id="c96254140"
      unitRef="USD">600000000</us-gaap:ContractsReceivableClaimsAndUncertainAmounts>
    <us-gaap:ContractsReceivableClaimsAndUncertainAmounts
      contextRef="i_2022-12-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-ResearchAndDevelopmentMilestonePaymentsMember_TypeOfArrangementAxis-CollaborativeArrangementMember"
      decimals="-6"
      id="c96254141"
      unitRef="USD">2403000000</us-gaap:ContractsReceivableClaimsAndUncertainAmounts>
    <us-gaap:ContractsReceivableClaimsAndUncertainAmounts
      contextRef="i_2022-12-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-SalesMilestonePaymentsMember_TypeOfArrangementAxis-CollaborativeArrangementMember"
      decimals="-7"
      id="c96254142"
      unitRef="USD">5240000000</us-gaap:ContractsReceivableClaimsAndUncertainAmounts>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i_2021-05-19_CounterpartyNameAxis-GenentechMember_ProductOrServiceAxis-LicenseMember"
      decimals="-7"
      id="c96253742"
      unitRef="USD">20000000</us-gaap:ContractWithCustomerLiability>
    <pirs:RevenueFromContractWithCustomerCollaborationFeeOnAdditionalProgram
      contextRef="d_2021-05-19_2021-05-19_CounterpartyNameAxis-GenentechMember"
      decimals="-7"
      id="c96253745"
      unitRef="USD">10000000</pirs:RevenueFromContractWithCustomerCollaborationFeeOnAdditionalProgram>
    <pirs:RevenueFromContractWithCustomerAgreementTerminationNoticePeriodWithinMaterialBreach
      contextRef="d_2021-05-19_2021-05-19_CounterpartyNameAxis-GenentechMember"
      id="c96253749">P90D</pirs:RevenueFromContractWithCustomerAgreementTerminationNoticePeriodWithinMaterialBreach>
    <pirs:RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodBeforeFirstCommercialSale
      contextRef="d_2021-05-19_2021-05-19_CounterpartyNameAxis-GenentechMember"
      id="c96253751">P90D</pirs:RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodBeforeFirstCommercialSale>
    <pirs:RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodAfterFirstCommercialSale
      contextRef="d_2021-05-19_2021-05-19_CounterpartyNameAxis-GenentechMember"
      id="c96253753">P180D</pirs:RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodAfterFirstCommercialSale>
    <pirs:NumberOfResearchPrograms
      contextRef="i_2021-05-19_CounterpartyNameAxis-GenentechMember"
      decimals="INF"
      id="c96253755"
      unitRef="Pure">4</pirs:NumberOfResearchPrograms>
    <pirs:NumberOfInitialResearchPrograms
      contextRef="i_2021-05-19_CounterpartyNameAxis-GenentechMember"
      decimals="INF"
      id="c96253756"
      unitRef="Pure">2</pirs:NumberOfInitialResearchPrograms>
    <pirs:NumberOfResearchPrograms
      contextRef="i_2021-05-19_CounterpartyNameAxis-GenentechMember"
      decimals="INF"
      id="c96253757"
      unitRef="Pure">4</pirs:NumberOfResearchPrograms>
    <pirs:NumberOfOptionalAdditionalResearchPrograms
      contextRef="i_2021-05-19_CounterpartyNameAxis-GenentechMember"
      decimals="INF"
      id="c96253758"
      unitRef="Pure">2</pirs:NumberOfOptionalAdditionalResearchPrograms>
    <pirs:NumberOfResearchPrograms
      contextRef="i_2021-05-19_CounterpartyNameAxis-GenentechMember"
      decimals="INF"
      id="c96253761"
      unitRef="Pure">4</pirs:NumberOfResearchPrograms>
    <pirs:NumberOfInitialResearchPrograms
      contextRef="i_2021-05-19_CounterpartyNameAxis-GenentechMember"
      decimals="INF"
      id="c96253764"
      unitRef="Pure">2</pirs:NumberOfInitialResearchPrograms>
    <pirs:NumberOfPerformanceObligations
      contextRef="i_2021-05-19_CounterpartyNameAxis-GenentechMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember"
      decimals="INF"
      id="c96253769"
      unitRef="Pure">5</pirs:NumberOfPerformanceObligations>
    <pirs:NumberOfPerformanceObligations
      contextRef="i_2021-05-19_CounterpartyNameAxis-GenentechMember_TypeOfArrangementAxis-PlatformTechnologyLicenseMember"
      decimals="INF"
      id="c96253770"
      unitRef="Pure">2</pirs:NumberOfPerformanceObligations>
    <pirs:NumberOfInitialResearchPrograms
      contextRef="i_2021-05-19_CounterpartyNameAxis-GenentechMember"
      decimals="INF"
      id="c96253772"
      unitRef="Pure">2</pirs:NumberOfInitialResearchPrograms>
    <pirs:NumberOfPerformanceObligations
      contextRef="i_2021-05-19_CounterpartyNameAxis-GenentechMember"
      decimals="INF"
      id="c96253773"
      unitRef="Pure">2</pirs:NumberOfPerformanceObligations>
    <pirs:NumberOfInitialResearchPrograms
      contextRef="i_2021-05-19_CounterpartyNameAxis-GenentechMember"
      decimals="INF"
      id="c96253775"
      unitRef="Pure">2</pirs:NumberOfInitialResearchPrograms>
    <pirs:NumberOfPerformanceObligations
      contextRef="i_2021-05-19_CounterpartyNameAxis-GenentechMember_TypeOfArrangementAxis-GovernanceCommitteeParticipationMember"
      decimals="INF"
      id="c96253776"
      unitRef="Pure">1</pirs:NumberOfPerformanceObligations>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i_2021-05-19_CounterpartyNameAxis-GenentechMember_ProductOrServiceAxis-LicenseMember"
      decimals="-7"
      id="c96253778"
      unitRef="USD">20000000.0</us-gaap:ContractWithCustomerLiability>
    <pirs:NumberOfInitialResearchPrograms
      contextRef="i_2021-05-19_CounterpartyNameAxis-GenentechMember"
      decimals="INF"
      id="c96253779"
      unitRef="Pure">2</pirs:NumberOfInitialResearchPrograms>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i_2022-12-31_CounterpartyNameAxis-GenentechMember"
      decimals="-5"
      id="c96253780"
      unitRef="USD">12600000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i_2022-12-31_CounterpartyNameAxis-GenentechMember_ProductOrServiceAxis-LicenseMember"
      decimals="-5"
      id="c96253782"
      unitRef="USD">7800000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i_2022-12-31_CounterpartyNameAxis-GenentechMember_ProductOrServiceAxis-LicenseMember"
      decimals="-5"
      id="c96253783"
      unitRef="USD">4800000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i_2021-04-24_CounterpartyNameAxis-BPAssetsXIIIncMember_ProductOrServiceAxis-LicenseMember_TypeOfArrangementAxis-ExclusiveProductLicenseAgreementMember"
      decimals="-7"
      id="c96253788"
      unitRef="USD">10000000.0</us-gaap:ContractWithCustomerLiability>
    <pirs:RevenueFromContractWithCustomerContributionTowardsManufacturingActivities
      contextRef="d_2021-04-24_2021-04-24_CounterpartyNameAxis-BPAssetsXIIIncMember_ProductOrServiceAxis-LicenseMember_TypeOfArrangementAxis-ExclusiveProductLicenseAgreementMember"
      decimals="-6"
      id="c96253790"
      unitRef="USD">4000000.0</pirs:RevenueFromContractWithCustomerContributionTowardsManufacturingActivities>
    <pirs:RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriod
      contextRef="d_2021-04-24_2021-04-24_CounterpartyNameAxis-BPAssetsXIIIncMember_ProductOrServiceAxis-LicenseMember_TypeOfArrangementAxis-ExclusiveProductLicenseAgreementMember"
      id="c96253793">P60D</pirs:RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriod>
    <pirs:RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodIfMarketingApprovalObtained
      contextRef="d_2021-04-24_2021-04-24_CounterpartyNameAxis-BPAssetsXIIIncMember_ProductOrServiceAxis-LicenseMember_TypeOfArrangementAxis-ExclusiveProductLicenseAgreementMember"
      id="c96253794">P120D</pirs:RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodIfMarketingApprovalObtained>
    <pirs:RevenueFromContractWithCustomerAgreementTerminationNoticePeriodUponMaterialBreach
      contextRef="d_2021-04-24_2021-04-24_CounterpartyNameAxis-BPAssetsXIIIncMember_ProductOrServiceAxis-LicenseMember_TypeOfArrangementAxis-ExclusiveProductLicenseAgreementMember"
      id="c96253795">P180D</pirs:RevenueFromContractWithCustomerAgreementTerminationNoticePeriodUponMaterialBreach>
    <pirs:RevenueFromContractWithCustomerAgreementTerminationNoticePeriodNonpaymentOfUndisputedAmounts
      contextRef="d_2021-04-24_2021-04-24_CounterpartyNameAxis-BPAssetsXIIIncMember_ProductOrServiceAxis-LicenseMember_TypeOfArrangementAxis-ExclusiveProductLicenseAgreementMember"
      id="c96253796">P60D</pirs:RevenueFromContractWithCustomerAgreementTerminationNoticePeriodNonpaymentOfUndisputedAmounts>
    <pirs:RevenueFromContractWithCustomerAgreementTerminationAdditionalNoticePeriodUponMaterialBreach
      contextRef="d_2021-04-24_2021-04-24_CounterpartyNameAxis-BPAssetsXIIIncMember_ProductOrServiceAxis-LicenseMember_TypeOfArrangementAxis-ExclusiveProductLicenseAgreementMember"
      id="c96253797">P180D</pirs:RevenueFromContractWithCustomerAgreementTerminationAdditionalNoticePeriodUponMaterialBreach>
    <pirs:RevenueFromContractWithCustomerAgreementObligationCost
      contextRef="d_2021-04-24_2021-04-24_CounterpartyNameAxis-BPAssetsXIIIncMember_ProductOrServiceAxis-LicenseMember_TypeOfArrangementAxis-ExclusiveProductLicenseAgreementMember"
      decimals="-6"
      id="c96253799"
      unitRef="USD">4000000.0</pirs:RevenueFromContractWithCustomerAgreementObligationCost>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i_2021-04-24_CounterpartyNameAxis-BPAssetsXIIIncMember_ProductOrServiceAxis-LicenseMember_TypeOfArrangementAxis-ExclusiveProductLicenseAgreementMember"
      decimals="-7"
      id="c96253803"
      unitRef="USD">10000000.0</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i_2021-04-24_CounterpartyNameAxis-BPAssetsXIIIncMember_ProductOrServiceAxis-LicenseMember"
      decimals="-6"
      id="c96253804"
      unitRef="USD">4000000.0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i_2021-04-24_CounterpartyNameAxis-BPAssetsXIIIncMember_ProductOrServiceAxis-LicenseMember"
      decimals="-6"
      id="c96253805"
      unitRef="USD">6000000.0</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-BPAssetsXIIIncMember_ProductOrServiceAxis-LicenseMember_TypeOfArrangementAxis-ExclusiveProductLicenseAgreementMember"
      decimals="-5"
      id="c96253810"
      unitRef="USD">5700000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <pirs:NumberOfResearchPrograms
      contextRef="i_2018-02-08_CounterpartyNameAxis-SeattleGeneticsIncMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember"
      decimals="INF"
      id="c96253812"
      unitRef="Pure">3</pirs:NumberOfResearchPrograms>
    <pirs:NumberOfResearchPrograms
      contextRef="i_2018-02-08_CounterpartyNameAxis-SeattleGeneticsIncMember_TypeOfArrangementAxis-OtherArrangementMember"
      decimals="INF"
      id="c96253814"
      unitRef="Pure">2</pirs:NumberOfResearchPrograms>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2018-02-08_2018-02-08_CounterpartyNameAxis-SeattleGeneticsIncMember_ProductOrServiceAxis-LicenseMember_TypeOfArrangementAxis-UpFrontPaymentArrangementMember"
      decimals="-7"
      id="c96253815"
      unitRef="USD">30000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="d_2018-02-08_2018-02-08_CounterpartyNameAxis-SeattleGeneticsIncMember_TypeOfArrangementAxis-UpFrontPaymentArrangementMember"
      decimals="-5"
      id="c96253816"
      unitRef="USD">4900000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <pirs:RevenueFromContractWithCustomerPeriodAfterEffectiveDateAgreementsMayBeTerminated
      contextRef="d_2018-02-08_2018-02-08_CounterpartyNameAxis-SeattleGeneticsIncMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember"
      id="c96253818">P12M</pirs:RevenueFromContractWithCustomerPeriodAfterEffectiveDateAgreementsMayBeTerminated>
    <pirs:RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriod
      contextRef="d_2018-02-08_2018-02-08_CounterpartyNameAxis-SeattleGeneticsIncMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember"
      id="c96253819">P90D</pirs:RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriod>
    <pirs:RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodIfMarketingApprovalObtained
      contextRef="d_2018-02-08_2018-02-08_CounterpartyNameAxis-SeattleGeneticsIncMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember"
      id="c96253820">P180D</pirs:RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodIfMarketingApprovalObtained>
    <pirs:RevenueFromContractWithCustomerAgreementTerminationNoticePeriodUponMaterialBreach
      contextRef="d_2018-02-08_2018-02-08_CounterpartyNameAxis-SeattleGeneticsIncMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember"
      id="c96253821">P90D</pirs:RevenueFromContractWithCustomerAgreementTerminationNoticePeriodUponMaterialBreach>
    <pirs:RevenueFromContractWithCustomerAgreementTerminationAdditionalNoticePeriodUponMaterialBreach
      contextRef="d_2018-02-08_2018-02-08_CounterpartyNameAxis-SeattleGeneticsIncMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember"
      id="c96253822">P90D</pirs:RevenueFromContractWithCustomerAgreementTerminationAdditionalNoticePeriodUponMaterialBreach>
    <pirs:NumberOfLicenses
      contextRef="d_2018-02-08_2018-02-08_CounterpartyNameAxis-SeattleGeneticsIncMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember"
      decimals="INF"
      id="c96253824"
      unitRef="Pure">3</pirs:NumberOfLicenses>
    <pirs:NumberOfSwapOptions
      contextRef="d_2018-02-08_2018-02-08_CounterpartyNameAxis-SeattleGeneticsIncMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember"
      decimals="INF"
      id="c96253825"
      unitRef="Pure">2</pirs:NumberOfSwapOptions>
    <pirs:NumberOfPerformanceObligations
      contextRef="i_2018-02-08_CounterpartyNameAxis-SeattleGeneticsIncMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember"
      decimals="INF"
      id="c96253830"
      unitRef="Pure">6</pirs:NumberOfPerformanceObligations>
    <pirs:NumberOfPerformanceObligations
      contextRef="i_2018-02-08_CounterpartyNameAxis-SeattleGeneticsIncMember_TypeOfArrangementAxis-PlatformTechnologyLicenseMember"
      decimals="INF"
      id="c96253831"
      unitRef="Pure">3</pirs:NumberOfPerformanceObligations>
    <pirs:NumberOfTargetPrograms
      contextRef="d_2018-02-08_2018-02-08_CounterpartyNameAxis-SeattleGeneticsIncMember_TypeOfArrangementAxis-PlatformTechnologyLicenseMember"
      decimals="INF"
      id="c96253833"
      unitRef="Pure">3</pirs:NumberOfTargetPrograms>
    <pirs:NumberOfPerformanceObligations
      contextRef="i_2018-02-08_CounterpartyNameAxis-SeattleGeneticsIncMember_TypeOfArrangementAxis-AntibodyTargetSwapMember"
      decimals="INF"
      id="c96253834"
      unitRef="Pure">2</pirs:NumberOfPerformanceObligations>
    <pirs:NumberOfPerformanceObligations
      contextRef="i_2018-02-08_CounterpartyNameAxis-SeattleGeneticsIncMember_TypeOfArrangementAxis-GovernanceCommitteeParticipationMember"
      decimals="INF"
      id="c96253838"
      unitRef="Pure">1</pirs:NumberOfPerformanceObligations>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2018-02-08_2018-02-08_CounterpartyNameAxis-SeattleGeneticsIncMember_ProductOrServiceAxis-LicenseMember_TypeOfArrangementAxis-UpFrontPaymentArrangementMember"
      decimals="-7"
      id="c96253840"
      unitRef="USD">30000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="d_2018-02-08_2018-02-08_CounterpartyNameAxis-SeattleGeneticsIncMember_TypeOfArrangementAxis-UpFrontPaymentArrangementMember"
      decimals="-5"
      id="c96253841"
      unitRef="USD">4900000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2018-02-08_2018-02-08_CounterpartyNameAxis-SeattleGeneticsIncMember_ProductOrServiceAxis-LicenseMember_TypeOfArrangementAxis-UpFrontPaymentArrangementMember"
      decimals="-7"
      id="c96253842"
      unitRef="USD">30000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="d_2018-02-08_2018-02-08_CounterpartyNameAxis-SeattleGeneticsIncMember_TypeOfArrangementAxis-UpFrontPaymentArrangementMember"
      decimals="-5"
      id="c96253843"
      unitRef="USD">4900000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <pirs:NumberOfPerformanceObligations
      contextRef="i_2018-02-08_CounterpartyNameAxis-SeattleGeneticsIncMember"
      decimals="INF"
      id="c96253844"
      unitRef="Pure">3</pirs:NumberOfPerformanceObligations>
    <pirs:NumberOfResearchPrograms
      contextRef="i_2018-02-08_CounterpartyNameAxis-SeattleGeneticsIncMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember"
      decimals="INF"
      id="c96253845"
      unitRef="Pure">3</pirs:NumberOfResearchPrograms>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i_2022-12-31_CounterpartyNameAxis-SeattleGeneticsIncMember"
      decimals="-5"
      id="c96253846"
      unitRef="USD">17100000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="d_2020-01-01_2020-12-31_CounterpartyNameAxis-SeattleGeneticsIncMember_TransactionTypeAxis-SalesMilestonePaymentsMember_TypeOfArrangementAxis-UpFrontPaymentArrangementMember"
      decimals="-5"
      id="c96253851"
      unitRef="USD">4200000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <pirs:CollaborativeArrangementAllocableArrangementConsiderationAllocation
      contextRef="d_2020-04-01_2020-06-30_CounterpartyNameAxis-SeattleGeneticsIncMember_TransactionTypeAxis-SalesMilestonePaymentsMember_TypeOfArrangementAxis-UpFrontPaymentArrangementMember"
      decimals="-6"
      id="c96253854"
      unitRef="USD">5000000.0</pirs:CollaborativeArrangementAllocableArrangementConsiderationAllocation>
    <pirs:NumberOfResearchPrograms
      contextRef="i_2021-03-24_CounterpartyNameAxis-SeattleGeneticsIncMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember"
      decimals="INF"
      id="c96253862"
      unitRef="Pure">3</pirs:NumberOfResearchPrograms>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="d_2021-03-24_2021-03-24_CounterpartyNameAxis-SeattleGeneticsIncMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="INF"
      id="c96253863"
      unitRef="Share">3706174</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="d_2021-03-24_2021-03-24_CounterpartyNameAxis-SeattleGeneticsIncMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="-6"
      id="c96253864"
      unitRef="USD">13000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i_2021-03-24_CounterpartyNameAxis-SeattleGeneticsIncMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="INF"
      id="c96253865"
      unitRef="USDPerShare">3.51</us-gaap:SaleOfStockPricePerShare>
    <pirs:AmendedCollaborationAgreementResaleOfStockPeriod
      contextRef="d_2021-03-24_2021-03-24_CounterpartyNameAxis-SeattleGeneticsIncMember"
      id="c96253869">P60D</pirs:AmendedCollaborationAgreementResaleOfStockPeriod>
    <pirs:SaleOfStockFairValuePricePerShare
      contextRef="i_2021-03-24_CounterpartyNameAxis-SeattleGeneticsIncMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="INF"
      id="c96253871"
      unitRef="USDPerShare">2.61</pirs:SaleOfStockFairValuePricePerShare>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i_2021-03-24_CounterpartyNameAxis-SeattleGeneticsIncMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="-5"
      id="c96253872"
      unitRef="USD">3300000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="d_2022-04-01_2022-06-30_CounterpartyNameAxis-SeattleGeneticsIncMember_TransactionTypeAxis-SalesMilestonePaymentsMember_TypeOfArrangementAxis-UpFrontPaymentArrangementMember"
      decimals="-5"
      id="c96253881"
      unitRef="USD">1500000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2023-01-01_2023-01-31_CounterpartyNameAxis-SeattleGeneticsIncMember_SubsequentEventTypeAxis-SubsequentEventMember_TypeOfArrangementAxis-CollaborativeArrangementMember"
      decimals="-6"
      id="c96253884"
      unitRef="USD">5000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2023-01-01_2023-01-31_CounterpartyNameAxis-SeattleGeneticsIncMember_SubsequentEventTypeAxis-SubsequentEventMember_TypeOfArrangementAxis-CollaborativeArrangementMember"
      decimals="-6"
      id="c96253886"
      unitRef="USD">5000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2022-01-01_2022-12-31_CounterpartyNameAxis-SeattleGeneticsIncMember_TypeOfArrangementAxis-CollaborativeArrangementMember"
      decimals="-6"
      id="c96253889"
      unitRef="USD">5000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i_2022-12-31_CounterpartyNameAxis-SeattleGeneticsIncMember"
      decimals="-5"
      id="c96253890"
      unitRef="USD">11600000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i_2022-12-31_CounterpartyNameAxis-SeattleGeneticsIncMember"
      decimals="-5"
      id="c96253891"
      unitRef="USD">2900000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <pirs:NumberOfNovelProteins
      contextRef="d_2017-05-02_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember"
      decimals="INF"
      id="c96253898"
      unitRef="Pure">4</pirs:NumberOfNovelProteins>
    <pirs:NumberOfCollaborationProducts
      contextRef="i_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_RangeAxis-MinimumMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember"
      decimals="INF"
      id="c96253902"
      unitRef="Pure">2</pirs:NumberOfCollaborationProducts>
    <pirs:NumberOfCollaborationProducts
      contextRef="i_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember"
      decimals="INF"
      id="c96253903"
      unitRef="Pure">4</pirs:NumberOfCollaborationProducts>
    <pirs:NumberOfPrograms
      contextRef="d_2017-05-02_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember"
      decimals="INF"
      id="c96253904"
      unitRef="Pure">2</pirs:NumberOfPrograms>
    <pirs:RevenueFromContractWithCustomerPeriodAfterEffectiveDateAgreementsMayBeTerminated
      contextRef="d_2017-05-02_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember"
      id="c96253906">P12M</pirs:RevenueFromContractWithCustomerPeriodAfterEffectiveDateAgreementsMayBeTerminated>
    <pirs:RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriod
      contextRef="d_2017-05-02_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember"
      id="c96253907">P90D</pirs:RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriod>
    <pirs:RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodIfMarketingApprovalObtained
      contextRef="d_2017-05-02_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember"
      id="c96253908">P180D</pirs:RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodIfMarketingApprovalObtained>
    <pirs:RevenueFromContractWithCustomerAgreementTerminationNoticePeriodUponMaterialBreach
      contextRef="d_2017-05-02_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember"
      id="c96253909">P180D</pirs:RevenueFromContractWithCustomerAgreementTerminationNoticePeriodUponMaterialBreach>
    <pirs:AgreementTerminationNoticePeriodUponOfBreachOfPaymentObligations
      contextRef="d_2017-05-02_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember"
      id="c96253910">P30D</pirs:AgreementTerminationNoticePeriodUponOfBreachOfPaymentObligations>
    <pirs:RevenueFromContractWithCustomerAgreementTerminationAdditionalNoticePeriodUponMaterialBreach
      contextRef="d_2017-05-02_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember"
      id="c96253912">P180D</pirs:RevenueFromContractWithCustomerAgreementTerminationAdditionalNoticePeriodUponMaterialBreach>
    <pirs:RevenueFromContractWithCustomerAgreementTerminationNoticePeriodUponMaterialBreach
      contextRef="d_2017-05-02_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember"
      id="c96253914">P180D</pirs:RevenueFromContractWithCustomerAgreementTerminationNoticePeriodUponMaterialBreach>
    <pirs:NumberOfCollaborationProducts
      contextRef="i_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember"
      decimals="INF"
      id="c96253915"
      unitRef="Pure">4</pirs:NumberOfCollaborationProducts>
    <pirs:NumberOfCollaborationProducts
      contextRef="i_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember"
      decimals="INF"
      id="c96253916"
      unitRef="Pure">4</pirs:NumberOfCollaborationProducts>
    <pirs:NumberOfCollaborationProducts
      contextRef="i_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember"
      decimals="INF"
      id="c96253917"
      unitRef="Pure">4</pirs:NumberOfCollaborationProducts>
    <pirs:NumberOfCollaborationProducts
      contextRef="i_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember"
      decimals="INF"
      id="c96253918"
      unitRef="Pure">4</pirs:NumberOfCollaborationProducts>
    <pirs:RevenueFromContractWithCustomerAllocableArrangementConsiderationAllocation
      contextRef="d_2017-05-02_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_TypeOfArrangementAxis-UpFrontPaymentArrangementMember"
      decimals="-6"
      id="c96253919"
      unitRef="USD">45000000.0</pirs:RevenueFromContractWithCustomerAllocableArrangementConsiderationAllocation>
    <pirs:NumberOfTechnologyLicenses
      contextRef="d_2017-05-02_2017-05-02"
      decimals="INF"
      id="c96253922"
      unitRef="Pure">5</pirs:NumberOfTechnologyLicenses>
    <pirs:NumberOfResearchLicenses
      contextRef="d_2017-05-02_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember"
      decimals="INF"
      id="c96253924"
      unitRef="Pure">4</pirs:NumberOfResearchLicenses>
    <pirs:NumberOfResearchLicenses
      contextRef="d_2017-05-02_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember"
      decimals="INF"
      id="c96253925"
      unitRef="Pure">4</pirs:NumberOfResearchLicenses>
    <pirs:NumberOfCollaborationProducts
      contextRef="i_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember"
      decimals="INF"
      id="c96253928"
      unitRef="Pure">4</pirs:NumberOfCollaborationProducts>
    <pirs:NumberOfPerformanceObligations
      contextRef="i_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember"
      decimals="INF"
      id="c96253939"
      unitRef="Pure">16</pirs:NumberOfPerformanceObligations>
    <pirs:NumberOfCollaborationProducts
      contextRef="i_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember"
      decimals="INF"
      id="c96253940"
      unitRef="Pure">4</pirs:NumberOfCollaborationProducts>
    <pirs:NumberOfCollaborationProducts
      contextRef="i_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember"
      decimals="INF"
      id="c96253941"
      unitRef="Pure">4</pirs:NumberOfCollaborationProducts>
    <pirs:NumberOfCollaborationProducts
      contextRef="i_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember"
      decimals="INF"
      id="c96253942"
      unitRef="Pure">4</pirs:NumberOfCollaborationProducts>
    <pirs:RevenueFromContractWithCustomerAllocableArrangementConsiderationAllocation
      contextRef="d_2017-05-02_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_TypeOfArrangementAxis-UpFrontPaymentArrangementMember"
      decimals="-6"
      id="c96253945"
      unitRef="USD">45000000.0</pirs:RevenueFromContractWithCustomerAllocableArrangementConsiderationAllocation>
    <pirs:RevenueFromContractWithCustomerAllocableArrangementConsiderationAllocation
      contextRef="d_2017-05-02_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_TransactionTypeAxis-EstimatedDevelopmentAndManufacturingServicesMember_TypeOfArrangementAxis-UpFrontPaymentArrangementMember"
      decimals="-5"
      id="c96253946"
      unitRef="USD">14200000</pirs:RevenueFromContractWithCustomerAllocableArrangementConsiderationAllocation>
    <pirs:RevenueFromContractWithCustomerAllocableArrangementConsiderationAllocation
      contextRef="d_2017-05-02_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_TransactionTypeAxis-SalesMilestonePaymentsMember_TypeOfArrangementAxis-UpFrontPaymentArrangementMember"
      decimals="-5"
      id="c96253948"
      unitRef="USD">12500000</pirs:RevenueFromContractWithCustomerAllocableArrangementConsiderationAllocation>
    <pirs:RevenueFromContractWithCustomerAllocableArrangementConsiderationAllocation
      contextRef="d_2017-05-02_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_TransactionTypeAxis-EstimatedPhase2aServicesMember_TypeOfArrangementAxis-UpFrontPaymentArrangementMember"
      decimals="-5"
      id="c96253950"
      unitRef="USD">4700000</pirs:RevenueFromContractWithCustomerAllocableArrangementConsiderationAllocation>
    <pirs:RevenueFromContractWithCustomerAllocableArrangementConsiderationAllocation
      contextRef="d_2017-05-02_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_TypeOfArrangementAxis-UpFrontPaymentArrangementMember"
      decimals="-6"
      id="c96253952"
      unitRef="USD">45000000.0</pirs:RevenueFromContractWithCustomerAllocableArrangementConsiderationAllocation>
    <pirs:RevenueFromContractWithCustomerAllocableArrangementConsiderationAllocation
      contextRef="d_2017-05-02_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_TransactionTypeAxis-EstimatedDevelopmentAndManufacturingServicesMember_TypeOfArrangementAxis-UpFrontPaymentArrangementMember"
      decimals="-5"
      id="c96253953"
      unitRef="USD">14200000</pirs:RevenueFromContractWithCustomerAllocableArrangementConsiderationAllocation>
    <pirs:RevenueFromContractWithCustomerAllocableArrangementConsiderationAllocation
      contextRef="d_2017-05-02_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_TransactionTypeAxis-SalesMilestonePaymentsMember_TypeOfArrangementAxis-UpFrontPaymentArrangementMember"
      decimals="-5"
      id="c96253955"
      unitRef="USD">12500000</pirs:RevenueFromContractWithCustomerAllocableArrangementConsiderationAllocation>
    <pirs:RevenueFromContractWithCustomerAllocableArrangementConsiderationAllocation
      contextRef="d_2017-05-02_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_TypeOfArrangementAxis-AdditionalOtherResearchServicesMember"
      decimals="-5"
      id="c96253957"
      unitRef="USD">4700000</pirs:RevenueFromContractWithCustomerAllocableArrangementConsiderationAllocation>
    <pirs:NumberOfCollaborationProducts
      contextRef="i_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember"
      decimals="INF"
      id="c96253959"
      unitRef="Pure">4</pirs:NumberOfCollaborationProducts>
    <pirs:NumberOfResearchLicenses
      contextRef="d_2017-05-02_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember"
      decimals="INF"
      id="c96253960"
      unitRef="Pure">4</pirs:NumberOfResearchLicenses>
    <pirs:RemainingPerformanceObligationEstimatedTerm
      contextRef="d_2017-05-02_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember"
      id="c96253964">P12M</pirs:RemainingPerformanceObligationEstimatedTerm>
    <pirs:NumberOfCollaborationProducts
      contextRef="i_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember"
      decimals="INF"
      id="c96253966"
      unitRef="Pure">4</pirs:NumberOfCollaborationProducts>
    <pirs:NumberOfCollaborationProducts
      contextRef="i_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember"
      decimals="INF"
      id="c96253967"
      unitRef="Pure">4</pirs:NumberOfCollaborationProducts>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i_2022-12-31_CounterpartyNameAxis-AstraZenecaABMember"
      decimals="-5"
      id="c96253968"
      unitRef="USD">7500000</us-gaap:RevenueRemainingPerformanceObligation>
    <pirs:NumberOfCollaborationProducts
      contextRef="i_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember_RangeAxis-MinimumMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember"
      decimals="INF"
      id="c96253969"
      unitRef="Pure">2</pirs:NumberOfCollaborationProducts>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="d_2021-04-01_2021-04-01_CounterpartyNameAxis-AstraZenecaABMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="INF"
      id="c96253983"
      unitRef="Share">3584230</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="d_2021-04-01_2021-04-01_CounterpartyNameAxis-AstraZenecaABMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="-7"
      id="c96253984"
      unitRef="USD">10000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i_2021-04-01_CounterpartyNameAxis-AstraZenecaABMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="INF"
      id="c96253985"
      unitRef="USDPerShare">2.79</us-gaap:SaleOfStockPricePerShare>
    <pirs:AmendedCollaborationAgreementResaleOfStockPeriod
      contextRef="d_2021-04-01_2021-04-01_CounterpartyNameAxis-AstraZenecaABMember"
      id="c96253989">P60D</pirs:AmendedCollaborationAgreementResaleOfStockPeriod>
    <pirs:SaleOfStockFairValuePricePerShare
      contextRef="i_2021-04-01_CounterpartyNameAxis-AstraZenecaABMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="INF"
      id="c96253991"
      unitRef="USDPerShare">2.60</pirs:SaleOfStockFairValuePricePerShare>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i_2022-12-31_CounterpartyNameAxis-AstraZenecaABMember"
      decimals="-5"
      id="c96253992"
      unitRef="USD">700000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:Revenues
      contextRef="d_2021-03-01_2021-03-31_CounterpartyNameAxis-AstraZenecaABMember"
      decimals="-6"
      id="c96253993"
      unitRef="USD">13000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="d_2021-03-01_2021-03-31_CounterpartyNameAxis-AstraZenecaABMember"
      decimals="-6"
      id="c96253999"
      unitRef="USD">13000000.0</us-gaap:Revenues>
    <pirs:NumberOfDiscoveryProgramsDiscontinued
      contextRef="i_2022-01-31_CounterpartyNameAxis-AstraZenecaABMember"
      decimals="INF"
      id="c96254000"
      unitRef="Pure">1</pirs:NumberOfDiscoveryProgramsDiscontinued>
    <pirs:RevenueFromContractWithCustomerAllocableArrangementConsiderationAllocation
      contextRef="d_2022-01-01_2022-01-31_CounterpartyNameAxis-AstraZenecaABMember"
      decimals="-5"
      id="c96254002"
      unitRef="USD">4700000</pirs:RevenueFromContractWithCustomerAllocableArrangementConsiderationAllocation>
    <pirs:RevenueFromContractWithCustomerAllocableArrangementConsiderationAllocation
      contextRef="d_2022-08-01_2022-08-31_CounterpartyNameAxis-AstraZenecaABMember"
      decimals="-6"
      id="c96254005"
      unitRef="USD">5000000.0</pirs:RevenueFromContractWithCustomerAllocableArrangementConsiderationAllocation>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i_2022-12-31_CounterpartyNameAxis-AstraZenecaABMember"
      decimals="-5"
      id="c96254006"
      unitRef="USD">500000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i_2022-12-31_CounterpartyNameAxis-AstraZenecaABMember"
      decimals="-5"
      id="c96254007"
      unitRef="USD">6900000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:CapitalizedContractCostNet
      contextRef="i_2017-05-02_CounterpartyNameAxis-AstraZenecaABMember"
      decimals="-5"
      id="c96254008"
      unitRef="USD">1600000</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostGross
      contextRef="i_2019-01-01_CounterpartyNameAxis-AstraZenecaABMember"
      decimals="-5"
      id="c96254011"
      unitRef="USD">1100000</us-gaap:CapitalizedContractCostGross>
    <us-gaap:CapitalizedContractCostNet
      contextRef="i_2022-12-31_CounterpartyNameAxis-AstraZenecaABMember"
      decimals="-5"
      id="c96254013"
      unitRef="USD">200000</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-AstraZenecaABMember"
      decimals="-5"
      id="c96254015"
      unitRef="USD">300000</us-gaap:CapitalizedContractCostAmortization>
    <pirs:NumberOfPrograms
      contextRef="d_2017-01-01_2017-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember"
      decimals="INF"
      id="c96254019"
      unitRef="Pure">5</pirs:NumberOfPrograms>
    <pirs:NumberOfNovelProteins
      contextRef="d_2017-01-01_2017-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember"
      decimals="INF"
      id="c96254020"
      unitRef="Pure">1</pirs:NumberOfNovelProteins>
    <pirs:NumberOfPrograms
      contextRef="d_2017-01-01_2017-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember"
      decimals="INF"
      id="c96254021"
      unitRef="Pure">3</pirs:NumberOfPrograms>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2017-01-01_2017-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_ProductOrServiceAxis-LicenseMember_TypeOfArrangementAxis-UpFrontPaymentArrangementMember"
      decimals="-6"
      id="c96254028"
      unitRef="USD">32000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="d_2022-01-01_2022-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_TypeOfArrangementAxis-CollaborativeArrangementMember"
      decimals="-5"
      id="c96254031"
      unitRef="USD">4300000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <pirs:NumberOfDevelopmentMilestones
      contextRef="d_2017-01-01_2017-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_ProductOrServiceAxis-ResearchAndDevelopmentServicesMember"
      decimals="INF"
      id="c96254032"
      unitRef="Pure">3</pirs:NumberOfDevelopmentMilestones>
    <pirs:RevenueFromContractWithCustomerAgreementTerminationNoticePeriodUponMaterialBreach
      contextRef="d_2017-01-01_2017-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_RangeAxis-MinimumMember_TypeOfArrangementAxis-CollaborativeArrangementMember"
      id="c96254036">P90D</pirs:RevenueFromContractWithCustomerAgreementTerminationNoticePeriodUponMaterialBreach>
    <pirs:RevenueFromContractWithCustomerAgreementTerminationNoticePeriodUponMaterialBreach
      contextRef="d_2017-01-01_2017-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-CollaborativeArrangementMember"
      id="c96254037">P120D</pirs:RevenueFromContractWithCustomerAgreementTerminationNoticePeriodUponMaterialBreach>
    <pirs:RevenueFromContractWithCustomerAgreementTerminationNoticePeriodUponMaterialBreach
      contextRef="d_2017-01-01_2017-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_RangeAxis-MinimumMember_TypeOfArrangementAxis-CollaborativeArrangementMember"
      id="c96254039">P90D</pirs:RevenueFromContractWithCustomerAgreementTerminationNoticePeriodUponMaterialBreach>
    <pirs:RevenueFromContractWithCustomerAgreementTerminationNoticePeriodUponMaterialBreach
      contextRef="d_2017-01-01_2017-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-CollaborativeArrangementMember"
      id="c96254040">P120D</pirs:RevenueFromContractWithCustomerAgreementTerminationNoticePeriodUponMaterialBreach>
    <pirs:NumberOfPerformanceObligations
      contextRef="i_2017-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember"
      decimals="INF"
      id="c96254052"
      unitRef="Pure">10</pirs:NumberOfPerformanceObligations>
    <pirs:NumberOfSeparatePerformanceObligations
      contextRef="d_2017-01-04_2017-01-04_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_TypeOfArrangementAxis-CollaborativeArrangementMember"
      decimals="INF"
      id="c96254054"
      unitRef="Pure">2</pirs:NumberOfSeparatePerformanceObligations>
    <pirs:NumberOfCombinedPerformanceObligations
      contextRef="d_2017-01-04_2017-01-04_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_TypeOfArrangementAxis-CollaborativeArrangementMember"
      decimals="INF"
      id="c96254056"
      unitRef="Pure">2</pirs:NumberOfCombinedPerformanceObligations>
    <pirs:NumberOfSeparatePerformanceObligations
      contextRef="d_2017-01-04_2017-01-04_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember"
      decimals="INF"
      id="c96254058"
      unitRef="Pure">2</pirs:NumberOfSeparatePerformanceObligations>
    <pirs:NumberOfCombinedPerformanceObligations
      contextRef="d_2017-01-04_2017-01-04_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember"
      decimals="INF"
      id="c96254059"
      unitRef="Pure">2</pirs:NumberOfCombinedPerformanceObligations>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2017-01-01_2017-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_ProductOrServiceAxis-LicenseMember_TypeOfArrangementAxis-UpFrontPaymentArrangementMember"
      decimals="-6"
      id="c96254062"
      unitRef="USD">32000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <pirs:NumberOfPerformanceObligations
      contextRef="i_2017-01-04_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember"
      decimals="INF"
      id="c96254063"
      unitRef="Pure">4</pirs:NumberOfPerformanceObligations>
    <pirs:NumberOfCollaborationProducts
      contextRef="i_2017-01-04_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_TypeOfArrangementAxis-CollaborativeArrangementMember"
      decimals="INF"
      id="c96254064"
      unitRef="Pure">4</pirs:NumberOfCollaborationProducts>
    <pirs:NumberOfCollaborationProducts
      contextRef="i_2017-01-04_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember"
      decimals="INF"
      id="c96254065"
      unitRef="Pure">2</pirs:NumberOfCollaborationProducts>
    <pirs:NumberOfPerformanceObligations
      contextRef="i_2017-01-04_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember"
      decimals="INF"
      id="c96254066"
      unitRef="Pure">4</pirs:NumberOfPerformanceObligations>
    <pirs:NumberOfPerformanceObligations
      contextRef="i_2017-01-04_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_TypeOfArrangementAxis-LicenseAndCollaborationAgreementMember"
      decimals="INF"
      id="c96254067"
      unitRef="Pure">4</pirs:NumberOfPerformanceObligations>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i_2022-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember"
      decimals="-6"
      id="c96254068"
      unitRef="USD">5000000.0</us-gaap:RevenueRemainingPerformanceObligation>
    <pirs:ResearchTermExtensionPeriod
      contextRef="d_2020-02-01_2020-02-29_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember"
      id="c96254076">P12Y</pirs:ResearchTermExtensionPeriod>
    <pirs:NumberOfPrograms
      contextRef="d_2020-02-01_2020-02-29_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember"
      decimals="INF"
      id="c96254077"
      unitRef="Pure">5</pirs:NumberOfPrograms>
    <pirs:NumberOfPreclinicalStagePrograms
      contextRef="i_2020-02-29_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember"
      decimals="INF"
      id="c96254078"
      unitRef="Pure">2</pirs:NumberOfPreclinicalStagePrograms>
    <pirs:NumberOfCollaborationProducts
      contextRef="i_2020-02-29_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_TypeOfArrangementAxis-CodevelopmentCollaborationProductCollaborationMember"
      decimals="INF"
      id="c96254080"
      unitRef="Pure">1</pirs:NumberOfCollaborationProducts>
    <pirs:NumberOfCollaborationProducts
      contextRef="i_2020-02-29_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember_TypeOfArrangementAxis-ServierDevelopedCollaborationProductsMember"
      decimals="INF"
      id="c96254081"
      unitRef="Pure">1</pirs:NumberOfCollaborationProducts>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="d_2020-01-01_2020-03-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember"
      decimals="-5"
      id="c96254082"
      unitRef="USD">7100000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <pirs:NumberOfPreclinicalStagePrograms
      contextRef="i_2020-02-29_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember"
      decimals="INF"
      id="c96254084"
      unitRef="Pure">2</pirs:NumberOfPreclinicalStagePrograms>
    <pirs:NumberOfPreclinicalStagePrograms
      contextRef="i_2020-02-29_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember"
      decimals="INF"
      id="c96254085"
      unitRef="Pure">2</pirs:NumberOfPreclinicalStagePrograms>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="d_2022-10-01_2022-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember"
      decimals="-5"
      id="c96254094"
      unitRef="USD">4900000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i_2022-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember"
      decimals="-5"
      id="c96254098"
      unitRef="USD">900000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i_2022-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember"
      decimals="-5"
      id="c96254099"
      unitRef="USD">4100000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:CapitalizedContractCostNet
      contextRef="i_2019-01-01_AdjustmentsForChangeInAccountingPrincipleAxis-AccountingStandardsUpdate201409Member_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember"
      decimals="-5"
      id="c96254101"
      unitRef="USD">500000</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="i_2022-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember"
      decimals="-3"
      id="c96254104"
      unitRef="USD">0</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="d_2022-01-01_2022-12-31_CounterpartyNameAxis-LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember"
      decimals="-5"
      id="c96254105"
      unitRef="USD">100000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96254107"
      unitRef="USD">0</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-5"
      id="c96254108"
      unitRef="USD">20400000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:GovernmentAssistanceTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2344189">
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 27pt;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;4.&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;Grant Income&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;One of the Company's proprietary respiratory assets is PRS-&lt;em style="font: inherit;"&gt;220,&lt;/em&gt; an oral inhaled Anticalin protein targeting connective tissue growth factor, or CTGF, and it is being developed as a local treatment for idiopathic pulmonary fibrosis. In &lt;em style="font: inherit;"&gt; June 2021, &lt;/em&gt;the Company received a &lt;span style="-sec-ix-hidden:c96254145"&gt;&#x20ac;14.2&lt;/span&gt; million (approximately $17.0 million) grant from the Bavarian Ministry of Economic Affairs, Regional Development and Energy (the Bavarian Grant) supporting research and development for post-acute sequelae of SARS-CoV-&lt;em style="font: inherit;"&gt;2&lt;/em&gt; infection (PASC) pulmonary fibrosis, or PASC-PF, also known as post-COVID-&lt;em style="font: inherit;"&gt;19&lt;/em&gt; syndrome pulmonary fibrosis, or &#x201c;long COVID&#x201d;.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Bavarian Grant provides partial reimbursement for qualifying research and development activities on PRS-&lt;em style="font: inherit;"&gt;220,&lt;/em&gt; including drug manufacturing costs, activities and costs to support an IND filing, and phase &lt;em style="font: inherit;"&gt;1&lt;/em&gt; clinical trials costs. The Bavarian Grant provides reimbursement of qualifying costs incurred through &lt;em style="font: inherit;"&gt; August 2023, &lt;/em&gt;which follows the expected development timeline of this program. Qualifying costs incurred &lt;em style="font: inherit;"&gt; may &lt;/em&gt;exceed the annual grant funding thresholds. If the Company receives any proceeds from the sale of or licensing income from PRS-&lt;em style="font: inherit;"&gt;220,&lt;/em&gt; the funds available for reimbursement will be reduced proportionally if they are obtained prior to &lt;em style="font: inherit;"&gt; August 2023. &lt;/em&gt;The Company is required to communicate such proceeds in each case with the request to draw-down the funds.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;
  </us-gaap:GovernmentAssistanceTextBlock>
    <us-gaap:GrantsReceivable
      contextRef="i_2021-06-30"
      decimals="-6"
      id="c96254146"
      unitRef="USD">17000000.0</us-gaap:GrantsReceivable>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2344190">
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 27pt;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;5.&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;Cash, Cash Equivalents and Investments&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;As of&#160;&lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt;, cash, cash equivalents and investments comprised funds in depository, money market accounts, U.S. and foreign treasury securities, asset-backed securities and corporate bonds. As of&#160;&lt;em style="font: inherit;"&gt; December 31, 2021&lt;/em&gt;, cash equivalents were comprised of only money market accounts. The following table presents the cash equivalents and investments carried at fair value in accordance with the hierarchy defined in Note&#160;&lt;em style="font: inherit;"&gt;2&lt;/em&gt;&#160;at &lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt;.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Quoted prices in active markets (Level 1)&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Significant other observable inputs (Level 2)&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Significant unobservable inputs (Level 3)&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Money market funds, included in cash equivalents&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;17,618&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;17,618&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Investments - US treasuries&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,573&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,573&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Investments - Foreign treasuries&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;896&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;896&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Investments - Asset-backed securities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;499&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;499&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Investments - Corporate bonds&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;15,566&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;15,566&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;38,152&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;22,087&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;16,065&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Quoted prices in active markets (Level 1)&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Significant other observable inputs (Level 2)&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Significant unobservable inputs (Level 3)&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;December 31, 2021&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Money market funds, included in cash equivalents&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;56,885&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;56,885&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;56,885&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;56,885&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;Cash equivalents and marketable securities have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing&#160;&lt;em style="font: inherit;"&gt;third&lt;/em&gt;&#160;party pricing services or other market observable data. The pricing services utilize industry standard valuation models, including both income and market-based approaches and observable market inputs to determine value. The Company validates the prices provided by its&#160;&lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party pricing services by reviewing their pricing methods and obtaining market values from other pricing sources, as needed. After completing its validation procedures, the Company did&#160;&lt;em style="font: inherit;"&gt;not&lt;/em&gt;&#160;adjust any fair value measurements provided by the pricing services as of&#160;&lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt;.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;Investments at&#160;&lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt;&#160;consist of the following (in thousands):&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 37%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 9%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Contractual maturity&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 11%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 11%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 37%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 9%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;span style="-sec-ix-hidden:c96254205"&gt;(in days)&lt;/span&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Amortized Cost&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Unrealized gains&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Unrealized losses&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Fair Value&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 37%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Investments&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 11%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 11%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 37%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;US treasuries&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;em style="font: inherit;"&gt;47&lt;/em&gt;-&lt;em style="font: inherit;"&gt;110&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,575&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(2&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,573&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 37%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Foreign treasuries&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;74&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;899&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(3&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;896&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 37%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Asset-backed securities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;15&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;500&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(1&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;499&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 37%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Corporate bonds&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;em style="font: inherit;"&gt;5&lt;/em&gt;-&lt;em style="font: inherit;"&gt;228&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;15,633&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(67&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;15,566&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 37%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 9%;"&gt;&lt;span style="-sec-ix-hidden:c96254241"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;20,607&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(73&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;20,534&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company recorded&#160;realized gains from the maturity of available-for-sale securities of&#160;$0.4 million for the year ended&#160;&lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt; and recorded&#160;&lt;span style="-sec-ix-hidden:c96254158"&gt;no&lt;/span&gt;&#160;realized gains or losses from the maturity of available-for-sale securities for the year ended&#160;&lt;em style="font: inherit;"&gt; December 31, 2021&lt;/em&gt;.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;As of&#160;&lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt;, there were&#160;&lt;em style="font: inherit;"&gt;no&lt;/em&gt;&#160;investments with a fair value that was significantly lower than the amortized cost basis or any investments that had been in an unrealized loss position for a significant period.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
  </us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="d_2022-01-01_2022-12-31"
      id="c947F62FA-00EE-4B56-8B71-707F0C74A1FC">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Quoted prices in active markets (Level 1)&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Significant other observable inputs (Level 2)&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Significant unobservable inputs (Level 3)&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Money market funds, included in cash equivalents&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;17,618&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;17,618&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Investments - US treasuries&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,573&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,573&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Investments - Foreign treasuries&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;896&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;896&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Investments - Asset-backed securities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;499&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;499&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Investments - Corporate bonds&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;15,566&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;15,566&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;38,152&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;22,087&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;16,065&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Quoted prices in active markets (Level 1)&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Significant other observable inputs (Level 2)&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Significant unobservable inputs (Level 3)&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;December 31, 2021&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Money market funds, included in cash equivalents&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;56,885&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;56,885&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;56,885&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;56,885&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2022-12-31_FinancialInstrumentAxis-MoneyMarketFundsMember"
      decimals="-3"
      id="c96254164"
      unitRef="USD">17618000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FinancialInstrumentAxis-MoneyMarketFundsMember"
      decimals="-3"
      id="c96254165"
      unitRef="USD">17618000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FinancialInstrumentAxis-MoneyMarketFundsMember"
      decimals="-3"
      id="c96254166"
      unitRef="USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FinancialInstrumentAxis-MoneyMarketFundsMember"
      decimals="-3"
      id="c96254167"
      unitRef="USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2022-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember"
      decimals="-3"
      id="c96254168"
      unitRef="USD">3573000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FinancialInstrumentAxis-USTreasurySecuritiesMember"
      decimals="-3"
      id="c96254169"
      unitRef="USD">3573000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FinancialInstrumentAxis-USTreasurySecuritiesMember"
      decimals="-3"
      id="c96254170"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FinancialInstrumentAxis-USTreasurySecuritiesMember"
      decimals="-3"
      id="c96254171"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2022-12-31_FinancialInstrumentAxis-ForeignGovernmentDebtSecuritiesMember"
      decimals="-3"
      id="c96254172"
      unitRef="USD">896000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FinancialInstrumentAxis-ForeignGovernmentDebtSecuritiesMember"
      decimals="-3"
      id="c96254173"
      unitRef="USD">896000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FinancialInstrumentAxis-ForeignGovernmentDebtSecuritiesMember"
      decimals="-3"
      id="c96254174"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FinancialInstrumentAxis-ForeignGovernmentDebtSecuritiesMember"
      decimals="-3"
      id="c96254175"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2022-12-31_FinancialInstrumentAxis-AssetBackedSecuritiesMember"
      decimals="-3"
      id="c96254176"
      unitRef="USD">499000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FinancialInstrumentAxis-AssetBackedSecuritiesMember"
      decimals="-3"
      id="c96254177"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FinancialInstrumentAxis-AssetBackedSecuritiesMember"
      decimals="-3"
      id="c96254178"
      unitRef="USD">499000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FinancialInstrumentAxis-AssetBackedSecuritiesMember"
      decimals="-3"
      id="c96254179"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2022-12-31_FinancialInstrumentAxis-CorporateBondSecuritiesMember"
      decimals="-3"
      id="c96254180"
      unitRef="USD">15566000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FinancialInstrumentAxis-CorporateBondSecuritiesMember"
      decimals="-3"
      id="c96254181"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FinancialInstrumentAxis-CorporateBondSecuritiesMember"
      decimals="-3"
      id="c96254182"
      unitRef="USD">15566000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FinancialInstrumentAxis-CorporateBondSecuritiesMember"
      decimals="-3"
      id="c96254183"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <pirs:CashEquivalentsAndInvestments
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c96254184"
      unitRef="USD">38152000</pirs:CashEquivalentsAndInvestments>
    <pirs:CashEquivalentsAndInvestments
      contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member"
      decimals="-3"
      id="c96254185"
      unitRef="USD">22087000</pirs:CashEquivalentsAndInvestments>
    <pirs:CashEquivalentsAndInvestments
      contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member"
      decimals="-3"
      id="c96254186"
      unitRef="USD">16065000</pirs:CashEquivalentsAndInvestments>
    <pirs:CashEquivalentsAndInvestments
      contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member"
      decimals="-3"
      id="c96254187"
      unitRef="USD">0</pirs:CashEquivalentsAndInvestments>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2021-12-31_FinancialInstrumentAxis-MoneyMarketFundsMember"
      decimals="-3"
      id="c96254189"
      unitRef="USD">56885000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2021-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FinancialInstrumentAxis-MoneyMarketFundsMember"
      decimals="-3"
      id="c96254190"
      unitRef="USD">56885000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2021-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FinancialInstrumentAxis-MoneyMarketFundsMember"
      decimals="-3"
      id="c96254191"
      unitRef="USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2021-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FinancialInstrumentAxis-MoneyMarketFundsMember"
      decimals="-3"
      id="c96254192"
      unitRef="USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <pirs:CashEquivalentsAndInvestments
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c96254193"
      unitRef="USD">56885000</pirs:CashEquivalentsAndInvestments>
    <pirs:CashEquivalentsAndInvestments
      contextRef="i_2021-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member"
      decimals="-3"
      id="c96254194"
      unitRef="USD">56885000</pirs:CashEquivalentsAndInvestments>
    <pirs:CashEquivalentsAndInvestments
      contextRef="i_2021-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member"
      decimals="-3"
      id="c96254195"
      unitRef="USD">0</pirs:CashEquivalentsAndInvestments>
    <pirs:CashEquivalentsAndInvestments
      contextRef="i_2021-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member"
      decimals="-3"
      id="c96254196"
      unitRef="USD">0</pirs:CashEquivalentsAndInvestments>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2344193">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 37%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 9%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Contractual maturity&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 11%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 11%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 37%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 9%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;span style="-sec-ix-hidden:c96254205"&gt;(in days)&lt;/span&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Amortized Cost&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Unrealized gains&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Unrealized losses&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Fair Value&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 37%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Investments&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 11%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 11%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 37%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;US treasuries&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;em style="font: inherit;"&gt;47&lt;/em&gt;-&lt;em style="font: inherit;"&gt;110&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,575&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(2&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,573&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 37%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Foreign treasuries&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;74&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;899&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(3&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;896&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 37%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Asset-backed securities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;15&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;500&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(1&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;499&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 37%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Corporate bonds&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;em style="font: inherit;"&gt;5&lt;/em&gt;-&lt;em style="font: inherit;"&gt;228&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;15,633&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(67&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;15,566&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 37%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 9%;"&gt;&lt;span style="-sec-ix-hidden:c96254241"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;20,607&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(73&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;20,534&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2022-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember"
      decimals="-3"
      id="c96254215"
      unitRef="USD">3575000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2022-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember"
      decimals="-3"
      id="c96254216"
      unitRef="USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i_2022-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember"
      decimals="-3"
      id="c96254217"
      unitRef="USD">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2022-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember"
      decimals="-3"
      id="c96254218"
      unitRef="USD">3573000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <pirs:DebtSecuritiesAvailableforsaleContractualMaturityPeriod
      contextRef="d_2022-01-01_2022-12-31_FinancialInstrumentAxis-ForeignGovernmentDebtSecuritiesMember"
      id="c96254220">P74D</pirs:DebtSecuritiesAvailableforsaleContractualMaturityPeriod>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2022-12-31_FinancialInstrumentAxis-ForeignGovernmentDebtSecuritiesMember"
      decimals="-3"
      id="c96254222"
      unitRef="USD">899000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2022-12-31_FinancialInstrumentAxis-ForeignGovernmentDebtSecuritiesMember"
      decimals="-3"
      id="c96254223"
      unitRef="USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i_2022-12-31_FinancialInstrumentAxis-ForeignGovernmentDebtSecuritiesMember"
      decimals="-3"
      id="c96254224"
      unitRef="USD">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2022-12-31_FinancialInstrumentAxis-ForeignGovernmentDebtSecuritiesMember"
      decimals="-3"
      id="c96254225"
      unitRef="USD">896000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <pirs:DebtSecuritiesAvailableforsaleContractualMaturityPeriod
      contextRef="d_2022-01-01_2022-12-31_FinancialInstrumentAxis-AssetBackedSecuritiesMember"
      id="c96254227">P15D</pirs:DebtSecuritiesAvailableforsaleContractualMaturityPeriod>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2022-12-31_FinancialInstrumentAxis-AssetBackedSecuritiesMember"
      decimals="-5"
      id="c96254229"
      unitRef="USD">500000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2022-12-31_FinancialInstrumentAxis-AssetBackedSecuritiesMember"
      decimals="-3"
      id="c96254230"
      unitRef="USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i_2022-12-31_FinancialInstrumentAxis-AssetBackedSecuritiesMember"
      decimals="-3"
      id="c96254231"
      unitRef="USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2022-12-31_FinancialInstrumentAxis-AssetBackedSecuritiesMember"
      decimals="-3"
      id="c96254232"
      unitRef="USD">499000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2022-12-31_FinancialInstrumentAxis-CorporateBondSecuritiesMember"
      decimals="-3"
      id="c96254236"
      unitRef="USD">15633000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2022-12-31_FinancialInstrumentAxis-CorporateBondSecuritiesMember"
      decimals="-3"
      id="c96254237"
      unitRef="USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i_2022-12-31_FinancialInstrumentAxis-CorporateBondSecuritiesMember"
      decimals="-3"
      id="c96254238"
      unitRef="USD">67000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2022-12-31_FinancialInstrumentAxis-CorporateBondSecuritiesMember"
      decimals="-3"
      id="c96254239"
      unitRef="USD">15566000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c96254243"
      unitRef="USD">20607000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c96254244"
      unitRef="USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c96254245"
      unitRef="USD">73000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c96254246"
      unitRef="USD">20534000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-5"
      id="c96254157"
      unitRef="USD">400000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2344194">
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 27pt;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;6.&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;Property and Equipment, Net&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Property and equipment are summarized as follows (in thousands):&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Years Ended December 31,&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2022&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Laboratory furniture and equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;11,970&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;11,354&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Office furniture and equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;1,861&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;1,959&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Computer equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;364&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;396&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Leasehold improvements&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;12,444&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;13,130&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Property and equipment, cost&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;26,639&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;26,839&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Accumulated depreciation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(9,647&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(7,717&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;&lt;b&gt;Property and equipment, net&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;16,992&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;19,122&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Depreciation expense was $2.3&#160;million and $2.4 million for the years ended &lt;em style="font: inherit;"&gt; December 31, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021&lt;/em&gt;, respectively. There were &lt;em style="font: inherit;"&gt;no&lt;/em&gt; other changes in accumulated depreciation other than the foreign currency impact.&lt;/p&gt;

   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
  </us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2344195">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Years Ended December 31,&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2022&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Laboratory furniture and equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;11,970&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;11,354&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Office furniture and equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;1,861&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;1,959&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Computer equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;364&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;396&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Leasehold improvements&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;12,444&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;13,130&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Property and equipment, cost&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;26,639&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;26,839&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Accumulated depreciation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(9,647&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(7,717&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;&lt;b&gt;Property and equipment, net&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;16,992&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;19,122&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember"
      decimals="-4"
      id="c96254253"
      unitRef="USD">11970000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember"
      decimals="-3"
      id="c96254254"
      unitRef="USD">11354000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-OfficeEquipmentMember"
      decimals="-3"
      id="c96254255"
      unitRef="USD">1861000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-OfficeEquipmentMember"
      decimals="-3"
      id="c96254256"
      unitRef="USD">1959000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember"
      decimals="-3"
      id="c96254257"
      unitRef="USD">364000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember"
      decimals="-3"
      id="c96254258"
      unitRef="USD">396000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"
      decimals="-3"
      id="c96254259"
      unitRef="USD">12444000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"
      decimals="-4"
      id="c96254260"
      unitRef="USD">13130000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c96254261"
      unitRef="USD">26639000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c96254262"
      unitRef="USD">26839000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c96254263"
      unitRef="USD">9647000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c96254264"
      unitRef="USD">7717000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c96254265"
      unitRef="USD">16992000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c96254266"
      unitRef="USD">19122000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-5"
      id="c96254248"
      unitRef="USD">2300000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-5"
      id="c96254249"
      unitRef="USD">2400000</us-gaap:Depreciation>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2344196">
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 27pt;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;7.&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;Accrued Expenses&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Accrued expenses and other current liabilities consisted of the following (in thousands):&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Years Ended December 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Research and development fees&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;5,758&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;5,682&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Compensation expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,015&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,581&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Accrued license obligations&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;245&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,541&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Accrued accounts payable&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,245&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,980&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Lease liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;859&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,049&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Other current liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;483&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;393&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Collaboration cost-sharing obligation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,610&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Total&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;11,605&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;16,836&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
  </us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2344197">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Years Ended December 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Research and development fees&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;5,758&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;5,682&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Compensation expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,015&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,581&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Accrued license obligations&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;245&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,541&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Accrued accounts payable&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,245&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,980&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Lease liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;859&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,049&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Other current liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;483&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;393&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Collaboration cost-sharing obligation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,610&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Total&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;11,605&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;16,836&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <pirs:AccruedResearchAndDevelopmentCosts
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c96254272"
      unitRef="USD">5758000</pirs:AccruedResearchAndDevelopmentCosts>
    <pirs:AccruedResearchAndDevelopmentCosts
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c96254273"
      unitRef="USD">5682000</pirs:AccruedResearchAndDevelopmentCosts>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c96254274"
      unitRef="USD">3015000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c96254275"
      unitRef="USD">3581000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <pirs:AccruedLicenseObligationsCurrent
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c96254276"
      unitRef="USD">245000</pirs:AccruedLicenseObligationsCurrent>
    <pirs:AccruedLicenseObligationsCurrent
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c96254277"
      unitRef="USD">1541000</pirs:AccruedLicenseObligationsCurrent>
    <pirs:AccruedAccountsPayableCurrent
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c96254278"
      unitRef="USD">1245000</pirs:AccruedAccountsPayableCurrent>
    <pirs:AccruedAccountsPayableCurrent
      contextRef="i_2021-12-31"
      decimals="-4"
      id="c96254279"
      unitRef="USD">2980000</pirs:AccruedAccountsPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i_2022-12-31_BalanceSheetLocationAxis-AccruedLiabilitiesAndOtherCurrentLiabilitiesMember"
      decimals="-3"
      id="c96254280"
      unitRef="USD">859000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i_2021-12-31_BalanceSheetLocationAxis-AccruedLiabilitiesAndOtherCurrentLiabilitiesMember"
      decimals="-3"
      id="c96254281"
      unitRef="USD">1049000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c96254282"
      unitRef="USD">483000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c96254283"
      unitRef="USD">393000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <pirs:AccruedCollaborationCostsCurrent
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c96254284"
      unitRef="USD">0</pirs:AccruedCollaborationCostsCurrent>
    <pirs:AccruedCollaborationCostsCurrent
      contextRef="i_2021-12-31"
      decimals="-4"
      id="c96254285"
      unitRef="USD">1610000</pirs:AccruedCollaborationCostsCurrent>
    <pirs:AccruedLiabilitiesAndOtherLiabilitiesCurrent
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c96254286"
      unitRef="USD">11605000</pirs:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <pirs:AccruedLiabilitiesAndOtherLiabilitiesCurrent
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c96254287"
      unitRef="USD">16836000</pirs:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2344198">
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 27pt;"&gt; &lt;p style="margin: 0pt; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;8.&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="margin: 0pt; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;Income Taxes&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company reported a loss before income taxes consisting of the following (in thousands):&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Years Ended December 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Domestic&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(11,765&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(11,312&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Foreign&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(21,512&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(34,426&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Loss before income taxes&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(33,277&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(45,738&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The components of the provision for income taxes are as follows (in thousands):&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Years Ended December 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Current:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Federal&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;State&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Foreign&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total current&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Deferred:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Federal&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;State&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Foreign&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total deferred&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Provision for income taxes&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The reconciliation of the federal statutory rate to the Company&#x2019;s effective tax rate is as follows:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Federal income tax rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;21.0&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;21.0&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Foreign rate differential&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;5.0&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;5.6&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;State tax, net of federal benefit&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2.0&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1.2&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Share-based awards compensation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(2.2&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(3.5&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Permanent items&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;0.3&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(0.2&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Provision to return&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;3.3&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1.0&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Credits&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1.2&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Change in valuation allowance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(28.3&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(27.4&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Effective income tax rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The components of deferred tax assets and liabilities related to net tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income taxes purposes were as follows (in thousands):&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Years Ended December 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Deferred tax assets:&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Net operating loss carryforwards&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;54,845&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;49,280&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Share-based awards compensation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,112&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,739&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Accrued expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;216&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;323&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt 0pt 0pt 18pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;R&amp;amp;D Credits&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;413&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Depreciation and other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;384&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;384&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Unrealized foreign currency&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;359&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;256&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt 0pt 0pt 18pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;Capitalized R&amp;amp;D&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;952&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt 0pt 0pt 18pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;Accrued Expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Lease liability&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3,541&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;4,022&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;"&gt;Total deferred tax assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;63,822&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;57,004&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Deferred tax liabilities:&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Right-of-use asset&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(3,270&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(3,729&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Accrued expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;(68&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;"&gt;Total deferred tax liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(3,270&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(3,797&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Less: valuation allowance:&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(60,552&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(53,207&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net deferred tax asset&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company operates in multiple jurisdictions. Accordingly, the Company files U.S. federal and state income tax returns as well as returns in multiple foreign jurisdictions. In assessing the realizability of deferred tax assets, management considers whether it is more likely than &lt;em style="font: inherit;"&gt;not&lt;/em&gt; that some portion or all deferred tax assets will &lt;em style="font: inherit;"&gt;not&lt;/em&gt; be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax-planning strategies in making this assessment. Management believes it is more likely than &lt;em style="font: inherit;"&gt;not&lt;/em&gt; that the results of future operations will &lt;em style="font: inherit;"&gt;not&lt;/em&gt; generate sufficient taxable income in the United States or in its foreign jurisdictions to realize the full benefits of its deferred tax assets. As of &lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt;, the Company continues to maintain a full valuation allowance against all net deferred tax assets.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The cumulative amount of earnings of our foreign subsidiaries are expected to be permanently invested in the foreign subsidiaries. Deferred taxes have &lt;em style="font: inherit;"&gt;not&lt;/em&gt; been provided on the excess of book basis over tax basis, or the excess tax basis over book basis in the shares of our foreign subsidiaries because these basis differences are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; expected to reverse in the foreseeable future and are essentially permanent in duration. Our intention is to reinvest the earnings of the foreign subsidiaries indefinitely.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The increase in the valuation allowance of deferred tax assets of $7.3 million for the year ended &lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt; was primarily a result of the operating losses generated in current tax year.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;As of &lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt;, the Company had net operating loss carryforwards for U.S. federal income tax purposes of $38.6&#160;million and net operating loss carryforwards for state income tax purposes of $42.4 million. Federal tax loss carryforwards that were created prior to &lt;em style="font: inherit;"&gt; December 31, 2017 &lt;/em&gt;expire through &lt;em style="font: inherit;"&gt;2037&lt;/em&gt; and federal losses created after that date do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; expire. State loss carryforwards expire starting in &lt;em style="font: inherit;"&gt;2035.&lt;/em&gt; Pursuant to Section &lt;em style="font: inherit;"&gt;382&lt;/em&gt; of the Internal Revenue Code, and similar state tax law, certain substantial changes in the Company&#x2019;s ownership &lt;em style="font: inherit;"&gt; may &lt;/em&gt;result in a limitation on the amount of net operating loss and tax credit carryforwards that &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be used in future years. Utilization of the net operating loss and tax credit carryforwards &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be subject to an annual limitation under Section &lt;em style="font: inherit;"&gt;382&lt;/em&gt; of the Internal Revenue Code of &lt;em style="font: inherit;"&gt;1986&lt;/em&gt; due to ownership change limitations that have occurred previously or that could occur in the future. These ownership changes &lt;em style="font: inherit;"&gt; may &lt;/em&gt;limit the amount of net operating loss and tax credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. The Company completed a Section &lt;em style="font: inherit;"&gt;382&lt;/em&gt; study through &lt;em style="font: inherit;"&gt; December 31, 2020. &lt;/em&gt;Based on the study, the Company underwent an ownership change for Section &lt;em style="font: inherit;"&gt;382&lt;/em&gt; purposes which occurred in &lt;em style="font: inherit;"&gt; February 2018. &lt;/em&gt;As a result of the ownership change, the Company&#x2019;s net operating loss and tax credit carryforwards as of the ownership change dates are subject to limitation under Section &lt;em style="font: inherit;"&gt;382;&lt;/em&gt; however, these limitations are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; expected to result in any of the impacted net operating loss and tax credit carryforwards to expire unutilized. Any net operating losses or tax credits generated after the &lt;em style="font: inherit;"&gt; February 2018 &lt;/em&gt;change are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; subject to this annual limitation. However, subsequent ownership changes, as defined by Section &lt;em style="font: inherit;"&gt;382,&lt;/em&gt; &lt;em style="font: inherit;"&gt; may &lt;/em&gt;potentially further limit the amount of net operating loss and tax credit carryforwards that could be utilized to offset future taxable income and tax. The Company is currently open to examination under the statute of limitations by the Internal Revenue Service and state jurisdictions for the tax years ended &lt;span style="-sec-ix-hidden:c96254311"&gt;2019&lt;/span&gt; through the current year. Carryforward tax attributes generated in years past &lt;em style="font: inherit;"&gt; may &lt;/em&gt;still be adjusted upon future examination if they have or will be used in a future period. The Company is currently under examination in Germany for &lt;span style="-sec-ix-hidden:c96254312"&gt;2014&lt;/span&gt; through &lt;span style="-sec-ix-hidden:c96254313"&gt;2017;&lt;/span&gt; however, the Company is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; under examination by the Internal Revenue Service or any other jurisdictions for any tax years.&lt;/p&gt;

   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;As of &lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt;, the Company had German corporate income tax and trade tax net operating loss carryforwards of approximately $163.3 million and $160.4 million respectively. Under current German laws, tax loss carryforwards &lt;em style="font: inherit;"&gt; may &lt;/em&gt;only be used to offset any relevant later assessment period (calendar year) of &lt;em style="font: inherit;"&gt;$1.2&lt;/em&gt; million plus &lt;em style="font: inherit;"&gt;60%&lt;/em&gt; of the exceeding taxable income and trade profit of such period and do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; expire. In addition, certain transactions, including transfers of shares or interest in the loss holding entity, &lt;em style="font: inherit;"&gt; may &lt;/em&gt;result in the partial or total forfeiture of tax losses existing at that date. Partial or total forfeiture of tax losses &lt;em style="font: inherit;"&gt; may &lt;/em&gt;further occur in corporate reorganizations of the loss holding entity.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company accounts for uncertain tax positions pursuant to ASC &lt;em style="font: inherit;"&gt;740,&lt;/em&gt; &lt;i&gt;Income Taxes&lt;/i&gt;, which prescribes a recognition threshold and measurement process for financial statement recognition of uncertain tax positions taken or expected to be taken in a tax return. If the tax position meets this threshold, the benefit to be recognized is measured at the largest amount of benefit that is more likely than &lt;em style="font: inherit;"&gt;not&lt;/em&gt; (determined by cumulative probability) of being realized upon ultimate settlement with the taxing authority. The Company recorded an uncertain tax position related to a prior year position, that if successfully challenged by tax authorities could result in the loss of certain tax attributes. The balance of uncertain tax positions will remain until such time that settlement is reached with the relevant tax authorities or should the statute of limitations expire. The Company recognizes interest and penalties, if any, related to uncertain tax positions in income tax expense. No interest and penalties related to uncertain tax positions were accrued at &lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt; and &lt;em style="font: inherit;"&gt; December 31, 2021&lt;/em&gt;.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;On &lt;em style="font: inherit;"&gt; December 22, 2017, &lt;/em&gt;the Tax Cuts and Jobs Act, or the TCJA, was signed into law. Under the TCJA provisions, effective with tax years beginning on or after &lt;em style="font: inherit;"&gt; January 1, 2022, &lt;/em&gt;taxpayers can &lt;em style="font: inherit;"&gt;no&lt;/em&gt; longer immediately expense qualified research and development expenditures. Taxpayers are now required to capitalize and amortize these costs over &lt;em style="font: inherit;"&gt;five&lt;/em&gt; years for research conducted within the United States or &lt;em style="font: inherit;"&gt;15&lt;/em&gt; years for research conducted abroad. As a result, the Company capitalized $1.0 million of research and development expenses for the year ended &lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt;.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The following table sets forth a reconciliation of the beginning and ending amounts of unrecognized tax benefits, excluding the impact of interest and penalties, for the years ended &lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt; (in thousands):&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 85%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Unrecognized tax benefits at December 31, 2021&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;5,665&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Currency translation adjustment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(302&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Unrecognized tax benefits at December 31, 2022&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;5,363&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; expect unrecognized tax benefits to change significantly over the next &lt;em style="font: inherit;"&gt;12&lt;/em&gt; months. The full amount of unrecognized tax benefits would impact the effective rate, subject to valuation allowance considerations, if recognized.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
  </us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2344199">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Years Ended December 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Domestic&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(11,765&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(11,312&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Foreign&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(21,512&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(34,426&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Loss before income taxes&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(33,277&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(45,738&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96254336"
      unitRef="USD">-11765000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96254337"
      unitRef="USD">-11312000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96254338"
      unitRef="USD">-21512000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96254339"
      unitRef="USD">-34426000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96254340"
      unitRef="USD">-33277000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96254341"
      unitRef="USD">-45738000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2344200">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Years Ended December 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Current:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Federal&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;State&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Foreign&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total current&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Deferred:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Federal&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;State&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Foreign&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total deferred&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Provision for income taxes&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96254347"
      unitRef="USD">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96254348"
      unitRef="USD">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96254349"
      unitRef="USD">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96254350"
      unitRef="USD">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96254351"
      unitRef="USD">0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96254352"
      unitRef="USD">0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96254353"
      unitRef="USD">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96254354"
      unitRef="USD">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96254356"
      unitRef="USD">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96254357"
      unitRef="USD">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96254358"
      unitRef="USD">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96254359"
      unitRef="USD">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96254360"
      unitRef="USD">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96254361"
      unitRef="USD">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96254362"
      unitRef="USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96254363"
      unitRef="USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96254364"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96254365"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2344201">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Federal income tax rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;21.0&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;21.0&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Foreign rate differential&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;5.0&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;5.6&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;State tax, net of federal benefit&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2.0&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1.2&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Share-based awards compensation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(2.2&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(3.5&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Permanent items&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;0.3&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(0.2&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Provision to return&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;3.3&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1.0&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Credits&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1.2&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Change in valuation allowance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(28.3&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(27.4&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Effective income tax rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="d_2022-01-01_2022-12-31"
      decimals="2"
      id="c96254368"
      unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="d_2021-01-01_2021-12-31"
      decimals="2"
      id="c96254369"
      unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="d_2022-01-01_2022-12-31"
      decimals="2"
      id="c96254370"
      unitRef="Pure">0.050</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="d_2021-01-01_2021-12-31"
      decimals="3"
      id="c96254371"
      unitRef="Pure">0.056</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="d_2022-01-01_2022-12-31"
      decimals="2"
      id="c96254372"
      unitRef="Pure">0.020</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="d_2021-01-01_2021-12-31"
      decimals="3"
      id="c96254373"
      unitRef="Pure">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="d_2022-01-01_2022-12-31"
      decimals="3"
      id="c96254374"
      unitRef="Pure">-0.022</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="d_2021-01-01_2021-12-31"
      decimals="3"
      id="c96254375"
      unitRef="Pure">-0.035</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="d_2022-01-01_2022-12-31"
      decimals="3"
      id="c96254376"
      unitRef="Pure">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="d_2021-01-01_2021-12-31"
      decimals="3"
      id="c96254377"
      unitRef="Pure">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <pirs:EffectiveIncomeTaxRateReconciliationProvisionToReturnPercent
      contextRef="d_2022-01-01_2022-12-31"
      decimals="0"
      id="c96254378"
      unitRef="Pure">0</pirs:EffectiveIncomeTaxRateReconciliationProvisionToReturnPercent>
    <pirs:EffectiveIncomeTaxRateReconciliationProvisionToReturnPercent
      contextRef="d_2021-01-01_2021-12-31"
      decimals="3"
      id="c96254379"
      unitRef="Pure">0.033</pirs:EffectiveIncomeTaxRateReconciliationProvisionToReturnPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="d_2022-01-01_2022-12-31"
      decimals="2"
      id="c96254380"
      unitRef="Pure">0.010</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="d_2021-01-01_2021-12-31"
      decimals="0"
      id="c96254381"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="d_2022-01-01_2022-12-31"
      decimals="3"
      id="c96254382"
      unitRef="Pure">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="d_2021-01-01_2021-12-31"
      decimals="0"
      id="c96254383"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="d_2022-01-01_2022-12-31"
      decimals="3"
      id="c96254384"
      unitRef="Pure">-0.283</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="d_2021-01-01_2021-12-31"
      decimals="3"
      id="c96254385"
      unitRef="Pure">-0.274</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="d_2022-01-01_2022-12-31"
      decimals="0"
      id="c96254386"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="d_2021-01-01_2021-12-31"
      decimals="0"
      id="c96254387"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2344202">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Years Ended December 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Deferred tax assets:&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Net operating loss carryforwards&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;54,845&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;49,280&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Share-based awards compensation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,112&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,739&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Accrued expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;216&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;323&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt 0pt 0pt 18pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;R&amp;amp;D Credits&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;413&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Depreciation and other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;384&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;384&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Unrealized foreign currency&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;359&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;256&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt 0pt 0pt 18pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;Capitalized R&amp;amp;D&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;952&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt 0pt 0pt 18pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;Accrued Expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Lease liability&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3,541&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;4,022&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;"&gt;Total deferred tax assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;63,822&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;57,004&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Deferred tax liabilities:&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Right-of-use asset&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(3,270&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(3,729&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Accrued expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;(68&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;"&gt;Total deferred tax liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(3,270&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(3,797&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Less: valuation allowance:&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(60,552&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(53,207&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net deferred tax asset&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c96254393"
      unitRef="USD">54845000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i_2021-12-31"
      decimals="-4"
      id="c96254394"
      unitRef="USD">49280000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c96254395"
      unitRef="USD">3112000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c96254396"
      unitRef="USD">2739000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <pirs:DeferredTaxAssetsAccruedCompensationAndOther
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c96254397"
      unitRef="USD">216000</pirs:DeferredTaxAssetsAccruedCompensationAndOther>
    <pirs:DeferredTaxAssetsAccruedCompensationAndOther
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c96254398"
      unitRef="USD">323000</pirs:DeferredTaxAssetsAccruedCompensationAndOther>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c96254399"
      unitRef="USD">413000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c96254400"
      unitRef="USD">0</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <pirs:DeferredTaxAssetsDepreciationAndOther
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c96254401"
      unitRef="USD">384000</pirs:DeferredTaxAssetsDepreciationAndOther>
    <pirs:DeferredTaxAssetsDepreciationAndOther
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c96254402"
      unitRef="USD">384000</pirs:DeferredTaxAssetsDepreciationAndOther>
    <us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c96254403"
      unitRef="USD">359000</us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses>
    <us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c96254404"
      unitRef="USD">256000</us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses>
    <pirs:DeferredTaxAssetsCapitalizedResearchAndDevelopment
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c96254405"
      unitRef="USD">952000</pirs:DeferredTaxAssetsCapitalizedResearchAndDevelopment>
    <pirs:DeferredTaxAssetsCapitalizedResearchAndDevelopment
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c96254406"
      unitRef="USD">0</pirs:DeferredTaxAssetsCapitalizedResearchAndDevelopment>
    <pirs:DeferredTaxAssetLeaseLiability
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c96254409"
      unitRef="USD">3541000</pirs:DeferredTaxAssetLeaseLiability>
    <pirs:DeferredTaxAssetLeaseLiability
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c96254410"
      unitRef="USD">4022000</pirs:DeferredTaxAssetLeaseLiability>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c96254411"
      unitRef="USD">63822000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c96254412"
      unitRef="USD">57004000</us-gaap:DeferredTaxAssetsGross>
    <pirs:DeferredTaxLiabilitiesLeaseRightofuseAsset
      contextRef="i_2022-12-31"
      decimals="-4"
      id="c96254414"
      unitRef="USD">3270000</pirs:DeferredTaxLiabilitiesLeaseRightofuseAsset>
    <pirs:DeferredTaxLiabilitiesLeaseRightofuseAsset
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c96254415"
      unitRef="USD">3729000</pirs:DeferredTaxLiabilitiesLeaseRightofuseAsset>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpense
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c96254416"
      unitRef="USD">-0</us-gaap:DeferredTaxLiabilitiesDeferredExpense>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpense
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c96254417"
      unitRef="USD">68000</us-gaap:DeferredTaxLiabilitiesDeferredExpense>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i_2022-12-31"
      decimals="-4"
      id="c96254418"
      unitRef="USD">3270000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c96254419"
      unitRef="USD">3797000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c96254420"
      unitRef="USD">60552000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c96254421"
      unitRef="USD">53207000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c96254422"
      unitRef="USD">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c96254423"
      unitRef="USD">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-5"
      id="c96254296"
      unitRef="USD">7300000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2022-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember"
      decimals="-5"
      id="c96254297"
      unitRef="USD">38600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2022-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember"
      decimals="-5"
      id="c96254298"
      unitRef="USD">42400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2022-12-31_IncomeTaxAuthorityAxis-ForeignCountryMember_TaxCreditCarryforwardAxis-CorporateIncomeTaxMember"
      decimals="-5"
      id="c96254316"
      unitRef="USD">163300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2022-12-31_IncomeTaxAuthorityAxis-ForeignCountryMember_TaxCreditCarryforwardAxis-TradeTaxMember"
      decimals="-5"
      id="c96254317"
      unitRef="USD">160400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c96254323"
      unitRef="USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <pirs:DeferredTaxAssetsCapitalizedResearchAndDevelopment
      contextRef="i_2022-12-31"
      decimals="-6"
      id="c96254327"
      unitRef="USD">1000000.0</pirs:DeferredTaxAssetsCapitalizedResearchAndDevelopment>
    <us-gaap:SummaryOfIncomeTaxContingenciesTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2344203">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 85%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Unrecognized tax benefits at December 31, 2021&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;5,665&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Currency translation adjustment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(302&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Unrecognized tax benefits at December 31, 2022&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;5,363&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:SummaryOfIncomeTaxContingenciesTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c96254424"
      unitRef="USD">5665000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96254425"
      unitRef="USD">302000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c96254426"
      unitRef="USD">5363000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2344204">
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 27pt;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;9.&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;Stockholders&lt;/b&gt;&#x2019;&lt;b&gt; equity&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company had 300,000,000 shares authorized and 74,519,103 and 72,222,661shares of common stock issued and outstanding as of &lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt; and &lt;em style="font: inherit;"&gt; December 31, 2021&lt;/em&gt;, respectively, with a par value of $0.001 per share.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company had 10,000,000 shares authorized and 15,617 shares of preferred stock issued and outstanding as of &lt;em style="font: inherit;"&gt; December 31, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021&lt;/em&gt;. Preferred stock has a par value of $0.001 per share, and consists of the following tranches:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:top;width:18pt;"&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#x2022;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:top;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Series A Convertible, 85 shares issued and outstanding at&#160;&lt;em style="font: inherit;"&gt; December 31, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:top;width:18pt;"&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#x2022;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:top;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Series B Convertible, 4,026 shares issued and outstanding at &lt;em style="font: inherit;"&gt; December 31, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:top;width:18pt;"&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#x2022;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:top;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Series C Convertible, 3,506 shares issued and outstanding at &lt;em style="font: inherit;"&gt; December 31, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:top;width:18pt;"&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#x2022;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:top;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Series D Convertible, 3,000 shares issued and outstanding at both &lt;em style="font: inherit;"&gt; December 31, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:top;width:18pt;"&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#x2022;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:top;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Series E Convertible, 5,000 shares issued and outstanding at &lt;em style="font: inherit;"&gt; December 31, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Common Stock&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Each share of the Company&#x2019;s common stock is entitled to one vote and all shares rank equally as to voting and other matters. Dividends &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be declared and paid on the common stock from funds legally available therefor, if, as and when determined by the Board of Directors.&lt;/p&gt;

   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Preferred Stock&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company has issued multiple series (Series A through E) of preferred stock to certain entities affiliated with Biotechnology Value Fund, L.P., or BVF. In each case, each share Preferred Stock is convertible into 1,000 shares of the Company's common stock (subject to adjustment as provided in the Certificate of Designation for each series) at any time at the option of the holder, provided that the holder is prohibited from converting the Preferred Stock into shares of the Company's common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 9.99% of the total number of shares of Common Stock then issued and outstanding, or the Beneficial Ownership Limitation. The holder &lt;em style="font: inherit;"&gt; may &lt;/em&gt;reset the Beneficial Ownership Limitation to a higher or lower number, &lt;em style="font: inherit;"&gt;not&lt;/em&gt; to exceed 19.99% of the total number of common shares issued and outstanding immediately after giving effect to a conversion, upon providing written notice to the Company. Any such notice providing for an increase to the Beneficial Ownership Limitation will be effective 61 days after delivery to the Company.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Series A, Series B, Series C, Series D and Series E Preferred Stock rank senior to the Company&#x2019;s common stock; senior to any class or series of capital stock of the Company created after the designation of and specifically ranking by its terms as junior to the &lt;em style="font: inherit;"&gt;five&lt;/em&gt; series of Preferred Stock; in parity with each other and with any class or series of capital stock of the Company created after the designation of and specifically ranking by its terms as in parity with the existing &lt;em style="font: inherit;"&gt;five&lt;/em&gt; series of Preferred Stock; and junior to any class or series of capital stock of the Company created after the designation of and specifically ranking by its terms as senior to the existing &lt;em style="font: inherit;"&gt;five&lt;/em&gt; series of Preferred Stock. In the event of the Company&#x2019;s liquidation, dissolution or winding up, subject to the rights of holders of, holders are entitled to receive a payment equal to $0.001 per share of Preferred Stock pursuant to the rights and preferences discussed above, plus an additional amount equal to any dividends declared but unpaid on such shares. However, if the assets of the Company are insufficient to comply with the preceding sentence, then all remaining assets of the Company shall be distributed ratably to holders of the shares of the existing &lt;em style="font: inherit;"&gt;five&lt;/em&gt; series of Preferred Stock.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;For each series of Preferred Stock, the Company designated the requisite number of shares of its authorized and unissued preferred stock as a specific series of Preferred Stock and filed a Certificate of Designation with the Nevada Secretary of State.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Shares of Preferred Stock generally have &lt;em style="font: inherit;"&gt;no&lt;/em&gt; voting rights, except as required by law and except that the consent of holders of a majority of the then outstanding Preferred Stock is required to amend the terms of the Certificate of Designation for each respective series of Preferred Stock. Holders of Preferred Stock are entitled to receive any dividends payable to holders of the Company's common stock subject to the rights and preferences discussed above, in each case, as to distributions of assets upon the Company&#x2019;s liquidation, dissolution or winding up whether voluntarily or involuntarily and/or the right to receive dividends.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Series A Preferred Stock&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;In &lt;em style="font: inherit;"&gt; June 2016, &lt;/em&gt;the Company entered into a securities purchase agreement for a private placement of the Company&#x2019;s securities with a select group of institutional investors, or the &lt;em style="font: inherit;"&gt;2016&lt;/em&gt; PIPE. The &lt;em style="font: inherit;"&gt;2016&lt;/em&gt; PIPE sale transaction, by the Company, consisted of 8,188,804 units at a price of $2.015 per unit for gross proceeds, to the Company, of approximately $16.5 million. After deducting for placement agent fees and offering expenses, the aggregate net proceeds from the private placement was approximately $15.3 million. In connection with the &lt;em style="font: inherit;"&gt;2016&lt;/em&gt; PIPE, the Company issued 3,225,804 shares of common stock and 4,963 shares of Series A Preferred Stock to the &lt;em style="font: inherit;"&gt;2016&lt;/em&gt; PIPE investors.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Series B Preferred Stock&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;On &lt;em style="font: inherit;"&gt; January 30, 2019, &lt;/em&gt;the Company and certain entities affiliated with Biotechnology Value Fund, L.P., or BVF entered into an exchange agreement pursuant to which BVF agreed to exchange an aggregate of 5,000,000 shares of the Company&#x2019;s common stock owned by BVF for an aggregate of 5,000 shares of Series B Preferred Stock.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Series C and &lt;em style="font: inherit;"&gt;2019&lt;/em&gt; Private Placement&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;In &lt;em style="font: inherit;"&gt; November 2019, &lt;/em&gt;the Company entered into a securities purchase agreement for a private placement, or the Purchase Agreement with a select group of institutional investors, including lead investor BVF as well as existing and new investors, or Investors. The private placement consisted of 9,014,960 units, at a price of $3.55 per unit, or the Financing, for gross proceeds of approximately $32.0 million, and net proceeds to the Company of approximately $31.0 million. Each unit consists of (i)&#160;&lt;span style="-sec-ix-hidden:c96254476"&gt;one&lt;/span&gt; share of the Company&#x2019;s common stock, or Common Shares, or 0.001 shares of non-voting Series C convertible preferred stock, or Series C Preferred Shares, and together with the Common Shares, or Shares, and (ii)&#160;&lt;span style="-sec-ix-hidden:c96254478"&gt;one&lt;/span&gt; immediately-exercisable warrant to purchase &lt;span style="-sec-ix-hidden:c96254479"&gt;one&lt;/span&gt; share of the Company&#x2019;s common stock with an exercise price of $7.10, or Exercise Price.&lt;/p&gt;

   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;If (i) the initial public disclosure of the phase &lt;em style="font: inherit;"&gt;2a&lt;/em&gt; Study of PRS-&lt;em style="font: inherit;"&gt;060/AZD1402&lt;/em&gt; that includes the &#x201c;p&#x201d; value achieved for the primary endpoint of such study reveals top-line data on the primary efficacy endpoint in the phase &lt;em style="font: inherit;"&gt;2a&lt;/em&gt; Study with a &#x201c;p&#x201d; value below &lt;em style="font: inherit;"&gt;0.05&lt;/em&gt; (i.e., p &amp;lt; &lt;em style="font: inherit;"&gt;0.05&lt;/em&gt;) in at least &lt;em style="font: inherit;"&gt;one&lt;/em&gt; dose level; and (ii) the &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-day volume weighted average stock price commencing on the trading day immediately after the initial public disclosure is at least &lt;span style="-sec-ix-hidden:c96254489"&gt;three&lt;/span&gt; percent more than the Exercise Price, ((i) and (ii), collectively, the &#x201c;Performance Condition&#x201d;), then the warrants will be exercisable for a period of &lt;em style="font: inherit;"&gt;60&lt;/em&gt; days from the date of the initial data disclosure and &lt;em style="font: inherit;"&gt; may &lt;/em&gt;only be exercised for cash. Otherwise, the warrants will be exercisable for a period of &lt;span style="-sec-ix-hidden:c96254491"&gt;five&lt;/span&gt; years from the date of issuance, or Exercise Date. If the Performance Condition has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; been met and the last reported sale price of the Company&#x2019;s common stock immediately prior to the Expiration Date was greater than the Exercise Price, then the warrants shall be automatically deemed exercised on a cashless basis on the Expiration Date.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Upon issuance, each Series C Preferred Share included an embedded beneficial conversion feature as the market price of the Company&#x2019;s Common Stock on the date of issuance of the Series C convertible preferred stock was $3.43 per share. As a result, the Company recorded the intrinsic value of the beneficial conversion feature of $2.8 million as a discount on the Series C convertible preferred stock at issuance. As the Series C Preferred Shares are immediately convertible upon issuance and do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; include a stated redemption date, the discount was immediately accreted as a deemed dividend.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Series D Preferred Stock Conversion&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;On &lt;em style="font: inherit;"&gt; March 31, 2020, &lt;/em&gt;the Company and certain entities affiliated with BVF entered into an exchange agreement pursuant to which, on &lt;em style="font: inherit;"&gt; April 1, 2020, &lt;/em&gt;BVF exchanged an aggregate of 3,000,000 shares of the Company&#x2019;s common stock owned by BVF for an aggregate of 3,000 shares of Series D Preferred Stock.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Series E Preferred Stock Conversion&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;On &lt;em style="font: inherit;"&gt; May 20, 2021, &lt;/em&gt;the Company and certain entities affiliated with BVF entered into an exchange agreement pursuant to which, BVF exchanged an aggregate of 5,000,000 shares of the Company&#x2019;s common stock owned by BVF for an aggregate of 5,000 shares of Series E Preferred Stock.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Open Market Sales Agreement&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;In &lt;em style="font: inherit;"&gt; August 2019, &lt;/em&gt;the Company entered into a sales agreement with Jefferies LLC pursuant to which the Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;offer and sell shares of its common stock, from time to time, up to an aggregate gross sales proceeds of $50.0 million (the &lt;em style="font: inherit;"&gt;2019&lt;/em&gt; ATM Program). In &lt;em style="font: inherit;"&gt; August 2021, &lt;/em&gt;the &lt;em style="font: inherit;"&gt;2019&lt;/em&gt; ATM Program expired, and the Company established a &lt;em style="font: inherit;"&gt;second&lt;/em&gt; ATM offering program, or the &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; ATM Program, under the existing sales agreement with Jefferies LLC, pursuant to which the Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;offer and sell shares of its common stock, par value $0.001 per share, from time to time, up to an aggregate amount of gross sales proceeds of $50.0&#160;million. In &lt;em style="font: inherit;"&gt; November 2022, &lt;/em&gt;the sales agreement was amended to provide for an increase in the aggregate offering amount, such that under the &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; ATM Program, as amended, the Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;offer and sell shares of its common stock, from time to time, up to an aggregate amount of gross sales proceeds of $75.0 million. The &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; ATM Program, as amended, is offered under a shelf registration statement on Form S-&lt;em style="font: inherit;"&gt;3&lt;/em&gt; that was filed with and declared effective by the SEC in &lt;em style="font: inherit;"&gt; August 2021. &lt;/em&gt;For the year ended &lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt;, the Company sold 2.1 million shares for gross proceeds of $7.2&#160;million under the &lt;em style="font: inherit;"&gt;2021ATM&lt;/em&gt; program at an average stock price of $3.46. For the year ended &lt;em style="font: inherit;"&gt; December 31, 2021&lt;/em&gt;, the Company sold 8.2 million shares for gross proceeds of $39.7&#160;million under both ATM programs at an average stock price of $4.85.&lt;/p&gt;
  </us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96254428"
      unitRef="Share">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96254429"
      unitRef="Share">74519103</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c96254430"
      unitRef="Share">72222661</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96254431"
      unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96254432"
      unitRef="Share">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96254433"
      unitRef="Share">15617</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c96254435"
      unitRef="USDPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2022-12-31_StatementClassOfStockAxis-SeriesAPreferredStockMember"
      decimals="INF"
      id="c96254436"
      unitRef="Share">85</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2022-12-31_StatementClassOfStockAxis-SeriesBPreferredStockMember"
      decimals="INF"
      id="c96254438"
      unitRef="Share">4026</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2022-12-31_StatementClassOfStockAxis-SeriesCPreferredStockMember"
      decimals="INF"
      id="c96254440"
      unitRef="Share">3506</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2022-12-31_StatementClassOfStockAxis-SeriesDPreferredStockMember"
      decimals="INF"
      id="c96254442"
      unitRef="Share">3000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2022-12-31_StatementClassOfStockAxis-SeriesEPreferredStockMember"
      decimals="INF"
      id="c96254444"
      unitRef="Share">5000</us-gaap:PreferredStockSharesOutstanding>
    <pirs:NumberOfVotesPerShare
      contextRef="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c96254446"
      unitRef="Pure">1</pirs:NumberOfVotesPerShare>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="i_2021-05-20_StatementClassOfStockAxis-SeriesAThroughEMember_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c96254448"
      unitRef="Share">1000</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <pirs:ConvertiblePreferredStockCommonStockOwnershipLimitPercent
      contextRef="i_2021-05-20_StatementClassOfStockAxis-SeriesAThroughEMember_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="4"
      id="c96254449"
      unitRef="Pure">0.0999</pirs:ConvertiblePreferredStockCommonStockOwnershipLimitPercent>
    <pirs:ConvertiblePreferredStockBeneficialOwnershipLimitationPercent
      contextRef="i_2021-05-20_StatementClassOfStockAxis-SeriesAThroughEMember_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="4"
      id="c96254451"
      unitRef="Pure">0.1999</pirs:ConvertiblePreferredStockBeneficialOwnershipLimitationPercent>
    <pirs:ConvertiblePreferredStockBeneficialOwnershipLimitationNoticePeriodBeforeIncrease
      contextRef="d_2021-05-20_2021-05-20_StatementClassOfStockAxis-SeriesAThroughEMember_StatementEquityComponentsAxis-PreferredStockMember"
      id="c96254452">P61Y</pirs:ConvertiblePreferredStockBeneficialOwnershipLimitationNoticePeriodBeforeIncrease>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i_2021-05-20_StatementClassOfStockAxis-SeriesAThroughEMember_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c96254456"
      unitRef="USDPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PartnersCapitalAccountUnitsSoldInPrivatePlacement
      contextRef="d_2016-06-01_2016-06-30_SubsidiarySaleOfStockAxis-SecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="c96254461"
      unitRef="Share">8188804</us-gaap:PartnersCapitalAccountUnitsSoldInPrivatePlacement>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i_2016-06-30_SubsidiarySaleOfStockAxis-SecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="c96254462"
      unitRef="USDPerShare">2.015</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="d_2016-06-01_2016-06-30_SubsidiarySaleOfStockAxis-SecuritiesPurchaseAgreementMember"
      decimals="-5"
      id="c96254463"
      unitRef="USD">16500000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <pirs:ProceedsFromIssuanceOfPrivatePlacementNet
      contextRef="d_2016-06-01_2016-06-30_SubsidiarySaleOfStockAxis-SecuritiesPurchaseAgreementMember"
      decimals="-5"
      id="c96254464"
      unitRef="USD">15300000</pirs:ProceedsFromIssuanceOfPrivatePlacementNet>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="d_2016-06-01_2016-06-30_SubsidiarySaleOfStockAxis-SecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="c96254466"
      unitRef="Share">3225804</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i_2016-06-30_SubsidiarySaleOfStockAxis-SecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="c96254467"
      unitRef="Share">4963</us-gaap:PreferredStockSharesIssued>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="d_2019-01-30_2019-01-30_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-StockExchangeSharesFromExistingShareholdersMember"
      decimals="INF"
      id="c96254469"
      unitRef="Share">5000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="d_2019-01-30_2019-01-30_StatementEquityComponentsAxis-PreferredStockMember_SubsidiarySaleOfStockAxis-PreferredShareExchangeMember"
      decimals="INF"
      id="c96254470"
      unitRef="Share">5000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="d_2019-11-01_2019-11-30_StatementClassOfStockAxis-SeriesCPreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="INF"
      id="c96254472"
      unitRef="Share">9014960</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i_2019-11-30_StatementClassOfStockAxis-SeriesCPreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="INF"
      id="c96254473"
      unitRef="USDPerShare">3.55</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="d_2019-11-01_2019-11-30_StatementClassOfStockAxis-SeriesCPreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="-6"
      id="c96254474"
      unitRef="USD">32000000.0</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <pirs:ProceedsFromIssuanceOfPrivatePlacementNet
      contextRef="d_2019-11-01_2019-11-30_StatementClassOfStockAxis-SeriesCPreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="-6"
      id="c96254475"
      unitRef="USD">31000000.0</pirs:ProceedsFromIssuanceOfPrivatePlacementNet>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="i_2019-11-30_StatementClassOfStockAxis-SeriesCPreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="INF"
      id="c96254477"
      unitRef="Share">0.001</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2019-11-30_StatementClassOfStockAxis-SeriesCPreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="INF"
      id="c96254480"
      unitRef="USDPerShare">7.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i_2019-11-30_StatementClassOfStockAxis-SeriesCPreferredStockMember_SubsidiarySaleOfStockAxis-PreferredShareExchangeMember"
      decimals="INF"
      id="c96254493"
      unitRef="USDPerShare">3.43</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature
      contextRef="d_2019-11-01_2019-11-30_StatementClassOfStockAxis-SeriesCPreferredStockMember_SubsidiarySaleOfStockAxis-PreferredShareExchangeMember"
      decimals="-5"
      id="c96254494"
      unitRef="USD">2800000</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="d_2020-04-01_2020-04-01_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member"
      decimals="INF"
      id="c96254496"
      unitRef="Share">3000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="d_2020-04-01_2020-04-01_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member"
      decimals="INF"
      id="c96254497"
      unitRef="Share">3000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="d_2021-05-20_2021-05-20_ConversionOfStockByUniqueDescriptionAxis-ConversionOfCommonStockIntoSeriesEPreferredStockMember"
      decimals="INF"
      id="c96254498"
      unitRef="Share">5000000</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="d_2021-05-20_2021-05-20_ConversionOfStockByUniqueDescriptionAxis-ConversionOfCommonStockIntoSeriesEPreferredStockMember"
      decimals="INF"
      id="c96254499"
      unitRef="Share">5000</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2019-08-01_2019-08-31"
      decimals="-7"
      id="c96254500"
      unitRef="USD">50000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2021-08-31_LegalEntityAxis-JefferiesLLCMember"
      decimals="INF"
      id="c96254505"
      unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <pirs:SaleOfStockAuthorizedAmount
      contextRef="d_2021-08-01_2021-08-31_LegalEntityAxis-JefferiesLLCMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember"
      decimals="-7"
      id="c96254506"
      unitRef="USD">50000000.0</pirs:SaleOfStockAuthorizedAmount>
    <pirs:SaleOfStockAuthorizedAmount
      contextRef="d_2022-11-01_2022-11-30_LegalEntityAxis-JefferiesLLCMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember"
      decimals="-6"
      id="c96254508"
      unitRef="USD">75000000.0</pirs:SaleOfStockAuthorizedAmount>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="d_2022-01-01_2022-12-31_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember"
      decimals="-5"
      id="c96254511"
      unitRef="Share">2100000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="d_2022-01-01_2022-12-31_LegalEntityAxis-JefferiesLLCMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember"
      decimals="-5"
      id="c96254512"
      unitRef="USD">7200000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i_2022-12-31_LegalEntityAxis-JefferiesLLCMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember"
      decimals="INF"
      id="c96254514"
      unitRef="USDPerShare">3.46</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="d_2021-01-01_2021-12-31_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember"
      decimals="-5"
      id="c96254515"
      unitRef="Share">8200000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="d_2021-01-01_2021-12-31_LegalEntityAxis-JefferiesLLCMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember"
      decimals="-5"
      id="c96254516"
      unitRef="USD">39700000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i_2021-12-31_LegalEntityAxis-JefferiesLLCMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingMember"
      decimals="INF"
      id="c96254517"
      unitRef="USDPerShare">4.85</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:EarningsPerShareTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2344205">
   &lt;p style="margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 27pt;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;10.&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;Net Loss per Share&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Basic net loss per share is calculated by dividing net income (loss) by the weighted average shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share calculation, preferred stock, stock options, and warrants are considered to be common stock equivalents but have been excluded from the calculation of diluted net loss per share, as their effect would be anti-dilutive for all periods presented. Therefore, basic and diluted net loss per share were the same for all periods presented.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;For the years ended &lt;em style="font: inherit;"&gt; December 31, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021&lt;/em&gt;, and as calculated using the treasury stock method, approximately 38.4 million and 36.8 million of weighted average shares, respectively, were excluded from the calculation of diluted weighted average shares outstanding as their effect was antidilutive.&lt;/p&gt;

  </us-gaap:EarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-5"
      id="c96254553"
      unitRef="Share">38400000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-5"
      id="c96254554"
      unitRef="Share">36800000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2344206">
    &#160;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 27pt;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;11.&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;Stock and Employee Benefit Plans&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Employee, Director and Consultant Equity Incentive Plans&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;At the Annual Shareholder Meeting, held on &lt;em style="font: inherit;"&gt; June 23, 2020, &lt;/em&gt;the shareholders approved the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Employee, Director and Consultant Equity Incentive Plan, or the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Plan. The &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Plan originally permitted the Company to issue up to&#160;3,500,000&#160;shares of common stock pursuant to awards granted under the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Plan. Upon approval of the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Plan, the &lt;em style="font: inherit;"&gt;2019&lt;/em&gt; Employee, Director and Consultant Equity Incentive Plan, or the &lt;em style="font: inherit;"&gt;2019&lt;/em&gt; Plan, was terminated; all unissued options were canceled and &lt;em style="font: inherit;"&gt;no&lt;/em&gt; additional awards will be made thereunder. All outstanding awards under the &lt;em style="font: inherit;"&gt;2019&lt;/em&gt; Plan will remain in effect and any awards forfeited from the outstanding awards will be allocated back into the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Plan. The &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Plan, similar to the &lt;em style="font: inherit;"&gt;2019&lt;/em&gt; Plan, provided for the grant of stock options, restricted and unrestricted stock awards, and other stock-based awards to employees of the Company, non-employee directors of the Company, and certain other consultants performing services for the Company as designated by either the Board of Directors or the compensation committee of the Board of Directors. At the &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; Annual Meeting of Stockholders, held on &lt;em style="font: inherit;"&gt; June 25, 2021, &lt;/em&gt;the Company&#x2019;s stockholders approved the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; amendment to the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Plan to add 2,250,000 shares for issuance under the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Plan, which increased the total permitted for issuance under the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Plan to 5,750,000. At the &lt;em style="font: inherit;"&gt;2022&lt;/em&gt; Annual Meeting of Stockholders, held on &lt;em style="font: inherit;"&gt; June 22, 2022, &lt;/em&gt;the Company&#x2019;s stockholders approved the &lt;em style="font: inherit;"&gt;second&lt;/em&gt; amendment to the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Plan to add an additional 3,000,000 shares for issuance under the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Plan, which increased the total permitted for issuance under the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Plan to 8,750,000.&lt;/p&gt;
   &lt;p style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;The &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Plan permits the Company to issue up to 8,750,000 shares reserved for issuance pursuant to the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Plan and any additional shares which &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be issued if awards outstanding under the Registrant&#x2019;s &lt;em style="font: inherit;"&gt;2014,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2016,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2019&lt;/em&gt; Plans are canceled or expire.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company&#x2019;s stock options have a maximum term of 10 years from the date of grant. Stock options granted &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be either incentive stock options or nonqualified stock options and the exercise price of stock options must be at least equal to the fair market value of the common stock on the date of grant. The Company&#x2019;s general policy is to issue common shares upon the exercise of stock options.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company estimates the fair value of each stock award on the grant date using the Black-Scholes option-pricing model based on the following assumptions:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Years Ended December 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Risk free interest rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1.43% - 3.39%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;0.46% - 1.20%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Expected term (in years)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;5.5 - 5.73&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;5.31 - 5.73&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Dividend yield&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Expected volatility&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;79.9% - 81.1%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;75.0% - 81.7%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The weighted-average fair value of the 3,075,282 and 3,182,696 options granted during the years ended &lt;em style="font: inherit;"&gt; December 31, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; was $1.96 and $2.04, respectively. As of &lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt;, there were 4,314,513 shares available for future grant under the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Plan.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The following table summarizes stock option activity for employees and non-employees:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted-&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted-&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Average&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Aggregate&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Average&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Remaining&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Intrinsic&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Number of&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Exercise&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Contractual&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Value&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Options&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Price&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Life (in years)&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;(in thousands)&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding, December 31, 2021&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;11,475,713&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3.35&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;11,310&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,075,282&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2.88&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Exercised&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;46,233&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2.07&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;66&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Canceled&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,031,396&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3.80&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;17&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding, December 31, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;13,473,366&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3.21&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;6.31&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Vested or expected to vest, December 31, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;13,473,366&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3.21&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;6.31&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Exercisable, December 31, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;9,096,001&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3.38&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;5.16&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Periodically, the Company grants inducement options, which are awards outside of approved stock option plans, and which are material awards to the executive officers or other personnel entering senior leadership roles with the Company. The terms of inducement option awards were substantially the same as those issued under our &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Plan. These awards are excluded from the table above. The following table summarizes stock option activity for these inducement options (in thousands):&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted-&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted-&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Average&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Aggregate&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Average&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Remaining&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Intrinsic&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Number of&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Exercise&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Contractual&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Value&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Options&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Price&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Life (in years)&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;(in thousands)&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding, December 31, 2021&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;660,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;4.01&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;108&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Canceled or Expired&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;360,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;3.48&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding, December 31, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;300,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4.65&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;6.66&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Vested or expected to vest, December 31, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;300,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4.65&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;6.66&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Exercisable, December 31, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;243,750&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4.65&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;6.66&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Employee Stock Purchase Plans&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; ESPP provides eligible employees with the opportunity, through regular payroll deductions, to purchase shares of the Company&#x2019;s common stock at&#160;85%&#160;of the lower closing market price of the common stock at the beginning date or ending date of each purchase period. The plan includes &lt;em style="font: inherit;"&gt;&lt;span style="-sec-ix-hidden:c96254613"&gt;two&lt;/span&gt; &lt;span style="-sec-ix-hidden:c96254614"&gt;six&lt;/span&gt;&lt;/em&gt;-month purchase periods per year beginning in both &lt;em style="font: inherit;"&gt; June &lt;/em&gt;and &lt;em style="font: inherit;"&gt; December. &lt;/em&gt;The Company has reserved 500,000 shares of common stock for the administration of the &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; ESPP. Total shares purchased under the plan were 181,466 and 64,257 for the years ended &lt;em style="font: inherit;"&gt; December 31, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021&lt;/em&gt;, respectively. The fair value of shares expected to be purchased under the &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; ESPP was determined using the Black-Scholes model with the following assumptions:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Years Ended December 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Risk free interest rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1.62% - 4.60%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;0.04% - 0.10%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Expected term (in years)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;0.5&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;0.5&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Dividend yield&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Expected volatility&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;53.46% - 70.17%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;60.46% - 131.21%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Total Stock-based Compensation Expense&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Total stock-based compensation expense is recorded in operating expenses based upon the functional responsibilities of the individuals holding the respective options as follows (in thousands):&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Years Ended December 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Research and development&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,905&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,274&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;General and administrative&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,497&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,941&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Total stock-based compensation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4,402&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;5,215&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;As of &lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt;, the total unrecognized compensation cost related to all non-vested awards was $7.0 million of which $0.2 million are for inducement options. The Company expects to recognize the compensation cost over a remaining weighted-average period of 2.49 years.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
  </us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i_2020-06-23_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member"
      decimals="INF"
      id="c96254560"
      unitRef="Share">3500000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="d_2021-06-25_2021-06-25_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member"
      decimals="INF"
      id="c96254573"
      unitRef="Share">2250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i_2021-06-25_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member"
      decimals="INF"
      id="c96254576"
      unitRef="Share">5750000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="d_2022-06-22_2022-06-22_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member"
      decimals="INF"
      id="c96254580"
      unitRef="Share">3000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i_2022-06-22_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member"
      decimals="INF"
      id="c96254583"
      unitRef="Share">8750000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i_2022-06-22_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member"
      decimals="INF"
      id="c96254585"
      unitRef="Share">8750000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="d_2022-01-01_2022-12-31_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member"
      id="c96254591">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="d_2022-01-01_2022-12-31"
      id="c579E1972-BF43-4B33-8F56-5F0D68443003">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Years Ended December 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Risk free interest rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1.43% - 3.39%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;0.46% - 1.20%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Expected term (in years)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;5.5 - 5.73&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;5.31 - 5.73&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Dividend yield&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Expected volatility&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;79.9% - 81.1%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;75.0% - 81.7%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Years Ended December 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Risk free interest rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1.62% - 4.60%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;0.04% - 0.10%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Expected term (in years)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;0.5&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;0.5&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Dividend yield&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Expected volatility&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;53.46% - 70.17%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;60.46% - 131.21%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="4"
      id="c96254627"
      unitRef="Pure">0.0143</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="4"
      id="c96254629"
      unitRef="Pure">0.0339</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="4"
      id="c96254630"
      unitRef="Pure">0.0046</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="3"
      id="c96254632"
      unitRef="Pure">0.0120</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember"
      id="c96254633">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember"
      id="c96254635">P5Y8M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember"
      id="c96254636">P5Y3M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember"
      id="c96254638">P5Y8M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="0"
      id="c96254640"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="0"
      id="c96254643"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="3"
      id="c96254645"
      unitRef="Pure">0.799</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="3"
      id="c96254647"
      unitRef="Pure">0.811</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="2"
      id="c96254648"
      unitRef="Pure">0.750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="3"
      id="c96254650"
      unitRef="Pure">0.817</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96254592"
      unitRef="Share">3075282</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96254593"
      unitRef="Share">3182696</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96254595"
      unitRef="USDPerShare">1.96</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96254596"
      unitRef="USDPerShare">2.04</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i_2022-12-31_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member"
      decimals="INF"
      id="c96254597"
      unitRef="Share">4314513</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="d_2022-01-01_2022-12-31"
      id="c8C585FE4-9F5E-478C-BF95-2582B3E44E41">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted-&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted-&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Average&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Aggregate&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Average&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Remaining&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Intrinsic&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Number of&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Exercise&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Contractual&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Value&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Options&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Price&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Life (in years)&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;(in thousands)&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding, December 31, 2021&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;11,475,713&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3.35&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;11,310&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,075,282&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2.88&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Exercised&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;46,233&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2.07&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;66&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Canceled&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,031,396&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3.80&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;17&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding, December 31, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;13,473,366&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3.21&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;6.31&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Vested or expected to vest, December 31, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;13,473,366&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3.21&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;6.31&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Exercisable, December 31, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;9,096,001&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3.38&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;5.16&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted-&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted-&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Average&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Aggregate&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Average&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Remaining&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Intrinsic&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Number of&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Exercise&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Contractual&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Value&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Options&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Price&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Life (in years)&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;(in thousands)&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding, December 31, 2021&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;660,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;4.01&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;108&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Canceled or Expired&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;360,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;3.48&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding, December 31, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;300,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4.65&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;6.66&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Vested or expected to vest, December 31, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;300,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4.65&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;6.66&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Exercisable, December 31, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;243,750&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4.65&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;6.66&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2021-12-31_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member"
      decimals="INF"
      id="c96254671"
      unitRef="Share">11475713</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2021-12-31_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member"
      decimals="INF"
      id="c96254672"
      unitRef="USDPerShare">3.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i_2021-12-31_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member"
      decimals="-4"
      id="c96254674"
      unitRef="USD">11310000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2022-01-01_2022-12-31_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member"
      decimals="INF"
      id="c96254675"
      unitRef="Share">3075282</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="d_2022-01-01_2022-12-31_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member"
      decimals="INF"
      id="c96254676"
      unitRef="USDPerShare">2.88</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <pirs:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodAggregateIntrinsicValue
      contextRef="d_2022-01-01_2022-12-31_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member"
      decimals="-3"
      id="c96254678"
      unitRef="USD">0</pirs:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodAggregateIntrinsicValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2022-01-01_2022-12-31_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member"
      decimals="INF"
      id="c96254679"
      unitRef="Share">46233</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="d_2022-01-01_2022-12-31_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member"
      decimals="INF"
      id="c96254680"
      unitRef="USDPerShare">2.07</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="d_2022-01-01_2022-12-31_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member"
      decimals="-3"
      id="c96254682"
      unitRef="USD">66000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="d_2022-01-01_2022-12-31_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member"
      decimals="INF"
      id="c96254683"
      unitRef="Share">1031396</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="d_2022-01-01_2022-12-31_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member"
      decimals="INF"
      id="c96254684"
      unitRef="USDPerShare">3.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <pirs:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAggregateIntrinsicValue
      contextRef="d_2022-01-01_2022-12-31_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member"
      decimals="-3"
      id="c96254686"
      unitRef="USD">17000</pirs:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2022-12-31_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member"
      decimals="INF"
      id="c96254687"
      unitRef="Share">13473366</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2022-12-31_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member"
      decimals="INF"
      id="c96254688"
      unitRef="USDPerShare">3.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="d_2022-01-01_2022-12-31_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member"
      id="c96254689">P6Y3M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i_2022-12-31_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member"
      decimals="-3"
      id="c96254690"
      unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i_2022-12-31_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member"
      decimals="INF"
      id="c96254691"
      unitRef="Share">13473366</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i_2022-12-31_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member"
      decimals="INF"
      id="c96254692"
      unitRef="USDPerShare">3.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="d_2022-01-01_2022-12-31_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member"
      id="c96254693">P6Y3M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i_2022-12-31_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member"
      decimals="-3"
      id="c96254694"
      unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i_2022-12-31_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member"
      decimals="INF"
      id="c96254695"
      unitRef="Share">9096001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i_2022-12-31_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member"
      decimals="INF"
      id="c96254696"
      unitRef="USDPerShare">3.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <pirs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm2Exercised
      contextRef="d_2022-01-01_2022-12-31_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member"
      id="c96254697">P5Y1M28D</pirs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm2Exercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="i_2022-12-31_PlanNameAxis-EmployeeDirectorAndConsultantEquityIncentivePlan2020Member"
      decimals="-3"
      id="c96254698"
      unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2021-12-31_TitleOfIndividualAxis-ExecutiveOfficersAndManagementMember"
      decimals="INF"
      id="c96254719"
      unitRef="Share">660000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2021-12-31_TitleOfIndividualAxis-ExecutiveOfficersAndManagementMember"
      decimals="INF"
      id="c96254720"
      unitRef="USDPerShare">4.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i_2021-12-31_TitleOfIndividualAxis-ExecutiveOfficersAndManagementMember"
      decimals="-3"
      id="c96254722"
      unitRef="USD">108000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2022-01-01_2022-12-31_TitleOfIndividualAxis-ExecutiveOfficersAndManagementMember"
      decimals="INF"
      id="c96254723"
      unitRef="Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="d_2022-01-01_2022-12-31_TitleOfIndividualAxis-ExecutiveOfficersAndManagementMember"
      decimals="INF"
      id="c96254724"
      unitRef="USDPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <pirs:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodAggregateIntrinsicValue
      contextRef="d_2022-01-01_2022-12-31_TitleOfIndividualAxis-ExecutiveOfficersAndManagementMember"
      decimals="-3"
      id="c96254726"
      unitRef="USD">0</pirs:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="d_2022-01-01_2022-12-31_TitleOfIndividualAxis-ExecutiveOfficersAndManagementMember"
      decimals="INF"
      id="c96254727"
      unitRef="Share">360000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="d_2022-01-01_2022-12-31_TitleOfIndividualAxis-ExecutiveOfficersAndManagementMember"
      decimals="INF"
      id="c96254728"
      unitRef="USDPerShare">3.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <pirs:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAggregateIntrinsicValue
      contextRef="d_2022-01-01_2022-12-31_TitleOfIndividualAxis-ExecutiveOfficersAndManagementMember"
      decimals="-3"
      id="c96254730"
      unitRef="USD">0</pirs:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2022-12-31_TitleOfIndividualAxis-ExecutiveOfficersAndManagementMember"
      decimals="INF"
      id="c96254731"
      unitRef="Share">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2022-12-31_TitleOfIndividualAxis-ExecutiveOfficersAndManagementMember"
      decimals="INF"
      id="c96254732"
      unitRef="USDPerShare">4.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="d_2022-01-01_2022-12-31_TitleOfIndividualAxis-ExecutiveOfficersAndManagementMember"
      id="c96254733">P6Y7M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i_2022-12-31_TitleOfIndividualAxis-ExecutiveOfficersAndManagementMember"
      decimals="-3"
      id="c96254734"
      unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i_2022-12-31_TitleOfIndividualAxis-ExecutiveOfficersAndManagementMember"
      decimals="INF"
      id="c96254735"
      unitRef="Share">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i_2022-12-31_TitleOfIndividualAxis-ExecutiveOfficersAndManagementMember"
      decimals="INF"
      id="c96254736"
      unitRef="USDPerShare">4.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="d_2022-01-01_2022-12-31_TitleOfIndividualAxis-ExecutiveOfficersAndManagementMember"
      id="c96254737">P6Y7M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i_2022-12-31_TitleOfIndividualAxis-ExecutiveOfficersAndManagementMember"
      decimals="-3"
      id="c96254738"
      unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i_2022-12-31_TitleOfIndividualAxis-ExecutiveOfficersAndManagementMember"
      decimals="INF"
      id="c96254739"
      unitRef="Share">243750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i_2022-12-31_TitleOfIndividualAxis-ExecutiveOfficersAndManagementMember"
      decimals="INF"
      id="c96254740"
      unitRef="USDPerShare">4.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <pirs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm2Exercised
      contextRef="d_2022-01-01_2022-12-31_TitleOfIndividualAxis-ExecutiveOfficersAndManagementMember"
      id="c96254741">P6Y7M28D</pirs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm2Exercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="i_2022-12-31_TitleOfIndividualAxis-ExecutiveOfficersAndManagementMember"
      decimals="-3"
      id="c96254742"
      unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="2"
      id="c96254602"
      unitRef="Pure">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c96254604"
      unitRef="Share">500000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c96254606"
      unitRef="Share">181466</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c96254607"
      unitRef="Share">64257</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockMember"
      decimals="4"
      id="c96254755"
      unitRef="Pure">0.0162</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockMember"
      decimals="3"
      id="c96254757"
      unitRef="Pure">0.0460</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockMember"
      decimals="4"
      id="c96254758"
      unitRef="Pure">0.0004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockMember"
      decimals="3"
      id="c96254760"
      unitRef="Pure">0.0010</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockMember"
      id="c96254762">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockMember"
      id="c96254765">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockMember"
      decimals="0"
      id="c96254768"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockMember"
      decimals="0"
      id="c96254771"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockMember"
      decimals="4"
      id="c96254773"
      unitRef="Pure">0.5346</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockMember"
      decimals="4"
      id="c96254775"
      unitRef="Pure">0.7017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockMember"
      decimals="4"
      id="c96254776"
      unitRef="Pure">0.6046</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockMember"
      decimals="4"
      id="c96254778"
      unitRef="Pure">1.3121</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2344211">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Years Ended December 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Research and development&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,905&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,274&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;General and administrative&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,497&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,941&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Total stock-based compensation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4,402&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;5,215&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2022-01-01_2022-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="c96254783"
      unitRef="USD">1905000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2021-01-01_2021-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="c96254784"
      unitRef="USD">2274000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2022-01-01_2022-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="c96254785"
      unitRef="USD">2497000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2021-01-01_2021-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="c96254786"
      unitRef="USD">2941000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96254787"
      unitRef="USD">4402000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96254788"
      unitRef="USD">5215000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i_2022-12-31"
      decimals="-6"
      id="c96254610"
      unitRef="USD">7000000.0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i_2022-12-31_TitleOfIndividualAxis-ExecutiveOfficersAndManagementMember"
      decimals="-5"
      id="c96254611"
      unitRef="USD">200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="d_2022-01-01_2022-12-31" id="c96254612">P2Y5M26D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <pirs:LicenseAndTransferAgreementTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2344212">
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 27pt;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;12.&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;License Agreement&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;TUM License&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company and the Technical University of Munich, or TUM, initiated discussions in the &lt;em style="font: inherit;"&gt;second&lt;/em&gt; quarter of &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; to clarify, expand and restructure the research and licensing agreement with TUM, the TUM License, including the parties&#x2019; obligations under the TUM License. The TUM License assigns or exclusively licenses to the Company certain intellectual property related to the Company's Anticalin platform technology. The parties' discussions relate to revised commercial terms and to re-initiating additional collaborations between faculty at TUM and Pieris.&#160; While an amended and restated license agreement has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; yet been completed, the Company intends to enter into such an&#160;amendment. These discussions &lt;em style="font: inherit;"&gt; may &lt;/em&gt;also lead to an increase in the Company's collaborative research activities with TUM.&lt;/p&gt;

   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
  </pirs:LicenseAndTransferAgreementTextBlock>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2344213">
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 27pt;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;13.&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;Leases&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company entered into a sublease to lease approximately 3,950 square feet in Boston, Massachusetts which expired on &lt;em style="font: inherit;"&gt; December 31, 2022. &lt;/em&gt;The Company generally conducts its operational functions in the United States remotely.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;In &lt;em style="font: inherit;"&gt; October 2018, &lt;/em&gt;Pieris GmbH entered into a lease for office and laboratory space located in Hallbergmoos, Germany, or the Hallbergmoos Lease. Pieris GmbH moved its operations to the Hallbergmoos facility in &lt;em style="font: inherit;"&gt; February 2020.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Under the Hallbergmoos Lease, Pieris GmbH rents approximately 105,000 square feet. An additional approximately 22,300 square feet is expected to be delivered by the lessor by &lt;em style="font: inherit;"&gt; October 2024. &lt;/em&gt;Pieris GmbH has a &lt;em style="font: inherit;"&gt;first&lt;/em&gt; right of refusal to lease an additional approximate 13,400 square feet.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Hallbergmoos Lease provides for an initial rental term of&#160;12.5 years which commenced in &lt;em style="font: inherit;"&gt; February 2020 &lt;/em&gt;when the leased property was delivered to Pieris GmbH. Pieris GmbH also has an option to extend the Hallbergmoos Lease for two additional 60-month periods. The Company is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; reasonably certain to exercise the option to extend the lease expiration beyond its current expiration date. Pieris GmbH &lt;em style="font: inherit;"&gt; may &lt;/em&gt;sublease space within the leased property with lessor&#x2019;s consent, which &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; be unreasonably withheld.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Monthly base rent for the 105,000 square feet of the leased property, including parking spaces, totals approximately $0.2 million per month, which amount shall be adjusted starting on the &lt;em style="font: inherit;"&gt;second&lt;/em&gt; anniversary of the commencement date by an amount equal to the German consumer price index. In addition to the base rent, Pieris GmbH is also responsible for certain administrative and operational costs in accordance with the Hallbergmoos Lease. Pieris GmbH provided a security deposit of $0.8 million at upon signing the lease agreement. The Company will serve as a guarantor for the Hallbergmoos Lease.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Hallbergmoos Lease included $11.5 million of tenant improvements allowance for normal tenant improvements which was incurred prior to commencing the lease. The Company capitalized the leasehold incentives which are included in Property and equipment, net on the Consolidated Balance Sheet and are amortized on a straight-line basis over the shorter of the useful life or the remaining lease term.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The following table summarizes operating lease costs included in operating expenses (in thousands):&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Year Ended December 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Operating lease costs&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,356&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,483&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Variable lease costs (1)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;737&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;739&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total lease cost&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,093&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,222&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td colspan="4" style="vertical-align:top;width:100%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;(&lt;em style="font: inherit;"&gt;1&lt;/em&gt;) Variable lease costs include certain additional charges for operating costs, including insurance, maintenance, taxes, utilities and other costs incurred, which are billed based on both usage and as a percentage of the Company&#x2019;s share of total square footage. These costs also included costs associated with increases rent expense based on CPI.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The following table summarizes the weighted-average remaining lease term and discount rate:&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 771px; text-align: center;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 187px; text-align: center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;As of December 31, 2022&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 771px;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Weighted-average remaining lease term (years)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 187px; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: right;"&gt;9.6&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 771px;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Weighted-average discount rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 187px; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: right;"&gt;10.5%&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Cash paid for amounts included in the measurement of the lease liabilities were $2.4 million and $2.6 million for the year&#160;ended &lt;em style="font: inherit;"&gt; December 31, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021&lt;/em&gt;, respectively.&lt;/p&gt;

   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;As of &lt;em style="font: inherit;"&gt; December 31, 2022&lt;/em&gt;, the maturities of the Company&#x2019;s operating lease liabilities and future minimum lease payments were as follows (in thousands):&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Total&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,116&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,116&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2025&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,116&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2026&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,116&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 85%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2027&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,116&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Thereafter&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;9,699&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total undiscounted lease payments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;20,279&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; vertical-align: top;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Less: present value adjustment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(7,176&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; vertical-align: top;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Present value of lease liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;13,103&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
  </us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i_2015-08-31_LeaseContractualTermAxis-SubleaseOfficeSpaceMember_StatementGeographicalAxis-BostonMassachusettsMember"
      decimals="INF"
      id="c96254795"
      unitRef="SquareFoot">3950</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i_2020-02-29_LeaseContractualTermAxis-OfficeAndLaboratorySpaceMember_StatementGeographicalAxis-HallbergmoosGermanyMember"
      decimals="INF"
      id="c96254796"
      unitRef="SquareFoot">105000</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i_2020-02-29_PropertyPlantAndEquipmentByTypeAxis-LeasesExpectedToBeDeliveredByOctober2024Member_StatementGeographicalAxis-HallbergmoosGermanyMember"
      decimals="INF"
      id="c96254797"
      unitRef="SquareFoot">22300</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i_2020-02-29_PropertyPlantAndEquipmentByTypeAxis-LeasesWithFirstRightOfRefusalForAdditionalAreaMember_StatementGeographicalAxis-HallbergmoosGermanyMember"
      decimals="INF"
      id="c96254799"
      unitRef="SquareFoot">13400</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i_2020-02-29_StatementGeographicalAxis-HallbergmoosGermanyMember"
      id="c96254800">P12Y6M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <pirs:NumberOfAgreementExtensionOptions
      contextRef="d_2020-02-29_2020-02-29_LeaseContractualTermAxis-OfficeAndLaboratorySpaceMember_StatementGeographicalAxis-HallbergmoosGermanyMember"
      decimals="INF"
      id="c96254801"
      unitRef="Pure">2</pirs:NumberOfAgreementExtensionOptions>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i_2020-02-29_LeaseContractualTermAxis-OfficeAndLaboratorySpaceMember_StatementGeographicalAxis-HallbergmoosGermanyMember"
      id="c96254802">P60M</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i_2020-02-29_LeaseContractualTermAxis-OfficeAndLaboratorySpaceMember_StatementGeographicalAxis-HallbergmoosGermanyMember"
      decimals="INF"
      id="c96254805"
      unitRef="SquareFoot">105000</us-gaap:AreaOfRealEstateProperty>
    <pirs:LesseeOperatingLeaseMonthlyRentExpense
      contextRef="d_2020-02-01_2020-02-29_LeaseContractualTermAxis-OfficeAndLaboratorySpaceMember_StatementGeographicalAxis-HallbergmoosGermanyMember"
      decimals="-5"
      id="c96254806"
      unitRef="USD">200000</pirs:LesseeOperatingLeaseMonthlyRentExpense>
    <us-gaap:SecurityDeposit
      contextRef="i_2020-02-29_LeaseContractualTermAxis-OfficeAndLaboratorySpaceMember_StatementGeographicalAxis-HallbergmoosGermanyMember"
      decimals="-5"
      id="c96254808"
      unitRef="USD">800000</us-gaap:SecurityDeposit>
    <us-gaap:TenantImprovements
      contextRef="i_2019-03-31_LeaseContractualTermAxis-OfficeAndLaboratorySpaceMember_StatementGeographicalAxis-HallbergmoosGermanyMember"
      decimals="-5"
      id="c96254809"
      unitRef="USD">11500000</us-gaap:TenantImprovements>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="d_2022-01-01_2022-12-31"
      id="c56919BDE-C600-4831-8383-5A7DCF685D6C">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Year Ended December 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Operating lease costs&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,356&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,483&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Variable lease costs (1)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;737&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;739&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total lease cost&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,093&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,222&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 771px; text-align: center;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 187px; text-align: center;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;As of December 31, 2022&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 771px;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Weighted-average remaining lease term (years)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 187px; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: right;"&gt;9.6&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 771px;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Weighted-average discount rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 187px; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: right;"&gt;10.5%&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96254819"
      unitRef="USD">1356000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96254820"
      unitRef="USD">1483000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96254821"
      unitRef="USD">737000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96254822"
      unitRef="USD">739000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c96254823"
      unitRef="USD">2093000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c96254824"
      unitRef="USD">2222000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="i_2022-12-31" id="c96254826">P9Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i_2022-12-31"
      decimals="3"
      id="c96254827"
      unitRef="Pure">0.105</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeasePayments
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-5"
      id="c96254811"
      unitRef="USD">2400000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-5"
      id="c96254812"
      unitRef="USD">2600000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="d_2022-01-01_2022-12-31" id="c2344216">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Total&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,116&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,116&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2025&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,116&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2026&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,116&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 85%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2027&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,116&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Thereafter&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;9,699&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total undiscounted lease payments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;20,279&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; vertical-align: top;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Less: present value adjustment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(7,176&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; vertical-align: top;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Present value of lease liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;13,103&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c96254829"
      unitRef="USD">2116000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c96254830"
      unitRef="USD">2116000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c96254831"
      unitRef="USD">2116000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c96254832"
      unitRef="USD">2116000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c96254833"
      unitRef="USD">2116000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c96254834"
      unitRef="USD">9699000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c96254835"
      unitRef="USD">20279000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c96254836"
      unitRef="USD">7176000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c96254837"
      unitRef="USD">13103000</us-gaap:OperatingLeaseLiability>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#c96254821"
          xlink:label="c96254821"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c96254822"
          xlink:label="c96254822"
          xlink:type="locator"/>
        <link:footnote id="f603ef05d-fab0-47c7-b353-aeccab7aaca7" xlink:label="f603ef05d-fab0-47c7-b353-aeccab7aaca7" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-us">Variable lease costs include certain additional charges for operating costs, including insurance, maintenance, taxes, utilities,
and other costs incurred, which are billed based on both usage and as a percentage of the Company&#x2019;s share of total square
footage.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c96254821"
          xlink:to="f603ef05d-fab0-47c7-b353-aeccab7aaca7"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c96254822"
          xlink:to="f603ef05d-fab0-47c7-b353-aeccab7aaca7"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>84
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M)E%>;*DO#B1;Y9O,'YB4+,Y?+BD)*,].4)\_,B;7!]D7;/YCP^A_4$L#!!0
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M!X0-I;@3M$UP%,=6NG:)!>#= .B."<DX%9Z2RKD V[3FA4'L];':8@$.0C*
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M'?0(^QVX!Z>?^?+XAL66,(DH;'2H-XKU2R3JT[SN*%[: _&)*WV\VF:N/X!
M&(&>WW"N]AUSQK:?5,E?4$L#!!0    ( #" ?U;RG+"I$ 4  (D4   8
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M> _LP/B>V3)3.@9V1S.WK]6.KMC-"&JBF#RPT>+GGW#D_6*+ZDQ@K1B#.L;
MA;Y8%F.829CS@\&6"&&!8-:=PX*$032;3PZG45BLXEG@U58M>F%-+W33$UE&
MGT4YT%T<2YCHY.N![W<8]FW\()[:"48UP<A)\*O0-',1BWH?)>',(QUJ?2L?
M!WB 6UQSBYWCMUHA^ :Q%] 5Q:R3/#[G4#X36"O<:1WNU%F*!T"D<K4MEL,$
M*I*)G5DM;4%/>_D.R6S:K4K?*HJB,+)795;3G#EI?F(<RI(5+&D"FI$J;<IT
ML Z?68\"COQ9T"%JLPIGOITH]AKQ\=XPN,6;AE$%U4K6S(^C#E.+V=0GP6R
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M!O#_6@C]^F ^4)\^+OX%4$L#!!0    ( #" ?U;=O5ZI6Q0  *]5 0 8
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MFY#8E,1F)#8G,9'=WG/G.E1#F[HX=/7,7"<O,>0E=7F)&2]15:T8C79RR)9
M)YFN_);IRIF9[O77/'?/1W]4'M;/&W>U?<US[I^[M]VD,)<IY@US)%8EL1J)
M&216)S&3Q"P2LTFL06)-$FN16)O$.B36);$>B?5);$!B0Q(;D=B8Q"8D-B6Q
M&8G-24QD]_7<80[5T*8N#ET]\\>L\I)#!\X,<_&2DJ9&?WIJRB%+7F)+UCH)
M<Y6W,%?)#'/6=ONR_V6Y]9==F-L]C6>[SW?!9_EEZ>^>,[=_)H[[I^L]++;[
MNM>"]687^K;OGQ*2E/PRE\^;_$BL2F(U$C-(K$YB)HE9)&:36(/$FB36(K$V
MB75(K$MB/1+KD]B Q(8D-B*Q,8E-2&Q*8C,2FY.8R X!N9,?JJ%-71RZ>N9M
MO'A)\59+>.X'>F)H'Q9H(Q9H)Q94*S[)L[=O>?;V7YMGDS)LYI)Y,RR)54FL
M1F(&B=5)S"0QB\1L$FN06)/$6B36)K$.B75)K$=B?1(;D-B0Q$8D-B:Q"8E-
M26Q&8G,2$]F-/W>&136TJ8M#5\^\>RDO.73@S+N7\1*U$/LYLRF'+'F)'3_C
MD[5.TM[=6]J[0]+>YL5[>')>TY[[O%FN?[KNH?+M79NE$][(E-W3S#RIO'F0
MQ*HD5B,Q@\3J)&:2F$5B-HDU2*Q)8BT2:Y-8A\2Z)-8CL3Z)#4AL2&(C$AN3
MV(3$IB0V([$YB8GL:) [#Z(:VM3%H:MGWM.,EY037O@&[<(";<,"[<,";<3"
M3OKT:J649S6KA;?XNIO4\N_/KTF9-?M,\H965*NB6@W5#%2KHYJ):A:JV:C6
M0+4FJK50K8UJ'53KHEH/U?JH-D"U(:J-4&V,:A-4FZ+:#-7FJ"8D02%WFF4Y
MMMV+L-]GWN \HR;LS9FW.!-JU'+L%S3/D*PS:NR$LWZ_VFE,?#=P2L5_J/W#
M\3QG-Y9*<B\S>^G<N9#4JJA60S4#U>JH9J*:A6HVJC50K8EJ+51KHUH'U;JH
MUD.U/JH-4&V(:B-4&Z/:!-6FJ#9#M3FJ"4DRR)\+48YM]R+L]YDW.A-J5/U.
M3;C7R9X<VZ(%VZ,%VZ0%UJ5/ Z]V#+S9XV9^)? FAEQT#@VJ55&MAFH&JM51
MS40U"]5L5&N@6A/56JC61K4.JG51K8=J?50;H-H0U4:H-D:U":I-46V&:G-4
M$Y(TD#_DLA-J6"[L]]DW/^,U:BS>QH?8Q&]^QFMN]>A+=IMG2-89-7;B:FD_
M(S\.<U&SI[F<FP4?3B8>;]ZF6[X6R^Z"ZK%3OX[__L1]]JGF3G[HB!=4,U"M
MCFHFJEFH9B==2*7"_K_3:ZF!KMM$M1:JM5&M@VI=5.NA6A_5!J@V1+41JHU1
M;8)J4U2;H=H<U82DK^=/=>Q8%Y9C>[E@F[E@N[E@V[E@^[E@&[JP*>XT_AXG
MWP1O_LOC;V+D+<J^#[G//K7<<5>Z8"VAY#KR=#1#SM3E)::\Q)*7V$GG6XKF
M/"G33"B)*"VYTI:7=.0E773/>ZC61[4!J@U1;81J8U2;H-H4U6:H-D<U(?E*
MGS\0H1S[Q5Y46:[&<@;+U5G.9#F+Y6R*.PU$QXDR:O9(F<L"T7EW =&9,VK\
MQ=?U6S7^0E-5=-D:JAFH5D<U$]6LA.TJQ?;*1M=LH%H3U5JHUD:U#JIU4:V'
M:GU4&Z#:$-5&J#9&M0FJ35%MAFIS5!.27IX_\K(#9%B.[>.";>2"[>2";>6"
M[>7"8CFLZY]&WN/ '35[XLZ_YT?@Z(P>-?YB]?&?IU?1-6NH9J!:'=5,5+-0
MS4:U!JHU4:V%:FU4ZZ!:%]5ZJ-9'M0&J#5%MA&IC5)N@VA359J@V1S4A:?WY
M$S([E8?EV'XOV(8OV(XOV)8OV)XOV*8OL*Y_FI"/4XS4"\<8R4(O.IX(U:JH
M5D,U ]7JJ&:BFH5J-JHU4*V):BU4:Z-:!]6ZJG3D2"^AY%:]C?]2<!\]LP&J
M#5%MA&IC5)O(=W2:4%+1[N([.D//;(YJ0M)5\X=/=C 0R[']5+ -5; =5; M
M5; ]5;!-56!=]31\'D<.J9?-'$H,G.@L(52KHEH-U0Q4JZ.:B6H6JMFHUD"U
M)JJU4*V-:AU4ZZK2X1^]A)+;:-24*H.$$GV76T_+AG)I)"\9IRP6.>V)7)K*
M/_B97)DGE*BW=X7H2P<*.27^.*/F/GD]58_4L5^E!?ME6K!?IP7[A5JP7ZD%
M^Z5:8%^K3V/,<9:.FCU,YP]GN4\Q[VZ9*8ZO5-V'WQ1=_;NB%30U,=*@XW!0
MK8IJ-50S4*V.:B:J6:AFHUH#U9JHUD*U-JIU4*V+:CU4ZZ/: -6&J#9"M3&J
M3=3X"(Z@-'J[;9I05M&"_Q)NS*&C;5!-2%IU_AMS['0;EF.;M&"[M&#;M&#[
MM& ;M6 [M<!:]4FBU8[C=;3L\3IAHCTGQ693>5,LJE51K89J!JK54<U$-0O5
M;%1KH%H3U5JHUD:U#JIU4:V':GU4&Z#:$-5&J#9&M8DFG6HR32BI:)'L*F?F
M"25ZH7QW=QN]?YE0>*O=1>]@)E1=:Z6*6HQ.B[Y/J"P5*J7H?5.VJ0FVJPFV
MK0FVKPFVL0FVLXFPM953KX#3.'<<@Z-EC\%IN[ZR7&\37^$[^]#<\0T=8X-J
M-50S4*V.:B:J6:AFHUH#U9JHUD*U-JIU4*V+:CU4ZZ/: -6&J#9"M3&J35!M
MBFHS5)NCFI!T]MSW,UF.;?<B[/>98VS.J#'.J*F?46.>46,EU%SKNE:I1 IM
M>>%INM..Z2Y[YHNQ]MS%UY7R\.)Y[NKAI^)[SFJ[=/S=TYF=QW^\;/UG=^4G
MAC]TO NJ55&MAFH&JM51S40U"]5L5&N@6A/56JC61K4.JG51K8=J?50;H-H0
MU4:H-D:U":I-46V&:G-4$Y+&GS_\L>-=6"[L]]GA3UYCG%%3/Z/&3*BY5@MJ
M/ ">,>!%:IU&O^.(%RU[Q,M@_U3=S\[6?=P]@6+CKK:OL<_]<_>VFYCYR%?Y
MOD>U*JK54,U M3JJF:AFH9J-:@U4:Z):"]7:J-9!M2ZJ]5"MCVH#5!NBV@C5
MQJ@V0;4IJLU0;8YJ0M+Q\V<^=O@+RX7]/COSR6N,,VKJ"37%8D&+Q3XY99U1
M8\N6.TU\QZDFP9M9B>^2 <^O!>O-+ADF_PPX<\W<D9#4JJA60S4#U>JH9J*:
MA6HVJC50K8EJ+51KHUH'U;JHUD.U/JH-4&V(:B-4&Z/:!-6FJ#9#M3FJ"4DD
MR!\)48YM]R+L]YE3GL^H"7MS=B2,U]Q%?]W2/ .RSJBQ$T[Z+NTW^XXS731F
MILOFQ7MX<E[CH/N\6:Y_NNZA\NU=FZ43/G]9]NI_V6>5.S"26A75:JAFH%H=
MU4Q4LU#-1K4&JC51K85J;53KH%H7U7JHUD>U :H-46V$:F-4FZ#:%-5FJ#9'
M-2$)#?D#(SL\AN7"?I]]#S%>H][&G]HNV 8MV XMV!8MV!XM[,1/LEHLEU-"
M[G&*B\9,<<D9<A.#+3K+!=6JJ%9#-0/5ZJAFHIJ%:C:J-5"MB6HM5&NC6@?5
MNJC60[4^J@U0;8AJ(U0;H]H$U::H-D.U.:H)25#('VS9F2\L%_;[[#NA\IJP
M-V??"8W7J'?1I["89TC6&35VPEF_7^TT)AY'F6@7CC+)^-'X#\?SG)4OO^&)
MCCM!M2JJU5#-0+4ZJIFH9J&:C6H-5&NB6@O5VJC60;4NJO50K8]J U0;HMH(
MU<:H-D&U*:K-4&V.:D*2#/+G0G8<"\N%_3[[AF>\IAA_T4_!]F?!-FC!=FC!
MMFB!]>C3N'L<GJ)=-CQ%&F7102JH5D6U&JH9J%9'-1/5+%2S4:V!:DU4:Z%:
M&]4ZJ-9%M1ZJ]5%M@&I#5!NAVAC5)J@V1;49JLU134BZ?OXHBW)LNQ=AO\^.
MLO$:K5"^2PJS[ @=EF-[M&";M,"Z]&F8/8[0T;)'Z.29!)A-Y0ZPZ-@<5*NA
MFH%J=50S4<U"-1O5&JC61+46JK51K8-J753KH5H?U0:H-D2U$:J-46V":E-4
MFZ':'-6$I-/G#[#L!!Z6"_M]]L_HXS719YV'O3G[9_3QFO*M'GU9>O,,RCJC
MQDY<KICRDD7Z<;2,GCU:9K3R7&>Y^#_W<?^2Y$J0]!:K[^[K:U0F_DYF-I@W
M[Z%:%=5JJ&:@6AW53%2S4,U&M0:J-5&MA6IM5.N@6A?5>JC61[4!J@U1;81J
M8U2;H-H4U6:H-D<U(>GWN?,>R['M7H3]/C/OG5$3]N;,O'=&C9E0<UV)3CZW
MSI!LB72:]HZ39_3LR3-GC,;6$C,?.I4&U:JH5D,U ]7JJ&:BFH5J-JHU4*V)
M:BU4:Z-:!]6ZJ-9#M3ZJ#5!MB&HC5!NCV@35IJ@V0[4YJ@E)U\^?^=BI-"P7
M]GO) '512ZBK%$MJTD^JV3-D^[1@&[5@.[7 6O5IHM6.B39[VD[*:.SD%(N.
MUT&U*JK54,U M3JJF:AFH9J-:@U4:Z):"]7:J-9!M2ZJ]5"MCVH#5!NBV@C5
MQJ@V0;4IJLU0;8YJ0M+I\Z=8=KP.RX7]/OO.9;RF$AU3;IP!U1-J=/6VI,?O
M7\8+K[52=$TKL>RN4-34V&W,>*56N7LWEOTU]MULGUS7KSJ^\^G#QOGJMASO
MZV*U59;NE^"XPF^5 / 67Y_>_N*O-Q^O@N3Y>>W[Z^?]FT^N\^AZNX+@_5_6
M:S_\RTW@_UA[W_9K?/I_4$L#!!0    ( #" ?U:D"_M.N0(  ( (   8
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M+:_,Y8Z2@@HMH/Z_Y;Q]N=$O.)Y0K_\/4$L#!!0    ( #" ?U9D2IDY<P(
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M!C821:S4*U!@T+7;@G24 )9A39*6-MM+N#XC 7?EIB ]8)Y6).VF(Y(./A!
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MY[3)N3<U*/_)"H/&^Q14P541ABE."+;%(RSP&/ SE?V;/] .PC4+ C*71_%
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MJ1,E)"-UBGS)W,8 =\$V.T4"#&2-7=/;X2':!H7N#A@O][E%..1(MASMD<!
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MZZS: 27[SG-<US&)AD9=3[]/=26M2L'K+-DM2=9Q(JK/E@FA'8F]LRB)K<F
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M"R,6OFVDT^G!D*;,IO$.C,86EB(U[MM&Q@1PJJ@WY29E.XS%9)-)[H2J44B
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M\T>-A$*%V?XUWD&%QC9P_V.Q_;6*,MH@=%IKJ\E#Y0<<[M\Z%OHH;Q'=PHO
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M=[JB'/P+F+&E8 N6$&% F@Q5R;EUN4H)$T6YXP[VN4MQE#.\.. 9MC3=-![
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M8N  30*#K(&YJ6'B(S!1S'[4RBTL^Z!RD6\##*!3IUC<*G83OXIX)[(^2Z*
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M <3H1PBC83"*CF"#!S,VXUKCZ_\%R:%X\>PXCD>G<,>U0*T7"$DNN+9BFO,
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M-.R ]M\-_(U5I3NKX_X73_[N,N,,QR$)X/N9PNU7?4,&FH\WX_\ 4$L#!!0
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MV4"O1ES6]$RC8P625Y9FW[!A!]/#O_D?4$L#!!0    ( #" ?U;#!"--R08
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M;M !S%F2>E$<8S>8LS1E5Z@;Z#%R%GH![HEAP]A?!"R<'P83L3 &F-B+P83
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M"+"_4GC%]1.Z8/R'QOE_ %!+ P04    "  P@']6.;@856H"  !6!0  &0
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M'3A2)>[$[72)K"C S()D!Z9L=;>Q;*HR>P@V0A&JMD$51:4G[#V^WG+,,F$
M!X'Y:$9)M+[T[A1-U!3,"'A#R*P+ ^^8EBS +9 #?$O+!BR0F@*H)C45X"MJ
M[5RT=A!J@6M%6I36,:\!!]ACB9NI<)O:1VHII$#;4K4M908<M.$*$/K<$_Y<
M!K6]'-<G"W@TG82JGXS[ MH%7LYT\N-QRON8Q8!TR4I$F-]7J^D;$:4;LHUT
M*V4@:!]LW5/@'BI\%ZCPW7@DA@S])S'T-ZTPID4./';SW[)&MC?C?,Q/CD4B
M;!03KAH1U1K*J88#J23 3PT"2Y=NT)C@._2V<UO1&Y12T^QZ@$=1-A@%KZ%Y
MI(XA9 "*GA5\$3H9[V/0N)W8)B+Z-LD8Z%ED(&@OK-!J7:# +U[^4'P /:N+
M^<'O!3V=7[N A0D]X NY:=PF(L>D,H[J3!72;&LK79,)E)VRPH%!(6VU2ZPQ
M('WPD;Y)?DNPL57M%PTB07F.4"?(<4+JF+2!LPVYV8P\=HP#"<@:=PUO^X=@
M&Y 5&\1XN4_-["%'DN5@CP &34A'=@RL;=?V;-?0LJS!%_W)/!6:S9)8(WUZ
MR]PZ%!V4-_0S$#+@TDNJ;/ALOT0_K _\<&):)X5!^[@OGA1_M^!O7Q97C8^.
MMVI_C_;.SV/M[?RAN@7TC/M['_?W6&5^\(KNY)*<=F2^HJ3P)11(@*[:D)A)
M[NYO[-2>A(^"E3M)@RGF]<X@@.2\837(TZ4N5>]"3NXVH,13E*.BP<A$W-<^
MB5-F8Z&3S\@S,Q ][R ./F,, ;9H4F;4<.]1;]GCV]JN*3>$6 U>,?6>59=3
M$?"<&OQ[Q6IOVK&BZ#RIX<Y'N7KEZ?\I,.;!\O)XR%?'8I!'=9CK< W-WG*)
M#%6\LOVR6_5UE!8D'UAHKC6&VDX%\D&TPBHL6 *PT#O5=@T&_!F7M[8QG6TE
M:68^:$QY:TS'V+GL$9&()^=,Z(W6-IH%?-\GREA^U"06JHD[.+$!#&D MG,0
M=9V0P(HM-KC^M_#D=@F ??T:_V]^GRU91!E8C'+J8XO)8P=6^F.MFAB<[[XE
M)!A?:[C,[1'(5RZRRSI</DP#5 FWG"%%PH!SP@XNC?(K%!70TZ!Z,<Z= 763
MF_"_W?"R6!)1=2D0DR@>9 U+.%/<JH_=K0^<(1A0[,*B*0'[A+)00ZX1BEL<
MW<P@/\5*<4.2(T(.B#H,CMCL^3 (B !Y6;OFP"G6+ %B27D_UA;[I8-<N0,#
M!;8$@ZB\E 9Y^<K<4681@&*%1^H9OX <PE,LG@/HKX*9A2Q\I:DTMFYMOZ-=
MG2:C0JU&_7#?%U>X<G&=9Z7O!M=Z BCMM6HA)_L GEMCJ0<9V0*QV?B3M0?"
MP^H9DFW"AA3M&L$4']02DA\P!_MBU;=@&-!-Y$A?3N?/,50WJ,\GGGDQG5\0
M8?N.3$!Z[Z*8%J^*,66-;:?Y:)_H]?N8H<&^(,#<64B4<4<?P#1-/X!054S5
MQP< #U]95JN3U8:33KA>QR=%SKB>N-&UU..DT#V8?6)YLZ,PELNBU$%8HOJA
MDI>F!2U'(2_I#B>7;#BSX$$RR4S;?$ &_S5ZC#FQRS8?[X)]XF(L.R'(_:@9
MR+6):VK(PH8>RHR'K03.U:X;-G[2(L-\46.[B;08:.V0D J5H<0*!U(# _&D
M?(..C[4 X7B?Z8NT8#XACK8[S_JKAIIOG":T:D?-.%!KJGR /8; IC6:'6B'
M)JH3]XN.S<4(+L$"E1A\:%B1RH\K5N4M%F1W$"FLK:U($M!M&&0X5^R1C<Q*
MH'G8R%<(-]H61>:X0!9=-BXFD:'X<N)9#^0*V*([CY!\RPG%SSM\DJGD$4@(
M;(W6715_0+30^>HLDAYG"3"ZV/6MZQ4WN*3SP-;1SQL0'TQI=MXG@Y&WCNV]
M2[I&P/,O/B*ZI;(H\12\ZXZZ8/80O5GQ?I4G6P]<E=S=?[/R!/<88J#8 U I
MHU+"8*I]>7XY&6,LW4<U'M0^EZN?@W3EJ &)J[P\?SD!;PC YY!Y7Q3/BQ>9
MR,0H$?THR.N6TE:6221!%$IN1RB9P:#RHE@"Z@;&#(/9#A+F>OAW !0Z9,=]
M56KZ4/Z :-ME;=:^W/]Y PS4216 <]6!ND<JK[A<HDP<W^RX(+ "^TPM)P.>
MN!'$[WF9\<37B?Z<( F=7-+ ($K,B V$&Z[C01^0-55UJJ(*.I-,>J,RKP R
M1O5$3N4D/,.F&NSHP(CAO1ZRJ;8F_X!1%P7_J/E9Z,)N9!<K3O)RX"[6K1BV
MU)6&('$5&5)(>]O@OE)BA@H81G&@?$YS74Q5F *&-')6?(@&/%4 1<9+U?L_
MI8KF)2Q;Y31M)T$0(?(,E0[V%MP:=Q!VE1L1WTC&R)P&P8*7X<"UM-NMZ3JM
MDR52_AT0 *PWT!)# C$-$@XH1\:(3##"7%)2-*P&P:8)V@<=3#0/UT!;A6VZ
M8!GP+[QB=]*<(]->549^FDYO W4HXHX0.:='7EB,?5THUQ_M(2APF9ND3(B,
M& %&!;'7TAF4PIA_<@)2*^5V[9\6[XGN!L/F%@L2+>8D@OJM[6NFP6?O6[FU
MAY4&UMXDZPP51-]QQ!VS90FN*M6_6P,&$9A'5:Z:4X?0Q"8;+\Z<RFD#5D[\
MA-_AK+B*%M.':,+=<%U8AUM&A:A/F4<V%8A:>V+GF*ESRA,\W B\6>)8*,KT
M,A2BE!-FVFNY+PZ4V:C,,680L,9F_R! J5/6[!(=-45K+"X[L#\T8D* N% A
M0J,*&GL86Q@>QOB-:S/ IJVFD!V)WQH2+HG?(^&8O&"KX(8Z@2_J/-T.1N#0
MAQ Y\<U4[>]A1NJA/3[NQ,8RN8[I[$G"'3N)DYQH@W]37'LLQ=8$2A[I$:Z'
MPHW__@N2G=.$0]\*?[F5T5684V(/0;'_GV)JI/66I#E'-,#A)K3N:3V"'-HI
M/'W+ "]CG:-!%.CJL>:H[B3K'R&I^414,@<6>@9ISVB@<5-3T1_VI%> 2Q>?
M)48.!?/)1 W5;8Y-')KCNQW;8]@K]F!K6);2VU-",;0<C6:<?(-H[\2G!/]+
M*.;15![_0/:%G6<7*81ZQ@E*DM[XL&7<CYZ.'^Y[,153J7_1"$%+-3JP.Z;A
M.1:\2H-"X//"<Y.C205?25M)GX;EQ$+.Z#AU@#P!,Q,G=5I2!7RH3=, 2.VG
M.&8#W."F0[^;P@U 9:4/:_\QQ*?V%W>'I)3%R]*LT^$,7]A,*.A.9-3I&%!"
M.DZ;N)KH46YC-G\4T(AW.IQ#& XW<X_.]CH87B(,A0\L52?$T4\EL)H=97)'
M(4 P1\<<.,F 8^_KMXL%H,. +@02\?$00(50/414 !PM&CR(#2&\O]2-7IF$
M  )[%E+'Q*0.F@M.["D"SQ+E8!*S]:4_P:,;H0 D:\V*WPSXY,XVHN.?[%[5
ME&%D7FT-HK<FJ=S&YZFNL[(]MJ!:1W%=2R3J&W$]W3Y6P:2&AEYG26Z)LXX3
M47VRC _M0.R-Q@+>&@QX<V!52C#A6 _*@'AVA/1K2'8[76X:['H=M$ VE+OU
M[J@7HDC,'HYWXK8*'!ZKI<928=VI0G59LHP0\+RV$20"3!166 DFAJ)HPK/\
MBYDO:1-.+;DIQQJMY^A$;J/@!#2QY2E-RS0R"?Z+('&7=&53KY1HA&PD#FB"
MR%4TDXC""NE+'K('A,3RY%H<A-^%W8L X;-4BWMBGD;-]-:+$.6V PWA/3'I
M4Z?]#./EK'B)V)Y@-%D.:!@^6HEP*?J:)^@+4!>IRQ&N/\50?;O%^0*<2\MU
MC5&.Y#B8T5KN_:9:,!X@P<)0'-MPV'=@*%$]TI2/#4>ZC\2L1Y'LT"BD CH<
M@^6:$3I0XEK4G=GVVR3LVUF<"SG<,:DOP6;DR(_E1=]0C&6]DD$<J:5$J*N>
MU#X!OA+>^>'H#*R31AE79 *^?AM90E6\\<<B/@\+I4H*:=0V"C+F'_8.P@T4
MD"CY"-9YJ7&T-_<8H(_N( "VX4E15E*Z/@NDR4I+!SJS^"IM<S\Q,ST;'(1X
MFB6\O#.NR/+<2#"7G-)3_)GB>)AN#VP]. (>1"'[FOM2E:3?G]-$.YVUDCU4
M6MX3*_$T&5A@FR!(^FH'.:?NP, S = *"V7QE //NG58'0R.2TKP8/0QP\S'
MD-0I*9X44AH\W@570Y:9LS?!5F% ![^DY@-R[7$^CNTI) IJ$X_NK/IZ!98!
M.[#7UK'C_9T=+^K6SWP;<,\[1"J&"+%4Y3*_?511SCP+*!D&H&*K*+S:*2.A
MDFFKXN+Y^:3XG8*^JSA-]]:SDY&%A\:FH^?QR-%\_%30I]11OTT<]3MN5C^Z
M/?F-RWTZ%3#$IGG>3)>XA8?K\]EZ5&L@N/37'P@9AXNI\HK!$M'8@T!)$__(
MF<L)>-(T.H@DP$7)J8D8V\(#*U5Z4:?5<)Y(3T.41FTN_T,>"'H2Z[5H8_@D
MQ.1X?$(F?/F"]NR,B:J/# B\UP*P;!:!Z$KDO?2#GR$,G'A%1(I0&W^7Y I@
MTHZ#I\DA]TX24?#,6#@FZ/$\U7S\5--[GK_^K.X>+=(/!7R8%.QV-0W,ATG4
M5\_/B^QQ/RZ,K\$5L"VB[K_:);P(O'[R^?K7JZ=X_N8/C69:\;DG!Z34?(R&
ME '>!2:O:PB5ZRF$+>!G##JT&LB$-_WT^2_O/WQ^_Q3-M$10O@8V=,#H.-[?
MJHIKH_&<QXYI&(YA S9'?6) P//5"QT\1KAX6<*9D?"P292/7+28? _$-O5^
M5"KBZ9#Y^+F-&Z3C] W9XH_BXI*^Y8-%Y)Y5\-"36'PD)VPBGJ8+XVY<@7#,
M6WDZ9!\#)S(3N9I?3@I:Y#3XWDDX^J96@,Q-"=*#ZKH+A4?*>W >.2\OY878
M9&X4V>N2G2GJ+L^*WPGD- ,9*^O<?<.!2:EHVMYY\<;"8W).-#6CL9$2(JU0
M[,-IH4G\61DZQU 5>Z/K:B)URZ\60UD<&9Q02[Q8X9@SG?C%(64^),A9W$K3
MZ) ;*"[3?F?%VU['4LC6T!F5,#RP,8[FE/)\6@2YAP"E3$[BP37D!WL=?C"<
M.&% P1^8+=J3*MD)'F!4DZ.@C=F!94_/-ZJT>OHD[TLVFRR4WL3(C4;%*-&%
M?8(G$RR-3D;5>5,U1?85NEPJE<N7&9AWSC^5O&^;.%)Q@+9'E<@]P,!TQ\[W
MX")D&9?9^EXW.AYPG#AX0T,PP#K3I=)%DSCD__U1)1(1,&0K0_G]SLKLHLP-
ML!17$.E1(;$1;YD0DK38=VN2F6+7XX2:\8>F\3 ):5BH7&MVJAS?'&M7EFCR
M()L[P4"4CF0&LE(8^V/&&*KY<7KHF(K^="9MQ*4'6^-D?:C(2]DZCEY^TWXH
M5<<PQS2L8.A"L41&93J+<;-4B%1*QYA8)W1(:8ZUN3:8D5S$4=ZPW9^*VE*C
MMW1I5S_5>-'7ZQ%]%;/JYXB.=31:U$'NDQ: OMN]%K()2)<PE$Z=G/_@R#!@
M-84NS'^0JOR$<[JEK)ZO 3Q4M9P\;$%TX178@3_>+/S" Q.T&+[ABX7A%.'A
M&)9_BQ&5@=1L410VK#2'G;$04-5XDX[A/@0T:NCTV(AS.)\5ZRAB^MR2?T5[
M$8XR2D8GQPSV?!X<YR+ @_;D$<(,P* \)\$R[>0X8.+Q2$SPV$I45J(^/*>I
M[TBB,>+QB0%3&2Y ^D[27?K"5QRF=CZ:2^,JJH%PX=P<'NL]F28UU<!);6Y_
M^9@,IQ1QU6^;;H_'_>;C1_!^H;D4#K\<]M<HS'EH]/5@V+] 9'<T!!M*5VN^
M2XV'=7@)O>]:&.%K6:T?_G&VX1Z\0X%IRF2J]<"H;=&2Q9$2V_  "Q[E[52Y
MB4DM83'8_N0[OI[I2S-C[;%D&8P L* HX..%HTX93JH+E*RWF->%&.=!$E W
M4'O7/X+$T1ZQ1-_EC5Q/SN'-^PH>9L&'ZX9.7X+!S(N 5ZF\M/2@H_O<*7=[
M!W<56DT>W@BG"9B,+A:H3I3OT^H\5QSR#D(40=F\X49B4\4&-X7ZX)YNQ =A
M=7WB'V<KD61<)[-N*7ADTPI*RLI9F22657Y)US#)V6WB2!RG4KLT;N*ZUN%9
MZ&_X?,*8U8G':^?C9U\_@'QH"/;HI()[L+FY#R@!RRH!Z3!MS?>/!FB?+SP>
M3^3<*ER!_TX>?3-'0\_4V^3S$MSLTHF_/.SKQ=+O05]%RL)4"15H2=3K2N "
M#9@+TN@$:!@7W=I\$6H:5YV?2-CBH7)"L*)V5DR5&'I:]Q5;9S#1:'%&&547
MJVYT>L>NIGU^O":XQ<SC^S-GX32B=$1XO9!4!Y6-J20]@*08)IH0-\[$5WSF
M&X>$4C9U^QTK(]4JLF%?@STF'/0/2Z'D&ZZ])6/ ZG QGUD[5N5&W\9G^+M#
M3/?D0TM4KSDXM*M.\$7(.?6VORKZ'=;O2_E 238RQ<WJ-(7RJ&R3KWU@S^3X
MJIAKKFD<#U[&AE'VDCAG;KZBVI+PQS%0[KOPH:)[PI)%/,"[&#].>TTSLO$C
M4=>4FT@T\-@ZXKUK);#Q$&9+$7HFY"OY5H8D25E8PH[SL%ON=2OIT\;2FL05
M^3R:]Q>\#A"9W*VX^7U,7$[$'1-VCY!>X"FO>L_><9*Z&^)\#3E9S5F=1@%*
M1ZBV_/V70F8WL1/$!X9)?<J61 I/;&KYVX^^9!N)6R<XL4^-I*7! OT5JT_U
MGMJ;U*SC8^QH%+\TF!4>?&=%@G[1TCRKRXX,R*1\Z,@F7QE)QI,3LN[@ 2/G
M_ ,/#P;Z^7-$S !*2KEN26I*.?(IU/" %55<>OJ81W(* 4?NP^</?(TNRGN<
MV@_X*2^8O@DP\#&P,>^\B*>>%^-GDV_T6EI#$J ^6N$>"1_LJW=,CN])T!-G
MK&@:0+[MXH\=)<4C;J(&DX:D;7$$,3V"'LL2\4!(,D&^,7J5>$@0<4-?2,7/
MZ]$$*_R1WJ!P=(-E?ALF,-#"VK[U0_\R9IC,>.2ZRZOQN=0PS"L4@'7XN%[(
M3W!3Z#CW1U$DGD@Q-C2*N'")39 R23B'1HS&-TWC*M>_O_UM0K]=LO7,Z6>%
M5OS(I#[.QP]GE=#M(FB*8/%OPN3=G2Y[JD;S<=)V5*#C$>[%^!'N=ZIMR-)]
M!$Y2Y^'1$OW !79^ 3016&].;W!E$DQL:Y9]Y\?O,!ZP^??9#DY3@X12:1TY
MA/$Z.8B'@!'1/OJ(GE06P2K1M/'@Y_/XHU%HN/)Y"O2$Z5KIYSYFQ5M3]U2%
M_'_:-T^*TB&H!VPBG,A$+%"*-'_JDFO\@R@/ON\I,/A=JD[J65.&10V"U12(
M!'@A?EP#E&I..H4;,--59..CZ/.W=#2(&M<RFT /3?)Z)1Z%P3HBN3L'L&-A
M7PKGE,%T1\Z1Q^5.$HP'4<*'6.\D^PQ3HPF*[.7^FQU/Y* :I"7"RS"?@B?W
MIX'3?L[*UP#"J-&,IS^QS3JAD*B4$:Z3:-WZ>1RGMF. QTQ3/+"^&#\V_G=(
M)M*/);>VL;UD!X\/=,?7PD^-''R-.EL.O\F#LT6_]HTN%N?SEQ.X,J._BOG%
MY,1';:;^JUT?.-22)/IB\=*_&4#0)Q= EN"]FJ<9_HY?)\#J)CQQ&9:[+.;?
M3;+/%Q;OTR\9@*R$1289C.\"C.^*^?SA, *F&; $UOF)[4]/;OYR_H+2=+]W
M_JB5_Q7*NO,74M;UXPBIUTRTTH^.E#SQ$L< <A9*\"A*Z8MX$L :@C'RF;1G
MR??.M[I=TU?=$0U8C#]]'JZ&+\=?\??2X^/\V?G?5+O&$VBU7L&KY[-7+\XX
M5?0_.KNCKZ<O;=?9+?VYT9 VM_@ W%]9B&CD!RX0OJ?_^O\ 4$L#!!0    (
M #" ?U909J4]L@(  -\%   9    >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM
M;'U4;4_;,!#^*Z=,FD "TJ;E1:R-U +3)L%64=@^3/O@)I?&PO%E]H7"OY_M
MM*%(I5\2O]SSW'.VGQNMR#S9$I'AI5+:CJ.2N;Z,8YN56 E[0C5JMU.0J02[
MJ5G&MC8H\@"J5)ST>F=Q):2.TE%8FYET1 TKJ7%FP#95)<SK%!6MQE$_VBS<
MRV7)?B%.1[58XASYL9X9-XL[EEQ6J*TD#0:+<33I7TZ'/CX$_)*XLEMC\)4L
MB)[\Y'L^CGI>$"K,V#,(]WO&*U3*$SD9_]:<49?2 [?'&_:OH797RT)8O"+U
M6^9<CJ.+"'(L1*/XGE;?<%W/J>?+2-GPA54;>YY$D#66J5J#G8)*ZO8O7M;G
ML 6XZ'T 2-: ).AN$P65UX)%.C*T N.C'9L?A%(#VHF3VE_*G(W;E0['Z0]B
MA 2.8=[>"E !<[G4LI"9T R3+*-&L]1+F)&2F40+!P]BH= >CF)V"CQ/G*VS
M3=MLR0?9^@G<D>;2PHW.,7]/$#OIG?YDHW^:[&6\QNP$!OTC2'I)LH=OT)W'
M(/ -]IR'A;; 7?6UZ.%NM'?0I:U%AN/(6<2B><8H_?RI?];[LD?;L-,VW,>>
MSHSSHN'7(Y@I?S="YW#SKY&U,PD?P8UEZ9XIYO!HL6@4W,H"X4^H!1[PA6&J
M*'OZNZNLO8EWES6QUO6,*R6L#8\EF.Q-0]-J4%[#@=3PBL+80[A%9Z&25 ZR
MJ@T]H]=NP99D&(U_?=M ,L[XOK7X]]>N%, E@O(T<"L69 23>[9%8[3DQF X
M%=R<"EP<]X?PLW "\<.8T^/^ *ZHJALOX?W>P%GC''9=7KQEN@K-,K06"\$N
MK?^ZU:Y[35K3OH6WK>].F*74UE55.&COY/PT M.VDW;"5 <++XA=0PC#TG5@
M-#[ [1?DGNUZXA-T/3W]#U!+ P04    "  P@']6^9\<'BD#   V!P  &0
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MK+%A^DAVV-+*7*J&&0K5PM>=0E:YI$;X41",_8;QULLG;NY6Y1.Y-(*W>*M
M+YN&J><9"KF:>J'W,G''%[6Q$WX^Z=@"[]%\[VX51?[ 4O$&6\UE"PKG4^\\
M/)TE%N\ /SBN]-88K)-"RD<;?*FF7F %H<#26 9&OR>\0"$L$<GXN^'TABUM
MXO;XA?V3\TY>"J;Q0HJ?O#+UU,L\J'#.EL+<R=5GW/A)+5\IA79?6/78E'8L
ME]K(9I-,<</;_L_6FW/82LB"-Q*B34+D=/<;.967S+!\HN0*E$43FQTXJRZ;
MQ/'67LJ]4;3**<_D7Z5!.(9#."]+M<0*KM9TWQHU?'A@A4#]<>(;VL>B_7+#
M.>LYHS<XPPAN9&MJ#5=MA=7_!#X)'%1&+RIGT5[&2RR/( Y'$ 51M(<O'ES'
MCB_>XUI#;W"7OSX[V9UMZ^14=ZS$J4>%H%$]H9<?O O'P=D>;<F@+=G'GM]3
MW55+@2#GPZ5<<U9PP0TGU;^=;'C M8&9D.7CGUT.]NZQV\$O9&IS94 'CDV!
M:CAT^PGACK!,E36PMJ*W_T0UW5&%&I@C*7L/Z>@XS=Q_G$5P(1O[EI@K/^S?
M%<2C($SIFV;A8$_PTJW)0O"%@VN(DA3"49J\HEA9RF5K-'3LV1U!.+*@:'22
M!7"-5)I$]'I.67I"B" Y@6^F)B?E4BDK=1N39#'$)S$I%8(54O522ZG-H:Z9
MXNUB2Q,<O,NB,#HCUG$8P(,T3)#7D,(@M8/Q*(O'L.L)^%L%VJ!:N#:DP?GI
M:W68'3K=>5_@K_"^3=XPM>!T/@+GE!H<':<>J+[U](&1G2OW0AIJ'FY84[=&
M90&T/I?T^#>!W6#H__D_4$L#!!0    ( #" ?U8H#?A=(P4  #8.   9
M>&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;)U7;6_;-A#^*P?W!0Z@V!+U8L5-
M#"1.BA5(NR!)-PS#/M#2V=8JB1Y)Q^E^_8[4BUW'U=Q^L$6)Q^?>GCN2YQLA
MOZ@EHH;G(B_516^I]6H\'*IDB057 ['"DF;F0A9<TZM<#-5*(D_MHB(?,M>-
MA@7/RM[DW'Z[DY-SL=9Y5N*=!+4N"BZ_7F$N-A<]K]=\N,\62VT^#"?G*[[
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MU2VE>M%B96\&,Z'IGF&'2[K8H30"-#\7=%:N7XR"]JHX^0]02P,$%     @
M,(!_5J4IELNH!   OPP  !D   !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL
MU5=M;]LV$/XK!S<I6D"1J7<[C0W8:=856-L@R5(,PS[0TMDF(HDN2=OQ?OV.
MDJQXF*L&Z:=]L$12]W[/'<\76ZD>]!+1P&.1EWK46QJS.N_W=;K$@FM7KK"D
M+W.I"FYHJQ9]O5+(LXJIR/L^8W&_X*+LC2^JLVLUOI!KDXL2KQ7H=5%PM9MB
M+K>CGM?;']R(Q=+8@_[X8L47>(OF]]6UHEV_E9*) DLM9 D*YZ/>Q#N?QI:^
M(K@7N-4':[">S*1\L)N/V:C'K$&88VJL!$ZO#5YBGEM!9,:W1F:O56D9#]=[
MZ;]4OI,O,Z[Q4N9?16:6H]Z@!QG.^3HW-W+[*S;^1%9>*G-=/6';T+(>I&MM
M9-$PDP6%*.LW?VSB\!P&OV'P*[MK1965[[GAXPLEMZ L-4FSB\K5BIN,$Z5-
MRJU1]%40GQE_E@;!\^ ,;HU,'X"7&5P5JUSN$&&*)<Z%@>N<EQK>W/%9COKM
M1=^08LO>3QLETUJ)_QTEG@^?9&F6&J[*#+-_"^B3Q:W9_M[LJ=\I\3VF+@2>
M S[S_0YY01N&H)(7=(1!0^W@,?]J[O XMRV<<[WB*8YZ5!D:U09[X]>OO)B]
MZ[ M;&T+NZ2/;ZD0LW6.(.=PN^0*SZ8$PPRN^8ZJP\!DRU7F-/G[LK)@UP[<
M\WS-*^!/-%5<?0Q_5B["'3X:F.;$\-<Q;SOM.>[M'\A5DUZ@Y& Q0]4FR#X\
MN!'Z >:*<"5*@\1I0'&+/C<,3@F @1L,3X&Y86QWGNNS4[AZ7%'YDDQB*."-
M*&%G%;V%R(V(*'*3@!Z!MU^_%QN1(6%X)S#/X/6K@>_Y[]IW*VXC<PI.+LP.
MDJ$[M H'GNN=0A*YK-DEI_!37L6^%12Z,;->L=#NF.MU><7(*_M[@1M1T 0N
M(1UD>MP&,J!0DF<=2(Q:)$;=2#R&/J5XN4"[=AKT.3"QO=9:]3R\=6H]CK>O
M5;O%[ R>5I,-*KI(8+)8*%S8).Q/;M#>3Z)<P,?2*$%72@J?UU4VJ:BN'E&E
M0B-<4I-2=$^L>5[5#^[+":Z52!%^$W,\3)==FJ5<:^J:M/VR-MK0DO0X_X&+
M1UW6"9/(2;P 3BS8(WK16> Q^$ QM/D,'$84_H"PY0X&!_FN#<P@C!T_".@K
M2R".X9*7*5UP&7@.(SW!,";! P9>TFV,3Z@@8P(G("'6&#(OMF5TTNJ\)R23
M8*D 6[1*V-#IB\0U+E@T'.,?.FP8.XQY=6@&5,U>?,#^/TQW'#-RB)$3H5OY
MY;%!F^B]7R='5FU2*?94Z4)98+3"J,P'!\0_2'/ GHR((TI*'+\XQ]VR?I!@
M/PR<)/H><T=OBMO>%/]<;[)-L[1?[8ASR5?"\%S\C71S3@JY)NKG]:I.*UY^
M-Q(M5^FR,B[##0W+J\H%@HTS9+95^(Z?A/"!1C)%>+5T/*.!4&C"L)ULB2 <
M)O0<AA[<2?(.M!T)SF953%)96/_KD8"RX(3,IS=U&R\Z&O_^P5!9H%I4H[,F
M.12K>KYL3]OI?%(/I4_D]6C_B:L%52'D."=6YB;4\%4]+M<;(U?5B#J3A@;>
M:KFD?QBH+ %]GTN:SYJ-5=#^9QG_ U!+ P04    "  P@']6P^+W"0P#   @
M!P  &0   'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6R-56U/VS 0_BNG[$4@
MA>:M32EK*U&V:9-@0\! T[0/;G)M/9PXLUT*_WYG)TV+5KI]2'RV[QX_]YQS
M&:ZDNM<+1 ./A2CUR%L84YT$@<X66##=D166M#.3JF"&IFH>Z$HARUU0(8(X
M#-.@8+STQD.W=JG&0[DT@I=XJ4 OBX*IIPD*N1IYD;=>N.+SA;$+P7A8L3E>
MH_E672J:!2U*S@LL-9<E*)R-O-/H9-*S_L[AEN-*;]E@,YE*>6\GG_.1%UI"
M*# S%H'1\(!G*(0%(AJ_&TRO/=(&;MMK](\N=\IERC2>27''<[,8><<>Y#AC
M2V&NY.H3-ODX@ID4VKUA5?NF70^RI3:R:(*)0<'+>F2/C0Y; <?A"P%Q$Q [
MWO5!CN5[9MAXJ.0*E/4F-&NX5%TTD>.E+<JU4;3+*<Z,OTB#$"5P!.=(R6DX
MN&%3@?IP&!B"MTY!UD!-:JCX!:@HA@M9FH6&#V6.^7. @'BUY.(UN4F\%_$]
M9AU((A_B,([WX"5MLHG#2_8DJZ%.<%=^=71W=[3]/$YTQ3(<>73_-:H'],9O
M7T5I^&X/MV[+K;L/?>SD]^%,:@,_'$6XP4<#$R&S^Y^[V.['^XY,U84 DA&+
M*:I62ON*X&N%BAE>SD'8LR&CHS6\ALA/>JD;N\<)W#+%'9MMIX/H$/I)GYX!
MW$C#Q-8N1<9^.$C<&--AIQKD; >)._?%8'[$'HC('.D;MUUD0\B@*N#@B1+1
MAS#HI']'Y%QG<ED:H$3H&H>=WIL]I>BUI>C]HQ1:(]5B(U!3G'-2@@MNGGRX
M8&:IR/K/6NT]</?-JG4EI6HEHRBUD^[&[&W,=&/V&_-F@=2D9Z0A#/QTL*[3
MLEQK1A>CEKEB3]1EJ:IQZ,?] =CT3\ 1(64?F%@BL/P7]2+K!@=]/^JG< B7
MSSRHQ#6<:$3BZ"Y3XD=A KNJ$FQUK0+5W/5F#8Y<W<#:U;;]G]9=;^->_SLN
MF)KS4A.#&86&G3[IK>I^7$^,K%P/G$I#'=69"_J%H;(.M#^3U!J:B3V@_2F.
M_P!02P,$%     @ ,(!_5HH,(IIJ P  ; H  !D   !X;"]W;W)K<VAE971S
M+W-H965T,S$N>&ULK5;;;MLX$/V5@;98)$ 261=;;=8V8%MI$V!3&$G:?5CL
M RV-+:(2Z9*4G?Y]AY*BVJXM;(N\2"(YY\S,H3B<X5:J+SI#-/!<Y$*/G,R8
M];7KZB3#@NDKN49!*TNI"F9HJ%:N7BMD:04J<M?O]09NP;APQL-J;J[&0UF:
MG N<*]!E43#U;8JYW(X<SWF9>."KS-@)=SQ<LQ4^HOFTGBL:N2U+R@L4FDL!
M"I<C9^)=QY&UKPP^<]SJG6^PF2RD_&('=^G(Z=F ,,?$6 9&KPW.,,\M$87Q
MM>%T6I<6N/O]POZ^RIUR63"-,YG_PU.3C9RW#J2X9&5N'N3V%IM\^I8OD;FN
MGK"M;:/0@:341A8-F"(HN*C?[+G180?@#4X _ ;@'P).>0@:0' ("$X P@80
M5LK4J50ZQ,RP\5#)+2AK36SVHQ*S0E/Z7-AM?S2*5CGAS/BC- @>7,),JK54
MC$9WHOZ;[+:<Q6@8SS4\X;,I67Y.EI\>8SA[<PYO@ MXRF2IF4CUT#44CB5U
MD\;UM';MGW#M^7 OA<DTW(@4TWT"E_)HD_%?DIGZG8PQ)E<0>!?@]WS_2$"S
M_P_WCL#C;O@]^]:@O: CF:#=F:"B"T_0S9C.+L ^X>9KR3<L1V'T!9#8\)A)
M92Z?4!6T6QO4IJC7GJ1A^;&=J%WU*U>V$FS&_7=4&8;N9E>>SH!L ;K6:Y;@
MR*$*HU%MT!G_^8<WZ/UU3*Q7(MO3+FRU"SNU^TCU\DXDLD X^UMJ?0X38Q1?
ME(8M<@0C8<X42=:A6.U@L*/891#X470@6?B3L)=A/PK>[IO%G>'^IAC]5HQ^
MIQ@/]@@+3.&&*<'%2L/9)$G*HLSIM*<0XY(GW)QW:-'_.4G_72^TAV1/C&-V
M_<@+PP,U.N/]334&K1J#3C7F'!77,,\8U;@$2\,31O7M0[&XA7_OL5B@^N^8
M!IVLOW@V9J])%K\2V9Z:4:MFU*GFM-0THS5,$JI1FMM+XP+FJ!(Z7=0V@%S"
M9VGHKZ/S:) ",(VM.JSXM<R=[GY5YM<DBVLRK[?S=__X_VOQW)U[N$"UJOH9
M#8DLA:EOL7:V;9DF5:=P,#_UKF=UY_.#IN[#[IE:<:$AQR51]JXB.DNJ[FWJ
M@9'KZK9?2$.]0_6943N(RAK0^E+2C=\,K(.VP1Q_!U!+ P04    "  P@']6
M#.A2-/@"   K#   &0   'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6RU5VUK
MVS 0_BN'!Z.#KG[):[LDT+0=&S1;:.C&&/N@V.=$5)8\26Y:V(^?9#M.!HU2
M,O(ED>2[YYY[3LY=!BLA']024<-3QK@:>DNM\PO?5_$2,Z+.1([</$F%S(@V
M6[GP52Z1)*53QOPH"+I^1BCW1H/R;"I' U%H1CE.):@BRXA\'B,3JZ$7>NN#
M.[I8:GO@CP8Y6> ,]7T^E6;G-R@)S9 K*CA(3(?>97@Q#MO6H;3X1G&EMM9@
M4YD+\6 WGY.A%UA&R##6%H*8KT>\0L8LDN'QNP;UFIC6<7N]1O]8)F^2F1.%
M5X)]IXE>#KV^!PFFI&#Z3JP^89U0Q^+%@JGR$U:U;>!!7"@MLMK9,,@HK[[)
M4RW$ED/8W>$0U0Y1R;L*5+*\)IJ,!E*L0%IK@V879:JEMR%'N:W*3$OSE!H_
M/?HB-$($[V%6E05$"C.ZX#2E,>$:+N-8%%Q3OH"I8#2FJ*RQN1Q)P=!:3Z6Y
M(E(_G\*460_"$[CY7=#<U$Z?PKW"M&!P:[17<'*-FE"FW@U\;<A;"GY<$QU7
M1*,=1,,()H+KI8(;GF#R+X!OLFY2C]:ICR,GXC7&9] *3R$*HLB!UVJD;)5X
M[1UXMV0N)-'"B-CD#S\GF,U1_H(_,*&<9D76'+VD@3."?4,O5$YB''KF%50H
M']$;O7T3=H,/#O[MAG_;R7]=R+*"N*E@4560T13AY <2^6+UW-A]>#:.RL&R
MT[#L_)_*Y&FORLX(!ZK<;?AWCZBR&SML[Y6YU]#L.:&^IN8'  ^_R$[T R7N
M-]S[1Y38C=W9J_!YP_+\<(5?<8F=Z <J' :;MA$<4>,]X&%KK\KA5H,+G6!7
M(LL+C?+PN^P.<*C4T2:!Z)A2N\%?H?2F_X7N!KA'Z5?<:7> 0Y7>-,#PF!UP
M#WAOM]+^UOR6H5R44ZJ"<O*J1KGFM)F$+ZOY;V->C=$3(A>4*V"8&M?@K&=Z
MG:PFTVJC15Y.@W.AS6Q9+I=FFD=I#<SS5)B)L-[8 ,W_@]%?4$L#!!0    (
M #" ?U;7X"1A=3T  $?S!  9    >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM
M;,W=>W/BUH+NX:^BZMDUE5W521M\SV2GRMVZW^_2G%/G#S7(-A4,'B$[Z=1\
M^!$8&DG&"^C^)7-J9R<8HV?)R/;KI<NK7WZ?5[\M[LNREOYXF,X6_WIW7]>/
M/W_XL!C=EP_%XJ?Y8SEK/G,[KQZ*NOFPNONP>*S*8KQ:Z&'Z87AR<O'AH9C,
MWOWZR^HYO_KUE_E3/9W,2K^2%D\/#T7UY6,YG?_^KW>#=YLGPLG=?;U\XL.O
MOSP6=V54ULFC7S4???BJC"</Y6PQF<^DJKS]U[N;P<_YX'*UQ.HEZ:3\?=%Z
M+"V_EL_S^6_+#XSQO]Z=+%>IG):C>FD4S7^>RT_E=+JDFA7YK[7Z[NN@RP7;
MCS>ZNOKJFZ_F<[$H/\VGV61<W__KW=4[:5S>%D_3.IS_KI?KK^A\Z8WFT\7J
MW]+OZ]>>O)-&3XMZ_K!>N%F#A\GLY;_%'^MWHK7 </#& L/U L/^ L,W%CA=
M+W#:6^#LK54Z6R]P=N@"Y^L%S@]=I8OU A>'?M&7ZP4N>PL,SMY8X&J]P-6A
MJW2]7N#ZT 4&)YLM=W+P(E\W]JNM_>8BF\T]Z&_O-[_TP6:##_I;_.U1-IM\
MT-_F;R^RV>B#@[?Z8+/9!Z^V^YN+;#;\H+_EWUYDL^D'!V_[P6;C#P[>^L/-
MUA\>O/6'FZT_/'CK#[_^L!_\TS[<;/WAP5M_N-GZP]76__#RRVOUFT\NZN+7
M7ZKY[U*U?'WC+1^L?GVNEF]^X4UFRU_U45TUGYTTR]6_NO.ZE$ZE'Z6P?"YG
M3Z7T@US6Q62ZD.+RC_JIF/Y3^H?T05K<%U6YD"8S*9E-ZL7[YLGF<7P_?UH4
MLW'S\;__V]7IQ=E_+)]U)M-I\TM\\<N'NEG!Y3 ?1NN5,5Y69OC&R@PD9SZK
M[Q>2,AN7XQW+N^+E3_<M'^X9?R@ /C3O[->W=[AY>S\.A:)3?)$&U^^EX<EP
M("61+/WPCW_N6*]/8N7FL?I)&I[M9>0#F)-!EVEOWI?_[("5?5_ECO4["%;%
ML%I^;M;X:@D/K@1?N+9_*YP,5\JE0-'%BEG,FI4Y>V%V?7,?L/CIR[M_*E@+
M<\]&?+K[R@P%C'7XVH@8^X M?SK8^YWI'+"=AR\_)R>[?N[%B\OEZ* OQMOS
MGCPMWY.3O8Q_.',B8(+#WUH1$S+O370,HR2A],/Z5_XN+#X<$WW7)(<SHG<H
M/9@1_GK(CF'VO4/Y(;]K7K#KW>O4R:/3KW%_NG+/WG _-?%6-;.KYN^,^E[Z
MM/H+HZS>2_:D^#R93NHO[YLGJZJ<U3O6^:/07DY*?UX\%J/R7^^:6>>BK)[+
M=[_^^[\-+D[^8U?DD9A,8@J)J22FD9A.8@:)F21FD9A-8@Z)N2_8^0I;[M]Y
M_G5X<C4\^^7#<SL R2%]$@M(+#SHS8C((>,=0YX/!A?=(1-RR)3$,A++(:P3
M<6=?(^[L>R/.G<]&;Z><D#\VY4A,)C&%Q%02TTA,)S&#Q$P2LTC,)C&'Q-P7
M[*+U6W9P=7G:3SER2)_$ A(+#WHS(G+(^/60IU=G)Z>]E".'3$DL([$<PCHI
M=_XUY<Z_-^4V>W3#<C2_FTW^W+E']*-PF&/3CL1D$E-(3"4QC<1T$C-(S"0Q
MB\1L$G-(S"4QC\1\$@M(+#Q_E5##D[.3DUXHDD/&)):06$IB&8GE$-;)SHNO
MV7DAS$[WZ>%S64GS6RDN1_>S^71^]Z4)SE$Y6^P\2/51R!V;D20FDYA"8BJ)
M:1>O?JC/NS_0.CF<06(FB5DD9I.80V(NB7DDYI-80&(AB44D%I-80F(IB64D
MED-8)Q\OO^;CI3 ?UQ/'Q7LIGM?%=%<B"H%C$Y'$9!)32$PE,8W$=!(S2,PD
M,8O$;!)S2,PE,8_$?!(+2"R\?#UK/+\^&?9FC>20\>LA3P=G@ZO>KE1RR)3$
M,A++(:P3=U=?X^Y*&'?&;%25Q6)UZNO+HW\N3V/=NX=U5RX*1SHV%TE,)C&%
MQ%02TTA,)S&#Q$P2LTC,)C&'Q%P2\TC,)[& Q,*K5R'5WY-*#A>36$)B*8EE
M))9#6"<ZK[]&Y[4P.K5R5L[J<G0O_5^G7.Y4_7^[0E%H'!N*)":3F$)B*HEI
M)*:3F$%B)HE9)&:3F$-B+HEY).:36$!B(8E%)!:36$)B*8EE))9#6"<_!R=?
M W1YZ?'^8Y'>K63,)O6DF$IA,TI1-9'J5_.[JGC8>41RK79V6'3_,/LD'OC8
MI$0U!=545--034<U ]5,5+-0S48U!]5<5/-0S4>U -5"5(M0+4:U!-525,M0
M+:>T;GRVV@L&!\:G][ALCFGR\V8\GJP?'A:E@_U1*ER)HZ.4U!144U%-0S4=
MU0Q4,U'-0C4;U1Q4<U'-0S4?U0)4"U$M0K48U1)42U$M0[6<TKI1.MQ&Z?"0
MLWZDVVK^\.;!ST_SZ;3X/*^*54V;6I:2-VLG[CIH=^;LR_#M*V0')R?],[,_
MB=?RZ*PE-0755%334$U'-0/53%2S4,U&-0?57%3S4,U'M0#50E2+4"U&M035
M4E3+4"VGM&[6;EMX!N(:GH.R]N:N*LN'<E9+<5D]3&8OF>O.Z\FHE/RRFLS'
M4M8LLJS<*^KFXR9_/U9ET<QW?Y"++[M:AS[N6:_K$VE<?-DU3?XD7O+H7$8+
M>U!-134-U714,U#-1#4+U6Q4<U#-134/U7Q4"U M1+4(U6)42U M1;4,U7)*
MZ^;RMCIH69[\U^3RS?BYF#7!W,WGC^7MO"HE=5(MZ@9\:(#1,J>C8EH*4EJ\
MEJ*4%BYY=$J3FH)J*JIIJ*:CFH%J)JI9J&:CFH-J+JIYJ.:C6H!J(:I%J!:C
M6H)J*:IEJ)936C>EM]5' W'W$9[2-[?-]/GHD!:OY.!*D-)H3Q*J*:BFHIJ&
M:CJJ&:AFHIJ%:C:J.:CFHIJ':CZJ!:@6HEJ$:C&J):B6HEJ&:CFE=5-Z6[(T
M.+1EZ;#3L%YW_)SU#PVCU4FHIJ":BFH:JNFH9J":B6H6JMFHYJ":BVH>JOFH
M%J!:B&H1JL6HEJ!:BFH9JN64UHW-;??20%R^M(W-9G*ZNI7G<K[J?9Y.[E93
MV-WAN:._I!^>:,L2JBFHIJ*:AFHZJAFH9J*:A6HVJCFHYJ*:AVH^J@6H%J):
MA&HQJB6HEJ):AFHYI77#<]OD-!!7.:WW#"^[[Y>WN9[,[MY(T??2S</\:??]
M7\1C'/F.?$(U&=445%-134,U'=4,5#-1S4(U&]4<5','K\N)!L.+_@4%'CJH
MCVH!JH6'O2$1.FB,:@FJI:B6H5I.:=VDW!8W#<3-30=T_(J%HW,0+6Y"-075
M5%334$U'-0/53%2S4,U&-0?57%3S4,U'M0#5PK76;> ]O>ZG)5K0M&/,P?5Y
M+Z$3=,P4U3)4RRFMDX+#;?O24-R^]+J_4/KOS9U@I&(V[EWONCVG2%1W*![S
MV-Q$-1G5%%1344U#-1W5#%0S4<U"-1O5'%1S4<U#-1_5 E0+42U"M1C5$E1+
M42U#M9S2NCF\K7$:'E3C=-Q!S^'KXJ;>7<$^B8<].CS1XB944U%-0S4=U0Q4
M,U'-0C4;U1Q4<U'-0S4?U0)4"U$M0K48U1)42U$M0[6<TKKA.=R&I[BX:><D
MUI\6]3)(=]SB5#QY)6LV/J&:C&H*JJFHIJ&:CFH&JIFH9J&:C6H.JKFHYJ&:
MCVH!JH6H%J%:C&H)JJ6HEJ%:3FG=_-V6.0W%I4G?-GD]?35Y[9^Q*Q[VZ/!$
M&Y=0344U#=5T5#-0S40U"]5L5'-0S44U#]5\5 M0+42U"-5B5$M0+46U#-5R
M2NN&Y[9QJ7EX].15FS^7U6P5H\LZADE=EZ7D%U4]&4T>7P[%"N>PPB&/GL.2
MFHQJ"JJIJ*:AFHYJ!JJ9J&:AFHUJ#JJYJ.:AFH]J :J%J!:A6HQJ":JEJ):A
M6DYIW1C>5BH-Q6U%WS:'/7]],EM_#HLV':&:@FHJJFFHIJ.:@6HFJEFH9J.:
M@VHNJGFHYJ-:@&HAJD6H%J-:@FHIJF6HEE-:-SRW34=#<=-15!9U/2VEY5RV
MF:(N)&,V^DD\0R4;*SZAFHQJ"JJIJ*:AFHYJ!JJ9J&:AFHUJ#JJYJ.:AFH]J
M :J%J!:A6HQJ":JEJ):A6DYIW9#=]B(-_X)>)+%Y=,ZB%4JHIJ":.GS=)W7:
MG=EKZ( ZJAFH9J*:A6HVJCFHYJ*:AVH^J@6H%J):A&HQJB6HEJ):AFHYI77#
M<]N+-/P;>I'$8QP=IF@O$JHIJ*:BFH9J.JH9J&:BFH5J-JHYJ.8.=]0 70Y>
M]2*A@_JH%J!:>-@;$J&#QJB6H%J*:AFJY9363<IM+])0W(OTUNUD[$GQ>3*=
MU%_>-T]65?E&1**52:@FHYJ":BJJ::BFHYJ!:B:J6:AFHYJ#:NYP1PW/X'5U
M(#JHCVH!JH6'O2$1.FB,:@FJI:B6H5I.:9V(/-V6)IV*2Y,.B$AW/AN]G9)B
M_]B41#49U1144U%-0S4=U0Q4,U'-0C4;U1Q4<]=:YQJUZU<AB8[IHUJ :N%!
M[T>$CAFC6H)J*:IEJ)936C<CMX5&I^)"HYN'<C8NW^P/7.Z(72SO+CJ_E:)Z
M/OKM_>96I&_>;E0\X-&AB18CH9JRYZV]>/.^JBJZ'AJJZ:AFH)J):A:JV:CF
MH)J+:AZJ^:@6H%J(:A&JQ:B6H%J*:AFJY936#=SA-G#%)4@']-F+A:,3%*TV
M0C4%U514TU!-1S4#U4Q4LU#-1C4'U5Q4\U#-1[4 U<*UUIZ>7@VO+OO34[2R
M:,>8EQ=7O3I[=,@4U3)4RRFM&X+;)J)3<1.1^$*492M@-7DNZG+9#CC:7V0O
M'NWHP$3KC%!-0345U314TU'-0#43U2Q4LU'-0347U3Q4\U$M0+40U2)4BU$M
M0;44U3)4RRFMF\#;.J/FX7<>&WU[?BJDCXY;4I-135EKYZV_&D]/^P=25'1,
M#=5T5#-0S40U"]5L5'-0S44U#]5\5 M0+42U"-5B5$M0+46U#-5R2NO&Z+:.
MZ%1<1Q1UCXUNK_V,[HMF/,E8+)[*L32927%5S!9-X"X/K_[0?+Q8O>"?S5SW
MY='.H"7+)SZAFHQJRNGKAJ;3RY.+P>59/VO1]B)4TU'-0#43U2Q4LU'-0347
MU3Q4\U$M0+40U2)4BU$M0;44U3)4RRFMF[7;]J+3/>U%W:QM9K"+R;A<G[$4
MEJ-R\MQ$[;P3M3M3%>TT0C49U92UUIZ^#IKIZZOY*UI6A&HZJAFH9J*:A6HV
MJCFHYJ*:AVH^J@6H%J):A&HQJB6HEJ):AFHYI74S=5M6="HN*^IEJE]-1N7R
M#-^7^>MJHCI>GAE<+:3'YMG55'4Y9_V']$$T;T7;C%!-1C5EK5VUYZT_G0_Z
M 4N.J:&:CFH&JIFH9J&:C6H.JKFHYJ&:CVH!JH6H%J%:C&H)JJ6HEJ%:3FG=
M@-T6&IV*"XUZ :L6DTI*B^FRXH@*6[3M"-5D5%/66CMLAS]=O I;M,4(U714
M,U#-1#4+U6Q4<U#-134/U7Q4"U M1+4(U6)42U M1;4,U7)*ZX;MMA/I5-R)
MM/>TXLV-Q8O9FU>\BD\T1FN34$U&-0755%334$U'-0/53%2S4,U&-0?57%3S
M4,U'M0#50E2+4"U&M0354E3+4"VGM$XFGVU+F,[$)4S;4Z+"1B^JT7TS\9W?
M5<7#SMFL6#LV85%-1C7E['5)2Z^Z7MW_$@U=)QW5#%0S4<U"-1O5'%1S4<U#
M-1_5 E0+42U"M1C5$E1+42U#M9S2NEFX+5LZ$S<"?=.M8<3FT8F(]BFAFH)J
MZEIKA^=%/SS1XB14,U#-1#4+U6Q4<U#-134/U7Q4"U M1+4(U6)42U M1;4,
MU7)*ZX;G<!N>!Q4G2;?5_$%ZZ_+5=3GAS6W=Y*QR>UN.ZLES*<G++HFONW@7
MDE-\D3Z64EQ6#Y-9\[FQ](/3B/<["PW%ZW5T *-U3*BFH)JZ9WL.AM+#\CW?
M]4>/AJZ)CFH&JIFH9J&:C6H.JKFHYJ&:CVH!JH6H%J%:C&H)JJ6HEJ%:3FG=
M9-ZV.9V)VYP.2N;M =9-ZJX.NXZ?5W-@=UZO3X82=@N+5^3H*$:+GE!-035U
MSP:\?K.I6$/70T<U ]5,5+-0S48U!]5<5/-0S4>U -5"5(M0+4:U!-525,M0
M+:>T;A!O2YV:AW]K$!NWS52Y^JVLES=BO7E\K.;/Q53R/M=%,[(HIX7K>71.
MDYJ,:@JJJ7NV[^!*$-3DBNBH9J":B6H6JMFHYJ":BVH>JOFH%J!:B&H1JL6H
MEJ!:BFH9JN64U@WJ;6W4F;@VZCN"NAO0R6/SE%/4S4=-,'^LRF)T+XAEM$\*
MU6144U!-W;,U1=-GM& *U0Q4,U'-0C4;U1Q4<U'-0S4?U0)4"U$M0K48U1)4
M2U$M0[6<TKJIO"V8.A,73'U[*C=/C\>3Y:,FA;\KH=%N*E2344U!-77/EA4E
M-%I7A6H&JIFH9J&:C6H.JKFHYJ&:CVH!JH6H%J%:C&H)JJ6HEJ%:3FG=A-[6
M59V)ZZK6)U![MYLK>7>?,8W63Z&:C&H*JJEK37BY$=H]A6H&JIFH9J&:C6H.
MJKFHYJ&:CVH!JH6H%J%:C&H)JJ6HEJ%:3FG=M-QV3YV)NZ>V:1G]7CQ*WN/;
MUQBA'5*H)J.:@FKJ6FLGYK"?F&B!%*H9J&:BFH5J-JHYJ.:BFH=J/JH%J!:B
M6H1J,:HEJ):B6H9J.:5U$W-;('7VG052_K2HEQ?N2G$YNI_-I_.[+U]+I43%
M4>)QCPY8M#@*U1144U%-0S4=U0Q4,U'-0C4;U1Q4<U'-0S4?U0)4"U$M0K48
MU1)42U$M0[6<TCI9?+XMCCH_M#CJB+(,L7ELSJ*:C&H*JJGG^YNFT %U5#-0
MS40U"]5L5'-0S44U#]5\5 M0+42U"-5B5$M0+46U#-5R2NN&Y[9IZOS0IJFX
MJ.[*6MBY*+:.#DVT80K5%%13SU\W3+T*3;1A"M4,5#-1S4(U&]4<5'-1S4,U
M']4"5 M1+4*U&-425$M1+4.UG-*ZH3G<AJ:XD6COWE]M_EQ6L]4\]-/\X6%2
MUV4I^475O'CR^')YCF@GL'CXHW,6+9)"-0755%334$U'-0/53%2S4,U&-0?5
M7%3S4,U'M0#50E2+4"U&M0354E3+4"VGM&XD;ZNESL7-1-^V$QAMB4(U&=44
M5%/76GL^.^C/9]$Z*%0S4,U$-0O5;%1S4,U%-0_5?%0+4"U$M0C58E1+4"U%
MM0S5<DKKAN>V#JIY^%WS6:^^;\+UIJJ*V=W^F]^)1SLZ5DE-1C4%U514TU!-
M1S4#U4Q4LU#-1C4'U5Q4\U#-1[4 U4)4BU M1K4$U5)4RU MI[1N F][GL[%
MS4!'WOQ.K!V=L&@_$ZHIJ*:N-=%E..B .JH9J&:BFH5J-JHYJ.:BFH=J/JH%
MJ!:B6H1J,:HEJ):B6H9J.:5U8W-;Q'0NKNO9.W%-'G^\K>;-?-4OOJSFK0?/
M8=%^)52344U!-175-%334<U -1/5+%2S4<U!-1?5/%3S42U M1#5(E2+42U!
MM135,E3+*:T;QMO.I7-QY]+7F6LQ&TMR^5Q.YX_]S'V_K4NLYYM#M5+SKY==
MS(OEYQ\>R]GBY20II:AFY7AG/J/53:@FHYJ":NI:.V_-@,^N3T[ZDV"TO0G5
M#%0S4<U"-1O5'%1S4<U#-1_5 E0+42U"M1C5$E1+42U#M9S2NKF[;6\Z%[<W
M,9/@YG51,2T7DC-I_EW/9^7FY0OQ1!EMA$(U&=445%-134,U'=4,5#-1S4(U
M&]4<5'-1S4,U']4"5 M1+4*U&-425$M1+4.UG-*Z@;TMCSH7ET>]=<< >U)\
MGDPG]9?WTN8. V$YFM_-)G^^,0E&RZ)0348U!=545--034<U ]5,5+-0S48U
M!]5<5//66GL7SN"\OPO'1\<,4"U$M0C58E1+=FRKLV%_6Z7HF!FJY936R<J+
M;;G3A;C<Z=-\.BT^SZNBGCR7G8GKS70Z'Q6?I]UGFVQ=3,9EM;Y9[>HURX>[
MXE,\]+'QB6HRJBFHIJ*:AFHZJAFH9J*:A6HVJCFHYJ*:AVK^6FO_@F^RN/<+
M/D#'#%$M0K48U1)42U$M0[6<TKHQNZV!NA#70.W=AWPSJR>?Y^,OFYJHU8T"
M1/N%Q0,>':YH5Q2J*:BFHIJ&:CJJ&:AFHIJ%:C:J.:CFHIJ':CZJ!:@6HEJ$
M:C&J):B6HEJ&:CFE=4-XN UA<:W4-W58B,VC<Q;MBD(U!=74M2:Z% @=4$<U
M ]5,5+-0S48U!]5<5/-0S4>U -5"5(M0+4:U!-525,M0+:>T;GAN"Z NQ 50
M>V>P;^])%DYCT8HH5)-134$U%=4T5--1S4 U$]4L5+-1S4$U%]4\5/-1+4"U
M$-4B5(M1+4&U%-4R5,LIK9O$VS:IYJ$HB3?G+MU6\P?IK7.=E#]&TZ?Q9'8G
MW2P69?//6(J+/W8FL'"THQ.8U&144U!-134-U714,U#-1#4+U6Q4<U#-134/
MU7Q4"U M7&OM'5&OCR!'Z)@QJB6HEJ):AFHYI763==L2=2%NB0+FN,O+?)X^
M+\K_>EH^JSSOG?^B35.H)J.:@FHJJFFHIJ.:@6HFJEFH9J.:@VHNJGFHYJ-:
M@&HAJD6H%J-:@FHIJF6HEE-:-Z6WI507XE(J>OZ+-E&AFHQJ"JJIJ*:AFHYJ
MQEH3GX-JHF-:J&:CFH-J+JIYJ.:C6H!J(:I%J!:C6H)J*:IEJ)936C=9MPU3
M%^*&J9M%DZ72_VEFOZ-"NI$^BF>N:$,4JLFHIJ":BFH:JNFH9J":B6H6JMFH
MYJ":BVH>JOFH%J!:B&H1JL6HEJ!:BFH9JN64ULW7;9/4A;A)ZH!BBGA>%].=
M<8OV0*&:C&H*JJFHIJ&:CFH&JIFH9J&:C6H.JKEKK7VX\;*_K\!#A_11+4"U
M\)"W(T*'C%$M0;44U3)4RRFM&X[;UJ8+<6M36*[KC5L'69<5$W=5^7*(U2^K
MR7PL_?"?S<O^N3,BT;HF5)-134$U%=6T/9OY7/K2;+]=EUKIZ'H8J&:BFH5J
M-JHYJ.:BFH=J/JH%J!:B6H1J,:HEJ):B6H9J.:5U O9R6_5T*:YZ6A\W798?
M/A23V?+8Z.[K8-]+-P_SIUF]*V/%8QR;L:@FHYJ":BJJ::BFHYJ!:B:J6:AF
MHYJ#:NY:Z\R[7I48>NB8/JH%J!8>]'Y$Z)@QJB6HEJ):AFHYI75S<MO5="GN
M:CI@+^VGIZHJWPA(M)<)U6144U!-134-U714,U#-1#4+U6Q4<U#-76N]RT+Z
M^8C6+:%:@&KA(6]'A X9HUJ":BFJ9:B64UHW'H?;>!2W*!T0C^Y\-A(D)-JH
MA&HRJBFHIJ*:AFHZJAFH9J*:A6HVJCFHYEZ^;O"Z>'4K0P\=TT>U -7"@]Z/
M"!TS1K4$U5)4RU MI[1N1F[+DB[%94DW#^5L7([?.I2YW 6[**;ELHHPJN>C
MW]Y_/;@I%U]V'ML4#WAT:*(]27O>C(L3:5Q\V77$3T'70T4U#=5T5#-0S40U
M"]5L5'-0S44U#]5\5 M0+42U"-5B5$M0+46U#-5R2NL&[K83J7EXP+%-\36A
MWW]'&_%:')W"I":CFH)J*JIIJ*:CFH%JYEH37WEJ[7C5V:N3+&UTS1Q4<U'-
M0S4?U0)4"U$M0K48U1)42U$M0[6<TKI)NNU NA1W(*V3="&X%$4L')V":&<1
MJBFHIJ*:AFHZJAFH9J*:A6KV6NO<+/3T540[Z* NJGFHYJ-:@&KA6FOOP;T>
M#"[[>W#1DJ$=8PZNK@?7W4$3=- 4U3)4RRFMFV_;]J!+<7O0]B8P\F0QFC^7
MU1?)K^9W5?&P>'EJ5D^: -QY0W"Q?73RH5U!J*:@FHIJ&JKIJ&:@FHEJUEKK
M_"KJ3Q+1HB!4<U'-0S4?U0)4"U$M0K48U1)42U$M0[6<TKHANBT*NA07!7TJ
M'B?-Y'#RY^H8YWIOZZ?YHGXON64MFCJBI4&H)J.:@FHJJFEKK3-IN>C/671T
M3 /53%2S4,U&-0?5W+76N2O?ZU-ZT(X?5 M0+3SD[8C0(6-42U M1;4,U7)*
MZR;>MKKG<D]US]N)IU7SQ<Y;AXK)H\,.K>Q!-0755%334$U'-0/53%2S4,U&
M-0?57%3S4,U'M0#50E2+4"U&M0354E3+4"U?:YVIP:#U)U$W/K?E/I?BUA=!
M?-X\S*MZ\N?;Y]R@K3ZH)J.:@FHJJFFHIJ.:@6HFJEFH9J.:@VHNJGFHYJ-:
M@&KA6FO/04]?ST'1 I]#ADS0(5-4RU MI[1.-EYM>WFNQ+T\;[:N2_\M^=7D
MN:A+R9\VX^^]F;9XH&.C$M5D5%-0344U#=5T5#-0S40U"]5L5'-0S44U#]5\
M5 M0+42U"-5B5$M0+46U#-5R2NN&[[;LYTI<]A-U+\/<GAT4W1?->)*Q6#PU
M<];)3(JK8K9HIJW+JT1^:#Y>K%[PSR:D7Q[M#&2T# C5Y*O7C1^GYU=GP]/>
M'X(*.JR*:AJJZ:AFH)J):A:JV:CFH)J+:AZJ^:@6H%J(:A&JQ:B6H%J*:AFJ
MY936S=KA-FO%S4&]K.U>>!F6HW+RW$3MO!.U.U,5+1!"-7FM=?:?G[RZ'D!!
M!U5134,U'=4,5#-1S4(U&]4<5'-1S4,U']4"5 M1+4*U&-425$M1+4.UG-*Z
MF;IM&KH2E^OT,M6O)J-R62;T,G]=353'RQ*B:B$]-L^NIJK+.>L_I ^B>2O:
M-H1J\EJ[:B7L\*?+ZW[ HLU"J*:AFHYJ!JJ9J&:AFHUJ#JJYJ.:AFH]J :J%
MJ!:A6HQJ":JEJ):A6DYIW8#=-@LU#X\(6+685%):3)?W4:'"5K@"1X<MJ<EK
MK1NV%_VL)8=444U#-1W5#%0S4<U"-1O5'%1S4<U#-1_5 E0+42U"M1C5$E1+
M42U#M9S2NEF[[1ZZ$G</B<Z$LINLG2U*J9B]6:LK/C<*+2U"-1G5%%1344U#
M-1W5#%0S4<U"-1O5'%1S4<U#-1_5 E0+42U"M1C5$E1+42U#M9S2NG&\K4JZ
M.K0J:?=]0G?/9M&*)%2344U!-175M*L=53^]:;N.CFB@FHEJ%JK9J.:@FHMJ
M'JKYJ!:@6HAJ$:K%J):@6HIJ&:KEE-9-SVU'TI6X(^F@2OKU;5]N;NLF:)7;
MVW)43YY+25Y>\_-U7KN0G.*+]+&4XK)ZF,R:SXVE'YQ&O-]YJQCQ>AV=P&C'
M$JHIJ*:BFK;GNV,PE!Z66W#7WU ZNB8&JIFH9J&:C6H.JKFHYJ&:CVH!JH6H
M%J%:C&H)JJ6HEJ%:3FG=9-YV.5V)NYP.NUG,U[W*F]1=[6L>/Z\FP>Z\7A_[
M%=ZU3;PB1T<QV@"%:@JJJ:BF[?EVN'[S_G0ZNAX&JIFH9J&:C6H.JKFHYJ&:
MCVH!JH6H%J%:C&H)JJ6HEJ%:3FG=(-ZV0EV)6Z'P(#9NFZER]5M93V9WTLWC
M8S5_+J:2][DNFI%%.8UV3*&:C&H*JJFHINWY;AE<"8(:+91"-1/5+%2S4<U!
M-1?5/%3S42U M1#5(E2+42U!M135,E3+*:T3U-?;BJIK<475=P1U-Z"3Q^8I
MIZB;CYI@_EB5Q>C^[5@6K]6QL8QJ,JHIJ*:BFK;G>T,4R^B*&*AFHIJ%:C:J
M.:CFHIJ':CZJ!:@6HEJ$:C&J):B6HEJ&:CFE=6-Y6UYU+2ZO^O98;IX>CR?+
M1TT,?U=$HPU7J":CFH)J*JII>[Y/A!&-=EZAFHEJ%JK9J.:@FHMJ'JKYJ!:@
M6HAJ$:K%J):@6HIJ&:KEE-:-Z.$VHL6=5]MSJ-WY<SE=WFJV+B>[3YT64T=G
M*=IKA6H*JJFHIJVU]JG39[TSI]$!#50S4<U"-1O5'%1S4<U#-1_5 E0+42U"
MM1C5$E1+42U#M9S2NIFY[;2Z%G=:';PCV;O=S$^;1W[Q9;5,Z_HDP;05+;A"
M-1G5%%1344W;\WUP*IBUHJ57J&:BFH5J-JHYJ.:BFH=J/JH%J!:B6H1J,:HE
MJ):B6H9J.:5U$WA;>M4\%.]8?B@FL^5)5+NO_'TO*8MZ\K"Z$FF9T:++D<1#
M'1VUI":CFH)J*JII>S:X\'(D=$T,5#-1S4(U&]4<5'-1S4,U']4"5 M1+4*U
M&-425$M1+4.UG-*Z8;MMO;K^>UJOFI<[36@_/#T(B[#$:W-T'J-%6*BFH)J*
M:AJJZ:AFH)J):A:JV:CFH)J+:AZJ^:@6H%J(:A&JQ:B6H%J*:AFJY9363>AM
M$=;UH458W0SVJ_GX:53O/IB+]F"AFHQJ"JJIJ*9=O^[!&O8/YJ(U6*AFHIJ%
M:C:J.:CFHIJ':CZJ!:@6HEJ$:C&J):B6HEJ&:CFE=;-S6X-U+2XZ(F>WQ1_[
M9[=H^16JR:BFH)J*:AJJZ:AFH)J):A:JV:CFH)J+:AZJ^:@6H%J(:A&JQ:B6
MH%J*:AFJY9363>AM'=:UN/_HFV:W:+$5JLFHIJ":BFK:6A.>JHPV6*&:B6H6
MJMFHYJ":BVH>JOFH%J!:B&H1JL6HEJ!:BFH9JN64ULW.;8/5M;B3J'6+A&I^
M5Q4/N],2K9="-1G5%%1344U;:\)]P6B-%*J9J&:AFHUJ#JJYJ.:AFH]J :J%
MJ!:A6HQJ":JEJ):A6DYIG;0<G&Q[I):/#\O+L/&+:G2_V0F\,SCW<,<F)\O)
M+*>PG,IRVH8333;9(0V6,UG.8CF;Y1R6<UG.8SF?Y0*6"UDN8KF8Y1*62UDN
M8[D<XWIY.FCEJ;C91W1T-7G\\;::S^JO5\;>5%4QN]M_J]P]@QZ?NFBK$\LI
M+*>RG,9R.LL9+&>RG,5R-LLY+.>RG,=R/LL%+!>R7,1R,<LE+)>R7,9R.<;U
M GK8"FAQ_]-A%8W3Z7Q4?)Z6G8AN7KV8C,O-&5&KURP?[HYLM#N*Y6264UA.
M93EMPYVW)\KG)R<GKR;+:(L4RYDL9[&<S7(.R[DLY[&<SW(!RX4L%[%<S'()
MRZ4LE[%<CG&]+#YM9?&>7JGOG2PWKXN*:;F0G$GS[WH^*S<O7^R94*-U4RPG
MLYS"<BK+:2RGLYS!<B;+62QGLYS#<B[+>2SGLUS <B'+12P7LUS"<BG+92R7
M8UPOQ,]:(7[V_\>$6K@:QT<VR<DLI["<RG+:AFL?>1X,SW=,J,EA#98S6<YB
M.9OE')9S6<YC.9_E I8+62YBN9CE$I9+62YCN1SC>EE\WLKB;V^N.G1"O2V2
ME)MDG\X?7UX\&TM.,7NZ;<+]J5H644;-^D]&Y;Z)-EINQ7(RRRDLI[*<QG(Z
MRQDL9[*<Q7(VRSDLY[*<QW(^RP4L%[)<Q'(QRR4LE[)<QG(YQO7"_:(5[N+2
MJ[]MHHT69;&<S'(*RZDLIVVXSD3[;+ACHHU69K&<R7(6R]DLY["<RW(>R_DL
M%[!<R'(1R\4LE[!<RG(9R^48U\OBRU86?WN)UO$3;?^^6)32L#AT3HU6:K&<
MS'(*RZDLI[&<SG(&RYDL9[&<S7(.R[DLY[&<SW(!RX4L%[%<S'()RZ4LE[%<
MCG&]'+]JY;BX:NMOFU.C]5PL)[.<PG(JRVD;KG/9].6.*37:T\5R)LM9+&>S
MG,-R+LMY+.>S7,!R(<M%+!>S7,)R*<ME+)=C7"^*KUM1+&[N$DVI;\;CR3);
MBZGDU?=EM2TK.7#&C/9]L9S,<@K+J2RGL9S.<@;+F2QGL9S-<@[+N2SGL9S/
M<@'+A2P7L5S,<@G+I2R7L5R.<=V8'K0*PP;BPK"_:\8L7HVC(QOE9)936$YE
M.6W#=:Z?WC%C1D<U6,YD.8OE;)9S6,YE.8_E?)8+6"YDN8CE8I9+6"YEN8SE
M<HSK17&K:VP@[AJSFVFO_7)[B/FD&>)E,MS,CI<G:QNS13VIGVI)+IO9\JB9
M-#?_7S1/UV4U*UXFTZU%A--G\7H<G\5L_1C**2RGLIS&<CK+&2QGLIS%<C;+
M.2SGLIS'<C[+!2P7LES$<C'+)2R7LES&<CG&]3)[V,IL<?U8Z_X4974[KQZ*
MV:B4O,_3R=TJE'>W;HO1XP.8+1-#.87E5);36$YG.8/E3):S6,YF.8?E7);S
M6,YGN8#E0I:+6"YFN83ET@W7N6:DMZ\N.^1%.;9BO;!L]8,-Q/U@ZWW-[YL)
M[$,QF2VO.MZ=FN^EFX?YTZS>'9YLUQ?*R2RGL)S*<AK+Z2QGL)S)<A;+V2SG
ML)R[X=J_GUXWMGKLJ#[+!2P7'O:>1.RH,<LE+)>R7,9R.<;U K35S=4\%@7H
M6\=G[4GQ>3*=U%_>-T]65?E6<@KUXY.3Y&264UA.93F-Y726,UC.9#F+Y6R6
M<UC.W7#ME+C>$9SDH#[+!2P7'O261.R@,<LE+)>R7,9R.<;U<K/5HS40]V@=
MD)ON?#8212?;>X5R,LLI+*>RG,9R.LL9+&>RG,5R-LLY+.=NN,Z588,=V<GV
M6:%<P'+A8>])Q(X:LUS"<BG+92R78UPO/%L]50-Q3]4!X;DYB3@L1_.[V>3/
M<KP[1-DF*I2364YA.97E-);36<Y@.9/E+):S6<YA.7?#=0)CUP24+:)"N6##
MM<]XOWR5>B$[:L1R,<LE+)>R7,9R.<;U0K15,#40%TQMSQ-RY\_E5/*K>5U.
MWCH]B"V$0CF9Y1264UE.8SF=Y0R6,UG.8CF;Y1R6<UG.8SF?Y0*6"UDN8KF8
MY1*62S=<Y\R?5V<'[7U-CJU6+R%;U4T#<753ZTS::GY7%0]O9"/;O(1R,LLI
M+*>RG,9R.LL9+&>RG,5R-LLY&ZYS:DKW%X;+#NFQG,]R <N%+!>Q7,QR"<NE
MN[XW3U\%WM[7Y-AJ]0*O59 T$!<DK7>:+MY+\;PNIKO3CBTZ0CF9Y1264UE.
M8SF=Y0R6,UG.8CF;Y1R6<UG.8SF?Y0*6"S=<YP^/T_/K5X<GV0*C':.>G5SV
M=@\G[*@IRV4LEV-<-QZ'K6*BH;B8Z%/Q.&EB<7DP<=M+]&F^J-]+;EF+0E,,
M'QV:*">SG,)R*LMI+*>SG,%R)LM9+&>SG,-R[H9K_PI^=8P1'=)GN8#EP@/>
MD(@=,F:YA.52ELM8+L>X7ERVRH.&XO(@05S>/,RK>O+GV]U\8OKXP&3[@%!.
M83F5Y326TUG.8#F3Y2R6LUG.83F7Y3R6\UDN8+EPPW6OEG^=KFS-SR&#)NR@
M*<ME+)=C7"\TAZW0/*B]Q[N5HO*QJ(JZ/*K&1ZP?GYMLC0_**2RGLIS&<OJ&
M:_^P#KL_J@8[I,ER%LO9+.>PG,MR'LOY+!>P7,AR$<O%+)>P7,IR&<OE&->+
MUU;?SU#<][,]I>?3_.%S\\GQ<?'*%OV@G,QR"LNI+*>QG+[AQ/'*MO>@G,5R
M-LLY+.>RG,=R/LL%+!>R7,1R,<LE+)>R7,9R.<;UXK75!M0\%I] M+YI6EQ6
M#])[Y8^ZG"V6MV)I0G8R'TL__&?SZ7_NCE:A?'RTDIS,<@K+J2RGL9S.<@;+
MF2QGL9S-<LZ^']_!4/K2_(#N^MO795?%8SF?Y0*6"UDN8KF8Y1*62UDN8[D<
MXWJ1VRH2&HJ+A+8[C/VJ'#6?G8R*J135Q5TIOFQ%[!X?N&Q_$,HI+*>RG,9R
M.LL9+&>RG,5R-LLY&TZP6\%EA_18SF>Y@.5"EHM8+F:YA.52ELM8+L>X7K"V
M2H:&XI*AO^+>9\L;C8]&RQ[Y9=-\$]*S<5&-%U+R.%X>Z1V>#,Y^/+D6WRI-
MO-K'YS9;681R"LNI+*>QG,YR!LN9+&>QG,UR#LNY+.>QG,]R <N%+!>Q7,QR
M"<NE+)>Q7(YQO8AO52 -Q15(WW%!#]N'A'(RRRDLI[*<QG(ZRQDL9[*<Q7(V
MRSDLY[*<QW(^RP4L%[)<Q'(QRR4LE[)<QG+YAFL749ZW3@+O96NK/&DH+D_Z
MBZ;/]F14SA:EU,R<FZ2>3E]&6!YBOKFKRO*AG-5[IL]L6Q/*R2RGL)S*<AK+
MZ2QGL)S)<A;+V2SGL)S+<A[+^2P7L%S(<A'+Q2R7L%S*<AG+Y1C7B_A67=10
M7!?U;7<:%Z/'!S!;((5R"LNI+*>QG+[A.J4UK\ZA9ENA4,YB.9OE')9S6<YC
M.9_E I8+62YBN9CE$I9+62YCN1SCNJEZVFJ9.A6W3+4O46K/;_UJ/GX:U;M#
M56P>':HH)[.<PG(JRVDLIV\XX85)Z) FRUDL9[.<PW(NRWDLY[-<P'(ART4L
M%[-<PG(IRV4LEV-<+U1;752GXBZJ ZO\Q<KQ,<K63J&<PG(JRVDLI[.<P7(F
MRUDL9[.<PW(NRWDLY[-<P'(ART4L%[-<PG+IAA/<D2([X#4YMEJ];!RVLE%<
M.?47':EMS5Z?2^FFJHK9W0''9\4K>WP$LPU6**>PG,IR&LOI+&>PG,ER%LO9
M+.>PG,MR'LOY+!>P7,AR$<O%+)>P7,IR&<OE&-<+]E;9U:FX[(J[3;IXH.-#
MF>V]0CF%Y526TUA.9SF#Y4R6LUC.9CF'Y5R6\UC.9[F Y<(-USF3X?1U'_/Z
M98-!ZW6G/UUU7Q:S*Y>P7,IR&<OE&-<+T5:E5?.8/QPK-(_/2Y*364YA.97E
M-);3-YSP'"=T2)/E+):S6<YA.9?E/);S62Y@N9#E(I:+62YAN93E,I;+,:X7
MJJW2JM-#2ZN^Z2X'8OWX>&6KJU!.83F5Y326TS><^&PGMH\*Y2R6LUG.83F7
MY3R6\UDN8+F0Y2*6BUDN8;F4Y3*6RS&N%Z^MZJI3<775=][E0*P?'Z]LPQ3*
M*2RGLIS&<OJ&$\<K6QN%<A;+V2SGL)S+<A[+^2P7L%S(<A'+Q2R7L%S*<AG+
MY1C7B]=6;=2IN#;J?^V$J>9%SF0V>7AZV',.%=M.A7(RRRDLI[*<QG(ZRQDL
M9[*<Q7(VRSDLY[*<QW(^RP4L%[)<Q'(QRR4LE[)<QG(YQO6ROE5C=2JNL=J<
M('5;S1^DMTZHVE9/+>][-'F)><F=UY-1N;GU4?+8/.44S5\!DV(J?:S*8G0O
M_2 77W;?#DF\6L='.%M3A7(*RZDLI[&<SG(&RYDL9[&<S7(.R[DLY[&<SW(!
MRX4L%[%<S'()RZ7[(NSZ1!H77W;MZLV^?=$<^R)ZT=RJGSH5UT_]KT[#BS\.
MF(:S35<H)[.<PG(JRVDLI[.<P7(FRUDL9[.<PW(NRWDLY[-<P'(ART4L%[-<
MPG(IRV4LEV-<-^O/6J589^)2K/^M:;AXM8Z.<)2364YA.97E-);36<Y@.9/E
M+):S6<YA.9?E/);S62Y@N9#E(I:+62YAN71?A V&@GGXMR^;8U]&+YQ;Y5IG
MXG*MOVPB_J/<Q/YT_KC*])V77_6>%4['Q5_%\5G.EGNAG,)R*LMI+*>SG,%R
M)LM9+&>SG,-R+LMY+.>S7,!R(<M%+!>S7,)R*<ME+)=C7"_QAZW$%U>&?=-%
MT6+S^/QEF[U03F$YE>4TEM-9SF YD^4LEK-9SMEP[3/\!]TS_%UV2(_E?)8+
M6"YDN8CE8I9+6"YEN8SE<HSKA6JKKNM,7-?U%TVC-T^MY])E_[Z)F\S>,WEF
M&\!03F8YA>54EM-83F<Y@^5,EK-8SF8YA^5<EO-8SF>Y@.5"EHM8+F:YA.52
MELM8+L>X7LZW&L6:Q_SD66@>G[\D)[.<PG(JRVDLI[.<P7(FRUDL9[.<L^'$
MDV=R2(_E?)8+6"YDN8CE8I9+6"YEN8SE<HSKA6JK4>Q,W"AF3T;E;%&V)[Y:
M.2N;Z?'H?L_,EBT30SF9Y1264UE.8SF=Y0R6,UG.8CF;Y1R6<UG.8SF?Y0*6
M"UDN8KF8Y1*62UDN8[D<XWHAW.H=.Q/WCAUPPXEX7A?3W3G\8I^W_O@>GIST
M2]<_[5F'XP.6K1-#.97E-);36<Y@.9/E+):S6<YA.9?E/);S62Y@N9#E(I:+
M62YAN93E,I;+,:X7L*WFL3-Q\]@! ?OIJ:J::>_NB&5[P5!.9CF%Y526TUA.
M9SF#Y4R6LUC.9CF'Y=P-U]XG?7G5_ZO88T?U62Y@N?"P]R1B1XU9+F&YE.4R
MELLQKI><K1ZO,W&3R0')Z<YG(U%XLHU<*">SG,)R*LMI+*>SG,%R)LM9+&>S
MG,-R[H9K[U,ZVQ6>;-,6R@4L%Q[VGD3LJ#'+)2R7LES&<CG&]<*SU;1UMJ=I
MZ_7!U8^2+]TL%F6]D'+)6/YO-MISG)5MPT(YF>44EE-93F,YG>4,EC-9SF(Y
MF^4<EG-9SF,YG^4"E@M9+F*YF.42EDM9+F.Y'..Z>7S>:L,Z/Z@-Z[T4E@_%
M9#:9W;UQ?Z?WTLW#_.F-":UXD*,#><VU_ZZ\>'7X5F9'55A.93F-Y726,UC.
M9#F+Y6R6<UC.93F/Y7R6"U@N9+F(Y6*62U@N9;F,Y7*,ZP5MJ]GJ7-QL]6;3
MY'+F^UXJ;NOEY;G3Z?SW5? V"2Q]JLKQI);L^6(A.MM)//#QX3MX=43D;%?X
MLB53**>RG,9R.LL9+&>RG,5R-LLY+.>RG,=R/LL%+!>R7,1R,<LE+)>R7,9R
M.<;UPG?8"E]QR=2Q>YV;SRM_C*9/B^5]&S;]D!MDVPTMW$DM7J7C8YGMJ$(Y
MA>54EM-83F<Y@^5,EK-8SF8YA^5<EO-8SF>Y@.5"EHM8+F:YA.52ELM8+L>X
M7GRWZJS.Q756WW4QD-@^/H=/7TV/!Z^O+9+981664UE.8SF=Y0R6,UG.8CF;
MY1R6<UG.8SF?Y0*6"UDN8KF8Y1*62UDN8[D<XWH!V^J1:A[_#4>!A8,<G[1G
M!R8M.:S"<BK+:2RGLYS!<B;+62QGLYS#<B[+>2SGLUS <B'+12P7LUS"<BG+
M92R78UPO:5OE4N?B<JF#[CZX>G[R^6G5Y1C/?R^J\4)RBMG3;?/BIVH9SS>C
M>O(\J2?E[HY'\5H<'\7GKT[(VGE,F&V80CF5Y326TUG.8#F3Y2R6LUG.83F7
MY3R6\UDN8+F0Y2*6BUDN8;F4Y3*6RS&NE\2MAJES<</404F\OM7OS>KL+.7V
MMES&;BG)1=TZ#KS,YB_2Q_+KO8++L?2#TXCWN^\$+%ZQX\-9_'5>2P_+5=GU
M=X+,KHK"<BK+:2RGLYS!<B;+62QGLYS#<B[+>2SGLUS <B'+12P7LUS"<BG+
M92R78UPOL5N55>?BRJJ#$GM[=M8FC9>3Z)OQ\VI/MCNO)\U_UK'^@UQ\>2.B
MV7JK/5_8Q9NW9);9-5%83F4YC>5TEC-8SF0YB^5LEG-8SF4YC^5\E@M8+F2Y
MB.5BEDM8+F6YC.5RC.LE=*L:ZUQ<C84GM'';S*VKW\IZM<_[\;&:/Q=3R?M<
M%\W(P@!G*[;V?-V#H2C!V3XME%-93F,YG>4,EC-9SF(YF^4<EG-9SF,YG^4"
ME@M9+F*YF.42EDM9+F.Y'.-Z"=[JYSH7]W-]1X)WDSMY;)YRBKKYJ$GLCU59
MC.Y%><U6>NWY*@=7HKQF^[M03F4YC>5TEC-8SF0YB^5LEG-8SF4YC^5\E@M8
M+F2YB.5BEDM8+F6YC.5RC.OF]46KO^OBH/ZN[\[K56?UCW[Q9?4R[U9*9N/)
MXO%I>2S[Y93OA2"]Q2MY='KO^9I%N\O1-5%83F4YC>5TEC-8SF0YB^5LEG-8
MSF4YC^5\E@M8+F2YB.5BEDM8+F6YC.5RC.N%=ZL3[$+<"?;MX=T\/1Y/EH^:
MR?5W3;S%JWA\=(N_8N'$&UT5A>54EM-83F<Y@^5,EK-8SF8YA^5<EO-8SF>Y
M@.5"EHM8+F:YA.52ELM8+L>X7G8/6]DMKA0[,KNWEU W+U[LOGY:/.+Q4?S"
M[;MH"QU583F5Y326TUG.8#F3Y2R6LUG.83F7Y3R6\UDN8+F0Y2*6BUDN8;F4
MY3*6RS&NE[JM)K"+[VX"VP1S6([F=[/)G^5X=]BRM6 H)[.<PG(JRVDLI[.<
MP7(FRUDL9[.<PW(NRWDLY[-<P'(ART4L%V^X]ESE_+(_5TG845.6RU@NQ[A>
MV+9:P9K'HK#=T9H=E45=3TM)*V=E/1DMEJW9/[5?D#S^V,R(FPGOYE#R3545
ML[L#^K+%*W-\().<S'(*RZDLI[&<SG(&RYDL9[&<S7(.R[DLY[&<SW(!RX4L
M%[%<S'()RZ4LE[%<CG&]X&Z5C%T )6.K&UR,5]=5+19E\\]8BHL_=D<SVR:&
M<C++*2RG;KCV7[:GKUM,-798G>4,EC-9SF(YF^4<EG-9SF,YG^4"E@M9+F*Y
MF.42EDM9+F.Y'.-ZF=NJ$[L0UVSMF"S;Y4*RB\_SJJCGDV;49O9</4^6MWF<
MC9N)\Z*>U$^U)*]V5=^75?/_Y7RZ+JN7<[R*:6L19HK-%H^AG,QR"LNI+*>Q
MG,YR!LN9+&>QG,UR#LNY+.>QG,]R <N%+!>Q7,QR"<NE+)>Q7(YQO;AO=9%=
M %UDQTRQV<(QE)-93F$YE>4TEM-9SF YD^4LEK-9SF$YE^4\EO-9+F"YD.4B
MEHM9+F&Y=,-U=BD.7^U2S#:O&PP[^QZ[K\JQE>M%::LT[&)?:=BB+)K9[VI:
M+#>Y.IT_KN:RJ[GOJ)D$MR:_RP//S12Y>;5XILO6?Z&<S'(*RZDLI[&<SG(&
MRYDL9[&<S7(.R[DLY[&<SW(!RX4L%[%<S'()RZ4LE[%<CG&]>&XU@EWL:P1;
MQ_.G^73ZLC=[U=?Y]=*F39GV?S8O>^,:8_$(I]*79M%=UP1_VK/H\<G+=GNA
MG,IR&LOI+&>PG,ER%LO9+.>PG,MR'LOY+!>P7,AR$<O%+)>P7,IR&<OE&-=-
MWLM6M]?EOFZO(R;&?\7!YIUA+E[IHZ?6*">SG,)R*LMI+*>SG,%R)LM9+&>S
MG,-R+LMY+.>S7,!R(<M%+!>S7,)R*<ME+)=C7"_@6_U?E^(V+/=I&;/2_+:3
M[LZDR>)Z/GOCULYB\_C\)3F9Y1264UE.8SF=Y0R6,UG.8CF;Y1R6<UG.8SF?
MY0*6"UDN8KF8Y1*62S?<1?L </\H\?[7Y-AJO23EA\5]6=9R41>__O)05G?E
MIW(Z74BC9<OT<I#6LU)5WBZ#].>;X;L/KYXW!C\[@QW/NX.?@UW/AX.?L]7S
M'[;#_OK+8W%7.D5U-YDMI&EYVZS"R4^7Y^^D:G)W__6#>O[89/L[Z?.\KN</
MJX?W93$NJ^4+FL_?SN?UYH/E +_/J]]67^:O_P-02P,$%     @ ,(!_5I\3
MGZF_ P  MA   !D   !X;"]W;W)K<VAE971S+W-H965T,S0N>&ULK5AKC]HX
M%/TK5K9:M=)V$B>$QRP@ =EM*W6JT=#N2KO:#R:YD*B)S=H&NO^^MI/)  GN
M(O)AACSN.=QS? B^C ^,?Q4I@$3?BIR*B9-*N;UW71&G4!!QQ[9 U9TUXP61
MZI1O7+'E0!(#*G+7][R^6Y",.M.QN?;(IV.VDWE&X9$CL2L*PO^;0\X.$P<[
MSQ>>LDTJ]05W.MZ2#2Q!?MD^<G7FUBQ)5@ 5&:.(PWKBS/!]A ,-,!5_9' 0
M1\=(2UDQ]E6??$@FCJ<[@AQBJ2F(>MG# O)<,ZD^_JU(G?H]-?#X^)G]=R->
MB5D1 0N6_YDE,ITX0P<EL":[7#ZQPWNH!(6:+V:Y,/_1H:KU'!3OA&1%!58=
M%!DM7\FWRH@C@.)I!_@5P#\']"\ @@H0G -Z%P"]"M SSI12C \1D60ZYNR
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MB4O1*+HUVR_8^3GS?(51+GQAV^4F$12-(U-W8%902]V.XJFKPPY@>+X'D':
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MN?$-8N$>&#3>P9VOM!NZ5O$!NB<K?0=02P,$%     @ ,(!_5GY\1CPA P
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M?U@-Y[*%!Z8"Y/J4RJZNGJ@FL?E3$/X#4$L#!!0    ( #" ?U:,1WEN) ,
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M%EK $I=4WK#-5V@""K6_A%%1?=&FL74LE)1"LJP1*X*,Y/4?/S:)Z C<8(?
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M/QZ1CQ_.R ?"!9G,9:Z9B'77-VB%Q?*CE<:K4F/XBD8:DALIS%R3GT0,\3:
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M(?_.!':C',MRW251=YN$73CVV.* @\D->'#J?HM6B:Y[)>INEMX.LEL>@]S
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MR\*,<)36P9QOA&GKUK 7='\*Z1]02P,$%     @ ,(!_5MHR*$_? @  D0D
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M_)B_>)\IG^(LB]?E7Q=1.(^28H/\Z_=QG#W]HQC@:YQ\+I_.U?\#4$L#!!0
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MBSW2/)$R2](LXO(!FOLU"_DC>I/(/"9+4?()B7J(K-V7@Y; 06D.*,T%I2U
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M$1Y>%TB_I+I. EW=@R0T$E_FKE2$];#NIB"WRLGY'>2PCQY9(O<"/20AA$T
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M9'%VN@<2 M<&ZOF6J>5]<:$'*'>'EO\"4$L#!!0    ( #" ?U8VQ=7H^ 8
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MU@#?SR1VCWIA/]#\>R3_ %!+ P04    "  P@']60R&?';@%  !;*   &0
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MDHLW;\E"_OJ+W;_\_=@(D7FNF>?"K$G:=L9S7GA',-[Y&-N \<V8.\I?,/;
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M"/IC*@*J>D94$R/WKK%2CJA-NV%&+R]4UH&^VW@?)W:!YBVW_!M02P,$%
M  @ ,(!_5HM6:P>1 @  2 <  !D   !X;"]W;W)K<VAE971S+W-H965T-3<N
M>&ULE95=;YLP%(;_BH5ZT4IK^4H@J0C2VFC:I':+^K%=.W (7@UFMDG:?[]C
MH#1=2++>!!O[/<][('Z)-D(^J1Q D^>"EVIFY5I7E[:MDAP*JBY$!26N9$(6
M5.-4KFQ52:!I(RJX[3E.8!>4E58<-?<6,HY$K3DK82&)JHN"RI<KX&(SLUSK
M]<8=6^7:W+#CJ*(KN ?]6"TDSNR^2LH**!43)9&0S:S/[N65ZQA!L^,G@XW:
M&A/3RE*()S/YELXLQS@"#HDV)2A>UG -G)M*Z.-/5]3JF4:X/7ZM_J5I'IM9
M4@77@O]BJ<YGUL0B*62TYOI.;+Y"U]#8U$L$5\TOV71['8LDM=*BZ,3HH&!E
M>Z7/W8/8$GC>'H'7";S&=PMJ7,ZIIG$DQ89(LQNKF4'3:J-&<ZPT;^5>2UQE
MJ-/Q=Z&!N#XY)S> S2D<W%)=2Z893D1&?E0@J6;EJMU ;AA=,MXNG\Y!4\;5
M&3DAK"0/N:@5+5,5V1JM&8"==#:N6AO>'AMS2"Z([WXBGN-YY/%^3DY/SMZ7
ML;&SOCVO;\]KZH[VU,5R_I";5C5N5.:/NXX]UPTB>SW \GN6?XPU&F*UJN"_
M6*.>-3K&&@^Q1A]@C7O6^!@K&&*-/\ *>E9PC!4.L8(/L,*>%1YD/>2 .99I
MD$/$<(<X#:;38>*D)TX.$X6FG-1ERE0BZE)#2GASJ"KZ@DFG!P_.9+=U?$A[
MG$Q[)].#3FY J4N".:X02]:4UT!H^AOSQO@8LC'=L7$>NN&>5^ Z;_'C'#2R
M>&<!\Z9](/PM90;#Q-DYOZ[O.OX_;NRM7#3?F%LJ5ZQ4R,A0YUR$6$"VL=U.
MM*B:J%P*C<';#'/\U($T&W ]$QB7W<2D;__QC/\"4$L#!!0    ( #" ?U;,
M:$:)<@,   D7   -    >&PO<W1Y;&5S+GAM;-U8T6[:,!3]E2A=IU::FD#6
M0%9 VI J3=JF2NW#WBI#'+#D.)DQ'>QQW[.OVI?,UPXD4%]&^[#"J-K8]^2<
M>VQ?!Z>]F5IR>CNE5'F+G(M9WY\J5;X+@MEX2G,RNRA**C22%3(G2G?E))B5
MDI)T!J2<!^TPC(.<,.$/>F*>7^=JYHV+N5!]OQ6N8YZ]?$QU-'[K>U9O6*2T
M[]^?O?XV+]35*\]>3]Z<G(3WYU?;\3,#G/N!4_1R#]&+,,2% <3$X_W$=VEC
MTIV]I'<H8\+=36%S]ZG6L;Q3C):X_?S^^0MU5&-_\=0)]Q+?(8T)MQR#U9->
MCQ<Z&+GM)H=-,IHY<I(;5$,,JJTQZ&6%J'=(Y-N 5B8Y]1X([_M#PME(,F!E
M)&=\:<-M"(P+7DA/Z:VI4[4@,OMAX9;MP:ZM='(F"FERVPSV[ZBZ?0M8]< @
MXWQML.W;P*!7$J6H%->Z8VXVP4>05[7OEJ5V.)%DV6I?^C7!7'2242%3*NLG
MA;\*#7J<9F!'LLD4KJHH P"5*G+=2!F9%((8#RM&U="R8\KY+3S2OF8;VHNL
ML6:F",6ZJ0U532MC.Z#?5+/:3=GX6;I>R1X*]6&NAR-,'XJ;WDB:L87I+[*U
M 4R]A:N3LN3+]YQ-1$[MX/=...B1%<^;%I+]T-F@5,8Z0*7O/5"IV+@9^2Y)
M>4<7:E5.BPSWW#Y"S_]VGB=44$EXT[2N_4.>Y6<[KHX +^'9/%:V'3M-1IW#
M]U@=>P[=9'P,)H]BN;O'8#(Y I.=%WMJ/L5DZQA,MH_!9'20)H/J4-DXN6Z<
M6]=1#]X/^OX7>-/@=5)O-&=<,5'UIBQ-J7AT?-7RBHST>_Z&OKX_I1F9<W6W
M!OM^W?Y,4S;/D_5=-S 1U5UU^Q,,3Y^%5R\G.A<3*5W0=%AUY61DFIYNZ*S5
M!PC;R+7YN!&,8S$W AB6!W. <2P+R_,_C:>+CL=BF+>N$^FBG"[*L2P7,C0_
M6!XW)]$?]TB3)(KB&)O1X=#I8(C-6QS#KUL-\P8,+ ]D>MI<XZN-5\CN.L#6
M=%>%8"/%*Q$;*3[7@+CG#1A)XEYM+ \PL%7 :@?RN_- 3;DY402KBGG#=C".
M) F&0"VZ:S2.D=F)X<>]/M@NB:(D<2. N1U$$8; ;L01S %XP) H,M^#6]]'
MP>I[*JC_^3WX U!+ P04    "  P@']6EXJ[',     3 @  "P   %]R96QS
M+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0
M"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#
ML%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S
M##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H
M5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    ( #" ?U;R.W_\H00  &$F   /
M    >&PO=V]R:V)O;VLN>&ULQ9I;;Z,X%(#_BL7+=J7M)MS2BR8C==KN;*5,
M)YI4\SIRP4FL&INU32_SZ_< RM1NP]&\X+PTM0'S<8S]'0,?GI1^N%?J@3Q7
M0IIYM+6V/I],3+%E%35_JYI)V+)6NJ(6BGHS,;5FM#1;QFPE)LET.IM4E,OH
MXX==6TL]<0O*LL)R):&RK?C.V9-YW=X6R2,W_)X+;E_F4?>_8!&IN.05_\G*
M>32-B-FJIW^5YC^5M%2L"JV$F$=QO^$[TY87[ZI7+>0=O3==C:7WWRB S*/9
M%!I<<VULMT?7/@7&1P8[]Z7&JG^XL$Q?4<L^:]747&[:9N J)LYE=''8_?9!
M/->_$T:U7O."7:FBJ9BT?1PU$RV@-%M>FXA(6K%YM-N%7,B27$L+02(WLF\*
M]FVO%$Y]4_97;0'7B:$^Y[!!WY0=^'B0EU!6@I=P]I)\HH+*@I$NN,8!3!#
MY&" Y&A)'<@4@4P#0JY:B/8 0]2:?*V9=B S!#([&.3EEKKW8XY Y@>$_)$X
MD#,$<G8X2&JV#N0) GER0$@ODJ<(Y.FXD+?@&!*38W*I=*TT0 Q,D6<(XUD
MQ@085TU54?W21G#%-Y+#\51:=QZ?8A/Y- !F"IC?V".3#7.Y4,&,;)B.*P.N
MSQJB!=U;J,J#P^02CVR7#BYO[S\8MW]U?\GU?PU_I*(=+"XFII=X9+]TF#/
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MH*)8:M+^].];L[Q][[%NA+B$NJ]RH6BY^T)J]W77Q_\!4$L#!!0    ( #"
M?U;S((MYZ0$  !(B   :    >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/-
MVCM.PT 4A>&M1%X D_N8\%!"14.+V( 5)@^1Q)9G$,GNB4(1CD5!@^94UMCR
M]5]]LL:>OZ1=6[;=(6^V?9X<][M#7C2;4OJ'$/)RD_9MONGZ=#A?677#OBWG
MY; .?;M\;]<IZ'0Z"\//&<WC_.?,R>NI3W^9V*U6VV5ZZI8?^W0HOPP.G]WP
MGC<IE6;RV@[K5!9-..ZNIW.X'.3F/+F9/+\MFN'Y39I0.T@A2.L'&019_2"'
M(*\?%"$HU@^:0="L?M M!-W6#[J#H+OZ0?<0=%\_2*8HXY0@:80U@=:"7 N!
MUX)@"X'8@F0+@=F": N!VH)L"X';@G +@=R"= N!W8)X"X'>BGHK@=Z*>BN!
MWCIZV2;06U%O)=!;46\ET%M1;R706U%O)=!;46\ET%M1;R706U%O)=#;4&\C
MT-M0;R/0VU!O(]#;1ILE!'H;ZFT$>AOJ;01Z&^IM!'H;ZFT$>AOJ;01Z&^IM
M!'H[ZNT$>COJ[01Z.^KM!'H[ZNT$>OMHLYM ;T>]G4!O1[V=0&]'O9U ;T>]
MG4!O1[V=0.^(>D<"O2/J'0GTCJAW)- [HMZ10.^(>D<"O>/H8R6!WA'UC@1Z
M1]0[_J?>N9QV*5][OM?X_/^DNISO3=?'7Y;?)T?L7' .\ O(XQ=02P,$%
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M              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @
M,(!_5GO&J^CM    *P(  !$              ( !KP   &1O8U!R;W!S+V-O
M<F4N>&UL4$L! A0#%     @ ,(!_5IE<G",0!@  G"<  !,
M ( !RP$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  P@']66W\J
M:XH'  #D,   &               @($,"   >&PO=V]R:W-H965T<R]S:&5E
M=#$N>&UL4$L! A0#%     @ ,(!_5DP[0"#)!0  U!<  !@
M ("!S \  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( #"
M?U;)3 6*J@(  %X)   8              " @<L5  !X;"]W;W)K<VAE971S
M+W-H965T,RYX;6Q02P$"% ,4    "  P@']6\IRPJ1 %  ")%   &
M        @(&K&   >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%
M  @ ,(!_5MV]7JE;%   KU4! !@              ("!\1T  'AL+W=O<FMS
M:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( #" ?U:D"_M.N0(  ( (   8
M              " @8(R  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"
M% ,4    "  P@']6RTY;_A8'  "M'@  &               @(%Q-0  >&PO
M=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ ,(!_5F1*F3ES @
MTP4  !@              ("!O3P  'AL+W=O<FMS:&5E=',O<VAE970X+GAM
M;%!+ 0(4 Q0    ( #" ?U;HR\S5G08   4/   8              " @68_
M  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    "  P@']6FP?=
MJ",;  #04@  &0              @($Y1@  >&PO=V]R:W-H965T<R]S:&5E
M=#$P+GAM;%!+ 0(4 Q0    ( #" ?U9_R_7WDQ4  ,5>   9
M  " @9-A  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @
M,(!_5F$AAXNR @  O 4  !D              ("!77<  'AL+W=O<FMS:&5E
M=',O<VAE970Q,BYX;6Q02P$"% ,4    "  P@']6**/*@6($  !U"P  &0
M            @(%&>@  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4
M Q0    ( #" ?U8/5] Y%P,  .8&   9              " @=]^  !X;"]W
M;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ ,(!_5N\0G1T) P
MCP8  !D              ("!+8(  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX
M;6Q02P$"% ,4    "  P@']6SW3/FR '   @$@  &0              @(%M
MA0  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( #" ?U:<
M#-.HIP8  ,@1   9              " @<2,  !X;"]W;W)K<VAE971S+W-H
M965T,3<N>&UL4$L! A0#%     @ ,(!_5I-!,55K P  ! @  !D
M     ("!HI,  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #" ?U909J4]L@(  -\%   9              "
M@6_#  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ ,(!_
M5OF?'!XI P  -@<  !D              ("!6,8  'AL+W=O<FMS:&5E=',O
M<VAE970R-"YX;6Q02P$"% ,4    "  P@']6J_6V+\,#   :"@  &0
M        @(&XR0  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0
M   ( #" ?U8?4O1XPP(  !0&   9              " @;+-  !X;"]W;W)K
M<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ ,(!_5GO,O2W0 @  "P8
M !D              ("!K-   'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q0
M2P$"% ,4    "  P@']6* WX72,%   V#@  &0              @(&STP
M>&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( #" ?U:E*9;+
MJ 0  +\,   9              " @0W9  !X;"]W;W)K<VAE971S+W-H965T
M,CDN>&UL4$L! A0#%     @ ,(!_5L/B]PD, P  ( <  !D
M ("![-T  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    "  P
M@']6B@PBFFH#  !L"@  &0              @($OX0  >&PO=V]R:W-H965T
M<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( #" ?U8,Z%(T^ (  "L,   9
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M970S-BYX;6Q02P$"% ,4    "  P@']6MJL&B$T"  #U!   &0
M    @('>+P$ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    (
M #" ?U8!MS,A\04  $<O   9              " @6(R 0!X;"]W;W)K<VAE
M971S+W-H965T,S@N>&UL4$L! A0#%     @ ,(!_5GK&&0Y:!   VQ,  !D
M             ("!BC@! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"
M% ,4    "  P@']6_ S%ABH"  "^!   &0              @($;/0$ >&PO
M=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( #" ?U9^?$8\(0,
M " ,   9              " @7P_ 0!X;"]W;W)K<VAE971S+W-H965T-#$N
M>&UL4$L! A0#%     @ ,(!_5HQ'>6XD P  T0D  !D              ("!
MU$(! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    "  P@']6
M-/K3M4@$  #F$@  &0              @($O1@$ >&PO=V]R:W-H965T<R]S
M:&5E=#0S+GAM;%!+ 0(4 Q0    ( #" ?U:P"ORZ=P(  " &   9
M      " @:Y* 0!X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%
M  @ ,(!_5MHR*$_? @  D0D  !D              ("!7$T! 'AL+W=O<FMS
M:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    "  P@']6&K4Z=U4#    "P
M&0              @(%R4 $ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+
M 0(4 Q0    ( #" ?U8LJ[L"OP,  *H,   9              " @?Y3 0!X
M;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ ,(!_5J@,GC)5
M @  604  !D              ("!]%<! 'AL+W=O<FMS:&5E=',O<VAE970T
M."YX;6Q02P$"% ,4    "  P@']6Z@/0NQX4  #@+P$ &0
M@(& 6@$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( #"
M?U:Y[-N%2P(   8%   9              " @=5N 0!X;"]W;W)K<VAE971S
M+W-H965T-3 N>&UL4$L! A0#%     @ ,(!_5D7<@VC2!@  CC$  !D
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M=#4U+GAM;%!+ 0(4 Q0    ( #" ?U9GZ0^\FP,  -<)   9
M  " @>^, 0!X;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @
M,(!_5HM6:P>1 @  2 <  !D              ("!P9 ! 'AL+W=O<FMS:&5E
M=',O<VAE970U-RYX;6Q02P$"% ,4    "  P@']6S&A&B7(#   )%P  #0
M            @ &)DP$ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( #" ?U:7
MBKL<P    !,"   +              "  2:7 0!?<F5L<R\N<F5L<U!+ 0(4
M Q0    ( #" ?U;R.W_\H00  &$F   /              "  0^8 0!X;"]W
M;W)K8F]O:RYX;6Q02P$"% ,4    "  P@']6\R"+>>D!   2(@  &@
M        @ '=G $ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M    "  P@']6LFA)V-4!  "_(0  $P              @ '^G@$ 6T-O;G1E
C;G1?5'EP97-=+GAM;%!+!08     00!! +X1   $H0$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>287</ContextCount>
  <ElementCount>371</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>81</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="pirs20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/20221231/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="pirs20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="pirs20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets-parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="pirs20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="pirs20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="pirs20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-parentheticals</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Equity (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="pirs20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="pirs20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Statement - Consolidated Statements of Cash Flows (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows-parentheticals</Role>
      <ShortName>Consolidated Statements of Cash Flows (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="pirs20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Note 1 - Corporate Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/20221231/role/statement-note-1-corporate-information-</Role>
      <ShortName>Note 1 - Corporate Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="pirs20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Note 2 - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies</Role>
      <ShortName>Note 2 - Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="pirs20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Note 3 - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/20221231/role/statement-note-3-revenue-</Role>
      <ShortName>Note 3 - Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="pirs20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Note 4 - Grant Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/20221231/role/statement-note-4-grant-income</Role>
      <ShortName>Note 4 - Grant Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="pirs20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Note 5 - Cash, Cash Equivalents and Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments</Role>
      <ShortName>Note 5 - Cash, Cash Equivalents and Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="pirs20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Note 6 - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/20221231/role/statement-note-6-property-and-equipment-net</Role>
      <ShortName>Note 6 - Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="pirs20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Note 7 - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/20221231/role/statement-note-7-accrued-expenses</Role>
      <ShortName>Note 7 - Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="pirs20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Note 8 - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/20221231/role/statement-note-8-income-taxes</Role>
      <ShortName>Note 8 - Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="pirs20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Note 9 - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity</Role>
      <ShortName>Note 9 - Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="pirs20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Note 10 - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/20221231/role/statement-note-10-net-loss-per-share</Role>
      <ShortName>Note 10 - Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="pirs20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Note 11 - Stock and Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans</Role>
      <ShortName>Note 11 - Stock and Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="pirs20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Note 12 - License Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/20221231/role/statement-note-12-license-agreement</Role>
      <ShortName>Note 12 - License Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="pirs20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Note 13 - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/20221231/role/statement-note-13-leases</Role>
      <ShortName>Note 13 - Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="pirs20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/20221231/role/statement-significant-accounting-policies-policies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.pieris.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="pirs20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables</Role>
      <ShortName>Note 2 - Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pieris.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="pirs20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Note 3 - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/20221231/role/statement-note-3-revenue-tables</Role>
      <ShortName>Note 3 - Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pieris.com/20221231/role/statement-note-3-revenue-</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="pirs20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Note 5 - Cash, Cash Equivalents and Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-tables</Role>
      <ShortName>Note 5 - Cash, Cash Equivalents and Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="pirs20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Note 6 - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/20221231/role/statement-note-6-property-and-equipment-net-tables</Role>
      <ShortName>Note 6 - Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pieris.com/20221231/role/statement-note-6-property-and-equipment-net</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="pirs20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Note 7 - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/20221231/role/statement-note-7-accrued-expenses-tables</Role>
      <ShortName>Note 7 - Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pieris.com/20221231/role/statement-note-7-accrued-expenses</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="pirs20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Note 8 - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/20221231/role/statement-note-8-income-taxes-tables</Role>
      <ShortName>Note 8 - Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pieris.com/20221231/role/statement-note-8-income-taxes</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="pirs20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Note 11 - Stock and Employee Benefit Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-tables</Role>
      <ShortName>Note 11 - Stock and Employee Benefit Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="pirs20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Note 13 - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/20221231/role/statement-note-13-leases-tables</Role>
      <ShortName>Note 13 - Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pieris.com/20221231/role/statement-note-13-leases</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="pirs20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Note 1 - Corporate Information (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/20221231/role/statement-note-1-corporate-information-details-textual</Role>
      <ShortName>Note 1 - Corporate Information (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pieris.com/20221231/role/statement-note-1-corporate-information-</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="pirs20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment, Useful Lives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-property-plant-and-equipment-useful-lives-details</Role>
      <ShortName>Note 2 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment, Useful Lives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="pirs20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Disclosure - Note 3 - Revenue (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual</Role>
      <ShortName>Note 3 - Revenue (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pieris.com/20221231/role/statement-note-3-revenue-tables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="pirs20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>033 - Disclosure - Note 3 - Revenue - Disaggregation of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/20221231/role/statement-note-3-revenue-disaggregation-of-revenue-details</Role>
      <ShortName>Note 3 - Revenue - Disaggregation of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="pirs20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>034 - Disclosure - Note 3 - Revenue - Potential Milestone Payments Received (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/20221231/role/statement-note-3-revenue-potential-milestone-payments-received-details</Role>
      <ShortName>Note 3 - Revenue - Potential Milestone Payments Received (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="pirs20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>035 - Disclosure - Note 4 - Grant Income (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/20221231/role/statement-note-4-grant-income-details-textual</Role>
      <ShortName>Note 4 - Grant Income (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pieris.com/20221231/role/statement-note-4-grant-income</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="pirs20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>036 - Disclosure - Note 5 - Cash, Cash Equivalents and Investments (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-details-textual</Role>
      <ShortName>Note 5 - Cash, Cash Equivalents and Investments (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-tables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="pirs20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>037 - Disclosure - Note 5 - Cash, Cash Equivalents and Investments - Cash Equivalents and Investments Carried at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-cash-equivalents-and-investments-carried-at-fair-value-details</Role>
      <ShortName>Note 5 - Cash, Cash Equivalents and Investments - Cash Equivalents and Investments Carried at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="pirs20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>038 - Disclosure - Note 5 - Cash, Cash Equivalents and Investments - Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-investments-details</Role>
      <ShortName>Note 5 - Cash, Cash Equivalents and Investments - Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="pirs20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>039 - Disclosure - Note 6 - Property and Equipment, Net (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/20221231/role/statement-note-6-property-and-equipment-net-details-textual</Role>
      <ShortName>Note 6 - Property and Equipment, Net (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pieris.com/20221231/role/statement-note-6-property-and-equipment-net-tables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="pirs20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>040 - Disclosure - Note 6 - Property and Equipment, Net - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/20221231/role/statement-note-6-property-and-equipment-net-property-and-equipment-details</Role>
      <ShortName>Note 6 - Property and Equipment, Net - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="pirs20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>041 - Disclosure - Note 7 - Accrued Expenses - Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/20221231/role/statement-note-7-accrued-expenses-accrued-expenses-and-other-current-liabilities-details</Role>
      <ShortName>Note 7 - Accrued Expenses - Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="pirs20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>042 - Disclosure - Note 8 - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/20221231/role/statement-note-8-income-taxes-details-textual</Role>
      <ShortName>Note 8 - Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pieris.com/20221231/role/statement-note-8-income-taxes-tables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="pirs20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>043 - Disclosure - Note 8 - Income Taxes - Schedule of Income Before Income Tax Domestic and Foreign (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details</Role>
      <ShortName>Note 8 - Income Taxes - Schedule of Income Before Income Tax Domestic and Foreign (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="pirs20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>044 - Disclosure - Note 8 - Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details</Role>
      <ShortName>Note 8 - Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="pirs20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>045 - Disclosure - Note 8 - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details</Role>
      <ShortName>Note 8 - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="pirs20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>046 - Disclosure - Note 8 - Income Tax - Schedule of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/20221231/role/statement-note-8-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details</Role>
      <ShortName>Note 8 - Income Tax - Schedule of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="pirs20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>047 - Disclosure - Note 8 - Income Taxes - Summary of Income Tax Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/20221231/role/statement-note-8-income-taxes-summary-of-income-tax-contingencies-details</Role>
      <ShortName>Note 8 - Income Taxes - Summary of Income Tax Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="pirs20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>048 - Disclosure - Note 9 - Stockholders' Equity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual</Role>
      <ShortName>Note 9 - Stockholders' Equity (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="pirs20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>049 - Disclosure - Note 10 - Net Loss Per Share (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/20221231/role/statement-note-10-net-loss-per-share-details-textual</Role>
      <ShortName>Note 10 - Net Loss Per Share (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pieris.com/20221231/role/statement-note-10-net-loss-per-share</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="pirs20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>050 - Disclosure - Note 11 - Stock and Employee Benefit Plans (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-details-textual</Role>
      <ShortName>Note 11 - Stock and Employee Benefit Plans (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-tables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="pirs20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>051 - Disclosure - Note 11 - Stock and Employee Benefit Plans - Schedule of Share-based Payment Award, Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-schedule-of-sharebased-payment-award-stock-options-details</Role>
      <ShortName>Note 11 - Stock and Employee Benefit Plans - Schedule of Share-based Payment Award, Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="pirs20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>052 - Disclosure - Note 11 - Stock and Employee Benefit Plans - Stock Options Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-stock-options-activity-details</Role>
      <ShortName>Note 11 - Stock and Employee Benefit Plans - Stock Options Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="pirs20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>053 - Disclosure - Note 11 - Stock and Employee Benefit Plans - Schedule of Employee Service Share-based Compensation Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-schedule-of-employee-service-sharebased-compensation-costs-details</Role>
      <ShortName>Note 11 - Stock and Employee Benefit Plans - Schedule of Employee Service Share-based Compensation Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="pirs20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>054 - Disclosure - Note 13 - Leases (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/20221231/role/statement-note-13-leases-details-textual</Role>
      <ShortName>Note 13 - Leases (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pieris.com/20221231/role/statement-note-13-leases-tables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="pirs20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>055 - Disclosure - Note 13 - Leases - Operating Lease Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/20221231/role/statement-note-13-leases-operating-lease-costs-details</Role>
      <ShortName>Note 13 - Leases - Operating Lease Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="pirs20221231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>056 - Disclosure - Note 13 - Leases - Maturities of Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pieris.com/20221231/role/statement-note-13-leases-maturities-of-operating-lease-liabilities-details</Role>
      <ShortName>Note 13 - Leases - Maturities of Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 68 fact(s) appearing in ix:hidden were eligible for transformation: dei:CurrentFiscalYearEndDate, dei:EntityRegistrantName, pirs:ConvertiblePreferredStockWeightedAverageStockPricePercent, pirs:DebtSecuritiesAvailableforsaleContractualMaturityPeriod, pirs:NumberOfInitialResearchPrograms, pirs:NumberOfOptionalAdditionalResearchPrograms, pirs:ResearchCollaborationAgreementPeriod, pirs:RevenueFromContractWithCustomerPeriodAfterEffectiveDateAgreementsMayBeTerminated, pirs:SaleOfStockNumberOfWarrantsPerUnit, pirs:ShareBasedCompensationArrangementBySharebasedPaymentAwardPurchasePeriod, pirs:SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfPurchasePeriods, us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts, us-gaap:CapitalizedContractCostAmortization, us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight, us-gaap:CommonStockParOrStatedValuePerShare, us-gaap:CommonStockSharesAuthorized, us-gaap:CommonStockSharesIssued, us-gaap:CommonStockSharesOutstanding, us-gaap:ContractWithCustomerLiabilityRevenueRecognized, us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss, us-gaap:GrantsReceivable, us-gaap:PaymentsOfStockIssuanceCosts, us-gaap:PreferredStockParOrStatedValuePerShare, us-gaap:PreferredStockSharesAuthorized, us-gaap:PreferredStockSharesIssued, us-gaap:PreferredStockSharesOutstanding, us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits, us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued, us-gaap:WarrantsAndRightsOutstandingTerm -  pirs20221231_10k.htm 8, 10, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="pirs20221231_10k.htm">pirs20221231_10k.htm</File>
    <File>ex_451890.htm</File>
    <File>ex_451891.htm</File>
    <File>ex_451892.htm</File>
    <File>ex_451893.htm</File>
    <File>ex_451894.htm</File>
    <File>ex_451895.htm</File>
    <File>ex_494066.htm</File>
    <File>pirs-20221231.xsd</File>
    <File>pirs-20221231_cal.xml</File>
    <File>pirs-20221231_def.xml</File>
    <File>pirs-20221231_lab.xml</File>
    <File>pirs-20221231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>figure4a.jpg</File>
    <File>p01.jpg</File>
    <File>pic2.jpg</File>
    <File>pirs20221231_10kimg001.jpg</File>
    <File>pirs20221231_10kimg002.jpg</File>
    <File>pirs20221231_10kimg004.jpg</File>
    <File>pirs20221231_10kimg005.jpg</File>
    <File>pirs20221231_10kimg006.jpg</File>
    <File>pirs20221231_10kimg007.jpg</File>
    <File>pirs20221231_10kimg008.jpg</File>
    <File>pirs20221231_10kimg009.jpg</File>
    <File>rpv4.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="778">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="36">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>90
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "pirs20221231_10k.htm": {
   "axisCustom": 0,
   "axisStandard": 27,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 778,
    "http://xbrl.sec.gov/dei/2022": 36
   },
   "contextCount": 287,
   "dts": {
    "calculationLink": {
     "local": [
      "pirs-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "pirs-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "pirs20221231_10k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "pirs-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "pirs-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "pirs-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/exch/2022/exch-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 560,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 60,
    "http://www.pieris.com/20221231": 11,
    "http://xbrl.sec.gov/dei/2022": 6,
    "total": 77
   },
   "keyCustom": 72,
   "keyStandard": 299,
   "memberCustom": 42,
   "memberStandard": 38,
   "nsprefix": "pirs",
   "nsuri": "http://www.pieris.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000 - Document - Document And Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.pieris.com/20221231/role/statement-document-and-entity-information",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "009 - Disclosure - Note 2 - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.pieris.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies",
     "shortName": "Note 2 - Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "010 - Disclosure - Note 3 - Revenue",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.pieris.com/20221231/role/statement-note-3-revenue-",
     "shortName": "Note 3 - Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GovernmentAssistanceTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "011 - Disclosure - Note 4 - Grant Income",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.pieris.com/20221231/role/statement-note-4-grant-income",
     "shortName": "Note 4 - Grant Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GovernmentAssistanceTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "012 - Disclosure - Note 5 - Cash, Cash Equivalents and Investments",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments",
     "shortName": "Note 5 - Cash, Cash Equivalents and Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "013 - Disclosure - Note 6 - Property and Equipment, Net",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.pieris.com/20221231/role/statement-note-6-property-and-equipment-net",
     "shortName": "Note 6 - Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "014 - Disclosure - Note 7 - Accrued Expenses",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.pieris.com/20221231/role/statement-note-7-accrued-expenses",
     "shortName": "Note 7 - Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "015 - Disclosure - Note 8 - Income Taxes",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.pieris.com/20221231/role/statement-note-8-income-taxes",
     "shortName": "Note 8 - Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "016 - Disclosure - Note 9 - Stockholders' Equity",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity",
     "shortName": "Note 9 - Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "017 - Disclosure - Note 10 - Net Loss Per Share",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.pieris.com/20221231/role/statement-note-10-net-loss-per-share",
     "shortName": "Note 10 - Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "018 - Disclosure - Note 11 - Stock and Employee Benefit Plans",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans",
     "shortName": "Note 11 - Stock and Employee Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "i_2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "001 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "i_2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pirs:LicenseAndTransferAgreementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "019 - Disclosure - Note 12 - License Agreement",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.pieris.com/20221231/role/statement-note-12-license-agreement",
     "shortName": "Note 12 - License Agreement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pirs:LicenseAndTransferAgreementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "020 - Disclosure - Note 13 - Leases",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.pieris.com/20221231/role/statement-note-13-leases",
     "shortName": "Note 13 - Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "021 - Disclosure - Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "22",
     "role": "http://www.pieris.com/20221231/role/statement-significant-accounting-policies-policies",
     "shortName": "Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pirs:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "022 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.pieris.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables",
     "shortName": "Note 2 - Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pirs:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "023 - Disclosure - Note 3 - Revenue (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.pieris.com/20221231/role/statement-note-3-revenue-tables",
     "shortName": "Note 3 - Revenue (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "024 - Disclosure - Note 5 - Cash, Cash Equivalents and Investments (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-tables",
     "shortName": "Note 5 - Cash, Cash Equivalents and Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "025 - Disclosure - Note 6 - Property and Equipment, Net (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.pieris.com/20221231/role/statement-note-6-property-and-equipment-net-tables",
     "shortName": "Note 6 - Property and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "026 - Disclosure - Note 7 - Accrued Expenses (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.pieris.com/20221231/role/statement-note-7-accrued-expenses-tables",
     "shortName": "Note 7 - Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "027 - Disclosure - Note 8 - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-tables",
     "shortName": "Note 8 - Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "028 - Disclosure - Note 11 - Stock and Employee Benefit Plans (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-tables",
     "shortName": "Note 11 - Stock and Employee Benefit Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "002 - Statement - Consolidated Balance Sheets (Parentheticals)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets-parentheticals",
     "shortName": "Consolidated Balance Sheets (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "029 - Disclosure - Note 13 - Leases (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.pieris.com/20221231/role/statement-note-13-leases-tables",
     "shortName": "Note 13 - Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "i_2022-12-31",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "030 - Disclosure - Note 1 - Corporate Information (Details Textual)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.pieris.com/20221231/role/statement-note-1-corporate-information-details-textual",
     "shortName": "Note 1 - Corporate Information (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "i_2022-12-31",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "pirs:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember_RangeAxis-MinimumMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "031 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment, Useful Lives (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.pieris.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-property-plant-and-equipment-useful-lives-details",
     "shortName": "Note 2 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment, Useful Lives (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "pirs:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember_RangeAxis-MinimumMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "i_2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "032 - Disclosure - Note 3 - Revenue (Details Textual)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual",
     "shortName": "Note 3 - Revenue (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "033 - Disclosure - Note 3 - Revenue - Disaggregation of Revenue (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.pieris.com/20221231/role/statement-note-3-revenue-disaggregation-of-revenue-details",
     "shortName": "Note 3 - Revenue - Disaggregation of Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31_CounterpartyNameAxis-BostonPharmaceuticalsMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "pirs:RevenueFromContractWithCustomerMilestonePaymentsTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "i_2022-12-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-ResearchAndDevelopmentMilestonePaymentsMember_TypeOfArrangementAxis-CollaborativeArrangementMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractsReceivableClaimsAndUncertainAmounts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "034 - Disclosure - Note 3 - Revenue - Potential Milestone Payments Received (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.pieris.com/20221231/role/statement-note-3-revenue-potential-milestone-payments-received-details",
     "shortName": "Note 3 - Revenue - Potential Milestone Payments Received (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "pirs:RevenueFromContractWithCustomerMilestonePaymentsTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "i_2022-12-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-ResearchAndDevelopmentMilestonePaymentsMember_TypeOfArrangementAxis-CollaborativeArrangementMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractsReceivableClaimsAndUncertainAmounts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:GovernmentAssistanceTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "i_2021-06-30",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:GrantsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "035 - Disclosure - Note 4 - Grant Income (Details Textual)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.pieris.com/20221231/role/statement-note-4-grant-income-details-textual",
     "shortName": "Note 4 - Grant Income (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:GovernmentAssistanceTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "i_2021-06-30",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:GrantsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "036 - Disclosure - Note 5 - Cash, Cash Equivalents and Investments (Details Textual)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-details-textual",
     "shortName": "Note 5 - Cash, Cash Equivalents and Investments (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "i_2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "037 - Disclosure - Note 5 - Cash, Cash Equivalents and Investments - Cash Equivalents and Investments Carried at Fair Value (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-cash-equivalents-and-investments-carried-at-fair-value-details",
     "shortName": "Note 5 - Cash, Cash Equivalents and Investments - Cash Equivalents and Investments Carried at Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "i_2022-12-31",
      "decimals": "-3",
      "lang": null,
      "name": "pirs:CashEquivalentsAndInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "i_2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "038 - Disclosure - Note 5 - Cash, Cash Equivalents and Investments - Investments (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-investments-details",
     "shortName": "Note 5 - Cash, Cash Equivalents and Investments - Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "i_2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "003 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "039 - Disclosure - Note 6 - Property and Equipment, Net (Details Textual)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.pieris.com/20221231/role/statement-note-6-property-and-equipment-net-details-textual",
     "shortName": "Note 6 - Property and Equipment, Net (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "i_2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "040 - Disclosure - Note 6 - Property and Equipment, Net - Property and Equipment (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.pieris.com/20221231/role/statement-note-6-property-and-equipment-net-property-and-equipment-details",
     "shortName": "Note 6 - Property and Equipment, Net - Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "i_2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "i_2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "pirs:AccruedResearchAndDevelopmentCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "041 - Disclosure - Note 7 - Accrued Expenses - Accrued Expenses and Other Current Liabilities (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.pieris.com/20221231/role/statement-note-7-accrued-expenses-accrued-expenses-and-other-current-liabilities-details",
     "shortName": "Note 7 - Accrued Expenses - Accrued Expenses and Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "i_2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "pirs:AccruedResearchAndDevelopmentCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "042 - Disclosure - Note 8 - Income Taxes (Details Textual)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-details-textual",
     "shortName": "Note 8 - Income Taxes (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "043 - Disclosure - Note 8 - Income Taxes - Schedule of Income Before Income Tax Domestic and Foreign (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details",
     "shortName": "Note 8 - Income Taxes - Schedule of Income Before Income Tax Domestic and Foreign (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "044 - Disclosure - Note 8 - Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details",
     "shortName": "Note 8 - Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "045 - Disclosure - Note 8 - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details",
     "shortName": "Note 8 - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "i_2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "046 - Disclosure - Note 8 - Income Tax - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.pieris.com/20221231/role/statement-note-8-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details",
     "shortName": "Note 8 - Income Tax - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "i_2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "i_2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "047 - Disclosure - Note 8 - Income Taxes - Summary of Income Tax Contingencies (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-summary-of-income-tax-contingencies-details",
     "shortName": "Note 8 - Income Taxes - Summary of Income Tax Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "i_2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfPrivatePlacement",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "048 - Disclosure - Note 9 - Stockholders' Equity (Details Textual)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual",
     "shortName": "Note 9 - Stockholders' Equity (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2019-08-01_2019-08-31",
      "decimals": "-7",
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "i_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "004 - Statement - Consolidated Statements of Changes in Stockholders' Equity",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity",
     "shortName": "Consolidated Statements of Changes in Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "i_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "049 - Disclosure - Note 10 - Net Loss Per Share (Details Textual)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.pieris.com/20221231/role/statement-note-10-net-loss-per-share-details-textual",
     "shortName": "Note 10 - Net Loss Per Share (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "050 - Disclosure - Note 11 - Stock and Employee Benefit Plans (Details Textual)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-details-textual",
     "shortName": "Note 11 - Stock and Employee Benefit Plans (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPerShare",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "051 - Disclosure - Note 11 - Stock and Employee Benefit Plans - Schedule of Share-based Payment Award, Stock Options (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-schedule-of-sharebased-payment-award-stock-options-details",
     "shortName": "Note 11 - Stock and Employee Benefit Plans - Schedule of Share-based Payment Award, Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "052 - Disclosure - Note 11 - Stock and Employee Benefit Plans - Stock Options Activity (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-stock-options-activity-details",
     "shortName": "Note 11 - Stock and Employee Benefit Plans - Stock Options Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "ix:continuation",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31_TitleOfIndividualAxis-ExecutiveOfficersAndManagementMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPerShare",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "053 - Disclosure - Note 11 - Stock and Employee Benefit Plans - Schedule of Employee Service Share-based Compensation Costs (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-schedule-of-employee-service-sharebased-compensation-costs-details",
     "shortName": "Note 11 - Stock and Employee Benefit Plans - Schedule of Employee Service Share-based Compensation Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "054 - Disclosure - Note 13 - Leases (Details Textual)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.pieris.com/20221231/role/statement-note-13-leases-details-textual",
     "shortName": "Note 13 - Leases (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "055 - Disclosure - Note 13 - Leases - Operating Lease Costs (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.pieris.com/20221231/role/statement-note-13-leases-operating-lease-costs-details",
     "shortName": "Note 13 - Leases - Operating Lease Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "i_2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "056 - Disclosure - Note 13 - Leases - Maturities of Operating Lease Liabilities (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.pieris.com/20221231/role/statement-note-13-leases-maturities-of-operating-lease-liabilities-details",
     "shortName": "Note 13 - Leases - Maturities of Operating Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "i_2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "005 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Parentheticals)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-parentheticals",
     "shortName": "Consolidated Statements of Changes in Stockholders' Equity (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "006 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": "-4",
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "007 - Statement - Consolidated Statements of Cash Flows (Parentheticals)",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows-parentheticals",
     "shortName": "Consolidated Statements of Cash Flows (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "008 - Disclosure - Note 1 - Corporate Information",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.pieris.com/20221231/role/statement-note-1-corporate-information-",
     "shortName": "Note 1 - Corporate Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "pirs20221231_10k.htm",
      "contextRef": "d_2022-01-01_2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 81,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r547",
      "r548",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r547",
      "r548",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r547",
      "r548",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r547",
      "r548",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets",
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows-parentheticals",
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss",
      "http://www.pieris.com/20221231/role/statement-document-and-entity-information",
      "http://www.pieris.com/20221231/role/statement-note-1-corporate-information-",
      "http://www.pieris.com/20221231/role/statement-note-1-corporate-information-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-10-net-loss-per-share",
      "http://www.pieris.com/20221231/role/statement-note-10-net-loss-per-share-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans",
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-schedule-of-employee-service-sharebased-compensation-costs-details",
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-schedule-of-sharebased-payment-award-stock-options-details",
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-stock-options-activity-details",
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-tables",
      "http://www.pieris.com/20221231/role/statement-note-12-license-agreement",
      "http://www.pieris.com/20221231/role/statement-note-13-leases",
      "http://www.pieris.com/20221231/role/statement-note-13-leases-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-13-leases-maturities-of-operating-lease-liabilities-details",
      "http://www.pieris.com/20221231/role/statement-note-13-leases-operating-lease-costs-details",
      "http://www.pieris.com/20221231/role/statement-note-13-leases-tables",
      "http://www.pieris.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://www.pieris.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-property-plant-and-equipment-useful-lives-details",
      "http://www.pieris.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-disaggregation-of-revenue-details",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-potential-milestone-payments-received-details",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-tables",
      "http://www.pieris.com/20221231/role/statement-note-4-grant-income",
      "http://www.pieris.com/20221231/role/statement-note-4-grant-income-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments",
      "http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-cash-equivalents-and-investments-carried-at-fair-value-details",
      "http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-investments-details",
      "http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-tables",
      "http://www.pieris.com/20221231/role/statement-note-6-property-and-equipment-net",
      "http://www.pieris.com/20221231/role/statement-note-6-property-and-equipment-net-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-6-property-and-equipment-net-property-and-equipment-details",
      "http://www.pieris.com/20221231/role/statement-note-6-property-and-equipment-net-tables",
      "http://www.pieris.com/20221231/role/statement-note-7-accrued-expenses",
      "http://www.pieris.com/20221231/role/statement-note-7-accrued-expenses-accrued-expenses-and-other-current-liabilities-details",
      "http://www.pieris.com/20221231/role/statement-note-7-accrued-expenses-tables",
      "http://www.pieris.com/20221231/role/statement-note-8-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details",
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes",
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details",
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details",
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details",
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-summary-of-income-tax-contingencies-details",
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-tables",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual",
      "http://www.pieris.com/20221231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r547",
      "r548",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets",
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows-parentheticals",
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss",
      "http://www.pieris.com/20221231/role/statement-document-and-entity-information",
      "http://www.pieris.com/20221231/role/statement-note-1-corporate-information-",
      "http://www.pieris.com/20221231/role/statement-note-1-corporate-information-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-10-net-loss-per-share",
      "http://www.pieris.com/20221231/role/statement-note-10-net-loss-per-share-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans",
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-schedule-of-employee-service-sharebased-compensation-costs-details",
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-schedule-of-sharebased-payment-award-stock-options-details",
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-stock-options-activity-details",
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-tables",
      "http://www.pieris.com/20221231/role/statement-note-12-license-agreement",
      "http://www.pieris.com/20221231/role/statement-note-13-leases",
      "http://www.pieris.com/20221231/role/statement-note-13-leases-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-13-leases-maturities-of-operating-lease-liabilities-details",
      "http://www.pieris.com/20221231/role/statement-note-13-leases-operating-lease-costs-details",
      "http://www.pieris.com/20221231/role/statement-note-13-leases-tables",
      "http://www.pieris.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://www.pieris.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-property-plant-and-equipment-useful-lives-details",
      "http://www.pieris.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-disaggregation-of-revenue-details",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-potential-milestone-payments-received-details",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-tables",
      "http://www.pieris.com/20221231/role/statement-note-4-grant-income",
      "http://www.pieris.com/20221231/role/statement-note-4-grant-income-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments",
      "http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-cash-equivalents-and-investments-carried-at-fair-value-details",
      "http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-investments-details",
      "http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-tables",
      "http://www.pieris.com/20221231/role/statement-note-6-property-and-equipment-net",
      "http://www.pieris.com/20221231/role/statement-note-6-property-and-equipment-net-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-6-property-and-equipment-net-property-and-equipment-details",
      "http://www.pieris.com/20221231/role/statement-note-6-property-and-equipment-net-tables",
      "http://www.pieris.com/20221231/role/statement-note-7-accrued-expenses",
      "http://www.pieris.com/20221231/role/statement-note-7-accrued-expenses-accrued-expenses-and-other-current-liabilities-details",
      "http://www.pieris.com/20221231/role/statement-note-7-accrued-expenses-tables",
      "http://www.pieris.com/20221231/role/statement-note-8-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details",
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes",
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details",
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details",
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details",
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-summary-of-income-tax-contingencies-details",
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-tables",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual",
      "http://www.pieris.com/20221231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "pirs_AccruedAccountsPayableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-note-7-accrued-expenses-accrued-expenses-and-other-current-liabilities-details": {
       "order": 4.0,
       "parentTag": "pirs_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current portion of accrued accounts payable.",
        "label": "Accrued accounts payable"
       }
      }
     },
     "localname": "AccruedAccountsPayableCurrent",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-7-accrued-expenses-accrued-expenses-and-other-current-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pirs_AccruedCollaborationCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-note-7-accrued-expenses-accrued-expenses-and-other-current-liabilities-details": {
       "order": 0.0,
       "parentTag": "pirs_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current portion of accrued collaboration costs.",
        "label": "Collaboration cost-sharing obligation"
       }
      }
     },
     "localname": "AccruedCollaborationCostsCurrent",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-7-accrued-expenses-accrued-expenses-and-other-current-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pirs_AccruedLiabilitiesAndOtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Relating to accrued liabilities and other current liabilities",
        "label": "Accrued Liabilities and Other Current Liabilities [Member]"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherCurrentLiabilitiesMember",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-7-accrued-expenses-accrued-expenses-and-other-current-liabilities-details"
     ],
     "xbrltype": "domainItemType"
    },
    "pirs_AccruedLiabilitiesAndOtherLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.pieris.com/20221231/role/statement-note-7-accrued-expenses-accrued-expenses-and-other-current-liabilities-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current portion of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.",
        "label": "Accrued expenses and other current liabilities",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilitiesCurrent",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets",
      "http://www.pieris.com/20221231/role/statement-note-7-accrued-expenses-accrued-expenses-and-other-current-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pirs_AccruedLicenseObligationsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-note-7-accrued-expenses-accrued-expenses-and-other-current-liabilities-details": {
       "order": 3.0,
       "parentTag": "pirs_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current portion of accrued license obligation.",
        "label": "Accrued license obligations"
       }
      }
     },
     "localname": "AccruedLicenseObligationsCurrent",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-7-accrued-expenses-accrued-expenses-and-other-current-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pirs_AccruedResearchAndDevelopmentCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-note-7-accrued-expenses-accrued-expenses-and-other-current-liabilities-details": {
       "order": 5.0,
       "parentTag": "pirs_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accrued research and development costs.",
        "label": "Research and development fees"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentCosts",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-7-accrued-expenses-accrued-expenses-and-other-current-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pirs_AdditionalOtherResearchServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional Other Research Services.",
        "label": "Additional Other Research Services [Member]"
       }
      }
     },
     "localname": "AdditionalOtherResearchServicesMember",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "pirs_AgreementTerminationNoticePeriodUponOfBreachOfPaymentObligations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement termination notice period upon breach of payment obligations by the Company.",
        "label": "pirs_AgreementTerminationNoticePeriodUponOfBreachOfPaymentObligations",
        "terseLabel": "Agreement Termination Notice Period Upon Of Breach Of Payment Obligations (Day)"
       }
      }
     },
     "localname": "AgreementTerminationNoticePeriodUponOfBreachOfPaymentObligations",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "pirs_AmendedCollaborationAgreementResaleOfStockPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Resale of stock period.",
        "label": "pirs_AmendedCollaborationAgreementResaleOfStockPeriod",
        "terseLabel": "Amended Collaboration Agreement, Resale of Stock, Period (Day)"
       }
      }
     },
     "localname": "AmendedCollaborationAgreementResaleOfStockPeriod",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "pirs_AntibodyTargetSwapMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Antibody Target Swap.",
        "label": "Antibody Target Swap [Member]"
       }
      }
     },
     "localname": "AntibodyTargetSwapMember",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "pirs_AstraZenecaABMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Astra Zeneca A B.",
        "label": "Astra Zeneca A B [Member]"
       }
      }
     },
     "localname": "AstraZenecaABMember",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-disaggregation-of-revenue-details",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-potential-milestone-payments-received-details"
     ],
     "xbrltype": "domainItemType"
    },
    "pirs_AtTheMarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents at the market offering.",
        "label": "At the Market Offering [Member]"
       }
      }
     },
     "localname": "AtTheMarketOfferingMember",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows-parentheticals",
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity",
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-parentheticals",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "pirs_BPAssetsXIIIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents BP Assets XII Inc.",
        "label": "B P Assets X I I Inc [Member]"
       }
      }
     },
     "localname": "BPAssetsXIIIncMember",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "pirs_BostonMassachusettsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boston Massachusetts",
        "label": "Boston Massachusetts [Member]"
       }
      }
     },
     "localname": "BostonMassachusettsMember",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-13-leases",
      "http://www.pieris.com/20221231/role/statement-note-13-leases-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "pirs_BostonPharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boston Pharmaceuticals.",
        "label": "Boston Pharmaceuticals [Member]"
       }
      }
     },
     "localname": "BostonPharmaceuticalsMember",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-disaggregation-of-revenue-details",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-potential-milestone-payments-received-details"
     ],
     "xbrltype": "domainItemType"
    },
    "pirs_CashEquivalentsAndInvestments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of cash, cash equivalents and investments.",
        "label": "Total"
       }
      }
     },
     "localname": "CashEquivalentsAndInvestments",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-cash-equivalents-and-investments-carried-at-fair-value-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pirs_CodevelopmentCollaborationProductCollaborationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Relating to collaboration in the Co-Development Collaboration Product",
        "label": "Co-Development Collaboration Product Collaboration [Member]"
       }
      }
     },
     "localname": "CodevelopmentCollaborationProductCollaborationMember",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "pirs_CollaborativeArrangementAllocableArrangementConsiderationAllocation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allocated to collaborative arrangement allocable arrangement consideration.",
        "label": "pirs_CollaborativeArrangementAllocableArrangementConsiderationAllocation",
        "terseLabel": "Collaborative Arrangement Allocable Arrangement Consideration Allocation"
       }
      }
     },
     "localname": "CollaborativeArrangementAllocableArrangementConsiderationAllocation",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pirs_ConversionOfCommonStockIntoSeriesEPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of Common Stock into Series E Preferred Stock.",
        "label": "Conversion of Common Stock into Series E Preferred Stock [Member]"
       }
      }
     },
     "localname": "ConversionOfCommonStockIntoSeriesEPreferredStockMember",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "pirs_ConversionOfPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents conversion of preferred stock.",
        "label": "Conversion of Preferred Stock [Member]"
       }
      }
     },
     "localname": "ConversionOfPreferredStockMember",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "domainItemType"
    },
    "pirs_ConversionOfSeriesEPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents conversion of series E preferred stock.",
        "label": "Conversion of Series E Preferred Stock [Member]"
       }
      }
     },
     "localname": "ConversionOfSeriesEPreferredStockMember",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "domainItemType"
    },
    "pirs_ConvertiblePreferredStockBeneficialOwnershipLimitationNoticePeriodBeforeIncrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period in which the entity must notify an increase in beneficial ownership limitation.",
        "label": "pirs_ConvertiblePreferredStockBeneficialOwnershipLimitationNoticePeriodBeforeIncrease",
        "terseLabel": "Convertible Preferred Stock, Beneficial Ownership Limitation, Notice Period Before Increase (Year)"
       }
      }
     },
     "localname": "ConvertiblePreferredStockBeneficialOwnershipLimitationNoticePeriodBeforeIncrease",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "pirs_ConvertiblePreferredStockBeneficialOwnershipLimitationPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of beneficial ownership limitation for convertible preferred stock",
        "label": "pirs_ConvertiblePreferredStockBeneficialOwnershipLimitationPercent",
        "terseLabel": "Convertible Preferred Stock, Beneficial Ownership Limitation, Percent"
       }
      }
     },
     "localname": "ConvertiblePreferredStockBeneficialOwnershipLimitationPercent",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "pirs_ConvertiblePreferredStockCommonStockOwnershipLimitPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of common stock ownership limit of convertible preferred stock",
        "label": "pirs_ConvertiblePreferredStockCommonStockOwnershipLimitPercent",
        "terseLabel": "Convertible Preferred Stock, Common Stock Ownership Limit, Percent"
       }
      }
     },
     "localname": "ConvertiblePreferredStockCommonStockOwnershipLimitPercent",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "pirs_ConvertiblePreferredStockWeightedAverageStockPricePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of weighted average convertible preferred stock price",
        "label": "pirs_ConvertiblePreferredStockWeightedAverageStockPricePercent",
        "terseLabel": "Convertible Preferred Stock, Weighted Average Stock Price, Percent"
       }
      }
     },
     "localname": "ConvertiblePreferredStockWeightedAverageStockPricePercent",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "pirs_CorporateIncomeTaxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Relating to corporate income tax",
        "label": "Corporate Income Tax [Member]"
       }
      }
     },
     "localname": "CorporateIncomeTaxMember",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes",
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "pirs_DebtSecuritiesAvailableforsaleContractualMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual maturity period for debt securities, available-for-sale securities.",
        "label": "Contractual Maturity Period (Day)"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableforsaleContractualMaturityPeriod",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-investments-details"
     ],
     "xbrltype": "durationItemType"
    },
    "pirs_DeferredTaxAssetLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-note-8-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liability",
        "label": "Lease liability"
       }
      }
     },
     "localname": "DeferredTaxAssetLeaseLiability",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-8-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pirs_DeferredTaxAssetsAccruedCompensationAndOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-note-8-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued compensation and other costs",
        "label": "Accrued expenses, tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsAccruedCompensationAndOther",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-8-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pirs_DeferredTaxAssetsCapitalizedResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-note-8-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to capitalized research and development.",
        "label": "Capitalized R&amp;D",
        "terseLabel": "Deferred Tax Assets, Capitalized Research and Development"
       }
      }
     },
     "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopment",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-8-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details",
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pirs_DeferredTaxAssetsDepreciationAndOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-note-8-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from depreciation and other expenses.",
        "label": "Depreciation and other"
       }
      }
     },
     "localname": "DeferredTaxAssetsDepreciationAndOther",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-8-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pirs_DeferredTaxLiabilitiesLeaseRightofuseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-note-8-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from lease right-of-use assets",
        "label": "pirs_DeferredTaxLiabilitiesLeaseRightofuseAsset",
        "negatedLabel": "Right-of-use asset"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesLeaseRightofuseAsset",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-8-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pirs_EffectiveIncomeTaxRateReconciliationProvisionToReturnPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) from provision to return.",
        "label": "Provision to return"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationProvisionToReturnPercent",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details"
     ],
     "xbrltype": "percentItemType"
    },
    "pirs_EmployeeDirectorAndConsultantEquityIncentivePlan2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Director And Consultant Equity Incentive Plan2020.",
        "label": "Employee Director And Consultant Equity Incentive Plan2020 [Member]"
       }
      }
     },
     "localname": "EmployeeDirectorAndConsultantEquityIncentivePlan2020Member",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans",
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-stock-options-activity-details",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "pirs_EstimatedDevelopmentAndManufacturingServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated Development And Manufacturing Services.",
        "label": "Estimated Development And Manufacturing Services [Member]"
       }
      }
     },
     "localname": "EstimatedDevelopmentAndManufacturingServicesMember",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "pirs_EstimatedPhase2aServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated Phase2a Services",
        "label": "Estimated Phase 2a Services [Member]"
       }
      }
     },
     "localname": "EstimatedPhase2aServicesMember",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "pirs_ExclusiveProductLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Exclusive Product License Agreement.",
        "label": "Exclusive Product License Agreement [Member]"
       }
      }
     },
     "localname": "ExclusiveProductLicenseAgreementMember",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "pirs_ExecutiveOfficersAndManagementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Relating to executive officers and management",
        "label": "Executive Officers and Management [Member]"
       }
      }
     },
     "localname": "ExecutiveOfficersAndManagementMember",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans",
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-stock-options-activity-details"
     ],
     "xbrltype": "domainItemType"
    },
    "pirs_GenentechMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Genentech.",
        "label": "Genentech [Member]"
       }
      }
     },
     "localname": "GenentechMember",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-disaggregation-of-revenue-details",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-potential-milestone-payments-received-details"
     ],
     "xbrltype": "domainItemType"
    },
    "pirs_GovernanceCommitteeParticipationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents governance committee participation.",
        "label": "Governance Committee Participation [Member]"
       }
      }
     },
     "localname": "GovernanceCommitteeParticipationMember",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "pirs_HallbergmoosGermanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hallbergmoos Germany.",
        "label": "Hallbergmoos Germany [Member]"
       }
      }
     },
     "localname": "HallbergmoosGermanyMember",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-13-leases",
      "http://www.pieris.com/20221231/role/statement-note-13-leases-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "pirs_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating lease liabilities.",
        "label": "pirs_IncreaseDecreaseInOperatingLeaseLiabilities",
        "negatedLabel": "Lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pirs_JefferiesLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Jefferies LLC.",
        "label": "Jefferies L L C [Member]"
       }
      }
     },
     "localname": "JefferiesLLCMember",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "pirs_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents laboratory equipment.",
        "label": "Laboratory Equipment [Member]"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-property-plant-and-equipment-useful-lives-details",
      "http://www.pieris.com/20221231/role/statement-note-6-property-and-equipment-net-property-and-equipment-details"
     ],
     "xbrltype": "domainItemType"
    },
    "pirs_LeasesExpectedToBeDeliveredByOctober2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leases Expected to be Delivered by October 2024.",
        "label": "Leases Expected to be Delivered by October 2024 [Member]"
       }
      }
     },
     "localname": "LeasesExpectedToBeDeliveredByOctober2024Member",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-13-leases",
      "http://www.pieris.com/20221231/role/statement-note-13-leases-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "pirs_LeasesWithFirstRightOfRefusalForAdditionalAreaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leases with First Right of Refusal for Additional Area.",
        "label": "Leases with First Right of Refusal for Additional Area [Member]"
       }
      }
     },
     "localname": "LeasesWithFirstRightOfRefusalForAdditionalAreaMember",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-13-leases",
      "http://www.pieris.com/20221231/role/statement-note-13-leases-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "pirs_LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Les Laboratoires Servier And Institut De Recherches Internationales Servier.",
        "label": "Les Laboratoires Servier And Institut De Recherches Internationales Servier [Member]"
       }
      }
     },
     "localname": "LesLaboratoiresServierAndInstitutDeRecherchesInternationalesServierMember",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-disaggregation-of-revenue-details",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-potential-milestone-payments-received-details"
     ],
     "xbrltype": "domainItemType"
    },
    "pirs_LesseeOperatingLeaseMonthlyRentExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Monthly rent expense under operating lease for lessee.",
        "label": "pirs_LesseeOperatingLeaseMonthlyRentExpense",
        "terseLabel": "Lessee, Operating Lease, Monthly Rent Expense"
       }
      }
     },
     "localname": "LesseeOperatingLeaseMonthlyRentExpense",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-13-leases-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pirs_LicenseAndCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents license and collaboration agreement.",
        "label": "License and Collaboration Agreement [Member]"
       }
      }
     },
     "localname": "LicenseAndCollaborationAgreementMember",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "pirs_LicenseAndTransferAgreementTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the entity's license and transfer agreements",
        "label": "License and Transfer Agreement [Text Block]"
       }
      }
     },
     "localname": "LicenseAndTransferAgreementTextBlock",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-12-license-agreement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pirs_NoteToFinancialStatementDetailsTextual": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note To Financial Statement Details Textual"
       }
      }
     },
     "localname": "NoteToFinancialStatementDetailsTextual",
     "nsuri": "http://www.pieris.com/20221231",
     "xbrltype": "stringItemType"
    },
    "pirs_NotesToFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes To Financial Statements [Abstract]"
       }
      }
     },
     "localname": "NotesToFinancialStatementsAbstract",
     "nsuri": "http://www.pieris.com/20221231",
     "xbrltype": "stringItemType"
    },
    "pirs_NumberOfAgreementExtensionOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of agreement extension options.",
        "label": "pirs_NumberOfAgreementExtensionOptions",
        "terseLabel": "Number of Agreement Extension Options"
       }
      }
     },
     "localname": "NumberOfAgreementExtensionOptions",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-13-leases-details-textual"
     ],
     "xbrltype": "integerItemType"
    },
    "pirs_NumberOfCollaborationProducts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of collaboration products.",
        "label": "pirs_NumberOfCollaborationProducts",
        "terseLabel": "Number of Collaboration Products"
       }
      }
     },
     "localname": "NumberOfCollaborationProducts",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "integerItemType"
    },
    "pirs_NumberOfCombinedPerformanceObligations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of combined performance obligations",
        "label": "pirs_NumberOfCombinedPerformanceObligations",
        "terseLabel": "Number of Combined Performance Obligations"
       }
      }
     },
     "localname": "NumberOfCombinedPerformanceObligations",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "integerItemType"
    },
    "pirs_NumberOfDevelopmentMilestones": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of development milestones.",
        "label": "pirs_NumberOfDevelopmentMilestones",
        "terseLabel": "Number of Development Milestones"
       }
      }
     },
     "localname": "NumberOfDevelopmentMilestones",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "integerItemType"
    },
    "pirs_NumberOfDiscoveryProgramsDiscontinued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of discovery programs discontinued.",
        "label": "pirs_NumberOfDiscoveryProgramsDiscontinued",
        "terseLabel": "Number of Discovery Programs Discontinued"
       }
      }
     },
     "localname": "NumberOfDiscoveryProgramsDiscontinued",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "integerItemType"
    },
    "pirs_NumberOfInitialResearchPrograms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents number of initial research programs.",
        "label": "pirs_NumberOfInitialResearchPrograms",
        "terseLabel": "Number Of Initial Research Programs"
       }
      }
     },
     "localname": "NumberOfInitialResearchPrograms",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "integerItemType"
    },
    "pirs_NumberOfLicenses": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of licenses.",
        "label": "pirs_NumberOfLicenses",
        "terseLabel": "Number Of Licenses"
       }
      }
     },
     "localname": "NumberOfLicenses",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "integerItemType"
    },
    "pirs_NumberOfNovelProteins": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of novel proteins.",
        "label": "pirs_NumberOfNovelProteins",
        "terseLabel": "Number of Novel Proteins"
       }
      }
     },
     "localname": "NumberOfNovelProteins",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "integerItemType"
    },
    "pirs_NumberOfOptionalAdditionalResearchPrograms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents number of optional additional research program.",
        "label": "pirs_NumberOfOptionalAdditionalResearchPrograms",
        "terseLabel": "Number Of Optional Additional Research Programs"
       }
      }
     },
     "localname": "NumberOfOptionalAdditionalResearchPrograms",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "integerItemType"
    },
    "pirs_NumberOfPerformanceObligations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents number of performance obligations.",
        "label": "pirs_NumberOfPerformanceObligations",
        "terseLabel": "Number of Performance Obligations"
       }
      }
     },
     "localname": "NumberOfPerformanceObligations",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "integerItemType"
    },
    "pirs_NumberOfPreclinicalStagePrograms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of preclinical stage programs",
        "label": "pirs_NumberOfPreclinicalStagePrograms",
        "terseLabel": "Number Of Preclinical Stage Programs"
       }
      }
     },
     "localname": "NumberOfPreclinicalStagePrograms",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "integerItemType"
    },
    "pirs_NumberOfPrograms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of programs.",
        "label": "pirs_NumberOfPrograms",
        "terseLabel": "Number of Programs"
       }
      }
     },
     "localname": "NumberOfPrograms",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "integerItemType"
    },
    "pirs_NumberOfResearchLicenses": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of research licenses.",
        "label": "pirs_NumberOfResearchLicenses",
        "terseLabel": "Number of Research Licenses"
       }
      }
     },
     "localname": "NumberOfResearchLicenses",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "integerItemType"
    },
    "pirs_NumberOfResearchPrograms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents number of research programs.",
        "label": "pirs_NumberOfResearchPrograms",
        "terseLabel": "Number of Research Programs"
       }
      }
     },
     "localname": "NumberOfResearchPrograms",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "integerItemType"
    },
    "pirs_NumberOfSeparatePerformanceObligations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents number of separate performance obligations",
        "label": "pirs_NumberOfSeparatePerformanceObligations",
        "terseLabel": "Number Of Separate Performance Obligations"
       }
      }
     },
     "localname": "NumberOfSeparatePerformanceObligations",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "integerItemType"
    },
    "pirs_NumberOfSwapOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of swap options.",
        "label": "pirs_NumberOfSwapOptions",
        "terseLabel": "Number Of Swap Options"
       }
      }
     },
     "localname": "NumberOfSwapOptions",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "integerItemType"
    },
    "pirs_NumberOfTargetPrograms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of target programs.",
        "label": "pirs_NumberOfTargetPrograms",
        "terseLabel": "Number of Target Programs"
       }
      }
     },
     "localname": "NumberOfTargetPrograms",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "integerItemType"
    },
    "pirs_NumberOfTechnologyLicenses": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of technology licenses.",
        "label": "pirs_NumberOfTechnologyLicenses",
        "terseLabel": "Number of Technology Licenses"
       }
      }
     },
     "localname": "NumberOfTechnologyLicenses",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "integerItemType"
    },
    "pirs_NumberOfVotesPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of votes per share",
        "label": "pirs_NumberOfVotesPerShare",
        "terseLabel": "Number Of Votes Per Share"
       }
      }
     },
     "localname": "NumberOfVotesPerShare",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "integerItemType"
    },
    "pirs_OfficeAndLaboratorySpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office and Laboratory Space.",
        "label": "Office and Laboratory Space [Member]"
       }
      }
     },
     "localname": "OfficeAndLaboratorySpaceMember",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-13-leases",
      "http://www.pieris.com/20221231/role/statement-note-13-leases-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "pirs_OperatingLeaseRightOfUseAssetAccretion": {
     "auth_ref": [],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents right of use asset accretion for operating lease.",
        "label": "pirs_OperatingLeaseRightOfUseAssetAccretion",
        "negatedLabel": "Right-of-use asset (accretion) amortization"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAccretion",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pirs_OtherArrangementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Arrangement.",
        "label": "Other Arrangement [Member]"
       }
      }
     },
     "localname": "OtherArrangementMember",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "pirs_PierisPharmaceuticalsGmbhMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Pieris Pharmaceuticals GmbH.",
        "label": "Pieris Pharmaceuticals GmbH [Member]"
       }
      }
     },
     "localname": "PierisPharmaceuticalsGmbhMember",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-1-corporate-information-",
      "http://www.pieris.com/20221231/role/statement-note-1-corporate-information-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "pirs_PlatformTechnologyLicenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents platform technology license.",
        "label": "Platform Technology License [Member]"
       }
      }
     },
     "localname": "PlatformTechnologyLicenseMember",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "pirs_PreferredShareExchangeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Relating to preferred share exchange",
        "label": "Preferred Share Exchange [Member]"
       }
      }
     },
     "localname": "PreferredShareExchangeMember",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "pirs_ProceedsFromIssuanceOfPrivatePlacementNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net proceeds from issuance of private placement",
        "label": "pirs_ProceedsFromIssuanceOfPrivatePlacementNet",
        "terseLabel": "Proceeds From Issuance Of Private Placement Net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPrivatePlacementNet",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pirs_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of estimated useful life of physical assets.",
        "label": "Property, Plant and Equipment, Estimated Useful Life [Table Text Block]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pirs_RemainingPerformanceObligationEstimatedTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of license performance obligation.",
        "label": "pirs_RemainingPerformanceObligationEstimatedTerm",
        "terseLabel": "Remaining Performance Obligation, Estimated Term (Month)"
       }
      }
     },
     "localname": "RemainingPerformanceObligationEstimatedTerm",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "pirs_ResearchAndDevelopmentMilestonePaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Milestone Payments.",
        "label": "Research And Development Milestone Payments [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentMilestonePaymentsMember",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-potential-milestone-payments-received-details"
     ],
     "xbrltype": "domainItemType"
    },
    "pirs_ResearchAndDevelopmentServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents research and development services.",
        "label": "Research And Development Services [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentServicesMember",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "pirs_ResearchCollaborationAgreementPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents research collaboration agreement period.",
        "label": "pirs_ResearchCollaborationAgreementPeriod",
        "terseLabel": "Research Collaboration Agreement Period (Year)"
       }
      }
     },
     "localname": "ResearchCollaborationAgreementPeriod",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "pirs_ResearchTermExtensionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period in which research term is extended.",
        "label": "pirs_ResearchTermExtensionPeriod",
        "terseLabel": "Research Term ,Extension Period (Year)"
       }
      }
     },
     "localname": "ResearchTermExtensionPeriod",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "pirs_RevenueFromContractWithCustomerAgreementObligationCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of agreement obligation cost of of revenue from contract with customers.",
        "label": "pirs_RevenueFromContractWithCustomerAgreementObligationCost",
        "terseLabel": "Revenue from Contract with Customer, Agreement Obligation Cost"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAgreementObligationCost",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pirs_RevenueFromContractWithCustomerAgreementTerminationAdditionalNoticePeriodUponMaterialBreach": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract termination due to material breach, additional notice period if the breach is not susceptible.",
        "label": "pirs_RevenueFromContractWithCustomerAgreementTerminationAdditionalNoticePeriodUponMaterialBreach",
        "terseLabel": "Revenue from Contract with Customer, Agreement Termination, Additional Notice Period Upon Material Breach (Day)"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAgreementTerminationAdditionalNoticePeriodUponMaterialBreach",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract termination advance notice period.",
        "label": "pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriod",
        "terseLabel": "Revenue from Contract with Customer, Agreement Termination Advance Notice Period (Day)"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriod",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodAfterFirstCommercialSale": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents agreement termination advance notice period after first commercial sale for revenue from contract with customer.",
        "label": "pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodAfterFirstCommercialSale",
        "terseLabel": "Revenue from Contract with Customer, Agreement Termination Advance Notice Period After First Commercial Sale (Day)"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodAfterFirstCommercialSale",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodBeforeFirstCommercialSale": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents termination advance notice period before first commercial sale for revenue from contract with customer agreement.",
        "label": "pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodBeforeFirstCommercialSale",
        "terseLabel": "Revenue from Contract with Customer, Agreement Termination Advance Notice Period Before First Commercial Sale (Day)"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodBeforeFirstCommercialSale",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodIfMarketingApprovalObtained": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement termination advance notice period if marketing approval obtained.",
        "label": "pirs_RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodIfMarketingApprovalObtained",
        "terseLabel": "Revenue from Contract with Customer, Agreement Termination Advance Notice Period If Marketing Approval Obtained (Day)"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAgreementTerminationAdvanceNoticePeriodIfMarketingApprovalObtained",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "pirs_RevenueFromContractWithCustomerAgreementTerminationNoticePeriodNonpaymentOfUndisputedAmounts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement termination notice period due to non-payment of undisputed amounts.",
        "label": "pirs_RevenueFromContractWithCustomerAgreementTerminationNoticePeriodNonpaymentOfUndisputedAmounts",
        "terseLabel": "Revenue from Contract with Customer, Agreement Termination Notice Period, Non-Payment Of Undisputed Amounts (Day)"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAgreementTerminationNoticePeriodNonpaymentOfUndisputedAmounts",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "pirs_RevenueFromContractWithCustomerAgreementTerminationNoticePeriodUponMaterialBreach": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement termination notice period upon material breach by the Company.",
        "label": "pirs_RevenueFromContractWithCustomerAgreementTerminationNoticePeriodUponMaterialBreach",
        "terseLabel": "Revenue from Contract with Customer, Agreement Termination Notice Period Upon Material Breach (Day)"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAgreementTerminationNoticePeriodUponMaterialBreach",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "pirs_RevenueFromContractWithCustomerAgreementTerminationNoticePeriodWithinMaterialBreach": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents revenue from contract with customer for termination notice period within material breach.",
        "label": "pirs_RevenueFromContractWithCustomerAgreementTerminationNoticePeriodWithinMaterialBreach",
        "terseLabel": "Revenue from Contract with Customer, Agreement Termination Notice Period Within Material Breach (Day)"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAgreementTerminationNoticePeriodWithinMaterialBreach",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "pirs_RevenueFromContractWithCustomerAllocableArrangementConsiderationAllocation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue from contract with customers allocable arrangement consideration allocation.",
        "label": "pirs_RevenueFromContractWithCustomerAllocableArrangementConsiderationAllocation",
        "terseLabel": "Revenue from Contract with Customer, Allocable Arrangement Consideration Allocation"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAllocableArrangementConsiderationAllocation",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pirs_RevenueFromContractWithCustomerCollaborationFeeOnAdditionalProgram": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents revenue from contract with customer related to collaboration fee on additional program.",
        "label": "pirs_RevenueFromContractWithCustomerCollaborationFeeOnAdditionalProgram",
        "terseLabel": "Revenue from Contract with Customer, Collaboration Fee On Additional Program"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerCollaborationFeeOnAdditionalProgram",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pirs_RevenueFromContractWithCustomerContributionTowardsManufacturingActivities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue from contract with customers contribution towards manufacturing activities.",
        "label": "pirs_RevenueFromContractWithCustomerContributionTowardsManufacturingActivities",
        "terseLabel": "Revenue from Contract with Customer, Contribution Towards Manufacturing Activities"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerContributionTowardsManufacturingActivities",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pirs_RevenueFromContractWithCustomerMilestonePaymentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the milestone payments for revenue from contract with customer.",
        "label": "Revenue From Contract With Customer, Milestone Payments [Table Text Block]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMilestonePaymentsTableTextBlock",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pirs_RevenueFromContractWithCustomerPeriodAfterEffectiveDateAgreementsMayBeTerminated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period after effective date agreements may be terminated.",
        "label": "pirs_RevenueFromContractWithCustomerPeriodAfterEffectiveDateAgreementsMayBeTerminated",
        "terseLabel": "Revenue from Contract with Customer, Period After Effective Date Agreements May Be Terminated (Month)"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPeriodAfterEffectiveDateAgreementsMayBeTerminated",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "pirs_SaleOfStockAuthorizedAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Authorized amount of sale of stock during a period of time.",
        "label": "pirs_SaleOfStockAuthorizedAmount",
        "terseLabel": "Sale of Stock, Authorized Amount"
       }
      }
     },
     "localname": "SaleOfStockAuthorizedAmount",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pirs_SaleOfStockFairValuePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price per share of sale of stock, fair value.",
        "label": "pirs_SaleOfStockFairValuePricePerShare",
        "terseLabel": "Sale of Stock, Fair Value, Price Per Share (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockFairValuePricePerShare",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "pirs_SaleOfStockNumberOfWarrantsPerUnit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of warrants issued per unit in a sale of stock",
        "label": "pirs_SaleOfStockNumberOfWarrantsPerUnit",
        "terseLabel": "Sale of Stock, Number of Warrants, Per Unit (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfWarrantsPerUnit",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "pirs_SalesMilestonePaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Milestone Payments.",
        "label": "Sales Milestone Payments [Member]"
       }
      }
     },
     "localname": "SalesMilestonePaymentsMember",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-potential-milestone-payments-received-details"
     ],
     "xbrltype": "domainItemType"
    },
    "pirs_SeattleGeneticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Seattle Genetics Inc..",
        "label": "Seattle Genetics Inc. [Member]"
       }
      }
     },
     "localname": "SeattleGeneticsIncMember",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-disaggregation-of-revenue-details",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-potential-milestone-payments-received-details"
     ],
     "xbrltype": "domainItemType"
    },
    "pirs_SecuritiesPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Relating to securities purchase agreement",
        "label": "Securities Purchase Agreement [Member]"
       }
      }
     },
     "localname": "SecuritiesPurchaseAgreementMember",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "pirs_SeriesAThroughEMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Relating to Series A through E Preferred stock",
        "label": "Series A Through E [Member]"
       }
      }
     },
     "localname": "SeriesAThroughEMember",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "pirs_ServierDevelopedCollaborationProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Relating to the Servier Developed Collaboration Products",
        "label": "Servier Developed Collaboration Products [Member]"
       }
      }
     },
     "localname": "ServierDevelopedCollaborationProductsMember",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "pirs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm2Exercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period in which stock options are exercisable",
        "label": "Exercisable, contractual life (Year)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm2Exercised",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-stock-options-activity-details"
     ],
     "xbrltype": "durationItemType"
    },
    "pirs_ShareBasedCompensationArrangementBySharebasedPaymentAwardPurchasePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period in which share based compensation awards that can be purchased",
        "label": "pirs_ShareBasedCompensationArrangementBySharebasedPaymentAwardPurchasePeriod",
        "terseLabel": "Share Based Compensation Arrangement by Sharebased Payment Award, Purchase Period (Year)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementBySharebasedPaymentAwardPurchasePeriod",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfPurchasePeriods": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of purchase periods for share based payment award",
        "label": "pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfPurchasePeriods",
        "terseLabel": "Share-Based Compensation Arrangement by Share-based Payment Award, Number of Purchase Periods"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfPurchasePeriods",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-details-textual"
     ],
     "xbrltype": "integerItemType"
    },
    "pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAggregateIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options canceled",
        "label": "Canceled, intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAggregateIntrinsicValue",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-stock-options-activity-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pirs_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodAggregateIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options granted",
        "label": "Granted, intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodAggregateIntrinsicValue",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-stock-options-activity-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pirs_StockExchangeSharesFromExistingShareholdersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Relating to stock exchange shares from existing shareholders",
        "label": "Stock Exchange Shares from Existing Shareholders [Member]"
       }
      }
     },
     "localname": "StockExchangeSharesFromExistingShareholdersMember",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "pirs_StockIssuedDuringPeriodSharesExerciseOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of exercising of warrants .",
        "label": "Issuance of common stock resulting from exercise of warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesExerciseOfWarrants",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "sharesItemType"
    },
    "pirs_StockIssuedDuringPeriodValueExerciseOfWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued during the period for exercising of warrants.",
        "label": "Issuance of common stock resulting from exercise of warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueExerciseOfWarrants",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pirs_SubleaseOfficeSpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sublease Office Space.",
        "label": "Sublease Office Space [Member]"
       }
      }
     },
     "localname": "SubleaseOfficeSpaceMember",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-13-leases",
      "http://www.pieris.com/20221231/role/statement-note-13-leases-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "pirs_TradeTaxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Relating to trade tax",
        "label": "Trade Tax [Member]"
       }
      }
     },
     "localname": "TradeTaxMember",
     "nsuri": "http://www.pieris.com/20221231",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes",
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "pirs_statement-statement-note-11-stock-and-employee-benefit-plans-schedule-of-employee-service-sharebased-compensation-costs-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 11 - Stock and Employee Benefit Plans - Schedule of Employee Service Share-based Compensation Costs (Details)"
       }
      }
     },
     "localname": "statement-statement-note-11-stock-and-employee-benefit-plans-schedule-of-employee-service-sharebased-compensation-costs-details",
     "nsuri": "http://www.pieris.com/20221231",
     "xbrltype": "stringItemType"
    },
    "pirs_statement-statement-note-11-stock-and-employee-benefit-plans-schedule-of-sharebased-payment-award-stock-options-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 11 - Stock and Employee Benefit Plans - Schedule of Share-based Payment Award, Stock Options (Details)"
       }
      }
     },
     "localname": "statement-statement-note-11-stock-and-employee-benefit-plans-schedule-of-sharebased-payment-award-stock-options-details",
     "nsuri": "http://www.pieris.com/20221231",
     "xbrltype": "stringItemType"
    },
    "pirs_statement-statement-note-11-stock-and-employee-benefit-plans-stock-options-activity-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 11 - Stock and Employee Benefit Plans - Stock Options Activity (Details)"
       }
      }
     },
     "localname": "statement-statement-note-11-stock-and-employee-benefit-plans-stock-options-activity-details",
     "nsuri": "http://www.pieris.com/20221231",
     "xbrltype": "stringItemType"
    },
    "pirs_statement-statement-note-11-stock-and-employee-benefit-plans-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 11 - Stock and Employee Benefit Plans"
       }
      }
     },
     "localname": "statement-statement-note-11-stock-and-employee-benefit-plans-tables",
     "nsuri": "http://www.pieris.com/20221231",
     "xbrltype": "stringItemType"
    },
    "pirs_statement-statement-note-13-leases-maturities-of-operating-lease-liabilities-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 13 - Leases - Maturities of Operating Lease Liabilities (Details)"
       }
      }
     },
     "localname": "statement-statement-note-13-leases-maturities-of-operating-lease-liabilities-details",
     "nsuri": "http://www.pieris.com/20221231",
     "xbrltype": "stringItemType"
    },
    "pirs_statement-statement-note-13-leases-operating-lease-costs-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 13 - Leases - Operating Lease Costs (Details)"
       }
      }
     },
     "localname": "statement-statement-note-13-leases-operating-lease-costs-details",
     "nsuri": "http://www.pieris.com/20221231",
     "xbrltype": "stringItemType"
    },
    "pirs_statement-statement-note-13-leases-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 13 - Leases"
       }
      }
     },
     "localname": "statement-statement-note-13-leases-tables",
     "nsuri": "http://www.pieris.com/20221231",
     "xbrltype": "stringItemType"
    },
    "pirs_statement-statement-note-2-summary-of-significant-accounting-policies-schedule-of-property-plant-and-equipment-useful-lives-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 2 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment, Useful Lives (Details)"
       }
      }
     },
     "localname": "statement-statement-note-2-summary-of-significant-accounting-policies-schedule-of-property-plant-and-equipment-useful-lives-details",
     "nsuri": "http://www.pieris.com/20221231",
     "xbrltype": "stringItemType"
    },
    "pirs_statement-statement-note-2-summary-of-significant-accounting-policies-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 2 - Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "statement-statement-note-2-summary-of-significant-accounting-policies-tables",
     "nsuri": "http://www.pieris.com/20221231",
     "xbrltype": "stringItemType"
    },
    "pirs_statement-statement-note-3-revenue-disaggregation-of-revenue-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 3 - Revenue - Disaggregation of Revenue (Details)"
       }
      }
     },
     "localname": "statement-statement-note-3-revenue-disaggregation-of-revenue-details",
     "nsuri": "http://www.pieris.com/20221231",
     "xbrltype": "stringItemType"
    },
    "pirs_statement-statement-note-3-revenue-potential-milestone-payments-received-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 3 - Revenue - Potential Milestone Payments Received (Details)"
       }
      }
     },
     "localname": "statement-statement-note-3-revenue-potential-milestone-payments-received-details",
     "nsuri": "http://www.pieris.com/20221231",
     "xbrltype": "stringItemType"
    },
    "pirs_statement-statement-note-3-revenue-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 3 - Revenue"
       }
      }
     },
     "localname": "statement-statement-note-3-revenue-tables",
     "nsuri": "http://www.pieris.com/20221231",
     "xbrltype": "stringItemType"
    },
    "pirs_statement-statement-note-5-cash-cash-equivalents-and-investments-cash-equivalents-and-investments-carried-at-fair-value-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 5 - Cash, Cash Equivalents and Investments - Cash Equivalents and Investments Carried at Fair Value (Details)"
       }
      }
     },
     "localname": "statement-statement-note-5-cash-cash-equivalents-and-investments-cash-equivalents-and-investments-carried-at-fair-value-details",
     "nsuri": "http://www.pieris.com/20221231",
     "xbrltype": "stringItemType"
    },
    "pirs_statement-statement-note-5-cash-cash-equivalents-and-investments-investments-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 5 - Cash, Cash Equivalents and Investments - Investments (Details)"
       }
      }
     },
     "localname": "statement-statement-note-5-cash-cash-equivalents-and-investments-investments-details",
     "nsuri": "http://www.pieris.com/20221231",
     "xbrltype": "stringItemType"
    },
    "pirs_statement-statement-note-5-cash-cash-equivalents-and-investments-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 5 - Cash, Cash Equivalents and Investments"
       }
      }
     },
     "localname": "statement-statement-note-5-cash-cash-equivalents-and-investments-tables",
     "nsuri": "http://www.pieris.com/20221231",
     "xbrltype": "stringItemType"
    },
    "pirs_statement-statement-note-6-property-and-equipment-net-property-and-equipment-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 6 - Property and Equipment, Net - Property and Equipment (Details)"
       }
      }
     },
     "localname": "statement-statement-note-6-property-and-equipment-net-property-and-equipment-details",
     "nsuri": "http://www.pieris.com/20221231",
     "xbrltype": "stringItemType"
    },
    "pirs_statement-statement-note-6-property-and-equipment-net-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 6 - Property and Equipment, Net"
       }
      }
     },
     "localname": "statement-statement-note-6-property-and-equipment-net-tables",
     "nsuri": "http://www.pieris.com/20221231",
     "xbrltype": "stringItemType"
    },
    "pirs_statement-statement-note-7-accrued-expenses-accrued-expenses-and-other-current-liabilities-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 7 - Accrued Expenses - Accrued Expenses and Other Current Liabilities (Details)"
       }
      }
     },
     "localname": "statement-statement-note-7-accrued-expenses-accrued-expenses-and-other-current-liabilities-details",
     "nsuri": "http://www.pieris.com/20221231",
     "xbrltype": "stringItemType"
    },
    "pirs_statement-statement-note-7-accrued-expenses-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 7 - Accrued Expenses"
       }
      }
     },
     "localname": "statement-statement-note-7-accrued-expenses-tables",
     "nsuri": "http://www.pieris.com/20221231",
     "xbrltype": "stringItemType"
    },
    "pirs_statement-statement-note-8-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 8 - Income Tax - Schedule of Deferred Tax Assets and Liabilities (Details)"
       }
      }
     },
     "localname": "statement-statement-note-8-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details",
     "nsuri": "http://www.pieris.com/20221231",
     "xbrltype": "stringItemType"
    },
    "pirs_statement-statement-note-8-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 8 - Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details)"
       }
      }
     },
     "localname": "statement-statement-note-8-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details",
     "nsuri": "http://www.pieris.com/20221231",
     "xbrltype": "stringItemType"
    },
    "pirs_statement-statement-note-8-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 8 - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)"
       }
      }
     },
     "localname": "statement-statement-note-8-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details",
     "nsuri": "http://www.pieris.com/20221231",
     "xbrltype": "stringItemType"
    },
    "pirs_statement-statement-note-8-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 8 - Income Taxes - Schedule of Income Before Income Tax Domestic and Foreign (Details)"
       }
      }
     },
     "localname": "statement-statement-note-8-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details",
     "nsuri": "http://www.pieris.com/20221231",
     "xbrltype": "stringItemType"
    },
    "pirs_statement-statement-note-8-income-taxes-summary-of-income-tax-contingencies-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 8 - Income Taxes - Summary of Income Tax Contingencies (Details)"
       }
      }
     },
     "localname": "statement-statement-note-8-income-taxes-summary-of-income-tax-contingencies-details",
     "nsuri": "http://www.pieris.com/20221231",
     "xbrltype": "stringItemType"
    },
    "pirs_statement-statement-note-8-income-taxes-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 8 - Income Taxes"
       }
      }
     },
     "localname": "statement-statement-note-8-income-taxes-tables",
     "nsuri": "http://www.pieris.com/20221231",
     "xbrltype": "stringItemType"
    },
    "pirs_statement-statement-significant-accounting-policies-policies": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies"
       }
      }
     },
     "localname": "statement-statement-significant-accounting-policies-policies",
     "nsuri": "http://www.pieris.com/20221231",
     "xbrltype": "stringItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r173",
      "r174",
      "r270",
      "r276",
      "r516",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-disaggregation-of-revenue-details",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-potential-milestone-payments-received-details"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r257",
      "r258",
      "r259",
      "r260",
      "r327",
      "r479",
      "r491",
      "r512",
      "r513",
      "r528",
      "r536",
      "r543",
      "r586",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-schedule-of-sharebased-payment-award-stock-options-details",
      "http://www.pieris.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-property-plant-and-equipment-useful-lives-details",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-investments-details",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r257",
      "r258",
      "r259",
      "r260",
      "r327",
      "r479",
      "r491",
      "r512",
      "r513",
      "r528",
      "r536",
      "r543",
      "r586",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-schedule-of-sharebased-payment-award-stock-options-details",
      "http://www.pieris.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-property-plant-and-equipment-useful-lives-details",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-investments-details"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r229",
      "r481",
      "r529",
      "r541",
      "r582",
      "r583",
      "r588",
      "r646"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r229",
      "r481",
      "r529",
      "r541",
      "r582",
      "r583",
      "r588",
      "r646"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r257",
      "r258",
      "r259",
      "r260",
      "r320",
      "r327",
      "r355",
      "r356",
      "r357",
      "r455",
      "r479",
      "r491",
      "r512",
      "r513",
      "r528",
      "r536",
      "r543",
      "r581",
      "r586",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-schedule-of-sharebased-payment-award-stock-options-details",
      "http://www.pieris.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-property-plant-and-equipment-useful-lives-details",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-investments-details",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r257",
      "r258",
      "r259",
      "r260",
      "r320",
      "r327",
      "r355",
      "r356",
      "r357",
      "r455",
      "r479",
      "r491",
      "r512",
      "r513",
      "r528",
      "r536",
      "r543",
      "r581",
      "r586",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-schedule-of-sharebased-payment-award-stock-options-details",
      "http://www.pieris.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-property-plant-and-equipment-useful-lives-details",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-investments-details",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r173",
      "r174",
      "r270",
      "r276",
      "r517",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-disaggregation-of-revenue-details",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-potential-milestone-payments-received-details"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r230",
      "r231",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r530",
      "r542",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-13-leases",
      "http://www.pieris.com/20221231/role/statement-note-13-leases-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r230",
      "r231",
      "r498",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r530",
      "r542",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-13-leases",
      "http://www.pieris.com/20221231/role/statement-note-13-leases-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r572",
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans",
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-stock-options-activity-details"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans",
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-stock-options-activity-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201409Member": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2014-09 Revenue from Contracts with Customers (Topic 606).",
        "label": "Accounting Standards Update 2014-09 [Member]"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201409Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-7-accrued-expenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r11",
      "r540"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r233",
      "r234"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r62",
      "r141"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-note-6-property-and-equipment-net-property-and-equipment-details": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
        "negatedLabel": "Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-6-property-and-equipment-net-property-and-equipment-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r23",
      "r24",
      "r25",
      "r148",
      "r487",
      "r496",
      "r497"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r22",
      "r25",
      "r102",
      "r447",
      "r492",
      "r493",
      "r560",
      "r561",
      "r562",
      "r568",
      "r569",
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r6",
      "r540"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r364",
      "r365",
      "r366",
      "r568",
      "r569",
      "r570",
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis": {
     "auth_ref": [
      "r178",
      "r179",
      "r180",
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of change in accounting principle. Excludes change from amendment to accounting standards.",
        "label": "Change in Accounting Principle, Type [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForChangeInAccountingPrincipleAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r82",
      "r83",
      "r328"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Stock based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r67",
      "r71"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Stock issuance costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-parentheticals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r359"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based payment arrangement expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-schedule-of-employee-service-sharebased-compensation-costs-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-10-net-loss-per-share-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of a real estate property.",
        "label": "us-gaap_AreaOfRealEstateProperty",
        "terseLabel": "Area of Real Estate Property (Square Foot)"
       }
      }
     },
     "localname": "AreaOfRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-13-leases-details-textual"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-potential-milestone-payments-received-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r531",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-Backed Securities [Member]"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-cash-equivalents-and-investments-carried-at-fair-value-details",
      "http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-investments-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r110",
      "r121",
      "r143",
      "r169",
      "r214",
      "r223",
      "r227",
      "r242",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r405",
      "r407",
      "r415",
      "r540",
      "r584",
      "r585",
      "r636"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "us-gaap_Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r137",
      "r149",
      "r169",
      "r242",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r405",
      "r407",
      "r415",
      "r540",
      "r584",
      "r585",
      "r636"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "us-gaap_AssetsCurrent",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r56"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-investments-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r57"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
        "negatedLabel": "Unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-investments-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r239",
      "r249"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-investments-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r55",
      "r238",
      "r249",
      "r482"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-cash-equivalents-and-investments-carried-at-fair-value-details",
      "http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-investments-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r330",
      "r331",
      "r332",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans",
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-schedule-of-sharebased-payment-award-stock-options-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-7-accrued-expenses-accrued-expenses-and-other-current-liabilities-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r104",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-7-accrued-expenses-accrued-expenses-and-other-current-liabilities-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r402",
      "r534",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-1-corporate-information-",
      "http://www.pieris.com/20221231/role/statement-note-1-corporate-information-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r100",
      "r101",
      "r402",
      "r534",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-1-corporate-information-",
      "http://www.pieris.com/20221231/role/statement-note-1-corporate-information-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired",
        "terseLabel": "Business Acquisition, Percentage of Voting Interests Acquired"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-1-corporate-information-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r43",
      "r44",
      "r45"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Property and equipment included in accounts payable"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostAmortization": {
     "auth_ref": [
      "r254"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.",
        "label": "us-gaap_CapitalizedContractCostAmortization",
        "terseLabel": "Capitalized Contract Cost, Amortization"
       }
      }
     },
     "localname": "CapitalizedContractCostAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostGross": {
     "auth_ref": [
      "r580"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.",
        "label": "us-gaap_CapitalizedContractCostGross",
        "terseLabel": "Capitalized Contract Cost, Gross"
       }
      }
     },
     "localname": "CapitalizedContractCostGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostNet": {
     "auth_ref": [
      "r253"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.",
        "label": "us-gaap_CapitalizedContractCostNet",
        "terseLabel": "Capitalized Contract Cost, Net, Total"
       }
      }
     },
     "localname": "CapitalizedContractCostNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r41",
      "r139",
      "r515"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Money market funds, included in cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-cash-equivalents-and-investments-carried-at-fair-value-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).",
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]"
       }
      }
     },
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r559"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "us-gaap_CashCashEquivalentsAndShortTermInvestments",
        "terseLabel": "Cash, Cash Equivalents, and Short-Term Investments, Total"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-1-corporate-information-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r36",
      "r41",
      "r46"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r36",
      "r108"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleMember": {
     "auth_ref": [
      "r178",
      "r179",
      "r180",
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in accounting principle. Excludes change from amendment to accounting standards.",
        "label": "Change in Accounting Principle, Type [Domain]"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r144",
      "r145",
      "r146",
      "r169",
      "r191",
      "r192",
      "r194",
      "r196",
      "r203",
      "r204",
      "r242",
      "r261",
      "r263",
      "r264",
      "r265",
      "r268",
      "r269",
      "r274",
      "r275",
      "r278",
      "r282",
      "r290",
      "r415",
      "r514",
      "r553",
      "r565",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
        "terseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.",
        "label": "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
        "terseLabel": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-potential-milestone-payments-received-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r16",
      "r115",
      "r125"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "auth_ref": [
      "r66",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
        "terseLabel": "Common Stock, Capital Shares Reserved for Future Issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r568",
      "r569",
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows-parentheticals",
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par Value (in dollars per share)",
        "terseLabel": "Common Stock, Par or Stated Value Per Share (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized (in shares)",
        "terseLabel": "Common Stock, Shares Authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued (in shares)",
        "terseLabel": "Common Stock, Shares, Issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r5",
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding (in shares)",
        "terseLabel": "Common Stock, Shares, Outstanding, Ending Balance (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r5",
      "r540"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock, $0.001 par value per share, 300,000,000 shares authorized and 74,519,103 and 72,222,661 shares issued and outstanding at December 21, 2022 and 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r26",
      "r154",
      "r156",
      "r162",
      "r483",
      "r488"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "us-gaap_ComprehensiveIncomeNetOfTax",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-property-plant-and-equipment-useful-lives-details",
      "http://www.pieris.com/20221231/role/statement-note-6-property-and-equipment-net-property-and-equipment-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r118",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r293",
      "r295",
      "r315"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "us-gaap_ContractWithCustomerAssetNet",
        "terseLabel": "Contract with Customer, Asset, after Allowance for Credit Loss, Total"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r293",
      "r294",
      "r315"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "us-gaap_ContractWithCustomerLiability",
        "terseLabel": "Contract with Customer, Liability, Total"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r293",
      "r294",
      "r315"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred revenues, current portion",
        "terseLabel": "Contract with Customer, Liability, Current"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r293",
      "r294",
      "r315"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Deferred revenue, net of current portion",
        "terseLabel": "Contract with Customer, Liability, Noncurrent"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r316"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "us-gaap_ContractWithCustomerLiabilityRevenueRecognized",
        "terseLabel": "Contract with Customer, Liability, Revenue Recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractsReceivableClaimsAndUncertainAmounts": {
     "auth_ref": [
      "r134",
      "r147"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of billed or unbilled claims or other similar items subject to uncertainty concerning their determination or ultimate realization under long-term contracts.",
        "label": "milestone"
       }
      }
     },
     "localname": "ContractsReceivableClaimsAndUncertainAmounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-potential-milestone-payments-received-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockByUniqueDescriptionAxis": {
     "auth_ref": [
      "r43",
      "r44",
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by description of stock conversions.",
        "label": "Stock Conversion Description [Axis]"
       }
      }
     },
     "localname": "ConversionOfStockByUniqueDescriptionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConversionOfStockNameDomain": {
     "auth_ref": [
      "r43",
      "r44",
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The unique name of a noncash or part noncash stock conversion.",
        "label": "Conversion of Stock, Name [Domain]"
       }
      }
     },
     "localname": "ConversionOfStockNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "auth_ref": [
      "r43",
      "r44",
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "us-gaap_ConversionOfStockSharesConverted1",
        "negatedLabel": "Issuance of common stock resulting from conversion of preferred stock (in shares)",
        "terseLabel": "Conversion of Stock, Shares Converted (in shares)"
       }
      }
     },
     "localname": "ConversionOfStockSharesConverted1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "auth_ref": [
      "r43",
      "r44",
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Issuance of common stock resulting from conversion of preferred stock (in shares)",
        "terseLabel": "Conversion of Stock, Shares Issued (in shares)"
       }
      }
     },
     "localname": "ConversionOfStockSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r3",
      "r4",
      "r68",
      "r69",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion",
        "terseLabel": "Convertible Preferred Stock, Shares Issued upon Conversion (in shares)"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-cash-equivalents-and-investments-carried-at-fair-value-details",
      "http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-investments-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r567",
      "r621",
      "r623"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r567",
      "r621"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Foreign, tax expense"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r98",
      "r386",
      "r394",
      "r567"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "us-gaap_CurrentIncomeTaxExpenseBenefit",
        "totalLabel": "Total current"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r567",
      "r621",
      "r623"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details": {
       "order": 0.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature": {
     "auth_ref": [
      "r70"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.",
        "label": "us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature",
        "terseLabel": "Debt Instrument, Convertible, Beneficial Conversion Feature"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleBeneficialConversionFeature",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": {
     "auth_ref": [
      "r574"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss",
        "terseLabel": "Debt Securities, Available-for-Sale, Realized Gain (Loss), Total"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r567",
      "r622",
      "r623"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Federal, deferred"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r98",
      "r567",
      "r622"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Foreign, deferred"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r39",
      "r98",
      "r387",
      "r393",
      "r394",
      "r567"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "us-gaap_DeferredIncomeTaxExpenseBenefit",
        "totalLabel": "Total deferred"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r1",
      "r2",
      "r111",
      "r119",
      "r380"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-note-8-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "us-gaap_DeferredIncomeTaxLiabilities",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-8-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r567",
      "r622",
      "r623"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "State, deferred"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r381"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-note-8-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "us-gaap_DeferredTaxAssetsGross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-8-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r619"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-note-8-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "us-gaap_DeferredTaxAssetsNet",
        "totalLabel": "Net deferred tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-8-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r96",
      "r620"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-note-8-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-8-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r94",
      "r96",
      "r620"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-note-8-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "R&amp;D Credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-8-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": {
     "auth_ref": [
      "r96",
      "r620"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-note-8-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.",
        "label": "Share-based awards compensation, tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-8-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses": {
     "auth_ref": [
      "r96",
      "r620"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-note-8-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from unrealized losses on foreign currency transactions.",
        "label": "Unrealized foreign currency"
       }
      }
     },
     "localname": "DeferredTaxAssetsUnrealizedCurrencyLosses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-8-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r382"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-note-8-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "us-gaap_DeferredTaxAssetsValuationAllowance",
        "negatedLabel": "Less: valuation allowance:"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-8-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesDeferredExpense": {
     "auth_ref": [
      "r96",
      "r620"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-note-8-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from capitalized costs.",
        "label": "us-gaap_DeferredTaxLiabilitiesDeferredExpense",
        "negatedLabel": "Accrued expenses"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesDeferredExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-8-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r39",
      "r60"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "us-gaap_Depreciation",
        "terseLabel": "Depreciation, Total"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-6-property-and-equipment-net-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r39",
      "r212"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r329",
      "r360",
      "r361",
      "r363",
      "r368",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DisclosureTextBlockAbstract",
        "terseLabel": "Notes to Financial Statements"
       }
      }
     },
     "localname": "DisclosureTextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-1-corporate-information-",
      "http://www.pieris.com/20221231/role/statement-note-10-net-loss-per-share",
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans",
      "http://www.pieris.com/20221231/role/statement-note-12-license-agreement",
      "http://www.pieris.com/20221231/role/statement-note-13-leases",
      "http://www.pieris.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-",
      "http://www.pieris.com/20221231/role/statement-note-4-grant-income",
      "http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments",
      "http://www.pieris.com/20221231/role/statement-note-6-property-and-equipment-net",
      "http://www.pieris.com/20221231/role/statement-note-7-accrued-expenses",
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes",
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per share"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r163",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r190",
      "r191",
      "r194",
      "r195",
      "r196",
      "r200",
      "r412",
      "r413",
      "r484",
      "r489",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Basic and diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of common shares outstanding"
       }
      }
     },
     "localname": "EarningsPerShareBasicOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r48",
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r197",
      "r198",
      "r199",
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-10-net-loss-per-share"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r630"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of exchange rate change on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r373"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
        "totalLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r171",
      "r373",
      "r396"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Federal income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r617",
      "r624"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r617",
      "r624"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Foreign rate differential"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "auth_ref": [
      "r617",
      "r624"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.",
        "label": "Permanent items"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r617",
      "r624"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.",
        "label": "Share-based awards compensation, tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r617",
      "r624"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details": {
       "order": 0.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r617",
      "r624"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "State tax, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "auth_ref": [
      "r617",
      "r624"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-note-7-accrued-expenses-accrued-expenses-and-other-current-liabilities-details": {
       "order": 6.0,
       "parentTag": "pirs_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Compensation expense"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-7-accrued-expenses-accrued-expenses-and-other-current-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r362"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
        "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
        "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-schedule-of-sharebased-payment-award-stock-options-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans",
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-schedule-of-sharebased-payment-award-stock-options-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r67",
      "r135",
      "r158",
      "r159",
      "r160",
      "r175",
      "r176",
      "r177",
      "r179",
      "r187",
      "r189",
      "r202",
      "r243",
      "r292",
      "r364",
      "r365",
      "r366",
      "r389",
      "r390",
      "r411",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r447",
      "r492",
      "r493",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows-parentheticals",
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r271",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r414",
      "r452",
      "r453",
      "r454",
      "r526",
      "r527",
      "r531",
      "r532",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-cash-equivalents-and-investments-carried-at-fair-value-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r271",
      "r321",
      "r326",
      "r414",
      "r452",
      "r531",
      "r532",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-cash-equivalents-and-investments-carried-at-fair-value-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r271",
      "r321",
      "r326",
      "r414",
      "r453",
      "r526",
      "r527",
      "r531",
      "r532",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-cash-equivalents-and-investments-carried-at-fair-value-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r271",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r414",
      "r454",
      "r526",
      "r527",
      "r531",
      "r532",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-cash-equivalents-and-investments-carried-at-fair-value-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r271",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r452",
      "r453",
      "r454",
      "r526",
      "r527",
      "r531",
      "r532",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-cash-equivalents-and-investments-carried-at-fair-value-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r106",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r240",
      "r241",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r250",
      "r251",
      "r252",
      "r273",
      "r288",
      "r409",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r525",
      "r576",
      "r577",
      "r578",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-cash-equivalents-and-investments-carried-at-fair-value-details",
      "http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-investments-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes",
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignGovernmentDebtSecuritiesMember": {
     "auth_ref": [
      "r590",
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt security issued by government not domiciled in United States of America (US).",
        "label": "Debt Security, Government, Non-US [Member]"
       }
      }
     },
     "localname": "ForeignGovernmentDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-cash-equivalents-and-investments-carried-at-fair-value-details",
      "http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-investments-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-schedule-of-employee-service-sharebased-compensation-costs-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GovernmentAssistanceAmount": {
     "auth_ref": [
      "r429"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of government assistance recognized.",
        "label": "Grant income"
       }
      }
     },
     "localname": "GovernmentAssistanceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GovernmentAssistancePolicyTextBlock": {
     "auth_ref": [
      "r428",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for government assistance.",
        "label": "Government Assistance [Policy Text Block]"
       }
      }
     },
     "localname": "GovernmentAssistancePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GovernmentAssistanceTextBlock": {
     "auth_ref": [
      "r427",
      "r430",
      "r431",
      "r432",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for government assistance.",
        "label": "Government Assistance [Text Block]"
       }
      }
     },
     "localname": "GovernmentAssistanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-4-grant-income"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GrantsReceivable": {
     "auth_ref": [
      "r557"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.",
        "label": "us-gaap_GrantsReceivable",
        "terseLabel": "Grants Receivable"
       }
      }
     },
     "localname": "GrantsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-4-grant-income-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r59",
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r170",
      "r395"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Domestic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r27",
      "r109",
      "r116",
      "r128",
      "r214",
      "r222",
      "r226",
      "r228",
      "r485",
      "r524"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r170",
      "r395"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r255",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-schedule-of-employee-service-sharebased-compensation-costs-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-schedule-of-employee-service-sharebased-compensation-costs-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes",
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes",
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of taxing authority.",
        "label": "Income Tax Authority, Name [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes",
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority, Name [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes",
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r171",
      "r374",
      "r378",
      "r385",
      "r391",
      "r397",
      "r399",
      "r400",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r172",
      "r188",
      "r189",
      "r213",
      "r372",
      "r392",
      "r398",
      "r490"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "us-gaap_IncomeTaxExpenseBenefit",
        "totalLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r157",
      "r370",
      "r371",
      "r378",
      "r379",
      "r384",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.",
        "label": "us-gaap_IncreaseDecreaseInAccountsPayableTrade",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "us-gaap_IncreaseDecreaseInAccountsReceivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r564"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
        "verboseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r480",
      "r564"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "us-gaap_IncreaseDecreaseInContractWithCustomerLiability",
        "terseLabel": "Increase (Decrease) in Contract with Customer, Liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r519"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
        "negatedTerseLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.",
        "label": "Internal Revenue Service (IRS) [Member]"
       }
      }
     },
     "localname": "InternalRevenueServiceIRSMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes",
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-13-leases",
      "http://www.pieris.com/20221231/role/statement-note-13-leases-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-13-leases",
      "http://www.pieris.com/20221231/role/statement-note-13-leases-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r444",
      "r539"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-note-13-leases-operating-lease-costs-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "us-gaap_LeaseCost",
        "totalLabel": "Total lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-13-leases-operating-lease-costs-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-13-leases-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-6-property-and-equipment-net-property-and-equipment-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-13-leases-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r445"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-note-13-leases-maturities-of-operating-lease-liabilities-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
        "totalLabel": "Total undiscounted lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-13-leases-maturities-of-operating-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r445"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-note-13-leases-maturities-of-operating-lease-liabilities-details": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-13-leases-maturities-of-operating-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r445"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-note-13-leases-maturities-of-operating-lease-liabilities-details": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-13-leases-maturities-of-operating-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r445"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-note-13-leases-maturities-of-operating-lease-liabilities-details": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-13-leases-maturities-of-operating-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r445"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-note-13-leases-maturities-of-operating-lease-liabilities-details": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-13-leases-maturities-of-operating-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r445"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-note-13-leases-maturities-of-operating-lease-liabilities-details": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-13-leases-maturities-of-operating-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r445"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-note-13-leases-maturities-of-operating-lease-liabilities-details": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-13-leases-maturities-of-operating-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r445"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
        "negatedLabel": "Less: present value adjustment"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-13-leases-maturities-of-operating-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "us-gaap_LesseeOperatingLeaseRenewalTerm",
        "terseLabel": "Lessee, Operating Lease, Renewal Term (Month)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-13-leases-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "us-gaap_LesseeOperatingLeaseTermOfContract",
        "terseLabel": "Lessee, Operating Lease, Term of Contract (Year)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-13-leases-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-13-leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r13",
      "r169",
      "r242",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r406",
      "r407",
      "r408",
      "r415",
      "r523",
      "r584",
      "r636",
      "r637"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "us-gaap_Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r10",
      "r112",
      "r123",
      "r540",
      "r566",
      "r579",
      "r629"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "us-gaap_LiabilitiesAndStockholdersEquity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r15",
      "r138",
      "r169",
      "r242",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r406",
      "r407",
      "r408",
      "r415",
      "r540",
      "r584",
      "r636",
      "r637"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "us-gaap_LiabilitiesCurrent",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-cash-equivalents-and-investments-carried-at-fair-value-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r166"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r166"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r36",
      "r37",
      "r40"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r28",
      "r40",
      "r117",
      "r127",
      "r136",
      "r153",
      "r155",
      "r160",
      "r169",
      "r178",
      "r182",
      "r183",
      "r184",
      "r185",
      "r188",
      "r189",
      "r193",
      "r214",
      "r222",
      "r226",
      "r228",
      "r242",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r413",
      "r415",
      "r524",
      "r584"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": {
       "order": 0.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss",
        "terseLabel": "Net Income (Loss) Attributable to Parent, Total",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity",
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss",
      "http://www.pieris.com/20221231/role/statement-note-1-corporate-information-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income (expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-property-plant-and-equipment-useful-lives-details",
      "http://www.pieris.com/20221231/role/statement-note-6-property-and-equipment-net-property-and-equipment-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OpenTaxYear": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax year that remains open to examination under enacted tax laws, in YYYY format.",
        "label": "us-gaap_OpenTaxYear",
        "terseLabel": "Open Tax Year"
       }
      }
     },
     "localname": "OpenTaxYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-details-textual"
     ],
     "xbrltype": "gYearListItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "us-gaap_OperatingExpenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r214",
      "r222",
      "r226",
      "r228",
      "r524"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "us-gaap_OperatingIncomeLoss",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r439",
      "r539"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-note-13-leases-operating-lease-costs-details": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating lease costs"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-13-leases-operating-lease-costs-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r436"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-13-leases-maturities-of-operating-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r436"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-note-7-accrued-expenses-accrued-expenses-and-other-current-liabilities-details": {
       "order": 1.0,
       "parentTag": "pirs_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-7-accrued-expenses-accrued-expenses-and-other-current-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r436"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r437",
      "r441"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "us-gaap_OperatingLeasePayments",
        "terseLabel": "Operating Lease, Payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-13-leases-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r443",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-13-leases-operating-lease-costs-details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r442",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Weighted-average remaining lease term (years) (Year)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-13-leases-operating-lease-costs-details"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r94"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "us-gaap_OperatingLossCarryforwards",
        "terseLabel": "Operating Loss Carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-1-corporate-information-"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-note-7-accrued-expenses-accrued-expenses-and-other-current-liabilities-details": {
       "order": 2.0,
       "parentTag": "pirs_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other current liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-7-accrued-expenses-accrued-expenses-and-other-current-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r142"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r21",
      "r23",
      "r416",
      "r417",
      "r418"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Foreign currency translation"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r150",
      "r151",
      "r152"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "Unrealized (loss) gain on available-for-sale securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r20"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive (loss) income:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r150",
      "r152"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "Unrealized loss on investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "us-gaap_OtherNoncashIncomeExpense",
        "negatedLabel": "Other non-cash transactions"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other income"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PartnersCapitalAccountUnitsSoldInPrivatePlacement": {
     "auth_ref": [
      "r71",
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of units sold in a private placement of each class of partners' capital account. Units represent shares of ownership of the general, limited, and preferred partners.",
        "label": "us-gaap_PartnersCapitalAccountUnitsSoldInPrivatePlacement",
        "terseLabel": "Partners' Capital Account, Units, Sold in Private Placement (in shares)"
       }
      }
     },
     "localname": "PartnersCapitalAccountUnitsSoldInPrivatePlacement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r35"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "us-gaap_PaymentsOfStockIssuanceCosts",
        "terseLabel": "Stock issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows-parentheticals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "us-gaap_PaymentsToAcquireInvestments",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans",
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-stock-options-activity-details",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans",
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-stock-options-activity-details",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PolicyTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PolicyTextBlockAbstract",
        "terseLabel": "Accounting Policies"
       }
      }
     },
     "localname": "PolicyTextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r4",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par Value (in dollars per share)",
        "terseLabel": "Preferred Stock, Par or Stated Value Per Share (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized (in shares)",
        "terseLabel": "Preferred Stock, Shares Authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r4",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued (in shares)",
        "terseLabel": "Preferred Stock, Shares Issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding (in shares)",
        "terseLabel": "Preferred Stock, Shares Outstanding, Ending Balance (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r4",
      "r540"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Convertible preferred stock, $0.001 par value per share, 10,000,000 shares authorized and 15,617 shares issued and outstanding at December 21, 2022 and 2021"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r559"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity",
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-parentheticals",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from issuance of common stock resulting from ATM sales, net of $1.2 million in transaction costs",
        "terseLabel": "Proceeds from Issuance of Common Stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.",
        "label": "us-gaap_ProceedsFromIssuanceOfPrivatePlacement",
        "terseLabel": "Proceeds from Issuance of Private Placement"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r54",
      "r164",
      "r165"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from maturity of investments"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r34",
      "r81"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r563"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from exercise of warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-13-leases",
      "http://www.pieris.com/20221231/role/statement-note-13-leases-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-property-plant-and-equipment-useful-lives-details",
      "http://www.pieris.com/20221231/role/statement-note-6-property-and-equipment-net-property-and-equipment-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r65",
      "r500",
      "r501",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-6-property-and-equipment-net"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r61",
      "r140"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-note-6-property-and-equipment-net-property-and-equipment-details": {
       "order": 0.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, cost"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-6-property-and-equipment-net-property-and-equipment-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r63",
      "r124",
      "r486",
      "r540"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.pieris.com/20221231/role/statement-note-6-property-and-equipment-net-property-and-equipment-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets",
      "http://www.pieris.com/20221231/role/statement-note-6-property-and-equipment-net-property-and-equipment-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r63",
      "r500",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-6-property-and-equipment-net-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-13-leases",
      "http://www.pieris.com/20221231/role/statement-note-13-leases-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-property-plant-and-equipment-useful-lives-details",
      "http://www.pieris.com/20221231/role/statement-note-6-property-and-equipment-net-property-and-equipment-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property and equipment, useful life (Year)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-property-plant-and-equipment-useful-lives-details"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RealizedInvestmentGainsLosses": {
     "auth_ref": [
      "r129"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment.",
        "label": "us-gaap_RealizedInvestmentGainsLosses",
        "negatedLabel": "Realized investment gains"
       }
      }
     },
     "localname": "RealizedInvestmentGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesFromStockholderMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Category of equity that is due from owners or affiliates of the reporting entity (including due from officers or directors) resulting from the sale of stock before the cash payment is received.",
        "label": "Receivables from Stockholder [Member]"
       }
      }
     },
     "localname": "ReceivablesFromStockholderMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r86",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-potential-milestone-payments-received-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned": {
     "auth_ref": [
      "r85",
      "r87"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.",
        "label": "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Compensation Earned"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r86",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-potential-milestone-payments-received-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r84",
      "r130",
      "r644"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-schedule-of-employee-service-sharebased-compensation-costs-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r7",
      "r71",
      "r122",
      "r495",
      "r497",
      "r540"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit",
        "terseLabel": "Retained Earnings (Accumulated Deficit), Total"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets",
      "http://www.pieris.com/20221231/role/statement-note-1-corporate-information-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r135",
      "r175",
      "r176",
      "r177",
      "r179",
      "r187",
      "r189",
      "r243",
      "r364",
      "r365",
      "r366",
      "r389",
      "r390",
      "r411",
      "r492",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer": {
     "auth_ref": [
      "r403",
      "r625"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": {
       "order": 0.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.",
        "label": "Collaboration revenue"
       }
      }
     },
     "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r210",
      "r211",
      "r221",
      "r224",
      "r225",
      "r229",
      "r230",
      "r232",
      "r313",
      "r314",
      "r481"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax",
        "terseLabel": "Revenue from Contract with Customer, Excluding Assessed Tax"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r210",
      "r211",
      "r221",
      "r224",
      "r225",
      "r229",
      "r230",
      "r232",
      "r313",
      "r314",
      "r481"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Customer revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r319",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r303",
      "r304",
      "r317",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r302"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "us-gaap_RevenueRemainingPerformanceObligation",
        "terseLabel": "Revenue, Remaining Performance Obligation, Amount"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r161",
      "r169",
      "r210",
      "r211",
      "r221",
      "r224",
      "r225",
      "r229",
      "r230",
      "r232",
      "r242",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r415",
      "r485",
      "r584"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Total revenue",
        "terseLabel": "Revenues, Total",
        "totalLabel": "Total revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-disaggregation-of-revenue-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "us-gaap_SaleOfStockConsiderationReceivedOnTransaction",
        "terseLabel": "Sale of Stock, Consideration Received on Transaction"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.",
        "label": "us-gaap_SaleOfStockConsiderationReceivedPerTransaction",
        "terseLabel": "Sale of Stock, Consideration Received Per Transaction"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedPerTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows-parentheticals",
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity",
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-parentheticals",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction",
        "terseLabel": "Sale of Stock, Number of Shares Issued in Transaction (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "us-gaap_SaleOfStockPricePerShare",
        "terseLabel": "Sale of Stock, Price Per Share (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-7-accrued-expenses-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r74",
      "r75",
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecurityDeposit": {
     "auth_ref": [
      "r554"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.",
        "label": "us-gaap_SecurityDeposit",
        "terseLabel": "Security Deposit"
       }
      }
     },
     "localname": "SecurityDeposit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-13-leases-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [
      "r555",
      "r556",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A preferred stock.",
        "label": "Series A Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "auth_ref": [
      "r555",
      "r556",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B preferred stock.",
        "label": "Series B Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesBPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "auth_ref": [
      "r555",
      "r556",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series C preferred stock.",
        "label": "Series C Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesCPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesDPreferredStockMember": {
     "auth_ref": [
      "r555",
      "r556",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series D preferred stock.",
        "label": "Series D Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesDPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesEPreferredStockMember": {
     "auth_ref": [
      "r555",
      "r556",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series E preferred stock.",
        "label": "Series E Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesEPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "us-gaap_ShareBasedCompensation",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-schedule-of-sharebased-payment-award-stock-options-details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Expected volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-schedule-of-sharebased-payment-award-stock-options-details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Expected volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-schedule-of-sharebased-payment-award-stock-options-details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-schedule-of-sharebased-payment-award-stock-options-details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-schedule-of-sharebased-payment-award-stock-options-details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Exercisable, balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-stock-options-activity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Exercisable, exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-stock-options-activity-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r349"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Exercised, intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-stock-options-activity-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Canceled, balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-stock-options-activity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Canceled, exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-stock-options-activity-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Granted, balance (in shares)",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-stock-options-activity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r80"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
        "periodEndLabel": "Outstanding, intrinsic value",
        "periodStartLabel": "Outstanding, intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-stock-options-activity-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r334",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
        "periodEndLabel": "Outstanding, balance (in shares)",
        "periodStartLabel": "Outstanding, balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-stock-options-activity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r334",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
        "periodEndLabel": "Outstanding, exercise price (in dollars per share)",
        "periodStartLabel": "Outstanding, exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-stock-options-activity-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r351"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Exercisable, intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-stock-options-activity-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r350"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Vested or expected to vest, intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-stock-options-activity-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Vested or expected to vest, balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-stock-options-activity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Vested or expected to vest, exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-stock-options-activity-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r330",
      "r331",
      "r332",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans",
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-schedule-of-sharebased-payment-award-stock-options-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Exercised, exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-stock-options-activity-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Granted, exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-stock-options-activity-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r333",
      "r352",
      "r353",
      "r354",
      "r355",
      "r358",
      "r367",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Expected term (in years) (Year)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-schedule-of-sharebased-payment-award-stock-options-details"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Outstanding, contractual life (Year)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-stock-options-activity-details"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Vested or expected to vest, contractual life (Year)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-stock-options-activity-details"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of options vested.",
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "us-gaap_SharesIssuedPricePerShare",
        "terseLabel": "Shares Issued, Price Per Share (in dollars per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "us-gaap_SharesOutstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r113",
      "r114",
      "r120",
      "r558"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r47",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes",
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r144",
      "r145",
      "r146",
      "r169",
      "r191",
      "r192",
      "r194",
      "r196",
      "r203",
      "r204",
      "r242",
      "r261",
      "r263",
      "r264",
      "r265",
      "r268",
      "r269",
      "r274",
      "r275",
      "r278",
      "r282",
      "r290",
      "r415",
      "r514",
      "r553",
      "r565",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r19",
      "r67",
      "r135",
      "r158",
      "r159",
      "r160",
      "r175",
      "r176",
      "r177",
      "r179",
      "r187",
      "r189",
      "r202",
      "r243",
      "r292",
      "r364",
      "r365",
      "r366",
      "r389",
      "r390",
      "r411",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r447",
      "r492",
      "r493",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows-parentheticals",
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets",
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows-parentheticals",
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity",
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-parentheticals",
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss",
      "http://www.pieris.com/20221231/role/statement-note-1-corporate-information-",
      "http://www.pieris.com/20221231/role/statement-note-1-corporate-information-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-10-net-loss-per-share",
      "http://www.pieris.com/20221231/role/statement-note-10-net-loss-per-share-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans",
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-schedule-of-employee-service-sharebased-compensation-costs-details",
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-schedule-of-sharebased-payment-award-stock-options-details",
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-stock-options-activity-details",
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-tables",
      "http://www.pieris.com/20221231/role/statement-note-12-license-agreement",
      "http://www.pieris.com/20221231/role/statement-note-13-leases",
      "http://www.pieris.com/20221231/role/statement-note-13-leases-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-13-leases-maturities-of-operating-lease-liabilities-details",
      "http://www.pieris.com/20221231/role/statement-note-13-leases-operating-lease-costs-details",
      "http://www.pieris.com/20221231/role/statement-note-13-leases-tables",
      "http://www.pieris.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://www.pieris.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-property-plant-and-equipment-useful-lives-details",
      "http://www.pieris.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-disaggregation-of-revenue-details",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-potential-milestone-payments-received-details",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-tables",
      "http://www.pieris.com/20221231/role/statement-note-4-grant-income",
      "http://www.pieris.com/20221231/role/statement-note-4-grant-income-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments",
      "http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-cash-equivalents-and-investments-carried-at-fair-value-details",
      "http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-investments-details",
      "http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-tables",
      "http://www.pieris.com/20221231/role/statement-note-6-property-and-equipment-net",
      "http://www.pieris.com/20221231/role/statement-note-6-property-and-equipment-net-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-6-property-and-equipment-net-property-and-equipment-details",
      "http://www.pieris.com/20221231/role/statement-note-6-property-and-equipment-net-tables",
      "http://www.pieris.com/20221231/role/statement-note-7-accrued-expenses",
      "http://www.pieris.com/20221231/role/statement-note-7-accrued-expenses-accrued-expenses-and-other-current-liabilities-details",
      "http://www.pieris.com/20221231/role/statement-note-7-accrued-expenses-tables",
      "http://www.pieris.com/20221231/role/statement-note-8-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details",
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes",
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details",
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details",
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details",
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-summary-of-income-tax-contingencies-details",
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-tables",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual",
      "http://www.pieris.com/20221231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r175",
      "r176",
      "r177",
      "r202",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets",
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows-parentheticals",
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity",
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-parentheticals",
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss",
      "http://www.pieris.com/20221231/role/statement-note-1-corporate-information-",
      "http://www.pieris.com/20221231/role/statement-note-1-corporate-information-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-10-net-loss-per-share",
      "http://www.pieris.com/20221231/role/statement-note-10-net-loss-per-share-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans",
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-schedule-of-employee-service-sharebased-compensation-costs-details",
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-schedule-of-sharebased-payment-award-stock-options-details",
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-stock-options-activity-details",
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-tables",
      "http://www.pieris.com/20221231/role/statement-note-12-license-agreement",
      "http://www.pieris.com/20221231/role/statement-note-13-leases",
      "http://www.pieris.com/20221231/role/statement-note-13-leases-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-13-leases-maturities-of-operating-lease-liabilities-details",
      "http://www.pieris.com/20221231/role/statement-note-13-leases-operating-lease-costs-details",
      "http://www.pieris.com/20221231/role/statement-note-13-leases-tables",
      "http://www.pieris.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://www.pieris.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-property-plant-and-equipment-useful-lives-details",
      "http://www.pieris.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-disaggregation-of-revenue-details",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-potential-milestone-payments-received-details",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-tables",
      "http://www.pieris.com/20221231/role/statement-note-4-grant-income",
      "http://www.pieris.com/20221231/role/statement-note-4-grant-income-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments",
      "http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-cash-equivalents-and-investments-carried-at-fair-value-details",
      "http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-investments-details",
      "http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-tables",
      "http://www.pieris.com/20221231/role/statement-note-6-property-and-equipment-net",
      "http://www.pieris.com/20221231/role/statement-note-6-property-and-equipment-net-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-6-property-and-equipment-net-property-and-equipment-details",
      "http://www.pieris.com/20221231/role/statement-note-6-property-and-equipment-net-tables",
      "http://www.pieris.com/20221231/role/statement-note-7-accrued-expenses",
      "http://www.pieris.com/20221231/role/statement-note-7-accrued-expenses-accrued-expenses-and-other-current-liabilities-details",
      "http://www.pieris.com/20221231/role/statement-note-7-accrued-expenses-tables",
      "http://www.pieris.com/20221231/role/statement-note-8-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details",
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes",
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details",
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details",
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details",
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-summary-of-income-tax-contingencies-details",
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-tables",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual",
      "http://www.pieris.com/20221231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r18",
      "r67",
      "r68",
      "r71",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Issuance of common stock resulting from conversion of stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": {
     "auth_ref": [
      "r4",
      "r5",
      "r67",
      "r68",
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).",
        "label": "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits",
        "terseLabel": "Stock Issued During Period, Shares, Conversion of Units (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfUnits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r4",
      "r5",
      "r67",
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Issuance of common stock resulting from purchase of employee stock purchase plan shares (in shares)",
        "terseLabel": "Stock Issued During Period, Shares, Employee Stock Purchase Plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity",
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r4",
      "r5",
      "r67",
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Issuance of common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r4",
      "r5",
      "r67",
      "r71",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Issuance of common stock resulting from exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity",
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-stock-options-activity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r19",
      "r67",
      "r71"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Issuance of common stock resulting from conversion of preferred stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r4",
      "r5",
      "r67",
      "r71"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Issuance of common stock resulting from purchase of employee stock purchase plan shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r4",
      "r5",
      "r67",
      "r71"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Issuance of common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r19",
      "r67",
      "r71"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Issuance of common stock resulting from exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r5",
      "r8",
      "r9",
      "r53",
      "r540",
      "r566",
      "r579",
      "r629"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "us-gaap_StockholdersEquity",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets",
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r73",
      "r168",
      "r275",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r286",
      "r287",
      "r289",
      "r292",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r425",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r425",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r425",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows-parentheticals",
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity",
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-parentheticals",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity",
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": {
     "auth_ref": [
      "r89",
      "r91",
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Summary of Income Tax Contingencies [Table Text Block]"
       }
      }
     },
     "localname": "SummaryOfIncomeTaxContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental cash flow disclosures:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_TableTextBlock",
        "terseLabel": "Notes Tables"
       }
      }
     },
     "localname": "TableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-11-stock-and-employee-benefit-plans-tables",
      "http://www.pieris.com/20221231/role/statement-note-13-leases-tables",
      "http://www.pieris.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-tables",
      "http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-tables",
      "http://www.pieris.com/20221231/role/statement-note-6-property-and-equipment-net-tables",
      "http://www.pieris.com/20221231/role/statement-note-7-accrued-expenses-tables",
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-tables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes",
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes",
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TenantImprovements": {
     "auth_ref": [
      "r126"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.",
        "label": "us-gaap_TenantImprovements",
        "terseLabel": "Tenant Improvements"
       }
      }
     },
     "localname": "TenantImprovements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-13-leases-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r131",
      "r132",
      "r133",
      "r235",
      "r236",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransactionDomain": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement between buyer and seller for the exchange of financial instruments.",
        "label": "Transaction [Domain]"
       }
      }
     },
     "localname": "TransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransactionTypeAxis": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments.",
        "label": "Transaction Type [Axis]"
       }
      }
     },
     "localname": "TransactionTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r240",
      "r241",
      "r273",
      "r288",
      "r409",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r576",
      "r577",
      "r578",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-cash-equivalents-and-investments-carried-at-fair-value-details",
      "http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-investments-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-potential-milestone-payments-received-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r521",
      "r531",
      "r533",
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-cash-equivalents-and-investments-carried-at-fair-value-details",
      "http://www.pieris.com/20221231/role/statement-note-5-cash-cash-equivalents-and-investments-investments-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r39"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment.",
        "label": "Net unrealized loss on investments"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r369",
      "r377"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "us-gaap_UnrecognizedTaxBenefits",
        "periodEndLabel": "Unrecognized tax benefits at December 31, 2022",
        "periodStartLabel": "Unrecognized tax benefits at December 31, 2021"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-summary-of-income-tax-contingencies-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation": {
     "auth_ref": [
      "r618"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from foreign currency translation.",
        "label": "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation",
        "negatedLabel": "Currency translation adjustment"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-summary-of-income-tax-contingencies-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r375"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
        "terseLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UpFrontPaymentArrangementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Category of deferred revenue by arrangement wherein all amount due is received from customer before delivery of goods or services, and revenue will be recognized upon customer acceptance of delivered goods or services.",
        "label": "Up-front Payment Arrangement [Member]"
       }
      }
     },
     "localname": "UpFrontPaymentArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-",
      "http://www.pieris.com/20221231/role/statement-note-3-revenue-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r50",
      "r51",
      "r52",
      "r205",
      "r206",
      "r208",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r383"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount",
        "terseLabel": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-8-income-taxes-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r440",
      "r539"
     ],
     "calculation": {
      "http://www.pieris.com/20221231/role/statement-note-13-leases-operating-lease-costs-details": {
       "order": 0.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable lease costs (1)"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-13-leases-operating-lease-costs-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "us-gaap_WarrantsAndRightsOutstandingTerm",
        "terseLabel": "Warrants and Rights Outstanding, Term (Year)"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r190",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Basic and diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pieris.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 10
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(f))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.3(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991585-234733",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(c)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a-c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905575&loc=SL49131252-203054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905575&loc=SL49131252-203054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=126928961&loc=SL5834089-161433",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28129-110885",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30304-110892",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342832&loc=SL128342943-244231",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342832&loc=SL128342943-244231",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342832&loc=SL128342943-244231",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342832&loc=SL128342950-244231",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342832&loc=SL128342950-244231",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342832&loc=SL128342950-244231",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342832&loc=SL128342950-244231",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342832&loc=SL128342957-244231",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r544": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r545": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r546": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r547": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r548": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r549": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r551": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r552": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905575&loc=SL49131252-203054",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r648": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r649": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r651": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r652": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r653": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r654": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.F)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187171-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>91
<FILENAME>0001437749-23-008834-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-23-008834-xbrl.zip
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M_XG7FR(.%KXC)!;WP, LNS0,BR:X72<Q<<MU8=(._DP;L^2I0./7/+1WT/[
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MFO./#/9V+(%=J=!&)08?PQN(J%C$(_& <IR[M],W#?O<66AI=XHJ34$Z0 S
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MDJLB<:\9P,1'5KJ"-D4;/7B&Q$5/RDCA2OUWA=2!2=T[X&J3H'4=G&51].B
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M>]1BZ$1-;4Z=C'LF?2E;^3KK"*^^!O#O#.0X V#!,("7 51(>OCH,X">V+[
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ML)1_@L?ZI6!)3<1JM'7^O:8(> @#^(B)4M^UN(_*'U%KHAS5CCW^(LLWXX8
M=^FGHF[GSB;D0S$M5^SF8"UWD)4*Y6?O=4;])#A,SAF %U6(D$+UB1T-KKM
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M8%&"&:'+JG*!4W++L#,Z19^=7CFC6K,L!R.U6M)+9$MMGITTC>ZC:IG\H#"
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M.@>,&[.5+/SF;/+5SG*%X^[V;,&* DSB=%.[?Y&RW_&^].N?'?BT&]VJ65Z
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MB<:6[.H=0(1XT)$$Y"U5+CE>)<=Y4; -F(/(WZL+5+EV;S1=R0]D>F8^.0,
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M"+"*G%DDZ] 56)/@HE8WP=K\X0HKD)$HJ$J*&9 BWC C77F9X7_8DTQ^4%Z
M_%$/]]L$OO%#F"L^ET 'ZUP-^/>DYF(2K0YV.6L>.1$Q>UJ5:N598"[R+N\3
MQH5!8TZ9^./+?5X*[CVD Y[\HHNRY*_:^+ O\'[P1%\GC2:R97P43W/H.M*H
M.->P!_6UT1X^+W<'?LGM?.+?TF59 02%GW"3J*,(= $*^#T"A"B/V_F(?@T.
MR:@ A]=+S25[3 A)M8Y#D_WO%3H?/91)LVIH"#:1HD\2_3Z9?)'N[79Z:Q<]
MO+4$)NB2-6W?]W#29.J1T\2KNGGKW8G^<FG%]J\"D.__J-T=/T,)E?-1]@#2
MPYKT0+8F^_$96_>FNYM)K(/>ZK%NIA-Z41\[>>UY;+_8U%>2I5N749YQRC,X
M"R91V(.(M9GC:7_&)Q_381JHN Y.=LX -[:A79#]./ [$/Y:+FQW'8X/=3G4
M!>W]JR7[,_HUO,-S*B7FE0"D- -W?6:3')2J2^ 9S@!O3\B62+B #"2]S@#6
M9&PG(XZG^[NYT"U:XBN\,XU7STPN/F;4K7#MBR$>'W&WDAY16Z*K(;I,L7=_
MGRJS%YK;1)[+*]!N*9-=]&SN#,42YDAPOXIDVJO.2V0/)HBT<9&=P_O/ 0S*
MG":5IP]H^P@V->LZN;P[XOY)@H.<*G$G]=;=4[S'&?$0;+E(3JK'H"_A+8V%
MZBURIS:&]/ 3/9!8B:AC&8[1]3A84QVL/!VV="_C N:TSAY"K,T[ [3*0<J1
MISP3LR#2'VMD*66O>]2174A)4F6-[P3HO@WN5:SDCI"W%:?L$.T\7_@6AJH!
M6IZ!EW(\U"=[P-2 *V> 'TYDQ4G4!YXWZI'%Y_*W^%#&/E[2Z[8L82[WH&J:
M 3LCF6+;G*HK?TD2N9D#)N8,SJJ2!X?<DTQ84^U_#1?H'RT(&?K?<PG\;L,9
M,9:VA"=!_ L[1ALU9./C";(&G:@C?\"(5 /H8T^R,?SXCZ9\<A/E>1/X<]^$
M&O'CWMOL+:[AOT9ZC=0%(X_TVS/ /X=:[U"/_ ,I 53__(%C]<-RT.WZPT-B
M8<"A,R@76@]KE87]MTYEDM6*W,\DX.Z_7K:=+-]S0DVBL7V-WE)*/P-@P_[*
M=*>ZC7>99X=37W-6H#4,9 UZT,@4R_Z2\7W9GFAUR&VP/#V5*2D?/3LI@N>U
M;4;_ON,2B9D+W9*8A8R+^Y15BA7!FF48OYX!G@=^<5 T2GG>6-.7;ONI="L#
MM_U[JA,2HDCV@0)0:B(#]@\?VY;SL[O@8\W7&)W9-LVF\.#FH]:.)6KZ(]G/
M\,CV4'NGS();%(]YYTJS<J?LQ8Z-#$>9RIUHRXV[) <>7J=]*=-KA!R'1Z*Q
M?XJ,S1R^P]6GW\'9$AD99IER2]2OFB5_'?"0$]_]]>*FZO72CZ*;F2EDTS3/
M"1X#DV+ML< SP(5*),E"AVJ14]UQ]R?:]-3G/X=$ XUUKM[,*Z$ERI.%244*
M_.N1KHB*I\0$FK%"NH[GKM-H,] \%^C\K;987A+QO]2B'EV>!-J-$WD'.EK0
M. ,L#;L3)/UP[8.@^QZ]#@N:B1X.C:$"X]4EI'L68VM[9H'I_=E?:!]\[@8^
M=SR@)MU>/8UW/P/PB9]/6:@X^://R.IP .TBCV27EN)%LEE1C#\#=!<U^T@H
MF"J8B] ;M&!BXU5BCNT:'U@'(.HU:'6H;A[7FY9/5+X<H:O#OY7!4)U 42<)
MH-GIF3$=V,^GI$NPF;2_9T#=H3XW2=<6*_"/_N<>W$\#;1B8F?1AR:8!JI.Z
MK#BVGV.AU'TM?0&H<6H!PKI -HO))D7LWVQ'%-DD[$&[D'^9%%IR\_AY<S&X
M^(MN']/ZRN+FZ'%1>8^UL^-!+GIVZ@PP9H!>N3=S@:P#[.KG A(CW1X[C5<[
M WQ.#;C\MW8;Y-@9[VW8E ;2=AKR5P[*OEN#(&Q)UX9//_<1%T?/I^$:N;\Y
M(*PS<C,/MG(/_=?[_A*X4;FJ *;Q(S&.H'L&\$L9#6="FZ'G.2%CJN?CS_U?
MXW\NUW5H%^C?IUGQ6#:HM(<8Y3@>K5F^'HA'CKJ<3SQ=X-Z_W11$_MUU4A=9
M:3ZG$/\Y&PW,"]J-PSI(</2KO8PQ_SGD:7@*A!339OEV90FDL4BZ[ /M:\Z@
MK ?FKIU\85N*3OQJ,FZZKF/5.71'C8[>8[R'C'@>M-"%K*M*#-]H=27B]%_"
M6&!82W9?7K)!;8/^FC9WQN."?WH52A_K-JHD3*O1]K'G$[K#26DP1QC^'G)3
M9!XR03MO&U$/)MC[Q,VYP(DF)9W>\Q8,FOBZ+#M':\\?=BE7;CW,FPP<8TVR
MJ7?! +$JY <36Z>>L"/I25/C1Q]+Y\#\,BA0%!=;72S/!LI44_?1X=HC8)\%
M(X&,WZZ?GV1A!.M?E2)Q(J_"=N\"L7-(_%WO4ZX@V-PXENQI[NA0S7+^__?^
MOWLO#(+&.L9@B#?R9VW/*W$>W!K:V,.A9X-@6 VL]&G%!/E-H\&@X^OHYZ#9
MA)D+C4S0GHQOU>\":+'@]M!Y8 LG,T&)P-[*:U0Y')VUO"ZEUT>*<PB[F"I\
M-P44HS(C8M_-QT.QRO]W *>UH&#O&(4?QBTTP2I"WR[A5.'$9UEXN98W6HR5
MXWEE/@E5;]0%+BK[<@2;EP'H5>^]E;O>_??6(R.H,O_OT*UAM%E1IA]ZR\[P
M)"^H>"UE)-6C;JZVK%;SH[7Y@=&3QT -; 9>H(_X-?^0'/*56Y^O5_8]O0-C
MU,AL']XW(C(X*@TZ0271$:B/V=\'B=>L[Z$6U1X*VSR];'4DQ"W"N;&B4^-P
M@CFT[A<F @F\/AF&J(C-DP1$T3BBH05)+*^^QGWI4%B/!_<#^6F^Y$D(1-9I
M;,@!A&>"8VL(5*&^WB/N?FXI]?:EMKO#T#M$?WQG<8 +/LP75F!?E1(XV>+V
M^*IU"#1@\4!0VQUOE.8 I:K'"<-]Q90$JYEXK8K>]UR19I7H;SC,+=K00C@P
MAVZM__XDF];TJ)V4A#$]FL'S+J7#$3XMK2F<*X>7AC%ASYG8G*HJ9*JJ:CZI
M(:-F;\0^#\C$=>XC(Q#AT09!*UF7'.SM2HD9D^C9C%\&;]ZTM[7<V/<FU(K-
M$E(W>JEU'-T&GOQJ;/X2E>.)?'6:"KVKZCH?QK4^O%,Z,-5J%TI[&\.R$K=E
M67$&N,1Y^@&A2.4PFM(0@N#*HBGMX_.&R$HN>+C=7Y\+)W;O?CO^=MUQP5\S
M6?"N1637C\,%QOW?');4H&Z# ,6!C3+\E,98*(U-0M%Q88/N-EII?2<<2'-
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M[RKFD>J4K&^#B->OJ#J\Y35Y<<\CC6:)@9828E?C[9X0PV774UV=ZB2&[8^
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MA<7EZ4%1.O/@<K@<<A\DLOF(M.,L@V%%3L!^KP2]^9I0.U-X/"4O:<LQ]5+
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M>@-8GH JFYVYCOPHP2K?/G:M=B<F--=J 11JNEVIZ;L/^9#(7%9HT-@H64J
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MT=?724*GT?(6+W+6@=0>>V]N,UO-\W"YA(H(_5ED\W[VE9-P9I'T$L3JNC(
M:D7^P U% :( 9,*]A8LC=!;<E'$MX.GW>EQCHF3#[)]),&O5G&[;BTY['6/5
M-=&.N?0<SGRL%'&0W!FLH9G*.1W:DM0OB2OTY<6[(%N+J'3' Q8.D._))BD(
M5@EN^G@&L#\#W A0P (W1^<@%/AR,U;MW(69T),(?%#SZ*=6[\M,)/"T:L,G
MTD[>$F#QK>,.',]_T#)^3HB%V:EG'UN29_D&']?79BN3$:?'E1[/%UB-/EA7
M..Z!XC@%?KP78%D,!5H':Z2%NFOHSV5,? )=/41^2-EY6T^''3C2':[LWD@S
ML58)7Y-\YWRA,RJ4582D%4"8*Q[^G/D]J84^Z#O-$F'OH#A=$/?G27V<$K6:
MD#.GB15O(84=* VJF?2<_^72YKKZ^*GX8-EIVX=6W:Q0O;PJ620'Z5?UM&**
M^NVA";6R9 WUBS+&V/K,BV[JY'ADV-+]Q1Q57?J>OHGPO6!V?QE._2HIVYH^
MQ L\4J6^;F A9,J]ZLG5_(LG(]6AE865Y/ G%S'<_UZK9++F-CB/*N"=91O-
M-8Z[["\VD;DE 9_WKO[N<:EHU75Z[,[W&CFAM^XR)G<8C.UKP:.N2#B:16S
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MS!T96'+:2DQ1:%*>E,NS/H\1_,GO/?A4="N *$JA\<8)88#8OX+E7X38A5-
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M+[XM[L]Z9G?$P .^UV=X+11M[X:SN,8E;2B86<!LBI8PM$ELQV:I!%=W6'F
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M#1G6K!>3"$6FFEM".]=Z]Z73]E';9,/Z8;-EMGVJHL$WFVVSMVX@GJ"-H4Y
MZA2X2HA=LOGAMA$^2/(-]S7^*RG:?)<1\3LJ^'_VGQ "T'Q0PE7>.&S3'P^&
M,,A^9 [&FF-<NON!@4+_G_SU,Q523KR0$M3#/&4G]A7T2#T']2/+H;^9@1E+
M6&(R+[6!OL!36G7_X>'[K^Y#$@2M08C#JB4?9$5B;NP">O>0\":Z\RW:3_>[
M 1F#!1!U")YUY=K>I/^E2L/&!?RH](!1V0T6QE-2("+-NG0'B66>#-,@F]O
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M3,C=Q%5YD0NG8P)//6@V[F].KYWVU@U4\91,<S%6Z++OB5A<UZ^9:X):!F=
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MU[I'G_C)L#W7]9RW&][G518W9M1M!?0F3?&F88=1K@)N&6-@>A '4!?'HN4
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M'H16-#9\&2+QN[%ZS]!^6073Y3F%<P\/#DR/]7=)*OR9EQ&F>7O[*7EKK7@
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M+C% LTOQ&]?*9AFH;B_5)SRDS^ZK4-QGG+I7DQTW3<WSI#DTN=O#(<Z4_.-
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M;:8L#^/?.KAY;F745TK%P_U(:ON.=;LCMQ#S']8?T5$X_T[N =B<MK$%6(?
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MS;Z6^.:RO:K[@Y-N!3ON<ORR!]M\T:?#4+1\EHX/LD9DD4P-BFG0':AWRH/
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M@+WUF0'Q!&Z,8)CP^^5FEJXBN.'LB[Z2/DUP;NM_4? YW(GS@^,= P6:&]Q
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MT4*!Z,:*D:]$19VR?O70+)>B,MO//KND72XO?;AR\I+S1E(^+Q_PQ@M!3<%
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M^X<OT2<D^G8C8T-D(X 1,62Q#2]I%2$(_&C;9O.(NU$<MD!EJ+X:-1S$QI_
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M%/\;1W-6FZ6@2@IKQY!Y\+%</:<#R:HY0,ZH*GF_,EEE<$R=G<*55(3)YH8
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M8*9W%;$R2Y8A[(4;8^X#4\XJ/&WA"32H3H1,*(UM'"F84=$$<3DV(SY<"1A
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ML=Q&\;[=[<-5^H,2*(?V9@R/51E*;W1Z!W(K 05].VFN$/:A*_UA>T/K#9F
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M91=5\HW]I$_9W5-,O@Q OA5K_7$S# Q:I;'#EIJVLONUM4?^3=1LPVE0H)1
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M^^#U2\/&LEK1H1'^AV;.UPWJ&5V\1]-XZ_Y<44D@>:'].#O)A"L@=OL<1:6
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M'48S.&5CQF[DHH2L!1D?C[,))K%A3F-Z?5C: 0'7>]GC_V2*$RX_5Y>2/E*
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M6+X?!8]US4#Y/^[VIDZ)C9!5,(MM. @2*0R1ZJ43#ER<F;1NM;=GOAV8^]"
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MJ]X#O+YIV66>.C&!9!6&U'[IHS42M2&J83-4E^L?=MY@>P"6.]L8^TU6O++
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M72@)*)SL[X9L$:(%7?F!S*&(@FO5Z<KW\P\_[*K'WF,;<TYS7Y*$V(JXOE-
MXBT@IPQ[9GC#QK2WW5626?S\+1P3V=K<M8],*&YNLF==_%@Q/)C<#YY\LF2!
M-.8)M3 @+#R@P_C+2F%\,]P!B9MH0./KA.H5'R,.84[#A(!(*\;\Z,^&O_86
M\?9S;F,:X?D6"GCMHIIKW>;J2FF4[]UX'=T_'E,L3I#I)VX$#@Q 6'#&=>(,
M5)AS88#C%50.1#HPWR7HH*@+4H-H]P]^EI+I]QV>Y0<,L@<)M8@6RCY>SPY(
M"7=RRA'@==UF"G9!I P3.M/.SS7"_!E4,Q^5&Q859'-;?V&#TP<O[I%FI'(D
MPEB! )31Q.I@D L* 2+]ZT(6U: @G)8(D\*>B&QIX*F<AE]4_#:\F>9TR9,(
M=X^Y7/>U[(S>Z/U'X+$FEB,W!T7Q1QW\:\E]5T>0LW2CO]#1 PM4OBS"^[25
M.DU<9_+5TU<%ZNL][%,(EC]$]4,]_ZD0:??I9^8D[_YJP+IDZW3U4&PLU']5
M!AML$W KZS;3*\H/JZJ6?M\6B9:N:*]]]W4'A&F2N\)?$L@SLR7-J?L7( V6
M;9 DWC%F#S%FE2SMG?V=<# G)&"OS.;[!4^J6K9E6N1Q^Z>[9R.^"3KO8<YW
M*9JQSC&REHE,05MF:CSY)#+O>./@S,?!NG$A_2T]@G WNL&XO%JU6ERU[(OJ
MAU>UAVCIYA"=%^;^^):+/%E>S^,=T++A[*H8]D(C$YQ("C%-+/P3[&23%>7.
MU !P"]:*]E=*&N*/W3/BIALGEJ**I@\HW"DY6?%^\&]8F<L.J(J")I4;UX\A
M>.#7&XAE D.PE5!G,]+ZZ5:[JUYL:\,.2)"$<F.>/"'"T'0@N,?0)U0JE$'/
M#*G?W17W@X)*>!,0$.<,.P3WU2CK23U8KBO_-T[;8.39PG9X^YG0ZG$;Q5'O
M;L640O/TBT>.:W5@X6PXYSCWE<0TZ]&G$;(F9N&\TG2K47B=;DFL\D@=6@QX
M]'V[D^:O_QSI*%KQL8E][*4C_0+\WEZ!KO"97D!M!]2&'P_C":W.@,&  KTD
MJ6Y9L)5:%8>P'EF?U&Z5:D+FE(\CV0$^FJ)B-=\R.J0>^HW+=]5_7KQ^>GA2
MD=*[LG3\JW9O(V4K?'X$(H.%TBC4#!:<"8U:QMXK:8B>K9!9;5.&#ZS0/MH9
MBM5_/-Z28!+Y<"O@"[V8^Y\>5)1C .RC04$ HL/ 5+,>0!?< 9S@;[5IV:CA
M8&:S"5-<XW"AA9"K[G>-7SN@_?@6K3JH&$<6J&>PA'OEL7K50Z8J9O1<!=N^
MI?6<LUIYU*\MJ**!"OMS^?![/T]""?(]FE],DHF/Y=<AHUX\H7):[Z@#HG%0
M3^N^]1^TB58!X.E]MQ\5..J?W>%Q&O']_<FMD1")J]_73*\F'9]-UW#90OVR
M_D2!:J5DL :YN21]]M4%B-"RR<59&'!YA:0P6V'<L7U-0^^$6GV0NV/ZJ&:4
MA +>>-<]ZK];$Y[@OIM*\[^C>9U3NH!M&:8/:UR &;(?VT"9>JNF"]204D(O
M"1A;63:X/\#]@IP]1K+F'4B;@47PC@.;,R?(*CY0,1*J"@+V#0XVE6&D1O\:
MT4FN[?;ONIF<G]3CIE^W*&[]XJ=%-^H7"4SO7?K#@+?O@!C6E)C'TL1.6#+U
MR8<1CIW/ZP5YRVA)6Z97G$Z]1L_%>KC"I'Z%'-6;:OWB5^N%K_?O7YV7%L^8
MH^22-WF(G\YU>)U^_K] )=>SZ!:)KW'#A-JJ1(YQ(1#3OWJ9V9"(S\]UN/(Q
M@7D/'J<DF&YPT_:E84;$XR1YV!AA)I>P5,H^#8!ID^32AZ7\@G>09.A& ^J%
MOUW>U'4<5]'0?((M?YXDF2+XPZ%UVR&*#X\5,)8@-_\H6@QKQH#&<!SH+^B4
MOO5>46? RX5QO50O^+T/R][)A61]]$4UT6/78>?:]/'_TEQD6\YKL)!-W!<[
M(&^P\&@;TXN6= 8CLVR"(>LD.@QLH*!6F?V_# >/)' ^2^V3K*F[D/PEXNSN
M\D^-< Y_A1[9 9WY30#4"<VI@KS/T%K_2,9J*]FX@5F1..6;7123/R*SJDKO
MQ6Q*^HD;#%_)>U!8=2UI)CMDZ1-#N151B^A831C)1B>_'M9/3<X[F=.)+H$]
MW/W%>Q&)\F.VEG44)E^V3>]ZY@R^NL6O$UN,@1G_++8?8.G,R.)HI>X!TB%[
MIL<M:;W_.D'"OTU/B&C*_'6L)F)N'O=\*")P)Y]::&30T:+5RNO""T ]H'OQ
M+5989:9R<R943"]<V=4H)94F68616-,1G5HT]*_9HOK7GMX3J5C4:KZG5CFT
M)M3\XKC#H2G;Q(4<=L[XYWCC$Z8].I0PPD,,@@9^BI/F3>%,@*J'3&%8:CM!
M0B\7TBJ:[SPU?EGK9PW[<G5<"UZWZ)FSY/LG%^1 OPC,V)F22$T\"K&/\X@)
M3GW',0Z?@1Y$8&P#N\>;PL(<.TOT;BI_7CMU<JO^Z.UPSN%P*N<G-Q_J"7OR
M.&NYGCXM[<*Y +0@"WOHG35,-:)L*Z //NAS4W^#]-=)^P/*L.5LTY5GKJ$I
M/SH[C]R^F_KOGLQ<7"]TETDXVWW!@7>26Z:'B&[\V8T*H:<*^3I9/'\G=_O/
MVITVS4MKZDA/@YHO[]..E5>G23M7^_TA'K\$JUB=&Q_Y/BY[MDA=>H!I.L\M
MX1NL<0BUMIVR/PCY*>!&/X5V"Y@:Z9(I1<I_SO[O/75B_-W!.YRW]G,I<U]F
MI\IXTXA:I5CV75PO@1$))+;_Q5C#<ESZ@^Z%*U@H%E638];.QKZXQ%D&*3[:
MI7[X/AG._43296L#9NV$O5KD(Q@*76^:D0RX4W]3#6/]]9%M=)3NK'68[2/-
M4(E/+4DM:K9S&5BW!ZJ7>'UY,MS_>*=PW?A=_B87*Y$_."<'_(,T>B0O-]:3
MR1D.*<8*STD1RZJB02+O=QV5D'%T2[L4TXW2>7G>H80^LK$IJ12_ W+"([1@
ME11O@@" 8'5R,TU<9CYSX![H?(Y%OS_)I+$S)T2T^9:1GN77<\=73EM,O'IF
MZ=O'S:LD:<S GN(@#%X\?5FGW0GV-'#193?JJC'@OFOY]14\]G.'[><;5]-/
MV>#PE-:J)R%XQO55I1V0!S! )SY9#P+>;[^A_IX2ABN&M,DOMJ$4&S)0!9\*
MDY_Z#??66;C>.F-#DA-2%%PR8Q_'[@*V&"/TD7][!!"QC<1%J!1&IS78B-0H
M$XU\G7L4%3UAZ_SBFX#!X!RI_E/84Q,_YG+"L82W3:]"_*>',KB(7^=\/.:W
M"3?P+6?YBD$0X+52:J82&99MID9$9A9'(Y:,'/OU(7*9H="TF#C,OFQKN/)^
M1*3@"+8,7&'(4@;VS1#&( B \-H;9U+/U*Y@(KNHE(X3?AX?&^ Y1\L.Y:8?
M[R-^:ES:YZZ<._;'U9K-A[F6D^OXL28Z]WFY*U#>OER.L6Q_C"/2!P?T*O3K
MD<G6MY E89O1]HXK40'[:=RQ>!F!L_LBXBG_.C)5_SHR.O$\:>9EG#%3,"%(
M9[]O]=38@GQ><G%'.<Q'(%DFS:?$)A2]UV_X_<4##1UV4[,![C_33_YYC%S0
M7JWZ'?X^P=WY5;F;ND "%A^P^/MXOF"?N93(\?_O3:%_GZU5WH'0V=Y8*)B?
MX15.L_1_@#(2O;KZ;GVNKR!=([BQ*=O#^I&V:N;QY83/9J$]FO=T<YOI9"?N
M,_(9WG>H*-2KBGI@&!:1E0>N9:3&*#@PIUZ:?D3.VH^L%\?,^EUB*305_2=M
MY? Y_?+8AU?[C,M7"-1(.KAM.@:_+RCY%KUH.!(U8V<>>5.^XWUC_8>#+?;*
M0O9_K75!1^Q59G>3P*RS0!/;2#W65 6Y Q+F.-#"96G?$XL[#"BT.(X^BL:%
MMB7*7^N?LI&$FSUH]?[[X:OK^>I[NSECWZ$^.H3,N,K2'1 \SW@'M+>6F=K\
M28&5_X&Q&8430F -F0W$?-C;/XW1O<E^),2\3W6W6+JXBNRF9Z^6BM=78[OJ
M%N,'QJN1^%I9OF3_91$9/Z?WU>&CC(C)=>%7Y^JMCY/0*INFDD_&KU<9$(J%
M5!/.A=2TVTF(I7U1_V;Z9X2;8'H,UP,5)YNZZ#3;!+2Y*GQP.190CD%8,J*,
M]H^(%R55;*5;7ZET%U\KNY_1S64Y6E$MS[//\/-&4H\P1J'//PVJ91K#F8(Q
M.)F)G*H#WA4T,/@/T7Z5Y8.ZM9R=6_1?2-83\S,KX&,O$<C/SBG!,36)F03&
MZC:;=2:S'S'\N9[9Q$)PLP98+^4S$PLXQX;)1BZ8A"Y;M*@OSS #EO+KY^2E
M_LF&5S56"I,J825)"H_ZK0Z':N3.PEBKW!R*1Y4<QYPT;!*.9'R')3H5Q>@M
MZ[@R"_.4$!)7T])0TA,/O^[MD]EE:"7RP17DMZ\RH!/*N'P>TC&M4"_J0U9#
M-O#V#YO<S#M%88PR\B)5.<3NX*RF6TY(L[>6XGEZ-(^_>^]VUASO-(#Z[H
MY1["LB&3TJ&D60UDE0'7N[I^= C&US4P@I]6?J)V[2?V%$V]]M)CN7?J1GG>
M& NRNV_C!5M"?.+JP?'7B*27 [A1?.WJTLCL><&6Q[%=W?A8LO2(9MWG]4FM
M.>8M .\;;8\\[I7@K81T?\8H1('FO;]4<-7;H/M-(;C/TP?'Z9X9C-AFG@RC
MHJ."%2\V1,LPZZ^<U63U>H6<2OUV_R.J>3>;</2IVH=5:B)/R,R+V=6A)#%B
M<H()OL70KJ#!1,8!:/A\]#I:NBVTY-+<K))K*<KPN:DCT4;.9797&\KY(M.8
MMY^=#Q2P0H!;,P01X*\K8ZJ$$;(,'<WN68DN7.R;""\-GMABR0;W>(9X_=0U
MEXM5=:-&_Q?_Q7P\; =T[7I/U6)Q5PG>FV,*##".;3H#3R&M<T!($>:)+U6[
MW*W*W#3]Q_CU"A_<YA'SPV=67>T<(]*2>](UE&D6L8SR69?Y3E1P+PRPH>O$
M*ADF?!5U<!T( C8\1H:%S0[_F-8V*?=>'KF;+&-Q*&UZ_[> =K[4[@UCK.$Z
M#1%"TUVN1\(O+78(SSHP#_7I12.6@YZ[']2K1G%S6=@WD7XHEA+<^/NVJ1@_
M>8\&0@6P8(!(0TAA_CHS+4J8>=^I7<[#FGJ*ZFU]XQV^JC)\!:ZN;;"^._O]
MT>K)JQZ[[-82WDIE)FM3P_G&;3CG2.)C!&6Q9&L#/&K&"N/FF<IB[XS,< GK
MB*A&8O1J73QM9 .EWI%:N?# Q>I![)*:G/P]Q5<)2A;M9<7FD":_3*7< +8T
MH-,"%2.#$7Q@P4<Z06)B%KIA0UY-F:)FK<.G.]17EA@IGI9I$2\*@\QOI7W>
M3=H!L?Z=,>  YWTG2-:C#V$*ND;P8OI\V0%/8.Y/'3=1?0/8]X_#\JX4/E=)
MM6YX6O+LQ0W!M+@DV=$RY^PQ;L8.:"8=(D!Q6PZ#C9@8%RYF9R7HO5SY63<<
M9!.\O3!W+,]1[IZ'#ZE$W(*NZGFI0_E2!T$SJ']Q8!L1;[2X"#CBTWYF$:K5
MEVT*@8Z@9?59^Z('VUGM3_%T&^5;(VH?!E9)1MGY'QLRK@E+&+PT<B+4]'B+
M/+M>G:EB[ _%'?J/T'A<..UZJ8.59;6+<]-_)M8AR.+?AD2'Q,;O4T*J'Q J
M/>13A>]'=VD] X,D'CO,C7 DO>A=2]UA;%O.N4$3,!LZ#4CL@.B*%>UD@6$U
M9G0,4?$=XEY8K&UQVUMGTZS&,<<'1R_D;[F_-H8M!+]^D-F0JI)2W75(\WM/
MW7%%J_-/%@F^0 GK(3#&/H%UY):MRYD> #):\A29R=^RL@S3O''@2-@.*.J7
M\IZ5BV'Z;^I*Y4QQJ&*1\=/6:A=O($A;I[):_IJ&-@"];*W4<2>(E,[2%EYI
M-=[VMRXF@R?1+1.-O1QD5V?="UA2ZD3:9-NA>5J&D>SE?.S&NL-R-_LTKQMW
M',@I]9W2&B!+3V.]A]ZUW?'&'6'6Y4%BVT<.Y*#Z6?N+QC7]+A7_.?+?\T-M
M=P_$=A(4*>[3LKSA8"-<*AVV%X.8-:<D^"T5,J53HU!S3612RIR]RXGZ$Q5*
MBG]GQAN^7"[ B3]GQNV ?*:!8SP"VQ)[EQD;=Q1X68Y!7P+2(NFY$)X8=X]#
MWN*FAO^T^Z".WUQC[3=?W>KQ[ONNYY,>'3,:B(##\4WH1=CIPOZW<P"6[R0
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MAE/=,J_/]TY;M^?J\AHLA.7GMDZ>(H7SQYO,8'UD'^?H 5[\>JJ )$.: %B
M_DITI<MOJGU=E0D=<:Y24[LBKZ>/M'5 Y:'%T:V]\-U/[?0@@')(9"74'7((
MJ\DT3,3:5KA@YAT08@M&/ +*AS:&JM_?)R&'0ND!;QJBI=UN]/UW3\WY\QVB
MU/-7I!W0#+Y%D(78&.'M&L7>X&;4+]HHLZ)S:->C:9 8T[- ;D'^ !91/&6E
M^*NBE)MW^6]E@;@T,=#S0&U)]@Y(]U%A_JT>WA=$S7P7XBFB7K1B)(&LYJND
M!QBC9YH2;:"PX:#0(,6 :T->C74OWS1^/)GXUO) UX-GDT::XX<+YB/"<U@>
MW$2> J^KP:D0<I!CK!-+'\X[A[:K-^[N,SY"+>$><S28D=Q\N)J]X=TID^@X
M:9K)(S/@CEM)=LTF!Q@ZP(G8%)XBYSPWF603SK1N?829;=F4E3&0]*XFV>K/
M?=M\UH9L\'%/.'M@PL1F7J\Z[NO*A&[V]MX4T=#YY1-,P6:H"$YHD4KL$,Z5
M&6E^T/Y^H:)\/#'QW$V+_=5U</@W[:4RL1.:5T 2YEYGV0WK)Z'2O;'X^XA$
M/J]1VOC@#:G;%P795V4B@=6BE;MX=1EAM[E52>.N_7/P.6+J<I_+1/G3GY/@
M8Y9F2FO!T>%#$([$;!<$%+A*C9@V9Z0VCT_'NNHP'6*UJ^IL+.8[[5VU'?4^
M4R=Z0:<0DPT$@L&>.;$X]H6]SZGGVUC:0"W;R,6'(%E/B<:I,<@9?,FV'JA0
M'>'H",94D* >M.;RP'[7;@6XF3&WZ+3P-1==9%3+U$'84A!3F>4&E#+7Z)"G
M1O,Q)H8A!JF8H%31WWD2L9?XH\@[H21*[/31NO_AV<7/M_8^A?8+/>BZYZ+_
MJW&9AQ^9\BI(^;0#^ES Z.9'ZP5V'_N.=PA$<#TUZC&E753'X?F&#90G&:_Z
M@=$N< X[GJBE9Z5G=3:\S%8YUK<I=_:0)R>4^P+O\9=][<M;GVUHJR)\MFB%
MB"REQ&R@%:R*NX(>#5BLAJCEI9O<=-GWK;QQHBY]GTI$R/Y_QTL>^_Z283BK
M$[7QQ51M47X^FJ>T *'B_J=Y/_06FT(O&>4W#FF]ZV?]N9!6(V]^^K"<2-3A
MMME4X)A!QBPL.;OSXS](=*YEH.-(-Z=.#9H8D25^J)'#-IMD4Y2'W6M1E\XF
MC39+9%WIRDP_"=JEX H=02\^_+IL_6.*2^'K0.\8NM,52AHF*SMQ=-$)VY7/
M:V$#03L@>2O:$%/#(JGA_91*@$ZN$'H2G7[BP<<;[P2HORG(JC$VRY=)C"%)
MAC*W(2# TK9_'5A?UK8RN;T-'AOQE=-<GD^!AV1.WM&62OX >JZHD<Y]#YU)
M&2;40[K TIC6-KIK">T0[JCC^"BFX#I:T%M^<_Q8S"X_BL>'02VU[,\O+/8G
M)\2JML:HY.*I>)Z0N1>SS9%A6DJ#QLE7/=E [P7\H?O;M%9C O'2;2$EG;?S
MO>NM?:("(IZ\+#@)/_M@XOYCU7F\33<;H5S,*(DU/<C1Y6;P#DU@K_?C1#&"
MEQBO2L-IO^\/Y^>8]1<+7!0><[U6'5I$#_\V_NB7P_>5DL*_'"%FUHS*]GR[
M!C[F% "V8@JRIN)+1Y'5O85Q*/],:]'+D[LDS SF[.\61M]W"(L(^$GFE["(
ML[^S8YMUHLE@!B&UODIT85K([5/JU6$=CG'!(M-%>$R$Z!H4/53K5.FNWKTF
MH:.*N]R*K<_'SZ0I'4:/%I'%( J8Q.78]H+.V';\Z/:-/7<DA4@MQ>%9;..E
MIBR(!_M<ZF'N#BBO[.;C^DDXAVM5$PQKH/SD!^Q '30:HH VU48ZN1(86>W3
M!SE>Q>-CBT;#.56696K$W7"3 +AK%_%+0\QQLIW=HP--N@<>P839!W'?$;6$
M-D+BU)'8F8.)#,(=QE1I 4PPKMY%IZ.G<N%9KVJKN/O=D!>J[Q)_&8L?B_A=
MX!8$!F!\08_XP=%A&-+GH[#PV9ZPCA!^UNBE+IT/L1M8/Z_19HWRJ[8ZC/>J
MJR:F3%PA(R76"HL8TIM'QNPI[KV JE;5$INIX\Q$))#"@YC"MD,FQ@&T*_>(
MC,Q$FO4=O<7X8^D>@?W+^3YS:H=:FX@KG=R$HB^GTZ]W(\/9.R!XD.C *GZ-
M1SPOANMT%67H="(B'W=%\V0QAI\!E!>^R'$Q?;);H(2&E--RO[*\+.L6_N:$
MO(5%BI7T_5L?+Y[=,S\MC6O'UYL3XO1%0_A")U\O5#Q""MJ[O9)8AJQUOF--
M ^K/^K_.N3HN@BJ>?+>?53/N"0^EI5]JMZJ.K>)]GF98H2/QU7E-18MYLOWU
MY=-2WA2?A!&GH:#N\:8,D;D62XNL+X^J*9F'NSY$[TT?<UO_J?SSIYU.\%47
M!\[9O-*.).6'$X**C^T@,KX&CRVC-S0^64"-8?5UF<BWWUS]@>="#VLA!K>5
MC-<KKCVT6]6>K:Y+1\9+'+IW<\WX65F"@)7Z^SVE^J=''TYP:KE/<9J\;ZML
M1T#V)H/0++P#VC>-6:#3H0*+MS#D-GC*6 ^IIEK>V2AJS:?IS<'31VY\I'8(
M==A^ GK86L3E7,.$'%8XQ7N$ON<WF@X%KB[9RXPXW$#:-_&5,V29C@;8(E,/
MZ_X*<7]-8(?6#9M[DRDU6>V]5(HY.G)*A8&.,0DZO_QM,]:<$?XI S-I\O)R
MY@X(E?U-[K;AJE7#<Y<D,]6L8R^9&K.$I5SZ*C7OO*$-$QI!TF"6@<7&QZSH
M83K[QWM#M29NE7TI:2AXZ*.RV\K@!4)"2( N_;RYXQ902M'Y4P7LSBS#%>Z
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M$9)Z.,.U97U2V'Y0ST:CW>>A2%RI#E5SM>)G@W;'1?OH8[J[[0R*9;*G&5?
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MIS1#2LL)E5D;DUMI,'/%Q_*06LK27X8T'[*GXTV5!OBKM6QQYOK'P(PO98[
MZ_JW]9\SC^=9)U]:\%0[\3K-HM7K483>W<\7=D-'<V8@S="#F-0NL7][38>
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M2XU .MR957 Q>)\,]SYO8MR!>$],4N.^),MQS@&X'1#C-<GP-5"YLNC:CX,
MQ2A3;[TO'B3W,.-.HML'&SU#F%_?.W^SCB9OA4:=1 K#"AHUK1"H$_48'5?
M-&<1&!$==8G[K]<_%!MZE[U+/&;UJ_M4B.;-6)O**C%0E*?9*F0/3QA LK"
M5S$ ;35"^I@J]K55%!6XV 3>/[BLC%OS"E707,)YGOTN"#KPD:_YG[A^*^*;
M-XD;1:GJ?):6Q'H#=@58R]A9KZ2ZZ<,+5$*BS7!DJ0_]REW4R?-G8/5Q.5XJ
M3MTJPYN2UB+NG:IY%F;UT>&@UQ?8]08GHB+P\DKO\N!^6&4^A@<S8UNV<$<
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M83@-(KD1.E3V9(99Z#Z&Q6XX%S>7FO*(+S?V<R9$OV6TCAS-#2P[;V\GM'L
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M6]D] ;KY:Q.&P*)[2\MD#6N.:"%ON,)U?Q%J(9TB^W4L$"#4'H!6;1_ZZ28
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MZ1;W?_,_6Z;=_M<7=)-[5Q9TZ$C2GGN2>F7[@CHE? [S+TO,;-R>70Q#X&U
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M\U]O:'*9'+O<*;7O:]4QZ$Q+]B.RY.8@99HE$%R @%+].J%VG..F\S"I@.H
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MB'GV8>Q6])U;RIDWU7P]WICS/=7GNW_[>NR18(0Z:XSN4)4[\F!SV.YEN\-
MQ6>D&)%A5.4VRW"@M!:\K3-<[Y1(R/CNH6KC42:ED%@<>^6A9QOW9[6P@LOH
M5X\B:RV[UWH6S8O+3(L"-KVF/4VAT  )6^.-3Y8D,[;::N.C('XKX]LU3&F$
M^0^F.ES"AJH?%YJGWRDM/;8ZMM;A.+R611[:4*+76,C]=N.];4C\"J$X8/@1
M%ZG$)X@C)"\1DD4G6 AA0#5[DY.=9A'G-\QRE%NX))4)*<6LC:5)#J/&S2(+
M-7E<R(FKC=XR3(X%ZCNR<"Q+^4D J J$#N!#5AV06#01Q0UM<9]9^1D3N>,
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ML"">]M7!4-M+Q0W57AR5]G^L0+X.8A?#:DRTXG37,#B7#G41,OLJ'_U\!_D
ME)9,075)R_S8ID^J+%!6,[<,5_LFW4P?+(>6*C38]QUNECG]+N).&OER[&'M
MZV6-*O7$S/TEED&VU>( PG_Z^*$./,'YF:D$F,^>K%L7 <)V/E? %,>)I!'Y
MH/.F?+<4WM\,N^?X@4,95/:!Q5\P]24L9_+>L8\G+73R<L!G;!5](D<'=2UA
MMH6MJ[&,!J/PH'N/R:W:K4 +R]U\6%-WB7IC ,VX5<0P&-I6K9CE'I@/TFP?
M\@X@-M@O=0]=<#8Z/G[9-%0R<"4\PNJ/]J94..&C?I>4:0>DH01MPKO(/#>(
MU # ERG(3+(EP\NG.*#!1?S"U.8 .\VL;W'0 GI6ZS)."Y$L)_\Q:.Z=<V_D
M=\WWLQ2KT2XP@6)"+$PZ8_U?EQ'^]XN)&HOP_06($(K%RFO2:[P!6?,D_/;&
M9H_[C3?$'-UEMVE1+S]UZ>T%:)"8].AN)U()82FSZ=IZ%BFMVMBSB1W" NHE
M[3 1!F0_$V_D.T<XL>Q]=E1G77SQ<4I3V,L$XK'CG6V_)%Z[!*Y[_DIB4&'C
MJ/ET9:8:;Q>$<:R&10G+%TJ+HW@7P&(?&1#C[AC2++3WRVY+;@ DMZKLWFWE
MSMF$KGB&MV8*! )8KZ&Z"78L%$WV5AW#0UG##5"J"LA2P>Y4Z3*E>O+Q.R.Z
M'@U-39FWQ[ %J6Z3+^KE;\A8,R8AK#H3;['4*"?YK=AZD.\!J%=WSXOU.@R(
M(,-8 >RC3.P61 0.<Z54M< ^ -'D*.WK"1:A]U\LNPQWNQXV%S<0>LK.=E8^
M^O3@'P(^!*X93_YRNUHS\0)64RTBZEU3R_1JQ4;C5G=CI1L0;OEI1)>S(E)"
MXOQ$P-I]1=?"IZ#>\+NR*D<RK$#.O!T'H.09$:"^H+<<[M0Y(T-5RCWRZD_3
ML.[QM8+$> 7M4Z>N&;3);W]A\=@S2#06'D]3I)K_6WQE<V5<;&S%#\LU#<%T
M7H<FO*MC_L#IBZ#&J5:2V?VPDQ%CHUY7^T_:O>*OW/Q'JYI)L"1C3?I=QH-1
M75N1[B&X4=?$L=C]W _+^4=CVO5R\#]T?X4?-A(M3.FI]S[%?)X/K>*Q/JK[
MP2G0I@9<H#!D15@NV":V8R?62<1NU+/'\6@=&>'%<W!3JY;&C_A1C;L>'I$!
MZG_\?6>&3@J9EH'>'&/C>W[IPMUTJD7'8Y;SH$C*U=1CB1&DAF=3J<XS>P9J
M^((=S'?VNX,Q+_*U("^;B"OA\U*:-$X*+%X'&X_4H%1F=V#2]N)PK*=7*5XM
MV]^+WXN%RE3/3KK:2)B57^*<<K7F<[XLS.]@T_XV2HC.#=>VW\\'^\J@I<\T
M42PZ9R4"Q+O+0C\LMHJ.&LO[OIN!OU%\X_"I;K @22M(ZEN"1?8Y]K!I>979
MZ-/ZM@-! @QY)FS@8L9.AOMT_48SD0*)H.D_8>K#]<G%(S_@D*Y6,:IB5Q.'
M4K+-J&PS_.6;^[<D^$6,[^R4P%WFE9\A8.1*F\N#B!ND58C[8)HN)Z>ZN6IR
MA4G/MU37&DGJE[E_J5HIMIKQ)[WAFN34%0@/_M8<. W"OV4%"TUUWB'M$^-"
M@E02&!47SG2[G4IU5W62;3N"^%#S==K\/&3<8BZ_((J,&K?H0$H!FN3U.*8)
M8!09K-^)XH< $5N3>O7"(L+$L]P72VWM5G<<3<_L:FKR[:(_EI;7_^Z[GTQ]
MO#]MU9*YC^)N9<9/T @-:9@/4(B@SK1RA[3LJ"93"/Z^H[TIQ2K8]SXN8]KM
MYW0B*:+DRL9\VJZ^JM CGYOEG:47&HKII@"G%3727Q]I2$FM:I9L'Z];K$^&
MKV4Y=__\9M:Q9I3-F;)Q 4J"34C0@JCKB76:$^42FL> Z&V\&_5=^^.QE.KQ
M6E2 F\=/($*I,9E.[:9MQMWZK 4N* ;P32+=,L#I%X'2Q@ []3 O.T)K3-9$
MJG'81&0J4(;R:CG^1&A%,U!PIB'L;?G%V%X_7NWG9>)#)0%N)H1?>2P54^YE
M\(C1NK,GOZ4$$5X,RQ:/Q4]DO@P.T%L.?XQ^4$Y[T$!6>"GPTJEZUQ@1_V/4
MC@]QC;+P#*\K75T!G=#(+K(3P4BM3F\]F.R5GJ9GF<ORX=ZD31%9M GGG#G/
M&TNH8U\]_? 698#,GEH(_*8\[NOP%LWM<%?+IO2636I@!;-PCLI]01NSIG+X
M+KZ7YQV_Z^6_^+>R5(&P!6[13_XUG'VZ5M\/;C/LS@XF&W%6:)I(G;[YXP]:
MW[+#_SKF=M[4_<\+Q8JJ+ 3$[>)0342E:U^9A%B"T>2OJ(>D65:8RM<8V^K7
MMJ+B8D,OV+C7T9%Y4&C%)1TB2WIOCBFX])6P_Y%\$,7MP>*(V>W@8ROJ:W@O
M<NJ1=AK1,<+>IGR)SUUMH.?K>W,)](6CR =P 1KG*%(B@+O<'W+"=Y!ARK[J
M$XJ=]'+W7Q8:)<1[,SWM)$JYLI3$1$F6:"A.,F<;!9RVB#,VK6*.M@H\AVOL
M(XS88ZO>QG<]UN]PF,^[#2W3$ C+%'R4J'Y/^(K]GPB22N?-IM+ U]83&GO[
MO<SWZ:F_[V?MNVT15T_16:A(\Z<0HK<K'>[KJNOW2)\>8IP."/95\[;%YSS+
ME6\*#[^Q(;*N?5H9)BN^Q7L,/FD!Q!=TE?L;=K^N"GC1(-\\O);QAUV^E.=9
MM$4QTHNP,CK/XIG1IY'?D+S4^':(.+S$B<*+UE%%"\//NZI_?ZNS+'6-5.+$
M<^51YT>VB7)$X\ER[-?VUK>LET* PV29"8%Y2"K>:"X/2NII)XAZ!IA>'*R_
M(+1U&J8QUZ :@6R*++>ZGR$@CMS0\=,2[CZN;%EY)W^Q!>G F/X6D5=(]-TE
M])DN+ZD4QES\'WLD_JTH';%J>B*<9$O._I_6DLR7CMS___9[0N.L!,. I9X[
M(\^O(LS>_IV1K8^&&*K4JXI6S2==%9HJ-)/5XQ!;CC8+N;%+. "QR__[*B<,
MGL.@:G$=*#Z&(M586FRT?E;$)+?42B,36JK8_['Z4W:?JC$,MW EJ+>^IN6!
MI<E[FY>W@SW;TSQB7"J<K;5L)U;_ULL5FQW?[+L3Q2(\7/643MY=9>G#>_\R
MA00<@+K_OJ"Y ;Z_]1D>J$-^[!C 8A4,3*-TP53^G=77!R S;3/6/RVN'H#F
M=<I8K=)@CL=6L^BG_A4&0OX]BIK#?)(]".ZTK*"+1Z(&.B,J$L[V3[YF*F]S
MDF9Y7>$N5QN&ZYI5+^C;UJ"_XNKJ8V_%3;.;7;$7Y+T)*@O-XQ_HU"N<V?L^
M1CN:KK11=<K-Z?'9D'MGNW_[.K.7RO(-Z))G*5>Q24@E8/$?<P TYV%B2[.3
M,V>HX3%UTY ;!+J:,R'P4_ZT0MA&P8U4).UL4D4/* 3[('_)R%(AQ\_U7:I-
M<_/1ZPZ]"OE/>+89X\ZYS]XH-H7MOAN]MO27+0A-:VTYDX>+7[VGJUKQ16U5
MKJEEDI8XI.BFH9>B03NB_N2!]AN>\V5;^]Y$MYJTI>]DB8J .$?7._SF^X_/
MGK\ MI8;J5QHRA==B+.J3$KT<>$:O"\F\<1 3#)EN[BXHU=H"\+M"MR?L RA
M2ZB;<"@&S!C!A173I[+"3UT\^CK-2EZ!ONFY$(ORPQX&Y+N)WHJ#" &2E$RG
MR^?*[C+?HLG)&;O\YM]7>()G\R.'0R%HIE1#/75HL3*"K.Y$F@H,S5.V;H#F
M_BV"/GPHR2$C\1O^VNVZ=#BO^[).OU6HE,;,G)F:'%GGI<69U71]T(..6JZY
MM.ZLKZ1??5<;(8N>V 0D!]RTR_M<-56XC 3F#D3*#G5/7KBV;AL'[;MY7/[.
MA^)LT17X*L1P>9;B.A _(]%*?;8CS0[TZL<BV"NF_S:M)U4:G](=2R[I#Z1K
MB!6GU$8\Q.!)9]DO',+:[A>C[F/9F=]8-L<X14YNEN$':H9[)BK?HTET&-?B
M@D/3J(;&[8@"OK?R9WHE)!<$ZVJR(Y%&47,[."R),!5YI'U(^&O5\ @J<IG)
M$AM_QYIX<KDS4RO_G6M-($7/**:IN'R\ 0*QOQ7%2K(TRMQ;;_;]XE9Y*/)X
M?37+/!A1)/KY;:,!+GBM6;;E2%=N0U=3JH+$W1C4ESN)KTT113%=D3Y3Y5>^
MMS6\59A[[(1<^Y WG92U)Y67MSHZHA=6[34;1+_:*_K?3:'NGRD<4_F!T/<A
MI?(3;8?5@D+V#;N%</7UN$N2>E25]L*WAVY<_/Q9M.L1JE9S58 T,#$PYQ*/
ME(/;8CTZ6E5PT J!\$-QMY^.\_P"A_\Q=<,($.YAXL'LK89P$5)^(UG5U3B4
M*AY1\&/+OU9WA*R2[Y(Y^NAVPIFS/(#CU&$[P;J?5=GZ#!$*9QN8FV$:50&$
MM[4*_M"-LGP1'O5^\:S[E)= K\;?@ESE-P)[1#,4B:[N2!LCD[^/D?]TO5Y]
MGZ'HA[OK6)R>H&CE>$F>+=K"&E]S_P9XIDI@SF*5F[0^8=0^D84E->"A7LJ>
MH\;@\TWQO:BZQ9V,\:E;=HIL/SYR_T@1UPSOVT>YOVUXT^-LK'M3%S?2E8JA
MQ731[C:=5,DK9)<[!TS7\5MZSBM5(^41W)3P;ITZ%DFWZS YXV5R2?WC:-T7
MF'$\V\G>/ZI!!B"JE]Q,U09&\S4N[%M*^O(!B/C!3@IA$?]Y[/'5V?''8Q]S
M&LJ@Q:5#J[:#./J5IT<[/X'5./(&E,V\ RHOA>FNZOS<HENNKI+B9D3M+00=
MGJ1WO[VI KH).GOVV(4*D3;(<6--RMBZ_2?*0MR6U.%YYY=V44JY)5W^.VG:
M<2\+HW_=V0@>V<OY"NC2K\##YRO@.#H'%DQ.(J[A]<LD$A#/<<ZDJ[E6]-YX
MT?MQY?[@NH5XO,,\(6%&8OC6*#84%<=Q;P_/Y\[O2S<K;8J]:;"_Z/]E+IR<
MK<?"2:^V[IEUS'RD1-- NPPG@.Y^C$K89JGHQ_1.=^O5FE$-': (7WL J@H^
ME^U=4B ZT%B&E&6H4(A=>6(ALT) N"E5(S^#PYEXHSII0^CA8/N7HB-KQP)[
MXO$/H56 MAU10ZYQL'*;T[4JQ3"'TVW5^'.1Q;GJ74GA$]?S)9+&H)F'7E$$
M?6N[CXJ[3\=4TE\ODJ3.PX/I,G3##KK4+;K^SZL<-(BJZ 8#'_237>)A2EBY
M#$^K(  E"6<J84@0GK\F8A\_O1I0;,CT$7KSR/)AMF_J1?7N<Y$^0PWW0B.]
M'-DRQLB<K^[8+RHXLCL[O3EYZ>^#!U&I#P] @F!_& ]#EKKSA&'T09<<".;3
M-:C+4^@Z!&?\K?1M0FD1GEYY0%#^U&72>D]]1QY?^ F#/@!);\F,U\YA$A$H
MLFF8,9ADPZ&K^J<^^?O+]AB%0C0^*C:D8>9T#>9:=5/ / [MR$&[I9TPX;C<
M>/W.1F>8Y##GLH]Y$C:\S,P'IC!\KH/KC+>55'11X#&KVW 0SQ]6#;-U\7&$
MN^MQ#P!<IZ.7'OIA6<"$YR,W,UI<!&R-5(>3/;)SM;8GZZ^(<KU4T-_6_9CB
M[WM)"=.EZ2^ EW=21LH?_6]ON3SR L!1:]O^Y>6[(%T[#^'W;Q4:4FI*Z](,
MM:FKQP7\^OYEI_%(<-!YL55/7H:QTYP$%[8;%@<_ %4G$5DZ$YM!F%N4\%]#
MS;UV7E:#*J H;_S'G>TO[19O'R-@8"M&YR)J679#8)%0(C-TAR'_&6M48,@D
MOLB<A.YB_#J,Y38#M<O+'VVT$L$5+ EZ5!#@B#D B623WJ&FNECZNXM8B-
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M']Z2$5UL6HCVI9O@2*EVUM"@^U]]3@Q((B\I@',E5,V_='F>;5N.&:YG'H"
M!\LP(\2 9ZFU%F.Y ^6G":B(Q(,#-%--%"A',<^0\H!/9S[?L.QHJ"O>K$!"
M],-\7O5AG=SQ*S6@[]5OM*[<[3Y[C3<:/%>&XD&@YE<EKN(^4HLQ\0R'#[TL
M?@4T;%[)T.1=;DJYMQ0TUSB@F'-:2"K3T?RR4&*W#11FUW,[(A,[N36R9VFU
MZ103AT6WGD9.,64I,EV:$R^L1G2C>#N0,H ^:99K:>):Z83DQ)NL@5)%TJ<
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MPSU2Q2TKS4G8-\-FU>]F/F5RR(KO\$ZHTEX/H_PNR%MD+%RDAB>%0O@@*+^
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M.C7.]6#+A/MX+9C?T=*K!1'LHMJ8$8A\I&QS_IN[R/UOP3T]^&I3I@BT6U8
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M\2-$-8$R.JM5#(7YOX[)7$@&S<Q'Z8G=29MX5U.[&QWJOSL%Z47?C[/[8WS
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M)[H/89]KO8]/%#-M 8G-@V4X!F;%SPP#T!\!0H!WMZPH[6E2T2\?\W*XOUV
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MTK+@*GW7'_LYZDV\,8OTSEQ9]\?%*_#A1)) )CQ>@U/W0(&M/>U8WQK=HK4
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M02,2?H^G4*WLML*IB7V-R5\F[.V%*U2=%V>XH&I71LH95$6<$X"?FOW9@@0
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MR#ZLLNX;G/QZZ?"'PSW(*TR()^PFCI><3N-3(QG$!4QRZ!IJQI&'6FX,16A
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MT($7D0:V1;8QGOLE\@^>:2?-*0?FDRZ&Y'^L_E(;Z%'MV28S6P+<-OY5Y5O
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MK]C$)E-U=&<M/U)O3!Z)<!PZ1OW9WC_9DV/XSJ@64[7OK95S%<]T>>AY\^D
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M,AICS8;M>L,LJ%@>LV]J%!G.QW8>_(47ZL4N,10+&&8-=&2X[TN%26X=)9V
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M0%8"<<+@#$"]#=['EL"6H B""9M-^X\ASK(S $['_OR"CT@7+/C7M-1Y?1-
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MIFQ_/U'PZ]=+:UJ.5P$&GE#1T\(V'L++'[_G'[43U3"P6(5Y.[W<JN81WYA
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M%G#_@*3;(C,LCO]OOX^Y*N]<+OO7DW3^KKCT1IZ*024^[GQ3P[*H52-BU1E
M)7ZVBVNHM<SH9;K5RR>QRYH?JX"3Y_?G#VM.3V7/  +&7^A^]I\!U(7. &W%
M98,_I0;[YD@5=JJ3B,+T24GI>]A?RN84N6E$)K03_@1,O)?W9RFW79@%@4F
M !='SY\&Y_^O(AN9&(G,VT +(I$D6J+87\M?:$ \R/KSMUYX$@21PT>_$80H
M_=/0LLCHG='C)S.G/Q&XD2=,SYYQF#J<<(%OD0"> 3)%__RISI\EK=><,WV#
M@\&%2?\WP6ENZ/]%)T.H:EGVRC]/(]_W)U[*J4["'^KC+*MZA ;57#X*L D2
MA:>"4W ?B@+D3GY5GO".[B^PD0R(V/@>XOK)?;0)]@J$R5/Y>>2#P&^",!7;
M&O(S.JE3QQ_AS^?VUAL)GW[!Z'<RZ-UV:G;I8&%^Z8Q=5J_-3B_])!+J<68'
MK&> *XB=#=C1>#9*/],;WP0^/1#%F=T9 C;CS@#M-P*X3RO;B:ZUC.'U_+(G
MPNUG@#II(NLN?[7HMO)R K)TV0 1\5O5K*8^QJTIM=2++BA#/_3FPKSRK0X:
MCJN-5"F&.XCFQBE@<P%LT1@6)DIX> ;X5_F6X_?)6.-@!(;&XE5;]2WP3.6A
M*Z9RNQ13-]R9=:4:K_Z1:JBA(8W!^_/WVXQJWP%SZ#>_6"Z:T)8 ?M-^^]YX
M.B^YGTP0^T>!>)),D.Q/?N'O^6@DUMA4NYPUY9R*V3D5HS]+QE^&+"4ESX6J
M/!<J[\]2;KOKB(7%GR Y_RRQD9M&?_NSAO^J2^P+5ZVIJ>_PS@;X7#?M/TM:
MKR=RJVLJ8/[W24:53VHD^;^4I2C_>UQ&3Q2=R\JVLN='$;O%P,[8/TLQ9*5:
M#D[6Q)V4,T"0'I'E+T5SAO]'Y;^CPI3^O_@F0Q.M_2/0U/:_93K26!-^N*#K
M&'TKY\-]%95P,^/KFE0AU#=[##'9(;]A9,X;1<ZO'F;D;F"K?.%?X/K.)@G&
M3 #K;.M'WO_?!"IW"<=[GWZQM(_+TO/LNT40)_.(7@U6WWA55X_Q[$Y]Q?/J
M/;*G-UO*SZ5HDZYH7BTL@&E.KJE[(?;QFPVP1,<2X@H42!J#17XIM5U/[K-D
M[P;1X028()>Q[@?QA8HUY)H.]%.FQAV"I=;ZM,?T@WD29;SO;@3)4,VRF/4
M68#.QV> I:Q%)A&,2(:O;W& 7^] 5Y;H!#R;;:NI#A$$*9QS]=XX&1I)W5PW
MZX;P?10(ERM)LM47Z0?XEH/(@N<7U":)JLY9[),9J(6,4N5(:1\&4/M(_BCN
M#[HX)75MJXE$C_MW+W[TI^%.>S,*J^X7T&?/9I%XC:>-QN%7Z@DL@:8X3[SK
M-%1]Q+TVT^I!58N-O-F8Z2351(43<=#=U-[C81YO^][VH$>.SS$J<9^S(:J?
M9LW2C, BV6,KBAO.WTR"&N)4+\8=)A2ZC+BF3CWJ1\G2VT#83L)+A?P'#M<,
M[JPC9S7CQ0J9D6G$"7K!-_I"G_ASQ\W6A[L8D46]"]=&H30O/P?L&XQL$_3+
M9G#Q9P"KQL9QF5P\PRKR#!#U;&PYK%+@7IQ/N;QNM("]DZXL+[6 -GD9YGSM
M1#?B$@%8:!T0O]_N=U>KU@6JOW28=8CO'DGY :S;A2NF0^HA@6+/D@=T"Z-O
MCTAI.9FFBP&H%A^;=9T!F(">NU%G  J":K%+\/5F' 2RO)9QOT:_U.#FW<(-
MY=&-ZDVNL/=YAA/EUSYVT&H*?)M*+1C=%V"[GBAJ@9<E3K/; G'^I/P:%ETA
M6G7^)COH110^4_]^?:J+M +^_4BV;4NJF-R:#?H <L^-\H7TBG5;NR[5Y'NS
M#O EX-)GONM8T%NX[L&0-PK\=C6T^PPPS;!\:LP!_%)KG/[XY./( &MAE3?K
M8"G/\UST^%7'*U_17-S>/' U/;PUX6&"#;:NBK((E0DS_;$2..!Y:4:DP.5B
MT@8?L\U][/")M?'U--,)*?=!L^O:G5?5>OSV8I_P?V(QZP37LA-8S@#+5&&R
MM3,M5U"+](LNP1+Q6Q:8LO3824.]95Z56^YH:<$$]*N"U*.V!A>'^,"GSY_6
M-XSM0Z325,U(.59(!'&TJ:BCD@>J7C^FYHX" Q;,-RQW8YT\+[?L6[B"[>#1
MD^KJ:/3/L)TLL_&8OLO>^\@H5J$ $VJJ21("V_.5:2$!77>P$Q^1@3CYVV"6
M@ R\R@IHHD)D0I'.(7)Z T)O&F'X&JW2M)DZ.F?>(W]OQ(JM^H]^H4X&?2)M
M\?*0:I?*463M.LY[A>$&:IPA+CQ^6;*2X6=W79-VBDRQVE2IA\:8N]\4I3C#
MI_FGS]ELPA8 C*UBE1$$WO.M@$EA8BQ4'-4<6'Z7I+POVL)C1\K3MY:=+4M1
M$L8:5YZ539E9;!.YEN0?4)"D6CKYNHQQ];[,!9T^?>QP+Y"9*+_QBO!J?C6+
M%V]2>Z(3\;OYU%5<,1)N8&_4(,]Y;7S"UIQP*Y\NLARI'.;0,A<9W<-!_EL[
M^KCRT..T1K;%%P/IA5U6TUH&16@(8'8C:KEAE[^V,>I'$+L<:Y+V5AXV-+P4
M"M_4S<&KTN1=KXFJ/OQ!SIG\G7B%.(=@;1,#!_AWO?(HQOAW<YT!HH5&W,\
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M%=ZNLATJ"TK6''?_W0%3WSZ2DUKP&?T\;929^OC]=ST? #_(",Q,.-]C_X^
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MA.W1A.MG9\<A7E-VH(H3>5(K/67*I9.F3$$5YK,>\[3@M"E/4$5 '-Q*4]C
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MH^ $[ Y?7P'=GRQO($@#VB$,>U]BLVFM'O/^!PMG%_!G*.==-Y,["E,OXEU
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MFXC&JN]0.72O&#^ODA!?9P<V<IYD0O%+FWA,IS'\HMRK)9)G?Q;JW?XW!\^
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M>L\IKOMXR"MN9B/CS2L><G-L(G@JM3_/$W$RLLA8VQ;4)^0?"%5UPKO)<3X
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M!P1II1EXQU/!,ZC$UN#Q/[PQK^T.'7B(H3!N(Z5T,IVIN5_:Z] ""\$:T&,
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MJB=#(:ASY$.I/VX]+.6SLA L+(O%90$EOZ&+YT 0.J><T[C-H;#K/" NX-&
M=1H<A_: F#L,3K_YF ![A7"=D$9+:8L;TFD0[*3!3GIZ=M(VU_U(K:8VDL#(
M+*:V@L)(K:56(L3(K*6ME=*16DO!*NM(+:<@I7:DYE.XQNO-B%KE6OC+),E$
M(SHIR O-)WFY7!*^EL6/]K^79DAI^:59E-"VA:2Z?\A3]@E7A 8;;+#!!CW:
M.YU?,KZK^_A 7L[JXFZJR36TQD#Y!8UX%1]U1W-Q@ 37N1+WSQ7C-'G*SDLA
MVV71^H&3+$^K[$9V2-N.'FPCP382;"/!-O(*$HB?CM08T@L']2OM_SR)2+ZH
M_T/_*)-GDLHHCJH>:E+55:ZB.H[^W4[<=_ E3_*^,TJ#P'_* K\B"=0%?2PV
M46Q"$YP^BVTAF?F<\5SLHX/7.Y](486Z'=>7/DP1U7&HWI,;A?*UH7RM=XJ&
M+5^;Y[0X(]'O--X?3&VA54 /OPBV7$3((_>"B[SB,5%4+LM46LL_<I;G4L(A
MJ91O/@H.?B99#Q62C@JKR[%',2LWXJ>^9J5Q;$RSLF2\D(2>LUSL\%Q=S[GE
M,(-BW1-X3"X0HZF[YW@\OI*/@.D9RZ!\"]3'*XJK)"-9E)#T.LN%WB?E;DW*
M+$-KOY37JM]']DQY)BDYWA/:=;#J&^S5)V"OKBP#<\KSJ3QX_#F)DNQI-F_8
MT+E\09LW_TF;JZR/3X0Y4G]B4)GUR_V#-$>5? UD.>8.P=8?RHF"DEV9;F'F
M@R>-SHUC)<-X7G:S[;R7A63V[ F5KVO@ X$A54BHG1EJ9YY>[4Q__M:^^6H+
M31.=W[;O.0);<]'%OO<],Q;V(K^[)H35A+":TPFK<><71L>[@3FI.CD3T+%E
M)Z#;.-9&^GJI!V?:2-\XM?,X^8TN^S#A])EF)9VLQ(_BTB'I9)FD5.89%K_;
MI P2C2*:/-.X9619QZ]XBBIS0F6(*/L&(\JF0OPF_TTS&I'IF;J@H*:9 R+J
MY."W"\*7)*)EG6/*5&A5V]P!41\%6B%A1@LU(8HF#CY^0_-M<NV$T[Q2JB@7
MZI74EY*B%/KSG?BN4#X6-*]JV&>DSEF[:ZPK6.IX< > [VA.Q?VQ$%1<"%:6
MLBJ+[Z<M#]MF@%.#:C6  \+E]9A;T EI[X(L2HHBI7*'BO,A5C'2D&1HVWM\
MWCDKY2Y;$5ZL/Y.E*I11UZS_&$*Z*L7V(CG=)3Q]38^R9*AUW]- ,VPT)>?2
M-%N=+L$3/@OVM?]-9; 2:JQ,4ZN/L&PWRNDC'71MSUF:UA>8D&8/"#<$G4$Z
M><916U/RNTHPEPK7>4J2I5R +UE$N9#2L^E2'BY5_%.;(;QB;+Z7#^9_B^"!
MW5(NE&CYF&E6".DC-Y:N=#KV6&9%TJT-+G(Z=IB5P[&'+;(98B)[H5,N[VQ^
ML!,T'$?;-D2N]1ZYIE4!6"=I&Q-4V'9CCN14C,C=7NVLU]MQM#& /<A/:$*E
M^EEOUMW:A,J?/X[CAB$.S.&Q P@1Z(Y1VPN&M5/ 41Z2OF[C3ML;3R03S$2+
M9F>W$Q49U"&&:@<[%YTQ<.3!+G^X"P?-A'3;[#TY#-%$B76;'9C[#$UT6#>P
M8-\[FABP;GBU+GZ_:QJ"C4.P\>D$&W=W8/D--WR=J%E<=7&94IFIF<[G-))*
MS6'.9OE<00;<L2Q*TJ2Z#AWELG;P94]AB;U1'D(5O\%0Q<OMEKFN=LP#>;D3
M^^7N:+O<<O:<R!OE@=W1HN29$.NC T9]&/;D8CROCJIF@L^KY/"E?'%5%TT]
M*+W\RGME/P "?,<+,BVNJ+C'2"IOEU(0M3YJ; 6\U<CH9N1\(979Z^QB4WI%
M-*I>$N:R)$F-+$W95UG,M</LM/@*NIG:/$(]:G&1B(Z\#IGO,#W0H='-R6<F
M[]%2-!."UZMBWRWF03?<*+!7Y5+.A*(8G[.E_$V]^X76ZWA6S!]"-U^586P:
M_T^Y24S<84940Z'#7"DQ0A6Y$22ENW;*5'TNAD0W!^*7YX+EJ^M:M!LD!$^%
M0J)*8\Z03J-@: N&MM,SM#G7@="X;]S/@YTXC\:UXWXB8+(*&E^/^PGH(KH#
MIP7;XW\W>AX0/):JIXXM@D#TV&JB=E?=@,"Q%4SMHL$ (?\Z0LBMK7Y0&<E?
M &.723%;R/WZ(M]]F*15$;#)LD["),O"LOF$U=1E3_6?)V(5'\52%NWKZ#KX
MDB=?HS-*@V_QE'V+G0TS-U0P0#K;[JH;N:EN-GMJO8T%O"A5)AO;[BBQ3><%
MY?^DA%\)3MD1:.-8*%%_%ISAX2M-G^DG<1\L5 ;$KL.AQ.YHL4>QSA61K%3E
M$6@[#%JL#^*;+A;V:!R\:+\R%UCWH^!!^B6+DSRJXEKCRY=(-*WCYMK@-8WE
M%;6"1@4N0^O@=@INIYW>%]Q.P>T4W$Y]6E3<B,,C]35U$BE&ZE;J*#*.U)?4
M32L8J:>HF]HW,@^10\/&2+U#[6Q7(_4(.=".1NH8 NE/WAP>0C++69K$,N_^
M9/?K0].^:# A62Q:+E><+J3$^4PG8BHMG!TNOM*_H\,=E<')$9P<VL2D!]NG
M=H5^IL5LKBY$#^CA-ZZ9\$RPL/R6\BI<9_J85\],%>2;F@]*NZPU$P$)/VH[
M/-55L,B%N"L%"RHYS2V7 32&5Y0R'P GZ32+I_%2<'5)BHP7T#^= ?;RBV17
MBV^:YX(B&<2AM1>;.WBEO\HS0O.B9C:;F?S,LIW#7_ ?!1*;KEXQB>_6--T<
MW-BOB&]LXY?*@YDZFD+#Z0;W&\:YL"%&->_*=L-2:YAS8_MAJ#?N<DU+OQ3+
MRZ=!N-E$B)^7G-,L6A\D=1-,OOHIK<1Q625-$C\5LKU <U%R\=^Z9)Y!HO+X
M910S6M&JK#NV#SAM.6UMAT<S-UO"ZB44OY>%RND%K?_7Q :<#>Q_/I37A@ZK
ML1."Q/9Z&* ^GE%4->:N.%NJ<GE>OD1I&8LY/VI;9_CY+2D6Y^*4B;50Q=;T
M\(7A9N@M36(CUK3+(&KQ?[&:C748:0C$Z@H=QW\>A#8#;U0U"X$B)U#<X3<A
M*RT*&D^%[DJ>Z.=26L=G\\JZD,_*0JJQ\ASI;"RMQ@CA,"$<)H3#A'"85Y#T
MEXW?$P9*H*P@]RVD]J(*NJ6T1NU25$47ZF0Q&Z<1M06TF:$[K&:ZC84YNCSE
M]G<^K8!:^5[0[5@KJ 83-;J PG;@5!9A=/!@W,;2*X*.Z\#I/P!M[X%#QX1:
MX8;Z4-'QH59H;2RQZ$YO*\0:Y^Q( YM=>P[0\2^'  '3UIOW#AU_]#NOW=Q[
MZ-AM/Y,'#M(;Z7L$6!0?.@YD)%L#L<'F/-)W%1UB_]"O* S+P61T<#E@B,R/
M2+Z8S%/VU4T(_MOA!HVU5Y$3@NI/.:A>497D]?U[G36_GTG>^,C;=G= ]/$W
M[B2OF<V_".%!)G>;1H*4XL#==DBO74^OKMZ#G(0R-V.=QXX>:60/[%R<W2J%
MHSBG9VM!>'PPXU.9^JT6&/4A WU^RN]##[)*"G$RI&8;)X6\E@0$J9S$9V7Q
MF17_I,4M26+%/-AV]XPM7\C_O_RC3)Z%.I#)&F-BKI-(L'3Y!Z%Q'?_BH.7.
M:R4N[!7+2?J1LW(EC>7RX5^5#I#&QH([0Y PGCEN5F!VL"]?HBK]I,S 6.=E
M[&.66Q/A=9XOJ%#<HCHII_AW2C<6@^F2\2+Y-VE@UVVZ#E!Z8C8_G.)9AN#4
MXB',\X.:UV= W.=5W<5;LI9FE0=.8E6HEUUG)+CV)2>M4;WM.CPFH<S&!_*B
MV%V5RKD7V92BJ.MA!YZ+;;KB350"&*RBW\!H=A.]D;8,LJG]  /CN^5T)63$
M[>1OO2R;;5;GFP9CM1G,]].^)H7@*LF(4!X.%0(%5OL!D.(SO1)L/1 &O-?9
MLY !.JRG9@"D^-JM)V @#'@;%'8[G)H!D.)KMY[8+!OC>$J]C9"0)F6;MVW*
M]EZIW^9\>F#32.@ZG-:'^J@LR"L D"[#8A ;6VSE8GV;DJP0@H/4XE:'T>\F
M1,8!_.+C+*(TSF7P\76>ES+B:#8_9\NEK.[$HM]5L*#]$*"YY4(5*ZB8\(CJ
M5LJJ\V"X/NWJ5U3";+V[Q#XZ)VF:S^;J* < [,YC#S8KU9Z;K2KSR.4+Y5$B
MKAT 8FV_8=%(!@%9M+>-!Z/[-R*?-Q3;B810K^KB^2DH29-_2SEE>]O( *M<
MWON:MZN /GX?7386GE.0KV\<'K>>P./6^W*UJI_HD53*Y%<I^WJ=S1E?UK6Y
M](*\96^OR+YD?'/ZMH&0L\PL7 )[A:>YX6EN>)H;GN:^@M35L($N"K$#(*=/
M&K"][^P_>@?=5N@5\L'4V@<;H&,6?4]5ZS Z=*?-UZ:":#+HGH_YFAP++17=
M"S1?<P2TFJ/;0[#KK*W#']TEU0*(=AI,L3KHKA[7$V ?#('NCG$])=H0'W0,
MH*\3H8[)0W=']# %K0/:T#V+;#<YW1Z>H'M>V&V'M W;0'=0.ADYP-$XZ(2&
M#H .IJ6M$Q^=".%H.MR[C-%)%CUM'*6_ 9UPX68"VH8QHKM+._%/<'3J6/@G
M!)""80 B+L;"-CO,@C[L82S<L.LV:(A:&0L?[  =&ER&3H;L<RJ4H8/H;@(W
ML]#VO08Z_<K-=&![5 F<9G\U>-U,\Y!OH8%3ZJ_2+X(I];%'L65R:A58ADXP
MMD5Q, %6<6CH9.$.P-OE ]G/0,\9JS)6T,F'":]M_Y,XR<G3$Z=/%2Z9V6GW
M%UJ0)+5(7M5VY/[S6'6C+*2T^@936DWE ?]OFM&(3,\^'7&*PU10FF8.B#AC
M><&RVP41;">B99%$),W5Q ":.R!*YI+/"AHMU(0HFCCX^ W-;^HR$RP1C/6>
M\F=Q_(4H<9WE8A>4Q87@C=&"<O'_>95@.ZL.N1!$MHW59#L?W '@>TJ*(J5R
M1L5ZRIM$3;^I;??H]9P7!Y'KXJ?]@14__.M<.E8I7Q%>K#^3)6TXM:9FO=-X
M1U>E6$"9)59< =7]\)J>1C[8JN]IH''&\D^MN%YXT]._DG(J[T7T0(QLD77B
M0'ZA.G@: [LFT.C+[9:&085(S^JQ_AV0\ZW:Z:50_R:!;FL+D\G0N,*Z@>U)
M@$;C+>LV.UJM"(T;K!M&L KJ]WB'QYKAL>;I/=8T%9ST84G^N:X$4/V'[ET^
M$Y+%DV1O[H<TX#RA\804DSE)^$2T:VV$]DN4)_OU$*""Z?L;-'V_\MY6XILJ
MZP2\@]\R"/)9SQF)?J?Q/A:WT7!JT<,O F5(\05]+(SYKFR[>T^87P5/'VV;
M*\&+_B%9T;X\D *<=7^_Z!A?216(GK$,NOM ?;RBV,WFV7KWS_\0-Y60+A;K
M&UDLN8$OM>L\#*[K;%46>47,.^W: 'H,CN"]-8+WR!!\L$;P 0."3Y1(1K,\
M8D"[K=XH570:X[11#NIHVD3$D50:JWA9U2?6L#A]:[^4U_54]W65C^]X_<FR
MZ>L5U2>6T?4GPG^GQ569Q7H8^L;!*7@"B?ZJPL!SRJ5^41F+9?3J;-YP$/,'
M05?>_"<ML^KC$V&.U)\8E-]_N7_@U9VT!K)*<X?@).\5"/3N93Y.-,J)L=.[
MF!-A='2Q!58B')H0@UYW-+.3I%"YN@;F"ABB%UP>BA:F&W1GI!TW:YH%D\T'
MYTGP<PU@V/E#;89&\QF:*)Y>H3?:W="M>M_7)%090+<G^IZ8%@8E-/%=ON8(
M[&Q$$Q7F:V8L'&%^3U:(( L19*<70=;2DX[N4@/FO&\5%('N=M*#M8W(\1LN
M^,MDM4DJ6(6ET6U&P4E&"]6?VL4 .OB2I\ ^9Y2&:+UO,%IO^^""KW?I.34O
MG$V-_<:X15&Y+%-Q&&)(S0S;HJ2NA_<<1;84&C?E^D4%MO9*>94Y><'2^'HI
MF-=S;7304@_HX17!;#Y/(@J;>6U;KU0K]^_96JIBFE@6BYXX$'WDZGK6L$XX
M<'RFFC*]QBXX,,@=H@T8L.AY.H@&C6P($4@M3 VMC2??0L2%S0W!.AS]T<82
M6%^AZ'RF-FO%[-0)5';-_K?T2/RBE@MN(?"B,P^VA K2JM"9!UN"!2MAHPMM
M"7X7Z]LE^%WZ]438**GHN"G0V=*+]0T=M^VXWF_4>;_NF#]/2%T*;D+KNHAY
MPR^R>,)D;;A)E<18=$WW9=%:.F><?]>3JZ8GNH/CYAMTW&R*,+XJ1WE>[YDF
MYPVH@SO"SEF:UOJ=.#SG+"]R,VW&/N[(:RA>N?G6P5\TB9M;C](KA(-?F6?;
MJK]+LB/)Z6:/:5)G4 >1:NCCCKP[FE,9UBKK2\AX559=M-5FU! (Z.75)GI&
M4EDRZ'Y!:7$C/RD%'+4+Q]1\<-JU!G5SA['2/Z@?X%)(0VQ-A918B>%&WF+=
MSZ]7MK$T[UH/!=;)+XZJ[O@;#F[  >H4O$S!RZ2T%.'W,ADO,69_98S6HP2[
MT=&YD0#KPAR)X*C,MF[W, 874K"\!\O[Z5C>6^EZ(S6]6\KO([.IMS K !'Z
M>T8'1PBQ]@'A82LC;Z.; 2%BJP)JH[8!(?HKQ@O?I$"S+Q"AO]JX-HS&VM3J
MUY/WETF2B49T4I 7FD_R:$'C,J6RN.7F#X]TSC@]:"9U,9H7252YK.;UN^V6
M#KV^/N_)K]<O^<&]=\KNO<Z&J>MJ3\D*R5>".YW7!;'EL_I=1>RS:O/5[1[D
M#KW8[#V%%<O!B-AGX/*EX$1<&$E&^+IBW9]9)M4F<;P%:4]5=2&!R-T,V7X1
M^PQN$G6XFZ!7 P9C=#!&*XTG(S?2!L-6,&PAT5*<W_DC-7JYNK!&9@WS+M#X
M56O?O9OD!8M^K]-?;.R:0AG+Q$>+R2HEV;&VMFN25\FIQ/\N"*>/1*S01'Q,
MAFA6LR%^R(NVT:M^B?*D @\!*BC&03'6Y0=)JP_1^%YNK3.YM<X/=M9E'7&M
M$)[M.GO%)0O!<I+*%Q#Q4AQA6?ZY2)[IAB9MO@FKO@.HH/O;RART".B! 8$V
M] _49]PH!HUA;/;50DZ*1<]@J@BF"I2F"EC<'(2/OE$50"QK=(89ZZL%70 =
M;'58!SZ'RC;5QQ[&$#W7QTJWD/U"R&"PK ;+:L>7["TT2<]6L@^35,90Y1.V
MC:FJ?]'-S&4WJB\[51NJ@J$I&)I,*4MEW)I"NWGS]P$?OFG(5#<<D-[?:/*T
M$,QS^BQ^^U2EE)<!K7?B4-\*80'Z= \^#!ZL=U2>MNT?'RA?OFN#53-,,%R<
M0&';?Q">R(^;CK>R73"S!+TEZ"U!;WD%R20.C#30P\ &1QJ_T0T-EI=+;N29
MDWC/9"NP>K,8"(:;LS2)I45C\E@_09[D\@VRA8$ ,$C_]@ P$4']/V7U?Z1)
MMER4SS%GCH,U'H3N.QK1Y%E2\YD6,.IU77QCV&8WK3-6L.6*TX64N9_I/A93
M4#F;/Y 7-:PVH_A%&L<5KR;I+4GBZ^R<K)*"I"I$^M9^*9=55E4VBN,_#D"7
M8<,WM1F.RNFC]#5&(&I?M_5*=7-!RVEQ3CA?"]&L*FNI0&'5UR\JMEPF=?%&
M26 5W/U$L^B@5N7;@F"F'MX1L.Q>!AAKET#1S#.M6;6!?TN*Q7F9%X(+<V"Z
M.9NN>##)L/_VL-[V]NN[V0MC*N_-VQ9#42BK9LO-+>LL4)Y+-E.LS61KNPV%
M17\2D,C(;\DP7&7F#AB27AI/++C?@&CNI(%D-O^2TTI^ "%1]!D@@6<E\IC7
M0=?6*]6W8A@J/A\;+V%-2]\4KX02L8FOV2K?$.G9HJ=G1.,O!'DGXVLR&E\2
M+FVX^5&=CWD2)2HD\(Y^O<0+Q@MIA&ZHD/[:5ZQI&CSQ)^")!\MF2*2QMV08
MI!MSAQ!+$&()0BQ!B"5X!0E@X4/WDD9/,^MD^$.WC&"P9B$&75P(&!O<380N
M2@2,T5JW01=" E_.SJ#\A8A8K)]]*4 D.6_!&"UL-D"0_K+>PD&:33M </X2
MWEH>/>3W C"R#FC112>_  AON/L<) KW)[7 (#I+Q(QDW]HMK+U/$9UP8P?8
MT7KZ$V@<KF?'F\2?O&.'V=(=A4[R:;V!D0L[MCL7&%2"C@%![38PZR@Z20%
M^+$&J??OH1,3[/#I@XC020-VX$ !E@C/GQ7&+F&QZ*0#.^RV7E)T@H$=7),C
M#9TD8 ?/+H;+VQ,@4\T3F;^59?*>/ZB (FN>T-KJN$L+Z[Q83-LO#U\GIAOE
MX872*;]0ZAZ^6POG5S26"<#$G;<Q_Y_5>^H5U9:]!D%2IUZW16+H-02274)U
M&R"&3D/@J%0D<4G)-'2V.PS6URNJBXV.L]G\=JMDUWD87/51:(D+U'D07.T
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M8\W!@BE.:+0Y7I#ZYD>;1P9':.98<]/T_$X0.BTGJA_8/?V#FDNQJ C(\E)
MI^_45 ='H?W[Z5/EC]K\7OY'WD[B-_\74$L#!!0    ( #& ?U9#W"#PW'H
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M^/'+.VK+[G%4E-\JG3"Y#"YR.\S'P40>QL[;M.1I+,^C^!><=%>-!A=-C3>
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MCB[W<F]YO^A#G/W2#1QX;0<&=#0M+=,79/V4YCC17Z;5WC19IL<I>%VFQZ&
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M1ADQTF$/BIT.IY7B#ZICY&VRT6E^D\=TUC/%)9DE@\\ Q?N@+==R28DANDT
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M*QXY@@1]U!9-?/?PZY85T[DFI KCUYD4'Z++1Z<VV=WV*4OCZXQ$QP>BH\^
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M$QHLN,36B/C.UWQ-^]^DN/MK6KU<T+TLW;46:GE#88V8Y7Y6).8^.19'(PZ
MV\2'7RD@U"":36 U<)A.<R*#>&_1CP]QX+OTW(=WV3OQU,_213\OS[RV2WY&
MOOB>_7D1;=(JRL1>D.7!*W8XN2;%];;:%KB)?YG>A.FU8[XE4Z/G+WV+)C##
MO9JKWAOOW&I@C5.Q@<:#^00XU,94S<AKHBF]PULYR*!X3 1V:(*6IU:J9))K
MO E. S9)P5\VRDDHL"25-GMH<J>#Y>'],P]3J3.>-?3#G-'I"!<QX*?9/"N+
MJC?'Z%_=_*)__/<]V\T-VJ*27S7GR5$K[N_844Z651I3/?Z);LFI\A*W1$/D
MDI!QD$RPQ7^U%I[2NJDK+M&EXP^;UFDY:-27QARF#E&2MOH!,&).4JVK]<.1
M4IR0DJ&J,R,L,]Q]'Z5L3Y]?JMO5EQ)SO;N,XP(/Y! %O G9B:M1<#T3-*!H
M;\JM]]#H/B@C?T969]L2BZPKZ%W48/A6(W&JQZ$T]D$4# IS/W2=;OO,MS5=
MP%/&H =P2VA.-&+ <D-E<I?B(BWOZ YI'<5XRVV,\J?UTXO<DZ?X"D1]3#3M
M6F\(\NB(/J( _@/NQ;/>)^,)--+- '-%59P(A)].=QF?HM=TO5U+]QF#OP-V
M&@?M.$^U)(@IRKN#O<4PU\@D*[SZ:E,17<HR-I&<:6R<QZEJ#6G]!@R\LVJ$
M?,3-U$CXC9@#++,K6@,8(&+.=;>Z*LW'==70[Q!=U6_'N:X2Q +JJD&ND4E6
M.!WJNX(DV[BZ+1YPL4MC/) />.HQP, /->?<7A,TN4:IR89(ZSO)3:+*(A]R
MP912#: <3,RK]"Q<0D[;#"(FH5RGTYPE6NP*=UXEO[ ^]JBM$RD/%]+':%LY
M<P+U 9"=E])!21.J446OPFLRC^,ER87Z:5ZY/T"2+)PGOT$/C_RDP)<<'859
M)D]Y1T89XDV['<8"C25*&'D2J-L&6O03L5:E3QD^CN(:SY[P?BIYPOL_+/[X
M_D\FF1*"Z*6Q424:0Q5(8!4NM4V_8$5\?5YM.XJT!%<L=-\OP FHK<YYF3!3
ME]Q4>>DO'=-Z$Z4%6PIOB\NTW) RRFY7'TG^_#'=X438'&KN/).FH.F: "2=
MIV]J,;&;8@TJ=D['<)UQ8.*2R?P<?D9#2&R.B\?U@QV35GN6<KVB>TR6V)H7
MV5;/=0YI KS&J)/RX$[@6*@4,S3<;FGQS"KK.6B B VN.]V<\<N9/'LT)L]%
MM'EANQO)9FWR6<#F3=JF:\GKTPNU@YMF*-'BDEM)P<_'"*0NS\EG(9(B:].O
MI(3R=4ZSE&CQ*?SB"%X2G2^$,UG^?GZ,F$]AMBL?;+T+;:R=>$-_*D@I"VD>
M?]B6_YTW&LP#SZE;\<$#^P&ND7?JAP\3TCPA)6.N^ &6!75[3:9$4WO)HOO+
M7V(TF9?(7FXTV_VSZ J;488T11&;<(D%SY/6S'61*)'.^(]I])1F/!/BQ'(S
M]HKAHC/4M.^E9PB#R0)DV*?#6P./5E:C3+5GCI>D44D:6)BF61EH>=+,H*;W
MLI7E*E0>M1.-[B*5FJNNVEC!WDQ"-4VAE"YP,TNKUCL EY]-?=F0O$L8(IFU
M!BV!P[JU*?I+NZ$-#99XPP,'0*DWNK"*B?/;+46'>HF#0ANP)F),+([,7+*M
MW?#RXBP5."M.6?+MKT0#&+3D)N_:$$7G$45-AK5"8)MC5K71D5!/K3;-7F]"
MW!:(O\DWVZK\2(%G/PQ>\M!X RB4(RV[%CY&6AA1+($EH[Y G#[Z(<SE$!UN
M$P +PWF>O^1%7<7W8DM_R./]:)UI[?=M^:=E=%R+8D>7W47'Z7..XAK //R\
MDP,PYOI5XZI_]=<+;2[;+_\CQ04%\;(?//,U:L-41:K0\J<T44N9G^9]7OXE
MS)FQV9 ,Z5%]/@==NM]K+]WOG2W=[T,OW>_GMW0?<WMBZ1YD85 !^Z M8!^<
M"=B'T +V87X"=LSM"0$;9*%_ 3O?G^I6CF\@* _VLJG8C1()N]#Z#^,##L&0
M+&KPU3!1T4\XIXLXCD<2$TD>@20B.FK*?;A>30Z>9L@8L7%:H19!@"1"LJ$G
M*MPQE,R/T1,IF&SMVW@QN8Q./@R15FFCKN6V(]P/ 82*L,5N& MSUO4,-V "
MR/6TN! ]YAG*^N<M:_)V=;MAC(VR99*DXA-+K\W4_UW!8GC7Q\L^\&W(;%"G
MXB4/I3H<[0GCLJ> TR\!!]VN4 ,(=8A0 PG-LKO&"B,7G2<K1)K.1UWGBZ;S
M&X$P@"H!3#YBR/CP\?I?2KS:9A_3E3SF1OE-VQ'['05?(?M\T]$N9PN60)4B
M0!F%@-[]%QW(4"$FZF.@$JTO8ZR_R\5U#;6F@MI-WCC2ZY-%B3 JOP>]-CS5
MOFM!; O.A3PD5N<R ;/.DIEUDU,]JV=;3;QB8E!)FO9J14DP@&T):WTRLI=J
M%!9M)&O]LF@8I74OCXVA,J U-#5=CDT@);YZ6V@^X^HB*AF*79K@Y'Q/E[[D
M)F_SB"_C*MWQ>.CE4\GC6"0K#[PAX%*D3]"UFNDJ3D0M[3 E> P&@]CCL#<A
MOEIO,K+'6%Y 4N%)H!@.M.A:SAJ26M4A'4G:&$.)!I>\R4J;5.!CFN,;^E%V
MO"1_$"@IIPWZ2-U7)^MC-!$G&D9.1KA)U%GD34J6<<S*.)?W.,;ICEU(9\J0
M!RS)%D"55X"2,]:T:QEJ:%.;JR$>1("4V$L@/ L7"4D_--]=O6YP7N(+LF;_
MBK)W>7*.<[Q*I:7'S!NT%2NI3-BYRN,W@I[H_CI!T=>H2%C%X0[)8G:7YO6'
M;"RZ$C@._BY-47N2_8]YVG915E<X>'@A1?6(B_5-OL-E-59M3[\!Z!4I94+>
M;D8I(P)=B'+87\@]* J%E1XN7U /T4)D8&>@SA@JU(.U0/Q"<IBK3_I22<Q9
M[\\::D]K[J*4[@#KJL@R0VC\::@---RJ<_.G.X';4+IG:8YB03F,%33!6Z+)
M,$,O\\0UIPMV 9D'%5 <UQC?YCU0PN\UY(BVURK$5VU.W8L[VQRFMF<X!&<
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M9U/DD/6WIHF4<+M:3B4"0!1YXTV>KU8K'%>WJZO7F-^EOZ<*]S:?@7-V/L"
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M\^;F)H_ELVCL.<B<&6K/]0PY1W=(4$7_B6[8_^4Q?$K8Z8'Q!#CO^G3#>Q1
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M):,W]L[@<7-*9#>.^\'CY)3LCHY2P>/CE+A>-ZP6#Y=30GL-ASD>*:>D=J/
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MJ#>#>C.HB:&E?3'*E?E4#\4F@OI)&D>[U 2MF[H^3)*BA&M-@Y:DNSVSE9(
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MS6SL+<Q35"1,9^O#DD>N^KV>%XF3<W&)N2PO35.9FPX_P.3#@#@\GKG3[(K
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M^JXEV[$%[SY,DJ+:W619Y@43]4;I?$)+"M.G\NL)3()'F E9_0+G+3S)6NQ
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M2#0%[3MX(I]SD?5V-B_L(WR69T(1%RM)926J-88[T6-8(X"/ ?,Q8#X&S,>
M21R1ZF/6%2RD7+Y%HKYTY\H2,@:K3:6@NQ"Y'H)-#)!47#(>]VPRC(=0&T5=
MV8_T[&K+LC5+4#+P26.$CY$CTJG]Q0@FK;^DNX#;T4 C=VV<5NBVH6?0E6T9
MSS8]5,!-W=>N[-*UX,)&7+BRX&J!9.(N<6K;KH66,@;CM*Z1M.U3=&5G;Q$7
M!-J=A0.X<G+8?1W-P@S<TA@Z =X@5/JT;JKA0K!=V62UW"J0J?#2G=9%O09A
MXJ[.'QP$!Q@V< D/XZY5&/#%9)[0K^U<JGH[7,^WIV0$^6M2G:9@?'V67Z?5
M]P_C-S%#IMUKIFZ2T'W\F#NQN&?S+R"+B)RVTQ"H$=.UBF1<S[X231WD?A:I
ML\L,ON1(C7V@Y[!6B@S;L"[.UD![=(#[5&2N+<57=1A5EX^R>X$O6,4@+A?F
M@"C.Q%$ + @-*SK+L\\T^P?);H,XDN!@VMTR;WPA_K_\,X^?03E)1<%CP#H.
M80L57X#:>/S!0<N=8QH.R17E0?*1T7PEG$7BXG61S9A$VD*;-DF8_.!1MH#R
MC^-#N5KUW#%^^1(6"<Y%HNXR?7<7.!L3T5,@[04!H2TL$[_#[PG9&)BF2\JR
M^-]!Q=E8IVL/I?UF\T.09^D 5NYP"+-](?75*@#A23AK^&VP%N:T!Q9$LD!C
M7.?)NX%Q!E(2@7<D#Z#&=.U+M*RD#?3UZ$!(ARE6:-5[(5DJ_[<U[&!>\K8R
MQB;L"LVNI%_/W.R@WHBW^@OCA@/TS-\M(RL0RK?@;WV!FXE6EC9!\XH9;)+^
MV@OKH)!5*6%7<1J PG:HA$G8Q0_0UR5U-(&Z6^NU!QH"O]?I,\@##=YHQ0##
M>J,5!-9[HXB!AL!OA:'$C,^* 8;U1LVM3O4'&G:"CUZHW 8#">.YR5WK-^W[
MDDFW"1,?Z#0$]8>1<F4?U;Y[Q8.JRV#8@.D-$SI;WR9!FH$<(72[(C8;RY1T
M@-Y89#0D).+BKL8UY[D(SIO-S^ER*8JTTO /&6?8?@/@YI:!AI81P#PDJI>%
MZCQYWSMGGW;E 0H!MYQB,)G.@R3AL[D\\ 7!>..Q>T.EF'6S56$YN7PA+(SA
M!$)PK.S7+S=BE\"\M+>->Z/[]T#<!\NV0&*HEW6QG*,@2.)_"Y%E>^J(4#TN
M1 !%6@5%G[XV].IJT!(.JAOWM,6--O4"G'L@>%V)( >-E(SIXM-'5-&9KU9)
M04.0;)&[3N>4+<N()PWL9KVM<O8E99MM9!L;/$OUTC*REWO)+U KR&? \!DP
M? 8,GP%#=M>QH:W*%;0:X""[B^7X E-.J^X#[UR9>)TB=?!&S(->.IBQ?99S
MZ1KH)I&W'=ZR(HP3MX V4]@[N 'K\BRN9\_IX%[;*8",]U6YD@\ )SW4C=3I
M0";H<QK6@$$)(B).K_,S_\'^>=0VC+4BJ5Q9P&V#J8PL["Y[Q3-ACW3L$Q$3
M3]S=C7-7(&P0Q]O!'>WQG3>-+TFB41Q#A=5F$[1^C-QI)?II&C/IF*#8 (X#
M4!L$:+EBW&P)R/9CB#H0'QV<L*HPR>XVR#X2Q;6"7_T8^]/*8]3TSH4KKHH&
M.$AV1T2\H>-'2P/PU+&"KA@<.IIT%1&B'9X0]HU>[<.&#P-WY73H$D/I[8 .
M; J#DU,,$:Q_N[,[T\(89^+0LCB@W\[/)S/5^TW=@GXAOYB^D%5!&HC;+#NY
MU](P/Q3ZI?Q:[Z5<IL-0_H?\2GZT=48/4?VM=6/ %9W7E/D#W(SN);BBYC;
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M(0TL7V][UCS/VV3JX/1Y-<?T;,G[]L68]X.KS#,#=5)9E V] ]P[P+T#W#O
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MH2[Z:V[H+D3(&?/;OAU9$7-#=N9' =-UY55?RO1KY/(!BJIM>IQ)[ZLO.GY
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M[&4T7OAWVM*Y"TRYLJ:ZM+<'%:TM0,4"0>-F>]> @.B+FA& (RE0_!J+\+F
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MWMM[<]4XW&\T6XID**$O/M6_-NF9>_7FQX]X9G4TC'V.J%!R4FURD1*%L!!
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M&=,<=<(*14J9^_&!2 .9]B-/2<!\ I:H!E0/(@_'8W9U  PB4;5:(!XQ.7V
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MNGKH'500!\8 *7BM;$0/Q$\$^XU,4M9#5'KXY)&T=L8>.HLY<F5UUS \ +>
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M;AC\K:Z/%#!G!CCL#_9C?<I M>%>_(:[PAY_5AJ_7>*E:NG!H)Q_6P62M](
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MOAJGY*OGI L7G-<?U\N$JC_Q*E*4JRK*"9NB%3FF9?3MVXNKTP%?&HZ']JZ
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MX+38GI8=RWS"%(4",R>8]B<!I#VW0:QKW,?X99AN\$UPP0"2S@0-^=GC8V'
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ME,K(3:J9'$SY#;FO(D#9NVXJ6XM.Y"0QF/FTX SRKMH1B["BNA-Q8I67>O_
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M,YG[ Z&S?$-(Q1'C*=8E#N-E+ETBJEK?]M/C9/I-;TJ-HLL@-2^4XGH?NE_
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M*G)D=XX&SPZ>#@Z?'?^28IRCUKFD._;5T>CD$&/5_.3!8\IT=D",!X$8SW9
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MP<4U8ZELS;6O3<,K@X\.A&M\XP1X29_#44B]12( $8<T,1E9".YIUH#.^+=
M(_72+Q.XH=B9U,?*9<_%.+_M90(@1A=5LN3):-7/3Q4#T!VS9Y[(H@1:.Z7#
M(8X252">&Z>;72/_\)3<3L$=@3<Z5;@2H@05\AKO2RC]CD@^@Q 2X*U[0]FV
MBX+0GSXT_A5T/%XWJS?@=8XK_HFH6@MV^6U:%K0Z+[9;TA.GD^$Y+0K*>M\2
M-VUB!EX\+A)M"'W\K4%3WG;4CT247&%(R*"<AI@,^-F3)[^S4./;M\]?7["1
MXS^SS!SDN"FK"0P=SIW+2XH[EJLX1][KRABIXX=]W&1(UV9HK?C(B%#,@[19
MT5(ZBRLP+G9@#=28EIC@WU>&!:==;*(+9A($]!\_*93TJR=N*+,R"O?*3H<6
M=Z=V77,!OAFJRW9S\,^#ULQG3W,( W*>PF\$5%?\,?'28RM1K'LO=&# @@V]
M$?#F5$HIRD./<AJ]6$0^V/0YQ[+@:+)64238^00FV,3*F&O*"@Q-3E&+*;ZS
MU['PAOT,9A-+W8EJ2V.WCR/[MFT_W@.UG@O_[AV'@&MLI62$(F>N8P2#-DTS
M_M*9=4)_#[0 3'EL5S7H"MG*%WO?FXEZNE!V4Z:K;8PU)>-*IU(2J /\+QW<
MU5_>YV46I&M+RUY-1UYQ)LZ2X\>)'F?I<\4I.>MU\UDNS;-'>E)A0&F-^',5
MD]@Y9TUY=,K^^ .05TPUB,9Z3>":N_QZ;USFR*CO"!M#-LW%?F$SBZ\N^NXC
M@R@G\/[C$ZBH8(%J,N5D'ZV!* .$-8D,RL 5KA*9#4JE%*2=!W4DAAIR[;/M
M]#^HQ0@_O Y."8 %HV^8^4[.[$R5XZ[=V.[.""_%G4IC$)[F?/4#99]Y-Z$2
M6W*>"@/Y+NYD#L$9(Y?HF"9P^,*$ZD@4+M-9GQ4_QG6(PR/:)U:(OJE8GJ8U
M@LEPY%7="Q?MPW4VLX[ZD(E4$CIE9L-5[W^9LXXC2GOT]#$_ @1SAHR-D4*R
M#)6VO(O.M\O%5_'-ZM$SNU<\V]-]'KD3/1[[Z[@)/?X&R^_1E_*+1=TMAP3)
M&O6/;V=5WI-?&I!AB;<N%[%8V(62QS)AY'!Y77U+$M[.)Y+[RR;7%L)(VQJ-
M#HU1MY8LSJ#E-G"I%X'/JS@F[5"H- 1+"B@7\@2(C1LI,W$"3-])*VS-]<?Y
M@^_#JKRX>W--B8'5TV=2$K*,3QY@:;8$<3UZ\<BE39MN?@BG=\3?<V2VL\V8
M^S72+LN0#4.E--DX$J*1ZW.T4FC<<J!Q^S#?,U$" G)+C^3%?SX--+CXN^%%
ML\C'R'.3?K6=^4=\EGX"])+51BK;S+K+G4*0L60HB+RK"@[C&69G/H7_>)3!
M'RX[*AV\WA[)+4D3AP()%A)+K(=%J0YQ'V:)$M[&GCX[]I1F3I8>4C75I6SG
MP@Z92TR9/OA<!L?ME@M1J%KWA$7LCJ7)0*<ME<*E_&Q"V*D==G$)SOT+H^%Y
ME?_"^'>2^">Y\;VX."PF8EK.T$UA"5GS/@=A\[T%NE["N:4LP_GJQ9%16WY+
MN>S\(V8/]PAVPJJBM@U,LNAX398>CZ_F,5H]3.7JN'O'KY%<0>$9R]XQM&B4
MG I=.(FARK'==T=? BCS^7&(RX607-"\8P8BV L8Y8QL5%BI60G@L0S/6EVA
MLL@1B+66>UFENPY4>/!"'%;DXDN;4%<,N3M$[]__81/ 34->MYS#UK$=5\\F
M]0^+:Q6_-6)*=$86;!R/X?*;*G!HSVG4#'9  WJ:^/T[<*H5. 9RQCZG[N!E
M:)U U2='7?J0R*P[&WSV#CYCT$XXS;,^S-9P-F0:['35"!U&=74%W#JE?&Z;
MY65QOOK1IF+9O*?$&65'AV^?UYQX5]"=9'MD)V$JH45/PU[-YA@5!B?K)GJR
M.2/</Q&)^ \+DS@K:LC5GSC?1OW)?%A)"V?HHOD-<CQ6.]G!)B<D:YMNXV9"
MF<"_C)NK,#W&!"Q\16631K66]G'5U^+!]]:+!G:-D)VI\XULR9?XGNT+I%B6
MLL%S)E07ARD0@MCM2VD&XKG(+NGT)1EZS$1?"=P#\""*5WBPVI1')Z!Y^KHU
M&_$]BS213KJ44U?9L W W4N-SX$6QT8XP8830=9G %Q^<P*XG  N)X!+*F5^
MW^VIQ1:HP2G%B=L)[POB)4G5RH.SRNEZR#D!F.>A/3(W"/X89[G J=Q1/+G,
MLRFR5!Z;6B[S+'--41@LM^%6.1Z>/7E2Q&W"Y>'[Q1"GL)3=S_K98GV%R6RM
ME5:+$F4:*&?5F(-:$,9:U!-%\D^AA'@Z.2"BEG1!'RW.C8;1)/)S@ZH D@S1
MAPA'GHJO2_X]]8^LCMF\@F 3$$5HDL4!Y&?*>(4O+! FT[EB5_6(W;")J9Z:
MM5ZZQN7R2K&S !-97Y=<$%)O;%SK&L1L7.J,9N3:%8X^G@4W<2IOB#2^H>(*
MZ:66'"E0/.7XMZ9-HG.,>-;>:H#Q3"<%TTYEG6.+*44!M7'-]"Y;ET'T-6)6
MNTBF6O%=1*]U,N?.\<?DU[QB94@+OJ0N5<U B(WK]I"#:@ZK&:R&!4(X<YFR
M9,G$Y2\^2(YWIWQ.? T(<;6C8%UUZW%'Z>,UK6I@P]#ZC$1,_K*S!S"-'[BL
MK"./8UR3[:GIH;%&!TOS3>[#[&!KP5Y07N"2J^G3!JWTH&6J%KL88=;ZO# 7
MYZMW[$Q3%_* T$R"@QC4UM2*S#V2D_X P11H9*=PAW[=\E[2+L_4-VZF!ME]
MF$[1^A8S]YO>\@'K$Y0!5LVV("E;,QSH.""B,9[#6H=$T%"Y[ -T< F8PD$\
M3,R-WL*&R77O ?" (+=9 Z)O"+XO3LBKECH>A:_0L1Z[1 OO6UDR+V\4<<F?
M:1M;Z&[*7O/P8KNYI615::LE+@N3BLR1GN=TZ':;CR'LE87Q1M05&<FI@C\;
M(I\*CMW$R2/8,Z;"%S6 RQTR$20O?E1PC@("D;B6=0R*,$^\Y5#U4Z4=<[LD
MI9OK*35Z%6'KY*UO;%(O8<\R>W,U+JK#GH?SPO)0[79[AAHB_4BS4! #Y.V\
MM'O&S8Z(2@]GDDDB !5)WT&+G'WO.#&E,J+8+$>'HV:Z'B'WJ>A\$ATFZ>>O
MPQ5[EN9R9;MZ-LA,Z8B2=WJZR=G%X) X/8%/5OI)+B0N1]^5R/:5AE8EF)6D
M;^I2^GC\'ABO>UU=5LH![UXF[=6307*R701"#7:TI0#:NL)!@1&MK3[HF#>3
MZRR09'D>V[H2=C&X, E;1+?T^=DD7*YVG,KQJA15-;F>E$E%M1/!1G6;V,BF
M:J6Y:..E\2,P %Q4V.DMX#B>M3/REA+]U2^$U)2]5_PKU2$*EPWSN-YT<QRK
M<.M]K0JY4?',L0^ECQIBZ)F #K ;Y=P,"PQ[\>A;ST72D*0U,J2I(*RM=2D!
MD/#91+472LH.YI/P6?QM]H]TBV#)&A@CX1GI;=AR0REW;/1S.JKQZD(=C/U
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M],=[_PX1' *XM_H8[](L7UQ9R?G-=^]$N"_>V7WEVQ@'L41JZ=5<;UL5\#%
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M/=W1[;DN3<Z6SJ_6=]@URC4,B<&M.C932__M5R@"/3E??7^L.H&%%NKJJE)
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M#E]Y@Y8RPHIWNICC99K>VJNV[D",YQY2R]6V@M%;$=JFY;2"'O8*\J<&[(@
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MO^BTQ,<EL4OJ[^!9HG2%L>+AF-[OX2PR"#V&CAN!NFJ@B#=(;E9YQ0[>C95
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M?<E._9A(I&5G=H@25GV-?PWZV+(8B1T+12>3$(C;&57(F ],,N/X*6,$K8V
M&P)4.$)=A@&\#7*0P!:),)F8Q3X"J"LT9$VHL=:H>1;<>W$5<8^BBWK26+>H
M;?0!&&J&.!KW=)&4*2<$U>5V6U:='&M"""XM&%ERV@$'#9K41,=FM8TO X?.
M?3%Z[O39P%-;O2B'\CZE9Q>S2N+H4Y#R]-G7/ PR[3/H124+([-X^C599[QU
M$-' R9?.5W\FX639%-UOX6P83Q:E$LJXO5]&HQT;V?P=30-Y;W4M<>)E? *A
MX"Q3*I<258:(HB+"1K;['I%8NRXE4?IM/"LH"'MSP9FD^+MW( U^L=J6:R[M
MYK_X+IX*<7JN=FT;5\:_XWD/+K5%%><XWJ=?GO_N?Q7S9[TE_)^[W'*+V--G
M7^$JO_W-^=//N8H-XT?QLQB)SS5$:W)'B-[0\5W"Q;1U;UM#)G8X;4;A-I$@
M8ER\3W1")@V/&P/B7ZZ[5F2Z(7Y\0EM]&FWUU0EM=4);G=!61TJB_T7\-U(>
M(3GK_CZ=O#^"E:$%:.PRALCA1@1\$(>P/RD1!N^^=3T_$X2,*V7MV['+JSOH
M^1B[/3>@"CP7R2;F$+J5G"<!5UP9T[H5GD\OALZHFD)U>D=7\?SYT')8& CE
M1;%H<X6&+L3MG,@ T"C^ZLQ4FD3P%:Q^R5VVCWG$Q8KAR\7*@$/Q$4"+=$_<
MRY^E:JVI]=<[I%'B^_M3G-?>*UG_W(L1QR[_^F?].#4R:-U0JB5J:E9=OF<R
MV[F3N8YNE18DV2J)M*_UBS'W>"V%3]_& 4#B=(/E-V2U:;95KRG9?+G E@YJ
M:[BDFVCE3<93T%=/M.DG=J]?:.1O2\8?G$C>'K09O(Y^Z171.9T,X6$;PLN?
MZ%V17-S)$AZV);P+_9[RY4(S<[*&!VT-B=^B.''"/GAK>+^ONFK@C%:-3'Z9
M@,,/AQG51VZ L9MR+$5J5RVA',(P:(NZM+.[?$AH&.2:*RIP.B9=69JR6:J6
MM%(!D"B;MCE0:YLD80"EB)>["8=>+ZP8 5)>96GT+/5B,:VHH3"RP%4'(/@K
MH"!? ]4>,[G-+?7+4!=+O/9-2N3A5G*+?B 6S[&I_CH*@0L28@6^Q(!1*DY!
M&*GM#!DE6"%NL&.83RCC-(]#1A&Z;==CKTA<EC)?EV#,IMH'1!SO1Q+IQV"E
MGQ)(L< ,K 3>;(0Z2 I;D/G<!\ZCF;KZ;C<V N9PD.C?$_Z96N@'*D53\BY>
M;P,&YRU)QJ,]KB^ (+;*$"Y>A[)K1)IRW/6"^P$WSCZ 2D0^)[0906VOP2\@
M5^3<B;WG_ANZ@[]%<]5"L7B_00[&#Y_)R>,/;AY;YL7L_S(<6B5&X^4R6R3<
M 1' GPY"(Z5U[\^:$* '4=X7T"]GVQ72@1R2H=UH$K_E1M9[E73_7C8Z!^M3
M,I N9"W).#"Y5\1_?UZ553;K6:)\'SH T(EFN&2E>46_"0W&'HU\5$0D.W=0
MD$)Q(-RO.S#7> 9#40K(?@0^LE..1J0.:2,=U]R@N+7=??[0EV4-#N8TBI4L
M38:/L!;S=4M5_="Q[C*E-_E?[@'/5^^)7HAVWCJ^IE/J\>1$_N*S3!>)[=^7
M)&;61U/M#+8,WD-55;[A]04@5X]>7#Y!]/?[EEN[J/A)@"IQF@JX-O&:(&JE
MGH\Z;(0\\RK0"ME?5VL#./PB/_9DF??&,C]$)ZJ%0GLI?BKUI\8]E??83#8E
M'1ZI\3-^:79J2*4,%5]J][3&>Z(#!@T^=N"2FSZC<^6W;W:'S<G!-U3AT[XS
M./AUNCUW)H(&F-K%SR[1U6B]JGH6@(SS9/</V^Y_U((^41X 8RH"N-+2:'\C
M*=D8?1$7:#L.A*G-O0XPMXA/J9@T! E5MQ.V3(8["-$%2J0#.TO6(V9L%6-W
MK&W$W2?G>G,.6/Q\?4U4-HPAY$B7FTT(+TC+L](%S$0<IV7PL)>!)%B415I3
M(;I5YA;8L=.RH>AQ%UV,04OXTL;/\:IP'R6  '>H C]+ BJ"[:9(O5V/.\;)
M#M==.UXQMF H:U9BMD2(II'*/LLZI59#RS5MF+Z*$$%[]%I)?[(*D-%'7[2=
M!.XG_^>T .IZ F8QQ\*1ME0JD5=$ ZPV CG#?]:AO D@&QNT/<^. P26U39(
M7JJ7K.<7Y7K-9-)*R)W0SNP?90FOI!=E%U;VRO8V#Y_[4"M?4BO]C-S@'L(@
MB#A*^&04 =LZ_,1];'$JS^+]B_0G@L]--<ED"D"'1EE'3$"A,Y4=312Z##21
M+4_9)B[]C_RLU<X?7!J-G/42;VO* +AX?>JXH#Z65\SDY7"#AM7&E<$S@,XR
M<CTW=QS6,0ZJV[[=7Q]2>ZOQV5&3%5*/S%O6!U9E!*%I=$OC*Y$^5J(S*IDF
MJ/FE!^K_8.KI[[\+)]Q>5.!$$*G5UXR.O%^</Z^;JZY4-A&?\*\$))CL"8L.
M9N$(I;&T^[@/,',T=3_MV?TCKF##JFM!0(-X6<)T0!.]%/T/>:+1KBGBN@Z-
M]FN/W'N!UD8J'6 YJ$PN>X'MO@X28%W&Y<5E#)8FPZVXZ3'4=/$5L28?J,O%
M<(#L.FZBIR ]5-+BPJDX:V3AT@?YM+S6^WVE!1JW;&F(.[2)=)@IWIZH(<=Q
MV4M'8V)2C-_:2;]:=+:WO(VR4UM-'N5H$Q!6\D\5W3QZY+]Y\K^LC%6WE_&F
MM.N!=Q<T#=L0+8$GX:OT50=6;I04D08,[9H]M:GTU'?6M;7VN/!U3NTCGVX?
M^;7>]M0^<FH?.;6/Y 6M%ZG=%7O2AXY[!N_32?MC$,[4K/)MY6W:<J6](N$-
M!FF=1*S)$:34-EU9R4N$ ;30H\^#*)G ;S7=V#M5I5XZG%P^T^),+YA"?"CX
MHQ6&)^W*T4>GV]*Y#=J)EYMQ+7YJ3SE_U-BJGN\ATBC**4%MU#)JEW^]IA @
M?&0>_+W00<6!YV4 +A=0*'^/*KZ"X6.._>__Z_6+LZ>_6]VG1?&MB08X";%G
M3[1(1+0:;*F<21%/"\(,]!77_\SU5;*=L)EV<S1>N2-C\AV[2ZX(Z^22?85=
MC-7LEJL=)3^WT;$<./+*$1C;KDP57 [%XF J\&%LC'A#%#B2\ $/HD@U:=!Q
MM!!)('<S#NYC"-QI)0"MMA/I'R,TIDQ5C0+"0#\CE(9_<&- EC 6RZ3<Q@C\
M5/4]Y99^*<!<N>7 N$*G@*.EZ-Q"$GG00DP.5MJNB4Z1XY_P,6[W# QBE(1/
M6LT>]Y3!?%!6]MIT&D24G5C,V7N0PP+L[?%="GN*\Q<DO2=Y.J+*)^;ZL6;V
ME;^,_2"D>B)62RV U%$+CH1K2A)PJA!IS9,A/FQ#O(#!P'0&8@*$^VK2QYD>
M!F,$R%VEQ%6TV8_@1NT2>Y"@L'P;=S(ZRG0/I"8<_W&RNH=M=6[[HR.V8;T8
M.S^9O068<BT3G"SF85O,VR5:9>8B8QFB00(+0@ZE1(M9%PB<637ERZ_#-SSI
MSHL_6=9#M:S77@V+7*I4STQ;$NOX=, SQ%!8Q4/&7@1P+2Q8&R CU4/"3WN0
M6V:V=[*Z!VUU<3^[CBXX>U[QH-M097 09N$,SD8ED+-H>&),0U?>A!HQ0191
M9L9UZH!\Z/;U#N3)K&[0?U2VT.B2-PK$2 B,?S'TP]\?\J@#41]2<E50+=/<
MJE#ZQZ5)<%#?$XF\#^<]MUL*EPCLKT$[ >@HT+DON?H+HV+.M*'N1Y*>.K%>
M8\L-@QWS57SWM[?G>S!'G:_;W?GJ>;L'_>0$R#CG 2^4W1E0Y-GG_V^A(GJS
M3W]+/V;8?CW12.;PV]CF,\D$^OS0CC':#D':+3M$[)SCI_S[:]3F6NARKWW_
MV&VX1"*IC)^T+$M!L5E<'Y>D(<I<\\P/M:66 ]"EJZ1ZSXL']%N L75MPXU7
MJVU%=,&T?EB#<.P:4NQ@/GZ3$OH 7'-21Z&B".-U3'2(<#1E Y9B,-$EY&F1
M/4 E8ID"-@4/G$!EWYD43N)J)Y0+P\>8WGZ3SX::0?.I"Q&NC" I+'-4-0*
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M(V*1&_E>9'!<<X[GS3I/O#1/_#N][#I/O,X3_Y+FB?^1QU:, \QP33CII5A
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MFZ8)5V]<)(!%2-QU%.H<E5J3X%KV;Z%&S!4A3F@ZZ@SZ/U RDU!X36 YRH0
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M'2X"C(B1%_I4MO[.0&[\Q/U??/_M?UV\>O7BQ>^*C5_3@SL<OI2:$X#^]_Q
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MI^U_Z7S7P,AJBD_<%/7L1CQXU4D53UO'>E 'IN7!T91%&93_4!"F$KT(]AA
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MS,5P@P'MA;P@)D0*(9N+R -7F%D%<GSWK<0/\9$Y%8L?J[*9A[QL3K=3HA$
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MVH*D$\)_V'VHMN[$8%;\^_/X[]^_>W_QXL4S;0Y0G, D&1*8<WAGU'"K>--
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MY&+-L?$N' :XZ6^_^OY=,1NN83H1L)LCU#X7EO?O8&_)Z_WGO$T*?-IR/SF
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M[S7>)-<+7,._L!V[O;^R6C6=;!T*E9 ](MX(KB,%SQ6JI+H;V+.%_JI@\U3
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MT<>_ZVR7=> WR./BF79R(5WN='\4]G11?C5Y8-XZ_,2D^V!ZVTM0!;QML/+
M1\"2%ZV&>25!8CZTNP^"+R42O[*&D0/@HY;4Z_+-OSN5O=%.#0,?RYZ'6.]D
M-BP2 0DAV\.Y\#CZ[P&=A>.R<6S25YWP2T*T4X\X,ZX[L:($?Z&:HLT9OS1<
MZR<%XOJHP$=O@1UALD(L(@OP\K%&:^CCK[+I#4 D%>K*>0_G5I(^PBMYN:'K
M*<$B_J2 WX)Y VJB(BN3'A)UJL$8D7>V)?C%'>Q]%%"AIUW!(>A-$E!:9$\$
MD!)ZY:H914>1B*:K,A#S51V9^#EY:/H],XB>H5M$E^=1[*V)EH]YRY,7:RG;
MV(YHF,.Q&65?AD7MH9=&7II_2Y;2'S(W*MH<"$R]AX;7_<KM'"A//G]>;"CQ
M+UC3:;]Y_N*WO"1D=Q>@E4WI3Y_+O_O7Z*^'=-(?O]DG^3H4YMG 8S;!(_4F
M)59E7F-_(?E:(4 M[J<;WEL%2M&VNJY4%]1$<,I.4-@[T!7J8'")(0)1;Y!W
MJ6GN=G2^X<\B"3=#:+^RAMZ/B/_=BHA?$?'MBH@7YI9 \9Z<XR%?BCXN2Z"-
MHP,7RD"HX^TY/]&A:IBB2?TW&>3&26; MC:;(PX$1E^&GS',DBO/REK,_T@[
MMQ$-;$OG+_(:FG"Q*EDY5S+CO!Z+IL)@#VT7#^M8ZUE[BJNES5I:D(%<I*WR
M7VV[H0\T5W'6-_F*+;&9KZ^&][0-SPCL8@JY&RL=[6$.._X/3LJTVZ6\RSR)
M'8]TS:)6HWK:1G6_-U.50?Q'&$B8<VO<(N56J"&=C'+SZO>0X@D739LV10*G
M-[5 :(:+@T3E)$=-E6]Q$!X$)JL'W&>UYJ=NS4K!P48A>I#7U:E7KMBJVS-X
MT%_'V[$JG+93M@1'I7WI$29RZ\QDT Q=R1Q*K;^BCD*JH&IRH=4JG[959E0?
MP<U"/:MBH533#<Q<K55>0-\4Q!S\0YJ<](Z;G+=NXVK!$82]L)K?TS8_$QX&
M%A;KSU)%+9H/\J>Y&BL7H(V+L^:8N%O+IHQ_U,@BFC2\9ENS9IOM\=@K4E)4
MMSW35>/S?10>V_L_K^#-U:C_P.T^-6G;<TF:,:8!8QJ++FW]/1T,YX^S""7J
M/9%+ $9!%  A&5'V'XPVE"%M(!!8FV$O1Q$\GLTH%IK(7(PS/6CZ@/53Q"WU
M&-JS+X$:$D0(Q"5U!-R;:RNZ'ED1B)$M-M$B=TU<6@3UZ;C ON<T*O[RS^]_
M?Y10XZP:NF"!'[<8NNPA,.R)69>[OXP^BC- 7L$ L=IJMG ,-]K[S80UD]P#
MT*/KMMZKN DQ"/*^6UCHB5;;HX*Z\#(72@.C8%LL>[+>[:%@C!Z1*G*M@( *
MF6+8+4GTU."\@Z%;)8I=>8H4+ 'X5FZB"'*BE^1?R& R0:EWA-PQ489G@8OV
M1 '.V,2^@O5OQ,"X8S4D>K4J:M+GSYD\HR)LUY;9&D)]; C5$\T(V77;"/(Q
M4%@2>R-<.#6("0B$/21.S3LNP?RHPHQU7DIP%B \A.@ _NA LQ3^$]?52DGQ
MU&T/-%A[MV440=D3[Y:EPEISO-5(V$C*(Q4'!,D7YHN40(!PH-Z]-%>89B!6
MMT&.2OHN=(0$IP).$R+>ZZK!7?B#><W^G*H)UJ2FED8;C<_W;MK.#J!0UI;/
M L5O-_8'"D.71YO;QU/G=I2)B($QIZ0]1]D&S;8-/H:ZPO"$Y0FFXM&IY5^,
M Q7R=?\()$I/+-3X"!+.[=F$RZJ!&R(G#.W)/(JW*E?,!O"2UE(&W! ;8$L*
MC ;V6?FL6*-V"]A?84RKR_L[R';X=WGLD[X]:##';G>-2?:82-H<)JI'K_VF
MIVY$WE#JVOM3)BSF.1B.TD,^"]Y:[S*I'$'#UWU)G^A-R=]JSJK4XVI83]NP
MM,X8CC\-QU;#>-J&02<4<KB3SE!;0+AE.,[G3Y.Q4QZ]+D^GVG^1C*-J]N[(
MO\.#/-3SZ>.,JIN;%-/?T2^?6<BC&U;VU"=NI@E]25#^G<$)?7#G6-!5_)I.
M;R-9Z$PDMOJ_IVY8^XIZ9>+Z8H=-2Z%]I%+E'JDWHZK;[,OSQ=!>[,OS9%IF
M-:BG;E!$AC#6+(%E836*B2D,((8;QDI%(0H0Y*I\P-_TL6,8DLJ5;O.I&Y@C
M_"H35.$LI$H9QOE!1,-Z8VB4-FT0?('@6]4FXNB@9L 7IKKPWDY)T\/^>BCG
MK1[NB1M@Y'93SDX*NL)<2B$4KR.3GS$@*0_ Z =\5+^VBIZ\-2&MO*ZHQ(^Q
MN9@66B5"T_WHW(G@5LW A/=H$>R19MX$$AI%,I4]$%?'+7%2I;"T_Y7-HY4;
M8HD;XO=ZV94;8N6&>/+<$(QG_,&?J']J$-W]AS_H]NUQ7JJ02R,B Z%9[.;K
MD13DRX9^0CRL $F#F$@$D%[5[9:&3WT.TQXQ<J#TI\5,VU9QQW.#,!E)D7 ?
MS@CO]@H@3!]1RX?I[3\J .7TO1(:L1)I9'Z7_L>7WJ3_/_]>-B/QT J!TS,F
M$]R['4JP@AP#G^3!=4)0Z,]*-IO=EZ\Z]U,U%/R?^R^%K995]I@3U.2G=!U*
M*EJBXSLR++W9..8,RZFDGC$+8!0,$")'O[M'GY1T9 P#W==1^#I)]TUSXD ;
M%O@^^4:9.^JZ1-_,7S[(5$AIT$<-PZUSL]:DCY:9D[]QHF>#P?+W?$+4 K&]
M<!.%@%WK&C.WS+3+FL]REQ!A]!'(CBF.DY%%8_^NN:E\^J5DE]-[+F9?NN+_
M0$9%_(E%6,6Q^="TMTTF&"YW9<05(P>G<!>S??AU&(\HVQ/>'=N2+Q5N(5R3
MN3>A<PV,B3[CHP"1SX!][:M_D&'Q #78/6F?T#8B2<ZKSC&P'R^*MB)]]0?^
M1_]#K]L 5]F\U \'27'_\=!>@8LP?9@2"9KZ ]Z$SSGW]_]$/WFHF!\TN=GO
M?>Y6E<PHU&R^*\-7+S<_^&#=W''%B(=F+YR0-"&FA,57:.XL;,1L872]LF4\
MM?UPP<O,.J<4X8S""4RJH1_V?L5@>-.=^8!%C!N'+W*A\+1DA-W0LLI*/>QM
M8W,5Y.3(D?! 'DM5^NVI,P;P&_YV-D>_=DKB=-6V>XY!;JJ=U@E=>Z*T]^=Z
ML\),=V"A@K8"OZ+, 3$P["<1&":"7.)2[0VG^[6/"^%J>F5^;@C.0NXQ>#5_
M';Z+R\VWU8W<;ET25/G F1@CU(@RQ>V936HP+FM7.^^ ;BD[-',P0WB;?.OT
MSJ7%V*M'8UI$A#(TC-'>!N"9,+>.C\8?48P?Q@[N]Q<S%G--I XZ#$I^B=[H
M;1*0'3KO"&[;[@/F'Z:ZM>J'A(>9R4YV/)L_LR?F?IF.IOW8#]W95BCQ8$UY
M@P%6K8O?MK._T-/EM=99TJ:JR&(K.43]4@?\H/T^VC^0)@XRPUW5BZ2RCLV)
M)WF8PYK0FX9NY4.\44Z&_=#XUW;MZ0"HA:9#'I599'F\3Q82^PMU9.(15P7S
M17'B.%TC8VW,4/W@^)Q]M_>M:(MPU _6FW96FX+YPV<XO!8NBD*/+%N,"]LP
M^AB^][<=$C095,@T13X]:<E+-=&96<>%^X<+)I'9/$'RQDGWXY0IA5'WS) L
M4Y@]S,M?ZT"ZXO@F<+YA)-2!S)K/G4V[VXU=H/G?@DA^%\8869Z[[>1=*4$,
ML6.0-L),GK;P1#HKM>POV-8SP\6&X3G&^APGZ1Y5(!FS]]=O__O-5Q?/?[\A
MIEY'B36:?<14[FT)\[?R0Z(B$!4F]!O*6GX//WE,P"/Y;4:P1RP_/G \4RJ%
M*,&_!@I0 @7US#CCH\J[WUHB&3H8MQ1F,3$QV.9;D0D96(@^6W$.#J^==[[7
M&W>J\'IZGAF^PB*F_3DI5,\3SEEXNJ:>EEVN-?R(_>#?+ -"F=LF_BR($)N1
MQ&6XMQSU'8J,LTG ,N83,3:.N6K\1[,N&(NUN#$);>EGQ3L8-G.XI*K;7P#9
M9>Y/YV?G'B.2RO=,=AW23!^P>W?W#9J;)7EWCG.\OT-Z0#= $?V&"F+J[Y7J
M_+#QN;9WX(V/(O:;]R_?O;]XW?[WQ8O-)[TCX03_O"-<;W^J.G9[_;G9>W=/
MQ1"?I9?\_1>?%CQI&OX4G!RM39]\V"\.1K[IAO U]0(DM-'6-S$[E*I;< XX
M@WMO!B7<]9'POVI;\F0^%B)G0%Z$M,<IZA7S>12N<]9I%LM>4_K9Z9*9$DET
MB^8(>S_@I*8?#5$,_<?+OBHOOB]W9.7V1S@21"),O\:AY$Q!A,>7Z[*A9E3;
M&>TISE:8<R73RX0H+QC30X"C/\6'Y3GQ2R9\CILP&6UGRZY#+2H;<9\A7?6K
M=S%U-@\=FOE;7_DZ,O-86[\OFV"##78LYK58-B5D(G&[Z#&8F:C?&\SFQE J
MJ5'485M(T;:4'QUFPR[AR-";R'>!;&P5J]WLVUY)CV@_G$GWEO SR&AXOV.'
MA@ BWZ9;^JVQYP=#J.W_YY[_32O9%-,K,LSOWLF]P3,4FX/S.P$J!>2VBDW=
M2GS@(W#GWZ$__6ZI&#PJ^9C)":T#_,M(^>! ?B >_/Z<]#%)2 SX.X 258/1
MW>*@9T?I801S#RU)',4UEES"7G-?04[D&CF[XBQ)U._ZW%._PWLN5,!HK?L9
M4FB9#J0"0=OU)HOROW?C,S_-HP!K'^C<]Z$:PERAK9*N!C(4L;A)5&P#X?"Z
M^J7 QFV^^>IE$5>0*FUMDXR]SIH@7#SFQ72]U%XH N3!GG1KY$:Z>";,QJI%
M,+NVBX_(^EGR>@I>-&[I<M- -X"0V(8BAVLZ'TQRE2E?^>R5:7K'K\MGA*7_
M'V7M7[C?RF]04):&!6IW=<NOJ9<= ^.T1UL:FZ_@CE\>N.,WSU9PQPKN^"6"
M.]9@]-$$HV]1C1%V3?3\+>'PT*9=O(&(,R$)%8H7G 82+(*""Y8A%:2#H*WQ
M)ZV'!BZI21&.&J4QKF'J OIJGZIV2GJ(D@<%9:XCN"2%<5PZ-L+)4M?C6T=G
MD?^LS44J_8XI2QSZO&8!A)]."$'EKI)Z(8MNZ-G^L&"$XW(NG-D84S)=\ \J
MRF4F[0]!5M6@M='&ZDH29B+LP_^X]J^&!&C#"#YZ)W5[RUUD_X/7/I*5G-Y&
M&?X!?;Q40?)!V/=BI-_//JGED+,K57"?:@8,9:UIH7VP8#9:-^- ]F&%Q:QH
M=HM.$"ZK8W.Q0(&" :'$Z*U0$_KU=V][$?ZF>)LBP]V'H"_GPS^?-?14)J.J
M=5UK;!R3%UJ0K 3S\OLWU!9/-DZH/'.68+<0+P9"9E,831Y\)I:W]9[3->IP
MI21Q1)I5^QSF0[5UIT+^]?EG+^2?Z6K?OWM_\?D77WSV_MGO?_WL^8O0!)3/
M9I]\\>(9KP?5[0?O? X']/V)6LYTYUK(B  9'QGS-7LPFT*02/-8@8^!!4#.
ME;^5@X?XT,C::DEZ$@&#36"<C.D\]U_+3M,J_CV[#01)PN$[7=U1PAK AVF!
M*M:]$U7,0@5^>=R *[_^9LARK)YT3>4_6\7U)G35E<?"O'"MTSVDFV(QY@E;
MYAU]DG7*X<E'%W_QR;P(.:,0K34N%8G,6JE<AQ:N7?*E_I^_A;#FF9K0';5C
MCRW1,+&HZW3KZ"%WXP^8PIJR.70ZA_9QU/&,^;74"%)BS/STSL*&!&,XQ!T>
MF&ZQG<^D)D=B]'03Q,M4;.B?!R<% 1 +5RH,W1(TM-%3]H.CGCNQ0%'OF[36
MJTB(=1P;I1PPQW>AO7#;>;[S09*ZCG;#&T>W14 ZQ$&E^&7@5+CLANW/!;GH
MW?WEG5^)78\;K(;!N21T1&3"Q3S;N)MK!)BC@?3[N@&R?01@B2TY;IX18];J
M=)Z\TTGE>8UQ6-#>8K!HVKVWU^T" SEV"RC[T$L&+ M8!09"$S!4\.$40I 2
M<(50XKRY<H,WZ]T'7%=5Q6,=FL%!!XE,&5D*Z$Z=J/W9FO^Q]='5.5#[VO I
M"W?-K/6AZKPS/OLEZ/,HI] GL_X@]MC4+[/_D/I]>^>R;YUW KSCS8/C5NRS
M4\7_NB74VLN:J,.OKMF9 K9/1?,C(WT5>6#2!?'VAX!V,R%DR#SDO<GMWO_J
MA!8;;I#>8:TXT5"R-S%XAA*(!>1,GC1/8@QFB**SU8$]<0?V1\;26-"9'G4,
MC8!0P8,:X!Q955T2JT^SFYFVS _<TE&!<L4M:W=M[N;R>V(00MW>\G8DOA"'
M7<0H=A_/^(MU%]HZVW,L$[\OW<6EQ+^P3T(Q!+%K4FJ$?E$@G>?"%>U=]/@$
M_6?0=M(0NJ<+<T?O!2!/1Y\M8[/L8MHNG'N.$&2ETV#\,'D]"$I=TQLQSR*Q
M;BZ/'#NVBTC7[)Q8D)@]EB%G#S3U=#3ZF_(/M"744#G]<;^.PX;$XFL=4G(W
M(8(+%_@KU=L&M PI8K[<O*?'E?\*'XJ#T5L7>GD/,6F#W(I 8VEJRGF0M]A7
M/_RD_? /3$BS9Q B2L9&"B&2T$<WLZW:$X%WRYT;>1@@JCI$9 3-D?B]>M,2
M',$;BP10R_WQZ.0$OGPHX>>%<H=^O2LK8#-VY:FB2'&X[A ]L?B:.I^,.A_^
MA#\A&\K_Z]AD/,I9<DLW@S25_F,/5H(^&<439+8+J:8 VC<,')^I<0M038NE
M!C0X=7#-/56J4/6[*>O1S3WY_^)>^3\//!AA%H@> ,#D0U]9KD-YX"Y_.H\^
MS*1W;/#A#U@Q_S#X*KT:,+Q&(! /ZQ&0<X^95!!\,P;<G&P&<-IHBD9 ?V;I
M]F:UKW8INH//QK%+!B%BWD/_=>4H#C_YW\TL4YHLA0WFJ?U#V1>-$\9<;5,J
M:H@T$RVE!Y^:]%Q8-Z=E'KTUX!2I_,,D\/H*PO(OK[H:OM9GAO*#:S2FHG6V
M&XO2G?V^P\@:"=#PA:00AWX1=S00 'DOD/0!O4OX$8.NM.04+4V&@"DS"G-S
M<LBV702DY=I,LRW!I*&CR5%A45<J""4-D61<_XR;Q$K/!95XSFH8^:V0@!\!
MJE?4RKVHE><K:F5%K?P242O_J*&F=]!7>)<"';^J^EV+MCFYT:]L)_JPH0KE
M5]32?1W2K\<R3!0DY\@]>T]]4R'#IA-<INKA>(.$8MJDYV -W6[3_&<P/KM_
M#@N<.>\UBM!T%!Z?0E2:*I@E6.'B@Y9R$SE'.\V8@!%Z1*]2EKWKUQ_5:)A_
MC]FT1M/&%8G*<WAX;_R'5'>.4@N<PE2=VDD+L$R(4(!(CN41';P$N/8G<)$,
MF&.% B^93N.W^>;@GX@+UZJL8E0I)6S(F]ZI$+ !/$ 6!9F+($"<,3<TN5[2
MX-3_N,;MRD*-PB>$;BB[\[V7$D0$'HG^]Q?/GA667\!<7NN_E' I&H5@4=.;
MF(%QT-J;MCZ*YL+=8@ LW$[3,B*NE#^0WG  "X#4I!?^<^X:*"#:__3;W= 2
MU0VE[A&:8H$A, &R$]=<E5<\0?V@WDN%*FA_DL2@)'D;NE1:3K_+75 ?(8QW
M\RI//MXYC7OWP6G36H+'T=;W_2V\^:^O+EQ#M &,K[JBZM_.!];TJJDAG>0]
ME<42&:M_N$NTDTF,;"OFO(Y6:8/O"MF--?0$FQ,7Q!HP_<N;MZ*$%XR94RSN
MM=,^Q"SUTF#=WR'22 [V?XZG>\4P'#Y9XO0YZXMC EWFW9.""@ VF4%QD6;$
MP)U(36'?M'7-4L'&PK%G2^I[(\$\2L.^<;%I?SNK@94?6KC.*N.TECH_5H%'
M,)3&K2:=30LJS 6>K>M2NH65+/EIVQ-+"E@;RI$_B4E%E[@:SM,VG&5BS-@N
MT+:T@G?O;$['YN5J6D_;M +?5^:)4CD=S6"2LP]T?,$0=:Y$R-TCZV :"6Y0
M<B>FMC+0>I5UO5F OZ_F^;3-<SM6A,[-ZR<*_U5*L,$!OU_) !#FDB@)H*+6
M.7+("#N>F65:[>MIVU=T?PD]'PEF"D*(629[M^L<,/2#P*C:A#O0_;2KQQYH
MRSO8SE9K>]K6)DFB=K&%&#*Z,95VE2*(22&-_ZO+L>'BR!*E'BE\LZ!/$ZK0
MJ^D];=/#@ UP(.[$4\BI 2V834'GI]2UB5]&LXV 5CP2F(0A731N$W#>\LE(
M[78JSVVW>L G;H8L+Z9J$CR?AJA,1^E=5Y[6N.S)V\E"7.9#L;^,E$4*LR;P
M3NA.E0*.ZUQUW(Y=CZ-UM:(G;D5-/\) &.FVGU8>FC.7,6(,E@S?TUQEKY04
M<^4SV]/FMIB(VF6_.C/A0,>HJ^5"(G:=?>O=U]^]EQ%A1B*'GQ?E 2KZM4FU
M+[U]G>7_\]A5_5X'OPC;RBM#O[%UC3M4D1!/(\IV'("PXO$#@O.LV^EI;Z?@
MAN.&DGB27G%?'MQP9NKQVN76E-"6A*:O% ]7[<?5N)CE*&&.MM.AI0\%B)D@
MX@(VY;95IESXXJ<VPO &L#N*@,8FC& +?!UHB8Z)$0+M_T'&CB$ )H.[1Z)4
M[8!\'Z@0#Z &#YB8Z<F$SSNAO)RM442HC3#5I[(.R^#"8K&F80E9[A0%V/"R
M" [_3L@C"G7I0BU>?A9P$B#TP T9,J6O(RPR>=B[%.XRSJ=8X%Z\*<;T"0XG
M8OX$0Q7X< HF26=L_U^#9U:!/GF11/H)VEHI/@6@S=52ZY'N$/!'4YP"QA]T
M\E%&.D CU61(&4ZN7N@SQL)$8=J88K%XJ?:>(3XC:#N"D#D%7LJ&&/P^$;&0
MCF<QRSYU+00U)+$;3/4D[S? G.SG%^!.F!5+*RA2.'D4#.NO,YA=BIT+X,T
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MO8^FLX",>APFORR=FNH TJG0GUC E;O 1[2:J/(+O##L26'0#$BG _0*&MS
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M8T2<:G?-=8GC'2F"+%6E9,+:16 =X/\1I,+0@\Z"59A^T:[<KNRAATF*;,Q
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M4GN:\?&3[D^[4[FF^.3Z/FA;(6\ [F@C/.^AVTW<\<D0U(%6Q6T)E4M)#7P
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M%J_3HHQ,=,G:>EPZ? T 7."<!$B/X]C\<7+[YV%>O"$)UIQ Y4Q8-=&=,[&
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MCIR,JMOYV;V*E/[W[]VLGXPTS8K1!S#ITOI17_;3^78ZP9D5CZ71$J4CHB=
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M\_=:2M4BJ&54]L1A.'9,!:PWM,6WF07A-5CL=&:^SA$T91 0Y0NB<[8]<DZ
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M?@@.)C!P9T3MCD_AEECKSC!*T/E5N$?:SAY)67)]&ITJJ<M::VMN\&0 \_N
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MF2Q[.?94[8@N=Q]&CR#E&Z(],+:ZQ@'R2E?Y"O_D=;S;D#:;PYN+W."I&8!
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M#'%;<FG-T,B"$)WI4AG%: HBW$>M2_-13HB7*/2,==[6<&>@[))WX=@\=-S
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M3LA3.R])_#AME\L=5?:U)# ;PO&17S[%XHF0K1(J)OW)76*5S)LRGV6XH#/
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MRQS ^IU@8=4.B=7A^Y.@X0'%3!G7SV![!TZ6_D$,<>,.D$K&3H"S-)GE!9+
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M-O[7P(V)4B=<JZ7X&-.:&]%\?/;(R*B49,DQ(8W=>-FZM5#_H>+_3J[/K4^
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MQ]3C]H([N"38F1P7F!XO;3-U*\QV9$CL2K+^]P:.$)"J78%R]&ULX0ZB":M
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M=!P^1L<.01#S^A@*&U?%G LQ+YG@@CLG8#(0X33-7%O X[W9<HT.W+\E5"5
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M[ZFO"F8^(OF"Y_ TJ4;W+!R,3.A:D"%$ %587I@.*8+H/\ )\9!49*+B?YE
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M".5Z;K1+?NIB9LBEM!0V6&!;9,AQUE?>Y0K8,[HH+VKC>Z?NIM0%GX)69C<
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MD^_C4O.16+X]_45P6XR\0+.G)) O1T [0& 65*6],A&=0#U,M&T7PS4IRH8
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M*OH5_ B,3[O0<*R.JS32]E,S:AZX,SH("E(2RR__XSI'JD;\K1UG]Q35[X2
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M7*@>X4+KR@@?G-/'^JAKGZ+J&,E-P:V@Q9DV=5,:5IWN7KTPQ4S3+8\O[E9
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M0SV/+NQ0SS/4!@SU/.N_LD,]SUJN[%#/<\?/^9/J><!YH\Q342X?.,SM3RQ
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M3A1]2*<7S%/6=W:Q#8M+7_8H^Y;E9:Y_WJ87S9.<&RMFF^WM,0(=1"K75SK
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M[??/UHS?NLHW+L)J!9.EO,(-+]0./H.\U5:K*>@P<&?]/2&FQX6=%J6;7]]
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M]Q6>L$(8A\;I^E"!'2"=$S@Y=#S@]BTGHN,S9 (?^]]LBV,[X$8J@]ZQ!J9
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M?X//RU(PAW?O['QVB:#TG%%Z49T-@M(+3.G-9JVCU('2%;G::3:R,K%+X&U
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MF=ZI=FJUS/(<&R4H>ES-TKQDN";SDF'!T8*CTW]9?CIK4U2E%XR@9;G9J;6
MH.5VM2ZW,R/H$I1-OB7H?3#QQBS,2?O'\(I\_?LE&0[^CK^^/NV=+C9Z9LV>
MJKOUZ17$G1_BGC?O$GV7B\#;45](@[<K_9?/RI5LJ+L$I9BW4VJA&?V+>F2H
MFC$V-B='_PS/SI(W9*G)T]*QKOP,5W;AW^AH!)? LUY?]XK,KJ4YCV01$8)@
MCY]@Z[56J]Y10%\VD6"Q-7Y=:5<[&3!K":HS8SJ5(L&NRXI@7D!%V1^[QK77
MSS6[+MJNA>76$!'8%A'6]K./#,&RQ\^R43.VU5@V8Y6G# HW&R4HW/RA6NHC
M;OW#4TB&U'DRM"CA;L:KD5:E!KP_^5V=C>")+ DN/+TXC;6+@S#AL1QM(DZ'
MRA7-RXJPHLO![[6G+!P5)2@BQ9.F_F<&]QT95.=I;N1VRK*-MSGD3U!Z/BB]
M\#G-@M*+0^E1QXA2XXZ1:K/:R(#)2U&--U7].I&MCF<U)N2"3F;>6"(_&&FO
MYN[MM\N"NDOOT%YVPPGFS@=S'_:TR8S)<.N7R\1E>^AS2@]V?U_6WOQ];H5A
MX>#BAMSN;'1$IR*?R@6V**[!3F"G8LP>7$,W5(R$'(ON_S])U^00LKOP]P>0
MW86_/W[9W<@5I-0*+;L]VW)Q P#BVW<LD./_5B?3S^2?]LQZ)-?7 R''0H[S
M+L<;]06L%5L']_#6([@YV]BC,O;H= Q;^>$I"+-.'8GTQ@8%*7^AVLPSGBBY
M'<'UL-_"W?W H:"Z65+$=.:X,[^\>4@U-EZMJN"8Z!88JLZ#:E&W<OMBTE?2
MU1AW*-7JT6SW!564ERHVBNX#52AEHHK[,8SCDJ\S((& )BX-2[4T0S4#FA#$
M((BAP,10WX@8%&%#)+8A.M7F^U0A$;E-?IX.3WNGX1_*M<8VA7^'I1#!(>7E
MD(T"DL APKC8S+@0C"$88R^,L0" ;$D#*^6N;H8%E?XK"Y,IR/]^O;LF5Y;K
M@913<F%K,TPR.!J)% )9,H$<]KZ70"#OU1?;LB>O8+Y[U')140ZU,9VH0D*%
MA.9<0GO=ZW)*:$\UM9G)K>EKP_KU@,U&A;P*><VWO%[T+\LIKQ=T9%B&$%<A
MKL<DKM?=K^44UVOU@9I"4H6D'HND#N[ZY914C"Z!! A+6 CL$0ELO:#"VK/A
MYF2@/N()08!R56/AX O54\FE85+R 6MY=)WJY-GPQH;E'R8T%W'=EUP6.M;@
M?BI\I1.X<E[KM%6IDY!K(==[DNO$JYUSJ4;)U0F>\(5"N\<V@4(DCEXD"BL3
M,\<RW+&0"R$72>#S?S,1"\W&HY^MOYZT3C89JUX[K67XC@/;P5V9&R3K^,E.
M1'4HL2>&A_T!HOD]=_0Q"&D,*[^3*X].2+,J?WCX^$&N?OQ@/'T\)3U[BOT4
M_1%GED-UL#%AH&#P9\,TR0,EHU ^8626*M3OD=D4QG;H'S/J>F].@<@S7+9I
M17"L<+FR=,P/@S%4,L&V<;P%!>X!<!]!; <^3Z:P[U<]VWDE4U-]<]YH9 WA
M8W@B.7S&8]/YY]B')V\.:I?XR?82<:ECC/Q#[]GK$/8^Q']XPGY8/D%^H80<
M[XK'Q+-'Y+_G3W4D9\?SY2?L1'C^IH:%";WX[B^?5QP OP)1!-,P3V)0[-^D
M+;,G3[I,RZOT?K;F R9L&OI?3U2YZ<XF\.7K"?$,#V\=^0U/Z?SMA+6 06KZ
M<O80S._#N=P\Q9_72:G_?NK,L_?\?I>W=S^P7\CO9/CSQX_NW3_C'C6QY*2.
MTDS(Y1\4Y/65/-GFS/+@.O.5&)9FSG0*;.,O,FH5P\)34;D20D5A./Q<SJ#G
MRN^\-Q!H%,/E&@J6GL#H8_4)-)Q)F3*R;*;0@CNX,VT<WB1RA]/4W_D==\1;
M3B*:J;KN7T\&W[[^'B_O?( *DIK/=?YOV+'<[%<! RR,=WE_%PX894?_N4CD
M)@$=1 <8CRJ._3PGBL6OD*C(X-O-SQ]K[_&&LQ=D;7E^3SA!P_]D60[N&W+T
MPN?HQW%(=8/NMW[EZUV_^WNE>WG?OP-I-Y_55_>SS[F? !C84VIA?L>4SZ,"
M5(H:V8;+?F,'2X*6>%"U7X^.#9BK+'YU0L[B)OW[1?RDX^JE,>7WMSWTL8?W
MT T7U##,I<%<>)4'T]9^O=6&<\(G87;\;YZMG2S _MF?"18H!S#[RX=7+/\R
M@/WRM:N6^K__F-G>YZ4%Y[]<(MB3\WNF)8$+>C " ,E%QM\4#I%/"31^YE;(
MGG@&E,[PZMM-]_[G77\8:ILC5R&#R%8%-Q2^>D CE6U(_"H#_BAR#>U5N?%!
M_QC6*E!MY@!:X2'F)S/Q@@6Y4ZM+_J!A=[6QZA)]!HI*4V<N[F-0Y3AT"KLJ
M? 38X[@P__ %J"H#'N&!CE5S%!PBS=04OX"-[%!0?#8?$&R0L>W F^NP4*<'
M6)^DAN@6RQGX1H!BHQJ,F5\+"BPPR.)LV/<W6\3?(07<VJQOL-U25FVWED>K
M[S58 6 87/7OKH9D\+U[]Z/;Z_^\O^IUKX<2N;KIQ1JX6^^9MYFO+>9HEP%J
M2CK>([:S67ROS)JJ1\[7K&WA&L@87PL/^?7UT[HGX\)?X0\$RFSZ0ES;-'3B
M/#Y\J$H$__GXF6RT=AF]P9E[]J;4M;@"D%5;43&!.X;4-RFM+MEN_CU3;$-S
M:VY/H:WU@!UN?9/J@9KV<V!*C6P3?L)#+*9@4C&'MA586_[-G,6FN'Y>@Z:B
M"<,>P?"=F\'0>)7-K]*9SS.\X!VG@+#%-I?KZK[-IRVZ2@]A&-6;.33L++W>
M??@>!>W,82D'2U.=K'MTQZ8S47+*77Q3?<\+(( UK[FSKN02D=;N9 WFPL'D
M30>3D\9PTS$DT^:*K0W)8Y;U1=T\;_>RQG39YO6C^ZH]B^_ZG=9N6\1,(7=0
MN$7?,E.LA8>*?3'./PP<P]*,J6J^1=R7,^-\FYS1U,A)\'%>^3C:?Z:P7+RB
MK8X@WVSQ=3!L[8UX%_EV#C#<UG8US9Y9'NZ7!?T*^HVGW[^I.,8WZJBP[W\M
M, &K!OS6"OQ$7VW5T?&'P'+9BA\*Q,7[Q%O>L+;+"((*"T>%/PQMK%*3W,%_
M)V]36@O#A0'EE93Q]F9]Y@Y/@N\$WT7Y3GU5R=TI&:J&+I&A=GKQIA1#<)[@
MO"TS8G*(*<%[@O<BO#>@(&_D=X-:V-CZXG0P-LP<H%0PWU$S7TY1);A/<%^$
M^WICQW!!)L8,JX[AN3GPPPCF.VKFRR6FCHWWBC\Y1\*07<LB7U7GP4 U_@/V
M+Q(9C'.QC1$T>>P!D/QB2]!EWB;G2.CRA^IY8QCA^I0,P0" 83BR#P]I09?'
M3I?YQ5:VC/#EL)5"HAO%RFX42G!?T8U"=*,H3C>*]<_T_K=Y*XS_KWTPY1Y?
M.@9[>WW3')8F^E6):+1L:'AULBRRWZ*V#*C.OR[^!-J "'E%[,GY':^,A=6_
M@F&FE'5\PQZ-A@M8H3H9S!Y,0XNF^UX:SH2?8<M*V,B'0:][^Y5<70 A5*M?
MC!=X!^MF-@'RT(BE3I"RJ?&I.],-L&SQKZ_T$];P#Y[N#I]&_Q>8CTJE*L,_
M_*.L5&KRR7E=^7*V,%XTP7C#WHC-S"QB!IDWIP+[V@LTC6\K+,WX967I!&!N
MF^4&:QL"Z,'%/O 6VS6RBN>OJLD._ 1CFGHN45F)]@75L!6\PP7>WR@H+($<
M/BP=IWYD"XHS<%FI%6$QC>7%''KPG[#0_G9*.=FX;.5Z]F3JT#$>S?%$R;7M
MNF B."SS^96JCDN01?1"K[W!UKY>A+7'I@K>Z]KU[[&^"MB] +X 8WMLF]AV
M"A96J<J=SWR!^VR<TB$AF+[+2J,(:-!&ZY&@NF-R:=K/Y1-YG)G+2K,(BVS9
M'@4"N\'_8'.5A06?EWG-E_ZH%\Y_V\M**W;M?'?8W!7F;TDYAO\KV(SN92N4
MJG-L1]?82B_-'MUBEQ5YA:MC_N&0KK"='&%;37!R)]A_^1ZP_'F]HDZY> _8
M.XN_7C:S=6SML[4,[USN;R"#KN7!CPLMRQ-OYX_=M_7OF>L9H]>E"FW_3(B(
MS<ILD?@:3?QA8  R7#(8JW #C<Z8<@/ 7%G::0$G",!U.P7!MJV@35F\]B\D
M.H)V[BHZIBA'A:KAX1.J]8J2H47-H@??O>%R]\8[6"$?<+0>'^OCDC.$O#&,
M@Z[ )KO5PGW=!?O;7MR):PL[<1-VXA+1YILU-V:S1OB&1>)_C^;\*#3GJ:J-
M@QIF[]GV37N_S1W<V;#U)4,_?!4I%*S@+9C913Z WL1V^?!\YBM\-Z*.PT]K
M@3G!R_ES:9\77GH4HG#^^OQ"_?/'4YAA8L\<F P&73YY[_X]F?(S1,E(-1P3
M)@#>2P7-.H$+'+P4OI["D[I\O/D04]OE1WK[,^.O*E&]M2LZGP]W9O+5P_[-
M2RN(OTIS%> RF D\>P WXWA@%?EY.CPECY@Y#J_[BA"G4YPD=:X#IKS)@TG=
M@K+<5]4U^.SZ?)<'3MO]'O=C@/0&T,>SF'PL3N%BV V:"(]%0/_%C1S(<TIN
M0<*6KC?8;I&^H"0A? ,)#)2'/U! ->X&3X;G^+(>F2C0C(E==M &/K%*IMQ:
MB2!U!-:*WX>3V3,,X7AOW[ )A#/:GN2)M4@?>[[.__#3,D+/AOO1CU]\9.*(
MMPT/!.'MUXV((<7NYO-$T)4TN"/2"=S4T9F:")^+2=^(ZBA]8'>&W4I-]7EN
MC*C3*3P\LX"=F4GY%TYX4%9<MU.\(NQX"L\P,5QV4G(P)'NI@TOS[O?X!\.W
M/F,GKLQ!LFJZ 5J6#JL<3AF?!VP$Y4:_]1<9+@$:?Z;LF"DV=T"PR)Y\6?!6
MN,[V QY0"W^DNK;%E@DV9S.'W5I]L&<PQ)AB^_T-51'";.10MM\)]0^N8'")
M% ZHSR@3.L<!\H)_1@X\%;Y/!'DN.XHFBELT;"3XK0/O!O>"%Z36(X@V^])_
M1511_BOZNLG [8<%C\).X[)-PL[YG;\!WW* 3)V2+NA3E>\T(HOR3-](D#]U
M<"M^5@&N $HE.X5GP]N1!YAA?,7 YSB=.5-<3QC$9R.\ZBTAT=&(VQX6$M8B
MW<U9:IO79I"#CVA X*SZ7&C9_/@?__X%D+O;J*BQ XY"V> 6@ZU1'5M?<5O.
MQ5E@*L9P?[DK<1VL09Q4O(-Y*2J>RX^ 4LR5E7\2(**#/<HI&>+"1"X.7X>^
MP&19,)2$>%%AP^]ZJ) ,>!3ZA-TM-=;S664KSAEA@EJ%LZ]NN!J8W/Z8*U^+
M:U)_*F&#8$<>X$DU9ZH7#AYGD!%V*@C>#YM6&R-0$S"-\*3&A'64GJ@ZQ1;6
M<]4MH6G]C$XC^._2+1#9:/3ZMK :M6O?I2VFF!^H:= GGS@CH@\3C%,&TQAA
MR8?0[(K8ZQ%?9Q2Y43],G /QK2\.<Y5EN86F;Y/]WT?F[KJL*!'/4)8.5N%Z
M%*['@K@>5VV<>FAN:D #+'V')>1CI[^";)Z(%KP>MX,F[/70K3*960N=_ U^
M7BG[&L9D]L;(L;F="$:Y@\K-WYR'-M4JE>!;G:J[>"?;6=Y[+'SM[S?XZ/@-
MGJU+?8-?!3'Y('_TO2]<*7-UXN*X45W%;HYF6JBA_9'C3548_H/R$63PR3:?
M?!N<[8 ,YDZ '8AI@G')U*@[>_@W-[B"<UQ-^D+^/=,??07"YCQ\J:CRB5T(
MW:;<ME5-_)'9D:\P<:]1?1(8>^_J+XEXZB]JH5I4P=:P3<IM"M]JA?M(J$DC
MS^=KS?B'8\"0?,7'[$\0;C"*X79O'BUV %2+5E3SOUTJ&Y[3 //%\(*576M:
MILT!)/BWO2IM,T&NYA8\_98FMU74"\F<:3_-R;JH_W)A1OW/B=75VVGPI[SB
MV=-/I(;V0_";H*2KQL[LC12";/ZH2GZ?-)I*T3[(C*[*HM_EWHO6CB^8"T9
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M'NO8&ZQ_*W;]RVD+#U<7AXDR%E'&(JK#4CL=S[;8RV 1Z]0)PE2L-E,B?]J
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MJO6*O68MVX-;P/J#?B,&_,$C-DV?JHZ'AJDWIBY%Y+$@M(K6Z\BP5$LSX")
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M%W*IVX0>R1M^7'JZ58K3E\SE>3\477YY.(=U1D5,_Y@9WNL)\0P/;QO\Z$,
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MN+^GB/(!O/]YK$,7,K1W&<HR'2,S&1*J7XA0CER;6>9M))>AM()HNZ0U-?'
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M>"[++:G5S-+_* ):1PS\6@SPJX4 ?JLJU3,MA1<!L2S4(\7SM(Y%,;XKDS4
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MHI-U>Y.8=#&Y5JDV0-;_]77F@AYV77;"B\LRX[LOAEOA#[WTS-\F#^,?=/)
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M11V%(X!G2#!MSB\X?\D5*EM^=AE'%_4B@3TK1F"/BI2B0A1*FI<!UV;;F6J
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M8D'2@ZC>T#$3Y:M5VOSR:"';RJLI9J?G>X(7H[I5'5G>"[XT7Y_K?\JH*0>
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MQ,RZVP(];%/-@T"*W9J[RSEGUR9MJ?]'9:WVLIGCHZ2"O@LNPZN8+8=)-9W
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M<#]#A )6O;Z:-2L\^O%%'#-Y/(5TMN2DG1%,AA0614LE2ZU#HUB%A<IK;,>
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MPR-N&-3D,T1X6"2<AL]0)5<S*6K2B\^!$TSA:1R@9B^BN(G&!0AGI(3'*?5
M1D/6?*.#J$ZMS@D$06$8#L6K%(O#$$8_Q 9E8)2,2KN"?F2E5,I+\ DN+NF1
MNFJ8_#Q[:'O!IY(+B8D!IJBE&]QI&*9(B^:SQ[ D1":/!5..\4R:R).!7HC
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MBXH!!TY*HG@9P"JS>K9ZVU<7+W0U)MN!NL>A+DPA+#L_B0( F2EODTI[]>G
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MZRT9HHO!O9ZK.5HB':;@2U]%Q9KVWU?0_(ZXP>;"-[!S+WLP8M69P/-^4T;
MM+O.\JB(4]NN^_3;1]CCK,H;IIUQCXP1EJ731>>D?7CY34_Z$_N,&YH[^0!+
MITZ&C#BKL 0)DAHEDP3N8Q55PY.%D;P.JP9C*'C?AR ZF$2&\[-<C'PXXZ<N
M1K8!3UW?<SB/L14NM7NNBQ^/7=UM4[]KS7P0U$VOV9<Y#\2X5G<ID#5?ER(<
M*K #WO3X,LLP%N8$O2C:$5]@,. J3*82=E06CT1)X'LC$PF)H[UZT.$R!%.I
MAS_]\C4,_1*$77G4W />W#$UP\O>6?P8!E[$_ZK(Q>/IN;$@B@1,BZQ;6/)X
M/@WQ:DOU1/U+9YU@<O/#E U^_GPO^%MV'5/T/.QT.Y0S-,\2&+@*%^5HRH#E
M2;9,F';)ZHD/F/"DSK>UDOZEQNOR^C(97\K2D$^87F3H.C64PY[#LA??C*=5
M%"M:NRBY4DQU7W_Y^/U;)XV615VG>/&<)UQ.AGEVK3^J?X8,><'77W[[_?-R
MLJ[>G'C/WLK+@N#C4+VX2[X.3EB^U!A_@$'JR5C_X?S[4N.SOI[]\F'X\[</
M9_]G>/;Q^X=O/\(1NB8WBK/!"'K"+)Y#\P<:Y>(21G$XOWD3"*SK?^[3_X/?
M-1!?\M&SX ?O-OWMO7^;,+^\F4WZ_N7=KTGZAWX+^-F@!!:XC)BC'(Z0-M&%
M2M#+S5.#G\( 5!<<H?]99N-GCF%Y+:LAE[_:<?Q&_8\:25;[;IMT=(#5!BPZ
MH,]!$"8P5*)E1)6&[@6CS,*5Q((.KG.>6B!T#4N]-I8V"(F'DQV7^>'2V'A[
MA ;DP7K>RB;FV17HKD*'K,%K2XL)W %R<9B,PD66105%;3@/6/Q(<25:S4)"
MV)*0<'*LFCG51,5M!6D,(HYHX&$<FH>"$)<4,4]F.%:>A#R1?@*_<5YLA_G5
M2/&+5R]X"RBK,4[F_/8$0Q@7F-=)T0_51FS,*8'GZE=RI<[,S:POW"Q=P7OL
MN@1]Q!5/T&W0W@+%'4)X,MA#E-V>@ $& Y-[\)JNP:*(*1H(ALU,@F2,X=J6
M/.3G, WE[,57X;2B@"SX3^J P7+-$ER!QOE244X^,QQ/$1'GV"Z:;;24%$?E
MWU.45C\ E[B(06K0P)3<$\FY%9YV+4SKV01O(/N9CYMV4<@>M)5* H^<<X*]
MN*2TPHB.THC'J#)(2\^I&.*BE"*M,?)X2LLF)\_XHXC!B!=D3/4*'H=S=8.,
M8I3(B-B?QV#JGG4] +8AC\3&Y:0?3;+/*V$ZH6 '9%H]EP(S!.*_8)(0;,LQ
M'.@2SX](#AC;</.#.U%QC@CV5\+T?Z39]32.*+O[KRIIYAXMS>@@=(3%NM_$
MTGB2E":FK*4$]SNK2I';G#.;E"-0;UTN<@TMC7_TZ6EX'4B!VD>1"+.*8R6-
M,GEXQVA!R=2J+' S:#^W1-6<872>$WH#T*9:[X#R((M'4MRL%KIN(E]]V4J8
M(3_R5$!#9VGD)&=U=*C_-?;5J+(O1I.MZ]&!G=&\QI:IS4 D5>N^CBP*64HB
M NW+_LI74[2!9?\J)M1WC3IK0V_=SWJWQ';DMFA9[@$#-A#;D--UB7'WM+_U
M.5C1LJ1<^5(EK2ZH6QM_KVX+TWLDQI_C6=AV?=?<?<2'FY[[W4MPFY[PR&W-
MU"4Q"I5U4UR'<X4&V9Q\W4<BYH'DBQRU9)F0W38ITZ)<?]$VR3MEDGRU;9<'
MDM L]5QI?@EU9;-I?&7MQM>6V$VV,8K9S3$Y&V.$XT6Q0=;1TK0<<HVFT>X*
M73%@E&>Y91PDN:!OIPC,*L!\I_8PN<\HINLFCMI_0-I!6]UHUL[GTP5^#E9@
M4OP1A!&&A-!?2\EK@G,)EQ<ZH7#!Q6 QSP3\,:G(KS#UG..PN PFE.>%A^99
MB$!]]C43RY8D@",^(!LALMB)9;?>F>0[S@Q$?AJG%^ @DA\1]O/"ANR%B4.5
M.[#JA DZIS"IZ70(<XP#](%@UFP*(R(307;5'+<&9U'$K8Z)V@/R*5KV@;9!
M'XG:X8%=J3 G99GC9N;V%N ;PE1^B6:0\QCPIW*-)T_$B<&0XQ^PL62ERB#0
M9D5W4_\\W9I RG<5G13ESHL?6M$'Q) YRFR2W#0.,ORY"[SZZK9ITT=9+[&W
M#+2:.$43'$:ZIF2C4H<(+49+1MT1=ZT(0ZXB=$?0]69M*W5L[FT=VT=B!361
M&0:%/LXN4CA4D4;GR<)CC,A:.4;BV34!>'*FL=HCVFL+GZYTE>45V7#:)(T2
MT,48B6IF,[OWTV,+6ZEY%67W3%#@K.*'DZ;W/"^^F2.K<Y#!-9%,-.@Z&O1:
M(#1Z.''?,G\>;JB#D@%*](5*IR_@VS.Y&:-X$N=<7D8P.8Q]9^"BEFZ(M)YG
M6'8:?+::N8W:Y ([2.#R##$Y6)^K?0\U9XNQ:\\>GZW9N&Z@@E*@;;H4\^EM
M&5=ZM7S\IK;+:XVOKGU?/GM[<+AWLD3[HD]X<9''%X0#:=YQ]J8;@6J+YV_'
M=?][%SK>14^![/IJ]/#I655H81W8]NC CA%1TH3J[735!&LMQ+MA-8"4SI4+
M$Z%&>6%3DHW?[K"^>:X^DJ!@$_A&%%S 8/GG)K[OK5I2-3]<N"6:MU%R:A>7
MUK%#]5 [Y:%(BZXR<C2H4'_@8[A2(BEQG2+<'*R-RT:<\Z!7<''K!&8#3U.Z
M#_]O#DO.S^R3;\C&XRK?$MF^M:[$_]6I+%?N*72O5NP[K(=+R[74Z:N])O^I
MJTU1@CL79^5&*_>Z.+]E7"^XYOH<+UT?5"_\ EHJC(JK_Z[;* /+!)PN!B81
MF[4B?)_L"=TL(40;Q_2?BQWB# R8:7!XW,D/\?-7,!X+L/7__T^?+(H(_PIB
M'@=1LDF4(*<"R++SO>!OV113S?"]7W]]5R>72(,/.OTC9[B#5 +'Y;))"(?$
MUV_GPXY9'QT?#OC.Z@QG'7,HJPOW^////_SR]=V1( ^LPN9D-JO2; B:@CDI
M-+7$$&UW9*4)1HF&#4RJ0I!699RD3_>$]JGO=S?-+T,F:SA=J  J^&!9/HVN
M$1/ ^"/<\>4[O<>;8QM:8G]B580.JEC%TYU74TOTZ7AX>-S"&_V5SDX!9\>T
M65A^/[5D,_3QD">HC'UKAOY>XE<'R^-7J$?  IU4.5FS&,8NI\IA8G? ,?YS
MTW59&_]#CETU"Z<'+E<'%D]SR4J#;P.=:W8D8*.7"X]H"1A :-%\T 7MQ"RU
M1(T6;2(M#@AY)9QC!"VID)>J1HT"%%K@3?VQ?6@"RD6.+U$N9"1EGDT;FE:_
MVL-6024*],-D5(%+RZO5)?BO]_V< 23X3^<,]",FD'6!)?B>78=Y5'P.TVH"
M7ZMRN+K.-)W'6@2%QTO/2DDOQ8R$>:E%(K(K/G OX5>[XH-=\<&N^*!??LY*
M"3B72IQ& @BG6^J&^-54Z'/:<;NHN):76(.B(72-\27DO'(-GHS.ZQ6O=[0K
M\KA<2+HU!46?Q)0MB&$A*"K;HTKP]>&SM_!=720H[ Q<)4BO<:L$^Q;P/^++
M<N,L 0X;P.L.-H 3/QF EBNA <#T$&4WTH6VE%H,),9!8#A5VV6<B:=[%.$2
M5^%TL-LUSZY]FGQ6*W4F"_6%HN=Q;4./.^@=#GOM*)$MV;N)Z<X>1]W#!D?5
MOP@GL3Q#Q17$M1>:X&D]+43V<E]5)-$)-4(66LQ1$#..SGZV$_G\Z073EDBD
MW^Q@YWG]<G6>D;IJ>;Y;:U[KW[)4;O$OD]]3-!+!.8PT7;2]["<K*W3E 8]#
M=G@QK&U%72K]/IU+QPH;XG(,%VC:O7!X V"#8#44!M?+NO"GW$_#]+#**7JU
M!EL/[*=B+,4]E=(VWJ$!%6Y.I_R)HOK%[<6$13:M5&GI.(;W*$C1[;6R591E
M:523>S74:&Y4I/_[],N:=D?29B-CM&:*,,J8JY_@5DTB8;F@&S D?V59Y,=+
M%@O^"H/KM@57X  \L[@?ZQQ9 $2G87L?&4)XDJ(,EF7_A3>TW<MIV1&+@:/.
M%H,E; ;"#4.9P"/Z!-I>_VD";?I!!L#S#E;_CJ)JJ*807#P0A#0Z UE5#K/)
M<)Z-$:=;8X/ML$#I66D:\^YI<)B)V-$-)Z1CK<)SQP?IWDYK@[Z@Y0SUYS*P
MZO%,/9@5+.^=X,/2)GZ.6UOV-8&O%J;$S"4LX%\HUF<LUAU>9M<.28$D)RFZ
M1A ]IS#M^=4+;>@7P?-0BHS(%:$0#(%Q)@+0\0G'BZ>KS9?EZ3=3<._<O$^Y
MZ-X^!$;4C/0H4%FKR.VU6AWKUXJ;DZ(0*(USV%5'[IL3/4E/Z^F*]WH5W6$A
MM(3MNT$E8<)@V55JRZ)YYY46I_LM99]/P?RX8]1POYQWK69C( T<T+#H7/<6
MGIF-K_OJ, %ZS6_QG9IHMH2*YX\V<XN.(_Q ,AM5>4$>&4/@XQO$Q*'D.P:>
MFU$5:U!J>XGKLGFHEIV1EK+=>]ZK.Q)SV+2399NV%UCW.3D^BC&(+3J!_I 2
MQ:UT-[CK0K=UJ&8=44SYH%.EO,0&.TLP59&^2U&%%-'*UPA ,8K'857$MLIN
MC'V&M9/3Y \$(7%(REL18L94!/^.\VQ+;K:U2KRBI)^],8MC,1O@ S0(-,.G
MJ8*A8A>L&>I3!L1&4N4M0R*,.U-?HJC!(WO0V_@KL=73,=>P" KX8\'DG-A\
MQ3)AI545"KR)>W;?ZB32RFX20J 6G1=*9ZN$HTD\M5#EO=J,P3"58:/<XWJU
M$02MC:NS1X^+00:XLQ3M<TJ6D[1EB!WCM_ZK IW*YF7'+U 5RS!7!_3[P+"7
M860+%BDXS#HUK@V"J';=&P<M<"K\__S/#K3[XS.S.B&%^G)2"[<6;/[EWJON
MBXB*S'7IGFH7M+1MA;0)::T"W!)UOAHX_CR&6S&]9S#\))Y,'A@._S$>Y17"
MUD]1!QR<>G2 "UC7.I,-%J<A8@.OSJM:ZYMH1?<99^HZVZ8GH8Y5F?HQ\_:V
M=REJ*86BET9:V45,MI,V8I8-S?J._BO8SO1[_KM5&*#^0&V_0NZ&I*F5W:YE
M"K&O._%Q32V:<@8>_^D+:-@X+-G,0GN=F\*7U2S+^>X?3;,LPCMN'.?;$EMH
M =![MD%5AX>I7EA:^]BLJZ< P:TZP'1KKGJTF?)AL(K%7&J\5_,ERB<A<0O8
M?;)B)#]<VCW@],!3#'=P.MP_'.Z?^F] >&-93F,L;X)I%>86O&M>NTV1!C %
M?2LS*\JX@LI;>:J]X"MU2!$KG /4&J47S),K\6(3Q#?96JM7?A-VCM7:Q30;
M(<E,-JQ7M_Z^=[[GZ;LGHMGQ%EB0+%44G:H2'Z.RE]RSPKRSD$9H\*V)(/:1
M1^Y?2%U QOZ>$C@2=% %\513P0PXS=9L(FLRPEV"Z(F\;%00J3UX5TOO.Q>\
M+D)@O;#]L^'X^"BV#KN%PM"-)ZV^5BJGXBJ8-GE'N<CCLLH-T9K58*\J>O;5
M&[B-];;C=OC>?LES1J(P>MD;O[=!!'ZFVEHQ::<ILBUW;KW9L^>VE3^MUN?Y
M],#3=%/KEK75S-I>W^_SCQB8_LI'I$LEM8<;V_+ZY%%B'NA,PFG?PYNU8NQ'
MOAA[X&DBS::S@P'KW(N3N]B+.UEH5I-@N;PW:M%ZB%K^[YF$?#]F.5TR!4HE
M2 '=SQ_"/%W3[3[>>]V^ YC5,KP[P@V.Q\)M?]Q*-%>8V+VO:ZI-?A2GFOW0
M8;RY;?MP57S8*"#,["[?;,)2C*Q142AM-V%"JD!Q*9_)P$MHTFA/[F1]]66*
M3X6=9?P*1\WD]9.J24?28JME16P]DJ#8HM9:F][>P?WN],L52,9:5WI;K]Q=
M?1SB-W?U<;OZN%U]W$KU<3:38C/PT:-8CG_TU\);%L>0+^ZRZ/:3[H[#K5DR
M)P_-6KH!<P:MHV"N&TU_5X93WZ!-?[RIU;[V@RK@>P^+9';V<[CX.?ZN%^^9
M8S2>>C'R5!N(14\-D/PFJ@:?SN*N419X>K!Z:^V_=M4#7G/G/AT(*\HJ8C3V
M*(Y3%2]#J-Z?<NU[%O>='GIB2LNJ0?ZJJ_K.K U90U^%I=&=;'TN+Q14@0XZ
M::CCP#@7="W^6[/R$"_?[>H'>PYEKN*T\NMU!D2^#E&DVL.Q:([LD0V"455J
M?()<-NR499,)+4LMG&M,>QDS)58:Q9*;N)'\Y9/J6KJ/<LFG?9;[5W*='J[>
MY5X=W4V5USWMM5ZG?N[T\'#E5<=JL=)F0Q8!YZ!KP15S<(KC1ENCVU;9W=&)
M[E]Z1U/H]1JKQ!!^7N*%YM3O<)PI+*C-XR0HPDE<+@:U@77:O7O!!UQUUB3K
M5@$V/0397%M-K5\#Z(E!=Q<"VMO<2 YP^V<]?G9CC/S7O)Y61 #86C2Y.O$&
M[$CW@F]'HF 9@+ I$IX:$#P'5@E,05R\Z<74+:EB03@[?]<EGR?[TH-9M5RD
M*I?X)AY7I>'[+T UDO,AI.7UPBUMO=RRZ>RR5FJGA\?W%X'?7/9?GK3AK+^.
MHYJHJ2ZQ(7F2!E4IE;)2IK^E45H3&31@N\]\M_UE/5NJ#:R:.F^@6^I\;*2]
M%?%W\=,\LXXA6>5X#2)]11_N[3JINDY=]9#%.\G,W;4LGE^'\R^L[S>)!=#H
MH&:SLV+7%WC7%WB]OL!UJ=HU")9LV:8:!,O%_3B[ XOQT:FO=UV"5ZXI#3N;
M!)\>>?JQ/-*[;*.=%8OD9H/-@AMV?#_[]NC@CA?_T?4,;K%MU^D:_)#F[<8Z
MNIX>'=V?6;D!:?A.-_/=X)J9<S'6UU2;.;"T%?'IT5TC=,]D:+P<:&1O4POC
MYM*OW\Q8\5+T!'TODP%\>8]"+1M_9%<26UV&ERMG#XG_1H7H3]-SN-.DVQ)S
MS+9U=\V'=\V'=\V''^LIO7M*G&-/V?8.Q'\;$+^OKW$+5\BRO3G8@?HW >I'
M]&.SE^Z2R)_&\4>,ZF_Y%?6(=+L:U]#\>(X[=_EP=P+OK(Q&W>)Y+.8 A^%\
MBE+"VQ[FBX?M2MXI._?HD6^SADC2-A5=JQA<KCT26U94E#Q$EAIY1-=V;BP6
M\%BB96XX9,EAT?CS414Q98(3PZ)3)T_:'A-O948J'=/HD",/A]LC#93?+?U
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MQ"KHG\I8.CQ//D/XKU)%1J;3L00Z1HV^[*F$,:*41=L158C_I>.S4JZ'1V:
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M/M+X6P87,8AD&2>MK:_62A* Y@"[PE&2\A:7/;(!3T3BCCR)2TS)&.:U++@
M2X=XZ),TS:Z8Z^W3%UORH[RZ .\EC2B74)#VXE>T\SFXET+?7LWQ#8Q9T.;5
M'$?7)0P'3T48;JF:RDM0ADU)"'4=LU\WU>J3.((L/BRLK*EQ%1QY'= NE WB
M^_P.LX2-.4? 6]$G+W]T=&C9$:)%@BG6.2N@>Z4A^8ZX: '[)#_"XFB^T[D\
MMP"3=QKF:C+$WDK"TA4)H#6DY)A9-[56ED@/+6K2U@Y'#*A7^LN@;[#K2D&5
M<K[>'V9ME>LDWBAG18S:S?)I=)U$L1Z6>M,_U">M9^\#M2RE6 >#K9P1A:FR
M(8BV80ZCP7H KG>3<G5R?*ES"KK(\*OR4LG J(HN^&_-34.=DHH]A_B"G.:$
M,>R*\!<C6(KK7<6R:VL?[2J6=Q7+NXKEGE'N'JJYMZ6A4ZRJ'<U 8I04RLH(
MGM74;BK+R^U[J($69E.OL*N4LFI_WSO?"SYF642Z\#W:3F<1AFDT:%S4YX<*
MF\:#2OX<1\DXP8*N,S#&QHN]WOK^GJ8KEB"Y!K$NGC8L@0/LW<5.P1Q?I,<_
MBK%C3O,>TM=#DU',.]$M\;/.2M-'?6#,A]"T+R*8':Q =HT;HVB0K,ZV/LZL
MB==<>N[T7*TU/F_]B?I- M;^51)5H56][C!&V=1-'5+(%%5XR;794MRLXJKY
MWMYDT85W.O3@#8Y4I8&XM%Z)K"H$=6P]ZV"8HS-:>(PF/;Y&U&G0,"^5C+03
MIX4>?B_412V+LX+!6U[&S?:2B/<GCUUBSRKARF3S;,:"2X<"KW?(<2-X;'V5
MW2U&L27ZX[L_/(DKP$WJF-8QU<6\7,-"'>?H!D"BMG%5VN$>=C+^_N'=@%Q2
M:5"78F]$/(/DP:*@S\C;+1KUI': <@\3.TE!^#81=WBP%F FSUH0\!GVL )#
M]3*[1D8'371$O!^,C0%#SXKVQL:OH<==AE?8D0.<.,P(T#OA^7_0E5R5EUF.
M'=ZPZV,I<(!"R07VODS&C)",<_@> B+A]7Q_%95^SR6W0*NY;.(5*WFVGC:7
MNPI1=,K'5"^E]>T1@E85:(6I03?TGA.7<0PS(/I>"(._G[^3%E'P[_?O1)OK
MG<=VD%0S7['?"[Y?N:A+P:>O[^H*6?U>WP*UGWQ[QX$&?<4C/"319;*%PT,*
MPKU HIAYS,U))5:E*5=Z>\PM*GH[CGFKPEY!67O3!WDS1N&/"-08[#@7;E/A
MJ<B10%?9&%7F8F/7Z$B8X]VLK R3*9U/S2.)O2&]H:H5[BPU[4LIIM!-KQ6F
MTH+:U>2N+:*#.O76B[$=0FKH-)HW4KV&1!';Z2Y+ S+NP"='2@IN>KI0%M52
MDM_C_<-7-,G#_7#\YHBJQ9GL5^7&GX>]<>V'+2WS[CDY)E+[)9>F%W9N;//=
M;&H5-&V VP\43P ]?29%5-_#F[60M4>''=#:%\Z%V8M[;"GGV,!'.F:UZ#-=
MH>&J(B2A(DN12#*V@(VR"M\;P?O+0E]5]$PT_*USS3DS/O=BR*A#H4R,!*W=
M\X1HK94+:(KC>Z2E'8)*1>_5RYUI84KCX+O'G"32"KR=>YS$HWWK).Z=WN(@
M'GFR.6Z!R0-FJ:V=N8I7/&2=,%K-#:R :&N6K+0#A5X,Z-8"46,#=Q2/87@!
MO'[*04>2UR2W $2.CTLIORVYL[Y;B2C+GK5/'9:$#/R.@\<<\QL>8#61G2!6
M!AH.78+?TK;Q,=Q JKD)/-"RN%H;,[67T)D?ZV9M&\Z&,O10>Z?Q9"+"'%EM
MVAT@C9@J2T"'3AAU5J'[!)I,UQ/1YG86#@64QD<(,M6,HH 5[ *S)XX<:W-J
M#;_LE-U6_.^OG;@T<_!'MA ?6ICNN/$-B(KICLNZ2GYDH1>4@6B5T/$-1AY[
MXR568PW/%==WO[G46[7"4P]B(OT4-'<24^.3&*9/*.,N4ALA>>.^'T$X$:(8
MT+PU6:65Z7K2Z;[BSUL4:H7 H"[A3 I+SIHS#I$,H77:.D4N3ALB412]_RBG
MO>:A+^_S<L^Z;36:\V67_0H5:VK]O\N"PNA^HWUB9AT,*'^6)?R95O"9<S.<
MM'/MO&YR[3CB8.Z<Q[D//7IN/)Y]>-6^#P>'2S:"SZ4%=5D6 521^79PJUOM
MA/G'Q&$XLF.2.I+9IVQ\7*$O1 I5#K1$<:TG/FJI>E*GNX-)JWFZA_#WW:'>
MX/(?>ZS.CD--ZS_'-Q%$%D^*=&5@"Q)A*55)H8EL6G$./<_&,3P2S"F3!93P
M@'6@FO81Y39&2+S*J6!-?K>Y:SVJ= M? 9^A=!AS*TEA&E<(1D"A8S++(IS$
M!"LKI)%%KY<CIE!RI/#0$HNPBMI@,NDKA_['<+08SDT;E!_(U +YS1?XB?R3
M\UKNHC2HG2F&J]\B]J81E=[!E[5'MX0>Y6,\RA4_RK[%I."R$R XH*^SX9J8
M.BU3>QJ\(W4?J6@9^ENO2PBS[*EM%>/-6=&97%'-E76[H)#->IW'2YL!0CN/
MFW(V&SPBHK.$9S@<^$GQA^)\O@[!.1[HDX4>.$4E$=0#0J@H)=M>)"ES^48Q
MSN9QC[+6T_U3BV'+:OO)B10-YV>#Q.1(;<X#%^!RD6413TDUIK12FEW!32K6
MP)'T!XF GFZ%T.C//% 9IUUXO8%#HY]F&P:G9Z=&!X/3*[KK1^?T ]OTGU8;
M),;MI26)MO8LKAFD./^WP./T=N(U4*1D5 &?$)']285\[FZ(W:)X(UM8_0;N
M\<NLFD9TLA6O'+*$U9H<AA;,:TLBIY\)7L+1&]TD36(UDO:<4<M[/M&9U8K7
M4C2Z9KI&I,>1Z:8RX *D(H;#4V\VZW2W_^[?/.T0-3%#Y?]C[TV;W,2RA.'O
M\RL(=]<SY0A)UK[8?AV1J]L]+CL?.]T3\WZ90.(J11<):D!.JW_]<\ZY][)(
M@  AA"0ZNJHR4P@N9]^/:$J(R<1LM"/X:!?M3($I+;MYB*L"STV+K56+XUEO
M(:L,J\4E7;%D?Q64!&K*<6$S=2D+D*<,Y3)0O O P0EA*<<-B=(<@E.:1R(+
MB:R>@$PZ:#:"IJO7H>2O]N%HC2IUP3O^:5HO!M.>6"A_+^B*W])[3E"YSS*\
ME\GFNNL'HCUD(,58*U<P@LU+"Z@*1CYS-R%O:1'\H]S$%-SW"Z0@<2BELD>/
M,TG,XKV]DB\X'9HO')=UJT:X5:-?MVK4K1IUJT8:%TGN06V(JE2Q^71S$CM.
M"[<3.]<'$2.^J]36&;7(-RZMN6.N>B=ZJGKDZ,A=UDM@R!5I%-_?BKUC;H?P
M+1>+OP=Z#;B!%#,*#SY?VF0I4I%O:O>M$>%%-&(+X??WUY*H,F)!BXB[]H,_
M5KM2)9:JOPMS.Q-UYUK2N\NPYS[R!L5X!):!=#9]Y$8&(J$SI*DX3>FYRVJ
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M)];<;RSG47:Z1D?'U$J+M!8'6BA[%^[:QWKO%5(9"DD,K'F \4)ZJL."^^A
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MKL#OFPWN1_>CWNBVV;[OWS;[]^-1$[XT:-Y.VC?]Z]YU=S3HR%!B=OTDHHY
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M2UEBYB&75.$&^;OXG$DA+05[I$\$1(,)INW'>!.UA^DG:I=3V%+R2&WZ__^
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M)0=6'*.W]Y,YLY[9H_IK5P/O^ P;>/^Y<EQ]OMX@P@/V\(X+[^$]S"MPJE"
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MIQ%G6]9 N\7!<TT;I 0ST>W"%@+1U0L:4/#Z6VA&Q9;EO/[Z=HK1>/20+.!
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M@/^=7"B_I@LX;.[YE?(><"K,SU*\P#LN5]JB\D3<4IP(W6FLPN'OHBFBKL8
MA"#;^:Z[]VWD@;QU.[]K#/CY608B A48 ,"IJ"I[S1^'=.UMS"&7TRO+ O'J
M&ARP+[J[D$ @+I6*+.Q=XMO:&L4]8X"/LEH5$%=%FH;ROO*"AGAUDHN(;"RC
M66.,Q0 1_L3?B(P><02L'."QB[#L(<Z%5PR>PG?6^;FGJB'3[W&T0MXUD!]^
M CC2#2ZO 41,U,GY4-*QZ$_%6C ?8)YNVCPSIOL6=.Z$6(@4\IM )I)R?+F-
MC+)DX.7R^C* 'ES9" ([[OVPLLJW),5$C):28.I$UMNF*C7 +2Z2'4 <R(7D
MGGGT(-_@RM0^B5<3LSH\LZ4=,ELPL("FRPN0G</,S>+<+]:VT1(-LS2@H@RC
M*F:'[,@+Q10IX#.S?*U#7]NE<?95!:7HFZ_)X7OOS;M=GHQM<)6-S &DH=RL
M7![%_+LU=92KF>L56CW>_/VJ0>4?.+>#8F 88%=?I"DJ+^+E7 ZWB=A\SDU6
MP:I>T'#*X,Q4<RGJ7BD,G73TOZLF1: %IN7!U5]+=8VFUFR7V.:T85@@WL J
M>7X&TY$[9H(=E7^M0$#/=:HOY>LON*7H+\#@EVID&:%P\QZ.47#3>H$O_FNE
MVYS 9]XZ#5[D]8Q5OO^6]64SRW%%M5K"J>< .GYN#C94R=[A0#Q@U:R0@W%%
MG4G)PT&*>ZM3VU(U*N.469Z-RLS KJ$DYZU;T&KX]&M*4CM?0X!%:[NKW_-,
M0%\DDP3:QH446)V%$'JDVD,L=./.&;IF5&D'( (IP.U0L"H-/92P]V4"PACY
M#']\YC8S&0\!.X\J/H5J:R@\MB4KT'E2C8J28U1W$%=._FJXWXGIK)4#MW=>
MORW=90DUE*0K4@S;"M]7S_" ]=>Y9QW<4)WU$P/T,.<1;G>-$=17G)&[/>R6
M!LL$? IUB4%=T-(RE/J>(YH'E\F$P BMV'#A_>X :KS?>2P7? R*<'JQUU!$
M.EN0G8<@=>I@P*#D+^QJ$LTX1Y^,*2/>X\%OI;:#OI]^^!''.VAB1=A#,6-I
MJ]R 5WYC77+#7.Z]C#$&?+[V[,9P.+CX/8QE,IM<G<FC@(:H0:=T,]H+56>K
M"YBA,"B@GC^&1T&24A>"\XT,95!T][;U+%,0@C(>?<+(-]^G7>G1()<VACJ'
M@NV>I((]]P[WW.-1BU78O>%VAK1N<Z](#D>SDK-@&Y6?\3XK18AX"24&U/0Y
M"#]>S?=3!--,(,3$Z(U,G\+?%R+43MVP?IXC_NDO%!,7CC(E4[U('2;J&L%Z
MS:A6.MF9K<KDYSR0A"D[=Q=%<E@LQ NN^+7\.ED14X#G[();C/DH9CMW_UKI
M[OJ+Y;);W9D9%F:?HEWG?J3KG-USCG*44WF^FVK6M9;O7D5(ENYH4X4F%OKD
M+FZ*T&.@3!.H?M(2*SB3%:BZ<JWCG3](''A26?$.'RF,B&7C_ GB]%PD)Y97
M)6G?="->OV,UQ28OPB- "!+0Z7-'5 #].S:C%:^#/WVY1PN[W6CS?[:#PJ*@
M0_6>P?--":^6;F-FNE?[Y#CQB;H=KS7J-P:=2:/3CBC!VO$.O73[%$MXAVZC
MV^TVAL/MS9]^C_^,G@@4#8]4='H:O:"U<K$WC@>6<Q8-YLPNAGN.&CP?IF+M
M#NE7MJ/WM-]+O0;O@=F[T/"@VE]M2A%IV)C._*_D04F[U6YO8P.+K3BOG&$I
MSPYAUDLWV2T230^V2'@5*,\Z18JS7KK*A-0OMX\TZ P:P\[V],G N(^E?&+A
MTH GH'=( [^Z0'G8.,E"=3()@*CU.ID$0!CXY<H WKI,7H/C!@:4>$E"&]R*
M!6W$*UE6[&=[D^F=0<H$;?)MLU5LSHF.Y&R8[FBYA[YU2(@AJ;V+M+<C3A5[
ME'TE\'=&$VRNL ^"G@N8:R2*JJ2R^N^RH/$&TY!?Y\05?&8#/><JS"];!>&I
M!=Q77\[D8Z[Q=@9'2K@X<>8*&CJ<0$OGO=3<=6K<=9V>NY+&H>SBKNO*<!<N
M:-^>+;.3P0YI+-2\=9Z\=9.:M_H).PEV\M9-97BKUQBT:]ZJ>:L$WKI-SUL)
MWOE.WKJM$&\E^?/QO#6UW&P#:FH&JQD,;G"7GL$25DCO9+"[RC#8(">#'9VW
M3CG*^G[Z@0>J%4*EER<[^1>[4V<+3CLR^K4U#FLC;<$[80W>39+$;JFB'#Q)
MC<^T<+2P(X8">#F!+49[6/E\1IT87U9XQ=?Y/RR7.3O"A0DM8\1;<(9MSOH)
M-^:],H8AV<Q6S3\Q9TKCF%0JFX#+9), 'RL##W493@&\U7&0M)EAF!\<RU!M
MP<=+5?<&L(5P,;>M9V6^PAL;[(D?Y:>J&Z3#\ @,7AV+(&@Z%=[J9<%,)=P@
MBG>]MG"B$>#_5K?9S+7JF3<;R.FUZYDW]<R;>N9-&CWI)Y3.3%6&,ZV>J>7M
M=W&X0?J[EP^0X]#N7D>E_+#23K0:DT:EK0?S.;6?R2;R:QUTSVQA HL_K15*
MB"GWP/0-Y7/KH45=L-?_N*<Y(-A[KLQ4!VQ@YNOT#630"#C?7.;=LDDZ/"J6
MVFFV!\UN>W>FXI&__YV8;I.L\_/8UP'+/SZ%^P.>PB]T@J7MV1*ZB39WV'#Z
MSPV+Z??@9%ZOX4*AB?5BPX0<A(SO@A67?!; +<,23%[BB)V!'*T$VM=HT-.0
M.AQ%( 9*6,M@VR*O\VKX#_$6NO!/D!3@LX4^I<Y<LB4D:8B&Q2WB06I)]<[2
MY C,7Z7)"3,/#XW0(5WKB2\N(JJG\G3)"2#P>%6H]6+RB1A\%$8"T4;O/#X"
MT6[9JK$$&[!XO\K9HI]Q%@08M+-@\W"SFY)N^UB4.)EL$>UO$G5\IHY)UG-P
M(A#J-M_3P4O-&*_2Z\+GI>4TC\4[O?(Y,$/UT2>[M).$F)OFUGR4R )L WP)
M6S&L%_B!OU3BU")_SY$E)C8ED=0@>L%II4G*AUR8H@AN^Y!5)QM=2<&0&)\(
M#C[@0Q>>P&G"L4M4 ,[1')0>-*V&RS:\[ 6P"O88V-$NCO>D<;Z>=.(#B$D
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M(^E+]E1^6@80@Z&[Z]I)R1R?&:5<[%1)_OV'A_E](S2#7JN_76"S(T0S.L4
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M71&E,JK#B,JZB?7TSZV,]Q@R8 FUCR;^QKSX#CA>.;Q"SO317:9V25*(J5)
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M2@)T([CO+-7:*I'QM3$#_A!C?N%\K?S+X!/U *G;F;YH*]BL*$H&T5")?@'
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M/KC&-6YN]M<Z-  ZJ6?JNG\_"P<]S?\/4$L#!!0    ( #& ?U95S6ZO41H
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MZ[KGH&\ :9XXI@M]R6&=:WITMQ*E1L?>2L=G?K8*)8^_P?*^N3T1ZP%763]
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M+ (R@A Q<2DI*79^.259"45122F)/YN B(F)2:^3,I"1,4APLG!*_#\O[&>
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M6+P51=ZNH:7D;F8;(OJF1FM3;13>][)\(U F]N30RB+$+[^,;XK=IR/VI<N
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MY]SN\>Y]_]ZJFC]J[#7V6G.M3^;WC8)/PY>!QZ\E920!$ @$O'OX / YX"6
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M$.L[9$-Y1 R/892959+^FX_"XO42!Z9^[E$90ADH2.L?^B-HZYS<\>W8X5K
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MCY-$<"@5;7<Q#K4HZ?(4#;#B8AH0?X5!BUM(U[GH75N@^(,,W%K:61<>H'Y
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M^V'#BWZYC3ST)G(Q[J=66F UVH(,]X(P"Y74@EFK-.L7[[G[6#ZANY\-LV]
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M 0"D-TC_9P'^KT)"1D%]@X:.@8F%_=^$%GP ,A(*"C(JRILWJ*C_C0;]-PY
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M0C]-$$D4T;V;/:BCZ6&3SE3T,9,X8TCMFKJ/MB*HW2?<;D0W#:^Q7K7_A7M
MJ@7D(>F/^X;(EX:DUK GY0_U>H6B X$T=\FE*]4K.989'#O>1IYZ?6P+X@G7
MI;F9$?'R7D0I^+N?M[:*?Z!57XAM)E;C:LZ/D.W'^=6); I*\_!Q3;OE.>>\
M H2,.%1WC'A)KBBA(6C@[%R>! DY5=LV\Y4-O(W-Q'+GBZ+&-KL#U_*?L="@
MD.KR.\KM"DG<:QEK2''$<_],Z?E(L_-I0<]G@T$BK7;65B2QYM8U75;I:N,O
M)"2)WRC=2[7''D8/T1$SGQB_.U3\+'LSM?[HA0,;XSH=D20#PEOT_3A.BR:(
M)5P!Y[!6X<R&4F.17PUGK:GOGN?- [RIOPKYG*)+.$R?YO]<^L#4U-RI,HGS
M;;+XC?)6T$;92<RM]'Q[ EKC*\#1./\Z5%Y^P(N6$W'YKX7+B9&;]S*XARJ1
M>,E\%>KBZD.(>"X#EJDI)HEP[""Q-=FKF^V%HH9AB@IY$EU$![,N_F4I/FJR
M<[)(-MF$V<]_0=F3K7X[Z2H+@!G6;-61'3_U1G]L5E%4H54GN9]P_81+_;O@
M31:-D65>5J]I&,0;Y8Y:6&/><_VA#7D'>;P82%5QZA'W"D@ROC$V3HWY_!8[
MX0Y*CDU$=JQ7JM"'*)7Q">8-RGQ;:PGX("="(UA+)R\2/TMB:26()D'LC4B"
M485P;33'.AECB]LF17EE\8 Q!@5P!O//?G547AZ_XYC^7?J57=$/-[&D$TVT
M@^Q@.6MD16^2<%2;!R44(G1UB]XCP[8A.[MFT&SA2-L,BFT7@@K=]P-/CK3O
M9PGJ&"8GLS1&YA9RW;3AF@&VJ85^NXG)^T :O=D#LK\LT6ZD2531$2T_K"0<
M6[J++F35'@+BGA>KRTFV3I-*^UD+(G^3=F:_ DB7O\WJX[X,J6<L[SF;N>N4
MQ-_7BX[,"_P]<CK7X7>"NKI:"@_LO0*ZPC?*QYP^#3=KR;&6#+#8CDGHA(Y@
MWM%95U<5=1^2OU_5>\@UHX?P1/3-("0(/RW=-*X6"?JI'E"F^D $OI2UZ'4L
MF6+O&47CV ]B@9GH>]/%_KKIU%[T=2Y89HR,6D_&O6/'/!1V^ULEK=N:LZ_O
M['[DNCOTWJ/='P$)3M7]I4[OI&BK$/_A[^QT ID%&M*+6__9KYAZL3DW0M2,
M[//G<7UD.8F K?V*-2,URJ'"Q9?*]UBD.APLZ)$B]]2"-2B@*U,6"S 5LR;7
MHL>?)VU[6"&UEP=7)W29NX9,O4QP@K_V*\H4-V6TYI?,';N,Z;7Z/@E152&;
M'JDY=FB?[.V@:[7;M'_>S4;ML1K);N,[(F8Q2[+!7<^#"S?9 689#H0AD5"D
M@H7RI !*F^K@7>'.H[(]B=TX,.JA53*I*U<(*RG#(EZ'6+^=@9_*;4'@=DIJ
M?R[M'0"JD"MZO1?[1O!@;\OF1!D,[LP;YZ(L'"?UW@NT] >7TVIEYIU=J^8=
M7H<?X/MD< /(1LDJ^7:%G&YTPOGVY02V/*X33"4KG[*G"]485M&C4*7^3+3^
MW:TSE:LCLB7AR]-*TN<Q3K5=B=3WB$.9/2BG:>'/ LES7ZM$,OA @]2^J"[%
M[O&!\"?VR 9Y(<="B6+F)[D]]MX0J:NU#Z92OC;ID9J^Q_XOZ"4DN-AS&S4;
M*\5IVWYX?#^G_<;K;W?RP&[!%5F.W1H?J#/<+8%Q.*\ +HTI#R\7+/X4J'%<
MX#SG<\<)I#2#LCI1S@V$=\TU:!9"Y/&+=KXL7[_Q(PE=TJ<Y'+)MR3>A!PP)
M:B7LADG0W2APWM1XK1H&YU?6";VFSASSM-%'2^CF3V#!K<AR;<XN^Q'KR/LV
MC"$VZ' 4L%<UI^-D&1(R+U<TI]"U,J<?)?<*T-U4G)Y_!2PKW!(7O@*.X4?Z
M:0\<COJ5X4D;/\A^"EY&O +B6IQ(YFIS%V2:O3MRC?R\IZU1",X0<>X>%^I_
MQ/O]$\*[C2I%2!LW;5?C6-@F?/B.AD=!A+Z[^/XO;#Y:5_0+[#1'9W_7BP'1
M2]$"1.L?A[2.22YX#*OM:>W#LY-"9TYD?E (U:W''COP51NOBXZ:C)+:(8A-
M?X15'N,;KZW^J'&>:CI@"#L +L!/=,L+< YJ;W.TM+\P/ET:P2O0^<XB'?%Z
ME>]Y5\YY7[CU33=Q;6.6IUC<)1-II+^*+*?N39)J?;5B&[A6HR35&QL SWJ)
MQW-O*CQJ"K>T^6X+1ELDV(+NV$7MZ]:0+)<^$,?GW0=J$$\Z05\!/P#:>CX/
MNB.@=(+U=]>XKX#.%)\9*O#?S.D\Z?;Y#8>HDILS> C(&Q<?Y)'TT'!BF$8A
M4V0HPS;#@$A4RYU_EWV' F^AP.FU$6GC/$];+TBDXG;&$<N'Y"\>[*'F$KDK
M'++QG2BW&7GA#PSW8U-@DC'OVL3=#NL'\4V-;0*L_IUPL3W:$#43:&DLTX5B
MR3G^^D[K):LG^KUW6Z?Y:^NCUKH<$:5ULDLBVB F%:V+_\]5;3MV'D-^Z.6!
M_9W46PW(9H1&>]=B\UZNE@UR0=!DX&1"^:$?3%K%<!5C1=(5:JWPWO=J#$L[
M_/&V0A*'NYC@&-=\5:[*=%W9Q8KK=W@HOL9-!?E)PI?YYE^J;7$6(-MIL5MG
M2?$OABI(]HTM#L *I3?U[;Y+_,(8FSAOR<1?["/5SC!:")!G/%S+]@>(-*O@
M@F3_6ISGV01]5"CDH=_9Z.SPM@;#<^U65T/?K+;F65"7I;FPX[SE<>!WQ'F;
M=6CG>7*WLEQ(+C+Z(SZ#'.5OMHY?M0O'W9=6HZ\ED8\:C"+#,/"1'J*UTU8>
M*F^>]-/:5@O4YI$L,>XC%+2TM^;#+8<L]#?44$J6)VFAHJ*YQ;*[TR G=RN[
MB>5E@V<V '([L;+-M_SDM30)-19;PR\F-_H%+%-L<[$WN\$:BR:C3<F.&!O]
MVUM#.HN1NZA0Q]Z4YJFO!HU#4E=X[%4.]@(:R#EY<=QR,"?-RH+7K]_EXFT:
MIBVS_5B?O&&K +"6BWB-[4,%K.T8>?C/)T.+C*_;_WVO88N"LMD6@.DTKQ^2
M.L#_:",8\X*;CEL+R4G'K8&)[C [Q&6E86GA94-3JVY NO*VK#PJ0J"*0F1$
M5'=U<857$?\;.,P53?4K!4=)WXF:XM9?7.8@W5U*]_@]_NF OX/ A:=?O@YC
MGBK^3A_\+K9;I=^1*&!S"<MN0^5,UCR)"FLSE,#%?S*VX]6&GE0S2%)QLV\,
MC@G6>?D=/[NSAE_GXDE.6?^1ZW_:*XNG_;)8W>STGL#:Z>=P\3E<F&3Z80LG
MIELDP'4.-&$'D .])W$Z"X?DIK+Z+N_+6O+-?1ZJ5SG<Y40'['J?R &Q*8)Y
M3)Y8&8UYE)%3J?'>'AF386(D.\Z]8UQ,LAG301%@1?]:XG(L]/>I-%MFR%4J
MFE$GU%E^%+&H)^SD1OTWECS"4B7#,1OG.N .ILIC.&Q@$,JJ #(O$N$%!3^Y
MI CT31M1=WF512.Q)Q6LC7^NU#X@V[H9\<BSK\;@)&B)"4\SZ4M++A7\=R2N
MZ &?XJ7?(R@L H^O)Y.(L]^LAK#'!D1\%D#F%S-CB> FF$V#?3E2E8O_"W-(
MM=##*[Y] O?($9XU/0O394C:<<9',%'A\_3#'!]*6GV+Y?=M8,6QU^A/H1N9
M!((O@PT9#5BP*.1:(LL#ILV- AHMU72M;@+H([>(&:%;W)87*KC&B&.O/%-/
M+UIV#W<% 6_1C5B3C67H5N.:WM,59QF1Q3B5 3",9%'5';#$V&AT37U<R^7^
M.9##WE#^C?LQ&9;P <PB('YZ.]-0)LWLB\B4X)B]5A3'0N^=+_+;[H@QLB9\
MM UG80:]>TC $D \0E+LW^@?I.XFG9<DK@FU_E;[[T#>UI'!EHLY0-,-GT;6
M&LPC!RL/D'H2:%+&SNLL%SF3FDFJ8XY2GM? J.YRXA&@5N!T4HDY=^G Q:BZ
MY-'M_5B19!INOX'TT$^;M*%&!?CFH> .E"JK@D*R4P[I=S13PGUPCCA%6H#P
M(-CUP;5 $ZY)YVIL4R!:^<EVVRKRD^>D;568$L%*0ED;T1<) KIX'VYS0\F!
M\+G.?X':G8$L]T9=L1&4D>HN_:AW,XY/,554#5&$@E)CX=,'@J.':H#L&_4-
M21[EZ7%"6LXS0MRB?%H)M8,8TR)*G#.JAI^WN"QK5UO(Z!6BZ&13\ONT(+6'
MO394/IXX&P'T\Z30!;2".?9BPOH.=@NI?"K:G$ML0%$](L]>-S1PJ3T&/MG6
M_N/4=<_@+>!O622M(G'DQ+OU_G)3!>88UV\%.-7M&B%\=R.X=B/G'S-).+K&
MQS'Q \M04$21T#K87G2)7.KER' C085F9GBRL[YH25Y*.FF?VI7/L *'&$;<
M9A\0,55?I!RG"]+VJ2=X/61&)(]Y-G-3D=><S0H>")+[_HNQ?UX<6'&=#Z<Y
M'#^ $A\A%30^SLK(9>BBUVR&$R:D,ID.GG:%0;408FI^/+2@A(/,7-WOKIG[
M%[LW( 6-?SH<>/+.OU\!=S&-;Y-0[1B)!&_T4?H$41)<[,MS09'S.[9?7,9+
M=N5G$[__W&%U,G5A4_/!*0G/9\ '4YF!%S)US6:T9CK^EA=/:!@0LKT"JEQ*
M/)9F>_^S:#U1*11A_0AG]A*%% PP-EW@33M-7JK4PB"JTOYCFJZ]]TA7:_?/
M,FJ[=,.<KNJ;D:N9/4"B7/;WP#O87D)!]<3)QP]V+9@7ECX12=Z*W'%#MXA\
MF/F9;B*FS5<WCJ$K.ZM<6SQ]Q4<[HMP(3$29<<QAC0N%4?3[/$?N..)O+Z?^
MSP>KY?N;FNT1A".V&OK_'IP'0^' TJ#CQ2?1;PT$W'RS M:)>T']3#'4(4UN
M/M3=#9_[,Q4\6N3:0,FS6%,T[[_OWG"4QA%*IP$Q1%59II/\G&P<A->,NWVY
MA;\S]T2?A1YME+3-:_*0YPQMJ*\6D:&O)6@I29!PB&%>H.5;8*9J9JF!GJ"B
M7;JINFV-;2WNL[ 62$!NCINNK1F#S1C0X,O$+GS,E1%I0R"*/7YFTET"RRVA
MQJ"["S*^.9U<NA5^K/I&QNS:*DW'Z;Q0ESW8V;>?=D#T#0;&06_W*B%<J8.;
M_TI01OM!Y$;%KB7B6_T"79JZ@$SG".)/'7'A=;%"IQS6S^(E%ET3!4,4JEG#
MO)^[IW[HA0^ !U%; B/EGXMW B:[K0EJVD[=;9E??J&'_CU>FL[^H'?0D0Y$
M]1R1DX[IK*P,U7ZC0P;P1 Y[*RG3!T'BC$#=,Y3@-/"G]4_OH>-=*58H- ":
MC0ZR#O;0D>/0*"D/3S1#2<>HT<UOB?8EVQO+U_RSW>TEEQN:UU7O[7!\6JL+
M2GUW4O5LS3#[Z6Y6<[)03)#(1TM$,4=<>0R>LH[="G]FTWG,%A<][5>NP(*"
M*$77IMNWA  DJGX#!'T/%S*=H>Y*425-_*18X.@O7(FJ"%B;]**N07N84E29
ME;RC*K$!N32)<P3$X[^H/P_=L"OQ#4R]UMOCGH9W]\D):"Q0>55'>]XXN;&S
M>#LSFO] ) 'D_3URSQ:(Y6TDB>^ZYS'F9;CQ5=>NN4X.[8<]2LEO/Y,&R_]X
M\YC"SY! #GJHZ5)*:(:#5HSYZ2H$Q'.4).2!7W@F!3G@3&7S-0:$'X%],TR7
M.U5+6;1__B9<_=/^YIAYA9JV:"B;V&# V.Z6??ZH@%BT=!*/"/ [,J7EZ(=@
MIRN9](T'[KNCT\51X4D\_#VN2(EM+;,:RP3B#?23)6(3W_6/(18Z:DAC%':L
M6J,UE(*OJ%WU@'2)_LM*+:.9!L#0HOA?K.-P'RZ41+?15X#HD<CWUO:OW-17
MCV;"_8P[@XLHR\W@]XN9-V<$\!0]'4T=4H#95]*&&6+_Y3E$W)H*=L:[N# ,
MMMP0FR-8BQ!V6N8RDU^F IJV316>H/G)-,_?XT53<!1\/.ZQ*S6QX_%=@Z,7
ME7=9?:U$XJ@1J5N#A _ [?K)(^X >%MU-<8]TJ@(L*%<"CV;Y;^>XK=,,N9U
M:_=#+4X+#O$/$M+V8-?C$I1*'"'P'JAV:V^;=O4[D_]L)ENQ5TZ_0DC!TTPB
M^@HP]$DGYPRJ10*-1_)E\JV<NCVTOJP]7]N3U7S/].9,CB]1HFWW-]LIPR'7
MR0 QJ-)ZH(T(',QGZ2&A<*49*?G-VTF%S"GA#52N.4][MPHC,EO*8;AQM-8Z
MJ65).DP=\4N6P$,_X%%"C79GBX<SC<$.A!=U%<:]EQ%"!?%%KCDV59ZB:;!M
MF*$*'\_:>VX_]%CTIQTH*I_LL*J/)"/"="X9LX3H_RU?^NXM.>&/*)$GZJ=4
MH4&(.$'PI--$_M-X@OLGG3(7>C#:Q]0'TD ;NZ-1$3#5\Y+@.<=9)@N8'[6.
MN1P/G]"'RO,6"$F5T$H(G.>]R?BMWI0&9+(IO$>O#5A,X]=<-UD])51 S]AW
M1#V7A&#3_ !X#G/IG@OH;G5#R@\$!-"9F% )N69MXG3BWYLTJ $@S):I!I8>
M>>LC@M,!$!G^^G=?CAF-)HS4*<>267WX #-(/^[$%2,#0C_D[YIWEW>7AS[J
MN8Z>0#(.X@(6.6$4K(7O54#)+C<&TUCA(Z1USNT7"JZUAIQG]+$>0MT.T^=_
M[O?3$_&P1>[K8Z.^>4BWRIA_-_XH0FOJOP_E;-.%#KK^\S0*SSGIE U\LLG?
M\D0)UUP=G85WS[/B@_6W99+IX2*![2=Q-FVFB_7"?=?=RF%[2B2)M;.2)]/B
M="I*ABFQUN>41LU\809%T/==_0+&S[=DE=S"LLXB<%_4X7#9P[W6+:K_I!;;
MS+M/<#^;RS>:.9U1!TO>$<WX%J9\D)ED(15%E">2ME;3E@V0,_W^UZX*\X>A
MVO=S$1D'-Y!A:J<\[(<:0U!0GXBN=5'A22ZM'"1 C6^%94(*N^*)IC=/,?><
MQ?.W[%CNZN'8<R',93S@73_B6,;[*;CC):D,])-^J?E.@9,>3F_M CX.3E5I
M/N>[%3 AG+?]E$.!4.;P< !5S[QGT2S:&Q<0Q3@Q^DG7FZ5TQ?'RD!H+ $=?
M<YHJV[#EMA\&MRP<9:Y'EK ?J"X6=7/=[!8'R!\<C9UEUE7TNU2<UB]S_%Q(
MP_U1Q H>ZQN;^5)6HB;664">2QJ&LFTBK9F!7#,+OL$+IQ;\RX9\_WS::9J.
M:KX&H^#]YBH!0LI3#;^NW=1H7;CP]./5SJA!>8?!C$'9CF"*R_[W*7W[%8!C
M<-29.M0FU,PO94E -A@Z^R!6&,%09>8_';0<8Q)[)&-!WW1.<DTT\O+=V=^&
M^ "OK:T T=6#;)[ 0F>FJRGH6#Y-VB;RJVA2PRPI.R14P<(?3#P%2KN2BJ!A
MWC'#VHI I4G9.06^T3WS0O+R*AU=OBPDQM!#>G+!3NI[LBX,B#6:P([ZN?C3
MTIT!ED99.LLM'-Q2^>O+:HV'C;UWL8RNPMBYWP#D+][/NSQA?97*C:.DWU%[
M[4G4N[ )+K*9';2OK,W(AS?KPT$@5IQ6"$X[NIAA4J(D3/ H+K/E?E"LYDV3
M$"?[/"_'D@09REKXV&W5#'ECV([M^"U[53.@")179SC6ULI/.@4B;(Z0]/9H
M=O1X\!OQ0V<Z4I(KIY@WZ7=QKZ]6MO36$7[WZ]>1[M61P;7=N7G'^R]\?O72
M_!/-H:%QGM5CIUX?Z=/N52X_^SSFV5DA_C2UH0OL!K$8(-6!*^#'A&LP0#+?
M1<,$/2#/Q;!+'VHP<G-T4;:&QHR)-_V% )'[/3O/]$YQ^>0+].E")=?!&\JX
M2745DO'EO/[@)$DFY&B\*HX[3.B:#>]>+Z.@:Z[$H"Q-BCQP)B6$TUT<1[?Z
M0>.W?L\4O!*DT"E++7IE/)TL(LR0VR??I$)^/=0 [<]I9[HDASEJF?3U5BN)
M;D3S\I/XD/P")7#LH$F0^;SQ^XNKLFUT].DM'GR*/^^ C5?MH$)OO($J_"P&
MRI*ND"E,#LK=5Y Z-4,"/3#-UZJ5&QJ-S*L)C9#6(L+S%&F6D7/.>W CAA*5
M7'A&2SXKX:]9SES#>FOL;?;&T$O=( [O!2P7E4SA:W!.RR''JJ[DDQEGP1IW
M3&/GP:1%;['FG&]6)L=C]ZE-W\3VWY0ZQU.!*P#_M,6ZBE?ZBJ=U.0%(VE">
MA03#Z86=;H<.,FGJ<8D]D]2!QS@AKXM-\F';+_:&P8=G-G&8!S,I(,F'2)Z9
MAF&=U!$5O@;G>")[:)<2W%R]]\*F!+?BZ#+QQJ16;;Q:&W'(6IM>Q>X]0?VR
M)I'\HYA==DM-]6N4;G8]?/.]H)B%-^L:YRVBA2F?/+[6:,K#V6)M>>^J%Q5M
MAK:@!KOKS^F]2(PRZIF?=GQ#[N^G9.VZ9JVO0H+MG*P?%O&?@M[2_JNT+K+E
M.&,_K5$$64L@@_=3OZ_? SO$%FW?9.58,^<>,X/]K$.)+\6.UEP%*[W5NY]'
M"3F.4)MKN1ML2H4MGSV)9AKAJQ.?H,+R8Q13/%R4.='T<@N"-48>Q-^\EUV8
M+JBH._Z]%Q29:^VSD,==U$.[M[SA"#<#X_1TB&),8\RT./_NUECY74;@$B]%
MOW5 /L(F;JS31J!LP8%:/"S$B.8QZJ(<)O2\!/>E4(HZWU4/?7^]D^#JB.SG
M^!S"TO,-WX0WS& _"1A*G>C/A\>MYNP[;'<T7>=#"41#%Z [:+%8-9!H_"(U
M)_!.I:>-AO;H#*9V51/T88/-H5@>C%%6_Z0]WN="<77DQ$BP)M"JI\L^^)#O
MEWW]5E2LY92Q.TS?^6RH.M0Z,%4+&'1W$'D:<%^F7*RMT]Z-?&>=1)^^]YM6
MHH<K?!-8\@7;VO%^+9E*N8?(R>L@#MP:9%^2I,5J0MY )OZ3F[JD'@/P=GLW
M(;-:<5Z:8N* O;;L!_*>D4 ?.CRWYWC3/"HYUL$WSE7)OM1*?BZES5GV[9>!
MVD+E:U!$_^AVWP&PK34XU3 @%CZAP?A(WQ[O2Q@/8UHH$]C);%)QH9(;G8A#
MLV90"A'VI_&%V2-!FT2'N(<:A68H,0:+ *[^+ ) D:O-%A77?A):CB3&I&7\
M>9S=<Q2F7W6*Y8T??TP0E>>#V\;2!,?NQ%[LP4C7.Q+[:A]D4OD_8-*%PZA'
MB8T(M>N[_6H0;W***;L7-XH<D.4084)O3>]\!RKV2)U*=4!4KB\PFI?*B-[?
MX(Y%IQ^/8CKP28-0]8)ZO7V4GVX)_G-9_K]AG]ICMC,NGZ\ZM.]I5;/W$XE^
MFZI(P(0;NVV$PZ[Q.-UR5_JF3.8B=:\Q5GY(L4^/2N+XX7SS!EEDNA1[1KN0
M\ $C^E F1&<;SN(H,O;352YE7AY2WHQ%_W%)%SFC+5.K(?3'&8RY9_X4;F/C
MPI4PH9O2O:,_FTK[/O17[@'3?%D:\FHL^T+EV/X;*//C]7]ODS)*^(SYA8;^
M:FF>S9X17(%F11+G60V8/R;8+Z+U@8YQSJEF7<_#)0/QI=WCAL5Y[>'0MGY$
MSKHI\=B4G@ZKT%B^P&]/XJ3_A?49QI-E]GVBS5W'NV(-@XH+5BM$DTK<TM.2
MG 1Z+C5K9)9CD* ]>VO:7K&.:.U\60S5<N#9:Y2;?06(-1M+IY%9+UI$B0P&
MVDH<^H)HLVCC"2)BIA6<[C ^OB=,C EI>)N-H.9&?P545D9"=.U ZLY6M"P6
MJD2>_2=38BNR' PMWQ[UG>)Z?2V]!(MGAZ6@K4-)B4-PGTX\G<ZM  \M!?LH
MT[G6E*1&ZD1GQ_#K5/$TNWFC-9=(@^IQ2?(U"MO^K8^TTIN,^9H43"DJ^US]
M>M[3.VHH[3/S(>3O!NV(7.4W7-F:N>O8LK<"KO(,>\$T$[*=\0SR26U% L^O
M@ V47LF8 B![NA+-"B+F$ZTP$^ @1-3MZ2"F^\%^K'5'Y1O56ZYV)B 9=0>,
M%Q/2$;:Z@TF]G7"Z8!9ME#X& [_X6W2L@R4(X2@N5%J?:Z[3T/?NR&!4".+9
M85:SB7<*H*Y>?YWO$Q=CA[9&O^F[#2S0E!$^8X-/ 3:9]BJ./*GI:ETQ\\(<
M']:.ZB,^>O#*.28+[,:O2SWCL8$'N-=/GD!)FY-MR!L2L^,(-!:B6Q!5GJF#
MFK9W:DE$)J=B?:!YUJ$X1<E6FQ(;?$(PRB##1Y!,_0^UQ!U,2WKY?4> >IB1
ME^_&CE6:'4IT4K!)QXQJN%A>*M"0]=C/@ !\H^X7)O(C<3=7#=V-V@_X*;Y@
M74G\OJ;9,'8">R3=NTE>"3_.N_[@IYR:X::=,[V^&3:V+*7WD=OH.<;?5P#K
M]Q5O4;X8Y?^4U%+^MZRY&XS5/PZ2>G"SLC'ADU6NZ5M$-PS2*&<5^UY!W:67
M_[^?"(J]C^>&\W,EGV\8F!S=#BZX#ED+^SB*6EI:N:7:]1Y_]T9/"T'],V>:
ME^BMAX>$R1FL]"PPR46^BN@HR+<M%+1V\2BY[5=GV/:I>^2$BZ(A#1LM>(Z>
M5P/3-:*MO==&(=Q *7?21QK[D 1=_OGJ_SP(O@JL;(]V/X^3V,T%G&1[J,U%
M#/ET?C,"/G-F[6+!=LFVWAK_(RM>/# B6QY8G?J<+F?IZ-:2< =<F-5-R[-L
M)8G%.YMY*'8$>]"TWQ)Y(B]9'.LU306]9. XQK9Y+J0CZ0@_[^IVE^&/NLL2
M99<?E-GO$QX;353E9WW]2H9-+W!8!'P\())!\E&)I&09TC6L)NS[[4=PGW[4
MC^I=I9LH#7K02U3C5@!E&5_*T630^EQ54L@FDCR?*3<\:M0NOOS6/&C[LDVU
M=97]K#N\>&062_<M"1037^^?;3G;GY%Y%EGW%4O:B:,@VDK/J2_23-A?.TV(
M]S*4MRF_'4.J&KRG"R2?:7%$9!H:3R^C9#F]OSYZ4/&SG2(DTL_'3?P]PZYF
M6,9JOR$1\]F[,2>&TV.?.RDW!Z;:XO^@ZB2TZ50W]39S?NM22[11](EBLGD1
M%-*<;OY;B1RE*8U @ JQAK=D%IO)<2IDV89O["C#W/@QQ;V8IL\;05NCY%65
MD:F@/+#\YDMJ6 9.[!J5YS^ODE(X^Y/R1TX%\GY/B_ (D?*_\9:,Z5_-+6<W
MY#]N3\,=Y('PZ=,]>$7?A<(GUT^\'F_JOI\9O2?;U1S%6/4;H_)'M(#7!Y39
M1"<3V!L;="RXX?*GXM^\'VK*$3\[<1G6NY5ZL1+/IX?/U7I54X/H8ICO,69M
M:HD\9$Z'/*"F+Q4,G.Q:1G(D(Y3MNB(XGN0P^]SS^WWL@*] KVYA@# "-7>=
MY]>:__+B7'Y+$K$.VGSP8=_#;?6WQ@1U;GA617?Y?:H.;%12-$K4_^!ZF)0,
M3CE8]ILRL ?.Q,5,:61W-U,B4<5Q-\[;%OMF\BR%X.<K@$/R.=\M3-:O"M\V
MS5^]HZ.K ^JK@(/:VR?W7^H2'!9R,ITF>98&I",I@F1%ZL&S4#0Y,L1\@@0=
M+O $[UKB^A50?$;IRA-WQB0J<7]AF%E2T!$*TG5CZ(I69^FS$*8863 UX:.L
M,3TJA;*T%KN%0M?RLJB;\L9K&'N95LO04&TU+FNZ[%"<93W.69HO\M],C%7]
ML=".=5G%]O--O"3COZ+I2YA=SBF>Y_4HCJJ\[)"AYLYW#6K2OYDV:TE0C]F0
M:4E$SUVK7PU_[H-P0;J7&[PIPLCF0#%[:/)T^ !QKCNJT#_SMI_1T-ISL2/T
M^*I(":H0N(=!<HC59MY'ZW3=MFNKA''-#0MBP9$-P;M=7:^%-4..O@B%B*\!
MW4A1,%?2/UVW1WJW0:J4/8K,9_,&^"@9WMMRU*RF?9[[W2XSX>IMF2"K%?(B
M_<N5OEV(?T#FO?1\MYVF +L^IKD"D#U4_7P]&>J*1BH^GXTE3>%&. HQ;_?4
M^<)@M!NTCH98\5@H95X8XZ=1CMU7="<;+5&,NQ/[ [/7WU,2CIK_)*NOCT_@
M0_BUI_DF.[GOCMC=SPOUAL8 B^AC@XF[K)S'"JWB_ -SC9>K,Z-)(O'CN$B2
M7/<X:4[OP[(?T3.YR E<;OT=RXY'2R/E_NB(:]'1<J48M*ERG6-T(TOQ5'H&
MN$_=03VCH7F4GFO;;G2Y[WXJ.3U 1,/ICR__GZ1+&L^'(CC9,)9YZ;I0^E&>
MKM0BB75=&3/.4>KC)ACU4#VIED!PD;E8/UT6#)%1'T*A[(_!?Y<M?SH7[1O]
M9C;R9=3.]-%JQ=EMH$,(H-2U%S3HKT,5Z RLR-JM$W!"W!@](A[H@EOBA=96
MB&12EW3-ULK%S($YL&RS5\!'_Y[>T6;C=.6\]:J0VD<R5 B:*OJLAM>[J(?\
MI*14U&#]Y]V']6G 49Z_+6J'AT,)#^8KX"N%M5^A.*/\0*+\08W+4'3@)PY6
MW^6=]8+X0@-N31G+TX#XP3;%_M86^8(T+<+A=P+,;P5 V?%%<5Y'AD)43L23
M+/B)C^Z*D!X)O4%DS,/\"L1&J9*D\0&O!NB>2:$K1M\JQ,^] )V5WW-]3;<N
M]5Y@56$=U>&Y?4Y/$)S3?BY/FZKPM7Q-I=R8TK= __,_#?!UV[BK06]/<A^Q
MYLQIYK?K9'>+'HT?.TFMH4DA*X>81R=J)2L3)'/CC1)S),Z51OD:"9V2Q[XG
M"YEI^AP(2<<HXDU*9,XQIGT0^*[<G(,]SYJ?C5Z6 UBXYPT1NQ2I'U;$,HU*
MDM0EXVA'QGHZ(#_XR6*+S#%I5()C<\-?JPY+%Z0..699OBF^$H$&SC70%<+Z
M^V%T6HQ<@Z"DOPUC^X1 W4%B@>FWFCRW4R258\X;VAKPLUV2KSW3WG7.^XEC
M[]NB[!5%DMFXY9LJ;7#)J9Q-'Q\J.4$__65<[.N(Y$T_H1(.YLJ?PMIFYRJ,
M-R0*C91%1J]R&MH$9V3%6C[M\O3';N,.9RFY%DUXH8.]/E3SA/XBI[8[I4@#
MS]U]Y%6@Z/P\U &1I=JU(1.Y>Z@L[[HP9;FB[M?:!])OR%U&"IXEA\?IM#7%
M7*C$;Y#F[">MK9$KGE%C,U_D;L;+W7MSPC,,!1G"-),()[GS!L@0HN7*:!G*
M?#\RHLR&02DC2$Q_?,#P1YU8+RZ9^]]$[%P= PAQSBT*S8XUIM'X(B\K,\7Z
M,0&FO,$>C<X\"Y!Z]02C-L@6;P =] P1%"BFQK""K)_MYSKD2R:Z6*- W(G5
ME)/C[FI-+[2RGC4W'&SOY4/;L ,%"3S:XQY.8"TN_?F^X2;M2A6ZS!S9.?_%
MN(C1QS"DLQ&'DK8Y$<'MWTZ9GZ,V!+F&.?K7@<F_:'_%U :@1<'^^)5PV_&3
M\F/^BQ>$$XH$^+Q/CNP_2 K_HZ=!$F^FC,OKIK2'/ZJ_RW+J[G]U8JSS$.M%
MK7BAT;'P"G KTS?D_);Z"C ")D;!5JBVP"TJ-::F8]M![S0B'\"C1Z@'2)\S
M!$:ID;86>>'8/*L"A<DNO4?_"T'CL7[8+WW?VA:(#^Z=YS?A:Z93!-?O;735
M.L,3>?XM+R3'W&)>.^T.G NKHM<1#Z^\Y/X;<RJ.%.=>3Y&/&8RD[J=N>ESZ
MC-'R]:/]9/@,81+E^T1W--6O[ ?$!58!N&<=4$+..(WTYV(J7;X:&R(^;A.[
M4SH[JG1T]X/D]M"7BP.#S$&1>^\V+N:V^$3T-)E'D(BK7&^-H9Z$RX8]1N=2
M38<.G'8&%#>XAX-!]=7P5[6HT-*= /3^EFD*(]X;F>P:D^F:N",[,PWIKIK2
MB1#;25FF9X.6(T,]M)]IT?/VH>:XB(KNQ(>4QES83/[>)G1,L(#S(]Z/OVPY
M/VG!RVG[DR8F<D"+^]]X?Q;F+OTY$:$FV+CCLO(S_]W-Q$I9"F8$5J4_TJ^-
M;Z=(.%>J)86N*R?'8D4M2CJER&P_SB5> :7NX.>R G'IO\=!_0TMH0?9%!+J
MOTS2E;AJSQ;D&Y![9%6T2-SL1I3L2E*D.?5N!MTM33N>ELZTIM,VK1J^</,1
M<HF&"/X]QJQUO%.R8K9(TXXOP=C*QA=G#X\IJ:<@:6/Q<6Z2C6MH6\?I4D5O
ML\^L6I%J7?5JQGS09* MT:_ 'P,:@&UW348'46W**]7M&HW8DV2"!-JLQXL"
MIVC+<?Q@R\W,A5OJ.<&3YKC"6=9.4$P\/U$Q\#0/#*&#.WZ$-=KZ"K!UW)%T
M;J=ON*[%W 7'[;>2$^JPO*\"NHX/TOWZ1%FRWLQ9-($ZKWPY\OO?&X&9/Q0E
MY>_:%S^FXWV+TI;7@UB*DM+D>_S!BC+(JC$\W,18I;23[H:Z=;BEGD&XDN]J
ML+-:%E1Z4CO14Y>RT\6]Y!BR?C$V+._XXNBEV5['MECGRD[ Z*GK5;5H4I:+
M^#ZL*HW1X^-S2-+VD-%!!6#U_[PDV;<7:N>Q.PCEF3ZKG+=;6<V GO*T8CS?
M%-QP;$%Y7/BG\4[KW=&5_6GL.DO.>I:JN^C!;C0$?T>X$''W0-%_*7]#8G6Y
M_YVOJB_/P1/U(Y$%4RXI+V_OJOPE^*_>\K@9F8$A5@(<N45B*\2R9Q]ZMPE:
M#<[^KHUR=WQL>+LN<BV!V"QAS"CW4U^7%LGB*&1BK\KF?#X)'9M1,PQ"-8"N
M3HGL/)4L-IP#I _0QL2_?UT@+MJ>B#+K;FO6WPM5XHS'HA+7RGZH-D)R"2KG
M;(M^'T'*,LUW\ROW%6#84VJTKH:(-5J)'7-H2!F7U0YIWTK04JAA[[M%F>]V
M6QG>GVSCJGR,:Y2]"N&)\SI_JYIZ:E/B.UU$$F%35EM8>%;<B==Z)<.#.BU_
M&!"<BF]%;U!34YN?9X=#G(%J(\"VD(T2Y@NK^?)-QK/Q.^6YKQFMN.<+8G07
M!>*_K-/9,IU8$[RA"V.OQI.Z%#-&A'@\Z3R3[^E\8,K5RF-5Y9KP:,,]YAH]
MRFS,'2YW!LER6^D8W!/F _IN 0\PT0C+F7Q)CI74_=7C*3IE3DVAN].O> XV
M**J1&SS<Y7GNE9S3&Z\ +M#-S!_M^V=B),S]=W3QDH'>N\\W.L%#B?!N!NON
MA=,=HV:S)K]Q@V0@DQW-?HVTFU>UI)<-.P<^%\O']R$\><[YH7]TI%;C/A+7
MQ+7>7[C^M&SB#<CX <5$F06("WW77ZQ;&'PJQO8VU6F^ 7;$\^5UHWC>HN5;
MZCZ&&0RM=I/Z8/#L&LI<Y_^CZK(I^V)8YT@A[-(\Q>9D8\W)N3;\71D!B#N8
M+UMPBCE*W!%8EB2]O"PB/W?+[1&V+N[HQ']T-V:._Q4)OF&SB0,_?15J?I]3
MQ>/GH_5CS+VR1$%<$!5Q-/+&^1 :=5$J)VRZ)RT7WD?G+EZW;4"R?.$D.M4=
M3YL6TRA2W+9Y$@HG$Z#9J08U2O+J?;&:;*@]C"W=;H:\I=JR_EX;QLD+=TCA
MAV9@KV$:.UH^ZBKG94%^'POIC*%"BPVL;/_F)X,3:UY./9GJ_BR-#FG UY2/
MJ/1\K8,.@#@*XI%VF[R9UKGC)/R>K, 9/)]M-714C^6P6CGB9K<9\AN#8AOW
MX]AOJ(CLT$./T(WF6FHKK,_PT6T0*ZFST,WF5?7A1T-]M_MO>@88G&>C.&B8
M L6><1>DW'^G^AX;QDX>(<SU+>P]WUX!+DJ_Y=6S<;LA.:J^@B<PA#J!\[-%
M4K_9\P158I]WWZ&[W)ZFL:F:2,- U%2B3@JG.I&9E>0!8Q-82>M?8IC.D%,K
M8R"F);M$_PP=OH+HE=*B]8\,I_.ADB*KJ ] MGYG6,'80]E@ !6^FL>]I\.8
MQ+OJZV1:$,)6[&>J)AGUJ3J7M243T)9<K..?CH,Y?@&.#H3<E1^-U7=,W#A
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M,CV(4G4A7$6Z\U@7E3J$";'XG^O)+-:\R9XO//>2T@E2L^<GB,71\^'ZD/G
M'7SF>LWJ*( >!X83>T^H/;.?0U&3C#C:Z[8?<SWNJEI;=U;7P:A-X'UO0?8
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M?;/7K4%NZS0Q,H5][G8W(!/7&.[<8]*A%U'<^>8U D4XD+DJ001GCU'Z4<J
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MU/J>WTH:5)].:2UW-P58M\JX'<'Z5&\'VM;4$R1F)APCYW8]"1S^5 R2VRT
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MP5;J/RX-4Y@D%PDR2&,SA5+2?,JL.V/7.>_:M1YFWKY$J2R",E40YY/^?PH
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M=A&T2!BN"<9(/K3Z"*LAN#'&J,SPQG)9L9YZ'![=*EAE-O>1R'"R2?,748#
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M-C?[1;GJ3D>G2K]_I-YJ$).L7QECX86XPB<=#M!R>?>K<4VFP*$<-M4@C:,
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M2Y!4\[ >P) SBKEMINE+>6XOKN9[@$'9)$4+$-QGVR>!4%W;21W%Q]H4MG>
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M>::VMC9V[@O%*5R7!& %YPH[Y/-3*DAD6",F25SSGJ[>I/\ C4;R,\CKG:H
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M\UKSS>9"\23QQ6X+[E9LL",%??GO_P#6K"O].U"]A:WM]/D:9Y%P9<(%7H6
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M\J-BXQM&/I1S!S'D-QI\$_D70A59I$8L<$^6PX! QSQUY%26TQN29'L(&<@
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M3^Z.#GIWI<P-CJ***D1__]E02P,$%     @ ,8!_5N2 _A'A+0  33$  !H
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M'\+,0&'9S/5^?!-OQ&L^=!__7$K5(_]7/%/\9SSS2,/A/;+,Q=JLR*''JI7
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M35EL7NC,\7[8F+>&M1COJ&GX\/\VK=M8@$[3V2$GOI=IO5_-"AU^%Z)]H!8
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M=@ (T '+")U("'0 1 ($) *$QQX #0" @(+PMP+XMX* B(2,@HJ&CH&)]?0
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MN;@W]YN';#Z^^13TS<7&RL;U?W@QWP.\;#L.[_S)LD,"V,F[@X5W![,)@ '
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M!^<:',2+P^?7DV\'VGN9H_,5#S\QK?WL;R]U3TYF4K[&W;<KK>JQ9$4_=KR
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MIM7N1CRI?N(7=P]S<.^.?C7R&'%[1#LV0S?:-INAU8I:*?RU4N@$^OED4%G
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MZ46_):I]S]\(4@SM'Z")CG<L=))%&4+5Q*@&?!R,G2&-'IH@HNZKHW@O=[Q
M)_6;%=5YS=R+%(UP17)=.R;GC!3Z0^J@C2F<+E".XD<GDU:C:RS&Y7)KO4B(
M!S5RI%Q1/<DK82K#QD6=^QKY8T:,8R.>-+P1N-POVJA\A2^+B$B%S?K %Z&B
M&0%4T"F;"BDQ^-M6M!7*U]=2-CQ?%AO/P)NPH-)K7%[H6="Y$ G?2S<GF>H*
MAN7IE^6B6R]T)R-ZU1;,NLRU2C_(OBV+41;)>VWX/."1S:,_5@_Z*)#P;'"4
M4CBB!!;]4XTG"LL6BL8(@27UVH0[=!]U)B DQ9#I]RX3%A[R<HLY[(J4KEMX
M(WE/_H6;9:I_Q0?7L;^[$IL3O.?;;Y\_'?>0=EW#S5URF/[F<  J#S4_X'OU
M-4/WEY$7&VNML7<0>T+ELM&':U0+/#564_IC FHMO3SAUY])FM_X,L-KTGF*
M1ZFP/6(41$'9V.@.$F@G/)_KD#MB%6O@E,8F:IUT.9;;4X-W3O^@O>R@LTM^
M,$J]-('3,(95_[+O^30V*5Z(P">S;%BT;JQ!2>7#LG'I2PAFJP*^(2Z@>A!V
M>6$6-'MLO?'$1@$<XE?1&)X^7:T\NSDQ/;","7!R+I3,FH?L37O:1>IV+@X6
MY3-5>74DM#W];,@UFW)L/:1J=ITLI@/!@A$<FQ7CZM47KW=$D<9BJJ(BRRX'
MVH<9(&*^(OLB0]X(DY*(WI=&+>(NJKWB(GLME[K 5C3A6\4XE0OK'B=_<UF"
M"K$5GD9^<W8+,Q6$^SGJRD$[EP]:U ^MTPX$\@ TB>P(O0Y-.=WOL>N2S?P3
M+]Y"Q?1WHZ^-(M:CP&M*\?CJ5(:QY<Z#P19_<F(/^,>%]/6^>F2W@GB6IC,;
MS/+<9@9APO@"(Y_OX,6TP=X2FF 1=1PUE*"(FJL3EL(SHU)1S2**V=3#2"^4
M3Y&YY[#)DV<:U#43W5^%*8//").)+?"Y< B"N\HIM%S<)H/)R6:SN-%!^'Y@
M\DBH;!TH2?U65;+Q"(M$13'DHIH<Y"G&"[MEH]Q0O%?'V%,^_JJ>K@QZI[)?
M*M+P6FZ%N+<6J2X<[(!B^^D=F$_3<$!JU E3K&,IJM;D!_CQ.=J'LA!I<E6]
MYX7 H1/E#51;Z0?'7[/_Y#IF*NX726?H5&"SMS/SP L-;._5[<B^3>*^ES92
M47D>(J$P[]#-IO2$?@A,I)FU4AK@X1C-*-)H+:F6IZE.XOET<V==O//&\Y,I
M>BI#1R:0(M-QJ1-*B2V?0X>K>2((9'L8%UT?G,A 5Z&B1F6J8RW M@ELC((W
M_TIQ:=*H>+>//*F4ZZSN@-VX:M&:T&$.4T=<AX,I-#KX;U.N-J@]XVADJ+5=
M6!$1,&6XX?@O70^;H1W"UCO5P&E*H.:X1FKP. ^O9]3X8K0N(F]$_76ZMX@G
M,E^^X<C$-WVC:#/-GT+BH95?Y-HQAS'?L)P8+0S4ML);\1RZM@6A=J 7F31,
M?!X;@B25O24WE2?=SLQ?:>)MI9:_,_E@=-]M24K\$:LHYM(: >IQF^W.RA4B
M>_V;E?356S6U"DL5ZV.Y<".,+A.H]Z9S4MRIF-Y0P0RZ*F4ZLO]B3XUL;N/K
MO<YG'Y_\^KK31V'4/.1(QMVC-=4)G"6F:H],I]ZU].RR@7IZA>:"L#/- 3,(
MX\,<159=_7G?>:+==>6R&NTCGWFLH<>$Q8,/9H^?R-Z]%;.$32W]#=H(!:A2
M^VSS5Z0QI]&3RG1"MKK<6:\DH['&CK6C^D+09-Z>S'C2>A6Q$ )QDQ *"N(F
M4"TXN]]&EOQ#AVY&_K!4H-5W';T$8V"<J="\FCY+\&H8(_=C!7#)OEA2>1]N
MG]8<5OE7_I7D4H>XZ.:EZ\&@8\P"W,TRUA?3,5:ZV@B/MK%6G4TB\-389Z*3
M0N2"+B91Y M([SP24B>M'86!YSLDU9LB'_]=W]A1:],0H[Z]R."_,>GY^7Q5
M4-&OK&84>+0"5Z>.Z4_!/J@Y3RJ,UA<G*\92]B@)S]3Q]02VOHOY)%2XN\%>
MHDA9+@>(.3'$/@'8O!K%UMN'JOL'43!>N,BJI'P416?B>0+%[[H22IP&'Y@O
MY"-9J$PL^@1?,O,Y]W'YAG(]&*ZTZ;3M]A9I#7'3+99@H_NV]!#A<Y?Z;*OS
MKUP21$$$L0T8M1Y]$8W'X[ 8<V_R<NOJJ+)1'<4[+6V\O+HX920_7_KM7>D*
MFHX%[>F@5/Q$W'W;V")^]450B3O"G\($&AGB96 0*;=6#!ZUWGI;US ?,3IS
M'&RUCSI?558EZ-G7=S]+OKS+MD'2IMSUH;D&/<D*_@?@39C]'=%=FO3E*B;P
M/@CR62M-A\<+_KF3E"LV"67[CHTB!+4?[,V<HU+K)(J^TI5>#()>QK&('L>Z
MGI2AG?,N:>,Q1WB?F[J@%-GZU';M/C2G26I=4':DB%)E06GR\T.RYTKK0,L<
M\/&YJA[7)%7O-P6YZC4)>6;Z@<IK\J*^T^)Q2ZRXUY3-46K;5<DAV Z=K8I5
M\*;S5:4534>(9O: X?2BONW6A3:7BX9/\2M!V[",_WQRHWV+A>579GSK2*3J
M14XPSH^Y,P%7'\3&<>E@,6S:K>:V"KI.0_<J1)0_VCYE CE09?ZPF_6,34+2
M-CXVAS;M&P^J4B[&?K5M<4:E%[[1E89L/T'!-B@-\#1@63&'YARTR&*5Z>A6
M*XI,>H''4'U)U(7RJF@)>_ZX*&]<Y%J=PSV7_K9JZ/BV;=TS1:'LW<KC\U9I
M6IGM7R6/MCK/+(8CR.=B+:-@);"[=,Y<#VUJ=2[H/E&+;Y$;.5_H[)AMR'7S
MHW2V4C+-H%1^U#F4 -<-QV<S]F+KWS-V@0@* 4%YA6>GAZ'"<D*->^CN\; K
MW=Y,H-R[T)%7H>!5U_LE^.#[$1'[-A$M]IJ'W%A%=B=HXL=N#0^R[?@5&\26
MWRIGK[TYNZKV0"*G$_8"NPL^7OI<%-2B2<PBN'TP8NB*9L4AF;*7=AYV?16N
M(>.T5L+S8.?:=S$F>S=*HV5VFES_Z1QC;2W9IO3D"Y@).2H;=1]6K#;*RP3N
MH5JL,?H]NBS.Y+ES-19N[;I:"FG%>=XAWS/?U8;<=SJ7S_7X*0M??8A-/?$R
M%G+55L4]R<6SGHO?VIK/_H'Q<1VEQ9,\RYSG4* L?*&5'$75 %TGVE#[05:2
M6RZ%I<4L)8P0IRM=,(A,P465?CWW$>4N]:%]UV-BE^U%'X]O.<6!A<\8T@YH
ME!6(R[\":EKVJ^$YKURM2;GZO.16<E5$*>O#DB^WY1^Y2[UET<H[6+39G;<]
M@WL*:;4U\.<C.^^YS2J,/?LSQ^S<>2\GQZY:2:H*G)("VT.8#_U*^$7<'?Q@
MZI\!OE:.JB2/A; 5CJ^"6EW"HH'N>SHVJW'![N*CR5L)_'+SO@P(@@G#33"J
M4!T3Z+KO&;.2.ZHQ6J=-V>/XKH-:NT@OPJZ!CX=*@C3I2[]Y[/E'DW;W,N3F
MC=_8I;9I1ODBCGNS+A7F$L9?C9$OX<0P(TQ I.;J&R1&&KQ#)$0Z2)NKX^HU
MUY?;G-DBV3I[,^[7O"SXT?[^1["P^E*EF^/GWXGSV!_*L6V/GS\6,-63^=7O
M25?QF0T9,!^*YU<R#+?Y%P$($Q QL;!'S_P"&9.78C67XN6AO?]'4%\R7[TS
MUTU*>_EW^VJUDH^2:P]J)+AL$N#T QWU&)F-'+AG!S_Z<;V#RCNRX (\L_WU
M"'+H;):[5Y['^S:NH@]2B5)W'CB)QSGS)+Q[H*^^ T<OJMPBR0?XH)$P^QW=
M>XPN]^R:AP)!%0N-+>.0*^Z6_E"@\%SH3WY?M?0QA*;=2M8S'EI8-4"7MPE2
M<1N^WU0G-^BW O(7A^P9G!@"C,'O:3U&C@7'+"E!<03BH=CF\VE.[]%HPTR]
M:O@ ,:93,>VG_N=7L=EI3HHW??T0P-+F.+>5K4FMZZG;L#3N\5TES%KV>8F5
MT="8SG)XN>!".D62E/0L$^%Q4U^KCSN3&Q\L?^.*75;2_2@/QBF,)5'JVH.S
M[(5'O^P]7K)9Q;;.,1'^9VY]=Z/AF/) RY7VD?0EV&-*X8^Q__9Y)?8/@@ZV
M[3<9072VTD5.-6'K-4(-EXJQS7X8C(L<?N3DG,/-Z_UONZNTWRI[OL[ZD=RD
M(--%L[__4S[/1^@4@,S/2+C]+>2M#$$RU)]F3;>A6"Z44$H:D@C\^E)H&P,R
MMFD/>33>D0@;7+2@1$1DID<./K$,^^YCO%?NNXGM7?J@>!RF%OU]XC*.4<DS
MY361CV6PVWO)-H^)@8V-<#$F@(1%78#F1M$F[99G1!0O,NE6<'7  XT 4[6U
M@WL3WC2:M++DAXYHV8J59MST&^79J C$13U7WLB4H1CAB%A^)(8%S/<B'MK#
MV3;"TT"]I1Z7<B6(RZWZW>6F&*EO)W8BV[0C1 UXT\D$!D?6BU!T%'$OX0Z&
M8Q8CWEMW'*G])1OE+MV7YI)R;,;&%(663<LX]H%%P/2BX[+(N+!*;5 \8?P)
M8P<%'Q^(VF](PMT7$;ROKA3-2S<-M^I>X>153,S.CQK@>%\\6.,F<_N&M+'O
M0N4AY2]9\\-,8-=G,NM\&8FP<T[L4)^N7YAF8S5LWTS51>WR=._ @P_G;/Q&
MKK+'#$L].H#N,6JN'TZ;.N5_<5;&4L[X&2C(X!@A#T^@X@.5.$!L8Y5/FE\!
M$B.!9??:Z__*P3S,/]- $CX4\&M/B)*JERE;FDFBD\\>W]#4\58Z_ZGIB60Z
M7TBK@VZW_/?'#N!5\FS#8A-BW_6 M$,U8[P?#ZA8>GN]_LCSI)VO[NJ( -?#
M-WD8U_5PHBR=#X()Q EQ@IXB2;$%H2>N*IKK.72<(=-3\@E4FZC^BQW#8H/6
M(ZY!TE %L3K[]N>UVSL-_:WA9*/""&W9^MJ0]RD.^106XZ^ZMN39-F)=>9)F
MWWF-0F]W\1!OH_-4*_R0<O8C)?7SYS.>]68X\?=,X9[:/O=BI1^X< 6$4=JH
MMZLHR7?<*5$-A*BZP^37?Z[7QB?A7)D 6T1!=I8M:\++@1('M]GISWY?FE")
M14NXT^3-CUV\B.[13, S!!MU'$29T_:NQO[4W>U5$%9HAGS=FQ[_[6>W'_7-
M?%K&(_XJQ[>?;E_;8S4TJ@D5 @NH!P@VH02]4J)B]8_N52)QY[^<K3M"_JQ=
MFW=+IB;@J7=&2:1'\YNGIT7ZM&!MB8>&)3&?Q6=J1*'03I-A=[ >U;AH.X?<
M"?O3>$05Q1GMIF>VZ^N%RY5QK0I3O;>OO-6)91,COK#1:0IY:S!]\E.' G@2
M*HGFQ6##\QV#9/W5!BI!P*T_ +?;,^7/];"5I*S<&2]?BU=%IW)5C#4'OTGA
MFTXZL*K/C;U-'&N"9O'0733C5IY=8%"C_A\5/04*=6U[(RK6#7.BAW0BC]S1
M=PO>.<_"$<-]114&48Z[6"B0<E \G__BB1+I;U((:1+IB*T[B/"J2DI(-\YK
M#22FB2V?KZH<"4'!'A5OO!CZ+.AEYA2?-BC)Y8]PW749A-G=-R\RT_M$(#^8
M(?QB[\*2]\ 8,CC0.&!L?=<,'&3A80+[;72_X(].Q0^NT'."G]YXB:=+5J$V
M=@;@Z3L@UGP_@\$[HLFXHVW) "!RV-3;H2I&2-PKHZ,Y:?XLZMA1J'OHO&8"
M7V6AX>F]$!9,"<7 ND]WXN?3I+Q]T471!Z<+;FX<^[+POKM_PY,)U,'3]-T.
MYA9EAA$/R9A7VI:&"0^F/2WJ)DK?EY5Z5"GU)[[EI1A/YT<F\% Q!OX3Q@KI
MYQ"T]=\O(O)##V]$8'30U8U!73,.$N3"QK%]<]H6OSSSJ$$WU[T_O_V4?L?*
MZK0U</>/:<D8,GR@A/J&LMJL-(RW)"='ZQKJIQ,'">X=7.B/\T-"O0B;ZDJ7
M=U4?S@VGG=CM7^I_QRCO%NP:9,ZA#-S:W1\$4 F:E^]#@XF=)7A:[3;V.^=+
M)C!>!;FO;O_FGYU!H3'419'WGWC< -^S*%E$$8ST*=5S;M5>XWU'9J2&Y=H-
M#-N>*MYS(2A(^KUS JW:PPU5\\/K QR:@H:7(2QP8,=?($1"-?,P70C>.DY0
ML_X6-FKRZS7RV)W\&D,OW=6D!TMY2Z:\2[%F1?/6":>?.P/?_#SE;6+@%^#$
MO9U,X ?GRUL0=]6&5'K,V-<.8]R&M.-\P01(7D3L+DB_"W6*:!9B!\18P<;Q
M!T43A3@1W&UIRFK3(27S'N\ -?)HXBZ2P+O!X]=6;PB<4K"Y)H5_YM?:"R^R
M69"670BA*:"52"'HFRCVQ@DOS9[\@.Q"_7[UVJ+G%^\\/Q&M^9'O55PZYM2D
MIOY("^RXG"H!XGM*$ I>*$*PN?L#@@*<R-F%_<&9_MMO97<^O'P]GRNIW]A@
M=[5VGD_F<4:KE(^PK?QA:ROM?:>^7UL5>H,E\G1:6@B>GL"ML1I <.MK)M!#
MC1GD GM2?].&TCBN 7L W687B#,E/T_VR[V:] ?7PY8O-O %9U1/3(';@ <"
MTD+'^"\M0$@+!&@0X N%[R\U"#J$\40"^1P4W935!ROY/!.6L:5,X* #NIO8
M3F@>XQKVZ+1O"WS9T'5%-)]-ZH\Q/RZ)P;MU0L^4!_I:ZW&@HF(V[4(H+QB?
MCV8E/HB2J242=E\%<\TK$(<&Q]0?-US6*\CVGC142.OQHHT=M;K\35(VA7U/
M;A+DFGK)$?UU2U:/:<:U=9@N#DS>-!&*))O# V/ZG8"3*]WCF]%;EB-BZ0>&
MJ?$]H2=IRJ.6X^8= G,PWCH>!)@TUW#3KC>^QD$N3:(H:<P^9>8EIU.QL51Q
M6!K_Y^LS8K WB^H\H.+/3%(\RWM-?0#D+$1WS;4B]@8J1><CE6+R \J[]I^M
M3AKZ.>3F<>CRT<A3Q:_-'XM$1Y(^K;EN*(=DC<')41ZS<,A=OR G!L#I%C#H
M FT3_C!:Y&8%Z/^ *.ZG"[!CD1W10T;/":QT5^+87K";N++8!-\S&Z1=EMC<
M$>V=]USHYS4O%W%[^#.5O.O+^\9]=%A<%A@-</+%5.RP[$3_?<S!,;2.)?E+
M[8L?&@QI/J3^\5**^HN[MEQN?21[=.>UVOM%==(J;SKX#EY<^EP8L!X-*OT=
MV!]P,,67[(!C B>N[M_DJ$R HOXJ?'+C:,/K^9M&EO3#MRPW=D#J"VZZN#LJ
M?#N#L=M //)R_J9! &'7CZ"JR\NE%F*G(P9R4H7*"_RJ60ZZLRSQKT6]P=9W
MC)5PI^5<':QH@$<_TDMK*O_R\04RU3;CYBDC'^-=V7,/Y%8,3D%UZB)A41TK
MZB!5P@1B*NP_,(&GF8NH]>"D*G)IK]%:G)=YXE58%0N#^_Y&\BHTG$484$3A
M5*49+/VQ&7S\!V+P-A-H%P?CYYB !",9&DK5029 'J-J]N@&D4]UD 32)RRC
M,)SD+^GY(^"M+L2^V1M#M>V]I<?;57)>62[E6 I_L]324_Y2T<0#R@HV6T;Y
MH9^E&ECR:D:J6ZA:).CJMN?JK<]J6(8A@ZX?/N5:AMY7\:R%$S ZR9(U8#6T
MN*BU\:JCKP.,$:0Z,H&7)RD0_63?4&("CSQ@Y #!^09C^B-8]!@HWL4$UF0(
M^T*ER?BF45W<.6_.1GVI?D%388+VS62]KT6SV-#S/,E?-^8#7@_052@"6>-S
M.-XA$-LD*':H-/GCN]Z,[M=>;##Q \$-0KUWQ/?9A]<WPRY%X4?%^MQ_LM(-
M66G'F4#G83 >2N M/ZA!-(85SOB\"_M1 H2X\-V]FUIYD1G3Q)9J]_$Y!&_[
MB[FOZ!M+!EPBI56A'QUUOL?G:B$4'IP4XO(J!]5ILK-C0G31;/0#!"^H5*\O
MW*TNI!;9&WH^)Y8S>-%M]Z-1<?Z1@6/);NQE-H^0&]9IA86C'*6%SE1Y*%&A
MX+/!EDSJ)+'CX>9,X'O*)6B2>XYU$V "*8:4_7_YR(N2W PKQC7Q<(1:4FS"
MQ^I')7K5%W>-E#TO$4AP5$P_E!IHK7(JK_J0[^R(L(ED^'E&.Q,HP=^'>Q;&
MWK*\2Q=TJWI0E&NL\*F(R[&\(H+KT;=/G_*LI41/7C]8DK,B+KAB9UV%6I0=
MMG2F!A/&IPL'[_&L22%XL63\5CC^))#]F<#\I[<?1>A2X$/)A,0TH_#,A1N5
M0R:TL^Q7VW$6K3W]I*!X?>XY,2Y*7?J+LOBI='\G16E3!?GIH\&[=GRN4&:-
MOYI^_N"]RA."SNZB%K=@<4S@VA@,+4FDII-L%7XMG.VP8#2I#,]TU?8.Q]NU
MV,]9)>2XWHX45/%?\O[A:Z*?;YR+16^4=O1!=8Q5A_$Y&'*+ 440XE<B"-B:
M*N0\7AW,9^PODSJ)OWQ)UT+P."C&BV52=0KG!Z4U.D>%4N>7S !GH<>BYKNO
MF7PY(9X0GM)5#;J21&'<E[ULQ [U+_RZ:G<ILO5\\MEG\HN'ZF:;CUH\:'UK
M9;J0@KV8.;)!HB[#O:/H!R=IRF\A!;9"!"G !*0@M7C_8/P7!<PHLHV6^] R
M7UJ\48U5U%CN5U>O3Q*ZW<K-&Z*\V&+?\.V[%?&1W]T:U"/ELR JNE#THR2O
M_XV]+XV'\FW_GI(D)'O6J8C*EFQEFR140I)=IE+9DF0;&3,A^S*A4L2$I&Q#
M=F'LRM)DSSIF%(EAQGHQVW/Y_7[W_;_OY\7S^3SOGA?/BYG/7*?S.LYC/X[O
MS'F=I!U7]GZN+JOM5XC[,RO,2Y#S/;W7W\;VV/.#D*^'K;>+59:7^7W4-SZS
MCGHS7ULR^F$Q6.#(7W;" +'5&W<(C!15<.B?2!*> [3)XZIB3@B4#S>0 ST(
M/_K5.Z\Q^6'UR'[#(RF"&:,7^;YP+:5K8)^Z'!^IOQ% 8L):#8XUTCAC7 /R
MG.;]ND/=Q203GIT4.W?ZM/V!BE#;M*#-B+8KS&(HU<]NL0N,6U@,_!\&GJ.;
M>V'EBJ#SH _BI;G^5H)%/TH,$>'25\EWN;-UF[F!S:TH^R,6N.W?;W2;=K*^
M4+W@14).G2BOX=4_%KN$ZS9;S4-:'%%IP47N.ANIKL6JK_,M0]_W^AS(:?#C
MT0D[W$SX^B;.B\OL,_WKQKIW#NP^/T.JCWX:L_4.>Q!--<IC0U;,=P[IZ"&6
M*Z)[Y0"PO0J7_CN(1L @8D/B&=S48*1WB7OU8YDT^8HZ0:<_6BMC1#W"_0>B
MQE'&-_J$]W!]X]G=4'X-Z-ZPHV'"#$01UAUI$OJ3<U'(&Z &#=&WO)5[&['W
M5>Y6M0_&91P)I3;NTOOPS2/4-F427X^V_X!J1;==(9:?G,:U^,1<OO[3U;!_
M&VP+S'4L@;.Y&VY9)LDL(>0%M^1X=6FN*\=B?Z:@!KXRO6A* (>MTU8Q^E,
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M9DBDA_XDCO,I1*E<.UN\_!1;!_5(S#)V+_NUV,R78EJ$W-FX<Y6A2HT."Z#
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M2AB@SHQ<1)WL@5$M,?&M+ ^[I&TVY/NQ/\=,XH/FH%7IMA?GT/=Z[4BLV'R
M:$)M;RRFEK?+G*1J=D2ZDOE\VN\M3:KRM;_!24R8^@B-*E&-_/A?O^3JW=\C
M)M] )I!'HBAKV(,(MZNTM$@]^$RQ-0D7M7:(81Y$OF%ZN?RS%\_\;,. !>Z^
M[:R\O_N^VQ>"H&Z[ODIZ];CN/#S)<#$BM."ET=-YO198JB4;$O\4_561UL%?
MDC)HQF_\)P]X(3&D<X%"!LK!-$+.![M780^TP#J.SYRD>YRA37[1V,\Y-)2%
M*W2/E3#WVH@O(O@I#^5>\ASA]5,_GYBR>PZ\X^YRG!F,\N(C\ASM9:%,="%0
M0'3P'_YE<O?[NN*XQ\NIN4?A7XZD&-_XS6T8SB45*(!J@HN&N[)$@I)@U.OK
MMV W8?'B4)H7PWN %>;C:)*X)]V:^/V;S<F&8,OS3*S,'^B><80^2GY>&RN@
MI[^3[<HMR8#F61\* ^81."P_]8-X>LD;)]V6?^MN/$4RNO?9J76\Q/PF?H\F
MD:.7)FD^A/3B;]G'T \F\U,RHBJ&'^2.W&F,MC3KA$QH5H)Z+T<6N=TQ.?M0
MG7&6?HCA24UUR=1N@A]<&QXL^C50TEN94*;96U&S>OB13@?=Y#KUH?[)>G0I
MO/VJVLZWX1T%N?F,RV^&/2-%5#$6&2*4]\/)^JHSRVV)"N3-ME!_@(M<%3T=
M4@B+4VAWC,I7*?9];XH;U<J\*]+0\^C"TV_#O;Q]P5RSDBO"$>D8<^:[-47^
M6#QG"5*7O( ] %@0R)MQ>L:%\QLCUWX8>;^_\:=7B<^/]X[J\^$5V)>FDN%;
M2>;!#'2I3[MQ)\/)4@(]75S0@FI!"V/@45F:FV"*=++>$-8AK*R)514T?ET-
MQ$^;!=$L/MP?%K@WLKF7V 6?W+IG-UK-S,SPI5BU3\N8=F_;#?2AP&HC+,;R
MP"?@J8Y#&O!28AO8O:?[S*@R1#4#"YZ_?-.]?+96?G+,P#6^";;6@SI?A L[
MS3U:<>"2YMH8J@TJ5$-H11_"T*,T0_GH!]#-BDOU7N1C-/ZV7IEEL^_^6WX^
M.9,FMS.L7UP\W*53Q%&W[A?6],6]."[OLMX(/OLZ=37CU^7.$V /BP*]V!^(
M6R;+Q]/B;>N'ZE5SYE4([UJ]U*JQ+M]LZIM@O[ZOOI#=C-[CNVKWIT*6APT9
MF;\ZOY'LX-BY1ZU3^-2'BS/&^\L^'-H/F8:<X>@O"HO;\AS*=/ KG\J]9(TY
MN?]XSB>-_<=SS[S=^^6AX@Z2/Q%-87Y =<,$ZL5R$6@7ZFRJ?(:W:D*]S8$"
MFE+ZR\0]?4X9DMX_!7S5TB\)XW2]#P7<@KLYJZPS^()#4%\;#PPV'D$LM$M4
MOFD\#'YT=/(8F?\8,Q?5WS\E%JM,Z6AR3=A*^3*JY/#+]<U-GO?]0<FC8<4F
M+VRNU0>GS!.W[;9^K !LR/3; 3AK< 3&KT'A:J6>K]8:KKJVD'64U3VH=SYU
MM#- FO*4C\?4SZ/.4O;$B;2>*/0D(R+H#:L33[T&BR$*,;BH^"LTL2?^3*\.
M&15JPV9\I??E >?P3HO2@>)*SDH/IQZK:(/;MS6_;#VRYTU>D#!E"&6TUGF/
M1'H_T/.EP1RIQ(BE-<KY[M:Z]Q^] _*9)4TFRFY3PVR(1X+J"X%3K1H/=>5G
M8\K/>K)V#@:YP="EPJ-*_!TT526\')VG1 <98M(-K/=/'#VT-^.#CM7IJ9EL
M)0XJ/=+5"$/<\_LRDLXM$UW5G2LFXT0IQ*<O5=<%KDR0UGS&XWS&>"QH+Z.U
M$RJ@3T=D#O;=ID6.Q#'4"QP!C&6$A5VR6Y2'?*2K@]#-"9L;%\_:GIE[!MRE
M^S*, .YI+/]7&H=31)L.OH.'SC1K%D"T&9$J^M84CV<SE[*/U:M6D4GYB</'
M8IX+?KA_W\\EGHP!Y$PC&+=(;,BG/V@!UBD7%V9*JP7K.VNH]))!MZN_BO?A
M%=$>QRW?+X7)/U&;[A[(#LG" A] H: WP/6C"^,.0"A 8(W3+VF@#TX2/:[]
MD;A@;?QK8OP"_J;H,B_IMDJJL4(O[Y5(\4=>Z5E,OL:RM&-@6Q;@;9-VR7/]
M)>ZK@\PM$@%0?)\W XVNRT_TAT?J1':&UT/SY^LP<25+E37%./_!VHGRO(;:
M!&8V950ZR4'T8I/[:/S)(2\<H)P?Z6^N?9TFFI<=W,B7Q'?-7&\^C0WQ&CGT
M(\V&;IZ=>&V7?]^+Z,W>[D[\O9GJ\1(VY":&B\C0H1&CEBI])(BM-,E+I7WK
M&0L-3A2=IQ_=(.%GG_8?<54_/K%$WU13@/@Z;*"I%JH<A+>(^%:PA9])="7A
M8MX.*O^D*@]_*/MM&XNTG]C'^-#_.[&'(O%5MXAW]*G)^6=^UHTMVQU7V9!?
M \3/8]ULB'S#]C$O7AJ!8D2#DF"M@4/U'M.X:)9P8TW]I\K*%#:DTT/TE=Y:
M\B^'8^Y[WMM?YAP5MIP5ZY(N:+O.S$0=\X!50!>)"FW%)Y37I%7;[(+Z/3>T
MJ[WDM$9>VODY=FLVC"5V[1EN)Z<>&B^K^C@MT<D0"F]M2T$$TFV!6EJN/4T[
M F>[>H[&.5MX2W/V6<XD)5WNZ6AHBN5I<0<7A[<II"1H[U1VM T)^B.^!;6/
MF9D+N-[Z@"A>.Q2@VW#]Q@U/M/N@3$A&;<DO58TX9-/=+*/5*(6$%!.O.2""
M@T*]]F*_9T!.1B11I5B3YG5GX]YUKYO/A8/3O0LK,FL#&A,7^HHQ(FS(TP?T
MC73:W4$)F\2"2N:8,U1@ZIRW7*+KU3SOD;./'IIY=Z5<GWYH^L-%N(_8.B51
M5NH5G]%1%J;<V][ZX.6C.+$0F45?0L-#U"[FR_JSTTX+/)%I3D/W^G_H?QS$
M3=VINKF/T_5&V<?F,RUQZX<R?BU,-4);&_EQS\^7*)PR&Q]\/#KI%'+,Z\%4
M7?50^MQHL=[U7%-^QAE*0/&:W8A+EEGWQV:DR<!L[<C(W<6-/\F[*D7V*60%
M[QGFVM#O9'*JL"'+$VB&>8#!F3DX;+T778SDH*6R>':1?2+&-CN\;1JYOA8R
M5  A<C()+XS(@1YR=)HRP?_^57*T-$73(S#^^1:'H*54EN+Z\?<;!H_GQO _
M1F!KPO5L"-X73=- NTZ@O]LNL'8VT\7BH@W.HIL]*V%/7<X"#7QI+:'\]E1L
M\^=5[T)/.ZR DD;BY:4CWM)?7XY;9HI>LGQQN$51NF?_BJ'($-('S$0UW=.$
M^+J@B'I.:JXM$%;@C#!H[1C1TI8Y7-X7<&EQ678U)[RE:V8S/7+LK6XVYEG3
M\:V8O6_N#F;="?5C)OJR(89F>/HFE T1,NQ;XF*T/]@1'<XP=_5JU!WT;N1U
M1I1?HD;'5O8:T0][!F:)JYFZ%DQ><3U0E: B+GBB6KI([J9P%,$"J=V$KTY+
MTO/XP+A"1<(X?7 H5:1ZZGFZ6Z0_7MC1V?&K:%%*O;KF:LRPVNY6M==:NGRY
M-Q\V#1;;3Q2%BC$3_;!;^V^@B0)_:<<9NQ5W@PW9N=)<>1_-AG":U]"B7N3]
M=E1MS1]L5/Z#/[@.CUH@O:/QPD>3B1Y5MUE+,W2S6WP/JGH28$'U7U@NWXU#
MJA>SZ2;S\,KJQ2T2-L91.6\8ZT8^+IW>]2NBUU7O6KWZN9YZK:]6:;+AIT+Z
M%(M;?E/P90_POT\$LR$HL"R2W5GM=6S(V[PY)GW'3L6'_8PM3_40%YUPV_M=
MT,2:G1_O_^L&K\MQ9Y_T_O==N731!59X&G9S294E7_$A]Q7O?Q'PUS'NZL'2
M-.KIK<#1#3;D7@7_Y>MLB"-^&3-G>DHB2$>3.'8')-,PO861N6Y:"\[(975\
M)C"B5&'+@Z"9[C#00'L.B@#ETO, X9*0F9R!--4@,1CG:7YP+[Q\_,)*38*@
M]L7FP(*YEW>E%^9@HZD;-<S<1K6%K%TC#$.ZWF\=&-CZQ!2D"4S9([ZJ:.)X
M';K%4W@R?LM=-[6[@57B[<FKLU$,6Q?H*XEA0YZUSS&W_Y9+8H$5(?:W7(UR
MM<P:M"?X=V]N@_VMU/SI$"^CUA6@1;>:=G=[//.83V1!F8^L#+HGL72W6L?2
MR:5DT*8BP"IMH75[,\F F\%-38M'B?U^G#GUXI9O":+>0Z(S06;82'CE1UO?
MEI7)';OKZF>42[/4C5_K=8X2?U3#UP[M!)/5CKO<G@3!A\LJBVF\LR>Z U;1
MR1#&D>&MRV-D(@G^5$^!FFKV&LGM-F/V&1<CH^HM?T8FF/&RW.&V7=0E@9BS
MUN$%;3*OMS=)!RI+$&DD3/2ZJI!A]A@0<76 5#-XM,_'<=7"P<$0YO;ZR>DV
MDWV/SBX,".N+=&F@RU1AOY5W;)_SE[.T@0R]K?Q'/<673P8_(53TJ30.R02$
M$.IAOYZ#QC+1B*^&K8C^P[EF,=??.^KY-V( )LEGU'H:&]-X%#&V,F-)K8Y4
M'EZPJJVN"GE]._&=?8<L_'6C&P='^MDG\Z"7LB&_U?Z]LH1R'VSE7^K07%7M
MP -*FTWH)S!A/3,25,#31<?;NKEJP^[QSS&W"$WER]V7HI;Z%6ONI),/C9T9
M;-:X;R:09.KJ"!6#39<0.5@'@/C6.N>QZOAZ*U\R@6\<^&R&YD987J7ML=-Q
M7KDD9<=9[/HH+%W[T,-]LM*(@LW/N];L-HX1F9S+?WLD]$<:=NW?,JZB0'5P
M>@,WR#@,:A<0G&</_)EQ!IXHN1 H6:*#1:@V%?)+=P9)N88GAG0L:5&%=7'L
M%RK'Y$MGGK+M]#TVY+8+^KOC/\;M8\:"4AMZ$>CK?VTX>7YMED.5+KC*"A_!
M;O[9V9*R:$;8Y@%CZP,86X,Y23=/LR'_928/D]A@[!;/%)A<=J8,@%/X^$WJ
MZ7N7*86_]E/>M._0A9_9.4\AA/F*4O(^RG+,K-E#0U#CVHGZ^.-=[?;0U \W
M34GPJ^Y&.A>(._O-=7#1[P>1'CA3+S??X*-_M%<^&?)<[HKW5=1]]O99P:YC
M&,AN"\7[^B(V%3T%UW_"/E@"2/[%%MCL+SVP2(:5H6G"N3LG]]!/I;(A"B>F
ML0P^,.'%X&9UIW'-B5X;X0#V+0!K":RJBZHE*T95?[KT0%026:"1M'(993]S
ML6\RL\;FFL4IWRD/;.E(@IXQ3=N2FA^]CHDT4!]4K5CHO1U"X 4VKPQ59(I^
M&SQ14S.H>COU:T6B2 2*%B9[9F\=JI S%YV<-JSP@Y6()RWCRZ%,J;1P/%5+
ME74T#%0#DOF*P)CXUP@^LU>(Q4V@F<$!;"A)UUN[!7V_;&"->4W9Q%+XAWQB
MP?@?025'/P=X<);YP(VN*6=%\6,3 BO3(UF(B.FT&.2Q:1Z8D&>=YWR=2VZ1
MRV^M;KUL%;?/Y:,;I:5,RK.*6$G8Y"JWX<M#^5)RDI_0SQK+5#K7OL&F<>AR
M<38D(X4*9^W=V3QT#0,H$A:_H&=_(L7^5J((H_:2ETCU]G"L@7-BCW#8!!DK
MI?4'M::O_B;!=>0WC'!_9#"7N"(VG/>#E=/)$)G9N,N&Y#ZCNOU-\"ILY[_K
ME8/X*^-?8QT+6X'VE)\*L]'O+0_3%MH?(#4 [P](9UI'!HEX8,SH@Y=$-KK<
M<#:'BUNH9\[W#,14\@U((JDF]X^5(W%%8<&RC*F-;IW$WW-&?_V"T&9#.&ZS
M(3/^4$ 1M[.;U!0Z363PQ?]E:Q\2?TNHZ\Q(FP\?8-KR.'@(:4RF_R[2^'RC
M&XI5>CKC5[8_[JUHH-[)0J'^ J"U>7X:=%.BA_<'(,C>V\#R!,Y?WT+?TKSF
MS+>;M9C-1SCZ9=_FM>R;N2%^**/MP>(0Z$ 00Y^PLV<S%T/U8>TU_D=D=+DI
M4PH=@::J[-@V#<A]VF7G?S>>DZ.$_'C74L@!-L1%\3T5VB+M2G:))E,LC:LJ
M:\JI6BF:O7?' DS"OT\8>3=P'1O_5A,;F/1P]#>?=E@X'?[LI8KE';29*VL_
MB:Z![NO\2_2C8/"=L&2(X#<\9%D6NLUX0!RTG "\1TJM5772W2F!VIKO-X_Q
M=0FC$C;NT13:?7CG'T^]2N=]K%)(CM$[)DW9*'.[F4R\)-A;F=B6_+Y/:+?!
MPQNE,>)?.)DFTG>WN$:.]4'[P"K<[ 2[!T:2MC2H7=X=[;X%QQS!NIG]K\&_
MPZM[AJMYG!".%M$S).E?\SZY1&_=[/_1K84-]0GQ.9$XJLT5]O.JQ6FKC,=9
MAQ1W*V:9:P:%#A4D[>8'<Q($4:L2O38%FR[&EULRI8+^46 :2V:4KLF_54/<
M"^)99SC#&'WZ1'[)\CHZZ<1"O@IZB'DFGXF56:8J+*0LHLU!!8W0-;'_F@YC
M&*LR]',WO$ C)5"#6)P[?FFWJJ3QO9["/&G<SR!\%INWI&OI$Z>ASFFNVR ?
MT9]8O<4#&PE4-(NS]6^3%F'+/4 GCM\9^IN OFC<',N>]4(/)95,V"[;LF)F
M@"SPEQATKE6R(?RNS(PZ=*L) L:&[ 9Q(?DXE&JK.EJ/[NWX:VBGKU'<*L2T
M7-,-G4")W-(3WOJESH;LROV;$9=0S+PV2Z:5KEUM.:;8S(8 8CMFO0R;+B26
M@TDW(XZ*^1<C0="P((%7X_EYCO%-YXVA=2 )Z1T2L _\HVS(1@Z IE_G,V.)
MC+0KJW9PF-YUZGMOR4OPJA>,'+EY6.L _WD3Q?ZHL-!JEE$:$7Y2!4T;8\'1
M]^!Q6:>9R2RU>1==ZMY<>0R9[T15%L[G0Y/%G<H:S)D4<4@S--A"_'+I'K01
MOE2;LDR"C@^0Y!X/@VX@2#SHD2T[HG'B[J1OWI6FZ0VB$"GN\E[)/:'330_)
MI2FY!4.2))K QWSK43Q)&@];E6K\5]/1HHL&*]'GY7\J49^,FF6)^KL.$/8$
MLB&LB"#BW_4(, 5[]-_:H?^4'Z][<9#_/^?_G3GM!E*-LBRC?V;@Y@,%[<]W
M*[>E7;$(TBF886U!;.J.<\32"#KTH)U_A>4(1)-@#$$ATF0GQ8H60LYOM]P-
M\'?*'*:YM7&0\?M="%+5ZAY:X?M$S[Q/#.^<5>I3]SXRLL?O1VC#3%AF*'XA
M':3Q933,1EQ#09A P"5!J<8"-((-L$4>GZ\7=Z.9MKN<K:;A6F&"&9:5W=F:
M#15'E'V07[XM!-]-;.W('KF?46J_RXE89;<H3FO=* [$6K$A42&T1&P<4MTK
MW]-1(4DC(_Z''G>ADK%"X_>EG,1[[IFQSXR/7#ECE)Q@-S'.5?W+K)JV3- (
MN<3S JKJ@&I%:0-GJ:OF0R"^]>N4(+1#]P,RT/V_^Q!I+FC : F74^D4,/B@
M:(]%[W%8(YV29O/-\&A]&@F^*$TW1/(R8QE!T] ]YM2Y5KAP?4"P6U AXP*V
M0VP["X?K/O+<TZ[\\H;93^=]PX<H+5P7VU:R>#WAR\5@F5S_H!:5??U6%])X
M9]L4-HDES#@-*"B$,?2IY<VLXP WV=S,IG\M6,\HM&!^2C'Z6FE*_XK7PD:5
MV=-Z#_G@B)@)Z;!'NR11X<Q(_+T3,%?\J'4+[,"2YG'->(KHB3E\0W5L=CCY
M#SFHYE5'<8HLORSGUV\0A?Z&^R9BV_2!<'*LQ?;NQ,PVJSC'XQ^/'\^)@^R\
M_@=Z77Q\+7][B U!HG4@O<Q\UI[?;$@E=.?\Z^6HQL,>I#YD:/:4NYA?DW"O
M9YI /<H_) Q^^K11R;3)3Y'5SL5V*FRC!O!&4U=;#)2!:*HE2P3;6D,JK\/W
M54C6:A+%[9O%7O#5E_5,F2>/':Q(5D^Y[IH0L;[>U#OXUP:IL(>A3,_:(D49
M3NAB&9D31/E8_L3$H-SJIVP(R1X6[MC9DTKI18PEV#EU4<9_;KF;!#V8,.TR
M1J;2\*Q]W33+-CCG.B:,!:T'^&=4PS=UIK)+@-N;G3JH7&;#-#<..7 X7-?N
MX*2&2;"CN/2SC^A7IZXJKA%NLB%'PS_CM]?\RA[EDF#16*KQ,M\/5#]*<A")
MS@.$R)A6.!?CZ( !='[X\=*K\LE+'QUO*%;.C4XZ'G^1/6%@IZ3M/3^R),W1
MNF$@TJ=4T:ORC6@YX/]#<+A_>$I-2JOO:.3%/M/]!6\A7.=.CE[9WK[6=P)N
M:]ML+'S]R0(: #!,$GSGN21/QK$B!!BYW#:T0F,J*[G0:VR2E<@;F![XVN/8
MY&0?_<Z>&'*"V&UAH:9OZC_LAFS9$-HJE-Z2_?2%GKKJ]^_%-= T% \SSN T
M,I")1WOQZ/.3M>,-]@&F[>FJ3_W'%W# ^;>#LK0K"JU:+U?S&MJ'^R1;+I25
MQ:047;POTOY @2$4Y$(E,(1U6QHY *\98CR<FR% !8OTWHRWHT"U47F4[>"[
M:(=Z^6]>L20$;XVO6N*Y6S52G+C^3Z^=K\TH5BO9?<>NSMM1Q/7R>U@[>W]O
M(K2O,#]40!,<YV+U/,@$:?= VZO, C;D*F*FH;:J-*[7YTZ<O#UCA%LNH2#\
M], 7K>G5M5(IK,4K@J$%Q]Z$V_GIOSB%K2[NCCO^=N?%I\S#,GR$KB=VX5/@
MX1()4\+,/%BE,NLHG*'PLM4._P;QOH,G/CY3^WX_=K)]EUTR=HE3[H3RJM0]
M?'$Q[\S%YVQ(Q1 #C8C[TX/ .4X&^+P84N473.(?D]O$&:G:/3JK9F?KOKT]
ML(&C$MHQ8YBF(!C?<H5E9*/&]Z+U$ <#1:#\PH WO'U3:+2;UVK*WJFC2NOV
M54>UA[,FUEIS"ESZSVA[PSXBC\,.U,-Q2 7,##&I4<IK6Z:XV.-Q4H9/CC'_
M1F;Q5.*MD!!WT7:<RQG<]:YWG)=N.\#E7*=]*NUKFFLK%1/01<+ S_([8^6.
M%$J4<RBJP>+QS_2E[4\#UOSW^S:<V1"I==7P+"U G(IKV2:V9%I?IVY&K%'$
MVC:W!Y_]R9+J"] 87EJ/#_FPY)I^YF>&Y>I0=5&BY*5:M6/V )X-V1^R$<?,
M8,#)'1EF<3X\#EZ.\,C9>IKJZ'KQB>(2[PSS1(W2+I4DG-+V"^:OYL0O663#
M!E$-1Z!#X(&LC4.VC;3(G?VY5"[IZ $1I<#2KZOBRM4'GM;]],NJ&);0G<!Z
M*WJ&0NE' ;PS%;\(IUTCD#!)&OQ1,+$2/>/W-PP:BA9LQZ2"'/<$5AMX5P2E
M'8HI<%Y,]WHX_CY!]>O1;)'U:(9PT$PB,8(ECS2AHK T'4*S%WDY:5A+YL2I
M;ZD<.=VDPGWY+V<)QWZ5\9II7-&KU7IZMD-Q&AX.KX G&.QR^&.;)3'LKSD0
M$$Q96M:8=#(M'5X\5E-]SRLDV2=8N.P=[:7WIYSHJYWILPS3CY[0@WH.8)S-
MELN7%2^,I!#_.$;V=K[V#=4K<KDD_3FEC=9G H% =B-</"8;N#>^FAJM6U\$
MRDCC/M+  4LQI'GUL ]2FU9]8:B"3A!$6O1ICD1;\ 0);U:]W#@AI7,C/N(0
M_4S@F-;2]3%N*G$T8N,KC2N!P4W]#*=9MB-NT=:CVS$'W3?J7K"J.3.GTK(G
M?S^*F9Y\L>(_@*@:-]JU6\?$9#*G422Z9;A)^I-3R5+S<XZ!:HN6XG:2EQV]
M?SSKATH]QF@!V,9:F]]T'8IH5^;/0T]GX@7K%:D1K/V<5+3-D.:RU&^TP!&:
M<!5+CZ951NXU\.:XNJI<8C#<K><IGO/25Y(KQ<VTZ:Q<N#['AC<M#/B,IJLR
MKM'$VG#<L4BA:6D?8]H-8DR]M8]/<6?A9<V]%[/$G2UE+3=BOCS;_:9JEBL.
M&!YO&2Z4Z=.L(IK/,, B]V?"0+C"S795.2@LD7C\_F.W;7]R@?V9AM=J;7*A
M/OFL?C]/EA0UNC74NF/8#ZE2QWSI-K .YT\TV97?6VR:\V68UJ7#9Z@B*"!J
M^28IIC"),Q O9G""4()4 >;UL()Z8J%4R389GCYO!A=),A35,^E0%+3M1/#>
M^V9?3?5KV;AE@N3UKC;M;^?N E'\^\>T&575>C\9,S#G.5Q-82E@T7/QCJ!3
M836-&^+S#?.Q8\&E>;WP/J://Q%> 7WB@SHVU3MS0@]*MGRJC3U8H6_4 G<'
M8KW(^]8RSJAL%FW?B^=\E6I>9793MBX\6(#WOIV@ 1\"W[D<XW*RGPUQPQSH
MI:5V9HD#M84>:'%K>'EY'Q+N$1PB\^IE_IW"8_A7KA&]SJT\F&=\T=V\D*TD
M?NZQZ GYRJE@)3E)S. Z+-&Y@OJBH.K7RT'M*U$WB%BX3[[TR=PPLR" HUW[
M^UPCC#C/AH@:G 7P;6,R:0&Y\ZBCPRJ5QY4?J*#Z3F[U5T2^KBKA>?#5ZED#
MQRG(B)I8N$-=]/9(H3')S ]#=**Q?A0^1-@280N'852U&U;Y=Y())Q,_9YE#
MP\2Q2PTWJJE[EZ=A+Q[WR A5*S#O&!!/%5:Q_OHHR]H#ZR@<3?DY^K,4 7%;
MPG;AG "N)4;BEEUA?N1-@J#1%H96^)(E7 U;Z2=BKIT<%-#)LN1_$HZI.;-1
M^ QQ$!TTOC129$QR\F5#E(\PVITC6K3F6(Y&!!C">N/6QY]40(CYDE'P4X9C
M C7/*!R^17W12'SIKE^[NW@<N":%+HIG;0MO(2-[@O7Q3V _&+YV1ZC[;.CX
M/)!9P0B.S6=HHA'#<T+F8+7LZR.,0^A$%?A1E6 ]@SU6# 6,86\H/QNRYSN@
M3=-V81:M.2U'!IF_\QR[[#,4<+8OJV7<,@A^6O&%E$YWA7>\;KS\KXZ6F: -
M#R8F8'DLGBRLPQ7M>CW25S[[X\7:ZH$C!)6? :Y]5Q]U?K\;O:B]2*)K _"-
M6X"'!PG+,QH?@B!D!#QJ"LV]^B9!H[^4WG-N>]<3';O,5[=S+0QZ':J";E)7
M,N8>R]977"M<=0VB'3S%O2$=76EN;M\B$8"<IX %[]S_[4L&39-P^EU_[OV4
MI(=5CE1]GN1'2L36,/]8@,_6VB<VI"EJI_4OH(WHU*/7OZ#5X:>!3M9^+%V'
MH0NTAX(U'@Y\)NE+=C@^>%^G/YP1/'=A>.2^S0556867W"JYQ\(9K;,=YM?/
M;?)7_"&NSM]E0\+X=KZ8W,AT8H4JX:E'\$ Z%1^+I]K@1UNG">WZ3LT&2D S
M29^C74+Z1]F@DLK+GYK/VW:+F@K<=SDDW5XU/5O'GT2D7L6&L2'ET-B*1&@G
M4;A>EA1J=J,Z::.+I_"]JV9]M "A3O/NQ5?)E1,%R=]\OU2BFA[G_Y=$[G2+
M8C;$X"4<.$ADF#N6-V"L*J+(8_8JRDL"=Z+LG2])?6D2N2L;_NZ@H=1!0YQ>
M Q/7*#9?QX71=,)((5#ZVJ2 E7F44NUI[1<Y-ZIZJU:D\1H)=Q+/OR<[#)U3
M\C6SY?+[3Q$-!@K1A+PTUA[MG2<BO4+H_@SH (K[!^-"!EDT7$^RT)/_G0.Q
MH(?B]SAI_EA!T\%O;N<Q=3#51YQR87%K, Y@P13(F*:HMKG(#"D%]/(X5IM]
MYCO_S4JYX:?%:>E# 5S8P4 -N%D8[/\@I/N'=F7+4^)XCR'\7'\W&[);<N=G
M"8I.-6/; 3UMA*9IYAE+-=UCYH/M(=9,E;'/!\2 _V6UX1?"?KLR_E,N^Y)*
M2RV]L=$5$W2_Y#@SKD]A=TS'J!B3QO@]RW%M=L%V]2<;8E1*[V2Y. VR(657
MZ+9_<00#!(D,8X\IZ%JL07[U< V:#_6]49B&Z5P689P:6%ZZ1\L/]^^6AMM_
MTK*6"QRNSG(;G;QW5^#KYR[?R-MV'GL"CGS<U1]:N,.I$Y3![<,ZBJGT)*XN
MN(*<FH.<VH9KO\J>N>M__UD7Z?G,QR]ROA9;U:X_Y51FHKAX_H0V_)X+#?]-
M^)N9JK^9T:8X@IKX 3:M9FB:2-Y+!>B1)MZ'3=,RA@81.(7^Q"([7YYRR>H'
MDKX+6<_]&IO]_NL&X?]BIA;]%%X1_12E"V [TV&1ZXKQ%#-221WR+'G?N[)T
MXF):R[&T;J.C'Y(#=3)_7WY#]9*U998W2OS&5YK$4RW@PHZ]-&WXP)*FD[?H
M\ D5&1Z$=4_RDMRY:Q.4/05=74[0XV>%M^J?K.F:93I10$2;8Q]*8D-4E4'!
MK]^>L>7X55$&>L#+G6^BK@U5.YNR@ ^NNB8(R<<I#SFEILY9_5MN85!NJ"?H
M#\.=H#]DL"$QQ2>TY1<IDA;#S5P>"Q'SP(@";6XF*!I]#Q<A(PN$S2C.:^!Y
M$!8=YF;7ZY+&S%XK4P9VO3&6*&\\?>:J^^P*Q_T;H!GF=\RPP\VU_S;1?N ]
MH8,ETE]9K&6*-1_VOC6H+.<^II4BGNL@>[N(0\7F.>F);+9X\>6S]4^Z_T],
M7CX^M\*A^F_]6X/ZSUGXCY4J?N=BO_#B_^T2?_$27^P$HRW<^N?2-E.XEO$D
M,-*O$.W&J'H<W/UF]A<>B)LC3JM&_;QW#_"C,E_'WK; 'KBDE\K*;PB4."A[
M"00! :_B6-;KR\!)# 4F%E<9,P/0:>?/D <?S%RX<9W3V.&GS56M-<@NP/:Y
M>U<N\GW R>.%Y=LHZ"X]#=CL&X8!=),_@@U)^&ZP&W!']YX%T'^?]-2+5E5D
M0SBMF1\@<QM/=HXBC0#Y;!N,!0>MF/FOV)"O*. =>NDD#$B?WWY#SU4M-BIC
MGD>W1%&_LR'I06 :!F>"[[1T*ZILJVM^*QZ"DD#"&/?P:6O@$GFL@6^PGXV,
MJR!8+-WY50?L!#@O,_.CT&06\E^#[MLO+'[#':)=MU%L2*0X:9%&W6R" ;O
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M-UT?92,93](UA)EL%VWZS"A'JC\@7?B"PF;S*7@&9W.*XK=CU46FUP]_003
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MDLNZ'_$7,<:>>Q#U=0R>T9,JWE@* TXRMWC-9C*T^0 DX^I1=5VB@9.GW^T
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M;4D6ZR;MZ;(5=QP\!,XI17;(F73#\K[69!A$0<\$!,CV,!!1SW="+[QDWUD
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MQ*7&3G;$MF%C73_ZAUBN%A7ES_E$5:7<PDPL[UJ4?/#RX2%\Y;KQ958PV55
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MKXW:@SA"O\[S??+I)&ZGIT94]Y"-"A&E[FA]K+3[UB$_\<<E/\)")#S>F\Q
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M6S2.(^,7!;^8LD44VRXC;038SQ)R:^:+T2?S/3@2]B"'BL'-R0O*H>"W'#A
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M)BP,)5OI\S]\=J^-:+1D%9<SS]6'["'=/[8D3?_:#<4S,VTIV49Z&[&3LP9
MQ)1M'P7_E(7Y92S*K>C7?"9*<B%+C_]=M%92HS_WK_8'2";RZ>E#J&EF^$#$
M.0CA W/N_A-T8VH,D19070!>7%EHFWJ?Y!;AG#,C&7IFFS88VJ@  ('[UK)%
M A^"9:?J_DI+KAT4O7,W'KR)H/6S^BG%Y:?"F.#*3+;@YB$[[5LFFD[NR<;R
M.+7D_%YVS.'$OY RKV'K'P,G%+ 3:0GBIZPK2'&R$1JQ\F)"11U6NKC-'5&.
MMZ@[#1AJ\FZ!Q@=]UZLK3Z\/ :=.+NC6&8AQL:3QK\_STF00VADI5"3?!/75
M+- -&%(2)TG==2Y&[O KM9G?3/J+-8P#FC'QUO2WOQ8P!QH\\KG\V82Q::ZI
M#Q" Z3$BW\[MSHW-X9VN5V6SF,WD!?8S/84&C#*XIG&D8)]VW6K$8'*6A!OC
MY\*9KBH*!V]#IPK)V;A-V;.'I",".TRV;+A^=^/X%N^G)NJA)(P=3]+O:MHD
M6PERR[$5N?[B-,]Y9U6>%9%!7;\AF!/#"O^GN64&9=J.)5M_RLHC_9X\\T.K
M'D5DT$>_?-CII!Q[TRS*=85H8!1KF=B#$EG1)O*%KI,_V@[BVA1,8\RK"DYO
M5O-$[\-E__9NIK,92!A;:4HD%89K][^4#PY*'%I3O</K.ODDY?GDVK1TP7VP
M17TW0^S'3J$:W>P?!;3OZ5:GY<EYN/4)]R/J*I?\_GY4K9558#-(9-GJW7K+
M'A:=?&5"<^@JV9Z9+(+IBV=8&WBW7W%D=&T;*_T./[%:-^UMT)B#P]76OI<P
MY+9 CPN0[*5,"0((WMG!I0@;(XL+$'N)?#D=Q#V'G=L\IR7NWMT9??L/0#>3
M6ZXEJ_;<(@J(Q__>>?K)AFXC($,P <'GLM:(E9*)KJ,^]&YU+"ZN!69Z\X (
M8GFG3WQR78SJ]#DHARR_/&R8?UQ1K Q8&R#0XU#SM9VQ>'7@DBNPV0WS%3*&
MCDCW+ENR6GQR*A C'N#R,U-'M.96)\TG@"$RO3"H?^5Z^V4*:A+IZ(Q#T9)S
M5KK]#=L^<1>FUUIMMPOH20)G9J@9- C.*NZ[EAO+CV+TTED?ZC/F')R^.!]6
MPA#NKTE'S+QU;4Z+Q:DSN"KX'Q=X%+K60K E"\!A0L4$EUT/#<BUT?<!];W/
M7;2 2R[_ *MY'?1&W;>1'@K1E16']/73Q"&&8> )]F3%Q/G%J6R#YT,I ;LF
M\PQ!X^JO[]]'>KL@#<\:S[DIO.0BVM!6S2IKRQT36?H'D;IMS363EKB&!?32
MXCW5M@(#RB6_ZU]_>@PC#TBY%RH?C=2N)JFE?"9C>OE8B'NQ^39:N"C[J4GC
M5I)4;5"\5%X9E$/AS;#XOAW4_9VY/K>6,BW#'0&?' 4R%RFT#U77GUV)W6RG
M&X,-3\=A@NY,RIT.!93'TO7"U'+]BC^X2']*DM&]_W6N,OSA#?Y@?\<JPCH1
M8TR>O+A,IHYHD=Q>$!PF^"/Q<6N@Q$HE848=>TFZ^JS,Y^M=O^57KUY4(LK4
M7:07(G'[NSUX!E[I/DR.D+6N\>2>W&O,.$6Z;">>J9 Q6FCB+&89+JR@"!C$
M^/"X^S2HS*X:=8'BSJF)AHG=0Q^1#+@5:K(K_2ZZU;;0JO5DIH@'[B*55YO)
MQE2_Z6R69F'I#3'1I7L4?'7MG'[(@P3"YT;)24?9*)#?54(*-":1XG;>$+Q?
M73G!I_^>A^JDJ[A] ^E>,K3$L/0S3?0;39]OM/G8"V&I$<2YO7*C @DJVK81
MFI6#:=8=Q:SI$7/*2R&AA+$!U5K50WD"E+M.9N"6\P<:75/[SQMMGT;K7_P#
M((+5Z@\2=WM.KUS</ ,%5H%8LZUK3NQ7L!&;EF-@GZQ?F/,:,GQ@8\![A[FZ
M,-IMV2:5/9\=D>400J7,7CZC(DX<?4FLZH6S0@\00WV99SGU7[$N"O\ KZV5
M=>:Q"T/OA'D2GTLD!]@'/V!F1'5IM',@>M;$B,(YU>C*9F\#]#4Q=Z1<V0(D
MG>-X2- 0QDY)VX$(?;F5=34Y>?G)QY')Q,=&,7R\@==F3;B/8\]R Q7F"97M
M2QPI'E*$?-G !8O82W?I'U3%'XZ2A77*F'<#'4IL$9$V,^T2\FGPO5?3*L\"
MU2-69RH_#9=EN5#-7_KAU(JQ,%7=8I]<91K.>8[GH+#YXG7CD/P=\^?4Y/MY
M5M#,WI,X;B$.5K745=$ :,"CC%<N3.U%-]]W#WLPIU K=^S]C*^5! 0NK:[$
MG(/(T:4[,_Y\:,@7*X2ML9+IES1"RZZ9)CN6@] J7L;OM10ZHFU/ICW.(NKV
MGNGVFV*EVN">*\Q'M!,438EJU5:EP&ZI7WRO\YY-O]'TDLA+_?#^93 QF_E8
MEYRZ"F) I+P@FE8SA[1:ET*;VZ:X'<..$_-=\;^W^MH+2CGJ%%B-X.[;W4))
M+^KHPJ,DH.]F+VPW(T>&;(0+B&?H]B] OB16*"A=/MT,4IS"8;A/S/41-OUX
M*/3E%6F9 &CWA% Q!/;8H$G(%7#J";H)40"6J?@7YPJQZMX<$K#J?U:0%-/_
M=T2^]M+G0]%WP_8(T-J?T""A+1\%+"A:-O#Q[(OFIMJ:9.54D'O:LM;-'3I[
MQA8N/6&JF]Y;MA+S07VVK"GX0GD2&85+B%R%[I-UI:0+)N$BYKMVD\*-[4JP
M^NHPYMO;)G^';[WA4W"<*W1J7>C\!R ^E@:!D=IDF.JAOWKDH;7@DXEK^9GR
MY3#,H^;:I.)F \= E>\;&YX7CBMS,?<^-/*J#-4)5RFBX^F$G+BR>,L.#WA)
M,P8+'E;2%1[G?>3ZU/S=(,"I'--KS0238T@DH&\O;,EPPM<Y/#[NWGR5FEH;
M]8WF32\?=$,=6W*L=2&)0-B#[N7;DUY5ERJ3"OM@C#:W6AI3ZWD%;O@)YTC7
MR*AX?I_@S&&(>HU) UK5ZG6((SAZ<LDB1KW_32]C](9!K>N(';%2;GN'T7)&
MS*[-'WR!?*(UDQPF:089PPW9]'XY^".1%QFBGK?F)N3-7&@W_P$H(LVV:<-G
M17;USXJ<3A_:&<MW#Z1THM)5%1B]*U \2"_B?[5%V]CB(K2E9&6DBCRF>RZK
M">V4J1US&WL[5(\W>^KR0L[;L9M(+2+TF)^<[4O<[U(*S$G'62OT\(D0$R-O
MS596PBMO3<F^YJC=SHS_!'2DD_C#P1^9;)O*DL(%&#]5_J_9BIH84J6C9<I;
M%?PXTA2\\UJ_I#WDA&&_=N3/4.F3]_.6K7'N$XMTOY(A["JDC>SN8#4BB.60
M!5IFQ0O5/U6+(0#SI!<$?N_R&OVHE=_5T5619P(WD;3C<Z)./LRF?=T:[SF.
M:$YVU*-!?//\25B(N_F+_6]>(:KK]KF,:(\UQ.F\"S,E56]]];>A%*_K@'L3
M>_*VFO_B$]DD-_W&E@CO YB(D_E#Y900M2B2[NXS? =C4.\*8Q#?EL^)>B]#
M%6!YP78[$Q1U="7T"4D@+W4X+U/Q[JT8"Y9\G= A,3BW#%4GX \,=?R9:!09
M)(E0[_R]$_*K]URIOG%*-L" 1[_*-,"<G=L@6BB<6_'6WS%ZX==FHE?-2>:6
MMH1IXH Y>>L?X.K&0B_'?40!X0 B'B] A-2L]+ 92B;;?FS_-JO/K2S+<.\]
MC5L5+1_L]'I03V;D[AGITDZOS>UJ8EQS*B825@>[8RW AC$\D*[:KX*M+K<4
M-#SWAC%"<YM@GVXK5AK^-R\22VM(SJZ$<E]))^YTS\XR^\]:5F94VC1DX<OV
M !$,?V4S'%QV]UZ9@B.3A'R35ETP-4--&JK+^\<;9 <H+A<$!1&3]>5SB?U_
MO?:OJ[9G^"J#%^]'32@^$Y#TM#2QOT+%+R,NNFQ*+6APP3D)%-$IBGBEZWX%
M(M;(B-D0"O=U*$,8F7Z=%DK>RH8E,XBATS9P12X_7U[O__G!;FZMU^L?@"Q<
M6;\ZF-Y%1)2#224]@>8(3U5+:U_CA(47"4Q2>[_7/T?OXL((?B()AG\/#.K"
M.IZXNH*^[L>T \FV_9:VX2JB.&E>B/] =/Y4?FSON>C4K%GSU^MIX8+3# :J
M=3-F3S9$>-Z%?[R4X'N=N;"=(V@BAXD\0&Q>Z\_DJROH:1#!P2OE>"!>@[+%
MF-$<C/%BA>="W2O'M!<F5+1Y5YHZ0FTQOA<2*K&YH<P95\5J*-1LF'O\*;%T
MRRS32L$4'')6LVQ06F"0]:I/,Y.5%#*4QA.!3+0XBU 31AJ??5#1QN6R(9_.
M%) XHE7NE;N@YJI4S+!7VWXD\Q@U6,G5V"S+WN-$KV<-ZV2P#UH/" ?)443)
M.Z>/_^L5RYIXF7(G])3-[&M'8M?*0CJ'S[E0#!=O2<C&7W3W $-N;;/63T5)
MVGUZ4RQ +:F./(XK_P?@!B.">"WIZPV&>>O)[.R97&ZFVO'%;%3K[[D^7.=1
M?.61 ,T@*1"B5T'TR.NUY&B_<EM4M_@70]Z&7 EN[?6^C3*)9,ZU!.R$8GSO
M[FYA_@ /\%FK8Y#KWXV5<_JSM6'UKMQKA^4,^TR;*%@@Z@FI!B(M(8\5B2]?
MU U0S4DN=/X#<T]+NN_&$IO^Z?;MZEEOTJ]5W[X.&K+)R0I.I]X7+SPKO1I[
M>M]B:O?P(Y*WN(^Q?!W"JFV_\8#S(WY%\4-^R- !XQAMS04[U!F%4;2)&%U2
M<5;98!D"WLL,YPV?+BJ<5!E5*;\J%OWB6YP0K))+-[W^#P$[-TKN.+6@J)/9
M5TF5B)3>M/?S:B7P_-ZT>^U%;U4)72]CEA4EPY);(_VSOQ2&_TVXP6;SG%1^
M;$ORC0VBH4@21T,/T3S_%>7%+(V6NRKY'E?4:K%W;W&'^8P7[A;K?YNJA#E#
MK!S#6Y(9Y/QB+YR;F!2ZU5"N,M9A=85YT]2C='PC8MH&:E!NR]R6FGHJ]J2^
ML[VC/;50PA:&SI/0HP*HC1A%*S&X8"S3CY=3SG)+FF+V-I?Z;]5Y! ^*IX2]
M,G<$T^:DABL0!%?G*([>N,VC;])R0SSE#.+ERHJ%S<DSX*ED _A='72UC6+V
MGYMWOJ397Z$G.^/4*:QK>-T>YHBT/PK<S*&MMJ4&E9 #5SXFTK6F&YF29VVI
MX4<59B8&L)*'R4^<VT^UHE\E%8*A;R;@\>8^:B(71ON&//ER2L6\^6GL!2"@
MUX>'A^-',KQE+_T5').4+>>Q>#BPH7VU?/MQD/,=(=.;R0!:+ /)J"<>]P]
M@!/.V$Y%WY8L!*UPS/\.B^!S(K2^^I5S;U@Z/DAP2_W:X8VI^MBJ6NRPBOS[
MOQZR$U:&]Z/P";(:EKH^KP#&^B,><6NX!1!9Q#D6J8TC!!D^[^I@J(,&6AS%
M!Q@0O>,BUK3&ZO5EH;PB78_K;J=<K[9>-!2+NO2[/\^\\H"@SM7.!6UGF@ZB
M(OOV>*@>18:M3KD1N'^V=&=^XKXY#OF]J,8\V-OSEOJ@^:;[@@;O?U9,OLW1
MPQRGSF9'3 LOATZZSOIR^#2\M48X/*^9/.*"66IG2^X[80P@\T],2#?C&W7Z
M/*GDWAJ>M00!=T"T1XF\%N2,RM;[>=L3+F8<=[<P)@:2VXJ)@R%47)FX[ P?
MO]MXC<X\NV%$4/8_ ,VW1B*H<X79)8B+I!!;3#*9Z\DS^K(=)-;<U$!$UW?3
MU1NTW9D_N&&F \Q1U-/\^JTD/U6RX2R"@B+:XG[%JXCA-KU ,<L<T_76=\Y'
M9ON5$H_=\X2N;XW/JSRSFEOH;ZC1F$E+O!'+(HSLU'-[ #C:62'?[N@&2T<"
MU43@UUUA5\I0\JFPHCX<0<?:WZ!1 _+Y?,B<:7N06^;;:K=\__=?5[L2(<3R
MXTRB4?]&/1_[K,#T^4+A0.5#$WH'9I<#@RN4YCB98<924NZRSE#$2\71D>4K
M9[GMJA3^5N)HO"2,PK,V"@P,-9Z0]AKVM6W2EP7K[P/QXX)3<<S":YJL0C)#
M$JX'-%JYZ1N'H/G3GAQ^DC.!'8THM^0.$(U44: -<VJ9=%L>Z3&=&OZ1[KL/
MY:F]K\DF>_=OV*?OHC=E[@) 6L\,G_^6"A2;^G\%@UDHJNMA^UUR* [>%<@W
MVWT?:DQ.[#L7G92]+3KNEGQJ4E</Z<6&S8PI*0W*F%_H&"Y>K7 G4^,7IZVY
M;V83SR]4&B>2F2CRJS.(GQ016^HZFYXC5D?\$[DGX94V)24[1- ^_U83<L7>
MI(;=B<N^,-Q470Q -(I8:9!."+KJPG<[LG^F76BVPDW6VK9/"38:ESRI,QLT
MZ";QN0Z3N3PC+6GY^\1O+1*A?PE<?:?O YT*^!_@,ALYFKC]:X##$AXB"^)>
MV%0*2QYEGXW*U3>@2S[AO:/,8-*0(C<]W;>]&-7:Q?AZ(#*)RC@HF7Q$?(ZS
MC88]'UAA51''J1J3@=^A4]/>,#DI6WU,'/I'7&'9*_8\_;M4M]ZS#/L%99!"
MCP,GVJ\A$OLSTR,J*(*X; [+=]+7,+@,"='FMKHIIJ/"KYWC?U.^21L8 ?ND
M1!C?W+P.4*SB^&^>8/LMA*T6Z6*QW55$E<ST'FC DFU?B!'?T.6H25Q+Y@S[
M9'&@HNKTSPGPHHY FN(MBUM8)S5[MC(\G"R6&Z7"M9;M(0>*5%)18P,S7S?$
M$315#,5=N7M/7I[%1\RC+R<!B:-O43=NCP^I]'U_1\^4U+3&TQ'\['PBAYX8
MT4+\<FS$M752V-.-#1_HR=J2)4NM+P7*OG<%.<NO,3>;I?SH_DXOI';9)TB-
M#"=>98".,B.R#,C@2Y6);TL6M[ I6)WQK7ZOUL;XI#GVV)'?OQS&%'5%%66I
MUH+^RUU_1.J0JU>'4&3=<W:RR3] 'S"ZTGI[$_DR$%YLB=UZ"^Z=Z#R )"W]
M^*TO\36JL#XL&OWS<@/R: NK0"A3B%=W-HKJ8*TXS +;7B7#G_AY\8PCW(5F
M]ASJ5Y1IYKY\+>HI:N;M*W0ILK_A-BI.DC8C"Y^JD:FMB"NA[K*YX9EQF<)S
MF!G* QP<@R[Z%"V"]AK;C<]/\>02N57#F'[OTWV]O#;ISF-;>CNRX84[#?]:
M&=%,'UZ'EN[!=NHY34V,:%2:T/O4=;VV[INZ#A9M R"'<:-80?QLYSY NXQ\
M;!1GBAWYTA7&=T^-J[XNWNUP8<GT&*Q9G%%X#U0=ZXD1YN%@P?6XNVZU_C<X
ME)6<BC.B=>66CE8#(4SAW.2G!]]F]@I(KVL@$ >^:"!:=3=YP&XCL%*Q\&6
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MF9HK[Y=XH&%WY OM22'5+ZA:!7&8 50"]Y^PW=; LSQ21,\3DG5KNS^BS"O
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MX:Q=T'^PURT6\:6V[M#\Y!W:XEB)<F1'B2 0.;L#4_%C=*EG*9M_^5@/.]M
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MKY\>3/*8@OZBC=KO -/O<H 9/EZK/TDQ^GS__#U\FI&]#B_.D6)\?!^A23&
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M?P 1:/,IQ?8_+):)7:1]=5K>4>V^; <PT%A=IHBGU),5CL/U9M5#W21>!VC
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M@[55T$_8T6Y*_A7Y[((N_UE9=:PHQ]4Y;@2%<ZG?8CTI(]B9<#JVN.74.N#
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M;>EJD\7]2Z> P*P$24#Q_Q4EG5?-S^G]/V+I?_%1MM.Y_P%02P$"% ,4
M"  Q@']6<\J1'Y<"  !K#   #0              @ $     97A?-#4Q.#DP
M+FAT;5!+ 0(4 Q0    ( #& ?U; MKJ0_P0  .@F   -              "
M <("  !E>%\T-3$X.3$N:'1M4$L! A0#%     @ ,8!_5L3H=;P]!P  9Q\
M  T              ( ![ <  &5X7S0U,3@Y,BYH=&U02P$"% ,4    "  Q
M@']6"9E\%B\'  #Q'@  #0              @ %4#P  97A?-#4Q.#DS+FAT
M;5!+ 0(4 Q0    ( #& ?U;6-9_FR@0  $\2   -              "  :X6
M  !E>%\T-3$X.30N:'1M4$L! A0#%     @ ,8!_5CT&'4:R!   \Q$   T
M             ( !HQL  &5X7S0U,3@Y-2YH=&U02P$"% ,4    "  Q@']6
M>%F=R0P.  "#50  #0              @ & (   97A?-#DT,#8V+FAT;5!+
M 0(4 Q0    ( #& ?U;9>JV,,.$  /(# 0 ,              "  ;<N  !F
M:6=U<F4T82YJ<&=02P$"% ,4    "  Q@']6JM+CL-"$ 0!<LP$ !P
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M '!I<G,M,C R,C$R,S%?;&%B+GAM;%!+ 0(4 Q0    ( #& ?U85FJ !<5\
M !;J!P 5              "  9)7! !P:7)S+3(P,C(Q,C,Q7W!R92YX;6Q0
M2P$"% ,4    "  Q@']6>Q.ENS,N! !]'B0 %               @ $VMP0
M<&ER<S(P,C(Q,C,Q7S$P:RYH=&U02P$"% ,4    "  Q@']6;?5<&?03  #*
M%   &@              @ &;Y0@ <&ER<S(P,C(Q,C,Q7S$P:VEM9S P,2YJ
M<&=02P$"% ,4    "  Q@']68BH16G$=  "T'@  &@              @ ''
M^0@ <&ER<S(P,C(Q,C,Q7S$P:VEM9S P,BYJ<&=02P$"% ,4    "  Q@']6
M5<UNKU$:   O(   &@              @ %P%PD <&ER<S(P,C(Q,C,Q7S$P
M:VEM9S P-"YJ<&=02P$"% ,4    "  Q@']6*$9II'4<  "D'P  &@
M        @ 'Y,0D <&ER<S(P,C(Q,C,Q7S$P:VEM9S P-2YJ<&=02P$"% ,4
M    "  Q@']65$51)#(L  !Z,   &@              @ &F3@D <&ER<S(P
M,C(Q,C,Q7S$P:VEM9S P-BYJ<&=02P$"% ,4    "  Q@']6]3*=\6MO  #T
M;P  &@              @ $0>PD <&ER<S(P,C(Q,C,Q7S$P:VEM9S P-RYJ
M<&=02P$"% ,4    "  Q@']6Y(#^$>$M  !-,0  &@              @ &S
MZ@D <&ER<S(P,C(Q,C,Q7S$P:VEM9S P."YJ<&=02P$"% ,4    "  Q@']6
M=#Q((0HS  #Z-P  &@              @ ',& H <&ER<S(P,C(Q,C,Q7S$P
M:VEM9S P.2YJ<&=02P$"% ,4    "  Q@']6ZVA%+/,Z 0#M:@$ "
J        @ $.3 H <G!V-"YJ<&=02P4&     !D &0!%!@  )X<+

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
